early O
onset O
fa O
##mi O
##lia O
##l O
brief O
communications O
directly O
related O
to O
mitochondrial O
function O
park O
##in O
and O
dj O
1 O
have O
been O
associated O
with O
auto O
##som O
##al O
recess O
##ive O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
guido O
david O
##zon O
md O
1 O
paul O
greene O
md O
1 O
michelangelo O
man O
##cus O
##o O
md O
2 O
kevin O
j O
k O
##los O
md O
3 O
j O
eric O
ahl O
##sko O
##g O
md O
phd O
##3 O
mic O
##hi O
##o O
hi O
##rano O
md O
1 O
and O
salvatore O
dim O
##aur O
##o O
md O
##1 O
objective O
to O
define O
the O
molecular O
et O
##iology O
of O
early O
onset O
parkinson O
##ism O
and O
peripheral O
ne O
##uro O
##pathy O

methods O
two O
sisters O
had O
early O
onset O
parkinson O
##ism O
d O
##yst O
##onic O
toe O
curling O
action O
tremor O
masked O
face O
brady O
##kin O
##es O
##ia O
st O
##ooped O
posture O
and O
rigid O
##ity O
together O
with O
clinical O
and O
electro O
##phy O
##sio O
##logical O
signs O
of O
sensor O
##imo O
##tor O
ax O
##onal O
peripheral O
ne O
##uro O
##pathy O

results O
no O
mutations O
were O
found O
in O
the O
genes O
for O
park O
##in O
or O
pink O
##1 O
muscle O
bio O
##ps O
##ies O
showed O
ragged O
red O
and O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
fibers O
and O
biochemistry O
showed O
decreased O
activities O
of O
respiratory O
chain O
complexes O
containing O
mitochondrial O
dna O
encoded O
subunit O
##s O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
were O
seen O
by O
long O
polymer O
##ase O
chain O
reaction O
and O
sequencing O
of O
the O
pol O
##g O
gene O
showed O
that O
the O
patients O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
two O
pat O
##ogenic O
mutations O
interpretation O
pol O
##g O
mutations O
can O
cause O
early O
onset O
parkinson O
##ism O
in O
the O
absence O
of O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O

ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

mitochondrial O
involvement O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O
disease O
pd O
was O
suspected O
since O
the O
late O
1980s O
when O
respiratory O
chain O
complex O
i O
activity O
was O
found O
to O
be O
reduced O
in O
tissues O
from O
patients O
reviewed O
in O
mi O
##zu O
##no O
and O
colleagues O
##1 O
and O
in O
animals O
into O
##xi O
##cated O
with O
the O
pd O
inducing O
molecule O
1 O
methyl O
4 O
ph O
##en O
##yl O
##1 O
2 O
3 O
6 O
te O
##tra O
##hy O
##drop O
##yr O
##idi O
##ne O
mp O
##tp O
2 O
it O
was O
also O
suggested O
that O
pd O
may O
result O
from O
excessive O
age O
related O
accumulation O
of O
mitochondrial O
dna O
mt O
##dna O
mutations O
in O
the O
sub O
##stan O
##tia O
ni O
##gra O
but O
this O
mechanism O
was O
never O
convincing O
##ly O
sub O
##stan O
##tia O
##ted O
3 O
however O
in O
the O
past O
few O
years O
mutations O
in O
three O
nuclear O
genes O
encoding O
the O
mitochondrial O
protein O
pink O
##1 O
and O
two O
proteins O

from O
the O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
columbia O
university O
medical O
center O
new O
york O
ny O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
neurological O
institute O
university O
of O
pisa O
pisa O
italy O
and O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
mayo O
clinic O
rochester O
mn O
received O
dec O
21 O
2005 O
and O
in O
revised O
form O
feb O
1 O
2006 O
accepted O
for O
publication O
feb O
10 O
2006 O
published O
online O
apr O
24 O
2006 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
ana O
208 O
##31 O
address O
correspondence O
to O
dr O
dim O
##aur O
##o O
4 O
420 O
college O
of O
physicians O
surgeons O
630 O
west O
168 O
##th O
street O
new O
york O
ny O
100 O
##32 O
e O
mail O
sd O
##12 O
columbia O
ed O
##u O

and O
early O
onset O
forms O
of O
pd O
4 O
6 O
mutations O
in O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
a O
nuclear O
encoded O
protein O
involved O
in O
the O
synthesis O
replication O
and O
repair O
of O
mt O
##dna O
have O
been O
associated O
with O
de O
##ple O
##tion O
or O
multiple O
del O
##eti O
##ons O
of O
mt O
##dna O
in O
a O
striking O
variety O
of O
neurological O
ph O
##eno O
##type O
##s O
including O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
ata O
##xia O
peripheral O
ne O
##uro O
##pathy O
and O
an O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
disorder O
known O
as O
al O
##pers O
syndrome O
7 O
8 O
several O
families O
harbor O
##ing O
mutations O
in O
pol O
##g O
suffered O
from O
parkinson O
##ism O
usually O
associated O
with O
other O
clinical O
manifestation O
##s O
most O
commonly O
pe O
##o O
7 O
9 O

here O
we O
describe O
two O
sisters O
with O
early O
onset O
par O
kin O
##son O
##ism O
and O
ne O
##uro O
##pathy O
but O
without O
pe O
##o O
who O
were O
compound O
het O
##ero O
##zy O
##go O
##tes O
for O
two O
auto O
##som O
##al O
recess O
##ive O
pol O
##g O
mutations O
one O
in O
the O
polymer O
##ase O
domain O
and O
the O
other O
in O
the O
link O
##er O
region O
of O
the O
enzyme O
patients O
and O
methods O
patients O
two O
sisters O
ages O
27 B-AGE_ONSET
patient B-PATIENT
1 I-PATIENT
and O
33 B-AGE_ONSET
patient B-PATIENT
2 I-PATIENT
the O
only O
children O
of O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
were O
normal O
at O
birth O
and O
through O
childhood O
except O
for O
mig B-HPO_TERM
##raine I-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
and O
anxiety B-HPO_TERM

when O
first O
seen O
at O
age O
26 O
patient B-PATIENT
1 I-PATIENT
had O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
post O
##ural O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
reduced B-HPO_TERM
arm I-HPO_TERM
swing I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##ore I-HPO_TERM
##fle I-HPO_TERM
##xia I-HPO_TERM
foot B-HPO_TERM
numb I-HPO_TERM
##ness I-HPO_TERM
and O
mild O
distal B-HPO_TERM
weakness I-HPO_TERM
of O
toes O
and O
fingers O
an O
electro O
##my O
##og O
##ram O
showed O
length O
##de O
##pen O
##dent O
ax B-HPO_TERM
##onal I-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
within O
1 O
year O
she O
developed O
facial B-HPO_TERM
mask I-HPO_TERM
##ing I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##op I-HPO_TERM
##hon I-HPO_TERM
##ia I-HPO_TERM
co B-HPO_TERM
##g I-HPO_TERM
##wheel I-HPO_TERM
##ing I-HPO_TERM
of O
the O
wrists O
st B-HPO_TERM
##ooping I-HPO_TERM
shuffling B-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
and O
positive O
pull O
test O
resting O
ve O
##nous O
lac B-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
2 O
5 O
and O
3 O
1 O
##mm O
##ol O
l O
reference O
range O
0 O
93 O
1 O
65 O
##mm O
##ol O
l O
serum O
cr O
##ea O
##tine O
kinase O
was O
normal O
because O
of O
her O
sister O
s O
into O
##ler O
##ance O
to O
car O
##bid O
##opa O
l O
do O
##pa O
sin O
##eme O
##t O
she O
was O
started O
on O
pr O
##ami O
##pe O
##x O
##ole O
0 O
5 O
##mg O
three O
times O
daily O
with O
moderate O
improvement O
of O
her O
action O
tremor O

patient B-PATIENT
2 I-PATIENT
presented O
at O
age O
20 O
with O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
intermittent O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
and O
facial B-HPO_TERM
mask I-HPO_TERM
##ing I-HPO_TERM
and O
stiff B-HPO_TERM
##ness I-HPO_TERM
leading O
to O
the O
diagnosis O
of O
parkinson B-HPO_TERM
##ism I-HPO_TERM
at O
age O
27 O
she O
developed O
numb B-HPO_TERM
##ness I-HPO_TERM
in I-HPO_TERM
her I-HPO_TERM
feet I-HPO_TERM
and O
a O
year O
later O
when O
seen O
at O
the O
mayo O
clinic O
she O
had O
signs O
of O
both O
parkinson B-HPO_TERM
##ism I-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
st B-HPO_TERM
##ooped I-HPO_TERM
posture I-HPO_TERM
and O
rigid B-HPO_TERM
##ity I-HPO_TERM
and O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
bilateral O
stock O
##ing O
and O
glove O
sensory O
deficit O
##s O
an O
electro O
##my O
##og O
##ram O
showed O
ax O
##onal O
sensor B-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
magnetic O
resonance O
imaging O
of O
the O
brain O
showed O
moderate O
generalized B-HPO_TERM
cerebral I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
serum O
lac O
##tate O
and O
cr O
##ea O
##tine O
kinase O
values O
were O
normal O
her O
tremor O
improved O
on O
a O
low O
dose O
of O
car O
##bid O
##opa O
lev O
##od O
##opa O
25 O
100 O
immediate O
release O
tablet O
three O
times O
daily O
higher O
doses O
caused O
severe O
oral O
d O
##ys O
##kin O
##es O
##ia O

muscle O
morphology O
and O
his O
##to O
##chemist O
##ry O
routine O
his O
##to O
##logical O
and O
his O
##to O
##chemical O
studies O
were O
performed O
as O
described O
previously O
10 O
2006 O
american O
neurological O
association O
85 O
##9 O
published O
by O
wiley O
li O
##ss O
inc O
through O
wiley O
subscription O
services O
bio O
##chemical O
analysis O
respiratory O
chain O
enzyme O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
in O
muscle O
were O
measured O
by O
previously O
described O
methods O
11 O

dna O
analysis O
total O
dna O
from O
each O
patient O
s O
muscle O
was O
extracted O
using O
standard O
protocols O
12 O
southern O
b O
##lot O
analysis O
and O
long O
polymer O
##ase O
chain O
reaction O
pc O
##r O
were O
performed O
as O
described O
previously O
13 O
the O
gene O
for O
pink O
##1 O
was O
screened O
with O
prime O
##rs O
designed O
according O
to O
gen O
##bank O
accession O
number O
np O
00 O
##46 O
##10 O
and O
the O
gene O
for O
park O
##in O
was O
5 O

16 O
cd O
##na O
c2 O
##8 O
##39 O
##t O
see O
the O
human O
dna O
polymer O
##ase O
gamma O
mutation O
database O
for O
more O
information O
http O
dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
index O
cf O
##m O
edit O
all O
##pol O
##g O
in O
the O
polymer O
##ase O
domain O
and O
a O
novel O
g O
##7 O
##37 O
##r O
in O
ex O
##on O
13 O
cd O
##na O
g O
##24 O
##9 O
##1 O
##c O
mutation O
in O
the O
link O
##er O
region O
fig O
the O
father O
carried O
the O
g O
##7 O
##37 O
##r O
mutation O
and O
the O
mother O
carried O
the O
r O
##85 O
##3 O
##w O
mutation O
discussion O
these O
sisters O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
two O
screened O
as O
described O
previously O
the O
entire O
coding O
region O

of O
the O
pol O
##g O
gene O
was O
amplified O
by O
pc O
##r O
14 O
and O
mutations O
were O
detected O
by O
direct O
sequencing O
of O
all O
ex O
##ons O
utilizing O
intro O
##nic O
prime O
##rs O
apparently O
pathogen O
##ic O
changes O
were O
confirmed O
by O
reverse O
transcript O
##ase O
pc O
##r O
and O
by O
complementary O
dna O
cd O
##na O
sequencing O
analysis O
as O
described O
previously O
15 O
results O

the O
muscle O
bio O
##psy O
from O
patient B-PATIENT
1 I-PATIENT
showed O
2 O
to O
3 O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
rr O
##fs O
and O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibers I-HPO_TERM
focal O
fiber O
type O
grouping O
and O
scarce O
target O
##oid O
structures O
were O
also O
seen O
common O
mt O
##dna O
mutations O
for O
mel O
##as O
mitochondrial O
en O
##ce O
##pha O
##lo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
##like O
episodes O
mer O
##rf O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
and O
ragged O
red O
fiber O
disease O
and O
ne O
##uro O
##pathy O
ata O
##xia O
re O
##tin O
##itis O
pigment O
##osa O
na O
##rp O
were O
absent O
bio O
##chemical O
studies O
of O
mitochondrial O
enzyme O
showed O
increased O
ci O
##tra O
##te O
synth O
##ase O
activity O
when O
normal O
##ized O
to O
the O
nucleus O
encoded O
ci O
##tra O
##te O
synth O
##ase O
the O
activities O
of O
respiratory B-HPO_TERM
chain I-HPO_TERM
complexes I-HPO_TERM
containing I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
encoded I-HPO_TERM
subunit I-HPO_TERM
##s I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
varying O
from O
10 O
to O
18 O
of O
normal O
data O
not O
shown O
both O
his O
##to O
##logical O
and O
bio O
##chemical O
abnormalities O
were O
consistent O
with O
mitochondrial B-HPO_TERM
proliferation I-HPO_TERM
and O
a O
defect O
of O
mitochondrial O
protein O
synthesis O

the O
muscle O
bio O
##psy O
specimen O
from O
patient B-PATIENT
2 I-PATIENT
showed O

1 O
to O
2 O
rr B-HPO_TERM
##fs I-HPO_TERM
which O
were O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
mild O
focal B-HPO_TERM
fiber I-HPO_TERM
type I-HPO_TERM
grouping I-HPO_TERM
and O
sparse O
target O
##oid O
fibers O
consistent O
with O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
the O
activity O
of O
ci O
##tra O
##te O
synth O
##ase O
was O
not O
increased O
but O
when O
respiratory O
chain O
enzyme O
activities O
were O
referred O
to O
the O
activity O
of O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
another O
nucleus O
##en O
##code O
##d O
enzyme O
all O
complexes O
containing O
mt O
##dna O
##en O
##code O
##d O
subunit O
##s O
were O
decreased O
with O
residual O
activities O
varying O
from O
40 O
to O
60 O
of O
normal O
data O
not O
shown O
real O
time O
pc O
##r O
showed O
only O
37 O
mt O
##dna O
de O
##ple O
##tion O
and O
southern O
b O
##lot O
analysis O
for O
multiple O
del O
##eti O
##ons O
was O
negative O
on O
two O
occasions O
however O
long O
pc O
##r O
ass O
##ays O
showed O
multiple O
del O
##eti O
##ons O
direct O
sequencing O
of O
the O
mt O
##dna O
genes O
encoding O
the O
seven O
subunit O
##s O
of O
complex O
i O
cy O
##to O
##chrome O
b O
and O
12 O
##s O
rna O
demonstrated O
only O
some O
known O
non O
##path O
##ogenic O
poly O
##morphism O
##s O
the O
nuclear O
genes O
encoding O
park O
##in O
and O
pink O
##1 O
were O
also O
normal O
however O
dna O
and O
cd O
##na O
sequencing O
of O
the O
catalytic O
subunit O
of O
pol B-GENE
##g I-GENE
gen O
##bank O
accession O
numbers O
np O
00 O
##26 O
##8 O
##4 O
and O
nm O
00 O
##26 O
##9 O
##3 O
showed O
the O
already O
reported O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
in O
ex O
##on O

miss O
##ense O
mutations O
in O
the O
pol B-GENE
##g I-GENE
gene O
a O
novel O
g B-GENE_VARIANT
##7 I-GENE_VARIANT
##37 I-GENE_VARIANT
##r I-GENE_VARIANT
mutation O
and O
the O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
which O
had O
been O
associated O
with O
pe O
##o O
see O
the O
human O
dna O
polymer O
##ase O
gamma O
mutation O
database O
for O
more O
information O
http O

dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
index O
cf O
##m O
edit O
all O
##pol O
##g O
we O
consider O
these O
mutations O
to O
be O
pathogen O
##ic O
for O
several O
reasons O
first O
although O
the O
clinical O
ph O
##eno O
##type O
is O
at O
##yp O
##ical O
there O
is O
a O
good O
correlation O
between O
gen O
##otype O
and O
bio O
##chemical O
and O
molecular O
ph O
##eno O
##type O
second O
the O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
already O
documented O
as O
pathogen O
##ic O
is O
in O
the O
polymer O
##ase O
domain O
where O
the O
catalytic O
function O
resides O
whereas O
the O
novel O
mutation O
affects O
the O
link O
##er O
region O
and O
changes O
in O
this O
domain O
have O
been O
associated O
with O
severe O
manifestation O
##s O
16 O
third O
this O
latter O
mutation O
alter O
##s O
a O
highly O
conserved O
site O
table O
1 O
finally O
both O
mutations O
were O
absent O
in O
more O
than O
100 O
controls O

the O
clinical O
presentation O
in O
these O
sisters O
was O
dominated O
by O
parkinson B-HPO_TERM
##ism I-HPO_TERM
and O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
this O
disorder O
differed O
from O
id O
##io O
##pathic O
pd O
because O
of O
early O
onset O
symmetrical O
involvement O
post B-HPO_TERM
##ural I-HPO_TERM
action I-HPO_TERM
tremor I-HPO_TERM
but O
no O
resting O
tremor O
in O
the O
four O
limbs O
and O
incomplete O
l O
do O
##pa O
response O
in O
both O
patients O
the O
clinical O
and O
electro O
##phy O
##sio O
##logical O
evidence O
of O
a O
predominantly O
sensory B-HPO_TERM
poly I-HPO_TERM
##ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
was O
also O
distinctive O
and O
at O
##yp O
##ical O
for O
pd O
anxiety B-HPO_TERM
was O
notable O
in O
both O
sisters O
and O
dated O
back O
to O
childhood O
in O
patient O
1 O
this O
is O
interesting O
because O
anxiety O
is O
commonly O
experienced O
by O
patients O
with O
id O
##io O
##pathic O
pd O
and O
may O
pre O
##cede O
motor O
symptoms O
by O
two O
decades O
or O
more O
17 O
the O
presenting O

early O
onset O
fa O
##mi O
##lia O
##l O
brief O
communications O
directly O
related O
to O
mitochondrial O
function O
park O
##in O
and O
dj O
1 O
have O
been O
associated O
with O
auto O
##som O
##al O
recess O
##ive O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
guido O
david O
##zon O
md O
1 O
paul O
greene O
md O
1 O
michelangelo O
man O
##cus O
##o O
md O
2 O
kevin O
j O
k O
##los O
md O
3 O
j O
eric O
ahl O
##sko O
##g O
md O
phd O
##3 O
mic O
##hi O
##o O
hi O
##rano O
md O
1 O
and O
salvatore O
dim O
##aur O
##o O
md O
##1 O
objective O
to O
define O
the O
molecular O
et O
##iology O
of O
early O
onset O
parkinson O
##ism O
and O
peripheral O
ne O
##uro O
##pathy O

methods O
two O
sisters O
had O
early O
onset O
parkinson O
##ism O
d O
##yst O
##onic O
toe O
curling O
action O
tremor O
masked O
face O
brady O
##kin O
##es O
##ia O
st O
##ooped O
posture O
and O
rigid O
##ity O
together O
with O
clinical O
and O
electro O
##phy O
##sio O
##logical O
signs O
of O
sensor O
##imo O
##tor O
ax O
##onal O
peripheral O
ne O
##uro O
##pathy O

results O
no O
mutations O
were O
found O
in O
the O
genes O
for O
park O
##in O
or O
pink O
##1 O
muscle O
bio O
##ps O
##ies O
showed O
ragged O
red O
and O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
fibers O
and O
biochemistry O
showed O
decreased O
activities O
of O
respiratory O
chain O
complexes O
containing O
mitochondrial O
dna O
encoded O
subunit O
##s O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
were O
seen O
by O
long O
polymer O
##ase O
chain O
reaction O
and O
sequencing O
of O
the O
pol O
##g O
gene O
showed O
that O
the O
patients O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
two O
pat O
##ogenic O
mutations O
interpretation O
pol O
##g O
mutations O
can O
cause O
early O
onset O
parkinson O
##ism O
in O
the O
absence O
of O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O

ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

mitochondrial O
involvement O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O
disease O
pd O
was O
suspected O
since O
the O
late O
1980s O
when O
respiratory O
chain O
complex O
i O
activity O
was O
found O
to O
be O
reduced O
in O
tissues O
from O
patients O
reviewed O
in O
mi O
##zu O
##no O
and O
colleagues O
##1 O
and O
in O
animals O
into O
##xi O
##cated O
with O
the O
pd O
inducing O
molecule O
1 O
methyl O
4 O
ph O
##en O
##yl O
##1 O
2 O
3 O
6 O
te O
##tra O
##hy O
##drop O
##yr O
##idi O
##ne O
mp O
##tp O
2 O
it O
was O
also O
suggested O
that O
pd O
may O
result O
from O
excessive O
age O
related O
accumulation O
of O
mitochondrial O
dna O
mt O
##dna O
mutations O
in O
the O
sub O
##stan O
##tia O
ni O
##gra O
but O
this O
mechanism O
was O
never O
convincing O
##ly O
sub O
##stan O
##tia O
##ted O
3 O
however O
in O
the O
past O
few O
years O
mutations O
in O
three O
nuclear O
genes O
encoding O
the O
mitochondrial O
protein O
pink O
##1 O
and O
two O
proteins O

from O
the O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
columbia O
university O
medical O
center O
new O
york O
ny O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
neurological O
institute O
university O
of O
pisa O
pisa O
italy O
and O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
mayo O
clinic O
rochester O
mn O
received O
dec O
21 O
2005 O
and O
in O
revised O
form O
feb O
1 O
2006 O
accepted O
for O
publication O
feb O
10 O
2006 O
published O
online O
apr O
24 O
2006 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
ana O
208 O
##31 O
address O
correspondence O
to O
dr O
dim O
##aur O
##o O
4 O
420 O
college O
of O
physicians O
surgeons O
630 O
west O
168 O
##th O
street O
new O
york O
ny O
100 O
##32 O
e O
mail O
sd O
##12 O
columbia O
ed O
##u O

and O
early O
onset O
forms O
of O
pd O
4 O
6 O
mutations O
in O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
a O
nuclear O
encoded O
protein O
involved O
in O
the O
synthesis O
replication O
and O
repair O
of O
mt O
##dna O
have O
been O
associated O
with O
de O
##ple O
##tion O
or O
multiple O
del O
##eti O
##ons O
of O
mt O
##dna O
in O
a O
striking O
variety O
of O
neurological O
ph O
##eno O
##type O
##s O
including O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
ata O
##xia O
peripheral O
ne O
##uro O
##pathy O
and O
an O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
disorder O
known O
as O
al O
##pers O
syndrome O
7 O
8 O
several O
families O
harbor O
##ing O
mutations O
in O
pol O
##g O
suffered O
from O
parkinson O
##ism O
usually O
associated O
with O
other O
clinical O
manifestation O
##s O
most O
commonly O
pe O
##o O
7 O
9 O

here O
we O
describe O
two O
sisters O
with O
early O
onset O
par O
kin O
##son O
##ism O
and O
ne O
##uro O
##pathy O
but O
without O
pe O
##o O
who O
were O
compound O
het O
##ero O
##zy O
##go O
##tes O
for O
two O
auto O
##som O
##al O
recess O
##ive O
pol O
##g O
mutations O
one O
in O
the O
polymer O
##ase O
domain O
and O
the O
other O
in O
the O
link O
##er O
region O
of O
the O
enzyme O
patients O
and O
methods O
patients O
two O
sisters O
ages O
27 B-AGE_ONSET
patient B-PATIENT
1 I-PATIENT
and O
33 B-AGE_ONSET
patient B-PATIENT
2 I-PATIENT
the O
only O
children O
of O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
were O
normal O
at O
birth O
and O
through O
childhood O
except O
for O
mig B-HPO_TERM
##raine I-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
and O
anxiety B-HPO_TERM

when O
first O
seen O
at O
age O
26 O
patient B-PATIENT
1 I-PATIENT
had O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
post O
##ural O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
reduced B-HPO_TERM
arm I-HPO_TERM
swing I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##ore I-HPO_TERM
##fle I-HPO_TERM
##xia I-HPO_TERM
foot B-HPO_TERM
numb I-HPO_TERM
##ness I-HPO_TERM
and O
mild O
distal B-HPO_TERM
weakness I-HPO_TERM
of O
toes O
and O
fingers O
an O
electro O
##my O
##og O
##ram O
showed O
length O
##de O
##pen O
##dent O
ax B-HPO_TERM
##onal I-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
within O
1 O
year O
she O
developed O
facial B-HPO_TERM
mask I-HPO_TERM
##ing I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##op I-HPO_TERM
##hon I-HPO_TERM
##ia I-HPO_TERM
co B-HPO_TERM
##g I-HPO_TERM
##wheel I-HPO_TERM
##ing I-HPO_TERM
of O
the O
wrists O
st B-HPO_TERM
##ooping I-HPO_TERM
shuffling B-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
and O
positive O
pull O
test O
resting O
ve O
##nous O
lac B-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
2 O
5 O
and O
3 O
1 O
##mm O
##ol O
l O
reference O
range O
0 O
93 O
1 O
65 O
##mm O
##ol O
l O
serum O
cr O
##ea O
##tine O
kinase O
was O
normal O
because O
of O
her O
sister O
s O
into O
##ler O
##ance O
to O
car O
##bid O
##opa O
l O
do O
##pa O
sin O
##eme O
##t O
she O
was O
started O
on O
pr O
##ami O
##pe O
##x O
##ole O
0 O
5 O
##mg O
three O
times O
daily O
with O
moderate O
improvement O
of O
her O
action O
tremor O

patient B-PATIENT
2 I-PATIENT
presented O
at O
age O
20 O
with O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
toe I-HPO_TERM
curling I-HPO_TERM
intermittent O
action B-HPO_TERM
tremor I-HPO_TERM
of O
all O
limbs O
and O
facial B-HPO_TERM
mask I-HPO_TERM
##ing I-HPO_TERM
and O
stiff B-HPO_TERM
##ness I-HPO_TERM
leading O
to O
the O
diagnosis O
of O
parkinson B-HPO_TERM
##ism I-HPO_TERM
at O
age O
27 O
she O
developed O
numb B-HPO_TERM
##ness I-HPO_TERM
in I-HPO_TERM
her I-HPO_TERM
feet I-HPO_TERM
and O
a O
year O
later O
when O
seen O
at O
the O
mayo O
clinic O
she O
had O
signs O
of O
both O
parkinson B-HPO_TERM
##ism I-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
st B-HPO_TERM
##ooped I-HPO_TERM
posture I-HPO_TERM
and O
rigid B-HPO_TERM
##ity I-HPO_TERM
and O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
bilateral O
stock O
##ing O
and O
glove O
sensory O
deficit O
##s O
an O
electro O
##my O
##og O
##ram O
showed O
ax O
##onal O
sensor B-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
predominantly I-HPO_TERM
sensory I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
magnetic O
resonance O
imaging O
of O
the O
brain O
showed O
moderate O
generalized B-HPO_TERM
cerebral I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
serum O
lac O
##tate O
and O
cr O
##ea O
##tine O
kinase O
values O
were O
normal O
her O
tremor O
improved O
on O
a O
low O
dose O
of O
car O
##bid O
##opa O
lev O
##od O
##opa O
25 O
100 O
immediate O
release O
tablet O
three O
times O
daily O
higher O
doses O
caused O
severe O
oral O
d O
##ys O
##kin O
##es O
##ia O

muscle O
morphology O
and O
his O
##to O
##chemist O
##ry O
routine O
his O
##to O
##logical O
and O
his O
##to O
##chemical O
studies O
were O
performed O
as O
described O
previously O
10 O
2006 O
american O
neurological O
association O
85 O
##9 O
published O
by O
wiley O
li O
##ss O
inc O
through O
wiley O
subscription O
services O
bio O
##chemical O
analysis O
respiratory O
chain O
enzyme O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
in O
muscle O
were O
measured O
by O
previously O
described O
methods O
11 O

dna O
analysis O
total O
dna O
from O
each O
patient O
s O
muscle O
was O
extracted O
using O
standard O
protocols O
12 O
southern O
b O
##lot O
analysis O
and O
long O
polymer O
##ase O
chain O
reaction O
pc O
##r O
were O
performed O
as O
described O
previously O
13 O
the O
gene O
for O
pink O
##1 O
was O
screened O
with O
prime O
##rs O
designed O
according O
to O
gen O
##bank O
accession O
number O
np O
00 O
##46 O
##10 O
and O
the O
gene O
for O
park O
##in O
was O
5 O

16 O
cd O
##na O
c2 O
##8 O
##39 O
##t O
see O
the O
human O
dna O
polymer O
##ase O
gamma O
mutation O
database O
for O
more O
information O
http O
dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
index O
cf O
##m O
edit O
all O
##pol O
##g O
in O
the O
polymer O
##ase O
domain O
and O
a O
novel O
g O
##7 O
##37 O
##r O
in O
ex O
##on O
13 O
cd O
##na O
g O
##24 O
##9 O
##1 O
##c O
mutation O
in O
the O
link O
##er O
region O
fig O
the O
father O
carried O
the O
g O
##7 O
##37 O
##r O
mutation O
and O
the O
mother O
carried O
the O
r O
##85 O
##3 O
##w O
mutation O
discussion O
these O
sisters O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
two O
screened O
as O
described O
previously O
the O
entire O
coding O
region O

of O
the O
pol O
##g O
gene O
was O
amplified O
by O
pc O
##r O
14 O
and O
mutations O
were O
detected O
by O
direct O
sequencing O
of O
all O
ex O
##ons O
utilizing O
intro O
##nic O
prime O
##rs O
apparently O
pathogen O
##ic O
changes O
were O
confirmed O
by O
reverse O
transcript O
##ase O
pc O
##r O
and O
by O
complementary O
dna O
cd O
##na O
sequencing O
analysis O
as O
described O
previously O
15 O
results O

the O
muscle O
bio O
##psy O
from O
patient B-PATIENT
1 I-PATIENT
showed O
2 O
to O
3 O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
rr O
##fs O
and O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibers I-HPO_TERM
focal O
fiber O
type O
grouping O
and O
scarce O
target O
##oid O
structures O
were O
also O
seen O
common O
mt O
##dna O
mutations O
for O
mel O
##as O
mitochondrial O
en O
##ce O
##pha O
##lo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
##like O
episodes O
mer O
##rf O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
and O
ragged O
red O
fiber O
disease O
and O
ne O
##uro O
##pathy O
ata O
##xia O
re O
##tin O
##itis O
pigment O
##osa O
na O
##rp O
were O
absent O
bio O
##chemical O
studies O
of O
mitochondrial O
enzyme O
showed O
increased O
ci O
##tra O
##te O
synth O
##ase O
activity O
when O
normal O
##ized O
to O
the O
nucleus O
encoded O
ci O
##tra O
##te O
synth O
##ase O
the O
activities O
of O
respiratory B-HPO_TERM
chain I-HPO_TERM
complexes I-HPO_TERM
containing I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
encoded I-HPO_TERM
subunit I-HPO_TERM
##s I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
varying O
from O
10 O
to O
18 O
of O
normal O
data O
not O
shown O
both O
his O
##to O
##logical O
and O
bio O
##chemical O
abnormalities O
were O
consistent O
with O
mitochondrial B-HPO_TERM
proliferation I-HPO_TERM
and O
a O
defect O
of O
mitochondrial O
protein O
synthesis O

the O
muscle O
bio O
##psy O
specimen O
from O
patient B-PATIENT
2 I-PATIENT
showed O

1 O
to O
2 O
rr B-HPO_TERM
##fs I-HPO_TERM
which O
were O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
mild O
focal B-HPO_TERM
fiber I-HPO_TERM
type I-HPO_TERM
grouping I-HPO_TERM
and O
sparse O
target O
##oid O
fibers O
consistent O
with O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
the O
activity O
of O
ci O
##tra O
##te O
synth O
##ase O
was O
not O
increased O
but O
when O
respiratory O
chain O
enzyme O
activities O
were O
referred O
to O
the O
activity O
of O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
another O
nucleus O
##en O
##code O
##d O
enzyme O
all O
complexes O
containing O
mt O
##dna O
##en O
##code O
##d O
subunit O
##s O
were O
decreased O
with O
residual O
activities O
varying O
from O
40 O
to O
60 O
of O
normal O
data O
not O
shown O
real O
time O
pc O
##r O
showed O
only O
37 O
mt O
##dna O
de O
##ple O
##tion O
and O
southern O
b O
##lot O
analysis O
for O
multiple O
del O
##eti O
##ons O
was O
negative O
on O
two O
occasions O
however O
long O
pc O
##r O
ass O
##ays O
showed O
multiple O
del O
##eti O
##ons O
direct O
sequencing O
of O
the O
mt O
##dna O
genes O
encoding O
the O
seven O
subunit O
##s O
of O
complex O
i O
cy O
##to O
##chrome O
b O
and O
12 O
##s O
rna O
demonstrated O
only O
some O
known O
non O
##path O
##ogenic O
poly O
##morphism O
##s O
the O
nuclear O
genes O
encoding O
park O
##in O
and O
pink O
##1 O
were O
also O
normal O
however O
dna O
and O
cd O
##na O
sequencing O
of O
the O
catalytic O
subunit O
of O
pol B-GENE
##g I-GENE
gen O
##bank O
accession O
numbers O
np O
00 O
##26 O
##8 O
##4 O
and O
nm O
00 O
##26 O
##9 O
##3 O
showed O
the O
already O
reported O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
in O
ex O
##on O

miss O
##ense O
mutations O
in O
the O
pol B-GENE
##g I-GENE
gene O
a O
novel O
g B-GENE_VARIANT
##7 I-GENE_VARIANT
##37 I-GENE_VARIANT
##r I-GENE_VARIANT
mutation O
and O
the O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
which O
had O
been O
associated O
with O
pe O
##o O
see O
the O
human O
dna O
polymer O
##ase O
gamma O
mutation O
database O
for O
more O
information O
http O

dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
index O
cf O
##m O
edit O
all O
##pol O
##g O
we O
consider O
these O
mutations O
to O
be O
pathogen O
##ic O
for O
several O
reasons O
first O
although O
the O
clinical O
ph O
##eno O
##type O
is O
at O
##yp O
##ical O
there O
is O
a O
good O
correlation O
between O
gen O
##otype O
and O
bio O
##chemical O
and O
molecular O
ph O
##eno O
##type O
second O
the O
r B-GENE_VARIANT
##85 I-GENE_VARIANT
##3 I-GENE_VARIANT
##w I-GENE_VARIANT
mutation O
already O
documented O
as O
pathogen O
##ic O
is O
in O
the O
polymer O
##ase O
domain O
where O
the O
catalytic O
function O
resides O
whereas O
the O
novel O
mutation O
affects O
the O
link O
##er O
region O
and O
changes O
in O
this O
domain O
have O
been O
associated O
with O
severe O
manifestation O
##s O
16 O
third O
this O
latter O
mutation O
alter O
##s O
a O
highly O
conserved O
site O
table O
1 O
finally O
both O
mutations O
were O
absent O
in O
more O
than O
100 O
controls O

the O
clinical O
presentation O
in O
these O
sisters O
was O
dominated O
by O
parkinson B-HPO_TERM
##ism I-HPO_TERM
and O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
this O
disorder O
differed O
from O
id O
##io O
##pathic O
pd O
because O
of O
early O
onset O
symmetrical O
involvement O
post B-HPO_TERM
##ural I-HPO_TERM
action I-HPO_TERM
tremor I-HPO_TERM
but O
no O
resting O
tremor O
in O
the O
four O
limbs O
and O
incomplete O
l O
do O
##pa O
response O
in O
both O
patients O
the O
clinical O
and O
electro O
##phy O
##sio O
##logical O
evidence O
of O
a O
predominantly O
sensory B-HPO_TERM
poly I-HPO_TERM
##ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
was O
also O
distinctive O
and O
at O
##yp O
##ical O
for O
pd O
anxiety B-HPO_TERM
was O
notable O
in O
both O
sisters O
and O
dated O
back O
to O
childhood O
in O
patient O
1 O
this O
is O
interesting O
because O
anxiety O
is O
commonly O
experienced O
by O
patients O
with O
id O
##io O
##pathic O
pd O
and O
may O
pre O
##cede O
motor O
symptoms O
by O
two O
decades O
or O
more O
17 O
the O
presenting O

fig O
electro O
##pher O
##og O
##ram O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
sequence O
showing O
the O
novel O
g B-GENE_VARIANT
##24 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##c I-GENE_VARIANT
substitution O
under O
##lined O
resulting O
in O
a O
g B-GENE_VARIANT
##7 I-GENE_VARIANT
##37 I-GENE_VARIANT
##r I-GENE_VARIANT
amino O
acid O
change O
86 O
##0 O
annals O
of O
ne O
##uro O
##logy O
vol O
59 O
no O
5 O
may O
2006 O
table O
regions O
of O
pol O
##g O
##1 O
containing O
g O
##ly O
##cine O
wild O
type O
or O
ar O
##gin O
##ine O
mu O
##tated O
at O
position O
737 O
are O
aligned O
with O
sequences O
of O
pol O
##g O
##1 O
from O
other O
species O

ar O
##gg O
##p O
##k O
##dt O
##q O
##psy O
##hh O
##gn O
##rp O
##yn O
##d O
##vd O
##ip O
##gc O
##w O
##ff O
##k O
##l O
patients O
ar O
##gg O
##p O
##k O
##dt O
##q O
##psy O
##hh O
##gn O
##gp O
##yn O
##d O
##vd O
##ip O
##gc O
##w O
##ff O
##k O
##l O
homo O
sap O
##iens O
aa O
##gg O
##p O
##kas O
##q O
##pa O
##y O
##hh O
##gn O
##gp O
##yn O
##d O
##vd O
##ip O
##gc O
##w O
##ff O
##k O
##l O
bo O
##s O
tau O
##rus O
aa O
##cap O
##ks O
##s O
##q O
##pt O
##y O
##hh O
##gn O
##gp O
##yn O
##d O
##vn O
##ip O
##gc O
##w O
##ff O
##k O
##l O
mu O
##s O
mu O
##scu O
##lus O
vs O
##ras O
##al O
##g O
##q O
##pa O
##y O
##hh O
##gn O
##gp O
##yn O
##d O
##vd O
##ip O
##gc O
##w O
##ff O
##k O
##l O
can O
##is O
familiar O
##is O
le O
##l O
##ve O
##ess O
##q O
##ps O
##f O
##hh O
##gn O
##gp O
##yn O
##d O
##vn O
##ip O
##gc O
##w O
##ff O
##k O
##l O
gall O
##us O
gall O
##us O
sv O
##fk O
##sl O
##nge O
##cp O
##y O
##hh O
##gn O
##gp O
##yn O
##d O
##vn O
##ip O
##gc O
##w O
##ff O
##k O
##l O
dani O
##o O
re O
##rio O
d O
##gt O
##lp O
##e O
##q O
##s O
##q O
##chy O
##hh O
##gn O
##gp O
##ys O
##d O
##vd O
##v O
##pg O
##c O
##w O
##ff O
##k O
##l O
te O
##tra O
##odon O
ni O
##gr O
##ov O
##iri O
##dis O
sy O
##mpt O
##om O
of O
d O
##yst O
##onic O
toe O
curling O
in O
both O
sisters O
is O
also O
common O
in O
id O
##io O
##pathic O
pd O
patient B-PATIENT
2 I-PATIENT
also O
suffered O
from O
depression B-HPO_TERM
which O
has O
been O
associated O
with O
pd O
and O
with O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
9 O

in O
contrast O
in O
the O
absence O
of O
pe O
##o O
no O
clinical O
clues O
pointed O
to O
a O
mitochondrial O
disorder O
which O
was O
suggested O
only O
by O
the O
increased O
blood O
lac O
##tate O
in O
patient B-PATIENT
1 I-PATIENT
and O
by O
the O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
negative I-HPO_TERM
rr B-HPO_TERM
##fs I-HPO_TERM
in O
the O
muscle O
bio O
##ps O
##ies O
of O
both O
patients O
parkinson O
##ism O
has O
been O
described O
in O
a O
few O
families O
with O
mt O
##dna O
mutations O
including O
a O
micro O
##del O
##eti O
##on O
in O
the O
cy O
##to O
##chrome O
b O
gene O
##18 O
and O
a O
mutation O
in O
the O
12 O
##s O
rib O
##osomal O
rna O
gene O
19 O
but O
is O
not O
a O
common O
presentation O
of O
primary O
mt O
##dna O
related O
syndrome O
##s O

in O
contrast O
parkinson O
##ism O
has O
been O
reported O
in O
several O
patients O
with O
pe O
##o O
and O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
muscle O
due O
to O
mutations O
in O
pol O
##g O
##1 O
the O
largest O
series O
included O
seven O
families O
from O
finland O
sweden O
and O
the O
united O
kingdom O
and O
the O
clinical O
picture O
was O
characterized O
by O
pe O
##o O
parkinson O
##ism O
and O
premature O
men O
##opa O
##use O
9 O
transmission O
was O
auto O
##som O
##al O
recess O
##ive O
in O
one O
family O
and O
auto O
##som O
##al O
dominant O
in O
all O
others O
we O
have O
also O
described O
a O
us O
family O
with O
auto O
##som O
##al O
dominant O
pe O
##o O
ne O
##uro O
##pathy O
h O
##yp O
##ogo O
##nad O
##ism O
and O
parkinson O
##ism O
20 O
there O
are O
several O
interesting O
differences O
between O
the O
patients O
in O
these O
families O
and O
the O
two O
sisters O
described O
here O
first O
all O
other O
patients O
had O
pe O
##o O
which O
had O
invariably O
preceded O
the O
appearance O
of O
parkinson O
##ism O
by O
several O
years O
second O
the O
age O
at O
onset O
of O
parkinson O
##ism O
ranged O
from O
36 O
to O
75 O
years O
in O
the O
european O
families O
and O
was O
46 O
years O
in O
the O
us O
patient O
whereas O
both O
sisters O
described O
here O
started O
showing O
parkinson O
##ian O
symptoms O
in O
their O
20 O
s O
interesting O
##ly O
the O
age O
at O
onset O
was O
younger O
36 O
46 O
years O
in O
the O
one O
european O
family O
with O
auto O
##som O
##al O
recess O
##ive O
inheritance O
and O
those O
patients O
were O
similar O
to O
ours O
compound O
het O
##ero O
##zy O
##go O
##tes O
for O
pol O
##g O
mutations O
third O
parkinson O
##ism O
was O
part O
of O
complex O
syndrome O
##s O
in O
previous O
reports O
whereas O
the O
only O
major O
additional O
clinical O
feature O
in O
our O
patients O
was O
peripheral O
ne O
##uro O
##pathy O
as O
a O
consequence O
these O
two O
sisters O
presented O
as O
juvenile O
pd O
leading O
us O
to O
suspect O
pink O
##1 O
mutations O
before O
sequencing O
pol O
##g O
a O
step O
that O
was O
motivated O
by O
the O
coe O
##xi O
##sten O
##ce O
of O
peripheral O
ne O
##uro O
##pathy O
and O
by O
presence O
of O
rr O
##fs O
and O
multiple O

mt O
##dna O
del O
##eti O
##ons O
albeit O
detected O
only O
by O
long O
pc O
##r O
in O
muscle O
we O
conclude O
that O
mutations O
in O
pol O
##g O
have O
to O
be O
included O
in O
the O
differential O
diagnosis O
of O
fa O
##mi O
##lia O
##l O
early O
##ons O
##et O
parkinson O
##ism O
even O
in O
the O
absence O
of O
pe O
##o O
this O
study O
was O
supported O
by O
the O
ni O
##h O
national O
institute O
for O
neurological O
disorders O
and O
stroke O
ns O
##11 O
##7 O
##66 O
m O
h O
s O
d O
m O
national O
institute O
of O
child O
health O
and O
development O
hd O
##32 O
##0 O
##6 O
##2 O
s O
d O
m O
the O
muscular O
d O
##yst O
##rop O
##hy O
association O
m O
h O
s O
d O
m O
and O
the O
marriott O
mitochondrial O
disorder O
clinical O
research O
fund O
m O
h O
s O
d O
m O
references O

mi O
##zu O
##no O
y O
yo O
##shin O
##o O
h O
ike O
##be O
s O
i O
et O
al O
mitochondrial O
dysfunction O
in O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
1998 O
44 O
su O
##pp O
##l O
1 O
s O
##9 O
##9 O
s O
##10 O
##9 O
v O
##yas O
i O
he O
##ik O
##ki O
##la O
re O
nick O
##las O
w O
##j O
studies O
on O
the O
ne O
##uro O
##to O
##xi O
##city O
of O
1 O
methyl O
4 O
ph O
##en O
##yl O
1 O
2 O
5 O
6 O
te O
##tra O
##hy O
##drop O
##iri O
##dine O
inhibition O
of O
nad O
linked O
substrate O
oxidation O
by O
its O
meta O
##bol O
##ite O
1 O
methyl O
4 O
##py O
##rid O
##inium O
j O
ne O
##uro O
##che O
##m O
1986 O
46 O
150 O
##1 O
150 O
##7 O
dim O
##aur O
##o O
s O
mitochondrial O
involvement O
in O
parkinson O
s O
disease O
the O
controversy O
continues O
ne O
##uro O
##logy O
1993 O
43 O
217 O
##0 O
217 O
##2 O

vale O
##nte O
em O
ab O
##ou O
sl O
##eim O
##an O
pm O
cap O
##uto O
v O
et O
al O
hereditary O
early O
onset O
parkinson O
s O
disease O
caused O
by O
mutations O
in O
pink O
##1 O
science O
2004 O
304 O
115 O
##8 O
116 O
##0 O
abbas O
n O
luck O
##ing O
cb O
rica O
##rd O
s O
et O
al O
a O
wide O
variety O
of O
mutations O
in O
the O
park O
##in O
gene O
are O
responsible O
for O
auto O
##som O
##al O
recess O
##ive O
parkinson O
##ism O
in O
europe O
hum O
mo O
##l O
gene O
##t O
1999 O
8 O
56 O
##7 O
57 O
##4 O
bea O
##l O
m O
##f O
mit O
##och O
##ond O
##ria O
take O
center O
stage O
in O
aging O
and O
ne O
##uro O
##de O
##gen O
##eration O
ann O
ne O
##uro O
##l O
2005 O
58 O
495 O
505 O
spin O
##az O
##zo O
##la O
a O
zev O
##iani O
m O
disorders O
of O
nuclear O
mitochondrial O
inter O
##gen O
##omic O
signaling O
gene O
2005 O
354 O
162 O
168 O

long O
##ley O
m O
##j O
bien O
##stock O
r O
##j O
copeland O
wc O
consequences O
of O
mutations O
in O
human O
dna O
polymer O
##ase O
gamma O
gene O
2005 O
18 O
125 O
131 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O
sci O
##ac O
##co O
m O
bon O
##illa O
e O
cy O
##to O
##chemist O
##ry O
and O
im O
##mun O
##oc O
##yt O
##oche O
##mist O
##ry O
of O
mit O
##och O
##ond O
##ria O
in O
tissue O
sections O
met O
##h O
en O
##zy O
##mo O
##l O
1996 O
264 O
50 O
##9 O
521 O
dim O
##aur O
##o O
s O
ser O
##vid O
##ei O
s O
zev O
##iani O
m O
et O
al O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
deficiency O
in O
leigh O
syndrome O
ann O
ne O
##uro O
##l O
1987 O
22 O
49 O
##8 O
50 O
##6 O

sam O
##brook O
j O
russell O
d O
##w O
molecular O
cl O
##oning O
a O
laboratory O
manual O
cold O
spring O
harbor O
cold O
spring O
harbor O
laboratory O
press O
2001 O
6 O
4 O
6 O
11 O
david O
##zon O
et O
al O
pol O
##g O
mutations O
in O
parkinson O
##ism O
86 O
##1 O
ni O
##shi O
##ga O
##ki O
y O
mart O
##i O
ra O
hi O
##rano O
m O
n O
##d O
##5 O
is O
a O
hot O
##sp O
##ot O
for O
multiple O
at O
##yp O
##ical O
mitochondrial O
dna O
del O
##eti O
##ons O
in O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
hum O
mo O
##l O
gene O
##t O
2004 O
13 O
91 O
101 O
fi O
##los O
##to O
m O
man O
##cus O
##o O
m O
ni O
##shi O
##ga O
##ki O
y O
et O
al O
clinical O
and O
genetic O
het O
##ero O
##gen O
##eit O
##y O
in O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
due O
to O
mutations O
in O
polymer O
##ase O
y O
arch O
ne O
##uro O
##l O
2003 O
60 O
127 O
##9 O
128 O
##4 O

tay O
sk O
##h O
ak O
##man O
ho O
chung O
w O
##k O
et O
al O
fatal O
infant O
##ile O
ne O
##uro O
##mus O
##cular O
presentation O
of O
g O
##ly O
##co O
##gen O
storage O
disease O
type O
iv O
ne O
##uro O
##mus O
##c O
di O
##sor O
##d O
2004 O
14 O
253 O
260 O
lu O
##oma O
pt O
lu O
##o O
n O
los O
##cher O
w O
##n O
et O
al O
functional O
defects O
due O
to O
space O
##r O
region O
mutations O
of O
human O
mitochondrial O
dna O
polymer O
##ase O
in O
a O
family O
with O
an O
ata O
##xia O
my O
##opa O
##thy O
syndrome O
hum O
mo O
##l O
gene O
##t O
2005 O
14 O
1907 O
1920 O
shi O
##ba O
m O
bow O
##er O
j O
##h O
mara O
##gano O
##re O
d O
##m O
et O
al O
anxiety O
disorders O
and O
de O
##pressive O
disorders O
preceding O
parkinson O
s O
disease O
a O
case O
##con O
##tro O
##l O
study O
movement O
di O
##sor O
##d O
2000 O
15 O
66 O
##9 O
67 O
##7 O

de O
co O
##o O
if O
##m O
ren O
##ier O
wo O
ru O
##ite O
##nb O
##ee O
##k O
w O
et O
al O
a O
4 O
base O
pair O
del O
##eti O
##on O
in O
the O
mitochondrial O
cy O
##to O
##chrome O
b O
gene O
associated O
with O
parkinson O
##ism O
mel O
##as O
overlap O
syndrome O
ann O
ne O
##uro O
##l O
1999 O
45 O
130 O
133 O
thy O
##aga O
##raj O
##an O
d O
br O
##ess O
##man O
s O
bruno O
c O
et O
al O
a O
novel O
mitochondrial O
12 O
##s O
rr O
##na O
point O
mutation O
in O
parkinson O
##ism O
deaf O
##ness O
and O
ne O
##uro O
##pathy O
ann O
ne O
##uro O
##l O
2000 O
48 O
730 O
73 O
##6 O
man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
oh O
s O
##j O
dim O
##aur O
##o O
s O
a O
novel O
pol O
##g O
mutation O
in O
a O
family O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O
2004 O
61 O
1777 O
1779 O
rapid O
diagnosis O
of O
g O
##ly O
##cine O
en O
##ce O
##pha O
##lo O
##pathy O
by O
13 O
##c O
##gly O
##cine O
breath O
test O

shi O
##ge O
##o O
ku O
##re O
md O
1 O
stanley O
h O
ko O
##rman O
mb O
##bs O
fra O
##cp O
2 O
junk O
##o O
kan O
##no O
md O
1 O
a O
##yu O
##mi O
na O
##ris O
##awa O
md O
1 O
mit O
##sur O
##u O
ku O
##bot O
##a O
md O
3 O
to O
##shi O
##mit O
##su O
tak O
##ayan O
##agi O
md O
4 O
mas O
##aki O
tak O
##ayan O
##agi O
md O
5 O
tak O
##ashi O
sai O
##to O
md O
6 O
akira O
mats O
##ui O
md O
6 O
fu O
##mia O
##ki O
kam O
##ada O
md O
1 O
7 O
yoko O
ao O
##ki O
md O
1 O
to O
##shi O
##hiro O
oh O
##ura O
md O
8 O
and O
yo O
##ichi O
mats O
##uba O
##ra O
md O
##1 O
7 O

objective O
it O
is O
currently O
problematic O
to O
confirm O
the O
clinical O
diagnosis O
of O
g O
##ly O
##cine O
en O
##ce O
##pha O
##lo O
##pathy O
requiring O
either O
invasive O
liver O
bio O
##psy O
for O
en O
##zy O
##matic O
analysis O
of O
the O
g O
##ly O
##cine O
cleavage O
system O
or O
exhaust O
##ive O
mutation O
analysis O
because O
the O
g O
##ly O
##cine O
cleavage O
system O
breaks O
down O
g O
##ly O
##cine O
generating O
carbon O
dioxide O
we O
suppose O
that O
the O
g O
##ly O
##cine O
cleavage O
system O
activity O
could O
be O
evaluated O
in O
vivo O
by O
measuring O
exhaled O
13 O
##co O
##2 O
after O
administration O
of O
1 O
13 O
##c O
g O
##ly O
##cine O

methods O
the O
1 O
13 O
##c O
g O
##ly O
##cine O
breath O
test O
was O
performed O
in O
10 O
control O
subjects O
and O
5 O
g O
##ly O
##cine O
en O
##ce O
##pha O
##lo O
##pathy O
patients O
with O
g O
##ld O
##c O
mutation O
including O
1 O
patient O
with O
mild O
g O
##ly O
##cine O
en O
##ce O
##pha O
##lo O
##pathy O
results O
all O
the O
patients O
showed O
lower O
13 O
##co O
##2 O
ex O
##cre O
##tion O
than O
any O
control O
subject O
interpretation O
not O
only O
typical O
ge O
but O
also O
at O
##yp O
##ical O
ge O
can O
be O
re O
##lia O
##bly O
diagnosed O
by O
the O
13 O
##c O
g O
##ly O
##cine O
breath O
test O
because O
it O
is O
rapid O
non O
invasive O
and O
requires O
little O
expertise O
the O
breath O
test O
could O
be O
useful O
as O
a O
standard O
test O
for O
dia O
##gno O
##sing O
ge O
ann O
ne O
##uro O
##l O
2006 O
59 O
86 O
##2 O
86 O
##7 O

g O
##ly O
##cine O
en O
##ce O
##pha O
##lo O
##pathy O
ge O
mi O
##m O
60 O
##58 O
##9 O
##9 O
also O
termed O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##cine O
##mia O
nk O
##h O
is O
an O
in O
##born O
error O
of O
g O
##ly O
##cine O
metabolism O
caused O
by O
deficiency O

from O
the O
1 O
##de O
##par O
##tment O
of O
medical O
genetics O
to O
##ho O
##ku O
university O
school O
of O
medicine O
send O
##ai O
japan O
2 O
##met O
##ab O
##olic O
diseases O
unit O
division O
of O
pediatric O
##s O
had O
##ass O
##ah O
hebrew O
university O
medical O
center O
jerusalem O
israel O
3d O
##ep O
##art O
##ment O
of O
pediatric O
##s O
hokkaido O
university O
hospital O
sap O
##por O
##o O
4 O
##de O
##par O
##tment O
of O
pediatric O
##s O
national O
organization O
saga O
hospital O
saga O
5 O
##de O
##par O
##tment O
of O
metabolic O
disorder O
chiba O
children O
s O
hospital O
chiba O
6 O
##de O
##par O
##tment O
of O
pediatric O
##s O
institute O
of O
clinical O
medicine O
university O
of O
ts O
##uk O
##uba O
ts O
##uk O
##uba O
7 O
##to O
##ho O
##ku O
university O
21st O
coe O
program O
comprehensive O
research O
and O
education O
center O
for O
planning O
of O
drug O
development O
and O
clinical O
evaluation O
and O
8 O
##de O
##par O
##tment O
of O
pediatric O
##s O
to O
##ho O
##ku O
university O
school O
of O
medicine O
send O
##ai O
japan O

received O
jan O
14 O
2006 O
and O
in O
revised O
form O
feb O
20 O
accepted O
for O
publication O
mar O
10 O
2006 O
published O
online O
apr O
24 O
2006 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
ana O
208 O
##53 O
address O
correspondence O
to O
dr O
ku O
##re O
department O
of O
medical O
genetics O
to O
##ho O
##ku O
university O
school O
of O
medicine O
1 O
1 O
se O
##ir O
##yo O
##mac O
##hi O
ao O
##ba O
##ku O
send O
##ai O
980 O
85 O
##7 O
##4 O
japan O
e O
mail O
sk O
##ure O
mail O
tai O
##ns O
to O
##ho O
##ku O
ac O
jp O
86 O
##2 O
2006 O
american O
neurological O
association O
published O
by O
wiley O
li O
##ss O
inc O
through O
wiley O
subscription O
services O

two O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
progressive O

external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
lev O
##od O
##opa O
responsive O

pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O

fed O
##eric O
##a O
in O
##vern O
##iz O
##zi O
a O
1 O

sara O
var O
##ane O
##se O
b O
c O
1 O
astrid O
thomas O
b O
c O
franco O
carr O
##ara O
a O

marco O
ono O
##fr O
##j O
b O
c O

massimo O
zev O
##iani O
a O

a O
unit O
of O
molecular O
ne O
##uro O
##gen O
##etic O
##s O
pier O
##fra O
##nco O
e O
luisa O
marian O
##i O
center O
for O
the O
study O
of O
children O
s O
mitochondrial O
disorders O

c O
best O
##a O
neurological O
institute O
foundation O
ir O
##cc O
##s O
milan O
italy O

b O
department O
of O
on O
##cology O
neuroscience O
and O
ne O
##uro O
##phy O
##sio O
##path O
##ology O
university O
g O
d O
ann O
##un O
##zio O
chi O
##eti O
pe O
##sca O
##ra O
italy O

c O
aging O
research O
center O
ce O
s O
i O
g O
d O
ann O
##un O
##zio O
university O
foundation O
chi O
##eti O
pe O
##sca O
##ra O
italy O

received O
31 O
january O
2008 O
received O
in O
revised O
form O
31 O
january O
2008 O
accepted O
2 O
april O
2008 O

abstract O

different O
mutations O
or O
combinations O
of O
mutations O
in O
pol O
##g O
##1 O
the O
gene O
encoding O
pol O
ca O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O

polymer O
##ase O
are O
associated O
with O
a O
spectrum O
of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
parkinson O
##ian O
features O
have O
been O
reported O

as O
a O
late O
com O
##plication O
of O
pol O
##g O
##1 O
associated O
dominant O
pe O
##o O
good O
response O
to O
lev O
##od O
##opa O
or O
do O
##pa O
##mine O
ago O
##nist O
##s O
reduced O
do O
##pa O
##mine O

up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
and O
ne O
##uron O
##al O
loss O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
compact O
##a O
have O
been O
documented O
in O
a O
few O
cases O
here O

we O
report O
two O
novel O
mutations O
in O
pol O
##g O
##1 O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient O
with O
auto O
##som O
##al O
recess O
##ive O
pe O
##o O
followed O
by O
pseudo O

or O
##th O
##osta O
##tic O
tremor O
evolving O
into O
lev O
##od O
##opa O
responsive O
parkinson O
##ism O
these O
observations O
support O
the O
hypothesis O
that O
mt O
##dna O
dysfunction O

is O
engaged O
in O
the O
pathogen O
##esis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O

o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O

key O
##words O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
parkinson O
##ism O
polymer O
##ase O
gamma O
mitochondrial O
dna O
multiple O
mt O
##dna O
del O
##eti O
##ons O

1 O
introduction O

mitochondrial O
dna O
mt O
##dna O
is O
faithful O
##ly O
replicate O
##d O

by O
dna O
polymer O
##ase O
v O
pol O
v O
an O
enzyme O
composed O
of O

a O
single O
145 O
k O
##da O
catalytic O
subunit O
pol O
ca O
bound O
to O

two O
55 O
k O
##da O
accessory O
subunit O
##s O
pol O
cb O
pol O
ca O
is O
encoded O

by O
pol O
##g O
##1 O
a O
23 O
ex O
##on O
gene O
located O
on O
human O
chromosome O

15 O
functional O
genetic O
variants O
of O
pol O
##g O
##1 O
are O
present O
in O

approximately O
0 O
5 O
of O
the O
general O
population O
numerous O

pol O
##g O
##1 O
mutations O
have O
been O
associated O
with O
a O
spectrum O

of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O

recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O

juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##l O

och O
##er O
syndrome O
at O
the O
molecular O
level O
pe O
##o O
patients O
are O

characterized O
by O
the O
accumulation O
of O
a O
collection O
of O
deleted O

mt O
##dna O
species O
in O
affected O
tissues O
notably O
skeletal O
muscle O

and O
brain O
additional O
symptoms O
including O
mig O
##raine O
ep O
##i O

le O
##psy O
peripheral O
ne O
##uro O
##pathy O
ata O
##xia O
premature O
o O
##var O
##ian O

failure O
h O
##yp O
##ogo O
##nad O
##ism O
and O
male O
h O
##yp O
##of O
##ert O
##ility O
may O
occur O

in O
different O
pe O
##o O
families O
and O
with O
different O
pol O
##g O
##1 O
mu O
##ta O

ti O
##ons O
1 O
4 O
parkinson O
##ism O
is O
a O
rare O
and O
late O
onset O
com O
##pl O
##ica O

ti O
##on O
of O
pol O
##g O
##1 O
associated O
pe O
##o O
3 O
5 O
we O
report O
here O
on O
a O

patient O
presenting O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O

followed O
by O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O

molecular O
analysis O
showed O
that O
this O
patient O
is O
a O
compound O

het O
##ero O
##zy O
##go O
##us O
for O
two O
novel O
mutations O
of O
the O
pol O
##g O
##1 O
gene O

09 O
##60 O
89 O
##66 O
see O
front O
matter O
o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O

doi O
10 O
1016 O
j O
nm O
##d O
2008 O
04 O
00 O
##5 O

corresponding O
author O
fa O
##x O
39 O
02 O
239 O
##4 O
261 O
##9 O

e O
mail O
address O
zev O
##iani O
ist O
##it O
##uto O
best O
##a O
it O
m O
zev O
##iani O

1 O
these O
authors O
contributed O
equally O
to O
this O
work O

www O
else O
##vier O
com O
locate O
nm O
##d O

ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

2 O
case O
description O

the O
patient O
is O
a O
54 O
year O
old O
yo O
man O
from O
central O
italy O

his O
father O
died O
at O
71 O
years O
of O
lung O
cancer O
had O
non O
insulin O

dependent O
diabetes O
mel O
##lit O
##us O
but O
was O
free O
from O
any O
ne O
##uro O

logical O
sy O
##mpt O
##om O
the O
82 O
yo O
mother O
a O
47 O
yo O
brother O
and O

two O
29 O
and O
24 O
yo O
daughters O
are O
all O
alive O
and O
well O
the O
pro O

po O
##sit O
##us O
was O
born O
at O
term O
after O
an O
uneven O
##tf O
##ul O
pregnancy O
in O

contrast O
to O
what O
was O
reported O
previously O
6 O
this O
patient O

developed O
pe O
##o O
with O
bilateral O
pt O
##osis O
at O
30 O
years O
of O
age O
f O
##ol O

lowe O
##d O
by O
progressive O
d O
##ys O
##phon O
##ia O
with O
rhino O
##lal O
##ia O
d O
##ys O
##pha O
##gia O

pro O
##xi O
##mal O
muscle O
weakness O
and O
wasting O
and O
tend O
##on O
are O

flex O
##ia O
reduction O
of O
cal O
##oric O
intake O
caused O
by O
severe O
d O
##ys O

ph O
##agi O
##a O
and O
the O
onset O
of O
chronic O
dia O
##rr O
##hoe O
##a O
resulted O
in O

severe O
body O
weight O
loss O
at O
50 O
years O
of O
age O
the O
patient O

developed O
tremor O
in O
the O
standing O
position O
dominant O
fr O
##e O

que O
##ncy O
at O
6 O
2 O
hz O
initially O
affecting O
the O
left O
lower O
limb O
then O

both O
lower O
limbs O
with O
occasional O
mild O
resting O
tremor O
of O

the O
hands O
this O
patient O
was O
included O
in O
a O
recent O
report O

on O
4 O
cases O
affected O
by O
lev O
##od O
##opa O
responsive O
pseudo O
or O
##th O
##o O

static O
tremor O
in O
parkinson O
##ism O
case O
3 O
in O
6 O
in O
the O
follow O

ing O
2 O
years O
he O
developed O
extra O
pyramid O
##al O
rigid O
##ity O
with O
a O

co O
##g O
##wheel O
sign O
reduced O
tapping O
left O
right O
and O
post O
##ural O

instability O
unified O
parkinson O
s O
disease O
rating O
scale O

up O
##dr O
##s O
motor O
score O
21 O
points O
physical O
examination O

showed O
a O
h O
##yp O
##omi O
##mic O
face O
h O
##yp O
##op O
##hon O
##ia O
bilateral O
pt O
##osis O

op O
##ht O
##hal O
##mo O
##ple O
##gia O
mild O
symmetrical O
pro O
##xi O
##mal O
muscle O
weak O

ness O
medical O
research O
council O
grade O
4 O
and O
absence O
of O

lower O
limb O
tend O
##on O
reflex O
##es O
an O
ec O
##g O
and O
structural O
brain O

mri O
were O
both O
normal O
a O
single O
photon O
emission O
com O

put O
##ed O
tom O
##ography O
spec O
##t O
using O
123 O
i O
2 O
##b O
car O
##bo O
##me O

tho O
##xy O
3 O
##b O
4 O
io O
##do O
##ph O
##en O
##yl O
n O
3 O
flu O
##oro O
##pro O
##py O
##l O
nor O
##tro O
##pan O
##e O

i O
f O
##p O
ci O
##t O
spec O
##t O
revealed O
a O
bilateral O
##ly O
reduced O
do O
##pa O

mine O
up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
right O
left O
serum O

cr O
##ea O
##tine O
kinase O
ck O
level O
was O
215 O
##6 O
u O
l O
normal O
140 O

u O
l O
an O
em O
##g O
was O
compatible O
with O
ax O
##onal O
sensory O
ne O
##u O

ro O
##pathy O
associated O
with O
my O
##opa O
##thic O
features O
the O
patient O

was O
initially O
treated O
with O
low O
doses O
of O
do O
##pa O
##mine O
ago O
##nist O
##s O

pr O
##ami O
##pe O
##x O
##ole O
2 O
1 O
mg O
day O
associated O
with O
lev O
##od O
##opa O
up O
to O

400 O
mg O
day O
with O
disappearance O
of O
standing O
legs O
tremor O

and O
reduction O
in O
up O
##dr O
##s O
motor O
score O

two O
years O
later O
he O
complained O
of O
end O
of O
dose O
deter O
##ior O
##a O

ti O
##on O
with O
re O
occurrence O
of O
the O
di O
##sa O
##bling O
standing O
tremor O

which O
appeared O
1 O
5 O
2 O
5 O
h O
after O
each O
single O
lev O
##od O
##opa O

up O
##dr O
##s O
motor O
score O
was O
27 O
in O
on O
state O
and O
42 O
in O
off O

state O
and O
was O
associated O
with O
severe O
anxiety O
and O
panic O

attacks O
during O
the O
off O
states O
lev O
##od O
##opa O
was O
increased O

to O
600 O
mg O
day O
and O
en O
##ta O
##cap O
##one O
was O
added O
1200 O
mg O
day O

the O
patient O
did O
not O
report O
further O
fluctuations O
for O
the O
next O

6 O
months O
when O
he O
developed O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
re O

occurrence O
of O
end O
of O
dose O
deterioration O
and O
severe O
stand O

ing O
tremor O
en O
##ta O
##cap O
##one O
was O
substituted O
with O
to O
##lc O
##ap O
##one O

100 O
mg O
t O
i O
d O
with O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
and O
off O
state O

since O
then O
d O
##ys O
##pha O
##gia O
has O
progressively O
worsened O
with O
fur O

the O
##r O
loss O
of O
weight O
because O
of O
mal O
##nut O
##rit O
##ion O
requiring O
the O

positioning O
of O
a O
per O
##cut O
##aneous O
end O
##os O
##copic O
gas O
##tro O
##sto O
##my O
for O

enter O
##al O
nutrition O
onset O
of O
vent O
##ila O
##tory O
failure O
has O
required O

mechanical O
ventilation O
the O
serum O
ck O
level O
remains O
high O

61 O
##43 O
u O
l O
with O
worse O
##ning O
and O
spreading O
of O
the O
muscle O

weakness O
high O
serum O
ck O
is O
an O
unusual O
but O
occasionally O

reported O
finding O
in O
pol O
##g O
##1 O
associated O
pe O
##o O
with O
multiple O

mt O
##dna O
del O
##eti O
##ons O
for O
instance O
hudson O
et O
al O
5 O
report O
a O

patient O
individual O
ii O
8 O
with O
serum O
ck O
levels O
2500 O
u O
l O

the O
tremor O
and O
the O
off O
state O
now O
occur O
1 O
5 O
2 O
h O
after O

lev O
##od O
##opa O
administration O
which O
must O
be O
repeated O
7 O
8 O
times O

per O
day O
in O
the O
last O
months O
the O
patient O
has O
also O
developed O

progressive O
cognitive O
dysfunction O
associated O
with O
psychotic O

features O

3 O
methods O

southern O
b O
##lot O
analysis O
of O
mt O
##dna O
was O
carried O
out O
on O

dna O
extracted O
from O
skeletal O
muscle O
following O
standard O

procedures O
7 O
and O
using O
the O
ec O
##l O
che O
##mi O
##lum O
##ines O
##cence O
as O

the O
detection O
method O
dna O
from O
peripheral O
blood O
l O
##ym O

ph O
##ocytes O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
the O
22 O
coding O

ex O
##ons O
of O
the O
pol O
##g O
##1 O
gene O
ex O
##ons O
223 O
polymer O
##ase O
chain O

reaction O
pc O
##r O
conditions O
were O
96 O
for O
30 O
s O
56 O
for O

20 O
s O
and O
72 O
for O
60 O
s O
for O
30 O
cycles O
plus O
as O
initial O
den O
##at O
##ur O

at O
##ion O
step O
at O
96 O
for O
2 O
min O
pc O
##r O
fragments O
were O
ana O

l O
##y O
##zed O
by O
automated O
nu O
##cle O
##otide O
sequencing O
using O
the O
big O

dye O
term O
##inator O
ready O
reaction O
kit O
version O
2 O
on O
a O
310 O
##0 O

genetic O
analyze O
##r O
automated O
sequence O
##r O
applied O
bio O
##sy O
##s O

te O
##ms O
the O
sequence O
variants O
found O
in O
the O
patient O
were O

searched O
for O
in O
available O
relatives O
as O
well O
as O
in O
100 O
con O
##se O
##c O

ut O
##ive O
control O
subjects O
200 O
all O
##eles O

4 O
results O

a O
skeletal O
muscle O
bio O
##psy O
taken O
when O
the O
patient O
was O
32 O

years O
old O
showed O
the O
presence O
of O
several O
ragged O
red O
fibers O

with O
variation O
of O
fiber O
caliber O
and O
nuclear O
central O
##ization O

and O
reduced O
or O
absent O
react O
##ivity O
to O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O

fig O
1a O
sequence O
analysis O
of O
mt O
##dna O
excluded O
the O
pre O
##s O

en O
##ce O
of O
point O
mutations O
commonly O
associated O
with O

mer O
##rf O
and O
mel O
##as O
however O
southern O
b O
##lot O
analysis O

revealed O
the O
presence O
of O
a O
collection O
of O
deleted O
mt O
##dna O

species O
in O
addition O
to O
wild O
type O
mt O
##dna O
fig O
1b O
6 O

these O
results O
prompted O
us O
to O
consider O
the O
possibility O

of O
mutation O
s O
in O
one O
of O
the O
nucleus O
encoded O
genes O
com O

mon O
##ly O
associated O
with O
mt O
##dna O
instability O
and O
pe O
##o O

namely O
twinkle O
ant O
##1 O
and O
pol O
##g O
##1 O
sequence O
analysis O

of O
the O
first O
two O
genes O
ruled O
out O
the O
presence O
of O
path O
##o O

gen O
##ic O
mutations O
however O
sequence O
analysis O
of O
the O
entire O

coding O
region O
of O
the O
pol O
##g O
##1 O
gene O
led O
us O
to O
the O
id O
##ent O
##if O
##i O

cat O
##ion O
of O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
mutations O
one O
is O
a O

c O
128 O
##8 O
##a O
t O
trans O
##version O
predicting O
a O
p O
m O
##43 O
##0 O
##l O
amino O

acid O
substitution O
the O
second O
is O
a O
c O
275 O
##2 O
##t O
c O
transition O

determining O
the O
amino O
##ac O
##id O
substitution O
p O
w O
##9 O
##18 O
##r O

fig O
2a O
segregation O
analysis O
carried O
out O
in O
available O

members O
of O
the O
family O
fig O
2 O
##b O
revealed O
the O
presence O

of O
the O
275 O
##2 O
##t O
c O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
the O
mother O

of O
the O
patient O
and O
in O
the O
two O
healthy O
daughters O
while O

no O
mutation O
was O
detected O
in O
his O
brother O

f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
46 O
##1 O

5 O
discussion O

we O
found O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
in O

a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient O
characterized O
by O
pe O
##o O

muscle O
weakness O
and O
later O
onset O
lev O
##od O
##opa O
responsive O

pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
6 O

the O
maternal O
all O
##ele O
predict O
##s O
a O
p O
w O
##9 O
##18 O
##r O
amino O
##ac O
##id O
sub O

st O
##it O
##ution O
in O
a O
highly O
conserved O
position O
in O
the O
pol O
ca O
poly O

mer O
##ase O
domain O
http O
dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
8 O

the O
paternal O
all O
##ele O
harbor O
##s O
a O
c O
128 O
##8 O
##a O
t O
trans O
##version O
pre O

di O
##cting O
the O
replacement O
of O
the O
p O
m O
##43 O
##0 O
residue O
into O
an O
l O

residue O
m O
##43 O
##0 O
is O
contained O
within O
the O
so O
called O
space O
##r O

fig O
1 O
morphological O
and O
molecular O
findings O
in O
skeletal O
muscle O
a O
top O
panel O
nad O
##h O
de O
##hy O
##dro O
##genase O
stain O
##ing O
shows O
rr O
##f O
as O
##ter O
##isk O
##s O
bottom O
panel O

cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
stain O
##ing O
of O
a O
serial O
muscle O
section O
shows O
several O
fibers O
with O
reduced O
or O
absent O
react O
##ivity O
including O
the O
same O
two O
rr O
##f O
shown O
in O
the O

top O
panel O
as O
##ter O
##isk O
##s O
b O
southern O
b O
##lot O
analysis O
on O
pv O
##ui O
##i O
linear O
##ized O
mt O
##dna O
performed O
on O
the O
muscle O
bio O
##psy O
of O
the O
patient O
p O
and O
a O
control O
c O
both O
p O

and O
c O
samples O
show O
a O
16 O
6 O
kb O
band O
corresponding O
to O
wild O
type O
mt O
##dna O
arrow O
in O
addition O
the O
p O
sample O
shows O
a O
collection O
of O
smaller O
bands O

corresponding O
to O
del O
##eti O
##on O
containing O
mt O
##dna O
species O

fig O
2 O
a O
identification O
of O
pol O
##g O
##1 O
mutations O
by O
sequence O
analysis O
the O
electro O
##pher O
##og O
##ram O
##s O
show O
the O
c O
128 O
##8 O
##a O
t O
trans O
##version O
predicting O
a O
p O
m O
##43 O
##0 O
##l O

amino O
##ac O
##id O
substitution O
and O
the O
c O
275 O
##2 O
##t O
c O
transition O
predicting O
a O
p O
w O
##9 O
##18 O
##r O
amino O
##ac O
##id O
substitution O
b O
family O
pe O
##di O
##gree O
the O
solid O
black O
square O
symbol O

indicates O
the O
pro O
##band O
open O
symbols O
indicate O
unaffected O
individuals O
the O
and O
symbols O
indicate O
mutant O
vs O
wild O
type O
all O
##eles O
c O
multiple O

alignment O
of O
mutation O
containing O
pol O
ca O
regions O
in O
different O
species O
the O
red O
boxes O
indicate O
the O
amino O
##ac O
##id O
substitution O
##s O
found O
in O
the O
patient O

46 O
##2 O
f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

domain O
a O
region O
encompassing O
the O
mid O
##port O
##ion O
of O
pol O
ca O

which O
in O
multi O
##cellular O
eu O
##kar O
##yo O
##tes O
interact O
##s O
with O
two O
pol O
cb O

accessory O
subunit O
##s O
to O
form O
a O
functional O
##ly O
active O
trim O
##eric O

ho O
##loe O
##nz O
##yme O
pol O
cb O
or O
##th O
##olo O
##gs O
are O
absent O
in O
fungi O
which O

can O
explain O
why O
m O
##43 O
##0 O
is O
conserved O
in O
meta O
##zo O
##an O
pol O
ca O

sequences O
but O
not O
in O
fungal O
or O
##th O
##olo O
##gs O
for O
instance O

mi O
##p O
##1 O
in O
sac O
##cha O
##rom O
##yce O
##s O
ce O
##re O
##vis O
##iae O
fig O
2 O
##c O
segregation O

analysis O
in O
the O
family O
and O
absence O
of O
either O
mutation O
in O

200 O
control O
all O
##eles O
further O
support O
the O
pathogen O
##ic O
role O
of O

the O
mutations O

the O
role O
of O
pol O
##g O
##1 O
genetic O
variants O
in O
the O
pathogen O
##esis O

of O
parkinson O
##ism O
is O
suggested O
by O
several O
reports O
parkinson O

is O
##m O
was O
documented O
in O
13 O
affected O
members O
of O
five O
out O
of O

seven O
pol O
##g O
##1 O
mutant O
pe O
##o O
families O
reported O
by O
lu O
##oma O

et O
al O
3 O
three O
of O
these O
families O
displayed O
dominant O
trans O

mission O
of O
the O
trait O
and O
were O
found O
to O
carry O
a O
het O
##ero O
##zy O
##go O
##us O

c O
286 O
##4 O
##a O
g O
p O
y O
##9 O
##55 O
##c O
mutation O
one O
of O
the O
most O
com O

mon O
pathogen O
##ic O
variants O
of O
pol O
##g O
##1 O
9 O
in O
two O
additional O

families O
both O
parkinson O
##ism O
and O
pe O
##o O
were O
transmitted O
as O

an O
allegedly O
recess O
##ive O
trait O
however O
while O
the O
three O

affected O
members O
of O
the O
first O
of O
these O
families O
carried O
two O

all O
##eli O
##c O
pol O
##g O
##1 O
mutations O
namely O
c O
140 O
##2 O
##a O
g O

p O
n O
##46 O
##8 O
##d O
and O
c O
331 O
##3 O
##g O
a O
p O
a1 O
##10 O
##5 O
##t O
only O
the O
latter O

was O
found O
in O
het O
##ero O
##zy O
##gos O
##ity O
in O
the O
single O
patient O
of O
the O
sec O

on O
##d O
family O
good O
response O
to O
lev O
##od O
##opa O
was O
documented O
in O

all O
patients O
to O
whom O
this O
treatment O
had O
been O
given O

five O
additional O
pol O
##g O
##1 O
mutant O
patients O
belonging O
to O

three O
families O
were O
described O
with O
a O
combination O
of O
pe O
##o O

and O
parkinson O
##ism O
but O
in O
some O
of O
these O
cases O
the O
path O
##o O

gen O
##ic O
role O
of O
the O
mutations O
remains O
controversial O
this O
is O

the O
case O
for O
a O
family O
including O
a O
49 O
yo O
woman O
with O
auto O
##so O

mal O
dominant O
pe O
##o O
ne O
##uro O
##pathy O
h O
##yp O
##ogo O
##nad O
##ism O
and O
par O

kin O
##son O
##ism O
and O
her O
59 O
yo O
brother O
with O
over O
##t O
parkinson O
##ian O

features O
4 O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
in O

muscle O
and O
a O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
miss O
##ense O
mutation O

c O
249 O
##2 O
##a O
g O
leading O
to O
p O
y O
##8 O
##31 O
##c O
amino O
##ac O
##id O
replacement O

were O
found O
in O
the O
pro O
##band O
and O
her O
affected O
brother O
the O

patient O
was O
successfully O
treated O
with O
lev O
##od O
##opa O
however O

the O
c O
249 O
##2 O
##a O
g O
transition O
has O
been O
reported O
in O
about O

2 O
of O
control O
subjects O
in O
poland O
and O
in O
normal O
controls O

in O
finn O
##s O
10 O
11 O
and O
italians O
m O
##z O
and O
fi O
personal O
ob O
##ser O

va O
##tion O
these O
observations O
suggest O
that O
the O
p O
y O
##8 O
##31 O
##c O
ami O

no O
##ac O
##id O
substitution O
is O
a O
non O
pathogen O
##ic O
variant O
in O
different O

european O
populations O

a O
second O
family O
included O
several O
pe O
##o O
patients O
one O
also O

being O
affected O
by O
parkinson O
##ism O
in O
this O
family O
auto O
##som O
##al O

dominant O
pe O
##o O
segregated O
with O
a O
c O
153 O
##2 O
##g O
a O
het O
##ero O
##zy O

go O
##us O
miss O
##ense O
mutation O
p O
s O
##51 O
##1 O
##n O
in O
ex O
##on O
8 O
in O
comb O
##ina O

ti O
##on O
with O
an O
intro O
##nic O
variant O
c O
207 O
##0 O
c O
158 O
##g O
a O
in O
cis O

5 O
the O
subject O
also O
affected O
by O
parkinson O
##ism O
was O
found O

to O
carry O
an O
all O
##eli O
##c O
in O
trans O
change O
c O
138 O
##9 O
##g O
t O
p O
l O
##46 O
##3 O
##f O

the O
pathogen O
##ic O
role O
of O
which O
is O
as O
yet O
not O
determined O

although O
the O
latter O
was O
the O
only O
change O
detected O
in O
an O

unaffected O
sibling O

a O
third O
family O
was O
composed O
of O
two O
sisters O
with O
early O

onset O
parkinson O
##ism O
and O
signs O
of O
sensor O
##imo O
##tor O
ax O
##onal O

peripheral O
ne O
##uro O
##pathy O
without O
pe O
##o O
both O
were O
compound O

het O
##ero O
##zy O
##go O
##us O
carrying O
the O
already O
reported O
c O
255 O
##7 O
##c O
t O

p O
r O
##85 O
##3 O
##w O
in O
ex O
##on O
16 O
12 O
of O
one O
all O
##ele O
while O
the O
other O

all O
##ele O
carried O
a O
second O
novel O
mutation O
c O
220 O
##9 O
##c O
a O

p O
g O
##7 O
##37 O
##r O
in O
ex O
##on O
13 O
one O
sister O
was O
treated O
with O
lev O
##od O
##opa O

at O
low O
dos O
##age O
but O
she O
developed O
early O
oro O
##man O
##di O
##bular O

d O
##ys O
##kin O
##es O
##ias O
the O
other O
was O
treated O
with O
do O
##pa O
##mine O
ago O
##nist O
##s O

besides O
the O
pol O
##g O
##1 O
mutant O
patients O
mentioned O
above O
a O

het O
##ero O
##zy O
##go O
##us O
mutation O
c O
112 O
##1 O
##g O
a O
p O
r O
##37 O
##4 O
##q O
was O

reported O
in O
ex O
##on O
1 O
of O
the O
twinkle O
in O
a O
single O
family O
com O

posed O
of O
10 O
pe O
##o O
patients O
three O
of O
whom O
had O
also O
park O
##in O

son O
##ism O
13 O
finally O
a O
pe O
##o O
patient O
with O
a O
lev O
##od O
##opa O

responsive O
parkinson O
##ism O
d O
##ys O
##kin O
##es O
##ias O
and O
motor O
flu O
##ct O
##ua O

ti O
##ons O
14 O
was O
shown O
to O
harbor O
mt O
##dna O
del O
##eti O
##ons O
in O
muscle O

but O
no O
mutation O
was O
found O
in O
either O
of O
the O
known O
pe O
##o O

associated O
genes O

a O
comparative O
study O
of O
420 O
parkinson O
s O
disease O
patients O

and O
controls O
did O
not O
support O
the O
role O
for O
common O
pol O
##g O
##1 O

genetic O
variants O
in O
parkinson O
##ism O
concluding O
that O
dom O
##i O

nan O
##t O
pol O
##g O
##1 O
mutations O
are O
a O
rare O
cause O
of O
parkinson O
##ism O

15 O
the O
hypothesis O
that O
length O
variants O
of O
the O
pol O
ca O

poly O
##gl O
##uta O
##mine O
tract O
may O
pre O
##dis O
##pose O
to O
id O
##io O
##pathic O
sporadic O

parkinson O
s O
disease O
was O
suggested O
by O
studies O
on O
finn O
##s O

3 O
11 O
but O
has O
not O
as O
yet O
been O
confirmed O
in O
other O
pop O
##ula O

ti O
##ons O
on O
the O
other O
hand O
pol O
##g O
##1 O
mutations O
are O
not O
the O

only O
cause O
of O
mt O
##dna O
defects O
associated O
with O
parkinson O

is O
##m O
16 O

interesting O
##ly O
high O
levels O
of O
deleted O
mt O
##dna O
##s O
were O

recently O
reported O
in O
neurons O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O

compact O
##a O
in O
aged O
individuals O
patients O
with O
parkinson O
s O

disease O
showed O
levels O
of O
deleted O
mt O
##dna O
that O
were O
sign O
##if O
##i O

can O
##tly O
higher O
than O
in O
age O
matched O
control O
brains O
17 O

these O
recent O
results O
support O
the O
long O
lasting O
hypothesis O

that O
mitochondrial O
dysfunction O
##s O
play O
a O
role O
in O
the O
path O
##o O

genesis O
of O
parkinson O
s O
disease O
as O
well O
as O
other O
adult O
onset O

ne O
##uro O
##de O
##gen O
##erative O
diseases O
including O
alzheimer O
s O
disease O

huntington O
s O
disease O
and O
amy O
##ot O
##rop O
##hic O
lateral O
sc O
##ler O
##osis O

18 O
interesting O
##ly O
in O
two O
patients O
12 O
including O
ours O

d O
##ys O
##kin O
##es O
##ias O
herald O
##ed O
the O
parkinson O
##ism O
associated O
with O

pol O
##g O
##1 O
mutations O
the O
latter O
can O
be O
concealed O
by O
the O
pre O
##s O

en O
##ce O
of O
peripheral O
ne O
##uro O
##pathy O
and O
muscle O
weakness O

the O
identification O
of O
two O
novel O
pol O
##g O
##1 O
mutations O

expressing O
a O
ph O
##eno O
##type O
characterized O
by O
pe O
##o O
and O
park O
##in O

son O
##ism O
supports O
the O
hypothesis O
that O
loss O
of O
mt O
##dna O
int O
##eg O

ri O
##ty O
is O
implicated O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O

disease O
combination O
of O
my O
##opa O
##thic O
and O
ne O
##uro O
##mus O
##cular O

symptoms O
with O
parkinson O
##ism O
should O
prompt O
to O
include O

the O
screening O
of O
the O
pol O
##g O
##1 O
gene O
in O
the O
diagnostic O
work O

out O
especially O
but O
not O
exclusively O
when O
the O
syndrome O
is O

inherited O

ac O
##k O
##now O
##led O
##gm O
##ents O

this O
work O
was O
supported O
by O
the O
pier O
##fra O
##nco O
and O
luisa O

marian O
##i O
foundation O
the O
tel O
##eth O
##on O
italy O
foundation O

grant O
no O
g O
##gp O
##0 O
##70 O
##19 O
the O
italian O
ministry O
of O
university O

and O
research O
fir O
##b O
2003 O
project O
rb O
##la O
##0 O
##38 O
##rma O
the O

italian O
ministry O
of O
health O
rf O
##200 O
##6 O
ex O
56 O
05 O
21 O
mit O
##o O

f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
46 O
##3 O

circle O
and O
eu O
##mit O
##oco O
##mba O
##t O
l O
##sh O
##m O
ct O
2004 O

50 O
##31 O
##16 O
network O
grants O
from O
the O
european O
union O
frame O

work O
program O
6 O
the O
authors O
are O
grateful O
to O
the O
patient O

and O
his O
family O
for O
their O
collaboration O
in O
the O
study O

references O

1 O
graz O
##ie O
##wicz O
ma O
bien O
##stock O
r O
##j O
copeland O
wc O
the O
dna O
polymer O
##ase O

c O
y O
##9 O
##55 O
##c O
disease O
variant O
associated O
with O
pe O
##o O
and O
parkinson O
##ism O

media O
##tes O
the O
incorporation O
and O
trans O
##les O
##ion O
synthesis O
opposite O
7 O
8 O

di O
##hy O
##dro O
8 O
ox O
##o O
20 O
de O
##ox O
##y O
##gua O
##nos O
##ine O
hum O
mo O
##l O
gene O
##t O
2007 O
16 O
272 O
##9 O
39 O

2 O
hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
polymer O
##ase O
c O
and O
human O

disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
r O
##24 O
##4 O
52 O

3 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O

men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
c O
mutations O

clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
82 O

4 O
man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
oh O
s O
##j O
dim O
##aur O
##o O
s O
a O
novel O
polymer O
##ase O
c O

mutation O
in O
a O
family O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
and O

parkinson O
##ism O
arch O
ne O
##uro O
##l O
2004 O
61 O
1777 O
9 O

5 O
hudson O
g O
sc O
##hae O
##fer O
am O
taylor O
r O
##w O
et O
al O
mutation O
of O
the O
link O
##er O

region O
of O
the O
polymer O
##ase O
c O
1 O
pol O
##g O
##1 O
gene O
associated O
with O
pro O
##gre O
##s O

si O
##ve O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O

2007 O
64 O
55 O
##3 O
7 O

6 O
thomas O
a O
bon O
##ann O
##i O
l O
anton O
##ini O
a O
baron O
##e O
p O
ono O
##fr O
##j O
m O
do O
##pa O

responsive O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
in O
parkinson O
##ism O
mo O
##v O
di O
##sor O
##d O

2007 O
22 O
1652 O
6 O

7 O
zev O
##iani O
m O
ser O
##vid O
##ei O
s O
gel O
##ler O
##a O
c O
bert O
##ini O
e O
di O
ma O
##uro O
s O
di O
dona O
##to O

s O
an O
auto O
##som O
##al O
dominant O
disorder O
with O
multiple O
del O
##eti O
##ons O
of O

mitochondrial O
dna O
starting O
at O
the O
d O
loop O
region O
nature O

1989 O
339 O
309 O
11 O

8 O
long O
##ley O
m O
##j O
graz O
##ie O
##wicz O
ma O
bien O
##stock O
r O
##j O
copeland O
wc O
con O
##se O

que O
##nce O
##s O
of O
mutations O
in O
human O
dna O
polymer O
##ase O
c O
gene O

2005 O
354 O
125 O
31 O

9 O
lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
et O
al O
mutations O
of O
mitochondrial O

dna O
polymer O
##ase O
ca O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O

recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O

2002 O
52 O
211 O
9 O

10 O
stop O
##in O
##´s O
##ka O
k O
gr O
##zy O
##bow O
##ski O
t O
mal O
##yar O
##chuk O
ba O
der O
##enko O
mv O

mis O
##´ O
##cic O
##ka O
sl O
##i O
##wk O
##a O
d O
optimization O
of O
the O
y O
##8 O
##31 O
##c O
mutation O
in O
human O

dna O
polymer O
##ase O
c O
by O
all O
##eli O
##c O
discrimination O
ass O
##ay O
act O
##a O
bio O
##chi O
##m O
pol O

2006 O
53 O
59 O
##1 O
5 O

11 O
lu O
##oma O
pt O
ee O
##rol O
##a O
j O
ah O
##ola O
s O
et O
al O
mitochondrial O
dna O
polymer O
##ase O

gamma O
variants O
in O
id O
##io O
##pathic O
sporadic O
parkinson O
disease O
ne O
##uro O
##logy O

2007 O
69 O
115 O
##2 O
9 O

12 O
david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O

parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
62 O

13 O
bal O
##oh O
r O
##h O
sal O
##ava O
##ggio O
##ne O
e O
mil O
##brand O
##t O
j O
pest O
##ron O
##k O
a O
fa O
##mi O
##lia O
##l O

parkinson O
##ism O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
from O
a O
mutation O
in O
the O
mit O
##o O

cho O
##nd O
##rial O
dna O
he O
##lica O
##se O
twinkle O
arch O
ne O
##uro O
##l O
2007 O
64 O
99 O
##8 O
1000 O

14 O
wilcox O
ra O
churchyard O
a O
dahl O
h O
##h O
hut O
##chison O
w O
##m O
kirby O
d O
##m O

thy O
##aga O
##raj O
##an O
d O
lev O
##od O
##opa O
response O
in O
parkinson O
##ism O
with O
multiple O

mitochondrial O
dna O
del O
##eti O
##ons O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
102 O
##0 O
3 O

15 O
tian O
##gy O
##ou O
w O
hudson O
g O
g O
##he O
##zzi O
d O
et O
al O
pol O
##g O
##1 O
in O
id O
##io O
##pathic O

parkinson O
disease O
ne O
##uro O
##logy O
2006 O
67 O
169 O
##8 O
700 O

16 O
ho O
##rva O
##th O
r O
k O
##ley O
ra O
loch O
##mu O
##ller O
h O
vo O
##rger O
##d O
m O
parkinson O

syndrome O
ne O
##uro O
##pathy O
and O
my O
##opa O
##thy O
caused O
by O
the O
mutation O

a O
##8 O
##34 O
##4 O
##g O
mer O
##rf O
in O
tr O
##nal O
##ys O

ne O
##uro O
##logy O
2007 O
68 O
56 O
8 O

17 O
bender O
a O
krishna O
##n O
k O
##j O
morris O
cm O
et O
al O
high O
levels O
of O
mit O
##och O
##on O

dr O
##ial O
dna O
del O
##eti O
##ons O
in O
sub O
##stan O
##tia O
ni O
##gra O
neurons O
in O
aging O
and O

parkinson O
disease O
nat O
gene O
##t O
2006 O
38 O
51 O
##5 O
7 O

18 O
sc O
##ha O
##pi O
##ra O
ah O
mitochondrial O
disease O
lance O
##t O
2006 O
36 O
##8 O
70 O
82 O

46 O
##4 O
f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

two O
novel O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
in O
a O
patient B-PATIENT
with O
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
lev O
##od O
##opa O
responsive O
pseudo O
or B-HPO_TERM
##th I-HPO_TERM
##osta I-HPO_TERM
##tic I-HPO_TERM
tremor I-HPO_TERM
and O
parkinson B-HPO_TERM
##ism I-HPO_TERM
fed O
##eric O
##a O
in O
##vern O
##iz O
##zi O
a O
1 O
sara O
var O
##ane O
##se O
b O
c O
1 O
astrid O
thomas O
b O
c O
franco O
carr O
##ara O
a O
marco O
ono O
##fr O
##j O
b O
c O
massimo O
zev O
##iani O
a O
a O
unit O
of O
molecular O
ne O
##uro O
##gen O
##etic O
##s O
pier O
##fra O
##nco O
e O
luisa O
marian O
##i O
center O
for O
the O
study O
of O
children O
s O
mitochondrial O
disorders O
c O
best O
##a O
neurological O
institute O
foundation O
ir O
##cc O
##s O
milan O
italy O
b O
department O
of O
on O
##cology O
neuroscience O
and O
ne O
##uro O
##phy O
##sio O
##path O
##ology O
university O
g O
d O
ann O
##un O
##zio O
chi O
##eti O
pe O
##sca O
##ra O
italy O

two O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
progressive O

external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
lev O
##od O
##opa O
responsive O

pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O

fed O
##eric O
##a O
in O
##vern O
##iz O
##zi O
a O
1 O

sara O
var O
##ane O
##se O
b O
c O
1 O
astrid O
thomas O
b O
c O
franco O
carr O
##ara O
a O

marco O
ono O
##fr O
##j O
b O
c O

massimo O
zev O
##iani O
a O

a O
unit O
of O
molecular O
ne O
##uro O
##gen O
##etic O
##s O
pier O
##fra O
##nco O
e O
luisa O
marian O
##i O
center O
for O
the O
study O
of O
children O
s O
mitochondrial O
disorders O

c O
best O
##a O
neurological O
institute O
foundation O
ir O
##cc O
##s O
milan O
italy O

b O
department O
of O
on O
##cology O
neuroscience O
and O
ne O
##uro O
##phy O
##sio O
##path O
##ology O
university O
g O
d O
ann O
##un O
##zio O
chi O
##eti O
pe O
##sca O
##ra O
italy O

c O
aging O
research O
center O
ce O
s O
i O
g O
d O
ann O
##un O
##zio O
university O
foundation O
chi O
##eti O
pe O
##sca O
##ra O
italy O

received O
31 O
january O
2008 O
received O
in O
revised O
form O
31 O
january O
2008 O
accepted O
2 O
april O
2008 O

abstract O

different O
mutations O
or O
combinations O
of O
mutations O
in O
pol O
##g O
##1 O
the O
gene O
encoding O
pol O
ca O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O

polymer O
##ase O
are O
associated O
with O
a O
spectrum O
of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
parkinson O
##ian O
features O
have O
been O
reported O

as O
a O
late O
com O
##plication O
of O
pol O
##g O
##1 O
associated O
dominant O
pe O
##o O
good O
response O
to O
lev O
##od O
##opa O
or O
do O
##pa O
##mine O
ago O
##nist O
##s O
reduced O
do O
##pa O
##mine O

up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
and O
ne O
##uron O
##al O
loss O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
compact O
##a O
have O
been O
documented O
in O
a O
few O
cases O
here O

we O
report O
two O
novel O
mutations O
in O
pol O
##g O
##1 O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient O
with O
auto O
##som O
##al O
recess O
##ive O
pe O
##o O
followed O
by O
pseudo O

or O
##th O
##osta O
##tic O
tremor O
evolving O
into O
lev O
##od O
##opa O
responsive O
parkinson O
##ism O
these O
observations O
support O
the O
hypothesis O
that O
mt O
##dna O
dysfunction O

is O
engaged O
in O
the O
pathogen O
##esis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O

o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O

key O
##words O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
parkinson O
##ism O
polymer O
##ase O
gamma O
mitochondrial O
dna O
multiple O
mt O
##dna O
del O
##eti O
##ons O

1 O
introduction O

mitochondrial O
dna O
mt O
##dna O
is O
faithful O
##ly O
replicate O
##d O

by O
dna O
polymer O
##ase O
v O
pol O
v O
an O
enzyme O
composed O
of O

a O
single O
145 O
k O
##da O
catalytic O
subunit O
pol O
ca O
bound O
to O

two O
55 O
k O
##da O
accessory O
subunit O
##s O
pol O
cb O
pol O
ca O
is O
encoded O

by O
pol O
##g O
##1 O
a O
23 O
ex O
##on O
gene O
located O
on O
human O
chromosome O

15 O
functional O
genetic O
variants O
of O
pol O
##g O
##1 O
are O
present O
in O

approximately O
0 O
5 O
of O
the O
general O
population O
numerous O

pol O
##g O
##1 O
mutations O
have O
been O
associated O
with O
a O
spectrum O

of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O

recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O

juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##l O

och O
##er O
syndrome O
at O
the O
molecular O
level O
pe O
##o O
patients O
are O

characterized O
by O
the O
accumulation O
of O
a O
collection O
of O
deleted O

mt O
##dna O
species O
in O
affected O
tissues O
notably O
skeletal O
muscle O

and O
brain O
additional O
symptoms O
including O
mig O
##raine O
ep O
##i O

le O
##psy O
peripheral O
ne O
##uro O
##pathy O
ata O
##xia O
premature O
o O
##var O
##ian O

failure O
h O
##yp O
##ogo O
##nad O
##ism O
and O
male O
h O
##yp O
##of O
##ert O
##ility O
may O
occur O

in O
different O
pe O
##o O
families O
and O
with O
different O
pol O
##g O
##1 O
mu O
##ta O

ti O
##ons O
1 O
4 O
parkinson O
##ism O
is O
a O
rare O
and O
late O
onset O
com O
##pl O
##ica O

ti O
##on O
of O
pol O
##g O
##1 O
associated O
pe O
##o O
3 O
5 O
we O
report O
here O
on O
a O

patient O
presenting O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O

followed O
by O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O

molecular O
analysis O
showed O
that O
this O
patient O
is O
a O
compound O

het O
##ero O
##zy O
##go O
##us O
for O
two O
novel O
mutations O
of O
the O
pol O
##g O
##1 O
gene O

09 O
##60 O
89 O
##66 O
see O
front O
matter O
o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O

doi O
10 O
1016 O
j O
nm O
##d O
2008 O
04 O
00 O
##5 O

corresponding O
author O
fa O
##x O
39 O
02 O
239 O
##4 O
261 O
##9 O

e O
mail O
address O
zev O
##iani O
ist O
##it O
##uto O
best O
##a O
it O
m O
zev O
##iani O

1 O
these O
authors O
contributed O
equally O
to O
this O
work O

www O
else O
##vier O
com O
locate O
nm O
##d O

ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

2 O
case O
description O

the O
patient O
is O
a O
54 O
year O
old O
yo O
man O
from O
central O
italy O

his O
father O
died O
at O
71 O
years O
of O
lung O
cancer O
had O
non O
insulin O

dependent O
diabetes O
mel O
##lit O
##us O
but O
was O
free O
from O
any O
ne O
##uro O

logical O
sy O
##mpt O
##om O
the O
82 O
yo O
mother O
a O
47 O
yo O
brother O
and O

two O
29 O
and O
24 O
yo O
daughters O
are O
all O
alive O
and O
well O
the O
pro O

po O
##sit O
##us O
was O
born O
at O
term O
after O
an O
uneven O
##tf O
##ul O
pregnancy O
in O

contrast O
to O
what O
was O
reported O
previously O
6 O
this O
patient O

developed O
pe O
##o O
with O
bilateral O
pt O
##osis O
at O
30 O
years O
of O
age O
f O
##ol O

lowe O
##d O
by O
progressive O
d O
##ys O
##phon O
##ia O
with O
rhino O
##lal O
##ia O
d O
##ys O
##pha O
##gia O

pro O
##xi O
##mal O
muscle O
weakness O
and O
wasting O
and O
tend O
##on O
are O

flex O
##ia O
reduction O
of O
cal O
##oric O
intake O
caused O
by O
severe O
d O
##ys O

ph O
##agi O
##a O
and O
the O
onset O
of O
chronic O
dia O
##rr O
##hoe O
##a O
resulted O
in O

severe O
body O
weight O
loss O
at O
50 O
years O
of O
age O
the O
patient O

developed O
tremor O
in O
the O
standing O
position O
dominant O
fr O
##e O

que O
##ncy O
at O
6 O
2 O
hz O
initially O
affecting O
the O
left O
lower O
limb O
then O

both O
lower O
limbs O
with O
occasional O
mild O
resting O
tremor O
of O

the O
hands O
this O
patient O
was O
included O
in O
a O
recent O
report O

on O
4 O
cases O
affected O
by O
lev O
##od O
##opa O
responsive O
pseudo O
or O
##th O
##o O

static O
tremor O
in O
parkinson O
##ism O
case O
3 O
in O
6 O
in O
the O
follow O

ing O
2 O
years O
he O
developed O
extra O
pyramid O
##al O
rigid O
##ity O
with O
a O

co O
##g O
##wheel O
sign O
reduced O
tapping O
left O
right O
and O
post O
##ural O

instability O
unified O
parkinson O
s O
disease O
rating O
scale O

up O
##dr O
##s O
motor O
score O
21 O
points O
physical O
examination O

showed O
a O
h O
##yp O
##omi O
##mic O
face O
h O
##yp O
##op O
##hon O
##ia O
bilateral O
pt O
##osis O

op O
##ht O
##hal O
##mo O
##ple O
##gia O
mild O
symmetrical O
pro O
##xi O
##mal O
muscle O
weak O

ness O
medical O
research O
council O
grade O
4 O
and O
absence O
of O

lower O
limb O
tend O
##on O
reflex O
##es O
an O
ec O
##g O
and O
structural O
brain O

mri O
were O
both O
normal O
a O
single O
photon O
emission O
com O

put O
##ed O
tom O
##ography O
spec O
##t O
using O
123 O
i O
2 O
##b O
car O
##bo O
##me O

tho O
##xy O
3 O
##b O
4 O
io O
##do O
##ph O
##en O
##yl O
n O
3 O
flu O
##oro O
##pro O
##py O
##l O
nor O
##tro O
##pan O
##e O

i O
f O
##p O
ci O
##t O
spec O
##t O
revealed O
a O
bilateral O
##ly O
reduced O
do O
##pa O

mine O
up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
right O
left O
serum O

cr O
##ea O
##tine O
kinase O
ck O
level O
was O
215 O
##6 O
u O
l O
normal O
140 O

u O
l O
an O
em O
##g O
was O
compatible O
with O
ax O
##onal O
sensory O
ne O
##u O

ro O
##pathy O
associated O
with O
my O
##opa O
##thic O
features O
the O
patient O

was O
initially O
treated O
with O
low O
doses O
of O
do O
##pa O
##mine O
ago O
##nist O
##s O

pr O
##ami O
##pe O
##x O
##ole O
2 O
1 O
mg O
day O
associated O
with O
lev O
##od O
##opa O
up O
to O

400 O
mg O
day O
with O
disappearance O
of O
standing O
legs O
tremor O

and O
reduction O
in O
up O
##dr O
##s O
motor O
score O

two O
years O
later O
he O
complained O
of O
end O
of O
dose O
deter O
##ior O
##a O

ti O
##on O
with O
re O
occurrence O
of O
the O
di O
##sa O
##bling O
standing O
tremor O

which O
appeared O
1 O
5 O
2 O
5 O
h O
after O
each O
single O
lev O
##od O
##opa O

up O
##dr O
##s O
motor O
score O
was O
27 O
in O
on O
state O
and O
42 O
in O
off O

state O
and O
was O
associated O
with O
severe O
anxiety O
and O
panic O

attacks O
during O
the O
off O
states O
lev O
##od O
##opa O
was O
increased O

to O
600 O
mg O
day O
and O
en O
##ta O
##cap O
##one O
was O
added O
1200 O
mg O
day O

the O
patient O
did O
not O
report O
further O
fluctuations O
for O
the O
next O

6 O
months O
when O
he O
developed O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
re O

occurrence O
of O
end O
of O
dose O
deterioration O
and O
severe O
stand O

ing O
tremor O
en O
##ta O
##cap O
##one O
was O
substituted O
with O
to O
##lc O
##ap O
##one O

100 O
mg O
t O
i O
d O
with O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
and O
off O
state O

since O
then O
d O
##ys O
##pha O
##gia O
has O
progressively O
worsened O
with O
fur O

the O
##r O
loss O
of O
weight O
because O
of O
mal O
##nut O
##rit O
##ion O
requiring O
the O

positioning O
of O
a O
per O
##cut O
##aneous O
end O
##os O
##copic O
gas O
##tro O
##sto O
##my O
for O

enter O
##al O
nutrition O
onset O
of O
vent O
##ila O
##tory O
failure O
has O
required O

mechanical O
ventilation O
the O
serum O
ck O
level O
remains O
high O

61 O
##43 O
u O
l O
with O
worse O
##ning O
and O
spreading O
of O
the O
muscle O

weakness O
high O
serum O
ck O
is O
an O
unusual O
but O
occasionally O

reported O
finding O
in O
pol O
##g O
##1 O
associated O
pe O
##o O
with O
multiple O

mt O
##dna O
del O
##eti O
##ons O
for O
instance O
hudson O
et O
al O
5 O
report O
a O

patient O
individual O
ii O
8 O
with O
serum O
ck O
levels O
2500 O
u O
l O

the O
tremor O
and O
the O
off O
state O
now O
occur O
1 O
5 O
2 O
h O
after O

lev O
##od O
##opa O
administration O
which O
must O
be O
repeated O
7 O
8 O
times O

per O
day O
in O
the O
last O
months O
the O
patient O
has O
also O
developed O

progressive O
cognitive O
dysfunction O
associated O
with O
psychotic O

features O

3 O
methods O

southern O
b O
##lot O
analysis O
of O
mt O
##dna O
was O
carried O
out O
on O

dna O
extracted O
from O
skeletal O
muscle O
following O
standard O

procedures O
7 O
and O
using O
the O
ec O
##l O
che O
##mi O
##lum O
##ines O
##cence O
as O

the O
detection O
method O
dna O
from O
peripheral O
blood O
l O
##ym O

ph O
##ocytes O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
the O
22 O
coding O

ex O
##ons O
of O
the O
pol O
##g O
##1 O
gene O
ex O
##ons O
223 O
polymer O
##ase O
chain O

reaction O
pc O
##r O
conditions O
were O
96 O
for O
30 O
s O
56 O
for O

20 O
s O
and O
72 O
for O
60 O
s O
for O
30 O
cycles O
plus O
as O
initial O
den O
##at O
##ur O

at O
##ion O
step O
at O
96 O
for O
2 O
min O
pc O
##r O
fragments O
were O
ana O

l O
##y O
##zed O
by O
automated O
nu O
##cle O
##otide O
sequencing O
using O
the O
big O

dye O
term O
##inator O
ready O
reaction O
kit O
version O
2 O
on O
a O
310 O
##0 O

genetic O
analyze O
##r O
automated O
sequence O
##r O
applied O
bio O
##sy O
##s O

te O
##ms O
the O
sequence O
variants O
found O
in O
the O
patient O
were O

searched O
for O
in O
available O
relatives O
as O
well O
as O
in O
100 O
con O
##se O
##c O

ut O
##ive O
control O
subjects O
200 O
all O
##eles O

4 O
results O

a O
skeletal O
muscle O
bio O
##psy O
taken O
when O
the O
patient O
was O
32 O

years O
old O
showed O
the O
presence O
of O
several O
ragged O
red O
fibers O

with O
variation O
of O
fiber O
caliber O
and O
nuclear O
central O
##ization O

and O
reduced O
or O
absent O
react O
##ivity O
to O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O

fig O
1a O
sequence O
analysis O
of O
mt O
##dna O
excluded O
the O
pre O
##s O

en O
##ce O
of O
point O
mutations O
commonly O
associated O
with O

mer O
##rf O
and O
mel O
##as O
however O
southern O
b O
##lot O
analysis O

revealed O
the O
presence O
of O
a O
collection O
of O
deleted O
mt O
##dna O

species O
in O
addition O
to O
wild O
type O
mt O
##dna O
fig O
1b O
6 O

these O
results O
prompted O
us O
to O
consider O
the O
possibility O

of O
mutation O
s O
in O
one O
of O
the O
nucleus O
encoded O
genes O
com O

mon O
##ly O
associated O
with O
mt O
##dna O
instability O
and O
pe O
##o O

namely O
twinkle O
ant O
##1 O
and O
pol O
##g O
##1 O
sequence O
analysis O

of O
the O
first O
two O
genes O
ruled O
out O
the O
presence O
of O
path O
##o O

gen O
##ic O
mutations O
however O
sequence O
analysis O
of O
the O
entire O

coding O
region O
of O
the O
pol O
##g O
##1 O
gene O
led O
us O
to O
the O
id O
##ent O
##if O
##i O

cat O
##ion O
of O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
mutations O
one O
is O
a O

c O
128 O
##8 O
##a O
t O
trans O
##version O
predicting O
a O
p O
m O
##43 O
##0 O
##l O
amino O

acid O
substitution O
the O
second O
is O
a O
c O
275 O
##2 O
##t O
c O
transition O

determining O
the O
amino O
##ac O
##id O
substitution O
p O
w O
##9 O
##18 O
##r O

fig O
2a O
segregation O
analysis O
carried O
out O
in O
available O

members O
of O
the O
family O
fig O
2 O
##b O
revealed O
the O
presence O

of O
the O
275 O
##2 O
##t O
c O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
the O
mother O

of O
the O
patient O
and O
in O
the O
two O
healthy O
daughters O
while O

no O
mutation O
was O
detected O
in O
his O
brother O

f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
46 O
##1 O

5 O
discussion O

we O
found O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
in O

a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient O
characterized O
by O
pe O
##o O

muscle O
weakness O
and O
later O
onset O
lev O
##od O
##opa O
responsive O

pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
6 O

the O
maternal O
all O
##ele O
predict O
##s O
a O
p O
w O
##9 O
##18 O
##r O
amino O
##ac O
##id O
sub O

st O
##it O
##ution O
in O
a O
highly O
conserved O
position O
in O
the O
pol O
ca O
poly O

mer O
##ase O
domain O
http O
dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
8 O

the O
paternal O
all O
##ele O
harbor O
##s O
a O
c O
128 O
##8 O
##a O
t O
trans O
##version O
pre O

di O
##cting O
the O
replacement O
of O
the O
p O
m O
##43 O
##0 O
residue O
into O
an O
l O

residue O
m O
##43 O
##0 O
is O
contained O
within O
the O
so O
called O
space O
##r O

fig O
1 O
morphological O
and O
molecular O
findings O
in O
skeletal O
muscle O
a O
top O
panel O
nad O
##h O
de O
##hy O
##dro O
##genase O
stain O
##ing O
shows O
rr O
##f O
as O
##ter O
##isk O
##s O
bottom O
panel O

cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
stain O
##ing O
of O
a O
serial O
muscle O
section O
shows O
several O
fibers O
with O
reduced O
or O
absent O
react O
##ivity O
including O
the O
same O
two O
rr O
##f O
shown O
in O
the O

top O
panel O
as O
##ter O
##isk O
##s O
b O
southern O
b O
##lot O
analysis O
on O
pv O
##ui O
##i O
linear O
##ized O
mt O
##dna O
performed O
on O
the O
muscle O
bio O
##psy O
of O
the O
patient O
p O
and O
a O
control O
c O
both O
p O

and O
c O
samples O
show O
a O
16 O
6 O
kb O
band O
corresponding O
to O
wild O
type O
mt O
##dna O
arrow O
in O
addition O
the O
p O
sample O
shows O
a O
collection O
of O
smaller O
bands O

corresponding O
to O
del O
##eti O
##on O
containing O
mt O
##dna O
species O

fig O
2 O
a O
identification O
of O
pol O
##g O
##1 O
mutations O
by O
sequence O
analysis O
the O
electro O
##pher O
##og O
##ram O
##s O
show O
the O
c O
128 O
##8 O
##a O
t O
trans O
##version O
predicting O
a O
p O
m O
##43 O
##0 O
##l O

amino O
##ac O
##id O
substitution O
and O
the O
c O
275 O
##2 O
##t O
c O
transition O
predicting O
a O
p O
w O
##9 O
##18 O
##r O
amino O
##ac O
##id O
substitution O
b O
family O
pe O
##di O
##gree O
the O
solid O
black O
square O
symbol O

indicates O
the O
pro O
##band O
open O
symbols O
indicate O
unaffected O
individuals O
the O
and O
symbols O
indicate O
mutant O
vs O
wild O
type O
all O
##eles O
c O
multiple O

alignment O
of O
mutation O
containing O
pol O
ca O
regions O
in O
different O
species O
the O
red O
boxes O
indicate O
the O
amino O
##ac O
##id O
substitution O
##s O
found O
in O
the O
patient O

46 O
##2 O
f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

domain O
a O
region O
encompassing O
the O
mid O
##port O
##ion O
of O
pol O
ca O

which O
in O
multi O
##cellular O
eu O
##kar O
##yo O
##tes O
interact O
##s O
with O
two O
pol O
cb O

accessory O
subunit O
##s O
to O
form O
a O
functional O
##ly O
active O
trim O
##eric O

ho O
##loe O
##nz O
##yme O
pol O
cb O
or O
##th O
##olo O
##gs O
are O
absent O
in O
fungi O
which O

can O
explain O
why O
m O
##43 O
##0 O
is O
conserved O
in O
meta O
##zo O
##an O
pol O
ca O

sequences O
but O
not O
in O
fungal O
or O
##th O
##olo O
##gs O
for O
instance O

mi O
##p O
##1 O
in O
sac O
##cha O
##rom O
##yce O
##s O
ce O
##re O
##vis O
##iae O
fig O
2 O
##c O
segregation O

analysis O
in O
the O
family O
and O
absence O
of O
either O
mutation O
in O

200 O
control O
all O
##eles O
further O
support O
the O
pathogen O
##ic O
role O
of O

the O
mutations O

the O
role O
of O
pol O
##g O
##1 O
genetic O
variants O
in O
the O
pathogen O
##esis O

of O
parkinson O
##ism O
is O
suggested O
by O
several O
reports O
parkinson O

is O
##m O
was O
documented O
in O
13 O
affected O
members O
of O
five O
out O
of O

seven O
pol O
##g O
##1 O
mutant O
pe O
##o O
families O
reported O
by O
lu O
##oma O

et O
al O
3 O
three O
of O
these O
families O
displayed O
dominant O
trans O

mission O
of O
the O
trait O
and O
were O
found O
to O
carry O
a O
het O
##ero O
##zy O
##go O
##us O

c O
286 O
##4 O
##a O
g O
p O
y O
##9 O
##55 O
##c O
mutation O
one O
of O
the O
most O
com O

mon O
pathogen O
##ic O
variants O
of O
pol O
##g O
##1 O
9 O
in O
two O
additional O

families O
both O
parkinson O
##ism O
and O
pe O
##o O
were O
transmitted O
as O

an O
allegedly O
recess O
##ive O
trait O
however O
while O
the O
three O

affected O
members O
of O
the O
first O
of O
these O
families O
carried O
two O

all O
##eli O
##c O
pol O
##g O
##1 O
mutations O
namely O
c O
140 O
##2 O
##a O
g O

p O
n O
##46 O
##8 O
##d O
and O
c O
331 O
##3 O
##g O
a O
p O
a1 O
##10 O
##5 O
##t O
only O
the O
latter O

was O
found O
in O
het O
##ero O
##zy O
##gos O
##ity O
in O
the O
single O
patient O
of O
the O
sec O

on O
##d O
family O
good O
response O
to O
lev O
##od O
##opa O
was O
documented O
in O

all O
patients O
to O
whom O
this O
treatment O
had O
been O
given O

five O
additional O
pol O
##g O
##1 O
mutant O
patients O
belonging O
to O

three O
families O
were O
described O
with O
a O
combination O
of O
pe O
##o O

and O
parkinson O
##ism O
but O
in O
some O
of O
these O
cases O
the O
path O
##o O

gen O
##ic O
role O
of O
the O
mutations O
remains O
controversial O
this O
is O

the O
case O
for O
a O
family O
including O
a O
49 O
yo O
woman O
with O
auto O
##so O

mal O
dominant O
pe O
##o O
ne O
##uro O
##pathy O
h O
##yp O
##ogo O
##nad O
##ism O
and O
par O

kin O
##son O
##ism O
and O
her O
59 O
yo O
brother O
with O
over O
##t O
parkinson O
##ian O

features O
4 O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
in O

muscle O
and O
a O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
miss O
##ense O
mutation O

c O
249 O
##2 O
##a O
g O
leading O
to O
p O
y O
##8 O
##31 O
##c O
amino O
##ac O
##id O
replacement O

were O
found O
in O
the O
pro O
##band O
and O
her O
affected O
brother O
the O

patient O
was O
successfully O
treated O
with O
lev O
##od O
##opa O
however O

the O
c O
249 O
##2 O
##a O
g O
transition O
has O
been O
reported O
in O
about O

2 O
of O
control O
subjects O
in O
poland O
and O
in O
normal O
controls O

in O
finn O
##s O
10 O
11 O
and O
italians O
m O
##z O
and O
fi O
personal O
ob O
##ser O

va O
##tion O
these O
observations O
suggest O
that O
the O
p O
y O
##8 O
##31 O
##c O
ami O

no O
##ac O
##id O
substitution O
is O
a O
non O
pathogen O
##ic O
variant O
in O
different O

european O
populations O

a O
second O
family O
included O
several O
pe O
##o O
patients O
one O
also O

being O
affected O
by O
parkinson O
##ism O
in O
this O
family O
auto O
##som O
##al O

dominant O
pe O
##o O
segregated O
with O
a O
c O
153 O
##2 O
##g O
a O
het O
##ero O
##zy O

go O
##us O
miss O
##ense O
mutation O
p O
s O
##51 O
##1 O
##n O
in O
ex O
##on O
8 O
in O
comb O
##ina O

ti O
##on O
with O
an O
intro O
##nic O
variant O
c O
207 O
##0 O
c O
158 O
##g O
a O
in O
cis O

5 O
the O
subject O
also O
affected O
by O
parkinson O
##ism O
was O
found O

to O
carry O
an O
all O
##eli O
##c O
in O
trans O
change O
c O
138 O
##9 O
##g O
t O
p O
l O
##46 O
##3 O
##f O

the O
pathogen O
##ic O
role O
of O
which O
is O
as O
yet O
not O
determined O

although O
the O
latter O
was O
the O
only O
change O
detected O
in O
an O

unaffected O
sibling O

a O
third O
family O
was O
composed O
of O
two O
sisters O
with O
early O

onset O
parkinson O
##ism O
and O
signs O
of O
sensor O
##imo O
##tor O
ax O
##onal O

peripheral O
ne O
##uro O
##pathy O
without O
pe O
##o O
both O
were O
compound O

het O
##ero O
##zy O
##go O
##us O
carrying O
the O
already O
reported O
c O
255 O
##7 O
##c O
t O

p O
r O
##85 O
##3 O
##w O
in O
ex O
##on O
16 O
12 O
of O
one O
all O
##ele O
while O
the O
other O

all O
##ele O
carried O
a O
second O
novel O
mutation O
c O
220 O
##9 O
##c O
a O

p O
g O
##7 O
##37 O
##r O
in O
ex O
##on O
13 O
one O
sister O
was O
treated O
with O
lev O
##od O
##opa O

at O
low O
dos O
##age O
but O
she O
developed O
early O
oro O
##man O
##di O
##bular O

d O
##ys O
##kin O
##es O
##ias O
the O
other O
was O
treated O
with O
do O
##pa O
##mine O
ago O
##nist O
##s O

besides O
the O
pol O
##g O
##1 O
mutant O
patients O
mentioned O
above O
a O

het O
##ero O
##zy O
##go O
##us O
mutation O
c O
112 O
##1 O
##g O
a O
p O
r O
##37 O
##4 O
##q O
was O

reported O
in O
ex O
##on O
1 O
of O
the O
twinkle O
in O
a O
single O
family O
com O

posed O
of O
10 O
pe O
##o O
patients O
three O
of O
whom O
had O
also O
park O
##in O

son O
##ism O
13 O
finally O
a O
pe O
##o O
patient O
with O
a O
lev O
##od O
##opa O

responsive O
parkinson O
##ism O
d O
##ys O
##kin O
##es O
##ias O
and O
motor O
flu O
##ct O
##ua O

ti O
##ons O
14 O
was O
shown O
to O
harbor O
mt O
##dna O
del O
##eti O
##ons O
in O
muscle O

but O
no O
mutation O
was O
found O
in O
either O
of O
the O
known O
pe O
##o O

associated O
genes O

a O
comparative O
study O
of O
420 O
parkinson O
s O
disease O
patients O

and O
controls O
did O
not O
support O
the O
role O
for O
common O
pol O
##g O
##1 O

genetic O
variants O
in O
parkinson O
##ism O
concluding O
that O
dom O
##i O

nan O
##t O
pol O
##g O
##1 O
mutations O
are O
a O
rare O
cause O
of O
parkinson O
##ism O

15 O
the O
hypothesis O
that O
length O
variants O
of O
the O
pol O
ca O

poly O
##gl O
##uta O
##mine O
tract O
may O
pre O
##dis O
##pose O
to O
id O
##io O
##pathic O
sporadic O

parkinson O
s O
disease O
was O
suggested O
by O
studies O
on O
finn O
##s O

3 O
11 O
but O
has O
not O
as O
yet O
been O
confirmed O
in O
other O
pop O
##ula O

ti O
##ons O
on O
the O
other O
hand O
pol O
##g O
##1 O
mutations O
are O
not O
the O

only O
cause O
of O
mt O
##dna O
defects O
associated O
with O
parkinson O

is O
##m O
16 O

interesting O
##ly O
high O
levels O
of O
deleted O
mt O
##dna O
##s O
were O

recently O
reported O
in O
neurons O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O

compact O
##a O
in O
aged O
individuals O
patients O
with O
parkinson O
s O

disease O
showed O
levels O
of O
deleted O
mt O
##dna O
that O
were O
sign O
##if O
##i O

can O
##tly O
higher O
than O
in O
age O
matched O
control O
brains O
17 O

these O
recent O
results O
support O
the O
long O
lasting O
hypothesis O

that O
mitochondrial O
dysfunction O
##s O
play O
a O
role O
in O
the O
path O
##o O

genesis O
of O
parkinson O
s O
disease O
as O
well O
as O
other O
adult O
onset O

ne O
##uro O
##de O
##gen O
##erative O
diseases O
including O
alzheimer O
s O
disease O

huntington O
s O
disease O
and O
amy O
##ot O
##rop O
##hic O
lateral O
sc O
##ler O
##osis O

18 O
interesting O
##ly O
in O
two O
patients O
12 O
including O
ours O

d O
##ys O
##kin O
##es O
##ias O
herald O
##ed O
the O
parkinson O
##ism O
associated O
with O

pol O
##g O
##1 O
mutations O
the O
latter O
can O
be O
concealed O
by O
the O
pre O
##s O

en O
##ce O
of O
peripheral O
ne O
##uro O
##pathy O
and O
muscle O
weakness O

the O
identification O
of O
two O
novel O
pol O
##g O
##1 O
mutations O

expressing O
a O
ph O
##eno O
##type O
characterized O
by O
pe O
##o O
and O
park O
##in O

son O
##ism O
supports O
the O
hypothesis O
that O
loss O
of O
mt O
##dna O
int O
##eg O

ri O
##ty O
is O
implicated O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O

disease O
combination O
of O
my O
##opa O
##thic O
and O
ne O
##uro O
##mus O
##cular O

symptoms O
with O
parkinson O
##ism O
should O
prompt O
to O
include O

the O
screening O
of O
the O
pol O
##g O
##1 O
gene O
in O
the O
diagnostic O
work O

out O
especially O
but O
not O
exclusively O
when O
the O
syndrome O
is O

inherited O

ac O
##k O
##now O
##led O
##gm O
##ents O

this O
work O
was O
supported O
by O
the O
pier O
##fra O
##nco O
and O
luisa O

marian O
##i O
foundation O
the O
tel O
##eth O
##on O
italy O
foundation O

grant O
no O
g O
##gp O
##0 O
##70 O
##19 O
the O
italian O
ministry O
of O
university O

and O
research O
fir O
##b O
2003 O
project O
rb O
##la O
##0 O
##38 O
##rma O
the O

italian O
ministry O
of O
health O
rf O
##200 O
##6 O
ex O
56 O
05 O
21 O
mit O
##o O

f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
46 O
##3 O

circle O
and O
eu O
##mit O
##oco O
##mba O
##t O
l O
##sh O
##m O
ct O
2004 O

50 O
##31 O
##16 O
network O
grants O
from O
the O
european O
union O
frame O

work O
program O
6 O
the O
authors O
are O
grateful O
to O
the O
patient O

and O
his O
family O
for O
their O
collaboration O
in O
the O
study O

references O

1 O
graz O
##ie O
##wicz O
ma O
bien O
##stock O
r O
##j O
copeland O
wc O
the O
dna O
polymer O
##ase O

c O
y O
##9 O
##55 O
##c O
disease O
variant O
associated O
with O
pe O
##o O
and O
parkinson O
##ism O

media O
##tes O
the O
incorporation O
and O
trans O
##les O
##ion O
synthesis O
opposite O
7 O
8 O

di O
##hy O
##dro O
8 O
ox O
##o O
20 O
de O
##ox O
##y O
##gua O
##nos O
##ine O
hum O
mo O
##l O
gene O
##t O
2007 O
16 O
272 O
##9 O
39 O

2 O
hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
polymer O
##ase O
c O
and O
human O

disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
r O
##24 O
##4 O
52 O

3 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O

men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
c O
mutations O

clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
82 O

4 O
man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
oh O
s O
##j O
dim O
##aur O
##o O
s O
a O
novel O
polymer O
##ase O
c O

mutation O
in O
a O
family O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
and O

parkinson O
##ism O
arch O
ne O
##uro O
##l O
2004 O
61 O
1777 O
9 O

5 O
hudson O
g O
sc O
##hae O
##fer O
am O
taylor O
r O
##w O
et O
al O
mutation O
of O
the O
link O
##er O

region O
of O
the O
polymer O
##ase O
c O
1 O
pol O
##g O
##1 O
gene O
associated O
with O
pro O
##gre O
##s O

si O
##ve O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O

2007 O
64 O
55 O
##3 O
7 O

6 O
thomas O
a O
bon O
##ann O
##i O
l O
anton O
##ini O
a O
baron O
##e O
p O
ono O
##fr O
##j O
m O
do O
##pa O

responsive O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
in O
parkinson O
##ism O
mo O
##v O
di O
##sor O
##d O

2007 O
22 O
1652 O
6 O

7 O
zev O
##iani O
m O
ser O
##vid O
##ei O
s O
gel O
##ler O
##a O
c O
bert O
##ini O
e O
di O
ma O
##uro O
s O
di O
dona O
##to O

s O
an O
auto O
##som O
##al O
dominant O
disorder O
with O
multiple O
del O
##eti O
##ons O
of O

mitochondrial O
dna O
starting O
at O
the O
d O
loop O
region O
nature O

1989 O
339 O
309 O
11 O

8 O
long O
##ley O
m O
##j O
graz O
##ie O
##wicz O
ma O
bien O
##stock O
r O
##j O
copeland O
wc O
con O
##se O

que O
##nce O
##s O
of O
mutations O
in O
human O
dna O
polymer O
##ase O
c O
gene O

2005 O
354 O
125 O
31 O

9 O
lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
et O
al O
mutations O
of O
mitochondrial O

dna O
polymer O
##ase O
ca O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O

recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O

2002 O
52 O
211 O
9 O

10 O
stop O
##in O
##´s O
##ka O
k O
gr O
##zy O
##bow O
##ski O
t O
mal O
##yar O
##chuk O
ba O
der O
##enko O
mv O

mis O
##´ O
##cic O
##ka O
sl O
##i O
##wk O
##a O
d O
optimization O
of O
the O
y O
##8 O
##31 O
##c O
mutation O
in O
human O

dna O
polymer O
##ase O
c O
by O
all O
##eli O
##c O
discrimination O
ass O
##ay O
act O
##a O
bio O
##chi O
##m O
pol O

2006 O
53 O
59 O
##1 O
5 O

11 O
lu O
##oma O
pt O
ee O
##rol O
##a O
j O
ah O
##ola O
s O
et O
al O
mitochondrial O
dna O
polymer O
##ase O

gamma O
variants O
in O
id O
##io O
##pathic O
sporadic O
parkinson O
disease O
ne O
##uro O
##logy O

2007 O
69 O
115 O
##2 O
9 O

12 O
david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O

parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
62 O

13 O
bal O
##oh O
r O
##h O
sal O
##ava O
##ggio O
##ne O
e O
mil O
##brand O
##t O
j O
pest O
##ron O
##k O
a O
fa O
##mi O
##lia O
##l O

parkinson O
##ism O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
from O
a O
mutation O
in O
the O
mit O
##o O

cho O
##nd O
##rial O
dna O
he O
##lica O
##se O
twinkle O
arch O
ne O
##uro O
##l O
2007 O
64 O
99 O
##8 O
1000 O

14 O
wilcox O
ra O
churchyard O
a O
dahl O
h O
##h O
hut O
##chison O
w O
##m O
kirby O
d O
##m O

thy O
##aga O
##raj O
##an O
d O
lev O
##od O
##opa O
response O
in O
parkinson O
##ism O
with O
multiple O

mitochondrial O
dna O
del O
##eti O
##ons O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
102 O
##0 O
3 O

15 O
tian O
##gy O
##ou O
w O
hudson O
g O
g O
##he O
##zzi O
d O
et O
al O
pol O
##g O
##1 O
in O
id O
##io O
##pathic O

parkinson O
disease O
ne O
##uro O
##logy O
2006 O
67 O
169 O
##8 O
700 O

16 O
ho O
##rva O
##th O
r O
k O
##ley O
ra O
loch O
##mu O
##ller O
h O
vo O
##rger O
##d O
m O
parkinson O

syndrome O
ne O
##uro O
##pathy O
and O
my O
##opa O
##thy O
caused O
by O
the O
mutation O

a O
##8 O
##34 O
##4 O
##g O
mer O
##rf O
in O
tr O
##nal O
##ys O

ne O
##uro O
##logy O
2007 O
68 O
56 O
8 O

17 O
bender O
a O
krishna O
##n O
k O
##j O
morris O
cm O
et O
al O
high O
levels O
of O
mit O
##och O
##on O

dr O
##ial O
dna O
del O
##eti O
##ons O
in O
sub O
##stan O
##tia O
ni O
##gra O
neurons O
in O
aging O
and O

parkinson O
disease O
nat O
gene O
##t O
2006 O
38 O
51 O
##5 O
7 O

18 O
sc O
##ha O
##pi O
##ra O
ah O
mitochondrial O
disease O
lance O
##t O
2006 O
36 O
##8 O
70 O
82 O

46 O
##4 O
f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O

two O
novel O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
in O
a O
patient B-PATIENT
with O
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
lev O
##od O
##opa O
responsive O
pseudo O
or B-HPO_TERM
##th I-HPO_TERM
##osta I-HPO_TERM
##tic I-HPO_TERM
tremor I-HPO_TERM
and O
parkinson B-HPO_TERM
##ism I-HPO_TERM
fed O
##eric O
##a O
in O
##vern O
##iz O
##zi O
a O
1 O
sara O
var O
##ane O
##se O
b O
c O
1 O
astrid O
thomas O
b O
c O
franco O
carr O
##ara O
a O
marco O
ono O
##fr O
##j O
b O
c O
massimo O
zev O
##iani O
a O
a O
unit O
of O
molecular O
ne O
##uro O
##gen O
##etic O
##s O
pier O
##fra O
##nco O
e O
luisa O
marian O
##i O
center O
for O
the O
study O
of O
children O
s O
mitochondrial O
disorders O
c O
best O
##a O
neurological O
institute O
foundation O
ir O
##cc O
##s O
milan O
italy O
b O
department O
of O
on O
##cology O
neuroscience O
and O
ne O
##uro O
##phy O
##sio O
##path O
##ology O
university O
g O
d O
ann O
##un O
##zio O
chi O
##eti O
pe O
##sca O
##ra O
italy O

c O
aging O
research O
center O
ce O
s O
i O
g O
d O
ann O
##un O
##zio O
university O
foundation O
chi O
##eti O
pe O
##sca O
##ra O
italy O
received O
31 O
january O
2008 O
received O
in O
revised O
form O
31 O
january O
2008 O
accepted O
2 O
april O
2008 O
abstract O
different O
mutations O
or O
combinations O
of O
mutations O
in O
pol O
##g O
##1 O
the O
gene O
encoding O
pol O
ca O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O
polymer O
##ase O
are O
associated O
with O
a O
spectrum O
of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
parkinson O
##ian O
features O
have O
been O
reported O

as O
a O
late O
com O
##plication O
of O
pol O
##g O
##1 O
associated O
dominant O
pe O
##o O
good O
response O
to O
lev O
##od O
##opa O
or O
do O
##pa O
##mine O
ago O
##nist O
##s O
reduced O
do O
##pa O
##mine O
up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
and O
ne O
##uron O
##al O
loss O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
compact O
##a O
have O
been O
documented O
in O
a O
few O
cases O
here O
we O
report O
two O
novel O
mutations O
in O
pol B-GENE
##g I-GENE
##1 I-GENE
in O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient B-PATIENT
with O
auto O
##som O
##al O
recess O
##ive O
pe B-HPO_TERM
##o I-HPO_TERM
followed O
by O
pseudo B-HPO_TERM
or I-HPO_TERM
##th I-HPO_TERM
##osta I-HPO_TERM
##tic I-HPO_TERM
tremor I-HPO_TERM
evolving O
into O
lev O
##od O
##opa O
responsive O
parkinson B-HPO_TERM
##ism I-HPO_TERM
these O
observations O
support O
the O
hypothesis O
that O
mt O
##dna O
dysfunction O
is O
engaged O
in O
the O
pathogen O
##esis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O

o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O
key O
##words O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
parkinson O
##ism O
polymer O
##ase O
gamma O
mitochondrial O
dna O
multiple O
mt O
##dna O
del O
##eti O
##ons O
1 O
introduction O
mitochondrial O
dna O
mt O
##dna O
is O
faithful O
##ly O
replicate O
##d O
by O
dna O
polymer O
##ase O
v O
pol O
v O
an O
enzyme O
composed O
of O
a O
single O
145 O
k O
##da O
catalytic O
subunit O
pol O
ca O
bound O
to O
two O
55 O
k O
##da O
accessory O
subunit O
##s O
pol O
cb O
pol O
ca O
is O
encoded O
by O
pol O
##g O
##1 O
a O
23 O
ex O
##on O
gene O
located O
on O
human O
chromosome O
15 O
functional O
genetic O
variants O
of O
pol O
##g O
##1 O
are O
present O
in O
approximately O
0 O
5 O
of O
the O
general O
population O
numerous O

pol O
##g O
##1 O
mutations O
have O
been O
associated O
with O
a O
spectrum O
of O
clinical O
presentations O
including O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
juvenile O
onset O
ata O
##xia O
and O
ep O
##ile O
##psy O
and O
al O
##pers O
hut O
##ten O
##l O
och O
##er O
syndrome O
at O
the O
molecular O
level O
pe O
##o O
patients O
are O
characterized O
by O
the O
accumulation O
of O
a O
collection O
of O
deleted O
mt O
##dna O
species O
in O
affected O
tissues O
notably O
skeletal O
muscle O
and O
brain O
additional O
symptoms O
including O
mig O
##raine O
ep O
##i O
le O
##psy O
peripheral O
ne O
##uro O
##pathy O
ata O
##xia O
premature O
o O
##var O
##ian O
failure O
h O
##yp O
##ogo O
##nad O
##ism O
and O
male O
h O
##yp O
##of O
##ert O
##ility O
may O
occur O

in O
different O
pe O
##o O
families O
and O
with O
different O
pol O
##g O
##1 O
mu O
##ta O
ti O
##ons O
1 O
4 O
parkinson O
##ism O
is O
a O
rare O
and O
late O
onset O
com O
##pl O
##ica O
ti O
##on O
of O
pol O
##g O
##1 O
associated O
pe O
##o O
3 O
5 O
we O
report O
here O
on O
a O
patient O
presenting O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
followed O
by O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
molecular O
analysis O
showed O
that O
this O
patient O
is O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
two O
novel O
mutations O
of O
the O
pol O
##g O
##1 O
gene O
09 O
##60 O
89 O
##66 O
see O
front O
matter O
o O
2008 O
else O
##vier O
b O
v O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
nm O
##d O
2008 O
04 O
00 O
##5 O
corresponding O
author O
fa O
##x O
39 O
02 O
239 O
##4 O
261 O
##9 O

e O
mail O
address O
zev O
##iani O
ist O
##it O
##uto O
best O
##a O
it O
m O
zev O
##iani O
1 O
these O
authors O
contributed O
equally O
to O
this O
work O
www O
else O
##vier O
com O
locate O
nm O
##d O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
2 O
case O
description O
the O
patient B-PATIENT
is O
a O
54 B-AGE_FOLLOWUP
year O
old O
yo O
man O
from O
central O
italy O
his O
father O
died O
at O
71 O
years O
of O
lung O
cancer O
had O
non O
insulin O
dependent O
diabetes O
mel O
##lit O
##us O
but O
was O
free O
from O
any O
ne O
##uro O
logical O
sy O
##mpt O
##om O
the O
82 O
yo O
mother O
a O
47 O
yo O
brother O
and O
two O
29 O
and O
24 O
yo O
daughters O
are O
all O
alive O
and O
well O
the O
pro O
po O
##sit O
##us O
was O
born O
at O
term O
after O
an O
uneven O
##tf O
##ul O
pregnancy O
in O

contrast O
to O
what O
was O
reported O
previously O
6 O
this O
patient B-PATIENT
developed O
pe B-HPO_TERM
##o I-HPO_TERM
with O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
at O
30 B-AGE_ONSET
years O
of O
age O
f O
##ol O
lowe O
##d O
by O
progressive B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
with O
rhino B-HPO_TERM
##lal I-HPO_TERM
##ia I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
and O
wasting B-HPO_TERM
and O
tend B-HPO_TERM
##on I-HPO_TERM
are I-HPO_TERM
flex I-HPO_TERM
##ia I-HPO_TERM
reduction O
of O
cal O
##oric O
intake O
caused O
by O
severe O
d B-HPO_TERM
##ys I-HPO_TERM
ph I-HPO_TERM
##agi I-HPO_TERM
##a I-HPO_TERM
and O
the O
onset O
of O
chronic B-HPO_TERM
dia I-HPO_TERM
##rr I-HPO_TERM
##hoe I-HPO_TERM
##a I-HPO_TERM
resulted O
in O
severe B-HPO_TERM
body I-HPO_TERM
weight I-HPO_TERM
loss I-HPO_TERM
at O
50 O
years O
of O
age O
the O
patient O
developed O
tremor B-HPO_TERM
in O
the O
standing O
position O
dominant O
fr O
##e O
que O
##ncy O
at O
6 O
2 O
hz O
initially O
affecting O
the O
left O
lower O
limb O
then O
both O
lower O
limbs O
with O
occasional O
mild O
resting B-HPO_TERM
tremor I-HPO_TERM
of O

the O
hands O
this O
patient B-PATIENT
was O
included O
in O
a O
recent O
report O
on O
4 O
cases O
affected O
by O
lev O
##od O
##opa O
responsive O
pseudo O
or O
##th O
##o O
static O
tremor O
in O
parkinson O
##ism O
case O
3 O
in O
6 O
in O
the O
follow O
ing O
2 O
years O
he O
developed O
extra B-HPO_TERM
pyramid I-HPO_TERM
##al I-HPO_TERM
rigid I-HPO_TERM
##ity I-HPO_TERM
with O
a O
co B-HPO_TERM
##g I-HPO_TERM
##wheel I-HPO_TERM
sign I-HPO_TERM
reduced O
tapping O
left O
right O
and O
post B-HPO_TERM
##ural I-HPO_TERM
instability I-HPO_TERM
unified O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
21 O
points O
physical O
examination O
showed O
a O
h B-HPO_TERM
##yp I-HPO_TERM
##omi I-HPO_TERM
##mic I-HPO_TERM
face I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##op I-HPO_TERM
##hon I-HPO_TERM
##ia I-HPO_TERM
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
mild O
symmetrical O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
muscle I-HPO_TERM
weak I-HPO_TERM
ness I-HPO_TERM
medical O
research O
council O
grade O
4 O
and O
absence O
of O

lower O
limb O
tend O
##on O
reflex O
##es O
an O
ec O
##g O
and O
structural O
brain O
mri O
were O
both O
normal O
a O
single O
photon O
emission O
com O
put O
##ed O
tom O
##ography O
spec O
##t O
using O
123 O
i O
2 O
##b O
car O
##bo O
##me O
tho O
##xy O
3 O
##b O
4 O
io O
##do O
##ph O
##en O
##yl O
n O
3 O
flu O
##oro O
##pro O
##py O
##l O
nor O
##tro O
##pan O
##e O
i O
f O
##p O
ci O
##t O
spec O
##t O
revealed O
a O
bilateral O
##ly O
reduced O
do O
##pa O
mine O
up O
##take O
in O
the O
corpus O
st O
##ria O
##tum O
right O
left O
serum O
cr B-HPO_TERM
##ea I-HPO_TERM
##tine I-HPO_TERM
kinase I-HPO_TERM
ck I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
215 I-HPO_TERM
##6 I-HPO_TERM
u O
l O
normal O
140 O
u O
l O
an O
em O
##g O
was O
compatible O
with O
ax B-HPO_TERM
##onal I-HPO_TERM
sensory I-HPO_TERM
ne I-HPO_TERM
##u I-HPO_TERM
ro I-HPO_TERM
##pathy I-HPO_TERM
associated O
with O
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
features O
the O
patient O
was O
initially O
treated O
with O
low O
doses O
of O
do O
##pa O
##mine O
ago O
##nist O
##s O

pr O
##ami O
##pe O
##x O
##ole O
2 O
1 O
mg O
day O
associated O
with O
lev O
##od O
##opa O
up O
to O
400 O
mg O
day O
with O
disappearance O
of O
standing O
legs O
tremor O
and O
reduction O
in O
up O
##dr O
##s O
motor O
score O
two O
years O
later O
he O
complained O
of O
end O
of O
dose O
deter O
##ior O
##a O
ti O
##on O
with O
re O
occurrence O
of O
the O
di O
##sa O
##bling O
standing B-HPO_TERM
tremor I-HPO_TERM
which O
appeared O
1 O
5 O
2 O
5 O
h O
after O
each O
single O
lev O
##od O
##opa O
up O
##dr O
##s O
motor O
score O
was O
27 O
in O
on O
state O
and O
42 O
in O
off O
state O
and O
was O
associated O
with O
severe B-HPO_TERM
anxiety I-HPO_TERM
and O
panic B-HPO_TERM
attacks I-HPO_TERM
during O
the O
off O
states O
lev O
##od O
##opa O
was O
increased O
to O
600 O
mg O
day O
and O
en O
##ta O
##cap O
##one O
was O
added O
1200 O
mg O
day O
the O
patient O
did O
not O
report O
further O
fluctuations O
for O
the O
next O

6 O
months O
when O
he O
developed O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
re O
occurrence O
of O
end O
of O
dose O
deterioration O
and O
severe B-HPO_TERM
stand I-HPO_TERM
ing I-HPO_TERM
tremor I-HPO_TERM
en O
##ta O
##cap O
##one O
was O
substituted O
with O
to O
##lc O
##ap O
##one O
100 O
mg O
t O
i O
d O
with O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
and O
off O
state O
since O
then O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
has O
progressively O
worsened O
with O
fur O
the O
##r O
loss B-HPO_TERM
of I-HPO_TERM
weight I-HPO_TERM
because O
of O
mal B-HPO_TERM
##nut I-HPO_TERM
##rit I-HPO_TERM
##ion I-HPO_TERM
requiring O
the O
positioning O
of O
a O
per B-HPO_TERM
##cut I-HPO_TERM
##aneous I-HPO_TERM
end I-HPO_TERM
##os I-HPO_TERM
##copic I-HPO_TERM
gas I-HPO_TERM
##tro I-HPO_TERM
##sto I-HPO_TERM
##my I-HPO_TERM
for O
enter O
##al O
nutrition O
onset O
of O
vent B-HPO_TERM
##ila I-HPO_TERM
##tory I-HPO_TERM
failure I-HPO_TERM
has O
required O
mechanical B-HPO_TERM
ventilation I-HPO_TERM
the O
serum B-HPO_TERM
ck I-HPO_TERM
level I-HPO_TERM
remains I-HPO_TERM
high I-HPO_TERM
61 O
##43 O
u O
l O
with O
worse O
##ning O
and O
spreading O
of O
the O
muscle O

weakness O
high O
serum O
ck O
is O
an O
unusual O
but O
occasionally O
reported O
finding O
in O
pol O
##g O
##1 O
associated O
pe O
##o O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
for O
instance O
hudson O
et O
al O
5 O
report O
a O
patient O
individual O
ii O
8 O
with O
serum O
ck O
levels O
2500 O
u O
l O
the O
tremor O
and O
the O
off O
state O
now O
occur O
1 O
5 O
2 O
h O
after O
lev O
##od O
##opa O
administration O
which O
must O
be O
repeated O
7 O
8 O
times O
per O
day O
in O
the O
last O
months O
the O
patient O
has O
also O
developed O
progressive B-HPO_TERM
cognitive I-HPO_TERM
dysfunction I-HPO_TERM
associated O
with O
psychotic B-HPO_TERM
features I-HPO_TERM
3 O
methods O
southern O
b O
##lot O
analysis O
of O
mt O
##dna O
was O
carried O
out O
on O
dna O
extracted O
from O
skeletal O
muscle O
following O
standard O

procedures O
7 O
and O
using O
the O
ec O
##l O
che O
##mi O
##lum O
##ines O
##cence O
as O
the O
detection O
method O
dna O
from O
peripheral O
blood O
l O
##ym O
ph O
##ocytes O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
the O
22 O
coding O
ex O
##ons O
of O
the O
pol O
##g O
##1 O
gene O
ex O
##ons O
223 O
polymer O
##ase O
chain O
reaction O
pc O
##r O
conditions O
were O
96 O
for O
30 O
s O
56 O
for O
20 O
s O
and O
72 O
for O
60 O
s O
for O
30 O
cycles O
plus O
as O
initial O
den O
##at O
##ur O
at O
##ion O
step O
at O
96 O
for O
2 O
min O
pc O
##r O
fragments O
were O
ana O
l O
##y O
##zed O
by O
automated O
nu O
##cle O
##otide O
sequencing O
using O
the O
big O
dye O
term O
##inator O
ready O
reaction O
kit O
version O
2 O
on O
a O
310 O
##0 O
genetic O
analyze O
##r O
automated O
sequence O
##r O
applied O
bio O
##sy O
##s O

te O
##ms O
the O
sequence O
variants O
found O
in O
the O
patient O
were O
searched O
for O
in O
available O
relatives O
as O
well O
as O
in O
100 O
con O
##se O
##c O
ut O
##ive O
control O
subjects O
200 O
all O
##eles O
4 O
results O
a O
skeletal O
muscle O
bio O
##psy O
taken O
when O
the O
patient O
was O
32 O
years O
old O
showed O
the O
presence O
of O
several O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
with O
variation B-HPO_TERM
of I-HPO_TERM
fiber I-HPO_TERM
caliber I-HPO_TERM
and O
nuclear B-HPO_TERM
central I-HPO_TERM
##ization I-HPO_TERM
and O
reduced O
or O
absent B-HPO_TERM
react I-HPO_TERM
##ivity I-HPO_TERM
to I-HPO_TERM
cy I-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
fig O
1a O
sequence O
analysis O
of O
mt O
##dna O
excluded O
the O
pre O
##s O
en O
##ce O
of O
point O
mutations O
commonly O
associated O
with O
mer O
##rf O
and O
mel O
##as O
however O
southern O
b O
##lot O
analysis O

revealed O
the O
presence O
of O
a O
collection O
of O
deleted O
mt O
##dna O
species O
in O
addition O
to O
wild O
type O
mt O
##dna O
fig O
1b O
6 O
these O
results O
prompted O
us O
to O
consider O
the O
possibility O
of O
mutation O
s O
in O
one O
of O
the O
nucleus O
encoded O
genes O
com O
mon O
##ly O
associated O
with O
mt O
##dna O
instability O
and O
pe O
##o O
namely O
twinkle O
ant O
##1 O
and O
pol O
##g O
##1 O
sequence O
analysis O
of O
the O
first O
two O
genes O
ruled O
out O
the O
presence O
of O
path O
##o O
gen O
##ic O
mutations O
however O
sequence O
analysis O
of O
the O
entire O
coding O
region O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
led O
us O
to O
the O
id O
##ent O
##if O
##i O
cat O
##ion O
of O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
mutations O
one O
is O
a O
c B-GENE_VARIANT
128 I-GENE_VARIANT
##8 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
trans O
##version O
predicting O
a O
p B-GENE_VARIANT
m I-GENE_VARIANT
##43 I-GENE_VARIANT
##0 I-GENE_VARIANT
##l I-GENE_VARIANT
amino O

acid O
substitution O
the O
second O
is O
a O
c B-GENE_VARIANT
275 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
c I-GENE_VARIANT
transition O
determining O
the O
amino O
##ac O
##id O
substitution O
p B-GENE_VARIANT
w I-GENE_VARIANT
##9 I-GENE_VARIANT
##18 I-GENE_VARIANT
##r I-GENE_VARIANT
fig O
2a O
segregation O
analysis O
carried O
out O
in O
available O
members O
of O
the O
family O
fig O
2 O
##b O
revealed O
the O
presence O
of O
the O
275 O
##2 O
##t O
c O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
the O
mother O
of O
the O
patient O
and O
in O
the O
two O
healthy O
daughters O
while O
no O
mutation O
was O
detected O
in O
his O
brother O
f O
in O
##vern O
##iz O
##zi O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
18 O
2008 O
460 O
46 O
##4 O
46 O
##1 O
5 O
discussion O
we O
found O
two O
novel O
het O
##ero O
##zy O
##go O
##us O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
patient B-PATIENT
characterized O
by O
pe B-HPO_TERM
##o I-HPO_TERM

muscle B-HPO_TERM
weakness I-HPO_TERM
and O
later O
onset O
lev B-HPO_TERM
##od I-HPO_TERM
##opa I-HPO_TERM
responsive I-HPO_TERM
pseudo I-HPO_TERM
or I-HPO_TERM
##th I-HPO_TERM
##osta I-HPO_TERM
##tic I-HPO_TERM
tremor I-HPO_TERM
and O
parkinson B-HPO_TERM
##ism I-HPO_TERM
6 O
the O
maternal O
all O
##ele O
predict O
##s O
a O
p B-GENE_VARIANT
w I-GENE_VARIANT
##9 I-GENE_VARIANT
##18 I-GENE_VARIANT
##r I-GENE_VARIANT
amino O
##ac O
##id O
sub O
st O
##it O
##ution O
in O
a O
highly O
conserved O
position O
in O
the O
pol O
ca O
poly O
mer O
##ase O
domain O
http O
dir O
apps O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
8 O
the O
paternal O
all O
##ele O
harbor O
##s O
a O
c B-GENE_VARIANT
128 I-GENE_VARIANT
##8 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
trans O
##version O
pre O
di O
##cting O
the O
replacement O
of O
the O
p B-GENE_VARIANT
m I-GENE_VARIANT
##43 I-GENE_VARIANT
##0 I-GENE_VARIANT
residue O
into O
an O
l O
residue O
m O
##43 O
##0 O
is O
contained O
within O
the O
so O
called O
space O
##r O
fig O
1 O
morphological O
and O
molecular O
findings O
in O
skeletal O
muscle O
a O
top O
panel O
nad O
##h O
de O
##hy O
##dro O
##genase O
stain O
##ing O
shows O
rr B-HPO_TERM
##f I-HPO_TERM
as O
##ter O
##isk O
##s O
bottom O
panel O

cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
stain O
##ing O
of O
a O
serial O
muscle O
section O
shows O
several O
fibers O
with O
reduced O
or O
absent O
react O
##ivity O
including O
the O
same O
two O
rr B-HPO_TERM
##f I-HPO_TERM
shown O
in O
the O
top O
panel O
as O
##ter O
##isk O
##s O
b O
southern O
b O
##lot O
analysis O
on O
pv O
##ui O
##i O
linear O
##ized O
mt O
##dna O
performed O
on O
the O
muscle O
bio O
##psy O
of O
the O
patient O
p O
and O
a O
control O
c O
both O
p O
and O
c O
samples O
show O
a O
16 O
6 O
kb O
band O
corresponding O
to O
wild O
type O
mt O
##dna O
arrow O
in O
addition O
the O
p O
sample O
shows O
a O
collection O
of O
smaller O
bands O
corresponding O
to O
del O
##eti O
##on O
containing O
mt O
##dna O
species O

fig O
2 O
a O
identification O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
by O
sequence O
analysis O
the O
electro O
##pher O
##og O
##ram O
##s O
show O
the B-GENE_VARIANT
c I-GENE_VARIANT
128 I-GENE_VARIANT
##8 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
trans O
##version O
predicting O
a O
p B-GENE_VARIANT
m I-GENE_VARIANT
##43 I-GENE_VARIANT
##0 I-GENE_VARIANT
##l I-GENE_VARIANT
amino O
##ac O
##id O
substitution O
and O
the O
c B-GENE_VARIANT
275 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
c I-GENE_VARIANT
transition O
predicting O
a O
p B-GENE_VARIANT
w I-GENE_VARIANT
##9 I-GENE_VARIANT
##18 I-GENE_VARIANT
##r I-GENE_VARIANT
amino O
##ac O
##id O
substitution O
b O
family O
pe O
##di O
##gree O
the O
solid O
black O
square O
symbol O
indicates O
the O
pro O
##band O
open O
symbols O
indicate O
unaffected O
individuals O
the O
and O
symbols O
indicate O
mutant O
vs O
wild O
type O
all O
##eles O
c O
multiple O
alignment O
of O
mutation O
containing O
pol O
ca O
regions O
in O
different O
species O
the O
red O
boxes O
indicate O
the O
amino O
##ac O
##id O
substitution O
##s O
found O
in O
the O
patient O

movement O
disorders O

vol O
23 O
no O
9 O
2008 O
pp O
128 O
##6 O
132 O
##0 O

2008 O
movement O
disorder O
society O

brief O
reports O

apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O

sebastian O
pau O
##s O
md O
1 O
ga O
##bor O
z O
##sur O
##ka O
phd O
md O
2 O
miriam O
baron O
phd O
2 O
marcus O
des O
##cha O
##uer O
md O
3 O
christian O
bam O
##berg O
md O
4 O
thomas O
k O
##lock O
##get O
##her O
md O
1 O
wolf O
##ram O
s O
kun O
##z O
phd O
2 O
and O
corn O
##elia O
ko O
##rn O
##bl O
##um O
md O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
2d O
##ep O
##art O
##ment O
of O
ep O
##ile O
##pt O
##ology O
and O
life O
and O
brain O
center O
university O
of O
bonn O
bonn O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
university O
of O
halle O
wit O
##tenberg O

halle O
sa O
##ale O
germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
r O
##hein O
mo O
##sel O
fa O
##ch O
##k O
##lini O
##k O
and O
##ern O
##ach O
germany O

abstract O
patients O
harbor O
##ing O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
present O
with O
a O
broad O
variety O
of O
neurological O
ph O
##eno O
##type O
##s O
including O
ce O
##re O
##bella O
##r O
ata O
##xia O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
my O
##oc O
##lon O
##us O
ep O
##ile O
##psy O
and O
peripheral O
ne O
##uro O
##pathy O
with O
exception O
of O
ata O
##xia O
and O
my O
##oc O
##lon O
##us O
movement O
disorders O
are O
not O
typical O
features O
of O
pol O
##g O
##1 O
associated O
disorders O
we O
report O
on O
two O
affected O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
mutations O
one O
suffering O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
due O
to O
focal O
eye O
##lid O
d O
##yst O
##onia O
that O
mimic O
##ked O
progression O
of O
pt O
##osis O
resulting O
in O
functional O
blindness O
so O
far O
focal O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O
and O
should O
be O
considered O
when O
investigating O
patients O
with O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O
2008 O
movement O
disorder O
society O

key O
words O
focal O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
pt O
##osis O
pol O
##g O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O

mutations O
in O
the O
polymer O
##ase O
g O
gene O
pol O
##g O
##1 O
coding O
for O
a O
protein O
involved O
in O
mitochondrial O
dna O
mt O
##dna O
maintenance O
cause O
a O
broad O
variety O
of O
auto O
##som O
##al O
dom O
##i O

correspondence O
to O
dr O
sebastian O
pau O
##s O
department O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O

e O
mail O
spa O
##us O
un O
##i O
bonn O
de O

received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O

april O
2008 O

published O
online O
10 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O

nan O
##t O
and O
recess O
##ive O
neurological O
ph O
##eno O
##type O
##s O
including O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
pt O
##osis O
ce O
##re O
##bella O
##r O
ata O
##xia O
ep O
##ile O
##psy O
dementia O
my O
##opa O
##thy O
my O
##oc O
##lon O
##us O
peripheral O
ne O
##uro O
##pathy O
and O
headache O
in O
some O
cases O
accompanied O
by O
liver O
involvement O
1 O
in O
pol O
##g O
##1 O
associated O
disorders O
relationship O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
is O
complex O
with O
a O
considerable O
overlap O
of O
clinical O
spectrum O
2 O
3 O
with O
exception O
of O
ata O
##xia O
and O
my O
##oc O
##lon O
##us O
movement O
disorders O
are O
not O
typical O
features O
of O
pol O
##g O
##1 O
mutations O
recently O
parkinson O
##ism O
has O
been O
associated O
to O
pol O
##g O
##1 O
accompanied O
either O
by O
pe O
##o O
and O
other O
characteristic O
symptoms O
4 O
or O
ne O
##uro O
##pathy O
alone O
5 O
one O
study O
in O
finnish O
patients O
with O
recess O
##ive O
ata O
##xia O
due O
to O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutations O
described O
involuntary O
movements O
namely O
at O
##het O
##oid O
and O
cho O
##re O
##oat O
##het O
##oid O
movements O
of O
ex O
##tre O
##mit O
##ies O
and O
face O
and O
tremor O
of O
head O
and O
limbs O
6 O

here O
we O
report O
on O
two O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
the O
most O
frequent O
recess O
##ive O
pol O
##g O
##1 O
mutations O
presenting O
with O
a O
remarkably O
later O
onset O
and O
longer O
survival O
than O
most O
patients O
of O
the O
same O
gen O
##otype O
one O
suffered O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
al O
##o O
due O
to O
d O
##yst O
##onic O
activity O
of O
eye O
##lid O
muscles O
resulting O
in O
functional O
blindness O
so O
far O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O

subjects O
and O
methods O

subjects O

three O
sisters O
ages O
39 O
patient O
1 O
38 O
and O
37 O
patient O
2 O
the O
children O
of O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
were O
normal O
at O
birth O
and O
through O
childhood O
the O
oldest O
developed O
neurological O
symptoms O
at O
the O
age O
of O
28 O
herald O
##ed O
by O
ep O
##iso O
##dic O
headache O
cognitive O
decline O
and O
seizures O
repeatedly O
resulting O
in O
generalized O
status O
ep O
##ile O
##ptic O
##us O
when O
seen O
ﬁ O
##rst O
at O
age O
32 O
patient O
1 O
presented O
with O
marked O
ata O
##xia O
both O
due O
to O
ce O
##re O
##bella O
##r O
affection O
and O
sensor O
##imo O
##tor O
peripheral O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
pe O
##o O
with O
dip O
##lo O
##pia O
mild O
bilateral O
pt O
##osis O
ep O
##ile O
##psy O
moderate O
cognitive O
impairment O
my O
##oc O
##lon O
##us O
and O
cho O
##re O
##oat O
##het O
##oid O
movements O
of O
the O
arms O
and O
per O
##ior O
##al O
muscles O
she O
had O
never O
been O
treated O
with O
ne O
##uro O
##le O
##ptic O
##s O
mri O
of O
the O
brain O
showed O
moderate O
generalized O
cerebral O
at O
##rop O
##hy O
including O
mid O
##bra O
##in O
and O
ce O
##re O
##bell O
##um O
his O
##tology O
of O
vast O
##us O
lateral O
##is O
muscle O
revealed O
mild O
un O
##sp O
##ec O
##i O
##ﬁ O
##c O
my O
##opa O
##th O
##ological O
alterations O
without O
ragged O

128 O
##6 O

apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
128 O
##7 O

table O
1 O
ph O
##eno O
##type O
##s O
gen O
##otype O
##s O
and O
mt O
##dna O
copy O
numbers O
in O
blood O

age O
years O

copy O
numbers O
are O
given O
in O
mean O
6 O
sd O

pol O
##g O
##1 O
gen O
##otype O
the O
two O
sides O
of O
the O
slash O
indicate O
gen O
##ot O
##yp O
##ing O
results O
of O
the O
two O
chromosomes O
as O
determined O
by O
pc O
##r O
rf O
##lp O
the O
term O
w O
##t O
in O
this O
respect O
indicates O
that O
none O
of O
the O
three O
pol O
##g O
##1 O
mutations O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
and O
a O
##46 O
##7 O
##t O
were O
detected O

sd O
standard O
deviation O
d O
onset O
disease O
onset O
na O
not O
applicable O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
w O
##t O
wild O
type O

red O
or O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
ﬁ O
##bers O
while O
bio O
##chemical O
analyses O
of O
respiratory O
chain O
enzymes O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
were O
normal O
table O
1 O

patient O
2 O
was O
healthy O
until O
the O
age O
of O
36 O
when O
she O
developed O
pe O
##o O
mild O
bilateral O
pt O
##osis O
d O
##ys O
##arth O
##ria O
ata O
##xia O
and O
ne O
##uro O
##pathy O
brain O
mri O
was O
normal O
examination O
of O
muscle O
tissue O
was O
identical O
to O
patient O
1 O

mother O
father O
and O
the O
third O
sister O
were O
seen O
at O
ages O
64 O
64 O
and O
38 O
respectively O
besides O
ob O
##ste O
##tric O
cho O
##les O
##tas O
##is O
in O
the O
sister O
no O
liver O
disease O
diabetes O
or O
neurological O
symptoms O
became O
evident O

genetic O
analysis O

total O
dna O
was O
extracted O
from O
muscle O
tissue O
in O
both O
patients O
followed O
by O
long O
range O
pc O
##r O
to O
test O
for O
mt O
##dna O
rear O
##rang O
##ement O
##s O
also O
total O
dna O
was O
extracted O
from O
blood O
in O
all O
subjects O
at O
ﬁ O
##rst O
analyzed O
for O
the O
two O
most O
frequent O
recess O
##ive O
mutations O
in O
pol O
##g O
##1 O
a O
##46 O
##7 O
##t O
w O
##7 O
##48 O
##s O
and O
the O
e O
##11 O
##43 O
##g O
poly O
##morphism O
by O
pc O
##r O
rf O
##lp O
followed O
by O
sequencing O

copy O
numbers O
of O
the O
mitochondrial O
genome O
were O
determined O
in O
blood O
le O
##uk O
##ocytes O
in O
all O
subjects O
by O
real O
##time O
pc O
##r O
as O
described O
earlier O
7 O
in O
all O
subjects O
quad O
##rup O
##le O
experiments O
were O
performed O
and O
arithmetic O
means O
and O
standard O
deviation O
##s O
were O
calculated O
copy O
numbers O
were O
compared O
to O
those O
of O
15 O
age O
##and O
sex O
matched O
healthy O
controls O
f O
m O
13 O
2 O
using O
student O
s O
t O
test O

results O

clinical O
course O

after O
initial O
presentation O
patient O
1 O
was O
seen O
at O
regular O
intervals O
and O
a O
slow O
worse O
##ning O
of O
dip O
##lo O
##pia O
ne O
##uro O
##pathy O
and O
ata O
##xia O
was O
documented O
whereas O
ep O
##ile O
##psy O

cho O
##re O
##oat O
##het O
##osis O
and O
cognitive O
function O
remained O
stable O
involuntary O
closing O
of O
the O
eyes O
due O
to O
lowering O
of O
the O
lids O
also O
worsened O
at O
ﬁ O
##rst O
attributed O
to O
ag O
##gra O
##vation O
of O
pt O
##osis O
resulting O
in O
phases O
of O
functional O
blindness O
at O
the O
age O
of O
35 O
at O
this O
time O
she O
started O
to O
rec O
##line O
her O
head O
and O
to O
hold O
open O
her O
eyes O
with O
her O
ﬁ O
##nger O
##s O
during O
conversation O
or O
reading O
attempts O
accompanied O
by O
voluntary O
contraction O
of O
the O
frontal O
##is O
muscle O
as O
sometimes O
observed O
in O
al O
##o O
although O
no O
apparent O
b O
##le O
##pha O
##ros O
##pas O
##m O
was O
observed O
and O
the O
patient O
s O
maneuvers O
did O
not O
function O
as O
a O
sensory O
trick O
we O
assumed O
d O
##yst O
##onic O
closing O
of O
the O
eyelids O
in O
contrast O
to O
my O
##opa O
##thic O
pt O
##osis O
and O
needle O
electro O
##my O
##ography O
revealed O
persistent O
and O
d O
##yst O
##onic O
muscle O
activity O
of O
the O
pre O
##tar O
##sal O
part O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
injection O
##s O
of O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
a O
bon O
##t O
a O
bot O
##ox O
##1 O
into O
both O
upper O
eyelids O
4 O
units O
per O
side O
led O
to O
marked O
improvement O
with O
mild O
residual O
pt O
##osis O
only O
similar O
to O
the O
initial O
clinical O
examination O
bon O
##t O
a O
injection O
##s O
were O
continued O
in O

3 O
months O
intervals O
with O
ongoing O
success O
until O
now O
when O
patient O
2 O
was O
seen O
1 O
year O
after O
disease O
onset O
there O
were O
no O
involuntary O
movements O
of O
any O
kind O

long O
range O
pc O
##r O
detected O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
skeletal O
muscle O
of O
patients O
1 O
and O
2 O
both O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
mother O
and O
healthy O
sister O
were O
het O
##ero O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
the O
father O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
as O
described O
before O
3 O
6 O
w O
##7 O
##48 O
##s O
was O
found O
together O
with O
e O
##11 O
##43 O
##g O
in O
each O
case O
suggesting O
all O
##eli O
##c O
coupling O
of O
both O
mutations O

mt O
##dna O
copy O
numbers O
in O
blood O
were O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
controls O
even O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O

128 O
##8 O
pau O
##s O
et O
al O

more O
obvious O
in O
patient O
1 O
with O
earlier O
disease O
onset O
and O
more O
severe O
clinical O
ph O
##eno O
##type O
reduction O
of O
68 O
and O
56 O
respectively O
also O
mean O
copy O
numbers O
of O
the O
healthy O
family O
members O
were O
lower O
when O
compared O
with O
mean O
values O
of O
controls O
reaching O
sign O
##i O
##ﬁ O
##can O
##ce O
in O
the O
mother O
only O

discussion O

our O
study O
on O
a O
family O
of O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutation O
carriers O
including O
two O
affected O
siblings O
extends O
previous O
observations O
on O
the O
diversity O
of O
clinical O
spectrum O
in O
pol O
##g O
##1 O
associated O
disorders O
in O
patient O
1 O
diagnosis O
of O
al O
##o O
due O
to O
focal O
eye O
##lid O
d O
##yst O
##onia O
was O
probably O
delayed O
because O
it O
accompanied O
mild O
pt O
##osis O
in O
pe O
##o O
and O
mimic O
##ked O
severe O
par O
##esis O
of O
eye O
##lid O
muscles O
indeed O
al O
##o O
is O
known O
to O
occur O
without O
any O
obvious O
spa O
##sms O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
as O
seen O
in O
typical O
b O
##le O
##pha O
##ros O
##pas O
##m O
frequently O
ham O
##per O
##ing O
recognition O
8 O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
separating O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
al O
##o O
from O
my O
##ast O
##hen O
##ic O
or O
my O
##opa O
##thic O
pt O
##osis O
were O
reported O
before O
and O
in O
some O
cases O
the O
underlying O
disorder O
was O
only O
un O
##mas O
##ked O
by O
a O
poor O
response O
with O
severe O
pt O
##osis O
after O
bon O
##t O
a O
treatment O
9 O
10 O
in O
isolated O
al O
##o O
bon O
##t O
a O
was O
shown O
to O
be O
effective O
11 O
and O
our O
patient O
suffered O
no O
side O
effects O
after O
repeated O
injection O
##s O
in O
ambiguous O
cases O
distinct O
electro O
##my O
##ographic O
features O
of O
the O
various O
compounds O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
al O
##o O
offer O
cl O
##ari O
##ﬁ O
##cation O
12 O

frequently O
al O
##o O
with O
and O
without O
b O
##le O
##pha O
##ros O
##pas O
##m O
is O
associated O
to O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
mostly O
parkinson O
s O
disease O
and O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
8 O
focal O
d O
##yst O
##onia O
was O
reported O
in O
leigh O
s O
syndrome O
and O
le O
##ber O
s O
hereditary O
optic O
ne O
##uro O
##pathy O
13 O
but O
is O
not O
a O
typical O
feature O
of O
mitochondrial O
disease O
in O
adulthood O
so O
far O
it O
was O
unknown O
in O
patients O
harbor O
##ing O
pol O
##g O
##1 O
mutations O
as O
a O
defect O
of O
mitochondrial O
complex O
i O
was O
implicated O
in O
the O
pathogen O
##esis O
of O
focal O
d O
##yst O
##onia O
before O
14 O
and O
mitochondrial O
disease O
presenting O
with O
d O
##yst O
##onia O
as O
dominant O
clinical O
ph O
##eno O
##type O
was O
reported O
very O
recently O
15 O
our O
observation O
just O
##i O
##ﬁ O
##es O
further O
examination O
of O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
in O
fact O
it O
was O
shown O
that O
pol O
##g O
##1 O
mutations O
can O
lead O
to O
basal O
gang O
##lia O
dysfunction O
namely O
parkinson O
##ism O
even O
in O
the O
absence O
of O
primary O
clinical O
features O
of O
pol O
##g O
##1 O
associated O
disorders O
5 O

finally O
our O
observations O
might O
further O
el O
##uc O
##ida O
##te O
the O
complex O
relationship O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
in O
pol O
##g O
##1 O
and O
diagnostic O
procedures O
first O
our O
patients O
had O
a O
later O
disease O
onset O
and O
longer O
survival O
time O
than O
most O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
compound O
het O
##ero O
##zy O
##go O
##tes O
reported O
before O
and O
those O
of O
similar O
course O
of O
disease O
featured O
a O
ph O
##eno O
##type O
resembling O
our O
affected O

siblings O
2 O
3 O
we O
h O
##yp O
##oth O
##es O
##ize O
that O
although O
often O
severe O
a O
subgroup O
of O
compound O
het O
##ero O
##zy O
##go O
##tes O
shows O
a O
considerable O
mild O
##er O
ph O
##eno O
##type O
of O
later O
disease O
onset O
and O
longer O
survival O
eventually O
distinguished O
by O
ata O
##xia O
and O
adult O
onset O
pe O
##o O
probably O
de O
##ﬁ O
##ned O
by O
further O
yet O
unknown O
gen O
##omic O
variations O
second O
mt O
##dna O
content O
in O
blood O
was O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
age O
##and O
sex O
matched O
healthy O
controls O
suggesting O
that O
mt O
##dna O
de O
##ple O
##tion O
is O
not O
restricted O
to O
liver O
or O
muscle O
tissue O
in O
pol O
##g O
1 O
associated O
disorders O
but O
may O
be O
detected O
in O
easily O
obtain O
##able O
blood O
samples O
as O
well O

in O
conclusion O
pol O
##g O
##1 O
mutations O
might O
present O
with O
treat O
##able O
focal O
d O
##yst O
##onia O
which O
should O
be O
considered O
in O
cases O
of O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O

references O

hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
dna O
polymer O
##ase O
gamma O
and O
human O
disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
244 O
252 O

ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
167 O
##4 O
168 O
##4 O

t O
##zo O
##uli O
##s O
c O
nielsen O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O

lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
##1 O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O

baron O
m O
ku O
##din O
ap O
kun O
##z O
w O
##s O
mitochondrial O
dysfunction O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
bio O
##che O
##m O
soc O
trans O
2007 O
35 O
122 O
##8 O
123 O
##1 O

k O
##rac O
##k O
p O
marion O
m O
##h O
apr O
##ax O
##ia O
of O
lid O
opening O
a O
focal O
eye O
##lid O
d O
##yst O
##onia O
clinical O
study O
of O
32 O
patients O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
610 O
61 O
##5 O

roberts O
me O
ste O
##iger O
m O
##j O
hart O
ik O
presentation O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mimic O
##king O
b O
##le O
##pha O
##ros O
##pas O
##m O
ne O
##uro O
##logy O
2002 O
58 O
150 O
151 O

muller O
va O
##hl O
k O
##r O
ko O
##lb O
##e O
h O
e O
##gens O
##per O
##ger O
r O
deng O
##ler O
r O
mit O
##och O
##ond O
##rio O
##pathy O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
treatment O
with O
bot O
##ulin O
##um O
toxin O
muscle O
nerve O
2000 O
23 O
64 O
##7 O
64 O
##8 O

forget O
r O
to O
##z O
##lova O
##nu O
v O
ian O
##cu O
a O
bog O
##hen O
d O
bot O
##ulin O
##um O
toxin O
improves O
lid O
opening O
delays O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
associated O
apr O
##ax O
##ia O
of O
lid O
opening O
ne O
##uro O
##logy O
2002 O
58 O
1843 O
1846 O

ara O
##mide O
##h O
m O
on O
##ger O
##bo O
##er O
de O
vis O
##ser O
b O
##w O
dev O
##ries O
##e O
pp O
bo O
##ur O
l O
##j O
sp O
##ee O
##lman O
jd O
electro O
##my O
##ographic O
features O
of O
lev O
##ator O
pal O
##pe O
##bra O
##e O
superior O
##is O
and O
orb O
##icular O
##is O
o O
##cu O
##li O
muscles O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
brain O
1994 O
117 O
27 O
38 O

hanna O
mg O
b O
##hat O
##ia O
k O
##p O
movement O
disorders O
and O
mitochondrial O
dysfunction O
cu O
##rr O
op O
##in O
ne O
##uro O
##l O
1997 O
10 O
351 O
356 O

sc O
##ha O
##pi O
##ra O
ah O
warner O
t O
gas O
##h O
mt O
cl O
##eet O
##er O
mw O
marin O
##ho O
cf O
cooper O
j O
##m O
complex O
i O
function O
in O
fa O
##mi O
##lia O
##l O
and O
sporadic O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
1997 O
41 O
55 O
##6 O
55 O
##9 O

mc O
##far O
##land O
r O
chin O
##nery O
p O
##f O
blake O
##ly O
el O
et O
al O
homo O
##pl O
##as O
##my O
het O
##ero O
##pl O
##as O
##my O
and O
mitochondrial O
d O
##yst O
##onia O
ne O
##uro O
##logy O
2007 O
69 O
911 O
91 O
##6 O

gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
128 O
##9 O

gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
results O
on O
motor O
function O
and O
cognition O
in O
a O
72 O
year O
old O
case O

alfonso O
fa O
##san O
##o O
md O
1 O
paolo O
ma O
##zzo O
##ne O
md O
2 O
carla O
piano O
md O
1 O
david O
##e O
qu O
##aran O
##ta O
md O
1 O
francesco O
sole O
##ti O
md O
1 O
and O
anna O
rita O
bent O
##ivo O
##glio O
md O
phd O
##1 O

1 O
##ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
roma O
italia O
2 O
##ne O
##uro O
##chi O
##ru O
##rg O
##ia O
fun O
##zio O
##nal O
##e O
e O
stereo O
##tas O
##sic O
##a O
ct O
##o O
ale O
##sin O
##i O
roma O
italia O

video O

abstract O
huntington O
s O
disease O
hd O
produces O
de O
##bil O
##itating O
motor O
abnormalities O
that O
are O
poorly O
responsive O
to O
medical O
therapy O
deep O
brain O
stimulation O
db O
##s O
of O
the O
poster O
##oven O
##tral O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
may O
offer O
a O
treatment O
option O
for O
patients O
with O
disk O
##ine O
##tic O
ph O
##eno O
##type O
and O
minimal O
cognitive O
impairment O
but O
its O
role O
in O
the O
management O
of O
hd O
remains O
unclear O
and O
to O
date O
only O
two O
cases O
have O
been O
reported O
we O
report O
the O
outcome O
of O
gp O
##i O
db O
##s O
in O
a O
72 O
##year O
old O
man O
with O
hd O
stimulation O
at O
130 O
hz O
caused O
a O
rapid O
am O
##eli O
##oration O
of O
cho O
##rea O
producing O
the O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
whereas O
40 O
hz O
stimulation O
maintaining O
constant O
the O
total O
electrical O
energy O
delivered O
improved O
cho O
##rea O
while O
preserving O
the O
ability O
to O
walk O
at O
1 O
year O
follow O
up O
cho O
##rea O
has O
completely O
disappeared O
however O
the O
patient O
was O
unable O
to O
stand O
and O
walk O
the O
cognitive O
pro O
##ﬁ O
##le O
showed O
a O
progressive O
deterioration O
with O
an O
extension O
of O
de O
##ﬁ O
##cit O
from O
the O
mainly O
d O
##yse O
##x O
##ec O
##utive O
alterations O
at O
baseline O
to O
a O
more O
diffuse O
##d O
cognitive O
deterioration O
2008 O
movement O
disorder O
society O

key O
words O
huntington O
s O
disease O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
surgery O
therapy O

huntington O
s O
disease O
hd O
is O
an O
auto O
##som O
##al O
dominant O
ne O
##uro O
##de O
##gen O
##erative O
disorder O
characterized O
by O
progressive O
cognitive O
impairment O
movement O
disorders O
and O
psychiatric O
symptoms O
when O
the O
movement O
disorder O
particularly O
the O
cho O
##rea O
is O
di O
##sa O
##bling O
ph O
##arm O
##aco O
##logical O
treatment O
is O
the O
main O
##sta O
##y O
of O
treatment O
but O
it O
is O
often O
ineffective O
thus O
the O
following O
surgical O
the O
##ra O
##pies O
have O
been O
introduced O
pal O
##lid O
##oto O
##my O
1 O
2 O
human O
fetal O
st O
##ria O
##tal O
transplant O
##a O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
alfonso O
fa O
##san O
##o O
md O
ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
la O
##rgo O
ago O
##sti O
##no O
gem O
##elli O
8 O
001 O
##6 O
##8 O
rome O
e O
mail O
alfonso O
fa O
##san O
##o O
rm O
un O
##ica O
##tt O
it O

received O
3 O
august O
2007 O
revised O
2 O
april O
2008 O
accepted O
5 O
april O

2008 O

published O
online O
30 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##16 O

ti O
##on O
3 O
and O
deep O
brain O
stimulation O
db O
##s O
4 O
5 O
the O
preferred O
target O
of O
db O
##s O
is O
the O
poster O
##oven O
##tral O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
because O
of O
the O
striking O
effects O
of O
pal O
##lid O
##al O
surgery O
for O
cho O
##re O
##od O
##yst O
##onic O
movements O
induced O
by O
lev O
##od O
##opa O
l O
do O
##pa O
in O
parkinson O
s O
disease O
pd O
6 O
sen O
##ile O
cho O
##rea O
7 O
and O
cho O
##rea O
associated O
with O
cerebral O
pal O
##sy O
8 O
to O
date O
two O
hd O
cases O
treated O
with O
gp O
##i O
db O
##s O
have O
been O
reported O
4 O
5 O
further O
experience O
is O
needed O
to O
con O
##ﬁ O
##rm O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
db O
##s O
in O
hd O
to O
guide O
the O
development O
of O
patient O
selection O
criteria O
and O
to O
determine O
the O
optimal O
target O
sites O
and O
stimulation O
parameters O
in O
this O
report O
we O
describe O
the O
use O
of O
bilateral O
gp O
##i O
db O
##s O
in O
a O

hd O
patient O
with O
medical O
##ly O
intra O
##ctable O
cho O
##rea O

methods O

db O
##s O
leads O
model O
338 O
##7 O
med O
##tron O
##ic O
were O
bilateral O
##ly O
implant O
##ed O
under O
general O
an O
##esthesia O
brain O
magnetic O
resonance O
imaging O
and O
computed O
tom O
##ography O
were O
utilized O
for O
targeting O
procedures O
the O
leads O
were O
connected O
to O
an O
implant O
##able O
pulse O
generator O
ip O
##g O
kin O
##et O
##ra O
med O
##tron O
##ic O
which O
was O
secured O
in O
the O
sub O
##cut O
##aneous O
tissues O
of O
the O
chest O

the O
effect O
of O
the O
stimulation O
by O
means O
of O
each O
of O
the O
four O
electrode O
contacts O
was O
investigated O
using O
different O
settings O
of O
stimulation O
frequency O
40 O
130 O
and O
180 O
hz O
pulse O
width O
60 O
90 O
120 O
180 O
and O
210 O
mc O
##se O
##c O
voltage O
from O
1 O
to O
7 O
v O
the O
patient O
was O
evaluated O
15 O
min O
after O
the O
change O
of O
parameters O
and O
after O
24 O
hours O
when O
a O
new O
set O
of O
parameters O
was O
tested O

when O
comparing O
the O
different O
settings O
we O
maintained O
constant O
the O
total O
electrical O
energy O
delivered O
tee O
##d O
determined O
using O
the O
equations O
proposed O
by O
mor O
##o O
et O
al O
4 O
as O
follows O

tee O
##d O
##¼ O
##½ O
##ð O
##vo O
##lta O
##ge O
3 O
##pu O
##ls O
##ew O
##id O
##th O
##3 O
##fr O
##e O
##que O
##ncy O
##þ O

imp O
##edance O
½ O
##tee O
##d O

an O
equation O
empirical O
##ly O
derived O
from O
their O
previous O
studies O
on O
patients O
affected O
by O
pd O
##9 O
but O
believed O
to O
be O
incorrect O
by O
ko O
##ss O
et O
al O
10 O
who O
suggested O

tee O
##d O
##1 O
##se O
##c O
ð O
##vo O
##lta O
##ge O
##2 O
3 O
pulse O
##wi O
##dt O
##h O
3 O
frequency O
##þ O

imp O
##edance O
3 O
1 O
sec O
½ O
##tee O
##d O

clinical O
assessments O
were O
prospective O
##ly O
performed O
using O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
##11 O
and O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
##12 O
table O
1 O

at O
baseline O
and O
at O
follow O
up O
visits O
the O
patient O
underwent O
an O
extensive O
ne O
##uro O
##psy O
##cho O
##logical O
exam O
##ina O

129 O
##0 O
a O
fa O
##san O
##o O
et O
al O

ti O
##on O
by O
means O
of O
a O
previously O
reported O
standardized O
battery O
##13 O
table O
2 O

the O
patient O
is O
a O
72 O
year O
old O
man O
with O
genetically O
con O
##ﬁ O
##rmed O
hd O
his O
motor O
symptoms O
began O
at O
age O
55 O
and O
progressed O
to O
severe O
generalized O
cho O
##rea O
##the O
##tosis O
within O
the O
previous O
2 O
years O
he O
showed O
weight O
loss O
and O
balance O
impairment O
with O
falls O
the O
introduction O
of O
halo O
##per O
##ido O
##l O
induced O
a O
marked O
se O
##dation O
whereas O
te O
##tra O
##ben O
##azi O
##ne O
was O
tolerated O
only O
at O
low O
doses O
with O
only O
modest O
ben O
##e O
##ﬁ O
##t O
table O
1 O
because O
of O
the O
absence O
of O
severe O
psychiatric O
disorders O
and O
ne O
##uro O
##psy O
##cho O
##logical O
de O
##ﬁ O
##cit O
##s O
table O
2 O
the O
patient O
was O
considered O
eligible O
for O
bilateral O
gp O
##i O
db O
##s O
surgical O
procedure O
was O
well O
tolerated O

effect O
on O
motor O
function O

the O
patient O
was O
discharged O
from O
the O
hospital O
with O
ip O
##g O
left O
off O
to O
allow O
stabilization O
of O
the O
micro O
##pal O
##lid O
##oto O
##my O
effect O
which O
caused O
only O
a O
mild O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
table O
1 O
one O
month O
after O
surgery O
mono O
##pol O
##ar O
stimulation O
using O
ventral O
contacts O
seemed O
to O
be O
more O
e O
##f O
##ﬁ O
##ca O
##cious O
on O
cho O
##rea O
but O
it O
was O
associated O
with O
a O
severe O
h O
##yp O
##oton O
##ia O
of O
axial O
muscles O
causing O
ﬂ O
##ex O
##ion O
of O
the O
head O
and O
loss O
of O
trunk O
control O
parameters O
was O
maintained O
as O
follows O
right O
gp O
##i O
2 O
6 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
2 O
negative O
and O
case O
positive O
left O
gp O
##i O

2 O
7 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
6 O
negative O
and O
case O
positive O

four O
months O
after O
the O
surgery O
we O
found O
that O
stimulation O
at O
40 O
hz O
sign O
##i O
##ﬁ O
##can O
##tly O
improved O
cho O
##rea O
five O
minutes O
after O
the O
ip O
##g O
was O
switched O
on O
limbs O
cho O
##rea O
improved O
consistently O
while O
mild O
d O
##ys O
##kin O
##es O
##ias O
were O
still O
present O
on O
the O
face O
and O
shoulders O
cho O
##rea O
gradually O
reappeared O
15 O
min O
after O
the O
ip O
##g O
has O
been O
switched O
off O
stimulation O
at O
130 O
hz O
caused O
further O
improvement O
of O
cho O
##rea O
but O
also O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
and O
a O
severe O
disturbance O
of O
ga O
##it O
characterized O
by O
freezing O
and O
start O
hesitation O
the O
effect O
of O
these O
different O
frequencies O
was O
con O
##ﬁ O
##rmed O
in O
double O
blind O
fashion O
maintaining O
constant O
tee O
##d O
calculated O
by O
means O
of O
both O
the O
proposed O
methods O
table O
1 O
accordingly O
stimulation O
parameters O
were O
changed O
as O
follows O
right O
gp O
##i O
2 O
0 O
v O
40 O
hz O
90 O
mc O
##se O
##c O
contact O
1 O
negative O
and O
case O
positive O
left O
gp O

2 O
0 O
v O
40 O
hz O
90 O
mc O
##se O
##c O
contact O
5 O
negative O
and O
case O
positive O

during O
the O
following O
months O
ga O
##it O
and O
ap O
##athy O
progressively O
worsened O
despite O
the O
complete O
resolution O
of O
cho O
##rea O
and O
an O
associated O
weight O
gain O
which O
allowed O
the O
withdrawal O
of O
the O
medications O
the O
patient O
s O
level O
of O
independence O
worsened O
due O
to O
the O
severe O
impairment O
of O
autonomous O
ga O
##it O
the O
lowering O
of O
amplitude O
of O
stimulation O
did O
not O
improve O
the O
axial O
impairment O
eleven O
months O
after O
surgery O
the O
stimulation O
was O
switched O
off O
and O
surprisingly O
this O
did O
not O
cause O
the O
re O
##oc O
##cu O
##rre O
##nce O
of O
cho O
##rea O
table O
1 O
a O
250 O
mg O
l O
do O
##pa O
challenge O
improved O
the O
patient O
s O
ability O
to O
arise O

table O
1 O
motor O
function O
during O
follow O
up O
visits O

cho O
##rea O
score O
was O
de O
##ﬁ O
##ned O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
12 O
##a O
12 O
##g O
maximum O
score O
28 O
d O
##yst O
##onia O
score O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
11 O
##a O
11 O
##e O
maximum O
score O
20 O
brady O
##kin O
##es O
##ia O
rigid O
##ity O
score O
as O
the O
sum O
of O
the O
uh O
##dr O
##s O
items O
11 O
12 O
14 O
15 O
maximum O
score O
28 O
axial O
symptoms O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
18 O
19 O
20 O
and O
of O
up O
##dr O
##s O
item O
27 O
arising O
from O
chair O
maximum O
score O
16 O

numbers O
in O
brackets O
indicate O
the O
corrected O
scores O
for O
age O
and O
years O
of O
education O
according O
to O
an O
italian O
population O
based O
standardization O
scores O
in O
bold O
are O
below O
the O
cut O
off O
of O
normal O
##ity O

are O
##verse O
scores O
lower O
scores O
indicate O
better O
performances O

bb O
##elo O
##w O
10th O
percent O
##ile O

cbe O
##low O
1st O
percent O
##ile O

iv O
##m O
immediate O
visual O
memory O
m O
##ft O
##c O
multi O
##fe O
##at O
##ures O
targets O
cancellation O
mm O
##se O
mini O
mental O
state O
examination O
np O
not O
performed O
pm O
47 O
raven O
s O
progressive O
matrices O
47 O
ra O
##v O
##lt O
rey O
s O
auditory O
verbal O
learning O
test O
roc O
##f O
rey O
os O
##ter O
##rie O
##th O
complex O
ﬁ O
##gur O
##e O
wc O
##st O
wisconsin O
card O
sorting O
test O

from O
chair O
without O
assistance O
and O
slightly O
the O
ga O
##it O
so O
the O
patient O
started O
chronic O
therapy O
with O
l O
do O
##pa O
up O
to O
800 O
mg O
die O
with O
a O
mild O
improvement O
of O
brady O
##kin O
##es O
##ia O
ga O
##it O
and O
ap O
##athy O
table O
1 O

effect O
on O
cognitive O
functions O
table O
2 O

at O
baseline O
evaluation O
1 O
month O
before O
surgery O
the O
patient O
s O
cognitive O
pro O
##ﬁ O
##le O
was O
characterized O
mainly O
by O
d O
##yse O
##x O
##ec O
##utive O
syndrome O
on O
the O
ﬁ O
##rst O
follow O
up O
visit O
6 O
months O
after O
surgery O
the O
score O
of O
mini O
mental O
state O
examination O
worsened O
as O
did O
scores O
of O
test O
for O
executive O
functions O
scores O
of O
linguistic O
and O
memory O
task O

were O
lower O
as O
well O
on O
the O
second O
follow O
up O
visit O
1 O
year O
after O
surgery O
he O
performed O
worse O
on O
all O
executive O
tasks O
in O
comparison O
with O
both O
the O
baseline O
and O
1st O
follow O
up O
visits O
scores O
worsened O
also O
on O
ph O
##ono O
##logical O
ﬂ O
##uen O
##cy O
task O
and O
on O
elementary O
construction O
##al O
abilities O

we O
have O
con O
##ﬁ O
##rmed O
that O
bilateral O
gp O
##i O
db O
##s O
produces O
a O
long O
term O
reduction O
of O
cho O
##rea O
due O
to O
hd O
despite O
the O
ben O
##e O
##ﬁ O
##t O
surgery O
has O
been O
related O
to O
worse O
##ning O
of O
ga O
##it O
ap O
##athy O
and O
decline O
of O
cognitive O
function O

129 O
##2 O
a O
fa O
##san O
##o O
et O
al O

in O
the O
past O
pal O
##lid O
##oto O
##my O
has O
been O
associated O
with O
only O
modest O
pal O
##lia O
##tive O
functional O
improvement O
in O
d O
##yst O
##onic O
features O
##1 O
or O
worse O
##ning O
of O
parkinson O
##ism O
2 O
4 O
based O
on O
this O
it O
has O
been O
suggested O
that O
the O
use O
of O
db O
##s O
to O
maximize O
ben O
##e O
##ﬁ O
##ts O
and O
minimize O
potential O
side O
effects O
such O
as O
brady O
##kin O
##es O
##ia O
in O
the O
ﬁ O
##rst O
8 O
month O
follow O
up O
report O
on O
the O
use O
of O
gp O
##i O
db O
##s O
to O
treat O
hd O
cho O
##rea O
authors O
reported O
a O
dramatic O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
stimulation O
##s O
at O
40 O
and O
130 O
hz O
maintaining O
constant O
the O
tee O
##d O
were O
equally O
effective O
but O
the O
second O
worsened O
brady O
##kin O
##es O
##ia O
4 O
according O
to O
ko O
##ss O
et O
al O
the O
equation O
utilized O
to O
calculate O
the O
tee O
##d O
was O
incorrect O
and O
it O
was O
not O
possible O
to O
disc O
##ern O
whether O
the O
observed O
clinical O
effects O
resulted O
from O
changes O
in O
stimulation O
frequency O
or O
from O
the O
overall O
increase O
in O
tee O
##d O
10 O
we O
con O
##ﬁ O
##rmed O
the O
ﬁ O
##nding O
##s O
of O
mor O
##o O
et O
al O
by O
maintaining O
constant O
tee O
##d O
calculated O
with O
both O
the O
equations O
proposed O
this O
would O
suggest O
that O
in O
hd O
the O
clinical O
effect O
of O
db O
##s O
is O
frequency O
dependent O
and O
support O
the O
concept O
that O
brady O
##kin O
##es O
##ia O
and O
cho O
##rea O
probably O
re O
##ﬂ O
##ect O
underlying O
differences O
in O
ne O
##uron O
##al O
ﬁ O
##ring O
patterns O
and O
coding O
14 O
however O
it O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
say O
to O
what O
extend O
tee O
##d O
re O
##ﬂ O
##ect O
##s O
the O
real O
impact O
of O
the O
stimulation O
on O
the O
neurons O
and O
ax O
##ons O
for O
at O
least O
two O
reasons O
1 O
tee O
##d O
does O
not O
re O
##ﬂ O
##ect O
the O
size O
and O
the O
shape O
of O
the O
electrical O
ﬁ O
##eld O
2 O
it O
is O
known O
that O
voltage O
is O
the O
most O
critical O
factor O
for O
alteration O
of O
cell O
population O
activity O
in O
the O
human O
brain O
9 O

the O
secondly O
reported O
hd O
patient O
had O
a O
12 O
months O
lasting O
rev O
##ers O
##ible O
suppression O
of O
his O
cho O
##rea O
##the O
##to O
##id O
movements O
after O
surgery O
a O
trial O
of O
reduced O
frequency O
to O
40 O
hz O
produced O
a O
poor O
control O
of O
cho O
##rea O
and O
required O
reins O
##ti O
##tu O
##tion O
of O
high O
frequency O
stimulation O
180 O
hz O
at O
10 O
months O
the O
patient O
s O
g O
##lot O
##tic O
function O
worsened O
and O
concerns O
of O
d O
##ys O
##pha O
##gia O
and O
air O
##way O
protection O
prompted O
institutional O
##ization O
by O
12 O
months O
his O
rigid O
##ity O
also O
progressed O
these O
side O
effects O
were O
not O
improved O
by O
lowered O
ip O
##g O
voltage O
or O
by O
turning O
the O
st O
##im O
##ulator O
off O
5 O
similar O
to O
our O
case O
a O
delayed O
worse O
##ning O
of O
parkinson O
##ism O
was O
present O
and O
it O
did O
not O
change O
even O
after O
a O
prolonged O
period O
without O
stimulation O

the O
path O
##op O
##hy O
##sio O
##logy O
of O
the O
evolving O
and O
delayed O
worse O
##ning O
of O
ga O
##it O
and O
akin O
##es O
##ia O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
explain O
in O
this O
single O
case O
it O
is O
not O
possible O
to O
exclude O
that O
it O
was O
at O
least O
in O
part O
related O
to O
the O
evolution O
of O
the O
disease O
and O
that O
also O
the O
long O
term O
improvement O
of O
cho O
##rea O
was O
related O
to O
its O
progression O
toward O
a O
parkinson O
##ian O
ph O
##eno O
##type O
however O
db O
##s O
may O
have O
actually O
produced O
a O
pal O
##lid O
##oto O
##mic O
effect O
analogous O
to O
the O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
observed O
after O
pal O
##lid O
##oto O
##my O
in O
hd O
patients O
2 O
4 O
the O
effect O
of O
isolated O
lesions O
of O
gp O
##i O
in O
subjects O
not O
affected O
by O
pd O
or O
d O
##yst O
##onia O
has O
been O

recently O
reviewed O
as O
follows O
the O
clinical O
picture O
is O
characterized O
mainly O
by O
axial O
parkinson O
##ism O
and O
delayed O
onset O
of O
symptoms O
after O
the O
initial O
insult O
15 O
our O
patient O
shares O
some O
of O
these O
features O

this O
is O
the O
ﬁ O
##rst O
study O
systematically O
assessing O
the O
cognitive O
pro O
##ﬁ O
##le O
of O
an O
hd O
patient O
treated O
with O
db O
##s O
evaluation O
##s O
showed O
a O
progressive O
deterioration O
with O
an O
extension O
of O
de O
##ﬁ O
##cit O
from O
the O
mainly O
d O
##yse O
##x O
##ec O
##utive O
alterations O
at O
baseline O
to O
a O
more O
diffuse O
##d O
cognitive O
deterioration O
the O
cause O
of O
such O
worse O
##ning O
is O
only O
speculative O
since O
it O
is O
not O
possible O
to O
disc O
##ern O
whether O
it O
has O
been O
caused O
by O
the O
effect O
of O
surgery O
or O
by O
the O
natural O
course O
of O
the O
disease O
in O
addition O
it O
is O
not O
possible O
to O
estimate O
the O
real O
impact O
of O
stimulation O
on O
cognitive O
functions O
since O
the O
patient O
was O
always O
assessed O
in O
stimulation O
on O
condition O

the O
outcome O
of O
the O
patient O
hence O
reported O
highlights O
the O
important O
ethical O
decisions O
that O
must O
be O
made O
in O
treating O
patients O
with O
hd O
db O
##s O
may O
aid O
the O
symptoms O
but O
will O
not O
stem O
the O
in O
##ex O
##ora O
##ble O
deterioration O
of O
patients O
with O
this O
disease O
in O
addition O
similarly O
to O
another O
case O
5 O
the O
functional O
gain O
of O
our O
patient O
was O
ne O
##gli O
##gible O
whether O
or O
not O
db O
##s O
should O
be O
used O
on O
a O
regular O
basis O
in O
such O
patients O
still O
remains O
to O
be O
determined O
further O
experience O
with O
this O
population O
will O
guide O
the O
development O
of O
patient O
selection O
criteria O
de O
##ﬁ O
##ne O
the O
optimal O
sites O
and O
stimulation O
parameters O
for O
db O
##s O
and O
el O
##uc O
##ida O
##te O
the O
electro O
##phy O
##sio O
##logical O
changes O
in O
hd O

legends O
to O
the O
video O

segment O
1 O
the O
patient O
6 O
months O
before O
surgery O
presents O
severe O
cho O
##rea O
of O
facial O
muscles O
trunk O
and O
limbs O
the O
patient O
is O
able O
to O
stand O
up O
without O
assistance O
and O
to O
walk O
for O
a O
few O
meters O
cho O
##rea O
of O
the O
lower O
limbs O
and O
impairment O
of O
post O
##ural O
stability O
as O
revealed O
by O
the O
retro O
##pu O
##ls O
##ion O
pull O
test O
des O
##ta O
##bil O
##ize O
him O
during O
walking O

segment O
2 O
three O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
180 O
hz O
provides O
a O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
especially O
of O
the O
lower O
limbs O
stimulation O
of O
ventral O
contacts O
causes O
head O
drop O

segment O
3 O
four O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O

segment O
4 O
four O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
40 O
hz O
provides O
a O
reduction O
of O
cho O
##rea O
and O
an O
improvement O
of O
axial O
symptoms O
the O
patient O
is O
able O
to O
walk O
with O
un O
##ila O
##tera O
##l O
assistance O

segment O
5 O
nine O
months O
after O
surgery O
limbs O
cho O
##rea O
has O
disappeared O
while O
facial O
grimace O
##s O
are O
still O
pre O
##s O

db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##3 O

en O
##t O
despite O
the O
use O
of O
40 O
hz O
stimulation O
the O
patient O
cannot O
arise O
from O
chair O
and O
walk O
due O
to O
a O
severe O
start O
hesitation O

segment O
6 O
nine O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
only O
with O
very O
mild O
d O
##ys O
##kin O
##es O
##ias O
of O
upper O
limbs O
the O
patient O
is O
able O
to O
arise O
from O
chair O
and O
ga O
##it O
impairment O
is O
improved O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
supported O
in O
part O
by O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
grant O
line O
##a O
d O
##1 O
to O
ar O
##b O
af O
f O
##s O
and O
ar O
##b O
are O
members O
of O
euro O
hd O
network O

cub O
##o O
e O
shannon O
km O
penn O
rd O
k O
##roi O
##n O
j O
##s O
internal O
g O
##lo O
##bus O
pal O
##lid O
##oto O
##my O
in O
d O
##yst O
##onia O
secondary O
to O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
124 O
##8 O
125 O
##1 O

vi O
##tek O
j O
##l O
jones O
r O
ba O
##ka O
##y O
re O
##a O
hers O
##ch O
sm O
pal O
##lid O
##oto O
##my O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2000 O
48 O
42 O
##9 O

bach O
##oud O
levi O
ac O
ga O
##ura O
v O
br O
##ug O
##iere O
##s O
p O
et O
al O
effect O
of O
fetal O
neural O
transplant O
##s O
in O
patients O
with O
huntington O
s O
disease O
6 O
years O
after O
surgery O
a O
long O
term O
follow O
up O
study O
lance O
##t O
ne O
##uro O
##l O
2006 O
5 O
303 O
309 O

mor O
##o O
e O
lang O
ae O
st O
##raf O
##ella O
ap O
et O
al O
bilateral O
g O
##lo O
##bus O
pal O
##lid O
##us O

deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O

jan O
her O
##zog O
md O
1 O
oliver O
po O
##gar O
##ell O
md O
2 O
marcus O
o O
pins O
##ker O
md O
3 O
andreas O
ku O
##ps O
##ch O
md O
phd O
4 O

wolfgang O
h O
o O
##ert O
##el O
md O
phd O
5 O
ol O
##le O
lin O
##d O
##val O
##l O
md O
phd O
6 O

gu O
##¨ O
##nt O
##her O
de O
##us O
##ch O
##l O
md O
phd O
1 O
and O
jens O
vol O
##km O
##ann O
md O
phd O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
christian O
albrecht O
##s O
university O
kiel O
germany O
2d O
##ep O
##art O
##ment O
of O
psychiatry O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
christian O
albrecht O
##s O
university O
kiel O

germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
char O
##ite O
##´ O
humboldt O
university O
berlin O
germany O
5 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
philipp O
##s O
university O
mar O
##burg O
germany O
6 O
##section O
of O
rest O
##ora O
##tive O
ne O
##uro O
##logy O
wall O
##enberg O
neuroscience O
centre O
lund O
sweden O

stimulation O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2004 O
56 O
290 O

294 O

he O
##bb O
mo O
garcia O
r O
ga O
##ude O
##t O
p O
mendez O
im O
bilateral O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
to O
treat O
cho O
##rea O
##the O
##tosis O
in O
huntington O
s O
disease O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
58 O
e O
##38 O
##3 O

lang O
ae O
surgery O
for O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##19 O
##3 O
s O
##19 O
##9 O

yi O
##ann O
##i O
j O
nan O
##di O
d O
bradley O
k O
et O
al O
sen O
##ile O
cho O
##rea O
treated O
by O
deep O
brain O
stimulation O
a O
clinical O
ne O
##uro O
##phy O
##sio O
##logical O
and O
functional O
imaging O
study O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
59 O
##7 O
60 O
##2 O

k O
##raus O
##s O
j O
##k O
lo O
##her O
t O
##j O
wei O
##gel O
r O
cape O
##lle O
h O
##h O
weber O
s O
bu O
##rg O
##under O
j O
##m O
chronic O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
treatment O
of O
non O
d O
##yt O
##1 O
generalized O
d O
##yst O
##onia O
and O
cho O
##re O
##oat O
##het O
##osis O
2 O
year O
follow O
up O
j O
ne O
##uro O
##sur O
##g O
2003 O
98 O
78 O
##5 O
79 O
##2 O

mor O
##o O
e O
es O
##sel O
##ink O
r O
##j O
xi O
##e O
j O
homme O
##l O
m O
ben O
##abi O
##d O
al O
poll O
##ak O
p O
the O
impact O
on O
parkinson O
s O
disease O
of O
electrical O
parameter O
settings O
in O
st O
##n O
stimulation O
ne O
##uro O
##logy O
2002 O
59 O
70 O
##6 O
71 O
##3 O

ko O
##ss O
am O
alter O
##man O
r O
##l O
tag O
##lia O
##ti O
m O
shi O
##ls O
j O
##l O
calculating O
total O
electrical O
energy O
delivered O
by O
deep O
brain O
stimulation O
systems O
ann O
ne O
##uro O
##l O
2005 O
58 O
168 O

huntington O
study O
group O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
reliability O
and O
consistency O
mo O
##v O
di O
##sor O
##d O
1996 O
11 O
136 O
142 O

go O
##etz O
c O
##g O
ste O
##bb O
##ins O
gt O
ch O
##mura O
ta O
fa O
##hn O
s O
k O
##law O
##ans O
h O
##l O
marsden O
cd O
teaching O
tape O
for O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
mo O
##v O
di O
##sor O
##d O
1995 O
10 O
263 O
266 O

con O
##tar O
##ino O
m O
##f O
daniel O
##e O
a O
si O
##bil O
##ia O
ah O
et O
al O
cognitive O
outcome O
5 O
years O
after O
bilateral O
chronic O
stimulation O
of O
sub O
##thal O
##ami O
##c O
nucleus O

abstract O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
have O
been O
reported O
as O
a O

consequence O
of O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
for O
parkinson O
s O
disease O
this O
type O
of O
d O
##ys O
##kin O
##es O
##ias O
may O
appear O
in O
patients O
even O
in O
the O
prolonged O
absence O
of O
anti O
##park O
##ins O
##on O
medication O
and O
be O
aggravated O
by O
lev O
##od O
##opa O
therefore O
ph O
##arm O
##aco O
##logical O
therapeutic O
approaches O
in O
these O
patients O
are O
limited O
here O
we O
report O
two O
patients O
with O
bilateral O
fetal O
ni O
##gra O
##l O
graf O
##ts O
in O
the O
ca O
##uda O
##te O
and O
put O
##amen O
subjected O
to O
deep O
brain O
stimulation O
db O
##s O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
or O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
clinical O
assessment O
was O
performed O
according O
to O
up O
##dr O
##s O
and O
the O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
in O
both O
patients O
we O
found O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
in O
off O
period O
symptoms O
as O
well O
as O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
however O
only O
gp O
##i O
db O
##s O
led O
to O
a O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
whereas O
st O
##n O
db O
##s O
did O
not O
in O
##ﬂ O
##uen O
##ce O
d O
##ys O
##kin O
##es O
##ias O
unrelated O
to O
external O
do O
##pa O
##mine O
##rg O
##ic O
application O
these O
ﬁ O
##nding O
##s O
based O
on O
two O
case O
reports O
highlight O
the O
pivotal O
role O
of O
the O
gp O
##i O
in O
media O
##ting O
d O
##ys O
##kin O
##es O
##ia O
related O
neural O
activity O
within O
the O
basal O
gang O
##lia O
loop O
2008 O
movement O
disorder O
society O

key O
words O
parkinson O
s O
disease O
neural O
transplant O
##ation O
deep O
brain O
stimulation O
d O
##ys O
##kin O
##es O
##ias O

in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O

try O
2007 O
78 O
248 O
252 O

be O
##rard O
##elli O
a O
not O
##h O
j O
thomson O
pd O
et O
al O
path O
##op O
##hy O
##sio O
##logy O
of O
cho O
##rea O
and O
brady O
##kin O
##es O
##ia O
in O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O

1999 O
14 O
39 O
##8 O
403 O

ku O
##op O
##pa O
##ma O
##¨ O
##ki O
m O
roth O
##well O
jc O
brown O
r O
##g O
quinn O
n O
b O
##hat O
##ia O
k O
##p O
ja O
##han O
##shah O
##i O
m O
parkinson O
##ism O
following O
bilateral O
lesions O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
performance O
on O
a O
variety O
of O
motor O
tasks O
shows O
similarities O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
48 O
##2 O
490 O

correspondence O
to O
j O
vol O
##km O
##ann O
md O
phd O
department O
of O
ne O
##uro O
##logy O
un O
##iver O
##sit O
##a O
##¨ O
##tsk O
##lini O
##ku O
##m O
schleswig O
holstein O
campus O
kiel O
sc O
##hit O
##ten O
##helm O
##st O
##r O
10 O
241 O
##0 O
##5 O
kiel O
germany O

e O
mail O
j O
vol O
##km O
##ann O
ne O
##uro O
##logie O
un O
##i O
kiel O
de O

received O
31 O
may O
2007 O
revised O
28 O
august O
2007 O
accepted O
13 O

september O
2007 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##6 O
##8 O

129 O
##4 O
j O
her O
##zog O
et O
al O

table O
1 O
characteristics O
of O
patients O
at O
baseline O
and O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
deep O
brain O
stimulation O

patient O
1 O
patient O
2 O

before O
transplant O
##ation O
up O
##dr O
##s O
iii O

med O
off O
74 O
49 O

med O
on O
24 O
14 O

d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O

d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O

item O
32 O
0 O
0 O

item O
33 O
0 O
0 O

medication O
mg O
d O
lev O
##od O
##opa O
1 O
400 O
lev O
##od O
##opa O
250 O

per O
##gol O
##ide O
0 O
5 O

de O
##pre O
##ny O
##l O
10 O

led O
##d O
mg O
1 O
400 O
mg O
400 O
mg O
before O
db O
##s O

following O
db O
##s O

follow O
up O
period O
3 O
y O
##r O
2 O
y O
##r O

up O
##dr O
##s O
iii O
50 O
28 O

st O
##im O
off O
med O
off O

st O
##im O
on O
med O
off O
33 O
11 O

st O
##im O
on O
med O
off O
10 O
2 O

st O
##im O
on O
med O
on O
a O
4 O

item O
32 O
1 O
0 O

item O
33 O
2 O
0 O

medication O
mg O
d O

led O
##d O
mg O
0 O
0 O

persisted O
even O
after O
withdrawal O
of O
lev O
##od O
##opa O
l O
do O
##pa O
medication O
because O
of O
the O
d O
##ys O
##kin O
##etic O
states O
which O
are O
usually O
aggravated O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
ph O
##arm O
##aco O
##logical O
approaches O
are O
limited O
and O
db O
##s O
might O
be O
an O
alternative O
therapeutic O
option O
here O
we O
report O
the O
long O
term O
outcome O
in O
two O
patients O
with O
persistent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
graf O
##ting O
who O
later O
underwent O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
or O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
db O
##s O

case O
reports O

patient O
1 O

the O
53 O
year O
old O
man O
pd O
since O
14 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
selected O
for O
simultaneous O
bilateral O
graf O
##ting O
of O
fetal O
ni O
##gra O
##l O
cells O
5 O
tr O
##aj O
##ect O
##ories O
into O
put O
##amen O
2 O
into O
the O
head O
of O
the O
ca O
##uda O
##te O
nucleus O
the O
tissue O
preparation O
ne O
##uro O
##sur O
##gical O
procedure O
and O
post O
##oper O
##ative O
management O
have O
been O
described O
elsewhere O
1 O
long O
##ter O
##m O
do O
##pa O
##mine O
##rg O
##ic O
graf O
##t O
survival O
was O
demonstrated O
by O
18 O
##f O
ﬂ O
##uo O
##rod O
##opa O
pet O
and O
n O
3 O
io O
##do O
##pro O
##pen O
2 O
y O
##l O
2 O
##b O
car O
##bo O
##met O
##ho O
##xy O
3 O
##b O
4 O
ch O
##lor O
##op O
##hen O
##yl O
tr O
##opa O
##ne O
spec O
##t O
1 O
4 O

the O
transplant O
##ation O
initially O
resulted O
in O
am O
##eli O
##oration O
of O
off O
period O
symptoms O
subsequently O
he O
developed O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
cd O
##rs O
10 O
28 O
particularly O
on O
the O
left O
body O
side O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O
video O
##ta O
##pe O
because O
of O
ag O
##gra O
##vation O
of O
d O
##ys O
##kin O
##etic O
states O
by O
l O
do O
##pa O
cd O
##rs O
15 O
28 O
the O
use O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
had O
to O
be O
limited O
with O
the O
consequence O
of O
progressive O
decline O
in O
severity O
of O
off O
phase O
symptoms O
table O
1 O
and O
return O

stereo O
##ta O
##ctic O
coordinates O
x O
y O
z O
relative O
to O
mid O
##ac O
##pc O

r O
11 O
4 O
22 O
1 O
22 O
2 O
r O
21 O
3 O
4 O
5 O
23 O
6 O

l O
211 O
2 O
22 O
1 O
23 O
0 O
l O
220 O
5 O
1 O
9 O
22 O
4 O

of O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
which O
could O
not O
be O
con O

troll O
##ed O
by O
various O
therapeutic O
approaches O

because O
of O
prominent O
off O
phase O
symptoms O
and O

aa O
##ft O
##er O
st O
##n O
db O
##s O
patient O
1 O
refused O
assessment O
in O
the O
medication O
on O
condition O

up O
##dr O
##s O
iii O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
max O
108 O
cd O
##rs O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
max O
28 O
db O
##s O
deep O
brain O
stimulation O
led O
##d O
lev O
##od O
##opa O
equivalent O
daily O
dos O
##age O

since O
the O
1980 O
s O
intra O
##st O
##ria O
##tal O
transplant O
##ation O
of O
human O
fetal O
ni O
##gra O
##l O
ne O
##uron O
##es O
has O
been O
used O
as O
an O
experimental O
therapy O
to O
restore O
baseline O
do O
##pa O
##mine O
synthesis O
in O
pd O
the O
graf O
##ted O
do O
##pa O
##mine O
ne O
##uron O
##es O
can O
rein O
##ner O
##vate O
the O
de O
##gen O
##erated O
st O
##ria O
##tum O
release O
do O
##pa O
##mine O
and O
become O
functional O
##ly O
integrated O
into O
patients O
neural O
circuit O
##ries O
1 O
whereas O
open O
trials O
have O
reported O
clinical O
ben O
##e O
##ﬁ O
##cial O
effects O
two O
double O
blind O
studies O
failed O
to O
show O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
of O
motor O
symptoms O
compared O
to O
sham O
surgery O
2 O
3 O
additionally O
a O
sign O
##i O
##ﬁ O
##can O
##t O
number O
of O
transplant O
##ed O
patients O
developed O
severe O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
runaway O
d O
##ys O
##kin O
##es O
##ias O
that O

h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
8 O
years O
after O
transplant O
##ation O
the O
patient O
was O
selected O
for O
st O
##n O
db O
##s O
as O
a O
result O
of O
st O
##n O
db O
##s O
the O
patient O
experienced O
a O
permanent O
functional O
on O
state O
with O
su O
##f O
##ﬁ O
##cie O
##nt O
mobility O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##rds O
total O
58 O
220 O
up O
##dr O
##s O
iii O
33 O
108 O
in O
the O
l O
do O
##pa O
test O
table O
1 O
do O
##pa O
##mine O
##rg O
##ic O
medication O
was O
completely O
withdrawn O
the O
adjustment O
of O
stimulation O
parameters O
however O
was O
di O
##f O
##ﬁ O
##cu O
##lt O
due O
to O
a O
very O
low O
threshold O
for O
stimulation O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ias O
that O
resembled O
the O
previous O
ld O
##opa O
induced O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
despite O
different O
ph O
##arm O
##aco O
##logical O
and O
programming O
measures O
we O
were O
unable O
to O
completely O
ab O
##olis O
##h O
d O
##ys O
##kin O
##es O
##ias O
throughout O
the O
day O
video O
##ta O
##pe O
three O
years O
after O
surgery O
however O
the O
overall O
severity O
and O
duration O
of O
d O
##ys O
##kin O
##es O
##ias O
has O
improved O
compared O
to O
the O
state O
before O
st O
##n O
db O
##s O
3 O
years O
post O
db O
##s O
up O
##dr O
##s O
iv O
item O
32 O
duration O
1 O
4 O
and O

db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##5 O

33 O
disability O
2 O
4 O
while O
the O
ben O
##e O
##ﬁ O
##t O
on O
off O
period O
symptoms O
was O
sustained O

patient O
2 O

the O
41 O
year O
old O
man O
pd O
since O
12 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
treated O
by O
staged O
bilateral O
neural O
transplant O
##ation O
with O
the O
second O
graf O
##t O
right O
st O
##ria O
##tum O
6 O
months O
after O
the O
ﬁ O
##rst O
graf O
##t O
cell O
preparation O
surgical O
procedure O
im O
##mun O
##os O
##up O
##press O
##ion O
and O
demonstration O
of O
long O
term O
graf O
##t O
survival O
were O
identical O
to O
patient O
1 O
1 O

following O
transplant O
##ation O
he O
experienced O
considerable O
reduction O
of O
off O
phase O
symptoms O
in O
the O
medication O
off O
condition O
which O
was O
stable O
for O
8 O
years O
table O
1 O
one O
year O
following O
transplant O
##ation O
however O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
gradually O
occurred O
with O
continuous O
cho O
##re O
##oat O
##het O
##oid O
movements O
in O
arms O
and O
ﬁ O
##nger O
##s O
cd O
##rs O
6 O
28 O
video O
##ta O
##pe O
additionally O
he O
was O
suffering O
from O
severe O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
10 O
28 O
despite O
reduction O
of O
led O
##d O
to O
100 O
mg O
and O
anti O
##dy O
##skin O
##etic O
therapy O
with O
ama O
##nta O
##dine O
he O
continued O
to O
have O
d O
##ys O
##kin O
##es O
##ias O
throughout O
the O
day O
up O
##dr O
##s O
iv O
item O
32 O
4 O
4 O
which O
were O
rated O
as O
severely O
di O
##sa O
##bling O
up O
##dr O
##s O
iv O
item O
33 O
3 O
4 O
table O
1 O

because O
of O
the O
prominent O
hyper O
##kin O
##es O
##ias O
but O
relatively O
few O
off O
period O
symptoms O
8 O
years O
after O
bilateral O
graf O
##ting O
the O
patient O
was O
selected O
for O
bilateral O
gp O
##i O
db O
##s O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
2 O
28 O
in O
the O
formal O
assessment O
video O
##ta O
##pe O
in O
contrast O
the O
patient O
reported O
complete O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
during O
the O
day O
item O
32 O
und O
33 O
0 O
4 O
because O
off O
period O
symptoms O
were O
con O
##com O
##itan O
##tly O
improved O
up O
##dr O
##s O
iii O
11 O
108 O
in O
the O
formal O
assessment O
all O
do O
##pa O
##mine O
##rg O
##ic O
medication O
could O
be O
stopped O

these O
two O
case O
reports O
demonstrate O
that O
disease O
##and O
treatment O
related O
complications O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
in O
pd O
can O
be O
effectively O
treated O
by O
db O
##s O
in O
patient O
1 O
st O
##n O
db O
##s O
primarily O
improved O
off O
period O
symptoms O
which O
reduced O
the O
necessity O
for O
additional O
do O
##pa O
##mine O
##rg O
##ic O
drug O
therapy O
the O
effect O
on O
d O
##ys O
##kin O
##es O
##ias O
however O
was O
not O
immediate O
in O
fact O
this O
patient O
became O
very O
sensitive O
to O
stimulation O
induced O
d O
##ys O
##kin O
##es O
##ias O
and O
continued O
to O
exhibit O
ﬂ O
##uc O
##tua O
##ting O
cho O
##re O
##oat O
##het O
##oid O
d O
##ys O
##kin O
##es O
##ias O
with O
stable O
stimulation O
parameters O
even O
after O
complete O
withdrawal O
of O
any O
do O
##pa O
##mine O
##rg O
##ic O
drug O
##therapy O
these O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
resembled O
clinical O
##ly O
the O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
before O
surgery O
and O
were O
probably O
the O
result O
of O
an O
interaction O
between O
st O
##nd O
##bs O
and O
di O
##urn O
##al O
ﬂ O
##uc O
##tua O
##tions O
in O
the O
release O
of O
do O
##pa O
##mine O

from O
the O
fetal O
graf O
##t O
the O
failure O
to O
reduce O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
our O
patient O
contrasts O
with O
a O
previous O
report O
##5 O
that O
found O
marked O
reduction O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
by O
st O
##n O
db O
##s O
however O
in O
this O
abstract O
the O
stereo O
##ta O
##ctic O
position O
of O
the O
stimulation O
contacts O
has O
not O
been O
spec O
##i O
##ﬁ O
##ed O
and O
therefore O
the O
ben O
##e O
##ﬁ O
##cial O
effect O
may O
not O
be O
attributed O
to O
stimulation O
of O
the O
st O
##n O
proper O
but O
rather O
the O
adjacent O
sub O
##thal O
##ami O
##c O
area O
following O
this O
notion O
a O
previous O
study O
reported O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
of O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
through O
st O
##n O
db O
##s O
most O
probably O
due O
to O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
area O
6 O
a O
recent O
computational O
model O
af O
##ﬁ O
##rmed O
the O
clinical O
ﬁ O
##nding O
that O
stimulation O
contacts O
positioned O
in O
the O
dorsal O
portion O
of O
the O
st O
##n O
simultaneously O
in O
##ﬂ O
##uen O
##ce O
gp O
##i O
ﬁ O
##bers O
of O
passage O
within O
the O
sub O
##thal O
##ami O
##c O
area O
and O
therefore O
potentially O
reduce O
d O
##ys O
##kin O
##es O
##ias O
7 O

in O
patient O
2 O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
improved O
both O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
and O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
and O
reduced O
the O
severity O
of O
off O
motor O
signs O
the O
ben O
##e O
##ﬁ O
##cial O
effect O
of O
gp O
##i O
db O
##s O
on O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
our O
patient O
parallels O
the O
outcome O
of O
a O
previously O
reported O
single O
case O
observation O
8 O

the O
et O
##iology O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
following O
st O
##ria O
##tal O
fetal O
ni O
##gra O
##l O
graf O
##ting O
is O
still O
unclear O
the O
development O
of O
d O
##ys O
##kin O
##es O
##ias O
after O
transplant O
##ation O
is O
probably O
not O
associated O
with O
do O
##pa O
##mine O
##rg O
##ic O
over O
##growth O
or O
excessive O
do O
##pa O
##mine O
release O
from O
the O
graf O
##ts O
accordingly O
18 O
##f O
pet O
studies O
in O
pd O
patients O
with O
post O
##gra O
##fting O
d O
##ys O
##kin O
##es O
##ias O
have O
not O
provided O
evidence O
for O
do O
##pa O
##mine O
##rg O
##ic O
over O
##growth O
4 O
favored O
h O
##yp O
##oth O
##eses O
rather O
involve O
patch O
##y O
and O
uneven O
do O
##pa O
##mine O
##rg O
##ic O
inner O
##vation O
resulting O
in O
do O
##pa O
##mine O
over O
##ﬂ O
##ow O
from O
rein O
##ner O
##vate O
##d O
into O
non O
##re O
##inn O
##er O
##vate O
##d O
st O
##ria O
##tal O
regions O
and O
activation O
of O
super O
##sen O
##sit O
##ive O
do O
##pa O
##mine O
receptors O
in O
##ﬂ O
##am O
##mat O
##ory O
reactions O
around O
the O
graf O
##ts O
may O
further O
promote O
d O
##ys O
##kin O
##es O
##ias O
eventually O
un O
##fa O
##vor O
##able O
composition O
of O
the O
graf O
##t O
with O
respect O
to O
the O
predominant O
type O
of O
do O
##pa O
##mine O
##rg O
##ic O
ne O
##uron O
##es O
from O
the O
sub O
##stan O
##tia O
ni O
##gra O
or O
ventral O
te O
##gm O
##ental O
area O
may O
play O
a O
role O
9 O

the O
path O
##op O
##hy O
##sio O
##logical O
sequel O
##ae O
of O
un O
##re O
##gul O
##ated O
intra O
##st O
##ria O
##tal O
do O
##pa O
##mine O
release O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
on O
the O
direct O
and O
indirect O
basal O
gang O
##lia O
pathway O
have O
not O
been O
spec O
##i O
##ﬁ O
##cal O
##ly O
investigated O
however O
experimental O
studies O
on O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
have O
highlighted O
the O
crucial O
role O
of O
d O
##1 O
do O
##pa O
##mine O
receptor O
mediated O
transmission O
at O
the O
level O
of O
the O
direct O
pathway O
from O
the O
st O
##ria O
##tum O
to O
the O
gp O
##i O
10 O
increased O
sensitivity O
of O
d O
##1 O
do O
##pa O
##mine O
receptors O
have O
recently O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
as O
a O
prominent O
risk O
factor O
for O
d O
##ys O
##kin O
##es O
##ias O
11 O
consequently O
in O
animal O
and O
human O
studies O
alterations O
of O
the O
direct O
pathway O
due O
to O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
led O
to O
fundamental O
changes O
in O
the O
electro O
##phy O
##sio O

129 O
##6 O
j O
her O
##zog O
et O
al O

logical O
properties O
of O
the O
gp O
##i O
with O
reduced O
gp O
##i O
ﬁ O
##ring O
rates O
and O
abnormal O
bursting O
discharge O
12 O
modulation O
of O
the O
path O
##ological O
activity O
within O
the O
gp O
##i O
by O
means O
of O
db O
##s O
immediately O
reduces O
d O
##ys O
##kin O
##es O
##ias O
ir O
##res O
##pe O
##ctive O
of O
the O
medication O
state O
13 O
in O
contrast O
intervening O
within O
the O
st O
##n O
probably O
does O
not O
directly O
am O
##eli O
##ora O
##te O
l O
do O
##pa O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ias O
but O
rather O
ex O
##ert O
##s O
its O
anti O
##dy O
##skin O
##etic O
in O
##ﬂ O
##uen O
##ce O
by O
post O
##oper O
##ative O
reduction O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
13 O
the O
superior O
effect O
of O
gp O
##i O
db O
##s O
compared O
to O
st O
##n O
db O
##s O
in O
reducing O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
unrelated O
to O
external O
do O
##pa O
##mine O
application O
supports O
this O
concept O
assign O
##ing O
a O
pivotal O
role O
to O
the O
direct O
pathway O
in O
media O
##ting O
d O
##ys O
##kin O
##es O
##ia O
related O
neural O
activity O
alternatively O
or O
complementary O
to O
the O
proposed O
systemic O
effects O
on O
neural O
activity O
within O
the O
basal O
gang O
##lia O
loop O
differential O
effects O
of O
st O
##n O
db O
##s O
versus O
gp O
##i O
db O
##s O
##14 O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
release O
may O
impact O
the O
different O
outcomes O
in O
our O
patients O
however O
in O
contrast O
to O
the O
results O
of O
aforementioned O
animal O
studies O
a O
pet O
study O
in O
pd O
patients O
with O
st O
##n O
db O
##s O
failed O
to O
detect O
any O
sign O
##i O
##ﬁ O
##can O
##t O
change O
in O
the O
extra O
##cellular O
st O
##ria O
##tal O
concentration O
of O
do O
##pa O
##mine O
15 O

in O
conclusion O
we O
showed O
that O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
patients O
can O
ben O
##e O
##ﬁ O
##t O
from O
additional O
ne O
##uro O
##mo O
##du O
##lation O
therapy O
the O
choice O
of O
target O
may O
need O
to O
be O
tailored O
to O
the O
individual O
clinical O
sy O
##mpt O
##oma O
##tology O
st O
##nd O
##bs O
in O
our O
patient O
led O
to O
marked O
improvement O
in O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
but O
was O
less O
effective O
in O
reducing O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
patients O
with O
prominent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
gp O
##i O
db O
##s O
may O
be O
the O
better O
option O
because O
of O
its O
immediate O
anti O
##dy O
##skin O
##etic O
effect O
however O
the O
small O
number O
of O
patients O
enrolled O
and O
some O
short O
##coming O
in O
trying O
all O
possible O
stimulation O
parameters O
patient O
1 O
may O
limit O
the O
conclusions O
that O
can O
be O
drawn O
from O
our O
data O

segment O
1 O
patient O
1 O
before O
st O
##n O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
1 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
2 O
months O
before O
implant O
##ation O
of O
bilateral O
sub O
##thal O
##ami O
##c O
leads O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
presents O
with O
marked O
limb O
h O
##yp O
##oki O
##nesia O
and O
simultaneously O
intermittent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O

segment O
2 O
patient O
1 O
following O
st O
##n O
db O
##s O
medication O
off O
stimulation O
on O
three O
years O
following O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
the O
patient O
continues O
to O
show O
off O
period O
d O
##ys O
##kin O
##es O
##ias O

segment O
3 O
patient O
2 O
before O
gp O
##i O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
2 O
was O
video O
##ta O
##ped O

8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
3 O
months O
before O
implant O
##ation O
of O
bilateral O
leads O
within O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
shows O
limb O
h O
##yp O
##oki O
##nesia O
with O
intermittent O
d O
##ys O
##kin O
##es O
##ias O
accent O
##uated O
in O
the O
right O
hand O
and O
ﬁ O
##nger O
##s O

segment O
4 O
patient O
2 O
following O
gp O
##i O
db O
##s O
medication O
off O
stimulation O
on O
two O
years O
following O
pal O
##lid O
##al O
deep O
brain O
stimulation O
severity O
of O
d O
##ys O
##kin O
##es O
##ias O
in O
the O
medication O
off O
condition O
is O
reduced O
despite O
complete O
ce O
##ssa O
##tion O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
off O
period O
symptoms O
are O
su O
##f O
##ﬁ O
##cie O
##ntly O
alleviate O
##d O
by O
deep O
brain O
stimulation O

br O
##und O
##in O
p O
po O
##gar O
##ell O
o O
ha O
##gel O
##l O
p O
et O
al O
bilateral O
ca O
##uda O
##te O
and O
put O
##amen O
graf O
##ts O
of O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
tissue O
treated O
with O
la O
##zar O
##oids O
in O
parkinson O
s O
disease O
brain O
2000 O
123 O
part O
7 O
138 O
##0 O
139 O
##0 O

freed O
cr O
greene O
pe O
breeze O
re O
et O
al O
transplant O
##ation O
of O
embryo O
##nic O
do O
##pa O
##mine O
neurons O
for O
severe O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2001 O
344 O
710 O
71 O
##9 O

ol O
##ano O
##w O
cw O
go O
##etz O
c O
##g O
ko O
##rdo O
##wer O
j O
##h O
et O
al O
a O
double O
blind O
controlled O
trial O
of O
bilateral O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
in O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
2003 O
54 O
403 O
41 O
##4 O

po O
##gar O
##ell O
o O
koch O
w O
gil O
##deh O
##aus O
f O
##j O
et O
al O
long O
term O
assessment O
of O
st O
##ria O
##tal O
do O
##pa O
##mine O
transport O
##ers O
in O
parkinson O
##ian O
patients O
with O
intra O
##st O
##ria O
##tal O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
graf O
##ts O
eu O
##r O
j O
nu O
##cl O
med O
mo O
##l O
imaging O
2006 O
33 O
407 O
411 O

cho O
c O
alter O
##man O
r O
##l O
mira O
##vite O
j O
et O
al O
sub O
##thal O
##ami O
##c O
db O
##s O
for O
the O
treatment O
of O
runaway O
d O
##ys O
##kin O
##es O
##ias O
after O
embryo O
##nic O
or O
fetal O
tissue O
transplant O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
123 O
##7 O

alter O
##man O
r O
##l O
shi O
##ls O
j O
##l O
gu O
##des O
##bla O
##tt O
m O
tag O
##lia O
##ti O
m O
immediate O
and O
sustained O
relief O
of O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
after O
dorsal O
relocation O
of O
a O
deep O
brain O
stimulation O
lead O
case O
report O
ne O
##uro O
##sur O
##g O
focus O
2004 O
17 O
e O
##6 O

mi O
##oc O
##ino O
##vic O
s O
parent O
m O
but O
##son O
cr O
et O
al O
computational O
analysis O
of O
sub O
##thal O
##ami O
##c O
nucleus O
and O
lent O
##icular O
fa O
##sc O
##ic O
##ulus O
activation O
during O
therapeutic O
deep O
brain O
stimulation O
j O
ne O
##uro O
##phy O
##sio O
##l O
2006 O
96 O
156 O
##9 O
1580 O

graf O
##f O
ra O
##df O
##ord O
j O
foot O
##e O
k O
##d O
rodriguez O
r O
##l O
et O
al O
deep O
brain O
stimulation O
of O
the O
internal O
segment O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
in O
delayed O
runaway O
d O
##ys O
##kin O
##es O
##ia O
arch O
ne O
##uro O
##l O
2006 O
63 O
118 O
##1 O
118 O
##4 O

winkler O
c O
ki O
##rik O
d O
b O
##jo O
##rk O
##lund O
a O
cell O
transplant O
##ation O
in O
parkinson O
s O
disease O
how O
can O
we O
make O
it O
work O
trends O
ne O
##uro O
##sc O
##i O
2005 O
28 O
86 O
92 O

ge O
##rf O
##en O
cr O
d O
##1 O
do O
##pa O
##mine O
receptor O
super O
##sen O
##sit O
##ivity O
in O
the O
do O
##pa O
##mine O
depleted O
st O
##ria O
##tum O
animal O
model O
of O
parkinson O
s O
disease O
ne O
##uro O
##sc O
##ient O
##ist O
2003 O
9 O
45 O
##5 O
46 O
##2 O

au O
##bert O
i O
gui O
##gon O
##i O
c O
ha O
##kan O
##sson O
k O
et O
al O
increased O
d O
##1 O
do O
##pa O
##mine O
receptor O
signaling O
in O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ia O
ann O
ne O
##uro O
##l O
2005 O
57 O
17 O
26 O

lo O
##zano O
am O
lang O
ae O
levy O
r O
et O
al O
ne O
##uron O
##al O
recordings O
in O
parkinson O
s O
disease O
patients O
with O
d O
##ys O
##kin O
##es O
##ias O
induced O
by O
ap O
##omo O
##rp O
##hine O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##14 O
##1 O
s O
##14 O
##6 O

vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
et O
al O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

mei O
##ss O
##ner O
w O
ha O
##rna O
##ck O
d O
ho O
##ess O
##le O
n O
et O
al O
high O
frequency O
stimulation O
of O
the O
en O
##top O
##ed O
##un O
##cular O
nucleus O
has O
no O
effect O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
transmission O
ne O
##uro O
##che O
##m O
int O
2004 O
44 O
281 O
286 O

tho O
##bo O
##is O
s O
fra O
##ix O
v O
sava O
##sta O
m O
et O
al O
chronic O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
and O
st O
##ria O
##tal O
d O
##2 O
do O
##pa O
##mine O
receptors O
in O
parkinson O
s O
disease O
a O
11 O
c O
ra O
##cl O
##op O
##ride O
pet O
study O
j O
ne O
##uro O
##l O
2003 O
250 O
121 O
##9 O
122 O
##3 O

l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##7 O

lev O
##od O
##opa O
therapy O
in O
a O
les O
##ch O
ny O
##han O
disease O
patient O

path O
##ological O
bio O
##chemical O
ne O
##uro O
##ima O
##ging O
and O
therapeutic O
remarks O

mercedes O
serra O
##no O
md O
1 O
3 O
bel O
##en O
pe O
##´ O
##re O
##z O
md O
phd O
##1 O
3 O

aid O
##a O
or O
##ma O
##za O
##´ O
##bal O
phd O
2 O
3 O
rafael O
art O
##uch O
md O
phd O
2 O
3 O
ja O
##ume O
camp O
##isto O
##l O
md O
phd O
1 O
3 O
rosa O
j O
torres O
md O
phd O
4 O
and O
angels O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
md O
phd O
##1 O
3 O

1 O
##ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
2 O
##cl O
##ini O
##cal O
biochemistry O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
3 O
##cent O
##re O
for O
biomedical O
research O
on O
rare O
diseases O
ci O
##ber O
##er O
instituto O
de O
sal O
##ud O
carlos O
iii O
barcelona O
spain O
4 O
##di O
##vision O
of O
clinical O
biochemistry O
la O
paz O
university O
hospital O
madrid O
spain O

abstract O
les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
of O
pu O
##rine O
metabolism O
causing O
severe O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
disturbances O
in O
which O
an O
abnormal O
central O
nervous O
system O
do O
##pa O
##mine O
##rg O
##ic O
function O
has O
been O
implied O
however O
lev O
##od O
##opa O
treatment O
has O
rarely O
been O
used O
and O
reports O
describe O
het O
##ero O
##gen O
##eous O
responses O
we O
report O
an O
l O
##nd O
patient O
with O
low O
do O
##pa O
##mine O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
for O
whom O
early O
lev O
##od O
##opa O
car O
##bid O
##opa O
therapy O
was O
begun O
with O
a O
notable O
clinical O
improvement O
we O
propose O
that O
very O
early O
treatment O
of O
l O
##nd O
patients O
with O
lev O
##od O
##opa O
may O
improve O
their O
neurological O
symptoms O
and O
may O
contribute O
to O
a O
better O
outcome O
2008 O
movement O
disorder O
society O

key O
words O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
do O
##pa O
##mine O
les O
##ch O
ny O
##han O
disease O
lu O
##mba O
##r O
pun O
##cture O
mono O
##amine O
##s O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O

les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
caused O
by O
de O
##ﬁ O
##cie O
##nt O
activity O
of O
the O
enzyme O
h O
##yp O
##ox O
##ant O
##hine O
gu O
##ani O
##ne O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
tran O
##fera O
##se O
hp O
##rt O
bio O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
a O
ng O
##els O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
pediatric O
ne O
##uro O
##logy O

department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
pass O
##ei O
##g O
de O
sant O
joan O
de O
de O
##´ O
##u O
2 O
08 O
##9 O
##50 O
es O
##pl O
##ug O
##ues O
de O
ll O
##ob O
##re O
##gat O
barcelona O
spain O

e O
mail O
ag O
##ar O
##cia O
hs O
##j O
##db O
##c O
##n O
org O

received O
17 O
july O
2007 O
revised O
11 O
september O
2007 O
accepted O
26 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##86 O

chemical O
##ly O
characterized O
by O
hyper O
##uri O
##ce O
##mia O
1 O
the O
clinical O
features O
associated O
with O
l O
##nd O
include O
those O
related O
directly O
to O
the O
hyper O
##uri O
##ce O
##mia O
go O
##ut O
ne O
##ph O
##rol O
##ith O
##ias O
##is O
arthritis O
etc O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
manifestation O
##s O
indicative O
of O
central O
nervous O
system O
cn O
##s O
disturbances O
and O
other O
clinical O
signs O
hyper O
##eme O
##sis O
an O
##emia O
etc O
1 O
delayed O
motor O
development O
d O
##yst O
##onia O
cho O
##re O
##oat O
##het O
##osis O
d O
##ys O
##arth O
##ria O
h O
##yp O
##oton O
##ia O
pyramid O
##al O
signs O
and O
aggressive O
and O
or O
self O
in O
##ju O
##rio O
##us O
behavior O
have O
been O
described O
as O
the O
most O
characteristic O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
manifestation O
##s O
2 O
the O
exact O
path O
##op O
##hy O
##sio O
##logical O
mechanism O
by O
which O
the O
impaired O
pu O
##rine O
metabolism O
causes O
these O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
disturbances O
remains O
unclear O
but O
abnormal O
central O
mono O
##amine O
metabolism O
may O
play O
a O
role O
in O
particular O
several O
lines O
of O
evidence O
suggest O
that O
l O
##nd O
is O
associated O
with O
an O
abnormal O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
however O
only O
a O
few O
studies O
have O
reported O
treatment O
protocols O
using O
sub O
##sti O
##tu O
##tive O
lev O
##od O
##opa O
and O
they O
describe O
very O
het O
##ero O
##gen O
##eous O
responses O
to O
therapy O

we O
report O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
low O
do O
##pa O
##mine O
da O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
was O
started O
during O
the O
early O
stages O
of O
his O
ne O
##uro O
##dev O
##elo O
##pment O

clinical O
report O

the O
patient O
is O
a O
boy O
the O
second O
child O
of O
healthy O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
pregnancy O
delivery O
and O
neon O
##atal O
period O
were O
uneven O
##tf O
##ul O
from O
the O
ﬁ O
##rst O
days O
of O
his O
life O
a O
lack O
of O
spontaneous O
movements O
and O
poor O
head O
control O
were O
present O
clinical O
examination O
at O
4 O
months O
revealed O
marked O
hyper O
##ton O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
brisk O
deep O
re O
##ﬂ O
##ex O
##es O
bilateral O
ba O
##bin O
##ski O
s O
sign O
and O
trunk O
##al O
h O
##yp O
##oton O
##ia O
with O
no O
abnormal O
movements O
head O
ci O
##rc O
##um O
##ference O
and O
o O
##cular O
pursuit O
were O
appropriate O
brain O
mri O
disclosed O
slight O
signs O
of O
co O
##rti O
##cal O
at O
##rop O
##hy O
blood O
cell O
count O
glucose O
trans O
##amina O
##ses O
ck O
cr O
##ea O
##tin O
##ine O
ur O
##ic O
acid O
ammonia O
lac O
##tate O
p O
##yr O
##u O
##vate O
plasma O
amino O
acids O
urine O
organic O
acids O
and O
ur O
##ic O
acid O
were O
normal O
o O
##cular O
examination O
ev O
##oked O
audit O
##ive O
potential O
##s O
nerve O
conduct O
##ion O
and O
electro O
##my O
##ography O
were O
also O
normal O
at O
the O
age O
of O
10 O
months O
he O
developed O
tremor O
and O
marked O
d O
##yst O
##onic O
movements O
of O
the O
hands O
and O
the O
mouth O
video O
1 O
serum O
ur O
##ate O
was O
elevated O
48 O
##4 O
l O
##mo O
##l O
l O
normal O
range O
100 O
330 O
l O
##mo O
##l O
l O
and O
in O
24 O
hours O
urine O
the O
ur O
##ina O
##ry O
ur O
##ic O
acid O
cr O
##ea O
##tin O
##ine O
ratio O
was O
in O
the O
upper O
normal O
limit O
2 O
1 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
normal O
range O
0 O
2 O
2 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
hp O
##rt O
activity O
was O
requested O
at O
the O
same O
time O
due O
to O
the O
presence O
of O
d O
##ys O
##kin O
##etic O
movements O
a O
lu O
##mba O
##r O
pun O
##cture O
was O
performed O
showing O
low O
levels O
of O
homo O
##vani O
##lli O
##c O
acid O

129 O
##8 O
m O
serra O
##no O
et O
al O

table O
1 O
bio O
##genic O
amin O
##e O
and O
pt O
##erine O
concentrations O
in O
cs O
##f O
before O
treatment O
and O
follow O
up O

after O
l O
do O
##pa O
therapy O
l O
do O
##pa O
plus O
car O
##bid O
##opa O
and O
f O
##olin O
##ic O
acid O

di O
##tions O
video O
3 O
he O
is O
able O
to O
transfer O
objects O
between O
hands O
and O
do O
pin O
##cer O
grasping O
comprehension O
has O
always O
seemed O
to O
be O
preserved O
he O
never O
presented O
self O
in O
##ju O
##rio O
##us O
behavior O
the O
cs O
##f O
h O
##va O
concentration O
is O
now O
in O
the O
normal O
range O
table O
1 O

before O
treatment O
6 O
mg O
kg O
day O

age O
10 O
mo O
3 O
y O
##r O
4 O
mo O

h O
##va O
homo O
##vani O
##lli O
##c O
acid O
5 O
hi O
##aa O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
m O
##hp O
##h O
3 O
##met O
##ho O
##xy O
4 O
hydro O
##xy O
##ph O
##en O
##yl O
##gly O
##col O

numbers O
in O
brackets O
represent O
the O
age O
related O
controls O
values O
3 O

h O
##va O
in O
cs O
##f O
compared O
to O
age O
normal O
range O
##3 O
table O
1 O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
1 O
0 O
25 O
proportion O
was O
gradually O
introduced O
up O
to O
3 O
mg O
kg O
day O
resulting O
in O
moderate O
improvement O
at O
the O
age O
of O
1 O
year O
and O
6 O
months O
the O
patient O
showed O
better O
head O
control O
and O
he O
started O
picking O
up O
objects O
d O
##ys O
##kin O
##etic O
movements O
were O
still O
present O
while O
peripheral O
hyper O
##ton O
##ia O
and O
brisk O
deep O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
decreased O
notably O
video O
2 O
the O
low O
cs O
##f O
h O
##va O
concentration O
together O
with O
the O
clinical O
improvement O
led O
us O
to O
h O
##yp O
##oth O
##es O
##ize O
a O
primary O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
synthesis O
defect O
but O
ty O
##ros O
##ine O
hydro O
##xy O
##lase O
gene O
study O
showed O
no O
mutations O
when O
ur O
##ic O
acid O
metabolism O
was O
assessed O
again O
the O
patient O
presented O
a O
serum O
ur O
##ate O
value O
of O
46 O
##3 O
l O
##mo O
##l O
l O
normal O
range O
100 O
330 O
l O
##mo O
##l O
l O
ur O
##ina O
##ry O
ur O
##ic O
acid O
cr O
##ea O
##tin O
##ine O
ratio O
at O
2 O
32 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
normal O
range O
0 O
2 O
2 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
and O
markedly O
elevated O
renal O
ex O
##cre O
##tion O
of O
x O
##ant O
##hine O
and O
h O
##yp O
##ox O
##ant O
##hine O
hp O
##rt O
activity O
in O
hem O
##olis O
##ate O
was O
und O
##ete O
##ctable O
and O
aden O
##ine O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fera O
##se O
activity O
was O
elevated O
59 O
nm O
##ol O
hour O
mg O
hem O
##og O
##lo O
##bin O
normal O
range O
19 O
38 O
nm O
##ol O
hour O
mg O
hem O
##og O
##lo O
##bin O
molecular O
analysis O
disclosed O
a O
5 O
bp O
del O
##eti O
##on O
in O
hp O
##rt O
ex O
##on O
3 O
corresponding O
to O
position O
261 O
265 O
of O
hp O
##rt O
mrna O
associated O
with O
a O
12 O
bp O
insertion O
in O
position O
261 O
this O
mutation O
has O
not O
been O
previously O
reported O
and O
it O
predicted O
a O
change O
in O
hp O
##rt O
protein O
with O
a O
frames O
##hi O
##ft O
after O
g O
##ly O
##58 O
and O
a O
stop O
cod O
##on O
in O
position O
74 O
the O
child O
has O
presented O
a O
moderate O
progressive O
improvement O
to O
date O
3 O
years O
of O
age O
therapy O
with O
l O
do O
##pa O
car O
##bid O
##opa O
up O
to O
6 O
mg O
kg O
day O
and O
f O
##olin O
##ic O
acid O
to O
avoid O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
has O
not O
been O
withdrawn O
head O
control O
has O
been O
fully O
attained O
tremor O
has O
completely O
disappeared O
the O
quality O
of O
movements O
is O
notably O
more O
precise O
and O
the O
patient O
sits O
without O
support O
d O
##yst O
##onic O
movements O
are O
still O
present O
although O
less O
pronounced O
##ly O
than O
baseline O
con O

we O
describe O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
clinical O
signs O
of O
impaired O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
the O
notable O
tremor O
the O
marked O
d O
##yst O
##onia O
developed O
during O
early O
infancy O
and O
the O
obvious O
sustained O
response O
to O
l O
do O
##pa O
led O
us O
to O
investigate O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
however O
some O
clinical O
characteristics O
such O
as O
the O
absence O
of O
o O
##cu O
##logy O
##ric O
crisis O
and O
the O
preservation O
of O
facial O
ge O
##stic O
##ulation O
did O
not O
ﬁ O
##t O
into O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
picture O

it O
has O
been O
suggested O
that O
l O
##nd O
may O
be O
associated O
with O
abnormal O
do O
##pa O
##mine O
##rg O
##ic O
function O
including O
ne O
##uro O
##path O
##ological O
bio O
##chemical O
and O
ne O
##uro O
##ima O
##ging O
studies O
while O
no O
morphological O
abnormalities O
in O
the O
cn O
##s O
of O
l O
##nd O
patients O
have O
been O
reported O
direct O
measurement O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
tissue O
has O
shown O
that O
da O
and O
h O
##va O
are O
sign O
##i O
##ﬁ O
##can O
##tly O
lower O
in O
the O
limb O
##ic O
and O
st O
##ria O
##tal O
regions O
of O
deceased O
l O
##nd O
patients O
4 O
5 O
moreover O
path O
##ological O
studies O
have O
shown O
increased O
do O
##pa O
##mine O
d O
##2 O
receptor O
im O
##mun O
##ore O
##act O
##ivity O
in O
put O
##amen O
and O
less O
evidently O
in O
the O
ca O
##uda O
##te O
nucleus O
5 O
as O
a O
result O
of O
recent O
ﬁ O
##nding O
##s O
a O
theory O
of O
posts O
##yna O
##ptic O
da O
super O
##sen O
##sit O
##ivity O
owing O
to O
a O
decreased O
pre O
##sy O
##na O
##ptic O
da O
activity O
has O
been O
formulated O
5 O
interesting O
##ly O
when O
the O
sub O
##stan O
##tia O
ni O
##gra O
was O
explored O
da O
levels O
turned O
out O
to O
be O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
lower O
than O
in O
controls O
4 O
and O
ty O
##ros O
##ine O
hydro O
##xi O
##lase O
neurons O
and O
ﬁ O
##bers O
were O
not O
decreased O
4 O
these O
ﬁ O
##nding O
##s O
suggest O
that O
the O
da O
terminals O
are O
reduced O
and O
damaged O
due O
to O
a O
developmental O
or O
a O
de O
##gen O
##erative O
process O
ﬁ O
##nally O
resulting O
in O
impaired O
activity O
in O
the O
st O
##ria O
##tum O

moreover O
evidence O
of O
do O
##pa O
##mine O
##rg O
##ic O
function O
abnormalities O
also O
comes O
from O
po O
##sit O
##ron O
emission O
tom O
##ography O
images O
which O
show O
an O
abnormal O
##ly O
reduced O
number O
of O
do O
##pa O
##mine O
##rg O
##ic O
nerve O
terminals O
and O
cell O
bodies O
involving O
all O
do O
##pa O
##mine O
##rg O
##ic O
pathways O
but O
especially O
in O
the O
put O
##amen O
6 O
7 O

the O
role O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
development O
has O
recently O
been O
documented O
8 O
interesting O
##ly O
the O
early O
do O
##pa O
##mine O
##rg O
##ic O
input O
from O
the O
mid O
##bra O
##in O
may O
play O
an O
important O
role O
in O
the O
development O
of O
the O
basal O
gang O
##lia O
and O
cerebral O
cortex O
9 O
furthermore O
brain O
development O
has O
to O
be O
completed O
during O
the O
ﬁ O
##rst O
months O
of O
life O
when O
ax O
##onal O
and O
den O
##dr O
##itic O
branching O
is O
ongoing O
and O
syn O
##ap O
##to O
##genesis O
is O
just O
beginning O
da O
disturbances O
in O

l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##9 O

these O
ne O
##uro O
##dev O
##elo O
##pment O
##al O
periods O
may O
be O
crucial O
for O
further O
cn O
##s O
function O

cs O
##f O
do O
##pa O
##mine O
meta O
##bol O
##ite O
analysis O
has O
previously O
been O
examined O
to O
assess O
the O
functioning O
of O
the O
cn O
##s O
do O
##pa O
##mine O
pathway O
in O
l O
##nd O
##10 O
13 O
by O
measuring O
the O
end O
product O
of O
da O
h O
##va O
these O
studies O
were O
performed O
some O
time O
ago O
during O
the O
70s O
and O
the O
80s O
and O
sometimes O
their O
results O
were O
not O
adequately O
evaluated O
11 O
obtained O
h O
##va O
values O
must O
be O
properly O
compared O
to O
age O
related O
control O
ranges O
so O
as O
to O
permit O
an O
accurate O
interpretation O
of O
the O
results O
the O
concentration O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
is O
inverse O
##ly O
correlated O
with O
age O
3 O
the O
patient O
described O
above O
initially O
presented O
slightly O
decreased O
levels O
of O
cs O
##f O
h O
##va O
compared O
to O
age O
related O
controls O
table O
1 O
silver O
##stein O
et O
al O
described O
age O
##rel O
##ated O
changes O
of O
h O
##va O
in O
cs O
##f O
and O
their O
results O
showed O
that O
the O
de O
##ﬁ O
##cie O
##ncies O
of O
h O
##va O
increased O
from O
infancy O
to O
adolescence O
13 O
perhaps O
our O
patient O
s O
young O
age O
obscured O
da O
de O
##ﬁ O
##ciency O
nonetheless O
bio O
##chemical O
response O
to O
l O
do O
##pa O
treatment O
was O
remarkable O
and O
second O
sample O
h O
##va O
values O
were O
higher O
and O
inside O
the O
normal O
range O
however O
the O
notably O
clinical O
improvement O
described O
could O
have O
been O
developmental O
and O
or O
due O
to O
l O
do O
##pa O
therapy O
their O
respective O
contributions O
are O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
evaluate O
owing O
to O
the O
het O
##ero O
##gen O
##eit O
##y O
of O
l O
##nd O

among O
the O
previously O
reported O
l O
do O
##pa O
treated O
patients O
some O
failed O
to O
improve O
while O
some O
even O
presented O
into O
##ler O
##able O
side O
effects O
10 O
13 O
an O
important O
limitation O
in O
the O
evaluation O
of O
the O
the O
##ra O
##pies O
used O
in O
the O
preceding O
reports O
was O
the O
different O
ages O
at O
which O
treatment O
was O
started O
it O
is O
likely O
that O
delayed O
l O
do O
##pa O
treatments O
do O
not O
help O
to O
recover O
the O
previously O
damaged O
nerve O
terminals O
furthermore O
due O
to O
the O
already O
decreased O
pre O
##sy O
##na O
##ptic O
da O
activity O
these O
patients O
may O
present O
a O
posts O
##yna O
##ptic O
da O
super O
##sen O
##sit O
##ivity O
##5 O
that O
would O
account O
for O
the O
lack O
of O
effectiveness O
and O
even O
for O
the O
presence O
of O
side O
effects O
like O
watts O
et O
al O
reported O
14 O
some O
time O
before O
mi O
##zu O
##no O
et O
al O
had O
described O
4 O
patients O
with O
no O
cs O
##f O
examination O
treated O
at O
different O
un O
##re O
##port O
##ed O
ages O
but O
they O
did O
not O
evaluate O
the O
impact O
on O
movement O
disturbances O
15 O
jan O
##kovich O
et O
al O
performed O
pre O
##tre O
##at O
##ment O
cs O
##f O
analysis O
but O
l O
do O
##pa O
doses O
and O
therapy O
duration O
were O
not O
detailed O
age O
at O
beginning O
of O
the O
treatment O
was O
very O
variable O
and O
their O
clinical O
results O
were O
mixed O
12 O

our O
clinical O
observation O
points O
out O
the O
need O
to O
develop O
neurological O
the O
##ra O
##pies O
for O
hp O
##rt O
de O
##ﬁ O
##cie O
##nt O
patients O
among O
which O
l O
do O
##pa O
may O
be O
promising O
however O
no O
general O
conclusions O
can O
be O
obtained O
from O
a O
single O
case O
report O
due O
to O
l O
##nd O
het O
##ero O
##gen O
##eit O
##y O
in O
any O
case O
we O
found O
that O
early O
l O
do O
##pa O
treatment O
is O
ad O
##vis O
##able O
to O
enable O
good O

response O
and O
to O
opt O
##imi O
##ze O
neurological O
outcome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
analysis O
may O
be O
a O
useful O
bio O
##chemical O
aid O
to O
select O
l O
##nd O
patients O
for O
l O
do O
##pa O
therapy O
and O
monitor O
their O
treatment O
further O
studies O
clinical O
observations O
and O
double O
blind O
trials O
are O
needed O
to O
establish O
the O
useful O
##ness O
of O
l O
do O
##pa O
in O
patients O
with O
l O
##nd O

video O
1 O
frequent O
d O
##ys O
##kin O
##etic O
movements O
of O
the O
mouth O
and O
the O
ex O
##tre O
##mit O
##ies O
absence O
of O
voluntary O
grasping O
no O
head O
control O
explosive O
un O
##co O
##ord O
##inated O
movements O

video O
2 O
better O
head O
control O
able O
to O
pick O
up O
objects O
fine O
motor O
movements O
have O
improved O

video O
3 O
head O
control O
is O
fully O
reached O
d O
##yst O
##onic O
movements O
are O
clearly O
improved O
able O
to O
transfer O
objects O
between O
hands O
put O
rings O
in O
a O
bar O
and O
do O
pin O
##cer O
grasping O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fis O
grant O
pi O
##0 O
##51 O
##31 O
##8 O
and O
ci O
##ber O
er O
is O
##c O
iii O
we O
thank O
the O
patient O
and O
his O
family O
for O
their O
participation O

jin O
##nah O
ha O
friedman O
##n O
t O
les O
##ch O
ny O
##han O
disease O
and O
its O
variants O
in O
sc O
##river O
cr O
beau O
##de O
##t O
al O
sly O
w O
##s O
valle O
d O
editors O
the O
metabolic O
and O
molecular O
bases O
of O
inherited O
disease O
8th O
ed O
new O
york O
mcgraw O
hill O
2001 O
p O
253 O
##7 O
257 O
##0 O

jin O
##nah O
ha O
vis O
##ser O
je O
harris O
jc O
et O
al O
del O
##ine O
##ation O
of O
the O
motor O
disorder O
of O
les O
##ch O
ny O
##han O
disease O
brain O
2006 O
129 O
120 O
##1 O
121 O
##7 O

or O
##ma O
##za O
##´ O
##bal O
a O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
a O
fern O
##a O
##´ O
##nde O
##z O
y O
fern O
##a O
##´ O
##nde O
##za O
##´ O
l O
##var O
##ez O
e O
camp O
##isto O
##l O
j O
art O
##uch O
r O
hp O
##lc O
with O
electro O
##chemical O
and O
ﬂ O
##uo O
##res O
##cence O
detection O
procedures O
for O
the O
diagnosis O
of O
in O
##born O

errors O
of O
bio O
##genic O
amin O
##es O
and O
pt O
##erine O
##s O
j O
ne O
##uro O
##sc O
##i O
methods O
2005 O
142 O
153 O
158 O

lloyd O
kg O
horn O
##yk O
##ie O
##wicz O
o O
davidson O
l O
et O
al O
bio O
##chemical O
evidence O
of O
dysfunction O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
the O
les O
##ch O
##ny O
##han O
syndrome O
n O
eng O
##l O
j O
med O
1981 O
305 O
110 O
##6 O
111 O
##1 O

sai O
##to O
y O
ito O
m O
hana O
##oka O
s O
oh O
##ama O
e O
aka O
##bos O
##hi O
s O
tak O
##ashi O
##ma O
s O
do O
##pa O
##mine O
receptor O
up O
##re O
##gul O
##ation O
in O
les O
##ch O
ny O
##han O
syndrome O
a O
post O
##mo O
##rte O
##m O
study O
ne O
##uro O
##ped O
##ia O
##trics O
1999 O
30 O
66 O
71 O

ernst O
m O
za O
##met O
##kin O
aj O
mat O
##och O
##ik O
ja O
et O
al O
pre O
##sy O
##na O
##ptic O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
##s O
in O
les O
##ch O
ny O
##han O
disease O
n O
eng O
j O
med O
1996 O
334 O
156 O
##8 O
157 O
##2 O

wong O
d O
##f O
harris O
jc O
na O
##id O
##u O
s O
et O
al O
do O
##pa O
##mine O
transport O
##ers O
are O
markedly O
reduced O
in O
les O
##ch O
ny O
##han O
disease O
in O
vivo O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1996 O
93 O
55 O
##39 O
55 O
##43 O

her O
##len O
##ius O
e O
la O
##ger O
##cr O
##ant O
##z O
h O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
and O
ne O
##uro O
##mo O
##du O
##lat O
##ors O
during O
early O
human O
development O
early O
hum O
dev O
2001 O
65 O
21 O
37 O

schmidt O
u O
bey O
##er O
c O
o O
##est O
##re O
##iche O
##r O
ab O
rei O
##ser O
##t O
i O
sc O
##hill O
##ing O
k O
pilgrim O
c O
activation O
of O
do O
##pa O
##mine O
##rg O
##ic O
d O
##1 O
receptors O
promotes O
mor O
##ph O
##ogen O
##esis O
of O
developing O
st O
##ria O
##tal O
neurons O
neuroscience O
1996 O
74 O
45 O
##3 O
460 O

caste O
##lls O
s O
cha O
##kra O
##bar O
##ti O
c O
wins O
##berg O
b O
##g O
hu O
##r O
##wi O
##c O
m O
pere O
##l O
j O
##m O
ny O
##han O
w O
##l O
effects O
of O
l O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
on O
mono O
##amine O
and O
amino O
acids O
turnover O
in O
the O
les O
##ch O
ny O
##han O
syndrome O
j O
autism O
dev O
di O
##sor O
##d O
1979 O
9 O
95 O
103 O

1300 O
s O
de O
##hn O
##ing O
et O
al O

cia O
##rane O
##llo O
rd O
anders O
t O
##f O
bar O
##cha O
##s O
jd O
berger O
pa O
can O
##n O
hm O
the O
use O
of O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
in O
a O
child O
with O
les O
##ch O
ny O
##han O
syndrome O
child O
psychiatry O
hum O
dev O
1976 O
7 O
127 O
133 O

jan O
##kovic O
j O
cas O
##key O
tc O
stout O
j O
##t O
butler O
i O
##j O
les O
##ch O
ny O
##han O
syndrome O
a O
study O
of O
motor O
behavior O
and O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
ann O
ne O
##uro O
##l O
1988 O
23 O
46 O
##6 O
46 O
##9 O

silver O
##stein O
f O
##s O
johnston O
mv O
hutchinson O
r O
##j O
edwards O
nl O
les O
##ch O
ny O
##han O
syndrome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
abnormalities O
ne O
##uro O
##logy O
1985 O
35 O
90 O
##7 O
911 O

watts O
r O
##we O
spell O
##acy O
e O
gibbs O
da O
all O
##sop O
j O
mc O
##ker O
##an O
ro O
sl O
##avi O
##n O
ge O
clinical O
post O
mort O
##em O
bio O
##chemical O
and O
therapeutic O
observations O
on O
the O
les O
##ch O
ny O
##han O
syndrome O
with O
particular O
reference O
to O
the O
neurological O
manifestation O
##s O
q O
##jm O
##ed O
1982 O
51 O
43 O
78 O

mi O
##zu O
##no O
t O
yu O
##gar O
##i O
y O
self O
mu O
##tila O
##tion O
in O
les O
##ch O
ny O
##han O
syndrome O
lance O
##t O
1974 O
1 O
76 O
##1 O

therapy O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
ben O
##e O
##ﬁ O
##cial O
outcome O
with O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
deep O
brain O
stimulation O

sandra O
de O
##hn O
##ing O
md O
1 O
jan O
hi O
##nne O
##rk O
me O
##hr O
##ken O
##s O
md O
2 O
nor O
##bert O
mu O
##¨ O
##ller O
phd O
1 O
and O
kai O
bo O
##¨ O
##tze O
##l O
md O
##3 O

1 O
##de O
##par O
##tment O
of O
psychiatry O
and O
psycho O
##therapy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
ludwig O
maximilian O
##s O

university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
ludwig O
maximilian O
##s O
university O
munich O
germany O

abstract O
we O
report O
on O
a O
female O
patient O
with O
tour O
##ette O
syndrome O
ts O
and O
a O
12 O
month O
follow O
up O
after O
chronic O
deep O
brain O
stimulation O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
which O
resulted O
in O
excellent O
re O
##mission O
of O
motor O
and O
vocal O
ti O
##cs O
2008 O
movement O
disorder O
society O

key O
words O
tour O
##ette O
syndrome O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O

tour O
##ette O
syndrome O
ts O
is O
a O
chronic O
and O
in O
severe O
cases O
de O
##bil O
##itating O
disorder O
characterized O
by O
motor O
and O
vocal O
ti O
##cs O
and O
additionally O
accompanied O
by O
features O

correspondence O
to O
dr O
sandra O
de O
##hn O
##ing O
psychiatric O
hospital O
of O
the O
ludwig O
maximilian O
##s O
university O
munich O
nu O
##bba O
##ums O
##tr O
7 O
munich O
d O
80 O
##33 O
##6 O
germany O

e O
mail O
sandra O
de O
##hn O
##ing O
med O
un O
##i O
mu O
##en O
##chen O
de O

received O
2 O
august O
2007 O
accepted O
29 O
november O
2007 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
219 O
##30 O

of O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
and O
self O
in O
##ju O
##rio O
##us O
behavior O
although O
the O
path O
##op O
##hy O
##sio O
##logical O
mechanisms O
are O
yet O
unknown O
and O
the O
involvement O
of O
infection O
and O
in O
##ﬂ O
##am O
##mation O
has O
been O
discussed O
1 O
several O
studies O
have O
shown O
the O
in O
##ﬂ O
##uen O
##ce O
of O
the O
do O
##pa O
##mine O
##rg O
##ic O
system O
as O
anti O
##psy O
##cho O
##tic O
agents O
are O
successful O
in O
the O
treatment O
of O
ts O
mostly O
as O
an O
antagonist O
2 O
but O
also O
partly O
as O
an O
ago O
##nist O
of O
do O
##pa O
##mine O
3 O
functional O
and O
ne O
##uro O
##ima O
##ging O
studies O
emphasize O
abnormal O
##ly O
functioning O
do O
##pa O
##mine O
##rg O
##ic O
st O
##ria O
##to O
co O
##rti O
##cal O
circuits O
to O
affect O
these O
loops O
in O
ts O
##patient O
##s O
ref O
##rac O
##tory O
to O
medical O
treatment O
the O
strategy O
of O
deep O
brain O
stimulation O
db O
##s O
has O
been O
replaced O
introduced O
by O
van O
##de O
##wall O
##e O
4 O
in O
general O
stimulation O
targets O
are O
the O
tha O
##lam O
##us O
5 O
6 O
the O
anterior O
internal O
capsule O
7 O
the O
nucleus O
acc O
##umb O
##ens O
##8 O
and O
the O
gp O
##i O
##9 O
11 O
case O
series O
by O
serve O
##llo O
is O
added O
or O
combined O
approaches O
12 O

here O
we O
report O
on O
a O
female O
patient O
with O
ts O
and O
a O
12 O
##mont O
##h O
follow O
up O
study O
after O
chronic O
db O
##s O
of O
the O
gp O
##i O

case O
report O

the O
44 O
year O
old O
female O
patient O
has O
been O
suffering O
from O
ts O
since O
childhood O
when O
she O
was O
5 O
year O
old O
she O
ﬁ O
##rst O
developed O
vocal O
ti O
##cs O
sq O
##ue O
##aling O
in O
church O
followed O
by O
motor O
ti O
##cs O
like O
blinking O
bouncing O
and O
touching O
after O
delivery O
of O
her O
son O
at O
the O
age O
of O
20 O
the O
symptoms O
worsened O
and O
the O
patient O
showed O
self O
##mut O
##ilation O
with O
biting O
beating O
as O
well O
as O
grunt O
##ing O
and O
screaming O
at O
this O
time O
she O
also O
showed O
com O
##pu O
##ls O
##ive O
behavior O
for O
clean O
##liness O
during O
the O
course O
of O
disease O
the O
patient O
regularly O
developed O
a O
de O
##pressive O
mood O
and O
agitation O
proportional O
to O
the O
extent O
of O
ti O
##cs O
the O
intensity O
of O
her O
condition O
ﬁ O
##nally O
led O
to O
three O
suicide O
attempts O
social O
isolation O
and O
disability O

for O
the O
last O
17 O
years O
the O
patient O
was O
continuously O
treated O
as O
in O
##patient O
and O
out O
##patient O
of O
our O
clinic O
and O
the O
diagnosis O
of O
ts O
was O
established O
according O
to O
the O
criteria O
of O
ds O
##m O
iv O

conventional O
medication O
attempts O
with O
a O
range O
of O
anti O
##psy O
##cho O
##tics O
over O
many O
years O
did O
not O
have O
any O
substantial O
effect O
ultimately O
the O
combination O
of O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
together O
with O
monthly O
out O
##patient O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
ec O
##t O
over O
the O
last O
5 O
years O
has O
led O
to O
a O
partial O
suppression O
of O
ti O
##cs O
the O
rational O
##e O
for O
ec O
##t O
was O
derived O
from O
case O
reports O
where O
a O
substantial O
improvement O
of O
ti O
##cs O
##13 O
14 O
was O
demonstrated O

previous O
the O
##ra O
##pies O
with O
a O
2 O
ad O
##ren O
##ore O
##ce O
##pt O
##or O
ago O
##nist O
##s O
do O
##pa O
##mine O
ago O
##nist O
##s O
and O
op O
##io O
##id O
ago O
##nist O
##s O
as O
well O
as O
alternative O
treatments O
like O
antibiotics O
im O
##mun O
##og O
##lo O
##bu O
##lins O
and O
plasma O
##pher O
##esis O
already O
described O
as O
possibly O
effective O
in O
single O
reports O
##15 O
only O
resulted O
in O
a O
temporary O
improvement O
of O
the O
ti O
##cs O

tour O
##ette O
syndrome O
and O
deep O
brain O
stimulation O
130 O
##1 O

fig O
1 O
axial O
mri O
of O
the O
patient O
s O
brain O
showing O
the O
tip O
of O
the O
electrode O
##s O
6 O
mm O
below O
the O
level O
of O
the O
anterior O
and O
posterior O
com O
##mis O
##sure O
##s O
on O
the O
right O
the O
optic O
tract O
can O
be O
seen O
on O
which O
the O
electrode O
tip O
projects O

before O
stereo O
##ta O
##ctic O
intervention O
primary O
symptoms O
were O
severe O
grinding O
of O
her O
teeth O
beating O
her O
hips O
as O
well O
as O
persistent O
grunt O
##ing O
and O
qu O
##ack O
##ing O

after O
informed O
consent O
electrode O
implant O
##ation O
db O
##s O
338 O
##9 O
med O
##tron O
##ic O
for O
bilateral O
gp O
##i O
stimulation O
was O
performed O
under O
prop O
##of O
##ol O
an O
##esthesia O
with O
mri O
guided O
stereo O
##ta O
##xy O
using O
a O
mod O
##i O
##ﬁ O
##ed O
le O
##ks O
##el O
le O
##rch O
system O
the O
coordinates O
of O
the O
stereo O
##ta O
##ctic O
target O
point O
were O
as O
follows O
3 O
mm O
anterior O
to O
the O
ac O
pc O
mid O
##point O
4 O
mm O
below O
the O
ac O
pc O
plane O
and O
20 O
mm O
lateral O
to O
the O
inter O
##com O
##mis O
##ural O
line O
before O
the O
implant O
##ata O
##tion O
three O
micro O
##ele O
##ct O
##rod O
##es O
were O
inserted O
on O
each O
side O
simultaneously O
in O
order O
to O
con O
##ﬁ O
##rm O
the O
single O
cell O
activity O
typical O
for O
gp O
##i O
and O
to O
prove O
the O
appropriate O
distance O
to O
the O
internal O
capsule O
by O
macro O
##ele O
##ct O
##rod O
##e O
stimulation O
a O
post O
##oper O
##ative O
mri O
showed O
both O
electrode O
tips O
on O
top O
of O
the O
optic O
tracts O
right O
electrode O
18 O
mm O
lateral O
1 O
mm O
anterior O
7 O
mm O
below O
mid O
##com O
##mis O
##sur O
##al O
point O
left O
electrode O
19 O
mm O
lateral O
1 O
mm O
anterior O
and O
5 O
mm O
below O
on O
the O
right O
side O
electrode O
contact O
2 O
was O
chosen O
for O
chronic O
stimulation O
because O
the O
deeper O
contacts O
caused O
visual O
symptoms O
on O
the O
left O
side O
electrode O
contact O
1 O
was O
chosen O
fig O
1 O
after O
5 O
days O
during O
which O
the O
electrode O
lead O
had O
been O
external O
##ized O
and O
further O
test O
stimulation O
##s O
had O
shown O
no O
unwanted O
effects O
implant O
##ation O
of O
the O
pulse O
generators O
sole O
##tra O
med O
##tron O
##ic O
was O
performed O
initially O
standard O
settings O
also O
used O
in O
gp O
##i O
db O
##s O
for O
d O
##yst O
##onia O
were O
chosen O
mono O
##pol O
##ar O
stimulation O
amplitude O
2 O
5 O
v O
pulse O
width O

120 O
l O
##s O
and O
frequency O
130 O
pp O
##s O
and O
slowly O
increased O
to O

3 O
2 O
v O
at O
discharge O
stimulation O
parameters O
were O
further O
increased O
3 O
months O
after O
stimulation O
3 O
5 O
v O
150 O
l O
##s O
145 O

pp O
##s O
4 O
months O
after O
implant O
##ation O
3 O
5 O
v O
180 O
l O
##s O
145 O
pp O
##s O
and O
at O
12 O
months O
after O
the O
implant O
##ation O
4 O
2 O
v O
210 O
l O
##s O
145 O
pp O
##s O
under O
this O
setting O
the O
current O
applied O
was O
94 O
la O
on O
each O
side O

a O
decrease O
in O
ti O
##c O
frequency O
and O
intensity O
was O
noted O
during O
the O
ﬁ O
##rst O
week O
after O
the O
start O
of O
the O
continuous O
stimulation O
and O
ti O
##cs O
almost O
disappeared O
after O
6 O
weeks O
of O
stimulation O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
were O
discontinued O
clinical O
outcome O
was O
assessed O
using O
the O
yale O
global O
ti O
##c O
severity O
scale O
y O
##gt O
##ss O
the O
verbal O
learning O
memory O
test O
v O
##lm O
##t O
and O
the O
st O
##ro O
##op O
test O
the O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
before O
and O
after O
the O
intervention O
revealed O
an O
identical O
performance O
pro O
##ﬁ O
##le O
the O
y O
##gt O
##ss O
score O
dropped O
from O
83 O
pre O
##oper O
##ative O
##ly O
to O
28 O
after O
6 O
weeks O
and O
to O
10 O
after O
12 O
months O
see O
table O
1 O
these O
10 O
points O
did O
not O
result O
from O
either O
motor O
or O
ph O
##onic O
score O
but O
from O
minimal O
impairment O
in O
job O
functioning O

during O
the O
follow O
up O
period O
of O
12 O
months O
the O
patient O
did O
not O
show O
ti O
##cs O
for O
the O
last O
17 O
years O
she O
never O
had O
ti O
##c O
free O
periods O
exceeding O
3 O
weeks O

in O
the O
ﬁ O
##rst O
few O
months O
after O
intervention O
the O
patient O
made O
frequent O
visits O
to O
our O
clinic O
as O
out O
##patient O
complaining O
of O
de O
##pressive O
moods O
vertigo O
and O
stomach O
ache O
##s O
at O
that O
time O
the O
patient O
emphasized O
having O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
adjusting O
to O
the O
new O
situation O
the O
absent O
necessity O
of O
being O
an O
in O
##patient O
and O
recognizing O
that O
the O
illness O
had O
been O
a O
big O
part O
of O
her O
life O
we O
supported O
her O
with O
regular O
out O
##patient O
appointments O
and O
centered O
psycho O
##ther O
##ape O
##uti O
##c O
interventions O
at O
present O
the O
patient O
is O
stabilized O
and O
has O
begun O
to O
engage O
in O
previously O
neglected O
activities O
such O
as O
horseback O
riding O

we O
demonstrate O
full O
re O
##mission O
of O
ti O
##c O
symptoms O
after O
gp O
##i O
db O
##s O
in O
a O
patient O
suffering O
from O
intra O
##ctable O
ts O

table O
1 O
follow O
up O
of O
yale O
global O
ti O
##c O
severity O
scale O

130 O
##2 O
s O
de O
##hn O
##ing O
et O
al O

with O
a O
follow O
up O
period O
of O
12 O
months O
this O
long O
time O
effectiveness O
might O
after O
all O
eliminate O
a O
place O
##bo O
effect O
as O
the O
patient O
was O
rec O
##eptive O
to O
other O
invasive O
treatments O
in O
her O
medical O
history O
only O
temporarily O
the O
cause O
of O
therapeutic O
effects O
is O
supposed O
to O
be O
due O
to O
a O
regulation O
over O
##ride O
of O
a O
possibly O
disturbed O
inhibitor O
##y O
output O
from O
the O
basal O
gang O
##lia O
to O
the O
tha O
##lam O
##us O
a O
disturbed O
gp O
##i O
out O
##ﬂ O
##ow O
could O
lead O
to O
a O
di O
##sin O
##hi O
##bit O
##ion O
of O
ex O
##cit O
##atory O
tha O
##lam O
##us O
neurons O
and O
consequently O
to O
tha O
##lam O
##o O
co O
##rti O
##cal O
hyper O
##act O
##ivity O
16 O
a O
just O
published O
case O
series O
with O
18 O
ts O
patients O
and O
successful O
db O
##s O
of O
the O
tha O
##lam O
##us O
##6 O
represents O
the O
ﬁ O
##rst O
publication O
on O
a O
bigger O
co O
##hort O
even O
when O
taking O
this O
into O
account O
there O
still O
is O
no O
consensus O
for O
the O
best O
stimulation O
target O
again O
serve O
##llo O
s O
report O
is O
discussed O

although O
most O
patients O
with O
chronic O
ts O
are O
used O
to O
a O
temporary O
wax O
##ing O
and O
wan O
##ing O
course O
of O
illness O
or O
an O
am O
##eli O
##oration O
of O
symptoms O
after O
medical O
treatment O
the O
relatively O
prompt O
recovery O
after O
surgical O
intervention O
was O
problematic O
for O
our O
patient O
psychological O
interventions O
are O
imperative O
in O
order O
to O
help O
patients O
to O
cope O
with O
their O
new O
life O
that O
is O
without O
the O
symptoms O
previously O
dominating O
their O
lives O

as O
demonstrated O
in O
patients O
with O
gp O
##i O
implant O
##s O
for O
d O
##yst O
##onia O
17 O
a O
low O
rate O
of O
side O
effects O
and O
a O
good O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
with O
this O
target O
has O
been O
established O
therefore O
we O
consider O
gp O
##i O
db O
##s O
as O
also O
very O
promising O
for O
the O
treatment O
of O
ts O

muller O
n O
ri O
##ede O
##l O
m O
blending O
##er O
c O
obe O
##rle O
k O
jacobs O
e O
abel O
##eh O
##orn O
m O
my O
##co O
##pl O
##as O
##ma O
pneumonia O
##e O
infection O
and O
tour O
##ette O
s O
syndrome O
psychiatry O
res O
2004 O
129 O
119 O
125 O

robertson O
mm O
stern O
j O
##s O
gilles O
de O
la O
tour O
##ette O
syndrome O
sy O
##mpt O
##oma O
##tic O
treatment O
based O
on O
evidence O
eu O
##r O
child O
ad O
##oles O
##c O
psychiatry O
2000 O
9 O
su O
##pp O
##l O
1 O
i O
##60 O
i O
##75 O

de O
##hn O
##ing O
s O
ri O
##ede O
##l O
m O
muller O
n O
ari O
##pi O
##pr O
##az O
##ole O
in O
a O
patient O
vulnerable O
to O
side O
effects O
am O
j O
psychiatry O
2005 O
162 O
625 O

van O
##de O
##wall O
##e O
v O
van O
der O
lc O
gr O
##oe O
##ne O
##we O
##gen O
h O
##j O
ca O
##ema O
##ert O
j O
stereo O
##ta O
##ctic O
treatment O
of O
gilles O
de O
la O
tour O
##ette O
syndrome O
by O
high O
frequency O
stimulation O
of O
tha O
##lam O
##us O
lance O
##t O
1999 O
35 O
##3 O
72 O
##4 O

vis O
##ser O
van O
##de O
##wall O
##e O
v O
te O
##mel O
y O
boon O
p O
et O
al O
chronic O
bilateral O
tha O
##lam O
##ic O
stimulation O
a O
new O
therapeutic O
approach O
in O
intra O
##ctable O
tour O
##ette O
syndrome O
report O
of O
three O
cases O
j O
ne O
##uro O
##sur O
##g O
2003 O
99 O
109 O
##4 O
1100 O

serve O
##llo O
d O
port O
##a O
m O
sas O
##si O
m O
bram O
##bill O
##a O
a O
robertson O
mm O
deep O
brain O
stimulation O
in O
18 O
patients O
with O
severe O
gilles O
de O
la O
tour O
##ette O
syndrome O
ref O
##rac O
##tory O
to O
treatment O
the O
surgery O
and O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
in O
press O

fl O
##ah O
##erty O
aw O
williams O
z O
##m O
amir O
##nov O
##in O
r O
et O
al O
deep O
brain O
stimulation O
of O
the O
anterior O
internal O
capsule O
for O
the O
treatment O
of O
tour O
##ette O
syndrome O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
e O
##40 O
##3 O

ku O
##hn O
j O
lena O
##rt O
##z O
d O
mai O
j O
##k O
et O
al O
deep O
brain O
stimulation O
of O
the O
nucleus O
acc O
##umb O
##ens O
and O
the O
internal O
capsule O
in O
therapeutic O
##ally O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
j O
ne O
##uro O
##l O
2007 O
254 O
96 O
##3 O
96 O
##5 O

ac O
##ker O
##mans O
l O
te O
##mel O
y O
cat O
##h O
d O
et O
al O
deep O
brain O
stimulation O
in O
tour O
##ette O
s O
syndrome O
two O
targets O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
70 O
##9 O
71 O
##3 O

died O
##eric O
##h O
nj O
ka O
##lt O
##eis O
k O
st O
##amen O
##kovic O
m O
pier O
##i O
v O
ale O
##sch O
f O
e O
##f O
##ﬁ O
##cie O
##nt O
internal O
pal O
##lid O
##al O
stimulation O
in O
gilles O
de O
la O
tour O
##ette O
syndrome O
a O
case O
report O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
149 O
##6 O
149 O
##9 O

gallagher O
cl O
ga O
##rell O
pc O
montgomery O
e O
##b O
jr O
hem O
##i O
ti O
##cs O
and O
deep O
brain O
stimulation O
ne O
##uro O
##logy O
2006 O
66 O
e O
##12 O

ho O
##uet O
##o O
j O
##l O
karachi O
c O
mall O
##et O
l O
et O
al O
tour O
##ette O
s O
syndrome O
and O
deep O
brain O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
99 O
##2 O
99 O
##5 O

rap O
##op O
##ort O
m O
fed O
##er O
v O
sand O
##or O
p O
response O
of O
major O
depression O
and O
tour O
##ette O
s O
syndrome O
to O
ec O
##t O
a O
case O
report O
psycho O
##som O
med O
1998 O
60 O
52 O
##8 O
52 O
##9 O

sw O
##er O
##dlow O
nr O
gi O
##er O
##z O
m O
be O
##rk O
##ow O
##itz O
a O
ne O
##mir O
##off O
r O
lo O
##hr O
j O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
in O
a O
patient O
with O
severe O
ti O
##c O
and O
major O
de O
##pressive O
episode O
j O
cl O
##in O
psychiatry O
1990 O
51 O
34 O
35 O

per O
##lm O
##utter O
s O
##j O
lei O
##tman O
sf O
ga O
##r O
##vey O
ma O
et O
al O
therapeutic O
plasma O
exchange O
and O
intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
for O
ob O
##ses O
##sive O
##com O
##pu O
##ls O
##ive O
disorder O
and O
ti O
##c O
disorders O
in O
childhood O
lance O
##t O
1999 O
354 O
115 O
##3 O
115 O
##8 O

min O
##k O
j O
##w O
ne O
##uro O
##biology O
of O
basal O
gang O
##lia O
and O
tour O
##ette O
syndrome O
basal O
gang O
##lia O
circuits O
and O
tha O
##lam O
##oco O
##rti O
##cal O
outputs O
ad O
##v O
ne O
##uro O
##l O
2006 O
99 O
89 O
98 O

be O
##re O
##z O
##nai O
b O
ste O
##ude O
u O
see O
##los O
k O
bot O
##zel O
k O
chronic O
high O
frequency O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
stimulation O
in O
different O
types O
of O
d O
##yst O
##onia O
a O
clinical O
video O
and O
mri O
report O
of O
six O
patients O
presenting O
with O
segment O
##al O
cervical O
and O
generalized O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
138 O
144 O

interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##3 O

novel O
complex O
interruption O
##s O
of O
the O
gaa O
repeat O
in O
small O
expanded O
all O
##eles O
of O
two O
affected O
siblings O
with O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O

catherine O
a O
st O
##oll O
##e O
phd O
1 O
edward O
c O
fra O
##cke O
##lton O
bs O
1 O
jennifer O
mccall O
##um O
ms O
1 O
jennifer O
m O
farmer O
ms O
2 O
amy O
ts O
##ou O
md O
2 O
robert O
b O
wilson O
md O
phd O
3 O

and O
david O
r O
lynch O
md O
phd O
##2 O

1 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
children O
s O
hospital O
of O
philadelphia O
philadelphia O
pennsylvania O
usa O
2 O
##the O
department O
of O
ne O
##uro O
##logy O

the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O
3 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O

abstract O
fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
associated O
with O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
two O
siblings O
presented O
with O
a O
mild O
form O
of O
fa O
at O
60 O
years O
of O
age O
both O
had O
a O
large O
expansion O
600 O
repeats O
and O
a O
small O
expansion O
120 O
repeats O
by O
long O
range O
pc O
##r O
sequence O
analysis O
of O
the O
small O
all O
##ele O
revealed O
multiple O
complex O
interruption O
##s O
in O
the O
gaa O
repeat O
these O
2 O
patients O
presented O
later O
than O
predicted O
from O
their O
all O
##ele O
size O
alone O
when O
compared O
with O
a O
large O
co O
##hort O
of O
fa O
patients O
accounting O
for O
the O
interruption O
##s O
in O
the O
gaa O
repeat O
though O
did O
not O
make O
the O
age O
of O
onset O
consistent O
with O
that O
noted O
in O
other O
patients O
three O
additional O
patients O
with O
late O
onset O
fa O
and O
small O
expanded O
all O
##eles O
also O
exhibited O
interrupted O
gaa O
repeats O
that O
were O
not O
associated O
with O
inappropriate O
##ly O
late O
onset O
our O
observations O
suggest O
that O
interrupted O
gaa O
repeats O
do O
not O
clearly O
impact O
the O
age O
of O
onset O
in O
fa O
2008 O
movement O
disorder O
society O

key O
words O
dorsal O
column O
ata O
##xia O
triple O
##t O
repeat O
spa O
##stic O
##ity O

fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
characterized O
by O
progressive O
ata O
##xia O
and O
onset O
usually O
before O
the O
age O
of O
25 O
years O
1 O
most O
patients O
have O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
normal O
all O
##eles O
contain O
5 O
to O
33 O
repeats O
while O
prem O
##uta O

correspondence O
to O
dr O
david O
r O
lynch O
division O
of O
ne O
##uro O
##logy O
children O
s O
hospital O
of O
philadelphia O
50 O
##2 O
abrams O
##on O
building O
philadelphia O
pa O
1910 O
##4 O
43 O
##18 O
usa O
e O
mail O
lynch O
ph O
##arm O
med O
up O
##en O
##n O
ed O
##u O

received O
10 O
september O
2007 O
revised O
18 O
november O
2007 O

accepted O
9 O
february O
2008 O

published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##12 O

ti O
##on O
all O
##eles O
contain O
34 O
to O
65 O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O
disease O
causing O
all O
##eles O
contain O
66 O
to O
1 O
700 O
repeats O
with O
the O
majority O
of O
all O
##eles O
having O
600 O
to O
1 O
200 O
repeats O
long O
stretches O
of O
gaa O
repeats O
assume O
a O
novel O
dna O
structure O
that O
interfere O
##s O
with O
transcription O
resulting O
in O
decreased O
expression O
of O
the O
gene O
product O
fra O
##ta O
##xin O
2 O
age O
of O
sy O
##mpt O
##om O
onset O
co O
##rre O
##lates O
with O
the O
size O
of O
the O
smaller O
expansion O
3 O
late O
onset O
26 O
39 O
years O
and O
very O
late O
onset O
40 O
years O
cases O
represent O
at O
##yp O
##ical O
presentations O
of O
fa O
4 O
almost O
all O
patients O
even O
with O
the O
shortest O
100 O
gaa O
repeats O
have O
some O
symptoms O
by O
age O
40 O

in O
the O
present O
work O
we O
present O
two O
siblings O
with O
onset O
at O
60 O
years O
of O
age O
with O
a O
mild O
form O
of O
the O
disease O
both O
had O
a O
large O
expansion O
600 O
1 O
000 O
repeats O
and O
a O
small O
expansion O
120 O
repeats O
as O
determined O
by O
long O
range O
pc O
##r O
in O
a O
previously O
reported O
similar O
family O
the O
mild O
ph O
##eno O
##type O
was O
explained O
by O
the O
presence O
of O
interruption O
##s O
in O
the O
gaa O
repeats O
5 O
such O
interruption O
##s O
might O
prevent O
further O
expansion O
by O
reducing O
slip O
##page O
during O
replication O
blocking O
the O
formation O
of O
the O
dna O
structure O
that O
reduces O
transcription O
of O
the O
fra O
##ta O
##xin O
all O
##ele O
thus O
leading O
to O
improved O
fra O
##ta O
##xin O
expression O
and O
less O
severe O
disease O
2 O
in O
the O
present O
work O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
further O
patients O
with O
interrupted O
repeats O
and O
late O
onset O
fa O
and O
compared O
their O
presentation O
to O
that O
noted O
in O
a O
large O
co O
##hort O
of O
patients O
with O
fa O

gen O
##omic O
dna O
was O
extracted O
from O
whole O
blood O
using O
the O
pure O
##gen O
##e O
dna O
extraction O
kit O
gen O
##tra O
systems O
according O
to O
the O
manufacturer O
s O
protocol O
the O
region O
of O
interest O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
was O
amp O
##li O
##ﬁ O
##ed O
using O
the O
expand O
long O
template O
pc O
##r O
system O
roche O
using O
prime O
##rs O
gaa O
f O
and O
gaa O
r O
6 O
with O
the O
following O
thermal O
pro O
##ﬁ O
##le O
92 O
##8 O
##c O
for O
2 O
minutes O
10 O
cycles O
of O
92 O
##8 O
##c O
for O
20 O
seconds O
62 O
##8 O
##c O
for O
30 O
seconds O
68 O
##8 O
##c O
for O
4 O
minutes O
15 O
cycles O
of O
92 O
##8 O
##c O
for O
20 O
seconds O
62 O
##8 O
##c O
for O
30 O
seconds O
68 O
##8 O
##c O
for O
4 O
minutes O
with O
a O
20 O
second O
extension O
per O
cycle O
followed O
by O
1 O
cycle O
at O
68 O
##8 O
##c O
for O
7 O
minutes O
pc O
##r O
products O
were O
electro O
##ph O
##ores O
##ed O
on O
a O
1 O
ag O
##aro O
##se O
gel O
and O
all O
##ele O
sizes O
were O
estimated O
relative O
to O
a O
500 O
bp O
ladder O
the O
shorter O
expanded O
all O
##eles O
were O
then O
ex O
##cise O
##d O
and O
gel O
pu O
##ri O
##ﬁ O
##ed O
using O
the O
qi O
##aq O
##ui O
##k O
gel O
extraction O
kit O
qi O
##age O
##n O
according O
to O
the O
manufacturer O
s O
protocol O
the O
extracted O
product O
was O
then O
re O
##amp O
##li O
##ﬁ O
##ed O
to O
obtain O
a O
large O
quantity O
of O
template O
for O
analysis O
products O
from O
the O
second O
round O
of O
pc O
##r O
were O
sequence O
##d O
using O
the O
big O
dye O
term O
##inator O
v O
##1 O
1 O
sequencing O
kit O
sequences O
were O
analyzed O
on O
an O
automated O
dna O
sequence O
##r O
ab O
##i O
310 O
##0 O

130 O
##4 O
c O
a O
st O
##oll O
##e O
et O
al O

patients O

patient O
1a O

this O
patient O
presented O
at O
age O
61 O
with O
increasing O
cl O
##ums O
##iness O
and O
gradual O
development O
of O
di O
##f O
##ﬁ O
##cu O
##lty O
standing O
on O
one O
foot O
there O
was O
no O
family O
history O
of O
ne O
##uro O
##logic O
disorder O
and O
the O
patient O
was O
not O
of O
known O
ac O
##adia O
##n O
descent O
on O
examination O
he O
was O
diffuse O
##ly O
hyper O
##re O
##ﬂ O
##ex O
##ic O
particularly O
in O
the O
lower O
ex O
##tre O
##mit O
##ies O
a O
ba O
##bin O
##ski O
sign O
was O
not O
observed O
diminished O
vi O
##bra O
##tory O
sensation O
was O
present O
to O
the O
ankles O
bilateral O
##ly O
ts O
##h O
b1 O
##2 O
f O
##olate O
and O
vitamin O
e O
levels O
were O
normal O
anti O
##glia O
##din O
and O
l O
##yme O
ti O
##ters O
were O
negative O
r O
##pr O
was O
non O
##rea O
##ctive O
electro O
##my O
##ography O
revealed O
absent O
sur O
##al O
sensory O
potential O
##s O
but O
intact O
motor O
nerve O
function O
lu O
##mba O
##r O
pun O
##cture O
and O
mri O
imaging O
of O
brain O
cervical O
spine O
and O
thor O
##ac O
##ic O
spine O
revealed O
no O
abnormalities O
a O
genetic O
test O
for O
fa O
performed O
12 O
years O
later O
found O
gaa O
repeat O
lengths O
of O
1 O
03 O
##4 O
and O
127 O
these O
all O
##eles O
were O
sized O
as O
1 O
04 O
##7 O
and O
114 O
in O
a O
second O
test O
he O
had O
a O
normal O
ek O
##g O
stress O
test O
and O
electro O
##ly O
##te O
panel O

patient O
1b O

this O
patient O
presented O
at O
age O
74 O
with O
un O
##stead O
##y O
ga O
##it O
that O
had O
been O
slowly O
progressive O
for O
6 O
years O
she O
noted O
mild O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
her O
hands O
she O
had O
one O
brother O
with O
fa O
patient O
1a O
but O
no O
other O
family O
history O
of O
movement O
disorder O
on O
examination O
she O
had O
hyper O
##active O
re O
##ﬂ O
##ex O
##es O
and O
mildly O
increased O
tone O
in O
her O
upper O
ex O
##tre O
##mit O
##ies O
but O
normal O
lower O
ex O
##tre O
##mity O
re O
##ﬂ O
##ex O
##es O
she O
had O
decreased O
vi O
##bra O
##tory O
sensation O
in O
her O
feet O
but O
otherwise O
intact O
sensation O
strength O
and O
speech O
mild O
right O
sided O
d O
##ys O
##met O
##ria O
was O
present O
she O
had O
square O
wave O
jerk O
##s O
in O
primary O
position O
with O
h O
##yp O
##ometric O
sac O
##cade O
##s O
mri O
of O
the O
head O
and O
cervical O
spine O
revealed O
mild O
ce O
##re O
##bella O
##r O
and O
o O
##cci O
##pit O
##al O
lobe O
at O
##rop O
##hy O
with O
a O
chronic O
right O
posterior O
tha O
##lam O
##ic O
lac O
##una O
##r O
in O
##far O
##ct O
and O
mild O
cervical O
spinal O
cord O
compression O
molecular O
analysis O
of O
her O
fra O
##ta O
##xin O
gene O

patient O
3 O

this O
is O
a O
45 O
year O
old O
man O
with O
progressive O
ata O
##xia O
for O
4 O
years O
this O
was O
associated O
with O
mild O
d O
##ys O
##arth O
##ria O
and O
d O
##ys O
##co O
##ord O
##ination O
of O
the O
hands O
he O
had O
a O
brother O
with O
a O
similar O
syndrome O
and O
examination O
revealed O
normal O
mental O
status O
and O
cr O
##anial O
nerves O
he O
had O
mild O
pseudo O
at O
##het O
##osis O
of O
the O
hands O
with O
arms O
extended O
and O
decreased O
vi O
##bra O
##tory O
sensation O
he O
was O
mildly O
d O
##ys O
##metric O
with O
a O
wide O
based O
ga O
##it O
and O
rom O
##berg O
s O
sign O
deep O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
were O
absent O
and O
he O
had O
ex O
##tens O
##or O
plant O
##ar O
responses O
sensory O
nerve O
action O
potential O
##s O
were O
absent O
and O
an O
mri O
scan O
of O
the O
brain O
was O
normal O
fr O
##da O
gene O
analysis O
revealed O
gaa O
repeat O
lengths O
of O
150 O
and O
1 O
02 O
##5 O
similar O
results O
were O
found O
in O
his O
brother O

patient O
4 O

this O
is O
a O
48 O
year O
old O
woman O
who O
presented O
at O
age O
34 O
with O
progressive O
ata O
##xia O
this O
slowly O
worsened O
over O
the O
next O
14 O
years O
and O
she O
developed O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
coordination O
of O
her O
hands O
on O
examination O
she O
had O
moderate O
d O
##ys O
##met O
##ria O
of O
her O
arms O
and O
a O
wide O
based O
ga O
##it O
re O
##ﬂ O
##ex O
##es O
were O
present O
but O
not O
hyper O
##active O
sensory O
examination O
revealed O
vi O
##bra O
##tory O
sensory O
loss O
with O
spa O
##ring O
of O
other O
mod O
##ali O
##ties O
mental O
status O
and O
cr O
##anial O
nerves O
were O
normal O
sensory O
nerve O
action O
potential O
##s O
were O
reduced O
mri O
of O
the O
brain O
was O
un O
##rem O
##ark O
##able O
commercial O
dna O
testing O
for O
fr O
##da O
expansion O
##s O
revealed O
expansion O
##s O
of O
290 O
and O
950 O

patient O
5 O

this O
patient O
presented O
at O
48 O
years O
after O
10 O
years O
of O
variable O
hand O
and O
leg O
cl O
##ums O
##iness O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
sl O
##ur O
##red O
speech O
on O
examination O
she O
had O
ny O
##sta O
##gm O
##us O

table O
1 O
interrupted O
gaa O
repeat O
sequences O
from O
fa O
patients O

revealed O
gaa O
repeat O
lengths O
of O
1 O
00 O
##5 O
and O
104 O

patient O
1a O
and O
1b O

gaa O
72 O
##1 O
gaga O
##a O
1 O
gaa O
##aa O

1 O
gaa O
201 O
gaa O
##aa O
1 O
gaa O

1 O
gag O
##ga O
##a O
4 O
1 O
gaa O
12 O

this O
patient O
presented O
with O
progressive O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
balance O
and O
coordination O
at O
age O
41 O
on O
initial O
examination O
at O
age O
48 O
prop O
##rio O
##ception O
was O
normal O
and O
re O
##ﬂ O
##ex O
##es O
were O
21 O
in O
the O
arms O
and O
legs O
over O
the O
next O
9 O
years O
he O
developed O
d O
##ys O
##arth O
##ria O
d O
##ys O
##met O
##ria O
diminished O
prop O
##rio O
##ception O
in O
the O
arms O
and O
legs O
spa O
##stic O
##ity O
and O
diffuse O
hyper O
##re O
##ﬂ O
##ex O
##ia O
with O
cl O
##onus O
and O
ex O
##tens O
##or O
plant O
##ar O
responses O
mri O
of O
the O
brain O
revealed O
mild O
ve O
##rmi O
##an O
at O
##rop O
##hy O
genetic O
testing O
of O
the O
fr O
##da O
gene O
revealed O
gaa O
repeat O
lengths O
of O
115 O
and O
1 O
02 O
##5 O

patient O
2 O
gaa O
89 O
1 O
gaga O
##a O
1 O
gaa O
41 O
gaga O
##a O

1 O
gaa O
41 O
gaa O
##aa O
1 O
gaa O
13 O

patient O
3 O
gaa O
78 O
##1 O
gaa O
##aa O
1 O
gaa O
171 O
gaa O
##aa O

1 O
gaa O
1 O
gag O
##ga O
##a O
5 O
1 O
gaa O
12 O

patient O
4 O
gaa O
103 O
##1 O
gaa O
##aga O
##a O
1 O
gaa O
15 O

patient O
5 O
gaa O
130 O
##1 O
aaa O

the O
number O
of O
gaa O
repeats O
plus O
the O
location O
and O
the O
sequence O
of O
repeat O
interruption O
##s O
are O
indicated O
the O
number O
of O
gaa O
repeats O
at O
the O
50 O
end O
represents O
a O
minimum O
repeat O
number O
since O
sequence O
analysis O
did O
not O
reach O
the O
50 O
non O
##re O
##pe O
##at O
sequence O
interruption O
##s O
clustered O
in O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
followed O
by O
short O
gaa O
repeats O
in O
all O
of O
the O
patients O
except O
no O
5 O
interruption O
##s O
are O
designated O
to O
be O
consistent O
with O
those O
previously O
id O
##ent O
##i O
##ﬁ O
##ed O
gag O
##ga O
##a O
ref O
7 O
gaa O
##aga O
##a O
ref O
8 O
gaa O
##aa O
ref O
9 O

interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##5 O

table O
2 O
repeat O
lengths O
and O
age O
of O
onset O
for O
patients O
1 O
5 O

patient O
repeat O
lengths O
as O
id O
##ent O
##i O
##ﬁ O
##ed O
by O
pc O
##r O
estimate O
and O
maximum O
number O
based O
on O
sequencing O

d O
##ys O
##arth O
##ria O
and O
severe O
d O
##ys O
##met O
##ria O
re O
##ﬂ O
##ex O
##es O
were O
absent O
except O
for O
the O
tri O
##ce O
##ps O
jerk O
##s O
prop O
##rio O
##ception O
and O
vi O
##bra O
##tory O
sensation O
were O
decreased O
and O
her O
ga O
##it O
was O
wide O
based O
mri O
of O
the O
brain O
was O
normal O
analysis O
of O
her O
fr O
##da O
gene O
revealed O
gaa O
repeat O
expansion O
##s O
of O
290 O
and O
850 O

based O
on O
previous O
reports O
suggesting O
small O
interruption O
##s O
in O
the O
gaa O
repeat O
in O
some O
patients O
with O
very O
late O
onset O
of O
fa O
we O
sequence O
##d O
the O
gaa O
repeat O
region O
in O
a O
series O
of O
patients O
table O
1 O
in O
sibling O
patients O
1a O
and O
1b O
identical O
interruption O
##s O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
gaa O
repeat O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
repeat O
was O

72 O
bases O
in O
other O
patients O
with O
short O
gaa O
repeats O
similar O
interruption O
##s O
in O
the O
30 O
end O
of O
the O
gaa O
repeat O
were O
found O
in O
three O
of O
four O
but O
the O
interruption O
##s O
were O
less O
complex O
one O
patient O
had O
only O
a O
single O
aaa O
sequence O
at O
the O
30 O
end O
of O
the O
gaa O
repeat O
7 O
9 O

we O
then O
correlated O
age O
of O
onset O
with O
presence O
or O
absence O
of O
interruption O
##s O
table O
2 O
fig O
1 O
two O
of O
5 O
patients O
patients O
1a O
and O
1b O
with O
interruption O
##s O
presented O
later O
than O
that O
expected O
based O
on O
the O
correlation O
of O
total O
gaa O
repeat O
length O
with O
age O
of O
onset O
from O
a O
large O
american O
co O
##hort O
10 O
but O
3 O
patients O
patients O
2 O
3 O
and O
4 O
had O
an O
age O
of O
onset O
similar O
to O
or O
only O
slightly O
later O
than O
that O
predicted O
based O
on O
the O
overall O
co O
##hort O
see O
fig O
1 O
the O
patient O
with O
the O
isolated O
aaa O
at O
the O

30 O
end O
of O
an O
interrupted O
repeat O
patient O
5 O
presented O

slightly O
later O
than O
the O
expected O
age O
similarly O
the O
total O
maximal O
un O
##int O
##er O
##rup O
##ted O
length O
did O
not O
co O
##rre O
##late O
substantially O
better O
with O
age O
of O
onset O
this O
suggests O
that O
the O
presence O
of O
interruption O
##s O
does O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
affect O
age O
of O
onset O

in O
this O
work O
a O
variety O
of O
small O
expanded O
all O
##eles O
of O
the O
fr O
##da O
gene O
had O
an O
altered O
sequence O
compared O

with O
the O
normal O
sequence O
gaa O
repeats O
in O
small O
expanded O
all O
##eles O
were O
interrupted O
in O
5 O
of O
6 O
patients O
analyzed O
with O
late O
to O
very O
late O
onset O
fa O
a O
sixth O
patient O
had O
an O
aaa O
expansion O
at O
the O
end O
of O
the O
sequence O
all O
observed O
interruption O
##s O
in O
the O
gaa O
repeats O
were O
localized O
to O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
preceded O
by O
72 O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O

the O
age O
of O
onset O
of O
fa O
co O
##rre O
##lates O
moderately O
r O
5 O
0 O
60 O
with O
the O
length O
of O
the O
gaa O
repeat O
sequence O
as O
de O
##ﬁ O
##ned O
by O
long O
range O
pc O
##r O
10 O
although O
the O
correlation O
is O
lower O
in O
the O
group O
of O
patients O
with O
gaa O
repeat O
lengths O
shorter O
than O
400 O
the O
presence O
of O
interruption O
##s O
did O
not O
clearly O
in O
##ﬂ O
##uen O
##ce O
the O
age O
of O
onset O
in O
a O
simple O
manner O
in O
the O
group O
of O
patients O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
with O
gaa O
interruption O
##s O
patients O
with O
id O
##ent O
##i O
##ﬁ O
##ed O
interruption O
##s O
did O
not O
consistently O
have O
later O
age O
of O
onset O
than O
others O
in O
the O
co O
##hort O
although O
in O
this O
study O
and O
in O
those O
reported O
previously O
the O
initially O
id O
##ent O
##i O
##ﬁ O
##ed O
siblings O
with O
interruption O
##s O
present O
later O
than O
expected O
other O
patients O
with O
interruption O
##s O
did O
not O
analysis O
of O
the O
age O
of O
onset O
in O
patients O
with O
id O
##ent O
##i O
##ﬁ O
##ed O
interruption O
##s O
using O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
stretch O
of O
gaa O
repeat O
did O
not O
substantially O
change O
the O
relation O
of O
age O
of O
onset O
to O
the O
typical O
age O
of O
onset O
based O
on O
the O
entire O
co O
##hort O
thus O
our O
data O
here O
provide O
no O
evidence O
for O
an O
effect O
of O
interrupted O
repeats O
in O
fa O

still O
it O
is O
possible O
that O
interrupted O
repeats O
alter O
the O
clinical O
features O
of O
fa O
interruption O
of O
the O
gaa O
repeat O

fig O
1 O
correlation O
of O
age O
of O
onset O
versus O
total O
repeat O
length O
and O
the O
maximum O
length O
of O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O
age O
of O
onset O
and O
gaa O
repeat O
length O
were O
plotted O
for O
a O
large O
american O
co O
##hort O
diamonds O
and O
each O
of O
the O
6 O
patients O
in O
the O
present O
study O
ﬁ O
##lled O
square O
estimated O
repeat O
length O
open O
square O
maximum O
possible O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeat O
length O
the O
age O
of O
onset O
from O
patients O
1a O
and O
1b O
remained O
greater O
than O
that O
predicted O
based O
on O
their O
repeat O
length O
patients O
2 O
and O
5 O
had O
a O
slightly O
later O
age O
of O
onset O
than O
expected O
patients O
3 O
and O
4 O
still O
plotted O
near O
the O
line O
patient O
5 O
had O
no O
interruption O
##s O
while O
patients O
1 O
to O
4 O
had O
interrupted O
repeats O

130 O
##6 O
c O
a O
st O
##oll O
##e O
et O
al O

with O
a O
change O
of O
a O
single O
gaa O
to O
a O
g O
##ga O
re O
##med O
##ies O
the O
defect O
in O
transcription O
and O
blocks O
formation O
of O
triple O
##x O
structures O
in O
vitro O
in O
other O
disorders O
the O
presence O
of O
interruption O
##s O
in O
repeat O
sequences O
has O
been O
suggested O
to O
modify O
the O
expression O
of O
disease O
severity O
11 O
14 O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
only O
one O
patient O
without O
a O
sign O
##i O
##ﬁ O
##can O
##t O
interruption O
showing O
that O
in O
late O
onset O
patients O
the O
frequency O
of O
interruption O
##s O
may O
be O
quite O
high O
if O
we O
examined O
further O
patients O
with O
late O
onset O
disease O
as O
well O
as O
patients O
with O
short O
repeats O
and O
earlier O
onset O
it O
might O
be O
possible O
to O
uncover O
a O
modest O
effect O
of O
repeat O
interruption O
##s O
with O
disease O
features O

in O
addition O
we O
have O
analyzed O
the O
data O
at O
present O
using O
simple O
approaches O
con O
##ce O
##iva O
##bly O
features O
beyond O
the O
simple O
size O
of O
un O
##int O
##er O
##rup O
##ted O
repeat O
such O
as O
interruption O
structure O
and O
complexity O
might O
play O
a O
crucial O
role O
alternatively O
spec O
##i O
##ﬁ O
##c O
ph O
##eno O
##typic O
features O
might O
be O
altered O
by O
the O
presence O
of O
interruption O
##s O
in O
addition O
to O
having O
a O
less O
progressive O
course O
patients O
with O
late O
onset O
fa O
frequently O
retain O
re O
##ﬂ O
##ex O
##es O
as O
noted O
for O
patients O
1a O
and O
1b O
here O
still O
our O
data O
overall O
are O
most O
consistent O
with O
the O
possibility O
that O
repeat O
interruption O
##s O
do O
not O
substantially O
in O
##ﬂ O
##uen O
##ce O
the O
age O
of O
onset O
of O
fa O

ac O
##k O
##now O
##led O
##gm O
##ents O
dr O
lynch O
is O
supported O
by O
grants O
from O
the O
fried O
##re O
##ich O
ata O
##xia O
research O
alliance O
and O
the O
muscular O
d O
##yst O
##rop O
##hy O
association O
we O
wish O
to O
thank O
the O
clinical O
research O
network O
for O
fried O
##re O
##ich O
ata O
##xia O
for O
providing O
access O
to O
data O
on O
the O
fa O
co O
##hort O

du O
##rr O
a O
co O
##ssee O
m O
ag O
##id O
y O
et O
al O
clinical O
and O
genetic O
abnormalities O
in O
patients O
with O
fried O
##re O
##ich O
s O
ata O
##xia O
n O
eng O
##l O
j O
med O
1996 O
335 O
116 O
##9 O
117 O
##5 O

sa O
##kam O
##oto O
n O
oh O
##shima O
k O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
sticky O
dna O
a O
self O
associated O
complex O
formed O
at O
long O
gaa O
tt O
##c O
repeats O
in O
intro O
##n O
1 O
of O
the O
fra O
##ta O
##xin O
gene O
inhibit O
##s O
transcription O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##1 O
271 O
##7 O
##7 O

monte O
##rmin O
##i O
l O
richter O
a O
morgan O
k O
et O
al O
ph O
##eno O
##typic O
variability O
in O
fried O
##re O
##ich O
ata O
##xia O
role O
of O
the O
associated O
gaa O
triple O
##t O
repeat O
expansion O
ann O
ne O
##uro O
##l O
1997 O
41 O
67 O
##5 O
68 O
##2 O

b O
##hid O
##aya O
##sir O
##i O
r O
per O
##lman O
sl O
pu O
##ls O
##t O
sm O
ge O
##sch O
##wind O
dh O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O
ph O
##eno O
##typic O
analysis O
magnetic O
resonance O
imaging O
ﬁ O
##nding O
##s O
and O
review O
of O
the O
literature O
arch O
ne O
##uro O
##l O
2005 O
62 O
1865 O
1869 O

mc O
##dan O
##iel O
do O
ke O
##ats O
b O
ve O
##dana O
##raya O
##nan O
v O
##v O
sub O
##ram O
##ony O
sh O
sequence O
variation O
in O
gaa O
repeat O
expansion O
##s O
may O
cause O
differential O
ph O
##eno O
##type O
display O
in O
fried O
##re O
##ich O
s O
ata O
##xia O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
115 O
##3 O
115 O
##8 O

camp O
##uz O
##ano O
v O
monte O
##rmin O
##i O
l O
mo O
##lto O
md O
et O
al O
fried O
##re O
##ich O
s O
ata O
##xia O
auto O
##som O
##al O
recess O
##ive O
disease O
caused O
by O
an O
intro O
##nic O
gaa O
triple O
##t O
repeat O
expansion O
science O
1996 O
271 O
142 O
##3 O
142 O
##7 O

monte O
##rmin O
##i O
l O
and O
##erman O
##n O
e O
lab O
##uda O
m O
et O
al O
the O
fried O
##re O
##ich O
ata O
##xia O
gaa O
triple O
##t O
repeat O
prem O
##utation O
and O
normal O
all O
##eles O
hum O
mo O
##l O
gene O
##t O
1997 O
6 O
126 O
##1 O
126 O
##6 O

co O
##ssee O
m O
sc O
##hmi O
##tt O
m O
camp O
##uz O
##ano O
v O
re O
##ute O
##na O
##uer O
l O
mo O
##uto O
##u O
c O
man O
##del O
j O
##l O
ko O
##eni O
##g O
m O
evolution O
of O
the O
fried O
##re O
##ich O
s O
ata O
##xia O
tri O
##nu O
##cle O
##otide O
repeat O
expansion O
founder O
effect O
and O
prem O
##utation O
##s O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1997 O
94 O
74 O
##52 O
74 O
##57 O

sa O
##kam O
##oto O
n O
larson O
je O
i O
##yer O
rr O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
g O
##ga O
tc O
##c O
interrupted O
triple O
##ts O
in O
long O
gaa O
tt O
##c O
repeats O
inhibit O
the O
formation O
of O
triple O
##x O
and O
sticky O
dna O
structures O
alleviate O
transcription O
inhibition O
and O
reduce O
genetic O
ins O
##ta O
##bilities O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##8 O
271 O
##8 O
##7 O

lynch O
dr O
farmer O
j O
##m O
ts O
##ou O
a O
##y O
et O
al O
measuring O
fried O
##re O
##ich O
ata O
##xia O
complementary O
features O
of O
examination O
and O
performance O
measures O
ne O
##uro O
##logy O
2006 O
66 O
1711 O
1716 O

charles O
p O
cam O
##uz O
##at O
a O
ben O
##am O
##mar O
n O
et O
al O
are O
interrupted O
sc O
##a O
##2 O
ca O
##g O
repeat O
expansion O
##s O
responsible O
for O
parkinson O
##ism O
ne O
##uro O
##logy O
2007 O
69 O
1970 O
1975 O

sob O
##cz O
##ak O
k O
k O
##ry O
##zos O
##ia O
##k O
w O
##j O
ca O
##g O
repeats O
containing O
ca O
##a O
interruption O
##s O
form O
branched O
hair O
##pin O
structures O
in O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
2 O
transcript O
##s O
j O
bio O
##l O
che O
##m O
2005 O
280 O
38 O
##9 O
##8 O
39 O
##10 O

cho O
##ud O
##hr O
##y O
s O
mu O
##ker O
##ji O
m O
sri O
##vas O
##ta O
##va O
ak O
jain O
s O
bra O
##hma O
##cha O
##ri O
sk O
ca O
##g O
repeat O
instability O
at O
sc O
##a O
##2 O
locus O
anchor O
##ing O
ca O
##a O
interruption O
##s O
and O
linked O
single O
nu O
##cle O
##otide O
poly O
##morphism O
##s O
hum O
mo O
##l O
gene O
##t O
2001 O
10 O
243 O
##7 O
244 O
##6 O

mats O
##u O
##ura O
t O
fang O
p O
pearson O
ce O
jaya O
##kar O
p O
ash O
##iza O
##wa O
t O
ro O
##a O
bb O
nelson O
dl O
interruption O
##s O
in O
the O
expanded O
at O
##tc O
##t O
repeat O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
10 O
repeat O
purity O
as O
a O
disease O
mod O
##i O
##ﬁ O
##er O
am O
j O
hum O
gene O
##t O
2006 O
78 O
125 O
129 O

structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
130 O
##7 O

on O
the O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

jan O
st O
##och O
##l O
phd O
msc O
1 O
anne O
boom O
##sma O
phd O
2 O
ev O
##zen O
ru O
##zic O
##ka O
md O
ds O
##c O
3 O

hana O
bro O
##zo O
##va O
md O
3 O
and O
pet O
##r O
blah O
##us O
ds O
##c O
##1 O

1 O
##de O
##par O
##tment O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
prague O
czech O
republic O
2d O
##ep O
##art O
##ment O
of O
sociology O
statistics O
and O
measurement O
theory O
university O
of O
groningen O
groningen O
the O
netherlands O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
charles O
university O
movement O
disorders O
centre O
prague O
czech O
republic O

abstract O
this O
study O
aims O
to O
investigate O
the O
structure O
of O
the O
motor O
symptoms O
of O
parkinson O
s O
disease O
pd O
as O
measured O
by O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
was O
studied O
using O
structural O
equation O
modeling O
the O
up O
##dr O
##s O
measures O
were O
obtained O
from O
405 O
patients O
with O
pd O
237 O
men O
39 O
off O
170 O
on O
28 O

unknown O
and O
168 O
women O
21 O
off O
140 O
on O
7 O
unknown O
the O
or O
##dina O
##l O
character O
of O
up O
##dr O
##s O
scores O
and O
sample O
size O
sub O
##stan O
##tia O
##ted O
the O
use O
of O
robust O
diagonal O
##ly O
weighted O
least O
squares O
model O
estimation O
it O
was O
shown O
that O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
incorporates O
ﬁ O
##ve O
main O
late O
##nt O
sy O
##mpt O
##om O
factors O
rigid O
##ity O
tremor O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
speech O
h O
##yp O
##omi O
##mia O
plus O
two O
additional O
factors O
for O
lateral O
##ity O
which O
account O
for O
as O
##ym O
##metry O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
tremor O
seems O
to O
be O
an O
independent O
sy O
##mpt O
##om O
factor O
of O
pd O
other O
late O
##nt O
variables O
are O
substantially O
correlated O
2008 O
movement O
disorder O
society O

key O
words O
parkinson O
s O
disease O
structural O
equation O
modeling O
dimensional O
##ity O
motor O
section O
of O
the O
up O
##dr O
##s O

the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
sy O
##mpt O
##om O
groups O
of O
neurological O
syndrome O
##s O
such O
as O
the O
combination O
of O
h O
##yp O
##oki O
##nesia O
rigid O
##ity O
resting O
tremor O
and O
post O
##ural O
abnormalities O
in O
parkinson O
s O
disease O
pd O
is O
important O
because O
knowledge O
about O
the O
co O
occurrence O
of O
symptoms O
may O
help O
to O
de O
##ﬁ O
##ne O
disease O
ph O
##eno O
##type O
##s O
and O
provide O
clues O
for O
differential O
diagnosis O
the O
number O
of O
sy O
##mpt O
##om O
groups O
dimensional O
##ity O
can O
be O
in O
##fer O
##red O
through O
statistical O
analysis O
of O
measurements O
used O
for O
impairment O
evaluation O
within O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
park O
##in O

correspondence O
to O
dr O
jan O
st O
##och O
##l O
department O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
jose O
##´ O
mart O
##´ O
##ı O
##ho O
31 O
c O
##z O
162 O
52 O
prague O
czech O
republic O
e O
mail O
st O
##och O
##l O
ft O
##vs O
cu O
##ni O
c O
##z O

received O
16 O
november O
2007 O
revised O
22 O
january O
2008 O
accepted O

17 O
february O
2008 O

published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##29 O

son O
s O
disease O
rating O
scale O
up O
##dr O
##s O
main O
motor O
symptoms O
of O
pd O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
and O
axial O
symptoms O
speech O
posture O
post O
##ural O
stability O
and O
ga O
##it O
de O
##ﬁ O
##ne O
sy O
##mpt O
##om O
groups O
which O
are O
in O
practice O
evaluated O
regarding O
their O
respective O
severity O
this O
paper O
discusses O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
and O
the O
structure O
of O
motor O
symptoms O
of O
pd O
within O
the O
framework O
of O
structural O
equation O
modeling O
se O
##m O
using O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O

in O
previous O
studies O
on O
dimensional O
##ity O
assessment O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
1 O
4 O
between O
three O
and O
six O
factors O
were O
found O
with O
percentage O
##s O
of O
explained O
total O
scale O
variance O
ranging O
between O
59 O
and O
78 O
all O
these O
studies O
used O
ex O
##pl O
##ora O
##tory O
factor O
analysis O
e O
##fa O
methods O
principal O
component O
analysis O
included O
such O
procedures O
rely O
on O
strong O
assumptions O
concerning O
either O
the O
distribution O
of O
observed O
variables O
their O
level O
of O
measurement O
or O
the O
number O
of O
observations O
principal O
component O
analysis O
requires O
a O
continuous O
measurement O
level O
##5 O
6 O
maximum O
likelihood O
estimation O
in O
e O
##fa O
requires O
continuous O
measurement O
levels O
and O
either O
normally O
distributed O
item O
responses O
or O
a O
large O
number O
of O
observations O
which O
may O
compensate O
for O
small O
degrees O
of O
non O
##nor O
##mal O
##ity O
7 O
8 O
given O
the O
or O
##dina O
##l O
distribution O
##al O
properties O
of O
the O
items O
in O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
previous O
conclusions O
on O
dimensional O
##ity O
may O
not O
be O
trust O
##worthy O
because O
the O
validity O
of O
assumptions O
of O
e O
##fa O
modeling O
is O
lacking O

instead O
of O
e O
##fa O
we O
used O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
cfa O
within O
a O
se O
##m O
framework O
to O
perform O
a O
statistical O
test O
and O
to O
evaluate O
a O
number O
of O
plausible O
factor O
models O
for O
the O
structure O
of O
symptoms O
underlying O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
some O
se O
##m O
est O
##ima O
##tors O
are O
designed O
for O
or O
##dina O
##l O
measurements O
and O
thus O
in O
principle O
suited O
for O
analyzing O
that O
structure O

patients O
and O
methods O

sample O

the O
study O
includes O
405 O
consecutive O
patients O
237 O
men O
168 O
women O
mean O
age O
61 O
range O
35 O
80 O
years O
with O
pd O
diagnosed O
according O
to O
current O
clinical O
criteria O
9 O
each O
patient O
was O
evaluated O
by O
one O
member O
of O
a O
group O
of O
ce O
##rti O
##ﬁ O
##ed O
ne O
##uro O
##logists O
movement O
disorder O
specialists O
who O
routinely O
use O
the O
up O
##dr O
##s O
sixty O
patients O
were O
examined O
in O
de O
##ﬁ O
##ned O
off O
state O
and O
310 O
patients O
in O
de O
##ﬁ O
##ned O
on O
state O
for O
35 O
patients O
the O
motor O
state O
during O
evaluation O
was O
not O
spec O
##i O
##ﬁ O
##ed O

this O
data O
consists O
of O
two O
sub O
##sam O
##ples O
the O
ﬁ O
##rst O
sub O
##sam O
##ple O
of O
size O
n O
5 O
147 O
96 O
men O
38 O
off O
30 O
on O

28 O
unknown O
and O
51 O
women O
15 O
off O
29 O
on O
7 O

130 O
##8 O
j O
st O
##och O
##l O
et O
al O

unknown O
was O
obtained O
at O
the O
movement O
disorder O
centre O
charles O
university O
prague O
czech O
republic O
the O
second O
of O
size O
n O
5 O
258 O
141 O
men O
1 O
off O
140 O

on O
and O
117 O
women O
6 O
off O
111 O
on O
was O
acquired O
at O
the O
university O
medical O
centre O
groningen O
in O
the O
netherlands O

methods O

for O
analyzing O
the O
late O
##nt O
structure O
of O
the O
27 O
items O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
the O
li O
##sr O
##el O
program O
##10 O
was O
used O
if O
the O
level O
of O
measurement O
is O
or O
##dina O
##l O
and O
sample O
size O
relatively O
small O
as O
in O
our O
case O
jo O
##¨ O
##res O
##ko O
##g O
and O
so O
##¨ O
##rb O
##om O
##11 O
recommend O
analyzing O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
of O
the O
observed O
variables O
along O
with O
the O
estimated O
matrix O
of O
as O
##ym O
##pt O
##otic O
co O
##var O
##iance O
##s O
of O
those O
estimated O
correlation O
##s O
and O
to O
apply O
robust O
diagonal O
##ly O
weighted O
least O
squares O
d O
##wl O
##s O
model O
estimation O
the O
poly O
##cho O
##ric O
correlation O
##s O
and O
the O
as O
##ym O
##pt O
##otic O
co O
##var O
##iance O
matrix O
were O
computed O
using O
the O
pre O
##lis O
program O
12 O

a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
for O
the O
ﬁ O
##nal O
model O
described O
here O
the O
path O
diagram O
with O
standardized O
parameter O
estimates O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
goodness O
of O
ﬁ O
##t O
statistics O
and O
indices O
a O
summary O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
and O
the O
ﬁ O
##tted O
residual O
matrix O
are O
reported O
for O
details O
see O
ref O
13 O

the O
ﬁ O
##nal O
model O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
is O
shown O
in O
figure O
1 O
a O
number O
of O
theoretically O
plausible O
models O
were O
tested O
and O
compared O
before O
the O
model O
in O
figure O
1 O
was O
chosen O
as O
a O
most O
plausible O
one O
13 O
following O
that O
conclusion O
based O
on O
both O
model O
estimates O
and O
theoretical O
pd O
background O
considerations O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
consists O
of O
seven O
factors O
five O
of O
them O
are O
substantive O
each O
re O
##ﬂ O
##ect O
##ing O
a O
pd O
motor O
sy O
##mpt O
##om O
tremor O
rigid O
##ity O
rig O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
brad O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
bb O
##rad O
and O
speech O
h O
##yp O
##omi O
##mia O
face O
two O
additional O
factors O
left O
and O
right O
re O
##ﬂ O
##ect O
the O
as O
##ym O
##metry O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O

although O
some O
ﬁ O
##tted O
residual O
##s O
see O
table O
1 O
remained O
high O
the O
ﬁ O
##t O
statistics O
and O
indices O
suggest O
that O
this O
model O
need O
not O
to O
be O
rejected O
generally O
the O
values O
of O
comparative O
ﬁ O
##t O
index O
cf O
##i O
and O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
suggest O
a O
very O
acceptable O
ﬁ O
##t O
whereas O
root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
and O

norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
indicate O
slightly O
less O
but O
still O
acceptable O
model O
ﬁ O
##t O
see O
the O
values O
below O
fig O
1 O
values O
in O
the O
matrix O
of O
residual O
correlation O
##s O
are O
ranging O
from O
20 O
40 O
to O
0 O
34 O
median O
of O
absolute O
value O
0 O
04 O
standard O
deviation O
0 O
07 O
the O
highest O
ﬁ O
##tted O
residual O
##s O
are O
those O
between O
action O
tremor O
items O
right O
hand O
and O
left O
hand O
0 O
34 O
and O
surprisingly O
between O
item O
action O
tremor O
left O
hand O
and O
item O
tremor O
right O
lower O
ex O
##tre O
##mity O
20 O
40 O
values O
of O
factor O
loading O
##s O
range O
from O

0 O
11 O
to O
0 O
92 O
median O
0 O
64 O
standard O
deviation O
0 O
19 O
see O
figure O
1 O
the O
lowest O
factor O
loading O
0 O
11 O
is O
for O
item O
tremor O
right O
lower O
ex O
##tre O
##mity O
as O
an O
indicator O
for O
late O
##nt O
factor O
right O
although O
the O
corresponding O
parameter O
test O
stat O
##istic O
is O
non O
##si O
##gni O
##ﬁ O
##can O
##t O
standard O
error O
0 O
17 O
it O
is O
theoretically O
meaningful O
to O
keep O
this O
parameter O
free O
in O
general O
values O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
ranged O
from O
0 O
02 O
to O
0 O
17 O
median O
0 O
07 O
standard O
deviation O
0 O
04 O
the O
estimated O
composite O
reliability O
of O
our O
model O
by O
st O
##rat O
##i O
##ﬁ O
##ed O
coe O
##f O
##ﬁ O
##cie O
##nt O
alpha O
##14 O
equals O
0 O
94 O

the O
four O
factors O
of O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
speech O
h O
##yp O
##omi O
##mia O
and O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
are O
correlated O
which O
is O
meaningful O
from O
a O
theoretical O
point O
of O
view O
the O
correlation O
##s O
range O
between O
0 O
54 O
and O
0 O
85 O
see O
fig O
1 O
indicating O
rather O
substantial O
relationships O
among O
these O
sy O
##mpt O
##om O
factors O
tremor O
however O
seems O
to O
be O
a O
pd O
sy O
##mpt O
##om O
occurring O
independently O
of O
other O
motor O
pd O
sy O
##mpt O
##om O
factors O

goodness O
of O
fit O
statistics O
and O
indices O

sample O
size O
405 O

degrees O
of O
freedom O
300 O

sato O
##rra O
bent O
##ler O
s O
scaled O
v O
##2 O
stat O
##istic O
89 O
##9 O
33 O
p O
5 O

0 O
0 O

root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
0 O
07 O
##0 O

90 O
con O
##ﬁ O
##den O
##ce O
interval O
for O
rms O
##ea O
0 O
06 O
##5 O
0 O
07 O
##6 O

norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
0 O
96 O

comparative O
ﬁ O
##t O
index O
cf O
##i O
0 O
97 O

standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
0 O
07 O
##7 O

goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
0 O
99 O

fitted O
residual O
##s O
range O
20 O
40 O
0 O
34 O
median O
0 O
04 O

standard O
deviation O
0 O
07 O

in O
this O
study O
the O
structure O
of O
motor O
symptoms O
of O
pd O
was O
investigated O
by O
applying O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
models O
to O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

153 O
##18 O
##25 O
##7 O
2008 O
9 O
downloaded O
from O
https O
movement O
##dis O
##ord O
##ers O
online O
##lib O
##rar O
##y O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O
by O
the O
university O
of O
manchester O
wiley O
online O
library O
on O
22 O
05 O
202 O
##5 O
see O
the O
terms O
and O
conditions O
https O
online O
##lib O
##rar O
##y O
wiley O
com O
terms O
and O
conditions O
on O
wiley O
online O
library O
for O
rules O
of O
use O
o O
##a O
articles O
are O
governed O
by O
the O
applicable O
creative O
commons O
license O

table O
1 O
poly O
##cho O
##ric O
correlation O
##s O
below O
diagonal O
and O
ﬁ O
##tted O
residual O
##s O
above O
diagonal O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

speech O
facial O
lips O
##chin O
##tr O
##ru O
##et O
##rl O
##uet O
##rr O
##let O
##rl O
##lea O
##tr O
##rh O
##anda O
##tr O
##l O
##hand O
##ri O
##gi O
##dity O
rue O
lu O
##e O
r O
##le O
ll O
##e O
fr O
##hand O
##fl O
##hand O
hr O
##hand O
##hl O
##hand O
##rr O
##hand O
##rl O
##hand O
l O
##rle O
##g O
ll O
##leg O
arising O
##post O
##ure O
ga O
##it O
stab O
##il O
body O
##bra O

structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
131 O
##1 O

the O
models O
were O
estimated O
using O
the O
d O
##wl O
##s O
est O
##ima O
##tor O
mainly O
because O
of O
the O
or O
##dina O
##l O
measurement O
level O
of O
the O
items O
and O
the O
relatively O
small O
sample O
size O

several O
studies O
##1 O
4 O
15 O
assessed O
the O
construct O
validity O
and O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
through O
e O
##fa O
as O
discussed O
earlier O
neither O
e O
##fa O
nor O
some O
of O
the O
cfa O
est O
##ima O
##tors O
are O
the O
most O
appropriate O
scaling O
techniques O
because O
the O
assumptions O
of O
the O
underlying O
statistical O
model O
may O
easily O
be O
violated O
in O
previous O
dimensional O
##ity O
studies O
of O
the O
up O
##dr O
##s O
sample O
sizes O
n O
300 O
were O
often O
used O
1 O
3 O
15 O
in O
addition O
measurement O
of O
the O
up O
##dr O
##s O
is O
obviously O
of O
or O
##dina O
##l O
rather O
than O
continuous O
type O
which O
may O
pose O
problems O
when O
using O
regular O
maximum O
likelihood O
estimation O
and O
pc O
##a O
6 O
to O
our O
knowledge O
the O
only O
study O
where O
the O
measurement O
level O
of O
the O
up O
##dr O
##s O
data O
was O
respected O
is O
one O
by O
k O
##ro O
##one O
##nberg O
et O
al O
16 O
however O
their O
study O
primarily O
focused O
on O
the O
differences O
in O
the O
structure O
of O
pd O
motor O
signs O
for O
on O
and O
off O
patients O
the O
results O
appeared O
to O
depend O
on O
the O
motor O
state O
of O
the O
patient O
their O
model O
did O
not O
ﬁ O
##t O
our O
data O
which O
might O
be O
due O
to O
a O
different O
scoring O
practice O
a O
problem O
that O
might O
also O
account O
for O
different O
validity O
and O
reliability O
results O
of O
the O
up O
##dr O
##s O
across O
countries O

the O
two O
factors O
of O
lateral O
##ity O
left O
and O
right O
re O
##ﬂ O
##ect O
the O
as O
##ym O
##metry O
of O
occurrence O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
in O
a O
clinical O
co O
##hort O
it O
has O
been O
shown O
that O
initial O
pd O
symptoms O
start O
more O
frequently O
on O
the O
right O
sided O
ex O
##tre O
##mit O
##ies O
than O
on O
the O
left O
17 O
in O
some O
e O
##fa O
studies O
side O
sensitivity O
of O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
was O
mentioned O
before O
2 O
3 O
as O
well O
as O
that O
of O
action O
post O
##ural O
tremor O
1 O
to O
our O
knowledge O
side O
sensitivity O
of O
rigid O
##ity O
and O
rest O
tremor O
however O
has O
not O
been O
previously O
reported O

the O
high O
correlation O
##s O
among O
the O
factors O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
and O
speech O
h O
##yp O
##omi O
##mia O
can O
be O
indicators O
of O
co O
occurrence O
of O
these O
pd O
symptoms O
for O
most O
patients O
in O
common O
pd O
populations O
however O
the O
main O
symptoms O
co O
occur O
whereas O
isolated O
tremor O
may O
only O
be O
present O
in O
very O
early O
stages O
of O
pd O
further O
the O
relative O
independence O
of O
tremor O
from O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
can O
be O
viewed O
as O
an O
indicator O
of O
the O
lack O
of O
substantive O
relationship O
between O
tremor O
and O
pd O
disability O
a O
ﬁ O
##nding O
consistent O
with O
other O
reports O
18 O
19 O

since O
a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
implying O
a O
partly O
ex O
##pl O
##ora O
##tory O
result O
future O
cross O
validation O
is O
necessary O
to O
challenge O
our O
ﬁ O
##nal O
factor O
structure O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
it O
should O
also O
be O
realized O
that O
larger O
sample O
sizes O
would O
make O
model O
estimation O
results O
especially O

when O
considering O
the O
or O
##dina O
##l O
character O
of O
item O
responses O
more O
reliable O
and O
ﬁ O
##nal O
conclusions O
more O
valid O

ac O
##k O
##now O
##led O
##gm O
##ents O
we O
are O
obliged O
to O
doctors O
jan O
roth O
pet O
##r O
me O
##ci O
##r O
robert O
je O
##ch O
ter O
##eza O
serra O
##nova O
and O
olga O
ul O
##man O
##ova O
who O
performed O
up O
##dr O
##s O
testing O
in O
some O
cases O
we O
are O
also O
grateful O
to O
prof O
dr O
k O
l O
lee O
##nder O
##s O
and O
mrs O
w O
j O
st O
##aa O
##l O
groningen O
for O
their O
helpful O
comments O
to O
the O
manuscript O
jan O
st O
##och O
##l O
was O
supported O
by O
mobility O
fund O
of O
charles O
university O
czech O
science O
foundation O
grant O
no O
406 O
07 O
p O
##51 O
##3 O
ministry O
of O
education O
youth O
and O
sports O
grant O
no O
ms O
##m O
00 O
##21 O
##6 O
##20 O
##86 O
##4 O
and O
foundation O
of O
josef O
marie O
a O
h O
##la O
##´ O
##v O
##kov O
##y O
##´ O
##ch O

cub O
##o O
e O
ste O
##bb O
##ins O
gt O
go O
##lb O
##e O
li O
et O
al O
application O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
factor O
analysis O
of O
the O
motor O
scale O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
276 O
279 O

ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
factor O
structure O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
motor O
examination O
section O
mo O
##v O
di O
##sor O
##d O
1998 O
13 O
63 O
##3 O
63 O
##6 O

ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
lang O
ae O
cub O
##o O
e O
factor O
analysis O
of O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
during O
the O
off O
state O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
58 O
##5 O
58 O
##9 O

martinez O
martin O
p O
gil O
na O
##gel O
a O
gr O
##ac O
##ia O
l O
##m O
gomez O
j O
##b O
martinez O
sar O
##ries O
j O
be O
##rm O
##ej O
##o O
f O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
characteristics O
and O
structure O
the O
cooperative O
multi O
##centric O
group O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
76 O
83 O

dun O
##tem O
##an O
g O
##h O
principal O
component O
analysis O
newbury O
park O
sage O
1989 O

hi O
##guchi O
i O
e O
##guchi O
s O
robust O
principal O
component O
analysis O
with O
adaptive O
selection O
for O
tuning O
parameters O
j O
machine O
learn O
res O
2004 O
5 O
45 O
##3 O
47 O
##1 O

elias O
##on O
sr O
maximum O
likelihood O
estimation O
logic O
and O
practice O
iowa O
sage O
1993 O

boom O
##sma O
a O
ho O
##og O
##land O
jj O
the O
robust O
##ness O
of O
li O
##sr O
##el O
modeling O
revisited O
in O
cu O
##deck O
r O
to O
##it O
s O
so O
##¨ O
##rb O
##om O
d O
editors O
structural O
equation O
modeling O
present O
and O
future O
a O
fest O
##sch O
##rift O
in O
honour O
of O
karl O
jo O
##¨ O
##res O
##ko O
##g O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2001 O
p O
139 O
168 O

hughes O
aj O
daniel O
se O
ki O
##lford O
l O
lee O
##s O
aj O
accuracy O
of O
clinical O
diagnosis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
a O
clinic O
##o O
path O
##ological O
study O
of O
100 O
cases O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1992 O
55 O
181 O
184 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
li O
##sr O
##el O
8 O
72 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2005 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
online O
help O
ﬁ O
##le O
for O
li O
##sr O
##el O
8 O
72 O
for O
windows O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2004 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
pre O
##lis O
2 O
54 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2002 O

j O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

phd O
thesis O
charles O
university O
prague O
2005 O

cr O
##on O
##bach O
l O
##j O
sc O
##ho O
##¨ O
##nem O
##ann O
p O
mc O
##kie O
d O
alpha O
coe O
##f O
##ﬁ O
##cie O
##nts O
for O
st O
##rat O
##i O
##ﬁ O
##ed O
parallel O
tests O
ed O
##uc O
psycho O
##l O
me O
##as O
1965 O
25 O
291 O
312 O

mart O
##ignon O
##i O
e O
fran O
##chi O
##gnon O
##i O
f O
pas O
##etti O
c O
fe O
##rrier O
##o O
g O
pic O
##co O
d O
psycho O
##metric O
properties O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
and O
of O
the O
short O
parkinson O
s O
evaluation O
scale O
ne O
##uro O
##l O
sci O
2003 O
24 O
190 O
191 O

k O
##ro O
##one O
##nberg O
pm O
o O
##ort O
f O
##j O
ste O
##bb O
##ins O
gt O
le O
##urg O
##ans O
se O
cub O
##o O
e O
go O
##etz O
c O
##g O
motor O
function O
in O
parkinson O
s O
disease O
and O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
simultaneous O
factor O
analysis O
of O
a O
clinical O
scale O
in O
several O
populations O
b O
##mc O
med O
res O
method O
2006 O
26 O
1 O
13 O

131 O
##2 O
d O
r O
williams O
et O
al O

poe O
##we O
w O
##h O
wen O
##ning O
g O
##k O
the O
natural O
history O
of O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
1998 O
44 O
3 O
su O
##pp O
##l O
1 O
s O
##1 O
s O
##9 O

henderson O
l O
ken O
##nard O
c O
crawford O
t O
scales O
for O
rating O
motor O
impairment O
in O
parkinson O
s O
disease O
studies O
of O
reliability O
and O
converge O
##nt O
validity O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1991 O
54 O
18 O
24 O

reynolds O
n O
montgomery O
g O
factor O
analysis O
of O
parkinson O
s O
impairment O
an O
evaluation O
of O
the O
ﬁ O
##nal O
common O
pathway O
arch O
ne O
##uro O
##l O
1987 O
44 O
101 O
##3 O
1016 O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

david O
r O
williams O
phd O
fra O
##cp O
1 O
2 O
max O
cow O
##ey O
bsc O
2 O
kate O
tuck O
bsc O
2 O
and O
bruce O
day O
fra O
##cp O
##2 O

1 O
##fa O
##cu O
##lty O
of O
medicine O
neuroscience O
##s O
mona O
##sh O
university O
alfred O
hospital O
campus O
melbourne O
australia O
2 O
##ne O
##uro O
##logy O
department O
the O
alfred O
hospital O

melbourne O
australia O

abstract O
we O
report O
a O
case O
of O
probable O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
in O
a O
patient O
who O
developed O
a O
sudden O
onset O
of O
di O
##sa O
##bling O
axial O
ﬂ O
##ex O
##or O
my O
##oc O
##lon O
##us O
following O
a O
cosmetic O
surgical O
procedure O
the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
were O
consistent O
with O
previous O
reports O
of O
ps O
##m O
spontaneous O
re O
##mission O
##s O
and O
disappearance O
of O
the O
jerk O
##s O
sustained O
for O
2 O
years O
following O
removal O
of O
super O
##ﬁ O
##cial O
surgical O
screw O
##s O
support O
the O
diagnosis O
of O
a O
psycho O
##genic O
movement O
disorder O
2008 O
movement O
disorder O
society O

key O
words O
psycho O
##genic O
my O
##oc O
##lon O
##us O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
is O
a O
form O
of O
spinal O
my O
##oc O
##lon O
##us O
characterized O
by O
involvement O
of O
muscles O
inner O
##vate O
##d O
from O
different O
segments O
of O
the O
spinal O
cord O
and O
sequential O
##ly O
activated O
via O
prop O
##rio O
##sp O
##inal O
pathways O
1 O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
of O
slow O
conduct O
##ion O
and O
selective O
recruitment O
of O
tr O
##un O
##cal O
and O
pro O
##xi O
##mal O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
dr O
david O
r O
williams O
neuroscience O
##s O
alfred O
hospital O
commercial O
road O
melbourne O
300 O
##4 O
australia O

e O
mail O
david O
williams O
med O
mona O
##sh O
ed O
##u O
au O

received O
4 O
july O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O

published O
online O
15 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##2 O

limb O
muscles O
help O
differentiate O
ps O
##m O
from O
spinal O
segment O
##al O
my O
##oc O
##lon O
##us O
2 O
ps O
##m O
has O
been O
documented O
secondary O
to O
intrinsic O
and O
ex O
##tri O
##ns O
##ic O
spinal O
cord O
lesions O
and O
in O
other O
cases O
no O
clear O
et O
##iology O
has O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
recently O
the O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
have O
been O
reported O
in O
a O
group O
of O
eight O
healthy O
volunteers O
sim O
##ulating O
the O
typical O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
of O
ps O
##m O
3 O
the O
differentiation O
between O
voluntary O
and O
involuntary O
movements O
of O
this O
nature O
is O
further O
blurred O
by O
our O
report O
of O
a O
patient O
with O
probable O
psycho O
##genic O
ps O
##m O

this O
65 O
year O
old O
woman O
fell O
after O
trip O
##ping O
over O
a O
concrete O
block O
on O
the O
pavement O
causing O
di O
##s O
##ﬁ O
##gur O
##ing O
soft O
tissue O
injuries O
above O
her O
right O
orbit O
apart O
from O
mig O
##raine O
there O
were O
no O
other O
medical O
problems O
at O
the O
time O
and O
no O
psychiatric O
history O
there O
was O
no O
documented O
injury O
or O
pain O
in O
the O
neck O
or O
back O
following O
the O
fall O
and O
at O
that O
time O
she O
was O
neurological O
##ly O
normal O
legal O
action O
relating O
to O
the O
circumstances O
of O
the O
incident O
was O
initiated O
a O
rec O
##ons O
##truct O
##ive O
right O
b O
##le O
##pha O
##rop O
##las O
##ty O
was O
performed O
for O
right O
sided O
pseudo O
##pt O
##osis O
she O
subsequently O
developed O
a O
right O
frontal O
headache O
the O
cosmetic O
results O
of O
the O
surgery O
were O
ins O
##uf O
##ﬁ O
##cie O
##nt O
and O
it O
was O
revised O
by O
brow O
##pl O
##ast O
##y O
that O
required O
the O
placement O
of O
three O
surgical O
screw O
##s O
into O
the O
right O
frontal O
bone O
including O
one O
that O
penetrated O
the O
frontal O
air O
sin O
##us O
the O
surgery O
was O
complicated O
by O
chronic O
pain O
around O
the O
operational O
site O
that O
was O
partially O
relieved O
by O
neck O
massage O
eighteen O
months O
after O
the O
fall O
and O
following O
massage O
of O
the O
neck O
she O
developed O
di O
##sa O
##bling O
par O
##ox O
##ys O
##ms O
of O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
were O
most O
severe O
when O
lying O
su O
##pine O
there O
was O
a O
suggestion O
of O
associated O
left O
sided O
weakness O
at O
onset O
but O
this O
resolved O
and O
mri O
and O
ang O
##io O
##gram O
were O
normal O
at O
ﬁ O
##rst O
the O
jerk O
##s O
occurred O
several O
times O
per O
day O
but O
rapidly O
increased O
in O
frequency O
with O
bouts O
of O
continuous O
jerking O
lasting O
for O
up O
to O
1 O
hour O
causing O
sign O
##i O
##ﬁ O
##can O
##t O
disability O
there O
was O
positive O
action O
my O
##oc O
##lon O
##us O
with O
coe O
##xi O
##sten O
##t O
stimulus O
sensitive O
my O
##oc O
##lon O
##us O
of O
variable O
late O
##ncy O
which O
diminished O
with O
distraction O
increasingly O
her O
mobility O
became O
affected O
by O
jerking O
and O
un O
##stead O
##y O
ga O
##it O
there O
were O
periods O
of O
complete O
re O
##mission O
lasting O
up O
to O
several O
months O
jerking O
was O
ex O
##ace O
##rba O
##ted O
by O
anxiety O
but O
no O
other O
pre O
##ci O
##pit O
##ants O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
spinal O
cord O
and O
brain O
mri O
were O
normal O
except O
for O
a O
few O
scattered O
deep O
white O
matter O
is O
##che O
##mic O
changes O
psychiatric O
evaluation O
did O
not O
identify O
features O
of O
so O
##mat O
##ization O
depression O
or O
mali O
##nger O
##ing O
she O
incomplete O
##ly O
responded O
to O
pi O
##race O
##tam O
16 O
g O
per O
day O
cl O
##ona O
##ze O
##pa O
##m O
4 O
mg O
per O
day O
sodium O
val O
##pro O
##ate O
2 O
g O
per O
day O
and O
ba O
##cl O
##of O
##en O
three O
surgical O
screw O
##s O
used O
in O
the O
b O
##le O
##pha O
##rop O
##las O
##ty O
were O
removed O
4 O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
131 O
##3 O

fig O
1 O
0 O
7 O
seconds O
epoch O
of O
order O
of O
activation O
study O
demonstrating O
surface O
em O
##g O
bursts O
in O
pe O
##ctor O
##alis O
pe O
##ct O
followed O
by O
stern O
##oma O
##sto O
##id O
sc O
##m O
and O
upper O
up O
##ab O
and O
lower O
abdominal O
muscles O
lo O
##ab O
solid O
line O
onset O
of O
jerk O

years O
after O
surgery O
at O
the O
patient O
s O
insistence O
and O
the O
axial O
jerk O
##s O
coincidentally O
resolved O
completely O
she O
returned O
to O
normal O
function O
and O
was O
sy O
##mpt O
##om O
free O
at O
follow O
up O
2 O
years O
later O

electro O
##phy O
##sio O
##logical O
investigations O

two O
years O
after O
the O
onset O
of O
jerking O
routine O
ee O
##g O
was O
normal O
median O
nerve O
sensory O
ev O
##oked O
potential O
##s O
were O
normal O
a O
jerk O
locked O
back O
averaged O
ee O
##g O
did O
not O
show O
pre O
movement O
co O
##rti O
##cal O
potential O
##s O
an O
order O
of O
activation O
study O
showed O
variable O
muscle O
activation O
but O
the O
most O
frequent O
pattern O
of O
activation O
was O
ca O
##uda O
##l O
from O
pe O
##ctor O
##al O
to O
abdominal O
muscles O
with O
propagation O
estimated O
at O
9 O
to O
15 O
m O
s O
see O
figure O
1 O
em O
##g O
burst O
length O
was O
between O
50 O
and O
150 O
mill O
##ise O
##con O
##ds O

this O
patient O
had O
some O
clinical O
and O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
previous O
reports O
of O
ps O
##m O
as O
well O
as O
features O
not O
usually O
reported O
to O
be O
associated O
such O
as O
ga O
##it O
un O
##stead O
##iness O
and O
axial O
jerk O
##s O
while O
standing O
unusually O
for O
ps O
##m O
there O
were O
periods O
of O
spontaneous O
re O
##mission O
and O
no O
id O
##ent O
##i O
##ﬁ O
##able O
path O
##ological O
les O
##ion O
to O

account O
for O
the O
my O
##oc O
##lon O
##us O
the O
sudden O
onset O
con O
##tem O
##por O
##aneous O
legal O
proceedings O
related O
to O
the O
injury O
the O
associated O
anxiety O
and O
spontaneous O
complete O
re O
##mission O
are O
supportive O
of O
a O
psycho O
##genic O
et O
##iology O
4 O

the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
reported O
in O
ps O
##m O
include O
ﬁ O
##xed O
patterns O
of O
muscle O
activation O
slow O
spinal O
cord O
conduct O
##ion O
5 O
15 O
m O
s O
em O
##g O
burst O
duration O
less O
than O
1 O
000 O
ms O
and O
sync O
##hr O
##ono O
##us O
activation O
of O
ago O
##nist O
and O
antagonist O
muscles O
reviewed O
in O
ref O
3 O
in O
our O
case O
the O
short O
em O
##g O
burst O
duration O
and O
slow O
conduct O
##ion O
was O
consistent O
with O
these O
reports O
in O
a O
number O
of O
similar O
cases O
with O
electro O
##phy O
##sio O
##logical O
characteristics O
of O
organic O
ps O
##m O
the O
possibility O
of O
psycho O
##genic O
et O
##iology O
has O
been O
raised O
3 O
5 O
healthy O
volunteers O
sim O
##ulating O
ps O
##m O
have O
electro O
##phy O
##sio O
##logical O
recordings O
that O
are O
also O
similar O
except O
for O
long O
em O
##g O
burst O
duration O
##s O
3 O
the O
ﬁ O
##nding O
##s O
in O
the O
present O
study O
support O
these O
authors O
contention O
that O
electro O
##phy O
##sio O
##logical O
parameters O
alone O
are O
ins O
##uf O
##ﬁ O
##cie O
##nt O
to O
identify O
organic O
ps O
##m O
to O
our O
knowledge O
re O
##mission O
##s O
have O
not O
been O
reported O
in O
ps O
##m O
and O
are O
said O
to O
count O
against O
the O
diagnosis O
6 O

the O
patient O
felt O
certain O
that O
the O
surgical O
screw O
##s O
caused O
the O
my O
##oc O
##lon O
##ic O
jerk O
##s O
but O
we O
were O
unable O
to O
identify O
a O
biological O
mechanism O
to O
account O
for O
this O
psycho O
##genic O
ps O
##m O
is O
the O
most O
likely O
diagnosis O
and O
removal O
of O
the O
perceived O
pre O
##ci O
##pit O
##ant O
was O
cu O
##rative O
in O
this O
case O
the O
clinical O
and O
imaging O
ﬁ O
##nding O
##s O
together O
with O
the O
long O
follow O
up O
in O
this O
patient O
effectively O
exclude O
any O
other O
diagnostic O
possibilities O

a O
psycho O
##genic O
et O
##iology O
should O
be O
considered O
when O
patients O
develop O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
occur O
when O
lying O
and O
standing O
without O
id O
##ent O
##i O
##ﬁ O
##able O
central O
nervous O
system O
lesions O
even O
in O
the O
presence O
of O
suggest O
##ive O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
spontaneous O
re O
##mission O
##s O
may O
differentiate O
psycho O
##genic O
and O
organic O
ps O
##m O

the O
patient O
is O
shown O
lying O
su O
##pine O
with O
bursts O
of O
spontaneous O
axial O
jerk O
##s O
occurring O
at O
rest O
without O
stimulation O

brown O
p O
thompson O
pd O
roth O
##well O
jc O
day O
b O
##l O
marsden O
cd O
axial O
my O
##oc O
##lon O
##us O
of O
prop O
##rio O
##sp O
##inal O
origin O
brain O
1991 O
114 O
197 O
214 O

roth O
##well O
jc O
path O
##op O
##hy O
##sio O
##logy O
of O
spinal O
my O
##oc O
##lon O
##us O
ad O
##v O
ne O
##uro O
##l O
2002 O
89 O
137 O
144 O

kang O
sy O
so O
##hn O
y O
##h O
electro O
##my O
##ography O
patterns O
of O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
can O
be O
mimic O
##ked O
voluntarily O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
124 O
##1 O
124 O
##4 O

fa O
##hn O
s O
williams O
dt O
psycho O
##genic O
d O
##yst O
##onia O
ad O
##v O
ne O
##uro O
##l O
1988 O
50 O
43 O
##1 O
45 O
##5 O

davies O
l O
king O
p O
##j O
leicester O
j O
morris O
j O
##g O
rec O
##umb O
##ent O
ti O
##c O
mo O
##v O
di O
##sor O
##d O
1992 O
7 O
35 O
##9 O
36 O
##3 O

brown O
j O
lan O
##tos O
p O
st O
##rat O
##ton O
m O
ro O
##ques O
p O
ross O
##or O
m O
fa O
##mi O
##lia O
##l O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1993 O
56 O
47 O
##3 O
47 O
##6 O

131 O
##4 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O

potassium O
channel O
block O
##er O

4 O
amino O
##py O
##rid O
##ine O
is O
effective O
in O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
a O
video O
case O
report O

matthias O
lo O
##¨ O
##hl O
##e O
md O
wi O
##eb O
##ke O
sc O
##hre O
##mp O
##f O
md O
martin O
wo O
##lz O
md O
heinz O
reich O
##mann O
md O
phd O
and O
alexander O
st O
##or O
##ch O
md O

department O
of O
ne O
##uro O
##logy O
technical O
university O
of O
dresden O
dresden O
germany O

abstract O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
an O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
clinical O
##ly O
characterized O
by O
rec O
##urrent O
attacks O
of O
vertigo O
im O
##balance O
and O
ata O
##xia O
studies O
have O
shown O
that O
4 O
amino O
##py O
##rid O
##ine O
4 O
ap O
is O
capable O
to O
prevent O
these O
attacks O
however O
there O
are O
no O
reports O
whether O
4 O
ap O
is O
able O
to O
at O
##ten O
##uate O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
using O
the O
scale O
for O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
we O
examined O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
4 O
ap O
on O
inter O
##ic O
##tal O
ata O
##xia O
in O
a O
63 O
##year O
old O
female O
patient O
who O
suffered O
from O
ea O
##2 O
since O
the O
age O
of O
57 O
ea O
##2 O
was O
diagnosed O
based O
on O
clinical O
criteria O
and O
not O
genetically O
proven O
when O
treatment O
with O
4 O
ap O
was O
paused O
the O
patient O
was O
suffering O
from O
marked O
ga O
##it O
and O
stance O
ata O
##xia O
after O
re O
initiation O
of O
treatment O
with O
5 O
mg O
4a O
##p O
t O
i O
d O
there O
was O
pronounced O
improvement O
in O
ga O
##it O
and O
stance O
ata O
##xia O
within O
24 O
hours O
sara O
score O
lowered O
from O

8 O
5 O
to O
4 O
5 O
points O
we O
conclude O
that O
4 O
ap O
may O
be O
ben O
##e O
##ﬁ O
##cial O
for O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
in O
late O
onset O
ea O
##2 O
2008 O
movement O
disorder O
society O

key O
words O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
4 O
amino O
##py O
##rid O
##ine O
inter O
##ic O
##tal O
ata O
##xia O
sara O
video O
case O
report O

ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
a O
rare O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
caused O
by O
mutations O
of O
the O
calcium O
channel O
gene O
ca O
##c O
##na O
##1 O
##a O
on O
chromosome O
19 O
##p O
##13 O
1 O
this O
gene O
codes O
for O
the O
ca O
##v O
##2 O
1 O
subunit O
of O
the O
p O
q O
type O
calcium O
channel O
which O
is O
expressed O
throughout O
the O
nervous O
system O
but O
mainly O
in O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O

correspondence O
to O
dr O
matthias O
lo O
##¨ O
##hl O
##e O
k O
##lini O
##k O
und O
pol O
##ik O
##lini O
##k O
fu O
##¨ O
##r O
ne O
##uro O
##logie O
fe O
##ts O
##chers O
##tra O
##sse O
74 O
01 O
##30 O
##7 O
dresden O
germany O

e O
mail O
matthias O
lo O
##eh O
##le O
ne O
##uro O
med O
tu O
dresden O
de O

received O
27 O
august O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O

march O
2008 O

published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##1 O

cells O
ea O
##2 O
usually O
starts O
before O
the O
age O
of O
20 O
however O
some O
patients O
reveal O
ﬁ O
##rst O
symptoms O
beyond O
the O
age O
of O

50 O
affected O
patients O
suffer O
from O
rec O
##urrent O
attacks O
of O
vertigo O
im O
##balance O
and O
ata O
##xia O
which O
may O
last O
for O
several O
hours O
up O
to O
days O
and O
can O
often O
be O
provoked O
by O
physical O
ex O
##ert O
##ion O
emotional O
stress O
and O
consumption O
of O
caf O
##fe O
##ine O
or O
alcohol O
most O
patients O
show O
central O
o O
##cular O
motor O
disturbances O
between O
these O
attacks O
such O
as O
gaze O
##holding O
de O
##ﬁ O
##cit O
##s O
down O
##beat O
ny O
##sta O
##gm O
##us O
sac O
##ca O
##dic O
eye O
pursuit O
movements O
and O
impaired O
visual O
suppression O
of O
the O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
2 O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
are O
a O
common O
condition O
in O
the O
course O
of O
the O
disease O
##1 O
and O
can O
be O
so O
marked O
that O
patients O
become O
wheelchair O
##bound O
because O
ea O
##2 O
is O
all O
##eli O
##c O
with O
fa O
##mi O
##lia O
##l O
hem O
##ip O
##leg O
##ic O
mig O
##raine O
type O
1 O
half O
of O
the O
patients O
suffer O
from O
mig O
##raine O
headache O
##s O
in O
the O
majority O
of O
cases O
there O
is O
a O
positive O
family O
history O
for O
the O
disease O
2 O

ace O
##ta O
##zo O
##lam O
##ide O
act O
##z O
is O
the O
drug O
of O
ﬁ O
##rst O
choice O
for O
treatment O
of O
ea O
##2 O
and O
prevents O
or O
at O
##ten O
##uate O
##s O
the O
attacks O
in O
50 O
to O
75 O
of O
all O
patients O
however O
many O
patients O
stop O
treatment O
with O
act O
##z O
in O
the O
long O
run O
due O
to O
adverse O
effects O
such O
as O
ne O
##ph O
##rol O
##ith O
##ias O
##is O
hyper O
##hy O
##dro O
##sis O
par O
##esthesia O
muscle O
stiff O
##ness O
and O
gas O
##tro O
##int O
##estinal O
disturbance O
or O
because O
of O
a O
loss O
of O
e O
##f O
##ﬁ O
##ca O
##cy O
so O
far O
treatment O
options O
for O
these O
patients O
are O
limited O
4 O
amino O
##py O
##rid O
##ine O
4 O
ap O
a O
potassium O
channel O
block O
##er O
has O
recently O
shown O
to O
be O
capable O
to O
prevent O
or O
markedly O
at O
##ten O
##uate O
attacks O
of O
ata O
##xia O
in O
patients O
in O
whom O
treatment O
with O
act O
##z O
had O
failed O
3 O
however O
there O
are O
so O
far O
no O
reports O
whether O
4 O
ap O
is O
able O
to O
at O
##ten O
##uate O
inter O
##ic O
##tal O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
that O
is O
often O
a O
key O
clinical O
feature O
in O
elderly O
ea O
##2 O
patients O

we O
examined O
a O
63 O
year O
old O
female O
patient O
who O
contacted O
our O
movement O
disorder O
out O
##patient O
clinic O
in O
may O
2004 O
in O
2000 O
at O
the O
age O
of O
57 O
she O
started O
to O
suffer O
from O
attacks O
with O
vertigo O
nausea O
and O
vomiting O
that O
were O
sometimes O
accompanied O
by O
d O
##ys O
##arth O
##ria O
and O
headache O
##s O
these O
attacks O
initially O
lasted O
for O
about O
30 O
min O
but O
prolonged O
within O
subsequent O
years O
additionally O
she O
had O
problems O
with O
visual O
ﬁ O
##xa O
##tion O
of O
objects O
and O
often O
had O
the O
impression O
that O
her O
visual O
image O
was O
rolling O
away O
consumption O
of O
coffee O
or O
alcoholic O
beverages O
led O
to O
deterioration O
of O
symptoms O
in O
2006 O
the O
attacks O
completely O
ceased O
and O
inter O
##ic O
##tal O
ga O
##it O
ata O
##xia O
became O
the O
main O
clinical O
problem O
making O
her O
incapable O
of O
walking O
or O
standing O
without O
support O
in O
the O
past O
the O
patient O
had O
suffered O
from O
mig O
##raine O
headache O
##s O
the O
mother O
of O
the O
patient O
also O
suffered O
from O
vertigo O

4 O
amino O
##py O
##rid O
##ine O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
131 O
##5 O

and O
headache O
##s O
a O
half O
sister O
complained O
about O
chronic O
headache O
##s O

clinical O
examination O
revealed O
central O
o O
##cu O
##lom O
##oto O
##r O
de O
##ﬁ O
##cit O
##s O
such O
as O
spontaneous O
ny O
##sta O
##gm O
##us O
to O
the O
left O
as O
well O
as O
down O
##beat O
ny O
##sta O
##gm O
##us O
at O
gaze O
to O
the O
left O
sac O
##ca O
##dic O
pursuit O
movements O
and O
impaired O
visual O
suppression O
of O
the O
vest O
##ib O
##ular O
o O
##cular O
re O
##ﬂ O
##ex O
additionally O
we O
observed O
d O
##ys O
##met O
##ria O
during O
the O
nose O
ﬁ O
##nger O
test O
and O
heel O
shin O
slide O
as O
well O
as O
marked O
stance O
and O
ga O
##it O
ata O
##xia O
magnetic O
resonance O
imaging O
showed O
decent O
at O
##rop O
##hy O
of O
the O
upper O
ve O
##rmi O
##s O
of O
the O
ce O
##re O
##bell O
##um O
but O
no O
further O
pathology O
electro O
##ence O
##pha O
##log O
##raphy O
was O
normal O
tumor O
screening O
including O
serum O
tumor O
markers O
was O
negative O
analysis O
of O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
did O
not O
show O
any O
abnormalities O
vest O
##ib O
##ular O
dysfunction O
was O
excluded O
as O
possible O
reason O
for O
vertigo O
by O
ot O
##or O
##hin O
##olar O
##yn O
##gol O
##og O
##ic O
examination O
that O
demonstrated O
regular O
function O
of O
both O
vest O
##ib O
##ular O
organs O
there O
was O
no O
sign O
for O
bar O
##ore O
##ce O
##pt O
##or O
or O
or O
##th O
##osta O
##tic O
dysfunction O
during O
auto O
##no O
##mic O
testing O
including O
metro O
##no O
##mic O
breathing O
val O
##sal O
##va O
maneuver O
and O
passive O
or O
##th O
##osta O
##sis O
on O
the O
tilt O
table O
since O
the O
patient O
did O
not O
undergo O
genetic O
testing O
ea O
##2 O
was O
diagnosed O
clinical O
##ly O
based O
on O
the O
medical O
history O
and O
the O
typical O
clinical O
ﬁ O
##nding O
##s O
mentioned O
above O

treatment O
was O
initiated O
with O
act O
##z O
in O
december O
2003 O
but O
had O
to O
be O
ceased O
due O
to O
tin O
##ni O
##tus O
and O
par O
##esthesia O
of O
hands O
and O
feet O
during O
treatment O
with O
act O
##z O
the O
patient O
had O
been O
able O
to O
ﬁ O
##xa O
##te O
objects O
better O
than O
before O
whereas O
ata O
##xia O
remained O
unchanged O
starting O
from O
july O
2006 O
we O
administered O
5 O
mg O
4 O
ap O
t O
i O
d O
provided O
by O
syn O
##op O
##har O
##m O
germany O
which O
was O
well O
tolerated O
without O
any O
adverse O
effects O
but O
initially O
did O
not O
seem O
to O
have O
any O
subjective O
ben O
##e O
##ﬁ O
##t O
for O
the O
patient O
after O
4 O
ap O
had O
been O
withdrawn O
due O
to O
suspected O
lack O
of O
e O
##f O
##ﬁ O
##ca O
##cy O
after O
only O
14 O
days O
of O
treatment O
and O
without O
further O
clinical O
evaluation O
the O
patient O
returned O
within O
1 O
week O
and O
reported O
about O
a O
distinct O
worse O
##ning O
of O
ga O
##it O
and O
stance O
ata O
##xia O
making O
her O
unable O
to O
walk O
una O
##ssi O
##sted O
after O
re O
initiation O
of O
4 O
ap O
symptoms O
markedly O
improved O
and O
are O
now O
stable O
over O
1 O
year O

evaluation O
##s O

after O
informed O
consent O
for O
video O
##ta O
##ping O
had O
been O
given O
the O
patient O
was O
asked O
to O
pause O
treatment O
with O
4a O
##p O
for O
24 O
hours O
and O
after O
that O
was O
video O
##ta O
##ped O
and O
rated O
according O
to O
the O
recently O
valid O
##ated O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
4 O
the O
patient O
was O
then O
given O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
and O
video O
##ta O
##ped O
and O
rated O
again O
as O
soon O
as O
she O
realized O
improvement O
of O
her O
symptoms O
a O
ﬁ O
##nal O
evaluation O
was O
done O
after O
the O
patient O
had O
taken O
3 O
3 O
5 O
mg O
4 O
ap O
over O
24 O

hours O
all O
evaluation O
##s O
were O
done O
in O
exact O
order O
as O
provided O
by O
sara O
the O
video O
##ta O
##pes O
were O
reviewed O
by O
a O
movement O
disorder O
expert O
a O
s O
who O
was O
blinded O
for O
the O
treatment O
scores O
were O
given O
according O
to O
the O
sara O
criteria O
based O
on O
a O
common O
judgment O
of O
the O
expert O
and O
the O
observer O
who O
had O
video O
##ta O
##ped O
the O
patient O
m O
l O
ec O
##g O
was O
performed O
before O
and O
during O
treatment O
to O
exclude O
clinical O
##ly O
relevant O
pro O
##long O
##ation O
of O
q O
##tc O
time O
which O
was O
calculated O
using O
ba O
##ze O
##tt O
s O
correction O
q O
##tc O
¼ O
q O
##t O
ð O
##mill O
##ise O
##con O
##ds O
##þ O
rr O
ð O
##se O
##con O
##ds O
##þ O
q O
##tc O
time O
was O
within O
normal O
range O
measuring O
42 O
##9 O
mill O
##ise O
##con O
##ds O
before O
and O
41 O
##4 O
mill O
##ise O
##con O
##ds O
during O
treatment O
with O
5 O
mg O
4 O
ap O
t O
i O
d O

after O
24 O
hours O
withdrawal O
of O
4 O
ap O
the O
patient O
was O
suffering O
from O
marked O
ga O
##it O
and O
stance O
ata O
##xia O
video O
minimal O
speech O
disturbance O
slight O
d O
##ys O
##met O
##ria O
during O
ﬁ O
##nger O
chase O
with O
the O
left O
hand O
tremor O
during O
the O
nose O
##ﬁ O
##nger O
test O
on O
both O
sides O
and O
a O
slightly O
abnormal O
heel O
shin O
slide O
because O
of O
ga O
##it O
ata O
##xia O
she O
preferred O
to O
use O
a O
walker O
in O
order O
to O
avoid O
falls O
total O
sara O
score O
without O
4 O
ap O
was O
8 O
5 O
points O
one O
hour O
after O
intake O
of O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
the O
patient O
noticed O
a O
slight O
relief O
of O
her O
symptoms O
that O
could O
only O
be O
object O
##i O
##ﬁ O
##ed O
during O
the O
nose O
ﬁ O
##nger O
test O
sara O
sub O
##sco O
##re O
decreased O
from O
1 O
0 O
to O
0 O
5 O
points O
where O
she O
had O
less O
tremor O
of O
her O
right O
hand O
total O
sara O
score O
8 O
0 O
points O

on O
the O
next O
day O
after O
completing O
her O
regular O
daily O
treatment O
with O
5 O
mg O
4 O
ap O
t O
i O
d O
the O
patient O
returned O
to O
our O
out O
##patient O
clinic O
without O
her O
walker O
ga O
##it O
had O
markedly O
stabilized O
so O
she O
was O
even O
able O
to O
do O
some O
steps O
of O
tandem O
walking O
video O
stance O
ata O
##xia O
also O
had O
improved O
sara O
sub O
##sco O
##re O
decreased O
from O
2 O
0 O
to O
1 O
0 O
points O
the O
patient O
was O
now O
capable O
of O
standing O
with O
her O
feet O
in O
tandem O
position O
for O
more O
than O
10 O
seconds O
video O
furthermore O
there O
was O
improvement O
in O
ﬁ O
##nger O
chase O
nose O
ﬁ O
##nger O
test O
and O
heel O
shin O
slide O
total O
sara O
score O
after O
treatment O
with O
4 O
ap O
t O
i O
d O
had O
lowered O
to O
4 O
5 O
points O

our O
report O
con O
##ﬁ O
##rm O
##s O
previous O
observations O
that O
4 O
ap O
treatment O
offers O
an O
option O
for O
ea O
##2 O
patients O
in O
whom O
act O
##z O
failed O
to O
relieve O
symptoms O
although O
4 O
ap O
in O
previous O
studies O
has O
shown O
to O
be O
effective O
in O
preventing O
or O
at O
##ten O
##uating O
ata O
##xia O
attacks O
3 O
our O
report O
for O
the O
ﬁ O
##rst O
time O
suggests O
that O
4 O
ap O
may O
also O
be O
ben O
##e O
##ﬁ O
##cial O
for O
patients O
with O
late O
onset O
of O
ea O
##2 O
in O
whom O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
has O
become O
the O
key O
clinical O
feature O

because O
of O
the O
ca O
##c O
##na O
##1 O
##a O
mutation O
current O
density O
from O
ca O
##v O
##2 O
1 O
channels O
in O
ea O
##2 O
is O
reduced O
which O
may O
lead O
to O
a O
general O
reduction O
in O
pu O
##rkin O
##je O
cell O
ﬁ O
##ring O
rates O
and O
a O
loss O
of O
inhibition O
at O
deep O
ce O
##re O
##bella O
##r O
nuclei O
5 O
an O
##i O

131 O
##6 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O

mal O
studies O
in O
guinea O
pigs O
have O
demonstrated O
that O
4a O
##p O
is O
able O
to O
increase O
the O
ex O
##cit O
##ability O
of O
pu O
##rkin O
##je O
cells O
by O
reducing O
the O
duration O
of O
the O
slowly O
de O
##pol O
##ari O
##zing O
potential O
and O
thus O
late O
##ncy O
to O
the O
ﬁ O
##ring O
of O
ca O
##21 O
spikes O
in O
response O
to O
intra O
##cellular O
current O
pulses O
6 O
thus O
it O
may O
be O
assumed O
that O
the O
ben O
##e O
##ﬁ O
##cial O
effects O
of O
4 O
ap O
are O
due O
to O
its O
capability O
to O
restore O
overall O
pu O
##rkin O
##je O
cell O
ex O
##cit O
##ability O
and O
thereby O
inhibitor O
##y O
effects O
of O
pu O
##rkin O
##je O
cells O
on O
deep O
ce O
##re O
##bella O
##r O
nuclei O
5 O

our O
patient O
reported O
sy O
##mpt O
##oma O
##tic O
relief O
1 O
hour O
after O
the O
ing O
##est O
##ion O
of O
5 O
mg O
4 O
ap O
which O
is O
in O
keeping O
with O
ph O
##arm O
##aco O
##kin O
##etic O
studies O
that O
found O
maximal O
plasma O
concentrations O
1 O
0 O
1 O
2 O
hours O
after O
intake O
7 O
however O
improvement O
at O
that O
time O
point O
was O
only O
visible O
during O
the O
ﬁ O
##nger O
nose O
test O
and O
was O
much O
more O
marked O
after O
4a O
##p O
had O
been O
taken O
three O
times O
a O
day O
this O
observation O
may O
indicate O
that O
ne O
##uron O
##al O
circuits O
affected O
by O
ea O
##2 O
need O
time O
to O
adjust O
to O
4 O
ap O
before O
sy O
##mpt O
##oma O
##tic O
effects O
can O
be O
measured O
the O
initial O
lack O
of O
subjective O
ben O
##e O
##ﬁ O
##t O
after O
the O
ﬁ O
##rst O
administration O
of O
4 O
ap O
might O
as O
well O
have O
been O
due O
to O
the O
short O
duration O
of O
initial O
treatment O
since O
therapy O
with O
4 O
ap O
supported O
by O
regular O
ga O
##it O
and O
balance O
training O
now O
shows O
a O
long O
lasting O
effect O
over O
1 O
year O

future O
treatment O
trials O
are O
warrant O
##ed O
to O
evaluate O
and O
compare O
the O
therapeutic O
effects O
of O
act O
##z O
and O
4 O
ap O
these O
trials O
should O
examine O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
both O
drugs O
on O
attacks O
as O
well O
as O
on O
inter O
##ic O
##tal O
ata O
##xia O
in O
order O
to O
identify O
the O
best O
treatment O
for O
patients O
of O
various O
ages O
and O
different O
disease O
stages O

full O
video O

jen O
j O
kim O
g O
##w O
bal O
##oh O
r O
##w O
clinical O
spectrum O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##logy O
2004 O
62 O
17 O
22 O

st O
##rup O
##p O
m O
z O
##wer O
##gal O
a O
brandt O
t O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##ther O
##ape O
##uti O
##cs O
2007 O
4 O
276 O
273 O

st O
##rup O
##p O
m O
ka O
##lla O
r O
di O
##ch O
##gan O
##s O
m O
fr O
##eil O
##inger O
t O
g O
##las O
##auer O
s O
brandt O

t O
treatment O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
with O
the O
potassium O
channel O
block O
##er O
4 O
amino O
##py O
##rid O
##ine O
ne O
##uro O
##logy O
2004 O
62 O
1623 O
1625 O

sc O
##hmi O
##tz O
hub O
##sch O
t O
du O
mont O
##cel O
st O
bali O
##ko O
l O
et O
al O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
development O
of O
a O
new O
clinical O
scale O
ne O
##uro O
##logy O
2006 O
66 O
1717 O
1720 O

wei O
##sz O
c O
##j O
rai O
##ke O
rs O
so O
##ria O
ja O
##sso O
le O
hess O
e O
##j O
potassium O
channel O
block O
##ers O
inhibit O
the O
triggers O
of O
attacks O
in O
the O
calcium O
channel O
mouse O
mutant O
to O
##ttering O
j O
ne O
##uro O
##sc O
##i O
2005 O
25 O
41 O
##41 O
41 O
##45 O

et O
##zio O
##n O
y O
gross O
##man O
y O
highly O
4 O
amino O
##py O
##rid O
##ine O
sensitive O
delayed O
rec O
##ti O
##ﬁ O
##er O
current O
mod O
##ulates O
the O
ex O
##cit O
##ability O
of O
guinea O
pig O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O
cells O
ex O
##p O
brain O
res O
2001 O
139 O
41 O
##9 O
425 O

hayes O
kc O
katz O
ma O
dev O
##ane O
j O
##g O
et O
al O
ph O
##arm O
##aco O
##kin O
##etic O
##s O
of O
an O
immediate O
release O
oral O
formulation O
of O
fa O
##mp O
##rid O
##ine O
4 O
amino O
##py O
##rid O
##ine O
in O
normal O
subjects O
and O
patients O
with O
spinal O
cord O
injury O
j O
cl O
##in O
ph O
##arm O
##aco O
##l O
2003 O
43 O
37 O
##9 O
385 O

time O
content O

00 O
00 O
00 O
00 O
00 O
23 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O

00 O
00 O
24 O
00 O
00 O
44 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O

00 O
00 O
45 O
00 O
01 O
01 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O

00 O
01 O
02 O
00 O
01 O
47 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O

00 O
01 O
48 O
00 O
02 O
29 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O

00 O
02 O
30 O
00 O
03 O
06 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O

dex O
##med O
##eto O
##mi O
##dine O
arousal O
se O
##dation O
and O
st O
##n O
neurons O
131 O
##7 O

dex O
##med O
##eto O
##mi O
##dine O
and O
arousal O
affect O
sub O
##thal O
##ami O
##c O
neurons O

william O
jeffrey O
elias O
md O
1 O
marcel O
e O
du O
##rie O
##ux O
md O
2 O
diane O
hu O
##ss O
p O
t O
ms O
##ed O
nc O
##s O
3 O

and O
robert O
c O
fry O
##sing O
##er O
phd O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##sur O
##ger O
##y O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
2d O
##ep O
##art O
##ment O
of O
an O
##est O
##hes O
##iology O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
3d O
##ep O
##art O
##ment O
of O
physical O
therapy O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O

abstract O
stereo O
##ta O
##ctic O
ne O
##uro O
##sur O
##ge O
##ons O
hesitate O
to O
employ O
se O
##dation O
in O
cases O
requiring O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
we O
report O
our O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
during O
mer O
of O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
eleven O
parkinson O
##ian O
patients O
received O
dex O
##med O
##eto O
##mi O
##dine O
during O
deep O
brain O
stimulation O
surgery O
seven O
received O
continuous O
iv O
in O
##fusion O
##s O
during O
mer O
in O
the O
st O
##n O
the O
bis O
##pe O
##ct O
##ral O
index O
bis O
was O
used O
to O
estimate O
the O
level O
of O
consciousness O
the O
quality O
of O
mer O
was O
evaluated O
as O
a O
function O
of O
bis O
clinical O
arousal O
and O
dex O
##med O
##eto O
##mi O
##dine O
dose O
mer O
during O
wake O
##fulness O
bis O
80 O
0 O
1 O
to O
0 O
4 O
mc O
##g O
kg O
hr O
dex O
##med O
##eto O
##mi O
##dine O
was O
similar O
to O
the O
un O
##med O
##icated O
state O
sub O
##thal O
##ami O
##c O
mer O
was O
reduced O
when O
the O
patient O
was O
asleep O
or O
una O
##rous O
##able O
bis O
80 O
an O
##xi O
##ol O
##ysis O
persisted O
for O
hours O
arousal O
affects O
st O
##n O
neurons O
dex O
##med O
##eto O
##mi O
##dine O
cooperative O
se O
##dation O
from O
which O
the O
patient O
is O
easily O
aroused O
provides O
interpret O
##able O
st O
##n O
mer O
and O
prolonged O
an O
##xi O
##ol O
##ysis O
we O
suggest O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
##s O
without O
a O
loading O
dose O
a O
relatively O
low O
in O
##fusion O
rate O
and O
disco O
##nti O
##nu O
##ation O
after O
completion O
of O
the O
bu O
##r O
holes O
2008 O
movement O
disorder O
society O

key O
words O
dex O
##med O
##eto O
##mi O
##dine O
deep O
brain O
stimulation O
sub O
##thal O
##ami O
##c O
nucleus O
micro O
##ele O
##ct O
##rod O
##e O
recording O

deep O
brain O
stimulation O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
has O
proven O
effective O
for O
treating O
the O
motor O
symptoms O
of O
parkinson O
s O
disease O
pd O
the O
st O
##n O
is O
relatively O
small O
and O
deep O
1 O
man O
##dating O
some O
form O
of O
intra O
##oper O
##ative O
local O
##ization O
for O
this O
reason O
local O
##izing O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
and O
test O
stimulation O
have O
become O
routine O
traditionally O
mer O
and O
intra O

correspondence O
to O
w O
jeffrey O
elias O
md O
department O
of O
neurological O
surgery O
university O
of O
virginia O
box O
800 O
##21 O
##2 O
charlotte O
##sville O
va O
229 O
##0 O
##8 O
e O
mail O
w O
##je O
##4 O
##r O
virginia O
ed O
##u O

this O
work O
was O
presented O
in O
poster O
format O
at O
the O
american O
society O
of O
stereo O
##ta O
##ctic O
and O
functional O
ne O
##uro O
##sur O
##ge O
##ons O
in O
boston O
massachusetts O
june O
2006 O

received O
9 O
may O
2007 O
revised O
9 O
october O
2007 O
accepted O
18 O

published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##80 O

operative O
testing O
require O
an O
awake O
cooperative O
patient O
2 O
3 O
patients O
fear O
awake O
surgical O
procedures O
but O
many O
stereo O
##ta O
##ctic O
ne O
##uro O
##sur O
##ge O
##ons O
remain O
hesitant O
to O
employ O
se O
##dation O
for O
fear O
of O
suppress O
##ing O
symptoms O
or O
at O
##ten O
##uating O
local O
##izing O
signals O

se O
##dation O
during O
mer O
guided O
db O
##s O
surgery O
poses O
a O
real O
challenge O
as O
even O
small O
doses O
of O
se O
##da O
##tive O
##s O
can O
affect O
the O
quality O
of O
mer O
##4 O
or O
suppress O
pd O
symptoms O
5 O
patient O
comfort O
would O
no O
doubt O
be O
maximize O
##d O
by O
general O
an O
##esthesia O
but O
probably O
at O
the O
expense O
of O
precise O
electrode O
positioning O
and O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
mal O
##tet O
##e O
et O
al O
reported O
generally O
successful O
db O
##s O
implant O
##s O
with O
general O
an O
##esthesia O
in O
15 O
parkinson O
s O
disease O
patients O
but O
motor O
score O
improvements O
post O
##oper O
##ative O
##ly O
were O
lower O
in O
the O
an O
##est O
##het O
##ized O
group O
6 O
her O
##tel O
et O
al O
recently O
reported O
decreased O
background O
of O
st O
##n O
mer O
in O
a O
setting O
of O
carefully O
ti O
##tra O
##ted O
general O
an O
##esthesia O
7 O

dex O
##med O
##eto O
##mi O
##dine O
pre O
##cede O
##x O
is O
an O
attractive O
se O
##da O

ti O
##ve O
for O
use O
in O
ne O
##uro O
##sur O
##gical O
procedures O
because O
of O
its O
minimal O
respiratory O
de O
##press O
##ant O
effects O
hem O
##od O
##yna O
##mic O
stab O
##ili O
##zing O
properties O
and O
rapid O
onset O
and O
offset O
initially O
approved O
for O
ic O
##u O
se O
##dation O
this O
a O
2 O
ago O
##nist O
affects O
receptors O
primarily O
in O
the O
locus O
ce O
##ru O
##le O
##us O
with O
minimal O
effects O
on O
cerebral O
cortex O
8 O
this O
results O
in O
a O
unique O
cooperative O
se O
##dation O
where O
patients O
may O
fall O
asleep O
but O
are O
easily O
aroused O
9 O

a O
recent O
report O
suggests O
that O
patient O
cooperation O
pd O

symptoms O
and O
the O
quality O
of O
mer O
were O
unaffected O
by O
continuous O
se O
##dation O
with O
dex O
##med O
##eto O
##mi O
##dine O
during O
db O
##s O
implant O
surgery O
in O
11 O
cases O
10 O
an O
extensive O
positive O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
during O
db O
##s O
surgery O
has O
been O
reported O
at O
rush O
university O
but O
the O
effects O
on O
mer O
of O
st O
##n O
neurons O
have O
not O
yet O
been O
published O
9 O

stefan O
##i O
et O
al O
found O
that O
spontaneous O
sleep O
can O
have O
a O
profound O
impact O
on O
the O
discharge O
of O
st O
##n O
neurons O
11 O
this O
suggests O
that O
behavioral O
arousal O
could O
play O
a O
clinical O
##ly O
relevant O
role O
in O
mer O
local O
##ization O
because O
patients O
may O
fall O
asleep O
even O
with O
low O
doses O
of O
dex O
##med O
##eto O
##mi O
##dine O
sleep O
waking O
state O
may O
be O
a O
factor O
related O
to O
an O
##xi O
##ol O
##ysis O
rather O
than O
frank O
se O
##dation O

in O
an O
effort O
to O
reduce O
discomfort O
and O
anxiety O
in O
our O
patients O
during O
db O
##s O
procedures O
we O
utilize O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
for O
se O
##dation O
here O
we O
report O
our O
observations O
of O
the O
effects O
of O
dex O
##med O
##eto O
##mi O
##dine O
on O
st O
##n O
mer O

we O
reviewed O
operative O
an O
##est O
##hetic O
and O
mer O
records O
from O
11 O
consecutive O
cases O
of O
patients O
with O
parkinson O
s O

131 O
##8 O
w O
j O
elias O
et O
al O

disease O
who O
underwent O
st O
##n O
db O
##s O
electrode O
implant O
##ation O
during O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O

surgery O

parkinson O
medications O
were O
held O
on O
the O
day O
of O
surgery O
and O
a O
le O
##ks O
##ell O
stereo O
##ta O
##ctic O
frame O
was O
placed O
using O
local O
an O
##esthesia O
direct O
targeting O
was O
based O
on O
t O
##2 O
and O
mp O
rage O
volume O
##tric O
mr O
12 O
the O
patient O
was O
placed O
in O
a O
semi O
##re O
##cum O
##ben O
##t O
position O
with O
the O
frame O
locked O
to O
the O
operating O
table O
blood O
pressure O
was O
monitored O
by O
an O
automatic O
cuff O
spontaneous O
res O
##piration O
was O
monitored O
along O
with O
o O
##2 O
sat O
##uration O

se O
##dation O

se O
##dation O
was O
provided O
with O
continuous O
in O
##fusion O
of O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
which O
usually O
started O
at O

0 O
7 O
mc O
##g O
kg O
hr O
and O
ti O
##tra O
##ted O
down O
based O
on O
clinical O
response O
in O
several O
patients O
an O
initial O
loading O
dose O
of O
1 O
mc O
##g O
kg O
was O
administered O
over O
20 O
min O
level O
of O
consciousness O
was O
assessed O
by O
the O
ne O
##uro O
##sur O
##ge O
##on O
and O
an O
##est O
##hes O
##iol O
##ogist O
using O
observation O
and O
verbal O
questioning O
the O
bis O
##pe O
##ct O
##ral O
index O
bis O
helped O
to O
estimate O
the O
level O
of O
co O
##rti O
##cal O
arousal O
##13 O

bis O
5 O
80 O
to O
100 O
suggests O
awake O
and O
alert O
bis O
5 O
60 O
to O
80 O
varying O
levels O
of O
se O
##dation O
and O
bis O
5 O
40 O
to O
60 O
general O
an O
##esthesia O

se O
##dation O
was O
ti O
##tra O
##ted O
to O
patient O
comfort O
and O
was O
transient O
##ly O
increased O
during O
bu O
##r O
hole O
placement O
no O
other O
drugs O
with O
se O
##da O
##tive O
properties O
were O
administered O

micro O
##ele O
##ct O
##rod O
##e O
recording O

mer O
was O
initiated O
25 O
mm O
above O
the O
target O
and O
recorded O
on O
an O
alpha O
omega O
system O
sample O
recordings O
were O
saved O
every O
0 O
5 O
mm O
during O
the O
trajectory O
we O
did O
not O
test O
for O
motor O
driving O
of O
neurons O
following O
satisfactory O
mer O
and O
intra O
##oper O
##ative O
macro O
##sti O
##mu O
##lation O
testing O
the O
db O
##s O
electrode O
was O
anchored O
in O
position O
and O
con O
##ﬁ O
##rmed O
with O
ﬂ O
##uo O
##ros O
##co O
##py O

post O
##oper O
##ative O

patients O
recovered O
in O
the O
post O
##ane O
##st O
##hes O
##ia O
care O
unit O
and O
on O
the O
ne O
##uro O
##sur O
##gical O
ward O
a O
local O
##izing O
mri O
was O
obtained O
the O
day O
following O
surgery O
baseline O
parkinson O
s O
medications O
were O
resumed O
and O
most O
patients O
were O
discharged O
on O
the O
second O
post O
##oper O
##ative O
day O

eleven O
parkinson O
##ian O
patients O
underwent O
mer O
##guide O
##d O
st O
##n O
db O
##s O
with O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
all O
were O
men O
average O
age O
62 O
3 O
years O
mean O
disease O

duration O
10 O
1 O
years O
eight O
patients O
underwent O
bilateral O
and O
three O
underwent O
un O
##ila O
##tera O
##l O
surgery O

micro O
##ele O
##ct O
##rod O
##e O
recordings O
were O
successful O
for O
all O
placement O
##s O
the O
mean O
number O
of O
electrode O
tr O
##aj O
##ect O
##ories O
per O
side O
was O
1 O
5 O
range O
1 O
4 O
the O
mean O
trajectory O
length O
through O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
4 O
4 O
mm O
range O
2 O
5 O
6 O
mm O
in O
4 O
patients O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
was O
discontinued O
following O
bu O
##r O
hole O
placement O
the O
most O
no O
##xious O
part O
of O
the O
procedure O
the O
other O
7 O
patients O
received O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
during O
micro O
##ele O
##ct O
##rod O
##e O
recording O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O

sub O
##thal O
##ami O
##c O
mer O
signals O
equivalent O
to O
the O
non O
##sed O
##ated O
state O
were O
obtained O
when O
dex O
##med O
##eto O
##mi O
##dine O
was O
ti O
##tra O
##ted O
to O
an O
easily O
ar O
##ous O
##able O
level O
of O
consciousness O
bis O
80 O
suppression O
of O
sub O
##thal O
##ami O
##c O
ne O
##uron O
##al O
discharge O
occurred O
with O
higher O
in O
##fusion O
rates O
and O
se O
##dation O
levels O
where O
the O
patient O
was O
una O
##rous O
##able O
bis O
80 O
fig O
##s O
1 O
and O
2 O
all O
patients O
were O
su O
##f O
##ﬁ O
##cie O
##ntly O
alert O
and O
cooperative O
for O
macro O
##sti O
##mu O
##lation O
testing O
following O
micro O
##ele O
##ct O
##rod O
##e O
recording O

following O
dex O
##med O
##eto O
##mi O
##dine O
administration O
and O
up O
to O
at O
least O
several O
hours O
after O
disco O
##nti O
##nu O
##ation O
we O
observed O
a O
prolonged O
an O
##xi O
##ol O
##ytic O
effect O
it O
was O
relatively O
common O
for O
these O
patients O
to O
laps O
##e O
into O
easily O
ar O
##ous O
##able O
sleep O
during O
the O
later O
stages O
of O
the O
operation O
in O
some O
patients O
we O
observed O
a O
clear O
step O
change O
increase O
in O
mer O
activity O
in O
the O
st O
##n O
upon O
behavioral O
arousal O
from O
sleep O
consistent O
with O
the O
report O
by O
stefan O
##i O
et O
al O
11 O

eleven O
parkinson O
##ian O
patients O
received O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
during O
db O
##s O
surgery O
and O
local O
##izing O
unit O
activity O
was O
recorded O
from O
st O
##n O
in O
every O
case O
mer O
of O
st O
##n O
was O
obtained O
during O
continuous O
in O
##fusion O
in O
7 O
of O
these O
patients O
low O
level O
in O
##fusion O
##s O
of O
dex O
##med O
##eto O
##mi O
##dine O
0 O
1 O
mc O
##g O
kg O
hr O
did O
not O
substantially O
suppress O

dex O
##med O
##eto O
##mi O
##dine O
arousal O
se O
##dation O
and O
st O
##n O
neurons O
131 O
##9 O

fig O
2 O
deep O
se O
##dation O
suppress O
##es O
st O
##n O
ne O
##uron O
##al O
activity O
all O
traces O
were O
recorded O
from O
the O
same O
micro O
##ele O
##ct O
##rod O
##e O
position O
upper O
trace O
st O
##n O
mer O
signals O
patient O
is O
awake O
with O
bis O
5 O
95 O
middle O
trace O
mer O
signals O
following O
an O
iv O
bo O
##lus O
of O
dex O
##med O
##eto O
##mi O
##dine O
1 O
l O
##g O
kg O
load O
over O
10 O
min O
then O
0 O
5 O
l O
##g O
kg O
hr O
patient O
becomes O
una O
##rous O
##able O
with O
bis O
5 O
70 O
lower O
trace O
mer O
signals O
20 O
min O
after O
stopping O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
patient O
awake O
##ns O
with O
some O
return O
of O
baseline O
background O
activity O
bis O
5 O
95 O

st O
##n O
ne O
##uron O
##al O
discharge O
##s O
but O
higher O
rates O
0 O
5 O
mc O
##g O
kg O
hr O
resulted O
in O
a O
deeper O
se O
##dation O
lower O
bis O
levels O
and O
suppressed O
ne O
##uron O
##al O
ﬁ O
##ring O
in O
the O
st O
##n O
see O
fig O
1 O

the O
clinical O
or O
setting O
of O
these O
recordings O
imposed O
some O
constraints O
on O
analysis O
of O
ne O
##uron O
##al O
activity O
high O
amplitude O
single O
cell O
activity O
is O
lost O
over O
time O
at O
a O
given O
position O
of O
the O
micro O
##ele O
##ct O
##rod O
##e O
mer O
across O
different O
medication O
or O
arousal O
conditions O
typically O
required O
10 O
min O
or O
more O
longer O
than O
we O
could O
re O
##lia O
##bly O
hold O
the O
activity O
of O
disc O
##rim O
##ina O
##ble O
single O
units O

the O
so O
called O
background O
multiple O
cell O
activity O
is O
more O
stable O
over O
time O
and O
may O
be O
a O
marker O
of O
ph O
##arm O
##aco O
##logic O
modulation O
7 O
we O
were O
able O
to O
obtain O
continuous O
mer O
of O
the O
st O
##n O
during O
relatively O
rapid O
changes O
from O
sleep O
to O
waking O
and O
on O
one O
occasion O
before O
and O
after O
a O
bo O
##lus O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
see O
fig O
2 O
we O
could O
not O
obtain O
mer O
activity O
during O
the O
transition O
from O
med O
##icated O
to O
non O
##med O
##icated O
or O
from O
wake O
##fulness O
to O
sleep O
because O
these O
are O
not O
rapid O
events O
there O
is O
thus O
an O
inevitable O
con O
##fo O
##und O
##ing O
of O
the O
effect O
of O
time O
with O
the O
effect O
of O
the O
manipulation O
particularly O
of O
drug O
levels O
we O
hope O
that O
future O
research O
may O
provide O
more O
details O
of O
the O
effects O
of O
arousal O
versus O
ph O
##arm O
##aco O
##logic O
effects O
on O
st O
##n O
neurons O

ro O
##ze O
##t O
et O
al O
reported O
that O
patient O
comfort O
was O
improved O
with O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
and O
mer O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
possible O
we O
agree O
however O
we O
observed O
that O
sub O
##thal O
##ami O
##c O
ne O
##uron O
##al O
ﬁ O
##ring O
varied O
with O
the O
dose O
of O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
and O
the O
patient O
s O
level O
of O
behavioral O
arousal O

intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
was O
highly O
successful O
in O
all O
##ev O
##iating O
anxiety O
during O
all O
stages O
of O
db O
##s O
surgery O

and O
particularly O
for O
placement O
of O
the O
bu O
##r O
holes O
the O
terminal O
elimination O
half O
life O
of O
dex O
##med O
##eto O
##mi O
##dine O
is O
recognized O
as O
2 O
hours O
but O
we O
observed O
prolonged O
clinical O
##ly O
effective O
an O
##xi O
##ol O
##ysis O
even O
when O
the O
in O
##fusion O
was O
discontinued O
several O
hours O
earlier O
we O
did O
not O
observe O
a O
ben O
##e O
##ﬁ O
##t O
with O
continuous O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
after O
placement O
of O
the O
bu O
##r O
holes O

there O
were O
no O
apparent O
complications O
from O
the O
medication O
mild O
h O
##yp O
##ote O
##ns O
##ion O
has O
been O
reported O
with O
loading O
doses O
and O
our O
practice O
has O
evolved O
to O
utilize O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
##s O
without O
a O
loading O
dose O
maintain O
a O
relatively O
low O
in O
##fusion O
rate O
and O
disco O
##nti O
##nu O
##e O
the O
in O
##fusion O
immediately O
after O
the O
completion O
of O
the O
bu O
##r O
holes O
the O
need O
for O
h O
##yp O
##ote O
##ns O
##ive O
agents O
to O
maintain O
norm O
##ote O
##ns O
##ion O
during O
electrode O
placement O
appeared O
to O
be O
reduced O
in O
these O
patients O
va O
##sop O
##ress O
##ors O
were O
not O
required O
in O
any O
of O
the O
cases O
in O
our O
series O

our O
experience O
indicates O
that O
dex O
##med O
##eto O
##mi O
##dine O
can O
be O
used O
safely O
to O
se O
##date O
patients O
with O
parkinson O
s O
disease O
during O
db O
##s O
placement O
without O
sign O
##i O
##ﬁ O
##can O
##t O
effect O
on O
the O
intra O
##oper O
##ative O
local O
##izing O
value O
of O
mer O
steady O
##sta O
##te O
in O
##fusion O
rates O
of O
0 O
1 O
to O
0 O
4 O
mc O
##g O
kg O
hr O
seem O
appropriate O
with O
in O
##fusion O
rates O
ti O
##tra O
##ted O
to O
maintain O
bis O
values O
above O
80 O
disco O
##nti O
##nu O
##ation O
after O
placement O
of O
bu O
##r O
holes O
and O
the O
patient O
kept O
awake O
and O
alert O
during O
mer O

conclusions O

st O
##n O
mer O
activity O
may O
vary O
with O
behavioral O
arousal O

intra O
##ven O
##ous O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
ti O
##tra O
##ted O
to O
easy O
ar O
##ous O
##ability O
will O
allow O
quality O
st O
##n O
mer O
in O
the O
awake O
and O
alert O
patient O

132 O
##0 O
w O
j O
elias O
et O
al O

higher O
doses O
of O
dex O
##med O
##eto O
##mi O
##dine O
which O
produce O
deep O
se O
##dation O
bis O
80 O
and O
patient O
una O
##rous O
##able O
will O
suppress O
st O
##n O
mer O
signals O

ac O
##k O
##now O
##led O
##gm O
##ents O
the O
authors O
thank O
mrs O
cindy O
robe O
##rson O
for O
assistance O
in O
preparation O
of O
this O
manuscript O

hard O
##man O
cd O
henderson O
j O
##m O
fin O
##kel O
##stein O
di O
horne O
mk O
pa O
##xin O
##os O
g O
hall O
##ida O
##y O
gm O
comparison O
of O
the O
basal O
gang O
##lia O
in O
rats O
mar O
##mos O
##ets O
mac O
##aq O
##ues O
ba O
##bo O
##ons O
and O
humans O
volume O
and O
ne O
##uron O
##al O
number O
for O
the O
output O
internal O
relay O
and O
st O
##ria O
##tal O
mod O
##ulating O
nuclei O
j O
com O
##p O
ne O
##uro O
##l O
2002 O
44 O
##5 O
238 O
255 O

cu O
##ny O
e O
gu O
##eh O
##l O
d O
bu O
##rba O
##ud O
p O
gross O
c O
do O
##uss O
##et O
v O
ro O
##ug O
##ier O
a O
lack O
of O
agreement O
between O
direct O
magnetic O
resonance O
imaging O
and O
statistical O
determination O
of O
a O
sub O
##thal O
##ami O
##c O
target O
the O
role O
of O
electro O
##phy O
##sio O
##logical O
guidance O
see O
comment O
j O
ne O
##uro O
##sur O
##g O
2002 O
97 O
59 O
##1 O
59 O
##7 O

ki O
##rs O
##chman O
dl O
mill O
##igan O
b O
wilkinson O
s O
et O
al O
pal O
##lid O
##oto O
##my O
micro O
##ele O
##ct O
##rod O
##e O
targeting O
ne O
##uro O
##phy O
##sio O
##logy O
based O
target O
re O
##ﬁ O
##nem O
##ent O
see O
comment O
ne O
##uro O
##sur O
##ger O
##y O
2000 O
46 O
61 O
##3 O
62 O
##2 O

hut O
##chison O
w O
##d O
lang O
ae O
dos O
##tro O
##vsky O
jo O
lo O
##zano O
am O
pal O
##lid O
##al O
ne O
##uron O
##al O
activity O
implications O
for O
models O
of O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
2003 O
53 O
480 O
48 O
##8 O

bo O
##hm O
##dorf O
##er O
w O
schwarz O
##inger O
p O
bind O
##er O
s O
sp O
##orn O
p O
temporary O
suppression O
of O
tremor O
by O
re O
##mi O
##fen O
##tani O
##l O
in O
a O
patient O
with O
parkinson O
s O
disease O
during O
cat O
##ara O
##ct O
extraction O
under O
local O
an O
##esthesia O
ana O
##est O
##hesis O
##t O
2003 O
52 O
79 O
##5 O
79 O
##7 O

mal O
##tet O
##e O
d O
navarro O
s O
we O
##lter O
ml O
et O
al O
sub O
##thal O
##ami O
##c O
stimulation O
in O
parkinson O
disease O
with O
or O
without O
an O
##esthesia O
arch O
ne O
##uro O
##l O
2004 O
61 O
390 O
39 O
##2 O

her O
##tel O
f O
zu O
##chner O
m O
weimar O
i O
et O
al O
implant O
##ation O
of O
electrode O
##s O
for O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
with O
the O
aid O
of O
intra O
##oper O
##ative O
micro O
##re O
##cor O
##ding O
under O
general O
an O
##esthesia O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
59 O
e O
##11 O
##38 O

co O
##urs O
##in O
db O
mac O
##cio O
##li O
ga O
dex O
##med O
##eto O
##mi O
##dine O
cu O
##rr O
op O
##in O
cr O
##it O
care O
2001 O
7 O
221 O
226 O

be O
##kker O
a O
stu O
##rai O
##tis O
mk O
dex O
##med O
##eto O
##mi O
##dine O
for O
neurological O
surgery O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
1 O
su O
##pp O
##l O
1 O
10 O

ro O
##ze O
##t O
i O
mu O
##ang O
##man O
s O
va O
##vil O
##ala O
ms O
et O
al O
clinical O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
for O
implant O
##ation O
of O
deep O
brain O
st O
##im O
##ulator O
##s O
in O
parkinson O
s O
disease O
an O
##est O
##h O
anal O
##g O
2006 O
103 O
122 O
##4 O
122 O
##8 O

stefan O
##i O
a O
gala O
##ti O
s O
pep O
##pe O
a O
et O
al O
spontaneous O
sleep O
mod O
##ulates O
the O
ﬁ O
##ring O
pattern O
of O
parkinson O
##ian O
sub O
##thal O
##ami O
##c O
nucleus O
ex O
##p O
brain O
res O
2006 O
168 O
277 O
280 O

hari O
##z O
mi O
k O
##rac O
##k O
p O
mel O
##vill O
r O
et O
al O
a O
quick O
and O
universal O
method O
for O
stereo O
##ta O
##ctic O
visual O
##ization O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
before O
and O
after O
implant O
##ation O
of O
deep O
brain O
stimulation O
electrode O
##s O
stereo O
##ta O
##ct O
fun O
##ct O
ne O
##uro O
##sur O
##g O
2003 O
80 O
96 O
101 O

singh O
h O
bis O
##pe O
##ct O
##ral O
index O
bis O
monitoring O
during O
prop O
##of O
##ol O
induced O
se O
##dation O
and O
ana O
##esthesia O
eu O
##r O
j O
ana O
##est O
##hes O
##iol O
1999 O
16 O
31 O
36 O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
pp O
128 O
##6 O
132 O
##0 O
2008 O
movement O
disorder O
society O
brief O
reports O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
sebastian O
pau O
##s O
md O
1 O
ga O
##bor O
z O
##sur O
##ka O
phd O
md O
2 O
miriam O
baron O
phd O
2 O
marcus O
des O
##cha O
##uer O
md O
3 O
christian O
bam O
##berg O
md O
4 O
thomas O
k O
##lock O
##get O
##her O
md O
1 O
wolf O
##ram O
s O
kun O
##z O
phd O
2 O
and O
corn O
##elia O
ko O
##rn O
##bl O
##um O
md O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
2d O
##ep O
##art O
##ment O
of O
ep O
##ile O
##pt O
##ology O
and O
life O
and O
brain O
center O
university O
of O
bonn O
bonn O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
university O
of O
halle O
wit O
##tenberg O
halle O
sa O
##ale O
germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
r O
##hein O
mo O
##sel O
fa O
##ch O
##k O
##lini O
##k O
and O
##ern O
##ach O
germany O

key O
words O
focal O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
pt O
##osis O
pol O
##g O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
mutations O
in O
the O
polymer O
##ase O
g O
gene O
pol O
##g O
##1 O
coding O
for O
a O
protein O
involved O
in O
mitochondrial O
dna O
mt O
##dna O
maintenance O
cause O
a O
broad O
variety O
of O
auto O
##som O
##al O
dom O
##i O
correspondence O
to O
dr O
sebastian O
pau O
##s O
department O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
e O
mail O
spa O
##us O
un O
##i O
bonn O
de O
received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O
april O
2008 O
published O
online O
10 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O

here O
we O
report O
on O
two O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
the O
most O
frequent O
recess O
##ive O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
presenting O
with O
a O
remarkably O
later O
onset O
and O
longer O
survival O
than O
most O
patients O
of O
the O
same O
gen O
##otype O
one O
suffered O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
al O
##o O
due O
to O
d O
##yst O
##onic O
activity O
of O
eye O
##lid O
muscles O
resulting O
in O
functional O
blindness O
so O
far O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O
subjects O
and O
methods O
subjects O

128 O
##6 O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
128 O
##7 O
table O
1 O
ph O
##eno O
##type O
##s O
gen O
##otype O
##s O
and O
mt O
##dna O
copy O
numbers O
in O
blood O
age O
years O
copy O
numbers O
are O
given O
in O
mean O
6 O
sd O
pol O
##g O
##1 O
gen O
##otype O
the O
two O
sides O
of O
the O
slash O
indicate O
gen O
##ot O
##yp O
##ing O
results O
of O
the O
two O
chromosomes O
as O
determined O
by O
pc O
##r O
rf O
##lp O
the O
term O
w O
##t O
in O
this O
respect O
indicates O
that O
none O
of O
the O
three O
pol O
##g O
##1 O
mutations O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
and O
a O
##46 O
##7 O
##t O
were O
detected O
sd O
standard O
deviation O
d O
onset O
disease O
onset O
na O
not O
applicable O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
w O
##t O
wild O
type O

red O
or O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
ﬁ O
##bers O
while O
bio O
##chemical O
analyses O
of O
respiratory O
chain O
enzymes O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
were O
normal O
table O
1 O
patient B-PATIENT
2 I-PATIENT
was O
healthy O
until O
the O
age O
of O
36 B-AGE_ONSET
when O
she O
developed O
pe B-HPO_TERM
##o I-HPO_TERM
mild O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
ata B-HPO_TERM
##xia I-HPO_TERM
and O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
brain O
mri O
was O
normal O
examination O
of O
muscle O
tissue O
was O
identical O
to O
patient B-PATIENT
1 I-PATIENT
mother O
father O
and O
the O
third O
sister O
were O
seen O
at O
ages O
64 O
64 O
and O
38 O
respectively O
besides O
ob O
##ste O
##tric O
cho O
##les O
##tas O
##is O
in O
the O
sister O
no O
liver O
disease O
diabetes O
or O
neurological O
symptoms O
became O
evident O
genetic O
analysis O

copy O
numbers O
of O
the O
mitochondrial O
genome O
were O
determined O
in O
blood O
le O
##uk O
##ocytes O
in O
all O
subjects O
by O
real O
##time O
pc O
##r O
as O
described O
earlier O
7 O
in O
all O
subjects O
quad O
##rup O
##le O
experiments O
were O
performed O
and O
arithmetic O
means O
and O
standard O
deviation O
##s O
were O
calculated O
copy O
numbers O
were O
compared O
to O
those O
of O
15 O
age O
##and O
sex O
matched O
healthy O
controls O
f O
m O
13 O
2 O
using O
student O
s O
t O
test O
results O
clinical O
course O
after O
initial O
presentation O
patient B-PATIENT
1 I-PATIENT
was O
seen O
at O
regular O
intervals O
and O
a O
slow O
worse B-HPO_TERM
##ning I-HPO_TERM
of I-HPO_TERM
dip I-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
and O
ata B-HPO_TERM
##xia I-HPO_TERM
was O
documented O
whereas O
ep B-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM

3 O
months O
intervals O
with O
ongoing O
success O
until O
now O
when O
patient B-PATIENT
2 I-PATIENT
was O
seen O
1 O
year O
after O
disease O
onset O
there O
were O
no O
involuntary O
movements O
of O
any O
kind O
genetic O
analysis O
long O
range O
pc O
##r O
detected O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
skeletal O
muscle O
of O
patients B-PATIENT
1 I-PATIENT
and O
2 O
both O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
mother O
and O
healthy O
sister O
were O
het O
##ero O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
the O
father O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
as O
described O
before O
3 O
6 O
w O
##7 O
##48 O
##s O
was O
found O
together O
with O
e O
##11 O
##43 O
##g O
in O
each O
case O
suggesting O
all O
##eli O
##c O
coupling O
of O
both O
mutations O

mt O
##dna O
copy O
numbers O
in O
blood O
were O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
controls O
even O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
128 O
##8 O
pau O
##s O
et O
al O
more O
obvious O
in O
patient B-PATIENT
1 I-PATIENT
with O
earlier O
disease O
onset O
and O
more O
severe O
clinical O
ph O
##eno O
##type O
reduction O
of O
68 O
and O
56 O
respectively O
also O
mean O
copy O
numbers O
of O
the O
healthy O
family O
members O
were O
lower O
when O
compared O
with O
mean O
values O
of O
controls O
reaching O
sign O
##i O
##ﬁ O
##can O
##ce O
in O
the O
mother O
only O
discussion O

in O
conclusion O
pol O
##g O
##1 O
mutations O
might O
present O
with O
treat O
##able O
focal O
d O
##yst O
##onia O
which O
should O
be O
considered O
in O
cases O
of O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O
references O
hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
dna O
polymer O
##ase O
gamma O
and O
human O
disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
244 O
252 O
ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
167 O
##4 O
168 O
##4 O

t O
##zo O
##uli O
##s O
c O
nielsen O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O
david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
##1 O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O
baron O
m O
ku O
##din O
ap O
kun O
##z O
w O
##s O
mitochondrial O
dysfunction O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
bio O
##che O
##m O
soc O
trans O
2007 O
35 O
122 O
##8 O
123 O
##1 O
k O
##rac O
##k O
p O
marion O
m O
##h O
apr O
##ax O
##ia O
of O
lid O
opening O
a O
focal O
eye O
##lid O
d O
##yst O
##onia O
clinical O
study O
of O
32 O
patients O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
610 O
61 O
##5 O
roberts O
me O
ste O
##iger O
m O
##j O
hart O
ik O
presentation O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mimic O
##king O
b O
##le O
##pha O
##ros O
##pas O
##m O
ne O
##uro O
##logy O
2002 O
58 O
150 O
151 O

muller O
va O
##hl O
k O
##r O
ko O
##lb O
##e O
h O
e O
##gens O
##per O
##ger O
r O
deng O
##ler O
r O
mit O
##och O
##ond O
##rio O
##pathy O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
treatment O
with O
bot O
##ulin O
##um O
toxin O
muscle O
nerve O
2000 O
23 O
64 O
##7 O
64 O
##8 O
forget O
r O
to O
##z O
##lova O
##nu O
v O
ian O
##cu O
a O
bog O
##hen O
d O
bot O
##ulin O
##um O
toxin O
improves O
lid O
opening O
delays O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
associated O
apr O
##ax O
##ia O
of O
lid O
opening O
ne O
##uro O
##logy O
2002 O
58 O
1843 O
1846 O
ara O
##mide O
##h O
m O
on O
##ger O
##bo O
##er O
de O
vis O
##ser O
b O
##w O
dev O
##ries O
##e O
pp O
bo O
##ur O
l O
##j O
sp O
##ee O
##lman O
jd O
electro O
##my O
##ographic O
features O
of O
lev O
##ator O
pal O
##pe O
##bra O
##e O
superior O
##is O
and O
orb O
##icular O
##is O
o O
##cu O
##li O
muscles O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
brain O
1994 O
117 O
27 O
38 O

hanna O
mg O
b O
##hat O
##ia O
k O
##p O
movement O
disorders O
and O
mitochondrial O
dysfunction O
cu O
##rr O
op O
##in O
ne O
##uro O
##l O
1997 O
10 O
351 O
356 O
sc O
##ha O
##pi O
##ra O
ah O
warner O
t O
gas O
##h O
mt O
cl O
##eet O
##er O
mw O
marin O
##ho O
cf O
cooper O
j O
##m O
complex O
i O
function O
in O
fa O
##mi O
##lia O
##l O
and O
sporadic O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
1997 O
41 O
55 O
##6 O
55 O
##9 O
mc O
##far O
##land O
r O
chin O
##nery O
p O
##f O
blake O
##ly O
el O
et O
al O
homo O
##pl O
##as O
##my O
het O
##ero O
##pl O
##as O
##my O
and O
mitochondrial O
d O
##yst O
##onia O
ne O
##uro O
##logy O
2007 O
69 O
911 O
91 O
##6 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
128 O
##9 O
gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
results O
on O
motor O
function O
and O
cognition O
in O
a O
72 O
year O
old O
case O

alfonso O
fa O
##san O
##o O
md O
1 O
paolo O
ma O
##zzo O
##ne O
md O
2 O
carla O
piano O
md O
1 O
david O
##e O
qu O
##aran O
##ta O
md O
1 O
francesco O
sole O
##ti O
md O
1 O
and O
anna O
rita O
bent O
##ivo O
##glio O
md O
phd O
##1 O
1 O
##ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
roma O
italia O
2 O
##ne O
##uro O
##chi O
##ru O
##rg O
##ia O
fun O
##zio O
##nal O
##e O
e O
stereo O
##tas O
##sic O
##a O
ct O
##o O
ale O
##sin O
##i O
roma O
italia O
video O

key O
words O
huntington O
s O
disease O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
surgery O
therapy O
huntington O
s O
disease O
hd O
is O
an O
auto O
##som O
##al O
dominant O
ne O
##uro O
##de O
##gen O
##erative O
disorder O
characterized O
by O
progressive O
cognitive O
impairment O
movement O
disorders O
and O
psychiatric O
symptoms O
when O
the O
movement O
disorder O
particularly O
the O
cho O
##rea O
is O
di O
##sa O
##bling O
ph O
##arm O
##aco O
##logical O
treatment O
is O
the O
main O
##sta O
##y O
of O
treatment O
but O
it O
is O
often O
ineffective O
thus O
the O
following O
surgical O
the O
##ra O
##pies O
have O
been O
introduced O
pal O
##lid O
##oto O
##my O
1 O
2 O
human O
fetal O
st O
##ria O
##tal O
transplant O
##a O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
alfonso O
fa O
##san O
##o O
md O
ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
la O
##rgo O
ago O
##sti O
##no O
gem O
##elli O
8 O
001 O
##6 O
##8 O
rome O
e O
mail O
alfonso O
fa O
##san O
##o O
rm O
un O
##ica O
##tt O
it O
received O
3 O
august O
2007 O
revised O
2 O
april O
2008 O
accepted O
5 O
april O
2008 O
published O
online O
30 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##16 O

hd O
patient O
with O
medical O
##ly O
intra O
##ctable O
cho O
##rea O
methods O
db O
##s O
leads O
model O
338 O
##7 O
med O
##tron O
##ic O
were O
bilateral O
##ly O
implant O
##ed O
under O
general O
an O
##esthesia O
brain O
magnetic O
resonance O
imaging O
and O
computed O
tom O
##ography O
were O
utilized O
for O
targeting O
procedures O
the O
leads O
were O
connected O
to O
an O
implant O
##able O
pulse O
generator O
ip O
##g O
kin O
##et O
##ra O
med O
##tron O
##ic O
which O
was O
secured O
in O
the O
sub O
##cut O
##aneous O
tissues O
of O
the O
chest O

the O
effect O
of O
the O
stimulation O
by O
means O
of O
each O
of O
the O
four O
electrode O
contacts O
was O
investigated O
using O
different O
settings O
of O
stimulation O
frequency O
40 O
130 O
and O
180 O
hz O
pulse O
width O
60 O
90 O
120 O
180 O
and O
210 O
mc O
##se O
##c O
voltage O
from O
1 O
to O
7 O
v O
the O
patient O
was O
evaluated O
15 O
min O
after O
the O
change O
of O
parameters O
and O
after O
24 O
hours O
when O
a O
new O
set O
of O
parameters O
was O
tested O
when O
comparing O
the O
different O
settings O
we O
maintained O
constant O
the O
total O
electrical O
energy O
delivered O
tee O
##d O
determined O
using O
the O
equations O
proposed O
by O
mor O
##o O
et O
al O
4 O
as O
follows O
tee O
##d O
##¼ O
##½ O
##ð O
##vo O
##lta O
##ge O
3 O
##pu O
##ls O
##ew O
##id O
##th O
##3 O
##fr O
##e O
##que O
##ncy O
##þ O
imp O
##edance O
½ O
##tee O
##d O

an O
equation O
empirical O
##ly O
derived O
from O
their O
previous O
studies O
on O
patients O
affected O
by O
pd O
##9 O
but O
believed O
to O
be O
incorrect O
by O
ko O
##ss O
et O
al O
10 O
who O
suggested O
tee O
##d O
##1 O
##se O
##c O
ð O
##vo O
##lta O
##ge O
##2 O
3 O
pulse O
##wi O
##dt O
##h O
3 O
frequency O
##þ O
imp O
##edance O
3 O
1 O
sec O
½ O
##tee O
##d O
clinical O
assessments O
were O
prospective O
##ly O
performed O
using O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
##11 O
and O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
##12 O
table O
1 O
at O
baseline O
and O
at O
follow O
up O
visits O
the O
patient O
underwent O
an O
extensive O
ne O
##uro O
##psy O
##cho O
##logical O
exam O
##ina O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##0 O
a O
fa O
##san O
##o O
et O
al O

ti O
##on O
by O
means O
of O
a O
previously O
reported O
standardized O
battery O
##13 O
table O
2 O
results O

effect O
on O
motor O
function O
the O
patient O
was O
discharged O
from O
the O
hospital O
with O
ip O
##g O
left O
off O
to O
allow O
stabilization O
of O
the O
micro O
##pal O
##lid O
##oto O
##my O
effect O
which O
caused O
only O
a O
mild O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
table O
1 O
one O
month O
after O
surgery O
mono O
##pol O
##ar O
stimulation O
using O
ventral O
contacts O
seemed O
to O
be O
more O
e O
##f O
##ﬁ O
##ca O
##cious O
on O
cho O
##rea O
but O
it O
was O
associated O
with O
a O
severe O
h O
##yp O
##oton O
##ia O
of O
axial O
muscles O
causing O
ﬂ O
##ex O
##ion O
of O
the O
head O
and O
loss O
of O
trunk O
control O
parameters O
was O
maintained O
as O
follows O
right O
gp O
##i O
2 O
6 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
2 O
negative O
and O
case O
positive O
left O
gp O
##i O

table O
1 O
motor O
function O
during O
follow O
up O
visits O
cho O
##rea O
score O
was O
de O
##ﬁ O
##ned O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
12 O
##a O
12 O
##g O
maximum O
score O
28 O
d O
##yst O
##onia O
score O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
11 O
##a O
11 O
##e O
maximum O
score O
20 O
brady O
##kin O
##es O
##ia O
rigid O
##ity O
score O
as O
the O
sum O
of O
the O
uh O
##dr O
##s O
items O
11 O
12 O
14 O
15 O
maximum O
score O
28 O
axial O
symptoms O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
18 O
19 O
20 O
and O
of O
up O
##dr O
##s O
item O
27 O
arising O
from O
chair O
maximum O
score O
16 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

numbers O
in O
brackets O
indicate O
the O
corrected O
scores O
for O
age O
and O
years O
of O
education O
according O
to O
an O
italian O
population O
based O
standardization O
scores O
in O
bold O
are O
below O
the O
cut O
off O
of O
normal O
##ity O
are O
##verse O
scores O
lower O
scores O
indicate O
better O
performances O
bb O
##elo O
##w O
10th O
percent O
##ile O
cbe O
##low O
1st O
percent O
##ile O
iv O
##m O
immediate O
visual O
memory O
m O
##ft O
##c O
multi O
##fe O
##at O
##ures O
targets O
cancellation O
mm O
##se O
mini O
mental O
state O
examination O
np O
not O
performed O
pm O
47 O
raven O
s O
progressive O
matrices O
47 O
ra O
##v O
##lt O
rey O
s O
auditory O
verbal O
learning O
test O
roc O
##f O
rey O
os O
##ter O
##rie O
##th O
complex O
ﬁ O
##gur O
##e O
wc O
##st O
wisconsin O
card O
sorting O
test O

from O
chair O
without O
assistance O
and O
slightly O
the O
ga O
##it O
so O
the O
patient O
started O
chronic O
therapy O
with O
l O
do O
##pa O
up O
to O
800 O
mg O
die O
with O
a O
mild O
improvement O
of O
brady O
##kin O
##es O
##ia O
ga O
##it O
and O
ap O
##athy O
table O
1 O
effect O
on O
cognitive O
functions O
table O
2 O
at O
baseline O
evaluation O
1 O
month O
before O
surgery O
the O
patient O
s O
cognitive O
pro O
##ﬁ O
##le O
was O
characterized O
mainly O
by O
d O
##yse O
##x O
##ec O
##utive O
syndrome O
on O
the O
ﬁ O
##rst O
follow O
up O
visit O
6 O
months O
after O
surgery O
the O
score O
of O
mini O
mental O
state O
examination O
worsened O
as O
did O
scores O
of O
test O
for O
executive O
functions O
scores O
of O
linguistic O
and O
memory O
task O

were O
lower O
as O
well O
on O
the O
second O
follow O
up O
visit O
1 O
year O
after O
surgery O
he O
performed O
worse O
on O
all O
executive O
tasks O
in O
comparison O
with O
both O
the O
baseline O
and O
1st O
follow O
up O
visits O
scores O
worsened O
also O
on O
ph O
##ono O
##logical O
ﬂ O
##uen O
##cy O
task O
and O
on O
elementary O
construction O
##al O
abilities O
discussion O
we O
have O
con O
##ﬁ O
##rmed O
that O
bilateral O
gp O
##i O
db O
##s O
produces O
a O
long O
term O
reduction O
of O
cho O
##rea O
due O
to O
hd O
despite O
the O
ben O
##e O
##ﬁ O
##t O
surgery O
has O
been O
related O
to O
worse O
##ning O
of O
ga O
##it O
ap O
##athy O
and O
decline O
of O
cognitive O
function O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##2 O
a O
fa O
##san O
##o O
et O
al O

legends O
to O
the O
video O
segment O
1 O
the O
patient O
6 O
months O
before O
surgery O
presents O
severe O
cho O
##rea O
of O
facial O
muscles O
trunk O
and O
limbs O
the O
patient O
is O
able O
to O
stand O
up O
without O
assistance O
and O
to O
walk O
for O
a O
few O
meters O
cho O
##rea O
of O
the O
lower O
limbs O
and O
impairment O
of O
post O
##ural O
stability O
as O
revealed O
by O
the O
retro O
##pu O
##ls O
##ion O
pull O
test O
des O
##ta O
##bil O
##ize O
him O
during O
walking O
segment O
2 O
three O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
180 O
hz O
provides O
a O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
especially O
of O
the O
lower O
limbs O
stimulation O
of O
ventral O
contacts O
causes O
head O
drop O

segment O
3 O
four O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
segment O
4 O
four O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
40 O
hz O
provides O
a O
reduction O
of O
cho O
##rea O
and O
an O
improvement O
of O
axial O
symptoms O
the O
patient O
is O
able O
to O
walk O
with O
un O
##ila O
##tera O
##l O
assistance O
segment O
5 O
nine O
months O
after O
surgery O
limbs O
cho O
##rea O
has O
disappeared O
while O
facial O
grimace O
##s O
are O
still O
pre O
##s O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##3 O

en O
##t O
despite O
the O
use O
of O
40 O
hz O
stimulation O
the O
patient O
cannot O
arise O
from O
chair O
and O
walk O
due O
to O
a O
severe O
start O
hesitation O
segment O
6 O
nine O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
only O
with O
very O
mild O
d O
##ys O
##kin O
##es O
##ias O
of O
upper O
limbs O
the O
patient O
is O
able O
to O
arise O
from O
chair O
and O
ga O
##it O
impairment O
is O
improved O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
supported O
in O
part O
by O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
grant O
line O
##a O
d O
##1 O
to O
ar O
##b O
af O
f O
##s O
and O
ar O
##b O
are O
members O
of O
euro O
hd O
network O
references O

cub O
##o O
e O
shannon O
km O
penn O
rd O
k O
##roi O
##n O
j O
##s O
internal O
g O
##lo O
##bus O
pal O
##lid O
##oto O
##my O
in O
d O
##yst O
##onia O
secondary O
to O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
124 O
##8 O
125 O
##1 O
vi O
##tek O
j O
##l O
jones O
r O
ba O
##ka O
##y O
re O
##a O
hers O
##ch O
sm O
pal O
##lid O
##oto O
##my O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2000 O
48 O
42 O
##9 O
bach O
##oud O
levi O
ac O
ga O
##ura O
v O
br O
##ug O
##iere O
##s O
p O
et O
al O
effect O
of O
fetal O
neural O
transplant O
##s O
in O
patients O
with O
huntington O
s O
disease O
6 O
years O
after O
surgery O
a O
long O
term O
follow O
up O
study O
lance O
##t O
ne O
##uro O
##l O
2006 O
5 O
303 O
309 O
mor O
##o O
e O
lang O
ae O
st O
##raf O
##ella O
ap O
et O
al O
bilateral O
g O
##lo O
##bus O
pal O
##lid O
##us O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O

jan O
her O
##zog O
md O
1 O
oliver O
po O
##gar O
##ell O
md O
2 O
marcus O
o O
pins O
##ker O
md O
3 O
andreas O
ku O
##ps O
##ch O
md O
phd O
4 O
wolfgang O
h O
o O
##ert O
##el O
md O
phd O
5 O
ol O
##le O
lin O
##d O
##val O
##l O
md O
phd O
6 O
gu O
##¨ O
##nt O
##her O
de O
##us O
##ch O
##l O
md O
phd O
1 O
and O
jens O
vol O
##km O
##ann O
md O
phd O
##1 O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
christian O
albrecht O
##s O
university O
kiel O
germany O
2d O
##ep O
##art O
##ment O
of O
psychiatry O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
christian O
albrecht O
##s O
university O
kiel O

germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
char O
##ite O
##´ O
humboldt O
university O
berlin O
germany O
5 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
philipp O
##s O
university O
mar O
##burg O
germany O
6 O
##section O
of O
rest O
##ora O
##tive O
ne O
##uro O
##logy O
wall O
##enberg O
neuroscience O
centre O
lund O
sweden O
video O
stimulation O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2004 O
56 O
290 O
294 O
he O
##bb O
mo O
garcia O
r O
ga O
##ude O
##t O
p O
mendez O
im O
bilateral O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
to O
treat O
cho O
##rea O
##the O
##tosis O
in O
huntington O
s O
disease O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
58 O
e O
##38 O
##3 O
lang O
ae O
surgery O
for O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##19 O
##3 O
s O
##19 O
##9 O

yi O
##ann O
##i O
j O
nan O
##di O
d O
bradley O
k O
et O
al O
sen O
##ile O
cho O
##rea O
treated O
by O
deep O
brain O
stimulation O
a O
clinical O
ne O
##uro O
##phy O
##sio O
##logical O
and O
functional O
imaging O
study O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
59 O
##7 O
60 O
##2 O
k O
##raus O
##s O
j O
##k O
lo O
##her O
t O
##j O
wei O
##gel O
r O
cape O
##lle O
h O
##h O
weber O
s O
bu O
##rg O
##under O
j O
##m O
chronic O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
treatment O
of O
non O
d O
##yt O
##1 O
generalized O
d O
##yst O
##onia O
and O
cho O
##re O
##oat O
##het O
##osis O
2 O
year O
follow O
up O
j O
ne O
##uro O
##sur O
##g O
2003 O
98 O
78 O
##5 O
79 O
##2 O
mor O
##o O
e O
es O
##sel O
##ink O
r O
##j O
xi O
##e O
j O
homme O
##l O
m O
ben O
##abi O
##d O
al O
poll O
##ak O
p O
the O
impact O
on O
parkinson O
s O
disease O
of O
electrical O
parameter O
settings O
in O
st O
##n O
stimulation O
ne O
##uro O
##logy O
2002 O
59 O
70 O
##6 O
71 O
##3 O

ko O
##ss O
am O
alter O
##man O
r O
##l O
tag O
##lia O
##ti O
m O
shi O
##ls O
j O
##l O
calculating O
total O
electrical O
energy O
delivered O
by O
deep O
brain O
stimulation O
systems O
ann O
ne O
##uro O
##l O
2005 O
58 O
168 O
huntington O
study O
group O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
reliability O
and O
consistency O
mo O
##v O
di O
##sor O
##d O
1996 O
11 O
136 O
142 O
go O
##etz O
c O
##g O
ste O
##bb O
##ins O
gt O
ch O
##mura O
ta O
fa O
##hn O
s O
k O
##law O
##ans O
h O
##l O
marsden O
cd O
teaching O
tape O
for O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
mo O
##v O
di O
##sor O
##d O
1995 O
10 O
263 O
266 O
con O
##tar O
##ino O
m O
##f O
daniel O
##e O
a O
si O
##bil O
##ia O
ah O
et O
al O
cognitive O
outcome O
5 O
years O
after O
bilateral O
chronic O
stimulation O
of O
sub O
##thal O
##ami O
##c O
nucleus O

key O
words O
parkinson O
s O
disease O
neural O
transplant O
##ation O
deep O
brain O
stimulation O
d O
##ys O
##kin O
##es O
##ias O
in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O
try O
2007 O
78 O
248 O
252 O
be O
##rard O
##elli O
a O
not O
##h O
j O
thomson O
pd O
et O
al O
path O
##op O
##hy O
##sio O
##logy O
of O
cho O
##rea O
and O
brady O
##kin O
##es O
##ia O
in O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
39 O
##8 O
403 O
ku O
##op O
##pa O
##ma O
##¨ O
##ki O
m O
roth O
##well O
jc O
brown O
r O
##g O
quinn O
n O
b O
##hat O
##ia O
k O
##p O
ja O
##han O
##shah O
##i O
m O
parkinson O
##ism O
following O
bilateral O
lesions O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
performance O
on O
a O
variety O
of O
motor O
tasks O
shows O
similarities O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
48 O
##2 O
490 O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
j O
vol O
##km O
##ann O
md O
phd O
department O
of O
ne O
##uro O
##logy O
un O
##iver O
##sit O
##a O
##¨ O
##tsk O
##lini O
##ku O
##m O
schleswig O
holstein O
campus O
kiel O
sc O
##hit O
##ten O
##helm O
##st O
##r O
10 O
241 O
##0 O
##5 O
kiel O
germany O
e O
mail O
j O
vol O
##km O
##ann O
ne O
##uro O
##logie O
un O
##i O
kiel O
de O
received O
31 O
may O
2007 O
revised O
28 O
august O
2007 O
accepted O
13 O
september O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##6 O
##8 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##4 O
j O
her O
##zog O
et O
al O

table O
1 O
characteristics O
of O
patients O
at O
baseline O
and O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
deep O
brain O
stimulation O
patient O
1 O
patient O
2 O
before O
transplant O
##ation O
up O
##dr O
##s O
iii O
med O
off O
74 O
49 O
med O
on O
24 O
14 O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O
item O
32 O
0 O
0 O
item O
33 O
0 O
0 O
medication O
mg O
d O
lev O
##od O
##opa O
1 O
400 O
lev O
##od O
##opa O
250 O
per O
##gol O
##ide O
0 O
5 O
de O
##pre O
##ny O
##l O
10 O
led O
##d O
mg O
1 O
400 O
mg O
400 O
mg O
before O
db O
##s O
following O
db O
##s O
follow O
up O
period O
3 O
y O
##r O
2 O
y O
##r O
up O
##dr O
##s O
iii O
50 O
28 O
st O
##im O
off O
med O
off O
st O
##im O
on O
med O
off O
33 O
11 O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
st O
##im O
on O
med O
off O
10 O
2 O
st O
##im O
on O
med O
on O
a O
4 O
d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O
item O
32 O
1 O
0 O
item O
33 O
2 O
0 O
medication O
mg O
d O

led O
##d O
mg O
0 O
0 O
persisted O
even O
after O
withdrawal O
of O
lev O
##od O
##opa O
l O
do O
##pa O
medication O
because O
of O
the O
d O
##ys O
##kin O
##etic O
states O
which O
are O
usually O
aggravated O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
ph O
##arm O
##aco O
##logical O
approaches O
are O
limited O
and O
db O
##s O
might O
be O
an O
alternative O
therapeutic O
option O
here O
we O
report O
the O
long O
term O
outcome O
in O
two O
patients O
with O
persistent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
graf O
##ting O
who O
later O
underwent O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
or O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
db O
##s O
case O
reports O
patient O
1 O

the O
transplant O
##ation O
initially O
resulted O
in O
am O
##eli O
##oration O
of O
off O
period O
symptoms O
subsequently O
he O
developed O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
cd O
##rs O
10 O
28 O
particularly O
on O
the O
left O
body O
side O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O
video O
##ta O
##pe O
because O
of O
ag O
##gra O
##vation O
of O
d O
##ys O
##kin O
##etic O
states O
by O
l O
do O
##pa O
cd O
##rs O
15 O
28 O
the O
use O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
had O
to O
be O
limited O
with O
the O
consequence O
of O
progressive O
decline O
in O
severity O
of O
off O
phase O
symptoms O
table O
1 O
and O
return O
stereo O
##ta O
##ctic O
coordinates O
x O
y O
z O
relative O
to O
mid O
##ac O
##pc O

r O
11 O
4 O
22 O
1 O
22 O
2 O
r O
21 O
3 O
4 O
5 O
23 O
6 O
l O
211 O
2 O
22 O
1 O
23 O
0 O
l O
220 O
5 O
1 O
9 O
22 O
4 O
of O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
which O
could O
not O
be O
con O
troll O
##ed O
by O
various O
therapeutic O
approaches O
because O
of O
prominent O
off O
phase O
symptoms O
and O
aa O
##ft O
##er O
st O
##n O
db O
##s O
patient O
1 O
refused O
assessment O
in O
the O
medication O
on O
condition O
up O
##dr O
##s O
iii O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
max O
108 O
cd O
##rs O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
max O
28 O
db O
##s O
deep O
brain O
stimulation O
led O
##d O
lev O
##od O
##opa O
equivalent O
daily O
dos O
##age O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##5 O
33 O
disability O
2 O
4 O
while O
the O
ben O
##e O
##ﬁ O
##t O
on O
off O
period O
symptoms O
was O
sustained O
patient O
2 O
the O
41 O
year O
old O
man O
pd O
since O
12 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
treated O
by O
staged O
bilateral O
neural O
transplant O
##ation O
with O
the O
second O
graf O
##t O
right O
st O
##ria O
##tum O
6 O
months O
after O
the O
ﬁ O
##rst O
graf O
##t O
cell O
preparation O
surgical O
procedure O
im O
##mun O
##os O
##up O
##press O
##ion O
and O
demonstration O
of O
long O
term O
graf O
##t O
survival O
were O
identical O
to O
patient O
1 O
1 O

because O
of O
the O
prominent O
hyper O
##kin O
##es O
##ias O
but O
relatively O
few O
off O
period O
symptoms O
8 O
years O
after O
bilateral O
graf O
##ting O
the O
patient O
was O
selected O
for O
bilateral O
gp O
##i O
db O
##s O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
2 O
28 O
in O
the O
formal O
assessment O
video O
##ta O
##pe O
in O
contrast O
the O
patient O
reported O
complete O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
during O
the O
day O
item O
32 O
und O
33 O
0 O
4 O
because O
off O
period O
symptoms O
were O
con O
##com O
##itan O
##tly O
improved O
up O
##dr O
##s O
iii O
11 O
108 O
in O
the O
formal O
assessment O
all O
do O
##pa O
##mine O
##rg O
##ic O
medication O
could O
be O
stopped O
discussion O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##6 O
j O
her O
##zog O
et O
al O

legends O
to O
the O
video O
segment O
1 O
patient O
1 O
before O
st O
##n O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
1 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
2 O
months O
before O
implant O
##ation O
of O
bilateral O
sub O
##thal O
##ami O
##c O
leads O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
presents O
with O
marked O
limb O
h O
##yp O
##oki O
##nesia O
and O
simultaneously O
intermittent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O

segment O
2 O
patient O
1 O
following O
st O
##n O
db O
##s O
medication O
off O
stimulation O
on O
three O
years O
following O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
the O
patient O
continues O
to O
show O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
segment O
3 O
patient O
2 O
before O
gp O
##i O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
2 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
3 O
months O
before O
implant O
##ation O
of O
bilateral O
leads O
within O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
shows O
limb O
h O
##yp O
##oki O
##nesia O
with O
intermittent O
d O
##ys O
##kin O
##es O
##ias O
accent O
##uated O
in O
the O
right O
hand O
and O
ﬁ O
##nger O
##s O

segment O
4 O
patient O
2 O
following O
gp O
##i O
db O
##s O
medication O
off O
stimulation O
on O
two O
years O
following O
pal O
##lid O
##al O
deep O
brain O
stimulation O
severity O
of O
d O
##ys O
##kin O
##es O
##ias O
in O
the O
medication O
off O
condition O
is O
reduced O
despite O
complete O
ce O
##ssa O
##tion O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
off O
period O
symptoms O
are O
su O
##f O
##ﬁ O
##cie O
##ntly O
alleviate O
##d O
by O
deep O
brain O
stimulation O
references O
br O
##und O
##in O
p O
po O
##gar O
##ell O
o O
ha O
##gel O
##l O
p O
et O
al O
bilateral O
ca O
##uda O
##te O
and O
put O
##amen O
graf O
##ts O
of O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
tissue O
treated O
with O
la O
##zar O
##oids O
in O
parkinson O
s O
disease O
brain O
2000 O
123 O
part O
7 O
138 O
##0 O
139 O
##0 O

freed O
cr O
greene O
pe O
breeze O
re O
et O
al O
transplant O
##ation O
of O
embryo O
##nic O
do O
##pa O
##mine O
neurons O
for O
severe O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2001 O
344 O
710 O
71 O
##9 O
ol O
##ano O
##w O
cw O
go O
##etz O
c O
##g O
ko O
##rdo O
##wer O
j O
##h O
et O
al O
a O
double O
blind O
controlled O
trial O
of O
bilateral O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
in O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
2003 O
54 O
403 O
41 O
##4 O
po O
##gar O
##ell O
o O
koch O
w O
gil O
##deh O
##aus O
f O
##j O
et O
al O
long O
term O
assessment O
of O
st O
##ria O
##tal O
do O
##pa O
##mine O
transport O
##ers O
in O
parkinson O
##ian O
patients O
with O
intra O
##st O
##ria O
##tal O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
graf O
##ts O
eu O
##r O
j O
nu O
##cl O
med O
mo O
##l O
imaging O
2006 O
33 O
407 O
411 O

cho O
c O
alter O
##man O
r O
##l O
mira O
##vite O
j O
et O
al O
sub O
##thal O
##ami O
##c O
db O
##s O
for O
the O
treatment O
of O
runaway O
d O
##ys O
##kin O
##es O
##ias O
after O
embryo O
##nic O
or O
fetal O
tissue O
transplant O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
123 O
##7 O
alter O
##man O
r O
##l O
shi O
##ls O
j O
##l O
gu O
##des O
##bla O
##tt O
m O
tag O
##lia O
##ti O
m O
immediate O
and O
sustained O
relief O
of O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
after O
dorsal O
relocation O
of O
a O
deep O
brain O
stimulation O
lead O
case O
report O
ne O
##uro O
##sur O
##g O
focus O
2004 O
17 O
e O
##6 O
mi O
##oc O
##ino O
##vic O
s O
parent O
m O
but O
##son O
cr O
et O
al O
computational O
analysis O
of O
sub O
##thal O
##ami O
##c O
nucleus O
and O
lent O
##icular O
fa O
##sc O
##ic O
##ulus O
activation O
during O
therapeutic O
deep O
brain O
stimulation O
j O
ne O
##uro O
##phy O
##sio O
##l O
2006 O
96 O
156 O
##9 O
1580 O

graf O
##f O
ra O
##df O
##ord O
j O
foot O
##e O
k O
##d O
rodriguez O
r O
##l O
et O
al O
deep O
brain O
stimulation O
of O
the O
internal O
segment O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
in O
delayed O
runaway O
d O
##ys O
##kin O
##es O
##ia O
arch O
ne O
##uro O
##l O
2006 O
63 O
118 O
##1 O
118 O
##4 O
winkler O
c O
ki O
##rik O
d O
b O
##jo O
##rk O
##lund O
a O
cell O
transplant O
##ation O
in O
parkinson O
s O
disease O
how O
can O
we O
make O
it O
work O
trends O
ne O
##uro O
##sc O
##i O
2005 O
28 O
86 O
92 O
ge O
##rf O
##en O
cr O
d O
##1 O
do O
##pa O
##mine O
receptor O
super O
##sen O
##sit O
##ivity O
in O
the O
do O
##pa O
##mine O
depleted O
st O
##ria O
##tum O
animal O
model O
of O
parkinson O
s O
disease O
ne O
##uro O
##sc O
##ient O
##ist O
2003 O
9 O
45 O
##5 O
46 O
##2 O

au O
##bert O
i O
gui O
##gon O
##i O
c O
ha O
##kan O
##sson O
k O
et O
al O
increased O
d O
##1 O
do O
##pa O
##mine O
receptor O
signaling O
in O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ia O
ann O
ne O
##uro O
##l O
2005 O
57 O
17 O
26 O
lo O
##zano O
am O
lang O
ae O
levy O
r O
et O
al O
ne O
##uron O
##al O
recordings O
in O
parkinson O
s O
disease O
patients O
with O
d O
##ys O
##kin O
##es O
##ias O
induced O
by O
ap O
##omo O
##rp O
##hine O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##14 O
##1 O
s O
##14 O
##6 O
vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
et O
al O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

mei O
##ss O
##ner O
w O
ha O
##rna O
##ck O
d O
ho O
##ess O
##le O
n O
et O
al O
high O
frequency O
stimulation O
of O
the O
en O
##top O
##ed O
##un O
##cular O
nucleus O
has O
no O
effect O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
transmission O
ne O
##uro O
##che O
##m O
int O
2004 O
44 O
281 O
286 O
tho O
##bo O
##is O
s O
fra O
##ix O
v O
sava O
##sta O
m O
et O
al O
chronic O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
and O
st O
##ria O
##tal O
d O
##2 O
do O
##pa O
##mine O
receptors O
in O
parkinson O
s O
disease O
a O
11 O
c O
ra O
##cl O
##op O
##ride O
pet O
study O
j O
ne O
##uro O
##l O
2003 O
250 O
121 O
##9 O
122 O
##3 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##7 O
lev O
##od O
##opa O
therapy O
in O
a O
les O
##ch O
ny O
##han O
disease O
patient O
path O
##ological O
bio O
##chemical O
ne O
##uro O
##ima O
##ging O
and O
therapeutic O
remarks O

mercedes O
serra O
##no O
md O
1 O
3 O
bel O
##en O
pe O
##´ O
##re O
##z O
md O
phd O
##1 O
3 O
aid O
##a O
or O
##ma O
##za O
##´ O
##bal O
phd O
2 O
3 O
rafael O
art O
##uch O
md O
phd O
2 O
3 O
ja O
##ume O
camp O
##isto O
##l O
md O
phd O
1 O
3 O
rosa O
j O
torres O
md O
phd O
4 O
and O
angels O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
md O
phd O
##1 O
3 O
1 O
##ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
2 O
##cl O
##ini O
##cal O
biochemistry O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
3 O
##cent O
##re O
for O
biomedical O
research O
on O
rare O
diseases O
ci O
##ber O
##er O
instituto O
de O
sal O
##ud O
carlos O
iii O
barcelona O
spain O
4 O
##di O
##vision O
of O
clinical O
biochemistry O
la O
paz O
university O
hospital O
madrid O
spain O
video O

key O
words O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
do O
##pa O
##mine O
les O
##ch O
ny O
##han O
disease O
lu O
##mba O
##r O
pun O
##cture O
mono O
##amine O
##s O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
caused O
by O
de O
##ﬁ O
##cie O
##nt O
activity O
of O
the O
enzyme O
h O
##yp O
##ox O
##ant O
##hine O
gu O
##ani O
##ne O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
tran O
##fera O
##se O
hp O
##rt O
bio O
this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
a O
ng O
##els O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
pediatric O
ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
pass O
##ei O
##g O
de O
sant O
joan O
de O
de O
##´ O
##u O
2 O
08 O
##9 O
##50 O
es O
##pl O
##ug O
##ues O
de O
ll O
##ob O
##re O
##gat O
barcelona O
spain O

e O
mail O
ag O
##ar O
##cia O
hs O
##j O
##db O
##c O
##n O
org O
received O
17 O
july O
2007 O
revised O
11 O
september O
2007 O
accepted O
26 O
september O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##86 O

we O
report O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
low O
do O
##pa O
##mine O
da O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
was O
started O
during O
the O
early O
stages O
of O
his O
ne O
##uro O
##dev O
##elo O
##pment O
clinical O
report O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##8 O
m O
serra O
##no O
et O
al O
table O
1 O
bio O
##genic O
amin O
##e O
and O
pt O
##erine O
concentrations O
in O
cs O
##f O
before O
treatment O
and O
follow O
up O
after O
l O
do O
##pa O
therapy O
l O
do O
##pa O
plus O
car O
##bid O
##opa O
and O
f O
##olin O
##ic O
acid O
di O
##tions O
video O
3 O
he O
is O
able O
to O
transfer O
objects O
between O
hands O
and O
do O
pin O
##cer O
grasping O
comprehension O
has O
always O
seemed O
to O
be O
preserved O
he O
never O
presented O
self O
in O
##ju O
##rio O
##us O
behavior O
the O
cs O
##f O
h O
##va O
concentration O
is O
now O
in O
the O
normal O
range O
table O
1 O
before O
treatment O
6 O
mg O
kg O
day O
age O
10 O
mo O
3 O
y O
##r O
4 O
mo O

h O
##va O
homo O
##vani O
##lli O
##c O
acid O
5 O
hi O
##aa O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
m O
##hp O
##h O
3 O
##met O
##ho O
##xy O
4 O
hydro O
##xy O
##ph O
##en O
##yl O
##gly O
##col O
numbers O
in O
brackets O
represent O
the O
age O
related O
controls O
values O
3 O

discussion O
we O
describe O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
clinical O
signs O
of O
impaired O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
the O
notable O
tremor O
the O
marked O
d O
##yst O
##onia O
developed O
during O
early O
infancy O
and O
the O
obvious O
sustained O
response O
to O
l O
do O
##pa O
led O
us O
to O
investigate O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
however O
some O
clinical O
characteristics O
such O
as O
the O
absence O
of O
o O
##cu O
##logy O
##ric O
crisis O
and O
the O
preservation O
of O
facial O
ge O
##stic O
##ulation O
did O
not O
ﬁ O
##t O
into O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
picture O

the O
role O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
development O
has O
recently O
been O
documented O
8 O
interesting O
##ly O
the O
early O
do O
##pa O
##mine O
##rg O
##ic O
input O
from O
the O
mid O
##bra O
##in O
may O
play O
an O
important O
role O
in O
the O
development O
of O
the O
basal O
gang O
##lia O
and O
cerebral O
cortex O
9 O
furthermore O
brain O
development O
has O
to O
be O
completed O
during O
the O
ﬁ O
##rst O
months O
of O
life O
when O
ax O
##onal O
and O
den O
##dr O
##itic O
branching O
is O
ongoing O
and O
syn O
##ap O
##to O
##genesis O
is O
just O
beginning O
da O
disturbances O
in O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##9 O
these O
ne O
##uro O
##dev O
##elo O
##pment O
##al O
periods O
may O
be O
crucial O
for O
further O
cn O
##s O
function O

response O
and O
to O
opt O
##imi O
##ze O
neurological O
outcome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
analysis O
may O
be O
a O
useful O
bio O
##chemical O
aid O
to O
select O
l O
##nd O
patients O
for O
l O
do O
##pa O
therapy O
and O
monitor O
their O
treatment O
further O
studies O
clinical O
observations O
and O
double O
blind O
trials O
are O
needed O
to O
establish O
the O
useful O
##ness O
of O
l O
do O
##pa O
in O
patients O
with O
l O
##nd O
legends O
to O
the O
video O
video O
1 O
frequent O
d O
##ys O
##kin O
##etic O
movements O
of O
the O
mouth O
and O
the O
ex O
##tre O
##mit O
##ies O
absence O
of O
voluntary O
grasping O
no O
head O
control O
explosive O
un O
##co O
##ord O
##inated O
movements O
video O
2 O
better O
head O
control O
able O
to O
pick O
up O
objects O
fine O
motor O
movements O
have O
improved O

video O
3 O
head O
control O
is O
fully O
reached O
d O
##yst O
##onic O
movements O
are O
clearly O
improved O
able O
to O
transfer O
objects O
between O
hands O
put O
rings O
in O
a O
bar O
and O
do O
pin O
##cer O
grasping O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fis O
grant O
pi O
##0 O
##51 O
##31 O
##8 O
and O
ci O
##ber O
er O
is O
##c O
iii O
we O
thank O
the O
patient O
and O
his O
family O
for O
their O
participation O
references O
jin O
##nah O
ha O
friedman O
##n O
t O
les O
##ch O
ny O
##han O
disease O
and O
its O
variants O
in O
sc O
##river O
cr O
beau O
##de O
##t O
al O
sly O
w O
##s O
valle O
d O
editors O
the O
metabolic O
and O
molecular O
bases O
of O
inherited O
disease O
8th O
ed O
new O
york O
mcgraw O
hill O
2001 O
p O
253 O
##7 O
257 O
##0 O

jin O
##nah O
ha O
vis O
##ser O
je O
harris O
jc O
et O
al O
del O
##ine O
##ation O
of O
the O
motor O
disorder O
of O
les O
##ch O
ny O
##han O
disease O
brain O
2006 O
129 O
120 O
##1 O
121 O
##7 O
or O
##ma O
##za O
##´ O
##bal O
a O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
a O
fern O
##a O
##´ O
##nde O
##z O
y O
fern O
##a O
##´ O
##nde O
##za O
##´ O
l O
##var O
##ez O
e O
camp O
##isto O
##l O
j O
art O
##uch O
r O
hp O
##lc O
with O
electro O
##chemical O
and O
ﬂ O
##uo O
##res O
##cence O
detection O
procedures O
for O
the O
diagnosis O
of O
in O
##born O
errors O
of O
bio O
##genic O
amin O
##es O
and O
pt O
##erine O
##s O
j O
ne O
##uro O
##sc O
##i O
methods O
2005 O
142 O
153 O
158 O
lloyd O
kg O
horn O
##yk O
##ie O
##wicz O
o O
davidson O
l O
et O
al O
bio O
##chemical O
evidence O
of O
dysfunction O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
the O
les O
##ch O
##ny O
##han O
syndrome O
n O
eng O
##l O
j O
med O
1981 O
305 O
110 O
##6 O
111 O
##1 O

sai O
##to O
y O
ito O
m O
hana O
##oka O
s O
oh O
##ama O
e O
aka O
##bos O
##hi O
s O
tak O
##ashi O
##ma O
s O
do O
##pa O
##mine O
receptor O
up O
##re O
##gul O
##ation O
in O
les O
##ch O
ny O
##han O
syndrome O
a O
post O
##mo O
##rte O
##m O
study O
ne O
##uro O
##ped O
##ia O
##trics O
1999 O
30 O
66 O
71 O
ernst O
m O
za O
##met O
##kin O
aj O
mat O
##och O
##ik O
ja O
et O
al O
pre O
##sy O
##na O
##ptic O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
##s O
in O
les O
##ch O
ny O
##han O
disease O
n O
eng O
j O
med O
1996 O
334 O
156 O
##8 O
157 O
##2 O
wong O
d O
##f O
harris O
jc O
na O
##id O
##u O
s O
et O
al O
do O
##pa O
##mine O
transport O
##ers O
are O
markedly O
reduced O
in O
les O
##ch O
ny O
##han O
disease O
in O
vivo O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1996 O
93 O
55 O
##39 O
55 O
##43 O
her O
##len O
##ius O
e O
la O
##ger O
##cr O
##ant O
##z O
h O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
and O
ne O
##uro O
##mo O
##du O
##lat O
##ors O
during O
early O
human O
development O
early O
hum O
dev O
2001 O
65 O
21 O
37 O

schmidt O
u O
bey O
##er O
c O
o O
##est O
##re O
##iche O
##r O
ab O
rei O
##ser O
##t O
i O
sc O
##hill O
##ing O
k O
pilgrim O
c O
activation O
of O
do O
##pa O
##mine O
##rg O
##ic O
d O
##1 O
receptors O
promotes O
mor O
##ph O
##ogen O
##esis O
of O
developing O
st O
##ria O
##tal O
neurons O
neuroscience O
1996 O
74 O
45 O
##3 O
460 O
caste O
##lls O
s O
cha O
##kra O
##bar O
##ti O
c O
wins O
##berg O
b O
##g O
hu O
##r O
##wi O
##c O
m O
pere O
##l O
j O
##m O
ny O
##han O
w O
##l O
effects O
of O
l O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
on O
mono O
##amine O
and O
amino O
acids O
turnover O
in O
the O
les O
##ch O
ny O
##han O
syndrome O
j O
autism O
dev O
di O
##sor O
##d O
1979 O
9 O
95 O
103 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
1300 O
s O
de O
##hn O
##ing O
et O
al O

cia O
##rane O
##llo O
rd O
anders O
t O
##f O
bar O
##cha O
##s O
jd O
berger O
pa O
can O
##n O
hm O
the O
use O
of O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
in O
a O
child O
with O
les O
##ch O
ny O
##han O
syndrome O
child O
psychiatry O
hum O
dev O
1976 O
7 O
127 O
133 O
jan O
##kovic O
j O
cas O
##key O
tc O
stout O
j O
##t O
butler O
i O
##j O
les O
##ch O
ny O
##han O
syndrome O
a O
study O
of O
motor O
behavior O
and O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
ann O
ne O
##uro O
##l O
1988 O
23 O
46 O
##6 O
46 O
##9 O
silver O
##stein O
f O
##s O
johnston O
mv O
hutchinson O
r O
##j O
edwards O
nl O
les O
##ch O
ny O
##han O
syndrome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
abnormalities O
ne O
##uro O
##logy O
1985 O
35 O
90 O
##7 O
911 O

watts O
r O
##we O
spell O
##acy O
e O
gibbs O
da O
all O
##sop O
j O
mc O
##ker O
##an O
ro O
sl O
##avi O
##n O
ge O
clinical O
post O
mort O
##em O
bio O
##chemical O
and O
therapeutic O
observations O
on O
the O
les O
##ch O
ny O
##han O
syndrome O
with O
particular O
reference O
to O
the O
neurological O
manifestation O
##s O
q O
##jm O
##ed O
1982 O
51 O
43 O
78 O
mi O
##zu O
##no O
t O
yu O
##gar O
##i O
y O
self O
mu O
##tila O
##tion O
in O
les O
##ch O
ny O
##han O
syndrome O
lance O
##t O
1974 O
1 O
76 O
##1 O
therapy O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
ben O
##e O
##ﬁ O
##cial O
outcome O
with O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
deep O
brain O
stimulation O
sandra O
de O
##hn O
##ing O
md O
1 O
jan O
hi O
##nne O
##rk O
me O
##hr O
##ken O
##s O
md O
2 O
nor O
##bert O
mu O
##¨ O
##ller O
phd O
1 O
and O
kai O
bo O
##¨ O
##tze O
##l O
md O
##3 O

1 O
##de O
##par O
##tment O
of O
psychiatry O
and O
psycho O
##therapy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
abstract O
we O
report O
on O
a O
female O
patient O
with O
tour O
##ette O
syndrome O
ts O
and O
a O
12 O
month O
follow O
up O
after O
chronic O
deep O
brain O
stimulation O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
which O
resulted O
in O
excellent O
re O
##mission O
of O
motor O
and O
vocal O
ti O
##cs O
2008 O
movement O
disorder O
society O
key O
words O
tour O
##ette O
syndrome O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O

tour O
##ette O
syndrome O
ts O
is O
a O
chronic O
and O
in O
severe O
cases O
de O
##bil O
##itating O
disorder O
characterized O
by O
motor O
and O
vocal O
ti O
##cs O
and O
additionally O
accompanied O
by O
features O
correspondence O
to O
dr O
sandra O
de O
##hn O
##ing O
psychiatric O
hospital O
of O
the O
ludwig O
maximilian O
##s O
university O
munich O
nu O
##bba O
##ums O
##tr O
7 O
munich O
d O
80 O
##33 O
##6 O
germany O
e O
mail O
sandra O
de O
##hn O
##ing O
med O
un O
##i O
mu O
##en O
##chen O
de O
received O
2 O
august O
2007 O
accepted O
29 O
november O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
219 O
##30 O

here O
we O
report O
on O
a O
female O
patient O
with O
ts O
and O
a O
12 O
##mont O
##h O
follow O
up O
study O
after O
chronic O
db O
##s O
of O
the O
gp O
##i O
case O
report O

for O
the O
last O
17 O
years O
the O
patient O
was O
continuously O
treated O
as O
in O
##patient O
and O
out O
##patient O
of O
our O
clinic O
and O
the O
diagnosis O
of O
ts O
was O
established O
according O
to O
the O
criteria O
of O
ds O
##m O
iv O
conventional O
medication O
attempts O
with O
a O
range O
of O
anti O
##psy O
##cho O
##tics O
over O
many O
years O
did O
not O
have O
any O
substantial O
effect O
ultimately O
the O
combination O
of O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
together O
with O
monthly O
out O
##patient O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
ec O
##t O
over O
the O
last O
5 O
years O
has O
led O
to O
a O
partial O
suppression O
of O
ti O
##cs O
the O
rational O
##e O
for O
ec O
##t O
was O
derived O
from O
case O
reports O
where O
a O
substantial O
improvement O
of O
ti O
##cs O
##13 O
14 O
was O
demonstrated O

previous O
the O
##ra O
##pies O
with O
a O
2 O
ad O
##ren O
##ore O
##ce O
##pt O
##or O
ago O
##nist O
##s O
do O
##pa O
##mine O
ago O
##nist O
##s O
and O
op O
##io O
##id O
ago O
##nist O
##s O
as O
well O
as O
alternative O
treatments O
like O
antibiotics O
im O
##mun O
##og O
##lo O
##bu O
##lins O
and O
plasma O
##pher O
##esis O
already O
described O
as O
possibly O
effective O
in O
single O
reports O
##15 O
only O
resulted O
in O
a O
temporary O
improvement O
of O
the O
ti O
##cs O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
tour O
##ette O
syndrome O
and O
deep O
brain O
stimulation O
130 O
##1 O

fig O
1 O
axial O
mri O
of O
the O
patient O
s O
brain O
showing O
the O
tip O
of O
the O
electrode O
##s O
6 O
mm O
below O
the O
level O
of O
the O
anterior O
and O
posterior O
com O
##mis O
##sure O
##s O
on O
the O
right O
the O
optic O
tract O
can O
be O
seen O
on O
which O
the O
electrode O
tip O
projects O
before O
stereo O
##ta O
##ctic O
intervention O
primary O
symptoms O
were O
severe O
grinding O
of O
her O
teeth O
beating O
her O
hips O
as O
well O
as O
persistent O
grunt O
##ing O
and O
qu O
##ack O
##ing O

120 O
l O
##s O
and O
frequency O
130 O
pp O
##s O
and O
slowly O
increased O
to O
3 O
2 O
v O
at O
discharge O
stimulation O
parameters O
were O
further O
increased O
3 O
months O
after O
stimulation O
3 O
5 O
v O
150 O
l O
##s O
145 O
pp O
##s O
4 O
months O
after O
implant O
##ation O
3 O
5 O
v O
180 O
l O
##s O
145 O
pp O
##s O
and O
at O
12 O
months O
after O
the O
implant O
##ation O
4 O
2 O
v O
210 O
l O
##s O
145 O
pp O
##s O
under O
this O
setting O
the O
current O
applied O
was O
94 O
la O
on O
each O
side O

in O
the O
ﬁ O
##rst O
few O
months O
after O
intervention O
the O
patient O
made O
frequent O
visits O
to O
our O
clinic O
as O
out O
##patient O
complaining O
of O
de O
##pressive O
moods O
vertigo O
and O
stomach O
ache O
##s O
at O
that O
time O
the O
patient O
emphasized O
having O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
adjusting O
to O
the O
new O
situation O
the O
absent O
necessity O
of O
being O
an O
in O
##patient O
and O
recognizing O
that O
the O
illness O
had O
been O
a O
big O
part O
of O
her O
life O
we O
supported O
her O
with O
regular O
out O
##patient O
appointments O
and O
centered O
psycho O
##ther O
##ape O
##uti O
##c O
interventions O
at O
present O
the O
patient O
is O
stabilized O
and O
has O
begun O
to O
engage O
in O
previously O
neglected O
activities O
such O
as O
horseback O
riding O
discussion O

we O
demonstrate O
full O
re O
##mission O
of O
ti O
##c O
symptoms O
after O
gp O
##i O
db O
##s O
in O
a O
patient O
suffering O
from O
intra O
##ctable O
ts O
table O
1 O
follow O
up O
of O
yale O
global O
ti O
##c O
severity O
scale O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##2 O
s O
de O
##hn O
##ing O
et O
al O

as O
demonstrated O
in O
patients O
with O
gp O
##i O
implant O
##s O
for O
d O
##yst O
##onia O
17 O
a O
low O
rate O
of O
side O
effects O
and O
a O
good O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
with O
this O
target O
has O
been O
established O
therefore O
we O
consider O
gp O
##i O
db O
##s O
as O
also O
very O
promising O
for O
the O
treatment O
of O
ts O
references O
muller O
n O
ri O
##ede O
##l O
m O
blending O
##er O
c O
obe O
##rle O
k O
jacobs O
e O
abel O
##eh O
##orn O
m O
my O
##co O
##pl O
##as O
##ma O
pneumonia O
##e O
infection O
and O
tour O
##ette O
s O
syndrome O
psychiatry O
res O
2004 O
129 O
119 O
125 O
robertson O
mm O
stern O
j O
##s O
gilles O
de O
la O
tour O
##ette O
syndrome O
sy O
##mpt O
##oma O
##tic O
treatment O
based O
on O
evidence O
eu O
##r O
child O
ad O
##oles O
##c O
psychiatry O
2000 O
9 O
su O
##pp O
##l O
1 O
i O
##60 O
i O
##75 O

de O
##hn O
##ing O
s O
ri O
##ede O
##l O
m O
muller O
n O
ari O
##pi O
##pr O
##az O
##ole O
in O
a O
patient O
vulnerable O
to O
side O
effects O
am O
j O
psychiatry O
2005 O
162 O
625 O
van O
##de O
##wall O
##e O
v O
van O
der O
lc O
gr O
##oe O
##ne O
##we O
##gen O
h O
##j O
ca O
##ema O
##ert O
j O
stereo O
##ta O
##ctic O
treatment O
of O
gilles O
de O
la O
tour O
##ette O
syndrome O
by O
high O
frequency O
stimulation O
of O
tha O
##lam O
##us O
lance O
##t O
1999 O
35 O
##3 O
72 O
##4 O
vis O
##ser O
van O
##de O
##wall O
##e O
v O
te O
##mel O
y O
boon O
p O
et O
al O
chronic O
bilateral O
tha O
##lam O
##ic O
stimulation O
a O
new O
therapeutic O
approach O
in O
intra O
##ctable O
tour O
##ette O
syndrome O
report O
of O
three O
cases O
j O
ne O
##uro O
##sur O
##g O
2003 O
99 O
109 O
##4 O
1100 O

serve O
##llo O
d O
port O
##a O
m O
sas O
##si O
m O
bram O
##bill O
##a O
a O
robertson O
mm O
deep O
brain O
stimulation O
in O
18 O
patients O
with O
severe O
gilles O
de O
la O
tour O
##ette O
syndrome O
ref O
##rac O
##tory O
to O
treatment O
the O
surgery O
and O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
in O
press O
fl O
##ah O
##erty O
aw O
williams O
z O
##m O
amir O
##nov O
##in O
r O
et O
al O
deep O
brain O
stimulation O
of O
the O
anterior O
internal O
capsule O
for O
the O
treatment O
of O
tour O
##ette O
syndrome O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
e O
##40 O
##3 O

ku O
##hn O
j O
lena O
##rt O
##z O
d O
mai O
j O
##k O
et O
al O
deep O
brain O
stimulation O
of O
the O
nucleus O
acc O
##umb O
##ens O
and O
the O
internal O
capsule O
in O
therapeutic O
##ally O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
j O
ne O
##uro O
##l O
2007 O
254 O
96 O
##3 O
96 O
##5 O
ac O
##ker O
##mans O
l O
te O
##mel O
y O
cat O
##h O
d O
et O
al O
deep O
brain O
stimulation O
in O
tour O
##ette O
s O
syndrome O
two O
targets O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
70 O
##9 O
71 O
##3 O
died O
##eric O
##h O
nj O
ka O
##lt O
##eis O
k O
st O
##amen O
##kovic O
m O
pier O
##i O
v O
ale O
##sch O
f O
e O
##f O
##ﬁ O
##cie O
##nt O
internal O
pal O
##lid O
##al O
stimulation O
in O
gilles O
de O
la O
tour O
##ette O
syndrome O
a O
case O
report O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
149 O
##6 O
149 O
##9 O
gallagher O
cl O
ga O
##rell O
pc O
montgomery O
e O
##b O
jr O
hem O
##i O
ti O
##cs O
and O
deep O
brain O
stimulation O
ne O
##uro O
##logy O
2006 O
66 O
e O
##12 O

ho O
##uet O
##o O
j O
##l O
karachi O
c O
mall O
##et O
l O
et O
al O
tour O
##ette O
s O
syndrome O
and O
deep O
brain O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
99 O
##2 O
99 O
##5 O
rap O
##op O
##ort O
m O
fed O
##er O
v O
sand O
##or O
p O
response O
of O
major O
depression O
and O
tour O
##ette O
s O
syndrome O
to O
ec O
##t O
a O
case O
report O
psycho O
##som O
med O
1998 O
60 O
52 O
##8 O
52 O
##9 O
sw O
##er O
##dlow O
nr O
gi O
##er O
##z O
m O
be O
##rk O
##ow O
##itz O
a O
ne O
##mir O
##off O
r O
lo O
##hr O
j O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
in O
a O
patient O
with O
severe O
ti O
##c O
and O
major O
de O
##pressive O
episode O
j O
cl O
##in O
psychiatry O
1990 O
51 O
34 O
35 O

per O
##lm O
##utter O
s O
##j O
lei O
##tman O
sf O
ga O
##r O
##vey O
ma O
et O
al O
therapeutic O
plasma O
exchange O
and O
intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
for O
ob O
##ses O
##sive O
##com O
##pu O
##ls O
##ive O
disorder O
and O
ti O
##c O
disorders O
in O
childhood O
lance O
##t O
1999 O
354 O
115 O
##3 O
115 O
##8 O
min O
##k O
j O
##w O
ne O
##uro O
##biology O
of O
basal O
gang O
##lia O
and O
tour O
##ette O
syndrome O
basal O
gang O
##lia O
circuits O
and O
tha O
##lam O
##oco O
##rti O
##cal O
outputs O
ad O
##v O
ne O
##uro O
##l O
2006 O
99 O
89 O
98 O

be O
##re O
##z O
##nai O
b O
ste O
##ude O
u O
see O
##los O
k O
bot O
##zel O
k O
chronic O
high O
frequency O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
stimulation O
in O
different O
types O
of O
d O
##yst O
##onia O
a O
clinical O
video O
and O
mri O
report O
of O
six O
patients O
presenting O
with O
segment O
##al O
cervical O
and O
generalized O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
138 O
144 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##3 O
novel O
complex O
interruption O
##s O
of O
the O
gaa O
repeat O
in O
small O
expanded O
all O
##eles O
of O
two O
affected O
siblings O
with O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O

catherine O
a O
st O
##oll O
##e O
phd O
1 O
edward O
c O
fra O
##cke O
##lton O
bs O
1 O
jennifer O
mccall O
##um O
ms O
1 O
jennifer O
m O
farmer O
ms O
2 O
amy O
ts O
##ou O
md O
2 O
robert O
b O
wilson O
md O
phd O
3 O
and O
david O
r O
lynch O
md O
phd O
##2 O
1 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
children O
s O
hospital O
of O
philadelphia O
philadelphia O
pennsylvania O
usa O
2 O
##the O
department O
of O
ne O
##uro O
##logy O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O
3 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O

key O
words O
dorsal O
column O
ata O
##xia O
triple O
##t O
repeat O
spa O
##stic O
##ity O
fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
characterized O
by O
progressive O
ata O
##xia O
and O
onset O
usually O
before O
the O
age O
of O
25 O
years O
1 O
most O
patients O
have O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
normal O
all O
##eles O
contain O
5 O
to O
33 O
repeats O
while O
prem O
##uta O
correspondence O
to O
dr O
david O
r O
lynch O
division O
of O
ne O
##uro O
##logy O
children O
s O
hospital O
of O
philadelphia O
50 O
##2 O
abrams O
##on O
building O
philadelphia O
pa O
1910 O
##4 O
43 O
##18 O
usa O
e O
mail O
lynch O
ph O
##arm O
med O
up O
##en O
##n O
ed O
##u O
received O
10 O
september O
2007 O
revised O
18 O
november O
2007 O
accepted O
9 O
february O
2008 O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##4 O
c O
a O
st O
##oll O
##e O
et O
al O
patients O
patient O
1a O

this O
patient O
presented O
at O
age O
74 O
with O
un O
##stead O
##y O
ga O
##it O
that O
had O
been O
slowly O
progressive O
for O
6 O
years O
she O
noted O
mild O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
her O
hands O
she O
had O
one O
brother O
with O
fa O
patient O
1a O
but O
no O
other O
family O
history O
of O
movement O
disorder O
on O
examination O
she O
had O
hyper O
##active O
re O
##ﬂ O
##ex O
##es O
and O
mildly O
increased O
tone O
in O
her O
upper O
ex O
##tre O
##mit O
##ies O
but O
normal O
lower O
ex O
##tre O
##mity O
re O
##ﬂ O
##ex O
##es O
she O
had O
decreased O
vi O
##bra O
##tory O
sensation O
in O
her O
feet O
but O
otherwise O
intact O
sensation O
strength O
and O
speech O
mild O
right O
sided O
d O
##ys O
##met O
##ria O
was O
present O
she O
had O
square O
wave O
jerk O
##s O
in O
primary O
position O
with O
h O
##yp O
##ometric O
sac O
##cade O
##s O
mri O
of O
the O
head O
and O
cervical O
spine O
revealed O
mild O
ce O
##re O
##bella O
##r O
and O
o O
##cci O
##pit O
##al O
lobe O
at O
##rop O
##hy O
with O
a O
chronic O
right O
posterior O
tha O
##lam O
##ic O
lac O
##una O
##r O
in O
##far O
##ct O
and O
mild O
cervical O
spinal O
cord O
compression O
molecular O
analysis O
of O
her O
fra O
##ta O
##xin O
gene O

patient O
5 O
this O
patient O
presented O
at O
48 O
years O
after O
10 O
years O
of O
variable O
hand O
and O
leg O
cl O
##ums O
##iness O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
sl O
##ur O
##red O
speech O
on O
examination O
she O
had O
ny O
##sta O
##gm O
##us O
table O
1 O
interrupted O
gaa O
repeat O
sequences O
from O
fa O
patients O
revealed O
gaa O
repeat O
lengths O
of O
1 O
00 O
##5 O
and O
104 O
patient O
1a O
and O
1b O
gaa O
72 O
##1 O
gaga O
##a O
1 O
gaa O
##aa O
1 O
gaa O
201 O
gaa O
##aa O
1 O
gaa O
1 O
gag O
##ga O
##a O
4 O
1 O
gaa O
12 O
patient O
2 O

this O
patient O
presented O
with O
progressive O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
balance O
and O
coordination O
at O
age O
41 O
on O
initial O
examination O
at O
age O
48 O
prop O
##rio O
##ception O
was O
normal O
and O
re O
##ﬂ O
##ex O
##es O
were O
21 O
in O
the O
arms O
and O
legs O
over O
the O
next O
9 O
years O
he O
developed O
d O
##ys O
##arth O
##ria O
d O
##ys O
##met O
##ria O
diminished O
prop O
##rio O
##ception O
in O
the O
arms O
and O
legs O
spa O
##stic O
##ity O
and O
diffuse O
hyper O
##re O
##ﬂ O
##ex O
##ia O
with O
cl O
##onus O
and O
ex O
##tens O
##or O
plant O
##ar O
responses O
mri O
of O
the O
brain O
revealed O
mild O
ve O
##rmi O
##an O
at O
##rop O
##hy O
genetic O
testing O
of O
the O
fr O
##da O
gene O
revealed O
gaa O
repeat O
lengths O
of O
115 O
and O
1 O
02 O
##5 O
patient O
2 O
gaa O
89 O
1 O
gaga O
##a O
1 O
gaa O
41 O
gaga O
##a O
1 O
gaa O
41 O
gaa O
##aa O
1 O
gaa O
13 O

patient O
3 O
gaa O
78 O
##1 O
gaa O
##aa O
1 O
gaa O
171 O
gaa O
##aa O
1 O
gaa O
1 O
gag O
##ga O
##a O
5 O
1 O
gaa O
12 O
patient O
4 O
gaa O
103 O
##1 O
gaa O
##aga O
##a O
1 O
gaa O
15 O
patient O
5 O
gaa O
130 O
##1 O
aaa O

the O
number O
of O
gaa O
repeats O
plus O
the O
location O
and O
the O
sequence O
of O
repeat O
interruption O
##s O
are O
indicated O
the O
number O
of O
gaa O
repeats O
at O
the O
50 O
end O
represents O
a O
minimum O
repeat O
number O
since O
sequence O
analysis O
did O
not O
reach O
the O
50 O
non O
##re O
##pe O
##at O
sequence O
interruption O
##s O
clustered O
in O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
followed O
by O
short O
gaa O
repeats O
in O
all O
of O
the O
patients O
except O
no O
5 O
interruption O
##s O
are O
designated O
to O
be O
consistent O
with O
those O
previously O
id O
##ent O
##i O
##ﬁ O
##ed O
gag O
##ga O
##a O
ref O
7 O
gaa O
##aga O
##a O
ref O
8 O
gaa O
##aa O
ref O
9 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##5 O

table O
2 O
repeat O
lengths O
and O
age O
of O
onset O
for O
patients O
1 O
5 O
patient O
repeat O
lengths O
as O
id O
##ent O
##i O
##ﬁ O
##ed O
by O
pc O
##r O
estimate O
and O
maximum O
number O
based O
on O
sequencing O
d O
##ys O
##arth O
##ria O
and O
severe O
d O
##ys O
##met O
##ria O
re O
##ﬂ O
##ex O
##es O
were O
absent O
except O
for O
the O
tri O
##ce O
##ps O
jerk O
##s O
prop O
##rio O
##ception O
and O
vi O
##bra O
##tory O
sensation O
were O
decreased O
and O
her O
ga O
##it O
was O
wide O
based O
mri O
of O
the O
brain O
was O
normal O
analysis O
of O
her O
fr O
##da O
gene O
revealed O
gaa O
repeat O
expansion O
##s O
of O
290 O
and O
850 O
results O

based O
on O
previous O
reports O
suggesting O
small O
interruption O
##s O
in O
the O
gaa O
repeat O
in O
some O
patients O
with O
very O
late O
onset O
of O
fa O
we O
sequence O
##d O
the O
gaa O
repeat O
region O
in O
a O
series O
of O
patients O
table O
1 O
in O
sibling O
patients O
1a O
and O
1b O
identical O
interruption O
##s O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
gaa O
repeat O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
repeat O
was O
72 O
bases O
in O
other O
patients O
with O
short O
gaa O
repeats O
similar O
interruption O
##s O
in O
the O
30 O
end O
of O
the O
gaa O
repeat O
were O
found O
in O
three O
of O
four O
but O
the O
interruption O
##s O
were O
less O
complex O
one O
patient O
had O
only O
a O
single O
aaa O
sequence O
at O
the O
30 O
end O
of O
the O
gaa O
repeat O
7 O
9 O

we O
then O
correlated O
age O
of O
onset O
with O
presence O
or O
absence O
of O
interruption O
##s O
table O
2 O
fig O
1 O
two O
of O
5 O
patients O
patients O
1a O
and O
1b O
with O
interruption O
##s O
presented O
later O
than O
that O
expected O
based O
on O
the O
correlation O
of O
total O
gaa O
repeat O
length O
with O
age O
of O
onset O
from O
a O
large O
american O
co O
##hort O
10 O
but O
3 O
patients O
patients O
2 O
3 O
and O
4 O
had O
an O
age O
of O
onset O
similar O
to O
or O
only O
slightly O
later O
than O
that O
predicted O
based O
on O
the O
overall O
co O
##hort O
see O
fig O
1 O
the O
patient O
with O
the O
isolated O
aaa O
at O
the O
30 O
end O
of O
an O
interrupted O
repeat O
patient O
5 O
presented O

slightly O
later O
than O
the O
expected O
age O
similarly O
the O
total O
maximal O
un O
##int O
##er O
##rup O
##ted O
length O
did O
not O
co O
##rre O
##late O
substantially O
better O
with O
age O
of O
onset O
this O
suggests O
that O
the O
presence O
of O
interruption O
##s O
does O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
affect O
age O
of O
onset O
discussion O
in O
this O
work O
a O
variety O
of O
small O
expanded O
all O
##eles O
of O
the O
fr O
##da O
gene O
had O
an O
altered O
sequence O
compared O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##6 O
c O
a O
st O
##oll O
##e O
et O
al O

ac O
##k O
##now O
##led O
##gm O
##ents O
dr O
lynch O
is O
supported O
by O
grants O
from O
the O
fried O
##re O
##ich O
ata O
##xia O
research O
alliance O
and O
the O
muscular O
d O
##yst O
##rop O
##hy O
association O
we O
wish O
to O
thank O
the O
clinical O
research O
network O
for O
fried O
##re O
##ich O
ata O
##xia O
for O
providing O
access O
to O
data O
on O
the O
fa O
co O
##hort O
references O
du O
##rr O
a O
co O
##ssee O
m O
ag O
##id O
y O
et O
al O
clinical O
and O
genetic O
abnormalities O
in O
patients O
with O
fried O
##re O
##ich O
s O
ata O
##xia O
n O
eng O
##l O
j O
med O
1996 O
335 O
116 O
##9 O
117 O
##5 O

sa O
##kam O
##oto O
n O
oh O
##shima O
k O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
sticky O
dna O
a O
self O
associated O
complex O
formed O
at O
long O
gaa O
tt O
##c O
repeats O
in O
intro O
##n O
1 O
of O
the O
fra O
##ta O
##xin O
gene O
inhibit O
##s O
transcription O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##1 O
271 O
##7 O
##7 O
monte O
##rmin O
##i O
l O
richter O
a O
morgan O
k O
et O
al O
ph O
##eno O
##typic O
variability O
in O
fried O
##re O
##ich O
ata O
##xia O
role O
of O
the O
associated O
gaa O
triple O
##t O
repeat O
expansion O
ann O
ne O
##uro O
##l O
1997 O
41 O
67 O
##5 O
68 O
##2 O
b O
##hid O
##aya O
##sir O
##i O
r O
per O
##lman O
sl O
pu O
##ls O
##t O
sm O
ge O
##sch O
##wind O
dh O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O
ph O
##eno O
##typic O
analysis O
magnetic O
resonance O
imaging O
ﬁ O
##nding O
##s O
and O
review O
of O
the O
literature O
arch O
ne O
##uro O
##l O
2005 O
62 O
1865 O
1869 O

mc O
##dan O
##iel O
do O
ke O
##ats O
b O
ve O
##dana O
##raya O
##nan O
v O
##v O
sub O
##ram O
##ony O
sh O
sequence O
variation O
in O
gaa O
repeat O
expansion O
##s O
may O
cause O
differential O
ph O
##eno O
##type O
display O
in O
fried O
##re O
##ich O
s O
ata O
##xia O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
115 O
##3 O
115 O
##8 O
camp O
##uz O
##ano O
v O
monte O
##rmin O
##i O
l O
mo O
##lto O
md O
et O
al O
fried O
##re O
##ich O
s O
ata O
##xia O
auto O
##som O
##al O
recess O
##ive O
disease O
caused O
by O
an O
intro O
##nic O
gaa O
triple O
##t O
repeat O
expansion O
science O
1996 O
271 O
142 O
##3 O
142 O
##7 O
monte O
##rmin O
##i O
l O
and O
##erman O
##n O
e O
lab O
##uda O
m O
et O
al O
the O
fried O
##re O
##ich O
ata O
##xia O
gaa O
triple O
##t O
repeat O
prem O
##utation O
and O
normal O
all O
##eles O
hum O
mo O
##l O
gene O
##t O
1997 O
6 O
126 O
##1 O
126 O
##6 O

co O
##ssee O
m O
sc O
##hmi O
##tt O
m O
camp O
##uz O
##ano O
v O
re O
##ute O
##na O
##uer O
l O
mo O
##uto O
##u O
c O
man O
##del O
j O
##l O
ko O
##eni O
##g O
m O
evolution O
of O
the O
fried O
##re O
##ich O
s O
ata O
##xia O
tri O
##nu O
##cle O
##otide O
repeat O
expansion O
founder O
effect O
and O
prem O
##utation O
##s O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1997 O
94 O
74 O
##52 O
74 O
##57 O
sa O
##kam O
##oto O
n O
larson O
je O
i O
##yer O
rr O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
g O
##ga O
tc O
##c O
interrupted O
triple O
##ts O
in O
long O
gaa O
tt O
##c O
repeats O
inhibit O
the O
formation O
of O
triple O
##x O
and O
sticky O
dna O
structures O
alleviate O
transcription O
inhibition O
and O
reduce O
genetic O
ins O
##ta O
##bilities O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##8 O
271 O
##8 O
##7 O

lynch O
dr O
farmer O
j O
##m O
ts O
##ou O
a O
##y O
et O
al O
measuring O
fried O
##re O
##ich O
ata O
##xia O
complementary O
features O
of O
examination O
and O
performance O
measures O
ne O
##uro O
##logy O
2006 O
66 O
1711 O
1716 O
charles O
p O
cam O
##uz O
##at O
a O
ben O
##am O
##mar O
n O
et O
al O
are O
interrupted O
sc O
##a O
##2 O
ca O
##g O
repeat O
expansion O
##s O
responsible O
for O
parkinson O
##ism O
ne O
##uro O
##logy O
2007 O
69 O
1970 O
1975 O
sob O
##cz O
##ak O
k O
k O
##ry O
##zos O
##ia O
##k O
w O
##j O
ca O
##g O
repeats O
containing O
ca O
##a O
interruption O
##s O
form O
branched O
hair O
##pin O
structures O
in O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
2 O
transcript O
##s O
j O
bio O
##l O
che O
##m O
2005 O
280 O
38 O
##9 O
##8 O
39 O
##10 O

cho O
##ud O
##hr O
##y O
s O
mu O
##ker O
##ji O
m O
sri O
##vas O
##ta O
##va O
ak O
jain O
s O
bra O
##hma O
##cha O
##ri O
sk O
ca O
##g O
repeat O
instability O
at O
sc O
##a O
##2 O
locus O
anchor O
##ing O
ca O
##a O
interruption O
##s O
and O
linked O
single O
nu O
##cle O
##otide O
poly O
##morphism O
##s O
hum O
mo O
##l O
gene O
##t O
2001 O
10 O
243 O
##7 O
244 O
##6 O
mats O
##u O
##ura O
t O
fang O
p O
pearson O
ce O
jaya O
##kar O
p O
ash O
##iza O
##wa O
t O
ro O
##a O
bb O
nelson O
dl O
interruption O
##s O
in O
the O
expanded O
at O
##tc O
##t O
repeat O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
10 O
repeat O
purity O
as O
a O
disease O
mod O
##i O
##ﬁ O
##er O
am O
j O
hum O
gene O
##t O
2006 O
78 O
125 O
129 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
130 O
##7 O
on O
the O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

jan O
st O
##och O
##l O
phd O
msc O
1 O
anne O
boom O
##sma O
phd O
2 O
ev O
##zen O
ru O
##zic O
##ka O
md O
ds O
##c O
3 O
hana O
bro O
##zo O
##va O
md O
3 O
and O
pet O
##r O
blah O
##us O
ds O
##c O
##1 O
1 O
##de O
##par O
##tment O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
prague O
czech O
republic O
2d O
##ep O
##art O
##ment O
of O
sociology O
statistics O
and O
measurement O
theory O
university O
of O
groningen O
groningen O
the O
netherlands O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
charles O
university O
movement O
disorders O
centre O
prague O
czech O
republic O

correspondence O
to O
dr O
jan O
st O
##och O
##l O
department O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
jose O
##´ O
mart O
##´ O
##ı O
##ho O
31 O
c O
##z O
162 O
52 O
prague O
czech O
republic O
e O
mail O
st O
##och O
##l O
ft O
##vs O
cu O
##ni O
c O
##z O
received O
16 O
november O
2007 O
revised O
22 O
january O
2008 O
accepted O
17 O
february O
2008 O
published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##29 O

instead O
of O
e O
##fa O
we O
used O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
cfa O
within O
a O
se O
##m O
framework O
to O
perform O
a O
statistical O
test O
and O
to O
evaluate O
a O
number O
of O
plausible O
factor O
models O
for O
the O
structure O
of O
symptoms O
underlying O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
some O
se O
##m O
est O
##ima O
##tors O
are O
designed O
for O
or O
##dina O
##l O
measurements O
and O
thus O
in O
principle O
suited O
for O
analyzing O
that O
structure O
patients O
and O
methods O
sample O

the O
study O
includes O
405 O
consecutive O
patients O
237 O
men O
168 O
women O
mean O
age O
61 O
range O
35 O
80 O
years O
with O
pd O
diagnosed O
according O
to O
current O
clinical O
criteria O
9 O
each O
patient O
was O
evaluated O
by O
one O
member O
of O
a O
group O
of O
ce O
##rti O
##ﬁ O
##ed O
ne O
##uro O
##logists O
movement O
disorder O
specialists O
who O
routinely O
use O
the O
up O
##dr O
##s O
sixty O
patients O
were O
examined O
in O
de O
##ﬁ O
##ned O
off O
state O
and O
310 O
patients O
in O
de O
##ﬁ O
##ned O
on O
state O
for O
35 O
patients O
the O
motor O
state O
during O
evaluation O
was O
not O
spec O
##i O
##ﬁ O
##ed O
this O
data O
consists O
of O
two O
sub O
##sam O
##ples O
the O
ﬁ O
##rst O
sub O
##sam O
##ple O
of O
size O
n O
5 O
147 O
96 O
men O
38 O
off O
30 O
on O

28 O
unknown O
and O
51 O
women O
15 O
off O
29 O
on O
7 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##8 O
j O
st O
##och O
##l O
et O
al O
unknown O
was O
obtained O
at O
the O
movement O
disorder O
centre O
charles O
university O
prague O
czech O
republic O
the O
second O
of O
size O
n O
5 O
258 O
141 O
men O
1 O
off O
140 O
on O
and O
117 O
women O
6 O
off O
111 O
on O
was O
acquired O
at O
the O
university O
medical O
centre O
groningen O
in O
the O
netherlands O
methods O

a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
for O
the O
ﬁ O
##nal O
model O
described O
here O
the O
path O
diagram O
with O
standardized O
parameter O
estimates O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
goodness O
of O
ﬁ O
##t O
statistics O
and O
indices O
a O
summary O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
and O
the O
ﬁ O
##tted O
residual O
matrix O
are O
reported O
for O
details O
see O
ref O
13 O
results O

although O
some O
ﬁ O
##tted O
residual O
##s O
see O
table O
1 O
remained O
high O
the O
ﬁ O
##t O
statistics O
and O
indices O
suggest O
that O
this O
model O
need O
not O
to O
be O
rejected O
generally O
the O
values O
of O
comparative O
ﬁ O
##t O
index O
cf O
##i O
and O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
suggest O
a O
very O
acceptable O
ﬁ O
##t O
whereas O
root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
and O

the O
four O
factors O
of O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
speech O
h O
##yp O
##omi O
##mia O
and O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
are O
correlated O
which O
is O
meaningful O
from O
a O
theoretical O
point O
of O
view O
the O
correlation O
##s O
range O
between O
0 O
54 O
and O
0 O
85 O
see O
fig O
1 O
indicating O
rather O
substantial O
relationships O
among O
these O
sy O
##mpt O
##om O
factors O
tremor O
however O
seems O
to O
be O
a O
pd O
sy O
##mpt O
##om O
occurring O
independently O
of O
other O
motor O
pd O
sy O
##mpt O
##om O
factors O
goodness O
of O
fit O
statistics O
and O
indices O
sample O
size O
405 O
degrees O
of O
freedom O
300 O
sato O
##rra O
bent O
##ler O
s O
scaled O
v O
##2 O
stat O
##istic O
89 O
##9 O
33 O
p O
5 O
0 O
0 O

root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
0 O
07 O
##0 O
90 O
con O
##ﬁ O
##den O
##ce O
interval O
for O
rms O
##ea O
0 O
06 O
##5 O
0 O
07 O
##6 O
norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
0 O
96 O
comparative O
ﬁ O
##t O
index O
cf O
##i O
0 O
97 O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
0 O
07 O
##7 O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
0 O
99 O
fitted O
residual O
##s O
range O
20 O
40 O
0 O
34 O
median O
0 O
04 O
standard O
deviation O
0 O
07 O
discussion O
in O
this O
study O
the O
structure O
of O
motor O
symptoms O
of O
pd O
was O
investigated O
by O
applying O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
models O
to O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

153 O
##18 O
##25 O
##7 O
2008 O
9 O
downloaded O
from O
https O
movement O
##dis O
##ord O
##ers O
online O
##lib O
##rar O
##y O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O
by O
the O
university O
of O
manchester O
wiley O
online O
library O
on O
22 O
05 O
202 O
##5 O
see O
the O
terms O
and O
conditions O
https O
online O
##lib O
##rar O
##y O
wiley O
com O
terms O
and O
conditions O
on O
wiley O
online O
library O
for O
rules O
of O
use O
o O
##a O
articles O
are O
governed O
by O
the O
applicable O
creative O
commons O
license O
table O
1 O
poly O
##cho O
##ric O
correlation O
##s O
below O
diagonal O
and O
ﬁ O
##tted O
residual O
##s O
above O
diagonal O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

speech O
facial O
lips O
##chin O
##tr O
##ru O
##et O
##rl O
##uet O
##rr O
##let O
##rl O
##lea O
##tr O
##rh O
##anda O
##tr O
##l O
##hand O
##ri O
##gi O
##dity O
rue O
lu O
##e O
r O
##le O
ll O
##e O
fr O
##hand O
##fl O
##hand O
hr O
##hand O
##hl O
##hand O
##rr O
##hand O
##rl O
##hand O
l O
##rle O
##g O
ll O
##leg O
arising O
##post O
##ure O
ga O
##it O
stab O
##il O
body O
##bra O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
131 O
##1 O
the O
models O
were O
estimated O
using O
the O
d O
##wl O
##s O
est O
##ima O
##tor O
mainly O
because O
of O
the O
or O
##dina O
##l O
measurement O
level O
of O
the O
items O
and O
the O
relatively O
small O
sample O
size O

since O
a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
implying O
a O
partly O
ex O
##pl O
##ora O
##tory O
result O
future O
cross O
validation O
is O
necessary O
to O
challenge O
our O
ﬁ O
##nal O
factor O
structure O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
it O
should O
also O
be O
realized O
that O
larger O
sample O
sizes O
would O
make O
model O
estimation O
results O
especially O
when O
considering O
the O
or O
##dina O
##l O
character O
of O
item O
responses O
more O
reliable O
and O
ﬁ O
##nal O
conclusions O
more O
valid O

ac O
##k O
##now O
##led O
##gm O
##ents O
we O
are O
obliged O
to O
doctors O
jan O
roth O
pet O
##r O
me O
##ci O
##r O
robert O
je O
##ch O
ter O
##eza O
serra O
##nova O
and O
olga O
ul O
##man O
##ova O
who O
performed O
up O
##dr O
##s O
testing O
in O
some O
cases O
we O
are O
also O
grateful O
to O
prof O
dr O
k O
l O
lee O
##nder O
##s O
and O
mrs O
w O
j O
st O
##aa O
##l O
groningen O
for O
their O
helpful O
comments O
to O
the O
manuscript O
jan O
st O
##och O
##l O
was O
supported O
by O
mobility O
fund O
of O
charles O
university O
czech O
science O
foundation O
grant O
no O
406 O
07 O
p O
##51 O
##3 O
ministry O
of O
education O
youth O
and O
sports O
grant O
no O
ms O
##m O
00 O
##21 O
##6 O
##20 O
##86 O
##4 O
and O
foundation O
of O
josef O
marie O
a O
h O
##la O
##´ O
##v O
##kov O
##y O
##´ O
##ch O
references O

cub O
##o O
e O
ste O
##bb O
##ins O
gt O
go O
##lb O
##e O
li O
et O
al O
application O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
factor O
analysis O
of O
the O
motor O
scale O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
276 O
279 O
ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
factor O
structure O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
motor O
examination O
section O
mo O
##v O
di O
##sor O
##d O
1998 O
13 O
63 O
##3 O
63 O
##6 O
ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
lang O
ae O
cub O
##o O
e O
factor O
analysis O
of O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
during O
the O
off O
state O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
58 O
##5 O
58 O
##9 O

martinez O
martin O
p O
gil O
na O
##gel O
a O
gr O
##ac O
##ia O
l O
##m O
gomez O
j O
##b O
martinez O
sar O
##ries O
j O
be O
##rm O
##ej O
##o O
f O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
characteristics O
and O
structure O
the O
cooperative O
multi O
##centric O
group O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
76 O
83 O
dun O
##tem O
##an O
g O
##h O
principal O
component O
analysis O
newbury O
park O
sage O
1989 O
hi O
##guchi O
i O
e O
##guchi O
s O
robust O
principal O
component O
analysis O
with O
adaptive O
selection O
for O
tuning O
parameters O
j O
machine O
learn O
res O
2004 O
5 O
45 O
##3 O
47 O
##1 O
elias O
##on O
sr O
maximum O
likelihood O
estimation O
logic O
and O
practice O
iowa O
sage O
1993 O

boom O
##sma O
a O
ho O
##og O
##land O
jj O
the O
robust O
##ness O
of O
li O
##sr O
##el O
modeling O
revisited O
in O
cu O
##deck O
r O
to O
##it O
s O
so O
##¨ O
##rb O
##om O
d O
editors O
structural O
equation O
modeling O
present O
and O
future O
a O
fest O
##sch O
##rift O
in O
honour O
of O
karl O
jo O
##¨ O
##res O
##ko O
##g O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2001 O
p O
139 O
168 O
hughes O
aj O
daniel O
se O
ki O
##lford O
l O
lee O
##s O
aj O
accuracy O
of O
clinical O
diagnosis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
a O
clinic O
##o O
path O
##ological O
study O
of O
100 O
cases O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1992 O
55 O
181 O
184 O
jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
li O
##sr O
##el O
8 O
72 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2005 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
online O
help O
ﬁ O
##le O
for O
li O
##sr O
##el O
8 O
72 O
for O
windows O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2004 O
jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
pre O
##lis O
2 O
54 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2002 O
j O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
phd O
thesis O
charles O
university O
prague O
2005 O
cr O
##on O
##bach O
l O
##j O
sc O
##ho O
##¨ O
##nem O
##ann O
p O
mc O
##kie O
d O
alpha O
coe O
##f O
##ﬁ O
##cie O
##nts O
for O
st O
##rat O
##i O
##ﬁ O
##ed O
parallel O
tests O
ed O
##uc O
psycho O
##l O
me O
##as O
1965 O
25 O
291 O
312 O

mart O
##ignon O
##i O
e O
fran O
##chi O
##gnon O
##i O
f O
pas O
##etti O
c O
fe O
##rrier O
##o O
g O
pic O
##co O
d O
psycho O
##metric O
properties O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
and O
of O
the O
short O
parkinson O
s O
evaluation O
scale O
ne O
##uro O
##l O
sci O
2003 O
24 O
190 O
191 O
k O
##ro O
##one O
##nberg O
pm O
o O
##ort O
f O
##j O
ste O
##bb O
##ins O
gt O
le O
##urg O
##ans O
se O
cub O
##o O
e O
go O
##etz O
c O
##g O
motor O
function O
in O
parkinson O
s O
disease O
and O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
simultaneous O
factor O
analysis O
of O
a O
clinical O
scale O
in O
several O
populations O
b O
##mc O
med O
res O
method O
2006 O
26 O
1 O
13 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##2 O
d O
r O
williams O
et O
al O

poe O
##we O
w O
##h O
wen O
##ning O
g O
##k O
the O
natural O
history O
of O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
1998 O
44 O
3 O
su O
##pp O
##l O
1 O
s O
##1 O
s O
##9 O
henderson O
l O
ken O
##nard O
c O
crawford O
t O
scales O
for O
rating O
motor O
impairment O
in O
parkinson O
s O
disease O
studies O
of O
reliability O
and O
converge O
##nt O
validity O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1991 O
54 O
18 O
24 O
reynolds O
n O
montgomery O
g O
factor O
analysis O
of O
parkinson O
s O
impairment O
an O
evaluation O
of O
the O
ﬁ O
##nal O
common O
pathway O
arch O
ne O
##uro O
##l O
1987 O
44 O
101 O
##3 O
1016 O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
david O
r O
williams O
phd O
fra O
##cp O
1 O
2 O
max O
cow O
##ey O
bsc O
2 O
kate O
tuck O
bsc O
2 O
and O
bruce O
day O
fra O
##cp O
##2 O

1 O
##fa O
##cu O
##lty O
of O
medicine O
neuroscience O
##s O
mona O
##sh O
university O
alfred O
hospital O
campus O
melbourne O
australia O
2 O
##ne O
##uro O
##logy O
department O
the O
alfred O
hospital O
melbourne O
australia O
video O

abstract O
we O
report O
a O
case O
of O
probable O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
in O
a O
patient O
who O
developed O
a O
sudden O
onset O
of O
di O
##sa O
##bling O
axial O
ﬂ O
##ex O
##or O
my O
##oc O
##lon O
##us O
following O
a O
cosmetic O
surgical O
procedure O
the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
were O
consistent O
with O
previous O
reports O
of O
ps O
##m O
spontaneous O
re O
##mission O
##s O
and O
disappearance O
of O
the O
jerk O
##s O
sustained O
for O
2 O
years O
following O
removal O
of O
super O
##ﬁ O
##cial O
surgical O
screw O
##s O
support O
the O
diagnosis O
of O
a O
psycho O
##genic O
movement O
disorder O
2008 O
movement O
disorder O
society O
key O
words O
psycho O
##genic O
my O
##oc O
##lon O
##us O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
is O
a O
form O
of O
spinal O
my O
##oc O
##lon O
##us O
characterized O
by O
involvement O
of O
muscles O
inner O
##vate O
##d O
from O
different O
segments O
of O
the O
spinal O
cord O
and O
sequential O
##ly O
activated O
via O
prop O
##rio O
##sp O
##inal O
pathways O
1 O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
of O
slow O
conduct O
##ion O
and O
selective O
recruitment O
of O
tr O
##un O
##cal O
and O
pro O
##xi O
##mal O
this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
dr O
david O
r O
williams O
neuroscience O
##s O
alfred O
hospital O
commercial O
road O
melbourne O
300 O
##4 O
australia O

e O
mail O
david O
williams O
med O
mona O
##sh O
ed O
##u O
au O
received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O
april O
2008 O
received O
4 O
july O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O
2008 O
published O
online O
15 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##2 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

limb O
muscles O
help O
differentiate O
ps O
##m O
from O
spinal O
segment O
##al O
my O
##oc O
##lon O
##us O
2 O
ps O
##m O
has O
been O
documented O
secondary O
to O
intrinsic O
and O
ex O
##tri O
##ns O
##ic O
spinal O
cord O
lesions O
and O
in O
other O
cases O
no O
clear O
et O
##iology O
has O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
recently O
the O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
have O
been O
reported O
in O
a O
group O
of O
eight O
healthy O
volunteers O
sim O
##ulating O
the O
typical O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
of O
ps O
##m O
3 O
the O
differentiation O
between O
voluntary O
and O
involuntary O
movements O
of O
this O
nature O
is O
further O
blurred O
by O
our O
report O
of O
a O
patient O
with O
probable O
psycho O
##genic O
ps O
##m O
case O
report O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
131 O
##3 O
fig O
1 O
0 O
7 O
seconds O
epoch O
of O
order O
of O
activation O
study O
demonstrating O
surface O
em O
##g O
bursts O
in O
pe O
##ctor O
##alis O
pe O
##ct O
followed O
by O
stern O
##oma O
##sto O
##id O
sc O
##m O
and O
upper O
up O
##ab O
and O
lower O
abdominal O
muscles O
lo O
##ab O
solid O
line O
onset O
of O
jerk O
years O
after O
surgery O
at O
the O
patient O
s O
insistence O
and O
the O
axial O
jerk O
##s O
coincidentally O
resolved O
completely O
she O
returned O
to O
normal O
function O
and O
was O
sy O
##mpt O
##om O
free O
at O
follow O
up O
2 O
years O
later O
electro O
##phy O
##sio O
##logical O
investigations O

two O
years O
after O
the O
onset O
of O
jerking O
routine O
ee O
##g O
was O
normal O
median O
nerve O
sensory O
ev O
##oked O
potential O
##s O
were O
normal O
a O
jerk O
locked O
back O
averaged O
ee O
##g O
did O
not O
show O
pre O
movement O
co O
##rti O
##cal O
potential O
##s O
an O
order O
of O
activation O
study O
showed O
variable O
muscle O
activation O
but O
the O
most O
frequent O
pattern O
of O
activation O
was O
ca O
##uda O
##l O
from O
pe O
##ctor O
##al O
to O
abdominal O
muscles O
with O
propagation O
estimated O
at O
9 O
to O
15 O
m O
s O
see O
figure O
1 O
em O
##g O
burst O
length O
was O
between O
50 O
and O
150 O
mill O
##ise O
##con O
##ds O
discussion O

this O
patient O
had O
some O
clinical O
and O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
previous O
reports O
of O
ps O
##m O
as O
well O
as O
features O
not O
usually O
reported O
to O
be O
associated O
such O
as O
ga O
##it O
un O
##stead O
##iness O
and O
axial O
jerk O
##s O
while O
standing O
unusually O
for O
ps O
##m O
there O
were O
periods O
of O
spontaneous O
re O
##mission O
and O
no O
id O
##ent O
##i O
##ﬁ O
##able O
path O
##ological O
les O
##ion O
to O
account O
for O
the O
my O
##oc O
##lon O
##us O
the O
sudden O
onset O
con O
##tem O
##por O
##aneous O
legal O
proceedings O
related O
to O
the O
injury O
the O
associated O
anxiety O
and O
spontaneous O
complete O
re O
##mission O
are O
supportive O
of O
a O
psycho O
##genic O
et O
##iology O
4 O

a O
psycho O
##genic O
et O
##iology O
should O
be O
considered O
when O
patients O
develop O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
occur O
when O
lying O
and O
standing O
without O
id O
##ent O
##i O
##ﬁ O
##able O
central O
nervous O
system O
lesions O
even O
in O
the O
presence O
of O
suggest O
##ive O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
spontaneous O
re O
##mission O
##s O
may O
differentiate O
psycho O
##genic O
and O
organic O
ps O
##m O
legends O
to O
the O
video O
the O
patient O
is O
shown O
lying O
su O
##pine O
with O
bursts O
of O
spontaneous O
axial O
jerk O
##s O
occurring O
at O
rest O
without O
stimulation O
references O
brown O
p O
thompson O
pd O
roth O
##well O
jc O
day O
b O
##l O
marsden O
cd O
axial O
my O
##oc O
##lon O
##us O
of O
prop O
##rio O
##sp O
##inal O
origin O
brain O
1991 O
114 O
197 O
214 O

roth O
##well O
jc O
path O
##op O
##hy O
##sio O
##logy O
of O
spinal O
my O
##oc O
##lon O
##us O
ad O
##v O
ne O
##uro O
##l O
2002 O
89 O
137 O
144 O
kang O
sy O
so O
##hn O
y O
##h O
electro O
##my O
##ography O
patterns O
of O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
can O
be O
mimic O
##ked O
voluntarily O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
124 O
##1 O
124 O
##4 O
fa O
##hn O
s O
williams O
dt O
psycho O
##genic O
d O
##yst O
##onia O
ad O
##v O
ne O
##uro O
##l O
1988 O
50 O
43 O
##1 O
45 O
##5 O
davies O
l O
king O
p O
##j O
leicester O
j O
morris O
j O
##g O
rec O
##umb O
##ent O
ti O
##c O
mo O
##v O
di O
##sor O
##d O
1992 O
7 O
35 O
##9 O
36 O
##3 O
brown O
j O
lan O
##tos O
p O
st O
##rat O
##ton O
m O
ro O
##ques O
p O
ross O
##or O
m O
fa O
##mi O
##lia O
##l O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1993 O
56 O
47 O
##3 O
47 O
##6 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##4 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O
potassium O
channel O
block O
##er O

4 O
amino O
##py O
##rid O
##ine O
is O
effective O
in O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
a O
video O
case O
report O
matthias O
lo O
##¨ O
##hl O
##e O
md O
wi O
##eb O
##ke O
sc O
##hre O
##mp O
##f O
md O
martin O
wo O
##lz O
md O
heinz O
reich O
##mann O
md O
phd O
and O
alexander O
st O
##or O
##ch O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
of O
dresden O
dresden O
germany O
video O

8 O
5 O
to O
4 O
5 O
points O
we O
conclude O
that O
4 O
ap O
may O
be O
ben O
##e O
##ﬁ O
##cial O
for O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
in O
late O
onset O
ea O
##2 O
2008 O
movement O
disorder O
society O
key O
words O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
4 O
amino O
##py O
##rid O
##ine O
inter O
##ic O
##tal O
ata O
##xia O
sara O
video O
case O
report O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
a O
rare O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
caused O
by O
mutations O
of O
the O
calcium O
channel O
gene O
ca O
##c O
##na O
##1 O
##a O
on O
chromosome O
19 O
##p O
##13 O
1 O
this O
gene O
codes O
for O
the O
ca O
##v O
##2 O
1 O
subunit O
of O
the O
p O
q O
type O
calcium O
channel O
which O
is O
expressed O
throughout O
the O
nervous O
system O
but O
mainly O
in O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
dr O
matthias O
lo O
##¨ O
##hl O
##e O
k O
##lini O
##k O
und O
pol O
##ik O
##lini O
##k O
fu O
##¨ O
##r O
ne O
##uro O
##logie O
fe O
##ts O
##chers O
##tra O
##sse O
74 O
01 O
##30 O
##7 O
dresden O
germany O
e O
mail O
matthias O
lo O
##eh O
##le O
ne O
##uro O
med O
tu O
dresden O
de O
received O
27 O
august O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O
2008 O
published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##1 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

4 O
amino O
##py O
##rid O
##ine O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
131 O
##5 O
and O
headache O
##s O
a O
half O
sister O
complained O
about O
chronic O
headache O
##s O

evaluation O
##s O
after O
informed O
consent O
for O
video O
##ta O
##ping O
had O
been O
given O
the O
patient O
was O
asked O
to O
pause O
treatment O
with O
4a O
##p O
for O
24 O
hours O
and O
after O
that O
was O
video O
##ta O
##ped O
and O
rated O
according O
to O
the O
recently O
valid O
##ated O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
4 O
the O
patient O
was O
then O
given O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
and O
video O
##ta O
##ped O
and O
rated O
again O
as O
soon O
as O
she O
realized O
improvement O
of O
her O
symptoms O
a O
ﬁ O
##nal O
evaluation O
was O
done O
after O
the O
patient O
had O
taken O
3 O
3 O
5 O
mg O
4 O
ap O
over O
24 O

movement O
disorders O

vol O
23 O
no O
9 O
2008 O
pp O
128 O
##6 O
132 O
##0 O

2008 O
movement O
disorder O
society O

brief O
reports O

apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O

sebastian O
pau O
##s O
md O
1 O
ga O
##bor O
z O
##sur O
##ka O
phd O
md O
2 O
miriam O
baron O
phd O
2 O
marcus O
des O
##cha O
##uer O
md O
3 O
christian O
bam O
##berg O
md O
4 O
thomas O
k O
##lock O
##get O
##her O
md O
1 O
wolf O
##ram O
s O
kun O
##z O
phd O
2 O
and O
corn O
##elia O
ko O
##rn O
##bl O
##um O
md O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
2d O
##ep O
##art O
##ment O
of O
ep O
##ile O
##pt O
##ology O
and O
life O
and O
brain O
center O
university O
of O
bonn O
bonn O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
university O
of O
halle O
wit O
##tenberg O

halle O
sa O
##ale O
germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
r O
##hein O
mo O
##sel O
fa O
##ch O
##k O
##lini O
##k O
and O
##ern O
##ach O
germany O

abstract O
patients O
harbor O
##ing O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
present O
with O
a O
broad O
variety O
of O
neurological O
ph O
##eno O
##type O
##s O
including O
ce O
##re O
##bella O
##r O
ata O
##xia O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
my O
##oc O
##lon O
##us O
ep O
##ile O
##psy O
and O
peripheral O
ne O
##uro O
##pathy O
with O
exception O
of O
ata O
##xia O
and O
my O
##oc O
##lon O
##us O
movement O
disorders O
are O
not O
typical O
features O
of O
pol O
##g O
##1 O
associated O
disorders O
we O
report O
on O
two O
affected O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
mutations O
one O
suffering O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
due O
to O
focal O
eye O
##lid O
d O
##yst O
##onia O
that O
mimic O
##ked O
progression O
of O
pt O
##osis O
resulting O
in O
functional O
blindness O
so O
far O
focal O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O
and O
should O
be O
considered O
when O
investigating O
patients O
with O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O
2008 O
movement O
disorder O
society O

key O
words O
focal O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
pt O
##osis O
pol O
##g O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O

mutations O
in O
the O
polymer O
##ase O
g O
gene O
pol O
##g O
##1 O
coding O
for O
a O
protein O
involved O
in O
mitochondrial O
dna O
mt O
##dna O
maintenance O
cause O
a O
broad O
variety O
of O
auto O
##som O
##al O
dom O
##i O

correspondence O
to O
dr O
sebastian O
pau O
##s O
department O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O

e O
mail O
spa O
##us O
un O
##i O
bonn O
de O

received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O

april O
2008 O

published O
online O
10 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O

nan O
##t O
and O
recess O
##ive O
neurological O
ph O
##eno O
##type O
##s O
including O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
pt O
##osis O
ce O
##re O
##bella O
##r O
ata O
##xia O
ep O
##ile O
##psy O
dementia O
my O
##opa O
##thy O
my O
##oc O
##lon O
##us O
peripheral O
ne O
##uro O
##pathy O
and O
headache O
in O
some O
cases O
accompanied O
by O
liver O
involvement O
1 O
in O
pol O
##g O
##1 O
associated O
disorders O
relationship O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
is O
complex O
with O
a O
considerable O
overlap O
of O
clinical O
spectrum O
2 O
3 O
with O
exception O
of O
ata O
##xia O
and O
my O
##oc O
##lon O
##us O
movement O
disorders O
are O
not O
typical O
features O
of O
pol O
##g O
##1 O
mutations O
recently O
parkinson O
##ism O
has O
been O
associated O
to O
pol O
##g O
##1 O
accompanied O
either O
by O
pe O
##o O
and O
other O
characteristic O
symptoms O
4 O
or O
ne O
##uro O
##pathy O
alone O
5 O
one O
study O
in O
finnish O
patients O
with O
recess O
##ive O
ata O
##xia O
due O
to O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutations O
described O
involuntary O
movements O
namely O
at O
##het O
##oid O
and O
cho O
##re O
##oat O
##het O
##oid O
movements O
of O
ex O
##tre O
##mit O
##ies O
and O
face O
and O
tremor O
of O
head O
and O
limbs O
6 O

here O
we O
report O
on O
two O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
the O
most O
frequent O
recess O
##ive O
pol O
##g O
##1 O
mutations O
presenting O
with O
a O
remarkably O
later O
onset O
and O
longer O
survival O
than O
most O
patients O
of O
the O
same O
gen O
##otype O
one O
suffered O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
al O
##o O
due O
to O
d O
##yst O
##onic O
activity O
of O
eye O
##lid O
muscles O
resulting O
in O
functional O
blindness O
so O
far O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O

subjects O
and O
methods O

subjects O

three O
sisters O
ages O
39 O
patient O
1 O
38 O
and O
37 O
patient O
2 O
the O
children O
of O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
were O
normal O
at O
birth O
and O
through O
childhood O
the O
oldest O
developed O
neurological O
symptoms O
at O
the O
age O
of O
28 O
herald O
##ed O
by O
ep O
##iso O
##dic O
headache O
cognitive O
decline O
and O
seizures O
repeatedly O
resulting O
in O
generalized O
status O
ep O
##ile O
##ptic O
##us O
when O
seen O
ﬁ O
##rst O
at O
age O
32 O
patient O
1 O
presented O
with O
marked O
ata O
##xia O
both O
due O
to O
ce O
##re O
##bella O
##r O
affection O
and O
sensor O
##imo O
##tor O
peripheral O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
pe O
##o O
with O
dip O
##lo O
##pia O
mild O
bilateral O
pt O
##osis O
ep O
##ile O
##psy O
moderate O
cognitive O
impairment O
my O
##oc O
##lon O
##us O
and O
cho O
##re O
##oat O
##het O
##oid O
movements O
of O
the O
arms O
and O
per O
##ior O
##al O
muscles O
she O
had O
never O
been O
treated O
with O
ne O
##uro O
##le O
##ptic O
##s O
mri O
of O
the O
brain O
showed O
moderate O
generalized O
cerebral O
at O
##rop O
##hy O
including O
mid O
##bra O
##in O
and O
ce O
##re O
##bell O
##um O
his O
##tology O
of O
vast O
##us O
lateral O
##is O
muscle O
revealed O
mild O
un O
##sp O
##ec O
##i O
##ﬁ O
##c O
my O
##opa O
##th O
##ological O
alterations O
without O
ragged O

128 O
##6 O

apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
128 O
##7 O

table O
1 O
ph O
##eno O
##type O
##s O
gen O
##otype O
##s O
and O
mt O
##dna O
copy O
numbers O
in O
blood O

age O
years O

copy O
numbers O
are O
given O
in O
mean O
6 O
sd O

pol O
##g O
##1 O
gen O
##otype O
the O
two O
sides O
of O
the O
slash O
indicate O
gen O
##ot O
##yp O
##ing O
results O
of O
the O
two O
chromosomes O
as O
determined O
by O
pc O
##r O
rf O
##lp O
the O
term O
w O
##t O
in O
this O
respect O
indicates O
that O
none O
of O
the O
three O
pol O
##g O
##1 O
mutations O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
and O
a O
##46 O
##7 O
##t O
were O
detected O

sd O
standard O
deviation O
d O
onset O
disease O
onset O
na O
not O
applicable O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
w O
##t O
wild O
type O

red O
or O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
ﬁ O
##bers O
while O
bio O
##chemical O
analyses O
of O
respiratory O
chain O
enzymes O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
were O
normal O
table O
1 O

patient O
2 O
was O
healthy O
until O
the O
age O
of O
36 O
when O
she O
developed O
pe O
##o O
mild O
bilateral O
pt O
##osis O
d O
##ys O
##arth O
##ria O
ata O
##xia O
and O
ne O
##uro O
##pathy O
brain O
mri O
was O
normal O
examination O
of O
muscle O
tissue O
was O
identical O
to O
patient O
1 O

mother O
father O
and O
the O
third O
sister O
were O
seen O
at O
ages O
64 O
64 O
and O
38 O
respectively O
besides O
ob O
##ste O
##tric O
cho O
##les O
##tas O
##is O
in O
the O
sister O
no O
liver O
disease O
diabetes O
or O
neurological O
symptoms O
became O
evident O

genetic O
analysis O

total O
dna O
was O
extracted O
from O
muscle O
tissue O
in O
both O
patients O
followed O
by O
long O
range O
pc O
##r O
to O
test O
for O
mt O
##dna O
rear O
##rang O
##ement O
##s O
also O
total O
dna O
was O
extracted O
from O
blood O
in O
all O
subjects O
at O
ﬁ O
##rst O
analyzed O
for O
the O
two O
most O
frequent O
recess O
##ive O
mutations O
in O
pol O
##g O
##1 O
a O
##46 O
##7 O
##t O
w O
##7 O
##48 O
##s O
and O
the O
e O
##11 O
##43 O
##g O
poly O
##morphism O
by O
pc O
##r O
rf O
##lp O
followed O
by O
sequencing O

copy O
numbers O
of O
the O
mitochondrial O
genome O
were O
determined O
in O
blood O
le O
##uk O
##ocytes O
in O
all O
subjects O
by O
real O
##time O
pc O
##r O
as O
described O
earlier O
7 O
in O
all O
subjects O
quad O
##rup O
##le O
experiments O
were O
performed O
and O
arithmetic O
means O
and O
standard O
deviation O
##s O
were O
calculated O
copy O
numbers O
were O
compared O
to O
those O
of O
15 O
age O
##and O
sex O
matched O
healthy O
controls O
f O
m O
13 O
2 O
using O
student O
s O
t O
test O

results O

clinical O
course O

after O
initial O
presentation O
patient O
1 O
was O
seen O
at O
regular O
intervals O
and O
a O
slow O
worse O
##ning O
of O
dip O
##lo O
##pia O
ne O
##uro O
##pathy O
and O
ata O
##xia O
was O
documented O
whereas O
ep O
##ile O
##psy O

cho O
##re O
##oat O
##het O
##osis O
and O
cognitive O
function O
remained O
stable O
involuntary O
closing O
of O
the O
eyes O
due O
to O
lowering O
of O
the O
lids O
also O
worsened O
at O
ﬁ O
##rst O
attributed O
to O
ag O
##gra O
##vation O
of O
pt O
##osis O
resulting O
in O
phases O
of O
functional O
blindness O
at O
the O
age O
of O
35 O
at O
this O
time O
she O
started O
to O
rec O
##line O
her O
head O
and O
to O
hold O
open O
her O
eyes O
with O
her O
ﬁ O
##nger O
##s O
during O
conversation O
or O
reading O
attempts O
accompanied O
by O
voluntary O
contraction O
of O
the O
frontal O
##is O
muscle O
as O
sometimes O
observed O
in O
al O
##o O
although O
no O
apparent O
b O
##le O
##pha O
##ros O
##pas O
##m O
was O
observed O
and O
the O
patient O
s O
maneuvers O
did O
not O
function O
as O
a O
sensory O
trick O
we O
assumed O
d O
##yst O
##onic O
closing O
of O
the O
eyelids O
in O
contrast O
to O
my O
##opa O
##thic O
pt O
##osis O
and O
needle O
electro O
##my O
##ography O
revealed O
persistent O
and O
d O
##yst O
##onic O
muscle O
activity O
of O
the O
pre O
##tar O
##sal O
part O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
injection O
##s O
of O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
a O
bon O
##t O
a O
bot O
##ox O
##1 O
into O
both O
upper O
eyelids O
4 O
units O
per O
side O
led O
to O
marked O
improvement O
with O
mild O
residual O
pt O
##osis O
only O
similar O
to O
the O
initial O
clinical O
examination O
bon O
##t O
a O
injection O
##s O
were O
continued O
in O

3 O
months O
intervals O
with O
ongoing O
success O
until O
now O
when O
patient O
2 O
was O
seen O
1 O
year O
after O
disease O
onset O
there O
were O
no O
involuntary O
movements O
of O
any O
kind O

long O
range O
pc O
##r O
detected O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
skeletal O
muscle O
of O
patients O
1 O
and O
2 O
both O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
mother O
and O
healthy O
sister O
were O
het O
##ero O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
the O
father O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
as O
described O
before O
3 O
6 O
w O
##7 O
##48 O
##s O
was O
found O
together O
with O
e O
##11 O
##43 O
##g O
in O
each O
case O
suggesting O
all O
##eli O
##c O
coupling O
of O
both O
mutations O

mt O
##dna O
copy O
numbers O
in O
blood O
were O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
controls O
even O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O

128 O
##8 O
pau O
##s O
et O
al O

more O
obvious O
in O
patient O
1 O
with O
earlier O
disease O
onset O
and O
more O
severe O
clinical O
ph O
##eno O
##type O
reduction O
of O
68 O
and O
56 O
respectively O
also O
mean O
copy O
numbers O
of O
the O
healthy O
family O
members O
were O
lower O
when O
compared O
with O
mean O
values O
of O
controls O
reaching O
sign O
##i O
##ﬁ O
##can O
##ce O
in O
the O
mother O
only O

discussion O

our O
study O
on O
a O
family O
of O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutation O
carriers O
including O
two O
affected O
siblings O
extends O
previous O
observations O
on O
the O
diversity O
of O
clinical O
spectrum O
in O
pol O
##g O
##1 O
associated O
disorders O
in O
patient O
1 O
diagnosis O
of O
al O
##o O
due O
to O
focal O
eye O
##lid O
d O
##yst O
##onia O
was O
probably O
delayed O
because O
it O
accompanied O
mild O
pt O
##osis O
in O
pe O
##o O
and O
mimic O
##ked O
severe O
par O
##esis O
of O
eye O
##lid O
muscles O
indeed O
al O
##o O
is O
known O
to O
occur O
without O
any O
obvious O
spa O
##sms O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
as O
seen O
in O
typical O
b O
##le O
##pha O
##ros O
##pas O
##m O
frequently O
ham O
##per O
##ing O
recognition O
8 O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
separating O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
al O
##o O
from O
my O
##ast O
##hen O
##ic O
or O
my O
##opa O
##thic O
pt O
##osis O
were O
reported O
before O
and O
in O
some O
cases O
the O
underlying O
disorder O
was O
only O
un O
##mas O
##ked O
by O
a O
poor O
response O
with O
severe O
pt O
##osis O
after O
bon O
##t O
a O
treatment O
9 O
10 O
in O
isolated O
al O
##o O
bon O
##t O
a O
was O
shown O
to O
be O
effective O
11 O
and O
our O
patient O
suffered O
no O
side O
effects O
after O
repeated O
injection O
##s O
in O
ambiguous O
cases O
distinct O
electro O
##my O
##ographic O
features O
of O
the O
various O
compounds O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
al O
##o O
offer O
cl O
##ari O
##ﬁ O
##cation O
12 O

frequently O
al O
##o O
with O
and O
without O
b O
##le O
##pha O
##ros O
##pas O
##m O
is O
associated O
to O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
mostly O
parkinson O
s O
disease O
and O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
8 O
focal O
d O
##yst O
##onia O
was O
reported O
in O
leigh O
s O
syndrome O
and O
le O
##ber O
s O
hereditary O
optic O
ne O
##uro O
##pathy O
13 O
but O
is O
not O
a O
typical O
feature O
of O
mitochondrial O
disease O
in O
adulthood O
so O
far O
it O
was O
unknown O
in O
patients O
harbor O
##ing O
pol O
##g O
##1 O
mutations O
as O
a O
defect O
of O
mitochondrial O
complex O
i O
was O
implicated O
in O
the O
pathogen O
##esis O
of O
focal O
d O
##yst O
##onia O
before O
14 O
and O
mitochondrial O
disease O
presenting O
with O
d O
##yst O
##onia O
as O
dominant O
clinical O
ph O
##eno O
##type O
was O
reported O
very O
recently O
15 O
our O
observation O
just O
##i O
##ﬁ O
##es O
further O
examination O
of O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
in O
fact O
it O
was O
shown O
that O
pol O
##g O
##1 O
mutations O
can O
lead O
to O
basal O
gang O
##lia O
dysfunction O
namely O
parkinson O
##ism O
even O
in O
the O
absence O
of O
primary O
clinical O
features O
of O
pol O
##g O
##1 O
associated O
disorders O
5 O

finally O
our O
observations O
might O
further O
el O
##uc O
##ida O
##te O
the O
complex O
relationship O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
in O
pol O
##g O
##1 O
and O
diagnostic O
procedures O
first O
our O
patients O
had O
a O
later O
disease O
onset O
and O
longer O
survival O
time O
than O
most O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
compound O
het O
##ero O
##zy O
##go O
##tes O
reported O
before O
and O
those O
of O
similar O
course O
of O
disease O
featured O
a O
ph O
##eno O
##type O
resembling O
our O
affected O

siblings O
2 O
3 O
we O
h O
##yp O
##oth O
##es O
##ize O
that O
although O
often O
severe O
a O
subgroup O
of O
compound O
het O
##ero O
##zy O
##go O
##tes O
shows O
a O
considerable O
mild O
##er O
ph O
##eno O
##type O
of O
later O
disease O
onset O
and O
longer O
survival O
eventually O
distinguished O
by O
ata O
##xia O
and O
adult O
onset O
pe O
##o O
probably O
de O
##ﬁ O
##ned O
by O
further O
yet O
unknown O
gen O
##omic O
variations O
second O
mt O
##dna O
content O
in O
blood O
was O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
age O
##and O
sex O
matched O
healthy O
controls O
suggesting O
that O
mt O
##dna O
de O
##ple O
##tion O
is O
not O
restricted O
to O
liver O
or O
muscle O
tissue O
in O
pol O
##g O
1 O
associated O
disorders O
but O
may O
be O
detected O
in O
easily O
obtain O
##able O
blood O
samples O
as O
well O

in O
conclusion O
pol O
##g O
##1 O
mutations O
might O
present O
with O
treat O
##able O
focal O
d O
##yst O
##onia O
which O
should O
be O
considered O
in O
cases O
of O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O

references O

hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
dna O
polymer O
##ase O
gamma O
and O
human O
disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
244 O
252 O

ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
167 O
##4 O
168 O
##4 O

t O
##zo O
##uli O
##s O
c O
nielsen O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O

lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
##1 O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O

baron O
m O
ku O
##din O
ap O
kun O
##z O
w O
##s O
mitochondrial O
dysfunction O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
bio O
##che O
##m O
soc O
trans O
2007 O
35 O
122 O
##8 O
123 O
##1 O

k O
##rac O
##k O
p O
marion O
m O
##h O
apr O
##ax O
##ia O
of O
lid O
opening O
a O
focal O
eye O
##lid O
d O
##yst O
##onia O
clinical O
study O
of O
32 O
patients O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
610 O
61 O
##5 O

roberts O
me O
ste O
##iger O
m O
##j O
hart O
ik O
presentation O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mimic O
##king O
b O
##le O
##pha O
##ros O
##pas O
##m O
ne O
##uro O
##logy O
2002 O
58 O
150 O
151 O

muller O
va O
##hl O
k O
##r O
ko O
##lb O
##e O
h O
e O
##gens O
##per O
##ger O
r O
deng O
##ler O
r O
mit O
##och O
##ond O
##rio O
##pathy O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
treatment O
with O
bot O
##ulin O
##um O
toxin O
muscle O
nerve O
2000 O
23 O
64 O
##7 O
64 O
##8 O

forget O
r O
to O
##z O
##lova O
##nu O
v O
ian O
##cu O
a O
bog O
##hen O
d O
bot O
##ulin O
##um O
toxin O
improves O
lid O
opening O
delays O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
associated O
apr O
##ax O
##ia O
of O
lid O
opening O
ne O
##uro O
##logy O
2002 O
58 O
1843 O
1846 O

ara O
##mide O
##h O
m O
on O
##ger O
##bo O
##er O
de O
vis O
##ser O
b O
##w O
dev O
##ries O
##e O
pp O
bo O
##ur O
l O
##j O
sp O
##ee O
##lman O
jd O
electro O
##my O
##ographic O
features O
of O
lev O
##ator O
pal O
##pe O
##bra O
##e O
superior O
##is O
and O
orb O
##icular O
##is O
o O
##cu O
##li O
muscles O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
brain O
1994 O
117 O
27 O
38 O

hanna O
mg O
b O
##hat O
##ia O
k O
##p O
movement O
disorders O
and O
mitochondrial O
dysfunction O
cu O
##rr O
op O
##in O
ne O
##uro O
##l O
1997 O
10 O
351 O
356 O

sc O
##ha O
##pi O
##ra O
ah O
warner O
t O
gas O
##h O
mt O
cl O
##eet O
##er O
mw O
marin O
##ho O
cf O
cooper O
j O
##m O
complex O
i O
function O
in O
fa O
##mi O
##lia O
##l O
and O
sporadic O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
1997 O
41 O
55 O
##6 O
55 O
##9 O

mc O
##far O
##land O
r O
chin O
##nery O
p O
##f O
blake O
##ly O
el O
et O
al O
homo O
##pl O
##as O
##my O
het O
##ero O
##pl O
##as O
##my O
and O
mitochondrial O
d O
##yst O
##onia O
ne O
##uro O
##logy O
2007 O
69 O
911 O
91 O
##6 O

gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
128 O
##9 O

gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
results O
on O
motor O
function O
and O
cognition O
in O
a O
72 O
year O
old O
case O

alfonso O
fa O
##san O
##o O
md O
1 O
paolo O
ma O
##zzo O
##ne O
md O
2 O
carla O
piano O
md O
1 O
david O
##e O
qu O
##aran O
##ta O
md O
1 O
francesco O
sole O
##ti O
md O
1 O
and O
anna O
rita O
bent O
##ivo O
##glio O
md O
phd O
##1 O

1 O
##ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
roma O
italia O
2 O
##ne O
##uro O
##chi O
##ru O
##rg O
##ia O
fun O
##zio O
##nal O
##e O
e O
stereo O
##tas O
##sic O
##a O
ct O
##o O
ale O
##sin O
##i O
roma O
italia O

video O

abstract O
huntington O
s O
disease O
hd O
produces O
de O
##bil O
##itating O
motor O
abnormalities O
that O
are O
poorly O
responsive O
to O
medical O
therapy O
deep O
brain O
stimulation O
db O
##s O
of O
the O
poster O
##oven O
##tral O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
may O
offer O
a O
treatment O
option O
for O
patients O
with O
disk O
##ine O
##tic O
ph O
##eno O
##type O
and O
minimal O
cognitive O
impairment O
but O
its O
role O
in O
the O
management O
of O
hd O
remains O
unclear O
and O
to O
date O
only O
two O
cases O
have O
been O
reported O
we O
report O
the O
outcome O
of O
gp O
##i O
db O
##s O
in O
a O
72 O
##year O
old O
man O
with O
hd O
stimulation O
at O
130 O
hz O
caused O
a O
rapid O
am O
##eli O
##oration O
of O
cho O
##rea O
producing O
the O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
whereas O
40 O
hz O
stimulation O
maintaining O
constant O
the O
total O
electrical O
energy O
delivered O
improved O
cho O
##rea O
while O
preserving O
the O
ability O
to O
walk O
at O
1 O
year O
follow O
up O
cho O
##rea O
has O
completely O
disappeared O
however O
the O
patient O
was O
unable O
to O
stand O
and O
walk O
the O
cognitive O
pro O
##ﬁ O
##le O
showed O
a O
progressive O
deterioration O
with O
an O
extension O
of O
de O
##ﬁ O
##cit O
from O
the O
mainly O
d O
##yse O
##x O
##ec O
##utive O
alterations O
at O
baseline O
to O
a O
more O
diffuse O
##d O
cognitive O
deterioration O
2008 O
movement O
disorder O
society O

key O
words O
huntington O
s O
disease O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
surgery O
therapy O

huntington O
s O
disease O
hd O
is O
an O
auto O
##som O
##al O
dominant O
ne O
##uro O
##de O
##gen O
##erative O
disorder O
characterized O
by O
progressive O
cognitive O
impairment O
movement O
disorders O
and O
psychiatric O
symptoms O
when O
the O
movement O
disorder O
particularly O
the O
cho O
##rea O
is O
di O
##sa O
##bling O
ph O
##arm O
##aco O
##logical O
treatment O
is O
the O
main O
##sta O
##y O
of O
treatment O
but O
it O
is O
often O
ineffective O
thus O
the O
following O
surgical O
the O
##ra O
##pies O
have O
been O
introduced O
pal O
##lid O
##oto O
##my O
1 O
2 O
human O
fetal O
st O
##ria O
##tal O
transplant O
##a O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
alfonso O
fa O
##san O
##o O
md O
ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
la O
##rgo O
ago O
##sti O
##no O
gem O
##elli O
8 O
001 O
##6 O
##8 O
rome O
e O
mail O
alfonso O
fa O
##san O
##o O
rm O
un O
##ica O
##tt O
it O

received O
3 O
august O
2007 O
revised O
2 O
april O
2008 O
accepted O
5 O
april O

2008 O

published O
online O
30 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##16 O

ti O
##on O
3 O
and O
deep O
brain O
stimulation O
db O
##s O
4 O
5 O
the O
preferred O
target O
of O
db O
##s O
is O
the O
poster O
##oven O
##tral O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
because O
of O
the O
striking O
effects O
of O
pal O
##lid O
##al O
surgery O
for O
cho O
##re O
##od O
##yst O
##onic O
movements O
induced O
by O
lev O
##od O
##opa O
l O
do O
##pa O
in O
parkinson O
s O
disease O
pd O
6 O
sen O
##ile O
cho O
##rea O
7 O
and O
cho O
##rea O
associated O
with O
cerebral O
pal O
##sy O
8 O
to O
date O
two O
hd O
cases O
treated O
with O
gp O
##i O
db O
##s O
have O
been O
reported O
4 O
5 O
further O
experience O
is O
needed O
to O
con O
##ﬁ O
##rm O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
db O
##s O
in O
hd O
to O
guide O
the O
development O
of O
patient O
selection O
criteria O
and O
to O
determine O
the O
optimal O
target O
sites O
and O
stimulation O
parameters O
in O
this O
report O
we O
describe O
the O
use O
of O
bilateral O
gp O
##i O
db O
##s O
in O
a O

hd O
patient O
with O
medical O
##ly O
intra O
##ctable O
cho O
##rea O

methods O

db O
##s O
leads O
model O
338 O
##7 O
med O
##tron O
##ic O
were O
bilateral O
##ly O
implant O
##ed O
under O
general O
an O
##esthesia O
brain O
magnetic O
resonance O
imaging O
and O
computed O
tom O
##ography O
were O
utilized O
for O
targeting O
procedures O
the O
leads O
were O
connected O
to O
an O
implant O
##able O
pulse O
generator O
ip O
##g O
kin O
##et O
##ra O
med O
##tron O
##ic O
which O
was O
secured O
in O
the O
sub O
##cut O
##aneous O
tissues O
of O
the O
chest O

the O
effect O
of O
the O
stimulation O
by O
means O
of O
each O
of O
the O
four O
electrode O
contacts O
was O
investigated O
using O
different O
settings O
of O
stimulation O
frequency O
40 O
130 O
and O
180 O
hz O
pulse O
width O
60 O
90 O
120 O
180 O
and O
210 O
mc O
##se O
##c O
voltage O
from O
1 O
to O
7 O
v O
the O
patient O
was O
evaluated O
15 O
min O
after O
the O
change O
of O
parameters O
and O
after O
24 O
hours O
when O
a O
new O
set O
of O
parameters O
was O
tested O

when O
comparing O
the O
different O
settings O
we O
maintained O
constant O
the O
total O
electrical O
energy O
delivered O
tee O
##d O
determined O
using O
the O
equations O
proposed O
by O
mor O
##o O
et O
al O
4 O
as O
follows O

tee O
##d O
##¼ O
##½ O
##ð O
##vo O
##lta O
##ge O
3 O
##pu O
##ls O
##ew O
##id O
##th O
##3 O
##fr O
##e O
##que O
##ncy O
##þ O

imp O
##edance O
½ O
##tee O
##d O

an O
equation O
empirical O
##ly O
derived O
from O
their O
previous O
studies O
on O
patients O
affected O
by O
pd O
##9 O
but O
believed O
to O
be O
incorrect O
by O
ko O
##ss O
et O
al O
10 O
who O
suggested O

tee O
##d O
##1 O
##se O
##c O
ð O
##vo O
##lta O
##ge O
##2 O
3 O
pulse O
##wi O
##dt O
##h O
3 O
frequency O
##þ O

imp O
##edance O
3 O
1 O
sec O
½ O
##tee O
##d O

clinical O
assessments O
were O
prospective O
##ly O
performed O
using O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
##11 O
and O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
##12 O
table O
1 O

at O
baseline O
and O
at O
follow O
up O
visits O
the O
patient O
underwent O
an O
extensive O
ne O
##uro O
##psy O
##cho O
##logical O
exam O
##ina O

129 O
##0 O
a O
fa O
##san O
##o O
et O
al O

ti O
##on O
by O
means O
of O
a O
previously O
reported O
standardized O
battery O
##13 O
table O
2 O

the O
patient O
is O
a O
72 O
year O
old O
man O
with O
genetically O
con O
##ﬁ O
##rmed O
hd O
his O
motor O
symptoms O
began O
at O
age O
55 O
and O
progressed O
to O
severe O
generalized O
cho O
##rea O
##the O
##tosis O
within O
the O
previous O
2 O
years O
he O
showed O
weight O
loss O
and O
balance O
impairment O
with O
falls O
the O
introduction O
of O
halo O
##per O
##ido O
##l O
induced O
a O
marked O
se O
##dation O
whereas O
te O
##tra O
##ben O
##azi O
##ne O
was O
tolerated O
only O
at O
low O
doses O
with O
only O
modest O
ben O
##e O
##ﬁ O
##t O
table O
1 O
because O
of O
the O
absence O
of O
severe O
psychiatric O
disorders O
and O
ne O
##uro O
##psy O
##cho O
##logical O
de O
##ﬁ O
##cit O
##s O
table O
2 O
the O
patient O
was O
considered O
eligible O
for O
bilateral O
gp O
##i O
db O
##s O
surgical O
procedure O
was O
well O
tolerated O

effect O
on O
motor O
function O

the O
patient O
was O
discharged O
from O
the O
hospital O
with O
ip O
##g O
left O
off O
to O
allow O
stabilization O
of O
the O
micro O
##pal O
##lid O
##oto O
##my O
effect O
which O
caused O
only O
a O
mild O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
table O
1 O
one O
month O
after O
surgery O
mono O
##pol O
##ar O
stimulation O
using O
ventral O
contacts O
seemed O
to O
be O
more O
e O
##f O
##ﬁ O
##ca O
##cious O
on O
cho O
##rea O
but O
it O
was O
associated O
with O
a O
severe O
h O
##yp O
##oton O
##ia O
of O
axial O
muscles O
causing O
ﬂ O
##ex O
##ion O
of O
the O
head O
and O
loss O
of O
trunk O
control O
parameters O
was O
maintained O
as O
follows O
right O
gp O
##i O
2 O
6 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
2 O
negative O
and O
case O
positive O
left O
gp O
##i O

2 O
7 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
6 O
negative O
and O
case O
positive O

four O
months O
after O
the O
surgery O
we O
found O
that O
stimulation O
at O
40 O
hz O
sign O
##i O
##ﬁ O
##can O
##tly O
improved O
cho O
##rea O
five O
minutes O
after O
the O
ip O
##g O
was O
switched O
on O
limbs O
cho O
##rea O
improved O
consistently O
while O
mild O
d O
##ys O
##kin O
##es O
##ias O
were O
still O
present O
on O
the O
face O
and O
shoulders O
cho O
##rea O
gradually O
reappeared O
15 O
min O
after O
the O
ip O
##g O
has O
been O
switched O
off O
stimulation O
at O
130 O
hz O
caused O
further O
improvement O
of O
cho O
##rea O
but O
also O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
and O
a O
severe O
disturbance O
of O
ga O
##it O
characterized O
by O
freezing O
and O
start O
hesitation O
the O
effect O
of O
these O
different O
frequencies O
was O
con O
##ﬁ O
##rmed O
in O
double O
blind O
fashion O
maintaining O
constant O
tee O
##d O
calculated O
by O
means O
of O
both O
the O
proposed O
methods O
table O
1 O
accordingly O
stimulation O
parameters O
were O
changed O
as O
follows O
right O
gp O
##i O
2 O
0 O
v O
40 O
hz O
90 O
mc O
##se O
##c O
contact O
1 O
negative O
and O
case O
positive O
left O
gp O

2 O
0 O
v O
40 O
hz O
90 O
mc O
##se O
##c O
contact O
5 O
negative O
and O
case O
positive O

during O
the O
following O
months O
ga O
##it O
and O
ap O
##athy O
progressively O
worsened O
despite O
the O
complete O
resolution O
of O
cho O
##rea O
and O
an O
associated O
weight O
gain O
which O
allowed O
the O
withdrawal O
of O
the O
medications O
the O
patient O
s O
level O
of O
independence O
worsened O
due O
to O
the O
severe O
impairment O
of O
autonomous O
ga O
##it O
the O
lowering O
of O
amplitude O
of O
stimulation O
did O
not O
improve O
the O
axial O
impairment O
eleven O
months O
after O
surgery O
the O
stimulation O
was O
switched O
off O
and O
surprisingly O
this O
did O
not O
cause O
the O
re O
##oc O
##cu O
##rre O
##nce O
of O
cho O
##rea O
table O
1 O
a O
250 O
mg O
l O
do O
##pa O
challenge O
improved O
the O
patient O
s O
ability O
to O
arise O

table O
1 O
motor O
function O
during O
follow O
up O
visits O

cho O
##rea O
score O
was O
de O
##ﬁ O
##ned O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
12 O
##a O
12 O
##g O
maximum O
score O
28 O
d O
##yst O
##onia O
score O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
11 O
##a O
11 O
##e O
maximum O
score O
20 O
brady O
##kin O
##es O
##ia O
rigid O
##ity O
score O
as O
the O
sum O
of O
the O
uh O
##dr O
##s O
items O
11 O
12 O
14 O
15 O
maximum O
score O
28 O
axial O
symptoms O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
18 O
19 O
20 O
and O
of O
up O
##dr O
##s O
item O
27 O
arising O
from O
chair O
maximum O
score O
16 O

numbers O
in O
brackets O
indicate O
the O
corrected O
scores O
for O
age O
and O
years O
of O
education O
according O
to O
an O
italian O
population O
based O
standardization O
scores O
in O
bold O
are O
below O
the O
cut O
off O
of O
normal O
##ity O

are O
##verse O
scores O
lower O
scores O
indicate O
better O
performances O

bb O
##elo O
##w O
10th O
percent O
##ile O

cbe O
##low O
1st O
percent O
##ile O

iv O
##m O
immediate O
visual O
memory O
m O
##ft O
##c O
multi O
##fe O
##at O
##ures O
targets O
cancellation O
mm O
##se O
mini O
mental O
state O
examination O
np O
not O
performed O
pm O
47 O
raven O
s O
progressive O
matrices O
47 O
ra O
##v O
##lt O
rey O
s O
auditory O
verbal O
learning O
test O
roc O
##f O
rey O
os O
##ter O
##rie O
##th O
complex O
ﬁ O
##gur O
##e O
wc O
##st O
wisconsin O
card O
sorting O
test O

from O
chair O
without O
assistance O
and O
slightly O
the O
ga O
##it O
so O
the O
patient O
started O
chronic O
therapy O
with O
l O
do O
##pa O
up O
to O
800 O
mg O
die O
with O
a O
mild O
improvement O
of O
brady O
##kin O
##es O
##ia O
ga O
##it O
and O
ap O
##athy O
table O
1 O

effect O
on O
cognitive O
functions O
table O
2 O

at O
baseline O
evaluation O
1 O
month O
before O
surgery O
the O
patient O
s O
cognitive O
pro O
##ﬁ O
##le O
was O
characterized O
mainly O
by O
d O
##yse O
##x O
##ec O
##utive O
syndrome O
on O
the O
ﬁ O
##rst O
follow O
up O
visit O
6 O
months O
after O
surgery O
the O
score O
of O
mini O
mental O
state O
examination O
worsened O
as O
did O
scores O
of O
test O
for O
executive O
functions O
scores O
of O
linguistic O
and O
memory O
task O

were O
lower O
as O
well O
on O
the O
second O
follow O
up O
visit O
1 O
year O
after O
surgery O
he O
performed O
worse O
on O
all O
executive O
tasks O
in O
comparison O
with O
both O
the O
baseline O
and O
1st O
follow O
up O
visits O
scores O
worsened O
also O
on O
ph O
##ono O
##logical O
ﬂ O
##uen O
##cy O
task O
and O
on O
elementary O
construction O
##al O
abilities O

we O
have O
con O
##ﬁ O
##rmed O
that O
bilateral O
gp O
##i O
db O
##s O
produces O
a O
long O
term O
reduction O
of O
cho O
##rea O
due O
to O
hd O
despite O
the O
ben O
##e O
##ﬁ O
##t O
surgery O
has O
been O
related O
to O
worse O
##ning O
of O
ga O
##it O
ap O
##athy O
and O
decline O
of O
cognitive O
function O

129 O
##2 O
a O
fa O
##san O
##o O
et O
al O

in O
the O
past O
pal O
##lid O
##oto O
##my O
has O
been O
associated O
with O
only O
modest O
pal O
##lia O
##tive O
functional O
improvement O
in O
d O
##yst O
##onic O
features O
##1 O
or O
worse O
##ning O
of O
parkinson O
##ism O
2 O
4 O
based O
on O
this O
it O
has O
been O
suggested O
that O
the O
use O
of O
db O
##s O
to O
maximize O
ben O
##e O
##ﬁ O
##ts O
and O
minimize O
potential O
side O
effects O
such O
as O
brady O
##kin O
##es O
##ia O
in O
the O
ﬁ O
##rst O
8 O
month O
follow O
up O
report O
on O
the O
use O
of O
gp O
##i O
db O
##s O
to O
treat O
hd O
cho O
##rea O
authors O
reported O
a O
dramatic O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
stimulation O
##s O
at O
40 O
and O
130 O
hz O
maintaining O
constant O
the O
tee O
##d O
were O
equally O
effective O
but O
the O
second O
worsened O
brady O
##kin O
##es O
##ia O
4 O
according O
to O
ko O
##ss O
et O
al O
the O
equation O
utilized O
to O
calculate O
the O
tee O
##d O
was O
incorrect O
and O
it O
was O
not O
possible O
to O
disc O
##ern O
whether O
the O
observed O
clinical O
effects O
resulted O
from O
changes O
in O
stimulation O
frequency O
or O
from O
the O
overall O
increase O
in O
tee O
##d O
10 O
we O
con O
##ﬁ O
##rmed O
the O
ﬁ O
##nding O
##s O
of O
mor O
##o O
et O
al O
by O
maintaining O
constant O
tee O
##d O
calculated O
with O
both O
the O
equations O
proposed O
this O
would O
suggest O
that O
in O
hd O
the O
clinical O
effect O
of O
db O
##s O
is O
frequency O
dependent O
and O
support O
the O
concept O
that O
brady O
##kin O
##es O
##ia O
and O
cho O
##rea O
probably O
re O
##ﬂ O
##ect O
underlying O
differences O
in O
ne O
##uron O
##al O
ﬁ O
##ring O
patterns O
and O
coding O
14 O
however O
it O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
say O
to O
what O
extend O
tee O
##d O
re O
##ﬂ O
##ect O
##s O
the O
real O
impact O
of O
the O
stimulation O
on O
the O
neurons O
and O
ax O
##ons O
for O
at O
least O
two O
reasons O
1 O
tee O
##d O
does O
not O
re O
##ﬂ O
##ect O
the O
size O
and O
the O
shape O
of O
the O
electrical O
ﬁ O
##eld O
2 O
it O
is O
known O
that O
voltage O
is O
the O
most O
critical O
factor O
for O
alteration O
of O
cell O
population O
activity O
in O
the O
human O
brain O
9 O

the O
secondly O
reported O
hd O
patient O
had O
a O
12 O
months O
lasting O
rev O
##ers O
##ible O
suppression O
of O
his O
cho O
##rea O
##the O
##to O
##id O
movements O
after O
surgery O
a O
trial O
of O
reduced O
frequency O
to O
40 O
hz O
produced O
a O
poor O
control O
of O
cho O
##rea O
and O
required O
reins O
##ti O
##tu O
##tion O
of O
high O
frequency O
stimulation O
180 O
hz O
at O
10 O
months O
the O
patient O
s O
g O
##lot O
##tic O
function O
worsened O
and O
concerns O
of O
d O
##ys O
##pha O
##gia O
and O
air O
##way O
protection O
prompted O
institutional O
##ization O
by O
12 O
months O
his O
rigid O
##ity O
also O
progressed O
these O
side O
effects O
were O
not O
improved O
by O
lowered O
ip O
##g O
voltage O
or O
by O
turning O
the O
st O
##im O
##ulator O
off O
5 O
similar O
to O
our O
case O
a O
delayed O
worse O
##ning O
of O
parkinson O
##ism O
was O
present O
and O
it O
did O
not O
change O
even O
after O
a O
prolonged O
period O
without O
stimulation O

the O
path O
##op O
##hy O
##sio O
##logy O
of O
the O
evolving O
and O
delayed O
worse O
##ning O
of O
ga O
##it O
and O
akin O
##es O
##ia O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
explain O
in O
this O
single O
case O
it O
is O
not O
possible O
to O
exclude O
that O
it O
was O
at O
least O
in O
part O
related O
to O
the O
evolution O
of O
the O
disease O
and O
that O
also O
the O
long O
term O
improvement O
of O
cho O
##rea O
was O
related O
to O
its O
progression O
toward O
a O
parkinson O
##ian O
ph O
##eno O
##type O
however O
db O
##s O
may O
have O
actually O
produced O
a O
pal O
##lid O
##oto O
##mic O
effect O
analogous O
to O
the O
worse O
##ning O
of O
brady O
##kin O
##es O
##ia O
observed O
after O
pal O
##lid O
##oto O
##my O
in O
hd O
patients O
2 O
4 O
the O
effect O
of O
isolated O
lesions O
of O
gp O
##i O
in O
subjects O
not O
affected O
by O
pd O
or O
d O
##yst O
##onia O
has O
been O

recently O
reviewed O
as O
follows O
the O
clinical O
picture O
is O
characterized O
mainly O
by O
axial O
parkinson O
##ism O
and O
delayed O
onset O
of O
symptoms O
after O
the O
initial O
insult O
15 O
our O
patient O
shares O
some O
of O
these O
features O

this O
is O
the O
ﬁ O
##rst O
study O
systematically O
assessing O
the O
cognitive O
pro O
##ﬁ O
##le O
of O
an O
hd O
patient O
treated O
with O
db O
##s O
evaluation O
##s O
showed O
a O
progressive O
deterioration O
with O
an O
extension O
of O
de O
##ﬁ O
##cit O
from O
the O
mainly O
d O
##yse O
##x O
##ec O
##utive O
alterations O
at O
baseline O
to O
a O
more O
diffuse O
##d O
cognitive O
deterioration O
the O
cause O
of O
such O
worse O
##ning O
is O
only O
speculative O
since O
it O
is O
not O
possible O
to O
disc O
##ern O
whether O
it O
has O
been O
caused O
by O
the O
effect O
of O
surgery O
or O
by O
the O
natural O
course O
of O
the O
disease O
in O
addition O
it O
is O
not O
possible O
to O
estimate O
the O
real O
impact O
of O
stimulation O
on O
cognitive O
functions O
since O
the O
patient O
was O
always O
assessed O
in O
stimulation O
on O
condition O

the O
outcome O
of O
the O
patient O
hence O
reported O
highlights O
the O
important O
ethical O
decisions O
that O
must O
be O
made O
in O
treating O
patients O
with O
hd O
db O
##s O
may O
aid O
the O
symptoms O
but O
will O
not O
stem O
the O
in O
##ex O
##ora O
##ble O
deterioration O
of O
patients O
with O
this O
disease O
in O
addition O
similarly O
to O
another O
case O
5 O
the O
functional O
gain O
of O
our O
patient O
was O
ne O
##gli O
##gible O
whether O
or O
not O
db O
##s O
should O
be O
used O
on O
a O
regular O
basis O
in O
such O
patients O
still O
remains O
to O
be O
determined O
further O
experience O
with O
this O
population O
will O
guide O
the O
development O
of O
patient O
selection O
criteria O
de O
##ﬁ O
##ne O
the O
optimal O
sites O
and O
stimulation O
parameters O
for O
db O
##s O
and O
el O
##uc O
##ida O
##te O
the O
electro O
##phy O
##sio O
##logical O
changes O
in O
hd O

legends O
to O
the O
video O

segment O
1 O
the O
patient O
6 O
months O
before O
surgery O
presents O
severe O
cho O
##rea O
of O
facial O
muscles O
trunk O
and O
limbs O
the O
patient O
is O
able O
to O
stand O
up O
without O
assistance O
and O
to O
walk O
for O
a O
few O
meters O
cho O
##rea O
of O
the O
lower O
limbs O
and O
impairment O
of O
post O
##ural O
stability O
as O
revealed O
by O
the O
retro O
##pu O
##ls O
##ion O
pull O
test O
des O
##ta O
##bil O
##ize O
him O
during O
walking O

segment O
2 O
three O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
180 O
hz O
provides O
a O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
especially O
of O
the O
lower O
limbs O
stimulation O
of O
ventral O
contacts O
causes O
head O
drop O

segment O
3 O
four O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O

segment O
4 O
four O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
40 O
hz O
provides O
a O
reduction O
of O
cho O
##rea O
and O
an O
improvement O
of O
axial O
symptoms O
the O
patient O
is O
able O
to O
walk O
with O
un O
##ila O
##tera O
##l O
assistance O

segment O
5 O
nine O
months O
after O
surgery O
limbs O
cho O
##rea O
has O
disappeared O
while O
facial O
grimace O
##s O
are O
still O
pre O
##s O

db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##3 O

en O
##t O
despite O
the O
use O
of O
40 O
hz O
stimulation O
the O
patient O
cannot O
arise O
from O
chair O
and O
walk O
due O
to O
a O
severe O
start O
hesitation O

segment O
6 O
nine O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
only O
with O
very O
mild O
d O
##ys O
##kin O
##es O
##ias O
of O
upper O
limbs O
the O
patient O
is O
able O
to O
arise O
from O
chair O
and O
ga O
##it O
impairment O
is O
improved O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
supported O
in O
part O
by O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
grant O
line O
##a O
d O
##1 O
to O
ar O
##b O
af O
f O
##s O
and O
ar O
##b O
are O
members O
of O
euro O
hd O
network O

cub O
##o O
e O
shannon O
km O
penn O
rd O
k O
##roi O
##n O
j O
##s O
internal O
g O
##lo O
##bus O
pal O
##lid O
##oto O
##my O
in O
d O
##yst O
##onia O
secondary O
to O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
124 O
##8 O
125 O
##1 O

vi O
##tek O
j O
##l O
jones O
r O
ba O
##ka O
##y O
re O
##a O
hers O
##ch O
sm O
pal O
##lid O
##oto O
##my O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2000 O
48 O
42 O
##9 O

bach O
##oud O
levi O
ac O
ga O
##ura O
v O
br O
##ug O
##iere O
##s O
p O
et O
al O
effect O
of O
fetal O
neural O
transplant O
##s O
in O
patients O
with O
huntington O
s O
disease O
6 O
years O
after O
surgery O
a O
long O
term O
follow O
up O
study O
lance O
##t O
ne O
##uro O
##l O
2006 O
5 O
303 O
309 O

mor O
##o O
e O
lang O
ae O
st O
##raf O
##ella O
ap O
et O
al O
bilateral O
g O
##lo O
##bus O
pal O
##lid O
##us O

deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O

jan O
her O
##zog O
md O
1 O
oliver O
po O
##gar O
##ell O
md O
2 O
marcus O
o O
pins O
##ker O
md O
3 O
andreas O
ku O
##ps O
##ch O
md O
phd O
4 O

wolfgang O
h O
o O
##ert O
##el O
md O
phd O
5 O
ol O
##le O
lin O
##d O
##val O
##l O
md O
phd O
6 O

gu O
##¨ O
##nt O
##her O
de O
##us O
##ch O
##l O
md O
phd O
1 O
and O
jens O
vol O
##km O
##ann O
md O
phd O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
christian O
albrecht O
##s O
university O
kiel O
germany O
2d O
##ep O
##art O
##ment O
of O
psychiatry O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
christian O
albrecht O
##s O
university O
kiel O

germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
char O
##ite O
##´ O
humboldt O
university O
berlin O
germany O
5 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
philipp O
##s O
university O
mar O
##burg O
germany O
6 O
##section O
of O
rest O
##ora O
##tive O
ne O
##uro O
##logy O
wall O
##enberg O
neuroscience O
centre O
lund O
sweden O

stimulation O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2004 O
56 O
290 O

294 O

he O
##bb O
mo O
garcia O
r O
ga O
##ude O
##t O
p O
mendez O
im O
bilateral O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
to O
treat O
cho O
##rea O
##the O
##tosis O
in O
huntington O
s O
disease O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
58 O
e O
##38 O
##3 O

lang O
ae O
surgery O
for O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##19 O
##3 O
s O
##19 O
##9 O

yi O
##ann O
##i O
j O
nan O
##di O
d O
bradley O
k O
et O
al O
sen O
##ile O
cho O
##rea O
treated O
by O
deep O
brain O
stimulation O
a O
clinical O
ne O
##uro O
##phy O
##sio O
##logical O
and O
functional O
imaging O
study O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
59 O
##7 O
60 O
##2 O

k O
##raus O
##s O
j O
##k O
lo O
##her O
t O
##j O
wei O
##gel O
r O
cape O
##lle O
h O
##h O
weber O
s O
bu O
##rg O
##under O
j O
##m O
chronic O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
treatment O
of O
non O
d O
##yt O
##1 O
generalized O
d O
##yst O
##onia O
and O
cho O
##re O
##oat O
##het O
##osis O
2 O
year O
follow O
up O
j O
ne O
##uro O
##sur O
##g O
2003 O
98 O
78 O
##5 O
79 O
##2 O

mor O
##o O
e O
es O
##sel O
##ink O
r O
##j O
xi O
##e O
j O
homme O
##l O
m O
ben O
##abi O
##d O
al O
poll O
##ak O
p O
the O
impact O
on O
parkinson O
s O
disease O
of O
electrical O
parameter O
settings O
in O
st O
##n O
stimulation O
ne O
##uro O
##logy O
2002 O
59 O
70 O
##6 O
71 O
##3 O

ko O
##ss O
am O
alter O
##man O
r O
##l O
tag O
##lia O
##ti O
m O
shi O
##ls O
j O
##l O
calculating O
total O
electrical O
energy O
delivered O
by O
deep O
brain O
stimulation O
systems O
ann O
ne O
##uro O
##l O
2005 O
58 O
168 O

huntington O
study O
group O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
reliability O
and O
consistency O
mo O
##v O
di O
##sor O
##d O
1996 O
11 O
136 O
142 O

go O
##etz O
c O
##g O
ste O
##bb O
##ins O
gt O
ch O
##mura O
ta O
fa O
##hn O
s O
k O
##law O
##ans O
h O
##l O
marsden O
cd O
teaching O
tape O
for O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
mo O
##v O
di O
##sor O
##d O
1995 O
10 O
263 O
266 O

con O
##tar O
##ino O
m O
##f O
daniel O
##e O
a O
si O
##bil O
##ia O
ah O
et O
al O
cognitive O
outcome O
5 O
years O
after O
bilateral O
chronic O
stimulation O
of O
sub O
##thal O
##ami O
##c O
nucleus O

abstract O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
have O
been O
reported O
as O
a O

consequence O
of O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
for O
parkinson O
s O
disease O
this O
type O
of O
d O
##ys O
##kin O
##es O
##ias O
may O
appear O
in O
patients O
even O
in O
the O
prolonged O
absence O
of O
anti O
##park O
##ins O
##on O
medication O
and O
be O
aggravated O
by O
lev O
##od O
##opa O
therefore O
ph O
##arm O
##aco O
##logical O
therapeutic O
approaches O
in O
these O
patients O
are O
limited O
here O
we O
report O
two O
patients O
with O
bilateral O
fetal O
ni O
##gra O
##l O
graf O
##ts O
in O
the O
ca O
##uda O
##te O
and O
put O
##amen O
subjected O
to O
deep O
brain O
stimulation O
db O
##s O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
or O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
clinical O
assessment O
was O
performed O
according O
to O
up O
##dr O
##s O
and O
the O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
in O
both O
patients O
we O
found O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
in O
off O
period O
symptoms O
as O
well O
as O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
however O
only O
gp O
##i O
db O
##s O
led O
to O
a O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
whereas O
st O
##n O
db O
##s O
did O
not O
in O
##ﬂ O
##uen O
##ce O
d O
##ys O
##kin O
##es O
##ias O
unrelated O
to O
external O
do O
##pa O
##mine O
##rg O
##ic O
application O
these O
ﬁ O
##nding O
##s O
based O
on O
two O
case O
reports O
highlight O
the O
pivotal O
role O
of O
the O
gp O
##i O
in O
media O
##ting O
d O
##ys O
##kin O
##es O
##ia O
related O
neural O
activity O
within O
the O
basal O
gang O
##lia O
loop O
2008 O
movement O
disorder O
society O

key O
words O
parkinson O
s O
disease O
neural O
transplant O
##ation O
deep O
brain O
stimulation O
d O
##ys O
##kin O
##es O
##ias O

in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O

try O
2007 O
78 O
248 O
252 O

be O
##rard O
##elli O
a O
not O
##h O
j O
thomson O
pd O
et O
al O
path O
##op O
##hy O
##sio O
##logy O
of O
cho O
##rea O
and O
brady O
##kin O
##es O
##ia O
in O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O

1999 O
14 O
39 O
##8 O
403 O

ku O
##op O
##pa O
##ma O
##¨ O
##ki O
m O
roth O
##well O
jc O
brown O
r O
##g O
quinn O
n O
b O
##hat O
##ia O
k O
##p O
ja O
##han O
##shah O
##i O
m O
parkinson O
##ism O
following O
bilateral O
lesions O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
performance O
on O
a O
variety O
of O
motor O
tasks O
shows O
similarities O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
48 O
##2 O
490 O

correspondence O
to O
j O
vol O
##km O
##ann O
md O
phd O
department O
of O
ne O
##uro O
##logy O
un O
##iver O
##sit O
##a O
##¨ O
##tsk O
##lini O
##ku O
##m O
schleswig O
holstein O
campus O
kiel O
sc O
##hit O
##ten O
##helm O
##st O
##r O
10 O
241 O
##0 O
##5 O
kiel O
germany O

e O
mail O
j O
vol O
##km O
##ann O
ne O
##uro O
##logie O
un O
##i O
kiel O
de O

received O
31 O
may O
2007 O
revised O
28 O
august O
2007 O
accepted O
13 O

september O
2007 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##6 O
##8 O

129 O
##4 O
j O
her O
##zog O
et O
al O

table O
1 O
characteristics O
of O
patients O
at O
baseline O
and O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
deep O
brain O
stimulation O

patient O
1 O
patient O
2 O

before O
transplant O
##ation O
up O
##dr O
##s O
iii O

med O
off O
74 O
49 O

med O
on O
24 O
14 O

d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O

d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O

item O
32 O
0 O
0 O

item O
33 O
0 O
0 O

medication O
mg O
d O
lev O
##od O
##opa O
1 O
400 O
lev O
##od O
##opa O
250 O

per O
##gol O
##ide O
0 O
5 O

de O
##pre O
##ny O
##l O
10 O

led O
##d O
mg O
1 O
400 O
mg O
400 O
mg O
before O
db O
##s O

following O
db O
##s O

follow O
up O
period O
3 O
y O
##r O
2 O
y O
##r O

up O
##dr O
##s O
iii O
50 O
28 O

st O
##im O
off O
med O
off O

st O
##im O
on O
med O
off O
33 O
11 O

st O
##im O
on O
med O
off O
10 O
2 O

st O
##im O
on O
med O
on O
a O
4 O

item O
32 O
1 O
0 O

item O
33 O
2 O
0 O

medication O
mg O
d O

led O
##d O
mg O
0 O
0 O

persisted O
even O
after O
withdrawal O
of O
lev O
##od O
##opa O
l O
do O
##pa O
medication O
because O
of O
the O
d O
##ys O
##kin O
##etic O
states O
which O
are O
usually O
aggravated O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
ph O
##arm O
##aco O
##logical O
approaches O
are O
limited O
and O
db O
##s O
might O
be O
an O
alternative O
therapeutic O
option O
here O
we O
report O
the O
long O
term O
outcome O
in O
two O
patients O
with O
persistent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
graf O
##ting O
who O
later O
underwent O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
or O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
db O
##s O

case O
reports O

patient O
1 O

the O
53 O
year O
old O
man O
pd O
since O
14 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
selected O
for O
simultaneous O
bilateral O
graf O
##ting O
of O
fetal O
ni O
##gra O
##l O
cells O
5 O
tr O
##aj O
##ect O
##ories O
into O
put O
##amen O
2 O
into O
the O
head O
of O
the O
ca O
##uda O
##te O
nucleus O
the O
tissue O
preparation O
ne O
##uro O
##sur O
##gical O
procedure O
and O
post O
##oper O
##ative O
management O
have O
been O
described O
elsewhere O
1 O
long O
##ter O
##m O
do O
##pa O
##mine O
##rg O
##ic O
graf O
##t O
survival O
was O
demonstrated O
by O
18 O
##f O
ﬂ O
##uo O
##rod O
##opa O
pet O
and O
n O
3 O
io O
##do O
##pro O
##pen O
2 O
y O
##l O
2 O
##b O
car O
##bo O
##met O
##ho O
##xy O
3 O
##b O
4 O
ch O
##lor O
##op O
##hen O
##yl O
tr O
##opa O
##ne O
spec O
##t O
1 O
4 O

the O
transplant O
##ation O
initially O
resulted O
in O
am O
##eli O
##oration O
of O
off O
period O
symptoms O
subsequently O
he O
developed O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
cd O
##rs O
10 O
28 O
particularly O
on O
the O
left O
body O
side O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O
video O
##ta O
##pe O
because O
of O
ag O
##gra O
##vation O
of O
d O
##ys O
##kin O
##etic O
states O
by O
l O
do O
##pa O
cd O
##rs O
15 O
28 O
the O
use O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
had O
to O
be O
limited O
with O
the O
consequence O
of O
progressive O
decline O
in O
severity O
of O
off O
phase O
symptoms O
table O
1 O
and O
return O

stereo O
##ta O
##ctic O
coordinates O
x O
y O
z O
relative O
to O
mid O
##ac O
##pc O

r O
11 O
4 O
22 O
1 O
22 O
2 O
r O
21 O
3 O
4 O
5 O
23 O
6 O

l O
211 O
2 O
22 O
1 O
23 O
0 O
l O
220 O
5 O
1 O
9 O
22 O
4 O

of O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
which O
could O
not O
be O
con O

troll O
##ed O
by O
various O
therapeutic O
approaches O

because O
of O
prominent O
off O
phase O
symptoms O
and O

aa O
##ft O
##er O
st O
##n O
db O
##s O
patient O
1 O
refused O
assessment O
in O
the O
medication O
on O
condition O

up O
##dr O
##s O
iii O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
max O
108 O
cd O
##rs O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
max O
28 O
db O
##s O
deep O
brain O
stimulation O
led O
##d O
lev O
##od O
##opa O
equivalent O
daily O
dos O
##age O

since O
the O
1980 O
s O
intra O
##st O
##ria O
##tal O
transplant O
##ation O
of O
human O
fetal O
ni O
##gra O
##l O
ne O
##uron O
##es O
has O
been O
used O
as O
an O
experimental O
therapy O
to O
restore O
baseline O
do O
##pa O
##mine O
synthesis O
in O
pd O
the O
graf O
##ted O
do O
##pa O
##mine O
ne O
##uron O
##es O
can O
rein O
##ner O
##vate O
the O
de O
##gen O
##erated O
st O
##ria O
##tum O
release O
do O
##pa O
##mine O
and O
become O
functional O
##ly O
integrated O
into O
patients O
neural O
circuit O
##ries O
1 O
whereas O
open O
trials O
have O
reported O
clinical O
ben O
##e O
##ﬁ O
##cial O
effects O
two O
double O
blind O
studies O
failed O
to O
show O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
of O
motor O
symptoms O
compared O
to O
sham O
surgery O
2 O
3 O
additionally O
a O
sign O
##i O
##ﬁ O
##can O
##t O
number O
of O
transplant O
##ed O
patients O
developed O
severe O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
runaway O
d O
##ys O
##kin O
##es O
##ias O
that O

h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
8 O
years O
after O
transplant O
##ation O
the O
patient O
was O
selected O
for O
st O
##n O
db O
##s O
as O
a O
result O
of O
st O
##n O
db O
##s O
the O
patient O
experienced O
a O
permanent O
functional O
on O
state O
with O
su O
##f O
##ﬁ O
##cie O
##nt O
mobility O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##rds O
total O
58 O
220 O
up O
##dr O
##s O
iii O
33 O
108 O
in O
the O
l O
do O
##pa O
test O
table O
1 O
do O
##pa O
##mine O
##rg O
##ic O
medication O
was O
completely O
withdrawn O
the O
adjustment O
of O
stimulation O
parameters O
however O
was O
di O
##f O
##ﬁ O
##cu O
##lt O
due O
to O
a O
very O
low O
threshold O
for O
stimulation O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ias O
that O
resembled O
the O
previous O
ld O
##opa O
induced O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
despite O
different O
ph O
##arm O
##aco O
##logical O
and O
programming O
measures O
we O
were O
unable O
to O
completely O
ab O
##olis O
##h O
d O
##ys O
##kin O
##es O
##ias O
throughout O
the O
day O
video O
##ta O
##pe O
three O
years O
after O
surgery O
however O
the O
overall O
severity O
and O
duration O
of O
d O
##ys O
##kin O
##es O
##ias O
has O
improved O
compared O
to O
the O
state O
before O
st O
##n O
db O
##s O
3 O
years O
post O
db O
##s O
up O
##dr O
##s O
iv O
item O
32 O
duration O
1 O
4 O
and O

db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##5 O

33 O
disability O
2 O
4 O
while O
the O
ben O
##e O
##ﬁ O
##t O
on O
off O
period O
symptoms O
was O
sustained O

patient O
2 O

the O
41 O
year O
old O
man O
pd O
since O
12 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
treated O
by O
staged O
bilateral O
neural O
transplant O
##ation O
with O
the O
second O
graf O
##t O
right O
st O
##ria O
##tum O
6 O
months O
after O
the O
ﬁ O
##rst O
graf O
##t O
cell O
preparation O
surgical O
procedure O
im O
##mun O
##os O
##up O
##press O
##ion O
and O
demonstration O
of O
long O
term O
graf O
##t O
survival O
were O
identical O
to O
patient O
1 O
1 O

following O
transplant O
##ation O
he O
experienced O
considerable O
reduction O
of O
off O
phase O
symptoms O
in O
the O
medication O
off O
condition O
which O
was O
stable O
for O
8 O
years O
table O
1 O
one O
year O
following O
transplant O
##ation O
however O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
gradually O
occurred O
with O
continuous O
cho O
##re O
##oat O
##het O
##oid O
movements O
in O
arms O
and O
ﬁ O
##nger O
##s O
cd O
##rs O
6 O
28 O
video O
##ta O
##pe O
additionally O
he O
was O
suffering O
from O
severe O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
10 O
28 O
despite O
reduction O
of O
led O
##d O
to O
100 O
mg O
and O
anti O
##dy O
##skin O
##etic O
therapy O
with O
ama O
##nta O
##dine O
he O
continued O
to O
have O
d O
##ys O
##kin O
##es O
##ias O
throughout O
the O
day O
up O
##dr O
##s O
iv O
item O
32 O
4 O
4 O
which O
were O
rated O
as O
severely O
di O
##sa O
##bling O
up O
##dr O
##s O
iv O
item O
33 O
3 O
4 O
table O
1 O

because O
of O
the O
prominent O
hyper O
##kin O
##es O
##ias O
but O
relatively O
few O
off O
period O
symptoms O
8 O
years O
after O
bilateral O
graf O
##ting O
the O
patient O
was O
selected O
for O
bilateral O
gp O
##i O
db O
##s O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
2 O
28 O
in O
the O
formal O
assessment O
video O
##ta O
##pe O
in O
contrast O
the O
patient O
reported O
complete O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
during O
the O
day O
item O
32 O
und O
33 O
0 O
4 O
because O
off O
period O
symptoms O
were O
con O
##com O
##itan O
##tly O
improved O
up O
##dr O
##s O
iii O
11 O
108 O
in O
the O
formal O
assessment O
all O
do O
##pa O
##mine O
##rg O
##ic O
medication O
could O
be O
stopped O

these O
two O
case O
reports O
demonstrate O
that O
disease O
##and O
treatment O
related O
complications O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
in O
pd O
can O
be O
effectively O
treated O
by O
db O
##s O
in O
patient O
1 O
st O
##n O
db O
##s O
primarily O
improved O
off O
period O
symptoms O
which O
reduced O
the O
necessity O
for O
additional O
do O
##pa O
##mine O
##rg O
##ic O
drug O
therapy O
the O
effect O
on O
d O
##ys O
##kin O
##es O
##ias O
however O
was O
not O
immediate O
in O
fact O
this O
patient O
became O
very O
sensitive O
to O
stimulation O
induced O
d O
##ys O
##kin O
##es O
##ias O
and O
continued O
to O
exhibit O
ﬂ O
##uc O
##tua O
##ting O
cho O
##re O
##oat O
##het O
##oid O
d O
##ys O
##kin O
##es O
##ias O
with O
stable O
stimulation O
parameters O
even O
after O
complete O
withdrawal O
of O
any O
do O
##pa O
##mine O
##rg O
##ic O
drug O
##therapy O
these O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
resembled O
clinical O
##ly O
the O
peak O
dose O
d O
##ys O
##kin O
##es O
##ias O
before O
surgery O
and O
were O
probably O
the O
result O
of O
an O
interaction O
between O
st O
##nd O
##bs O
and O
di O
##urn O
##al O
ﬂ O
##uc O
##tua O
##tions O
in O
the O
release O
of O
do O
##pa O
##mine O

from O
the O
fetal O
graf O
##t O
the O
failure O
to O
reduce O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
our O
patient O
contrasts O
with O
a O
previous O
report O
##5 O
that O
found O
marked O
reduction O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
by O
st O
##n O
db O
##s O
however O
in O
this O
abstract O
the O
stereo O
##ta O
##ctic O
position O
of O
the O
stimulation O
contacts O
has O
not O
been O
spec O
##i O
##ﬁ O
##ed O
and O
therefore O
the O
ben O
##e O
##ﬁ O
##cial O
effect O
may O
not O
be O
attributed O
to O
stimulation O
of O
the O
st O
##n O
proper O
but O
rather O
the O
adjacent O
sub O
##thal O
##ami O
##c O
area O
following O
this O
notion O
a O
previous O
study O
reported O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
of O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
through O
st O
##n O
db O
##s O
most O
probably O
due O
to O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
area O
6 O
a O
recent O
computational O
model O
af O
##ﬁ O
##rmed O
the O
clinical O
ﬁ O
##nding O
that O
stimulation O
contacts O
positioned O
in O
the O
dorsal O
portion O
of O
the O
st O
##n O
simultaneously O
in O
##ﬂ O
##uen O
##ce O
gp O
##i O
ﬁ O
##bers O
of O
passage O
within O
the O
sub O
##thal O
##ami O
##c O
area O
and O
therefore O
potentially O
reduce O
d O
##ys O
##kin O
##es O
##ias O
7 O

in O
patient O
2 O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
improved O
both O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
and O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
and O
reduced O
the O
severity O
of O
off O
motor O
signs O
the O
ben O
##e O
##ﬁ O
##cial O
effect O
of O
gp O
##i O
db O
##s O
on O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
our O
patient O
parallels O
the O
outcome O
of O
a O
previously O
reported O
single O
case O
observation O
8 O

the O
et O
##iology O
of O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
following O
st O
##ria O
##tal O
fetal O
ni O
##gra O
##l O
graf O
##ting O
is O
still O
unclear O
the O
development O
of O
d O
##ys O
##kin O
##es O
##ias O
after O
transplant O
##ation O
is O
probably O
not O
associated O
with O
do O
##pa O
##mine O
##rg O
##ic O
over O
##growth O
or O
excessive O
do O
##pa O
##mine O
release O
from O
the O
graf O
##ts O
accordingly O
18 O
##f O
pet O
studies O
in O
pd O
patients O
with O
post O
##gra O
##fting O
d O
##ys O
##kin O
##es O
##ias O
have O
not O
provided O
evidence O
for O
do O
##pa O
##mine O
##rg O
##ic O
over O
##growth O
4 O
favored O
h O
##yp O
##oth O
##eses O
rather O
involve O
patch O
##y O
and O
uneven O
do O
##pa O
##mine O
##rg O
##ic O
inner O
##vation O
resulting O
in O
do O
##pa O
##mine O
over O
##ﬂ O
##ow O
from O
rein O
##ner O
##vate O
##d O
into O
non O
##re O
##inn O
##er O
##vate O
##d O
st O
##ria O
##tal O
regions O
and O
activation O
of O
super O
##sen O
##sit O
##ive O
do O
##pa O
##mine O
receptors O
in O
##ﬂ O
##am O
##mat O
##ory O
reactions O
around O
the O
graf O
##ts O
may O
further O
promote O
d O
##ys O
##kin O
##es O
##ias O
eventually O
un O
##fa O
##vor O
##able O
composition O
of O
the O
graf O
##t O
with O
respect O
to O
the O
predominant O
type O
of O
do O
##pa O
##mine O
##rg O
##ic O
ne O
##uron O
##es O
from O
the O
sub O
##stan O
##tia O
ni O
##gra O
or O
ventral O
te O
##gm O
##ental O
area O
may O
play O
a O
role O
9 O

the O
path O
##op O
##hy O
##sio O
##logical O
sequel O
##ae O
of O
un O
##re O
##gul O
##ated O
intra O
##st O
##ria O
##tal O
do O
##pa O
##mine O
release O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
on O
the O
direct O
and O
indirect O
basal O
gang O
##lia O
pathway O
have O
not O
been O
spec O
##i O
##ﬁ O
##cal O
##ly O
investigated O
however O
experimental O
studies O
on O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
have O
highlighted O
the O
crucial O
role O
of O
d O
##1 O
do O
##pa O
##mine O
receptor O
mediated O
transmission O
at O
the O
level O
of O
the O
direct O
pathway O
from O
the O
st O
##ria O
##tum O
to O
the O
gp O
##i O
10 O
increased O
sensitivity O
of O
d O
##1 O
do O
##pa O
##mine O
receptors O
have O
recently O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
as O
a O
prominent O
risk O
factor O
for O
d O
##ys O
##kin O
##es O
##ias O
11 O
consequently O
in O
animal O
and O
human O
studies O
alterations O
of O
the O
direct O
pathway O
due O
to O
l O
do O
##pa O
induced O
d O
##ys O
##kin O
##es O
##ias O
led O
to O
fundamental O
changes O
in O
the O
electro O
##phy O
##sio O

129 O
##6 O
j O
her O
##zog O
et O
al O

logical O
properties O
of O
the O
gp O
##i O
with O
reduced O
gp O
##i O
ﬁ O
##ring O
rates O
and O
abnormal O
bursting O
discharge O
12 O
modulation O
of O
the O
path O
##ological O
activity O
within O
the O
gp O
##i O
by O
means O
of O
db O
##s O
immediately O
reduces O
d O
##ys O
##kin O
##es O
##ias O
ir O
##res O
##pe O
##ctive O
of O
the O
medication O
state O
13 O
in O
contrast O
intervening O
within O
the O
st O
##n O
probably O
does O
not O
directly O
am O
##eli O
##ora O
##te O
l O
do O
##pa O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ias O
but O
rather O
ex O
##ert O
##s O
its O
anti O
##dy O
##skin O
##etic O
in O
##ﬂ O
##uen O
##ce O
by O
post O
##oper O
##ative O
reduction O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
13 O
the O
superior O
effect O
of O
gp O
##i O
db O
##s O
compared O
to O
st O
##n O
db O
##s O
in O
reducing O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
unrelated O
to O
external O
do O
##pa O
##mine O
application O
supports O
this O
concept O
assign O
##ing O
a O
pivotal O
role O
to O
the O
direct O
pathway O
in O
media O
##ting O
d O
##ys O
##kin O
##es O
##ia O
related O
neural O
activity O
alternatively O
or O
complementary O
to O
the O
proposed O
systemic O
effects O
on O
neural O
activity O
within O
the O
basal O
gang O
##lia O
loop O
differential O
effects O
of O
st O
##n O
db O
##s O
versus O
gp O
##i O
db O
##s O
##14 O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
release O
may O
impact O
the O
different O
outcomes O
in O
our O
patients O
however O
in O
contrast O
to O
the O
results O
of O
aforementioned O
animal O
studies O
a O
pet O
study O
in O
pd O
patients O
with O
st O
##n O
db O
##s O
failed O
to O
detect O
any O
sign O
##i O
##ﬁ O
##can O
##t O
change O
in O
the O
extra O
##cellular O
st O
##ria O
##tal O
concentration O
of O
do O
##pa O
##mine O
15 O

in O
conclusion O
we O
showed O
that O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
patients O
can O
ben O
##e O
##ﬁ O
##t O
from O
additional O
ne O
##uro O
##mo O
##du O
##lation O
therapy O
the O
choice O
of O
target O
may O
need O
to O
be O
tailored O
to O
the O
individual O
clinical O
sy O
##mpt O
##oma O
##tology O
st O
##nd O
##bs O
in O
our O
patient O
led O
to O
marked O
improvement O
in O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
but O
was O
less O
effective O
in O
reducing O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
in O
patients O
with O
prominent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
gp O
##i O
db O
##s O
may O
be O
the O
better O
option O
because O
of O
its O
immediate O
anti O
##dy O
##skin O
##etic O
effect O
however O
the O
small O
number O
of O
patients O
enrolled O
and O
some O
short O
##coming O
in O
trying O
all O
possible O
stimulation O
parameters O
patient O
1 O
may O
limit O
the O
conclusions O
that O
can O
be O
drawn O
from O
our O
data O

segment O
1 O
patient O
1 O
before O
st O
##n O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
1 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
2 O
months O
before O
implant O
##ation O
of O
bilateral O
sub O
##thal O
##ami O
##c O
leads O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
presents O
with O
marked O
limb O
h O
##yp O
##oki O
##nesia O
and O
simultaneously O
intermittent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O

segment O
2 O
patient O
1 O
following O
st O
##n O
db O
##s O
medication O
off O
stimulation O
on O
three O
years O
following O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
the O
patient O
continues O
to O
show O
off O
period O
d O
##ys O
##kin O
##es O
##ias O

segment O
3 O
patient O
2 O
before O
gp O
##i O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
2 O
was O
video O
##ta O
##ped O

8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
3 O
months O
before O
implant O
##ation O
of O
bilateral O
leads O
within O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
shows O
limb O
h O
##yp O
##oki O
##nesia O
with O
intermittent O
d O
##ys O
##kin O
##es O
##ias O
accent O
##uated O
in O
the O
right O
hand O
and O
ﬁ O
##nger O
##s O

segment O
4 O
patient O
2 O
following O
gp O
##i O
db O
##s O
medication O
off O
stimulation O
on O
two O
years O
following O
pal O
##lid O
##al O
deep O
brain O
stimulation O
severity O
of O
d O
##ys O
##kin O
##es O
##ias O
in O
the O
medication O
off O
condition O
is O
reduced O
despite O
complete O
ce O
##ssa O
##tion O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
off O
period O
symptoms O
are O
su O
##f O
##ﬁ O
##cie O
##ntly O
alleviate O
##d O
by O
deep O
brain O
stimulation O

br O
##und O
##in O
p O
po O
##gar O
##ell O
o O
ha O
##gel O
##l O
p O
et O
al O
bilateral O
ca O
##uda O
##te O
and O
put O
##amen O
graf O
##ts O
of O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
tissue O
treated O
with O
la O
##zar O
##oids O
in O
parkinson O
s O
disease O
brain O
2000 O
123 O
part O
7 O
138 O
##0 O
139 O
##0 O

freed O
cr O
greene O
pe O
breeze O
re O
et O
al O
transplant O
##ation O
of O
embryo O
##nic O
do O
##pa O
##mine O
neurons O
for O
severe O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2001 O
344 O
710 O
71 O
##9 O

ol O
##ano O
##w O
cw O
go O
##etz O
c O
##g O
ko O
##rdo O
##wer O
j O
##h O
et O
al O
a O
double O
blind O
controlled O
trial O
of O
bilateral O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
in O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
2003 O
54 O
403 O
41 O
##4 O

po O
##gar O
##ell O
o O
koch O
w O
gil O
##deh O
##aus O
f O
##j O
et O
al O
long O
term O
assessment O
of O
st O
##ria O
##tal O
do O
##pa O
##mine O
transport O
##ers O
in O
parkinson O
##ian O
patients O
with O
intra O
##st O
##ria O
##tal O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
graf O
##ts O
eu O
##r O
j O
nu O
##cl O
med O
mo O
##l O
imaging O
2006 O
33 O
407 O
411 O

cho O
c O
alter O
##man O
r O
##l O
mira O
##vite O
j O
et O
al O
sub O
##thal O
##ami O
##c O
db O
##s O
for O
the O
treatment O
of O
runaway O
d O
##ys O
##kin O
##es O
##ias O
after O
embryo O
##nic O
or O
fetal O
tissue O
transplant O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
123 O
##7 O

alter O
##man O
r O
##l O
shi O
##ls O
j O
##l O
gu O
##des O
##bla O
##tt O
m O
tag O
##lia O
##ti O
m O
immediate O
and O
sustained O
relief O
of O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
after O
dorsal O
relocation O
of O
a O
deep O
brain O
stimulation O
lead O
case O
report O
ne O
##uro O
##sur O
##g O
focus O
2004 O
17 O
e O
##6 O

mi O
##oc O
##ino O
##vic O
s O
parent O
m O
but O
##son O
cr O
et O
al O
computational O
analysis O
of O
sub O
##thal O
##ami O
##c O
nucleus O
and O
lent O
##icular O
fa O
##sc O
##ic O
##ulus O
activation O
during O
therapeutic O
deep O
brain O
stimulation O
j O
ne O
##uro O
##phy O
##sio O
##l O
2006 O
96 O
156 O
##9 O
1580 O

graf O
##f O
ra O
##df O
##ord O
j O
foot O
##e O
k O
##d O
rodriguez O
r O
##l O
et O
al O
deep O
brain O
stimulation O
of O
the O
internal O
segment O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
in O
delayed O
runaway O
d O
##ys O
##kin O
##es O
##ia O
arch O
ne O
##uro O
##l O
2006 O
63 O
118 O
##1 O
118 O
##4 O

winkler O
c O
ki O
##rik O
d O
b O
##jo O
##rk O
##lund O
a O
cell O
transplant O
##ation O
in O
parkinson O
s O
disease O
how O
can O
we O
make O
it O
work O
trends O
ne O
##uro O
##sc O
##i O
2005 O
28 O
86 O
92 O

ge O
##rf O
##en O
cr O
d O
##1 O
do O
##pa O
##mine O
receptor O
super O
##sen O
##sit O
##ivity O
in O
the O
do O
##pa O
##mine O
depleted O
st O
##ria O
##tum O
animal O
model O
of O
parkinson O
s O
disease O
ne O
##uro O
##sc O
##ient O
##ist O
2003 O
9 O
45 O
##5 O
46 O
##2 O

au O
##bert O
i O
gui O
##gon O
##i O
c O
ha O
##kan O
##sson O
k O
et O
al O
increased O
d O
##1 O
do O
##pa O
##mine O
receptor O
signaling O
in O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ia O
ann O
ne O
##uro O
##l O
2005 O
57 O
17 O
26 O

lo O
##zano O
am O
lang O
ae O
levy O
r O
et O
al O
ne O
##uron O
##al O
recordings O
in O
parkinson O
s O
disease O
patients O
with O
d O
##ys O
##kin O
##es O
##ias O
induced O
by O
ap O
##omo O
##rp O
##hine O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##14 O
##1 O
s O
##14 O
##6 O

vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
et O
al O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

mei O
##ss O
##ner O
w O
ha O
##rna O
##ck O
d O
ho O
##ess O
##le O
n O
et O
al O
high O
frequency O
stimulation O
of O
the O
en O
##top O
##ed O
##un O
##cular O
nucleus O
has O
no O
effect O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
transmission O
ne O
##uro O
##che O
##m O
int O
2004 O
44 O
281 O
286 O

tho O
##bo O
##is O
s O
fra O
##ix O
v O
sava O
##sta O
m O
et O
al O
chronic O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
and O
st O
##ria O
##tal O
d O
##2 O
do O
##pa O
##mine O
receptors O
in O
parkinson O
s O
disease O
a O
11 O
c O
ra O
##cl O
##op O
##ride O
pet O
study O
j O
ne O
##uro O
##l O
2003 O
250 O
121 O
##9 O
122 O
##3 O

l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##7 O

lev O
##od O
##opa O
therapy O
in O
a O
les O
##ch O
ny O
##han O
disease O
patient O

path O
##ological O
bio O
##chemical O
ne O
##uro O
##ima O
##ging O
and O
therapeutic O
remarks O

mercedes O
serra O
##no O
md O
1 O
3 O
bel O
##en O
pe O
##´ O
##re O
##z O
md O
phd O
##1 O
3 O

aid O
##a O
or O
##ma O
##za O
##´ O
##bal O
phd O
2 O
3 O
rafael O
art O
##uch O
md O
phd O
2 O
3 O
ja O
##ume O
camp O
##isto O
##l O
md O
phd O
1 O
3 O
rosa O
j O
torres O
md O
phd O
4 O
and O
angels O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
md O
phd O
##1 O
3 O

1 O
##ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
2 O
##cl O
##ini O
##cal O
biochemistry O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
3 O
##cent O
##re O
for O
biomedical O
research O
on O
rare O
diseases O
ci O
##ber O
##er O
instituto O
de O
sal O
##ud O
carlos O
iii O
barcelona O
spain O
4 O
##di O
##vision O
of O
clinical O
biochemistry O
la O
paz O
university O
hospital O
madrid O
spain O

abstract O
les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
of O
pu O
##rine O
metabolism O
causing O
severe O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
disturbances O
in O
which O
an O
abnormal O
central O
nervous O
system O
do O
##pa O
##mine O
##rg O
##ic O
function O
has O
been O
implied O
however O
lev O
##od O
##opa O
treatment O
has O
rarely O
been O
used O
and O
reports O
describe O
het O
##ero O
##gen O
##eous O
responses O
we O
report O
an O
l O
##nd O
patient O
with O
low O
do O
##pa O
##mine O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
for O
whom O
early O
lev O
##od O
##opa O
car O
##bid O
##opa O
therapy O
was O
begun O
with O
a O
notable O
clinical O
improvement O
we O
propose O
that O
very O
early O
treatment O
of O
l O
##nd O
patients O
with O
lev O
##od O
##opa O
may O
improve O
their O
neurological O
symptoms O
and O
may O
contribute O
to O
a O
better O
outcome O
2008 O
movement O
disorder O
society O

key O
words O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
do O
##pa O
##mine O
les O
##ch O
ny O
##han O
disease O
lu O
##mba O
##r O
pun O
##cture O
mono O
##amine O
##s O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O

les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
caused O
by O
de O
##ﬁ O
##cie O
##nt O
activity O
of O
the O
enzyme O
h O
##yp O
##ox O
##ant O
##hine O
gu O
##ani O
##ne O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
tran O
##fera O
##se O
hp O
##rt O
bio O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
a O
ng O
##els O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
pediatric O
ne O
##uro O
##logy O

department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
pass O
##ei O
##g O
de O
sant O
joan O
de O
de O
##´ O
##u O
2 O
08 O
##9 O
##50 O
es O
##pl O
##ug O
##ues O
de O
ll O
##ob O
##re O
##gat O
barcelona O
spain O

e O
mail O
ag O
##ar O
##cia O
hs O
##j O
##db O
##c O
##n O
org O

received O
17 O
july O
2007 O
revised O
11 O
september O
2007 O
accepted O
26 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##86 O

chemical O
##ly O
characterized O
by O
hyper O
##uri O
##ce O
##mia O
1 O
the O
clinical O
features O
associated O
with O
l O
##nd O
include O
those O
related O
directly O
to O
the O
hyper O
##uri O
##ce O
##mia O
go O
##ut O
ne O
##ph O
##rol O
##ith O
##ias O
##is O
arthritis O
etc O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
manifestation O
##s O
indicative O
of O
central O
nervous O
system O
cn O
##s O
disturbances O
and O
other O
clinical O
signs O
hyper O
##eme O
##sis O
an O
##emia O
etc O
1 O
delayed O
motor O
development O
d O
##yst O
##onia O
cho O
##re O
##oat O
##het O
##osis O
d O
##ys O
##arth O
##ria O
h O
##yp O
##oton O
##ia O
pyramid O
##al O
signs O
and O
aggressive O
and O
or O
self O
in O
##ju O
##rio O
##us O
behavior O
have O
been O
described O
as O
the O
most O
characteristic O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
manifestation O
##s O
2 O
the O
exact O
path O
##op O
##hy O
##sio O
##logical O
mechanism O
by O
which O
the O
impaired O
pu O
##rine O
metabolism O
causes O
these O
ne O
##uro O
##be O
##ha O
##vio O
##ral O
disturbances O
remains O
unclear O
but O
abnormal O
central O
mono O
##amine O
metabolism O
may O
play O
a O
role O
in O
particular O
several O
lines O
of O
evidence O
suggest O
that O
l O
##nd O
is O
associated O
with O
an O
abnormal O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
however O
only O
a O
few O
studies O
have O
reported O
treatment O
protocols O
using O
sub O
##sti O
##tu O
##tive O
lev O
##od O
##opa O
and O
they O
describe O
very O
het O
##ero O
##gen O
##eous O
responses O
to O
therapy O

we O
report O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
low O
do O
##pa O
##mine O
da O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
was O
started O
during O
the O
early O
stages O
of O
his O
ne O
##uro O
##dev O
##elo O
##pment O

clinical O
report O

the O
patient O
is O
a O
boy O
the O
second O
child O
of O
healthy O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
pregnancy O
delivery O
and O
neon O
##atal O
period O
were O
uneven O
##tf O
##ul O
from O
the O
ﬁ O
##rst O
days O
of O
his O
life O
a O
lack O
of O
spontaneous O
movements O
and O
poor O
head O
control O
were O
present O
clinical O
examination O
at O
4 O
months O
revealed O
marked O
hyper O
##ton O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
brisk O
deep O
re O
##ﬂ O
##ex O
##es O
bilateral O
ba O
##bin O
##ski O
s O
sign O
and O
trunk O
##al O
h O
##yp O
##oton O
##ia O
with O
no O
abnormal O
movements O
head O
ci O
##rc O
##um O
##ference O
and O
o O
##cular O
pursuit O
were O
appropriate O
brain O
mri O
disclosed O
slight O
signs O
of O
co O
##rti O
##cal O
at O
##rop O
##hy O
blood O
cell O
count O
glucose O
trans O
##amina O
##ses O
ck O
cr O
##ea O
##tin O
##ine O
ur O
##ic O
acid O
ammonia O
lac O
##tate O
p O
##yr O
##u O
##vate O
plasma O
amino O
acids O
urine O
organic O
acids O
and O
ur O
##ic O
acid O
were O
normal O
o O
##cular O
examination O
ev O
##oked O
audit O
##ive O
potential O
##s O
nerve O
conduct O
##ion O
and O
electro O
##my O
##ography O
were O
also O
normal O
at O
the O
age O
of O
10 O
months O
he O
developed O
tremor O
and O
marked O
d O
##yst O
##onic O
movements O
of O
the O
hands O
and O
the O
mouth O
video O
1 O
serum O
ur O
##ate O
was O
elevated O
48 O
##4 O
l O
##mo O
##l O
l O
normal O
range O
100 O
330 O
l O
##mo O
##l O
l O
and O
in O
24 O
hours O
urine O
the O
ur O
##ina O
##ry O
ur O
##ic O
acid O
cr O
##ea O
##tin O
##ine O
ratio O
was O
in O
the O
upper O
normal O
limit O
2 O
1 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
normal O
range O
0 O
2 O
2 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
hp O
##rt O
activity O
was O
requested O
at O
the O
same O
time O
due O
to O
the O
presence O
of O
d O
##ys O
##kin O
##etic O
movements O
a O
lu O
##mba O
##r O
pun O
##cture O
was O
performed O
showing O
low O
levels O
of O
homo O
##vani O
##lli O
##c O
acid O

129 O
##8 O
m O
serra O
##no O
et O
al O

table O
1 O
bio O
##genic O
amin O
##e O
and O
pt O
##erine O
concentrations O
in O
cs O
##f O
before O
treatment O
and O
follow O
up O

after O
l O
do O
##pa O
therapy O
l O
do O
##pa O
plus O
car O
##bid O
##opa O
and O
f O
##olin O
##ic O
acid O

di O
##tions O
video O
3 O
he O
is O
able O
to O
transfer O
objects O
between O
hands O
and O
do O
pin O
##cer O
grasping O
comprehension O
has O
always O
seemed O
to O
be O
preserved O
he O
never O
presented O
self O
in O
##ju O
##rio O
##us O
behavior O
the O
cs O
##f O
h O
##va O
concentration O
is O
now O
in O
the O
normal O
range O
table O
1 O

before O
treatment O
6 O
mg O
kg O
day O

age O
10 O
mo O
3 O
y O
##r O
4 O
mo O

h O
##va O
homo O
##vani O
##lli O
##c O
acid O
5 O
hi O
##aa O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
m O
##hp O
##h O
3 O
##met O
##ho O
##xy O
4 O
hydro O
##xy O
##ph O
##en O
##yl O
##gly O
##col O

numbers O
in O
brackets O
represent O
the O
age O
related O
controls O
values O
3 O

h O
##va O
in O
cs O
##f O
compared O
to O
age O
normal O
range O
##3 O
table O
1 O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
1 O
0 O
25 O
proportion O
was O
gradually O
introduced O
up O
to O
3 O
mg O
kg O
day O
resulting O
in O
moderate O
improvement O
at O
the O
age O
of O
1 O
year O
and O
6 O
months O
the O
patient O
showed O
better O
head O
control O
and O
he O
started O
picking O
up O
objects O
d O
##ys O
##kin O
##etic O
movements O
were O
still O
present O
while O
peripheral O
hyper O
##ton O
##ia O
and O
brisk O
deep O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
decreased O
notably O
video O
2 O
the O
low O
cs O
##f O
h O
##va O
concentration O
together O
with O
the O
clinical O
improvement O
led O
us O
to O
h O
##yp O
##oth O
##es O
##ize O
a O
primary O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
synthesis O
defect O
but O
ty O
##ros O
##ine O
hydro O
##xy O
##lase O
gene O
study O
showed O
no O
mutations O
when O
ur O
##ic O
acid O
metabolism O
was O
assessed O
again O
the O
patient O
presented O
a O
serum O
ur O
##ate O
value O
of O
46 O
##3 O
l O
##mo O
##l O
l O
normal O
range O
100 O
330 O
l O
##mo O
##l O
l O
ur O
##ina O
##ry O
ur O
##ic O
acid O
cr O
##ea O
##tin O
##ine O
ratio O
at O
2 O
32 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
normal O
range O
0 O
2 O
2 O
mm O
##ol O
mo O
##l O
cr O
##ea O
##tin O
##ine O
and O
markedly O
elevated O
renal O
ex O
##cre O
##tion O
of O
x O
##ant O
##hine O
and O
h O
##yp O
##ox O
##ant O
##hine O
hp O
##rt O
activity O
in O
hem O
##olis O
##ate O
was O
und O
##ete O
##ctable O
and O
aden O
##ine O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fera O
##se O
activity O
was O
elevated O
59 O
nm O
##ol O
hour O
mg O
hem O
##og O
##lo O
##bin O
normal O
range O
19 O
38 O
nm O
##ol O
hour O
mg O
hem O
##og O
##lo O
##bin O
molecular O
analysis O
disclosed O
a O
5 O
bp O
del O
##eti O
##on O
in O
hp O
##rt O
ex O
##on O
3 O
corresponding O
to O
position O
261 O
265 O
of O
hp O
##rt O
mrna O
associated O
with O
a O
12 O
bp O
insertion O
in O
position O
261 O
this O
mutation O
has O
not O
been O
previously O
reported O
and O
it O
predicted O
a O
change O
in O
hp O
##rt O
protein O
with O
a O
frames O
##hi O
##ft O
after O
g O
##ly O
##58 O
and O
a O
stop O
cod O
##on O
in O
position O
74 O
the O
child O
has O
presented O
a O
moderate O
progressive O
improvement O
to O
date O
3 O
years O
of O
age O
therapy O
with O
l O
do O
##pa O
car O
##bid O
##opa O
up O
to O
6 O
mg O
kg O
day O
and O
f O
##olin O
##ic O
acid O
to O
avoid O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
has O
not O
been O
withdrawn O
head O
control O
has O
been O
fully O
attained O
tremor O
has O
completely O
disappeared O
the O
quality O
of O
movements O
is O
notably O
more O
precise O
and O
the O
patient O
sits O
without O
support O
d O
##yst O
##onic O
movements O
are O
still O
present O
although O
less O
pronounced O
##ly O
than O
baseline O
con O

we O
describe O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
clinical O
signs O
of O
impaired O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
the O
notable O
tremor O
the O
marked O
d O
##yst O
##onia O
developed O
during O
early O
infancy O
and O
the O
obvious O
sustained O
response O
to O
l O
do O
##pa O
led O
us O
to O
investigate O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
however O
some O
clinical O
characteristics O
such O
as O
the O
absence O
of O
o O
##cu O
##logy O
##ric O
crisis O
and O
the O
preservation O
of O
facial O
ge O
##stic O
##ulation O
did O
not O
ﬁ O
##t O
into O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
picture O

it O
has O
been O
suggested O
that O
l O
##nd O
may O
be O
associated O
with O
abnormal O
do O
##pa O
##mine O
##rg O
##ic O
function O
including O
ne O
##uro O
##path O
##ological O
bio O
##chemical O
and O
ne O
##uro O
##ima O
##ging O
studies O
while O
no O
morphological O
abnormalities O
in O
the O
cn O
##s O
of O
l O
##nd O
patients O
have O
been O
reported O
direct O
measurement O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
tissue O
has O
shown O
that O
da O
and O
h O
##va O
are O
sign O
##i O
##ﬁ O
##can O
##tly O
lower O
in O
the O
limb O
##ic O
and O
st O
##ria O
##tal O
regions O
of O
deceased O
l O
##nd O
patients O
4 O
5 O
moreover O
path O
##ological O
studies O
have O
shown O
increased O
do O
##pa O
##mine O
d O
##2 O
receptor O
im O
##mun O
##ore O
##act O
##ivity O
in O
put O
##amen O
and O
less O
evidently O
in O
the O
ca O
##uda O
##te O
nucleus O
5 O
as O
a O
result O
of O
recent O
ﬁ O
##nding O
##s O
a O
theory O
of O
posts O
##yna O
##ptic O
da O
super O
##sen O
##sit O
##ivity O
owing O
to O
a O
decreased O
pre O
##sy O
##na O
##ptic O
da O
activity O
has O
been O
formulated O
5 O
interesting O
##ly O
when O
the O
sub O
##stan O
##tia O
ni O
##gra O
was O
explored O
da O
levels O
turned O
out O
to O
be O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
lower O
than O
in O
controls O
4 O
and O
ty O
##ros O
##ine O
hydro O
##xi O
##lase O
neurons O
and O
ﬁ O
##bers O
were O
not O
decreased O
4 O
these O
ﬁ O
##nding O
##s O
suggest O
that O
the O
da O
terminals O
are O
reduced O
and O
damaged O
due O
to O
a O
developmental O
or O
a O
de O
##gen O
##erative O
process O
ﬁ O
##nally O
resulting O
in O
impaired O
activity O
in O
the O
st O
##ria O
##tum O

moreover O
evidence O
of O
do O
##pa O
##mine O
##rg O
##ic O
function O
abnormalities O
also O
comes O
from O
po O
##sit O
##ron O
emission O
tom O
##ography O
images O
which O
show O
an O
abnormal O
##ly O
reduced O
number O
of O
do O
##pa O
##mine O
##rg O
##ic O
nerve O
terminals O
and O
cell O
bodies O
involving O
all O
do O
##pa O
##mine O
##rg O
##ic O
pathways O
but O
especially O
in O
the O
put O
##amen O
6 O
7 O

the O
role O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
development O
has O
recently O
been O
documented O
8 O
interesting O
##ly O
the O
early O
do O
##pa O
##mine O
##rg O
##ic O
input O
from O
the O
mid O
##bra O
##in O
may O
play O
an O
important O
role O
in O
the O
development O
of O
the O
basal O
gang O
##lia O
and O
cerebral O
cortex O
9 O
furthermore O
brain O
development O
has O
to O
be O
completed O
during O
the O
ﬁ O
##rst O
months O
of O
life O
when O
ax O
##onal O
and O
den O
##dr O
##itic O
branching O
is O
ongoing O
and O
syn O
##ap O
##to O
##genesis O
is O
just O
beginning O
da O
disturbances O
in O

l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##9 O

these O
ne O
##uro O
##dev O
##elo O
##pment O
##al O
periods O
may O
be O
crucial O
for O
further O
cn O
##s O
function O

cs O
##f O
do O
##pa O
##mine O
meta O
##bol O
##ite O
analysis O
has O
previously O
been O
examined O
to O
assess O
the O
functioning O
of O
the O
cn O
##s O
do O
##pa O
##mine O
pathway O
in O
l O
##nd O
##10 O
13 O
by O
measuring O
the O
end O
product O
of O
da O
h O
##va O
these O
studies O
were O
performed O
some O
time O
ago O
during O
the O
70s O
and O
the O
80s O
and O
sometimes O
their O
results O
were O
not O
adequately O
evaluated O
11 O
obtained O
h O
##va O
values O
must O
be O
properly O
compared O
to O
age O
related O
control O
ranges O
so O
as O
to O
permit O
an O
accurate O
interpretation O
of O
the O
results O
the O
concentration O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
is O
inverse O
##ly O
correlated O
with O
age O
3 O
the O
patient O
described O
above O
initially O
presented O
slightly O
decreased O
levels O
of O
cs O
##f O
h O
##va O
compared O
to O
age O
related O
controls O
table O
1 O
silver O
##stein O
et O
al O
described O
age O
##rel O
##ated O
changes O
of O
h O
##va O
in O
cs O
##f O
and O
their O
results O
showed O
that O
the O
de O
##ﬁ O
##cie O
##ncies O
of O
h O
##va O
increased O
from O
infancy O
to O
adolescence O
13 O
perhaps O
our O
patient O
s O
young O
age O
obscured O
da O
de O
##ﬁ O
##ciency O
nonetheless O
bio O
##chemical O
response O
to O
l O
do O
##pa O
treatment O
was O
remarkable O
and O
second O
sample O
h O
##va O
values O
were O
higher O
and O
inside O
the O
normal O
range O
however O
the O
notably O
clinical O
improvement O
described O
could O
have O
been O
developmental O
and O
or O
due O
to O
l O
do O
##pa O
therapy O
their O
respective O
contributions O
are O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
evaluate O
owing O
to O
the O
het O
##ero O
##gen O
##eit O
##y O
of O
l O
##nd O

among O
the O
previously O
reported O
l O
do O
##pa O
treated O
patients O
some O
failed O
to O
improve O
while O
some O
even O
presented O
into O
##ler O
##able O
side O
effects O
10 O
13 O
an O
important O
limitation O
in O
the O
evaluation O
of O
the O
the O
##ra O
##pies O
used O
in O
the O
preceding O
reports O
was O
the O
different O
ages O
at O
which O
treatment O
was O
started O
it O
is O
likely O
that O
delayed O
l O
do O
##pa O
treatments O
do O
not O
help O
to O
recover O
the O
previously O
damaged O
nerve O
terminals O
furthermore O
due O
to O
the O
already O
decreased O
pre O
##sy O
##na O
##ptic O
da O
activity O
these O
patients O
may O
present O
a O
posts O
##yna O
##ptic O
da O
super O
##sen O
##sit O
##ivity O
##5 O
that O
would O
account O
for O
the O
lack O
of O
effectiveness O
and O
even O
for O
the O
presence O
of O
side O
effects O
like O
watts O
et O
al O
reported O
14 O
some O
time O
before O
mi O
##zu O
##no O
et O
al O
had O
described O
4 O
patients O
with O
no O
cs O
##f O
examination O
treated O
at O
different O
un O
##re O
##port O
##ed O
ages O
but O
they O
did O
not O
evaluate O
the O
impact O
on O
movement O
disturbances O
15 O
jan O
##kovich O
et O
al O
performed O
pre O
##tre O
##at O
##ment O
cs O
##f O
analysis O
but O
l O
do O
##pa O
doses O
and O
therapy O
duration O
were O
not O
detailed O
age O
at O
beginning O
of O
the O
treatment O
was O
very O
variable O
and O
their O
clinical O
results O
were O
mixed O
12 O

our O
clinical O
observation O
points O
out O
the O
need O
to O
develop O
neurological O
the O
##ra O
##pies O
for O
hp O
##rt O
de O
##ﬁ O
##cie O
##nt O
patients O
among O
which O
l O
do O
##pa O
may O
be O
promising O
however O
no O
general O
conclusions O
can O
be O
obtained O
from O
a O
single O
case O
report O
due O
to O
l O
##nd O
het O
##ero O
##gen O
##eit O
##y O
in O
any O
case O
we O
found O
that O
early O
l O
do O
##pa O
treatment O
is O
ad O
##vis O
##able O
to O
enable O
good O

response O
and O
to O
opt O
##imi O
##ze O
neurological O
outcome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
analysis O
may O
be O
a O
useful O
bio O
##chemical O
aid O
to O
select O
l O
##nd O
patients O
for O
l O
do O
##pa O
therapy O
and O
monitor O
their O
treatment O
further O
studies O
clinical O
observations O
and O
double O
blind O
trials O
are O
needed O
to O
establish O
the O
useful O
##ness O
of O
l O
do O
##pa O
in O
patients O
with O
l O
##nd O

video O
1 O
frequent O
d O
##ys O
##kin O
##etic O
movements O
of O
the O
mouth O
and O
the O
ex O
##tre O
##mit O
##ies O
absence O
of O
voluntary O
grasping O
no O
head O
control O
explosive O
un O
##co O
##ord O
##inated O
movements O

video O
2 O
better O
head O
control O
able O
to O
pick O
up O
objects O
fine O
motor O
movements O
have O
improved O

video O
3 O
head O
control O
is O
fully O
reached O
d O
##yst O
##onic O
movements O
are O
clearly O
improved O
able O
to O
transfer O
objects O
between O
hands O
put O
rings O
in O
a O
bar O
and O
do O
pin O
##cer O
grasping O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fis O
grant O
pi O
##0 O
##51 O
##31 O
##8 O
and O
ci O
##ber O
er O
is O
##c O
iii O
we O
thank O
the O
patient O
and O
his O
family O
for O
their O
participation O

jin O
##nah O
ha O
friedman O
##n O
t O
les O
##ch O
ny O
##han O
disease O
and O
its O
variants O
in O
sc O
##river O
cr O
beau O
##de O
##t O
al O
sly O
w O
##s O
valle O
d O
editors O
the O
metabolic O
and O
molecular O
bases O
of O
inherited O
disease O
8th O
ed O
new O
york O
mcgraw O
hill O
2001 O
p O
253 O
##7 O
257 O
##0 O

jin O
##nah O
ha O
vis O
##ser O
je O
harris O
jc O
et O
al O
del O
##ine O
##ation O
of O
the O
motor O
disorder O
of O
les O
##ch O
ny O
##han O
disease O
brain O
2006 O
129 O
120 O
##1 O
121 O
##7 O

or O
##ma O
##za O
##´ O
##bal O
a O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
a O
fern O
##a O
##´ O
##nde O
##z O
y O
fern O
##a O
##´ O
##nde O
##za O
##´ O
l O
##var O
##ez O
e O
camp O
##isto O
##l O
j O
art O
##uch O
r O
hp O
##lc O
with O
electro O
##chemical O
and O
ﬂ O
##uo O
##res O
##cence O
detection O
procedures O
for O
the O
diagnosis O
of O
in O
##born O

errors O
of O
bio O
##genic O
amin O
##es O
and O
pt O
##erine O
##s O
j O
ne O
##uro O
##sc O
##i O
methods O
2005 O
142 O
153 O
158 O

lloyd O
kg O
horn O
##yk O
##ie O
##wicz O
o O
davidson O
l O
et O
al O
bio O
##chemical O
evidence O
of O
dysfunction O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
the O
les O
##ch O
##ny O
##han O
syndrome O
n O
eng O
##l O
j O
med O
1981 O
305 O
110 O
##6 O
111 O
##1 O

sai O
##to O
y O
ito O
m O
hana O
##oka O
s O
oh O
##ama O
e O
aka O
##bos O
##hi O
s O
tak O
##ashi O
##ma O
s O
do O
##pa O
##mine O
receptor O
up O
##re O
##gul O
##ation O
in O
les O
##ch O
ny O
##han O
syndrome O
a O
post O
##mo O
##rte O
##m O
study O
ne O
##uro O
##ped O
##ia O
##trics O
1999 O
30 O
66 O
71 O

ernst O
m O
za O
##met O
##kin O
aj O
mat O
##och O
##ik O
ja O
et O
al O
pre O
##sy O
##na O
##ptic O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
##s O
in O
les O
##ch O
ny O
##han O
disease O
n O
eng O
j O
med O
1996 O
334 O
156 O
##8 O
157 O
##2 O

wong O
d O
##f O
harris O
jc O
na O
##id O
##u O
s O
et O
al O
do O
##pa O
##mine O
transport O
##ers O
are O
markedly O
reduced O
in O
les O
##ch O
ny O
##han O
disease O
in O
vivo O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1996 O
93 O
55 O
##39 O
55 O
##43 O

her O
##len O
##ius O
e O
la O
##ger O
##cr O
##ant O
##z O
h O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
and O
ne O
##uro O
##mo O
##du O
##lat O
##ors O
during O
early O
human O
development O
early O
hum O
dev O
2001 O
65 O
21 O
37 O

schmidt O
u O
bey O
##er O
c O
o O
##est O
##re O
##iche O
##r O
ab O
rei O
##ser O
##t O
i O
sc O
##hill O
##ing O
k O
pilgrim O
c O
activation O
of O
do O
##pa O
##mine O
##rg O
##ic O
d O
##1 O
receptors O
promotes O
mor O
##ph O
##ogen O
##esis O
of O
developing O
st O
##ria O
##tal O
neurons O
neuroscience O
1996 O
74 O
45 O
##3 O
460 O

caste O
##lls O
s O
cha O
##kra O
##bar O
##ti O
c O
wins O
##berg O
b O
##g O
hu O
##r O
##wi O
##c O
m O
pere O
##l O
j O
##m O
ny O
##han O
w O
##l O
effects O
of O
l O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
on O
mono O
##amine O
and O
amino O
acids O
turnover O
in O
the O
les O
##ch O
ny O
##han O
syndrome O
j O
autism O
dev O
di O
##sor O
##d O
1979 O
9 O
95 O
103 O

1300 O
s O
de O
##hn O
##ing O
et O
al O

cia O
##rane O
##llo O
rd O
anders O
t O
##f O
bar O
##cha O
##s O
jd O
berger O
pa O
can O
##n O
hm O
the O
use O
of O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
in O
a O
child O
with O
les O
##ch O
ny O
##han O
syndrome O
child O
psychiatry O
hum O
dev O
1976 O
7 O
127 O
133 O

jan O
##kovic O
j O
cas O
##key O
tc O
stout O
j O
##t O
butler O
i O
##j O
les O
##ch O
ny O
##han O
syndrome O
a O
study O
of O
motor O
behavior O
and O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
ann O
ne O
##uro O
##l O
1988 O
23 O
46 O
##6 O
46 O
##9 O

silver O
##stein O
f O
##s O
johnston O
mv O
hutchinson O
r O
##j O
edwards O
nl O
les O
##ch O
ny O
##han O
syndrome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
abnormalities O
ne O
##uro O
##logy O
1985 O
35 O
90 O
##7 O
911 O

watts O
r O
##we O
spell O
##acy O
e O
gibbs O
da O
all O
##sop O
j O
mc O
##ker O
##an O
ro O
sl O
##avi O
##n O
ge O
clinical O
post O
mort O
##em O
bio O
##chemical O
and O
therapeutic O
observations O
on O
the O
les O
##ch O
ny O
##han O
syndrome O
with O
particular O
reference O
to O
the O
neurological O
manifestation O
##s O
q O
##jm O
##ed O
1982 O
51 O
43 O
78 O

mi O
##zu O
##no O
t O
yu O
##gar O
##i O
y O
self O
mu O
##tila O
##tion O
in O
les O
##ch O
ny O
##han O
syndrome O
lance O
##t O
1974 O
1 O
76 O
##1 O

therapy O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
ben O
##e O
##ﬁ O
##cial O
outcome O
with O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
deep O
brain O
stimulation O

sandra O
de O
##hn O
##ing O
md O
1 O
jan O
hi O
##nne O
##rk O
me O
##hr O
##ken O
##s O
md O
2 O
nor O
##bert O
mu O
##¨ O
##ller O
phd O
1 O
and O
kai O
bo O
##¨ O
##tze O
##l O
md O
##3 O

1 O
##de O
##par O
##tment O
of O
psychiatry O
and O
psycho O
##therapy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
ludwig O
maximilian O
##s O

university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
ludwig O
maximilian O
##s O
university O
munich O
germany O

abstract O
we O
report O
on O
a O
female O
patient O
with O
tour O
##ette O
syndrome O
ts O
and O
a O
12 O
month O
follow O
up O
after O
chronic O
deep O
brain O
stimulation O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
which O
resulted O
in O
excellent O
re O
##mission O
of O
motor O
and O
vocal O
ti O
##cs O
2008 O
movement O
disorder O
society O

key O
words O
tour O
##ette O
syndrome O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O

tour O
##ette O
syndrome O
ts O
is O
a O
chronic O
and O
in O
severe O
cases O
de O
##bil O
##itating O
disorder O
characterized O
by O
motor O
and O
vocal O
ti O
##cs O
and O
additionally O
accompanied O
by O
features O

correspondence O
to O
dr O
sandra O
de O
##hn O
##ing O
psychiatric O
hospital O
of O
the O
ludwig O
maximilian O
##s O
university O
munich O
nu O
##bba O
##ums O
##tr O
7 O
munich O
d O
80 O
##33 O
##6 O
germany O

e O
mail O
sandra O
de O
##hn O
##ing O
med O
un O
##i O
mu O
##en O
##chen O
de O

received O
2 O
august O
2007 O
accepted O
29 O
november O
2007 O

published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
219 O
##30 O

of O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
and O
self O
in O
##ju O
##rio O
##us O
behavior O
although O
the O
path O
##op O
##hy O
##sio O
##logical O
mechanisms O
are O
yet O
unknown O
and O
the O
involvement O
of O
infection O
and O
in O
##ﬂ O
##am O
##mation O
has O
been O
discussed O
1 O
several O
studies O
have O
shown O
the O
in O
##ﬂ O
##uen O
##ce O
of O
the O
do O
##pa O
##mine O
##rg O
##ic O
system O
as O
anti O
##psy O
##cho O
##tic O
agents O
are O
successful O
in O
the O
treatment O
of O
ts O
mostly O
as O
an O
antagonist O
2 O
but O
also O
partly O
as O
an O
ago O
##nist O
of O
do O
##pa O
##mine O
3 O
functional O
and O
ne O
##uro O
##ima O
##ging O
studies O
emphasize O
abnormal O
##ly O
functioning O
do O
##pa O
##mine O
##rg O
##ic O
st O
##ria O
##to O
co O
##rti O
##cal O
circuits O
to O
affect O
these O
loops O
in O
ts O
##patient O
##s O
ref O
##rac O
##tory O
to O
medical O
treatment O
the O
strategy O
of O
deep O
brain O
stimulation O
db O
##s O
has O
been O
replaced O
introduced O
by O
van O
##de O
##wall O
##e O
4 O
in O
general O
stimulation O
targets O
are O
the O
tha O
##lam O
##us O
5 O
6 O
the O
anterior O
internal O
capsule O
7 O
the O
nucleus O
acc O
##umb O
##ens O
##8 O
and O
the O
gp O
##i O
##9 O
11 O
case O
series O
by O
serve O
##llo O
is O
added O
or O
combined O
approaches O
12 O

here O
we O
report O
on O
a O
female O
patient O
with O
ts O
and O
a O
12 O
##mont O
##h O
follow O
up O
study O
after O
chronic O
db O
##s O
of O
the O
gp O
##i O

case O
report O

the O
44 O
year O
old O
female O
patient O
has O
been O
suffering O
from O
ts O
since O
childhood O
when O
she O
was O
5 O
year O
old O
she O
ﬁ O
##rst O
developed O
vocal O
ti O
##cs O
sq O
##ue O
##aling O
in O
church O
followed O
by O
motor O
ti O
##cs O
like O
blinking O
bouncing O
and O
touching O
after O
delivery O
of O
her O
son O
at O
the O
age O
of O
20 O
the O
symptoms O
worsened O
and O
the O
patient O
showed O
self O
##mut O
##ilation O
with O
biting O
beating O
as O
well O
as O
grunt O
##ing O
and O
screaming O
at O
this O
time O
she O
also O
showed O
com O
##pu O
##ls O
##ive O
behavior O
for O
clean O
##liness O
during O
the O
course O
of O
disease O
the O
patient O
regularly O
developed O
a O
de O
##pressive O
mood O
and O
agitation O
proportional O
to O
the O
extent O
of O
ti O
##cs O
the O
intensity O
of O
her O
condition O
ﬁ O
##nally O
led O
to O
three O
suicide O
attempts O
social O
isolation O
and O
disability O

for O
the O
last O
17 O
years O
the O
patient O
was O
continuously O
treated O
as O
in O
##patient O
and O
out O
##patient O
of O
our O
clinic O
and O
the O
diagnosis O
of O
ts O
was O
established O
according O
to O
the O
criteria O
of O
ds O
##m O
iv O

conventional O
medication O
attempts O
with O
a O
range O
of O
anti O
##psy O
##cho O
##tics O
over O
many O
years O
did O
not O
have O
any O
substantial O
effect O
ultimately O
the O
combination O
of O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
together O
with O
monthly O
out O
##patient O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
ec O
##t O
over O
the O
last O
5 O
years O
has O
led O
to O
a O
partial O
suppression O
of O
ti O
##cs O
the O
rational O
##e O
for O
ec O
##t O
was O
derived O
from O
case O
reports O
where O
a O
substantial O
improvement O
of O
ti O
##cs O
##13 O
14 O
was O
demonstrated O

previous O
the O
##ra O
##pies O
with O
a O
2 O
ad O
##ren O
##ore O
##ce O
##pt O
##or O
ago O
##nist O
##s O
do O
##pa O
##mine O
ago O
##nist O
##s O
and O
op O
##io O
##id O
ago O
##nist O
##s O
as O
well O
as O
alternative O
treatments O
like O
antibiotics O
im O
##mun O
##og O
##lo O
##bu O
##lins O
and O
plasma O
##pher O
##esis O
already O
described O
as O
possibly O
effective O
in O
single O
reports O
##15 O
only O
resulted O
in O
a O
temporary O
improvement O
of O
the O
ti O
##cs O

tour O
##ette O
syndrome O
and O
deep O
brain O
stimulation O
130 O
##1 O

fig O
1 O
axial O
mri O
of O
the O
patient O
s O
brain O
showing O
the O
tip O
of O
the O
electrode O
##s O
6 O
mm O
below O
the O
level O
of O
the O
anterior O
and O
posterior O
com O
##mis O
##sure O
##s O
on O
the O
right O
the O
optic O
tract O
can O
be O
seen O
on O
which O
the O
electrode O
tip O
projects O

before O
stereo O
##ta O
##ctic O
intervention O
primary O
symptoms O
were O
severe O
grinding O
of O
her O
teeth O
beating O
her O
hips O
as O
well O
as O
persistent O
grunt O
##ing O
and O
qu O
##ack O
##ing O

after O
informed O
consent O
electrode O
implant O
##ation O
db O
##s O
338 O
##9 O
med O
##tron O
##ic O
for O
bilateral O
gp O
##i O
stimulation O
was O
performed O
under O
prop O
##of O
##ol O
an O
##esthesia O
with O
mri O
guided O
stereo O
##ta O
##xy O
using O
a O
mod O
##i O
##ﬁ O
##ed O
le O
##ks O
##el O
le O
##rch O
system O
the O
coordinates O
of O
the O
stereo O
##ta O
##ctic O
target O
point O
were O
as O
follows O
3 O
mm O
anterior O
to O
the O
ac O
pc O
mid O
##point O
4 O
mm O
below O
the O
ac O
pc O
plane O
and O
20 O
mm O
lateral O
to O
the O
inter O
##com O
##mis O
##ural O
line O
before O
the O
implant O
##ata O
##tion O
three O
micro O
##ele O
##ct O
##rod O
##es O
were O
inserted O
on O
each O
side O
simultaneously O
in O
order O
to O
con O
##ﬁ O
##rm O
the O
single O
cell O
activity O
typical O
for O
gp O
##i O
and O
to O
prove O
the O
appropriate O
distance O
to O
the O
internal O
capsule O
by O
macro O
##ele O
##ct O
##rod O
##e O
stimulation O
a O
post O
##oper O
##ative O
mri O
showed O
both O
electrode O
tips O
on O
top O
of O
the O
optic O
tracts O
right O
electrode O
18 O
mm O
lateral O
1 O
mm O
anterior O
7 O
mm O
below O
mid O
##com O
##mis O
##sur O
##al O
point O
left O
electrode O
19 O
mm O
lateral O
1 O
mm O
anterior O
and O
5 O
mm O
below O
on O
the O
right O
side O
electrode O
contact O
2 O
was O
chosen O
for O
chronic O
stimulation O
because O
the O
deeper O
contacts O
caused O
visual O
symptoms O
on O
the O
left O
side O
electrode O
contact O
1 O
was O
chosen O
fig O
1 O
after O
5 O
days O
during O
which O
the O
electrode O
lead O
had O
been O
external O
##ized O
and O
further O
test O
stimulation O
##s O
had O
shown O
no O
unwanted O
effects O
implant O
##ation O
of O
the O
pulse O
generators O
sole O
##tra O
med O
##tron O
##ic O
was O
performed O
initially O
standard O
settings O
also O
used O
in O
gp O
##i O
db O
##s O
for O
d O
##yst O
##onia O
were O
chosen O
mono O
##pol O
##ar O
stimulation O
amplitude O
2 O
5 O
v O
pulse O
width O

120 O
l O
##s O
and O
frequency O
130 O
pp O
##s O
and O
slowly O
increased O
to O

3 O
2 O
v O
at O
discharge O
stimulation O
parameters O
were O
further O
increased O
3 O
months O
after O
stimulation O
3 O
5 O
v O
150 O
l O
##s O
145 O

pp O
##s O
4 O
months O
after O
implant O
##ation O
3 O
5 O
v O
180 O
l O
##s O
145 O
pp O
##s O
and O
at O
12 O
months O
after O
the O
implant O
##ation O
4 O
2 O
v O
210 O
l O
##s O
145 O
pp O
##s O
under O
this O
setting O
the O
current O
applied O
was O
94 O
la O
on O
each O
side O

a O
decrease O
in O
ti O
##c O
frequency O
and O
intensity O
was O
noted O
during O
the O
ﬁ O
##rst O
week O
after O
the O
start O
of O
the O
continuous O
stimulation O
and O
ti O
##cs O
almost O
disappeared O
after O
6 O
weeks O
of O
stimulation O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
were O
discontinued O
clinical O
outcome O
was O
assessed O
using O
the O
yale O
global O
ti O
##c O
severity O
scale O
y O
##gt O
##ss O
the O
verbal O
learning O
memory O
test O
v O
##lm O
##t O
and O
the O
st O
##ro O
##op O
test O
the O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
before O
and O
after O
the O
intervention O
revealed O
an O
identical O
performance O
pro O
##ﬁ O
##le O
the O
y O
##gt O
##ss O
score O
dropped O
from O
83 O
pre O
##oper O
##ative O
##ly O
to O
28 O
after O
6 O
weeks O
and O
to O
10 O
after O
12 O
months O
see O
table O
1 O
these O
10 O
points O
did O
not O
result O
from O
either O
motor O
or O
ph O
##onic O
score O
but O
from O
minimal O
impairment O
in O
job O
functioning O

during O
the O
follow O
up O
period O
of O
12 O
months O
the O
patient O
did O
not O
show O
ti O
##cs O
for O
the O
last O
17 O
years O
she O
never O
had O
ti O
##c O
free O
periods O
exceeding O
3 O
weeks O

in O
the O
ﬁ O
##rst O
few O
months O
after O
intervention O
the O
patient O
made O
frequent O
visits O
to O
our O
clinic O
as O
out O
##patient O
complaining O
of O
de O
##pressive O
moods O
vertigo O
and O
stomach O
ache O
##s O
at O
that O
time O
the O
patient O
emphasized O
having O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
adjusting O
to O
the O
new O
situation O
the O
absent O
necessity O
of O
being O
an O
in O
##patient O
and O
recognizing O
that O
the O
illness O
had O
been O
a O
big O
part O
of O
her O
life O
we O
supported O
her O
with O
regular O
out O
##patient O
appointments O
and O
centered O
psycho O
##ther O
##ape O
##uti O
##c O
interventions O
at O
present O
the O
patient O
is O
stabilized O
and O
has O
begun O
to O
engage O
in O
previously O
neglected O
activities O
such O
as O
horseback O
riding O

we O
demonstrate O
full O
re O
##mission O
of O
ti O
##c O
symptoms O
after O
gp O
##i O
db O
##s O
in O
a O
patient O
suffering O
from O
intra O
##ctable O
ts O

table O
1 O
follow O
up O
of O
yale O
global O
ti O
##c O
severity O
scale O

130 O
##2 O
s O
de O
##hn O
##ing O
et O
al O

with O
a O
follow O
up O
period O
of O
12 O
months O
this O
long O
time O
effectiveness O
might O
after O
all O
eliminate O
a O
place O
##bo O
effect O
as O
the O
patient O
was O
rec O
##eptive O
to O
other O
invasive O
treatments O
in O
her O
medical O
history O
only O
temporarily O
the O
cause O
of O
therapeutic O
effects O
is O
supposed O
to O
be O
due O
to O
a O
regulation O
over O
##ride O
of O
a O
possibly O
disturbed O
inhibitor O
##y O
output O
from O
the O
basal O
gang O
##lia O
to O
the O
tha O
##lam O
##us O
a O
disturbed O
gp O
##i O
out O
##ﬂ O
##ow O
could O
lead O
to O
a O
di O
##sin O
##hi O
##bit O
##ion O
of O
ex O
##cit O
##atory O
tha O
##lam O
##us O
neurons O
and O
consequently O
to O
tha O
##lam O
##o O
co O
##rti O
##cal O
hyper O
##act O
##ivity O
16 O
a O
just O
published O
case O
series O
with O
18 O
ts O
patients O
and O
successful O
db O
##s O
of O
the O
tha O
##lam O
##us O
##6 O
represents O
the O
ﬁ O
##rst O
publication O
on O
a O
bigger O
co O
##hort O
even O
when O
taking O
this O
into O
account O
there O
still O
is O
no O
consensus O
for O
the O
best O
stimulation O
target O
again O
serve O
##llo O
s O
report O
is O
discussed O

although O
most O
patients O
with O
chronic O
ts O
are O
used O
to O
a O
temporary O
wax O
##ing O
and O
wan O
##ing O
course O
of O
illness O
or O
an O
am O
##eli O
##oration O
of O
symptoms O
after O
medical O
treatment O
the O
relatively O
prompt O
recovery O
after O
surgical O
intervention O
was O
problematic O
for O
our O
patient O
psychological O
interventions O
are O
imperative O
in O
order O
to O
help O
patients O
to O
cope O
with O
their O
new O
life O
that O
is O
without O
the O
symptoms O
previously O
dominating O
their O
lives O

as O
demonstrated O
in O
patients O
with O
gp O
##i O
implant O
##s O
for O
d O
##yst O
##onia O
17 O
a O
low O
rate O
of O
side O
effects O
and O
a O
good O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
with O
this O
target O
has O
been O
established O
therefore O
we O
consider O
gp O
##i O
db O
##s O
as O
also O
very O
promising O
for O
the O
treatment O
of O
ts O

muller O
n O
ri O
##ede O
##l O
m O
blending O
##er O
c O
obe O
##rle O
k O
jacobs O
e O
abel O
##eh O
##orn O
m O
my O
##co O
##pl O
##as O
##ma O
pneumonia O
##e O
infection O
and O
tour O
##ette O
s O
syndrome O
psychiatry O
res O
2004 O
129 O
119 O
125 O

robertson O
mm O
stern O
j O
##s O
gilles O
de O
la O
tour O
##ette O
syndrome O
sy O
##mpt O
##oma O
##tic O
treatment O
based O
on O
evidence O
eu O
##r O
child O
ad O
##oles O
##c O
psychiatry O
2000 O
9 O
su O
##pp O
##l O
1 O
i O
##60 O
i O
##75 O

de O
##hn O
##ing O
s O
ri O
##ede O
##l O
m O
muller O
n O
ari O
##pi O
##pr O
##az O
##ole O
in O
a O
patient O
vulnerable O
to O
side O
effects O
am O
j O
psychiatry O
2005 O
162 O
625 O

van O
##de O
##wall O
##e O
v O
van O
der O
lc O
gr O
##oe O
##ne O
##we O
##gen O
h O
##j O
ca O
##ema O
##ert O
j O
stereo O
##ta O
##ctic O
treatment O
of O
gilles O
de O
la O
tour O
##ette O
syndrome O
by O
high O
frequency O
stimulation O
of O
tha O
##lam O
##us O
lance O
##t O
1999 O
35 O
##3 O
72 O
##4 O

vis O
##ser O
van O
##de O
##wall O
##e O
v O
te O
##mel O
y O
boon O
p O
et O
al O
chronic O
bilateral O
tha O
##lam O
##ic O
stimulation O
a O
new O
therapeutic O
approach O
in O
intra O
##ctable O
tour O
##ette O
syndrome O
report O
of O
three O
cases O
j O
ne O
##uro O
##sur O
##g O
2003 O
99 O
109 O
##4 O
1100 O

serve O
##llo O
d O
port O
##a O
m O
sas O
##si O
m O
bram O
##bill O
##a O
a O
robertson O
mm O
deep O
brain O
stimulation O
in O
18 O
patients O
with O
severe O
gilles O
de O
la O
tour O
##ette O
syndrome O
ref O
##rac O
##tory O
to O
treatment O
the O
surgery O
and O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
in O
press O

fl O
##ah O
##erty O
aw O
williams O
z O
##m O
amir O
##nov O
##in O
r O
et O
al O
deep O
brain O
stimulation O
of O
the O
anterior O
internal O
capsule O
for O
the O
treatment O
of O
tour O
##ette O
syndrome O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
e O
##40 O
##3 O

ku O
##hn O
j O
lena O
##rt O
##z O
d O
mai O
j O
##k O
et O
al O
deep O
brain O
stimulation O
of O
the O
nucleus O
acc O
##umb O
##ens O
and O
the O
internal O
capsule O
in O
therapeutic O
##ally O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
j O
ne O
##uro O
##l O
2007 O
254 O
96 O
##3 O
96 O
##5 O

ac O
##ker O
##mans O
l O
te O
##mel O
y O
cat O
##h O
d O
et O
al O
deep O
brain O
stimulation O
in O
tour O
##ette O
s O
syndrome O
two O
targets O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
70 O
##9 O
71 O
##3 O

died O
##eric O
##h O
nj O
ka O
##lt O
##eis O
k O
st O
##amen O
##kovic O
m O
pier O
##i O
v O
ale O
##sch O
f O
e O
##f O
##ﬁ O
##cie O
##nt O
internal O
pal O
##lid O
##al O
stimulation O
in O
gilles O
de O
la O
tour O
##ette O
syndrome O
a O
case O
report O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
149 O
##6 O
149 O
##9 O

gallagher O
cl O
ga O
##rell O
pc O
montgomery O
e O
##b O
jr O
hem O
##i O
ti O
##cs O
and O
deep O
brain O
stimulation O
ne O
##uro O
##logy O
2006 O
66 O
e O
##12 O

ho O
##uet O
##o O
j O
##l O
karachi O
c O
mall O
##et O
l O
et O
al O
tour O
##ette O
s O
syndrome O
and O
deep O
brain O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
99 O
##2 O
99 O
##5 O

rap O
##op O
##ort O
m O
fed O
##er O
v O
sand O
##or O
p O
response O
of O
major O
depression O
and O
tour O
##ette O
s O
syndrome O
to O
ec O
##t O
a O
case O
report O
psycho O
##som O
med O
1998 O
60 O
52 O
##8 O
52 O
##9 O

sw O
##er O
##dlow O
nr O
gi O
##er O
##z O
m O
be O
##rk O
##ow O
##itz O
a O
ne O
##mir O
##off O
r O
lo O
##hr O
j O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
in O
a O
patient O
with O
severe O
ti O
##c O
and O
major O
de O
##pressive O
episode O
j O
cl O
##in O
psychiatry O
1990 O
51 O
34 O
35 O

per O
##lm O
##utter O
s O
##j O
lei O
##tman O
sf O
ga O
##r O
##vey O
ma O
et O
al O
therapeutic O
plasma O
exchange O
and O
intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
for O
ob O
##ses O
##sive O
##com O
##pu O
##ls O
##ive O
disorder O
and O
ti O
##c O
disorders O
in O
childhood O
lance O
##t O
1999 O
354 O
115 O
##3 O
115 O
##8 O

min O
##k O
j O
##w O
ne O
##uro O
##biology O
of O
basal O
gang O
##lia O
and O
tour O
##ette O
syndrome O
basal O
gang O
##lia O
circuits O
and O
tha O
##lam O
##oco O
##rti O
##cal O
outputs O
ad O
##v O
ne O
##uro O
##l O
2006 O
99 O
89 O
98 O

be O
##re O
##z O
##nai O
b O
ste O
##ude O
u O
see O
##los O
k O
bot O
##zel O
k O
chronic O
high O
frequency O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
stimulation O
in O
different O
types O
of O
d O
##yst O
##onia O
a O
clinical O
video O
and O
mri O
report O
of O
six O
patients O
presenting O
with O
segment O
##al O
cervical O
and O
generalized O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
138 O
144 O

interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##3 O

novel O
complex O
interruption O
##s O
of O
the O
gaa O
repeat O
in O
small O
expanded O
all O
##eles O
of O
two O
affected O
siblings O
with O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O

catherine O
a O
st O
##oll O
##e O
phd O
1 O
edward O
c O
fra O
##cke O
##lton O
bs O
1 O
jennifer O
mccall O
##um O
ms O
1 O
jennifer O
m O
farmer O
ms O
2 O
amy O
ts O
##ou O
md O
2 O
robert O
b O
wilson O
md O
phd O
3 O

and O
david O
r O
lynch O
md O
phd O
##2 O

1 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
children O
s O
hospital O
of O
philadelphia O
philadelphia O
pennsylvania O
usa O
2 O
##the O
department O
of O
ne O
##uro O
##logy O

the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O
3 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O

abstract O
fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
associated O
with O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
two O
siblings O
presented O
with O
a O
mild O
form O
of O
fa O
at O
60 O
years O
of O
age O
both O
had O
a O
large O
expansion O
600 O
repeats O
and O
a O
small O
expansion O
120 O
repeats O
by O
long O
range O
pc O
##r O
sequence O
analysis O
of O
the O
small O
all O
##ele O
revealed O
multiple O
complex O
interruption O
##s O
in O
the O
gaa O
repeat O
these O
2 O
patients O
presented O
later O
than O
predicted O
from O
their O
all O
##ele O
size O
alone O
when O
compared O
with O
a O
large O
co O
##hort O
of O
fa O
patients O
accounting O
for O
the O
interruption O
##s O
in O
the O
gaa O
repeat O
though O
did O
not O
make O
the O
age O
of O
onset O
consistent O
with O
that O
noted O
in O
other O
patients O
three O
additional O
patients O
with O
late O
onset O
fa O
and O
small O
expanded O
all O
##eles O
also O
exhibited O
interrupted O
gaa O
repeats O
that O
were O
not O
associated O
with O
inappropriate O
##ly O
late O
onset O
our O
observations O
suggest O
that O
interrupted O
gaa O
repeats O
do O
not O
clearly O
impact O
the O
age O
of O
onset O
in O
fa O
2008 O
movement O
disorder O
society O

key O
words O
dorsal O
column O
ata O
##xia O
triple O
##t O
repeat O
spa O
##stic O
##ity O

fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
characterized O
by O
progressive O
ata O
##xia O
and O
onset O
usually O
before O
the O
age O
of O
25 O
years O
1 O
most O
patients O
have O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
normal O
all O
##eles O
contain O
5 O
to O
33 O
repeats O
while O
prem O
##uta O

correspondence O
to O
dr O
david O
r O
lynch O
division O
of O
ne O
##uro O
##logy O
children O
s O
hospital O
of O
philadelphia O
50 O
##2 O
abrams O
##on O
building O
philadelphia O
pa O
1910 O
##4 O
43 O
##18 O
usa O
e O
mail O
lynch O
ph O
##arm O
med O
up O
##en O
##n O
ed O
##u O

received O
10 O
september O
2007 O
revised O
18 O
november O
2007 O

accepted O
9 O
february O
2008 O

published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##12 O

ti O
##on O
all O
##eles O
contain O
34 O
to O
65 O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O
disease O
causing O
all O
##eles O
contain O
66 O
to O
1 O
700 O
repeats O
with O
the O
majority O
of O
all O
##eles O
having O
600 O
to O
1 O
200 O
repeats O
long O
stretches O
of O
gaa O
repeats O
assume O
a O
novel O
dna O
structure O
that O
interfere O
##s O
with O
transcription O
resulting O
in O
decreased O
expression O
of O
the O
gene O
product O
fra O
##ta O
##xin O
2 O
age O
of O
sy O
##mpt O
##om O
onset O
co O
##rre O
##lates O
with O
the O
size O
of O
the O
smaller O
expansion O
3 O
late O
onset O
26 O
39 O
years O
and O
very O
late O
onset O
40 O
years O
cases O
represent O
at O
##yp O
##ical O
presentations O
of O
fa O
4 O
almost O
all O
patients O
even O
with O
the O
shortest O
100 O
gaa O
repeats O
have O
some O
symptoms O
by O
age O
40 O

in O
the O
present O
work O
we O
present O
two O
siblings O
with O
onset O
at O
60 O
years O
of O
age O
with O
a O
mild O
form O
of O
the O
disease O
both O
had O
a O
large O
expansion O
600 O
1 O
000 O
repeats O
and O
a O
small O
expansion O
120 O
repeats O
as O
determined O
by O
long O
range O
pc O
##r O
in O
a O
previously O
reported O
similar O
family O
the O
mild O
ph O
##eno O
##type O
was O
explained O
by O
the O
presence O
of O
interruption O
##s O
in O
the O
gaa O
repeats O
5 O
such O
interruption O
##s O
might O
prevent O
further O
expansion O
by O
reducing O
slip O
##page O
during O
replication O
blocking O
the O
formation O
of O
the O
dna O
structure O
that O
reduces O
transcription O
of O
the O
fra O
##ta O
##xin O
all O
##ele O
thus O
leading O
to O
improved O
fra O
##ta O
##xin O
expression O
and O
less O
severe O
disease O
2 O
in O
the O
present O
work O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
further O
patients O
with O
interrupted O
repeats O
and O
late O
onset O
fa O
and O
compared O
their O
presentation O
to O
that O
noted O
in O
a O
large O
co O
##hort O
of O
patients O
with O
fa O

gen O
##omic O
dna O
was O
extracted O
from O
whole O
blood O
using O
the O
pure O
##gen O
##e O
dna O
extraction O
kit O
gen O
##tra O
systems O
according O
to O
the O
manufacturer O
s O
protocol O
the O
region O
of O
interest O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
was O
amp O
##li O
##ﬁ O
##ed O
using O
the O
expand O
long O
template O
pc O
##r O
system O
roche O
using O
prime O
##rs O
gaa O
f O
and O
gaa O
r O
6 O
with O
the O
following O
thermal O
pro O
##ﬁ O
##le O
92 O
##8 O
##c O
for O
2 O
minutes O
10 O
cycles O
of O
92 O
##8 O
##c O
for O
20 O
seconds O
62 O
##8 O
##c O
for O
30 O
seconds O
68 O
##8 O
##c O
for O
4 O
minutes O
15 O
cycles O
of O
92 O
##8 O
##c O
for O
20 O
seconds O
62 O
##8 O
##c O
for O
30 O
seconds O
68 O
##8 O
##c O
for O
4 O
minutes O
with O
a O
20 O
second O
extension O
per O
cycle O
followed O
by O
1 O
cycle O
at O
68 O
##8 O
##c O
for O
7 O
minutes O
pc O
##r O
products O
were O
electro O
##ph O
##ores O
##ed O
on O
a O
1 O
ag O
##aro O
##se O
gel O
and O
all O
##ele O
sizes O
were O
estimated O
relative O
to O
a O
500 O
bp O
ladder O
the O
shorter O
expanded O
all O
##eles O
were O
then O
ex O
##cise O
##d O
and O
gel O
pu O
##ri O
##ﬁ O
##ed O
using O
the O
qi O
##aq O
##ui O
##k O
gel O
extraction O
kit O
qi O
##age O
##n O
according O
to O
the O
manufacturer O
s O
protocol O
the O
extracted O
product O
was O
then O
re O
##amp O
##li O
##ﬁ O
##ed O
to O
obtain O
a O
large O
quantity O
of O
template O
for O
analysis O
products O
from O
the O
second O
round O
of O
pc O
##r O
were O
sequence O
##d O
using O
the O
big O
dye O
term O
##inator O
v O
##1 O
1 O
sequencing O
kit O
sequences O
were O
analyzed O
on O
an O
automated O
dna O
sequence O
##r O
ab O
##i O
310 O
##0 O

130 O
##4 O
c O
a O
st O
##oll O
##e O
et O
al O

patients O

patient O
1a O

this O
patient O
presented O
at O
age O
61 O
with O
increasing O
cl O
##ums O
##iness O
and O
gradual O
development O
of O
di O
##f O
##ﬁ O
##cu O
##lty O
standing O
on O
one O
foot O
there O
was O
no O
family O
history O
of O
ne O
##uro O
##logic O
disorder O
and O
the O
patient O
was O
not O
of O
known O
ac O
##adia O
##n O
descent O
on O
examination O
he O
was O
diffuse O
##ly O
hyper O
##re O
##ﬂ O
##ex O
##ic O
particularly O
in O
the O
lower O
ex O
##tre O
##mit O
##ies O
a O
ba O
##bin O
##ski O
sign O
was O
not O
observed O
diminished O
vi O
##bra O
##tory O
sensation O
was O
present O
to O
the O
ankles O
bilateral O
##ly O
ts O
##h O
b1 O
##2 O
f O
##olate O
and O
vitamin O
e O
levels O
were O
normal O
anti O
##glia O
##din O
and O
l O
##yme O
ti O
##ters O
were O
negative O
r O
##pr O
was O
non O
##rea O
##ctive O
electro O
##my O
##ography O
revealed O
absent O
sur O
##al O
sensory O
potential O
##s O
but O
intact O
motor O
nerve O
function O
lu O
##mba O
##r O
pun O
##cture O
and O
mri O
imaging O
of O
brain O
cervical O
spine O
and O
thor O
##ac O
##ic O
spine O
revealed O
no O
abnormalities O
a O
genetic O
test O
for O
fa O
performed O
12 O
years O
later O
found O
gaa O
repeat O
lengths O
of O
1 O
03 O
##4 O
and O
127 O
these O
all O
##eles O
were O
sized O
as O
1 O
04 O
##7 O
and O
114 O
in O
a O
second O
test O
he O
had O
a O
normal O
ek O
##g O
stress O
test O
and O
electro O
##ly O
##te O
panel O

patient O
1b O

this O
patient O
presented O
at O
age O
74 O
with O
un O
##stead O
##y O
ga O
##it O
that O
had O
been O
slowly O
progressive O
for O
6 O
years O
she O
noted O
mild O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
her O
hands O
she O
had O
one O
brother O
with O
fa O
patient O
1a O
but O
no O
other O
family O
history O
of O
movement O
disorder O
on O
examination O
she O
had O
hyper O
##active O
re O
##ﬂ O
##ex O
##es O
and O
mildly O
increased O
tone O
in O
her O
upper O
ex O
##tre O
##mit O
##ies O
but O
normal O
lower O
ex O
##tre O
##mity O
re O
##ﬂ O
##ex O
##es O
she O
had O
decreased O
vi O
##bra O
##tory O
sensation O
in O
her O
feet O
but O
otherwise O
intact O
sensation O
strength O
and O
speech O
mild O
right O
sided O
d O
##ys O
##met O
##ria O
was O
present O
she O
had O
square O
wave O
jerk O
##s O
in O
primary O
position O
with O
h O
##yp O
##ometric O
sac O
##cade O
##s O
mri O
of O
the O
head O
and O
cervical O
spine O
revealed O
mild O
ce O
##re O
##bella O
##r O
and O
o O
##cci O
##pit O
##al O
lobe O
at O
##rop O
##hy O
with O
a O
chronic O
right O
posterior O
tha O
##lam O
##ic O
lac O
##una O
##r O
in O
##far O
##ct O
and O
mild O
cervical O
spinal O
cord O
compression O
molecular O
analysis O
of O
her O
fra O
##ta O
##xin O
gene O

patient O
3 O

this O
is O
a O
45 O
year O
old O
man O
with O
progressive O
ata O
##xia O
for O
4 O
years O
this O
was O
associated O
with O
mild O
d O
##ys O
##arth O
##ria O
and O
d O
##ys O
##co O
##ord O
##ination O
of O
the O
hands O
he O
had O
a O
brother O
with O
a O
similar O
syndrome O
and O
examination O
revealed O
normal O
mental O
status O
and O
cr O
##anial O
nerves O
he O
had O
mild O
pseudo O
at O
##het O
##osis O
of O
the O
hands O
with O
arms O
extended O
and O
decreased O
vi O
##bra O
##tory O
sensation O
he O
was O
mildly O
d O
##ys O
##metric O
with O
a O
wide O
based O
ga O
##it O
and O
rom O
##berg O
s O
sign O
deep O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
were O
absent O
and O
he O
had O
ex O
##tens O
##or O
plant O
##ar O
responses O
sensory O
nerve O
action O
potential O
##s O
were O
absent O
and O
an O
mri O
scan O
of O
the O
brain O
was O
normal O
fr O
##da O
gene O
analysis O
revealed O
gaa O
repeat O
lengths O
of O
150 O
and O
1 O
02 O
##5 O
similar O
results O
were O
found O
in O
his O
brother O

patient O
4 O

this O
is O
a O
48 O
year O
old O
woman O
who O
presented O
at O
age O
34 O
with O
progressive O
ata O
##xia O
this O
slowly O
worsened O
over O
the O
next O
14 O
years O
and O
she O
developed O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
coordination O
of O
her O
hands O
on O
examination O
she O
had O
moderate O
d O
##ys O
##met O
##ria O
of O
her O
arms O
and O
a O
wide O
based O
ga O
##it O
re O
##ﬂ O
##ex O
##es O
were O
present O
but O
not O
hyper O
##active O
sensory O
examination O
revealed O
vi O
##bra O
##tory O
sensory O
loss O
with O
spa O
##ring O
of O
other O
mod O
##ali O
##ties O
mental O
status O
and O
cr O
##anial O
nerves O
were O
normal O
sensory O
nerve O
action O
potential O
##s O
were O
reduced O
mri O
of O
the O
brain O
was O
un O
##rem O
##ark O
##able O
commercial O
dna O
testing O
for O
fr O
##da O
expansion O
##s O
revealed O
expansion O
##s O
of O
290 O
and O
950 O

patient O
5 O

this O
patient O
presented O
at O
48 O
years O
after O
10 O
years O
of O
variable O
hand O
and O
leg O
cl O
##ums O
##iness O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
sl O
##ur O
##red O
speech O
on O
examination O
she O
had O
ny O
##sta O
##gm O
##us O

table O
1 O
interrupted O
gaa O
repeat O
sequences O
from O
fa O
patients O

revealed O
gaa O
repeat O
lengths O
of O
1 O
00 O
##5 O
and O
104 O

patient O
1a O
and O
1b O

gaa O
72 O
##1 O
gaga O
##a O
1 O
gaa O
##aa O

1 O
gaa O
201 O
gaa O
##aa O
1 O
gaa O

1 O
gag O
##ga O
##a O
4 O
1 O
gaa O
12 O

this O
patient O
presented O
with O
progressive O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
balance O
and O
coordination O
at O
age O
41 O
on O
initial O
examination O
at O
age O
48 O
prop O
##rio O
##ception O
was O
normal O
and O
re O
##ﬂ O
##ex O
##es O
were O
21 O
in O
the O
arms O
and O
legs O
over O
the O
next O
9 O
years O
he O
developed O
d O
##ys O
##arth O
##ria O
d O
##ys O
##met O
##ria O
diminished O
prop O
##rio O
##ception O
in O
the O
arms O
and O
legs O
spa O
##stic O
##ity O
and O
diffuse O
hyper O
##re O
##ﬂ O
##ex O
##ia O
with O
cl O
##onus O
and O
ex O
##tens O
##or O
plant O
##ar O
responses O
mri O
of O
the O
brain O
revealed O
mild O
ve O
##rmi O
##an O
at O
##rop O
##hy O
genetic O
testing O
of O
the O
fr O
##da O
gene O
revealed O
gaa O
repeat O
lengths O
of O
115 O
and O
1 O
02 O
##5 O

patient O
2 O
gaa O
89 O
1 O
gaga O
##a O
1 O
gaa O
41 O
gaga O
##a O

1 O
gaa O
41 O
gaa O
##aa O
1 O
gaa O
13 O

patient O
3 O
gaa O
78 O
##1 O
gaa O
##aa O
1 O
gaa O
171 O
gaa O
##aa O

1 O
gaa O
1 O
gag O
##ga O
##a O
5 O
1 O
gaa O
12 O

patient O
4 O
gaa O
103 O
##1 O
gaa O
##aga O
##a O
1 O
gaa O
15 O

patient O
5 O
gaa O
130 O
##1 O
aaa O

the O
number O
of O
gaa O
repeats O
plus O
the O
location O
and O
the O
sequence O
of O
repeat O
interruption O
##s O
are O
indicated O
the O
number O
of O
gaa O
repeats O
at O
the O
50 O
end O
represents O
a O
minimum O
repeat O
number O
since O
sequence O
analysis O
did O
not O
reach O
the O
50 O
non O
##re O
##pe O
##at O
sequence O
interruption O
##s O
clustered O
in O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
followed O
by O
short O
gaa O
repeats O
in O
all O
of O
the O
patients O
except O
no O
5 O
interruption O
##s O
are O
designated O
to O
be O
consistent O
with O
those O
previously O
id O
##ent O
##i O
##ﬁ O
##ed O
gag O
##ga O
##a O
ref O
7 O
gaa O
##aga O
##a O
ref O
8 O
gaa O
##aa O
ref O
9 O

interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##5 O

table O
2 O
repeat O
lengths O
and O
age O
of O
onset O
for O
patients O
1 O
5 O

patient O
repeat O
lengths O
as O
id O
##ent O
##i O
##ﬁ O
##ed O
by O
pc O
##r O
estimate O
and O
maximum O
number O
based O
on O
sequencing O

d O
##ys O
##arth O
##ria O
and O
severe O
d O
##ys O
##met O
##ria O
re O
##ﬂ O
##ex O
##es O
were O
absent O
except O
for O
the O
tri O
##ce O
##ps O
jerk O
##s O
prop O
##rio O
##ception O
and O
vi O
##bra O
##tory O
sensation O
were O
decreased O
and O
her O
ga O
##it O
was O
wide O
based O
mri O
of O
the O
brain O
was O
normal O
analysis O
of O
her O
fr O
##da O
gene O
revealed O
gaa O
repeat O
expansion O
##s O
of O
290 O
and O
850 O

based O
on O
previous O
reports O
suggesting O
small O
interruption O
##s O
in O
the O
gaa O
repeat O
in O
some O
patients O
with O
very O
late O
onset O
of O
fa O
we O
sequence O
##d O
the O
gaa O
repeat O
region O
in O
a O
series O
of O
patients O
table O
1 O
in O
sibling O
patients O
1a O
and O
1b O
identical O
interruption O
##s O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
gaa O
repeat O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
repeat O
was O

72 O
bases O
in O
other O
patients O
with O
short O
gaa O
repeats O
similar O
interruption O
##s O
in O
the O
30 O
end O
of O
the O
gaa O
repeat O
were O
found O
in O
three O
of O
four O
but O
the O
interruption O
##s O
were O
less O
complex O
one O
patient O
had O
only O
a O
single O
aaa O
sequence O
at O
the O
30 O
end O
of O
the O
gaa O
repeat O
7 O
9 O

we O
then O
correlated O
age O
of O
onset O
with O
presence O
or O
absence O
of O
interruption O
##s O
table O
2 O
fig O
1 O
two O
of O
5 O
patients O
patients O
1a O
and O
1b O
with O
interruption O
##s O
presented O
later O
than O
that O
expected O
based O
on O
the O
correlation O
of O
total O
gaa O
repeat O
length O
with O
age O
of O
onset O
from O
a O
large O
american O
co O
##hort O
10 O
but O
3 O
patients O
patients O
2 O
3 O
and O
4 O
had O
an O
age O
of O
onset O
similar O
to O
or O
only O
slightly O
later O
than O
that O
predicted O
based O
on O
the O
overall O
co O
##hort O
see O
fig O
1 O
the O
patient O
with O
the O
isolated O
aaa O
at O
the O

30 O
end O
of O
an O
interrupted O
repeat O
patient O
5 O
presented O

slightly O
later O
than O
the O
expected O
age O
similarly O
the O
total O
maximal O
un O
##int O
##er O
##rup O
##ted O
length O
did O
not O
co O
##rre O
##late O
substantially O
better O
with O
age O
of O
onset O
this O
suggests O
that O
the O
presence O
of O
interruption O
##s O
does O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
affect O
age O
of O
onset O

in O
this O
work O
a O
variety O
of O
small O
expanded O
all O
##eles O
of O
the O
fr O
##da O
gene O
had O
an O
altered O
sequence O
compared O

with O
the O
normal O
sequence O
gaa O
repeats O
in O
small O
expanded O
all O
##eles O
were O
interrupted O
in O
5 O
of O
6 O
patients O
analyzed O
with O
late O
to O
very O
late O
onset O
fa O
a O
sixth O
patient O
had O
an O
aaa O
expansion O
at O
the O
end O
of O
the O
sequence O
all O
observed O
interruption O
##s O
in O
the O
gaa O
repeats O
were O
localized O
to O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
preceded O
by O
72 O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O

the O
age O
of O
onset O
of O
fa O
co O
##rre O
##lates O
moderately O
r O
5 O
0 O
60 O
with O
the O
length O
of O
the O
gaa O
repeat O
sequence O
as O
de O
##ﬁ O
##ned O
by O
long O
range O
pc O
##r O
10 O
although O
the O
correlation O
is O
lower O
in O
the O
group O
of O
patients O
with O
gaa O
repeat O
lengths O
shorter O
than O
400 O
the O
presence O
of O
interruption O
##s O
did O
not O
clearly O
in O
##ﬂ O
##uen O
##ce O
the O
age O
of O
onset O
in O
a O
simple O
manner O
in O
the O
group O
of O
patients O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
with O
gaa O
interruption O
##s O
patients O
with O
id O
##ent O
##i O
##ﬁ O
##ed O
interruption O
##s O
did O
not O
consistently O
have O
later O
age O
of O
onset O
than O
others O
in O
the O
co O
##hort O
although O
in O
this O
study O
and O
in O
those O
reported O
previously O
the O
initially O
id O
##ent O
##i O
##ﬁ O
##ed O
siblings O
with O
interruption O
##s O
present O
later O
than O
expected O
other O
patients O
with O
interruption O
##s O
did O
not O
analysis O
of O
the O
age O
of O
onset O
in O
patients O
with O
id O
##ent O
##i O
##ﬁ O
##ed O
interruption O
##s O
using O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
stretch O
of O
gaa O
repeat O
did O
not O
substantially O
change O
the O
relation O
of O
age O
of O
onset O
to O
the O
typical O
age O
of O
onset O
based O
on O
the O
entire O
co O
##hort O
thus O
our O
data O
here O
provide O
no O
evidence O
for O
an O
effect O
of O
interrupted O
repeats O
in O
fa O

still O
it O
is O
possible O
that O
interrupted O
repeats O
alter O
the O
clinical O
features O
of O
fa O
interruption O
of O
the O
gaa O
repeat O

fig O
1 O
correlation O
of O
age O
of O
onset O
versus O
total O
repeat O
length O
and O
the O
maximum O
length O
of O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeats O
age O
of O
onset O
and O
gaa O
repeat O
length O
were O
plotted O
for O
a O
large O
american O
co O
##hort O
diamonds O
and O
each O
of O
the O
6 O
patients O
in O
the O
present O
study O
ﬁ O
##lled O
square O
estimated O
repeat O
length O
open O
square O
maximum O
possible O
un O
##int O
##er O
##rup O
##ted O
gaa O
repeat O
length O
the O
age O
of O
onset O
from O
patients O
1a O
and O
1b O
remained O
greater O
than O
that O
predicted O
based O
on O
their O
repeat O
length O
patients O
2 O
and O
5 O
had O
a O
slightly O
later O
age O
of O
onset O
than O
expected O
patients O
3 O
and O
4 O
still O
plotted O
near O
the O
line O
patient O
5 O
had O
no O
interruption O
##s O
while O
patients O
1 O
to O
4 O
had O
interrupted O
repeats O

130 O
##6 O
c O
a O
st O
##oll O
##e O
et O
al O

with O
a O
change O
of O
a O
single O
gaa O
to O
a O
g O
##ga O
re O
##med O
##ies O
the O
defect O
in O
transcription O
and O
blocks O
formation O
of O
triple O
##x O
structures O
in O
vitro O
in O
other O
disorders O
the O
presence O
of O
interruption O
##s O
in O
repeat O
sequences O
has O
been O
suggested O
to O
modify O
the O
expression O
of O
disease O
severity O
11 O
14 O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
only O
one O
patient O
without O
a O
sign O
##i O
##ﬁ O
##can O
##t O
interruption O
showing O
that O
in O
late O
onset O
patients O
the O
frequency O
of O
interruption O
##s O
may O
be O
quite O
high O
if O
we O
examined O
further O
patients O
with O
late O
onset O
disease O
as O
well O
as O
patients O
with O
short O
repeats O
and O
earlier O
onset O
it O
might O
be O
possible O
to O
uncover O
a O
modest O
effect O
of O
repeat O
interruption O
##s O
with O
disease O
features O

in O
addition O
we O
have O
analyzed O
the O
data O
at O
present O
using O
simple O
approaches O
con O
##ce O
##iva O
##bly O
features O
beyond O
the O
simple O
size O
of O
un O
##int O
##er O
##rup O
##ted O
repeat O
such O
as O
interruption O
structure O
and O
complexity O
might O
play O
a O
crucial O
role O
alternatively O
spec O
##i O
##ﬁ O
##c O
ph O
##eno O
##typic O
features O
might O
be O
altered O
by O
the O
presence O
of O
interruption O
##s O
in O
addition O
to O
having O
a O
less O
progressive O
course O
patients O
with O
late O
onset O
fa O
frequently O
retain O
re O
##ﬂ O
##ex O
##es O
as O
noted O
for O
patients O
1a O
and O
1b O
here O
still O
our O
data O
overall O
are O
most O
consistent O
with O
the O
possibility O
that O
repeat O
interruption O
##s O
do O
not O
substantially O
in O
##ﬂ O
##uen O
##ce O
the O
age O
of O
onset O
of O
fa O

ac O
##k O
##now O
##led O
##gm O
##ents O
dr O
lynch O
is O
supported O
by O
grants O
from O
the O
fried O
##re O
##ich O
ata O
##xia O
research O
alliance O
and O
the O
muscular O
d O
##yst O
##rop O
##hy O
association O
we O
wish O
to O
thank O
the O
clinical O
research O
network O
for O
fried O
##re O
##ich O
ata O
##xia O
for O
providing O
access O
to O
data O
on O
the O
fa O
co O
##hort O

du O
##rr O
a O
co O
##ssee O
m O
ag O
##id O
y O
et O
al O
clinical O
and O
genetic O
abnormalities O
in O
patients O
with O
fried O
##re O
##ich O
s O
ata O
##xia O
n O
eng O
##l O
j O
med O
1996 O
335 O
116 O
##9 O
117 O
##5 O

sa O
##kam O
##oto O
n O
oh O
##shima O
k O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
sticky O
dna O
a O
self O
associated O
complex O
formed O
at O
long O
gaa O
tt O
##c O
repeats O
in O
intro O
##n O
1 O
of O
the O
fra O
##ta O
##xin O
gene O
inhibit O
##s O
transcription O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##1 O
271 O
##7 O
##7 O

monte O
##rmin O
##i O
l O
richter O
a O
morgan O
k O
et O
al O
ph O
##eno O
##typic O
variability O
in O
fried O
##re O
##ich O
ata O
##xia O
role O
of O
the O
associated O
gaa O
triple O
##t O
repeat O
expansion O
ann O
ne O
##uro O
##l O
1997 O
41 O
67 O
##5 O
68 O
##2 O

b O
##hid O
##aya O
##sir O
##i O
r O
per O
##lman O
sl O
pu O
##ls O
##t O
sm O
ge O
##sch O
##wind O
dh O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O
ph O
##eno O
##typic O
analysis O
magnetic O
resonance O
imaging O
ﬁ O
##nding O
##s O
and O
review O
of O
the O
literature O
arch O
ne O
##uro O
##l O
2005 O
62 O
1865 O
1869 O

mc O
##dan O
##iel O
do O
ke O
##ats O
b O
ve O
##dana O
##raya O
##nan O
v O
##v O
sub O
##ram O
##ony O
sh O
sequence O
variation O
in O
gaa O
repeat O
expansion O
##s O
may O
cause O
differential O
ph O
##eno O
##type O
display O
in O
fried O
##re O
##ich O
s O
ata O
##xia O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
115 O
##3 O
115 O
##8 O

camp O
##uz O
##ano O
v O
monte O
##rmin O
##i O
l O
mo O
##lto O
md O
et O
al O
fried O
##re O
##ich O
s O
ata O
##xia O
auto O
##som O
##al O
recess O
##ive O
disease O
caused O
by O
an O
intro O
##nic O
gaa O
triple O
##t O
repeat O
expansion O
science O
1996 O
271 O
142 O
##3 O
142 O
##7 O

monte O
##rmin O
##i O
l O
and O
##erman O
##n O
e O
lab O
##uda O
m O
et O
al O
the O
fried O
##re O
##ich O
ata O
##xia O
gaa O
triple O
##t O
repeat O
prem O
##utation O
and O
normal O
all O
##eles O
hum O
mo O
##l O
gene O
##t O
1997 O
6 O
126 O
##1 O
126 O
##6 O

co O
##ssee O
m O
sc O
##hmi O
##tt O
m O
camp O
##uz O
##ano O
v O
re O
##ute O
##na O
##uer O
l O
mo O
##uto O
##u O
c O
man O
##del O
j O
##l O
ko O
##eni O
##g O
m O
evolution O
of O
the O
fried O
##re O
##ich O
s O
ata O
##xia O
tri O
##nu O
##cle O
##otide O
repeat O
expansion O
founder O
effect O
and O
prem O
##utation O
##s O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1997 O
94 O
74 O
##52 O
74 O
##57 O

sa O
##kam O
##oto O
n O
larson O
je O
i O
##yer O
rr O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
g O
##ga O
tc O
##c O
interrupted O
triple O
##ts O
in O
long O
gaa O
tt O
##c O
repeats O
inhibit O
the O
formation O
of O
triple O
##x O
and O
sticky O
dna O
structures O
alleviate O
transcription O
inhibition O
and O
reduce O
genetic O
ins O
##ta O
##bilities O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##8 O
271 O
##8 O
##7 O

lynch O
dr O
farmer O
j O
##m O
ts O
##ou O
a O
##y O
et O
al O
measuring O
fried O
##re O
##ich O
ata O
##xia O
complementary O
features O
of O
examination O
and O
performance O
measures O
ne O
##uro O
##logy O
2006 O
66 O
1711 O
1716 O

charles O
p O
cam O
##uz O
##at O
a O
ben O
##am O
##mar O
n O
et O
al O
are O
interrupted O
sc O
##a O
##2 O
ca O
##g O
repeat O
expansion O
##s O
responsible O
for O
parkinson O
##ism O
ne O
##uro O
##logy O
2007 O
69 O
1970 O
1975 O

sob O
##cz O
##ak O
k O
k O
##ry O
##zos O
##ia O
##k O
w O
##j O
ca O
##g O
repeats O
containing O
ca O
##a O
interruption O
##s O
form O
branched O
hair O
##pin O
structures O
in O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
2 O
transcript O
##s O
j O
bio O
##l O
che O
##m O
2005 O
280 O
38 O
##9 O
##8 O
39 O
##10 O

cho O
##ud O
##hr O
##y O
s O
mu O
##ker O
##ji O
m O
sri O
##vas O
##ta O
##va O
ak O
jain O
s O
bra O
##hma O
##cha O
##ri O
sk O
ca O
##g O
repeat O
instability O
at O
sc O
##a O
##2 O
locus O
anchor O
##ing O
ca O
##a O
interruption O
##s O
and O
linked O
single O
nu O
##cle O
##otide O
poly O
##morphism O
##s O
hum O
mo O
##l O
gene O
##t O
2001 O
10 O
243 O
##7 O
244 O
##6 O

mats O
##u O
##ura O
t O
fang O
p O
pearson O
ce O
jaya O
##kar O
p O
ash O
##iza O
##wa O
t O
ro O
##a O
bb O
nelson O
dl O
interruption O
##s O
in O
the O
expanded O
at O
##tc O
##t O
repeat O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
10 O
repeat O
purity O
as O
a O
disease O
mod O
##i O
##ﬁ O
##er O
am O
j O
hum O
gene O
##t O
2006 O
78 O
125 O
129 O

structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
130 O
##7 O

on O
the O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

jan O
st O
##och O
##l O
phd O
msc O
1 O
anne O
boom O
##sma O
phd O
2 O
ev O
##zen O
ru O
##zic O
##ka O
md O
ds O
##c O
3 O

hana O
bro O
##zo O
##va O
md O
3 O
and O
pet O
##r O
blah O
##us O
ds O
##c O
##1 O

1 O
##de O
##par O
##tment O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
prague O
czech O
republic O
2d O
##ep O
##art O
##ment O
of O
sociology O
statistics O
and O
measurement O
theory O
university O
of O
groningen O
groningen O
the O
netherlands O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
charles O
university O
movement O
disorders O
centre O
prague O
czech O
republic O

abstract O
this O
study O
aims O
to O
investigate O
the O
structure O
of O
the O
motor O
symptoms O
of O
parkinson O
s O
disease O
pd O
as O
measured O
by O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
was O
studied O
using O
structural O
equation O
modeling O
the O
up O
##dr O
##s O
measures O
were O
obtained O
from O
405 O
patients O
with O
pd O
237 O
men O
39 O
off O
170 O
on O
28 O

unknown O
and O
168 O
women O
21 O
off O
140 O
on O
7 O
unknown O
the O
or O
##dina O
##l O
character O
of O
up O
##dr O
##s O
scores O
and O
sample O
size O
sub O
##stan O
##tia O
##ted O
the O
use O
of O
robust O
diagonal O
##ly O
weighted O
least O
squares O
model O
estimation O
it O
was O
shown O
that O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
incorporates O
ﬁ O
##ve O
main O
late O
##nt O
sy O
##mpt O
##om O
factors O
rigid O
##ity O
tremor O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
speech O
h O
##yp O
##omi O
##mia O
plus O
two O
additional O
factors O
for O
lateral O
##ity O
which O
account O
for O
as O
##ym O
##metry O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
tremor O
seems O
to O
be O
an O
independent O
sy O
##mpt O
##om O
factor O
of O
pd O
other O
late O
##nt O
variables O
are O
substantially O
correlated O
2008 O
movement O
disorder O
society O

key O
words O
parkinson O
s O
disease O
structural O
equation O
modeling O
dimensional O
##ity O
motor O
section O
of O
the O
up O
##dr O
##s O

the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
sy O
##mpt O
##om O
groups O
of O
neurological O
syndrome O
##s O
such O
as O
the O
combination O
of O
h O
##yp O
##oki O
##nesia O
rigid O
##ity O
resting O
tremor O
and O
post O
##ural O
abnormalities O
in O
parkinson O
s O
disease O
pd O
is O
important O
because O
knowledge O
about O
the O
co O
occurrence O
of O
symptoms O
may O
help O
to O
de O
##ﬁ O
##ne O
disease O
ph O
##eno O
##type O
##s O
and O
provide O
clues O
for O
differential O
diagnosis O
the O
number O
of O
sy O
##mpt O
##om O
groups O
dimensional O
##ity O
can O
be O
in O
##fer O
##red O
through O
statistical O
analysis O
of O
measurements O
used O
for O
impairment O
evaluation O
within O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
park O
##in O

correspondence O
to O
dr O
jan O
st O
##och O
##l O
department O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
jose O
##´ O
mart O
##´ O
##ı O
##ho O
31 O
c O
##z O
162 O
52 O
prague O
czech O
republic O
e O
mail O
st O
##och O
##l O
ft O
##vs O
cu O
##ni O
c O
##z O

received O
16 O
november O
2007 O
revised O
22 O
january O
2008 O
accepted O

17 O
february O
2008 O

published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##29 O

son O
s O
disease O
rating O
scale O
up O
##dr O
##s O
main O
motor O
symptoms O
of O
pd O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
and O
axial O
symptoms O
speech O
posture O
post O
##ural O
stability O
and O
ga O
##it O
de O
##ﬁ O
##ne O
sy O
##mpt O
##om O
groups O
which O
are O
in O
practice O
evaluated O
regarding O
their O
respective O
severity O
this O
paper O
discusses O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
and O
the O
structure O
of O
motor O
symptoms O
of O
pd O
within O
the O
framework O
of O
structural O
equation O
modeling O
se O
##m O
using O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O

in O
previous O
studies O
on O
dimensional O
##ity O
assessment O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
1 O
4 O
between O
three O
and O
six O
factors O
were O
found O
with O
percentage O
##s O
of O
explained O
total O
scale O
variance O
ranging O
between O
59 O
and O
78 O
all O
these O
studies O
used O
ex O
##pl O
##ora O
##tory O
factor O
analysis O
e O
##fa O
methods O
principal O
component O
analysis O
included O
such O
procedures O
rely O
on O
strong O
assumptions O
concerning O
either O
the O
distribution O
of O
observed O
variables O
their O
level O
of O
measurement O
or O
the O
number O
of O
observations O
principal O
component O
analysis O
requires O
a O
continuous O
measurement O
level O
##5 O
6 O
maximum O
likelihood O
estimation O
in O
e O
##fa O
requires O
continuous O
measurement O
levels O
and O
either O
normally O
distributed O
item O
responses O
or O
a O
large O
number O
of O
observations O
which O
may O
compensate O
for O
small O
degrees O
of O
non O
##nor O
##mal O
##ity O
7 O
8 O
given O
the O
or O
##dina O
##l O
distribution O
##al O
properties O
of O
the O
items O
in O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
previous O
conclusions O
on O
dimensional O
##ity O
may O
not O
be O
trust O
##worthy O
because O
the O
validity O
of O
assumptions O
of O
e O
##fa O
modeling O
is O
lacking O

instead O
of O
e O
##fa O
we O
used O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
cfa O
within O
a O
se O
##m O
framework O
to O
perform O
a O
statistical O
test O
and O
to O
evaluate O
a O
number O
of O
plausible O
factor O
models O
for O
the O
structure O
of O
symptoms O
underlying O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
some O
se O
##m O
est O
##ima O
##tors O
are O
designed O
for O
or O
##dina O
##l O
measurements O
and O
thus O
in O
principle O
suited O
for O
analyzing O
that O
structure O

patients O
and O
methods O

sample O

the O
study O
includes O
405 O
consecutive O
patients O
237 O
men O
168 O
women O
mean O
age O
61 O
range O
35 O
80 O
years O
with O
pd O
diagnosed O
according O
to O
current O
clinical O
criteria O
9 O
each O
patient O
was O
evaluated O
by O
one O
member O
of O
a O
group O
of O
ce O
##rti O
##ﬁ O
##ed O
ne O
##uro O
##logists O
movement O
disorder O
specialists O
who O
routinely O
use O
the O
up O
##dr O
##s O
sixty O
patients O
were O
examined O
in O
de O
##ﬁ O
##ned O
off O
state O
and O
310 O
patients O
in O
de O
##ﬁ O
##ned O
on O
state O
for O
35 O
patients O
the O
motor O
state O
during O
evaluation O
was O
not O
spec O
##i O
##ﬁ O
##ed O

this O
data O
consists O
of O
two O
sub O
##sam O
##ples O
the O
ﬁ O
##rst O
sub O
##sam O
##ple O
of O
size O
n O
5 O
147 O
96 O
men O
38 O
off O
30 O
on O

28 O
unknown O
and O
51 O
women O
15 O
off O
29 O
on O
7 O

130 O
##8 O
j O
st O
##och O
##l O
et O
al O

unknown O
was O
obtained O
at O
the O
movement O
disorder O
centre O
charles O
university O
prague O
czech O
republic O
the O
second O
of O
size O
n O
5 O
258 O
141 O
men O
1 O
off O
140 O

on O
and O
117 O
women O
6 O
off O
111 O
on O
was O
acquired O
at O
the O
university O
medical O
centre O
groningen O
in O
the O
netherlands O

methods O

for O
analyzing O
the O
late O
##nt O
structure O
of O
the O
27 O
items O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
the O
li O
##sr O
##el O
program O
##10 O
was O
used O
if O
the O
level O
of O
measurement O
is O
or O
##dina O
##l O
and O
sample O
size O
relatively O
small O
as O
in O
our O
case O
jo O
##¨ O
##res O
##ko O
##g O
and O
so O
##¨ O
##rb O
##om O
##11 O
recommend O
analyzing O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
of O
the O
observed O
variables O
along O
with O
the O
estimated O
matrix O
of O
as O
##ym O
##pt O
##otic O
co O
##var O
##iance O
##s O
of O
those O
estimated O
correlation O
##s O
and O
to O
apply O
robust O
diagonal O
##ly O
weighted O
least O
squares O
d O
##wl O
##s O
model O
estimation O
the O
poly O
##cho O
##ric O
correlation O
##s O
and O
the O
as O
##ym O
##pt O
##otic O
co O
##var O
##iance O
matrix O
were O
computed O
using O
the O
pre O
##lis O
program O
12 O

a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
for O
the O
ﬁ O
##nal O
model O
described O
here O
the O
path O
diagram O
with O
standardized O
parameter O
estimates O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
goodness O
of O
ﬁ O
##t O
statistics O
and O
indices O
a O
summary O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
and O
the O
ﬁ O
##tted O
residual O
matrix O
are O
reported O
for O
details O
see O
ref O
13 O

the O
ﬁ O
##nal O
model O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
is O
shown O
in O
figure O
1 O
a O
number O
of O
theoretically O
plausible O
models O
were O
tested O
and O
compared O
before O
the O
model O
in O
figure O
1 O
was O
chosen O
as O
a O
most O
plausible O
one O
13 O
following O
that O
conclusion O
based O
on O
both O
model O
estimates O
and O
theoretical O
pd O
background O
considerations O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
consists O
of O
seven O
factors O
five O
of O
them O
are O
substantive O
each O
re O
##ﬂ O
##ect O
##ing O
a O
pd O
motor O
sy O
##mpt O
##om O
tremor O
rigid O
##ity O
rig O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
brad O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
bb O
##rad O
and O
speech O
h O
##yp O
##omi O
##mia O
face O
two O
additional O
factors O
left O
and O
right O
re O
##ﬂ O
##ect O
the O
as O
##ym O
##metry O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O

although O
some O
ﬁ O
##tted O
residual O
##s O
see O
table O
1 O
remained O
high O
the O
ﬁ O
##t O
statistics O
and O
indices O
suggest O
that O
this O
model O
need O
not O
to O
be O
rejected O
generally O
the O
values O
of O
comparative O
ﬁ O
##t O
index O
cf O
##i O
and O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
suggest O
a O
very O
acceptable O
ﬁ O
##t O
whereas O
root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
and O

norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
indicate O
slightly O
less O
but O
still O
acceptable O
model O
ﬁ O
##t O
see O
the O
values O
below O
fig O
1 O
values O
in O
the O
matrix O
of O
residual O
correlation O
##s O
are O
ranging O
from O
20 O
40 O
to O
0 O
34 O
median O
of O
absolute O
value O
0 O
04 O
standard O
deviation O
0 O
07 O
the O
highest O
ﬁ O
##tted O
residual O
##s O
are O
those O
between O
action O
tremor O
items O
right O
hand O
and O
left O
hand O
0 O
34 O
and O
surprisingly O
between O
item O
action O
tremor O
left O
hand O
and O
item O
tremor O
right O
lower O
ex O
##tre O
##mity O
20 O
40 O
values O
of O
factor O
loading O
##s O
range O
from O

0 O
11 O
to O
0 O
92 O
median O
0 O
64 O
standard O
deviation O
0 O
19 O
see O
figure O
1 O
the O
lowest O
factor O
loading O
0 O
11 O
is O
for O
item O
tremor O
right O
lower O
ex O
##tre O
##mity O
as O
an O
indicator O
for O
late O
##nt O
factor O
right O
although O
the O
corresponding O
parameter O
test O
stat O
##istic O
is O
non O
##si O
##gni O
##ﬁ O
##can O
##t O
standard O
error O
0 O
17 O
it O
is O
theoretically O
meaningful O
to O
keep O
this O
parameter O
free O
in O
general O
values O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
ranged O
from O
0 O
02 O
to O
0 O
17 O
median O
0 O
07 O
standard O
deviation O
0 O
04 O
the O
estimated O
composite O
reliability O
of O
our O
model O
by O
st O
##rat O
##i O
##ﬁ O
##ed O
coe O
##f O
##ﬁ O
##cie O
##nt O
alpha O
##14 O
equals O
0 O
94 O

the O
four O
factors O
of O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
speech O
h O
##yp O
##omi O
##mia O
and O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
are O
correlated O
which O
is O
meaningful O
from O
a O
theoretical O
point O
of O
view O
the O
correlation O
##s O
range O
between O
0 O
54 O
and O
0 O
85 O
see O
fig O
1 O
indicating O
rather O
substantial O
relationships O
among O
these O
sy O
##mpt O
##om O
factors O
tremor O
however O
seems O
to O
be O
a O
pd O
sy O
##mpt O
##om O
occurring O
independently O
of O
other O
motor O
pd O
sy O
##mpt O
##om O
factors O

goodness O
of O
fit O
statistics O
and O
indices O

sample O
size O
405 O

degrees O
of O
freedom O
300 O

sato O
##rra O
bent O
##ler O
s O
scaled O
v O
##2 O
stat O
##istic O
89 O
##9 O
33 O
p O
5 O

0 O
0 O

root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
0 O
07 O
##0 O

90 O
con O
##ﬁ O
##den O
##ce O
interval O
for O
rms O
##ea O
0 O
06 O
##5 O
0 O
07 O
##6 O

norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
0 O
96 O

comparative O
ﬁ O
##t O
index O
cf O
##i O
0 O
97 O

standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
0 O
07 O
##7 O

goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
0 O
99 O

fitted O
residual O
##s O
range O
20 O
40 O
0 O
34 O
median O
0 O
04 O

standard O
deviation O
0 O
07 O

in O
this O
study O
the O
structure O
of O
motor O
symptoms O
of O
pd O
was O
investigated O
by O
applying O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
models O
to O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

153 O
##18 O
##25 O
##7 O
2008 O
9 O
downloaded O
from O
https O
movement O
##dis O
##ord O
##ers O
online O
##lib O
##rar O
##y O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O
by O
the O
university O
of O
manchester O
wiley O
online O
library O
on O
22 O
05 O
202 O
##5 O
see O
the O
terms O
and O
conditions O
https O
online O
##lib O
##rar O
##y O
wiley O
com O
terms O
and O
conditions O
on O
wiley O
online O
library O
for O
rules O
of O
use O
o O
##a O
articles O
are O
governed O
by O
the O
applicable O
creative O
commons O
license O

table O
1 O
poly O
##cho O
##ric O
correlation O
##s O
below O
diagonal O
and O
ﬁ O
##tted O
residual O
##s O
above O
diagonal O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

speech O
facial O
lips O
##chin O
##tr O
##ru O
##et O
##rl O
##uet O
##rr O
##let O
##rl O
##lea O
##tr O
##rh O
##anda O
##tr O
##l O
##hand O
##ri O
##gi O
##dity O
rue O
lu O
##e O
r O
##le O
ll O
##e O
fr O
##hand O
##fl O
##hand O
hr O
##hand O
##hl O
##hand O
##rr O
##hand O
##rl O
##hand O
l O
##rle O
##g O
ll O
##leg O
arising O
##post O
##ure O
ga O
##it O
stab O
##il O
body O
##bra O

structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
131 O
##1 O

the O
models O
were O
estimated O
using O
the O
d O
##wl O
##s O
est O
##ima O
##tor O
mainly O
because O
of O
the O
or O
##dina O
##l O
measurement O
level O
of O
the O
items O
and O
the O
relatively O
small O
sample O
size O

several O
studies O
##1 O
4 O
15 O
assessed O
the O
construct O
validity O
and O
the O
dimensional O
##ity O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
through O
e O
##fa O
as O
discussed O
earlier O
neither O
e O
##fa O
nor O
some O
of O
the O
cfa O
est O
##ima O
##tors O
are O
the O
most O
appropriate O
scaling O
techniques O
because O
the O
assumptions O
of O
the O
underlying O
statistical O
model O
may O
easily O
be O
violated O
in O
previous O
dimensional O
##ity O
studies O
of O
the O
up O
##dr O
##s O
sample O
sizes O
n O
300 O
were O
often O
used O
1 O
3 O
15 O
in O
addition O
measurement O
of O
the O
up O
##dr O
##s O
is O
obviously O
of O
or O
##dina O
##l O
rather O
than O
continuous O
type O
which O
may O
pose O
problems O
when O
using O
regular O
maximum O
likelihood O
estimation O
and O
pc O
##a O
6 O
to O
our O
knowledge O
the O
only O
study O
where O
the O
measurement O
level O
of O
the O
up O
##dr O
##s O
data O
was O
respected O
is O
one O
by O
k O
##ro O
##one O
##nberg O
et O
al O
16 O
however O
their O
study O
primarily O
focused O
on O
the O
differences O
in O
the O
structure O
of O
pd O
motor O
signs O
for O
on O
and O
off O
patients O
the O
results O
appeared O
to O
depend O
on O
the O
motor O
state O
of O
the O
patient O
their O
model O
did O
not O
ﬁ O
##t O
our O
data O
which O
might O
be O
due O
to O
a O
different O
scoring O
practice O
a O
problem O
that O
might O
also O
account O
for O
different O
validity O
and O
reliability O
results O
of O
the O
up O
##dr O
##s O
across O
countries O

the O
two O
factors O
of O
lateral O
##ity O
left O
and O
right O
re O
##ﬂ O
##ect O
the O
as O
##ym O
##metry O
of O
occurrence O
of O
tremor O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
in O
a O
clinical O
co O
##hort O
it O
has O
been O
shown O
that O
initial O
pd O
symptoms O
start O
more O
frequently O
on O
the O
right O
sided O
ex O
##tre O
##mit O
##ies O
than O
on O
the O
left O
17 O
in O
some O
e O
##fa O
studies O
side O
sensitivity O
of O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
was O
mentioned O
before O
2 O
3 O
as O
well O
as O
that O
of O
action O
post O
##ural O
tremor O
1 O
to O
our O
knowledge O
side O
sensitivity O
of O
rigid O
##ity O
and O
rest O
tremor O
however O
has O
not O
been O
previously O
reported O

the O
high O
correlation O
##s O
among O
the O
factors O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
and O
speech O
h O
##yp O
##omi O
##mia O
can O
be O
indicators O
of O
co O
occurrence O
of O
these O
pd O
symptoms O
for O
most O
patients O
in O
common O
pd O
populations O
however O
the O
main O
symptoms O
co O
occur O
whereas O
isolated O
tremor O
may O
only O
be O
present O
in O
very O
early O
stages O
of O
pd O
further O
the O
relative O
independence O
of O
tremor O
from O
rigid O
##ity O
and O
brady O
##kin O
##es O
##ia O
can O
be O
viewed O
as O
an O
indicator O
of O
the O
lack O
of O
substantive O
relationship O
between O
tremor O
and O
pd O
disability O
a O
ﬁ O
##nding O
consistent O
with O
other O
reports O
18 O
19 O

since O
a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
implying O
a O
partly O
ex O
##pl O
##ora O
##tory O
result O
future O
cross O
validation O
is O
necessary O
to O
challenge O
our O
ﬁ O
##nal O
factor O
structure O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
it O
should O
also O
be O
realized O
that O
larger O
sample O
sizes O
would O
make O
model O
estimation O
results O
especially O

when O
considering O
the O
or O
##dina O
##l O
character O
of O
item O
responses O
more O
reliable O
and O
ﬁ O
##nal O
conclusions O
more O
valid O

ac O
##k O
##now O
##led O
##gm O
##ents O
we O
are O
obliged O
to O
doctors O
jan O
roth O
pet O
##r O
me O
##ci O
##r O
robert O
je O
##ch O
ter O
##eza O
serra O
##nova O
and O
olga O
ul O
##man O
##ova O
who O
performed O
up O
##dr O
##s O
testing O
in O
some O
cases O
we O
are O
also O
grateful O
to O
prof O
dr O
k O
l O
lee O
##nder O
##s O
and O
mrs O
w O
j O
st O
##aa O
##l O
groningen O
for O
their O
helpful O
comments O
to O
the O
manuscript O
jan O
st O
##och O
##l O
was O
supported O
by O
mobility O
fund O
of O
charles O
university O
czech O
science O
foundation O
grant O
no O
406 O
07 O
p O
##51 O
##3 O
ministry O
of O
education O
youth O
and O
sports O
grant O
no O
ms O
##m O
00 O
##21 O
##6 O
##20 O
##86 O
##4 O
and O
foundation O
of O
josef O
marie O
a O
h O
##la O
##´ O
##v O
##kov O
##y O
##´ O
##ch O

cub O
##o O
e O
ste O
##bb O
##ins O
gt O
go O
##lb O
##e O
li O
et O
al O
application O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
factor O
analysis O
of O
the O
motor O
scale O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
276 O
279 O

ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
factor O
structure O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
motor O
examination O
section O
mo O
##v O
di O
##sor O
##d O
1998 O
13 O
63 O
##3 O
63 O
##6 O

ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
lang O
ae O
cub O
##o O
e O
factor O
analysis O
of O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
during O
the O
off O
state O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
58 O
##5 O
58 O
##9 O

martinez O
martin O
p O
gil O
na O
##gel O
a O
gr O
##ac O
##ia O
l O
##m O
gomez O
j O
##b O
martinez O
sar O
##ries O
j O
be O
##rm O
##ej O
##o O
f O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
characteristics O
and O
structure O
the O
cooperative O
multi O
##centric O
group O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
76 O
83 O

dun O
##tem O
##an O
g O
##h O
principal O
component O
analysis O
newbury O
park O
sage O
1989 O

hi O
##guchi O
i O
e O
##guchi O
s O
robust O
principal O
component O
analysis O
with O
adaptive O
selection O
for O
tuning O
parameters O
j O
machine O
learn O
res O
2004 O
5 O
45 O
##3 O
47 O
##1 O

elias O
##on O
sr O
maximum O
likelihood O
estimation O
logic O
and O
practice O
iowa O
sage O
1993 O

boom O
##sma O
a O
ho O
##og O
##land O
jj O
the O
robust O
##ness O
of O
li O
##sr O
##el O
modeling O
revisited O
in O
cu O
##deck O
r O
to O
##it O
s O
so O
##¨ O
##rb O
##om O
d O
editors O
structural O
equation O
modeling O
present O
and O
future O
a O
fest O
##sch O
##rift O
in O
honour O
of O
karl O
jo O
##¨ O
##res O
##ko O
##g O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2001 O
p O
139 O
168 O

hughes O
aj O
daniel O
se O
ki O
##lford O
l O
lee O
##s O
aj O
accuracy O
of O
clinical O
diagnosis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
a O
clinic O
##o O
path O
##ological O
study O
of O
100 O
cases O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1992 O
55 O
181 O
184 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
li O
##sr O
##el O
8 O
72 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2005 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
online O
help O
ﬁ O
##le O
for O
li O
##sr O
##el O
8 O
72 O
for O
windows O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2004 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
pre O
##lis O
2 O
54 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2002 O

j O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

phd O
thesis O
charles O
university O
prague O
2005 O

cr O
##on O
##bach O
l O
##j O
sc O
##ho O
##¨ O
##nem O
##ann O
p O
mc O
##kie O
d O
alpha O
coe O
##f O
##ﬁ O
##cie O
##nts O
for O
st O
##rat O
##i O
##ﬁ O
##ed O
parallel O
tests O
ed O
##uc O
psycho O
##l O
me O
##as O
1965 O
25 O
291 O
312 O

mart O
##ignon O
##i O
e O
fran O
##chi O
##gnon O
##i O
f O
pas O
##etti O
c O
fe O
##rrier O
##o O
g O
pic O
##co O
d O
psycho O
##metric O
properties O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
and O
of O
the O
short O
parkinson O
s O
evaluation O
scale O
ne O
##uro O
##l O
sci O
2003 O
24 O
190 O
191 O

k O
##ro O
##one O
##nberg O
pm O
o O
##ort O
f O
##j O
ste O
##bb O
##ins O
gt O
le O
##urg O
##ans O
se O
cub O
##o O
e O
go O
##etz O
c O
##g O
motor O
function O
in O
parkinson O
s O
disease O
and O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
simultaneous O
factor O
analysis O
of O
a O
clinical O
scale O
in O
several O
populations O
b O
##mc O
med O
res O
method O
2006 O
26 O
1 O
13 O

131 O
##2 O
d O
r O
williams O
et O
al O

poe O
##we O
w O
##h O
wen O
##ning O
g O
##k O
the O
natural O
history O
of O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
1998 O
44 O
3 O
su O
##pp O
##l O
1 O
s O
##1 O
s O
##9 O

henderson O
l O
ken O
##nard O
c O
crawford O
t O
scales O
for O
rating O
motor O
impairment O
in O
parkinson O
s O
disease O
studies O
of O
reliability O
and O
converge O
##nt O
validity O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1991 O
54 O
18 O
24 O

reynolds O
n O
montgomery O
g O
factor O
analysis O
of O
parkinson O
s O
impairment O
an O
evaluation O
of O
the O
ﬁ O
##nal O
common O
pathway O
arch O
ne O
##uro O
##l O
1987 O
44 O
101 O
##3 O
1016 O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

david O
r O
williams O
phd O
fra O
##cp O
1 O
2 O
max O
cow O
##ey O
bsc O
2 O
kate O
tuck O
bsc O
2 O
and O
bruce O
day O
fra O
##cp O
##2 O

1 O
##fa O
##cu O
##lty O
of O
medicine O
neuroscience O
##s O
mona O
##sh O
university O
alfred O
hospital O
campus O
melbourne O
australia O
2 O
##ne O
##uro O
##logy O
department O
the O
alfred O
hospital O

melbourne O
australia O

abstract O
we O
report O
a O
case O
of O
probable O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
in O
a O
patient O
who O
developed O
a O
sudden O
onset O
of O
di O
##sa O
##bling O
axial O
ﬂ O
##ex O
##or O
my O
##oc O
##lon O
##us O
following O
a O
cosmetic O
surgical O
procedure O
the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
were O
consistent O
with O
previous O
reports O
of O
ps O
##m O
spontaneous O
re O
##mission O
##s O
and O
disappearance O
of O
the O
jerk O
##s O
sustained O
for O
2 O
years O
following O
removal O
of O
super O
##ﬁ O
##cial O
surgical O
screw O
##s O
support O
the O
diagnosis O
of O
a O
psycho O
##genic O
movement O
disorder O
2008 O
movement O
disorder O
society O

key O
words O
psycho O
##genic O
my O
##oc O
##lon O
##us O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
is O
a O
form O
of O
spinal O
my O
##oc O
##lon O
##us O
characterized O
by O
involvement O
of O
muscles O
inner O
##vate O
##d O
from O
different O
segments O
of O
the O
spinal O
cord O
and O
sequential O
##ly O
activated O
via O
prop O
##rio O
##sp O
##inal O
pathways O
1 O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
of O
slow O
conduct O
##ion O
and O
selective O
recruitment O
of O
tr O
##un O
##cal O
and O
pro O
##xi O
##mal O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O

correspondence O
to O
dr O
david O
r O
williams O
neuroscience O
##s O
alfred O
hospital O
commercial O
road O
melbourne O
300 O
##4 O
australia O

e O
mail O
david O
williams O
med O
mona O
##sh O
ed O
##u O
au O

received O
4 O
july O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O

published O
online O
15 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##2 O

limb O
muscles O
help O
differentiate O
ps O
##m O
from O
spinal O
segment O
##al O
my O
##oc O
##lon O
##us O
2 O
ps O
##m O
has O
been O
documented O
secondary O
to O
intrinsic O
and O
ex O
##tri O
##ns O
##ic O
spinal O
cord O
lesions O
and O
in O
other O
cases O
no O
clear O
et O
##iology O
has O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
recently O
the O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
have O
been O
reported O
in O
a O
group O
of O
eight O
healthy O
volunteers O
sim O
##ulating O
the O
typical O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
of O
ps O
##m O
3 O
the O
differentiation O
between O
voluntary O
and O
involuntary O
movements O
of O
this O
nature O
is O
further O
blurred O
by O
our O
report O
of O
a O
patient O
with O
probable O
psycho O
##genic O
ps O
##m O

this O
65 O
year O
old O
woman O
fell O
after O
trip O
##ping O
over O
a O
concrete O
block O
on O
the O
pavement O
causing O
di O
##s O
##ﬁ O
##gur O
##ing O
soft O
tissue O
injuries O
above O
her O
right O
orbit O
apart O
from O
mig O
##raine O
there O
were O
no O
other O
medical O
problems O
at O
the O
time O
and O
no O
psychiatric O
history O
there O
was O
no O
documented O
injury O
or O
pain O
in O
the O
neck O
or O
back O
following O
the O
fall O
and O
at O
that O
time O
she O
was O
neurological O
##ly O
normal O
legal O
action O
relating O
to O
the O
circumstances O
of O
the O
incident O
was O
initiated O
a O
rec O
##ons O
##truct O
##ive O
right O
b O
##le O
##pha O
##rop O
##las O
##ty O
was O
performed O
for O
right O
sided O
pseudo O
##pt O
##osis O
she O
subsequently O
developed O
a O
right O
frontal O
headache O
the O
cosmetic O
results O
of O
the O
surgery O
were O
ins O
##uf O
##ﬁ O
##cie O
##nt O
and O
it O
was O
revised O
by O
brow O
##pl O
##ast O
##y O
that O
required O
the O
placement O
of O
three O
surgical O
screw O
##s O
into O
the O
right O
frontal O
bone O
including O
one O
that O
penetrated O
the O
frontal O
air O
sin O
##us O
the O
surgery O
was O
complicated O
by O
chronic O
pain O
around O
the O
operational O
site O
that O
was O
partially O
relieved O
by O
neck O
massage O
eighteen O
months O
after O
the O
fall O
and O
following O
massage O
of O
the O
neck O
she O
developed O
di O
##sa O
##bling O
par O
##ox O
##ys O
##ms O
of O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
were O
most O
severe O
when O
lying O
su O
##pine O
there O
was O
a O
suggestion O
of O
associated O
left O
sided O
weakness O
at O
onset O
but O
this O
resolved O
and O
mri O
and O
ang O
##io O
##gram O
were O
normal O
at O
ﬁ O
##rst O
the O
jerk O
##s O
occurred O
several O
times O
per O
day O
but O
rapidly O
increased O
in O
frequency O
with O
bouts O
of O
continuous O
jerking O
lasting O
for O
up O
to O
1 O
hour O
causing O
sign O
##i O
##ﬁ O
##can O
##t O
disability O
there O
was O
positive O
action O
my O
##oc O
##lon O
##us O
with O
coe O
##xi O
##sten O
##t O
stimulus O
sensitive O
my O
##oc O
##lon O
##us O
of O
variable O
late O
##ncy O
which O
diminished O
with O
distraction O
increasingly O
her O
mobility O
became O
affected O
by O
jerking O
and O
un O
##stead O
##y O
ga O
##it O
there O
were O
periods O
of O
complete O
re O
##mission O
lasting O
up O
to O
several O
months O
jerking O
was O
ex O
##ace O
##rba O
##ted O
by O
anxiety O
but O
no O
other O
pre O
##ci O
##pit O
##ants O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
spinal O
cord O
and O
brain O
mri O
were O
normal O
except O
for O
a O
few O
scattered O
deep O
white O
matter O
is O
##che O
##mic O
changes O
psychiatric O
evaluation O
did O
not O
identify O
features O
of O
so O
##mat O
##ization O
depression O
or O
mali O
##nger O
##ing O
she O
incomplete O
##ly O
responded O
to O
pi O
##race O
##tam O
16 O
g O
per O
day O
cl O
##ona O
##ze O
##pa O
##m O
4 O
mg O
per O
day O
sodium O
val O
##pro O
##ate O
2 O
g O
per O
day O
and O
ba O
##cl O
##of O
##en O
three O
surgical O
screw O
##s O
used O
in O
the O
b O
##le O
##pha O
##rop O
##las O
##ty O
were O
removed O
4 O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
131 O
##3 O

fig O
1 O
0 O
7 O
seconds O
epoch O
of O
order O
of O
activation O
study O
demonstrating O
surface O
em O
##g O
bursts O
in O
pe O
##ctor O
##alis O
pe O
##ct O
followed O
by O
stern O
##oma O
##sto O
##id O
sc O
##m O
and O
upper O
up O
##ab O
and O
lower O
abdominal O
muscles O
lo O
##ab O
solid O
line O
onset O
of O
jerk O

years O
after O
surgery O
at O
the O
patient O
s O
insistence O
and O
the O
axial O
jerk O
##s O
coincidentally O
resolved O
completely O
she O
returned O
to O
normal O
function O
and O
was O
sy O
##mpt O
##om O
free O
at O
follow O
up O
2 O
years O
later O

electro O
##phy O
##sio O
##logical O
investigations O

two O
years O
after O
the O
onset O
of O
jerking O
routine O
ee O
##g O
was O
normal O
median O
nerve O
sensory O
ev O
##oked O
potential O
##s O
were O
normal O
a O
jerk O
locked O
back O
averaged O
ee O
##g O
did O
not O
show O
pre O
movement O
co O
##rti O
##cal O
potential O
##s O
an O
order O
of O
activation O
study O
showed O
variable O
muscle O
activation O
but O
the O
most O
frequent O
pattern O
of O
activation O
was O
ca O
##uda O
##l O
from O
pe O
##ctor O
##al O
to O
abdominal O
muscles O
with O
propagation O
estimated O
at O
9 O
to O
15 O
m O
s O
see O
figure O
1 O
em O
##g O
burst O
length O
was O
between O
50 O
and O
150 O
mill O
##ise O
##con O
##ds O

this O
patient O
had O
some O
clinical O
and O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
previous O
reports O
of O
ps O
##m O
as O
well O
as O
features O
not O
usually O
reported O
to O
be O
associated O
such O
as O
ga O
##it O
un O
##stead O
##iness O
and O
axial O
jerk O
##s O
while O
standing O
unusually O
for O
ps O
##m O
there O
were O
periods O
of O
spontaneous O
re O
##mission O
and O
no O
id O
##ent O
##i O
##ﬁ O
##able O
path O
##ological O
les O
##ion O
to O

account O
for O
the O
my O
##oc O
##lon O
##us O
the O
sudden O
onset O
con O
##tem O
##por O
##aneous O
legal O
proceedings O
related O
to O
the O
injury O
the O
associated O
anxiety O
and O
spontaneous O
complete O
re O
##mission O
are O
supportive O
of O
a O
psycho O
##genic O
et O
##iology O
4 O

the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
reported O
in O
ps O
##m O
include O
ﬁ O
##xed O
patterns O
of O
muscle O
activation O
slow O
spinal O
cord O
conduct O
##ion O
5 O
15 O
m O
s O
em O
##g O
burst O
duration O
less O
than O
1 O
000 O
ms O
and O
sync O
##hr O
##ono O
##us O
activation O
of O
ago O
##nist O
and O
antagonist O
muscles O
reviewed O
in O
ref O
3 O
in O
our O
case O
the O
short O
em O
##g O
burst O
duration O
and O
slow O
conduct O
##ion O
was O
consistent O
with O
these O
reports O
in O
a O
number O
of O
similar O
cases O
with O
electro O
##phy O
##sio O
##logical O
characteristics O
of O
organic O
ps O
##m O
the O
possibility O
of O
psycho O
##genic O
et O
##iology O
has O
been O
raised O
3 O
5 O
healthy O
volunteers O
sim O
##ulating O
ps O
##m O
have O
electro O
##phy O
##sio O
##logical O
recordings O
that O
are O
also O
similar O
except O
for O
long O
em O
##g O
burst O
duration O
##s O
3 O
the O
ﬁ O
##nding O
##s O
in O
the O
present O
study O
support O
these O
authors O
contention O
that O
electro O
##phy O
##sio O
##logical O
parameters O
alone O
are O
ins O
##uf O
##ﬁ O
##cie O
##nt O
to O
identify O
organic O
ps O
##m O
to O
our O
knowledge O
re O
##mission O
##s O
have O
not O
been O
reported O
in O
ps O
##m O
and O
are O
said O
to O
count O
against O
the O
diagnosis O
6 O

the O
patient O
felt O
certain O
that O
the O
surgical O
screw O
##s O
caused O
the O
my O
##oc O
##lon O
##ic O
jerk O
##s O
but O
we O
were O
unable O
to O
identify O
a O
biological O
mechanism O
to O
account O
for O
this O
psycho O
##genic O
ps O
##m O
is O
the O
most O
likely O
diagnosis O
and O
removal O
of O
the O
perceived O
pre O
##ci O
##pit O
##ant O
was O
cu O
##rative O
in O
this O
case O
the O
clinical O
and O
imaging O
ﬁ O
##nding O
##s O
together O
with O
the O
long O
follow O
up O
in O
this O
patient O
effectively O
exclude O
any O
other O
diagnostic O
possibilities O

a O
psycho O
##genic O
et O
##iology O
should O
be O
considered O
when O
patients O
develop O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
occur O
when O
lying O
and O
standing O
without O
id O
##ent O
##i O
##ﬁ O
##able O
central O
nervous O
system O
lesions O
even O
in O
the O
presence O
of O
suggest O
##ive O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
spontaneous O
re O
##mission O
##s O
may O
differentiate O
psycho O
##genic O
and O
organic O
ps O
##m O

the O
patient O
is O
shown O
lying O
su O
##pine O
with O
bursts O
of O
spontaneous O
axial O
jerk O
##s O
occurring O
at O
rest O
without O
stimulation O

brown O
p O
thompson O
pd O
roth O
##well O
jc O
day O
b O
##l O
marsden O
cd O
axial O
my O
##oc O
##lon O
##us O
of O
prop O
##rio O
##sp O
##inal O
origin O
brain O
1991 O
114 O
197 O
214 O

roth O
##well O
jc O
path O
##op O
##hy O
##sio O
##logy O
of O
spinal O
my O
##oc O
##lon O
##us O
ad O
##v O
ne O
##uro O
##l O
2002 O
89 O
137 O
144 O

kang O
sy O
so O
##hn O
y O
##h O
electro O
##my O
##ography O
patterns O
of O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
can O
be O
mimic O
##ked O
voluntarily O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
124 O
##1 O
124 O
##4 O

fa O
##hn O
s O
williams O
dt O
psycho O
##genic O
d O
##yst O
##onia O
ad O
##v O
ne O
##uro O
##l O
1988 O
50 O
43 O
##1 O
45 O
##5 O

davies O
l O
king O
p O
##j O
leicester O
j O
morris O
j O
##g O
rec O
##umb O
##ent O
ti O
##c O
mo O
##v O
di O
##sor O
##d O
1992 O
7 O
35 O
##9 O
36 O
##3 O

brown O
j O
lan O
##tos O
p O
st O
##rat O
##ton O
m O
ro O
##ques O
p O
ross O
##or O
m O
fa O
##mi O
##lia O
##l O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1993 O
56 O
47 O
##3 O
47 O
##6 O

131 O
##4 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O

potassium O
channel O
block O
##er O

4 O
amino O
##py O
##rid O
##ine O
is O
effective O
in O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
a O
video O
case O
report O

matthias O
lo O
##¨ O
##hl O
##e O
md O
wi O
##eb O
##ke O
sc O
##hre O
##mp O
##f O
md O
martin O
wo O
##lz O
md O
heinz O
reich O
##mann O
md O
phd O
and O
alexander O
st O
##or O
##ch O
md O

department O
of O
ne O
##uro O
##logy O
technical O
university O
of O
dresden O
dresden O
germany O

abstract O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
an O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
clinical O
##ly O
characterized O
by O
rec O
##urrent O
attacks O
of O
vertigo O
im O
##balance O
and O
ata O
##xia O
studies O
have O
shown O
that O
4 O
amino O
##py O
##rid O
##ine O
4 O
ap O
is O
capable O
to O
prevent O
these O
attacks O
however O
there O
are O
no O
reports O
whether O
4 O
ap O
is O
able O
to O
at O
##ten O
##uate O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
using O
the O
scale O
for O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
we O
examined O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
4 O
ap O
on O
inter O
##ic O
##tal O
ata O
##xia O
in O
a O
63 O
##year O
old O
female O
patient O
who O
suffered O
from O
ea O
##2 O
since O
the O
age O
of O
57 O
ea O
##2 O
was O
diagnosed O
based O
on O
clinical O
criteria O
and O
not O
genetically O
proven O
when O
treatment O
with O
4 O
ap O
was O
paused O
the O
patient O
was O
suffering O
from O
marked O
ga O
##it O
and O
stance O
ata O
##xia O
after O
re O
initiation O
of O
treatment O
with O
5 O
mg O
4a O
##p O
t O
i O
d O
there O
was O
pronounced O
improvement O
in O
ga O
##it O
and O
stance O
ata O
##xia O
within O
24 O
hours O
sara O
score O
lowered O
from O

8 O
5 O
to O
4 O
5 O
points O
we O
conclude O
that O
4 O
ap O
may O
be O
ben O
##e O
##ﬁ O
##cial O
for O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
in O
late O
onset O
ea O
##2 O
2008 O
movement O
disorder O
society O

key O
words O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
4 O
amino O
##py O
##rid O
##ine O
inter O
##ic O
##tal O
ata O
##xia O
sara O
video O
case O
report O

ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
a O
rare O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
caused O
by O
mutations O
of O
the O
calcium O
channel O
gene O
ca O
##c O
##na O
##1 O
##a O
on O
chromosome O
19 O
##p O
##13 O
1 O
this O
gene O
codes O
for O
the O
ca O
##v O
##2 O
1 O
subunit O
of O
the O
p O
q O
type O
calcium O
channel O
which O
is O
expressed O
throughout O
the O
nervous O
system O
but O
mainly O
in O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O

correspondence O
to O
dr O
matthias O
lo O
##¨ O
##hl O
##e O
k O
##lini O
##k O
und O
pol O
##ik O
##lini O
##k O
fu O
##¨ O
##r O
ne O
##uro O
##logie O
fe O
##ts O
##chers O
##tra O
##sse O
74 O
01 O
##30 O
##7 O
dresden O
germany O

e O
mail O
matthias O
lo O
##eh O
##le O
ne O
##uro O
med O
tu O
dresden O
de O

received O
27 O
august O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O

march O
2008 O

published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##1 O

cells O
ea O
##2 O
usually O
starts O
before O
the O
age O
of O
20 O
however O
some O
patients O
reveal O
ﬁ O
##rst O
symptoms O
beyond O
the O
age O
of O

50 O
affected O
patients O
suffer O
from O
rec O
##urrent O
attacks O
of O
vertigo O
im O
##balance O
and O
ata O
##xia O
which O
may O
last O
for O
several O
hours O
up O
to O
days O
and O
can O
often O
be O
provoked O
by O
physical O
ex O
##ert O
##ion O
emotional O
stress O
and O
consumption O
of O
caf O
##fe O
##ine O
or O
alcohol O
most O
patients O
show O
central O
o O
##cular O
motor O
disturbances O
between O
these O
attacks O
such O
as O
gaze O
##holding O
de O
##ﬁ O
##cit O
##s O
down O
##beat O
ny O
##sta O
##gm O
##us O
sac O
##ca O
##dic O
eye O
pursuit O
movements O
and O
impaired O
visual O
suppression O
of O
the O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
2 O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
are O
a O
common O
condition O
in O
the O
course O
of O
the O
disease O
##1 O
and O
can O
be O
so O
marked O
that O
patients O
become O
wheelchair O
##bound O
because O
ea O
##2 O
is O
all O
##eli O
##c O
with O
fa O
##mi O
##lia O
##l O
hem O
##ip O
##leg O
##ic O
mig O
##raine O
type O
1 O
half O
of O
the O
patients O
suffer O
from O
mig O
##raine O
headache O
##s O
in O
the O
majority O
of O
cases O
there O
is O
a O
positive O
family O
history O
for O
the O
disease O
2 O

ace O
##ta O
##zo O
##lam O
##ide O
act O
##z O
is O
the O
drug O
of O
ﬁ O
##rst O
choice O
for O
treatment O
of O
ea O
##2 O
and O
prevents O
or O
at O
##ten O
##uate O
##s O
the O
attacks O
in O
50 O
to O
75 O
of O
all O
patients O
however O
many O
patients O
stop O
treatment O
with O
act O
##z O
in O
the O
long O
run O
due O
to O
adverse O
effects O
such O
as O
ne O
##ph O
##rol O
##ith O
##ias O
##is O
hyper O
##hy O
##dro O
##sis O
par O
##esthesia O
muscle O
stiff O
##ness O
and O
gas O
##tro O
##int O
##estinal O
disturbance O
or O
because O
of O
a O
loss O
of O
e O
##f O
##ﬁ O
##ca O
##cy O
so O
far O
treatment O
options O
for O
these O
patients O
are O
limited O
4 O
amino O
##py O
##rid O
##ine O
4 O
ap O
a O
potassium O
channel O
block O
##er O
has O
recently O
shown O
to O
be O
capable O
to O
prevent O
or O
markedly O
at O
##ten O
##uate O
attacks O
of O
ata O
##xia O
in O
patients O
in O
whom O
treatment O
with O
act O
##z O
had O
failed O
3 O
however O
there O
are O
so O
far O
no O
reports O
whether O
4 O
ap O
is O
able O
to O
at O
##ten O
##uate O
inter O
##ic O
##tal O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
that O
is O
often O
a O
key O
clinical O
feature O
in O
elderly O
ea O
##2 O
patients O

we O
examined O
a O
63 O
year O
old O
female O
patient O
who O
contacted O
our O
movement O
disorder O
out O
##patient O
clinic O
in O
may O
2004 O
in O
2000 O
at O
the O
age O
of O
57 O
she O
started O
to O
suffer O
from O
attacks O
with O
vertigo O
nausea O
and O
vomiting O
that O
were O
sometimes O
accompanied O
by O
d O
##ys O
##arth O
##ria O
and O
headache O
##s O
these O
attacks O
initially O
lasted O
for O
about O
30 O
min O
but O
prolonged O
within O
subsequent O
years O
additionally O
she O
had O
problems O
with O
visual O
ﬁ O
##xa O
##tion O
of O
objects O
and O
often O
had O
the O
impression O
that O
her O
visual O
image O
was O
rolling O
away O
consumption O
of O
coffee O
or O
alcoholic O
beverages O
led O
to O
deterioration O
of O
symptoms O
in O
2006 O
the O
attacks O
completely O
ceased O
and O
inter O
##ic O
##tal O
ga O
##it O
ata O
##xia O
became O
the O
main O
clinical O
problem O
making O
her O
incapable O
of O
walking O
or O
standing O
without O
support O
in O
the O
past O
the O
patient O
had O
suffered O
from O
mig O
##raine O
headache O
##s O
the O
mother O
of O
the O
patient O
also O
suffered O
from O
vertigo O

4 O
amino O
##py O
##rid O
##ine O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
131 O
##5 O

and O
headache O
##s O
a O
half O
sister O
complained O
about O
chronic O
headache O
##s O

clinical O
examination O
revealed O
central O
o O
##cu O
##lom O
##oto O
##r O
de O
##ﬁ O
##cit O
##s O
such O
as O
spontaneous O
ny O
##sta O
##gm O
##us O
to O
the O
left O
as O
well O
as O
down O
##beat O
ny O
##sta O
##gm O
##us O
at O
gaze O
to O
the O
left O
sac O
##ca O
##dic O
pursuit O
movements O
and O
impaired O
visual O
suppression O
of O
the O
vest O
##ib O
##ular O
o O
##cular O
re O
##ﬂ O
##ex O
additionally O
we O
observed O
d O
##ys O
##met O
##ria O
during O
the O
nose O
ﬁ O
##nger O
test O
and O
heel O
shin O
slide O
as O
well O
as O
marked O
stance O
and O
ga O
##it O
ata O
##xia O
magnetic O
resonance O
imaging O
showed O
decent O
at O
##rop O
##hy O
of O
the O
upper O
ve O
##rmi O
##s O
of O
the O
ce O
##re O
##bell O
##um O
but O
no O
further O
pathology O
electro O
##ence O
##pha O
##log O
##raphy O
was O
normal O
tumor O
screening O
including O
serum O
tumor O
markers O
was O
negative O
analysis O
of O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
did O
not O
show O
any O
abnormalities O
vest O
##ib O
##ular O
dysfunction O
was O
excluded O
as O
possible O
reason O
for O
vertigo O
by O
ot O
##or O
##hin O
##olar O
##yn O
##gol O
##og O
##ic O
examination O
that O
demonstrated O
regular O
function O
of O
both O
vest O
##ib O
##ular O
organs O
there O
was O
no O
sign O
for O
bar O
##ore O
##ce O
##pt O
##or O
or O
or O
##th O
##osta O
##tic O
dysfunction O
during O
auto O
##no O
##mic O
testing O
including O
metro O
##no O
##mic O
breathing O
val O
##sal O
##va O
maneuver O
and O
passive O
or O
##th O
##osta O
##sis O
on O
the O
tilt O
table O
since O
the O
patient O
did O
not O
undergo O
genetic O
testing O
ea O
##2 O
was O
diagnosed O
clinical O
##ly O
based O
on O
the O
medical O
history O
and O
the O
typical O
clinical O
ﬁ O
##nding O
##s O
mentioned O
above O

treatment O
was O
initiated O
with O
act O
##z O
in O
december O
2003 O
but O
had O
to O
be O
ceased O
due O
to O
tin O
##ni O
##tus O
and O
par O
##esthesia O
of O
hands O
and O
feet O
during O
treatment O
with O
act O
##z O
the O
patient O
had O
been O
able O
to O
ﬁ O
##xa O
##te O
objects O
better O
than O
before O
whereas O
ata O
##xia O
remained O
unchanged O
starting O
from O
july O
2006 O
we O
administered O
5 O
mg O
4 O
ap O
t O
i O
d O
provided O
by O
syn O
##op O
##har O
##m O
germany O
which O
was O
well O
tolerated O
without O
any O
adverse O
effects O
but O
initially O
did O
not O
seem O
to O
have O
any O
subjective O
ben O
##e O
##ﬁ O
##t O
for O
the O
patient O
after O
4 O
ap O
had O
been O
withdrawn O
due O
to O
suspected O
lack O
of O
e O
##f O
##ﬁ O
##ca O
##cy O
after O
only O
14 O
days O
of O
treatment O
and O
without O
further O
clinical O
evaluation O
the O
patient O
returned O
within O
1 O
week O
and O
reported O
about O
a O
distinct O
worse O
##ning O
of O
ga O
##it O
and O
stance O
ata O
##xia O
making O
her O
unable O
to O
walk O
una O
##ssi O
##sted O
after O
re O
initiation O
of O
4 O
ap O
symptoms O
markedly O
improved O
and O
are O
now O
stable O
over O
1 O
year O

evaluation O
##s O

after O
informed O
consent O
for O
video O
##ta O
##ping O
had O
been O
given O
the O
patient O
was O
asked O
to O
pause O
treatment O
with O
4a O
##p O
for O
24 O
hours O
and O
after O
that O
was O
video O
##ta O
##ped O
and O
rated O
according O
to O
the O
recently O
valid O
##ated O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
4 O
the O
patient O
was O
then O
given O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
and O
video O
##ta O
##ped O
and O
rated O
again O
as O
soon O
as O
she O
realized O
improvement O
of O
her O
symptoms O
a O
ﬁ O
##nal O
evaluation O
was O
done O
after O
the O
patient O
had O
taken O
3 O
3 O
5 O
mg O
4 O
ap O
over O
24 O

hours O
all O
evaluation O
##s O
were O
done O
in O
exact O
order O
as O
provided O
by O
sara O
the O
video O
##ta O
##pes O
were O
reviewed O
by O
a O
movement O
disorder O
expert O
a O
s O
who O
was O
blinded O
for O
the O
treatment O
scores O
were O
given O
according O
to O
the O
sara O
criteria O
based O
on O
a O
common O
judgment O
of O
the O
expert O
and O
the O
observer O
who O
had O
video O
##ta O
##ped O
the O
patient O
m O
l O
ec O
##g O
was O
performed O
before O
and O
during O
treatment O
to O
exclude O
clinical O
##ly O
relevant O
pro O
##long O
##ation O
of O
q O
##tc O
time O
which O
was O
calculated O
using O
ba O
##ze O
##tt O
s O
correction O
q O
##tc O
¼ O
q O
##t O
ð O
##mill O
##ise O
##con O
##ds O
##þ O
rr O
ð O
##se O
##con O
##ds O
##þ O
q O
##tc O
time O
was O
within O
normal O
range O
measuring O
42 O
##9 O
mill O
##ise O
##con O
##ds O
before O
and O
41 O
##4 O
mill O
##ise O
##con O
##ds O
during O
treatment O
with O
5 O
mg O
4 O
ap O
t O
i O
d O

after O
24 O
hours O
withdrawal O
of O
4 O
ap O
the O
patient O
was O
suffering O
from O
marked O
ga O
##it O
and O
stance O
ata O
##xia O
video O
minimal O
speech O
disturbance O
slight O
d O
##ys O
##met O
##ria O
during O
ﬁ O
##nger O
chase O
with O
the O
left O
hand O
tremor O
during O
the O
nose O
##ﬁ O
##nger O
test O
on O
both O
sides O
and O
a O
slightly O
abnormal O
heel O
shin O
slide O
because O
of O
ga O
##it O
ata O
##xia O
she O
preferred O
to O
use O
a O
walker O
in O
order O
to O
avoid O
falls O
total O
sara O
score O
without O
4 O
ap O
was O
8 O
5 O
points O
one O
hour O
after O
intake O
of O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
the O
patient O
noticed O
a O
slight O
relief O
of O
her O
symptoms O
that O
could O
only O
be O
object O
##i O
##ﬁ O
##ed O
during O
the O
nose O
ﬁ O
##nger O
test O
sara O
sub O
##sco O
##re O
decreased O
from O
1 O
0 O
to O
0 O
5 O
points O
where O
she O
had O
less O
tremor O
of O
her O
right O
hand O
total O
sara O
score O
8 O
0 O
points O

on O
the O
next O
day O
after O
completing O
her O
regular O
daily O
treatment O
with O
5 O
mg O
4 O
ap O
t O
i O
d O
the O
patient O
returned O
to O
our O
out O
##patient O
clinic O
without O
her O
walker O
ga O
##it O
had O
markedly O
stabilized O
so O
she O
was O
even O
able O
to O
do O
some O
steps O
of O
tandem O
walking O
video O
stance O
ata O
##xia O
also O
had O
improved O
sara O
sub O
##sco O
##re O
decreased O
from O
2 O
0 O
to O
1 O
0 O
points O
the O
patient O
was O
now O
capable O
of O
standing O
with O
her O
feet O
in O
tandem O
position O
for O
more O
than O
10 O
seconds O
video O
furthermore O
there O
was O
improvement O
in O
ﬁ O
##nger O
chase O
nose O
ﬁ O
##nger O
test O
and O
heel O
shin O
slide O
total O
sara O
score O
after O
treatment O
with O
4 O
ap O
t O
i O
d O
had O
lowered O
to O
4 O
5 O
points O

our O
report O
con O
##ﬁ O
##rm O
##s O
previous O
observations O
that O
4 O
ap O
treatment O
offers O
an O
option O
for O
ea O
##2 O
patients O
in O
whom O
act O
##z O
failed O
to O
relieve O
symptoms O
although O
4 O
ap O
in O
previous O
studies O
has O
shown O
to O
be O
effective O
in O
preventing O
or O
at O
##ten O
##uating O
ata O
##xia O
attacks O
3 O
our O
report O
for O
the O
ﬁ O
##rst O
time O
suggests O
that O
4 O
ap O
may O
also O
be O
ben O
##e O
##ﬁ O
##cial O
for O
patients O
with O
late O
onset O
of O
ea O
##2 O
in O
whom O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
has O
become O
the O
key O
clinical O
feature O

because O
of O
the O
ca O
##c O
##na O
##1 O
##a O
mutation O
current O
density O
from O
ca O
##v O
##2 O
1 O
channels O
in O
ea O
##2 O
is O
reduced O
which O
may O
lead O
to O
a O
general O
reduction O
in O
pu O
##rkin O
##je O
cell O
ﬁ O
##ring O
rates O
and O
a O
loss O
of O
inhibition O
at O
deep O
ce O
##re O
##bella O
##r O
nuclei O
5 O
an O
##i O

131 O
##6 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O

mal O
studies O
in O
guinea O
pigs O
have O
demonstrated O
that O
4a O
##p O
is O
able O
to O
increase O
the O
ex O
##cit O
##ability O
of O
pu O
##rkin O
##je O
cells O
by O
reducing O
the O
duration O
of O
the O
slowly O
de O
##pol O
##ari O
##zing O
potential O
and O
thus O
late O
##ncy O
to O
the O
ﬁ O
##ring O
of O
ca O
##21 O
spikes O
in O
response O
to O
intra O
##cellular O
current O
pulses O
6 O
thus O
it O
may O
be O
assumed O
that O
the O
ben O
##e O
##ﬁ O
##cial O
effects O
of O
4 O
ap O
are O
due O
to O
its O
capability O
to O
restore O
overall O
pu O
##rkin O
##je O
cell O
ex O
##cit O
##ability O
and O
thereby O
inhibitor O
##y O
effects O
of O
pu O
##rkin O
##je O
cells O
on O
deep O
ce O
##re O
##bella O
##r O
nuclei O
5 O

our O
patient O
reported O
sy O
##mpt O
##oma O
##tic O
relief O
1 O
hour O
after O
the O
ing O
##est O
##ion O
of O
5 O
mg O
4 O
ap O
which O
is O
in O
keeping O
with O
ph O
##arm O
##aco O
##kin O
##etic O
studies O
that O
found O
maximal O
plasma O
concentrations O
1 O
0 O
1 O
2 O
hours O
after O
intake O
7 O
however O
improvement O
at O
that O
time O
point O
was O
only O
visible O
during O
the O
ﬁ O
##nger O
nose O
test O
and O
was O
much O
more O
marked O
after O
4a O
##p O
had O
been O
taken O
three O
times O
a O
day O
this O
observation O
may O
indicate O
that O
ne O
##uron O
##al O
circuits O
affected O
by O
ea O
##2 O
need O
time O
to O
adjust O
to O
4 O
ap O
before O
sy O
##mpt O
##oma O
##tic O
effects O
can O
be O
measured O
the O
initial O
lack O
of O
subjective O
ben O
##e O
##ﬁ O
##t O
after O
the O
ﬁ O
##rst O
administration O
of O
4 O
ap O
might O
as O
well O
have O
been O
due O
to O
the O
short O
duration O
of O
initial O
treatment O
since O
therapy O
with O
4 O
ap O
supported O
by O
regular O
ga O
##it O
and O
balance O
training O
now O
shows O
a O
long O
lasting O
effect O
over O
1 O
year O

future O
treatment O
trials O
are O
warrant O
##ed O
to O
evaluate O
and O
compare O
the O
therapeutic O
effects O
of O
act O
##z O
and O
4 O
ap O
these O
trials O
should O
examine O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
both O
drugs O
on O
attacks O
as O
well O
as O
on O
inter O
##ic O
##tal O
ata O
##xia O
in O
order O
to O
identify O
the O
best O
treatment O
for O
patients O
of O
various O
ages O
and O
different O
disease O
stages O

full O
video O

jen O
j O
kim O
g O
##w O
bal O
##oh O
r O
##w O
clinical O
spectrum O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##logy O
2004 O
62 O
17 O
22 O

st O
##rup O
##p O
m O
z O
##wer O
##gal O
a O
brandt O
t O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##ther O
##ape O
##uti O
##cs O
2007 O
4 O
276 O
273 O

st O
##rup O
##p O
m O
ka O
##lla O
r O
di O
##ch O
##gan O
##s O
m O
fr O
##eil O
##inger O
t O
g O
##las O
##auer O
s O
brandt O

t O
treatment O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
with O
the O
potassium O
channel O
block O
##er O
4 O
amino O
##py O
##rid O
##ine O
ne O
##uro O
##logy O
2004 O
62 O
1623 O
1625 O

sc O
##hmi O
##tz O
hub O
##sch O
t O
du O
mont O
##cel O
st O
bali O
##ko O
l O
et O
al O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
development O
of O
a O
new O
clinical O
scale O
ne O
##uro O
##logy O
2006 O
66 O
1717 O
1720 O

wei O
##sz O
c O
##j O
rai O
##ke O
rs O
so O
##ria O
ja O
##sso O
le O
hess O
e O
##j O
potassium O
channel O
block O
##ers O
inhibit O
the O
triggers O
of O
attacks O
in O
the O
calcium O
channel O
mouse O
mutant O
to O
##ttering O
j O
ne O
##uro O
##sc O
##i O
2005 O
25 O
41 O
##41 O
41 O
##45 O

et O
##zio O
##n O
y O
gross O
##man O
y O
highly O
4 O
amino O
##py O
##rid O
##ine O
sensitive O
delayed O
rec O
##ti O
##ﬁ O
##er O
current O
mod O
##ulates O
the O
ex O
##cit O
##ability O
of O
guinea O
pig O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O
cells O
ex O
##p O
brain O
res O
2001 O
139 O
41 O
##9 O
425 O

hayes O
kc O
katz O
ma O
dev O
##ane O
j O
##g O
et O
al O
ph O
##arm O
##aco O
##kin O
##etic O
##s O
of O
an O
immediate O
release O
oral O
formulation O
of O
fa O
##mp O
##rid O
##ine O
4 O
amino O
##py O
##rid O
##ine O
in O
normal O
subjects O
and O
patients O
with O
spinal O
cord O
injury O
j O
cl O
##in O
ph O
##arm O
##aco O
##l O
2003 O
43 O
37 O
##9 O
385 O

time O
content O

00 O
00 O
00 O
00 O
00 O
23 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O

00 O
00 O
24 O
00 O
00 O
44 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O

00 O
00 O
45 O
00 O
01 O
01 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O

00 O
01 O
02 O
00 O
01 O
47 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O

00 O
01 O
48 O
00 O
02 O
29 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O

00 O
02 O
30 O
00 O
03 O
06 O
patient O
during O
normal O
stance O
stance O
with O
feet O

together O
and O
tandem O
stance O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O

dex O
##med O
##eto O
##mi O
##dine O
arousal O
se O
##dation O
and O
st O
##n O
neurons O
131 O
##7 O

dex O
##med O
##eto O
##mi O
##dine O
and O
arousal O
affect O
sub O
##thal O
##ami O
##c O
neurons O

william O
jeffrey O
elias O
md O
1 O
marcel O
e O
du O
##rie O
##ux O
md O
2 O
diane O
hu O
##ss O
p O
t O
ms O
##ed O
nc O
##s O
3 O

and O
robert O
c O
fry O
##sing O
##er O
phd O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##sur O
##ger O
##y O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
2d O
##ep O
##art O
##ment O
of O
an O
##est O
##hes O
##iology O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
3d O
##ep O
##art O
##ment O
of O
physical O
therapy O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O

abstract O
stereo O
##ta O
##ctic O
ne O
##uro O
##sur O
##ge O
##ons O
hesitate O
to O
employ O
se O
##dation O
in O
cases O
requiring O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
we O
report O
our O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
during O
mer O
of O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
eleven O
parkinson O
##ian O
patients O
received O
dex O
##med O
##eto O
##mi O
##dine O
during O
deep O
brain O
stimulation O
surgery O
seven O
received O
continuous O
iv O
in O
##fusion O
##s O
during O
mer O
in O
the O
st O
##n O
the O
bis O
##pe O
##ct O
##ral O
index O
bis O
was O
used O
to O
estimate O
the O
level O
of O
consciousness O
the O
quality O
of O
mer O
was O
evaluated O
as O
a O
function O
of O
bis O
clinical O
arousal O
and O
dex O
##med O
##eto O
##mi O
##dine O
dose O
mer O
during O
wake O
##fulness O
bis O
80 O
0 O
1 O
to O
0 O
4 O
mc O
##g O
kg O
hr O
dex O
##med O
##eto O
##mi O
##dine O
was O
similar O
to O
the O
un O
##med O
##icated O
state O
sub O
##thal O
##ami O
##c O
mer O
was O
reduced O
when O
the O
patient O
was O
asleep O
or O
una O
##rous O
##able O
bis O
80 O
an O
##xi O
##ol O
##ysis O
persisted O
for O
hours O
arousal O
affects O
st O
##n O
neurons O
dex O
##med O
##eto O
##mi O
##dine O
cooperative O
se O
##dation O
from O
which O
the O
patient O
is O
easily O
aroused O
provides O
interpret O
##able O
st O
##n O
mer O
and O
prolonged O
an O
##xi O
##ol O
##ysis O
we O
suggest O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
##s O
without O
a O
loading O
dose O
a O
relatively O
low O
in O
##fusion O
rate O
and O
disco O
##nti O
##nu O
##ation O
after O
completion O
of O
the O
bu O
##r O
holes O
2008 O
movement O
disorder O
society O

key O
words O
dex O
##med O
##eto O
##mi O
##dine O
deep O
brain O
stimulation O
sub O
##thal O
##ami O
##c O
nucleus O
micro O
##ele O
##ct O
##rod O
##e O
recording O

deep O
brain O
stimulation O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
has O
proven O
effective O
for O
treating O
the O
motor O
symptoms O
of O
parkinson O
s O
disease O
pd O
the O
st O
##n O
is O
relatively O
small O
and O
deep O
1 O
man O
##dating O
some O
form O
of O
intra O
##oper O
##ative O
local O
##ization O
for O
this O
reason O
local O
##izing O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
and O
test O
stimulation O
have O
become O
routine O
traditionally O
mer O
and O
intra O

correspondence O
to O
w O
jeffrey O
elias O
md O
department O
of O
neurological O
surgery O
university O
of O
virginia O
box O
800 O
##21 O
##2 O
charlotte O
##sville O
va O
229 O
##0 O
##8 O
e O
mail O
w O
##je O
##4 O
##r O
virginia O
ed O
##u O

this O
work O
was O
presented O
in O
poster O
format O
at O
the O
american O
society O
of O
stereo O
##ta O
##ctic O
and O
functional O
ne O
##uro O
##sur O
##ge O
##ons O
in O
boston O
massachusetts O
june O
2006 O

received O
9 O
may O
2007 O
revised O
9 O
october O
2007 O
accepted O
18 O

published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##80 O

operative O
testing O
require O
an O
awake O
cooperative O
patient O
2 O
3 O
patients O
fear O
awake O
surgical O
procedures O
but O
many O
stereo O
##ta O
##ctic O
ne O
##uro O
##sur O
##ge O
##ons O
remain O
hesitant O
to O
employ O
se O
##dation O
for O
fear O
of O
suppress O
##ing O
symptoms O
or O
at O
##ten O
##uating O
local O
##izing O
signals O

se O
##dation O
during O
mer O
guided O
db O
##s O
surgery O
poses O
a O
real O
challenge O
as O
even O
small O
doses O
of O
se O
##da O
##tive O
##s O
can O
affect O
the O
quality O
of O
mer O
##4 O
or O
suppress O
pd O
symptoms O
5 O
patient O
comfort O
would O
no O
doubt O
be O
maximize O
##d O
by O
general O
an O
##esthesia O
but O
probably O
at O
the O
expense O
of O
precise O
electrode O
positioning O
and O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
mal O
##tet O
##e O
et O
al O
reported O
generally O
successful O
db O
##s O
implant O
##s O
with O
general O
an O
##esthesia O
in O
15 O
parkinson O
s O
disease O
patients O
but O
motor O
score O
improvements O
post O
##oper O
##ative O
##ly O
were O
lower O
in O
the O
an O
##est O
##het O
##ized O
group O
6 O
her O
##tel O
et O
al O
recently O
reported O
decreased O
background O
of O
st O
##n O
mer O
in O
a O
setting O
of O
carefully O
ti O
##tra O
##ted O
general O
an O
##esthesia O
7 O

dex O
##med O
##eto O
##mi O
##dine O
pre O
##cede O
##x O
is O
an O
attractive O
se O
##da O

ti O
##ve O
for O
use O
in O
ne O
##uro O
##sur O
##gical O
procedures O
because O
of O
its O
minimal O
respiratory O
de O
##press O
##ant O
effects O
hem O
##od O
##yna O
##mic O
stab O
##ili O
##zing O
properties O
and O
rapid O
onset O
and O
offset O
initially O
approved O
for O
ic O
##u O
se O
##dation O
this O
a O
2 O
ago O
##nist O
affects O
receptors O
primarily O
in O
the O
locus O
ce O
##ru O
##le O
##us O
with O
minimal O
effects O
on O
cerebral O
cortex O
8 O
this O
results O
in O
a O
unique O
cooperative O
se O
##dation O
where O
patients O
may O
fall O
asleep O
but O
are O
easily O
aroused O
9 O

a O
recent O
report O
suggests O
that O
patient O
cooperation O
pd O

symptoms O
and O
the O
quality O
of O
mer O
were O
unaffected O
by O
continuous O
se O
##dation O
with O
dex O
##med O
##eto O
##mi O
##dine O
during O
db O
##s O
implant O
surgery O
in O
11 O
cases O
10 O
an O
extensive O
positive O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
during O
db O
##s O
surgery O
has O
been O
reported O
at O
rush O
university O
but O
the O
effects O
on O
mer O
of O
st O
##n O
neurons O
have O
not O
yet O
been O
published O
9 O

stefan O
##i O
et O
al O
found O
that O
spontaneous O
sleep O
can O
have O
a O
profound O
impact O
on O
the O
discharge O
of O
st O
##n O
neurons O
11 O
this O
suggests O
that O
behavioral O
arousal O
could O
play O
a O
clinical O
##ly O
relevant O
role O
in O
mer O
local O
##ization O
because O
patients O
may O
fall O
asleep O
even O
with O
low O
doses O
of O
dex O
##med O
##eto O
##mi O
##dine O
sleep O
waking O
state O
may O
be O
a O
factor O
related O
to O
an O
##xi O
##ol O
##ysis O
rather O
than O
frank O
se O
##dation O

in O
an O
effort O
to O
reduce O
discomfort O
and O
anxiety O
in O
our O
patients O
during O
db O
##s O
procedures O
we O
utilize O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
for O
se O
##dation O
here O
we O
report O
our O
observations O
of O
the O
effects O
of O
dex O
##med O
##eto O
##mi O
##dine O
on O
st O
##n O
mer O

we O
reviewed O
operative O
an O
##est O
##hetic O
and O
mer O
records O
from O
11 O
consecutive O
cases O
of O
patients O
with O
parkinson O
s O

131 O
##8 O
w O
j O
elias O
et O
al O

disease O
who O
underwent O
st O
##n O
db O
##s O
electrode O
implant O
##ation O
during O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O

surgery O

parkinson O
medications O
were O
held O
on O
the O
day O
of O
surgery O
and O
a O
le O
##ks O
##ell O
stereo O
##ta O
##ctic O
frame O
was O
placed O
using O
local O
an O
##esthesia O
direct O
targeting O
was O
based O
on O
t O
##2 O
and O
mp O
rage O
volume O
##tric O
mr O
12 O
the O
patient O
was O
placed O
in O
a O
semi O
##re O
##cum O
##ben O
##t O
position O
with O
the O
frame O
locked O
to O
the O
operating O
table O
blood O
pressure O
was O
monitored O
by O
an O
automatic O
cuff O
spontaneous O
res O
##piration O
was O
monitored O
along O
with O
o O
##2 O
sat O
##uration O

se O
##dation O

se O
##dation O
was O
provided O
with O
continuous O
in O
##fusion O
of O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
which O
usually O
started O
at O

0 O
7 O
mc O
##g O
kg O
hr O
and O
ti O
##tra O
##ted O
down O
based O
on O
clinical O
response O
in O
several O
patients O
an O
initial O
loading O
dose O
of O
1 O
mc O
##g O
kg O
was O
administered O
over O
20 O
min O
level O
of O
consciousness O
was O
assessed O
by O
the O
ne O
##uro O
##sur O
##ge O
##on O
and O
an O
##est O
##hes O
##iol O
##ogist O
using O
observation O
and O
verbal O
questioning O
the O
bis O
##pe O
##ct O
##ral O
index O
bis O
helped O
to O
estimate O
the O
level O
of O
co O
##rti O
##cal O
arousal O
##13 O

bis O
5 O
80 O
to O
100 O
suggests O
awake O
and O
alert O
bis O
5 O
60 O
to O
80 O
varying O
levels O
of O
se O
##dation O
and O
bis O
5 O
40 O
to O
60 O
general O
an O
##esthesia O

se O
##dation O
was O
ti O
##tra O
##ted O
to O
patient O
comfort O
and O
was O
transient O
##ly O
increased O
during O
bu O
##r O
hole O
placement O
no O
other O
drugs O
with O
se O
##da O
##tive O
properties O
were O
administered O

micro O
##ele O
##ct O
##rod O
##e O
recording O

mer O
was O
initiated O
25 O
mm O
above O
the O
target O
and O
recorded O
on O
an O
alpha O
omega O
system O
sample O
recordings O
were O
saved O
every O
0 O
5 O
mm O
during O
the O
trajectory O
we O
did O
not O
test O
for O
motor O
driving O
of O
neurons O
following O
satisfactory O
mer O
and O
intra O
##oper O
##ative O
macro O
##sti O
##mu O
##lation O
testing O
the O
db O
##s O
electrode O
was O
anchored O
in O
position O
and O
con O
##ﬁ O
##rmed O
with O
ﬂ O
##uo O
##ros O
##co O
##py O

post O
##oper O
##ative O

patients O
recovered O
in O
the O
post O
##ane O
##st O
##hes O
##ia O
care O
unit O
and O
on O
the O
ne O
##uro O
##sur O
##gical O
ward O
a O
local O
##izing O
mri O
was O
obtained O
the O
day O
following O
surgery O
baseline O
parkinson O
s O
medications O
were O
resumed O
and O
most O
patients O
were O
discharged O
on O
the O
second O
post O
##oper O
##ative O
day O

eleven O
parkinson O
##ian O
patients O
underwent O
mer O
##guide O
##d O
st O
##n O
db O
##s O
with O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
all O
were O
men O
average O
age O
62 O
3 O
years O
mean O
disease O

duration O
10 O
1 O
years O
eight O
patients O
underwent O
bilateral O
and O
three O
underwent O
un O
##ila O
##tera O
##l O
surgery O

micro O
##ele O
##ct O
##rod O
##e O
recordings O
were O
successful O
for O
all O
placement O
##s O
the O
mean O
number O
of O
electrode O
tr O
##aj O
##ect O
##ories O
per O
side O
was O
1 O
5 O
range O
1 O
4 O
the O
mean O
trajectory O
length O
through O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
4 O
4 O
mm O
range O
2 O
5 O
6 O
mm O
in O
4 O
patients O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
was O
discontinued O
following O
bu O
##r O
hole O
placement O
the O
most O
no O
##xious O
part O
of O
the O
procedure O
the O
other O
7 O
patients O
received O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
during O
micro O
##ele O
##ct O
##rod O
##e O
recording O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O

sub O
##thal O
##ami O
##c O
mer O
signals O
equivalent O
to O
the O
non O
##sed O
##ated O
state O
were O
obtained O
when O
dex O
##med O
##eto O
##mi O
##dine O
was O
ti O
##tra O
##ted O
to O
an O
easily O
ar O
##ous O
##able O
level O
of O
consciousness O
bis O
80 O
suppression O
of O
sub O
##thal O
##ami O
##c O
ne O
##uron O
##al O
discharge O
occurred O
with O
higher O
in O
##fusion O
rates O
and O
se O
##dation O
levels O
where O
the O
patient O
was O
una O
##rous O
##able O
bis O
80 O
fig O
##s O
1 O
and O
2 O
all O
patients O
were O
su O
##f O
##ﬁ O
##cie O
##ntly O
alert O
and O
cooperative O
for O
macro O
##sti O
##mu O
##lation O
testing O
following O
micro O
##ele O
##ct O
##rod O
##e O
recording O

following O
dex O
##med O
##eto O
##mi O
##dine O
administration O
and O
up O
to O
at O
least O
several O
hours O
after O
disco O
##nti O
##nu O
##ation O
we O
observed O
a O
prolonged O
an O
##xi O
##ol O
##ytic O
effect O
it O
was O
relatively O
common O
for O
these O
patients O
to O
laps O
##e O
into O
easily O
ar O
##ous O
##able O
sleep O
during O
the O
later O
stages O
of O
the O
operation O
in O
some O
patients O
we O
observed O
a O
clear O
step O
change O
increase O
in O
mer O
activity O
in O
the O
st O
##n O
upon O
behavioral O
arousal O
from O
sleep O
consistent O
with O
the O
report O
by O
stefan O
##i O
et O
al O
11 O

eleven O
parkinson O
##ian O
patients O
received O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
during O
db O
##s O
surgery O
and O
local O
##izing O
unit O
activity O
was O
recorded O
from O
st O
##n O
in O
every O
case O
mer O
of O
st O
##n O
was O
obtained O
during O
continuous O
in O
##fusion O
in O
7 O
of O
these O
patients O
low O
level O
in O
##fusion O
##s O
of O
dex O
##med O
##eto O
##mi O
##dine O
0 O
1 O
mc O
##g O
kg O
hr O
did O
not O
substantially O
suppress O

dex O
##med O
##eto O
##mi O
##dine O
arousal O
se O
##dation O
and O
st O
##n O
neurons O
131 O
##9 O

fig O
2 O
deep O
se O
##dation O
suppress O
##es O
st O
##n O
ne O
##uron O
##al O
activity O
all O
traces O
were O
recorded O
from O
the O
same O
micro O
##ele O
##ct O
##rod O
##e O
position O
upper O
trace O
st O
##n O
mer O
signals O
patient O
is O
awake O
with O
bis O
5 O
95 O
middle O
trace O
mer O
signals O
following O
an O
iv O
bo O
##lus O
of O
dex O
##med O
##eto O
##mi O
##dine O
1 O
l O
##g O
kg O
load O
over O
10 O
min O
then O
0 O
5 O
l O
##g O
kg O
hr O
patient O
becomes O
una O
##rous O
##able O
with O
bis O
5 O
70 O
lower O
trace O
mer O
signals O
20 O
min O
after O
stopping O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
patient O
awake O
##ns O
with O
some O
return O
of O
baseline O
background O
activity O
bis O
5 O
95 O

st O
##n O
ne O
##uron O
##al O
discharge O
##s O
but O
higher O
rates O
0 O
5 O
mc O
##g O
kg O
hr O
resulted O
in O
a O
deeper O
se O
##dation O
lower O
bis O
levels O
and O
suppressed O
ne O
##uron O
##al O
ﬁ O
##ring O
in O
the O
st O
##n O
see O
fig O
1 O

the O
clinical O
or O
setting O
of O
these O
recordings O
imposed O
some O
constraints O
on O
analysis O
of O
ne O
##uron O
##al O
activity O
high O
amplitude O
single O
cell O
activity O
is O
lost O
over O
time O
at O
a O
given O
position O
of O
the O
micro O
##ele O
##ct O
##rod O
##e O
mer O
across O
different O
medication O
or O
arousal O
conditions O
typically O
required O
10 O
min O
or O
more O
longer O
than O
we O
could O
re O
##lia O
##bly O
hold O
the O
activity O
of O
disc O
##rim O
##ina O
##ble O
single O
units O

the O
so O
called O
background O
multiple O
cell O
activity O
is O
more O
stable O
over O
time O
and O
may O
be O
a O
marker O
of O
ph O
##arm O
##aco O
##logic O
modulation O
7 O
we O
were O
able O
to O
obtain O
continuous O
mer O
of O
the O
st O
##n O
during O
relatively O
rapid O
changes O
from O
sleep O
to O
waking O
and O
on O
one O
occasion O
before O
and O
after O
a O
bo O
##lus O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
see O
fig O
2 O
we O
could O
not O
obtain O
mer O
activity O
during O
the O
transition O
from O
med O
##icated O
to O
non O
##med O
##icated O
or O
from O
wake O
##fulness O
to O
sleep O
because O
these O
are O
not O
rapid O
events O
there O
is O
thus O
an O
inevitable O
con O
##fo O
##und O
##ing O
of O
the O
effect O
of O
time O
with O
the O
effect O
of O
the O
manipulation O
particularly O
of O
drug O
levels O
we O
hope O
that O
future O
research O
may O
provide O
more O
details O
of O
the O
effects O
of O
arousal O
versus O
ph O
##arm O
##aco O
##logic O
effects O
on O
st O
##n O
neurons O

ro O
##ze O
##t O
et O
al O
reported O
that O
patient O
comfort O
was O
improved O
with O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
and O
mer O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
possible O
we O
agree O
however O
we O
observed O
that O
sub O
##thal O
##ami O
##c O
ne O
##uron O
##al O
ﬁ O
##ring O
varied O
with O
the O
dose O
of O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
and O
the O
patient O
s O
level O
of O
behavioral O
arousal O

intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
was O
highly O
successful O
in O
all O
##ev O
##iating O
anxiety O
during O
all O
stages O
of O
db O
##s O
surgery O

and O
particularly O
for O
placement O
of O
the O
bu O
##r O
holes O
the O
terminal O
elimination O
half O
life O
of O
dex O
##med O
##eto O
##mi O
##dine O
is O
recognized O
as O
2 O
hours O
but O
we O
observed O
prolonged O
clinical O
##ly O
effective O
an O
##xi O
##ol O
##ysis O
even O
when O
the O
in O
##fusion O
was O
discontinued O
several O
hours O
earlier O
we O
did O
not O
observe O
a O
ben O
##e O
##ﬁ O
##t O
with O
continuous O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
after O
placement O
of O
the O
bu O
##r O
holes O

there O
were O
no O
apparent O
complications O
from O
the O
medication O
mild O
h O
##yp O
##ote O
##ns O
##ion O
has O
been O
reported O
with O
loading O
doses O
and O
our O
practice O
has O
evolved O
to O
utilize O
dex O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
##s O
without O
a O
loading O
dose O
maintain O
a O
relatively O
low O
in O
##fusion O
rate O
and O
disco O
##nti O
##nu O
##e O
the O
in O
##fusion O
immediately O
after O
the O
completion O
of O
the O
bu O
##r O
holes O
the O
need O
for O
h O
##yp O
##ote O
##ns O
##ive O
agents O
to O
maintain O
norm O
##ote O
##ns O
##ion O
during O
electrode O
placement O
appeared O
to O
be O
reduced O
in O
these O
patients O
va O
##sop O
##ress O
##ors O
were O
not O
required O
in O
any O
of O
the O
cases O
in O
our O
series O

our O
experience O
indicates O
that O
dex O
##med O
##eto O
##mi O
##dine O
can O
be O
used O
safely O
to O
se O
##date O
patients O
with O
parkinson O
s O
disease O
during O
db O
##s O
placement O
without O
sign O
##i O
##ﬁ O
##can O
##t O
effect O
on O
the O
intra O
##oper O
##ative O
local O
##izing O
value O
of O
mer O
steady O
##sta O
##te O
in O
##fusion O
rates O
of O
0 O
1 O
to O
0 O
4 O
mc O
##g O
kg O
hr O
seem O
appropriate O
with O
in O
##fusion O
rates O
ti O
##tra O
##ted O
to O
maintain O
bis O
values O
above O
80 O
disco O
##nti O
##nu O
##ation O
after O
placement O
of O
bu O
##r O
holes O
and O
the O
patient O
kept O
awake O
and O
alert O
during O
mer O

conclusions O

st O
##n O
mer O
activity O
may O
vary O
with O
behavioral O
arousal O

intra O
##ven O
##ous O
in O
##fusion O
of O
dex O
##med O
##eto O
##mi O
##dine O
ti O
##tra O
##ted O
to O
easy O
ar O
##ous O
##ability O
will O
allow O
quality O
st O
##n O
mer O
in O
the O
awake O
and O
alert O
patient O

132 O
##0 O
w O
j O
elias O
et O
al O

higher O
doses O
of O
dex O
##med O
##eto O
##mi O
##dine O
which O
produce O
deep O
se O
##dation O
bis O
80 O
and O
patient O
una O
##rous O
##able O
will O
suppress O
st O
##n O
mer O
signals O

ac O
##k O
##now O
##led O
##gm O
##ents O
the O
authors O
thank O
mrs O
cindy O
robe O
##rson O
for O
assistance O
in O
preparation O
of O
this O
manuscript O

hard O
##man O
cd O
henderson O
j O
##m O
fin O
##kel O
##stein O
di O
horne O
mk O
pa O
##xin O
##os O
g O
hall O
##ida O
##y O
gm O
comparison O
of O
the O
basal O
gang O
##lia O
in O
rats O
mar O
##mos O
##ets O
mac O
##aq O
##ues O
ba O
##bo O
##ons O
and O
humans O
volume O
and O
ne O
##uron O
##al O
number O
for O
the O
output O
internal O
relay O
and O
st O
##ria O
##tal O
mod O
##ulating O
nuclei O
j O
com O
##p O
ne O
##uro O
##l O
2002 O
44 O
##5 O
238 O
255 O

cu O
##ny O
e O
gu O
##eh O
##l O
d O
bu O
##rba O
##ud O
p O
gross O
c O
do O
##uss O
##et O
v O
ro O
##ug O
##ier O
a O
lack O
of O
agreement O
between O
direct O
magnetic O
resonance O
imaging O
and O
statistical O
determination O
of O
a O
sub O
##thal O
##ami O
##c O
target O
the O
role O
of O
electro O
##phy O
##sio O
##logical O
guidance O
see O
comment O
j O
ne O
##uro O
##sur O
##g O
2002 O
97 O
59 O
##1 O
59 O
##7 O

ki O
##rs O
##chman O
dl O
mill O
##igan O
b O
wilkinson O
s O
et O
al O
pal O
##lid O
##oto O
##my O
micro O
##ele O
##ct O
##rod O
##e O
targeting O
ne O
##uro O
##phy O
##sio O
##logy O
based O
target O
re O
##ﬁ O
##nem O
##ent O
see O
comment O
ne O
##uro O
##sur O
##ger O
##y O
2000 O
46 O
61 O
##3 O
62 O
##2 O

hut O
##chison O
w O
##d O
lang O
ae O
dos O
##tro O
##vsky O
jo O
lo O
##zano O
am O
pal O
##lid O
##al O
ne O
##uron O
##al O
activity O
implications O
for O
models O
of O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
2003 O
53 O
480 O
48 O
##8 O

bo O
##hm O
##dorf O
##er O
w O
schwarz O
##inger O
p O
bind O
##er O
s O
sp O
##orn O
p O
temporary O
suppression O
of O
tremor O
by O
re O
##mi O
##fen O
##tani O
##l O
in O
a O
patient O
with O
parkinson O
s O
disease O
during O
cat O
##ara O
##ct O
extraction O
under O
local O
an O
##esthesia O
ana O
##est O
##hesis O
##t O
2003 O
52 O
79 O
##5 O
79 O
##7 O

mal O
##tet O
##e O
d O
navarro O
s O
we O
##lter O
ml O
et O
al O
sub O
##thal O
##ami O
##c O
stimulation O
in O
parkinson O
disease O
with O
or O
without O
an O
##esthesia O
arch O
ne O
##uro O
##l O
2004 O
61 O
390 O
39 O
##2 O

her O
##tel O
f O
zu O
##chner O
m O
weimar O
i O
et O
al O
implant O
##ation O
of O
electrode O
##s O
for O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
with O
the O
aid O
of O
intra O
##oper O
##ative O
micro O
##re O
##cor O
##ding O
under O
general O
an O
##esthesia O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
59 O
e O
##11 O
##38 O

co O
##urs O
##in O
db O
mac O
##cio O
##li O
ga O
dex O
##med O
##eto O
##mi O
##dine O
cu O
##rr O
op O
##in O
cr O
##it O
care O
2001 O
7 O
221 O
226 O

be O
##kker O
a O
stu O
##rai O
##tis O
mk O
dex O
##med O
##eto O
##mi O
##dine O
for O
neurological O
surgery O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
1 O
su O
##pp O
##l O
1 O
10 O

ro O
##ze O
##t O
i O
mu O
##ang O
##man O
s O
va O
##vil O
##ala O
ms O
et O
al O
clinical O
experience O
with O
dex O
##med O
##eto O
##mi O
##dine O
for O
implant O
##ation O
of O
deep O
brain O
st O
##im O
##ulator O
##s O
in O
parkinson O
s O
disease O
an O
##est O
##h O
anal O
##g O
2006 O
103 O
122 O
##4 O
122 O
##8 O

stefan O
##i O
a O
gala O
##ti O
s O
pep O
##pe O
a O
et O
al O
spontaneous O
sleep O
mod O
##ulates O
the O
ﬁ O
##ring O
pattern O
of O
parkinson O
##ian O
sub O
##thal O
##ami O
##c O
nucleus O
ex O
##p O
brain O
res O
2006 O
168 O
277 O
280 O

hari O
##z O
mi O
k O
##rac O
##k O
p O
mel O
##vill O
r O
et O
al O
a O
quick O
and O
universal O
method O
for O
stereo O
##ta O
##ctic O
visual O
##ization O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
before O
and O
after O
implant O
##ation O
of O
deep O
brain O
stimulation O
electrode O
##s O
stereo O
##ta O
##ct O
fun O
##ct O
ne O
##uro O
##sur O
##g O
2003 O
80 O
96 O
101 O

singh O
h O
bis O
##pe O
##ct O
##ral O
index O
bis O
monitoring O
during O
prop O
##of O
##ol O
induced O
se O
##dation O
and O
ana O
##esthesia O
eu O
##r O
j O
ana O
##est O
##hes O
##iol O
1999 O
16 O
31 O
36 O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
pp O
128 O
##6 O
132 O
##0 O
2008 O
movement O
disorder O
society O
brief O
reports O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
sebastian O
pau O
##s O
md O
1 O
ga O
##bor O
z O
##sur O
##ka O
phd O
md O
2 O
miriam O
baron O
phd O
2 O
marcus O
des O
##cha O
##uer O
md O
3 O
christian O
bam O
##berg O
md O
4 O
thomas O
k O
##lock O
##get O
##her O
md O
1 O
wolf O
##ram O
s O
kun O
##z O
phd O
2 O
and O
corn O
##elia O
ko O
##rn O
##bl O
##um O
md O
##1 O

1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
2d O
##ep O
##art O
##ment O
of O
ep O
##ile O
##pt O
##ology O
and O
life O
and O
brain O
center O
university O
of O
bonn O
bonn O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
university O
of O
halle O
wit O
##tenberg O
halle O
sa O
##ale O
germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
r O
##hein O
mo O
##sel O
fa O
##ch O
##k O
##lini O
##k O
and O
##ern O
##ach O
germany O

key O
words O
focal O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
pt O
##osis O
pol O
##g O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
mutations O
in O
the O
polymer O
##ase O
g O
gene O
pol O
##g O
##1 O
coding O
for O
a O
protein O
involved O
in O
mitochondrial O
dna O
mt O
##dna O
maintenance O
cause O
a O
broad O
variety O
of O
auto O
##som O
##al O
dom O
##i O
correspondence O
to O
dr O
sebastian O
pau O
##s O
department O
of O
ne O
##uro O
##logy O
university O
of O
bonn O
bonn O
germany O
e O
mail O
spa O
##us O
un O
##i O
bonn O
de O
received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O
april O
2008 O
published O
online O
10 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O

here O
we O
report O
on O
two O
siblings O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
the O
most O
frequent O
recess O
##ive O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
presenting O
with O
a O
remarkably O
later O
onset O
and O
longer O
survival O
than O
most O
patients O
of O
the O
same O
gen O
##otype O
one O
suffered O
from O
cho O
##re O
##oat O
##het O
##osis O
and O
apr O
##ax O
##ia O
of O
lid O
opening O
al O
##o O
due O
to O
d O
##yst O
##onic O
activity O
of O
eye O
##lid O
muscles O
resulting O
in O
functional O
blindness O
so O
far O
d O
##yst O
##onia O
has O
not O
been O
reported O
in O
pol O
##g O
##1 O
mutation O
carriers O
subjects O
and O
methods O
subjects O

128 O
##6 O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
128 O
##7 O
table O
1 O
ph O
##eno O
##type O
##s O
gen O
##otype O
##s O
and O
mt O
##dna O
copy O
numbers O
in O
blood O
age O
years O
copy O
numbers O
are O
given O
in O
mean O
6 O
sd O
pol O
##g O
##1 O
gen O
##otype O
the O
two O
sides O
of O
the O
slash O
indicate O
gen O
##ot O
##yp O
##ing O
results O
of O
the O
two O
chromosomes O
as O
determined O
by O
pc O
##r O
rf O
##lp O
the O
term O
w O
##t O
in O
this O
respect O
indicates O
that O
none O
of O
the O
three O
pol O
##g O
##1 O
mutations O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
and O
a O
##46 O
##7 O
##t O
were O
detected O
sd O
standard O
deviation O
d O
onset O
disease O
onset O
na O
not O
applicable O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
w O
##t O
wild O
type O

red O
or O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
negative O
ﬁ O
##bers O
while O
bio O
##chemical O
analyses O
of O
respiratory O
chain O
enzymes O
and O
ci O
##tra O
##te O
synth O
##ase O
activities O
were O
normal O
table O
1 O
patient B-PATIENT
2 I-PATIENT
was O
healthy O
until O
the O
age O
of O
36 B-AGE_ONSET
when O
she O
developed O
pe B-HPO_TERM
##o I-HPO_TERM
mild O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
ata B-HPO_TERM
##xia I-HPO_TERM
and O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
brain O
mri O
was O
normal O
examination O
of O
muscle O
tissue O
was O
identical O
to O
patient B-PATIENT
1 I-PATIENT
mother O
father O
and O
the O
third O
sister O
were O
seen O
at O
ages O
64 O
64 O
and O
38 O
respectively O
besides O
ob O
##ste O
##tric O
cho O
##les O
##tas O
##is O
in O
the O
sister O
no O
liver O
disease O
diabetes O
or O
neurological O
symptoms O
became O
evident O
genetic O
analysis O

copy O
numbers O
of O
the O
mitochondrial O
genome O
were O
determined O
in O
blood O
le O
##uk O
##ocytes O
in O
all O
subjects O
by O
real O
##time O
pc O
##r O
as O
described O
earlier O
7 O
in O
all O
subjects O
quad O
##rup O
##le O
experiments O
were O
performed O
and O
arithmetic O
means O
and O
standard O
deviation O
##s O
were O
calculated O
copy O
numbers O
were O
compared O
to O
those O
of O
15 O
age O
##and O
sex O
matched O
healthy O
controls O
f O
m O
13 O
2 O
using O
student O
s O
t O
test O
results O
clinical O
course O
after O
initial O
presentation O
patient B-PATIENT
1 I-PATIENT
was O
seen O
at O
regular O
intervals O
and O
a O
slow O
worse B-HPO_TERM
##ning I-HPO_TERM
of I-HPO_TERM
dip I-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
and O
ata B-HPO_TERM
##xia I-HPO_TERM
was O
documented O
whereas O
ep B-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM

3 O
months O
intervals O
with O
ongoing O
success O
until O
now O
when O
patient B-PATIENT
2 I-PATIENT
was O
seen O
1 O
year O
after O
disease O
onset O
there O
were O
no O
involuntary O
movements O
of O
any O
kind O
genetic O
analysis O
long O
range O
pc O
##r O
detected O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
skeletal O
muscle O
of O
patients B-PATIENT
1 I-PATIENT
and O
2 O
both O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
mother O
and O
healthy O
sister O
were O
het O
##ero O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
the O
father O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
as O
described O
before O
3 O
6 O
w O
##7 O
##48 O
##s O
was O
found O
together O
with O
e O
##11 O
##43 O
##g O
in O
each O
case O
suggesting O
all O
##eli O
##c O
coupling O
of O
both O
mutations O

mt O
##dna O
copy O
numbers O
in O
blood O
were O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
in O
both O
patients O
compared O
to O
controls O
even O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
128 O
##8 O
pau O
##s O
et O
al O
more O
obvious O
in O
patient B-PATIENT
1 I-PATIENT
with O
earlier O
disease O
onset O
and O
more O
severe O
clinical O
ph O
##eno O
##type O
reduction O
of O
68 O
and O
56 O
respectively O
also O
mean O
copy O
numbers O
of O
the O
healthy O
family O
members O
were O
lower O
when O
compared O
with O
mean O
values O
of O
controls O
reaching O
sign O
##i O
##ﬁ O
##can O
##ce O
in O
the O
mother O
only O
discussion O

in O
conclusion O
pol O
##g O
##1 O
mutations O
might O
present O
with O
treat O
##able O
focal O
d O
##yst O
##onia O
which O
should O
be O
considered O
in O
cases O
of O
pe O
##o O
and O
pt O
##osis O
further O
studies O
on O
pol O
##g O
##1 O
mutations O
in O
focal O
d O
##yst O
##onia O
are O
warrant O
##ed O
references O
hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
dna O
polymer O
##ase O
gamma O
and O
human O
disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
244 O
252 O
ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
167 O
##4 O
168 O
##4 O

t O
##zo O
##uli O
##s O
c O
nielsen O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O
david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
##1 O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O
baron O
m O
ku O
##din O
ap O
kun O
##z O
w O
##s O
mitochondrial O
dysfunction O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
bio O
##che O
##m O
soc O
trans O
2007 O
35 O
122 O
##8 O
123 O
##1 O
k O
##rac O
##k O
p O
marion O
m O
##h O
apr O
##ax O
##ia O
of O
lid O
opening O
a O
focal O
eye O
##lid O
d O
##yst O
##onia O
clinical O
study O
of O
32 O
patients O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
610 O
61 O
##5 O
roberts O
me O
ste O
##iger O
m O
##j O
hart O
ik O
presentation O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mimic O
##king O
b O
##le O
##pha O
##ros O
##pas O
##m O
ne O
##uro O
##logy O
2002 O
58 O
150 O
151 O

muller O
va O
##hl O
k O
##r O
ko O
##lb O
##e O
h O
e O
##gens O
##per O
##ger O
r O
deng O
##ler O
r O
mit O
##och O
##ond O
##rio O
##pathy O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
treatment O
with O
bot O
##ulin O
##um O
toxin O
muscle O
nerve O
2000 O
23 O
64 O
##7 O
64 O
##8 O
forget O
r O
to O
##z O
##lova O
##nu O
v O
ian O
##cu O
a O
bog O
##hen O
d O
bot O
##ulin O
##um O
toxin O
improves O
lid O
opening O
delays O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
associated O
apr O
##ax O
##ia O
of O
lid O
opening O
ne O
##uro O
##logy O
2002 O
58 O
1843 O
1846 O
ara O
##mide O
##h O
m O
on O
##ger O
##bo O
##er O
de O
vis O
##ser O
b O
##w O
dev O
##ries O
##e O
pp O
bo O
##ur O
l O
##j O
sp O
##ee O
##lman O
jd O
electro O
##my O
##ographic O
features O
of O
lev O
##ator O
pal O
##pe O
##bra O
##e O
superior O
##is O
and O
orb O
##icular O
##is O
o O
##cu O
##li O
muscles O
in O
b O
##le O
##pha O
##ros O
##pas O
##m O
brain O
1994 O
117 O
27 O
38 O

hanna O
mg O
b O
##hat O
##ia O
k O
##p O
movement O
disorders O
and O
mitochondrial O
dysfunction O
cu O
##rr O
op O
##in O
ne O
##uro O
##l O
1997 O
10 O
351 O
356 O
sc O
##ha O
##pi O
##ra O
ah O
warner O
t O
gas O
##h O
mt O
cl O
##eet O
##er O
mw O
marin O
##ho O
cf O
cooper O
j O
##m O
complex O
i O
function O
in O
fa O
##mi O
##lia O
##l O
and O
sporadic O
d O
##yst O
##onia O
ann O
ne O
##uro O
##l O
1997 O
41 O
55 O
##6 O
55 O
##9 O
mc O
##far O
##land O
r O
chin O
##nery O
p O
##f O
blake O
##ly O
el O
et O
al O
homo O
##pl O
##as O
##my O
het O
##ero O
##pl O
##as O
##my O
and O
mitochondrial O
d O
##yst O
##onia O
ne O
##uro O
##logy O
2007 O
69 O
911 O
91 O
##6 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
128 O
##9 O
gp O
##i O
db O
##s O
in O
huntington O
s O
disease O
results O
on O
motor O
function O
and O
cognition O
in O
a O
72 O
year O
old O
case O

alfonso O
fa O
##san O
##o O
md O
1 O
paolo O
ma O
##zzo O
##ne O
md O
2 O
carla O
piano O
md O
1 O
david O
##e O
qu O
##aran O
##ta O
md O
1 O
francesco O
sole O
##ti O
md O
1 O
and O
anna O
rita O
bent O
##ivo O
##glio O
md O
phd O
##1 O
1 O
##ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
roma O
italia O
2 O
##ne O
##uro O
##chi O
##ru O
##rg O
##ia O
fun O
##zio O
##nal O
##e O
e O
stereo O
##tas O
##sic O
##a O
ct O
##o O
ale O
##sin O
##i O
roma O
italia O
video O

key O
words O
huntington O
s O
disease O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
surgery O
therapy O
huntington O
s O
disease O
hd O
is O
an O
auto O
##som O
##al O
dominant O
ne O
##uro O
##de O
##gen O
##erative O
disorder O
characterized O
by O
progressive O
cognitive O
impairment O
movement O
disorders O
and O
psychiatric O
symptoms O
when O
the O
movement O
disorder O
particularly O
the O
cho O
##rea O
is O
di O
##sa O
##bling O
ph O
##arm O
##aco O
##logical O
treatment O
is O
the O
main O
##sta O
##y O
of O
treatment O
but O
it O
is O
often O
ineffective O
thus O
the O
following O
surgical O
the O
##ra O
##pies O
have O
been O
introduced O
pal O
##lid O
##oto O
##my O
1 O
2 O
human O
fetal O
st O
##ria O
##tal O
transplant O
##a O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
alfonso O
fa O
##san O
##o O
md O
ist O
##it O
##uto O
di O
ne O
##uro O
##log O
##ia O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
la O
##rgo O
ago O
##sti O
##no O
gem O
##elli O
8 O
001 O
##6 O
##8 O
rome O
e O
mail O
alfonso O
fa O
##san O
##o O
rm O
un O
##ica O
##tt O
it O
received O
3 O
august O
2007 O
revised O
2 O
april O
2008 O
accepted O
5 O
april O
2008 O
published O
online O
30 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##16 O

hd O
patient O
with O
medical O
##ly O
intra O
##ctable O
cho O
##rea O
methods O
db O
##s O
leads O
model O
338 O
##7 O
med O
##tron O
##ic O
were O
bilateral O
##ly O
implant O
##ed O
under O
general O
an O
##esthesia O
brain O
magnetic O
resonance O
imaging O
and O
computed O
tom O
##ography O
were O
utilized O
for O
targeting O
procedures O
the O
leads O
were O
connected O
to O
an O
implant O
##able O
pulse O
generator O
ip O
##g O
kin O
##et O
##ra O
med O
##tron O
##ic O
which O
was O
secured O
in O
the O
sub O
##cut O
##aneous O
tissues O
of O
the O
chest O

the O
effect O
of O
the O
stimulation O
by O
means O
of O
each O
of O
the O
four O
electrode O
contacts O
was O
investigated O
using O
different O
settings O
of O
stimulation O
frequency O
40 O
130 O
and O
180 O
hz O
pulse O
width O
60 O
90 O
120 O
180 O
and O
210 O
mc O
##se O
##c O
voltage O
from O
1 O
to O
7 O
v O
the O
patient O
was O
evaluated O
15 O
min O
after O
the O
change O
of O
parameters O
and O
after O
24 O
hours O
when O
a O
new O
set O
of O
parameters O
was O
tested O
when O
comparing O
the O
different O
settings O
we O
maintained O
constant O
the O
total O
electrical O
energy O
delivered O
tee O
##d O
determined O
using O
the O
equations O
proposed O
by O
mor O
##o O
et O
al O
4 O
as O
follows O
tee O
##d O
##¼ O
##½ O
##ð O
##vo O
##lta O
##ge O
3 O
##pu O
##ls O
##ew O
##id O
##th O
##3 O
##fr O
##e O
##que O
##ncy O
##þ O
imp O
##edance O
½ O
##tee O
##d O

an O
equation O
empirical O
##ly O
derived O
from O
their O
previous O
studies O
on O
patients O
affected O
by O
pd O
##9 O
but O
believed O
to O
be O
incorrect O
by O
ko O
##ss O
et O
al O
10 O
who O
suggested O
tee O
##d O
##1 O
##se O
##c O
ð O
##vo O
##lta O
##ge O
##2 O
3 O
pulse O
##wi O
##dt O
##h O
3 O
frequency O
##þ O
imp O
##edance O
3 O
1 O
sec O
½ O
##tee O
##d O
clinical O
assessments O
were O
prospective O
##ly O
performed O
using O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
##11 O
and O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
##12 O
table O
1 O
at O
baseline O
and O
at O
follow O
up O
visits O
the O
patient O
underwent O
an O
extensive O
ne O
##uro O
##psy O
##cho O
##logical O
exam O
##ina O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##0 O
a O
fa O
##san O
##o O
et O
al O

ti O
##on O
by O
means O
of O
a O
previously O
reported O
standardized O
battery O
##13 O
table O
2 O
results O

effect O
on O
motor O
function O
the O
patient O
was O
discharged O
from O
the O
hospital O
with O
ip O
##g O
left O
off O
to O
allow O
stabilization O
of O
the O
micro O
##pal O
##lid O
##oto O
##my O
effect O
which O
caused O
only O
a O
mild O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
table O
1 O
one O
month O
after O
surgery O
mono O
##pol O
##ar O
stimulation O
using O
ventral O
contacts O
seemed O
to O
be O
more O
e O
##f O
##ﬁ O
##ca O
##cious O
on O
cho O
##rea O
but O
it O
was O
associated O
with O
a O
severe O
h O
##yp O
##oton O
##ia O
of O
axial O
muscles O
causing O
ﬂ O
##ex O
##ion O
of O
the O
head O
and O
loss O
of O
trunk O
control O
parameters O
was O
maintained O
as O
follows O
right O
gp O
##i O
2 O
6 O
v O
130 O
hz O
90 O
mc O
##se O
##c O
contact O
2 O
negative O
and O
case O
positive O
left O
gp O
##i O

table O
1 O
motor O
function O
during O
follow O
up O
visits O
cho O
##rea O
score O
was O
de O
##ﬁ O
##ned O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
12 O
##a O
12 O
##g O
maximum O
score O
28 O
d O
##yst O
##onia O
score O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
11 O
##a O
11 O
##e O
maximum O
score O
20 O
brady O
##kin O
##es O
##ia O
rigid O
##ity O
score O
as O
the O
sum O
of O
the O
uh O
##dr O
##s O
items O
11 O
12 O
14 O
15 O
maximum O
score O
28 O
axial O
symptoms O
as O
the O
sum O
of O
uh O
##dr O
##s O
items O
18 O
19 O
20 O
and O
of O
up O
##dr O
##s O
item O
27 O
arising O
from O
chair O
maximum O
score O
16 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

numbers O
in O
brackets O
indicate O
the O
corrected O
scores O
for O
age O
and O
years O
of O
education O
according O
to O
an O
italian O
population O
based O
standardization O
scores O
in O
bold O
are O
below O
the O
cut O
off O
of O
normal O
##ity O
are O
##verse O
scores O
lower O
scores O
indicate O
better O
performances O
bb O
##elo O
##w O
10th O
percent O
##ile O
cbe O
##low O
1st O
percent O
##ile O
iv O
##m O
immediate O
visual O
memory O
m O
##ft O
##c O
multi O
##fe O
##at O
##ures O
targets O
cancellation O
mm O
##se O
mini O
mental O
state O
examination O
np O
not O
performed O
pm O
47 O
raven O
s O
progressive O
matrices O
47 O
ra O
##v O
##lt O
rey O
s O
auditory O
verbal O
learning O
test O
roc O
##f O
rey O
os O
##ter O
##rie O
##th O
complex O
ﬁ O
##gur O
##e O
wc O
##st O
wisconsin O
card O
sorting O
test O

from O
chair O
without O
assistance O
and O
slightly O
the O
ga O
##it O
so O
the O
patient O
started O
chronic O
therapy O
with O
l O
do O
##pa O
up O
to O
800 O
mg O
die O
with O
a O
mild O
improvement O
of O
brady O
##kin O
##es O
##ia O
ga O
##it O
and O
ap O
##athy O
table O
1 O
effect O
on O
cognitive O
functions O
table O
2 O
at O
baseline O
evaluation O
1 O
month O
before O
surgery O
the O
patient O
s O
cognitive O
pro O
##ﬁ O
##le O
was O
characterized O
mainly O
by O
d O
##yse O
##x O
##ec O
##utive O
syndrome O
on O
the O
ﬁ O
##rst O
follow O
up O
visit O
6 O
months O
after O
surgery O
the O
score O
of O
mini O
mental O
state O
examination O
worsened O
as O
did O
scores O
of O
test O
for O
executive O
functions O
scores O
of O
linguistic O
and O
memory O
task O

were O
lower O
as O
well O
on O
the O
second O
follow O
up O
visit O
1 O
year O
after O
surgery O
he O
performed O
worse O
on O
all O
executive O
tasks O
in O
comparison O
with O
both O
the O
baseline O
and O
1st O
follow O
up O
visits O
scores O
worsened O
also O
on O
ph O
##ono O
##logical O
ﬂ O
##uen O
##cy O
task O
and O
on O
elementary O
construction O
##al O
abilities O
discussion O
we O
have O
con O
##ﬁ O
##rmed O
that O
bilateral O
gp O
##i O
db O
##s O
produces O
a O
long O
term O
reduction O
of O
cho O
##rea O
due O
to O
hd O
despite O
the O
ben O
##e O
##ﬁ O
##t O
surgery O
has O
been O
related O
to O
worse O
##ning O
of O
ga O
##it O
ap O
##athy O
and O
decline O
of O
cognitive O
function O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##2 O
a O
fa O
##san O
##o O
et O
al O

legends O
to O
the O
video O
segment O
1 O
the O
patient O
6 O
months O
before O
surgery O
presents O
severe O
cho O
##rea O
of O
facial O
muscles O
trunk O
and O
limbs O
the O
patient O
is O
able O
to O
stand O
up O
without O
assistance O
and O
to O
walk O
for O
a O
few O
meters O
cho O
##rea O
of O
the O
lower O
limbs O
and O
impairment O
of O
post O
##ural O
stability O
as O
revealed O
by O
the O
retro O
##pu O
##ls O
##ion O
pull O
test O
des O
##ta O
##bil O
##ize O
him O
during O
walking O
segment O
2 O
three O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
180 O
hz O
provides O
a O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
especially O
of O
the O
lower O
limbs O
stimulation O
of O
ventral O
contacts O
causes O
head O
drop O

segment O
3 O
four O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
segment O
4 O
four O
months O
after O
surgery O
gp O
##i O
db O
##s O
at O
40 O
hz O
provides O
a O
reduction O
of O
cho O
##rea O
and O
an O
improvement O
of O
axial O
symptoms O
the O
patient O
is O
able O
to O
walk O
with O
un O
##ila O
##tera O
##l O
assistance O
segment O
5 O
nine O
months O
after O
surgery O
limbs O
cho O
##rea O
has O
disappeared O
while O
facial O
grimace O
##s O
are O
still O
pre O
##s O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##3 O

en O
##t O
despite O
the O
use O
of O
40 O
hz O
stimulation O
the O
patient O
cannot O
arise O
from O
chair O
and O
walk O
due O
to O
a O
severe O
start O
hesitation O
segment O
6 O
nine O
months O
after O
surgery O
fifteen O
minutes O
after O
the O
ip O
##g O
has O
been O
switched O
off O
cho O
##rea O
re O
##app O
##ears O
only O
with O
very O
mild O
d O
##ys O
##kin O
##es O
##ias O
of O
upper O
limbs O
the O
patient O
is O
able O
to O
arise O
from O
chair O
and O
ga O
##it O
impairment O
is O
improved O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
supported O
in O
part O
by O
un O
##iver O
##sit O
##a O
cat O
##to O
##lica O
del O
sac O
##ro O
cu O
##ore O
grant O
line O
##a O
d O
##1 O
to O
ar O
##b O
af O
f O
##s O
and O
ar O
##b O
are O
members O
of O
euro O
hd O
network O
references O

cub O
##o O
e O
shannon O
km O
penn O
rd O
k O
##roi O
##n O
j O
##s O
internal O
g O
##lo O
##bus O
pal O
##lid O
##oto O
##my O
in O
d O
##yst O
##onia O
secondary O
to O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
124 O
##8 O
125 O
##1 O
vi O
##tek O
j O
##l O
jones O
r O
ba O
##ka O
##y O
re O
##a O
hers O
##ch O
sm O
pal O
##lid O
##oto O
##my O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2000 O
48 O
42 O
##9 O
bach O
##oud O
levi O
ac O
ga O
##ura O
v O
br O
##ug O
##iere O
##s O
p O
et O
al O
effect O
of O
fetal O
neural O
transplant O
##s O
in O
patients O
with O
huntington O
s O
disease O
6 O
years O
after O
surgery O
a O
long O
term O
follow O
up O
study O
lance O
##t O
ne O
##uro O
##l O
2006 O
5 O
303 O
309 O
mor O
##o O
e O
lang O
ae O
st O
##raf O
##ella O
ap O
et O
al O
bilateral O
g O
##lo O
##bus O
pal O
##lid O
##us O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O

jan O
her O
##zog O
md O
1 O
oliver O
po O
##gar O
##ell O
md O
2 O
marcus O
o O
pins O
##ker O
md O
3 O
andreas O
ku O
##ps O
##ch O
md O
phd O
4 O
wolfgang O
h O
o O
##ert O
##el O
md O
phd O
5 O
ol O
##le O
lin O
##d O
##val O
##l O
md O
phd O
6 O
gu O
##¨ O
##nt O
##her O
de O
##us O
##ch O
##l O
md O
phd O
1 O
and O
jens O
vol O
##km O
##ann O
md O
phd O
##1 O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
christian O
albrecht O
##s O
university O
kiel O
germany O
2d O
##ep O
##art O
##ment O
of O
psychiatry O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
christian O
albrecht O
##s O
university O
kiel O

germany O
4 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
char O
##ite O
##´ O
humboldt O
university O
berlin O
germany O
5 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
philipp O
##s O
university O
mar O
##burg O
germany O
6 O
##section O
of O
rest O
##ora O
##tive O
ne O
##uro O
##logy O
wall O
##enberg O
neuroscience O
centre O
lund O
sweden O
video O
stimulation O
for O
huntington O
s O
disease O
ann O
ne O
##uro O
##l O
2004 O
56 O
290 O
294 O
he O
##bb O
mo O
garcia O
r O
ga O
##ude O
##t O
p O
mendez O
im O
bilateral O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
to O
treat O
cho O
##rea O
##the O
##tosis O
in O
huntington O
s O
disease O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2006 O
58 O
e O
##38 O
##3 O
lang O
ae O
surgery O
for O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##19 O
##3 O
s O
##19 O
##9 O

yi O
##ann O
##i O
j O
nan O
##di O
d O
bradley O
k O
et O
al O
sen O
##ile O
cho O
##rea O
treated O
by O
deep O
brain O
stimulation O
a O
clinical O
ne O
##uro O
##phy O
##sio O
##logical O
and O
functional O
imaging O
study O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
59 O
##7 O
60 O
##2 O
k O
##raus O
##s O
j O
##k O
lo O
##her O
t O
##j O
wei O
##gel O
r O
cape O
##lle O
h O
##h O
weber O
s O
bu O
##rg O
##under O
j O
##m O
chronic O
stimulation O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
treatment O
of O
non O
d O
##yt O
##1 O
generalized O
d O
##yst O
##onia O
and O
cho O
##re O
##oat O
##het O
##osis O
2 O
year O
follow O
up O
j O
ne O
##uro O
##sur O
##g O
2003 O
98 O
78 O
##5 O
79 O
##2 O
mor O
##o O
e O
es O
##sel O
##ink O
r O
##j O
xi O
##e O
j O
homme O
##l O
m O
ben O
##abi O
##d O
al O
poll O
##ak O
p O
the O
impact O
on O
parkinson O
s O
disease O
of O
electrical O
parameter O
settings O
in O
st O
##n O
stimulation O
ne O
##uro O
##logy O
2002 O
59 O
70 O
##6 O
71 O
##3 O

ko O
##ss O
am O
alter O
##man O
r O
##l O
tag O
##lia O
##ti O
m O
shi O
##ls O
j O
##l O
calculating O
total O
electrical O
energy O
delivered O
by O
deep O
brain O
stimulation O
systems O
ann O
ne O
##uro O
##l O
2005 O
58 O
168 O
huntington O
study O
group O
un O
##i O
##ﬁ O
##ed O
huntington O
s O
disease O
rating O
scale O
reliability O
and O
consistency O
mo O
##v O
di O
##sor O
##d O
1996 O
11 O
136 O
142 O
go O
##etz O
c O
##g O
ste O
##bb O
##ins O
gt O
ch O
##mura O
ta O
fa O
##hn O
s O
k O
##law O
##ans O
h O
##l O
marsden O
cd O
teaching O
tape O
for O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
mo O
##v O
di O
##sor O
##d O
1995 O
10 O
263 O
266 O
con O
##tar O
##ino O
m O
##f O
daniel O
##e O
a O
si O
##bil O
##ia O
ah O
et O
al O
cognitive O
outcome O
5 O
years O
after O
bilateral O
chronic O
stimulation O
of O
sub O
##thal O
##ami O
##c O
nucleus O

key O
words O
parkinson O
s O
disease O
neural O
transplant O
##ation O
deep O
brain O
stimulation O
d O
##ys O
##kin O
##es O
##ias O
in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O
try O
2007 O
78 O
248 O
252 O
be O
##rard O
##elli O
a O
not O
##h O
j O
thomson O
pd O
et O
al O
path O
##op O
##hy O
##sio O
##logy O
of O
cho O
##rea O
and O
brady O
##kin O
##es O
##ia O
in O
huntington O
s O
disease O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
39 O
##8 O
403 O
ku O
##op O
##pa O
##ma O
##¨ O
##ki O
m O
roth O
##well O
jc O
brown O
r O
##g O
quinn O
n O
b O
##hat O
##ia O
k O
##p O
ja O
##han O
##shah O
##i O
m O
parkinson O
##ism O
following O
bilateral O
lesions O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
performance O
on O
a O
variety O
of O
motor O
tasks O
shows O
similarities O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
48 O
##2 O
490 O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
j O
vol O
##km O
##ann O
md O
phd O
department O
of O
ne O
##uro O
##logy O
un O
##iver O
##sit O
##a O
##¨ O
##tsk O
##lini O
##ku O
##m O
schleswig O
holstein O
campus O
kiel O
sc O
##hit O
##ten O
##helm O
##st O
##r O
10 O
241 O
##0 O
##5 O
kiel O
germany O
e O
mail O
j O
vol O
##km O
##ann O
ne O
##uro O
##logie O
un O
##i O
kiel O
de O
received O
31 O
may O
2007 O
revised O
28 O
august O
2007 O
accepted O
13 O
september O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##6 O
##8 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##4 O
j O
her O
##zog O
et O
al O

table O
1 O
characteristics O
of O
patients O
at O
baseline O
and O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
deep O
brain O
stimulation O
patient O
1 O
patient O
2 O
before O
transplant O
##ation O
up O
##dr O
##s O
iii O
med O
off O
74 O
49 O
med O
on O
24 O
14 O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O
item O
32 O
0 O
0 O
item O
33 O
0 O
0 O
medication O
mg O
d O
lev O
##od O
##opa O
1 O
400 O
lev O
##od O
##opa O
250 O
per O
##gol O
##ide O
0 O
5 O
de O
##pre O
##ny O
##l O
10 O
led O
##d O
mg O
1 O
400 O
mg O
400 O
mg O
before O
db O
##s O
following O
db O
##s O
follow O
up O
period O
3 O
y O
##r O
2 O
y O
##r O
up O
##dr O
##s O
iii O
50 O
28 O
st O
##im O
off O
med O
off O
st O
##im O
on O
med O
off O
33 O
11 O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
st O
##im O
on O
med O
off O
10 O
2 O
st O
##im O
on O
med O
on O
a O
4 O
d O
##ys O
##kin O
##es O
##ias O
up O
##dr O
##s O
iv O
item O
32 O
1 O
0 O
item O
33 O
2 O
0 O
medication O
mg O
d O

led O
##d O
mg O
0 O
0 O
persisted O
even O
after O
withdrawal O
of O
lev O
##od O
##opa O
l O
do O
##pa O
medication O
because O
of O
the O
d O
##ys O
##kin O
##etic O
states O
which O
are O
usually O
aggravated O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
ph O
##arm O
##aco O
##logical O
approaches O
are O
limited O
and O
db O
##s O
might O
be O
an O
alternative O
therapeutic O
option O
here O
we O
report O
the O
long O
term O
outcome O
in O
two O
patients O
with O
persistent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
after O
graf O
##ting O
who O
later O
underwent O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
or O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
gp O
##i O
db O
##s O
case O
reports O
patient O
1 O

the O
transplant O
##ation O
initially O
resulted O
in O
am O
##eli O
##oration O
of O
off O
period O
symptoms O
subsequently O
he O
developed O
di O
##sa O
##bling O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
cd O
##rs O
10 O
28 O
particularly O
on O
the O
left O
body O
side O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O
video O
##ta O
##pe O
because O
of O
ag O
##gra O
##vation O
of O
d O
##ys O
##kin O
##etic O
states O
by O
l O
do O
##pa O
cd O
##rs O
15 O
28 O
the O
use O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
had O
to O
be O
limited O
with O
the O
consequence O
of O
progressive O
decline O
in O
severity O
of O
off O
phase O
symptoms O
table O
1 O
and O
return O
stereo O
##ta O
##ctic O
coordinates O
x O
y O
z O
relative O
to O
mid O
##ac O
##pc O

r O
11 O
4 O
22 O
1 O
22 O
2 O
r O
21 O
3 O
4 O
5 O
23 O
6 O
l O
211 O
2 O
22 O
1 O
23 O
0 O
l O
220 O
5 O
1 O
9 O
22 O
4 O
of O
h O
##yp O
##oki O
##net O
##ic O
ﬂ O
##uc O
##tua O
##tions O
which O
could O
not O
be O
con O
troll O
##ed O
by O
various O
therapeutic O
approaches O
because O
of O
prominent O
off O
phase O
symptoms O
and O
aa O
##ft O
##er O
st O
##n O
db O
##s O
patient O
1 O
refused O
assessment O
in O
the O
medication O
on O
condition O
up O
##dr O
##s O
iii O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
max O
108 O
cd O
##rs O
clinical O
d O
##ys O
##kin O
##es O
##ia O
rating O
scale O
max O
28 O
db O
##s O
deep O
brain O
stimulation O
led O
##d O
lev O
##od O
##opa O
equivalent O
daily O
dos O
##age O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
db O
##s O
following O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
129 O
##5 O
33 O
disability O
2 O
4 O
while O
the O
ben O
##e O
##ﬁ O
##t O
on O
off O
period O
symptoms O
was O
sustained O
patient O
2 O
the O
41 O
year O
old O
man O
pd O
since O
12 O
years O
baseline O
characteristics O
in O
table O
1 O
was O
treated O
by O
staged O
bilateral O
neural O
transplant O
##ation O
with O
the O
second O
graf O
##t O
right O
st O
##ria O
##tum O
6 O
months O
after O
the O
ﬁ O
##rst O
graf O
##t O
cell O
preparation O
surgical O
procedure O
im O
##mun O
##os O
##up O
##press O
##ion O
and O
demonstration O
of O
long O
term O
graf O
##t O
survival O
were O
identical O
to O
patient O
1 O
1 O

because O
of O
the O
prominent O
hyper O
##kin O
##es O
##ias O
but O
relatively O
few O
off O
period O
symptoms O
8 O
years O
after O
bilateral O
graf O
##ting O
the O
patient O
was O
selected O
for O
bilateral O
gp O
##i O
db O
##s O
gp O
##i O
db O
##s O
sign O
##i O
##ﬁ O
##can O
##tly O
reduced O
d O
##ys O
##kin O
##es O
##ias O
cd O
##rs O
2 O
28 O
in O
the O
formal O
assessment O
video O
##ta O
##pe O
in O
contrast O
the O
patient O
reported O
complete O
reduction O
of O
d O
##ys O
##kin O
##es O
##ias O
during O
the O
day O
item O
32 O
und O
33 O
0 O
4 O
because O
off O
period O
symptoms O
were O
con O
##com O
##itan O
##tly O
improved O
up O
##dr O
##s O
iii O
11 O
108 O
in O
the O
formal O
assessment O
all O
do O
##pa O
##mine O
##rg O
##ic O
medication O
could O
be O
stopped O
discussion O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##6 O
j O
her O
##zog O
et O
al O

legends O
to O
the O
video O
segment O
1 O
patient O
1 O
before O
st O
##n O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
1 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
2 O
months O
before O
implant O
##ation O
of O
bilateral O
sub O
##thal O
##ami O
##c O
leads O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
presents O
with O
marked O
limb O
h O
##yp O
##oki O
##nesia O
and O
simultaneously O
intermittent O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
with O
involuntary O
arm O
elevation O
continuous O
eye O
rubbing O
and O
head O
scratching O

segment O
2 O
patient O
1 O
following O
st O
##n O
db O
##s O
medication O
off O
stimulation O
on O
three O
years O
following O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
the O
patient O
continues O
to O
show O
off O
period O
d O
##ys O
##kin O
##es O
##ias O
segment O
3 O
patient O
2 O
before O
gp O
##i O
db O
##s O
medication O
off O
the O
patient O
from O
case O
report O
2 O
was O
video O
##ta O
##ped O
8 O
years O
following O
fetal O
ni O
##gra O
##l O
graf O
##ting O
and O
3 O
months O
before O
implant O
##ation O
of O
bilateral O
leads O
within O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
for O
deep O
brain O
stimulation O
in O
the O
medication O
off O
condition O
the O
patient O
shows O
limb O
h O
##yp O
##oki O
##nesia O
with O
intermittent O
d O
##ys O
##kin O
##es O
##ias O
accent O
##uated O
in O
the O
right O
hand O
and O
ﬁ O
##nger O
##s O

segment O
4 O
patient O
2 O
following O
gp O
##i O
db O
##s O
medication O
off O
stimulation O
on O
two O
years O
following O
pal O
##lid O
##al O
deep O
brain O
stimulation O
severity O
of O
d O
##ys O
##kin O
##es O
##ias O
in O
the O
medication O
off O
condition O
is O
reduced O
despite O
complete O
ce O
##ssa O
##tion O
of O
do O
##pa O
##mine O
##rg O
##ic O
medication O
off O
period O
symptoms O
are O
su O
##f O
##ﬁ O
##cie O
##ntly O
alleviate O
##d O
by O
deep O
brain O
stimulation O
references O
br O
##und O
##in O
p O
po O
##gar O
##ell O
o O
ha O
##gel O
##l O
p O
et O
al O
bilateral O
ca O
##uda O
##te O
and O
put O
##amen O
graf O
##ts O
of O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
tissue O
treated O
with O
la O
##zar O
##oids O
in O
parkinson O
s O
disease O
brain O
2000 O
123 O
part O
7 O
138 O
##0 O
139 O
##0 O

freed O
cr O
greene O
pe O
breeze O
re O
et O
al O
transplant O
##ation O
of O
embryo O
##nic O
do O
##pa O
##mine O
neurons O
for O
severe O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2001 O
344 O
710 O
71 O
##9 O
ol O
##ano O
##w O
cw O
go O
##etz O
c O
##g O
ko O
##rdo O
##wer O
j O
##h O
et O
al O
a O
double O
blind O
controlled O
trial O
of O
bilateral O
fetal O
ni O
##gra O
##l O
transplant O
##ation O
in O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
2003 O
54 O
403 O
41 O
##4 O
po O
##gar O
##ell O
o O
koch O
w O
gil O
##deh O
##aus O
f O
##j O
et O
al O
long O
term O
assessment O
of O
st O
##ria O
##tal O
do O
##pa O
##mine O
transport O
##ers O
in O
parkinson O
##ian O
patients O
with O
intra O
##st O
##ria O
##tal O
embryo O
##nic O
me O
##sen O
##ce O
##pha O
##lic O
graf O
##ts O
eu O
##r O
j O
nu O
##cl O
med O
mo O
##l O
imaging O
2006 O
33 O
407 O
411 O

cho O
c O
alter O
##man O
r O
##l O
mira O
##vite O
j O
et O
al O
sub O
##thal O
##ami O
##c O
db O
##s O
for O
the O
treatment O
of O
runaway O
d O
##ys O
##kin O
##es O
##ias O
after O
embryo O
##nic O
or O
fetal O
tissue O
transplant O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
123 O
##7 O
alter O
##man O
r O
##l O
shi O
##ls O
j O
##l O
gu O
##des O
##bla O
##tt O
m O
tag O
##lia O
##ti O
m O
immediate O
and O
sustained O
relief O
of O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
after O
dorsal O
relocation O
of O
a O
deep O
brain O
stimulation O
lead O
case O
report O
ne O
##uro O
##sur O
##g O
focus O
2004 O
17 O
e O
##6 O
mi O
##oc O
##ino O
##vic O
s O
parent O
m O
but O
##son O
cr O
et O
al O
computational O
analysis O
of O
sub O
##thal O
##ami O
##c O
nucleus O
and O
lent O
##icular O
fa O
##sc O
##ic O
##ulus O
activation O
during O
therapeutic O
deep O
brain O
stimulation O
j O
ne O
##uro O
##phy O
##sio O
##l O
2006 O
96 O
156 O
##9 O
1580 O

graf O
##f O
ra O
##df O
##ord O
j O
foot O
##e O
k O
##d O
rodriguez O
r O
##l O
et O
al O
deep O
brain O
stimulation O
of O
the O
internal O
segment O
of O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
in O
delayed O
runaway O
d O
##ys O
##kin O
##es O
##ia O
arch O
ne O
##uro O
##l O
2006 O
63 O
118 O
##1 O
118 O
##4 O
winkler O
c O
ki O
##rik O
d O
b O
##jo O
##rk O
##lund O
a O
cell O
transplant O
##ation O
in O
parkinson O
s O
disease O
how O
can O
we O
make O
it O
work O
trends O
ne O
##uro O
##sc O
##i O
2005 O
28 O
86 O
92 O
ge O
##rf O
##en O
cr O
d O
##1 O
do O
##pa O
##mine O
receptor O
super O
##sen O
##sit O
##ivity O
in O
the O
do O
##pa O
##mine O
depleted O
st O
##ria O
##tum O
animal O
model O
of O
parkinson O
s O
disease O
ne O
##uro O
##sc O
##ient O
##ist O
2003 O
9 O
45 O
##5 O
46 O
##2 O

au O
##bert O
i O
gui O
##gon O
##i O
c O
ha O
##kan O
##sson O
k O
et O
al O
increased O
d O
##1 O
do O
##pa O
##mine O
receptor O
signaling O
in O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ia O
ann O
ne O
##uro O
##l O
2005 O
57 O
17 O
26 O
lo O
##zano O
am O
lang O
ae O
levy O
r O
et O
al O
ne O
##uron O
##al O
recordings O
in O
parkinson O
s O
disease O
patients O
with O
d O
##ys O
##kin O
##es O
##ias O
induced O
by O
ap O
##omo O
##rp O
##hine O
ann O
ne O
##uro O
##l O
2000 O
47 O
s O
##14 O
##1 O
s O
##14 O
##6 O
vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
et O
al O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

mei O
##ss O
##ner O
w O
ha O
##rna O
##ck O
d O
ho O
##ess O
##le O
n O
et O
al O
high O
frequency O
stimulation O
of O
the O
en O
##top O
##ed O
##un O
##cular O
nucleus O
has O
no O
effect O
on O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
transmission O
ne O
##uro O
##che O
##m O
int O
2004 O
44 O
281 O
286 O
tho O
##bo O
##is O
s O
fra O
##ix O
v O
sava O
##sta O
m O
et O
al O
chronic O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
and O
st O
##ria O
##tal O
d O
##2 O
do O
##pa O
##mine O
receptors O
in O
parkinson O
s O
disease O
a O
11 O
c O
ra O
##cl O
##op O
##ride O
pet O
study O
j O
ne O
##uro O
##l O
2003 O
250 O
121 O
##9 O
122 O
##3 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##7 O
lev O
##od O
##opa O
therapy O
in O
a O
les O
##ch O
ny O
##han O
disease O
patient O
path O
##ological O
bio O
##chemical O
ne O
##uro O
##ima O
##ging O
and O
therapeutic O
remarks O

mercedes O
serra O
##no O
md O
1 O
3 O
bel O
##en O
pe O
##´ O
##re O
##z O
md O
phd O
##1 O
3 O
aid O
##a O
or O
##ma O
##za O
##´ O
##bal O
phd O
2 O
3 O
rafael O
art O
##uch O
md O
phd O
2 O
3 O
ja O
##ume O
camp O
##isto O
##l O
md O
phd O
1 O
3 O
rosa O
j O
torres O
md O
phd O
4 O
and O
angels O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
md O
phd O
##1 O
3 O
1 O
##ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
2 O
##cl O
##ini O
##cal O
biochemistry O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
university O
of O
barcelona O
barcelona O
spain O
3 O
##cent O
##re O
for O
biomedical O
research O
on O
rare O
diseases O
ci O
##ber O
##er O
instituto O
de O
sal O
##ud O
carlos O
iii O
barcelona O
spain O
4 O
##di O
##vision O
of O
clinical O
biochemistry O
la O
paz O
university O
hospital O
madrid O
spain O
video O

key O
words O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
do O
##pa O
##mine O
les O
##ch O
ny O
##han O
disease O
lu O
##mba O
##r O
pun O
##cture O
mono O
##amine O
##s O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
les O
##ch O
ny O
##han O
disease O
l O
##nd O
is O
a O
hereditary O
disorder O
caused O
by O
de O
##ﬁ O
##cie O
##nt O
activity O
of O
the O
enzyme O
h O
##yp O
##ox O
##ant O
##hine O
gu O
##ani O
##ne O
ph O
##os O
##ph O
##ori O
##bos O
##yl O
tran O
##fera O
##se O
hp O
##rt O
bio O
this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
a O
ng O
##els O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
pediatric O
ne O
##uro O
##logy O
department O
hospital O
sant O
joan O
de O
de O
##´ O
##u O
pass O
##ei O
##g O
de O
sant O
joan O
de O
de O
##´ O
##u O
2 O
08 O
##9 O
##50 O
es O
##pl O
##ug O
##ues O
de O
ll O
##ob O
##re O
##gat O
barcelona O
spain O

e O
mail O
ag O
##ar O
##cia O
hs O
##j O
##db O
##c O
##n O
org O
received O
17 O
july O
2007 O
revised O
11 O
september O
2007 O
accepted O
26 O
september O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
217 O
##86 O

we O
report O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
low O
do O
##pa O
##mine O
da O
meta O
##bol O
##ite O
values O
in O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
treatment O
with O
l O
do O
##pa O
car O
##bid O
##opa O
was O
started O
during O
the O
early O
stages O
of O
his O
ne O
##uro O
##dev O
##elo O
##pment O
clinical O
report O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
129 O
##8 O
m O
serra O
##no O
et O
al O
table O
1 O
bio O
##genic O
amin O
##e O
and O
pt O
##erine O
concentrations O
in O
cs O
##f O
before O
treatment O
and O
follow O
up O
after O
l O
do O
##pa O
therapy O
l O
do O
##pa O
plus O
car O
##bid O
##opa O
and O
f O
##olin O
##ic O
acid O
di O
##tions O
video O
3 O
he O
is O
able O
to O
transfer O
objects O
between O
hands O
and O
do O
pin O
##cer O
grasping O
comprehension O
has O
always O
seemed O
to O
be O
preserved O
he O
never O
presented O
self O
in O
##ju O
##rio O
##us O
behavior O
the O
cs O
##f O
h O
##va O
concentration O
is O
now O
in O
the O
normal O
range O
table O
1 O
before O
treatment O
6 O
mg O
kg O
day O
age O
10 O
mo O
3 O
y O
##r O
4 O
mo O

h O
##va O
homo O
##vani O
##lli O
##c O
acid O
5 O
hi O
##aa O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
m O
##hp O
##h O
3 O
##met O
##ho O
##xy O
4 O
hydro O
##xy O
##ph O
##en O
##yl O
##gly O
##col O
numbers O
in O
brackets O
represent O
the O
age O
related O
controls O
values O
3 O

discussion O
we O
describe O
the O
case O
of O
a O
child O
affected O
with O
l O
##nd O
presenting O
clinical O
signs O
of O
impaired O
cn O
##s O
do O
##pa O
##mine O
##rg O
##ic O
function O
the O
notable O
tremor O
the O
marked O
d O
##yst O
##onia O
developed O
during O
early O
infancy O
and O
the O
obvious O
sustained O
response O
to O
l O
do O
##pa O
led O
us O
to O
investigate O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
however O
some O
clinical O
characteristics O
such O
as O
the O
absence O
of O
o O
##cu O
##logy O
##ric O
crisis O
and O
the O
preservation O
of O
facial O
ge O
##stic O
##ulation O
did O
not O
ﬁ O
##t O
into O
a O
primary O
do O
##pa O
##mine O
##rg O
##ic O
defect O
picture O

the O
role O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
brain O
development O
has O
recently O
been O
documented O
8 O
interesting O
##ly O
the O
early O
do O
##pa O
##mine O
##rg O
##ic O
input O
from O
the O
mid O
##bra O
##in O
may O
play O
an O
important O
role O
in O
the O
development O
of O
the O
basal O
gang O
##lia O
and O
cerebral O
cortex O
9 O
furthermore O
brain O
development O
has O
to O
be O
completed O
during O
the O
ﬁ O
##rst O
months O
of O
life O
when O
ax O
##onal O
and O
den O
##dr O
##itic O
branching O
is O
ongoing O
and O
syn O
##ap O
##to O
##genesis O
is O
just O
beginning O
da O
disturbances O
in O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
l O
do O
##pa O
treatment O
in O
les O
##ch O
ny O
##han O
disease O
129 O
##9 O
these O
ne O
##uro O
##dev O
##elo O
##pment O
##al O
periods O
may O
be O
crucial O
for O
further O
cn O
##s O
function O

response O
and O
to O
opt O
##imi O
##ze O
neurological O
outcome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
analysis O
may O
be O
a O
useful O
bio O
##chemical O
aid O
to O
select O
l O
##nd O
patients O
for O
l O
do O
##pa O
therapy O
and O
monitor O
their O
treatment O
further O
studies O
clinical O
observations O
and O
double O
blind O
trials O
are O
needed O
to O
establish O
the O
useful O
##ness O
of O
l O
do O
##pa O
in O
patients O
with O
l O
##nd O
legends O
to O
the O
video O
video O
1 O
frequent O
d O
##ys O
##kin O
##etic O
movements O
of O
the O
mouth O
and O
the O
ex O
##tre O
##mit O
##ies O
absence O
of O
voluntary O
grasping O
no O
head O
control O
explosive O
un O
##co O
##ord O
##inated O
movements O
video O
2 O
better O
head O
control O
able O
to O
pick O
up O
objects O
fine O
motor O
movements O
have O
improved O

video O
3 O
head O
control O
is O
fully O
reached O
d O
##yst O
##onic O
movements O
are O
clearly O
improved O
able O
to O
transfer O
objects O
between O
hands O
put O
rings O
in O
a O
bar O
and O
do O
pin O
##cer O
grasping O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fis O
grant O
pi O
##0 O
##51 O
##31 O
##8 O
and O
ci O
##ber O
er O
is O
##c O
iii O
we O
thank O
the O
patient O
and O
his O
family O
for O
their O
participation O
references O
jin O
##nah O
ha O
friedman O
##n O
t O
les O
##ch O
ny O
##han O
disease O
and O
its O
variants O
in O
sc O
##river O
cr O
beau O
##de O
##t O
al O
sly O
w O
##s O
valle O
d O
editors O
the O
metabolic O
and O
molecular O
bases O
of O
inherited O
disease O
8th O
ed O
new O
york O
mcgraw O
hill O
2001 O
p O
253 O
##7 O
257 O
##0 O

jin O
##nah O
ha O
vis O
##ser O
je O
harris O
jc O
et O
al O
del O
##ine O
##ation O
of O
the O
motor O
disorder O
of O
les O
##ch O
ny O
##han O
disease O
brain O
2006 O
129 O
120 O
##1 O
121 O
##7 O
or O
##ma O
##za O
##´ O
##bal O
a O
ga O
##rc O
##´ O
##ı O
##a O
ca O
##zo O
##rl O
##a O
a O
fern O
##a O
##´ O
##nde O
##z O
y O
fern O
##a O
##´ O
##nde O
##za O
##´ O
l O
##var O
##ez O
e O
camp O
##isto O
##l O
j O
art O
##uch O
r O
hp O
##lc O
with O
electro O
##chemical O
and O
ﬂ O
##uo O
##res O
##cence O
detection O
procedures O
for O
the O
diagnosis O
of O
in O
##born O
errors O
of O
bio O
##genic O
amin O
##es O
and O
pt O
##erine O
##s O
j O
ne O
##uro O
##sc O
##i O
methods O
2005 O
142 O
153 O
158 O
lloyd O
kg O
horn O
##yk O
##ie O
##wicz O
o O
davidson O
l O
et O
al O
bio O
##chemical O
evidence O
of O
dysfunction O
of O
brain O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
in O
the O
les O
##ch O
##ny O
##han O
syndrome O
n O
eng O
##l O
j O
med O
1981 O
305 O
110 O
##6 O
111 O
##1 O

sai O
##to O
y O
ito O
m O
hana O
##oka O
s O
oh O
##ama O
e O
aka O
##bos O
##hi O
s O
tak O
##ashi O
##ma O
s O
do O
##pa O
##mine O
receptor O
up O
##re O
##gul O
##ation O
in O
les O
##ch O
ny O
##han O
syndrome O
a O
post O
##mo O
##rte O
##m O
study O
ne O
##uro O
##ped O
##ia O
##trics O
1999 O
30 O
66 O
71 O
ernst O
m O
za O
##met O
##kin O
aj O
mat O
##och O
##ik O
ja O
et O
al O
pre O
##sy O
##na O
##ptic O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
##s O
in O
les O
##ch O
ny O
##han O
disease O
n O
eng O
j O
med O
1996 O
334 O
156 O
##8 O
157 O
##2 O
wong O
d O
##f O
harris O
jc O
na O
##id O
##u O
s O
et O
al O
do O
##pa O
##mine O
transport O
##ers O
are O
markedly O
reduced O
in O
les O
##ch O
ny O
##han O
disease O
in O
vivo O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1996 O
93 O
55 O
##39 O
55 O
##43 O
her O
##len O
##ius O
e O
la O
##ger O
##cr O
##ant O
##z O
h O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
and O
ne O
##uro O
##mo O
##du O
##lat O
##ors O
during O
early O
human O
development O
early O
hum O
dev O
2001 O
65 O
21 O
37 O

schmidt O
u O
bey O
##er O
c O
o O
##est O
##re O
##iche O
##r O
ab O
rei O
##ser O
##t O
i O
sc O
##hill O
##ing O
k O
pilgrim O
c O
activation O
of O
do O
##pa O
##mine O
##rg O
##ic O
d O
##1 O
receptors O
promotes O
mor O
##ph O
##ogen O
##esis O
of O
developing O
st O
##ria O
##tal O
neurons O
neuroscience O
1996 O
74 O
45 O
##3 O
460 O
caste O
##lls O
s O
cha O
##kra O
##bar O
##ti O
c O
wins O
##berg O
b O
##g O
hu O
##r O
##wi O
##c O
m O
pere O
##l O
j O
##m O
ny O
##han O
w O
##l O
effects O
of O
l O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
on O
mono O
##amine O
and O
amino O
acids O
turnover O
in O
the O
les O
##ch O
ny O
##han O
syndrome O
j O
autism O
dev O
di O
##sor O
##d O
1979 O
9 O
95 O
103 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
1300 O
s O
de O
##hn O
##ing O
et O
al O

cia O
##rane O
##llo O
rd O
anders O
t O
##f O
bar O
##cha O
##s O
jd O
berger O
pa O
can O
##n O
hm O
the O
use O
of O
5 O
hydro O
##xy O
##try O
##pt O
##op O
##han O
in O
a O
child O
with O
les O
##ch O
ny O
##han O
syndrome O
child O
psychiatry O
hum O
dev O
1976 O
7 O
127 O
133 O
jan O
##kovic O
j O
cas O
##key O
tc O
stout O
j O
##t O
butler O
i O
##j O
les O
##ch O
ny O
##han O
syndrome O
a O
study O
of O
motor O
behavior O
and O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
ann O
ne O
##uro O
##l O
1988 O
23 O
46 O
##6 O
46 O
##9 O
silver O
##stein O
f O
##s O
johnston O
mv O
hutchinson O
r O
##j O
edwards O
nl O
les O
##ch O
ny O
##han O
syndrome O
cs O
##f O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
abnormalities O
ne O
##uro O
##logy O
1985 O
35 O
90 O
##7 O
911 O

watts O
r O
##we O
spell O
##acy O
e O
gibbs O
da O
all O
##sop O
j O
mc O
##ker O
##an O
ro O
sl O
##avi O
##n O
ge O
clinical O
post O
mort O
##em O
bio O
##chemical O
and O
therapeutic O
observations O
on O
the O
les O
##ch O
ny O
##han O
syndrome O
with O
particular O
reference O
to O
the O
neurological O
manifestation O
##s O
q O
##jm O
##ed O
1982 O
51 O
43 O
78 O
mi O
##zu O
##no O
t O
yu O
##gar O
##i O
y O
self O
mu O
##tila O
##tion O
in O
les O
##ch O
ny O
##han O
syndrome O
lance O
##t O
1974 O
1 O
76 O
##1 O
therapy O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
ben O
##e O
##ﬁ O
##cial O
outcome O
with O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
deep O
brain O
stimulation O
sandra O
de O
##hn O
##ing O
md O
1 O
jan O
hi O
##nne O
##rk O
me O
##hr O
##ken O
##s O
md O
2 O
nor O
##bert O
mu O
##¨ O
##ller O
phd O
1 O
and O
kai O
bo O
##¨ O
##tze O
##l O
md O
##3 O

1 O
##de O
##par O
##tment O
of O
psychiatry O
and O
psycho O
##therapy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
2d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##sur O
##ger O
##y O
ludwig O
maximilian O
##s O
university O
munich O
germany O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
abstract O
we O
report O
on O
a O
female O
patient O
with O
tour O
##ette O
syndrome O
ts O
and O
a O
12 O
month O
follow O
up O
after O
chronic O
deep O
brain O
stimulation O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
which O
resulted O
in O
excellent O
re O
##mission O
of O
motor O
and O
vocal O
ti O
##cs O
2008 O
movement O
disorder O
society O
key O
words O
tour O
##ette O
syndrome O
deep O
brain O
stimulation O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O

tour O
##ette O
syndrome O
ts O
is O
a O
chronic O
and O
in O
severe O
cases O
de O
##bil O
##itating O
disorder O
characterized O
by O
motor O
and O
vocal O
ti O
##cs O
and O
additionally O
accompanied O
by O
features O
correspondence O
to O
dr O
sandra O
de O
##hn O
##ing O
psychiatric O
hospital O
of O
the O
ludwig O
maximilian O
##s O
university O
munich O
nu O
##bba O
##ums O
##tr O
7 O
munich O
d O
80 O
##33 O
##6 O
germany O
e O
mail O
sandra O
de O
##hn O
##ing O
med O
un O
##i O
mu O
##en O
##chen O
de O
received O
2 O
august O
2007 O
accepted O
29 O
november O
2007 O
published O
online O
4 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
219 O
##30 O

here O
we O
report O
on O
a O
female O
patient O
with O
ts O
and O
a O
12 O
##mont O
##h O
follow O
up O
study O
after O
chronic O
db O
##s O
of O
the O
gp O
##i O
case O
report O

for O
the O
last O
17 O
years O
the O
patient O
was O
continuously O
treated O
as O
in O
##patient O
and O
out O
##patient O
of O
our O
clinic O
and O
the O
diagnosis O
of O
ts O
was O
established O
according O
to O
the O
criteria O
of O
ds O
##m O
iv O
conventional O
medication O
attempts O
with O
a O
range O
of O
anti O
##psy O
##cho O
##tics O
over O
many O
years O
did O
not O
have O
any O
substantial O
effect O
ultimately O
the O
combination O
of O
ari O
##pi O
##pr O
##az O
##ole O
and O
tia O
##pr O
##ide O
together O
with O
monthly O
out O
##patient O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
ec O
##t O
over O
the O
last O
5 O
years O
has O
led O
to O
a O
partial O
suppression O
of O
ti O
##cs O
the O
rational O
##e O
for O
ec O
##t O
was O
derived O
from O
case O
reports O
where O
a O
substantial O
improvement O
of O
ti O
##cs O
##13 O
14 O
was O
demonstrated O

previous O
the O
##ra O
##pies O
with O
a O
2 O
ad O
##ren O
##ore O
##ce O
##pt O
##or O
ago O
##nist O
##s O
do O
##pa O
##mine O
ago O
##nist O
##s O
and O
op O
##io O
##id O
ago O
##nist O
##s O
as O
well O
as O
alternative O
treatments O
like O
antibiotics O
im O
##mun O
##og O
##lo O
##bu O
##lins O
and O
plasma O
##pher O
##esis O
already O
described O
as O
possibly O
effective O
in O
single O
reports O
##15 O
only O
resulted O
in O
a O
temporary O
improvement O
of O
the O
ti O
##cs O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
tour O
##ette O
syndrome O
and O
deep O
brain O
stimulation O
130 O
##1 O

fig O
1 O
axial O
mri O
of O
the O
patient O
s O
brain O
showing O
the O
tip O
of O
the O
electrode O
##s O
6 O
mm O
below O
the O
level O
of O
the O
anterior O
and O
posterior O
com O
##mis O
##sure O
##s O
on O
the O
right O
the O
optic O
tract O
can O
be O
seen O
on O
which O
the O
electrode O
tip O
projects O
before O
stereo O
##ta O
##ctic O
intervention O
primary O
symptoms O
were O
severe O
grinding O
of O
her O
teeth O
beating O
her O
hips O
as O
well O
as O
persistent O
grunt O
##ing O
and O
qu O
##ack O
##ing O

120 O
l O
##s O
and O
frequency O
130 O
pp O
##s O
and O
slowly O
increased O
to O
3 O
2 O
v O
at O
discharge O
stimulation O
parameters O
were O
further O
increased O
3 O
months O
after O
stimulation O
3 O
5 O
v O
150 O
l O
##s O
145 O
pp O
##s O
4 O
months O
after O
implant O
##ation O
3 O
5 O
v O
180 O
l O
##s O
145 O
pp O
##s O
and O
at O
12 O
months O
after O
the O
implant O
##ation O
4 O
2 O
v O
210 O
l O
##s O
145 O
pp O
##s O
under O
this O
setting O
the O
current O
applied O
was O
94 O
la O
on O
each O
side O

in O
the O
ﬁ O
##rst O
few O
months O
after O
intervention O
the O
patient O
made O
frequent O
visits O
to O
our O
clinic O
as O
out O
##patient O
complaining O
of O
de O
##pressive O
moods O
vertigo O
and O
stomach O
ache O
##s O
at O
that O
time O
the O
patient O
emphasized O
having O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
adjusting O
to O
the O
new O
situation O
the O
absent O
necessity O
of O
being O
an O
in O
##patient O
and O
recognizing O
that O
the O
illness O
had O
been O
a O
big O
part O
of O
her O
life O
we O
supported O
her O
with O
regular O
out O
##patient O
appointments O
and O
centered O
psycho O
##ther O
##ape O
##uti O
##c O
interventions O
at O
present O
the O
patient O
is O
stabilized O
and O
has O
begun O
to O
engage O
in O
previously O
neglected O
activities O
such O
as O
horseback O
riding O
discussion O

we O
demonstrate O
full O
re O
##mission O
of O
ti O
##c O
symptoms O
after O
gp O
##i O
db O
##s O
in O
a O
patient O
suffering O
from O
intra O
##ctable O
ts O
table O
1 O
follow O
up O
of O
yale O
global O
ti O
##c O
severity O
scale O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##2 O
s O
de O
##hn O
##ing O
et O
al O

as O
demonstrated O
in O
patients O
with O
gp O
##i O
implant O
##s O
for O
d O
##yst O
##onia O
17 O
a O
low O
rate O
of O
side O
effects O
and O
a O
good O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
with O
this O
target O
has O
been O
established O
therefore O
we O
consider O
gp O
##i O
db O
##s O
as O
also O
very O
promising O
for O
the O
treatment O
of O
ts O
references O
muller O
n O
ri O
##ede O
##l O
m O
blending O
##er O
c O
obe O
##rle O
k O
jacobs O
e O
abel O
##eh O
##orn O
m O
my O
##co O
##pl O
##as O
##ma O
pneumonia O
##e O
infection O
and O
tour O
##ette O
s O
syndrome O
psychiatry O
res O
2004 O
129 O
119 O
125 O
robertson O
mm O
stern O
j O
##s O
gilles O
de O
la O
tour O
##ette O
syndrome O
sy O
##mpt O
##oma O
##tic O
treatment O
based O
on O
evidence O
eu O
##r O
child O
ad O
##oles O
##c O
psychiatry O
2000 O
9 O
su O
##pp O
##l O
1 O
i O
##60 O
i O
##75 O

de O
##hn O
##ing O
s O
ri O
##ede O
##l O
m O
muller O
n O
ari O
##pi O
##pr O
##az O
##ole O
in O
a O
patient O
vulnerable O
to O
side O
effects O
am O
j O
psychiatry O
2005 O
162 O
625 O
van O
##de O
##wall O
##e O
v O
van O
der O
lc O
gr O
##oe O
##ne O
##we O
##gen O
h O
##j O
ca O
##ema O
##ert O
j O
stereo O
##ta O
##ctic O
treatment O
of O
gilles O
de O
la O
tour O
##ette O
syndrome O
by O
high O
frequency O
stimulation O
of O
tha O
##lam O
##us O
lance O
##t O
1999 O
35 O
##3 O
72 O
##4 O
vis O
##ser O
van O
##de O
##wall O
##e O
v O
te O
##mel O
y O
boon O
p O
et O
al O
chronic O
bilateral O
tha O
##lam O
##ic O
stimulation O
a O
new O
therapeutic O
approach O
in O
intra O
##ctable O
tour O
##ette O
syndrome O
report O
of O
three O
cases O
j O
ne O
##uro O
##sur O
##g O
2003 O
99 O
109 O
##4 O
1100 O

serve O
##llo O
d O
port O
##a O
m O
sas O
##si O
m O
bram O
##bill O
##a O
a O
robertson O
mm O
deep O
brain O
stimulation O
in O
18 O
patients O
with O
severe O
gilles O
de O
la O
tour O
##ette O
syndrome O
ref O
##rac O
##tory O
to O
treatment O
the O
surgery O
and O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
in O
press O
fl O
##ah O
##erty O
aw O
williams O
z O
##m O
amir O
##nov O
##in O
r O
et O
al O
deep O
brain O
stimulation O
of O
the O
anterior O
internal O
capsule O
for O
the O
treatment O
of O
tour O
##ette O
syndrome O
technical O
case O
report O
ne O
##uro O
##sur O
##ger O
##y O
2005 O
57 O
e O
##40 O
##3 O

ku O
##hn O
j O
lena O
##rt O
##z O
d O
mai O
j O
##k O
et O
al O
deep O
brain O
stimulation O
of O
the O
nucleus O
acc O
##umb O
##ens O
and O
the O
internal O
capsule O
in O
therapeutic O
##ally O
ref O
##rac O
##tory O
tour O
##ette O
syndrome O
j O
ne O
##uro O
##l O
2007 O
254 O
96 O
##3 O
96 O
##5 O
ac O
##ker O
##mans O
l O
te O
##mel O
y O
cat O
##h O
d O
et O
al O
deep O
brain O
stimulation O
in O
tour O
##ette O
s O
syndrome O
two O
targets O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
70 O
##9 O
71 O
##3 O
died O
##eric O
##h O
nj O
ka O
##lt O
##eis O
k O
st O
##amen O
##kovic O
m O
pier O
##i O
v O
ale O
##sch O
f O
e O
##f O
##ﬁ O
##cie O
##nt O
internal O
pal O
##lid O
##al O
stimulation O
in O
gilles O
de O
la O
tour O
##ette O
syndrome O
a O
case O
report O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
149 O
##6 O
149 O
##9 O
gallagher O
cl O
ga O
##rell O
pc O
montgomery O
e O
##b O
jr O
hem O
##i O
ti O
##cs O
and O
deep O
brain O
stimulation O
ne O
##uro O
##logy O
2006 O
66 O
e O
##12 O

ho O
##uet O
##o O
j O
##l O
karachi O
c O
mall O
##et O
l O
et O
al O
tour O
##ette O
s O
syndrome O
and O
deep O
brain O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2005 O
76 O
99 O
##2 O
99 O
##5 O
rap O
##op O
##ort O
m O
fed O
##er O
v O
sand O
##or O
p O
response O
of O
major O
depression O
and O
tour O
##ette O
s O
syndrome O
to O
ec O
##t O
a O
case O
report O
psycho O
##som O
med O
1998 O
60 O
52 O
##8 O
52 O
##9 O
sw O
##er O
##dlow O
nr O
gi O
##er O
##z O
m O
be O
##rk O
##ow O
##itz O
a O
ne O
##mir O
##off O
r O
lo O
##hr O
j O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
in O
a O
patient O
with O
severe O
ti O
##c O
and O
major O
de O
##pressive O
episode O
j O
cl O
##in O
psychiatry O
1990 O
51 O
34 O
35 O

per O
##lm O
##utter O
s O
##j O
lei O
##tman O
sf O
ga O
##r O
##vey O
ma O
et O
al O
therapeutic O
plasma O
exchange O
and O
intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
for O
ob O
##ses O
##sive O
##com O
##pu O
##ls O
##ive O
disorder O
and O
ti O
##c O
disorders O
in O
childhood O
lance O
##t O
1999 O
354 O
115 O
##3 O
115 O
##8 O
min O
##k O
j O
##w O
ne O
##uro O
##biology O
of O
basal O
gang O
##lia O
and O
tour O
##ette O
syndrome O
basal O
gang O
##lia O
circuits O
and O
tha O
##lam O
##oco O
##rti O
##cal O
outputs O
ad O
##v O
ne O
##uro O
##l O
2006 O
99 O
89 O
98 O

be O
##re O
##z O
##nai O
b O
ste O
##ude O
u O
see O
##los O
k O
bot O
##zel O
k O
chronic O
high O
frequency O
g O
##lo O
##bus O
pal O
##lid O
##us O
intern O
##us O
stimulation O
in O
different O
types O
of O
d O
##yst O
##onia O
a O
clinical O
video O
and O
mri O
report O
of O
six O
patients O
presenting O
with O
segment O
##al O
cervical O
and O
generalized O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
138 O
144 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##3 O
novel O
complex O
interruption O
##s O
of O
the O
gaa O
repeat O
in O
small O
expanded O
all O
##eles O
of O
two O
affected O
siblings O
with O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O

catherine O
a O
st O
##oll O
##e O
phd O
1 O
edward O
c O
fra O
##cke O
##lton O
bs O
1 O
jennifer O
mccall O
##um O
ms O
1 O
jennifer O
m O
farmer O
ms O
2 O
amy O
ts O
##ou O
md O
2 O
robert O
b O
wilson O
md O
phd O
3 O
and O
david O
r O
lynch O
md O
phd O
##2 O
1 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
children O
s O
hospital O
of O
philadelphia O
philadelphia O
pennsylvania O
usa O
2 O
##the O
department O
of O
ne O
##uro O
##logy O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O
3 O
##the O
department O
of O
pathology O
and O
laboratory O
medicine O
the O
university O
of O
pennsylvania O
school O
of O
medicine O
philadelphia O
pennsylvania O
usa O

key O
words O
dorsal O
column O
ata O
##xia O
triple O
##t O
repeat O
spa O
##stic O
##ity O
fried O
##re O
##ich O
ata O
##xia O
fa O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
characterized O
by O
progressive O
ata O
##xia O
and O
onset O
usually O
before O
the O
age O
of O
25 O
years O
1 O
most O
patients O
have O
expanded O
gaa O
repeats O
in O
intro O
##n O
1 O
of O
the O
fr O
##da O
gene O
normal O
all O
##eles O
contain O
5 O
to O
33 O
repeats O
while O
prem O
##uta O
correspondence O
to O
dr O
david O
r O
lynch O
division O
of O
ne O
##uro O
##logy O
children O
s O
hospital O
of O
philadelphia O
50 O
##2 O
abrams O
##on O
building O
philadelphia O
pa O
1910 O
##4 O
43 O
##18 O
usa O
e O
mail O
lynch O
ph O
##arm O
med O
up O
##en O
##n O
ed O
##u O
received O
10 O
september O
2007 O
revised O
18 O
november O
2007 O
accepted O
9 O
february O
2008 O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##4 O
c O
a O
st O
##oll O
##e O
et O
al O
patients O
patient O
1a O

this O
patient O
presented O
at O
age O
74 O
with O
un O
##stead O
##y O
ga O
##it O
that O
had O
been O
slowly O
progressive O
for O
6 O
years O
she O
noted O
mild O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
her O
hands O
she O
had O
one O
brother O
with O
fa O
patient O
1a O
but O
no O
other O
family O
history O
of O
movement O
disorder O
on O
examination O
she O
had O
hyper O
##active O
re O
##ﬂ O
##ex O
##es O
and O
mildly O
increased O
tone O
in O
her O
upper O
ex O
##tre O
##mit O
##ies O
but O
normal O
lower O
ex O
##tre O
##mity O
re O
##ﬂ O
##ex O
##es O
she O
had O
decreased O
vi O
##bra O
##tory O
sensation O
in O
her O
feet O
but O
otherwise O
intact O
sensation O
strength O
and O
speech O
mild O
right O
sided O
d O
##ys O
##met O
##ria O
was O
present O
she O
had O
square O
wave O
jerk O
##s O
in O
primary O
position O
with O
h O
##yp O
##ometric O
sac O
##cade O
##s O
mri O
of O
the O
head O
and O
cervical O
spine O
revealed O
mild O
ce O
##re O
##bella O
##r O
and O
o O
##cci O
##pit O
##al O
lobe O
at O
##rop O
##hy O
with O
a O
chronic O
right O
posterior O
tha O
##lam O
##ic O
lac O
##una O
##r O
in O
##far O
##ct O
and O
mild O
cervical O
spinal O
cord O
compression O
molecular O
analysis O
of O
her O
fra O
##ta O
##xin O
gene O

patient O
5 O
this O
patient O
presented O
at O
48 O
years O
after O
10 O
years O
of O
variable O
hand O
and O
leg O
cl O
##ums O
##iness O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
sl O
##ur O
##red O
speech O
on O
examination O
she O
had O
ny O
##sta O
##gm O
##us O
table O
1 O
interrupted O
gaa O
repeat O
sequences O
from O
fa O
patients O
revealed O
gaa O
repeat O
lengths O
of O
1 O
00 O
##5 O
and O
104 O
patient O
1a O
and O
1b O
gaa O
72 O
##1 O
gaga O
##a O
1 O
gaa O
##aa O
1 O
gaa O
201 O
gaa O
##aa O
1 O
gaa O
1 O
gag O
##ga O
##a O
4 O
1 O
gaa O
12 O
patient O
2 O

this O
patient O
presented O
with O
progressive O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
balance O
and O
coordination O
at O
age O
41 O
on O
initial O
examination O
at O
age O
48 O
prop O
##rio O
##ception O
was O
normal O
and O
re O
##ﬂ O
##ex O
##es O
were O
21 O
in O
the O
arms O
and O
legs O
over O
the O
next O
9 O
years O
he O
developed O
d O
##ys O
##arth O
##ria O
d O
##ys O
##met O
##ria O
diminished O
prop O
##rio O
##ception O
in O
the O
arms O
and O
legs O
spa O
##stic O
##ity O
and O
diffuse O
hyper O
##re O
##ﬂ O
##ex O
##ia O
with O
cl O
##onus O
and O
ex O
##tens O
##or O
plant O
##ar O
responses O
mri O
of O
the O
brain O
revealed O
mild O
ve O
##rmi O
##an O
at O
##rop O
##hy O
genetic O
testing O
of O
the O
fr O
##da O
gene O
revealed O
gaa O
repeat O
lengths O
of O
115 O
and O
1 O
02 O
##5 O
patient O
2 O
gaa O
89 O
1 O
gaga O
##a O
1 O
gaa O
41 O
gaga O
##a O
1 O
gaa O
41 O
gaa O
##aa O
1 O
gaa O
13 O

patient O
3 O
gaa O
78 O
##1 O
gaa O
##aa O
1 O
gaa O
171 O
gaa O
##aa O
1 O
gaa O
1 O
gag O
##ga O
##a O
5 O
1 O
gaa O
12 O
patient O
4 O
gaa O
103 O
##1 O
gaa O
##aga O
##a O
1 O
gaa O
15 O
patient O
5 O
gaa O
130 O
##1 O
aaa O

the O
number O
of O
gaa O
repeats O
plus O
the O
location O
and O
the O
sequence O
of O
repeat O
interruption O
##s O
are O
indicated O
the O
number O
of O
gaa O
repeats O
at O
the O
50 O
end O
represents O
a O
minimum O
repeat O
number O
since O
sequence O
analysis O
did O
not O
reach O
the O
50 O
non O
##re O
##pe O
##at O
sequence O
interruption O
##s O
clustered O
in O
the O
30 O
end O
of O
the O
repeat O
sequence O
and O
were O
followed O
by O
short O
gaa O
repeats O
in O
all O
of O
the O
patients O
except O
no O
5 O
interruption O
##s O
are O
designated O
to O
be O
consistent O
with O
those O
previously O
id O
##ent O
##i O
##ﬁ O
##ed O
gag O
##ga O
##a O
ref O
7 O
gaa O
##aga O
##a O
ref O
8 O
gaa O
##aa O
ref O
9 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
interruption O
##s O
in O
gaa O
repeats O
in O
fried O
##re O
##ich O
ata O
##xia O
130 O
##5 O

table O
2 O
repeat O
lengths O
and O
age O
of O
onset O
for O
patients O
1 O
5 O
patient O
repeat O
lengths O
as O
id O
##ent O
##i O
##ﬁ O
##ed O
by O
pc O
##r O
estimate O
and O
maximum O
number O
based O
on O
sequencing O
d O
##ys O
##arth O
##ria O
and O
severe O
d O
##ys O
##met O
##ria O
re O
##ﬂ O
##ex O
##es O
were O
absent O
except O
for O
the O
tri O
##ce O
##ps O
jerk O
##s O
prop O
##rio O
##ception O
and O
vi O
##bra O
##tory O
sensation O
were O
decreased O
and O
her O
ga O
##it O
was O
wide O
based O
mri O
of O
the O
brain O
was O
normal O
analysis O
of O
her O
fr O
##da O
gene O
revealed O
gaa O
repeat O
expansion O
##s O
of O
290 O
and O
850 O
results O

based O
on O
previous O
reports O
suggesting O
small O
interruption O
##s O
in O
the O
gaa O
repeat O
in O
some O
patients O
with O
very O
late O
onset O
of O
fa O
we O
sequence O
##d O
the O
gaa O
repeat O
region O
in O
a O
series O
of O
patients O
table O
1 O
in O
sibling O
patients O
1a O
and O
1b O
identical O
interruption O
##s O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
gaa O
repeat O
the O
longest O
un O
##int O
##er O
##rup O
##ted O
repeat O
was O
72 O
bases O
in O
other O
patients O
with O
short O
gaa O
repeats O
similar O
interruption O
##s O
in O
the O
30 O
end O
of O
the O
gaa O
repeat O
were O
found O
in O
three O
of O
four O
but O
the O
interruption O
##s O
were O
less O
complex O
one O
patient O
had O
only O
a O
single O
aaa O
sequence O
at O
the O
30 O
end O
of O
the O
gaa O
repeat O
7 O
9 O

we O
then O
correlated O
age O
of O
onset O
with O
presence O
or O
absence O
of O
interruption O
##s O
table O
2 O
fig O
1 O
two O
of O
5 O
patients O
patients O
1a O
and O
1b O
with O
interruption O
##s O
presented O
later O
than O
that O
expected O
based O
on O
the O
correlation O
of O
total O
gaa O
repeat O
length O
with O
age O
of O
onset O
from O
a O
large O
american O
co O
##hort O
10 O
but O
3 O
patients O
patients O
2 O
3 O
and O
4 O
had O
an O
age O
of O
onset O
similar O
to O
or O
only O
slightly O
later O
than O
that O
predicted O
based O
on O
the O
overall O
co O
##hort O
see O
fig O
1 O
the O
patient O
with O
the O
isolated O
aaa O
at O
the O
30 O
end O
of O
an O
interrupted O
repeat O
patient O
5 O
presented O

slightly O
later O
than O
the O
expected O
age O
similarly O
the O
total O
maximal O
un O
##int O
##er O
##rup O
##ted O
length O
did O
not O
co O
##rre O
##late O
substantially O
better O
with O
age O
of O
onset O
this O
suggests O
that O
the O
presence O
of O
interruption O
##s O
does O
not O
sign O
##i O
##ﬁ O
##can O
##tly O
affect O
age O
of O
onset O
discussion O
in O
this O
work O
a O
variety O
of O
small O
expanded O
all O
##eles O
of O
the O
fr O
##da O
gene O
had O
an O
altered O
sequence O
compared O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##6 O
c O
a O
st O
##oll O
##e O
et O
al O

ac O
##k O
##now O
##led O
##gm O
##ents O
dr O
lynch O
is O
supported O
by O
grants O
from O
the O
fried O
##re O
##ich O
ata O
##xia O
research O
alliance O
and O
the O
muscular O
d O
##yst O
##rop O
##hy O
association O
we O
wish O
to O
thank O
the O
clinical O
research O
network O
for O
fried O
##re O
##ich O
ata O
##xia O
for O
providing O
access O
to O
data O
on O
the O
fa O
co O
##hort O
references O
du O
##rr O
a O
co O
##ssee O
m O
ag O
##id O
y O
et O
al O
clinical O
and O
genetic O
abnormalities O
in O
patients O
with O
fried O
##re O
##ich O
s O
ata O
##xia O
n O
eng O
##l O
j O
med O
1996 O
335 O
116 O
##9 O
117 O
##5 O

sa O
##kam O
##oto O
n O
oh O
##shima O
k O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
sticky O
dna O
a O
self O
associated O
complex O
formed O
at O
long O
gaa O
tt O
##c O
repeats O
in O
intro O
##n O
1 O
of O
the O
fra O
##ta O
##xin O
gene O
inhibit O
##s O
transcription O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##1 O
271 O
##7 O
##7 O
monte O
##rmin O
##i O
l O
richter O
a O
morgan O
k O
et O
al O
ph O
##eno O
##typic O
variability O
in O
fried O
##re O
##ich O
ata O
##xia O
role O
of O
the O
associated O
gaa O
triple O
##t O
repeat O
expansion O
ann O
ne O
##uro O
##l O
1997 O
41 O
67 O
##5 O
68 O
##2 O
b O
##hid O
##aya O
##sir O
##i O
r O
per O
##lman O
sl O
pu O
##ls O
##t O
sm O
ge O
##sch O
##wind O
dh O
late O
onset O
fried O
##re O
##ich O
ata O
##xia O
ph O
##eno O
##typic O
analysis O
magnetic O
resonance O
imaging O
ﬁ O
##nding O
##s O
and O
review O
of O
the O
literature O
arch O
ne O
##uro O
##l O
2005 O
62 O
1865 O
1869 O

mc O
##dan O
##iel O
do O
ke O
##ats O
b O
ve O
##dana O
##raya O
##nan O
v O
##v O
sub O
##ram O
##ony O
sh O
sequence O
variation O
in O
gaa O
repeat O
expansion O
##s O
may O
cause O
differential O
ph O
##eno O
##type O
display O
in O
fried O
##re O
##ich O
s O
ata O
##xia O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
115 O
##3 O
115 O
##8 O
camp O
##uz O
##ano O
v O
monte O
##rmin O
##i O
l O
mo O
##lto O
md O
et O
al O
fried O
##re O
##ich O
s O
ata O
##xia O
auto O
##som O
##al O
recess O
##ive O
disease O
caused O
by O
an O
intro O
##nic O
gaa O
triple O
##t O
repeat O
expansion O
science O
1996 O
271 O
142 O
##3 O
142 O
##7 O
monte O
##rmin O
##i O
l O
and O
##erman O
##n O
e O
lab O
##uda O
m O
et O
al O
the O
fried O
##re O
##ich O
ata O
##xia O
gaa O
triple O
##t O
repeat O
prem O
##utation O
and O
normal O
all O
##eles O
hum O
mo O
##l O
gene O
##t O
1997 O
6 O
126 O
##1 O
126 O
##6 O

co O
##ssee O
m O
sc O
##hmi O
##tt O
m O
camp O
##uz O
##ano O
v O
re O
##ute O
##na O
##uer O
l O
mo O
##uto O
##u O
c O
man O
##del O
j O
##l O
ko O
##eni O
##g O
m O
evolution O
of O
the O
fried O
##re O
##ich O
s O
ata O
##xia O
tri O
##nu O
##cle O
##otide O
repeat O
expansion O
founder O
effect O
and O
prem O
##utation O
##s O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
usa O
1997 O
94 O
74 O
##52 O
74 O
##57 O
sa O
##kam O
##oto O
n O
larson O
je O
i O
##yer O
rr O
monte O
##rmin O
##i O
l O
pan O
##do O
##lf O
##o O
m O
wells O
rd O
g O
##ga O
tc O
##c O
interrupted O
triple O
##ts O
in O
long O
gaa O
tt O
##c O
repeats O
inhibit O
the O
formation O
of O
triple O
##x O
and O
sticky O
dna O
structures O
alleviate O
transcription O
inhibition O
and O
reduce O
genetic O
ins O
##ta O
##bilities O
j O
bio O
##l O
che O
##m O
2001 O
276 O
271 O
##7 O
##8 O
271 O
##8 O
##7 O

lynch O
dr O
farmer O
j O
##m O
ts O
##ou O
a O
##y O
et O
al O
measuring O
fried O
##re O
##ich O
ata O
##xia O
complementary O
features O
of O
examination O
and O
performance O
measures O
ne O
##uro O
##logy O
2006 O
66 O
1711 O
1716 O
charles O
p O
cam O
##uz O
##at O
a O
ben O
##am O
##mar O
n O
et O
al O
are O
interrupted O
sc O
##a O
##2 O
ca O
##g O
repeat O
expansion O
##s O
responsible O
for O
parkinson O
##ism O
ne O
##uro O
##logy O
2007 O
69 O
1970 O
1975 O
sob O
##cz O
##ak O
k O
k O
##ry O
##zos O
##ia O
##k O
w O
##j O
ca O
##g O
repeats O
containing O
ca O
##a O
interruption O
##s O
form O
branched O
hair O
##pin O
structures O
in O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
2 O
transcript O
##s O
j O
bio O
##l O
che O
##m O
2005 O
280 O
38 O
##9 O
##8 O
39 O
##10 O

cho O
##ud O
##hr O
##y O
s O
mu O
##ker O
##ji O
m O
sri O
##vas O
##ta O
##va O
ak O
jain O
s O
bra O
##hma O
##cha O
##ri O
sk O
ca O
##g O
repeat O
instability O
at O
sc O
##a O
##2 O
locus O
anchor O
##ing O
ca O
##a O
interruption O
##s O
and O
linked O
single O
nu O
##cle O
##otide O
poly O
##morphism O
##s O
hum O
mo O
##l O
gene O
##t O
2001 O
10 O
243 O
##7 O
244 O
##6 O
mats O
##u O
##ura O
t O
fang O
p O
pearson O
ce O
jaya O
##kar O
p O
ash O
##iza O
##wa O
t O
ro O
##a O
bb O
nelson O
dl O
interruption O
##s O
in O
the O
expanded O
at O
##tc O
##t O
repeat O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
10 O
repeat O
purity O
as O
a O
disease O
mod O
##i O
##ﬁ O
##er O
am O
j O
hum O
gene O
##t O
2006 O
78 O
125 O
129 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
130 O
##7 O
on O
the O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O

jan O
st O
##och O
##l O
phd O
msc O
1 O
anne O
boom O
##sma O
phd O
2 O
ev O
##zen O
ru O
##zic O
##ka O
md O
ds O
##c O
3 O
hana O
bro O
##zo O
##va O
md O
3 O
and O
pet O
##r O
blah O
##us O
ds O
##c O
##1 O
1 O
##de O
##par O
##tment O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
prague O
czech O
republic O
2d O
##ep O
##art O
##ment O
of O
sociology O
statistics O
and O
measurement O
theory O
university O
of O
groningen O
groningen O
the O
netherlands O
3d O
##ep O
##art O
##ment O
of O
ne O
##uro O
##logy O
charles O
university O
movement O
disorders O
centre O
prague O
czech O
republic O

correspondence O
to O
dr O
jan O
st O
##och O
##l O
department O
of O
kin O
##ant O
##hr O
##op O
##ology O
charles O
university O
jose O
##´ O
mart O
##´ O
##ı O
##ho O
31 O
c O
##z O
162 O
52 O
prague O
czech O
republic O
e O
mail O
st O
##och O
##l O
ft O
##vs O
cu O
##ni O
c O
##z O
received O
16 O
november O
2007 O
revised O
22 O
january O
2008 O
accepted O
17 O
february O
2008 O
published O
online O
7 O
may O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##29 O

instead O
of O
e O
##fa O
we O
used O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
cfa O
within O
a O
se O
##m O
framework O
to O
perform O
a O
statistical O
test O
and O
to O
evaluate O
a O
number O
of O
plausible O
factor O
models O
for O
the O
structure O
of O
symptoms O
underlying O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
some O
se O
##m O
est O
##ima O
##tors O
are O
designed O
for O
or O
##dina O
##l O
measurements O
and O
thus O
in O
principle O
suited O
for O
analyzing O
that O
structure O
patients O
and O
methods O
sample O

the O
study O
includes O
405 O
consecutive O
patients O
237 O
men O
168 O
women O
mean O
age O
61 O
range O
35 O
80 O
years O
with O
pd O
diagnosed O
according O
to O
current O
clinical O
criteria O
9 O
each O
patient O
was O
evaluated O
by O
one O
member O
of O
a O
group O
of O
ce O
##rti O
##ﬁ O
##ed O
ne O
##uro O
##logists O
movement O
disorder O
specialists O
who O
routinely O
use O
the O
up O
##dr O
##s O
sixty O
patients O
were O
examined O
in O
de O
##ﬁ O
##ned O
off O
state O
and O
310 O
patients O
in O
de O
##ﬁ O
##ned O
on O
state O
for O
35 O
patients O
the O
motor O
state O
during O
evaluation O
was O
not O
spec O
##i O
##ﬁ O
##ed O
this O
data O
consists O
of O
two O
sub O
##sam O
##ples O
the O
ﬁ O
##rst O
sub O
##sam O
##ple O
of O
size O
n O
5 O
147 O
96 O
men O
38 O
off O
30 O
on O

28 O
unknown O
and O
51 O
women O
15 O
off O
29 O
on O
7 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
130 O
##8 O
j O
st O
##och O
##l O
et O
al O
unknown O
was O
obtained O
at O
the O
movement O
disorder O
centre O
charles O
university O
prague O
czech O
republic O
the O
second O
of O
size O
n O
5 O
258 O
141 O
men O
1 O
off O
140 O
on O
and O
117 O
women O
6 O
off O
111 O
on O
was O
acquired O
at O
the O
university O
medical O
centre O
groningen O
in O
the O
netherlands O
methods O

a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
for O
the O
ﬁ O
##nal O
model O
described O
here O
the O
path O
diagram O
with O
standardized O
parameter O
estimates O
the O
matrix O
of O
estimated O
poly O
##cho O
##ric O
correlation O
##s O
goodness O
of O
ﬁ O
##t O
statistics O
and O
indices O
a O
summary O
of O
estimated O
standard O
errors O
of O
the O
parameter O
estimates O
and O
the O
ﬁ O
##tted O
residual O
matrix O
are O
reported O
for O
details O
see O
ref O
13 O
results O

although O
some O
ﬁ O
##tted O
residual O
##s O
see O
table O
1 O
remained O
high O
the O
ﬁ O
##t O
statistics O
and O
indices O
suggest O
that O
this O
model O
need O
not O
to O
be O
rejected O
generally O
the O
values O
of O
comparative O
ﬁ O
##t O
index O
cf O
##i O
and O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
suggest O
a O
very O
acceptable O
ﬁ O
##t O
whereas O
root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
and O

the O
four O
factors O
of O
rigid O
##ity O
brady O
##kin O
##es O
##ia O
of O
the O
ex O
##tre O
##mit O
##ies O
speech O
h O
##yp O
##omi O
##mia O
and O
axial O
ga O
##it O
brady O
##kin O
##es O
##ia O
are O
correlated O
which O
is O
meaningful O
from O
a O
theoretical O
point O
of O
view O
the O
correlation O
##s O
range O
between O
0 O
54 O
and O
0 O
85 O
see O
fig O
1 O
indicating O
rather O
substantial O
relationships O
among O
these O
sy O
##mpt O
##om O
factors O
tremor O
however O
seems O
to O
be O
a O
pd O
sy O
##mpt O
##om O
occurring O
independently O
of O
other O
motor O
pd O
sy O
##mpt O
##om O
factors O
goodness O
of O
fit O
statistics O
and O
indices O
sample O
size O
405 O
degrees O
of O
freedom O
300 O
sato O
##rra O
bent O
##ler O
s O
scaled O
v O
##2 O
stat O
##istic O
89 O
##9 O
33 O
p O
5 O
0 O
0 O

root O
mean O
square O
error O
of O
approximation O
rms O
##ea O
0 O
07 O
##0 O
90 O
con O
##ﬁ O
##den O
##ce O
interval O
for O
rms O
##ea O
0 O
06 O
##5 O
0 O
07 O
##6 O
norm O
##ed O
ﬁ O
##t O
index O
n O
##fi O
0 O
96 O
comparative O
ﬁ O
##t O
index O
cf O
##i O
0 O
97 O
standardized O
root O
mean O
square O
residual O
sr O
##m O
##r O
0 O
07 O
##7 O
goodness O
of O
ﬁ O
##t O
index O
g O
##fi O
0 O
99 O
fitted O
residual O
##s O
range O
20 O
40 O
0 O
34 O
median O
0 O
04 O
standard O
deviation O
0 O
07 O
discussion O
in O
this O
study O
the O
structure O
of O
motor O
symptoms O
of O
pd O
was O
investigated O
by O
applying O
con O
##ﬁ O
##rma O
##tory O
factor O
analysis O
models O
to O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

153 O
##18 O
##25 O
##7 O
2008 O
9 O
downloaded O
from O
https O
movement O
##dis O
##ord O
##ers O
online O
##lib O
##rar O
##y O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##35 O
by O
the O
university O
of O
manchester O
wiley O
online O
library O
on O
22 O
05 O
202 O
##5 O
see O
the O
terms O
and O
conditions O
https O
online O
##lib O
##rar O
##y O
wiley O
com O
terms O
and O
conditions O
on O
wiley O
online O
library O
for O
rules O
of O
use O
o O
##a O
articles O
are O
governed O
by O
the O
applicable O
creative O
commons O
license O
table O
1 O
poly O
##cho O
##ric O
correlation O
##s O
below O
diagonal O
and O
ﬁ O
##tted O
residual O
##s O
above O
diagonal O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O

speech O
facial O
lips O
##chin O
##tr O
##ru O
##et O
##rl O
##uet O
##rr O
##let O
##rl O
##lea O
##tr O
##rh O
##anda O
##tr O
##l O
##hand O
##ri O
##gi O
##dity O
rue O
lu O
##e O
r O
##le O
ll O
##e O
fr O
##hand O
##fl O
##hand O
hr O
##hand O
##hl O
##hand O
##rr O
##hand O
##rl O
##hand O
l O
##rle O
##g O
ll O
##leg O
arising O
##post O
##ure O
ga O
##it O
stab O
##il O
body O
##bra O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
131 O
##1 O
the O
models O
were O
estimated O
using O
the O
d O
##wl O
##s O
est O
##ima O
##tor O
mainly O
because O
of O
the O
or O
##dina O
##l O
measurement O
level O
of O
the O
items O
and O
the O
relatively O
small O
sample O
size O

since O
a O
number O
of O
theoretically O
meaningful O
models O
were O
compared O
implying O
a O
partly O
ex O
##pl O
##ora O
##tory O
result O
future O
cross O
validation O
is O
necessary O
to O
challenge O
our O
ﬁ O
##nal O
factor O
structure O
of O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
it O
should O
also O
be O
realized O
that O
larger O
sample O
sizes O
would O
make O
model O
estimation O
results O
especially O
when O
considering O
the O
or O
##dina O
##l O
character O
of O
item O
responses O
more O
reliable O
and O
ﬁ O
##nal O
conclusions O
more O
valid O

ac O
##k O
##now O
##led O
##gm O
##ents O
we O
are O
obliged O
to O
doctors O
jan O
roth O
pet O
##r O
me O
##ci O
##r O
robert O
je O
##ch O
ter O
##eza O
serra O
##nova O
and O
olga O
ul O
##man O
##ova O
who O
performed O
up O
##dr O
##s O
testing O
in O
some O
cases O
we O
are O
also O
grateful O
to O
prof O
dr O
k O
l O
lee O
##nder O
##s O
and O
mrs O
w O
j O
st O
##aa O
##l O
groningen O
for O
their O
helpful O
comments O
to O
the O
manuscript O
jan O
st O
##och O
##l O
was O
supported O
by O
mobility O
fund O
of O
charles O
university O
czech O
science O
foundation O
grant O
no O
406 O
07 O
p O
##51 O
##3 O
ministry O
of O
education O
youth O
and O
sports O
grant O
no O
ms O
##m O
00 O
##21 O
##6 O
##20 O
##86 O
##4 O
and O
foundation O
of O
josef O
marie O
a O
h O
##la O
##´ O
##v O
##kov O
##y O
##´ O
##ch O
references O

cub O
##o O
e O
ste O
##bb O
##ins O
gt O
go O
##lb O
##e O
li O
et O
al O
application O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
factor O
analysis O
of O
the O
motor O
scale O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
276 O
279 O
ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
factor O
structure O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
motor O
examination O
section O
mo O
##v O
di O
##sor O
##d O
1998 O
13 O
63 O
##3 O
63 O
##6 O
ste O
##bb O
##ins O
gt O
go O
##etz O
c O
##g O
lang O
ae O
cub O
##o O
e O
factor O
analysis O
of O
the O
motor O
section O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
during O
the O
off O
state O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
58 O
##5 O
58 O
##9 O

martinez O
martin O
p O
gil O
na O
##gel O
a O
gr O
##ac O
##ia O
l O
##m O
gomez O
j O
##b O
martinez O
sar O
##ries O
j O
be O
##rm O
##ej O
##o O
f O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
characteristics O
and O
structure O
the O
cooperative O
multi O
##centric O
group O
mo O
##v O
di O
##sor O
##d O
1994 O
9 O
76 O
83 O
dun O
##tem O
##an O
g O
##h O
principal O
component O
analysis O
newbury O
park O
sage O
1989 O
hi O
##guchi O
i O
e O
##guchi O
s O
robust O
principal O
component O
analysis O
with O
adaptive O
selection O
for O
tuning O
parameters O
j O
machine O
learn O
res O
2004 O
5 O
45 O
##3 O
47 O
##1 O
elias O
##on O
sr O
maximum O
likelihood O
estimation O
logic O
and O
practice O
iowa O
sage O
1993 O

boom O
##sma O
a O
ho O
##og O
##land O
jj O
the O
robust O
##ness O
of O
li O
##sr O
##el O
modeling O
revisited O
in O
cu O
##deck O
r O
to O
##it O
s O
so O
##¨ O
##rb O
##om O
d O
editors O
structural O
equation O
modeling O
present O
and O
future O
a O
fest O
##sch O
##rift O
in O
honour O
of O
karl O
jo O
##¨ O
##res O
##ko O
##g O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2001 O
p O
139 O
168 O
hughes O
aj O
daniel O
se O
ki O
##lford O
l O
lee O
##s O
aj O
accuracy O
of O
clinical O
diagnosis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
a O
clinic O
##o O
path O
##ological O
study O
of O
100 O
cases O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1992 O
55 O
181 O
184 O
jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
li O
##sr O
##el O
8 O
72 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2005 O

jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
online O
help O
ﬁ O
##le O
for O
li O
##sr O
##el O
8 O
72 O
for O
windows O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2004 O
jo O
##¨ O
##res O
##ko O
##g O
kg O
so O
##¨ O
##rb O
##om O
d O
pre O
##lis O
2 O
54 O
ed O
lincoln O
##wood O
il O
sci O
##ent O
##i O
##ﬁ O
##c O
software O
international O
2002 O
j O
structure O
of O
motor O
symptoms O
of O
parkinson O
s O
disease O
phd O
thesis O
charles O
university O
prague O
2005 O
cr O
##on O
##bach O
l O
##j O
sc O
##ho O
##¨ O
##nem O
##ann O
p O
mc O
##kie O
d O
alpha O
coe O
##f O
##ﬁ O
##cie O
##nts O
for O
st O
##rat O
##i O
##ﬁ O
##ed O
parallel O
tests O
ed O
##uc O
psycho O
##l O
me O
##as O
1965 O
25 O
291 O
312 O

mart O
##ignon O
##i O
e O
fran O
##chi O
##gnon O
##i O
f O
pas O
##etti O
c O
fe O
##rrier O
##o O
g O
pic O
##co O
d O
psycho O
##metric O
properties O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
and O
of O
the O
short O
parkinson O
s O
evaluation O
scale O
ne O
##uro O
##l O
sci O
2003 O
24 O
190 O
191 O
k O
##ro O
##one O
##nberg O
pm O
o O
##ort O
f O
##j O
ste O
##bb O
##ins O
gt O
le O
##urg O
##ans O
se O
cub O
##o O
e O
go O
##etz O
c O
##g O
motor O
function O
in O
parkinson O
s O
disease O
and O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
simultaneous O
factor O
analysis O
of O
a O
clinical O
scale O
in O
several O
populations O
b O
##mc O
med O
res O
method O
2006 O
26 O
1 O
13 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##2 O
d O
r O
williams O
et O
al O

poe O
##we O
w O
##h O
wen O
##ning O
g O
##k O
the O
natural O
history O
of O
parkinson O
s O
disease O
ann O
ne O
##uro O
##l O
1998 O
44 O
3 O
su O
##pp O
##l O
1 O
s O
##1 O
s O
##9 O
henderson O
l O
ken O
##nard O
c O
crawford O
t O
scales O
for O
rating O
motor O
impairment O
in O
parkinson O
s O
disease O
studies O
of O
reliability O
and O
converge O
##nt O
validity O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1991 O
54 O
18 O
24 O
reynolds O
n O
montgomery O
g O
factor O
analysis O
of O
parkinson O
s O
impairment O
an O
evaluation O
of O
the O
ﬁ O
##nal O
common O
pathway O
arch O
ne O
##uro O
##l O
1987 O
44 O
101 O
##3 O
1016 O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
david O
r O
williams O
phd O
fra O
##cp O
1 O
2 O
max O
cow O
##ey O
bsc O
2 O
kate O
tuck O
bsc O
2 O
and O
bruce O
day O
fra O
##cp O
##2 O

1 O
##fa O
##cu O
##lty O
of O
medicine O
neuroscience O
##s O
mona O
##sh O
university O
alfred O
hospital O
campus O
melbourne O
australia O
2 O
##ne O
##uro O
##logy O
department O
the O
alfred O
hospital O
melbourne O
australia O
video O

abstract O
we O
report O
a O
case O
of O
probable O
psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
in O
a O
patient O
who O
developed O
a O
sudden O
onset O
of O
di O
##sa O
##bling O
axial O
ﬂ O
##ex O
##or O
my O
##oc O
##lon O
##us O
following O
a O
cosmetic O
surgical O
procedure O
the O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
were O
consistent O
with O
previous O
reports O
of O
ps O
##m O
spontaneous O
re O
##mission O
##s O
and O
disappearance O
of O
the O
jerk O
##s O
sustained O
for O
2 O
years O
following O
removal O
of O
super O
##ﬁ O
##cial O
surgical O
screw O
##s O
support O
the O
diagnosis O
of O
a O
psycho O
##genic O
movement O
disorder O
2008 O
movement O
disorder O
society O
key O
words O
psycho O
##genic O
my O
##oc O
##lon O
##us O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O

prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
ps O
##m O
is O
a O
form O
of O
spinal O
my O
##oc O
##lon O
##us O
characterized O
by O
involvement O
of O
muscles O
inner O
##vate O
##d O
from O
different O
segments O
of O
the O
spinal O
cord O
and O
sequential O
##ly O
activated O
via O
prop O
##rio O
##sp O
##inal O
pathways O
1 O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
of O
slow O
conduct O
##ion O
and O
selective O
recruitment O
of O
tr O
##un O
##cal O
and O
pro O
##xi O
##mal O
this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
dr O
david O
r O
williams O
neuroscience O
##s O
alfred O
hospital O
commercial O
road O
melbourne O
300 O
##4 O
australia O

e O
mail O
david O
williams O
med O
mona O
##sh O
ed O
##u O
au O
received O
22 O
january O
2008 O
revised O
16 O
april O
2008 O
accepted O
17 O
april O
2008 O
received O
4 O
july O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O
2008 O
published O
online O
15 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##2 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

limb O
muscles O
help O
differentiate O
ps O
##m O
from O
spinal O
segment O
##al O
my O
##oc O
##lon O
##us O
2 O
ps O
##m O
has O
been O
documented O
secondary O
to O
intrinsic O
and O
ex O
##tri O
##ns O
##ic O
spinal O
cord O
lesions O
and O
in O
other O
cases O
no O
clear O
et O
##iology O
has O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
recently O
the O
characteristic O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
have O
been O
reported O
in O
a O
group O
of O
eight O
healthy O
volunteers O
sim O
##ulating O
the O
typical O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
of O
ps O
##m O
3 O
the O
differentiation O
between O
voluntary O
and O
involuntary O
movements O
of O
this O
nature O
is O
further O
blurred O
by O
our O
report O
of O
a O
patient O
with O
probable O
psycho O
##genic O
ps O
##m O
case O
report O

psycho O
##genic O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
131 O
##3 O
fig O
1 O
0 O
7 O
seconds O
epoch O
of O
order O
of O
activation O
study O
demonstrating O
surface O
em O
##g O
bursts O
in O
pe O
##ctor O
##alis O
pe O
##ct O
followed O
by O
stern O
##oma O
##sto O
##id O
sc O
##m O
and O
upper O
up O
##ab O
and O
lower O
abdominal O
muscles O
lo O
##ab O
solid O
line O
onset O
of O
jerk O
years O
after O
surgery O
at O
the O
patient O
s O
insistence O
and O
the O
axial O
jerk O
##s O
coincidentally O
resolved O
completely O
she O
returned O
to O
normal O
function O
and O
was O
sy O
##mpt O
##om O
free O
at O
follow O
up O
2 O
years O
later O
electro O
##phy O
##sio O
##logical O
investigations O

two O
years O
after O
the O
onset O
of O
jerking O
routine O
ee O
##g O
was O
normal O
median O
nerve O
sensory O
ev O
##oked O
potential O
##s O
were O
normal O
a O
jerk O
locked O
back O
averaged O
ee O
##g O
did O
not O
show O
pre O
movement O
co O
##rti O
##cal O
potential O
##s O
an O
order O
of O
activation O
study O
showed O
variable O
muscle O
activation O
but O
the O
most O
frequent O
pattern O
of O
activation O
was O
ca O
##uda O
##l O
from O
pe O
##ctor O
##al O
to O
abdominal O
muscles O
with O
propagation O
estimated O
at O
9 O
to O
15 O
m O
s O
see O
figure O
1 O
em O
##g O
burst O
length O
was O
between O
50 O
and O
150 O
mill O
##ise O
##con O
##ds O
discussion O

this O
patient O
had O
some O
clinical O
and O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
previous O
reports O
of O
ps O
##m O
as O
well O
as O
features O
not O
usually O
reported O
to O
be O
associated O
such O
as O
ga O
##it O
un O
##stead O
##iness O
and O
axial O
jerk O
##s O
while O
standing O
unusually O
for O
ps O
##m O
there O
were O
periods O
of O
spontaneous O
re O
##mission O
and O
no O
id O
##ent O
##i O
##ﬁ O
##able O
path O
##ological O
les O
##ion O
to O
account O
for O
the O
my O
##oc O
##lon O
##us O
the O
sudden O
onset O
con O
##tem O
##por O
##aneous O
legal O
proceedings O
related O
to O
the O
injury O
the O
associated O
anxiety O
and O
spontaneous O
complete O
re O
##mission O
are O
supportive O
of O
a O
psycho O
##genic O
et O
##iology O
4 O

a O
psycho O
##genic O
et O
##iology O
should O
be O
considered O
when O
patients O
develop O
axial O
ﬂ O
##ex O
##or O
jerk O
##s O
that O
occur O
when O
lying O
and O
standing O
without O
id O
##ent O
##i O
##ﬁ O
##able O
central O
nervous O
system O
lesions O
even O
in O
the O
presence O
of O
suggest O
##ive O
electro O
##phy O
##sio O
##logical O
ﬁ O
##nding O
##s O
spontaneous O
re O
##mission O
##s O
may O
differentiate O
psycho O
##genic O
and O
organic O
ps O
##m O
legends O
to O
the O
video O
the O
patient O
is O
shown O
lying O
su O
##pine O
with O
bursts O
of O
spontaneous O
axial O
jerk O
##s O
occurring O
at O
rest O
without O
stimulation O
references O
brown O
p O
thompson O
pd O
roth O
##well O
jc O
day O
b O
##l O
marsden O
cd O
axial O
my O
##oc O
##lon O
##us O
of O
prop O
##rio O
##sp O
##inal O
origin O
brain O
1991 O
114 O
197 O
214 O

roth O
##well O
jc O
path O
##op O
##hy O
##sio O
##logy O
of O
spinal O
my O
##oc O
##lon O
##us O
ad O
##v O
ne O
##uro O
##l O
2002 O
89 O
137 O
144 O
kang O
sy O
so O
##hn O
y O
##h O
electro O
##my O
##ography O
patterns O
of O
prop O
##rio O
##sp O
##inal O
my O
##oc O
##lon O
##us O
can O
be O
mimic O
##ked O
voluntarily O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
124 O
##1 O
124 O
##4 O
fa O
##hn O
s O
williams O
dt O
psycho O
##genic O
d O
##yst O
##onia O
ad O
##v O
ne O
##uro O
##l O
1988 O
50 O
43 O
##1 O
45 O
##5 O
davies O
l O
king O
p O
##j O
leicester O
j O
morris O
j O
##g O
rec O
##umb O
##ent O
ti O
##c O
mo O
##v O
di O
##sor O
##d O
1992 O
7 O
35 O
##9 O
36 O
##3 O
brown O
j O
lan O
##tos O
p O
st O
##rat O
##ton O
m O
ro O
##ques O
p O
ross O
##or O
m O
fa O
##mi O
##lia O
##l O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1993 O
56 O
47 O
##3 O
47 O
##6 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##4 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O
potassium O
channel O
block O
##er O

4 O
amino O
##py O
##rid O
##ine O
is O
effective O
in O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
symptoms O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
a O
video O
case O
report O
matthias O
lo O
##¨ O
##hl O
##e O
md O
wi O
##eb O
##ke O
sc O
##hre O
##mp O
##f O
md O
martin O
wo O
##lz O
md O
heinz O
reich O
##mann O
md O
phd O
and O
alexander O
st O
##or O
##ch O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
of O
dresden O
dresden O
germany O
video O

8 O
5 O
to O
4 O
5 O
points O
we O
conclude O
that O
4 O
ap O
may O
be O
ben O
##e O
##ﬁ O
##cial O
for O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
in O
late O
onset O
ea O
##2 O
2008 O
movement O
disorder O
society O
key O
words O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
4 O
amino O
##py O
##rid O
##ine O
inter O
##ic O
##tal O
ata O
##xia O
sara O
video O
case O
report O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ea O
##2 O
is O
a O
rare O
auto O
##som O
##aldo O
##mina O
##nt O
hereditary O
disorder O
caused O
by O
mutations O
of O
the O
calcium O
channel O
gene O
ca O
##c O
##na O
##1 O
##a O
on O
chromosome O
19 O
##p O
##13 O
1 O
this O
gene O
codes O
for O
the O
ca O
##v O
##2 O
1 O
subunit O
of O
the O
p O
q O
type O
calcium O
channel O
which O
is O
expressed O
throughout O
the O
nervous O
system O
but O
mainly O
in O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O

this O
article O
includes O
supplementary O
video O
clips O
available O
online O
at O
http O
www O
inter O
##sc O
##ience O
wiley O
com O
jp O
##ages O
08 O
##85 O
318 O
##5 O
su O
##pp O
##mat O
correspondence O
to O
dr O
matthias O
lo O
##¨ O
##hl O
##e O
k O
##lini O
##k O
und O
pol O
##ik O
##lini O
##k O
fu O
##¨ O
##r O
ne O
##uro O
##logie O
fe O
##ts O
##chers O
##tra O
##sse O
74 O
01 O
##30 O
##7 O
dresden O
germany O
e O
mail O
matthias O
lo O
##eh O
##le O
ne O
##uro O
med O
tu O
dresden O
de O
received O
27 O
august O
2007 O
revised O
6 O
march O
2008 O
accepted O
12 O
march O
2008 O
published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##1 O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O

4 O
amino O
##py O
##rid O
##ine O
in O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
131 O
##5 O
and O
headache O
##s O
a O
half O
sister O
complained O
about O
chronic O
headache O
##s O

evaluation O
##s O
after O
informed O
consent O
for O
video O
##ta O
##ping O
had O
been O
given O
the O
patient O
was O
asked O
to O
pause O
treatment O
with O
4a O
##p O
for O
24 O
hours O
and O
after O
that O
was O
video O
##ta O
##ped O
and O
rated O
according O
to O
the O
recently O
valid O
##ated O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
sara O
4 O
the O
patient O
was O
then O
given O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
and O
video O
##ta O
##ped O
and O
rated O
again O
as O
soon O
as O
she O
realized O
improvement O
of O
her O
symptoms O
a O
ﬁ O
##nal O
evaluation O
was O
done O
after O
the O
patient O
had O
taken O
3 O
3 O
5 O
mg O
4 O
ap O
over O
24 O

discussion O
our O
report O
con O
##ﬁ O
##rm O
##s O
previous O
observations O
that O
4 O
ap O
treatment O
offers O
an O
option O
for O
ea O
##2 O
patients O
in O
whom O
act O
##z O
failed O
to O
relieve O
symptoms O
although O
4 O
ap O
in O
previous O
studies O
has O
shown O
to O
be O
effective O
in O
preventing O
or O
at O
##ten O
##uating O
ata O
##xia O
attacks O
3 O
our O
report O
for O
the O
ﬁ O
##rst O
time O
suggests O
that O
4 O
ap O
may O
also O
be O
ben O
##e O
##ﬁ O
##cial O
for O
patients O
with O
late O
onset O
of O
ea O
##2 O
in O
whom O
inter O
##ic O
##tal O
ce O
##re O
##bella O
##r O
ata O
##xia O
has O
become O
the O
key O
clinical O
feature O

because O
of O
the O
ca O
##c O
##na O
##1 O
##a O
mutation O
current O
density O
from O
ca O
##v O
##2 O
1 O
channels O
in O
ea O
##2 O
is O
reduced O
which O
may O
lead O
to O
a O
general O
reduction O
in O
pu O
##rkin O
##je O
cell O
ﬁ O
##ring O
rates O
and O
a O
loss O
of O
inhibition O
at O
deep O
ce O
##re O
##bella O
##r O
nuclei O
5 O
an O
##i O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##6 O
m O
lo O
##¨ O
##hl O
##e O
et O
al O

future O
treatment O
trials O
are O
warrant O
##ed O
to O
evaluate O
and O
compare O
the O
therapeutic O
effects O
of O
act O
##z O
and O
4 O
ap O
these O
trials O
should O
examine O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
both O
drugs O
on O
attacks O
as O
well O
as O
on O
inter O
##ic O
##tal O
ata O
##xia O
in O
order O
to O
identify O
the O
best O
treatment O
for O
patients O
of O
various O
ages O
and O
different O
disease O
stages O
legends O
to O
the O
video O
full O
video O
references O
jen O
j O
kim O
g O
##w O
bal O
##oh O
r O
##w O
clinical O
spectrum O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##logy O
2004 O
62 O
17 O
22 O
st O
##rup O
##p O
m O
z O
##wer O
##gal O
a O
brandt O
t O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
ne O
##uro O
##ther O
##ape O
##uti O
##cs O
2007 O
4 O
276 O
273 O
st O
##rup O
##p O
m O
ka O
##lla O
r O
di O
##ch O
##gan O
##s O
m O
fr O
##eil O
##inger O
t O
g O
##las O
##auer O
s O
brandt O

t O
treatment O
of O
ep O
##iso O
##dic O
ata O
##xia O
type O
2 O
with O
the O
potassium O
channel O
block O
##er O
4 O
amino O
##py O
##rid O
##ine O
ne O
##uro O
##logy O
2004 O
62 O
1623 O
1625 O
sc O
##hmi O
##tz O
hub O
##sch O
t O
du O
mont O
##cel O
st O
bali O
##ko O
l O
et O
al O
scale O
for O
the O
assessment O
and O
rating O
of O
ata O
##xia O
development O
of O
a O
new O
clinical O
scale O
ne O
##uro O
##logy O
2006 O
66 O
1717 O
1720 O
wei O
##sz O
c O
##j O
rai O
##ke O
rs O
so O
##ria O
ja O
##sso O
le O
hess O
e O
##j O
potassium O
channel O
block O
##ers O
inhibit O
the O
triggers O
of O
attacks O
in O
the O
calcium O
channel O
mouse O
mutant O
to O
##ttering O
j O
ne O
##uro O
##sc O
##i O
2005 O
25 O
41 O
##41 O
41 O
##45 O

et O
##zio O
##n O
y O
gross O
##man O
y O
highly O
4 O
amino O
##py O
##rid O
##ine O
sensitive O
delayed O
rec O
##ti O
##ﬁ O
##er O
current O
mod O
##ulates O
the O
ex O
##cit O
##ability O
of O
guinea O
pig O
ce O
##re O
##bella O
##r O
pu O
##rkin O
##je O
cells O
ex O
##p O
brain O
res O
2001 O
139 O
41 O
##9 O
425 O
hayes O
kc O
katz O
ma O
dev O
##ane O
j O
##g O
et O
al O
ph O
##arm O
##aco O
##kin O
##etic O
##s O
of O
an O
immediate O
release O
oral O
formulation O
of O
fa O
##mp O
##rid O
##ine O
4 O
amino O
##py O
##rid O
##ine O
in O
normal O
subjects O
and O
patients O
with O
spinal O
cord O
injury O
j O
cl O
##in O
ph O
##arm O
##aco O
##l O
2003 O
43 O
37 O
##9 O
385 O
time O
content O
00 O
00 O
00 O
00 O
00 O
23 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O
attempt O
of O
tandem O
walking O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O
00 O
00 O
24 O
00 O
00 O
44 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O

attempt O
of O
tandem O
walking O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
00 O
00 O
45 O
00 O
01 O
01 O
patient O
during O
normal O
ga O
##it O
half O
turn O
and O
attempt O
of O
tandem O
walking O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O
00 O
01 O
02 O
00 O
01 O
47 O
patient O
during O
normal O
stance O
stance O
with O
feet O
together O
and O
tandem O
stance O
after O
24 O
hr O
withdrawal O
of O
4 O
ap O
00 O
01 O
48 O
00 O
02 O
29 O
patient O
during O
normal O
stance O
stance O
with O
feet O
together O
and O
tandem O
stance O
1 O
hr O
after O
a O
single O
dose O
of O
5 O
mg O
4 O
ap O
00 O
02 O
30 O
00 O
03 O
06 O
patient O
during O
normal O
stance O
stance O
with O
feet O
together O
and O
tandem O
stance O
after O
treatment O
with O
3 O
3 O
5 O
mg O
4 O
ap O
per O
day O

movement O
disorders O
vol O
23 O
no O
9 O
2008 O
dex O
##med O
##eto O
##mi O
##dine O
arousal O
se O
##dation O
and O
st O
##n O
neurons O
131 O
##7 O
dex O
##med O
##eto O
##mi O
##dine O
and O
arousal O
affect O
sub O
##thal O
##ami O
##c O
neurons O
william O
jeffrey O
elias O
md O
1 O
marcel O
e O
du O
##rie O
##ux O
md O
2 O
diane O
hu O
##ss O
p O
t O
ms O
##ed O
nc O
##s O
3 O
and O
robert O
c O
fry O
##sing O
##er O
phd O
##1 O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##sur O
##ger O
##y O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
2d O
##ep O
##art O
##ment O
of O
an O
##est O
##hes O
##iology O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O
3d O
##ep O
##art O
##ment O
of O
physical O
therapy O
university O
of O
virginia O
charlotte O
##sville O
virginia O
usa O

key O
words O
dex O
##med O
##eto O
##mi O
##dine O
deep O
brain O
stimulation O
sub O
##thal O
##ami O
##c O
nucleus O
micro O
##ele O
##ct O
##rod O
##e O
recording O
deep O
brain O
stimulation O
db O
##s O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
has O
proven O
effective O
for O
treating O
the O
motor O
symptoms O
of O
parkinson O
s O
disease O
pd O
the O
st O
##n O
is O
relatively O
small O
and O
deep O
1 O
man O
##dating O
some O
form O
of O
intra O
##oper O
##ative O
local O
##ization O
for O
this O
reason O
local O
##izing O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
and O
test O
stimulation O
have O
become O
routine O
traditionally O
mer O
and O
intra O

correspondence O
to O
w O
jeffrey O
elias O
md O
department O
of O
neurological O
surgery O
university O
of O
virginia O
box O
800 O
##21 O
##2 O
charlotte O
##sville O
va O
229 O
##0 O
##8 O
e O
mail O
w O
##je O
##4 O
##r O
virginia O
ed O
##u O
this O
work O
was O
presented O
in O
poster O
format O
at O
the O
american O
society O
of O
stereo O
##ta O
##ctic O
and O
functional O
ne O
##uro O
##sur O
##ge O
##ons O
in O
boston O
massachusetts O
june O
2006 O
received O
9 O
may O
2007 O
revised O
9 O
october O
2007 O
accepted O
18 O
march O
2008 O
published O
online O
28 O
april O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##80 O

dex O
##med O
##eto O
##mi O
##dine O
pre O
##cede O
##x O
is O
an O
attractive O
se O
##da O
ti O
##ve O
for O
use O
in O
ne O
##uro O
##sur O
##gical O
procedures O
because O
of O
its O
minimal O
respiratory O
de O
##press O
##ant O
effects O
hem O
##od O
##yna O
##mic O
stab O
##ili O
##zing O
properties O
and O
rapid O
onset O
and O
offset O
initially O
approved O
for O
ic O
##u O
se O
##dation O
this O
a O
2 O
ago O
##nist O
affects O
receptors O
primarily O
in O
the O
locus O
ce O
##ru O
##le O
##us O
with O
minimal O
effects O
on O
cerebral O
cortex O
8 O
this O
results O
in O
a O
unique O
cooperative O
se O
##dation O
where O
patients O
may O
fall O
asleep O
but O
are O
easily O
aroused O
9 O
a O
recent O
report O
suggests O
that O
patient O
cooperation O
pd O

stefan O
##i O
et O
al O
found O
that O
spontaneous O
sleep O
can O
have O
a O
profound O
impact O
on O
the O
discharge O
of O
st O
##n O
neurons O
11 O
this O
suggests O
that O
behavioral O
arousal O
could O
play O
a O
clinical O
##ly O
relevant O
role O
in O
mer O
local O
##ization O
because O
patients O
may O
fall O
asleep O
even O
with O
low O
doses O
of O
dex O
##med O
##eto O
##mi O
##dine O
sleep O
waking O
state O
may O
be O
a O
factor O
related O
to O
an O
##xi O
##ol O
##ysis O
rather O
than O
frank O
se O
##dation O
in O
an O
effort O
to O
reduce O
discomfort O
and O
anxiety O
in O
our O
patients O
during O
db O
##s O
procedures O
we O
utilize O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
for O
se O
##dation O
here O
we O
report O
our O
observations O
of O
the O
effects O
of O
dex O
##med O
##eto O
##mi O
##dine O
on O
st O
##n O
mer O
methods O

we O
reviewed O
operative O
an O
##est O
##hetic O
and O
mer O
records O
from O
11 O
consecutive O
cases O
of O
patients O
with O
parkinson O
s O
movement O
disorders O
vol O
23 O
no O
9 O
2008 O
131 O
##8 O
w O
j O
elias O
et O
al O
disease O
who O
underwent O
st O
##n O
db O
##s O
electrode O
implant O
##ation O
during O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
se O
##dation O
surgery O

parkinson O
medications O
were O
held O
on O
the O
day O
of O
surgery O
and O
a O
le O
##ks O
##ell O
stereo O
##ta O
##ctic O
frame O
was O
placed O
using O
local O
an O
##esthesia O
direct O
targeting O
was O
based O
on O
t O
##2 O
and O
mp O
rage O
volume O
##tric O
mr O
12 O
the O
patient O
was O
placed O
in O
a O
semi O
##re O
##cum O
##ben O
##t O
position O
with O
the O
frame O
locked O
to O
the O
operating O
table O
blood O
pressure O
was O
monitored O
by O
an O
automatic O
cuff O
spontaneous O
res O
##piration O
was O
monitored O
along O
with O
o O
##2 O
sat O
##uration O
se O
##dation O
se O
##dation O
was O
provided O
with O
continuous O
in O
##fusion O
of O
intra O
##ven O
##ous O
dex O
##med O
##eto O
##mi O
##dine O
which O
usually O
started O
at O

0 O
7 O
mc O
##g O
kg O
hr O
and O
ti O
##tra O
##ted O
down O
based O
on O
clinical O
response O
in O
several O
patients O
an O
initial O
loading O
dose O
of O
1 O
mc O
##g O
kg O
was O
administered O
over O
20 O
min O
level O
of O
consciousness O
was O
assessed O
by O
the O
ne O
##uro O
##sur O
##ge O
##on O
and O
an O
##est O
##hes O
##iol O
##ogist O
using O
observation O
and O
verbal O
questioning O
the O
bis O
##pe O
##ct O
##ral O
index O
bis O
helped O
to O
estimate O
the O
level O
of O
co O
##rti O
##cal O
arousal O
##13 O
bis O
5 O
80 O
to O
100 O
suggests O
awake O
and O
alert O
bis O
5 O
60 O
to O
80 O
varying O
levels O
of O
se O
##dation O
and O
bis O
5 O
40 O
to O
60 O
general O
an O
##esthesia O

se O
##dation O
was O
ti O
##tra O
##ted O
to O
patient O
comfort O
and O
was O
transient O
##ly O
increased O
during O
bu O
##r O
hole O
placement O
no O
other O
drugs O
with O
se O
##da O
##tive O
properties O
were O
administered O
micro O
##ele O
##ct O
##rod O
##e O
recording O
mer O
was O
initiated O
25 O
mm O
above O
the O
target O
and O
recorded O
on O
an O
alpha O
omega O
system O
sample O
recordings O
were O
saved O
every O
0 O
5 O
mm O
during O
the O
trajectory O
we O
did O
not O
test O
for O
motor O
driving O
of O
neurons O
following O
satisfactory O
mer O
and O
intra O
##oper O
##ative O
macro O
##sti O
##mu O
##lation O
testing O
the O
db O
##s O
electrode O
was O
anchored O
in O
position O
and O
con O
##ﬁ O
##rmed O
with O
ﬂ O
##uo O
##ros O
##co O
##py O
post O
##oper O
##ative O

movement O
disorders O

vol O
23 O
no O
11 O
2008 O
pp O
161 O
##3 O
162 O
##7 O

2008 O
movement O
disorder O
society O

letters O
to O
the O
editor O
related O
to O
new O
topics O

alexander O
disease O
causing O
hereditary O
late O
onset O
ata O
##xia O
with O
only O
minimal O
white O

matter O
changes O
a O
report O
of O
two O
si O
##bs O

video O

classic O
alexander O
disease O
refers O
to O
a O
rare O
ne O
##uro O
##de O
##gen O
##erative O
le O
##uk O
##od O
##yst O
##rop O
##hy O
typically O
manifest O
##ing O
in O
early O
childhood O
with O
mega O
##loe O
##nce O
##pha O
##ly O
seizures O
spa O
##stic O
##ity O
and O
psycho O
##moto O
##r O
regression O
until O
recently O
its O
diagnosis O
was O
based O
on O
distinctive O
mri O
features O
such O
as O
white O
matter O
lesions O
that O
predominantly O
affect O
the O
front O
##ote O
##mp O
##ora O
##l O
and O
per O
##ive O
##nt O
##ric O
##ular O
regions O
the O
ﬁ O
##nding O
of O
ca O
##usa O
##tive O
mutations O
in O
the O
g O
##fa O
##p O
gene O
has O
enabled O
diagnostic O
con O
##ﬁ O
##rma O
##tion O
by O
mutation O
analysis O
this O
has O
also O
lead O
to O
the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
at O
##yp O
##ical O
and O
late O
onset O
cases O
with O
a O
highly O
variable O
spectrum O
of O
clinical O
and O
imaging O
abnormalities O

we O
report O
a O
case O
of O
an O
adult O
onset O
mutation O
proven O
alexander O
disease O
characterized O
by O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
the O
absence O
of O
pal O
##atal O
tremor O
and O
very O
mild O
white O
matter O
changes O
1 O
2 O

this O
61 O
year O
old O
man O
presented O
at O
the O
age O
of O
50 O
years O
with O
slowly O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
his O
past O
medical O
history O
revealed O
the O
onset O
of O
static O
but O
marked O
forward O
ﬂ O
##ex O
##ion O
of O
the O
trunk O
in O
his O
ﬁ O
##rst O
decade O
but O
without O
any O
motor O
abnormalities O
until O
recently O
his O
sister O
had O
been O
diagnosed O
with O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
there O
were O
no O
other O
affected O
relatives O

neurological O
examination O
see O
video O
revealed O
a O
normal O
mental O
status O
jerk O
##y O
pursuit O
and O
d O
##ys O
##metric O
sac O
##cade O
##s O
mild O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
mild O
ata O
##xia O
of O
the O
trunk O
and O
ex O
##tre O
##mit O
##ies O
that O
increased O
upon O
eye O
closure O
a O
broad O
based O
ata O
##xi O
##c O
ga O
##it O
cervical O
ky O
##ph O
##osis O
and O
thor O
##ac O
##ic O
sc O
##olio O
##sis O
with O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
hips O
and O
knees O
positive O
rom O
##berg O
s O
sign O
disturbed O
vibration O
sense O
in O
the O
lower O
limbs O
slightly O
diminished O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
in O
the O
lower O
ex O
##tre O
##mit O
##ies O
with O
normal O
plant O
##ar O
responses O

we O
screened O
for O
several O
of O
the O
genetic O
ata O
##xia O
##s O
but O
no O
mutations O
were O
detected O
in O
the O
sc O
##a1 O
2 O
3 O
6 O
7 O
14 O
genes O
or O
in O
the O
genes O
responsible O
for O
fried O
##re O
##ich O
s O
ata O
##xia O
and O
dent O
##ator O
##ub O
##ro O
pal O
##lid O
##o O
lu O
##ys O
##ian O
at O
##rop O
##hy O
electro O
##my O
##ography O
showed O
no O
signs O
of O
ne O
##uro O
##pathy O
or O
my O
##opa O
##thy O
ss O
##ep O
was O
not O
performed O
mri O
demonstrated O
subtle O
white O
matter O
lesions O
anterior O
##ly O
in O
both O
temporal O
lobes O
as O
well O
as O
mild O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bell O
##um O
brains O
##tem O
and O
cervical O
spinal O
cord O
on O
standard O
mri O
imaging O
fig O
1a O
c O

additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##53 O

the O
records O
of O
the O
affected O
sister O
who O
died O
at O
the O
age O
of O
64 O
mentioned O
horizontal O
ny O
##sta O
##gm O
##us O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
limb O
ata O
##xia O
and O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
addition O
the O
presence O
of O
pal O
##atal O
my O
##oc O
##lon O
##us O
was O
noted O
once O
while O
the O
d O
##ys O
##arth O
##ria O
was O
said O
to O
exist O
from O
an O
early O
age O
the O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
arose O
at O
the O
age O
of O
30 O
brain O
imaging O
at O
age O
58 O
years O
showed O
ce O
##re O
##bella O
##r O
and O
marked O
bulb O
##ome O
##du O
##llar O
at O
##rop O
##hy O
as O
well O
as O
white O
matter O
lesions O
in O
the O
per O
##ive O
##nt O
##ric O
##ular O
region O
corpus O
call O
##os O
##um O
and O
right O
medial O
ce O
##re O
##bella O
##r O
pe O
##dun O
##cle O
fig O
1 O
##d O
f O

as O
these O
combined O
clinical O
and O
imaging O
features O
were O
suggest O
##ive O
of O
alexander O
disease O
we O
sequence O
##d O
the O
g O
##fa O
##p O
gene O
and O
found O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
c O
69 O
##2 O
##t O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
4 O
predicting O
a O
p O
le O
##u O
##23 O
##1 O
##his O
amino O
acid O
change O
this O
mutation O
was O
not O
encountered O
in O
210 O
control O
chromosomes O

several O
cases O
of O
adult O
onset O
alexander O
disease O
have O
been O
reported O
mostly O
with O
an O
onset O
in O
the O
third O
or O
fourth O
decade O
of O
life O
ph O
##eno O
##typic O
het O
##ero O
##gen O
##eit O
##y O
is O
evident O
from O
the O
variable O
presence O
of O
bulb O
##ar O
symptoms O
ce O
##re O
##bella O
##r O
signs O
pal O
##atal O
tremor O
spa O
##stic O
par O
##esis O
and O
auto O
##no O
##mic O
dysfunction O

the O
index O
patient O
reported O
here O
displays O
a O
rather O
unique O
ph O
##eno O
##type O
of O
adult O
onset O
alexander O
disease O
first O
his O
age O
at O
onset O
was O
50 O
years O
which O
is O
one O
of O
the O
latest O
ever O
reported O
3 O
second O
his O
clinical O
presentation O
was O
dominated O
by O
the O
combined O
presence O
of O
slowly O
progressive O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
in O
the O
absence O
of O
pal O
##atal O
tremor O
the O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
his O
knee O
bent O
posture O
are O
very O
likely O
related O
to O
his O
alexander O
disease O
as O
these O
features O
have O
been O
observed O
previously O
4 O
13 O
yet O
the O
interval O
to O
the O
onset O
of O
ata O
##xia O
in O
our O
case O
is O
remarkable O
third O
ne O
##uro O
##ima O
##ging O
in O
our O
patient O
revealed O
ce O
##re O
##bella O
##r O
brains O
##tem O
and O
spinal O
cord O
at O
##rop O
##hy O
all O
previously O
reported O
imaging O
features O
of O
alexander O
disease O
but O
the O
white O
matter O
changes O
were O
extremely O
subtle O
involving O
a O
minor O
portion O
of O
the O
anterior O
poles O
of O
both O
temporal O
lobes O
only O
mri O
abnormalities O
in O
adult O
onset O
alexander O
disease O
are O
het O
##ero O
##gen O
##eous O
but O
the O
white O
matter O
changes O
are O
generally O
less O
extensive O
compared O
with O
the O
classic O
early O
onset O
disease O
17 O

the O
give O
away O
in O
this O
case O
was O
the O
presence O
of O
a O
pa O
##pt O
syndrome O
in O
the O
patient O
s O
sister O
the O
combination O
of O
ce O
##re O
##bella O
##r O
ata O
##xia O
and O
pal O
##atal O
tremor O
is O
relatively O
common O
in O
adult O
##ons O
##et O
alexander O
disease O
43 O
4 O
9 O
12 O
14 O
this O
clinical O
constellation O
is O
presently O
referred O
to O
as O
pa O
##pt O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
used O
to O
indicate O
a O
subgroup O
of O
the O
sy O
##mpt O
##oma O
##tic O
pal O
##atal O
tremor O
in O
which O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
are O
involved O
in O
case O
of O
a O
fa O
##mi O
##lia O
##l O
pa O
##pt O
the O
differential O
diagnosis O
is O
quite O
limited O
and O
in O
addition O
to O
alexander O
disease O
also O
includes O
sc O
##a O
##20 O
and O
perhaps O
other O
forms O
of O
de O
##gen O
##erative O
ce O
##re O
##bella O
##r O
ata O
##xia O
##s O
15 O
16 O

in O
conclusion O
we O
report O
two O
si O
##bs O
with O
late O
onset O
ata O
##xia O
due O
to O
alexander O
disease O
caused O
by O
a O
novel O
g O
##fa O
##p O
mutation O
alexander O
disease O
should O
thus O
be O
considered O
in O
the O
differential O
diagnosis O
of O
otherwise O
une O
##x O
##pl O
##aine O
##d O
hereditary O
late O
onset O

161 O
##3 O

161 O
##4 O
letters O
to O
the O
editor O

fig O
1 O
brain O
and O
cervical O
spine O
mri O
images O
of O
the O
index O
case O
a O
c O
and O
affected O
sister O
d O
f O
a O
subtle O
white O
matter O
changes O
in O
the O
anterior O
parts O
of O
left O
more O
than O
right O
temporal O
lobe O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bella O
##r O
hemisphere O
##s O
with O
en O
##lar O
##gement O
of O
the O
4th O
vent O
##ric O
##le O
axial O
t O
##2 O
b O
marked O
at O
##rop O
##hy O
of O
the O
lower O
med O
##ulla O
axial O
t O
##1 O
c O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
upper O
part O
of O
spinal O
cord O
the O
presence O
of O
sc O
##olio O
##sis O
is O
also O
evident O
axial O
t O
##2 O
d O
white O
matter O
defect O
in O
right O
medial O
ce O
##re O
##bella O
##r O
pe O
##dun O
##cle O
axial O
t O
##2 O
e O
white O
matter O
les O
##ion O
in O
the O
left O
per O
##ive O
##nt O
##ric O
##ular O
region O
axial O
t O
##2 O

f O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
and O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
with O
spa O
##ring O
of O
the O
po O
##ns O
and O
cervical O
spinal O
cord O
a O
small O
les O
##ion O
in O
the O
anterior O
part O
of O
the O
corpus O
call O
##os O
##um O
there O
are O
in O
addition O
high O
signal O
par O
##en O
##chy O
##mal O
changes O
in O
the O
posterior O
med O
##ulla O
and O
ce O
##re O
##bella O
##r O
white O
matter O
sa O
##git O
##tal O
flair O

ata O
##xia O
additional O
yet O
not O
ob O
##liga O
##te O
clinical O
features O
pal O
##atal O
tremor O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
more O
or O
less O
distinctive O
mri O
ﬁ O
##nding O
##s O
subtle O
white O
matter O
changes O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
spinal O
cord O
might O
constitute O
clues O
that O
hint O
towards O
this O
spec O
##i O
##ﬁ O
##c O
diagnosis O

legends O
to O
the O
video O

segment O
1 O
mild O
ata O
##xi O
##c O
and O
bouncing O
ga O
##it O
note O
the O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
knees O
di O
##f O
##ﬁ O
##cu O
##lty O
tandem O
walking O

segment O
2 O
bent O
hip O
and O
bent O
knee O
posture O

segment O
3 O
o O
##cular O
pursuit O
showing O
jerk O
##y O
pursuit O
movements O

segment O
4 O
horizontal O
sac O
##cade O
##s O
showing O
multi O
step O
sac O
##cade O
##s O
and O
o O
##cular O
d O
##ys O
##met O
##ria O
both O
h O
##yp O
##ometric O
and O
hyper O
##metric O

segment O
5 O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
on O
repeating O
the O
dutch O
sentence O
rode O
ron O
##de O
app O
##els O
roll O
##en O
van O
de O
z O
##old O
##ert O
##ra O
##p O
and O
on O
repeating O
pat O
##aka O

segment O
6 O
mild O
decomposition O
of O
movement O
during O
ﬁ O
##nger O
to O
nose O
testing O

catherine O
c O
s O
del O
##no O
##oz O
md O
jurgen O
h O
sc O
##hel O
##ha O
##as O
md O
phd O

bart O
p O
c O
van O
de O
warren O
##burg O
md O
phd O

department O
of O
ne O
##uro O
##logy O
ra O
##db O
##oud O
university O
ni O
##jm O
##ege O
##n O
medical O
center O

ni O
##jm O
##ege O
##n O
the O
netherlands O

e O
mail O
b O
van O
##de O
##war O
##ren O
##burg O
ne O
##uro O
um O
##c O
##n O
nl O

robert O
jan O
de O
gr O
##aa O
##f O
md O

department O
of O
ne O
##uro O
##logy O
amp O
##hia O
hospital O
bred O
##a O
o O
##ost O
##er O
##ho O
##ut O

the O
netherlands O

ga O
##j O
##ja O
s O
sal O
##omo O
##ns O
phd O

department O
of O
clinical O
chemistry O

metabolic O
unit O
vu O
university O
medical O
center O
amsterdam O
the O
netherlands O

references O

johnson O
a O
alexander O
disease O
review O
of O
the O
gene O
int O
j O
dev O
ne O
##uro O
##sc O
##i O
2002 O
20 O
39 O
##1 O
39 O
##4 O

li O
r O
johnson O
ab O
sal O
##omo O
##ns O
g O
et O
al O
g O
##fa O
##p O
mutations O
in O
infant O
##ile O
juvenile O
and O
adult O
forms O
of O
alexander O
disease O
ann O
ne O
##uro O
##l O
2005 O
57 O
310 O
326 O

howard O
k O
##l O
hall O
da O
moon O
m O
ag O
##ar O
##wal O
p O
newman O
e O
br O
##enne O
##r O

m O
adult O
onset O
alexander O
disease O
with O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
mo O
##v O
di O
##s O
2008 O
23 O
118 O
122 O

de O
##pre O
##z O
m O
d O
ho O
##og O
##he O
m O
miss O
##on O
jp O
et O
al O
infant O
##ile O
and O
juvenile O
presentations O
of O
alexander O
disease O
a O
report O
of O
two O
cases O
act O
##a O
ne O
##uro O
##l O
scan O
##d O
1999 O
99 O
158 O
165 O

sal O
##ma O
##gg O
##i O
a O
bot O
##tur O
##i O
a O
lamp O
##ert O
##i O
e O
et O
al O
a O
novel O
mutation O
in O
the O
g O
##fa O
##p O
gene O
in O
a O
fa O
##mi O
##lia O
##l O
adult O
onset O
alexander O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
127 O
##8 O
128 O
##0 O

sc O
##hwa O
##nk O
##haus O
j O
paris O
##i O
je O
gu O
##lled O
##ge O
wr O
chin O
l O
currie O
##r O
rd O
hereditary O
adult O
onset O
alexander O
disease O
with O
pal O
##atal O
my O
##oc O
##lon O
##us O
spa O
##stic O
para O
##par O
##esis O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
ne O
##uro O
##logy O
1995 O
45 O
226 O
##6 O
227 O
##1 O

saw O
##ais O
##hi O
##i O
y O
hat O
##az O
##awa O
j O
och O
##i O
n O
et O
al O
pet O
in O
juvenile O
alexander O
disease O
j O
ne O
##uro O
##l O
sci O
1999 O
165 O
116 O
120 O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O

letters O
to O
the O
editor O
161 O
##5 O

non O
##om O
##ura O
y O
shi O
##mi O
##zu O
k O
ni O
##shi O
##moto O
h O
ho O
##so O
##e O
h O
sa O
##ka O
##guchi O
y O
mi O
##yam O
##oto O
k O
sc O
##olio O
##sis O
in O
a O
patient O
with O
alexander O
disease O
j O
spin O
di O
##s O
2002 O
15 O
261 O
264 O

thy O
##aga O
##raj O
##an O
d O
chat O
##away O
t O
li O
r O
ga O
##i O
w O
##p O
br O
##enne O
##r O
m O
dominant O
##ly O
inherited O
adult O
onset O
le O
##uk O
##od O
##yst O
##rop O
##hy O
with O
pal O
##atal O
tremor O
caused O
by O
a O
mutation O
in O
the O
g O
##lia O
##l O
ﬁ O
##bri O
##llary O
acidic O
protein O
mo O
##v O
di O
##s O
2004 O
19 O
124 O
##4 O
124 O
##8 O

ok O
##amo O
##to O
y O
mit O
##su O
##yama O
h O
hi O
##rata O
k O
ari O
##mura O
k O
os O
##ame O
m O
nak O
##agawa O
m O
auto O
##som O
##al O
dominant O
pal O
##atal O
my O
##oc O
##lon O
##us O
and O
spinal O
cord O
at O
##rop O
##hy O
j O
ne O
##uro O
##l O
sci O
2002 O
195 O
71 O
76 O

stump O
##f O
e O
mass O
##on O
h O
du O
##quette O
a O
et O
al O
adult O
alexander O
disease O
with O
auto O
##som O
##al O
transmission O
arch O
ne O
##uro O
##l O
2003 O
60 O
130 O
##7 O
132 O
##0 O

bo O
##rret O
d O
becker O
le O
alexander O
disease O
of O
astro O
##cytes O
brain O
1985 O
108 O
36 O
##7 O
385 O

cole O
g O
de O
villiers O
f O
proctor O
ns O
fr O
##eim O
##an O
i O
bill O
p O
alexander O
disease O
case O
report O
including O
his O
##top O
##ath O
##ological O
and O
electron O
microscopic O
features O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
1979 O
42 O
61 O
##9 O
62 O
##4 O

ku O
##l O
##har O
##ni O
p O
mu O
##than O
##e O
u O
##b O
tal O
##y O
ab O
jaya O
##kumar O
p O
##n O
she O
##tty O
r O
sat O
##hya O
##nar O
##ayan O
##a O
swam O
##y O
h O
pal O
##atal O
tremor O
progressive O
multiple O
cr O
##anial O
nerve O
pal O
##sies O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
a O
case O
report O
and O
review O
of O
literature O
of O
pal O
##atal O
tremor O
##s O
in O
ne O
##uro O
##de O
##gen O
##erative O
disease O
mo O
##v O
di O
##s O
1999 O
14 O
68 O
##9 O
69 O
##3 O

samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O

storey O
e O
knight O
ma O
forrest O
sm O
gardner O
r O
##j O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
ce O
##re O
##bell O
##um O
2005 O
4 O
55 O
57 O

van O
der O
kn O
##aa O
##p O
ms O
na O
##id O
##u O
s O
br O
##eit O
##er O
s O
##n O
et O
al O
alexander O
disease O
diagnosis O
with O
mri O
am O
j O
ne O
##uro O
##rad O
##iol O
2001 O
22 O
54 O
##1 O
55 O
##2 O

anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
a O
case O
report O

my O
##oc O
##lon O
##us O
is O
a O
clinical O
sign O
de O
##ﬁ O
##ned O
as O
sudden O
brief O
shock O
##like O
involuntary O
movements O
caused O
by O
muscular O
contraction O
##s O
positive O
my O
##oc O
##lon O
##us O
or O
inhibition O
##s O
negative O
my O
##oc O
##lon O
##us O
as O
##ter O
##ix O
##is O
most O
causes O
of O
my O
##oc O
##lon O
##us O
are O
sy O
##mpt O
##oma O
##tic O
and O
include O
post O
##hy O
##po O
##xia O
toxic O
metabolic O
disorders O
and O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
1 O
various O
drugs O
including O
ne O
##uro O
##le O
##ptic O
##s O
anti O
##con O
##vu O
##ls O
##ants O
and O
cardiac O
medications O
can O
cause O
my O
##oc O
##lon O
##us O
1 O
2 O
but O
anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
is O
extremely O
rare O
2 O
3 O
here O
we O
report O
a O
case O
of O
transient O
my O
##oc O
##lon O
##us O
triggered O
by O
an O
anti O
##his O
##tam O
##ine O
ox O
##ato O
##mide O

an O
85 O
year O
old O
man O
taking O
am O
##lo O
##di O
##pine O
5 O
mg O
day O
can O
##des O
##art O
##an O
8 O
mg O
day O
ar O
##ot O
##ino O
##lo O
##l O
20 O
mg O
day O
and O
fur O
##ose O
##mide O
20 O
mg O
day O
for O
hyper O
##tension O
and O
all O
##op O
##uri O
##no O
##l O
200 O
mg O
day O
for O
hyper O
##uri O
##ce O
##mia O
developed O
an O
involuntary O
movement O
in O
his O
right O
hand O
it O
progressed O
over O
his O
upper O
limbs O
and O
face O
within O
several O
hours O
and O
he O
was O
referred O
to O
our O
hospital O
on O
physical O
examination O
he O
was O
af O
##eb O
##ril O
##e O
without O
abnormal O
##ity O
except O
for O
sy O
##sto O
##lic O
hyper O
##tension O
170 O
80 O
mm O
h O
##g O
the O
mini O
mental O
status O
test O
revealed O
cognitive O
impairment O
score O
20 O
at O
rest O
there O
was O
my O
##oc O
##lon O
##us O
in O
the O
patient O
s O
face O
tongue O
jaw O
neck O
and O
upper O
limbs O
predominantly O
on O
the O
left O
there O
was O
no O
pal O
##atal O
tremor O
an O
electro O
##phy O
##sio O
##logical O
study O
revealed O
4 O
hz O
rhythmic O
my O
##oc O
##lon O
##ic O
discharge O
##s O
in O
the O
left O
arm O
muscles O
with O
synchronized O
o O
##cular O
movement O
that O
increased O
with O
eye O
##lid O
closure O
see O
fig O
1 O
and O
suggested O
that O
the O
my O
##oc O
##lon O
##us O
was O
persistent O
and O
time O
locked O
in O
all O
locations O
generalized O
my O
##o O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##6 O

cl O
##onus O
limb O
my O
##oc O
##lon O
##us O
was O
exaggerated O
when O
the O
patient O
extended O
his O
upper O
limbs O
but O
it O
was O
not O
induced O
by O
external O
sensory O
stimuli O
the O
involuntary O
movements O
were O
not O
suppressed O
by O
mental O
stress O
or O
by O
alternate O
pro O
##nation O
and O
su O
##pina O
##tion O
of O
the O
forearm O
to O
an O
external O
rhythm O
as O
##ter O
##ix O
##is O
was O
evident O
when O
the O
patient O
s O
upper O
limbs O
were O
extended O
and O
his O
wrists O
do O
##rs O
##i O
##ﬂ O
##ex O
##ed O
and O
it O
caused O
the O
laps O
##e O
in O
posture O
between O
the O
positive O
my O
##oc O
##lon O
##ic O
jerk O
##s O
he O
was O
unable O
to O
maintain O
his O
tongue O
in O
the O
pro O
##tr O
##uded O
position O
owing O
to O
as O
##ter O
##ix O
##is O
of O
the O
tongue O
and O
he O
had O
di O
##f O
##ﬁ O
##cu O
##lty O
speaking O
neurological O
examination O
was O
otherwise O
normal O
laboratory O
examination O
revealed O
a O
mild O
elevation O
of O
ur O
##ea O
nitrogen O
25 O
mg O
dl O
and O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fera O
##se O
40 O
i O
##u O
l O
but O
the O
plasma O
ammonia O
concentration O
and O
thyroid O
function O
were O
normal O
chest O
x O
ray O
revealed O
card O
##iom O
##ega O
##ly O
and O
cardiac O
ultra O
##son O
##ography O
showed O
left O
vent O
##ric O
##ular O
hyper O
##tro O
##phy O
and O
mild O
mit O
##ral O
reg O
##urg O
##itation O
the O
plasma O
brain O
nat O
##ri O
##ure O
##tic O
peptide O
concentration O
was O
189 O
0 O
pg O
ml O
abdominal O
son O
##ography O
and O
computed O
tom O
##ography O
revealed O
no O
abnormal O
##ity O
and O
there O
was O
no O
portals O
##yst O
##emi O
##c O
shu O
##nt O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
analysis O
was O
normal O
brain O
magnetic O
resonance O
imaging O
showed O
diffuse O
cerebral O
at O
##rop O
##hy O
which O
was O
consistent O
with O
alzheimer O
s O
disease O
and O
an O
old O
is O
##che O
##mic O
les O
##ion O
in O
the O
right O
ce O
##re O
##bell O
##um O
electro O
##ence O
##pha O
##log O
##raphy O
showed O
a O
9 O
hz O
alpha O
background O
rhythm O
without O
ep O
##ile O
##pt O
##iform O
activity O
the O
involuntary O
movements O
disappeared O
immediately O
after O
the O
intra O
##ven O
##ous O
administration O
of O
10 O
mg O
diaz O
##ep O
##am O

five O
months O
later O
the O
patient O
suffered O
a O
rec O
##ur O
##rence O
of O
my O
##o O

cl O
##onus O
but O
it O
disappeared O
within O
several O
hours O
after O
oral O
administration O
of O
0 O
5 O
mg O
cl O
##ona O
##ze O
##pa O
##m O
all O
of O
the O
patient O
s O
medications O
were O
reviewed O
again O
the O
ﬁ O
##rst O
my O
##oc O
##lon O
##us O
occurred O
after O
18 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
the O
second O
occurred O
after O
8 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
ep O
##inas O
##tine O
20 O
mg O
day O
for O
chronic O
pr O
##uri O
##go O
the O
my O
##oc O
##lon O
##us O
has O
not O
rec O
##ur O
##red O
since O
the O
patient O
stopped O
the O
anti O
##his O
##tam O
##ines O

our O
patient O
ﬁ O
##rst O
presented O
with O
acute O
occurrences O
of O
both O
generalized O
my O
##oc O
##lon O
##us O
and O
as O
##ter O
##ix O
##is O
predominantly O
in O
the O
face O
neck O
and O
upper O
limbs O
the O
involuntary O
movements O
disappeared O
immediately O
after O
benz O
##od O
##ia O
##ze O
##pine O
treatment O
but O
he O
experienced O
a O
rec O
##ur O
##rence O
these O
clinical O
features O
are O
similar O
to O
the O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
previously O
reported O
by O
hash O
##imo O
##to O
et O
al O
4 O
the O
cause O
of O
that O
state O
is O
unclear O
although O
aging O
chronic O
diseases O
and O
viral O
infection O
could O
contribute O
however O
in O
our O
patient O
the O
temporal O
relationship O
between O
my O
##oc O
##lon O
##us O
and O
the O
anti O
##his O
##tam O
##ine O
medication O
history O
suggests O
that O
ox O
##ato O
##mide O
triggered O
the O
movement O
disorder O
ox O
##ato O
##mide O
a O
second O
generation O
anti O
##his O
##tam O
##ine O
is O
used O
to O
treat O
allergic O
diseases O
in O
europe O
and O
japan O
its O
ph O
##arm O
##aco O
##logic O
actions O
include O
his O
##tam O
##ine O
h O
##1 O
receptor O
ant O
##ago O
##nism O
and O
suppression O
of O
the O
production O
and O
release O
of O
chemical O
media O
##tors O
as O
well O
as O
anti O
cho O
##liner O
##gic O
and O
anti O
ser O
##oton O
##in O
actions O
5 O
anti O
##his O
##tam O
##ines O
can O
both O
stimulate O
and O
de O
##press O
the O
central O
nervous O
system O
cn O
##s O
but O
second O
generation O
drugs O
do O
not O
app O
##re O
##cia O
##bly O
cross O
the O
blood O
brain O
barrier O
therefore O
there O
are O
few O
reports O
of O
abnormal O
involuntary O
movements O
associated O
with O
anti O
##his O
##tam O
##ines O
however O
raj O
##put O
et O
al O
recently O
reported O
a O
pediatric O
case O
of O
d O
##yst O
##onia O
induced O
by O
a O
second O
generation O
anti O
##his O
##tam O
##ine O
ce O
##ti O
##riz O
##ine O
possibly O
because O
of O
do O
##pa O
##mine O
receptor O
blockade O
by O
the O
drug O
meta O
##bol O
##ite O
6 O
ox O
##ato O
##mide O
can O
also O
cause O
d O
##yst O
##onia O
7 O
however O
to O
our O
knowledge O
there O
is O
only O
one O
report O
of O
anti O
##his O
##tam O
##ine O
induced O
my O
##o O

161 O
##6 O
letters O
to O
the O
editor O

fig O
1 O
electro O
##oc O
##ulo O
##graphy O
and O
surface O
electro O
##my O
##ography O
rhythmic O
o O
##cular O
movement O
of O
the O
left O
l O
eye O
in O
the O
vertical O
direction O
l O
om O
vertical O
was O
sync O
##hr O
##ono O
##us O
with O
my O
##oc O
##lon O
##us O
in O
the O
l O
orb O
##icular O
##is O
o O
##cu O
##li O
rhythmic O
sync O
##hr O
##ono O
##us O
my O
##oc O
##lon O
##ic O
discharge O
##s O
were O
also O
evident O
in O
the O
l O
ﬁ O
##rst O
dorsal O
inter O
##oss O
##eous O
f O
##di O
and O
l O
abd O
##uc O
##tor O
poll O
##ici O
##s O
br O
##ev O
##is O
ap O
##b O
cal O
##ib O
##ration O
100 O
l O
##v O
in O
each O
lane O
time O
constant O
0 O
1 O
s O
in O
the O
ﬁ O
##rst O
lane O
and O

0 O
001 O
s O
in O
other O
lanes O
black O
bar O
1 O
s O

cl O
##onus O
in O
that O
case O
caused O
by O
abusive O
over O
##use O
of O
a O
ﬁ O
##rst O
generation O
anti O
##his O
##tam O
##ine O
trip O
##ele O
##nna O
##mine O
3 O
it O
remains O
unclear O
why O
ox O
##ato O
##mide O
triggered O
my O
##oc O
##lon O
##us O
in O
our O
patient O
we O
could O
not O
determine O
the O
plasma O
concentration O
of O
ox O
##ato O
##mide O
when O
he O
was O
suffering O
from O
the O
my O
##oc O
##lon O
##us O
however O
cardiac O
or O
renal O
dysfunction O
might O
raise O
the O
drug O
concentration O
to O
a O
toxic O
level O
in O
the O
cn O
##s O
and O
the O
drug O
might O
affect O
the O
ser O
##oton O
##er O
##gic O
system O
to O
cause O
my O
##oc O
##lon O
##us O
although O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
remains O
controversial O
8 O
on O
the O
other O
hand O
our O
patient O
was O
dem O
##ented O
and O
being O
treated O
with O
anti O
##hy O
##per O
##tens O
##ive O
agents O
dementia O
can O
lower O
the O
threshold O
for O
my O
##oc O
##lon O
##us O
or O
can O
be O
a O
cause O
of O
my O
##oc O
##lon O
##us O
in O
and O
of O
itself O
1 O
furthermore O
cardiac O
medications O
can O
also O
cause O
my O
##oc O
##lon O
##us O
1 O
therefore O
the O
minor O
toxic O
metabolic O
disturbance O
caused O
by O
anti O
##his O
##tam O
##ine O
use O
might O
have O
led O
our O
elderly O
my O
##oc O
##lon O
##us O
##pro O
##ne O
patient O
into O
a O
transient O
my O
##oc O
##lon O
##ic O
state O
this O
is O
the O
ﬁ O
##rst O
report O
of O
my O
##oc O
##lon O
##us O
triggered O
by O
a O
therapeutic O
dose O
of O
anti O
##his O
##tam O
##ines O
clinic O
##ians O
should O
recognize O
that O
anti O
##his O
##tam O
##ines O
could O
trigger O
this O
benign O
but O
dramatic O
cn O
##s O
side O
effect O

tak O
##ashi O
ir O
##io O
##ka O
md O
phd O
akira O
mach O
##ida O
md O
tak O
##anor O
##i O
yoko O
##ta O
md O
phd O

hide O
##hiro O
mi O
##zu O
##sa O
##wa O
md O
phd O
department O
of O
ne O
##uro O
##logy O
and O
neurological O
science O
graduate O
school O
tokyo O
medical O
and O
dental O
university O

tokyo O
japan O

e O
mail O
t O
ir O
##io O
##ka O
nur O
##o O
t O
##md O
ac O
jp O

ca O
##vine O
##ss O
j O
##n O
brown O
p O
my O
##oc O
##lon O
##us O
current O
concepts O
and O
recent O
advances O
lance O
##t O
ne O
##uro O
##l O
2004 O
3 O
59 O
##8 O
60 O
##7 O

gordon O
m O
##f O
toxin O
and O
drug O
induced O
my O
##oc O
##lon O
##us O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##l O

og O
##y O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
49 O
76 O

sc O
##hip O
##ior O
pg O
an O
unusual O
case O
of O
anti O
##his O
##tam O
##ine O
into O
##xi O
##cation O
j O
pediatric O
##s O
1967 O
71 O
58 O
##9 O
59 O
##1 O

hash O
##imo O
##to O
s O
ka O
##wa O
##mura O
j O
yamamoto O
t O
et O
al O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
in O
elderly O
patients O
a O
new O
syndrome O
j O
ne O
##uro O
##l O
sci O
1992 O
109 O
132 O
139 O

richards O
d O
##m O
bro O
##g O
##den O
rn O
heel O
rc O
sp O
##ei O
##ght O
t O
##m O
avery O
gs O
ox O
##ato O
##mide O
a O
review O
of O
its O
ph O
##arm O
##aco O
##dy O
##nami O
##c O
properties O
and O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
drugs O
1984 O
27 O
210 O
231 O

raj O
##put O
a O
bae O
##rg O
k O
ce O
##ti O
##riz O
##ine O
induced O
d O
##yst O
##onic O
movements O
ne O
##uro O
##logy O
2006 O
66 O
143 O
144 O

caste O
##els O
van O
da O
##ele O
m O
egg O
##er O
##mont O
e O
casa O
##er O
p O
van O
de O
cass O
##eye O
w O
de O
bo O
##eck O
k O
acute O
d O
##yst O
##onic O
reactions O
and O
long O
lasting O
impaired O
consciousness O
associated O
with O
ox O
##ato O
##mide O
in O
children O
lance O
##t O
1986 O
1 O
120 O
##4 O
120 O
##5 O

welsh O
jp O
pl O
##aca O
##nton O
##aki O
##s O
d O
##g O
wars O
##ets O
##ky O
si O
marquez O
r O
##g O
bernstein O
l O
ai O
##cher O
sa O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
from O
the O
perspective O
of O
ne O
##uron O
##al O
rhythmic O
##ity O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##logy O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
307 O
329 O

do O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
differ O
by O
route O
of O
environmental O
pre O
##ci O
##pit O
##ant O

bra O
##ak O
and O
colleagues O
followed O
their O
groundbreaking O
staging O
class O
##i O
##ﬁ O
##cation O
for O
the O
brain O
ne O
##uro O
##path O
##ology O
of O
alzheimer O
s O
disease O
with O
the O
more O
recent O
one O
for O
sporadic O
parkinson O
s O
disease O
pd O
1 O
their O
new O
pd O
staging O
system O
has O
revolution O
##ized O
thinking O
about O
the O
topographic O
sequence O
of O
ne O
##uro O
##path O
##ological O
changes O
as O
the O
illness O
progresses O
generally O
in O
a O
ca O
##uda O
##l O
ro O
##stra O
##l O
direction O
from O
lower O
brains O
##tem O
to O
neo O
##cor O
##te O
##x O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##23 O

letters O
to O
the O
editor O
161 O
##7 O

one O
of O
the O
most O
important O
of O
bra O
##ak O
et O
al O
s O
observations O
may O
be O
that O
ol O
##factory O
structures O
are O
one O
of O
the O
ﬁ O
##rst O
sites O
of O
ne O
##uro O
##path O
##ology O
in O
the O
central O
nervous O
system O
cn O
##s O
2 O
coupled O
with O
emerging O
evidence O
that O
characteristic O
syn O
##uc O
##lein O
##opa O
##thic O
changes O
can O
be O
seen O
in O
the O
peripheral O
auto O
##no O
##mic O
nervous O
system O
including O
the O
gas O
##tro O
##int O
##estinal O
tract O
even O
before O
cn O
##s O
involvement O
3 O
6 O
a O
critical O
implication O
of O
these O
ﬁ O
##nding O
##s O
is O
that O
the O
nose O
and O
mouth O
become O
suspect O
as O
portals O
of O
entry O
for O
an O
inc O
##iting O
pathogen O
##ic O
agent O

after O
nasal O
entry O
trans O
##ne O
##uron O
##al O
transmission O
along O
ol O
##factory O
pathways O
is O
a O
potential O
route O
to O
the O
brain O
it O
has O
been O
shown O
for O
example O
that O
inhaled O
ultra O
##ﬁ O
##ne O
heavy O
metal O
particles O
which O
might O
come O
from O
occupational O
exposure O
##s O
can O
pass O
through O
the O
nasal O
mu O
##cos O
##a O
and O
be O
trans O
##yna O
##ptic O
##ally O
transported O
to O
deeper O
brain O
regions O
7 O
once O
a O
pathogen O
##ic O
agent O
passes O
through O
the O
gas O
##tro O
##int O
##estinal O
mu O
##cos O
##a O
after O
oral O
entry O
the O
pathway O
via O
the O
enter O
##ic O
auto O
##no O
##mic O
nervous O
system O
to O
the O
va O
##gus O
nerve O
and O
the O
va O
##gal O
nuclei O
in O
the O
lower O
brains O
##tem O
also O
one O
of O
the O
early O
lo O
##ci O
of O
pd O
pathology O
in O
the O
cn O
##s O
##1 O
2 O
would O
be O
open O
thus O
environmental O
factors O
in O
the O
air O
water O
and O
food O
look O
to O
be O
integral O
##ly O
involved O
in O
the O
initial O
phases O
of O
the O
illness O
potential O
environmental O
agents O
that O
have O
been O
suggested O
include O
agricultural O
pest O
##icides O
and O
herb O
##icides O
reviewed O
in O
8 O
9 O
heavy O
metals O
7 O
viruses O
10 O
and O
pri O
##ons O
11 O
genetic O
factors O
might O
in O
##ﬂ O
##uen O
##ce O
individual O
su O
##sc O
##ept O
##ibility O
or O
response O
to O
the O
off O
##ending O
agents O

dementia O
with O
lew O
##y O
bodies O
dl O
##b O
differs O
from O
pd O
by O
diffuse O
syn O
##uc O
##lein O
##opa O
##thic O
de O
##gen O
##eration O
involving O
cortex O
and O
brains O
##tem O
at O
onset O
rather O
than O
the O
initial O
focal O
ol O
##factory O
and O
lower O
brains O
##tem O
pathology O
of O
pd O
12 O
it O
has O
been O
debated O
whether O
pd O
and O
dl O
##b O
are O
variants O
of O
the O
same O
disease O
or O
represent O
distinct O
entities O
13 O
based O
on O
the O
differences O
in O
their O
ne O
##uro O
##path O
##olo O
##gic O
temporal O
pro O
##ﬁ O
##le O
i O
h O
##yp O
##oth O
##es O
##ize O
that O
there O
is O
an O
et O
##iol O
##ogical O
difference O
that O
is O
primarily O
due O
to O
the O
route O
of O
exposure O
to O
inc O
##iting O
environmental O
agents O
under O
this O
view O
pd O
results O
from O
respiratory O
airborne O
or O
gas O
##tro O
##int O
##estinal O
water O
food O
##borne O
exposure O
while O
dl O
##b O
develops O
following O
systemic O
blood O
##borne O
exposure O
type O
of O
toxic O
##ant O
and O
level O
of O
exposure O
might O
determine O
whether O
sign O
##i O
##ﬁ O
##can O
##t O
concentrations O
are O
achieved O
in O
the O
circulation O
underlying O
genetic O
factors O
might O
also O
contribute O
to O
which O
route O
s O
and O
levels O
of O
exposure O
result O
in O
toxicity O
the O
hypothesis O
is O
test O
##able O
by O
comparing O
pd O
and O
dl O
##b O
patients O
for O
routes O
types O
and O
magnitude O
##s O
of O
environmental O
exposure O
##s O

roger O
ku O
##rl O
##an O
md O

department O
of O
ne O
##uro O
##logy O
university O
of O
rochester O
school O
of O
medicine O

rochester O
new O
york O
usa O

bra O
##ak O
h O
del O
tre O
##dic O
##i O
k O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
211 O

del O
tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
##e O
bra O
##ak O
h O
where O
does O
parkinson O
disease O
pathology O
begin O
in O
the O
brain O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2002 O
61 O
41 O
##3 O
42 O
##6 O

wa O
##ka O
##bay O
##ashi O
k O
takahashi O
h O
oh O
##ama O
e O
take O
##da O
s O
ik O
##uta O
f O
lew O
##y O
bodies O
in O
the O
vis O
##cera O
##l O
auto O
##no O
##mic O
nervous O
system O
in O
parkinson O
s O
disease O
in O
ik O
##uta O
f O
editor O
ne O
##uro O
##path O
##ology O
in O
brain O
research O
amsterdam O
london O
tokyo O
excerpt O
##a O
med O
##ica O
1991 O
p O
133 O
141 O

bra O
##ak O
h O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
del O
tre O
##dic O
##i O
k O
gas O
##tric O
alpha O
##sy O
##nu O
##cle O
##in O
im O
##mun O
##ore O
##active O
inclusion O
##s O
in O
mei O
##ss O
##ner O
s O
and O
au O
##er O
##bach O
s O
pl O
##ex O
##uses O
in O
cases O
staged O
for O
parkinson O
s O
disease O
related O
brain O
pathology O
ne O
##uro O
##sc O
##i O
let O
##t O
2006 O
39 O
##6 O
67 O
72 O

ming O
##uez O
caste O
##llan O
##os O
a O
char O
##orro O
ce O
es O
##cam O
##illa O
sevilla O
f O
et O
al O
do O
a O
syn O
##uc O
##lein O
aggregate O
##s O
in O
auto O
##no O
##mic O
pl O
##ex O
##uses O
pre O
##date O
lew O
##y O
body O
disorders O
a O
co O
##hort O
study O
ne O
##uro O
##logy O
2007 O
68 O
2012 O
2018 O

bra O
##ak O
h O
sas O
##tre O
m O
bo O
##hl O
jr O
##e O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
parkinson O
s O
disease O
lesions O
in O
dorsal O
horn O
layer O
i O
involvement O
of O
para O
##sy O
##mp O
##ath O
##etic O
and O
sympathetic O
pre O
##and O
post O
##gang O
##lion O
##ic O
neurons O
act O
##a O
ne O
##uro O
##path O
##ol O
be O
##r O
2007 O
113 O
421 O
42 O
##9 O

obe O
##rdo O
##¨ O
##rst O
##er O
g O
sharp O
z O
at O
##ud O
##ore O
##i O
v O
et O
al O
trans O
##lo O
##cation O
of O
inhaled O
ultra O
##ﬁ O
##ne O
particles O
to O
the O
brain O
in O
##hal O
toxic O
##ol O
2004 O
16 O
43 O
##7 O
44 O
##5 O

rat O
##ner O
m O
##h O
feldman O
r O
##g O
environmental O
toxin O
##s O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
51 O
62 O

st O
##rick O
##land O
d O
rural O
environment O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
63 O
71 O

bra O
##ak O
h O
bo O
##hl O
jr O
mu O
##¨ O
##ller O
cm O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O

k O
stanley O
fa O
##hn O
lecture O
2005 O
the O
staging O
procedure O
for O
the O
inclusion O
body O
pathology O
associated O
with O
sporadic O
parkinson O
s O
disease O
rec O
##ons O
##ider O
##ed O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
204 O
##2 O
205 O
##1 O

klein O
c O
sc O
##hl O
##oss O
##mac O
##her O
mg O
parkinson O
s O
disease O
10 O
years O
after O
its O
genetic O
revolution O
multiple O
clues O
to O
a O
complex O
disorder O
ne O
##uro O
##logy O
2007 O
69 O
209 O
##3 O
210 O
##4 O

mc O
##kei O
##th O
i O
##g O
gala O
##sko O
d O
ko O
##saka O
k O
consensus O
guidelines O
for O
the O
clinical O
and O
path O
##olo O
##gic O
diagnosis O
of O
dementia O
with O
lew O
##y O
bodies O
dl O
##b O
report O
of O
the O
consortium O
on O
dl O
##b O
international O
workshop O
ne O
##uro O
##logy O
1996 O
47 O
111 O
##3 O
112 O
##4 O

richard O
i O
##h O
pa O
##p O
##ka O
m O
rub O
##io O
a O
et O
al O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
one O
disease O
or O
two O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
116 O
##1 O
116 O
##5 O

d O
##yst O
##onia O
associated O
with O
hyper O
##int O
##ense O
basal O
gang O
##lia O
lesions O
on O
t O
##1 O
weighted O
brain O
mri O

a O
43 O
year O
old O
man O
presented O
with O
cardiac O
arrest O
due O
to O
an O
ana O
##phy O
##la O
##ctic O
shock O
after O
ﬂ O
##uo O
##res O
##ce O
##in O
application O
for O
re O
##tina O
##l O
ang O
##iography O
after O
card O
##io O
##pu O
##lm O
##ona O
##ry O
res O
##us O
##cit O
##ation O
the O
patient O
could O
be O
we O
##ane O
##d O
from O
tr O
##ache O
##al O
res O
##piration O
2 O
days O
later O
the O
initial O
neurological O
examination O
revealed O
generalized O
h O
##yp O
##oki O
##nesia O
rigid O
##ity O
of O
ex O
##tre O
##mit O
##ies O
and O
severe O
axial O
d O
##yst O
##onia O
with O
ant O
##ero O
##coll O
##is O
and O
increased O
oro O
##man O
##di O
##bular O
tone O
with O
almost O
inca O
##pa O
##bility O
to O
open O
the O
mouth O
fig O
1a O
a O
mild O
reduction O
of O
h O
##yp O
##oki O
##nesia O
occurred O
due O
to O
medication O
of O
ama O
##nta O
##dine O
and O
lev O
##od O
##opa O
the O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
improved O
considerably O
under O
repetitive O
local O
injection O
##s O
of O
bot O
##ulin O
##um O
toxin O
type O
a O
and O
the O
patient O
is O
able O
to O
eat O
and O
speak O
without O
assistance O
the O
clinical O
symptoms O
are O
stable O
since O
the O
initial O
attack O
over O
a O
period O
of O
3 O
5 O
years O
now O
see O
fig O
1a O
and O
video O
for O
current O
clinical O
state O

the O
initial O
ct O
was O
regular O
but O
the O
t O
##1 O
weighted O
mri O
without O
contrast O
demonstrated O
bilateral O
uniform O
area O
wide O
hyper O
##in O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##28 O

1618 O
letters O
to O
the O
editor O

fig O
1 O
a O
photograph O
of O
patient O
showing O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O

2 O
months O
after O
onset O
left O
picture O
and O
5 O
years O
later O
following O
local O
injection O
##s O
of O
bot O
##ulin O
##um O
toxin O
type O
a O
right O
picture O
b O
sequential O
ne O
##uro O
##ima O
##ging O
of O
t O
##1 O
hyper O
##int O
##ense O
st O
##ria O
##tal O
lesions O
associated O
with O
generalized O
d O
##yst O
##onia O
after O
card O
##io O
##pu O
##lm O
##ona O
##ry O
res O
##us O
##cit O
##ation O
upper O
row O
displays O
initial O
ct O
mri O
imaging O
within O
the O
ﬁ O
##rst O
2 O
weeks O
after O
onset O
t O
##1 O
##and O
t O
##2 O
weighted O
images O
no O
contrast O
and O
lower O
row O
shows O
imaging O
17 O
months O
later O
t O
##1 O
##and O
t O
##2 O
images O
note O
the O
hyper O
##int O
##ense O
bilateral O
st O
##ria O
##tal O
lesions O
in O
initial O
t O
##1 O
weighted O
mri O
with O
no O
indications O
of O
hem O
##or O
##rh O
##ages O
in O
all O
images O

tense O
lesions O
of O
the O
st O
##ria O
##tum O
fig O
1b O
upper O
row O
imaging O
showed O
no O
indications O
of O
hem O
##or O
##rh O
##ages O
the O
follow O
up O
imaging O
17 O
months O
later O
demonstrated O
nec O
##rosis O
of O
both O
st O
##ria O
##ta O
without O
any O
evidence O
of O
hem O
##osi O
##der O
##in O
deposits O
fig O
1b O
lower O
row O

similar O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
have O
been O
described O
previously O
in O
several O
patients O
with O
cho O
##rea O
after O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
1 O
2 O
and O
rarely O
in O
patients O
with O
h O
##yp O
##og O
##ly O
##ca O
##emi O
##c O
coma O
##3 O
or O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
4 O
in O
these O
cases O
post O
##ische O
##mic O
pete O
##chia O
##l O
hem O
##or O
##rh O
##age O
was O
suspected O
as O
a O
possible O
mechanism O
although O
sporadic O
post O
##mo O
##rte O
##m O
path O
##ological O
studies O
have O
reported O
selective O
ne O
##uron O
##al O
loss O
g O
##lio O
##sis O
and O
reactive O
astro O
##cy O
##tosis O
as O
common O
ﬁ O
##nding O
##s O
5 O
6 O
fuji O
##oka O
et O
al O
reported O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
mri O
in O
the O
st O
##ria O
##tum O
of O
rats O
7 O
days O
after O
brief O
focal O
is O
##che O
##mia O
7 O
his O
##to O
##logical O
preparation O
of O
the O
animal O
brains O
showed O
selective O
ne O
##uron O
##al O
death O
and O
proliferation O
of O
reactive O
astro O
##cytes O
and O
micro O
##glia O
without O
in O
##far O
##ct O
hem O
##or O
##rh O
##age O
lip O
##id O
accumulation O
or O
apparent O
cal O
##ci O
##ﬁ O
##cation O

together O
the O
reasons O
for O
the O
initial O
t O
##1 O
hyper O
##int O
##ens O
##ities O
remain O
elusive O
theoretically O
besides O
intra O
##cellular O
met O
##hem O
##og O
##lo O
##bin O
in O
hem O
##or O
##rh O
##agi O
##c O
tissue O
and O
cal O
##ci O
##ﬁ O
##cation O
##s O
para O
##ma O
##gne O
##tic O
compounds O
including O
metal O
ions O
e O
g O
iron O
manga O
##nese O
and O
copper O
molecular O
oxygen O
or O
free O
radicals O
could O
lead O
to O
these O

legend O
to O
the O
full O
video O

time O
content O

00 O
00 O
00 O
00 O
00 O
15 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O

00 O
00 O
16 O
00 O
00 O
28 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

forehead O
d O
##yst O
##onia O

00 O
00 O
29 O
00 O
00 O
37 O
listing O
the O
days O
of O
the O
week O
from O
monday O

to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O

00 O
00 O
38 O
00 O
00 O
47 O
patient O
closing O
and O
opening O
his O
eyes O
00 O
00 O
48 O
00 O
01 O
09 O
facial O
inner O
##vation O
mouth O
tongue O
and O

forehead O

00 O
01 O
10 O
00 O
01 O
31 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O

of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
01 O
32 O
00 O
02 O
01 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O

and O
pro O
##nation O
su O
##pina O
##tion O
test O

legend O
to O
the O
preview O
video O

00 O
00 O
00 O
00 O
00 O
03 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O

00 O
00 O
04 O
00 O
00 O
07 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

00 O
00 O
08 O
00 O
00 O
15 O
listing O
the O
days O
of O
the O
week O
from O
monday O

00 O
00 O
16 O
00 O
00 O
33 O
facial O
inner O
##vation O
eyes O
mouth O
tongue O

and O
forehead O

00 O
00 O
34 O
00 O
00 O
46 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O

of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
00 O
47 O
00 O
00 O
59 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O

mri O
changes O
in O
our O
case O
we O
found O
no O
evidence O
of O
hem O
##or O
##rh O
##agi O
##c O
changes O
or O
cal O
##ci O
##ﬁ O
##cation O
##s O
so O
that O
reported O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
may O
hypothetical O
##ly O
result O
from O
h O
##yp O
##ox O
##ic O
disruption O
of O
the O
cell O
mitochondrial O
heavy O
metal O
metabolism O

martin O
wo O
##lz O
md O
susan O
##n O
jung O
##han O
##ns O
md O
matthias O
lo O
##¨ O
##hl O
##e O
md O

department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O

dresden O
germany O

ru O
##¨ O
##di O
##ger O
von O
ku O
##mmer O
md O

department O
of O
ne O
##uro O
##rad O
##iology O
technical O
university O

dresden O
dresden O
germany O

alexander O
st O
##or O
##ch O
md O

e O
mail O
alexander O
st O
##or O
##ch O
ne O
##uro O
med O
tu O
dresden O
de O

lin O
jj O
chang O
mk O
hem O
##iba O
##llis O
##m O
hem O
##ich O
##ore O
##a O
and O
non O
ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1994 O
57 O
74 O
##8 O
750 O

letters O
to O
the O
editor O
161 O
##9 O

oh O
sh O
lee O
ky O
im O
j O
##h O
lee O
ms O
cho O
##rea O
associated O
with O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
and O
hyper O
##int O
##ens O
##ity O
basal O
gang O
##lia O
les O
##ion O
on O
t O
##1 O
weighted O
brain O
mri O
study O
a O
meta O
analysis O
of O
53 O
cases O
including O
four O
present O
cases O
j O
ne O
##uro O
##l O
sci O
2002 O
200 O
57 O
62 O

fuji O
##oka O
m O
hiram O
##ats O
##u O
k O
sa O
##ka O
##ki O
t O
sa O
##ka O
##guchi O
s O
is O
##hi O
##i O
y O
spec O
##i O
##ﬁ O
##c O
changes O
in O
human O
brain O
after O
h O
##yp O
##og O
##ly O
##ce O
##mic O
injury O
stroke O
1997 O
28 O
58 O
##4 O
58 O
##7 O

k O
##rie O
##ger O
d O
k O
##rie O
##ger O
s O
jan O
##sen O
o O
gas O
##s O
p O
the O
##il O
##mann O
l O
li O
##cht O
##neck O
##er O
h O
manga O
##nese O
and O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
lance O
##t O
1995 O
34 O
##6 O
270 O
274 O

oh O
##ara O
s O
nak O
##agawa O
s O
tab O
##ata O
k O
hash O
##imo O
##to O
t O
hem O
##iba O
##llis O
##m O
with O
hyper O
##gly O
##ce O
##mia O
and O
st O
##ria O
##tal O
t O
##1 O
mri O
hyper O
##int O
##ens O
##ity O
an O
autopsy O
report O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
521 O
525 O

shan O
de O
ho O
d O
##m O
chang O
c O
pan O
hc O
ten O
##g O
mm O
hem O
##ich O
##ore O
##ah O
##emi O
##ball O
##ism O
an O
explanation O
for O
mr O
signal O
changes O
am O
j O
ne O
##uro O
##rad O
##iol O
1998 O
19 O
86 O
##3 O
870 O

fuji O
##oka O
m O
tao O
##ka O
t O
mats O
##uo O
y O
hiram O
##ats O
##u O
ki O
sa O
##ka O
##ki O
t O
novel O
brain O
is O
##che O
##mic O
change O
on O
mri O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
images O
and O
selective O
ne O
##uron O
##al O
death O
in O
the O
ca O
##ud O
##op O
##uta O
##men O
of O
rats O
after O
brief O
focal O
is O
##che O
##mia O
stroke O
1999 O
30 O
104 O
##3 O
104 O
##6 O

successful O
treatment O
of O
the O
mei O
##ge O
syndrome O
with O
oral O
z O
##ol O
##pid O
##em O
mono O
##therapy O

z O
##ol O
##pid O
##em O
is O
an O
im O
##ida O
##zo O
##py O
##rid O
##ine O
ago O
##nist O
with O
a O
high O
af O
##ﬁ O
##nity O
for O
the O
benz O
##od O
##ia O
##ze O
##pine O
a1 O
subunit O
site O
1 O
it O
has O
been O
reported O
that O
this O
drug O
improves O
motor O
symptoms O
in O
patients O
with O
parkinson O
s O
disease O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
and O
xl O
##ink O
##ed O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
2 O
5 O
recently O
z O
##ol O
##pid O
##em O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
the O
mei O
##ge O
syndrome O
in O
combination O
with O
bot O
##ulin O
##um O
toxin O
a O
6 O

here O
we O
report O
a O
patient O
with O
mei O
##ge O
syndrome O
non O
##res O
##pon O
##sive O
to O
bot O
##ulin O
##um O
toxin O
a O
but O
successfully O
treated O
with O
oral O
z O
##ol O
##pid O
##em O
administration O

a O
59 O
year O
old O
man O
previously O
healthy O
presented O
with O
di O
##sa O
##bling O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
that O
began O
6 O
months O
before O
presentation O
before O
four O
years O
he O
reported O
an O
abnormal O
feeling O
of O
tension O
in O
the O
lower O
eye O
##lid O
and O
subsequently O
developed O
involuntary O
excessive O
blinking O
the O
d O
##yst O
##onic O
symptoms O
were O
usually O
provoked O
by O
speaking O
or O
chewing O
however O
they O
continued O
at O
rest O
and O
were O
relieved O
by O
placing O
a O
pencil O
between O
his O
teeth O
in O
addition O
the O
patient O
reported O
that O
the O
symptoms O
were O
improved O
after O
taking O
oral O
z O
##ol O
##pid O
##em O
prescribed O
for O
ins O
##om O
##nia O
by O
his O
primary O
physician O
he O
took O
this O
medication O
a O
half O
hour O
before O
going O
to O
sleep O
the O
patient O
had O
been O
treated O
with O
50 O
mg O
que O
##tia O
##pine O
8 O
mg O
tri O
##he O
##xi O
##ph O
##eni O
##dy O
##l O
and O
40 O
mg O
ba O
##cl O
##of O
##en O
without O
any O
ben O
##e O
##ﬁ O
##t O
in O
addition O
bot O
##ulin O
##um O
toxin O
a O
treatment O
was O
attempted O
bot O
##ox O
40 O
units O
injection O
in O
eight O
sites O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
and O
four O
sites O
of O
the O
orb O
##icular O
##is O
or O
##is O
muscle O
but O
this O
had O
little O
effect O
the O
patient O
reported O
no O
history O
of O
head O
trauma O
peripheral O
traumatic O
or O
surgical O
incidents O
or O
neurological O
diseases O
there O
was O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##9 O

no O
exposure O
to O
ne O
##uro O
##le O
##ptic O
medications O
there O
was O
no O
family O
history O
of O
movement O
disorders O

the O
neurological O
examination O
was O
normal O
except O
for O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
appearing O
sync O
##hr O
##ono O
##usly O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O
segment O
1 O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
for O
memory O
and O
frontal O
lobe O
functions O
was O
within O
normal O
limits O
the O
evaluation O
##s O
including O
magnetic O
resonance O
imaging O
of O
the O
brain O
electro O
##ence O
##pha O
##logram O
serum O
chemist O
##ries O
a O
complete O
blood O
count O
serum O
ce O
##ru O
##lo O
##pl O
##as O
##min O
thyroid O
function O
tests O
and O
genetic O
testing O
for O
the O
d O
##yt O
##1 O
mutation O
in O
the O
tor O
##sion O
a O
gene O
were O
normal O
the O
dental O
and O
op O
##ht O
##hal O
##mology O
examinations O
were O
also O
normal O

we O
evaluated O
whether O
oral O
z O
##ol O
##pid O
##em O
treatment O
could O
improve O
the O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
these O
symptoms O
completely O
resolved O
within O
1 O
hour O
after O
taking O
this O
medicine O
and O
the O
patient O
was O
sy O
##mpt O
##om O
free O
for O
4 O
hours O
without O
so O
##m O
##no O
##lence O
segment O
2 O
a O
long O
acting O
z O
##ol O
##pid O
##em O
tar O
##tra O
##te O
12 O
5 O
mg O
four O
times O
per O
day O
has O
been O
prescribed O
and O
this O
patient O
remains O
sy O
##mpt O
##om O
free O
during O
the O
daytime O

mei O
##ge O
syndrome O
is O
a O
form O
of O
cr O
##anial O
d O
##yst O
##onia O
it O
affects O
the O
cr O
##anial O
muscles O
and O
is O
characterized O
by O
involuntary O
blinking O
and O
chin O
thrusting O
7 O
this O
syndrome O
is O
considered O
a O
variant O
of O
id O
##io O
##pathic O
tor O
##sion O
d O
##yst O
##onia O
although O
bot O
##ulin O
##um O
toxin O
injection O
##s O
are O
useful O
for O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
as O
well O
as O
facial O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
the O
symptoms O
are O
usually O
ref O
##rac O
##tory O
or O
only O
partially O
relieved O
with O
this O
medication O
8 O

z O
##ol O
##pid O
##em O
completely O
abolished O
the O
symptoms O
associated O
with O
the O
mei O
##ge O
syndrome O
in O
our O
patient O
without O
causing O
so O
##m O
##no O
##lence O
the O
location O
of O
the O
highest O
density O
of O
z O
##ol O
##pid O
##em O
##bin O
##ding O
receptors O
is O
in O
the O
ventral O
g O
##lo O
##bus O
pal O
##lid O
##us O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
re O
##tic O
##ulate O
and O
the O
sub O
##thal O
##ami O
##c O
nucleus O
9 O
10 O
recently O
z O
##ol O
##pid O
##em O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
shown O
to O
enhance O
g O
amino O
##bu O
##ty O
##ric O
acid O
type O
a O
ga O
##ba O
##a O
receptor O
##media O
##ted O
inhibitor O
##y O
syn O
##ap O
##tic O
currents O
and O
therefore O
appears O
to O
mod O
##ulate O
motor O
behavior O
in O
awake O
animals O
##11 O
these O
results O
suggested O
that O
z O
##ol O
##pid O
##em O
may O
inhibit O
the O
ex O
##cit O
##ability O
of O
sub O
##thal O
##ami O
##c O
neurons O
and O
therefore O
compensate O
for O
the O
excessive O
inhibition O
of O
basal O
gang O
##lia O
targets O
in O
parkinson O
##ism O
leading O
to O
the O
improvement O
of O
symptoms O
in O
parkinson O
s O
disease O
however O
because O
other O
basal O
gang O
##lia O
nuclei O
also O
express O
z O
##ol O
##pid O
##em O
binding O
sites O
z O
##ol O
##pid O
##em O
may O
also O
ex O
##ert O
electro O
##phy O
##sio O
##logical O
effects O
on O
these O
other O
nuclei O
12 O
in O
addition O
other O
mechanisms O
may O
be O
involved O
in O
at O
##ten O
##uating O
d O
##ys O
##kin O
##etic O
symptoms O
for O
example O
ga O
##ba O
##er O
##gic O
drugs O
can O
be O
effective O
in O
am O
##eli O
##ora O
##ting O
experimental O
oro O
##fa O
##ical O
d O
##ys O
##kin O
##es O
##ia O
by O
rein O
##for O
##cing O
the O
involvement O
ga O
##ba O
##er O
##gic O
h O
##yp O
##of O
##un O
##ction O
13 O
and O
the O
ne O
##uro O
##pro O
##tec O
##tive O
and O
anti O
##ox O
##ida O
##nt O
properties O
of O
z O
##ol O
##pid O
##em O
in O
vivo O
and O
in O
vitro O
may O
contribute O
to O
the O
modulation O
of O
d O
##ys O
##kin O
##es O
##ia O
14 O

although O
the O
exact O
mechanism O
of O
binding O
to O
these O
sites O
is O
unknown O
z O
##ol O
##pid O
##em O
might O
reverse O
the O
path O
##op O
##hy O
##sio O
##logical O
changes O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
and O
therefore O
the O
whole O
basal O
gang O
##lia O
circuit O
in O
addition O
to O
the O
direct O
effects O
on O
the O
basal O
gang O
##lia O
we O
cannot O
rule O
out O
the O
possibility O
that O
the O
an O
##xi O
##ol O
##ytic O
in O
##ﬂ O
##uen O
##ce O
of O
z O
##ol O
##pid O
##em O
may O
contribute O
to O
its O
ben O
##e O
##ﬁ O
##cial O
effects O
on O
d O
##yst O
##onia O

in O
conclusion O
oral O
z O
##ol O
##pid O
##em O
may O
be O
a O
useful O
ph O
##arm O
##aco O
##logic O
alternative O
for O
patients O
with O
mei O
##ge O
syndrome O
who O
do O
not O
respond O
to O
bot O
##ulin O
##um O
toxin O
treatment O
however O
special O
precautions O
are O
necessary O
for O
long O
term O
management O
with O
this O
drug O
because O
of O
the O
risk O
of O
z O
##ol O
##pid O
##em O
abuse O
especially O
in O
patients O
with O
a O
previous O
history O
of O
substance O
abuse O
15 O

1620 O
letters O
to O
the O
editor O

segment O
1 O
the O
patient O
shows O
a O
mixture O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O

segment O
2 O
one O
hour O
after O
oral O
z O
##ol O
##pid O
##em O
administration O
the O
symptoms O
were O
completely O
resolved O
in O
the O
resting O
state O
while O
showing O
his O
teeth O
as O
well O
as O
grim O
##acing O
and O
whistling O

jae O
young O
an O
md O
joo O
##ng O
seo O
##k O
kim O
md O
ye O
##ong O
in O
kim O
md O
kwan O
##g O
soo O
lee O
md O
department O
of O
ne O
##uro O
##logy O

the O
catholic O
university O
of O
korea O
seoul O

south O
korea O

e O
mail O
ne O
##uron O
##et O
catholic O
ac O
k O
##r O

holm O
k O
##j O
goa O
k O
##l O
z O
##ol O
##pid O
##em O
an O
update O
of O
its O
ph O
##arm O
##aco O
##logy O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
and O
to O
##ler O
##ability O
in O
the O
treatment O
of O
ins O
##om O
##nia O
drugs O
2000 O
59 O
86 O
##5 O
88 O
##9 O

daniel O
##e O
a O
alba O
##nese O
a O
gain O
##otti O
g O
gregor O
##i O
b O
bart O
##olo O
##meo O
p O
z O
##ol O
##pid O
##em O
in O
parkinson O
s O
disease O
lance O
##t O
1997 O
34 O
##9 O
122 O
##2 O
122 O
##3 O

daniel O
##e O
a O
mor O
##o O
e O
bent O
##ivo O
##glio O
ar O
z O
##ol O
##pid O
##em O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
n O
eng O
##l O
j O
med O
1999 O
341 O
54 O
##3 O
54 O
##4 O

evident O
##e O
v O
##gh O
z O
##ol O
##pid O
##em O
improves O
d O
##yst O
##onia O
in O
lu O
##bag O
or O
x O
linked O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
ne O
##uro O
##logy O
2002 O
58 O
66 O
##2 O
66 O
##3 O

ru O
##zic O
##ka O
e O
roth O
j O
je O
##ch O
r O
bus O
##ek O
p O
sub O
##hy O
##p O
##not O
##ic O
doses O
of O
z O
##ol O
##pid O
##em O
oppose O
do O
##pa O
##mine O
##rg O
##ic O
induced O
d O
##ys O
##kin O
##es O
##ia O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
73 O
##4 O
73 O
##5 O

garrett O
##o O
ns O
bu O
##eri O
ja O
rey O
rd O
ara O
##ka O
##ki O
t O
nano O
g O
##v O
man O
##cus O
##o O

m O
improvement O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
with O
z O
##ol O
##pid O
##em O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
96 O
##7 O
96 O
##8 O

jan O
##kovic O
j O
clinical O
features O
differential O
diagnosis O
and O
pathogen O
##esis O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
cr O
##anial O
cervical O
d O
##yst O
##onia O
in O
bosnia O
##k O
l O
editor O
b O
##le O
##pha O
##ros O
##pas O
##m O
advances O
in O
op O
##ht O
##hal O
##mic O
plastic O
rec O
##ons O
##truct O
##ive O
surgery O
new O
york O
per O
##gam O
##on O
1985 O
p O
67 O
82 O

horn O
s O
come O
##lla O
c O
treatment O
of O
d O
##yst O
##onia O
in O
jan O
##kovic O
j O
to O
##los O
##a O
e O
editors O
parkinson O
s O
disease O
and O
movement O
disorders O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
35 O
##8 O
36 O
##4 O

ni O
##dda O
##m O
r O
dubois O
a O
sc O
##att O
##on O
b O
ar O
##bill O
##a O
s O
lange O
##r O
s O
##z O
auto O
##rad O
##io O
##graphic O
local O
##ization O
of O
3 O
##h O
z O
##ol O
##pid O
##em O
binding O
sites O
in O
the O
rat O
cn O
##s O
comparison O
with O
the O
distribution O
of O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
binding O
sites O
j O
ne O
##uro O
##che O
##m O
1987 O
49 O
89 O
##0 O
89 O
##9 O

dennis O
t O
dubois O
a O
ben O
##avi O
##des O
j O
sc O
##att O
##on O
b O
distribution O
of O
central O
omega O
1 O
benz O
##od O
##ia O
##ze O
##pine O
##1 O
and O
omega O
2 O
benz O
##od O
##ia O
##ze O
##pine O
##2 O
receptor O
sub O
##type O
##s O
in O
the O
monkey O
and O
human O
brain O
an O
auto O
##rad O
##io O
##graphic O
study O
with O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
and O
the O
omega O
1 O
selective O
ligand O
3 O
##h O
z O
##ol O
##pid O
##em O
j O
ph O
##arm O
##aco O
##l O
ex O
##p O
the O
##r O
1988 O
247 O
309 O
322 O

chen O
l O
xi O
##e O
j O
##x O
fun O
##g O
ks O
yun O
##g O
w O
##h O
z O
##ol O
##pid O
##em O
mod O
##ulates O
ga O
##ba O
##a O
receptor O
function O
in O
sub O
##thal O
##ami O
##c O
nucleus O
ne O
##uro O
##sc O
##i O
res O
2007 O
58 O
77 O
85 O

chen O
l O
sa O
##vio O
chang O
c O
yun O
##g O
w O
##h O
electro O
##phy O
##sio O
##logical O
and O
behavioral O
effects O
of O
z O
##ol O
##pid O
##em O
in O
rat O
g O
##lo O
##bus O
pal O
##lid O
##us O
ex O
##p O
ne O
##uro O
##l O
2004 O
186 O
212 O
220 O

pei O
##x O
##oto O
m O
##f O
ara O
##uj O
##o O
np O
silva O
r O
##h O
et O
al O
effects O
of O
ga O
##ba O
##er O
##gic O
drugs O
on O
res O
##er O
##pine O
induced O
oral O
d O
##ys O
##kin O
##es O
##ia O
be O
##ha O
##v O
brain O
res O
2005 O
160 O
51 O
59 O

ga O
##rc O
##´ O
##ı O
##a O
santos O
g O
herrera O
f O
mart O
##´ O
##ı O
##n O
v O
et O
al O
anti O
##ox O
##ida O
##nt O
activity O
and O
ne O
##uro O
##pro O
##tec O
##tive O
effects O
of O
z O
##ol O
##pid O
##em O
and O
several O
synthesis O
intermediate O
##s O
free O
ra O
##dic O
res O
2004 O
38 O
128 O
##9 O
129 O
##9 O

mad O
##rak O
l O
##n O
rosenberg O
m O
z O
##ol O
##pid O
##em O
abuse O
am O
j O
psychiatry O
2001 O
158 O
133 O
##0 O
133 O
##1 O

tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
induced O
by O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O

chronic O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
is O
effective O
in O
severe O
parkinson O
s O
disease O
pd O
1 O
however O
a O
few O
side O
effects O
especially O
o O
##cu O
##lom O
##oto O
##r O
manifestation O
##s O
have O
been O
reported O
2 O
understanding O
their O
mechanism O
may O
help O
to O
better O
de O
##ﬁ O
##ne O
functional O
anatomy O
of O
this O
region O

a O
66 O
year O
old O
woman O
was O
treated O
by O
bilateral O
st O
##n O
stimulation O
for O
pd O
a O
40 O
decrease O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
followed O
st O
##n O
stimulation O
alone O
with O
the O
following O
parameters O
left O
contact O
2 O
3 O
5 O
v O
60 O
l O
second O
160 O
hz O
right O
contact O
7 O
3 O
5 O
v O
90 O
l O
second O
160 O
hz O

during O
parameters O
setting O
she O
complained O
of O
vertigo O
nausea O
##s O
and O
os O
##ci O
##llo O
##ps O
##ia O
for O
high O
voltage O
##s O
of O
stimulation O
3 O
5 O
v O
on O
both O
sides O
especially O
on O
contacts O
1 O
left O
and O
6 O
right O
at O
high O
intensity O
respectively O
4 O
5 O
v O
and O
3 O
5 O
v O
we O
noticed O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
tn O
beating O
on O
the O
side O
opposite O
to O
the O
stimulation O
the O
direction O
is O
given O
by O
the O
upper O
pole O
of O
the O
eye O
relative O
to O
patient O
s O
table O
1 O
this O
completely O
disappeared O
when O
the O
parameters O
of O
stimulation O
were O
decreased O
and O
was O
rep O
##rod O
##ucible O
over O
time O
end O
of O
surgery O
stereo O
##ta O
##ctic O
coordinates O
of O
each O
contact O
were O
used O
to O
locate O
them O
within O
a O
3d O
def O
##or O
##mable O
atlas O
of O
the O
basal O
gang O
##lia O
see O
fig O
1 O
3 O
this O
con O
##ﬁ O
##rmed O
the O
unusual O
medial O
tr O
##aj O
##ect O
##ories O
of O
electrode O
##s O
already O
suspected O
on O
the O
brain O
mri O

under O
chronic O
stimulation O
parameters O
we O
observed O
a O
right O
sided O
head O
tilt O
and O
a O
right O
sk O
##ew O
deviation O
i O
e O
h O
##yp O
##ot O
##rop O
##ic O
right O
eye O
eye O
mo O
##tility O
was O
normal O
and O
there O
was O
no O
ny O
##sta O
##gm O
##us O
subjective O
visual O
vertical O
sv O
##v O
was O
tilted O
to O
the O
right O
13 O
48 O
fund O
##i O
disclosed O
bilateral O
right O
sided O
o O
##cular O
tor O
##sion O
this O
was O
consistent O
with O
a O
right O
sided O
o O
##cular O
tilt O
reaction O
ot O
##r O
eye O
movement O
recording O
practiced O
after O
the O
patient O
gave O
her O
written O
consent O
showed O
h O
##yp O
##ometric O
upward O
sac O
##cade O
##s O
normal O
horizontal O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
and O
smooth O
pursuit O
table O
2 O

with O
right O
stimulation O
on O
contact O
6 O
3 O
5 O
v O
a O
counter O
##cl O
##ock O
##wise O
tn O
was O
found O
except O
for O
lower O
gain O
of O
vo O
##r O
eye O
movements O
were O
not O
mod O
##i O
##ﬁ O
##ed O
table O
2 O
vertical O
sac O
##cade O
##s O
could O
not O
be O
correctly O
recorded O
the O
sk O
##ew O
deviation O
increased O
sv O
##v O
slightly O
decreased O
12 O
04 O
##8 O

with O
left O
stimulation O
on O
contact O
1 O
4 O
5 O
v O
we O
noticed O
a O
clockwise O
tn O
ve O
##lo O
##cit O
##ies O
of O
downward O
sac O
##cade O
##s O
downward O
smooth O
pursuit O
gain O
and O
horizontal O
pen O
##du O
##lar O
vo O
##r O
gain O
decreased O
table O
2 O
the O
right O
sided O
sk O
##ew O
deviation O
decreased O
sv O
##v O
normal O
##ized O
10 O
48 O

previously O
reported O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
of O
st O
##n O
stimulation O
consisted O
of O
eye O
##lid O
apr O
##ax O
##ia O
bin O
##oc O
##ular O
dip O
##lo O
##pia O
my O
##osis O
my O
##dr O
##ias O
##is O
and O
contra O
##vers O
##ive O
eye O
deviation O
1 O
2 O
4 O
14 O
tn O
has O
been O
observed O
during O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
matter O
15 O
but O
not O
during O
st O
##n O
stimulation O

st O
##n O
is O
involved O
in O
sac O
##cade O
##s O
and O
smooth O
pursuit O
in O
primate O
##s O
and O
humans O
##16 O
23 O
and O
its O
stimulation O
could O
explain O
some O
o O
##cular O
motor O
side O
effects O
such O
as O
contra O
##vers O
##ive O
eye O
deviation O
10 O
however O
it O
is O
unlikely O
that O
st O
##n O
could O
have O
induced O
the O
tn O
as O
it O
was O
not O
observed O
at O
low O
intensity O
of O
stimulation O

published O
online O
10 O
july O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##51 O

letter O
to O
the O
editor O
1621 O

table O
1 O
stimulation O
parameters O
and O
normal O
complaints O

v O
side O
effects O

contacts O
and O
voltage O
##s O
used O
for O
chronicle O
bilateral O
stimulation O
lc O

2 O
3 O
5 O
no O
visual O
complaint O
rc O

7 O
3 O
5 O
no O
visual O
complaint O
voltage O
##s O
giving O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O

lc O

rc O

7 O
3 O
5 O
slight O
cc O
##w O
tn O

6 O
3 O
5 O
marked O
cc O
##w O
tn O
nausea O
##s O
vertigo O

5 O
3 O
5 O
cc O
##w O
tn O
vertigo O

4 O
3 O
5 O
cc O
##w O
tn O
nausea O
##s O
vertigo O

lc O
left O
contacts O
0 O
is O
the O
deepest O
and O
3 O
is O
the O
upper O
rc O
right O
contacts O
4 O
is O
the O
deepest O
and O
7 O
is O
the O
upper O
v O
intensity O
of O
the O
stimulation O
expressed O
in O
vol O
##ts O
tn O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
cw O
clockwise O
cc O
##w O
counter O
##cl O
##ock O
##wise O

contacts O
on O
witch O
the O
ny O
##sta O
##gm O
##us O
was O
the O
more O
marked O
and O
used O
for O
the O
eyes O
movement O
recordings O

and O
as O
the O
contacts O
were O
medial O
to O
the O
st O
##n O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
can O
also O
be O
explained O
by O
intra O
##fa O
##sc O
##icular O
o O
##cu O
##lom O
##oto O
##r O
nerve O
stimulation O
but O
this O
could O
not O
explain O
bin O
##oc O
##ular O
ny O
##sta O
##gm O
##us O
24 O

fig O
1 O
axial O
view O
of O
the O
me O
##sen O
##ce O
##pha O
##lon O
derived O
from O
the O
def O
##or O
##mable O
3d O
atlas O
ref O
3 O
and O
ana O
##tom O
##ic O
relations O
between O
electrode O
##s O
contacts O
and O
main O
me O
##sen O
##ce O
##pha O
##lic O
structures O
the O
ﬁ O
##gur O
##e O
illustrates O
the O
unusually O
medial O
tr O
##aj O
##ect O
##ories O
of O
the O
stimulation O
electrode O
##s O
the O
four O
contacts O
on O
each O
side O
are O
represented O
by O
blue O
points O
contacts O
0 O
to O
3 O
are O
left O
sided O
0 O
being O
the O
deepest O
and O
3 O
the O
upper O
contacts O
4 O
to O
7 O
are O
right O
sided O
4 O
being O
the O
deepest O
and O
7 O
the O
upper O
coordinates O
of O
each O
contact O
lateral O
##ity O
below O
ac O
pc O
line O
ahead O
of O
cp O
line O
in O
mm O
are O
left O
side O
0 O
10 O
4 O
10 O
5 O
1 O
11 O
4 O
12 O
2 O
11 O
5 O
2 O
5 O
13 O
3 O
12 O
5 O

1 O
14 O
5 O
right O
side O
4 O
9 O
6 O
5 O
7 O
5 O
9 O
5 O
5 O
8 O
6 O
10 O
3 O
9 O
5 O
7 O
11 O

1 O
11 O
rn O
red O
nucleus O
s O
##n O
sub O
##stan O
##tia O
ni O
##gra O
st O
##n O
sub O
##thal O
##ami O
##c O
nucleus O

two O
pre O
##nu O
##cle O
##ar O
mid O
##bra O
##in O
structures O
adjacent O
to O
the O
st O
##n O
could O
be O
implicated O
in O
the O
tn O
the O
ro O
##stra O
##l O
inter O
##sti O
##tial O
nucleus O
of O
the O
medial O
longitudinal O
fa O
##sc O
##icle O
rim O
##lf O
and O
the O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
ic O
the O
rim O
##lf O
is O
the O
immediate O
prem O
##oto O
##r O
structure O
for O
the O
generation O
of O
tor O
##sion O
##al O
and O
vertical O
sac O
##cade O
##s O
25 O
on O
each O
side O
rim O
##lf O
would O
en O
##code O
signals O
for O
both O
upward O
and O
downward O
but O
only O
for O
ip O
##sitor O
##sion O
##al O
sac O
##cade O
##s O
26 O
the O
ic O
is O
involved O
in O
the O
control O
of O
vertical O
and O
ip O
##sil O
##ater O
##al O
tor O
##sion O
##al O
vo O
##r O
and O
velocity O
to O
position O
int O
##eg O
##rator O
25 O
in O
human O
lesions O
of O
rim O
##lf O
alone O
or O
ic O
combined O
essentially O
induce O
a O
contra O
##les O
##ional O
tn O
with O
slowing O
of O
vertical O
sac O
##cade O
##s O
contra O
##les O
##ional O
tor O
##sion O
##al O
deviation O
##s O
during O
sac O
##cade O
##s O
and O
absent O
quick O
phases O
during O
ip O
##si O
##di O
##re O
##ction O
##al O
head O
rotation O
##s O
in O
roll O
26 O
29 O
un O
##ila O
##tera O
##l O
ic O
les O
##ion O
leads O
to O
ip O
##sil O
##es O
##ional O
tn O
and O
un O
##ila O
##tera O
##l O
stimulation O
of O
the O
ic O
ev O
##oke O
##s O
ip O
##sil O
##ater O
##al O
eye O
tor O
##sion O
and O
head O
tilt O
in O
non O
##hum O
##an O
30 O
31 O
in O
humans O
ic O
les O
##ion O
spa O
##ring O
rim O
##lf O
may O
induce O
ip O
##sil O
##es O
##ional O
tn O
##28 O
and O
contra O
##vers O
##ive O
##32 O
33 O
or O
ip O
##sive O
##rs O
##ive O
##28 O
o O
##cular O
tilt O
reaction O

here O
the O
dysfunction O
of O
vertical O
sac O
##cade O
##s O
is O
consistent O
with O
an O
inhibition O
of O
the O
rim O
##lf O
but O
modulation O
of O
ot O
##r O
can O
also O
suggest O
a O
stimulation O
of O
the O
ic O
whether O
this O
is O
explained O
by O
nucleus O
or O
af O
##fer O
##ent O
e O
##ffer O
##ent O
ﬁ O
##bers O
is O
not O
clear O
either O
to O
clarify O
this O
point O
it O
could O
be O
helpful O
to O
simulate O
the O
current O
density O
around O
the O
stimulation O
area O
34 O

according O
to O
the O
close O
relationship O
of O
ic O
rim O
##lf O
and O
stimulation O
contacts O
the O
contra O
##lateral O
tn O
reported O
here O
could O
be O
due O
to O
an O
activation O
of O
the O
ic O
or O
an O
inhibition O
of O
the O
rim O
##lf O
or O
both O
either O
due O
to O
a O
direct O
nucleus O
or O
an O
indirect O
in O
out O
connecting O
pathways O
modulation O

alice O
po O
##isson O
md O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O

ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O

ne O
##uro O
##logie O
c O
lyon O
france O

caroline O
til O
##ike O
##te O
md O
phd O

universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O

ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
unite O
##´ O
de O
ne O
##uro O
op O
##hta O
##lm O
##olo O
##gie O

lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O

lyon O
france O

patrick O
mer O
##tens O
md O
phd O

ne O
##uro O
##chi O
##ru O
##rg O
##ie O
a O
lyon O
france O

ye O
##ln O
##ik O
md O
phd O

ins O
##er O
##m O
u O
67 O
##9 O

de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O

paris O
france O

table O
2 O
eye O
movements O
recording O
with O
2d O
video O
o O
##cu O
##log O
##raphy O
200 O
hz O
frequency O
vis O
##uo O
##200 O
syn O
##ap O
##sy O
##s O
france O

bilateral O
stimulation O
no O
stimulation O

velocity O
ve O
##l O
and O
gain O
of O
horizontal O
158 O
and O
vertical O
108 O
visually O
guided O
sac O
##cade O
##s O
gain O
of O
smooth O
pursuit O
0 O
15 O
hz O
308 O
horizontal O
and O
208 O
vertical O
pen O
##du O
##lar O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
0 O
25 O
hz O
maximum O
amplitude O
of O
45 O
##8 O
and O
maximal O
velocity O
of O
head O
shaking O
ny O
##sta O
##gm O
##us O
hs O
##n O
mean O
frequency O
2 O
hz O
mean O
amplitude O
258 O
in O
horizontal O
and O
vertical O
directions O
were O
recorded O

letter O
to O
the O
editor O
1623 O

eric O
bard O
##ine O
##t O
phd O

cn O
##rs O
up O
##r O
640 O
up O
##mc O

paris O
france O
centre O
de O
ne O
##uro O
image O
##rie O
de O
rec O
##her O
##che O

up O
##mc O

emmanuel O
bro O
##uss O
##oll O
##e O
md O
phd O
ste O
##´ O
##pha O
##ne O
tho O
##bo O
##is O
md O
phd O

ne O
##uro O
##logie O
c O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

email O
stephane O
tho O
##bo O
##is O
chu O
lyon O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
promoted O
by O
the O
hospice O
##s O
civil O
##s O
de O
lyon O
project O
no O
hc O
##l O
p O
2002 O
303 O

k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O

klein O
##er O
fis O
##man O
g O
her O
##zog O
j O
fis O
##man O
d O
##n O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
deep O
brain O
stimulation O
summary O
and O
meta O
analysis O
of O
outcomes O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
su O
##pp O
##l O
14 O
s O
##29 O
##0 O
s O
##30 O
##4 O

ye O
##ln O
##ik O
j O
bard O
##ine O
##t O
e O
dorm O
##ont O
d O
et O
al O
a O
three O
dimensional O
his O
##to O
##logical O
and O
def O
##or O
##mable O
atlas O
of O
the O
human O
basal O
gang O
##lia O
i O
atlas O
construction O
based O
on O
im O
##mun O
##oh O
##isto O
##chemical O
and O
mri O
data O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
61 O
##8 O
63 O
##8 O

ben O
##abi O
##d O
al O
ko O
##ud O
##sie O
a O
ben O
##az O
##zo O
##uz O
a O
et O
al O
deep O
brain O
stimulation O
of O
the O
corpus O
lu O
##ys O
##i O
sub O
##thal O
##ami O
##c O
nucleus O
and O
other O
targets O
in O
parkinson O
s O
disease O
extension O
to O
new O
indications O
such O
as O
d O
##yst O
##onia O
and O
ep O
##ile O
##psy O
j O
ne O
##uro O
##l O
2001 O
248 O
su O
##pp O
##l O
3 O
iii O
##37 O
iii O
##47 O

bro O
##gg O
##i O
g O
franz O
##ini O
a O
fe O
##rro O
##li O
p O
et O
al O
effect O
of O
bilateral O
sub O
##thal O
##ami O
##c O
electrical O
stimulation O
in O
parkinson O
s O
disease O
sur O
##g O
ne O
##uro O
##l O
2001 O
56 O
89 O
94 O
discussion O
94 O
86 O

her O
##zog O
j O
vol O
##km O
##ann O
j O
k O
##rac O
##k O
p O
et O
al O
two O
year O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2003 O
18 O
133 O
##2 O
133 O
##7 O

ian O
##se O
##k O
r O
rosen O
##feld O
j O
##v O
hu O
##x O
##ham O
fe O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
med O
j O
aus O
##t O
2002 O
177 O
142 O
146 O

os O
##ter O
##gaard O
k O
sun O
##de O
n O
dupont O
e O
effects O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
patients O
with O
severe O
parkinson O
s O
disease O
and O
motor O
ﬂ O
##uc O
##tua O
##tions O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
69 O
##3 O
700 O

rom O
##ito O
l O
##m O
sc O
##er O
##rat O
##i O
m O
con O
##tar O
##ino O
m O
##f O
bent O
##ivo O
##glio O
ar O
ton O
##ali O
p O
alba O
##nese O
a O
long O
term O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
ne O
##uro O
##logy O
2002 O
58 O
154 O
##6 O
1550 O

saul O
##eau O
p O
poll O
##ak O
p O
k O
##rac O
##k O
p O
et O
al O
contra O
##vers O
##ive O
eye O
deviation O
during O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
region O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1810 O
1813 O

tam O
##ma O
f O
ramp O
##ini O
p O
e O
##gi O
##di O
m O
et O
al O
deep O
brain O
stimulation O
for O
parkinson O
s O
disease O
the O
experience O
of O
the O
pol O
##ic O
##lini O
##co O
san O
paolo O
group O
in O
milan O
ne O
##uro O
##l O
sci O
2003 O
24 O
su O
##pp O
##l O
1 O
s O
##41 O
s O
##42 O

ta O
##vel O
##la O
a O
berg O
##ama O
##sco O
b O
bo O
##stic O
##co O
e O
et O
al O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
long O
term O
follow O
up O
ne O
##uro O
##l O
sci O
2002 O
23 O
su O
##pp O
##l O
2 O
s O
##11 O
##1 O
s O
##11 O
##2 O

tho O
##bo O
##is O
s O
mer O
##tens O
p O
gu O
##eno O
##t O
m O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
clinical O
evaluation O
of O
18 O
patients O
j O
ne O
##uro O
##l O
2002 O
249 O
52 O
##9 O
53 O
##4 O

vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
weiss O
ph O
fr O
##eu O
##nd O
h O
##j O
stu O
##rm O
v O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

lu O
##eck O
c O
##j O
has O
##ml O
##yn O
p O
crawford O
t O
##j O
levy O
is O
br O
##ind O
##ley O
gs O
watkins O
es O
ken O
##nard O
c O
a O
case O
of O
o O
##cular O
tilt O
reaction O
and O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
due O
to O
direct O
stimulation O
of O
the O
mid O
##bra O
##in O
in O
man O
brain O
1991 O
114 O
pt O
5 O
206 O
##9 O
207 O
##9 O

hue O
##rta O
m O
##f O
k O
##ru O
##bit O
##zer O
la O
ka O
##as O
j O
##h O
frontal O
eye O
ﬁ O
##eld O
as O
de O
##ﬁ O
##ned O
by O
intra O
##cor O
##tical O
micro O
##sti O
##mu O
##lation O
in O
squirrel O
monkeys O
owl O
monkeys O
and O
mac O
##aq O
##ue O
monkeys O
i O
sub O
##cor O
##tical O
connections O
j O
com O
##p O
ne O
##uro O
##l O
1986 O
253 O
415 O
43 O
##9 O

hue O
##rta O
m O
##f O
po O
##ns O
t O
##p O
primary O
motor O
cortex O
receives O
input O
from O
area O
3a O
in O
mac O
##aq O
##ues O
brain O
res O
1990 O
53 O
##7 O
36 O
##7 O
37 O
##1 O

stanton O
gb O
goldberg O
me O
bruce O
c O
##j O
frontal O
eye O
ﬁ O
##eld O
e O
##ffer O
##ents O
in O
the O
mac O
##aq O
##ue O
monkey O
ii O
topography O
of O
terminal O
ﬁ O
##eld O
##s O
in O
mid O
##bra O
##in O
and O
po O
##ns O
j O
com O
##p O
ne O
##uro O
##l O
1988 O
271 O
49 O
##3 O
50 O
##6 O

bass O
##o O
ma O
po O
##kor O
##ny O
jj O
liu O
p O
activity O
of O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
re O
##tic O
##ulata O
neurons O
during O
smooth O
pursuit O
eye O
movements O
in O
monkeys O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2005 O
22 O
44 O
##8 O
46 O
##4 O

mats O
##um O
##ura O
m O
ko O
##jima O
j O
gardiner O
t O
##w O
hi O
##kos O
##aka O
o O
visual O
and O
o O
##cu O
##lom O
##oto O
##r O
functions O
of O
monkey O
sub O
##thal O
##ami O
##c O
nucleus O
j O
ne O
##uro O
##phy O
##sio O
##l O
1992 O
67 O
161 O
##5 O
1632 O

fa O
##wc O
##ett O
ap O
cu O
##nic O
d O
ham O
##ani O
c O
et O
al O
sac O
##cade O
related O
potential O
##s O
recorded O
from O
human O
sub O
##thal O
##ami O
##c O
nucleus O
cl O
##in O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
118 O
155 O
163 O

fa O
##wc O
##ett O
ap O
dos O
##tro O
##vsky O
jo O
lo O
##zano O
am O
hut O
##chison O
w O
##d O
eye O
movement O
related O
responses O
of O
neurons O
in O
human O
sub O
##thal O
##ami O
##c O
nucleus O
ex O
##p O
brain O
res O
2005 O
162 O
357 O
365 O

ri O
##va O
##ud O
pe O
##cho O
##ux O
s O
ve O
##rm O
##ers O
##ch O
ai O
gay O
##mar O
##d O
b O
et O
al O
improvement O
of O
memory O
guided O
sac O
##cade O
##s O
in O
parkinson O
##ian O
patients O
by O
high O
frequency O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2000 O
68 O
381 O
38 O
##4 O

be O
##j O
##jan O
##i O
bp O
ar O
##nu O
##lf O
i O
ho O
##uet O
##o O
j O
##l O
et O
al O
concurrent O
ex O
##cit O
##atory O
and O
inhibitor O
##y O
effects O
of O
high O
frequency O
stimulation O
an O
o O
##cu O
##lom O
##oto O
##r O
study O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2002 O
72 O
51 O
##7 O
52 O
##2 O

bu O
##ut O
##tner O
u O
bu O
##ut O
##tner O
en O
##ne O
##ver O
ja O
ram O
##bold O
h O
helm O
##chen O
c O
the O
contribution O
of O
mid O
##bra O
##in O
circuits O
in O
the O
control O
of O
gaze O
ann O
n O
y O
ac O
##ad O
sci O
2002 O
95 O
##6 O
99 O
110 O

k O
##rem O
##my O
##da O
o O
bu O
##¨ O
##tt O
##ner O
en O
##ne O
##ver O
ja O
bu O
##¨ O
##tt O
##ner O
u O
g O
##las O
##auer O
s O
tor O
##sion O
##al O
deviation O
##s O
with O
voluntary O
sac O
##cade O
##s O
caused O
by O
a O
un O
##ila O
##tera O
##l O
mid O
##bra O
##in O
les O
##ion O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2007 O
78 O
115 O
##5 O
115 O
##7 O

b O
##hid O
##aya O
##sir O
##i O
r O
plant O
gt O
leigh O
r O
##j O
a O
hypothetical O
scheme O
for O
the O
brains O
##tem O
control O
of O
vertical O
gaze O
ne O
##uro O
##logy O
2000 O
54 O
1985 O
1993 O

helm O
##chen O
c O
ram O
##bold O
h O
kemp O
##erman O
##n O
u O
butt O
##ner O
en O
##ne O
##ver O
ja O
butt O
##ner O
u O
local O
##izing O
value O
of O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
in O
small O
mid O
##bra O
##in O
lesions O
ne O
##uro O
##logy O
2002 O
59 O
1956 O
1964 O

rio O
##rdan O
eva O
p O
fa O
##ldon O
m O
butt O
##ner O
en O
##ne O
##ver O
ja O
gas O
##s O
a O
bro O
##nstein O
am O
gr O
##est O
##y O
ma O
abnormalities O
of O
tor O
##sion O
##al O
fast O
phase O
eye O
movements O
in O
un O
##ila O
##tera O
##l O
ro O
##stra O
##l O
mid O
##bra O
##in O
disease O
ne O
##uro O
##logy O
1996 O
47 O
201 O
207 O

far O
##sha O
##dman O
##esh O
f O
k O
##lier O
em O
chang O
p O
wang O
h O
crawford O
jd O
three O
dimensional O
eye O
head O
coordination O
after O
injection O
of O
mu O
##sc O
##imo O
##l O
into O
the O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
inc O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
232 O
##2 O
233 O
##8 O

k O
##lier O
em O
wang O
h O
crawford O
jd O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
en O
##codes O
three O
dimensional O
head O
orientation O
##s O
in O
fi O
##ck O
like O
coordinates O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
60 O
##4 O
61 O
##7 O

dieter O
##ich O
m O
brandt O
t O
tha O
##lam O
##ic O
in O
##far O
##ctions O
differential O
effects O
on O
vest O
##ib O
##ular O
function O
in O
the O
roll O
plane O
35 O
patients O
ne O
##uro O
##logy O
1993 O
43 O
1732 O
1740 O

hal O
##ma O
##gy O
##i O
gm O
brandt O
t O
dieter O
##ich O
m O
curt O
##ho O
##ys O
is O
stark O
r O
##j O
ho O
##yt O
w O
##f O
tonic O
contra O
##vers O
##ive O
o O
##cular O
tilt O
reaction O
due O
to O
un O
##ila O
##tera O
##l O
me O
##so O
die O
##nce O
##pha O
##lic O
les O
##ion O
ne O
##uro O
##logy O
1990 O
40 O
150 O
##3 O
150 O
##9 O

1624 O
letters O
to O
the O
editor O

but O
##son O
cr O
cooper O
se O
henderson O
j O
##m O
mcintyre O
cc O
patients O
##pe O
##ci O
##ﬁ O
##c O
analysis O
of O
the O
volume O
of O
tissue O
activated O
during O
deep O
brain O
stimulation O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
66 O
##1 O
670 O

pal O
##atal O
tremor O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
in O
a O
patient O
with O
pol O
##g O
##1 O
mutation O

recently O
a O
progressive O
ata O
##xi O
##c O
syndrome O
msc O
##ae O
caused O
by O
za O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
was O
reported O
1 O
4 O
the O
nuclear O
gene O
pol O
##g O
##1 O
en O
##codes O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
dependent O
polymer O
##ase O
polymer O
##ase O
g O
##5 O
the O
catalytic O
subunit O
comprises O
three O
domains O
a O
polymer O
##ase O
and O
30 O
50 O
ex O
##on O
##uc O
##lea O
##se O
domain O
and O
an O
intervening O
link O
##er O
region O
over O
70 O
mutations O
have O
been O
reported O
in O
the O
catalytic O
subunit O
with O
both O
dominant O
and O
recess O
##ive O
modes O
of O
inheritance O
the O
carrier O
frequency O
of O
these O
two O
mutations O
is O
high O
in O
northern O
europe O
particularly O
scandinavia O
3 O
the O
clinical O
features O
associated O
with O
pol O
##g O
##1 O
mutation O
include O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
6 O
al O
##pers O
syndrome O
7 O
parkinson O
##ism O
8 O
or O
a O
syndrome O
with O
sensory O
ata O
##xia O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sand O
##o O
9 O
we O
present O
a O
young O
woman O
homo O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
msc O
##ae O
that O
developed O
pal O
##atal O
tremor O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
and O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
ol O
##ivar O
##y O
nuclei O

the O
patient O
is O
now O
35 O
years O
old O
without O
family O
history O
of O
ep O
##ile O
##psy O
or O
movement O
disorder O
she O
was O
ﬁ O
##rst O
seen O
at O
the O
age O
of O
19 O
with O
focal O
ep O
##ile O
##ptic O
seizures O
five O
years O
later O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
ga O
##it O
un O
##stead O
##iness O
were O
noted O
and O
aged O
28 O
during O
her O
ﬁ O
##rst O
pregnancy O
she O
was O
admitted O
with O
focal O
ep O
##ile O
##ptic O
seizures O
that O
were O
highly O
resistant O
to O
treatment O
two O
months O
later O
her O
symptoms O
worsened O
and O
included O
my O
##oc O
##lon O
##ic O
jerk O
##s O
in O
the O
ex O
##tre O
##mit O
##ies O
and O
facial O
d O
##ys O
##kin O
##es O
##ias O
treatment O
with O
sodium O
val O
##pro O
##ate O
resulted O
in O
acute O
severe O
he O
##pati O
##c O
failure O
and O
she O
underwent O
a O
successful O
liver O
transplant O
##ation O
two O
years O
later O
a O
cerebral O
mri O
scan O
showed O
marked O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
olive O
##s O
fig O
1 O
she O
denied O
symptoms O
of O
ear O
clicking O

on O
examination O
at O
age O
35 O
she O
had O
a O
mild O
cognitive O
de O
##ﬁ O
##cit O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
mild O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
no O
ny O
##sta O
##gm O
##us O
and O
no O
facial O
nerve O
dysfunction O
she O
had O
an O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
consisting O
of O
sound O
##less O
bilateral O
sync O
##hr O
##ono O
##us O
and O
symmetrical O
2 O
hz O
contraction O
##s O
of O
the O
soft O
pal O
##ate O
plus O
facial O
d O
##ys O
##kin O
##es O
##ias O
consisting O
of O
continuous O
rhythmic O
und O
##ulating O
wave O
like O
bilateral O
per O
##ior O
##bit O
##al O
movements O

intermittent O
as O
##ym O
##metric O
limb O
my O
##oc O
##lon O
##us O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
and O
signs O
of O
peripheral O
ne O
##uro O
##pathy O
with O
loss O
of O
re O
##ﬂ O
##ex O
##es O
and O
sensory O
disturbance O
were O
also O
present O
muscle O
bulk O
tone O
and O
power O
appeared O
normal O
dna O
analysis O
con O
##ﬁ O
##rmed O
that O
she O
was O
homo O
##zy O
##go O
##us O
for O
the O
c O
224 O
##3 O
##g O
c O
p O
w O
##7 O
##48 O
##s O
mutation O
in O
pol O
##g O
##1 O

our O
patient O
demonstrates O
the O
typical O
features O
of O
msc O
##ae O
with O
the O
combination O
of O
focal O
ep O
##ile O
##psy O
my O
##oc O
##lon O
##us O
and O
ata O
##xia O
as O
well O
as O
sensitivity O
to O
sodium O
val O
##pro O
##ate O
3 O
10 O
the O
interesting O
features O
are O
the O
rhythmic O
##al O
facial O
d O
##ys O
##kin O
##es O
##ia O
and O
the O
as O
##ym O
##p O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##8 O

tom O
##atic O
pal O
##atal O
tremor O
with O
its O
structural O
co O
##rre O
##late O
of O
inferior O
ol O
##ivar O
##y O
nuclei O
involvement O

hyper O
##tro O
##phic O
ol O
##ivar O
##y O
de O
##gen O
##eration O
ho O
##d O
is O
clinical O
##ly O
associated O
with O
pal O
##atal O
tremor O
and O
is O
often O
caused O
by O
pathology O
in O
the O
dent O
##ato O
rub O
##ro O
ol O
##ivar O
##y O
pathways O
or O
also O
called O
gui O
##lla O
##in O
mo O
##llar O
##et O
triangle O
usually O
the O
les O
##ion O
is O
caused O
by O
vascular O
is O
##che O
##mia O
hem O
##or O
##rh O
##age O
infection O
trauma O
neo O
##pl O
##as O
##m O
or O
dem O
##ye O
##lina O
##tion O
11 O
a O
syndrome O
called O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
pa O
##pt O
has O
been O
reported O
and O
shows O
similarities O
to O
our O
case O
even O
though O
sporadic O
pa O
##pt O
cases O
had O
a O
het O
##ero O
##gen O
##eous O
clinical O
picture O
the O
ce O
##re O
##bella O
##r O
de O
##gen O
##eration O
was O
the O
most O
sy O
##mpt O
##oma O
##tic O
feature O
and O
ho O
##d O
was O
common O
in O
the O
presented O
cases O
12 O
in O
the O
familiar O
forms O
of O
pa O
##pt O
however O
ol O
##ivar O
##y O
pathology O
was O
absent O
pal O
##atal O
tremor O
with O
ol O
##ivar O
##y O
hyper O
##tro O
##phy O
and O
dent O
##ate O
cal O
##ci O
##ﬁ O
##cation O
has O
also O
been O
described O
in O
a O
form O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
sc O
##a O
20 O
13 O

in O
our O
patient O
ho O
##d O
was O
an O
incident O
##al O
mri O
ﬁ O
##nding O
without O
any O
obvious O
clinical O
symptoms O
it O
occurred O
several O
years O
after O
disease O
onset O
the O
lack O
of O
ear O
clicks O
or O
other O
symptoms O
may O
explain O
why O
this O
clinical O
picture O
has O
not O
been O
reported O
by O
other O
authors O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
may O
also O
be O
easily O
overlooked O
in O
a O
routine O
clinical O
examination O

facial O
d O
##ys O
##kin O
##es O
##ia O
appeared O
as O
wave O
like O
per O
##ior O
##bit O
##al O
involuntary O
movements O
on O
both O
sides O
but O
not O
per O
##ior O
##al O
these O
as O
##ym O
##metric O
movements O
alternating O
from O
one O
side O
to O
the O
other O
were O
most O
prominent O
when O
she O
was O
in O
a O
resting O
position O
she O
had O
never O
been O
treated O
with O
ne O
##uro O
##le O
##ptic O
or O
anti O
##park O
##ins O
##onia O
##n O
drugs O
that O
might O
have O
induced O
this O
feature O
ee O
##g O
recorded O
routinely O
due O
to O
her O
ep O
##ile O
##psy O
has O
not O
shown O
any O
co O
##rre O
##late O
with O
these O
movements O
oro O
##fa O
##cial O
d O
##ys O
##kin O
##es O
##ia O
is O
reported O
in O
cho O
##rea O
ac O
##ant O
##ho O
##cy O
##tosis O
together O
with O
other O
symptoms O
like O
d O
##ys O
##pha O
##gia O
d O
##ys O
##arth O
##ria O
are O
##ﬂ O
##ex O
##ia O
seizures O
and O
dementia O
14 O
facial O
my O
##or O
##hy O
##th O
##mia O
is O
also O
path O
##og O
##no O
##mic O
for O
whip O
##ple O
s O
disease O
mostly O
localized O
around O
the O
eyes O
and O
jaw O
other O
symptoms O
as O
seizures O
my O
##oc O
##lon O
##us O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
d O
##ys O
##arth O
##ria O
are O
also O
common O
a O
diagnostic O
criterion O
for O
this O
entity O
is O
small O
int O
##est O
##ine O
bio O
##psy O
that O
excluded O
the O
disease O

we O
present O
a O
case O
with O
the O
typical O
clinical O
features O
of O
pol O
##g O
##1 O
mutation O
and O
additional O
novel O
ﬁ O
##nding O
##s O
of O
pal O
##atal O
tremor O
with O
ho O
##d O
on O
mri O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
these O
ﬁ O
##nding O
##s O
expand O
the O
clinical O
spectrum O
of O
the O
syndrome O
##s O
caused O
by O
mutation O
in O
this O
gene O
moreover O
since O
pal O
##atal O
tremor O
is O
a O
rare O
disorder O
and O
often O
reported O
as O
a O
sporadic O
entity O
we O
suggest O
that O
pol O
##g O
##1 O
mutation O
should O
be O
considered O
in O
patients O
with O
this O
disorder O

segment O
1 O
the O
patient O
shows O
ga O
##it O
ata O
##xia O
and O
mild O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
she O
has O
bilateral O
as O
##ym O
##metric O
##al O
rhythmic O
##al O
facial O
d O
##ys O
##kin O
##es O
##ias O
mainly O
in O
the O
per O
##ior O
##bit O
##al O
regions O
the O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
sound O
##less O
bilateral O
sync O
##hr O
##ono O
##us O
and O
symmetrical O
2 O
##h O
##z O
contraction O
##s O
of O
the O
soft O
pal O
##ate O

kris O
##z O
##tina O
k O
johan O
##sen O
md O

department O
of O
neuroscience O
norwegian O
university O
of O
science O
and O
technology O

trondheim O
norway O

letters O
to O
the O
editor O
1625 O

fig O
1 O
marked O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
olive O
##s O

laurence O
a O
bind O
##off O
md O
phd O

department O
of O
ne O
##uro O
##logy O
ha O
##uke O
##land O
university O
hospital O
bergen O
institute O
of O
clinical O
medicine O

university O
of O
bergen O
norway O

jana O
ry O
##dl O
##and O
md O

department O
of O
radio O
##logy O
st O
ol O
##avs O
hospital O

jan O
o O
aa O
##sl O
##y O
md O
phd O

department O
of O
ne O
##uro O
##logy O
st O
ol O
##avs O
hospital O
trondheim O
department O
of O
neuroscience O

norwegian O
university O
of O
science O
and O
technology O

e O
mail O
jan O
aa O
##sl O
##y O
nt O
##nu O
no O

van O
goethe O
##m O
g O
lu O
##oma O
p O
ran O
##tama O
##ki O
m O
et O
al O
pol O
##g O
mutations O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
with O
ata O
##xia O
but O
no O
muscle O
involvement O
ne O
##uro O
##logy O
2004 O
63 O
125 O
##1 O
125 O
##7 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O

winter O
##th O
##un O
s O
ferrari O
g O
he O
l O
et O
al O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
due O
to O
mitochondrial O
polymer O
##ase O
gamma O
mutations O
ne O
##uro O
##logy O
2005 O
64 O
120 O
##4 O
120 O
##8 O

t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O

ka O
##gun O
##i O
l O
##s O
dna O
polymer O
##ase O
gamma O
the O
mitochondrial O
replica O
##se O
ann O
rev O
bio O
##che O
##m O
2004 O
73 O
293 O
320 O

lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
et O
al O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O
2002 O
52 O
211 O
219 O

na O
##via O
##ux O
r O
##k O
nguyen O
kv O
pol O
##g O
mutations O
associated O
with O
al O
##pers O
syndrome O
and O
mitochondrial O
dna O
de O
##ple O
##tion O
ann O
ne O
##uro O
##l O
2004 O
55 O
70 O
##6 O
71 O
##2 O

lu O
##oma O
pt O
ee O
##rol O
##a O
j O
ah O
##ola O
s O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
gamma O
variants O
in O
id O
##io O
##pathic O
sporadic O
parkinson O
disease O
ne O
##uro O
##logy O
2007 O
69 O
115 O
##2 O
115 O
##9 O

fa O
##dic O
r O
russell O
ja O
ve O
##dana O
##raya O
##nan O
v O
##v O
le O
##har O
m O
kun O
##cl O
r O
##w O
johns O
dr O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
as O
the O
presenting O
feature O
of O
a O
novel O
mitochondrial O
disease O
ne O
##uro O
##logy O
1997 O
49 O
239 O
245 O

eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
et O
al O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
2008 O
131 O
81 O
##8 O
28 O

yoko O
##ta O
t O
hi O
##ras O
##hima O
f O
fur O
##uka O
##wa O
t O
ts O
##uka O
##gos O
##hi O
h O
yo O
##shi O
##kawa O

h O
mri O
ﬁ O
##nding O
##s O
of O
inferior O
olive O
##s O
in O
pal O
##atal O
my O
##oc O
##lon O
##us O
j O
ne O
##uro O
##l O
1989 O
236 O
115 O
116 O

samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
##s O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O

1626 O
letters O
to O
the O
editor O

knight O
ma O
gardner O
r O
##j O
ba O
##hl O
##o O
m O
et O
al O
dominant O
##ly O
inherited O
ata O
##xia O
and O
d O
##ys O
##phon O
##ia O
with O
dent O
##ate O
cal O
##ci O
##ﬁ O
##cation O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
brain O
2004 O
127 O
117 O
##2 O
118 O
##1 O

ramp O
##old O
##i O
l O
dane O
##k O
a O
monaco O
ap O
clinical O
features O
and O
molecular O
bases O
of O
ne O
##uro O
##aca O
##nt O
##ho O
##cy O
##tosis O
j O
mo O
##l O
med O
2002 O
80 O
475 O
49 O
##1 O

tha O
##lam O
##ic O
stimulation O
does O
not O
involve O
a O
high O
rate O
of O
suicide O

i O
read O
with O
some O
concern O
the O
paper O
of O
apple O
##by O
et O
al O
published O
in O
the O
september O
issue O
of O
md O
##j O
1 O
the O
authors O
write O
in O
the O
abstract O
reported O
rates O
of O
depression O
cognitive O
impairment O
mania O
and O
behavior O
change O
are O
low O
but O
there O
is O
a O
high O
rate O
of O
suicide O
in O
patients O
treated O
with O
db O
##s O
particularly O
with O
tha O
##lam O
##ic O
and O
gp O
##i O
stimulation O
in O
the O
results O
section O
the O
authors O
provide O
numbers O
and O
percentage O
of O
those O
patients O
that O
expressed O
suicidal O
##ity O
de O
##ﬁ O
##ned O
as O
suicidal O
idea O
##tion O
suicide O
attempt O
or O
completed O
suicide O
they O
wrote O
most O
patients O
underwent O
db O
##s O
for O
the O
treatment O
of O
parkinson O
s O
disease O
26 O
81 O
4 O
had O
d O
##yst O
##onia O
12 O
5 O
1 O
had O
essential O
tremor O
3 O
and O
another O
had O
o O
##cd O
3 O
then O
the O
authors O
provide O
details O
of O
the O
brain O
target O
for O
db O
##s O
in O
these O
patients O
26 O
patients O
81 O
were O
implant O
##ed O
in O
the O
st O
##n O
4 O
12 O
5 O
had O
gp O
##i O
implant O
##s O
and O
1 O
3 O
had O
a O
vi O
##m O
implant O
and O
the O
last O
patient O
received O
an O
anterior O
limb O
of O
the O
internal O
capsule O
implant O
then O
toward O
the O
end O
of O
the O
results O
section O
they O
wrote O
the O
rate O
of O
completed O
suicide O
was O
highest O
in O
the O
tha O
##lam O
##us O
group O
5 O
4 O

in O
my O
reading O
these O
results O
simply O
do O
not O
add O
up O
and O
the O
drawn O
conclusions O
expressed O
both O
in O
the O
abstract O
and O
in O
the O
discussion O
of O
that O
paper O
do O
not O
sub O
##stan O
##tia O
##te O
in O
fact O
contra O
##dict O
the O
ﬁ O
##gur O
##es O
and O
percentage O
cited O
this O
article O
is O
supposed O
to O
be O
a O
review O
of O
the O
literature O
and O
a O
meta O
analysis O
but O
nowhere O
can O
one O
read O
how O
the O
meta O
analysis O
was O
statistical O
##ly O
conducted O
to O
start O
with O
there O
is O
no O
information O
about O
the O
number O
of O
patients O
with O
the O
various O
dia O
##gno O
##ses O
or O
the O
number O
of O
patients O
operated O
on O
in O
the O
various O
brain O
targets O
there O
is O
instead O
information O
about O
number O
of O
publications O
their O
geographical O
origin O
gender O
of O
patients O
etc O
there O
is O
no O
mention O
of O
any O
data O
providing O
the O
percentage O
of O
patients O
with O
suicidal O
##ity O
in O
relation O
to O
the O
number O
of O
patients O
operated O
on O
in O
any O
of O
the O
brain O
targets O
or O
for O
any O
of O
the O
dia O
##gno O
##ses O

in O
the O
quoted O
references O
i O
cannot O
ﬁ O
##nd O
any O
reference O
that O
supports O
the O
authors O
claim O
that O
tha O
##lam O
##ic O
stimulation O
carries O
the O
highest O
risk O
for O
suicidal O
##ity O
and O
the O
authors O
do O
not O
give O
the O
citation O
reference O
numbers O
to O
back O
up O
their O
conclusions O
to O
name O
but O
one O
example O
the O
last O
patient O
who O
committed O
suicide O
and O
who O
received O
an O
anterior O
limb O
of O
the O
internal O
capsule O
implant O
is O
certainly O
the O
patient O
described O
by O
abel O
##son O
et O
al O
in O
the O
non O
##qu O
##oted O
paper O
on O
four O
patients O
with O
o O
##cd O
treated O
with O
db O
##s O
2 O

the O
authors O
wrote O
since O
its O
approval O
by O
the O
fda O
in O
1997 O
for O
use O
in O
parkinson O
s O
disease O
db O
##s O
has O
been O
used O
to O
treat O
essential O
tremor O
d O
##yst O
##onia O
cluster O
headache O
##s O
and O
chronic O
pain O
##1 O
4 O
and O
among O
these O
4 O
quoted O
references O
one O
ref O
4 O
was O
actually O
about O
db O
##s O
for O
ep O
##ile O
##psy O
besides O
it O
is O

true O
that O
fda O
granted O
approval O
for O
tha O
##lam O
##ic O
db O
##s O
for O
parkinson O
##ian O
and O
essential O
tremor O
in O
1997 O
then O
pal O
##lid O
##al O
db O
##s O
and O
st O
##n O
db O
##s O
for O
advanced O
pd O
in O
2001 O
however O
for O
d O
##yst O
##onia O
the O
fda O
granted O
in O
2003 O
a O
humanitarian O
device O
exemption O
which O
is O
not O
a O
full O
approval O

instead O
of O
providing O
several O
tables O
detailing O
device O
related O
adverse O
events O
table O
3 O
and O
so O
##matic O
adverse O
events O
table O
4 O
both O
of O
which O
are O
evidently O
out O
of O
the O
scope O
of O
this O
paper O
on O
psychiatric O
and O
ne O
##uro O
##psy O
##chia O
##tric O
adverse O
events O
it O
would O
have O
been O
more O
helpful O
to O
provide O
tables O
of O
the O
percentage O
or O
prevalence O
of O
suicide O
##s O
according O
to O
target O
and O
diagnosis O
in O
my O
review O
of O
the O
literature O
suicidal O
##ity O
following O
db O
##s O
is O
overall O
rare O
and O
its O
prevalence O
is O
higher O
in O
patients O
with O
sub O
##thal O
##ami O
##c O
db O
##s O
compared O
to O
tha O
##lam O
##ic O
db O
##s O
a O
ﬁ O
##nding O
contrary O
to O
their O
statement O
in O
the O
abstract O
and O
on O
page O
1726 O

the O
ﬁ O
##nal O
conclusion O
of O
this O
article O
reads O
our O
ﬁ O
##nding O
##s O
are O
optimistic O
regarding O
the O
use O
of O
db O
##s O
for O
psychiatric O
disorders O
which O
ﬁ O
##nding O
##s O
i O
looked O
repeatedly O
in O
the O
paper O
for O
any O
results O
ﬁ O
##gur O
##es O
or O
tables O
that O
would O
justify O
such O
a O
conclusion O
but O
could O
ﬁ O
##nd O
none O
in O
the O
context O
of O
this O
study O
such O
a O
conclusion O
seems O
to O
me O
in O
need O
of O
rec O
##ons O
##ider O
##ation O
and O
the O
data O
need O
to O
be O
clearly O
provided O

in O
my O
view O
we O
are O
left O
with O
a O
published O
study O
that O
could O
potentially O
have O
been O
an O
extremely O
inform O
##ative O
analysis O
had O
the O
authors O
separated O
tha O
##lam O
##us O
and O
sub O
##thal O
##am O
##us O
and O
had O
they O
carefully O
evaluated O
the O
literature O
that O
they O
set O
themselves O
to O
review O
the O
meta O
analysis O
promised O
in O
the O
title O
of O
this O
work O
was O
not O
provided O
and O
the O
authors O
fall O
short O
of O
answering O
the O
issues O
at O
stake O

mar O
##wan O
i O
hari O
##z O
md O
phd O

professor O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O

institute O
of O
ne O
##uro O
##logy O
queen O
square O
london O
united O
kingdom O

e O
mail O
m O
hari O
##z O
ion O
uc O
##l O
ac O
uk O
or O
mar O
##wan O
hari O
##z O
ne O
##uro O
um O
##u O
se O

apple O
##by O
bs O
dug O
##gan O
ps O
reg O
##enberg O
a O
ra O
##bin O
##s O
pv O
psychiatric O
and O
ne O
##uro O
##psy O
##chia O
##tric O
adverse O
events O
associated O
with O
deep O
brain O
stimulation O
a O
meta O
analysis O
of O
ten O
years O
experience O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1722 O
1728 O

abel O
##son O
j O
##l O
curtis O
g O
##c O
sa O
##gh O
##er O
o O
al O
##buch O
##er O
rc O
ha O
##rrigan O
m O
taylor O
m O
##f O
mart O
##is O
b O
gi O
##ord O
##ani O
b O
deep O
brain O
stimulation O
for O
ref O
##rac O
##tory O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
bio O
##l O
psychiatry O
2005 O
57 O
510 O
51 O
##6 O

d O
##yst O
##onia O
with O
super O
##im O
##posed O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
an O
experiment O
in O
nature O

ne O
##uro O
##mus O
##cular O
junction O
##al O
nm O
##j O
paralysis O
induced O
by O
bot O
##ulin O
##um O
toxin O
injection O
is O
currently O
the O
preferred O
treatment O
for O
focal O
or O
segment O
##al O
d O
##yst O
##onia O
whereas O
nm O
##j O
paralysis O
due O
to O
de O
##ple O
##tion O
of O
post O
##jun O
##ction O
##al O
ace O
##ty O
##lch O
##olin O
##e O
receptors O
is O
the O
pathogen O
##etic O
mechanism O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mg O
a O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##38 O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##66 O

letters O
to O
the O
editor O
162 O
##7 O

patient O
with O
d O
##yst O
##onia O
developing O
mg O
may O
therefore O
show O
improvement O
of O
d O
##yst O
##onic O
symptoms O
here O
we O
present O
2 O
patients O
with O
coe O
##xi O
##sti O
##ng O
d O
##yst O
##onia O
and O
mg O

a O
69 O
year O
old O
woman O
19 O
years O
earlier O
noticed O
intermittent O
turning O
of O
her O
head O
to O
the O
right O
side O
which O
had O
begun O
suddenly O
following O
a O
motor O
vehicle O
accident O
she O
had O
side O
##to O
side O
movement O
of O
her O
head O
with O
rotation O
and O
tilt O
to O
the O
right O
side O
it O
was O
aggravated O
by O
stress O
and O
suppressed O
with O
sensory O
tricks O
there O
was O
no O
family O
history O
of O
d O
##yst O
##onia O
or O
of O
prior O
treatment O
with O
ne O
##uro O
##le O
##ptic O
medications O
she O
was O
diagnosed O
with O
cervical O
d O
##yst O
##onia O
with O
mild O
head O
tremor O
she O
tried O
various O
oral O
medications O
with O
no O
improvement O
she O
was O
never O
treated O
with O
bot O
##ulin O
##um O
toxin O

seven O
years O
ago O
she O
developed O
double O
vision O
dr O
##ooping O
of O
the O
eyelids O
and O
generalized O
weakness O
she O
also O
noted O
marked O
reduction O
of O
d O
##yst O
##onic O
movements O
at O
the O
same O
time O
neurological O
examination O
revealed O
bilateral O
pt O
##osis O
and O
dip O
##lo O
##pia O
which O
worsened O
on O
fatigue O
she O
had O
minimal O
d O
##yst O
##onic O
head O
tremor O
with O
tor O
##tic O
##oll O
##is O
to O
the O
right O
of O
208 O
and O
right O
later O
##oco O
##llis O
of O
158 O
she O
also O
had O
bilateral O
orb O
##icular O
##is O
o O
##cu O
##li O
and O
generalized O
pro O
##xi O
##mal O
muscle O
weakness O
the O
remainder O
of O
her O
neurological O
examination O
disclosed O
no O
abnormalities O
she O
was O
diagnosed O
with O
generalized O
ser O
##op O
##osi O
##tive O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
started O
on O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
and O
co O
##rti O
##cos O
##ter O
##oids O
which O
resulted O
in O
the O
improvement O
of O
the O
my O
##ast O
##hen O
##ic O
symptoms O
and O
signs O
on O
recent O
follow O
up O
she O
had O
minimal O
head O
tremor O
in O
the O
side O
to O
side O
direction O
mild O
residual O
weakness O
of O
the O
cervical O
muscles O
and O
no O
re O
##la O
##pse O
of O
cervical O
d O
##yst O
##onia O

a O
61 O
year O
old O
man O
with O
cerebral O
pal O
##sy O
developed O
b O
##le O
##pha O
##ros O
##pas O
##m O
several O
years O
prior O
to O
presentation O
to O
our O
facility O
one O
year O
earlier O
he O
received O
bot O
##ulin O
##um O
toxin O
treatment O
which O
provided O
temporary O
improvement O
of O
this O
disorder O
about O
6 O
months O
before O
evaluation O
he O
complained O
of O
progressive O
bilateral O
lower O
ex O
##tre O
##mity O
weakness O
and O
d O
##ys O
##pha O
##gia O
to O
both O
solids O
and O
liquids O
neurological O
examination O
revealed O
bilateral O
pt O
##osis O
op O
##ht O
##hal O
##mo O
##par O
##esis O
and O
mild O
generalized O
pro O
##xi O
##mal O
muscle O
weakness O
his O
b O
##le O
##pha O
##ros O
##pas O
##m O
disappeared O
and O
none O
was O
observed O
during O
the O
examination O
following O
further O
investigations O
including O
ne O
##uro O
##phy O
##sio O
##logical O
testing O
which O
showed O
a O
sign O
##i O
##ﬁ O
##can O
##t O
dec O
##rem O
##ental O
response O
on O
repetitive O
nerve O
stimulation O
at O
3 O
hz O
he O
was O
diagnosed O
with O
ser O
##op O
##osi O
##tive O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
he O
was O
treated O
with O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
co O
##rti O
##cos O
##ter O
##oids O
and O
az O
##athi O
##op O
##rine O
a O
follow O
up O
examination O
2 O
years O
later O
showed O
marked O
improvement O
of O
my O
##ast O
##hen O
##ic O
symptoms O
but O
with O
mild O
residual O
weakness O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
he O
had O
no O
rec O
##ur O
##rence O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O

approximately O
33 O
of O
patients O
diagnosed O
with O
focal O
or O
segment O
##al O
d O
##yst O
##onia O
and O
treated O
with O
anti O
##cho O
##liner O
##gic O
drugs O
show O
a O
modest O
improvement O
in O
symptoms O
compared O
with O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
in O
90 O
treated O
with O
local O
intra O
##mus O
##cular O
bot O
##ulin O
##um O
toxin O
1 O
bot O
##ulin O
##um O
toxin O
binds O
at O
the O
ne O
##uro O
##mus O
##cular O
junction O
and O
prevents O
the O
release O
of O
ace O
##ty O
##lch O
##olin O
##e O
from O
the O
pre O
##sy O
##na O
##ptic O
terminal O
it O
results O
in O
temporary O
weakness O
of O
the O
skeletal O
muscles O
into O
which O
it O
is O
injected O
which O
can O
am O
##eli O
##ora O
##te O
the O
symptoms O
and O
signs O
of O
d O
##yst O
##onia O
the O
median O
duration O
of O

effect O
is O
about O
12 O
5 O
weeks O
2 O
it O
is O
the O
treatment O
of O
choice O
for O
cervical O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
spa O
##smo O
##dic O
d O
##ys O
##phon O
##ia O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
and O
limb O
d O
##yst O
##onia O
3 O

my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
is O
an O
auto O
##im O
##mun O
##e O
disorder O
caused O
by O
auto O
##ant O
##ib O
##odies O
against O
the O
nico O
##tin O
##ic O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
on O
the O
posts O
##yna O
##ptic O
membrane O
at O
the O
ne O
##uro O
##mus O
##cular O
junction O
4 O
both O
our O
patients O
had O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
antibody O
positive O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
both O
had O
improvement O
of O
their O
movement O
disorders O
there O
was O
marked O
improvement O
of O
tor O
##tic O
##oll O
##is O
in O
our O
ﬁ O
##rst O
patient O
and O
resolution O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
in O
the O
second O
after O
the O
development O
of O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
a O
review O
of O
the O
literature O
reveals O
two O
reports O
of O
patients O
who O
had O
both O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
d O
##yst O
##onia O
interesting O
##ly O
in O
contrast O
to O
our O
patients O
both O
of O
them O
developed O
only O
temporary O
improvement O
of O
the O
d O
##yst O
##onia O
5 O
6 O
furthermore O
in O
one O
of O
these O
patients O
the O
rec O
##urrent O
d O
##yst O
##onia O
was O
successfully O
treated O
with O
bot O
##ulin O
##um O
toxin O
6 O
it O
is O
possible O
that O
our O
patients O
did O
not O
develop O
a O
rec O
##ur O
##rence O
of O
d O
##yst O
##onia O
due O
to O
mild O
residual O
muscle O
weakness O
secondary O
to O
the O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O

clinical O
improvement O
of O
d O
##yst O
##onia O
after O
the O
onset O
of O
mg O
at O
##test O
##s O
to O
an O
intriguing O
relationship O
between O
d O
##yst O
##onia O
and O
mg O
serving O
as O
another O
example O
of O
an O
experiment O
of O
nature O
spontaneous O
improvement O
of O
symptoms O
in O
a O
d O
##yst O
##onic O
patient O
should O
direct O
attention O
to O
the O
possibility O
of O
developing O
a O
nm O
##j O
disorder O

arch O
##ana O
hindu O
##ja O
md O
sud O
##han O
##shu O
cho O
##kr O
##over O
##ty O
md O
fr O
##cp O

philip O
hanna O
md O
raj O
##i O
p O
grew O
##al O
md O

nj O
neuroscience O
institute O
seton O
hall O
university O

school O
of O
graduate O
medical O
education O

j O
##fk O
medical O
center O
edison O
new O
jersey O
usa O

e O
mail O
r O
##gre O
##wal O
solar O
##ish O
##s O
org O

jan O
##kovic O
j O
led O
##er O
s O
warner O
d O
schwartz O
k O
cervical O
d O
##yst O
##onia O
clinical O
ﬁ O
##nding O
##s O
and O
associated O
movement O
disorders O
ne O
##uro O
##logy O
1991 O
41 O
108 O
##8 O
109 O
##1 O

jan O
##kovic O
j O
bot O
##ulin O
##um O
toxin O
therapy O
for O
cervical O
d O
##yst O
##onia O
ne O
##uro O
##to O
##x O
res O
2006 O
9 O
145 O
148 O

jan O
##kovic O
j O
bot O
##ulin O
##um O
toxin O
in O
clinical O
practice O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2004 O
75 O
95 O
##1 O
95 O
##7 O

than O
##vi O
br O
lo O
tc O
##n O
update O
on O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
post O
##grad O
med O
j O
2004 O
80 O
690 O
700 O

hoffman O
l O
##m O
robinson O
j O
hannah O
h O
loss O
of O
d O
##yst O
##onia O
as O
a O
sign O
of O
my O
##ast O
##hen O
##ia O
south O
med O
j O
1991 O
84 O
115 O
##9 O
116 O
##0 O

tar O
##say O
d O
b O
##hat O
##ta O
##cha O
##ry O
##ya O
n O
bo O
##rod O
##ic O
g O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
after O
bot O
##ulin O
##um O
toxin O
a O
for O
mei O
##ge O
syndrome O
movement O
di O
##sor O
##d O
2000 O
15 O
73 O
##6 O
73 O
##8 O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O
pp O
161 O
##3 O
162 O
##7 O
2008 O
movement O
disorder O
society O
letters O
to O
the O
editor O
related O
to O
new O
topics O
alexander O
disease O
causing O
hereditary O
late O
onset O
ata O
##xia O
with O
only O
minimal O
white O
matter O
changes O
a O
report O
of O
two O
si O
##bs O
video O

we O
report O
a O
case O
of O
an O
adult O
onset O
mutation O
proven O
alexander O
disease O
characterized O
by O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
the O
absence O
of O
pal O
##atal O
tremor O
and O
very O
mild O
white O
matter O
changes O
1 O
2 O
this O
61 O
year O
old O
man O
presented O
at O
the O
age O
of O
50 O
years O
with O
slowly O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
his O
past O
medical O
history O
revealed O
the O
onset O
of O
static O
but O
marked O
forward O
ﬂ O
##ex O
##ion O
of O
the O
trunk O
in O
his O
ﬁ O
##rst O
decade O
but O
without O
any O
motor O
abnormalities O
until O
recently O
his O
sister O
had O
been O
diagnosed O
with O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
there O
were O
no O
other O
affected O
relatives O

we O
screened O
for O
several O
of O
the O
genetic O
ata O
##xia O
##s O
but O
no O
mutations O
were O
detected O
in O
the O
sc O
##a1 O
2 O
3 O
6 O
7 O
14 O
genes O
or O
in O
the O
genes O
responsible O
for O
fried O
##re O
##ich O
s O
ata O
##xia O
and O
dent O
##ator O
##ub O
##ro O
pal O
##lid O
##o O
lu O
##ys O
##ian O
at O
##rop O
##hy O
electro O
##my O
##ography O
showed O
no O
signs O
of O
ne O
##uro O
##pathy O
or O
my O
##opa O
##thy O
ss O
##ep O
was O
not O
performed O
mri O
demonstrated O
subtle O
white O
matter O
lesions O
anterior O
##ly O
in O
both O
temporal O
lobes O
as O
well O
as O
mild O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bell O
##um O
brains O
##tem O
and O
cervical O
spinal O
cord O
on O
standard O
mri O
imaging O
fig O
1a O
c O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

as O
these O
combined O
clinical O
and O
imaging O
features O
were O
suggest O
##ive O
of O
alexander O
disease O
we O
sequence O
##d O
the O
g O
##fa O
##p O
gene O
and O
found O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
c O
69 O
##2 O
##t O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
4 O
predicting O
a O
p O
le O
##u O
##23 O
##1 O
##his O
amino O
acid O
change O
this O
mutation O
was O
not O
encountered O
in O
210 O
control O
chromosomes O
several O
cases O
of O
adult O
onset O
alexander O
disease O
have O
been O
reported O
mostly O
with O
an O
onset O
in O
the O
third O
or O
fourth O
decade O
of O
life O
ph O
##eno O
##typic O
het O
##ero O
##gen O
##eit O
##y O
is O
evident O
from O
the O
variable O
presence O
of O
bulb O
##ar O
symptoms O
ce O
##re O
##bella O
##r O
signs O
pal O
##atal O
tremor O
spa O
##stic O
par O
##esis O
and O
auto O
##no O
##mic O
dysfunction O

in O
conclusion O
we O
report O
two O
si O
##bs O
with O
late O
onset O
ata O
##xia O
due O
to O
alexander O
disease O
caused O
by O
a O
novel O
g O
##fa O
##p O
mutation O
alexander O
disease O
should O
thus O
be O
considered O
in O
the O
differential O
diagnosis O
of O
otherwise O
une O
##x O
##pl O
##aine O
##d O
hereditary O
late O
onset O
161 O
##3 O
161 O
##4 O
letters O
to O
the O
editor O

f O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
and O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
with O
spa O
##ring O
of O
the O
po O
##ns O
and O
cervical O
spinal O
cord O
a O
small O
les O
##ion O
in O
the O
anterior O
part O
of O
the O
corpus O
call O
##os O
##um O
there O
are O
in O
addition O
high O
signal O
par O
##en O
##chy O
##mal O
changes O
in O
the O
posterior O
med O
##ulla O
and O
ce O
##re O
##bella O
##r O
white O
matter O
sa O
##git O
##tal O
flair O
ata O
##xia O
additional O
yet O
not O
ob O
##liga O
##te O
clinical O
features O
pal O
##atal O
tremor O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
more O
or O
less O
distinctive O
mri O
ﬁ O
##nding O
##s O
subtle O
white O
matter O
changes O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
spinal O
cord O
might O
constitute O
clues O
that O
hint O
towards O
this O
spec O
##i O
##ﬁ O
##c O
diagnosis O
legends O
to O
the O
video O

segment O
1 O
mild O
ata O
##xi O
##c O
and O
bouncing O
ga O
##it O
note O
the O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
knees O
di O
##f O
##ﬁ O
##cu O
##lty O
tandem O
walking O
segment O
2 O
bent O
hip O
and O
bent O
knee O
posture O
segment O
3 O
o O
##cular O
pursuit O
showing O
jerk O
##y O
pursuit O
movements O
segment O
4 O
horizontal O
sac O
##cade O
##s O
showing O
multi O
step O
sac O
##cade O
##s O
and O
o O
##cular O
d O
##ys O
##met O
##ria O
both O
h O
##yp O
##ometric O
and O
hyper O
##metric O
segment O
5 O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
on O
repeating O
the O
dutch O
sentence O
rode O
ron O
##de O
app O
##els O
roll O
##en O
van O
de O
z O
##old O
##ert O
##ra O
##p O
and O
on O
repeating O
pat O
##aka O
segment O
6 O
mild O
decomposition O
of O
movement O
during O
ﬁ O
##nger O
to O
nose O
testing O
catherine O
c O
s O
del O
##no O
##oz O
md O
jurgen O
h O
sc O
##hel O
##ha O
##as O
md O
phd O

bart O
p O
c O
van O
de O
warren O
##burg O
md O
phd O
department O
of O
ne O
##uro O
##logy O
ra O
##db O
##oud O
university O
ni O
##jm O
##ege O
##n O
medical O
center O
ni O
##jm O
##ege O
##n O
the O
netherlands O
e O
mail O
b O
van O
##de O
##war O
##ren O
##burg O
ne O
##uro O
um O
##c O
##n O
nl O
robert O
jan O
de O
gr O
##aa O
##f O
md O
department O
of O
ne O
##uro O
##logy O
amp O
##hia O
hospital O
bred O
##a O
o O
##ost O
##er O
##ho O
##ut O
the O
netherlands O
ga O
##j O
##ja O
s O
sal O
##omo O
##ns O
phd O
department O
of O
clinical O
chemistry O
metabolic O
unit O
vu O
university O
medical O
center O
amsterdam O
the O
netherlands O
references O
johnson O
a O
alexander O
disease O
review O
of O
the O
gene O
int O
j O
dev O
ne O
##uro O
##sc O
##i O
2002 O
20 O
39 O
##1 O
39 O
##4 O

li O
r O
johnson O
ab O
sal O
##omo O
##ns O
g O
et O
al O
g O
##fa O
##p O
mutations O
in O
infant O
##ile O
juvenile O
and O
adult O
forms O
of O
alexander O
disease O
ann O
ne O
##uro O
##l O
2005 O
57 O
310 O
326 O
howard O
k O
##l O
hall O
da O
moon O
m O
ag O
##ar O
##wal O
p O
newman O
e O
br O
##enne O
##r O
m O
adult O
onset O
alexander O
disease O
with O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
mo O
##v O
di O
##s O
2008 O
23 O
118 O
122 O
de O
##pre O
##z O
m O
d O
ho O
##og O
##he O
m O
miss O
##on O
jp O
et O
al O
infant O
##ile O
and O
juvenile O
presentations O
of O
alexander O
disease O
a O
report O
of O
two O
cases O
act O
##a O
ne O
##uro O
##l O
scan O
##d O
1999 O
99 O
158 O
165 O

sal O
##ma O
##gg O
##i O
a O
bot O
##tur O
##i O
a O
lamp O
##ert O
##i O
e O
et O
al O
a O
novel O
mutation O
in O
the O
g O
##fa O
##p O
gene O
in O
a O
fa O
##mi O
##lia O
##l O
adult O
onset O
alexander O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
127 O
##8 O
128 O
##0 O
sc O
##hwa O
##nk O
##haus O
j O
paris O
##i O
je O
gu O
##lled O
##ge O
wr O
chin O
l O
currie O
##r O
rd O
hereditary O
adult O
onset O
alexander O
disease O
with O
pal O
##atal O
my O
##oc O
##lon O
##us O
spa O
##stic O
para O
##par O
##esis O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
ne O
##uro O
##logy O
1995 O
45 O
226 O
##6 O
227 O
##1 O
saw O
##ais O
##hi O
##i O
y O
hat O
##az O
##awa O
j O
och O
##i O
n O
et O
al O
pet O
in O
juvenile O
alexander O
disease O
j O
ne O
##uro O
##l O
sci O
1999 O
165 O
116 O
120 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##5 O

non O
##om O
##ura O
y O
shi O
##mi O
##zu O
k O
ni O
##shi O
##moto O
h O
ho O
##so O
##e O
h O
sa O
##ka O
##guchi O
y O
mi O
##yam O
##oto O
k O
sc O
##olio O
##sis O
in O
a O
patient O
with O
alexander O
disease O
j O
spin O
di O
##s O
2002 O
15 O
261 O
264 O
thy O
##aga O
##raj O
##an O
d O
chat O
##away O
t O
li O
r O
ga O
##i O
w O
##p O
br O
##enne O
##r O
m O
dominant O
##ly O
inherited O
adult O
onset O
le O
##uk O
##od O
##yst O
##rop O
##hy O
with O
pal O
##atal O
tremor O
caused O
by O
a O
mutation O
in O
the O
g O
##lia O
##l O
ﬁ O
##bri O
##llary O
acidic O
protein O
mo O
##v O
di O
##s O
2004 O
19 O
124 O
##4 O
124 O
##8 O
ok O
##amo O
##to O
y O
mit O
##su O
##yama O
h O
hi O
##rata O
k O
ari O
##mura O
k O
os O
##ame O
m O
nak O
##agawa O
m O
auto O
##som O
##al O
dominant O
pal O
##atal O
my O
##oc O
##lon O
##us O
and O
spinal O
cord O
at O
##rop O
##hy O
j O
ne O
##uro O
##l O
sci O
2002 O
195 O
71 O
76 O

stump O
##f O
e O
mass O
##on O
h O
du O
##quette O
a O
et O
al O
adult O
alexander O
disease O
with O
auto O
##som O
##al O
transmission O
arch O
ne O
##uro O
##l O
2003 O
60 O
130 O
##7 O
132 O
##0 O
bo O
##rret O
d O
becker O
le O
alexander O
disease O
of O
astro O
##cytes O
brain O
1985 O
108 O
36 O
##7 O
385 O
cole O
g O
de O
villiers O
f O
proctor O
ns O
fr O
##eim O
##an O
i O
bill O
p O
alexander O
disease O
case O
report O
including O
his O
##top O
##ath O
##ological O
and O
electron O
microscopic O
features O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
1979 O
42 O
61 O
##9 O
62 O
##4 O

ku O
##l O
##har O
##ni O
p O
mu O
##than O
##e O
u O
##b O
tal O
##y O
ab O
jaya O
##kumar O
p O
##n O
she O
##tty O
r O
sat O
##hya O
##nar O
##ayan O
##a O
swam O
##y O
h O
pal O
##atal O
tremor O
progressive O
multiple O
cr O
##anial O
nerve O
pal O
##sies O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
a O
case O
report O
and O
review O
of O
literature O
of O
pal O
##atal O
tremor O
##s O
in O
ne O
##uro O
##de O
##gen O
##erative O
disease O
mo O
##v O
di O
##s O
1999 O
14 O
68 O
##9 O
69 O
##3 O
samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O
storey O
e O
knight O
ma O
forrest O
sm O
gardner O
r O
##j O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
ce O
##re O
##bell O
##um O
2005 O
4 O
55 O
57 O

van O
der O
kn O
##aa O
##p O
ms O
na O
##id O
##u O
s O
br O
##eit O
##er O
s O
##n O
et O
al O
alexander O
disease O
diagnosis O
with O
mri O
am O
j O
ne O
##uro O
##rad O
##iol O
2001 O
22 O
54 O
##1 O
55 O
##2 O
anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
a O
case O
report O

five O
months O
later O
the O
patient O
suffered O
a O
rec O
##ur O
##rence O
of O
my O
##o O
cl O
##onus O
but O
it O
disappeared O
within O
several O
hours O
after O
oral O
administration O
of O
0 O
5 O
mg O
cl O
##ona O
##ze O
##pa O
##m O
all O
of O
the O
patient O
s O
medications O
were O
reviewed O
again O
the O
ﬁ O
##rst O
my O
##oc O
##lon O
##us O
occurred O
after O
18 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
the O
second O
occurred O
after O
8 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
ep O
##inas O
##tine O
20 O
mg O
day O
for O
chronic O
pr O
##uri O
##go O
the O
my O
##oc O
##lon O
##us O
has O
not O
rec O
##ur O
##red O
since O
the O
patient O
stopped O
the O
anti O
##his O
##tam O
##ines O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O
161 O
##6 O
letters O
to O
the O
editor O
fig O
1 O
electro O
##oc O
##ulo O
##graphy O
and O
surface O
electro O
##my O
##ography O
rhythmic O
o O
##cular O
movement O
of O
the O
left O
l O
eye O
in O
the O
vertical O
direction O
l O
om O
vertical O
was O
sync O
##hr O
##ono O
##us O
with O
my O
##oc O
##lon O
##us O
in O
the O
l O
orb O
##icular O
##is O
o O
##cu O
##li O
rhythmic O
sync O
##hr O
##ono O
##us O
my O
##oc O
##lon O
##ic O
discharge O
##s O
were O
also O
evident O
in O
the O
l O
ﬁ O
##rst O
dorsal O
inter O
##oss O
##eous O
f O
##di O
and O
l O
abd O
##uc O
##tor O
poll O
##ici O
##s O
br O
##ev O
##is O
ap O
##b O
cal O
##ib O
##ration O
100 O
l O
##v O
in O
each O
lane O
time O
constant O
0 O
1 O
s O
in O
the O
ﬁ O
##rst O
lane O
and O
0 O
001 O
s O
in O
other O
lanes O
black O
bar O
1 O
s O

tak O
##ashi O
ir O
##io O
##ka O
md O
phd O
akira O
mach O
##ida O
md O
tak O
##anor O
##i O
yoko O
##ta O
md O
phd O
hide O
##hiro O
mi O
##zu O
##sa O
##wa O
md O
phd O
department O
of O
ne O
##uro O
##logy O
and O
neurological O
science O
graduate O
school O
tokyo O
medical O
and O
dental O
university O
tokyo O
japan O
e O
mail O
t O
ir O
##io O
##ka O
nur O
##o O
t O
##md O
ac O
jp O
references O
ca O
##vine O
##ss O
j O
##n O
brown O
p O
my O
##oc O
##lon O
##us O
current O
concepts O
and O
recent O
advances O
lance O
##t O
ne O
##uro O
##l O
2004 O
3 O
59 O
##8 O
60 O
##7 O
gordon O
m O
##f O
toxin O
and O
drug O
induced O
my O
##oc O
##lon O
##us O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##l O
og O
##y O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
49 O
76 O

sc O
##hip O
##ior O
pg O
an O
unusual O
case O
of O
anti O
##his O
##tam O
##ine O
into O
##xi O
##cation O
j O
pediatric O
##s O
1967 O
71 O
58 O
##9 O
59 O
##1 O
hash O
##imo O
##to O
s O
ka O
##wa O
##mura O
j O
yamamoto O
t O
et O
al O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
in O
elderly O
patients O
a O
new O
syndrome O
j O
ne O
##uro O
##l O
sci O
1992 O
109 O
132 O
139 O
richards O
d O
##m O
bro O
##g O
##den O
rn O
heel O
rc O
sp O
##ei O
##ght O
t O
##m O
avery O
gs O
ox O
##ato O
##mide O
a O
review O
of O
its O
ph O
##arm O
##aco O
##dy O
##nami O
##c O
properties O
and O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
drugs O
1984 O
27 O
210 O
231 O
raj O
##put O
a O
bae O
##rg O
k O
ce O
##ti O
##riz O
##ine O
induced O
d O
##yst O
##onic O
movements O
ne O
##uro O
##logy O
2006 O
66 O
143 O
144 O

caste O
##els O
van O
da O
##ele O
m O
egg O
##er O
##mont O
e O
casa O
##er O
p O
van O
de O
cass O
##eye O
w O
de O
bo O
##eck O
k O
acute O
d O
##yst O
##onic O
reactions O
and O
long O
lasting O
impaired O
consciousness O
associated O
with O
ox O
##ato O
##mide O
in O
children O
lance O
##t O
1986 O
1 O
120 O
##4 O
120 O
##5 O
welsh O
jp O
pl O
##aca O
##nton O
##aki O
##s O
d O
##g O
wars O
##ets O
##ky O
si O
marquez O
r O
##g O
bernstein O
l O
ai O
##cher O
sa O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
from O
the O
perspective O
of O
ne O
##uron O
##al O
rhythmic O
##ity O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##logy O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
307 O
329 O

do O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
differ O
by O
route O
of O
environmental O
pre O
##ci O
##pit O
##ant O
bra O
##ak O
and O
colleagues O
followed O
their O
groundbreaking O
staging O
class O
##i O
##ﬁ O
##cation O
for O
the O
brain O
ne O
##uro O
##path O
##ology O
of O
alzheimer O
s O
disease O
with O
the O
more O
recent O
one O
for O
sporadic O
parkinson O
s O
disease O
pd O
1 O
their O
new O
pd O
staging O
system O
has O
revolution O
##ized O
thinking O
about O
the O
topographic O
sequence O
of O
ne O
##uro O
##path O
##ological O
changes O
as O
the O
illness O
progresses O
generally O
in O
a O
ca O
##uda O
##l O
ro O
##stra O
##l O
direction O
from O
lower O
brains O
##tem O
to O
neo O
##cor O
##te O
##x O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##23 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##7 O

roger O
ku O
##rl O
##an O
md O
department O
of O
ne O
##uro O
##logy O
university O
of O
rochester O
school O
of O
medicine O
rochester O
new O
york O
usa O
references O
bra O
##ak O
h O
del O
tre O
##dic O
##i O
k O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
211 O
del O
tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
##e O
bra O
##ak O
h O
where O
does O
parkinson O
disease O
pathology O
begin O
in O
the O
brain O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2002 O
61 O
41 O
##3 O
42 O
##6 O

wa O
##ka O
##bay O
##ashi O
k O
takahashi O
h O
oh O
##ama O
e O
take O
##da O
s O
ik O
##uta O
f O
lew O
##y O
bodies O
in O
the O
vis O
##cera O
##l O
auto O
##no O
##mic O
nervous O
system O
in O
parkinson O
s O
disease O
in O
ik O
##uta O
f O
editor O
ne O
##uro O
##path O
##ology O
in O
brain O
research O
amsterdam O
london O
tokyo O
excerpt O
##a O
med O
##ica O
1991 O
p O
133 O
141 O
bra O
##ak O
h O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
del O
tre O
##dic O
##i O
k O
gas O
##tric O
alpha O
##sy O
##nu O
##cle O
##in O
im O
##mun O
##ore O
##active O
inclusion O
##s O
in O
mei O
##ss O
##ner O
s O
and O
au O
##er O
##bach O
s O
pl O
##ex O
##uses O
in O
cases O
staged O
for O
parkinson O
s O
disease O
related O
brain O
pathology O
ne O
##uro O
##sc O
##i O
let O
##t O
2006 O
39 O
##6 O
67 O
72 O

ming O
##uez O
caste O
##llan O
##os O
a O
char O
##orro O
ce O
es O
##cam O
##illa O
sevilla O
f O
et O
al O
do O
a O
syn O
##uc O
##lein O
aggregate O
##s O
in O
auto O
##no O
##mic O
pl O
##ex O
##uses O
pre O
##date O
lew O
##y O
body O
disorders O
a O
co O
##hort O
study O
ne O
##uro O
##logy O
2007 O
68 O
2012 O
2018 O
bra O
##ak O
h O
sas O
##tre O
m O
bo O
##hl O
jr O
##e O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
parkinson O
s O
disease O
lesions O
in O
dorsal O
horn O
layer O
i O
involvement O
of O
para O
##sy O
##mp O
##ath O
##etic O
and O
sympathetic O
pre O
##and O
post O
##gang O
##lion O
##ic O
neurons O
act O
##a O
ne O
##uro O
##path O
##ol O
be O
##r O
2007 O
113 O
421 O
42 O
##9 O
obe O
##rdo O
##¨ O
##rst O
##er O
g O
sharp O
z O
at O
##ud O
##ore O
##i O
v O
et O
al O
trans O
##lo O
##cation O
of O
inhaled O
ultra O
##ﬁ O
##ne O
particles O
to O
the O
brain O
in O
##hal O
toxic O
##ol O
2004 O
16 O
43 O
##7 O
44 O
##5 O

rat O
##ner O
m O
##h O
feldman O
r O
##g O
environmental O
toxin O
##s O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
51 O
62 O
st O
##rick O
##land O
d O
rural O
environment O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
63 O
71 O
bra O
##ak O
h O
bo O
##hl O
jr O
mu O
##¨ O
##ller O
cm O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
stanley O
fa O
##hn O
lecture O
2005 O
the O
staging O
procedure O
for O
the O
inclusion O
body O
pathology O
associated O
with O
sporadic O
parkinson O
s O
disease O
rec O
##ons O
##ider O
##ed O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
204 O
##2 O
205 O
##1 O

klein O
c O
sc O
##hl O
##oss O
##mac O
##her O
mg O
parkinson O
s O
disease O
10 O
years O
after O
its O
genetic O
revolution O
multiple O
clues O
to O
a O
complex O
disorder O
ne O
##uro O
##logy O
2007 O
69 O
209 O
##3 O
210 O
##4 O
mc O
##kei O
##th O
i O
##g O
gala O
##sko O
d O
ko O
##saka O
k O
consensus O
guidelines O
for O
the O
clinical O
and O
path O
##olo O
##gic O
diagnosis O
of O
dementia O
with O
lew O
##y O
bodies O
dl O
##b O
report O
of O
the O
consortium O
on O
dl O
##b O
international O
workshop O
ne O
##uro O
##logy O
1996 O
47 O
111 O
##3 O
112 O
##4 O
richard O
i O
##h O
pa O
##p O
##ka O
m O
rub O
##io O
a O
et O
al O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
one O
disease O
or O
two O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
116 O
##1 O
116 O
##5 O
d O
##yst O
##onia O
associated O
with O
hyper O
##int O
##ense O
basal O
gang O
##lia O
lesions O
on O
t O
##1 O
weighted O
brain O
mri O
video O

the O
initial O
ct O
was O
regular O
but O
the O
t O
##1 O
weighted O
mri O
without O
contrast O
demonstrated O
bilateral O
uniform O
area O
wide O
hyper O
##in O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##28 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
1618 O
letters O
to O
the O
editor O
fig O
1 O
a O
photograph O
of O
patient O
showing O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O

together O
the O
reasons O
for O
the O
initial O
t O
##1 O
hyper O
##int O
##ens O
##ities O
remain O
elusive O
theoretically O
besides O
intra O
##cellular O
met O
##hem O
##og O
##lo O
##bin O
in O
hem O
##or O
##rh O
##agi O
##c O
tissue O
and O
cal O
##ci O
##ﬁ O
##cation O
##s O
para O
##ma O
##gne O
##tic O
compounds O
including O
metal O
ions O
e O
g O
iron O
manga O
##nese O
and O
copper O
molecular O
oxygen O
or O
free O
radicals O
could O
lead O
to O
these O
legend O
to O
the O
full O
video O
time O
content O
00 O
00 O
00 O
00 O
00 O
15 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O
00 O
00 O
16 O
00 O
00 O
28 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O
forehead O
d O
##yst O
##onia O
00 O
00 O
29 O
00 O
00 O
37 O
listing O
the O
days O
of O
the O
week O
from O
monday O

to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O
00 O
00 O
38 O
00 O
00 O
47 O
patient O
closing O
and O
opening O
his O
eyes O
00 O
00 O
48 O
00 O
01 O
09 O
facial O
inner O
##vation O
mouth O
tongue O
and O
forehead O
00 O
01 O
10 O
00 O
01 O
31 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O
of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
01 O
32 O
00 O
02 O
01 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O
and O
pro O
##nation O
su O
##pina O
##tion O
test O
legend O
to O
the O
preview O
video O
time O
content O
00 O
00 O
00 O
00 O
00 O
03 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O
00 O
00 O
04 O
00 O
00 O
07 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

forehead O
d O
##yst O
##onia O
00 O
00 O
08 O
00 O
00 O
15 O
listing O
the O
days O
of O
the O
week O
from O
monday O
to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O
00 O
00 O
16 O
00 O
00 O
33 O
facial O
inner O
##vation O
eyes O
mouth O
tongue O
and O
forehead O
00 O
00 O
34 O
00 O
00 O
46 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O
of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
00 O
47 O
00 O
00 O
59 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O
and O
pro O
##nation O
su O
##pina O
##tion O
test O

mri O
changes O
in O
our O
case O
we O
found O
no O
evidence O
of O
hem O
##or O
##rh O
##agi O
##c O
changes O
or O
cal O
##ci O
##ﬁ O
##cation O
##s O
so O
that O
reported O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
may O
hypothetical O
##ly O
result O
from O
h O
##yp O
##ox O
##ic O
disruption O
of O
the O
cell O
mitochondrial O
heavy O
metal O
metabolism O
martin O
wo O
##lz O
md O
susan O
##n O
jung O
##han O
##ns O
md O
matthias O
lo O
##¨ O
##hl O
##e O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O
dresden O
germany O
ru O
##¨ O
##di O
##ger O
von O
ku O
##mmer O
md O
department O
of O
ne O
##uro O
##rad O
##iology O
technical O
university O
dresden O
dresden O
germany O
alexander O
st O
##or O
##ch O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O
dresden O
germany O

e O
mail O
alexander O
st O
##or O
##ch O
ne O
##uro O
med O
tu O
dresden O
de O
references O
lin O
jj O
chang O
mk O
hem O
##iba O
##llis O
##m O
hem O
##ich O
##ore O
##a O
and O
non O
ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1994 O
57 O
74 O
##8 O
750 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##9 O
oh O
sh O
lee O
ky O
im O
j O
##h O
lee O
ms O
cho O
##rea O
associated O
with O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
and O
hyper O
##int O
##ens O
##ity O
basal O
gang O
##lia O
les O
##ion O
on O
t O
##1 O
weighted O
brain O
mri O
study O
a O
meta O
analysis O
of O
53 O
cases O
including O
four O
present O
cases O
j O
ne O
##uro O
##l O
sci O
2002 O
200 O
57 O
62 O

fuji O
##oka O
m O
hiram O
##ats O
##u O
k O
sa O
##ka O
##ki O
t O
sa O
##ka O
##guchi O
s O
is O
##hi O
##i O
y O
spec O
##i O
##ﬁ O
##c O
changes O
in O
human O
brain O
after O
h O
##yp O
##og O
##ly O
##ce O
##mic O
injury O
stroke O
1997 O
28 O
58 O
##4 O
58 O
##7 O
k O
##rie O
##ger O
d O
k O
##rie O
##ger O
s O
jan O
##sen O
o O
gas O
##s O
p O
the O
##il O
##mann O
l O
li O
##cht O
##neck O
##er O
h O
manga O
##nese O
and O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
lance O
##t O
1995 O
34 O
##6 O
270 O
274 O
oh O
##ara O
s O
nak O
##agawa O
s O
tab O
##ata O
k O
hash O
##imo O
##to O
t O
hem O
##iba O
##llis O
##m O
with O
hyper O
##gly O
##ce O
##mia O
and O
st O
##ria O
##tal O
t O
##1 O
mri O
hyper O
##int O
##ens O
##ity O
an O
autopsy O
report O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
521 O
525 O
shan O
de O
ho O
d O
##m O
chang O
c O
pan O
hc O
ten O
##g O
mm O
hem O
##ich O
##ore O
##ah O
##emi O
##ball O
##ism O
an O
explanation O
for O
mr O
signal O
changes O
am O
j O
ne O
##uro O
##rad O
##iol O
1998 O
19 O
86 O
##3 O
870 O

fuji O
##oka O
m O
tao O
##ka O
t O
mats O
##uo O
y O
hiram O
##ats O
##u O
ki O
sa O
##ka O
##ki O
t O
novel O
brain O
is O
##che O
##mic O
change O
on O
mri O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
images O
and O
selective O
ne O
##uron O
##al O
death O
in O
the O
ca O
##ud O
##op O
##uta O
##men O
of O
rats O
after O
brief O
focal O
is O
##che O
##mia O
stroke O
1999 O
30 O
104 O
##3 O
104 O
##6 O
successful O
treatment O
of O
the O
mei O
##ge O
syndrome O
with O
oral O
z O
##ol O
##pid O
##em O
mono O
##therapy O
video O

z O
##ol O
##pid O
##em O
is O
an O
im O
##ida O
##zo O
##py O
##rid O
##ine O
ago O
##nist O
with O
a O
high O
af O
##ﬁ O
##nity O
for O
the O
benz O
##od O
##ia O
##ze O
##pine O
a1 O
subunit O
site O
1 O
it O
has O
been O
reported O
that O
this O
drug O
improves O
motor O
symptoms O
in O
patients O
with O
parkinson O
s O
disease O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
and O
xl O
##ink O
##ed O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
2 O
5 O
recently O
z O
##ol O
##pid O
##em O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
the O
mei O
##ge O
syndrome O
in O
combination O
with O
bot O
##ulin O
##um O
toxin O
a O
6 O
here O
we O
report O
a O
patient O
with O
mei O
##ge O
syndrome O
non O
##res O
##pon O
##sive O
to O
bot O
##ulin O
##um O
toxin O
a O
but O
successfully O
treated O
with O
oral O
z O
##ol O
##pid O
##em O
administration O

additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##9 O
no O
exposure O
to O
ne O
##uro O
##le O
##ptic O
medications O
there O
was O
no O
family O
history O
of O
movement O
disorders O

in O
conclusion O
oral O
z O
##ol O
##pid O
##em O
may O
be O
a O
useful O
ph O
##arm O
##aco O
##logic O
alternative O
for O
patients O
with O
mei O
##ge O
syndrome O
who O
do O
not O
respond O
to O
bot O
##ulin O
##um O
toxin O
treatment O
however O
special O
precautions O
are O
necessary O
for O
long O
term O
management O
with O
this O
drug O
because O
of O
the O
risk O
of O
z O
##ol O
##pid O
##em O
abuse O
especially O
in O
patients O
with O
a O
previous O
history O
of O
substance O
abuse O
15 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
1620 O
letters O
to O
the O
editor O
legends O
to O
the O
video O

segment O
1 O
the O
patient O
shows O
a O
mixture O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O
segment O
2 O
one O
hour O
after O
oral O
z O
##ol O
##pid O
##em O
administration O
the O
symptoms O
were O
completely O
resolved O
in O
the O
resting O
state O
while O
showing O
his O
teeth O
as O
well O
as O
grim O
##acing O
and O
whistling O
jae O
young O
an O
md O
joo O
##ng O
seo O
##k O
kim O
md O
ye O
##ong O
in O
kim O
md O
kwan O
##g O
soo O
lee O
md O
department O
of O
ne O
##uro O
##logy O
the O
catholic O
university O
of O
korea O
seoul O
south O
korea O
e O
mail O
ne O
##uron O
##et O
catholic O
ac O
k O
##r O
references O

holm O
k O
##j O
goa O
k O
##l O
z O
##ol O
##pid O
##em O
an O
update O
of O
its O
ph O
##arm O
##aco O
##logy O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
and O
to O
##ler O
##ability O
in O
the O
treatment O
of O
ins O
##om O
##nia O
drugs O
2000 O
59 O
86 O
##5 O
88 O
##9 O
daniel O
##e O
a O
alba O
##nese O
a O
gain O
##otti O
g O
gregor O
##i O
b O
bart O
##olo O
##meo O
p O
z O
##ol O
##pid O
##em O
in O
parkinson O
s O
disease O
lance O
##t O
1997 O
34 O
##9 O
122 O
##2 O
122 O
##3 O
daniel O
##e O
a O
mor O
##o O
e O
bent O
##ivo O
##glio O
ar O
z O
##ol O
##pid O
##em O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
n O
eng O
##l O
j O
med O
1999 O
341 O
54 O
##3 O
54 O
##4 O
evident O
##e O
v O
##gh O
z O
##ol O
##pid O
##em O
improves O
d O
##yst O
##onia O
in O
lu O
##bag O
or O
x O
linked O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
ne O
##uro O
##logy O
2002 O
58 O
66 O
##2 O
66 O
##3 O

ru O
##zic O
##ka O
e O
roth O
j O
je O
##ch O
r O
bus O
##ek O
p O
sub O
##hy O
##p O
##not O
##ic O
doses O
of O
z O
##ol O
##pid O
##em O
oppose O
do O
##pa O
##mine O
##rg O
##ic O
induced O
d O
##ys O
##kin O
##es O
##ia O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
73 O
##4 O
73 O
##5 O
garrett O
##o O
ns O
bu O
##eri O
ja O
rey O
rd O
ara O
##ka O
##ki O
t O
nano O
g O
##v O
man O
##cus O
##o O
m O
improvement O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
with O
z O
##ol O
##pid O
##em O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
96 O
##7 O
96 O
##8 O
jan O
##kovic O
j O
clinical O
features O
differential O
diagnosis O
and O
pathogen O
##esis O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
cr O
##anial O
cervical O
d O
##yst O
##onia O
in O
bosnia O
##k O
l O
editor O
b O
##le O
##pha O
##ros O
##pas O
##m O
advances O
in O
op O
##ht O
##hal O
##mic O
plastic O
rec O
##ons O
##truct O
##ive O
surgery O
new O
york O
per O
##gam O
##on O
1985 O
p O
67 O
82 O

horn O
s O
come O
##lla O
c O
treatment O
of O
d O
##yst O
##onia O
in O
jan O
##kovic O
j O
to O
##los O
##a O
e O
editors O
parkinson O
s O
disease O
and O
movement O
disorders O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
35 O
##8 O
36 O
##4 O
ni O
##dda O
##m O
r O
dubois O
a O
sc O
##att O
##on O
b O
ar O
##bill O
##a O
s O
lange O
##r O
s O
##z O
auto O
##rad O
##io O
##graphic O
local O
##ization O
of O
3 O
##h O
z O
##ol O
##pid O
##em O
binding O
sites O
in O
the O
rat O
cn O
##s O
comparison O
with O
the O
distribution O
of O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
binding O
sites O
j O
ne O
##uro O
##che O
##m O
1987 O
49 O
89 O
##0 O
89 O
##9 O

dennis O
t O
dubois O
a O
ben O
##avi O
##des O
j O
sc O
##att O
##on O
b O
distribution O
of O
central O
omega O
1 O
benz O
##od O
##ia O
##ze O
##pine O
##1 O
and O
omega O
2 O
benz O
##od O
##ia O
##ze O
##pine O
##2 O
receptor O
sub O
##type O
##s O
in O
the O
monkey O
and O
human O
brain O
an O
auto O
##rad O
##io O
##graphic O
study O
with O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
and O
the O
omega O
1 O
selective O
ligand O
3 O
##h O
z O
##ol O
##pid O
##em O
j O
ph O
##arm O
##aco O
##l O
ex O
##p O
the O
##r O
1988 O
247 O
309 O
322 O
chen O
l O
xi O
##e O
j O
##x O
fun O
##g O
ks O
yun O
##g O
w O
##h O
z O
##ol O
##pid O
##em O
mod O
##ulates O
ga O
##ba O
##a O
receptor O
function O
in O
sub O
##thal O
##ami O
##c O
nucleus O
ne O
##uro O
##sc O
##i O
res O
2007 O
58 O
77 O
85 O
chen O
l O
sa O
##vio O
chang O
c O
yun O
##g O
w O
##h O
electro O
##phy O
##sio O
##logical O
and O
behavioral O
effects O
of O
z O
##ol O
##pid O
##em O
in O
rat O
g O
##lo O
##bus O
pal O
##lid O
##us O
ex O
##p O
ne O
##uro O
##l O
2004 O
186 O
212 O
220 O

pei O
##x O
##oto O
m O
##f O
ara O
##uj O
##o O
np O
silva O
r O
##h O
et O
al O
effects O
of O
ga O
##ba O
##er O
##gic O
drugs O
on O
res O
##er O
##pine O
induced O
oral O
d O
##ys O
##kin O
##es O
##ia O
be O
##ha O
##v O
brain O
res O
2005 O
160 O
51 O
59 O
ga O
##rc O
##´ O
##ı O
##a O
santos O
g O
herrera O
f O
mart O
##´ O
##ı O
##n O
v O
et O
al O
anti O
##ox O
##ida O
##nt O
activity O
and O
ne O
##uro O
##pro O
##tec O
##tive O
effects O
of O
z O
##ol O
##pid O
##em O
and O
several O
synthesis O
intermediate O
##s O
free O
ra O
##dic O
res O
2004 O
38 O
128 O
##9 O
129 O
##9 O
mad O
##rak O
l O
##n O
rosenberg O
m O
z O
##ol O
##pid O
##em O
abuse O
am O
j O
psychiatry O
2001 O
158 O
133 O
##0 O
133 O
##1 O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
induced O
by O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O

chronic O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
is O
effective O
in O
severe O
parkinson O
s O
disease O
pd O
1 O
however O
a O
few O
side O
effects O
especially O
o O
##cu O
##lom O
##oto O
##r O
manifestation O
##s O
have O
been O
reported O
2 O
understanding O
their O
mechanism O
may O
help O
to O
better O
de O
##ﬁ O
##ne O
functional O
anatomy O
of O
this O
region O
a O
66 O
year O
old O
woman O
was O
treated O
by O
bilateral O
st O
##n O
stimulation O
for O
pd O
a O
40 O
decrease O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
followed O
st O
##n O
stimulation O
alone O
with O
the O
following O
parameters O
left O
contact O
2 O
3 O
5 O
v O
60 O
l O
second O
160 O
hz O
right O
contact O
7 O
3 O
5 O
v O
90 O
l O
second O
160 O
hz O

with O
right O
stimulation O
on O
contact O
6 O
3 O
5 O
v O
a O
counter O
##cl O
##ock O
##wise O
tn O
was O
found O
except O
for O
lower O
gain O
of O
vo O
##r O
eye O
movements O
were O
not O
mod O
##i O
##ﬁ O
##ed O
table O
2 O
vertical O
sac O
##cade O
##s O
could O
not O
be O
correctly O
recorded O
the O
sk O
##ew O
deviation O
increased O
sv O
##v O
slightly O
decreased O
12 O
04 O
##8 O
with O
left O
stimulation O
on O
contact O
1 O
4 O
5 O
v O
we O
noticed O
a O
clockwise O
tn O
ve O
##lo O
##cit O
##ies O
of O
downward O
sac O
##cade O
##s O
downward O
smooth O
pursuit O
gain O
and O
horizontal O
pen O
##du O
##lar O
vo O
##r O
gain O
decreased O
table O
2 O
the O
right O
sided O
sk O
##ew O
deviation O
decreased O
sv O
##v O
normal O
##ized O
10 O
48 O

previously O
reported O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
of O
st O
##n O
stimulation O
consisted O
of O
eye O
##lid O
apr O
##ax O
##ia O
bin O
##oc O
##ular O
dip O
##lo O
##pia O
my O
##osis O
my O
##dr O
##ias O
##is O
and O
contra O
##vers O
##ive O
eye O
deviation O
1 O
2 O
4 O
14 O
tn O
has O
been O
observed O
during O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
matter O
15 O
but O
not O
during O
st O
##n O
stimulation O
st O
##n O
is O
involved O
in O
sac O
##cade O
##s O
and O
smooth O
pursuit O
in O
primate O
##s O
and O
humans O
##16 O
23 O
and O
its O
stimulation O
could O
explain O
some O
o O
##cular O
motor O
side O
effects O
such O
as O
contra O
##vers O
##ive O
eye O
deviation O
10 O
however O
it O
is O
unlikely O
that O
st O
##n O
could O
have O
induced O
the O
tn O
as O
it O
was O
not O
observed O
at O
low O
intensity O
of O
stimulation O

published O
online O
10 O
july O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##51 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letter O
to O
the O
editor O
1621 O
table O
1 O
stimulation O
parameters O
and O
normal O
complaints O
v O
side O
effects O
contacts O
and O
voltage O
##s O
used O
for O
chronicle O
bilateral O
stimulation O
lc O
2 O
3 O
5 O
no O
visual O
complaint O
rc O
7 O
3 O
5 O
no O
visual O
complaint O
voltage O
##s O
giving O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
lc O
rc O
7 O
3 O
5 O
slight O
cc O
##w O
tn O
6 O
3 O
5 O
marked O
cc O
##w O
tn O
nausea O
##s O
vertigo O
5 O
3 O
5 O
cc O
##w O
tn O
vertigo O
4 O
3 O
5 O
cc O
##w O
tn O
nausea O
##s O
vertigo O

lc O
left O
contacts O
0 O
is O
the O
deepest O
and O
3 O
is O
the O
upper O
rc O
right O
contacts O
4 O
is O
the O
deepest O
and O
7 O
is O
the O
upper O
v O
intensity O
of O
the O
stimulation O
expressed O
in O
vol O
##ts O
tn O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
cw O
clockwise O
cc O
##w O
counter O
##cl O
##ock O
##wise O
contacts O
on O
witch O
the O
ny O
##sta O
##gm O
##us O
was O
the O
more O
marked O
and O
used O
for O
the O
eyes O
movement O
recordings O
and O
as O
the O
contacts O
were O
medial O
to O
the O
st O
##n O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
can O
also O
be O
explained O
by O
intra O
##fa O
##sc O
##icular O
o O
##cu O
##lom O
##oto O
##r O
nerve O
stimulation O
but O
this O
could O
not O
explain O
bin O
##oc O
##ular O
ny O
##sta O
##gm O
##us O
24 O

1 O
14 O
5 O
right O
side O
4 O
9 O
6 O
5 O
7 O
5 O
9 O
5 O
5 O
8 O
6 O
10 O
3 O
9 O
5 O
7 O
11 O
1 O
11 O
rn O
red O
nucleus O
s O
##n O
sub O
##stan O
##tia O
ni O
##gra O
st O
##n O
sub O
##thal O
##ami O
##c O
nucleus O

according O
to O
the O
close O
relationship O
of O
ic O
rim O
##lf O
and O
stimulation O
contacts O
the O
contra O
##lateral O
tn O
reported O
here O
could O
be O
due O
to O
an O
activation O
of O
the O
ic O
or O
an O
inhibition O
of O
the O
rim O
##lf O
or O
both O
either O
due O
to O
a O
direct O
nucleus O
or O
an O
indirect O
in O
out O
connecting O
pathways O
modulation O
alice O
po O
##isson O
md O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##logie O
c O
lyon O
france O
caroline O
til O
##ike O
##te O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
unite O
##´ O
de O
ne O
##uro O
op O
##hta O
##lm O
##olo O
##gie O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O
lyon O
france O
patrick O
mer O
##tens O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##chi O
##ru O
##rg O
##ie O
a O
lyon O
france O
ye O
##ln O
##ik O
md O
phd O
ins O
##er O
##m O
u O
67 O
##9 O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
table O
2 O
eye O
movements O
recording O
with O
2d O
video O
o O
##cu O
##log O
##raphy O
200 O
hz O
frequency O
vis O
##uo O
##200 O
syn O
##ap O
##sy O
##s O
france O
bilateral O
stimulation O
no O
stimulation O

velocity O
ve O
##l O
and O
gain O
of O
horizontal O
158 O
and O
vertical O
108 O
visually O
guided O
sac O
##cade O
##s O
gain O
of O
smooth O
pursuit O
0 O
15 O
hz O
308 O
horizontal O
and O
208 O
vertical O
pen O
##du O
##lar O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
0 O
25 O
hz O
maximum O
amplitude O
of O
45 O
##8 O
and O
maximal O
velocity O
of O
head O
shaking O
ny O
##sta O
##gm O
##us O
hs O
##n O
mean O
frequency O
2 O
hz O
mean O
amplitude O
258 O
in O
horizontal O
and O
vertical O
directions O
were O
recorded O
letter O
to O
the O
editor O
1623 O
eric O
bard O
##ine O
##t O
phd O
cn O
##rs O
up O
##r O
640 O
up O
##mc O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O
centre O
de O
ne O
##uro O
image O
##rie O
de O
rec O
##her O
##che O
up O
##mc O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O

emmanuel O
bro O
##uss O
##oll O
##e O
md O
phd O
ste O
##´ O
##pha O
##ne O
tho O
##bo O
##is O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##logie O
c O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O
if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O
lyon O
france O
email O
stephane O
tho O
##bo O
##is O
chu O
lyon O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
promoted O
by O
the O
hospice O
##s O
civil O
##s O
de O
lyon O
project O
no O
hc O
##l O
p O
2002 O
303 O
references O
k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O

klein O
##er O
fis O
##man O
g O
her O
##zog O
j O
fis O
##man O
d O
##n O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
deep O
brain O
stimulation O
summary O
and O
meta O
analysis O
of O
outcomes O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
su O
##pp O
##l O
14 O
s O
##29 O
##0 O
s O
##30 O
##4 O
ye O
##ln O
##ik O
j O
bard O
##ine O
##t O
e O
dorm O
##ont O
d O
et O
al O
a O
three O
dimensional O
his O
##to O
##logical O
and O
def O
##or O
##mable O
atlas O
of O
the O
human O
basal O
gang O
##lia O
i O
atlas O
construction O
based O
on O
im O
##mun O
##oh O
##isto O
##chemical O
and O
mri O
data O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
61 O
##8 O
63 O
##8 O

ben O
##abi O
##d O
al O
ko O
##ud O
##sie O
a O
ben O
##az O
##zo O
##uz O
a O
et O
al O
deep O
brain O
stimulation O
of O
the O
corpus O
lu O
##ys O
##i O
sub O
##thal O
##ami O
##c O
nucleus O
and O
other O
targets O
in O
parkinson O
s O
disease O
extension O
to O
new O
indications O
such O
as O
d O
##yst O
##onia O
and O
ep O
##ile O
##psy O
j O
ne O
##uro O
##l O
2001 O
248 O
su O
##pp O
##l O
3 O
iii O
##37 O
iii O
##47 O
bro O
##gg O
##i O
g O
franz O
##ini O
a O
fe O
##rro O
##li O
p O
et O
al O
effect O
of O
bilateral O
sub O
##thal O
##ami O
##c O
electrical O
stimulation O
in O
parkinson O
s O
disease O
sur O
##g O
ne O
##uro O
##l O
2001 O
56 O
89 O
94 O
discussion O
94 O
86 O
her O
##zog O
j O
vol O
##km O
##ann O
j O
k O
##rac O
##k O
p O
et O
al O
two O
year O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2003 O
18 O
133 O
##2 O
133 O
##7 O

ian O
##se O
##k O
r O
rosen O
##feld O
j O
##v O
hu O
##x O
##ham O
fe O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
med O
j O
aus O
##t O
2002 O
177 O
142 O
146 O
os O
##ter O
##gaard O
k O
sun O
##de O
n O
dupont O
e O
effects O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
patients O
with O
severe O
parkinson O
s O
disease O
and O
motor O
ﬂ O
##uc O
##tua O
##tions O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
69 O
##3 O
700 O
rom O
##ito O
l O
##m O
sc O
##er O
##rat O
##i O
m O
con O
##tar O
##ino O
m O
##f O
bent O
##ivo O
##glio O
ar O
ton O
##ali O
p O
alba O
##nese O
a O
long O
term O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
ne O
##uro O
##logy O
2002 O
58 O
154 O
##6 O
1550 O

saul O
##eau O
p O
poll O
##ak O
p O
k O
##rac O
##k O
p O
et O
al O
contra O
##vers O
##ive O
eye O
deviation O
during O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
region O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1810 O
1813 O
tam O
##ma O
f O
ramp O
##ini O
p O
e O
##gi O
##di O
m O
et O
al O
deep O
brain O
stimulation O
for O
parkinson O
s O
disease O
the O
experience O
of O
the O
pol O
##ic O
##lini O
##co O
san O
paolo O
group O
in O
milan O
ne O
##uro O
##l O
sci O
2003 O
24 O
su O
##pp O
##l O
1 O
s O
##41 O
s O
##42 O
ta O
##vel O
##la O
a O
berg O
##ama O
##sco O
b O
bo O
##stic O
##co O
e O
et O
al O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
long O
term O
follow O
up O
ne O
##uro O
##l O
sci O
2002 O
23 O
su O
##pp O
##l O
2 O
s O
##11 O
##1 O
s O
##11 O
##2 O

tho O
##bo O
##is O
s O
mer O
##tens O
p O
gu O
##eno O
##t O
m O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
clinical O
evaluation O
of O
18 O
patients O
j O
ne O
##uro O
##l O
2002 O
249 O
52 O
##9 O
53 O
##4 O
vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
weiss O
ph O
fr O
##eu O
##nd O
h O
##j O
stu O
##rm O
v O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O
lu O
##eck O
c O
##j O
has O
##ml O
##yn O
p O
crawford O
t O
##j O
levy O
is O
br O
##ind O
##ley O
gs O
watkins O
es O
ken O
##nard O
c O
a O
case O
of O
o O
##cular O
tilt O
reaction O
and O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
due O
to O
direct O
stimulation O
of O
the O
mid O
##bra O
##in O
in O
man O
brain O
1991 O
114 O
pt O
5 O
206 O
##9 O
207 O
##9 O

hue O
##rta O
m O
##f O
k O
##ru O
##bit O
##zer O
la O
ka O
##as O
j O
##h O
frontal O
eye O
ﬁ O
##eld O
as O
de O
##ﬁ O
##ned O
by O
intra O
##cor O
##tical O
micro O
##sti O
##mu O
##lation O
in O
squirrel O
monkeys O
owl O
monkeys O
and O
mac O
##aq O
##ue O
monkeys O
i O
sub O
##cor O
##tical O
connections O
j O
com O
##p O
ne O
##uro O
##l O
1986 O
253 O
415 O
43 O
##9 O
hue O
##rta O
m O
##f O
po O
##ns O
t O
##p O
primary O
motor O
cortex O
receives O
input O
from O
area O
3a O
in O
mac O
##aq O
##ues O
brain O
res O
1990 O
53 O
##7 O
36 O
##7 O
37 O
##1 O
stanton O
gb O
goldberg O
me O
bruce O
c O
##j O
frontal O
eye O
ﬁ O
##eld O
e O
##ffer O
##ents O
in O
the O
mac O
##aq O
##ue O
monkey O
ii O
topography O
of O
terminal O
ﬁ O
##eld O
##s O
in O
mid O
##bra O
##in O
and O
po O
##ns O
j O
com O
##p O
ne O
##uro O
##l O
1988 O
271 O
49 O
##3 O
50 O
##6 O

movement O
disorders O

vol O
23 O
no O
11 O
2008 O
pp O
161 O
##3 O
162 O
##7 O

2008 O
movement O
disorder O
society O

letters O
to O
the O
editor O
related O
to O
new O
topics O

alexander O
disease O
causing O
hereditary O
late O
onset O
ata O
##xia O
with O
only O
minimal O
white O

matter O
changes O
a O
report O
of O
two O
si O
##bs O

video O

classic O
alexander O
disease O
refers O
to O
a O
rare O
ne O
##uro O
##de O
##gen O
##erative O
le O
##uk O
##od O
##yst O
##rop O
##hy O
typically O
manifest O
##ing O
in O
early O
childhood O
with O
mega O
##loe O
##nce O
##pha O
##ly O
seizures O
spa O
##stic O
##ity O
and O
psycho O
##moto O
##r O
regression O
until O
recently O
its O
diagnosis O
was O
based O
on O
distinctive O
mri O
features O
such O
as O
white O
matter O
lesions O
that O
predominantly O
affect O
the O
front O
##ote O
##mp O
##ora O
##l O
and O
per O
##ive O
##nt O
##ric O
##ular O
regions O
the O
ﬁ O
##nding O
of O
ca O
##usa O
##tive O
mutations O
in O
the O
g O
##fa O
##p O
gene O
has O
enabled O
diagnostic O
con O
##ﬁ O
##rma O
##tion O
by O
mutation O
analysis O
this O
has O
also O
lead O
to O
the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
at O
##yp O
##ical O
and O
late O
onset O
cases O
with O
a O
highly O
variable O
spectrum O
of O
clinical O
and O
imaging O
abnormalities O

we O
report O
a O
case O
of O
an O
adult O
onset O
mutation O
proven O
alexander O
disease O
characterized O
by O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
the O
absence O
of O
pal O
##atal O
tremor O
and O
very O
mild O
white O
matter O
changes O
1 O
2 O

this O
61 O
year O
old O
man O
presented O
at O
the O
age O
of O
50 O
years O
with O
slowly O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
his O
past O
medical O
history O
revealed O
the O
onset O
of O
static O
but O
marked O
forward O
ﬂ O
##ex O
##ion O
of O
the O
trunk O
in O
his O
ﬁ O
##rst O
decade O
but O
without O
any O
motor O
abnormalities O
until O
recently O
his O
sister O
had O
been O
diagnosed O
with O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
there O
were O
no O
other O
affected O
relatives O

neurological O
examination O
see O
video O
revealed O
a O
normal O
mental O
status O
jerk O
##y O
pursuit O
and O
d O
##ys O
##metric O
sac O
##cade O
##s O
mild O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
mild O
ata O
##xia O
of O
the O
trunk O
and O
ex O
##tre O
##mit O
##ies O
that O
increased O
upon O
eye O
closure O
a O
broad O
based O
ata O
##xi O
##c O
ga O
##it O
cervical O
ky O
##ph O
##osis O
and O
thor O
##ac O
##ic O
sc O
##olio O
##sis O
with O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
hips O
and O
knees O
positive O
rom O
##berg O
s O
sign O
disturbed O
vibration O
sense O
in O
the O
lower O
limbs O
slightly O
diminished O
tend O
##on O
re O
##ﬂ O
##ex O
##es O
in O
the O
lower O
ex O
##tre O
##mit O
##ies O
with O
normal O
plant O
##ar O
responses O

we O
screened O
for O
several O
of O
the O
genetic O
ata O
##xia O
##s O
but O
no O
mutations O
were O
detected O
in O
the O
sc O
##a1 O
2 O
3 O
6 O
7 O
14 O
genes O
or O
in O
the O
genes O
responsible O
for O
fried O
##re O
##ich O
s O
ata O
##xia O
and O
dent O
##ator O
##ub O
##ro O
pal O
##lid O
##o O
lu O
##ys O
##ian O
at O
##rop O
##hy O
electro O
##my O
##ography O
showed O
no O
signs O
of O
ne O
##uro O
##pathy O
or O
my O
##opa O
##thy O
ss O
##ep O
was O
not O
performed O
mri O
demonstrated O
subtle O
white O
matter O
lesions O
anterior O
##ly O
in O
both O
temporal O
lobes O
as O
well O
as O
mild O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bell O
##um O
brains O
##tem O
and O
cervical O
spinal O
cord O
on O
standard O
mri O
imaging O
fig O
1a O
c O

additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##53 O

the O
records O
of O
the O
affected O
sister O
who O
died O
at O
the O
age O
of O
64 O
mentioned O
horizontal O
ny O
##sta O
##gm O
##us O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
limb O
ata O
##xia O
and O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
addition O
the O
presence O
of O
pal O
##atal O
my O
##oc O
##lon O
##us O
was O
noted O
once O
while O
the O
d O
##ys O
##arth O
##ria O
was O
said O
to O
exist O
from O
an O
early O
age O
the O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
arose O
at O
the O
age O
of O
30 O
brain O
imaging O
at O
age O
58 O
years O
showed O
ce O
##re O
##bella O
##r O
and O
marked O
bulb O
##ome O
##du O
##llar O
at O
##rop O
##hy O
as O
well O
as O
white O
matter O
lesions O
in O
the O
per O
##ive O
##nt O
##ric O
##ular O
region O
corpus O
call O
##os O
##um O
and O
right O
medial O
ce O
##re O
##bella O
##r O
pe O
##dun O
##cle O
fig O
1 O
##d O
f O

as O
these O
combined O
clinical O
and O
imaging O
features O
were O
suggest O
##ive O
of O
alexander O
disease O
we O
sequence O
##d O
the O
g O
##fa O
##p O
gene O
and O
found O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
c O
69 O
##2 O
##t O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
4 O
predicting O
a O
p O
le O
##u O
##23 O
##1 O
##his O
amino O
acid O
change O
this O
mutation O
was O
not O
encountered O
in O
210 O
control O
chromosomes O

several O
cases O
of O
adult O
onset O
alexander O
disease O
have O
been O
reported O
mostly O
with O
an O
onset O
in O
the O
third O
or O
fourth O
decade O
of O
life O
ph O
##eno O
##typic O
het O
##ero O
##gen O
##eit O
##y O
is O
evident O
from O
the O
variable O
presence O
of O
bulb O
##ar O
symptoms O
ce O
##re O
##bella O
##r O
signs O
pal O
##atal O
tremor O
spa O
##stic O
par O
##esis O
and O
auto O
##no O
##mic O
dysfunction O

the O
index O
patient O
reported O
here O
displays O
a O
rather O
unique O
ph O
##eno O
##type O
of O
adult O
onset O
alexander O
disease O
first O
his O
age O
at O
onset O
was O
50 O
years O
which O
is O
one O
of O
the O
latest O
ever O
reported O
3 O
second O
his O
clinical O
presentation O
was O
dominated O
by O
the O
combined O
presence O
of O
slowly O
progressive O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
in O
the O
absence O
of O
pal O
##atal O
tremor O
the O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
his O
knee O
bent O
posture O
are O
very O
likely O
related O
to O
his O
alexander O
disease O
as O
these O
features O
have O
been O
observed O
previously O
4 O
13 O
yet O
the O
interval O
to O
the O
onset O
of O
ata O
##xia O
in O
our O
case O
is O
remarkable O
third O
ne O
##uro O
##ima O
##ging O
in O
our O
patient O
revealed O
ce O
##re O
##bella O
##r O
brains O
##tem O
and O
spinal O
cord O
at O
##rop O
##hy O
all O
previously O
reported O
imaging O
features O
of O
alexander O
disease O
but O
the O
white O
matter O
changes O
were O
extremely O
subtle O
involving O
a O
minor O
portion O
of O
the O
anterior O
poles O
of O
both O
temporal O
lobes O
only O
mri O
abnormalities O
in O
adult O
onset O
alexander O
disease O
are O
het O
##ero O
##gen O
##eous O
but O
the O
white O
matter O
changes O
are O
generally O
less O
extensive O
compared O
with O
the O
classic O
early O
onset O
disease O
17 O

the O
give O
away O
in O
this O
case O
was O
the O
presence O
of O
a O
pa O
##pt O
syndrome O
in O
the O
patient O
s O
sister O
the O
combination O
of O
ce O
##re O
##bella O
##r O
ata O
##xia O
and O
pal O
##atal O
tremor O
is O
relatively O
common O
in O
adult O
##ons O
##et O
alexander O
disease O
43 O
4 O
9 O
12 O
14 O
this O
clinical O
constellation O
is O
presently O
referred O
to O
as O
pa O
##pt O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
used O
to O
indicate O
a O
subgroup O
of O
the O
sy O
##mpt O
##oma O
##tic O
pal O
##atal O
tremor O
in O
which O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
are O
involved O
in O
case O
of O
a O
fa O
##mi O
##lia O
##l O
pa O
##pt O
the O
differential O
diagnosis O
is O
quite O
limited O
and O
in O
addition O
to O
alexander O
disease O
also O
includes O
sc O
##a O
##20 O
and O
perhaps O
other O
forms O
of O
de O
##gen O
##erative O
ce O
##re O
##bella O
##r O
ata O
##xia O
##s O
15 O
16 O

in O
conclusion O
we O
report O
two O
si O
##bs O
with O
late O
onset O
ata O
##xia O
due O
to O
alexander O
disease O
caused O
by O
a O
novel O
g O
##fa O
##p O
mutation O
alexander O
disease O
should O
thus O
be O
considered O
in O
the O
differential O
diagnosis O
of O
otherwise O
une O
##x O
##pl O
##aine O
##d O
hereditary O
late O
onset O

161 O
##3 O

161 O
##4 O
letters O
to O
the O
editor O

fig O
1 O
brain O
and O
cervical O
spine O
mri O
images O
of O
the O
index O
case O
a O
c O
and O
affected O
sister O
d O
f O
a O
subtle O
white O
matter O
changes O
in O
the O
anterior O
parts O
of O
left O
more O
than O
right O
temporal O
lobe O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bella O
##r O
hemisphere O
##s O
with O
en O
##lar O
##gement O
of O
the O
4th O
vent O
##ric O
##le O
axial O
t O
##2 O
b O
marked O
at O
##rop O
##hy O
of O
the O
lower O
med O
##ulla O
axial O
t O
##1 O
c O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
upper O
part O
of O
spinal O
cord O
the O
presence O
of O
sc O
##olio O
##sis O
is O
also O
evident O
axial O
t O
##2 O
d O
white O
matter O
defect O
in O
right O
medial O
ce O
##re O
##bella O
##r O
pe O
##dun O
##cle O
axial O
t O
##2 O
e O
white O
matter O
les O
##ion O
in O
the O
left O
per O
##ive O
##nt O
##ric O
##ular O
region O
axial O
t O
##2 O

f O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
and O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
with O
spa O
##ring O
of O
the O
po O
##ns O
and O
cervical O
spinal O
cord O
a O
small O
les O
##ion O
in O
the O
anterior O
part O
of O
the O
corpus O
call O
##os O
##um O
there O
are O
in O
addition O
high O
signal O
par O
##en O
##chy O
##mal O
changes O
in O
the O
posterior O
med O
##ulla O
and O
ce O
##re O
##bella O
##r O
white O
matter O
sa O
##git O
##tal O
flair O

ata O
##xia O
additional O
yet O
not O
ob O
##liga O
##te O
clinical O
features O
pal O
##atal O
tremor O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
more O
or O
less O
distinctive O
mri O
ﬁ O
##nding O
##s O
subtle O
white O
matter O
changes O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
spinal O
cord O
might O
constitute O
clues O
that O
hint O
towards O
this O
spec O
##i O
##ﬁ O
##c O
diagnosis O

legends O
to O
the O
video O

segment O
1 O
mild O
ata O
##xi O
##c O
and O
bouncing O
ga O
##it O
note O
the O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
knees O
di O
##f O
##ﬁ O
##cu O
##lty O
tandem O
walking O

segment O
2 O
bent O
hip O
and O
bent O
knee O
posture O

segment O
3 O
o O
##cular O
pursuit O
showing O
jerk O
##y O
pursuit O
movements O

segment O
4 O
horizontal O
sac O
##cade O
##s O
showing O
multi O
step O
sac O
##cade O
##s O
and O
o O
##cular O
d O
##ys O
##met O
##ria O
both O
h O
##yp O
##ometric O
and O
hyper O
##metric O

segment O
5 O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
on O
repeating O
the O
dutch O
sentence O
rode O
ron O
##de O
app O
##els O
roll O
##en O
van O
de O
z O
##old O
##ert O
##ra O
##p O
and O
on O
repeating O
pat O
##aka O

segment O
6 O
mild O
decomposition O
of O
movement O
during O
ﬁ O
##nger O
to O
nose O
testing O

catherine O
c O
s O
del O
##no O
##oz O
md O
jurgen O
h O
sc O
##hel O
##ha O
##as O
md O
phd O

bart O
p O
c O
van O
de O
warren O
##burg O
md O
phd O

department O
of O
ne O
##uro O
##logy O
ra O
##db O
##oud O
university O
ni O
##jm O
##ege O
##n O
medical O
center O

ni O
##jm O
##ege O
##n O
the O
netherlands O

e O
mail O
b O
van O
##de O
##war O
##ren O
##burg O
ne O
##uro O
um O
##c O
##n O
nl O

robert O
jan O
de O
gr O
##aa O
##f O
md O

department O
of O
ne O
##uro O
##logy O
amp O
##hia O
hospital O
bred O
##a O
o O
##ost O
##er O
##ho O
##ut O

the O
netherlands O

ga O
##j O
##ja O
s O
sal O
##omo O
##ns O
phd O

department O
of O
clinical O
chemistry O

metabolic O
unit O
vu O
university O
medical O
center O
amsterdam O
the O
netherlands O

references O

johnson O
a O
alexander O
disease O
review O
of O
the O
gene O
int O
j O
dev O
ne O
##uro O
##sc O
##i O
2002 O
20 O
39 O
##1 O
39 O
##4 O

li O
r O
johnson O
ab O
sal O
##omo O
##ns O
g O
et O
al O
g O
##fa O
##p O
mutations O
in O
infant O
##ile O
juvenile O
and O
adult O
forms O
of O
alexander O
disease O
ann O
ne O
##uro O
##l O
2005 O
57 O
310 O
326 O

howard O
k O
##l O
hall O
da O
moon O
m O
ag O
##ar O
##wal O
p O
newman O
e O
br O
##enne O
##r O

m O
adult O
onset O
alexander O
disease O
with O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
mo O
##v O
di O
##s O
2008 O
23 O
118 O
122 O

de O
##pre O
##z O
m O
d O
ho O
##og O
##he O
m O
miss O
##on O
jp O
et O
al O
infant O
##ile O
and O
juvenile O
presentations O
of O
alexander O
disease O
a O
report O
of O
two O
cases O
act O
##a O
ne O
##uro O
##l O
scan O
##d O
1999 O
99 O
158 O
165 O

sal O
##ma O
##gg O
##i O
a O
bot O
##tur O
##i O
a O
lamp O
##ert O
##i O
e O
et O
al O
a O
novel O
mutation O
in O
the O
g O
##fa O
##p O
gene O
in O
a O
fa O
##mi O
##lia O
##l O
adult O
onset O
alexander O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
127 O
##8 O
128 O
##0 O

sc O
##hwa O
##nk O
##haus O
j O
paris O
##i O
je O
gu O
##lled O
##ge O
wr O
chin O
l O
currie O
##r O
rd O
hereditary O
adult O
onset O
alexander O
disease O
with O
pal O
##atal O
my O
##oc O
##lon O
##us O
spa O
##stic O
para O
##par O
##esis O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
ne O
##uro O
##logy O
1995 O
45 O
226 O
##6 O
227 O
##1 O

saw O
##ais O
##hi O
##i O
y O
hat O
##az O
##awa O
j O
och O
##i O
n O
et O
al O
pet O
in O
juvenile O
alexander O
disease O
j O
ne O
##uro O
##l O
sci O
1999 O
165 O
116 O
120 O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O

letters O
to O
the O
editor O
161 O
##5 O

non O
##om O
##ura O
y O
shi O
##mi O
##zu O
k O
ni O
##shi O
##moto O
h O
ho O
##so O
##e O
h O
sa O
##ka O
##guchi O
y O
mi O
##yam O
##oto O
k O
sc O
##olio O
##sis O
in O
a O
patient O
with O
alexander O
disease O
j O
spin O
di O
##s O
2002 O
15 O
261 O
264 O

thy O
##aga O
##raj O
##an O
d O
chat O
##away O
t O
li O
r O
ga O
##i O
w O
##p O
br O
##enne O
##r O
m O
dominant O
##ly O
inherited O
adult O
onset O
le O
##uk O
##od O
##yst O
##rop O
##hy O
with O
pal O
##atal O
tremor O
caused O
by O
a O
mutation O
in O
the O
g O
##lia O
##l O
ﬁ O
##bri O
##llary O
acidic O
protein O
mo O
##v O
di O
##s O
2004 O
19 O
124 O
##4 O
124 O
##8 O

ok O
##amo O
##to O
y O
mit O
##su O
##yama O
h O
hi O
##rata O
k O
ari O
##mura O
k O
os O
##ame O
m O
nak O
##agawa O
m O
auto O
##som O
##al O
dominant O
pal O
##atal O
my O
##oc O
##lon O
##us O
and O
spinal O
cord O
at O
##rop O
##hy O
j O
ne O
##uro O
##l O
sci O
2002 O
195 O
71 O
76 O

stump O
##f O
e O
mass O
##on O
h O
du O
##quette O
a O
et O
al O
adult O
alexander O
disease O
with O
auto O
##som O
##al O
transmission O
arch O
ne O
##uro O
##l O
2003 O
60 O
130 O
##7 O
132 O
##0 O

bo O
##rret O
d O
becker O
le O
alexander O
disease O
of O
astro O
##cytes O
brain O
1985 O
108 O
36 O
##7 O
385 O

cole O
g O
de O
villiers O
f O
proctor O
ns O
fr O
##eim O
##an O
i O
bill O
p O
alexander O
disease O
case O
report O
including O
his O
##top O
##ath O
##ological O
and O
electron O
microscopic O
features O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
1979 O
42 O
61 O
##9 O
62 O
##4 O

ku O
##l O
##har O
##ni O
p O
mu O
##than O
##e O
u O
##b O
tal O
##y O
ab O
jaya O
##kumar O
p O
##n O
she O
##tty O
r O
sat O
##hya O
##nar O
##ayan O
##a O
swam O
##y O
h O
pal O
##atal O
tremor O
progressive O
multiple O
cr O
##anial O
nerve O
pal O
##sies O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
a O
case O
report O
and O
review O
of O
literature O
of O
pal O
##atal O
tremor O
##s O
in O
ne O
##uro O
##de O
##gen O
##erative O
disease O
mo O
##v O
di O
##s O
1999 O
14 O
68 O
##9 O
69 O
##3 O

samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O

storey O
e O
knight O
ma O
forrest O
sm O
gardner O
r O
##j O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
ce O
##re O
##bell O
##um O
2005 O
4 O
55 O
57 O

van O
der O
kn O
##aa O
##p O
ms O
na O
##id O
##u O
s O
br O
##eit O
##er O
s O
##n O
et O
al O
alexander O
disease O
diagnosis O
with O
mri O
am O
j O
ne O
##uro O
##rad O
##iol O
2001 O
22 O
54 O
##1 O
55 O
##2 O

anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
a O
case O
report O

my O
##oc O
##lon O
##us O
is O
a O
clinical O
sign O
de O
##ﬁ O
##ned O
as O
sudden O
brief O
shock O
##like O
involuntary O
movements O
caused O
by O
muscular O
contraction O
##s O
positive O
my O
##oc O
##lon O
##us O
or O
inhibition O
##s O
negative O
my O
##oc O
##lon O
##us O
as O
##ter O
##ix O
##is O
most O
causes O
of O
my O
##oc O
##lon O
##us O
are O
sy O
##mpt O
##oma O
##tic O
and O
include O
post O
##hy O
##po O
##xia O
toxic O
metabolic O
disorders O
and O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
1 O
various O
drugs O
including O
ne O
##uro O
##le O
##ptic O
##s O
anti O
##con O
##vu O
##ls O
##ants O
and O
cardiac O
medications O
can O
cause O
my O
##oc O
##lon O
##us O
1 O
2 O
but O
anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
is O
extremely O
rare O
2 O
3 O
here O
we O
report O
a O
case O
of O
transient O
my O
##oc O
##lon O
##us O
triggered O
by O
an O
anti O
##his O
##tam O
##ine O
ox O
##ato O
##mide O

an O
85 O
year O
old O
man O
taking O
am O
##lo O
##di O
##pine O
5 O
mg O
day O
can O
##des O
##art O
##an O
8 O
mg O
day O
ar O
##ot O
##ino O
##lo O
##l O
20 O
mg O
day O
and O
fur O
##ose O
##mide O
20 O
mg O
day O
for O
hyper O
##tension O
and O
all O
##op O
##uri O
##no O
##l O
200 O
mg O
day O
for O
hyper O
##uri O
##ce O
##mia O
developed O
an O
involuntary O
movement O
in O
his O
right O
hand O
it O
progressed O
over O
his O
upper O
limbs O
and O
face O
within O
several O
hours O
and O
he O
was O
referred O
to O
our O
hospital O
on O
physical O
examination O
he O
was O
af O
##eb O
##ril O
##e O
without O
abnormal O
##ity O
except O
for O
sy O
##sto O
##lic O
hyper O
##tension O
170 O
80 O
mm O
h O
##g O
the O
mini O
mental O
status O
test O
revealed O
cognitive O
impairment O
score O
20 O
at O
rest O
there O
was O
my O
##oc O
##lon O
##us O
in O
the O
patient O
s O
face O
tongue O
jaw O
neck O
and O
upper O
limbs O
predominantly O
on O
the O
left O
there O
was O
no O
pal O
##atal O
tremor O
an O
electro O
##phy O
##sio O
##logical O
study O
revealed O
4 O
hz O
rhythmic O
my O
##oc O
##lon O
##ic O
discharge O
##s O
in O
the O
left O
arm O
muscles O
with O
synchronized O
o O
##cular O
movement O
that O
increased O
with O
eye O
##lid O
closure O
see O
fig O
1 O
and O
suggested O
that O
the O
my O
##oc O
##lon O
##us O
was O
persistent O
and O
time O
locked O
in O
all O
locations O
generalized O
my O
##o O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
220 O
##7 O
##6 O

cl O
##onus O
limb O
my O
##oc O
##lon O
##us O
was O
exaggerated O
when O
the O
patient O
extended O
his O
upper O
limbs O
but O
it O
was O
not O
induced O
by O
external O
sensory O
stimuli O
the O
involuntary O
movements O
were O
not O
suppressed O
by O
mental O
stress O
or O
by O
alternate O
pro O
##nation O
and O
su O
##pina O
##tion O
of O
the O
forearm O
to O
an O
external O
rhythm O
as O
##ter O
##ix O
##is O
was O
evident O
when O
the O
patient O
s O
upper O
limbs O
were O
extended O
and O
his O
wrists O
do O
##rs O
##i O
##ﬂ O
##ex O
##ed O
and O
it O
caused O
the O
laps O
##e O
in O
posture O
between O
the O
positive O
my O
##oc O
##lon O
##ic O
jerk O
##s O
he O
was O
unable O
to O
maintain O
his O
tongue O
in O
the O
pro O
##tr O
##uded O
position O
owing O
to O
as O
##ter O
##ix O
##is O
of O
the O
tongue O
and O
he O
had O
di O
##f O
##ﬁ O
##cu O
##lty O
speaking O
neurological O
examination O
was O
otherwise O
normal O
laboratory O
examination O
revealed O
a O
mild O
elevation O
of O
ur O
##ea O
nitrogen O
25 O
mg O
dl O
and O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fera O
##se O
40 O
i O
##u O
l O
but O
the O
plasma O
ammonia O
concentration O
and O
thyroid O
function O
were O
normal O
chest O
x O
ray O
revealed O
card O
##iom O
##ega O
##ly O
and O
cardiac O
ultra O
##son O
##ography O
showed O
left O
vent O
##ric O
##ular O
hyper O
##tro O
##phy O
and O
mild O
mit O
##ral O
reg O
##urg O
##itation O
the O
plasma O
brain O
nat O
##ri O
##ure O
##tic O
peptide O
concentration O
was O
189 O
0 O
pg O
ml O
abdominal O
son O
##ography O
and O
computed O
tom O
##ography O
revealed O
no O
abnormal O
##ity O
and O
there O
was O
no O
portals O
##yst O
##emi O
##c O
shu O
##nt O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
analysis O
was O
normal O
brain O
magnetic O
resonance O
imaging O
showed O
diffuse O
cerebral O
at O
##rop O
##hy O
which O
was O
consistent O
with O
alzheimer O
s O
disease O
and O
an O
old O
is O
##che O
##mic O
les O
##ion O
in O
the O
right O
ce O
##re O
##bell O
##um O
electro O
##ence O
##pha O
##log O
##raphy O
showed O
a O
9 O
hz O
alpha O
background O
rhythm O
without O
ep O
##ile O
##pt O
##iform O
activity O
the O
involuntary O
movements O
disappeared O
immediately O
after O
the O
intra O
##ven O
##ous O
administration O
of O
10 O
mg O
diaz O
##ep O
##am O

five O
months O
later O
the O
patient O
suffered O
a O
rec O
##ur O
##rence O
of O
my O
##o O

cl O
##onus O
but O
it O
disappeared O
within O
several O
hours O
after O
oral O
administration O
of O
0 O
5 O
mg O
cl O
##ona O
##ze O
##pa O
##m O
all O
of O
the O
patient O
s O
medications O
were O
reviewed O
again O
the O
ﬁ O
##rst O
my O
##oc O
##lon O
##us O
occurred O
after O
18 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
the O
second O
occurred O
after O
8 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
ep O
##inas O
##tine O
20 O
mg O
day O
for O
chronic O
pr O
##uri O
##go O
the O
my O
##oc O
##lon O
##us O
has O
not O
rec O
##ur O
##red O
since O
the O
patient O
stopped O
the O
anti O
##his O
##tam O
##ines O

our O
patient O
ﬁ O
##rst O
presented O
with O
acute O
occurrences O
of O
both O
generalized O
my O
##oc O
##lon O
##us O
and O
as O
##ter O
##ix O
##is O
predominantly O
in O
the O
face O
neck O
and O
upper O
limbs O
the O
involuntary O
movements O
disappeared O
immediately O
after O
benz O
##od O
##ia O
##ze O
##pine O
treatment O
but O
he O
experienced O
a O
rec O
##ur O
##rence O
these O
clinical O
features O
are O
similar O
to O
the O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
previously O
reported O
by O
hash O
##imo O
##to O
et O
al O
4 O
the O
cause O
of O
that O
state O
is O
unclear O
although O
aging O
chronic O
diseases O
and O
viral O
infection O
could O
contribute O
however O
in O
our O
patient O
the O
temporal O
relationship O
between O
my O
##oc O
##lon O
##us O
and O
the O
anti O
##his O
##tam O
##ine O
medication O
history O
suggests O
that O
ox O
##ato O
##mide O
triggered O
the O
movement O
disorder O
ox O
##ato O
##mide O
a O
second O
generation O
anti O
##his O
##tam O
##ine O
is O
used O
to O
treat O
allergic O
diseases O
in O
europe O
and O
japan O
its O
ph O
##arm O
##aco O
##logic O
actions O
include O
his O
##tam O
##ine O
h O
##1 O
receptor O
ant O
##ago O
##nism O
and O
suppression O
of O
the O
production O
and O
release O
of O
chemical O
media O
##tors O
as O
well O
as O
anti O
cho O
##liner O
##gic O
and O
anti O
ser O
##oton O
##in O
actions O
5 O
anti O
##his O
##tam O
##ines O
can O
both O
stimulate O
and O
de O
##press O
the O
central O
nervous O
system O
cn O
##s O
but O
second O
generation O
drugs O
do O
not O
app O
##re O
##cia O
##bly O
cross O
the O
blood O
brain O
barrier O
therefore O
there O
are O
few O
reports O
of O
abnormal O
involuntary O
movements O
associated O
with O
anti O
##his O
##tam O
##ines O
however O
raj O
##put O
et O
al O
recently O
reported O
a O
pediatric O
case O
of O
d O
##yst O
##onia O
induced O
by O
a O
second O
generation O
anti O
##his O
##tam O
##ine O
ce O
##ti O
##riz O
##ine O
possibly O
because O
of O
do O
##pa O
##mine O
receptor O
blockade O
by O
the O
drug O
meta O
##bol O
##ite O
6 O
ox O
##ato O
##mide O
can O
also O
cause O
d O
##yst O
##onia O
7 O
however O
to O
our O
knowledge O
there O
is O
only O
one O
report O
of O
anti O
##his O
##tam O
##ine O
induced O
my O
##o O

161 O
##6 O
letters O
to O
the O
editor O

fig O
1 O
electro O
##oc O
##ulo O
##graphy O
and O
surface O
electro O
##my O
##ography O
rhythmic O
o O
##cular O
movement O
of O
the O
left O
l O
eye O
in O
the O
vertical O
direction O
l O
om O
vertical O
was O
sync O
##hr O
##ono O
##us O
with O
my O
##oc O
##lon O
##us O
in O
the O
l O
orb O
##icular O
##is O
o O
##cu O
##li O
rhythmic O
sync O
##hr O
##ono O
##us O
my O
##oc O
##lon O
##ic O
discharge O
##s O
were O
also O
evident O
in O
the O
l O
ﬁ O
##rst O
dorsal O
inter O
##oss O
##eous O
f O
##di O
and O
l O
abd O
##uc O
##tor O
poll O
##ici O
##s O
br O
##ev O
##is O
ap O
##b O
cal O
##ib O
##ration O
100 O
l O
##v O
in O
each O
lane O
time O
constant O
0 O
1 O
s O
in O
the O
ﬁ O
##rst O
lane O
and O

0 O
001 O
s O
in O
other O
lanes O
black O
bar O
1 O
s O

cl O
##onus O
in O
that O
case O
caused O
by O
abusive O
over O
##use O
of O
a O
ﬁ O
##rst O
generation O
anti O
##his O
##tam O
##ine O
trip O
##ele O
##nna O
##mine O
3 O
it O
remains O
unclear O
why O
ox O
##ato O
##mide O
triggered O
my O
##oc O
##lon O
##us O
in O
our O
patient O
we O
could O
not O
determine O
the O
plasma O
concentration O
of O
ox O
##ato O
##mide O
when O
he O
was O
suffering O
from O
the O
my O
##oc O
##lon O
##us O
however O
cardiac O
or O
renal O
dysfunction O
might O
raise O
the O
drug O
concentration O
to O
a O
toxic O
level O
in O
the O
cn O
##s O
and O
the O
drug O
might O
affect O
the O
ser O
##oton O
##er O
##gic O
system O
to O
cause O
my O
##oc O
##lon O
##us O
although O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
remains O
controversial O
8 O
on O
the O
other O
hand O
our O
patient O
was O
dem O
##ented O
and O
being O
treated O
with O
anti O
##hy O
##per O
##tens O
##ive O
agents O
dementia O
can O
lower O
the O
threshold O
for O
my O
##oc O
##lon O
##us O
or O
can O
be O
a O
cause O
of O
my O
##oc O
##lon O
##us O
in O
and O
of O
itself O
1 O
furthermore O
cardiac O
medications O
can O
also O
cause O
my O
##oc O
##lon O
##us O
1 O
therefore O
the O
minor O
toxic O
metabolic O
disturbance O
caused O
by O
anti O
##his O
##tam O
##ine O
use O
might O
have O
led O
our O
elderly O
my O
##oc O
##lon O
##us O
##pro O
##ne O
patient O
into O
a O
transient O
my O
##oc O
##lon O
##ic O
state O
this O
is O
the O
ﬁ O
##rst O
report O
of O
my O
##oc O
##lon O
##us O
triggered O
by O
a O
therapeutic O
dose O
of O
anti O
##his O
##tam O
##ines O
clinic O
##ians O
should O
recognize O
that O
anti O
##his O
##tam O
##ines O
could O
trigger O
this O
benign O
but O
dramatic O
cn O
##s O
side O
effect O

tak O
##ashi O
ir O
##io O
##ka O
md O
phd O
akira O
mach O
##ida O
md O
tak O
##anor O
##i O
yoko O
##ta O
md O
phd O

hide O
##hiro O
mi O
##zu O
##sa O
##wa O
md O
phd O
department O
of O
ne O
##uro O
##logy O
and O
neurological O
science O
graduate O
school O
tokyo O
medical O
and O
dental O
university O

tokyo O
japan O

e O
mail O
t O
ir O
##io O
##ka O
nur O
##o O
t O
##md O
ac O
jp O

ca O
##vine O
##ss O
j O
##n O
brown O
p O
my O
##oc O
##lon O
##us O
current O
concepts O
and O
recent O
advances O
lance O
##t O
ne O
##uro O
##l O
2004 O
3 O
59 O
##8 O
60 O
##7 O

gordon O
m O
##f O
toxin O
and O
drug O
induced O
my O
##oc O
##lon O
##us O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##l O

og O
##y O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
49 O
76 O

sc O
##hip O
##ior O
pg O
an O
unusual O
case O
of O
anti O
##his O
##tam O
##ine O
into O
##xi O
##cation O
j O
pediatric O
##s O
1967 O
71 O
58 O
##9 O
59 O
##1 O

hash O
##imo O
##to O
s O
ka O
##wa O
##mura O
j O
yamamoto O
t O
et O
al O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
in O
elderly O
patients O
a O
new O
syndrome O
j O
ne O
##uro O
##l O
sci O
1992 O
109 O
132 O
139 O

richards O
d O
##m O
bro O
##g O
##den O
rn O
heel O
rc O
sp O
##ei O
##ght O
t O
##m O
avery O
gs O
ox O
##ato O
##mide O
a O
review O
of O
its O
ph O
##arm O
##aco O
##dy O
##nami O
##c O
properties O
and O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
drugs O
1984 O
27 O
210 O
231 O

raj O
##put O
a O
bae O
##rg O
k O
ce O
##ti O
##riz O
##ine O
induced O
d O
##yst O
##onic O
movements O
ne O
##uro O
##logy O
2006 O
66 O
143 O
144 O

caste O
##els O
van O
da O
##ele O
m O
egg O
##er O
##mont O
e O
casa O
##er O
p O
van O
de O
cass O
##eye O
w O
de O
bo O
##eck O
k O
acute O
d O
##yst O
##onic O
reactions O
and O
long O
lasting O
impaired O
consciousness O
associated O
with O
ox O
##ato O
##mide O
in O
children O
lance O
##t O
1986 O
1 O
120 O
##4 O
120 O
##5 O

welsh O
jp O
pl O
##aca O
##nton O
##aki O
##s O
d O
##g O
wars O
##ets O
##ky O
si O
marquez O
r O
##g O
bernstein O
l O
ai O
##cher O
sa O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
from O
the O
perspective O
of O
ne O
##uron O
##al O
rhythmic O
##ity O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##logy O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
307 O
329 O

do O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
differ O
by O
route O
of O
environmental O
pre O
##ci O
##pit O
##ant O

bra O
##ak O
and O
colleagues O
followed O
their O
groundbreaking O
staging O
class O
##i O
##ﬁ O
##cation O
for O
the O
brain O
ne O
##uro O
##path O
##ology O
of O
alzheimer O
s O
disease O
with O
the O
more O
recent O
one O
for O
sporadic O
parkinson O
s O
disease O
pd O
1 O
their O
new O
pd O
staging O
system O
has O
revolution O
##ized O
thinking O
about O
the O
topographic O
sequence O
of O
ne O
##uro O
##path O
##ological O
changes O
as O
the O
illness O
progresses O
generally O
in O
a O
ca O
##uda O
##l O
ro O
##stra O
##l O
direction O
from O
lower O
brains O
##tem O
to O
neo O
##cor O
##te O
##x O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##23 O

letters O
to O
the O
editor O
161 O
##7 O

one O
of O
the O
most O
important O
of O
bra O
##ak O
et O
al O
s O
observations O
may O
be O
that O
ol O
##factory O
structures O
are O
one O
of O
the O
ﬁ O
##rst O
sites O
of O
ne O
##uro O
##path O
##ology O
in O
the O
central O
nervous O
system O
cn O
##s O
2 O
coupled O
with O
emerging O
evidence O
that O
characteristic O
syn O
##uc O
##lein O
##opa O
##thic O
changes O
can O
be O
seen O
in O
the O
peripheral O
auto O
##no O
##mic O
nervous O
system O
including O
the O
gas O
##tro O
##int O
##estinal O
tract O
even O
before O
cn O
##s O
involvement O
3 O
6 O
a O
critical O
implication O
of O
these O
ﬁ O
##nding O
##s O
is O
that O
the O
nose O
and O
mouth O
become O
suspect O
as O
portals O
of O
entry O
for O
an O
inc O
##iting O
pathogen O
##ic O
agent O

after O
nasal O
entry O
trans O
##ne O
##uron O
##al O
transmission O
along O
ol O
##factory O
pathways O
is O
a O
potential O
route O
to O
the O
brain O
it O
has O
been O
shown O
for O
example O
that O
inhaled O
ultra O
##ﬁ O
##ne O
heavy O
metal O
particles O
which O
might O
come O
from O
occupational O
exposure O
##s O
can O
pass O
through O
the O
nasal O
mu O
##cos O
##a O
and O
be O
trans O
##yna O
##ptic O
##ally O
transported O
to O
deeper O
brain O
regions O
7 O
once O
a O
pathogen O
##ic O
agent O
passes O
through O
the O
gas O
##tro O
##int O
##estinal O
mu O
##cos O
##a O
after O
oral O
entry O
the O
pathway O
via O
the O
enter O
##ic O
auto O
##no O
##mic O
nervous O
system O
to O
the O
va O
##gus O
nerve O
and O
the O
va O
##gal O
nuclei O
in O
the O
lower O
brains O
##tem O
also O
one O
of O
the O
early O
lo O
##ci O
of O
pd O
pathology O
in O
the O
cn O
##s O
##1 O
2 O
would O
be O
open O
thus O
environmental O
factors O
in O
the O
air O
water O
and O
food O
look O
to O
be O
integral O
##ly O
involved O
in O
the O
initial O
phases O
of O
the O
illness O
potential O
environmental O
agents O
that O
have O
been O
suggested O
include O
agricultural O
pest O
##icides O
and O
herb O
##icides O
reviewed O
in O
8 O
9 O
heavy O
metals O
7 O
viruses O
10 O
and O
pri O
##ons O
11 O
genetic O
factors O
might O
in O
##ﬂ O
##uen O
##ce O
individual O
su O
##sc O
##ept O
##ibility O
or O
response O
to O
the O
off O
##ending O
agents O

dementia O
with O
lew O
##y O
bodies O
dl O
##b O
differs O
from O
pd O
by O
diffuse O
syn O
##uc O
##lein O
##opa O
##thic O
de O
##gen O
##eration O
involving O
cortex O
and O
brains O
##tem O
at O
onset O
rather O
than O
the O
initial O
focal O
ol O
##factory O
and O
lower O
brains O
##tem O
pathology O
of O
pd O
12 O
it O
has O
been O
debated O
whether O
pd O
and O
dl O
##b O
are O
variants O
of O
the O
same O
disease O
or O
represent O
distinct O
entities O
13 O
based O
on O
the O
differences O
in O
their O
ne O
##uro O
##path O
##olo O
##gic O
temporal O
pro O
##ﬁ O
##le O
i O
h O
##yp O
##oth O
##es O
##ize O
that O
there O
is O
an O
et O
##iol O
##ogical O
difference O
that O
is O
primarily O
due O
to O
the O
route O
of O
exposure O
to O
inc O
##iting O
environmental O
agents O
under O
this O
view O
pd O
results O
from O
respiratory O
airborne O
or O
gas O
##tro O
##int O
##estinal O
water O
food O
##borne O
exposure O
while O
dl O
##b O
develops O
following O
systemic O
blood O
##borne O
exposure O
type O
of O
toxic O
##ant O
and O
level O
of O
exposure O
might O
determine O
whether O
sign O
##i O
##ﬁ O
##can O
##t O
concentrations O
are O
achieved O
in O
the O
circulation O
underlying O
genetic O
factors O
might O
also O
contribute O
to O
which O
route O
s O
and O
levels O
of O
exposure O
result O
in O
toxicity O
the O
hypothesis O
is O
test O
##able O
by O
comparing O
pd O
and O
dl O
##b O
patients O
for O
routes O
types O
and O
magnitude O
##s O
of O
environmental O
exposure O
##s O

roger O
ku O
##rl O
##an O
md O

department O
of O
ne O
##uro O
##logy O
university O
of O
rochester O
school O
of O
medicine O

rochester O
new O
york O
usa O

bra O
##ak O
h O
del O
tre O
##dic O
##i O
k O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
211 O

del O
tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
##e O
bra O
##ak O
h O
where O
does O
parkinson O
disease O
pathology O
begin O
in O
the O
brain O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2002 O
61 O
41 O
##3 O
42 O
##6 O

wa O
##ka O
##bay O
##ashi O
k O
takahashi O
h O
oh O
##ama O
e O
take O
##da O
s O
ik O
##uta O
f O
lew O
##y O
bodies O
in O
the O
vis O
##cera O
##l O
auto O
##no O
##mic O
nervous O
system O
in O
parkinson O
s O
disease O
in O
ik O
##uta O
f O
editor O
ne O
##uro O
##path O
##ology O
in O
brain O
research O
amsterdam O
london O
tokyo O
excerpt O
##a O
med O
##ica O
1991 O
p O
133 O
141 O

bra O
##ak O
h O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
del O
tre O
##dic O
##i O
k O
gas O
##tric O
alpha O
##sy O
##nu O
##cle O
##in O
im O
##mun O
##ore O
##active O
inclusion O
##s O
in O
mei O
##ss O
##ner O
s O
and O
au O
##er O
##bach O
s O
pl O
##ex O
##uses O
in O
cases O
staged O
for O
parkinson O
s O
disease O
related O
brain O
pathology O
ne O
##uro O
##sc O
##i O
let O
##t O
2006 O
39 O
##6 O
67 O
72 O

ming O
##uez O
caste O
##llan O
##os O
a O
char O
##orro O
ce O
es O
##cam O
##illa O
sevilla O
f O
et O
al O
do O
a O
syn O
##uc O
##lein O
aggregate O
##s O
in O
auto O
##no O
##mic O
pl O
##ex O
##uses O
pre O
##date O
lew O
##y O
body O
disorders O
a O
co O
##hort O
study O
ne O
##uro O
##logy O
2007 O
68 O
2012 O
2018 O

bra O
##ak O
h O
sas O
##tre O
m O
bo O
##hl O
jr O
##e O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
parkinson O
s O
disease O
lesions O
in O
dorsal O
horn O
layer O
i O
involvement O
of O
para O
##sy O
##mp O
##ath O
##etic O
and O
sympathetic O
pre O
##and O
post O
##gang O
##lion O
##ic O
neurons O
act O
##a O
ne O
##uro O
##path O
##ol O
be O
##r O
2007 O
113 O
421 O
42 O
##9 O

obe O
##rdo O
##¨ O
##rst O
##er O
g O
sharp O
z O
at O
##ud O
##ore O
##i O
v O
et O
al O
trans O
##lo O
##cation O
of O
inhaled O
ultra O
##ﬁ O
##ne O
particles O
to O
the O
brain O
in O
##hal O
toxic O
##ol O
2004 O
16 O
43 O
##7 O
44 O
##5 O

rat O
##ner O
m O
##h O
feldman O
r O
##g O
environmental O
toxin O
##s O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
51 O
62 O

st O
##rick O
##land O
d O
rural O
environment O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
63 O
71 O

bra O
##ak O
h O
bo O
##hl O
jr O
mu O
##¨ O
##ller O
cm O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O

k O
stanley O
fa O
##hn O
lecture O
2005 O
the O
staging O
procedure O
for O
the O
inclusion O
body O
pathology O
associated O
with O
sporadic O
parkinson O
s O
disease O
rec O
##ons O
##ider O
##ed O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
204 O
##2 O
205 O
##1 O

klein O
c O
sc O
##hl O
##oss O
##mac O
##her O
mg O
parkinson O
s O
disease O
10 O
years O
after O
its O
genetic O
revolution O
multiple O
clues O
to O
a O
complex O
disorder O
ne O
##uro O
##logy O
2007 O
69 O
209 O
##3 O
210 O
##4 O

mc O
##kei O
##th O
i O
##g O
gala O
##sko O
d O
ko O
##saka O
k O
consensus O
guidelines O
for O
the O
clinical O
and O
path O
##olo O
##gic O
diagnosis O
of O
dementia O
with O
lew O
##y O
bodies O
dl O
##b O
report O
of O
the O
consortium O
on O
dl O
##b O
international O
workshop O
ne O
##uro O
##logy O
1996 O
47 O
111 O
##3 O
112 O
##4 O

richard O
i O
##h O
pa O
##p O
##ka O
m O
rub O
##io O
a O
et O
al O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
one O
disease O
or O
two O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
116 O
##1 O
116 O
##5 O

d O
##yst O
##onia O
associated O
with O
hyper O
##int O
##ense O
basal O
gang O
##lia O
lesions O
on O
t O
##1 O
weighted O
brain O
mri O

a O
43 O
year O
old O
man O
presented O
with O
cardiac O
arrest O
due O
to O
an O
ana O
##phy O
##la O
##ctic O
shock O
after O
ﬂ O
##uo O
##res O
##ce O
##in O
application O
for O
re O
##tina O
##l O
ang O
##iography O
after O
card O
##io O
##pu O
##lm O
##ona O
##ry O
res O
##us O
##cit O
##ation O
the O
patient O
could O
be O
we O
##ane O
##d O
from O
tr O
##ache O
##al O
res O
##piration O
2 O
days O
later O
the O
initial O
neurological O
examination O
revealed O
generalized O
h O
##yp O
##oki O
##nesia O
rigid O
##ity O
of O
ex O
##tre O
##mit O
##ies O
and O
severe O
axial O
d O
##yst O
##onia O
with O
ant O
##ero O
##coll O
##is O
and O
increased O
oro O
##man O
##di O
##bular O
tone O
with O
almost O
inca O
##pa O
##bility O
to O
open O
the O
mouth O
fig O
1a O
a O
mild O
reduction O
of O
h O
##yp O
##oki O
##nesia O
occurred O
due O
to O
medication O
of O
ama O
##nta O
##dine O
and O
lev O
##od O
##opa O
the O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
improved O
considerably O
under O
repetitive O
local O
injection O
##s O
of O
bot O
##ulin O
##um O
toxin O
type O
a O
and O
the O
patient O
is O
able O
to O
eat O
and O
speak O
without O
assistance O
the O
clinical O
symptoms O
are O
stable O
since O
the O
initial O
attack O
over O
a O
period O
of O
3 O
5 O
years O
now O
see O
fig O
1a O
and O
video O
for O
current O
clinical O
state O

the O
initial O
ct O
was O
regular O
but O
the O
t O
##1 O
weighted O
mri O
without O
contrast O
demonstrated O
bilateral O
uniform O
area O
wide O
hyper O
##in O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##28 O

1618 O
letters O
to O
the O
editor O

fig O
1 O
a O
photograph O
of O
patient O
showing O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O

2 O
months O
after O
onset O
left O
picture O
and O
5 O
years O
later O
following O
local O
injection O
##s O
of O
bot O
##ulin O
##um O
toxin O
type O
a O
right O
picture O
b O
sequential O
ne O
##uro O
##ima O
##ging O
of O
t O
##1 O
hyper O
##int O
##ense O
st O
##ria O
##tal O
lesions O
associated O
with O
generalized O
d O
##yst O
##onia O
after O
card O
##io O
##pu O
##lm O
##ona O
##ry O
res O
##us O
##cit O
##ation O
upper O
row O
displays O
initial O
ct O
mri O
imaging O
within O
the O
ﬁ O
##rst O
2 O
weeks O
after O
onset O
t O
##1 O
##and O
t O
##2 O
weighted O
images O
no O
contrast O
and O
lower O
row O
shows O
imaging O
17 O
months O
later O
t O
##1 O
##and O
t O
##2 O
images O
note O
the O
hyper O
##int O
##ense O
bilateral O
st O
##ria O
##tal O
lesions O
in O
initial O
t O
##1 O
weighted O
mri O
with O
no O
indications O
of O
hem O
##or O
##rh O
##ages O
in O
all O
images O

tense O
lesions O
of O
the O
st O
##ria O
##tum O
fig O
1b O
upper O
row O
imaging O
showed O
no O
indications O
of O
hem O
##or O
##rh O
##ages O
the O
follow O
up O
imaging O
17 O
months O
later O
demonstrated O
nec O
##rosis O
of O
both O
st O
##ria O
##ta O
without O
any O
evidence O
of O
hem O
##osi O
##der O
##in O
deposits O
fig O
1b O
lower O
row O

similar O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
have O
been O
described O
previously O
in O
several O
patients O
with O
cho O
##rea O
after O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
1 O
2 O
and O
rarely O
in O
patients O
with O
h O
##yp O
##og O
##ly O
##ca O
##emi O
##c O
coma O
##3 O
or O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
4 O
in O
these O
cases O
post O
##ische O
##mic O
pete O
##chia O
##l O
hem O
##or O
##rh O
##age O
was O
suspected O
as O
a O
possible O
mechanism O
although O
sporadic O
post O
##mo O
##rte O
##m O
path O
##ological O
studies O
have O
reported O
selective O
ne O
##uron O
##al O
loss O
g O
##lio O
##sis O
and O
reactive O
astro O
##cy O
##tosis O
as O
common O
ﬁ O
##nding O
##s O
5 O
6 O
fuji O
##oka O
et O
al O
reported O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
mri O
in O
the O
st O
##ria O
##tum O
of O
rats O
7 O
days O
after O
brief O
focal O
is O
##che O
##mia O
7 O
his O
##to O
##logical O
preparation O
of O
the O
animal O
brains O
showed O
selective O
ne O
##uron O
##al O
death O
and O
proliferation O
of O
reactive O
astro O
##cytes O
and O
micro O
##glia O
without O
in O
##far O
##ct O
hem O
##or O
##rh O
##age O
lip O
##id O
accumulation O
or O
apparent O
cal O
##ci O
##ﬁ O
##cation O

together O
the O
reasons O
for O
the O
initial O
t O
##1 O
hyper O
##int O
##ens O
##ities O
remain O
elusive O
theoretically O
besides O
intra O
##cellular O
met O
##hem O
##og O
##lo O
##bin O
in O
hem O
##or O
##rh O
##agi O
##c O
tissue O
and O
cal O
##ci O
##ﬁ O
##cation O
##s O
para O
##ma O
##gne O
##tic O
compounds O
including O
metal O
ions O
e O
g O
iron O
manga O
##nese O
and O
copper O
molecular O
oxygen O
or O
free O
radicals O
could O
lead O
to O
these O

legend O
to O
the O
full O
video O

time O
content O

00 O
00 O
00 O
00 O
00 O
15 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O

00 O
00 O
16 O
00 O
00 O
28 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

forehead O
d O
##yst O
##onia O

00 O
00 O
29 O
00 O
00 O
37 O
listing O
the O
days O
of O
the O
week O
from O
monday O

to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O

00 O
00 O
38 O
00 O
00 O
47 O
patient O
closing O
and O
opening O
his O
eyes O
00 O
00 O
48 O
00 O
01 O
09 O
facial O
inner O
##vation O
mouth O
tongue O
and O

forehead O

00 O
01 O
10 O
00 O
01 O
31 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O

of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
01 O
32 O
00 O
02 O
01 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O

and O
pro O
##nation O
su O
##pina O
##tion O
test O

legend O
to O
the O
preview O
video O

00 O
00 O
00 O
00 O
00 O
03 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O

00 O
00 O
04 O
00 O
00 O
07 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

00 O
00 O
08 O
00 O
00 O
15 O
listing O
the O
days O
of O
the O
week O
from O
monday O

00 O
00 O
16 O
00 O
00 O
33 O
facial O
inner O
##vation O
eyes O
mouth O
tongue O

and O
forehead O

00 O
00 O
34 O
00 O
00 O
46 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O

of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
00 O
47 O
00 O
00 O
59 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O

mri O
changes O
in O
our O
case O
we O
found O
no O
evidence O
of O
hem O
##or O
##rh O
##agi O
##c O
changes O
or O
cal O
##ci O
##ﬁ O
##cation O
##s O
so O
that O
reported O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
may O
hypothetical O
##ly O
result O
from O
h O
##yp O
##ox O
##ic O
disruption O
of O
the O
cell O
mitochondrial O
heavy O
metal O
metabolism O

martin O
wo O
##lz O
md O
susan O
##n O
jung O
##han O
##ns O
md O
matthias O
lo O
##¨ O
##hl O
##e O
md O

department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O

dresden O
germany O

ru O
##¨ O
##di O
##ger O
von O
ku O
##mmer O
md O

department O
of O
ne O
##uro O
##rad O
##iology O
technical O
university O

dresden O
dresden O
germany O

alexander O
st O
##or O
##ch O
md O

e O
mail O
alexander O
st O
##or O
##ch O
ne O
##uro O
med O
tu O
dresden O
de O

lin O
jj O
chang O
mk O
hem O
##iba O
##llis O
##m O
hem O
##ich O
##ore O
##a O
and O
non O
ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1994 O
57 O
74 O
##8 O
750 O

letters O
to O
the O
editor O
161 O
##9 O

oh O
sh O
lee O
ky O
im O
j O
##h O
lee O
ms O
cho O
##rea O
associated O
with O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
and O
hyper O
##int O
##ens O
##ity O
basal O
gang O
##lia O
les O
##ion O
on O
t O
##1 O
weighted O
brain O
mri O
study O
a O
meta O
analysis O
of O
53 O
cases O
including O
four O
present O
cases O
j O
ne O
##uro O
##l O
sci O
2002 O
200 O
57 O
62 O

fuji O
##oka O
m O
hiram O
##ats O
##u O
k O
sa O
##ka O
##ki O
t O
sa O
##ka O
##guchi O
s O
is O
##hi O
##i O
y O
spec O
##i O
##ﬁ O
##c O
changes O
in O
human O
brain O
after O
h O
##yp O
##og O
##ly O
##ce O
##mic O
injury O
stroke O
1997 O
28 O
58 O
##4 O
58 O
##7 O

k O
##rie O
##ger O
d O
k O
##rie O
##ger O
s O
jan O
##sen O
o O
gas O
##s O
p O
the O
##il O
##mann O
l O
li O
##cht O
##neck O
##er O
h O
manga O
##nese O
and O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
lance O
##t O
1995 O
34 O
##6 O
270 O
274 O

oh O
##ara O
s O
nak O
##agawa O
s O
tab O
##ata O
k O
hash O
##imo O
##to O
t O
hem O
##iba O
##llis O
##m O
with O
hyper O
##gly O
##ce O
##mia O
and O
st O
##ria O
##tal O
t O
##1 O
mri O
hyper O
##int O
##ens O
##ity O
an O
autopsy O
report O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
521 O
525 O

shan O
de O
ho O
d O
##m O
chang O
c O
pan O
hc O
ten O
##g O
mm O
hem O
##ich O
##ore O
##ah O
##emi O
##ball O
##ism O
an O
explanation O
for O
mr O
signal O
changes O
am O
j O
ne O
##uro O
##rad O
##iol O
1998 O
19 O
86 O
##3 O
870 O

fuji O
##oka O
m O
tao O
##ka O
t O
mats O
##uo O
y O
hiram O
##ats O
##u O
ki O
sa O
##ka O
##ki O
t O
novel O
brain O
is O
##che O
##mic O
change O
on O
mri O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
images O
and O
selective O
ne O
##uron O
##al O
death O
in O
the O
ca O
##ud O
##op O
##uta O
##men O
of O
rats O
after O
brief O
focal O
is O
##che O
##mia O
stroke O
1999 O
30 O
104 O
##3 O
104 O
##6 O

successful O
treatment O
of O
the O
mei O
##ge O
syndrome O
with O
oral O
z O
##ol O
##pid O
##em O
mono O
##therapy O

z O
##ol O
##pid O
##em O
is O
an O
im O
##ida O
##zo O
##py O
##rid O
##ine O
ago O
##nist O
with O
a O
high O
af O
##ﬁ O
##nity O
for O
the O
benz O
##od O
##ia O
##ze O
##pine O
a1 O
subunit O
site O
1 O
it O
has O
been O
reported O
that O
this O
drug O
improves O
motor O
symptoms O
in O
patients O
with O
parkinson O
s O
disease O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
and O
xl O
##ink O
##ed O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
2 O
5 O
recently O
z O
##ol O
##pid O
##em O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
the O
mei O
##ge O
syndrome O
in O
combination O
with O
bot O
##ulin O
##um O
toxin O
a O
6 O

here O
we O
report O
a O
patient O
with O
mei O
##ge O
syndrome O
non O
##res O
##pon O
##sive O
to O
bot O
##ulin O
##um O
toxin O
a O
but O
successfully O
treated O
with O
oral O
z O
##ol O
##pid O
##em O
administration O

a O
59 O
year O
old O
man O
previously O
healthy O
presented O
with O
di O
##sa O
##bling O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
that O
began O
6 O
months O
before O
presentation O
before O
four O
years O
he O
reported O
an O
abnormal O
feeling O
of O
tension O
in O
the O
lower O
eye O
##lid O
and O
subsequently O
developed O
involuntary O
excessive O
blinking O
the O
d O
##yst O
##onic O
symptoms O
were O
usually O
provoked O
by O
speaking O
or O
chewing O
however O
they O
continued O
at O
rest O
and O
were O
relieved O
by O
placing O
a O
pencil O
between O
his O
teeth O
in O
addition O
the O
patient O
reported O
that O
the O
symptoms O
were O
improved O
after O
taking O
oral O
z O
##ol O
##pid O
##em O
prescribed O
for O
ins O
##om O
##nia O
by O
his O
primary O
physician O
he O
took O
this O
medication O
a O
half O
hour O
before O
going O
to O
sleep O
the O
patient O
had O
been O
treated O
with O
50 O
mg O
que O
##tia O
##pine O
8 O
mg O
tri O
##he O
##xi O
##ph O
##eni O
##dy O
##l O
and O
40 O
mg O
ba O
##cl O
##of O
##en O
without O
any O
ben O
##e O
##ﬁ O
##t O
in O
addition O
bot O
##ulin O
##um O
toxin O
a O
treatment O
was O
attempted O
bot O
##ox O
40 O
units O
injection O
in O
eight O
sites O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
muscle O
and O
four O
sites O
of O
the O
orb O
##icular O
##is O
or O
##is O
muscle O
but O
this O
had O
little O
effect O
the O
patient O
reported O
no O
history O
of O
head O
trauma O
peripheral O
traumatic O
or O
surgical O
incidents O
or O
neurological O
diseases O
there O
was O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##9 O

no O
exposure O
to O
ne O
##uro O
##le O
##ptic O
medications O
there O
was O
no O
family O
history O
of O
movement O
disorders O

the O
neurological O
examination O
was O
normal O
except O
for O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
appearing O
sync O
##hr O
##ono O
##usly O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O
segment O
1 O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
for O
memory O
and O
frontal O
lobe O
functions O
was O
within O
normal O
limits O
the O
evaluation O
##s O
including O
magnetic O
resonance O
imaging O
of O
the O
brain O
electro O
##ence O
##pha O
##logram O
serum O
chemist O
##ries O
a O
complete O
blood O
count O
serum O
ce O
##ru O
##lo O
##pl O
##as O
##min O
thyroid O
function O
tests O
and O
genetic O
testing O
for O
the O
d O
##yt O
##1 O
mutation O
in O
the O
tor O
##sion O
a O
gene O
were O
normal O
the O
dental O
and O
op O
##ht O
##hal O
##mology O
examinations O
were O
also O
normal O

we O
evaluated O
whether O
oral O
z O
##ol O
##pid O
##em O
treatment O
could O
improve O
the O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
these O
symptoms O
completely O
resolved O
within O
1 O
hour O
after O
taking O
this O
medicine O
and O
the O
patient O
was O
sy O
##mpt O
##om O
free O
for O
4 O
hours O
without O
so O
##m O
##no O
##lence O
segment O
2 O
a O
long O
acting O
z O
##ol O
##pid O
##em O
tar O
##tra O
##te O
12 O
5 O
mg O
four O
times O
per O
day O
has O
been O
prescribed O
and O
this O
patient O
remains O
sy O
##mpt O
##om O
free O
during O
the O
daytime O

mei O
##ge O
syndrome O
is O
a O
form O
of O
cr O
##anial O
d O
##yst O
##onia O
it O
affects O
the O
cr O
##anial O
muscles O
and O
is O
characterized O
by O
involuntary O
blinking O
and O
chin O
thrusting O
7 O
this O
syndrome O
is O
considered O
a O
variant O
of O
id O
##io O
##pathic O
tor O
##sion O
d O
##yst O
##onia O
although O
bot O
##ulin O
##um O
toxin O
injection O
##s O
are O
useful O
for O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
as O
well O
as O
facial O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
the O
symptoms O
are O
usually O
ref O
##rac O
##tory O
or O
only O
partially O
relieved O
with O
this O
medication O
8 O

z O
##ol O
##pid O
##em O
completely O
abolished O
the O
symptoms O
associated O
with O
the O
mei O
##ge O
syndrome O
in O
our O
patient O
without O
causing O
so O
##m O
##no O
##lence O
the O
location O
of O
the O
highest O
density O
of O
z O
##ol O
##pid O
##em O
##bin O
##ding O
receptors O
is O
in O
the O
ventral O
g O
##lo O
##bus O
pal O
##lid O
##us O
the O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
re O
##tic O
##ulate O
and O
the O
sub O
##thal O
##ami O
##c O
nucleus O
9 O
10 O
recently O
z O
##ol O
##pid O
##em O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
was O
shown O
to O
enhance O
g O
amino O
##bu O
##ty O
##ric O
acid O
type O
a O
ga O
##ba O
##a O
receptor O
##media O
##ted O
inhibitor O
##y O
syn O
##ap O
##tic O
currents O
and O
therefore O
appears O
to O
mod O
##ulate O
motor O
behavior O
in O
awake O
animals O
##11 O
these O
results O
suggested O
that O
z O
##ol O
##pid O
##em O
may O
inhibit O
the O
ex O
##cit O
##ability O
of O
sub O
##thal O
##ami O
##c O
neurons O
and O
therefore O
compensate O
for O
the O
excessive O
inhibition O
of O
basal O
gang O
##lia O
targets O
in O
parkinson O
##ism O
leading O
to O
the O
improvement O
of O
symptoms O
in O
parkinson O
s O
disease O
however O
because O
other O
basal O
gang O
##lia O
nuclei O
also O
express O
z O
##ol O
##pid O
##em O
binding O
sites O
z O
##ol O
##pid O
##em O
may O
also O
ex O
##ert O
electro O
##phy O
##sio O
##logical O
effects O
on O
these O
other O
nuclei O
12 O
in O
addition O
other O
mechanisms O
may O
be O
involved O
in O
at O
##ten O
##uating O
d O
##ys O
##kin O
##etic O
symptoms O
for O
example O
ga O
##ba O
##er O
##gic O
drugs O
can O
be O
effective O
in O
am O
##eli O
##ora O
##ting O
experimental O
oro O
##fa O
##ical O
d O
##ys O
##kin O
##es O
##ia O
by O
rein O
##for O
##cing O
the O
involvement O
ga O
##ba O
##er O
##gic O
h O
##yp O
##of O
##un O
##ction O
13 O
and O
the O
ne O
##uro O
##pro O
##tec O
##tive O
and O
anti O
##ox O
##ida O
##nt O
properties O
of O
z O
##ol O
##pid O
##em O
in O
vivo O
and O
in O
vitro O
may O
contribute O
to O
the O
modulation O
of O
d O
##ys O
##kin O
##es O
##ia O
14 O

although O
the O
exact O
mechanism O
of O
binding O
to O
these O
sites O
is O
unknown O
z O
##ol O
##pid O
##em O
might O
reverse O
the O
path O
##op O
##hy O
##sio O
##logical O
changes O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
and O
therefore O
the O
whole O
basal O
gang O
##lia O
circuit O
in O
addition O
to O
the O
direct O
effects O
on O
the O
basal O
gang O
##lia O
we O
cannot O
rule O
out O
the O
possibility O
that O
the O
an O
##xi O
##ol O
##ytic O
in O
##ﬂ O
##uen O
##ce O
of O
z O
##ol O
##pid O
##em O
may O
contribute O
to O
its O
ben O
##e O
##ﬁ O
##cial O
effects O
on O
d O
##yst O
##onia O

in O
conclusion O
oral O
z O
##ol O
##pid O
##em O
may O
be O
a O
useful O
ph O
##arm O
##aco O
##logic O
alternative O
for O
patients O
with O
mei O
##ge O
syndrome O
who O
do O
not O
respond O
to O
bot O
##ulin O
##um O
toxin O
treatment O
however O
special O
precautions O
are O
necessary O
for O
long O
term O
management O
with O
this O
drug O
because O
of O
the O
risk O
of O
z O
##ol O
##pid O
##em O
abuse O
especially O
in O
patients O
with O
a O
previous O
history O
of O
substance O
abuse O
15 O

1620 O
letters O
to O
the O
editor O

segment O
1 O
the O
patient O
shows O
a O
mixture O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O

segment O
2 O
one O
hour O
after O
oral O
z O
##ol O
##pid O
##em O
administration O
the O
symptoms O
were O
completely O
resolved O
in O
the O
resting O
state O
while O
showing O
his O
teeth O
as O
well O
as O
grim O
##acing O
and O
whistling O

jae O
young O
an O
md O
joo O
##ng O
seo O
##k O
kim O
md O
ye O
##ong O
in O
kim O
md O
kwan O
##g O
soo O
lee O
md O
department O
of O
ne O
##uro O
##logy O

the O
catholic O
university O
of O
korea O
seoul O

south O
korea O

e O
mail O
ne O
##uron O
##et O
catholic O
ac O
k O
##r O

holm O
k O
##j O
goa O
k O
##l O
z O
##ol O
##pid O
##em O
an O
update O
of O
its O
ph O
##arm O
##aco O
##logy O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
and O
to O
##ler O
##ability O
in O
the O
treatment O
of O
ins O
##om O
##nia O
drugs O
2000 O
59 O
86 O
##5 O
88 O
##9 O

daniel O
##e O
a O
alba O
##nese O
a O
gain O
##otti O
g O
gregor O
##i O
b O
bart O
##olo O
##meo O
p O
z O
##ol O
##pid O
##em O
in O
parkinson O
s O
disease O
lance O
##t O
1997 O
34 O
##9 O
122 O
##2 O
122 O
##3 O

daniel O
##e O
a O
mor O
##o O
e O
bent O
##ivo O
##glio O
ar O
z O
##ol O
##pid O
##em O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
n O
eng O
##l O
j O
med O
1999 O
341 O
54 O
##3 O
54 O
##4 O

evident O
##e O
v O
##gh O
z O
##ol O
##pid O
##em O
improves O
d O
##yst O
##onia O
in O
lu O
##bag O
or O
x O
linked O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
ne O
##uro O
##logy O
2002 O
58 O
66 O
##2 O
66 O
##3 O

ru O
##zic O
##ka O
e O
roth O
j O
je O
##ch O
r O
bus O
##ek O
p O
sub O
##hy O
##p O
##not O
##ic O
doses O
of O
z O
##ol O
##pid O
##em O
oppose O
do O
##pa O
##mine O
##rg O
##ic O
induced O
d O
##ys O
##kin O
##es O
##ia O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
73 O
##4 O
73 O
##5 O

garrett O
##o O
ns O
bu O
##eri O
ja O
rey O
rd O
ara O
##ka O
##ki O
t O
nano O
g O
##v O
man O
##cus O
##o O

m O
improvement O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
with O
z O
##ol O
##pid O
##em O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
96 O
##7 O
96 O
##8 O

jan O
##kovic O
j O
clinical O
features O
differential O
diagnosis O
and O
pathogen O
##esis O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
cr O
##anial O
cervical O
d O
##yst O
##onia O
in O
bosnia O
##k O
l O
editor O
b O
##le O
##pha O
##ros O
##pas O
##m O
advances O
in O
op O
##ht O
##hal O
##mic O
plastic O
rec O
##ons O
##truct O
##ive O
surgery O
new O
york O
per O
##gam O
##on O
1985 O
p O
67 O
82 O

horn O
s O
come O
##lla O
c O
treatment O
of O
d O
##yst O
##onia O
in O
jan O
##kovic O
j O
to O
##los O
##a O
e O
editors O
parkinson O
s O
disease O
and O
movement O
disorders O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
35 O
##8 O
36 O
##4 O

ni O
##dda O
##m O
r O
dubois O
a O
sc O
##att O
##on O
b O
ar O
##bill O
##a O
s O
lange O
##r O
s O
##z O
auto O
##rad O
##io O
##graphic O
local O
##ization O
of O
3 O
##h O
z O
##ol O
##pid O
##em O
binding O
sites O
in O
the O
rat O
cn O
##s O
comparison O
with O
the O
distribution O
of O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
binding O
sites O
j O
ne O
##uro O
##che O
##m O
1987 O
49 O
89 O
##0 O
89 O
##9 O

dennis O
t O
dubois O
a O
ben O
##avi O
##des O
j O
sc O
##att O
##on O
b O
distribution O
of O
central O
omega O
1 O
benz O
##od O
##ia O
##ze O
##pine O
##1 O
and O
omega O
2 O
benz O
##od O
##ia O
##ze O
##pine O
##2 O
receptor O
sub O
##type O
##s O
in O
the O
monkey O
and O
human O
brain O
an O
auto O
##rad O
##io O
##graphic O
study O
with O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
and O
the O
omega O
1 O
selective O
ligand O
3 O
##h O
z O
##ol O
##pid O
##em O
j O
ph O
##arm O
##aco O
##l O
ex O
##p O
the O
##r O
1988 O
247 O
309 O
322 O

chen O
l O
xi O
##e O
j O
##x O
fun O
##g O
ks O
yun O
##g O
w O
##h O
z O
##ol O
##pid O
##em O
mod O
##ulates O
ga O
##ba O
##a O
receptor O
function O
in O
sub O
##thal O
##ami O
##c O
nucleus O
ne O
##uro O
##sc O
##i O
res O
2007 O
58 O
77 O
85 O

chen O
l O
sa O
##vio O
chang O
c O
yun O
##g O
w O
##h O
electro O
##phy O
##sio O
##logical O
and O
behavioral O
effects O
of O
z O
##ol O
##pid O
##em O
in O
rat O
g O
##lo O
##bus O
pal O
##lid O
##us O
ex O
##p O
ne O
##uro O
##l O
2004 O
186 O
212 O
220 O

pei O
##x O
##oto O
m O
##f O
ara O
##uj O
##o O
np O
silva O
r O
##h O
et O
al O
effects O
of O
ga O
##ba O
##er O
##gic O
drugs O
on O
res O
##er O
##pine O
induced O
oral O
d O
##ys O
##kin O
##es O
##ia O
be O
##ha O
##v O
brain O
res O
2005 O
160 O
51 O
59 O

ga O
##rc O
##´ O
##ı O
##a O
santos O
g O
herrera O
f O
mart O
##´ O
##ı O
##n O
v O
et O
al O
anti O
##ox O
##ida O
##nt O
activity O
and O
ne O
##uro O
##pro O
##tec O
##tive O
effects O
of O
z O
##ol O
##pid O
##em O
and O
several O
synthesis O
intermediate O
##s O
free O
ra O
##dic O
res O
2004 O
38 O
128 O
##9 O
129 O
##9 O

mad O
##rak O
l O
##n O
rosenberg O
m O
z O
##ol O
##pid O
##em O
abuse O
am O
j O
psychiatry O
2001 O
158 O
133 O
##0 O
133 O
##1 O

tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
induced O
by O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O

chronic O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
is O
effective O
in O
severe O
parkinson O
s O
disease O
pd O
1 O
however O
a O
few O
side O
effects O
especially O
o O
##cu O
##lom O
##oto O
##r O
manifestation O
##s O
have O
been O
reported O
2 O
understanding O
their O
mechanism O
may O
help O
to O
better O
de O
##ﬁ O
##ne O
functional O
anatomy O
of O
this O
region O

a O
66 O
year O
old O
woman O
was O
treated O
by O
bilateral O
st O
##n O
stimulation O
for O
pd O
a O
40 O
decrease O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
followed O
st O
##n O
stimulation O
alone O
with O
the O
following O
parameters O
left O
contact O
2 O
3 O
5 O
v O
60 O
l O
second O
160 O
hz O
right O
contact O
7 O
3 O
5 O
v O
90 O
l O
second O
160 O
hz O

during O
parameters O
setting O
she O
complained O
of O
vertigo O
nausea O
##s O
and O
os O
##ci O
##llo O
##ps O
##ia O
for O
high O
voltage O
##s O
of O
stimulation O
3 O
5 O
v O
on O
both O
sides O
especially O
on O
contacts O
1 O
left O
and O
6 O
right O
at O
high O
intensity O
respectively O
4 O
5 O
v O
and O
3 O
5 O
v O
we O
noticed O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
tn O
beating O
on O
the O
side O
opposite O
to O
the O
stimulation O
the O
direction O
is O
given O
by O
the O
upper O
pole O
of O
the O
eye O
relative O
to O
patient O
s O
table O
1 O
this O
completely O
disappeared O
when O
the O
parameters O
of O
stimulation O
were O
decreased O
and O
was O
rep O
##rod O
##ucible O
over O
time O
end O
of O
surgery O
stereo O
##ta O
##ctic O
coordinates O
of O
each O
contact O
were O
used O
to O
locate O
them O
within O
a O
3d O
def O
##or O
##mable O
atlas O
of O
the O
basal O
gang O
##lia O
see O
fig O
1 O
3 O
this O
con O
##ﬁ O
##rmed O
the O
unusual O
medial O
tr O
##aj O
##ect O
##ories O
of O
electrode O
##s O
already O
suspected O
on O
the O
brain O
mri O

under O
chronic O
stimulation O
parameters O
we O
observed O
a O
right O
sided O
head O
tilt O
and O
a O
right O
sk O
##ew O
deviation O
i O
e O
h O
##yp O
##ot O
##rop O
##ic O
right O
eye O
eye O
mo O
##tility O
was O
normal O
and O
there O
was O
no O
ny O
##sta O
##gm O
##us O
subjective O
visual O
vertical O
sv O
##v O
was O
tilted O
to O
the O
right O
13 O
48 O
fund O
##i O
disclosed O
bilateral O
right O
sided O
o O
##cular O
tor O
##sion O
this O
was O
consistent O
with O
a O
right O
sided O
o O
##cular O
tilt O
reaction O
ot O
##r O
eye O
movement O
recording O
practiced O
after O
the O
patient O
gave O
her O
written O
consent O
showed O
h O
##yp O
##ometric O
upward O
sac O
##cade O
##s O
normal O
horizontal O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
and O
smooth O
pursuit O
table O
2 O

with O
right O
stimulation O
on O
contact O
6 O
3 O
5 O
v O
a O
counter O
##cl O
##ock O
##wise O
tn O
was O
found O
except O
for O
lower O
gain O
of O
vo O
##r O
eye O
movements O
were O
not O
mod O
##i O
##ﬁ O
##ed O
table O
2 O
vertical O
sac O
##cade O
##s O
could O
not O
be O
correctly O
recorded O
the O
sk O
##ew O
deviation O
increased O
sv O
##v O
slightly O
decreased O
12 O
04 O
##8 O

with O
left O
stimulation O
on O
contact O
1 O
4 O
5 O
v O
we O
noticed O
a O
clockwise O
tn O
ve O
##lo O
##cit O
##ies O
of O
downward O
sac O
##cade O
##s O
downward O
smooth O
pursuit O
gain O
and O
horizontal O
pen O
##du O
##lar O
vo O
##r O
gain O
decreased O
table O
2 O
the O
right O
sided O
sk O
##ew O
deviation O
decreased O
sv O
##v O
normal O
##ized O
10 O
48 O

previously O
reported O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
of O
st O
##n O
stimulation O
consisted O
of O
eye O
##lid O
apr O
##ax O
##ia O
bin O
##oc O
##ular O
dip O
##lo O
##pia O
my O
##osis O
my O
##dr O
##ias O
##is O
and O
contra O
##vers O
##ive O
eye O
deviation O
1 O
2 O
4 O
14 O
tn O
has O
been O
observed O
during O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
matter O
15 O
but O
not O
during O
st O
##n O
stimulation O

st O
##n O
is O
involved O
in O
sac O
##cade O
##s O
and O
smooth O
pursuit O
in O
primate O
##s O
and O
humans O
##16 O
23 O
and O
its O
stimulation O
could O
explain O
some O
o O
##cular O
motor O
side O
effects O
such O
as O
contra O
##vers O
##ive O
eye O
deviation O
10 O
however O
it O
is O
unlikely O
that O
st O
##n O
could O
have O
induced O
the O
tn O
as O
it O
was O
not O
observed O
at O
low O
intensity O
of O
stimulation O

published O
online O
10 O
july O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##51 O

letter O
to O
the O
editor O
1621 O

table O
1 O
stimulation O
parameters O
and O
normal O
complaints O

v O
side O
effects O

contacts O
and O
voltage O
##s O
used O
for O
chronicle O
bilateral O
stimulation O
lc O

2 O
3 O
5 O
no O
visual O
complaint O
rc O

7 O
3 O
5 O
no O
visual O
complaint O
voltage O
##s O
giving O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O

lc O

rc O

7 O
3 O
5 O
slight O
cc O
##w O
tn O

6 O
3 O
5 O
marked O
cc O
##w O
tn O
nausea O
##s O
vertigo O

5 O
3 O
5 O
cc O
##w O
tn O
vertigo O

4 O
3 O
5 O
cc O
##w O
tn O
nausea O
##s O
vertigo O

lc O
left O
contacts O
0 O
is O
the O
deepest O
and O
3 O
is O
the O
upper O
rc O
right O
contacts O
4 O
is O
the O
deepest O
and O
7 O
is O
the O
upper O
v O
intensity O
of O
the O
stimulation O
expressed O
in O
vol O
##ts O
tn O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
cw O
clockwise O
cc O
##w O
counter O
##cl O
##ock O
##wise O

contacts O
on O
witch O
the O
ny O
##sta O
##gm O
##us O
was O
the O
more O
marked O
and O
used O
for O
the O
eyes O
movement O
recordings O

and O
as O
the O
contacts O
were O
medial O
to O
the O
st O
##n O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
can O
also O
be O
explained O
by O
intra O
##fa O
##sc O
##icular O
o O
##cu O
##lom O
##oto O
##r O
nerve O
stimulation O
but O
this O
could O
not O
explain O
bin O
##oc O
##ular O
ny O
##sta O
##gm O
##us O
24 O

fig O
1 O
axial O
view O
of O
the O
me O
##sen O
##ce O
##pha O
##lon O
derived O
from O
the O
def O
##or O
##mable O
3d O
atlas O
ref O
3 O
and O
ana O
##tom O
##ic O
relations O
between O
electrode O
##s O
contacts O
and O
main O
me O
##sen O
##ce O
##pha O
##lic O
structures O
the O
ﬁ O
##gur O
##e O
illustrates O
the O
unusually O
medial O
tr O
##aj O
##ect O
##ories O
of O
the O
stimulation O
electrode O
##s O
the O
four O
contacts O
on O
each O
side O
are O
represented O
by O
blue O
points O
contacts O
0 O
to O
3 O
are O
left O
sided O
0 O
being O
the O
deepest O
and O
3 O
the O
upper O
contacts O
4 O
to O
7 O
are O
right O
sided O
4 O
being O
the O
deepest O
and O
7 O
the O
upper O
coordinates O
of O
each O
contact O
lateral O
##ity O
below O
ac O
pc O
line O
ahead O
of O
cp O
line O
in O
mm O
are O
left O
side O
0 O
10 O
4 O
10 O
5 O
1 O
11 O
4 O
12 O
2 O
11 O
5 O
2 O
5 O
13 O
3 O
12 O
5 O

1 O
14 O
5 O
right O
side O
4 O
9 O
6 O
5 O
7 O
5 O
9 O
5 O
5 O
8 O
6 O
10 O
3 O
9 O
5 O
7 O
11 O

1 O
11 O
rn O
red O
nucleus O
s O
##n O
sub O
##stan O
##tia O
ni O
##gra O
st O
##n O
sub O
##thal O
##ami O
##c O
nucleus O

two O
pre O
##nu O
##cle O
##ar O
mid O
##bra O
##in O
structures O
adjacent O
to O
the O
st O
##n O
could O
be O
implicated O
in O
the O
tn O
the O
ro O
##stra O
##l O
inter O
##sti O
##tial O
nucleus O
of O
the O
medial O
longitudinal O
fa O
##sc O
##icle O
rim O
##lf O
and O
the O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
ic O
the O
rim O
##lf O
is O
the O
immediate O
prem O
##oto O
##r O
structure O
for O
the O
generation O
of O
tor O
##sion O
##al O
and O
vertical O
sac O
##cade O
##s O
25 O
on O
each O
side O
rim O
##lf O
would O
en O
##code O
signals O
for O
both O
upward O
and O
downward O
but O
only O
for O
ip O
##sitor O
##sion O
##al O
sac O
##cade O
##s O
26 O
the O
ic O
is O
involved O
in O
the O
control O
of O
vertical O
and O
ip O
##sil O
##ater O
##al O
tor O
##sion O
##al O
vo O
##r O
and O
velocity O
to O
position O
int O
##eg O
##rator O
25 O
in O
human O
lesions O
of O
rim O
##lf O
alone O
or O
ic O
combined O
essentially O
induce O
a O
contra O
##les O
##ional O
tn O
with O
slowing O
of O
vertical O
sac O
##cade O
##s O
contra O
##les O
##ional O
tor O
##sion O
##al O
deviation O
##s O
during O
sac O
##cade O
##s O
and O
absent O
quick O
phases O
during O
ip O
##si O
##di O
##re O
##ction O
##al O
head O
rotation O
##s O
in O
roll O
26 O
29 O
un O
##ila O
##tera O
##l O
ic O
les O
##ion O
leads O
to O
ip O
##sil O
##es O
##ional O
tn O
and O
un O
##ila O
##tera O
##l O
stimulation O
of O
the O
ic O
ev O
##oke O
##s O
ip O
##sil O
##ater O
##al O
eye O
tor O
##sion O
and O
head O
tilt O
in O
non O
##hum O
##an O
30 O
31 O
in O
humans O
ic O
les O
##ion O
spa O
##ring O
rim O
##lf O
may O
induce O
ip O
##sil O
##es O
##ional O
tn O
##28 O
and O
contra O
##vers O
##ive O
##32 O
33 O
or O
ip O
##sive O
##rs O
##ive O
##28 O
o O
##cular O
tilt O
reaction O

here O
the O
dysfunction O
of O
vertical O
sac O
##cade O
##s O
is O
consistent O
with O
an O
inhibition O
of O
the O
rim O
##lf O
but O
modulation O
of O
ot O
##r O
can O
also O
suggest O
a O
stimulation O
of O
the O
ic O
whether O
this O
is O
explained O
by O
nucleus O
or O
af O
##fer O
##ent O
e O
##ffer O
##ent O
ﬁ O
##bers O
is O
not O
clear O
either O
to O
clarify O
this O
point O
it O
could O
be O
helpful O
to O
simulate O
the O
current O
density O
around O
the O
stimulation O
area O
34 O

according O
to O
the O
close O
relationship O
of O
ic O
rim O
##lf O
and O
stimulation O
contacts O
the O
contra O
##lateral O
tn O
reported O
here O
could O
be O
due O
to O
an O
activation O
of O
the O
ic O
or O
an O
inhibition O
of O
the O
rim O
##lf O
or O
both O
either O
due O
to O
a O
direct O
nucleus O
or O
an O
indirect O
in O
out O
connecting O
pathways O
modulation O

alice O
po O
##isson O
md O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O

ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O

ne O
##uro O
##logie O
c O
lyon O
france O

caroline O
til O
##ike O
##te O
md O
phd O

universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O

ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
unite O
##´ O
de O
ne O
##uro O
op O
##hta O
##lm O
##olo O
##gie O

lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O

lyon O
france O

patrick O
mer O
##tens O
md O
phd O

ne O
##uro O
##chi O
##ru O
##rg O
##ie O
a O
lyon O
france O

ye O
##ln O
##ik O
md O
phd O

ins O
##er O
##m O
u O
67 O
##9 O

de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O

paris O
france O

table O
2 O
eye O
movements O
recording O
with O
2d O
video O
o O
##cu O
##log O
##raphy O
200 O
hz O
frequency O
vis O
##uo O
##200 O
syn O
##ap O
##sy O
##s O
france O

bilateral O
stimulation O
no O
stimulation O

velocity O
ve O
##l O
and O
gain O
of O
horizontal O
158 O
and O
vertical O
108 O
visually O
guided O
sac O
##cade O
##s O
gain O
of O
smooth O
pursuit O
0 O
15 O
hz O
308 O
horizontal O
and O
208 O
vertical O
pen O
##du O
##lar O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
0 O
25 O
hz O
maximum O
amplitude O
of O
45 O
##8 O
and O
maximal O
velocity O
of O
head O
shaking O
ny O
##sta O
##gm O
##us O
hs O
##n O
mean O
frequency O
2 O
hz O
mean O
amplitude O
258 O
in O
horizontal O
and O
vertical O
directions O
were O
recorded O

letter O
to O
the O
editor O
1623 O

eric O
bard O
##ine O
##t O
phd O

cn O
##rs O
up O
##r O
640 O
up O
##mc O

paris O
france O
centre O
de O
ne O
##uro O
image O
##rie O
de O
rec O
##her O
##che O

up O
##mc O

emmanuel O
bro O
##uss O
##oll O
##e O
md O
phd O
ste O
##´ O
##pha O
##ne O
tho O
##bo O
##is O
md O
phd O

ne O
##uro O
##logie O
c O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

email O
stephane O
tho O
##bo O
##is O
chu O
lyon O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
promoted O
by O
the O
hospice O
##s O
civil O
##s O
de O
lyon O
project O
no O
hc O
##l O
p O
2002 O
303 O

k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O

klein O
##er O
fis O
##man O
g O
her O
##zog O
j O
fis O
##man O
d O
##n O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
deep O
brain O
stimulation O
summary O
and O
meta O
analysis O
of O
outcomes O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
su O
##pp O
##l O
14 O
s O
##29 O
##0 O
s O
##30 O
##4 O

ye O
##ln O
##ik O
j O
bard O
##ine O
##t O
e O
dorm O
##ont O
d O
et O
al O
a O
three O
dimensional O
his O
##to O
##logical O
and O
def O
##or O
##mable O
atlas O
of O
the O
human O
basal O
gang O
##lia O
i O
atlas O
construction O
based O
on O
im O
##mun O
##oh O
##isto O
##chemical O
and O
mri O
data O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
61 O
##8 O
63 O
##8 O

ben O
##abi O
##d O
al O
ko O
##ud O
##sie O
a O
ben O
##az O
##zo O
##uz O
a O
et O
al O
deep O
brain O
stimulation O
of O
the O
corpus O
lu O
##ys O
##i O
sub O
##thal O
##ami O
##c O
nucleus O
and O
other O
targets O
in O
parkinson O
s O
disease O
extension O
to O
new O
indications O
such O
as O
d O
##yst O
##onia O
and O
ep O
##ile O
##psy O
j O
ne O
##uro O
##l O
2001 O
248 O
su O
##pp O
##l O
3 O
iii O
##37 O
iii O
##47 O

bro O
##gg O
##i O
g O
franz O
##ini O
a O
fe O
##rro O
##li O
p O
et O
al O
effect O
of O
bilateral O
sub O
##thal O
##ami O
##c O
electrical O
stimulation O
in O
parkinson O
s O
disease O
sur O
##g O
ne O
##uro O
##l O
2001 O
56 O
89 O
94 O
discussion O
94 O
86 O

her O
##zog O
j O
vol O
##km O
##ann O
j O
k O
##rac O
##k O
p O
et O
al O
two O
year O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2003 O
18 O
133 O
##2 O
133 O
##7 O

ian O
##se O
##k O
r O
rosen O
##feld O
j O
##v O
hu O
##x O
##ham O
fe O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
med O
j O
aus O
##t O
2002 O
177 O
142 O
146 O

os O
##ter O
##gaard O
k O
sun O
##de O
n O
dupont O
e O
effects O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
patients O
with O
severe O
parkinson O
s O
disease O
and O
motor O
ﬂ O
##uc O
##tua O
##tions O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
69 O
##3 O
700 O

rom O
##ito O
l O
##m O
sc O
##er O
##rat O
##i O
m O
con O
##tar O
##ino O
m O
##f O
bent O
##ivo O
##glio O
ar O
ton O
##ali O
p O
alba O
##nese O
a O
long O
term O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
ne O
##uro O
##logy O
2002 O
58 O
154 O
##6 O
1550 O

saul O
##eau O
p O
poll O
##ak O
p O
k O
##rac O
##k O
p O
et O
al O
contra O
##vers O
##ive O
eye O
deviation O
during O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
region O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1810 O
1813 O

tam O
##ma O
f O
ramp O
##ini O
p O
e O
##gi O
##di O
m O
et O
al O
deep O
brain O
stimulation O
for O
parkinson O
s O
disease O
the O
experience O
of O
the O
pol O
##ic O
##lini O
##co O
san O
paolo O
group O
in O
milan O
ne O
##uro O
##l O
sci O
2003 O
24 O
su O
##pp O
##l O
1 O
s O
##41 O
s O
##42 O

ta O
##vel O
##la O
a O
berg O
##ama O
##sco O
b O
bo O
##stic O
##co O
e O
et O
al O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
long O
term O
follow O
up O
ne O
##uro O
##l O
sci O
2002 O
23 O
su O
##pp O
##l O
2 O
s O
##11 O
##1 O
s O
##11 O
##2 O

tho O
##bo O
##is O
s O
mer O
##tens O
p O
gu O
##eno O
##t O
m O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
clinical O
evaluation O
of O
18 O
patients O
j O
ne O
##uro O
##l O
2002 O
249 O
52 O
##9 O
53 O
##4 O

vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
weiss O
ph O
fr O
##eu O
##nd O
h O
##j O
stu O
##rm O
v O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O

lu O
##eck O
c O
##j O
has O
##ml O
##yn O
p O
crawford O
t O
##j O
levy O
is O
br O
##ind O
##ley O
gs O
watkins O
es O
ken O
##nard O
c O
a O
case O
of O
o O
##cular O
tilt O
reaction O
and O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
due O
to O
direct O
stimulation O
of O
the O
mid O
##bra O
##in O
in O
man O
brain O
1991 O
114 O
pt O
5 O
206 O
##9 O
207 O
##9 O

hue O
##rta O
m O
##f O
k O
##ru O
##bit O
##zer O
la O
ka O
##as O
j O
##h O
frontal O
eye O
ﬁ O
##eld O
as O
de O
##ﬁ O
##ned O
by O
intra O
##cor O
##tical O
micro O
##sti O
##mu O
##lation O
in O
squirrel O
monkeys O
owl O
monkeys O
and O
mac O
##aq O
##ue O
monkeys O
i O
sub O
##cor O
##tical O
connections O
j O
com O
##p O
ne O
##uro O
##l O
1986 O
253 O
415 O
43 O
##9 O

hue O
##rta O
m O
##f O
po O
##ns O
t O
##p O
primary O
motor O
cortex O
receives O
input O
from O
area O
3a O
in O
mac O
##aq O
##ues O
brain O
res O
1990 O
53 O
##7 O
36 O
##7 O
37 O
##1 O

stanton O
gb O
goldberg O
me O
bruce O
c O
##j O
frontal O
eye O
ﬁ O
##eld O
e O
##ffer O
##ents O
in O
the O
mac O
##aq O
##ue O
monkey O
ii O
topography O
of O
terminal O
ﬁ O
##eld O
##s O
in O
mid O
##bra O
##in O
and O
po O
##ns O
j O
com O
##p O
ne O
##uro O
##l O
1988 O
271 O
49 O
##3 O
50 O
##6 O

bass O
##o O
ma O
po O
##kor O
##ny O
jj O
liu O
p O
activity O
of O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
re O
##tic O
##ulata O
neurons O
during O
smooth O
pursuit O
eye O
movements O
in O
monkeys O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2005 O
22 O
44 O
##8 O
46 O
##4 O

mats O
##um O
##ura O
m O
ko O
##jima O
j O
gardiner O
t O
##w O
hi O
##kos O
##aka O
o O
visual O
and O
o O
##cu O
##lom O
##oto O
##r O
functions O
of O
monkey O
sub O
##thal O
##ami O
##c O
nucleus O
j O
ne O
##uro O
##phy O
##sio O
##l O
1992 O
67 O
161 O
##5 O
1632 O

fa O
##wc O
##ett O
ap O
cu O
##nic O
d O
ham O
##ani O
c O
et O
al O
sac O
##cade O
related O
potential O
##s O
recorded O
from O
human O
sub O
##thal O
##ami O
##c O
nucleus O
cl O
##in O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
118 O
155 O
163 O

fa O
##wc O
##ett O
ap O
dos O
##tro O
##vsky O
jo O
lo O
##zano O
am O
hut O
##chison O
w O
##d O
eye O
movement O
related O
responses O
of O
neurons O
in O
human O
sub O
##thal O
##ami O
##c O
nucleus O
ex O
##p O
brain O
res O
2005 O
162 O
357 O
365 O

ri O
##va O
##ud O
pe O
##cho O
##ux O
s O
ve O
##rm O
##ers O
##ch O
ai O
gay O
##mar O
##d O
b O
et O
al O
improvement O
of O
memory O
guided O
sac O
##cade O
##s O
in O
parkinson O
##ian O
patients O
by O
high O
frequency O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2000 O
68 O
381 O
38 O
##4 O

be O
##j O
##jan O
##i O
bp O
ar O
##nu O
##lf O
i O
ho O
##uet O
##o O
j O
##l O
et O
al O
concurrent O
ex O
##cit O
##atory O
and O
inhibitor O
##y O
effects O
of O
high O
frequency O
stimulation O
an O
o O
##cu O
##lom O
##oto O
##r O
study O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2002 O
72 O
51 O
##7 O
52 O
##2 O

bu O
##ut O
##tner O
u O
bu O
##ut O
##tner O
en O
##ne O
##ver O
ja O
ram O
##bold O
h O
helm O
##chen O
c O
the O
contribution O
of O
mid O
##bra O
##in O
circuits O
in O
the O
control O
of O
gaze O
ann O
n O
y O
ac O
##ad O
sci O
2002 O
95 O
##6 O
99 O
110 O

k O
##rem O
##my O
##da O
o O
bu O
##¨ O
##tt O
##ner O
en O
##ne O
##ver O
ja O
bu O
##¨ O
##tt O
##ner O
u O
g O
##las O
##auer O
s O
tor O
##sion O
##al O
deviation O
##s O
with O
voluntary O
sac O
##cade O
##s O
caused O
by O
a O
un O
##ila O
##tera O
##l O
mid O
##bra O
##in O
les O
##ion O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2007 O
78 O
115 O
##5 O
115 O
##7 O

b O
##hid O
##aya O
##sir O
##i O
r O
plant O
gt O
leigh O
r O
##j O
a O
hypothetical O
scheme O
for O
the O
brains O
##tem O
control O
of O
vertical O
gaze O
ne O
##uro O
##logy O
2000 O
54 O
1985 O
1993 O

helm O
##chen O
c O
ram O
##bold O
h O
kemp O
##erman O
##n O
u O
butt O
##ner O
en O
##ne O
##ver O
ja O
butt O
##ner O
u O
local O
##izing O
value O
of O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
in O
small O
mid O
##bra O
##in O
lesions O
ne O
##uro O
##logy O
2002 O
59 O
1956 O
1964 O

rio O
##rdan O
eva O
p O
fa O
##ldon O
m O
butt O
##ner O
en O
##ne O
##ver O
ja O
gas O
##s O
a O
bro O
##nstein O
am O
gr O
##est O
##y O
ma O
abnormalities O
of O
tor O
##sion O
##al O
fast O
phase O
eye O
movements O
in O
un O
##ila O
##tera O
##l O
ro O
##stra O
##l O
mid O
##bra O
##in O
disease O
ne O
##uro O
##logy O
1996 O
47 O
201 O
207 O

far O
##sha O
##dman O
##esh O
f O
k O
##lier O
em O
chang O
p O
wang O
h O
crawford O
jd O
three O
dimensional O
eye O
head O
coordination O
after O
injection O
of O
mu O
##sc O
##imo O
##l O
into O
the O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
inc O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
232 O
##2 O
233 O
##8 O

k O
##lier O
em O
wang O
h O
crawford O
jd O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
en O
##codes O
three O
dimensional O
head O
orientation O
##s O
in O
fi O
##ck O
like O
coordinates O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
60 O
##4 O
61 O
##7 O

dieter O
##ich O
m O
brandt O
t O
tha O
##lam O
##ic O
in O
##far O
##ctions O
differential O
effects O
on O
vest O
##ib O
##ular O
function O
in O
the O
roll O
plane O
35 O
patients O
ne O
##uro O
##logy O
1993 O
43 O
1732 O
1740 O

hal O
##ma O
##gy O
##i O
gm O
brandt O
t O
dieter O
##ich O
m O
curt O
##ho O
##ys O
is O
stark O
r O
##j O
ho O
##yt O
w O
##f O
tonic O
contra O
##vers O
##ive O
o O
##cular O
tilt O
reaction O
due O
to O
un O
##ila O
##tera O
##l O
me O
##so O
die O
##nce O
##pha O
##lic O
les O
##ion O
ne O
##uro O
##logy O
1990 O
40 O
150 O
##3 O
150 O
##9 O

1624 O
letters O
to O
the O
editor O

but O
##son O
cr O
cooper O
se O
henderson O
j O
##m O
mcintyre O
cc O
patients O
##pe O
##ci O
##ﬁ O
##c O
analysis O
of O
the O
volume O
of O
tissue O
activated O
during O
deep O
brain O
stimulation O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
66 O
##1 O
670 O

pal O
##atal O
tremor O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
in O
a O
patient O
with O
pol O
##g O
##1 O
mutation O

recently O
a O
progressive O
ata O
##xi O
##c O
syndrome O
msc O
##ae O
caused O
by O
za O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
was O
reported O
1 O
4 O
the O
nuclear O
gene O
pol O
##g O
##1 O
en O
##codes O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
dependent O
polymer O
##ase O
polymer O
##ase O
g O
##5 O
the O
catalytic O
subunit O
comprises O
three O
domains O
a O
polymer O
##ase O
and O
30 O
50 O
ex O
##on O
##uc O
##lea O
##se O
domain O
and O
an O
intervening O
link O
##er O
region O
over O
70 O
mutations O
have O
been O
reported O
in O
the O
catalytic O
subunit O
with O
both O
dominant O
and O
recess O
##ive O
modes O
of O
inheritance O
the O
carrier O
frequency O
of O
these O
two O
mutations O
is O
high O
in O
northern O
europe O
particularly O
scandinavia O
3 O
the O
clinical O
features O
associated O
with O
pol O
##g O
##1 O
mutation O
include O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
6 O
al O
##pers O
syndrome O
7 O
parkinson O
##ism O
8 O
or O
a O
syndrome O
with O
sensory O
ata O
##xia O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sand O
##o O
9 O
we O
present O
a O
young O
woman O
homo O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
and O
msc O
##ae O
that O
developed O
pal O
##atal O
tremor O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
and O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
ol O
##ivar O
##y O
nuclei O

the O
patient O
is O
now O
35 O
years O
old O
without O
family O
history O
of O
ep O
##ile O
##psy O
or O
movement O
disorder O
she O
was O
ﬁ O
##rst O
seen O
at O
the O
age O
of O
19 O
with O
focal O
ep O
##ile O
##ptic O
seizures O
five O
years O
later O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
ga O
##it O
un O
##stead O
##iness O
were O
noted O
and O
aged O
28 O
during O
her O
ﬁ O
##rst O
pregnancy O
she O
was O
admitted O
with O
focal O
ep O
##ile O
##ptic O
seizures O
that O
were O
highly O
resistant O
to O
treatment O
two O
months O
later O
her O
symptoms O
worsened O
and O
included O
my O
##oc O
##lon O
##ic O
jerk O
##s O
in O
the O
ex O
##tre O
##mit O
##ies O
and O
facial O
d O
##ys O
##kin O
##es O
##ias O
treatment O
with O
sodium O
val O
##pro O
##ate O
resulted O
in O
acute O
severe O
he O
##pati O
##c O
failure O
and O
she O
underwent O
a O
successful O
liver O
transplant O
##ation O
two O
years O
later O
a O
cerebral O
mri O
scan O
showed O
marked O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
olive O
##s O
fig O
1 O
she O
denied O
symptoms O
of O
ear O
clicking O

on O
examination O
at O
age O
35 O
she O
had O
a O
mild O
cognitive O
de O
##ﬁ O
##cit O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
mild O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
no O
ny O
##sta O
##gm O
##us O
and O
no O
facial O
nerve O
dysfunction O
she O
had O
an O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
consisting O
of O
sound O
##less O
bilateral O
sync O
##hr O
##ono O
##us O
and O
symmetrical O
2 O
hz O
contraction O
##s O
of O
the O
soft O
pal O
##ate O
plus O
facial O
d O
##ys O
##kin O
##es O
##ias O
consisting O
of O
continuous O
rhythmic O
und O
##ulating O
wave O
like O
bilateral O
per O
##ior O
##bit O
##al O
movements O

intermittent O
as O
##ym O
##metric O
limb O
my O
##oc O
##lon O
##us O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
and O
signs O
of O
peripheral O
ne O
##uro O
##pathy O
with O
loss O
of O
re O
##ﬂ O
##ex O
##es O
and O
sensory O
disturbance O
were O
also O
present O
muscle O
bulk O
tone O
and O
power O
appeared O
normal O
dna O
analysis O
con O
##ﬁ O
##rmed O
that O
she O
was O
homo O
##zy O
##go O
##us O
for O
the O
c O
224 O
##3 O
##g O
c O
p O
w O
##7 O
##48 O
##s O
mutation O
in O
pol O
##g O
##1 O

our O
patient O
demonstrates O
the O
typical O
features O
of O
msc O
##ae O
with O
the O
combination O
of O
focal O
ep O
##ile O
##psy O
my O
##oc O
##lon O
##us O
and O
ata O
##xia O
as O
well O
as O
sensitivity O
to O
sodium O
val O
##pro O
##ate O
3 O
10 O
the O
interesting O
features O
are O
the O
rhythmic O
##al O
facial O
d O
##ys O
##kin O
##es O
##ia O
and O
the O
as O
##ym O
##p O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##8 O

tom O
##atic O
pal O
##atal O
tremor O
with O
its O
structural O
co O
##rre O
##late O
of O
inferior O
ol O
##ivar O
##y O
nuclei O
involvement O

hyper O
##tro O
##phic O
ol O
##ivar O
##y O
de O
##gen O
##eration O
ho O
##d O
is O
clinical O
##ly O
associated O
with O
pal O
##atal O
tremor O
and O
is O
often O
caused O
by O
pathology O
in O
the O
dent O
##ato O
rub O
##ro O
ol O
##ivar O
##y O
pathways O
or O
also O
called O
gui O
##lla O
##in O
mo O
##llar O
##et O
triangle O
usually O
the O
les O
##ion O
is O
caused O
by O
vascular O
is O
##che O
##mia O
hem O
##or O
##rh O
##age O
infection O
trauma O
neo O
##pl O
##as O
##m O
or O
dem O
##ye O
##lina O
##tion O
11 O
a O
syndrome O
called O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
pa O
##pt O
has O
been O
reported O
and O
shows O
similarities O
to O
our O
case O
even O
though O
sporadic O
pa O
##pt O
cases O
had O
a O
het O
##ero O
##gen O
##eous O
clinical O
picture O
the O
ce O
##re O
##bella O
##r O
de O
##gen O
##eration O
was O
the O
most O
sy O
##mpt O
##oma O
##tic O
feature O
and O
ho O
##d O
was O
common O
in O
the O
presented O
cases O
12 O
in O
the O
familiar O
forms O
of O
pa O
##pt O
however O
ol O
##ivar O
##y O
pathology O
was O
absent O
pal O
##atal O
tremor O
with O
ol O
##ivar O
##y O
hyper O
##tro O
##phy O
and O
dent O
##ate O
cal O
##ci O
##ﬁ O
##cation O
has O
also O
been O
described O
in O
a O
form O
of O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
sc O
##a O
20 O
13 O

in O
our O
patient O
ho O
##d O
was O
an O
incident O
##al O
mri O
ﬁ O
##nding O
without O
any O
obvious O
clinical O
symptoms O
it O
occurred O
several O
years O
after O
disease O
onset O
the O
lack O
of O
ear O
clicks O
or O
other O
symptoms O
may O
explain O
why O
this O
clinical O
picture O
has O
not O
been O
reported O
by O
other O
authors O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
may O
also O
be O
easily O
overlooked O
in O
a O
routine O
clinical O
examination O

facial O
d O
##ys O
##kin O
##es O
##ia O
appeared O
as O
wave O
like O
per O
##ior O
##bit O
##al O
involuntary O
movements O
on O
both O
sides O
but O
not O
per O
##ior O
##al O
these O
as O
##ym O
##metric O
movements O
alternating O
from O
one O
side O
to O
the O
other O
were O
most O
prominent O
when O
she O
was O
in O
a O
resting O
position O
she O
had O
never O
been O
treated O
with O
ne O
##uro O
##le O
##ptic O
or O
anti O
##park O
##ins O
##onia O
##n O
drugs O
that O
might O
have O
induced O
this O
feature O
ee O
##g O
recorded O
routinely O
due O
to O
her O
ep O
##ile O
##psy O
has O
not O
shown O
any O
co O
##rre O
##late O
with O
these O
movements O
oro O
##fa O
##cial O
d O
##ys O
##kin O
##es O
##ia O
is O
reported O
in O
cho O
##rea O
ac O
##ant O
##ho O
##cy O
##tosis O
together O
with O
other O
symptoms O
like O
d O
##ys O
##pha O
##gia O
d O
##ys O
##arth O
##ria O
are O
##ﬂ O
##ex O
##ia O
seizures O
and O
dementia O
14 O
facial O
my O
##or O
##hy O
##th O
##mia O
is O
also O
path O
##og O
##no O
##mic O
for O
whip O
##ple O
s O
disease O
mostly O
localized O
around O
the O
eyes O
and O
jaw O
other O
symptoms O
as O
seizures O
my O
##oc O
##lon O
##us O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
d O
##ys O
##arth O
##ria O
are O
also O
common O
a O
diagnostic O
criterion O
for O
this O
entity O
is O
small O
int O
##est O
##ine O
bio O
##psy O
that O
excluded O
the O
disease O

we O
present O
a O
case O
with O
the O
typical O
clinical O
features O
of O
pol O
##g O
##1 O
mutation O
and O
additional O
novel O
ﬁ O
##nding O
##s O
of O
pal O
##atal O
tremor O
with O
ho O
##d O
on O
mri O
and O
facial O
d O
##ys O
##kin O
##es O
##ia O
these O
ﬁ O
##nding O
##s O
expand O
the O
clinical O
spectrum O
of O
the O
syndrome O
##s O
caused O
by O
mutation O
in O
this O
gene O
moreover O
since O
pal O
##atal O
tremor O
is O
a O
rare O
disorder O
and O
often O
reported O
as O
a O
sporadic O
entity O
we O
suggest O
that O
pol O
##g O
##1 O
mutation O
should O
be O
considered O
in O
patients O
with O
this O
disorder O

segment O
1 O
the O
patient O
shows O
ga O
##it O
ata O
##xia O
and O
mild O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
she O
has O
bilateral O
as O
##ym O
##metric O
##al O
rhythmic O
##al O
facial O
d O
##ys O
##kin O
##es O
##ias O
mainly O
in O
the O
per O
##ior O
##bit O
##al O
regions O
the O
as O
##ym O
##pt O
##oma O
##tic O
pal O
##atal O
tremor O
sound O
##less O
bilateral O
sync O
##hr O
##ono O
##us O
and O
symmetrical O
2 O
##h O
##z O
contraction O
##s O
of O
the O
soft O
pal O
##ate O

kris O
##z O
##tina O
k O
johan O
##sen O
md O

department O
of O
neuroscience O
norwegian O
university O
of O
science O
and O
technology O

trondheim O
norway O

letters O
to O
the O
editor O
1625 O

fig O
1 O
marked O
hyper O
##tro O
##phic O
de O
##gen O
##eration O
of O
the O
inferior O
olive O
##s O

laurence O
a O
bind O
##off O
md O
phd O

department O
of O
ne O
##uro O
##logy O
ha O
##uke O
##land O
university O
hospital O
bergen O
institute O
of O
clinical O
medicine O

university O
of O
bergen O
norway O

jana O
ry O
##dl O
##and O
md O

department O
of O
radio O
##logy O
st O
ol O
##avs O
hospital O

jan O
o O
aa O
##sl O
##y O
md O
phd O

department O
of O
ne O
##uro O
##logy O
st O
ol O
##avs O
hospital O
trondheim O
department O
of O
neuroscience O

norwegian O
university O
of O
science O
and O
technology O

e O
mail O
jan O
aa O
##sl O
##y O
nt O
##nu O
no O

van O
goethe O
##m O
g O
lu O
##oma O
p O
ran O
##tama O
##ki O
m O
et O
al O
pol O
##g O
mutations O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
with O
ata O
##xia O
but O
no O
muscle O
involvement O
ne O
##uro O
##logy O
2004 O
63 O
125 O
##1 O
125 O
##7 O

ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O

winter O
##th O
##un O
s O
ferrari O
g O
he O
l O
et O
al O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
due O
to O
mitochondrial O
polymer O
##ase O
gamma O
mutations O
ne O
##uro O
##logy O
2005 O
64 O
120 O
##4 O
120 O
##8 O

t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O

ka O
##gun O
##i O
l O
##s O
dna O
polymer O
##ase O
gamma O
the O
mitochondrial O
replica O
##se O
ann O
rev O
bio O
##che O
##m O
2004 O
73 O
293 O
320 O

lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
et O
al O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O
2002 O
52 O
211 O
219 O

na O
##via O
##ux O
r O
##k O
nguyen O
kv O
pol O
##g O
mutations O
associated O
with O
al O
##pers O
syndrome O
and O
mitochondrial O
dna O
de O
##ple O
##tion O
ann O
ne O
##uro O
##l O
2004 O
55 O
70 O
##6 O
71 O
##2 O

lu O
##oma O
pt O
ee O
##rol O
##a O
j O
ah O
##ola O
s O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
gamma O
variants O
in O
id O
##io O
##pathic O
sporadic O
parkinson O
disease O
ne O
##uro O
##logy O
2007 O
69 O
115 O
##2 O
115 O
##9 O

fa O
##dic O
r O
russell O
ja O
ve O
##dana O
##raya O
##nan O
v O
##v O
le O
##har O
m O
kun O
##cl O
r O
##w O
johns O
dr O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
as O
the O
presenting O
feature O
of O
a O
novel O
mitochondrial O
disease O
ne O
##uro O
##logy O
1997 O
49 O
239 O
245 O

eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
et O
al O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
2008 O
131 O
81 O
##8 O
28 O

yoko O
##ta O
t O
hi O
##ras O
##hima O
f O
fur O
##uka O
##wa O
t O
ts O
##uka O
##gos O
##hi O
h O
yo O
##shi O
##kawa O

h O
mri O
ﬁ O
##nding O
##s O
of O
inferior O
olive O
##s O
in O
pal O
##atal O
my O
##oc O
##lon O
##us O
j O
ne O
##uro O
##l O
1989 O
236 O
115 O
116 O

samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
##s O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O

1626 O
letters O
to O
the O
editor O

knight O
ma O
gardner O
r O
##j O
ba O
##hl O
##o O
m O
et O
al O
dominant O
##ly O
inherited O
ata O
##xia O
and O
d O
##ys O
##phon O
##ia O
with O
dent O
##ate O
cal O
##ci O
##ﬁ O
##cation O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
brain O
2004 O
127 O
117 O
##2 O
118 O
##1 O

ramp O
##old O
##i O
l O
dane O
##k O
a O
monaco O
ap O
clinical O
features O
and O
molecular O
bases O
of O
ne O
##uro O
##aca O
##nt O
##ho O
##cy O
##tosis O
j O
mo O
##l O
med O
2002 O
80 O
475 O
49 O
##1 O

tha O
##lam O
##ic O
stimulation O
does O
not O
involve O
a O
high O
rate O
of O
suicide O

i O
read O
with O
some O
concern O
the O
paper O
of O
apple O
##by O
et O
al O
published O
in O
the O
september O
issue O
of O
md O
##j O
1 O
the O
authors O
write O
in O
the O
abstract O
reported O
rates O
of O
depression O
cognitive O
impairment O
mania O
and O
behavior O
change O
are O
low O
but O
there O
is O
a O
high O
rate O
of O
suicide O
in O
patients O
treated O
with O
db O
##s O
particularly O
with O
tha O
##lam O
##ic O
and O
gp O
##i O
stimulation O
in O
the O
results O
section O
the O
authors O
provide O
numbers O
and O
percentage O
of O
those O
patients O
that O
expressed O
suicidal O
##ity O
de O
##ﬁ O
##ned O
as O
suicidal O
idea O
##tion O
suicide O
attempt O
or O
completed O
suicide O
they O
wrote O
most O
patients O
underwent O
db O
##s O
for O
the O
treatment O
of O
parkinson O
s O
disease O
26 O
81 O
4 O
had O
d O
##yst O
##onia O
12 O
5 O
1 O
had O
essential O
tremor O
3 O
and O
another O
had O
o O
##cd O
3 O
then O
the O
authors O
provide O
details O
of O
the O
brain O
target O
for O
db O
##s O
in O
these O
patients O
26 O
patients O
81 O
were O
implant O
##ed O
in O
the O
st O
##n O
4 O
12 O
5 O
had O
gp O
##i O
implant O
##s O
and O
1 O
3 O
had O
a O
vi O
##m O
implant O
and O
the O
last O
patient O
received O
an O
anterior O
limb O
of O
the O
internal O
capsule O
implant O
then O
toward O
the O
end O
of O
the O
results O
section O
they O
wrote O
the O
rate O
of O
completed O
suicide O
was O
highest O
in O
the O
tha O
##lam O
##us O
group O
5 O
4 O

in O
my O
reading O
these O
results O
simply O
do O
not O
add O
up O
and O
the O
drawn O
conclusions O
expressed O
both O
in O
the O
abstract O
and O
in O
the O
discussion O
of O
that O
paper O
do O
not O
sub O
##stan O
##tia O
##te O
in O
fact O
contra O
##dict O
the O
ﬁ O
##gur O
##es O
and O
percentage O
cited O
this O
article O
is O
supposed O
to O
be O
a O
review O
of O
the O
literature O
and O
a O
meta O
analysis O
but O
nowhere O
can O
one O
read O
how O
the O
meta O
analysis O
was O
statistical O
##ly O
conducted O
to O
start O
with O
there O
is O
no O
information O
about O
the O
number O
of O
patients O
with O
the O
various O
dia O
##gno O
##ses O
or O
the O
number O
of O
patients O
operated O
on O
in O
the O
various O
brain O
targets O
there O
is O
instead O
information O
about O
number O
of O
publications O
their O
geographical O
origin O
gender O
of O
patients O
etc O
there O
is O
no O
mention O
of O
any O
data O
providing O
the O
percentage O
of O
patients O
with O
suicidal O
##ity O
in O
relation O
to O
the O
number O
of O
patients O
operated O
on O
in O
any O
of O
the O
brain O
targets O
or O
for O
any O
of O
the O
dia O
##gno O
##ses O

in O
the O
quoted O
references O
i O
cannot O
ﬁ O
##nd O
any O
reference O
that O
supports O
the O
authors O
claim O
that O
tha O
##lam O
##ic O
stimulation O
carries O
the O
highest O
risk O
for O
suicidal O
##ity O
and O
the O
authors O
do O
not O
give O
the O
citation O
reference O
numbers O
to O
back O
up O
their O
conclusions O
to O
name O
but O
one O
example O
the O
last O
patient O
who O
committed O
suicide O
and O
who O
received O
an O
anterior O
limb O
of O
the O
internal O
capsule O
implant O
is O
certainly O
the O
patient O
described O
by O
abel O
##son O
et O
al O
in O
the O
non O
##qu O
##oted O
paper O
on O
four O
patients O
with O
o O
##cd O
treated O
with O
db O
##s O
2 O

the O
authors O
wrote O
since O
its O
approval O
by O
the O
fda O
in O
1997 O
for O
use O
in O
parkinson O
s O
disease O
db O
##s O
has O
been O
used O
to O
treat O
essential O
tremor O
d O
##yst O
##onia O
cluster O
headache O
##s O
and O
chronic O
pain O
##1 O
4 O
and O
among O
these O
4 O
quoted O
references O
one O
ref O
4 O
was O
actually O
about O
db O
##s O
for O
ep O
##ile O
##psy O
besides O
it O
is O

true O
that O
fda O
granted O
approval O
for O
tha O
##lam O
##ic O
db O
##s O
for O
parkinson O
##ian O
and O
essential O
tremor O
in O
1997 O
then O
pal O
##lid O
##al O
db O
##s O
and O
st O
##n O
db O
##s O
for O
advanced O
pd O
in O
2001 O
however O
for O
d O
##yst O
##onia O
the O
fda O
granted O
in O
2003 O
a O
humanitarian O
device O
exemption O
which O
is O
not O
a O
full O
approval O

instead O
of O
providing O
several O
tables O
detailing O
device O
related O
adverse O
events O
table O
3 O
and O
so O
##matic O
adverse O
events O
table O
4 O
both O
of O
which O
are O
evidently O
out O
of O
the O
scope O
of O
this O
paper O
on O
psychiatric O
and O
ne O
##uro O
##psy O
##chia O
##tric O
adverse O
events O
it O
would O
have O
been O
more O
helpful O
to O
provide O
tables O
of O
the O
percentage O
or O
prevalence O
of O
suicide O
##s O
according O
to O
target O
and O
diagnosis O
in O
my O
review O
of O
the O
literature O
suicidal O
##ity O
following O
db O
##s O
is O
overall O
rare O
and O
its O
prevalence O
is O
higher O
in O
patients O
with O
sub O
##thal O
##ami O
##c O
db O
##s O
compared O
to O
tha O
##lam O
##ic O
db O
##s O
a O
ﬁ O
##nding O
contrary O
to O
their O
statement O
in O
the O
abstract O
and O
on O
page O
1726 O

the O
ﬁ O
##nal O
conclusion O
of O
this O
article O
reads O
our O
ﬁ O
##nding O
##s O
are O
optimistic O
regarding O
the O
use O
of O
db O
##s O
for O
psychiatric O
disorders O
which O
ﬁ O
##nding O
##s O
i O
looked O
repeatedly O
in O
the O
paper O
for O
any O
results O
ﬁ O
##gur O
##es O
or O
tables O
that O
would O
justify O
such O
a O
conclusion O
but O
could O
ﬁ O
##nd O
none O
in O
the O
context O
of O
this O
study O
such O
a O
conclusion O
seems O
to O
me O
in O
need O
of O
rec O
##ons O
##ider O
##ation O
and O
the O
data O
need O
to O
be O
clearly O
provided O

in O
my O
view O
we O
are O
left O
with O
a O
published O
study O
that O
could O
potentially O
have O
been O
an O
extremely O
inform O
##ative O
analysis O
had O
the O
authors O
separated O
tha O
##lam O
##us O
and O
sub O
##thal O
##am O
##us O
and O
had O
they O
carefully O
evaluated O
the O
literature O
that O
they O
set O
themselves O
to O
review O
the O
meta O
analysis O
promised O
in O
the O
title O
of O
this O
work O
was O
not O
provided O
and O
the O
authors O
fall O
short O
of O
answering O
the O
issues O
at O
stake O

mar O
##wan O
i O
hari O
##z O
md O
phd O

professor O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O

institute O
of O
ne O
##uro O
##logy O
queen O
square O
london O
united O
kingdom O

e O
mail O
m O
hari O
##z O
ion O
uc O
##l O
ac O
uk O
or O
mar O
##wan O
hari O
##z O
ne O
##uro O
um O
##u O
se O

apple O
##by O
bs O
dug O
##gan O
ps O
reg O
##enberg O
a O
ra O
##bin O
##s O
pv O
psychiatric O
and O
ne O
##uro O
##psy O
##chia O
##tric O
adverse O
events O
associated O
with O
deep O
brain O
stimulation O
a O
meta O
analysis O
of O
ten O
years O
experience O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1722 O
1728 O

abel O
##son O
j O
##l O
curtis O
g O
##c O
sa O
##gh O
##er O
o O
al O
##buch O
##er O
rc O
ha O
##rrigan O
m O
taylor O
m O
##f O
mart O
##is O
b O
gi O
##ord O
##ani O
b O
deep O
brain O
stimulation O
for O
ref O
##rac O
##tory O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
bio O
##l O
psychiatry O
2005 O
57 O
510 O
51 O
##6 O

d O
##yst O
##onia O
with O
super O
##im O
##posed O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
an O
experiment O
in O
nature O

ne O
##uro O
##mus O
##cular O
junction O
##al O
nm O
##j O
paralysis O
induced O
by O
bot O
##ulin O
##um O
toxin O
injection O
is O
currently O
the O
preferred O
treatment O
for O
focal O
or O
segment O
##al O
d O
##yst O
##onia O
whereas O
nm O
##j O
paralysis O
due O
to O
de O
##ple O
##tion O
of O
post O
##jun O
##ction O
##al O
ace O
##ty O
##lch O
##olin O
##e O
receptors O
is O
the O
pathogen O
##etic O
mechanism O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
mg O
a O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##38 O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##66 O

letters O
to O
the O
editor O
162 O
##7 O

patient O
with O
d O
##yst O
##onia O
developing O
mg O
may O
therefore O
show O
improvement O
of O
d O
##yst O
##onic O
symptoms O
here O
we O
present O
2 O
patients O
with O
coe O
##xi O
##sti O
##ng O
d O
##yst O
##onia O
and O
mg O

a O
69 O
year O
old O
woman O
19 O
years O
earlier O
noticed O
intermittent O
turning O
of O
her O
head O
to O
the O
right O
side O
which O
had O
begun O
suddenly O
following O
a O
motor O
vehicle O
accident O
she O
had O
side O
##to O
side O
movement O
of O
her O
head O
with O
rotation O
and O
tilt O
to O
the O
right O
side O
it O
was O
aggravated O
by O
stress O
and O
suppressed O
with O
sensory O
tricks O
there O
was O
no O
family O
history O
of O
d O
##yst O
##onia O
or O
of O
prior O
treatment O
with O
ne O
##uro O
##le O
##ptic O
medications O
she O
was O
diagnosed O
with O
cervical O
d O
##yst O
##onia O
with O
mild O
head O
tremor O
she O
tried O
various O
oral O
medications O
with O
no O
improvement O
she O
was O
never O
treated O
with O
bot O
##ulin O
##um O
toxin O

seven O
years O
ago O
she O
developed O
double O
vision O
dr O
##ooping O
of O
the O
eyelids O
and O
generalized O
weakness O
she O
also O
noted O
marked O
reduction O
of O
d O
##yst O
##onic O
movements O
at O
the O
same O
time O
neurological O
examination O
revealed O
bilateral O
pt O
##osis O
and O
dip O
##lo O
##pia O
which O
worsened O
on O
fatigue O
she O
had O
minimal O
d O
##yst O
##onic O
head O
tremor O
with O
tor O
##tic O
##oll O
##is O
to O
the O
right O
of O
208 O
and O
right O
later O
##oco O
##llis O
of O
158 O
she O
also O
had O
bilateral O
orb O
##icular O
##is O
o O
##cu O
##li O
and O
generalized O
pro O
##xi O
##mal O
muscle O
weakness O
the O
remainder O
of O
her O
neurological O
examination O
disclosed O
no O
abnormalities O
she O
was O
diagnosed O
with O
generalized O
ser O
##op O
##osi O
##tive O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
started O
on O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
and O
co O
##rti O
##cos O
##ter O
##oids O
which O
resulted O
in O
the O
improvement O
of O
the O
my O
##ast O
##hen O
##ic O
symptoms O
and O
signs O
on O
recent O
follow O
up O
she O
had O
minimal O
head O
tremor O
in O
the O
side O
to O
side O
direction O
mild O
residual O
weakness O
of O
the O
cervical O
muscles O
and O
no O
re O
##la O
##pse O
of O
cervical O
d O
##yst O
##onia O

a O
61 O
year O
old O
man O
with O
cerebral O
pal O
##sy O
developed O
b O
##le O
##pha O
##ros O
##pas O
##m O
several O
years O
prior O
to O
presentation O
to O
our O
facility O
one O
year O
earlier O
he O
received O
bot O
##ulin O
##um O
toxin O
treatment O
which O
provided O
temporary O
improvement O
of O
this O
disorder O
about O
6 O
months O
before O
evaluation O
he O
complained O
of O
progressive O
bilateral O
lower O
ex O
##tre O
##mity O
weakness O
and O
d O
##ys O
##pha O
##gia O
to O
both O
solids O
and O
liquids O
neurological O
examination O
revealed O
bilateral O
pt O
##osis O
op O
##ht O
##hal O
##mo O
##par O
##esis O
and O
mild O
generalized O
pro O
##xi O
##mal O
muscle O
weakness O
his O
b O
##le O
##pha O
##ros O
##pas O
##m O
disappeared O
and O
none O
was O
observed O
during O
the O
examination O
following O
further O
investigations O
including O
ne O
##uro O
##phy O
##sio O
##logical O
testing O
which O
showed O
a O
sign O
##i O
##ﬁ O
##can O
##t O
dec O
##rem O
##ental O
response O
on O
repetitive O
nerve O
stimulation O
at O
3 O
hz O
he O
was O
diagnosed O
with O
ser O
##op O
##osi O
##tive O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
he O
was O
treated O
with O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
co O
##rti O
##cos O
##ter O
##oids O
and O
az O
##athi O
##op O
##rine O
a O
follow O
up O
examination O
2 O
years O
later O
showed O
marked O
improvement O
of O
my O
##ast O
##hen O
##ic O
symptoms O
but O
with O
mild O
residual O
weakness O
of O
the O
orb O
##icular O
##is O
o O
##cu O
##li O
he O
had O
no O
rec O
##ur O
##rence O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O

approximately O
33 O
of O
patients O
diagnosed O
with O
focal O
or O
segment O
##al O
d O
##yst O
##onia O
and O
treated O
with O
anti O
##cho O
##liner O
##gic O
drugs O
show O
a O
modest O
improvement O
in O
symptoms O
compared O
with O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
in O
90 O
treated O
with O
local O
intra O
##mus O
##cular O
bot O
##ulin O
##um O
toxin O
1 O
bot O
##ulin O
##um O
toxin O
binds O
at O
the O
ne O
##uro O
##mus O
##cular O
junction O
and O
prevents O
the O
release O
of O
ace O
##ty O
##lch O
##olin O
##e O
from O
the O
pre O
##sy O
##na O
##ptic O
terminal O
it O
results O
in O
temporary O
weakness O
of O
the O
skeletal O
muscles O
into O
which O
it O
is O
injected O
which O
can O
am O
##eli O
##ora O
##te O
the O
symptoms O
and O
signs O
of O
d O
##yst O
##onia O
the O
median O
duration O
of O

effect O
is O
about O
12 O
5 O
weeks O
2 O
it O
is O
the O
treatment O
of O
choice O
for O
cervical O
d O
##yst O
##onia O
b O
##le O
##pha O
##ros O
##pas O
##m O
spa O
##smo O
##dic O
d O
##ys O
##phon O
##ia O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
and O
limb O
d O
##yst O
##onia O
3 O

my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
is O
an O
auto O
##im O
##mun O
##e O
disorder O
caused O
by O
auto O
##ant O
##ib O
##odies O
against O
the O
nico O
##tin O
##ic O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
on O
the O
posts O
##yna O
##ptic O
membrane O
at O
the O
ne O
##uro O
##mus O
##cular O
junction O
4 O
both O
our O
patients O
had O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
antibody O
positive O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
both O
had O
improvement O
of O
their O
movement O
disorders O
there O
was O
marked O
improvement O
of O
tor O
##tic O
##oll O
##is O
in O
our O
ﬁ O
##rst O
patient O
and O
resolution O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
in O
the O
second O
after O
the O
development O
of O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
a O
review O
of O
the O
literature O
reveals O
two O
reports O
of O
patients O
who O
had O
both O
generalized O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
and O
d O
##yst O
##onia O
interesting O
##ly O
in O
contrast O
to O
our O
patients O
both O
of O
them O
developed O
only O
temporary O
improvement O
of O
the O
d O
##yst O
##onia O
5 O
6 O
furthermore O
in O
one O
of O
these O
patients O
the O
rec O
##urrent O
d O
##yst O
##onia O
was O
successfully O
treated O
with O
bot O
##ulin O
##um O
toxin O
6 O
it O
is O
possible O
that O
our O
patients O
did O
not O
develop O
a O
rec O
##ur O
##rence O
of O
d O
##yst O
##onia O
due O
to O
mild O
residual O
muscle O
weakness O
secondary O
to O
the O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O

clinical O
improvement O
of O
d O
##yst O
##onia O
after O
the O
onset O
of O
mg O
at O
##test O
##s O
to O
an O
intriguing O
relationship O
between O
d O
##yst O
##onia O
and O
mg O
serving O
as O
another O
example O
of O
an O
experiment O
of O
nature O
spontaneous O
improvement O
of O
symptoms O
in O
a O
d O
##yst O
##onic O
patient O
should O
direct O
attention O
to O
the O
possibility O
of O
developing O
a O
nm O
##j O
disorder O

arch O
##ana O
hindu O
##ja O
md O
sud O
##han O
##shu O
cho O
##kr O
##over O
##ty O
md O
fr O
##cp O

philip O
hanna O
md O
raj O
##i O
p O
grew O
##al O
md O

nj O
neuroscience O
institute O
seton O
hall O
university O

school O
of O
graduate O
medical O
education O

j O
##fk O
medical O
center O
edison O
new O
jersey O
usa O

e O
mail O
r O
##gre O
##wal O
solar O
##ish O
##s O
org O

jan O
##kovic O
j O
led O
##er O
s O
warner O
d O
schwartz O
k O
cervical O
d O
##yst O
##onia O
clinical O
ﬁ O
##nding O
##s O
and O
associated O
movement O
disorders O
ne O
##uro O
##logy O
1991 O
41 O
108 O
##8 O
109 O
##1 O

jan O
##kovic O
j O
bot O
##ulin O
##um O
toxin O
therapy O
for O
cervical O
d O
##yst O
##onia O
ne O
##uro O
##to O
##x O
res O
2006 O
9 O
145 O
148 O

jan O
##kovic O
j O
bot O
##ulin O
##um O
toxin O
in O
clinical O
practice O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2004 O
75 O
95 O
##1 O
95 O
##7 O

than O
##vi O
br O
lo O
tc O
##n O
update O
on O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
post O
##grad O
med O
j O
2004 O
80 O
690 O
700 O

hoffman O
l O
##m O
robinson O
j O
hannah O
h O
loss O
of O
d O
##yst O
##onia O
as O
a O
sign O
of O
my O
##ast O
##hen O
##ia O
south O
med O
j O
1991 O
84 O
115 O
##9 O
116 O
##0 O

tar O
##say O
d O
b O
##hat O
##ta O
##cha O
##ry O
##ya O
n O
bo O
##rod O
##ic O
g O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
after O
bot O
##ulin O
##um O
toxin O
a O
for O
mei O
##ge O
syndrome O
movement O
di O
##sor O
##d O
2000 O
15 O
73 O
##6 O
73 O
##8 O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O
pp O
161 O
##3 O
162 O
##7 O
2008 O
movement O
disorder O
society O
letters O
to O
the O
editor O
related O
to O
new O
topics O
alexander O
disease O
causing O
hereditary O
late O
onset O
ata O
##xia O
with O
only O
minimal O
white O
matter O
changes O
a O
report O
of O
two O
si O
##bs O
video O

we O
report O
a O
case O
of O
an O
adult O
onset O
mutation O
proven O
alexander O
disease O
characterized O
by O
ce O
##re O
##bella O
##r O
and O
sensory O
ata O
##xia O
the O
absence O
of O
pal O
##atal O
tremor O
and O
very O
mild O
white O
matter O
changes O
1 O
2 O
this O
61 O
year O
old O
man O
presented O
at O
the O
age O
of O
50 O
years O
with O
slowly O
progressive O
ga O
##it O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
his O
past O
medical O
history O
revealed O
the O
onset O
of O
static O
but O
marked O
forward O
ﬂ O
##ex O
##ion O
of O
the O
trunk O
in O
his O
ﬁ O
##rst O
decade O
but O
without O
any O
motor O
abnormalities O
until O
recently O
his O
sister O
had O
been O
diagnosed O
with O
progressive O
ce O
##re O
##bella O
##r O
ata O
##xia O
there O
were O
no O
other O
affected O
relatives O

we O
screened O
for O
several O
of O
the O
genetic O
ata O
##xia O
##s O
but O
no O
mutations O
were O
detected O
in O
the O
sc O
##a1 O
2 O
3 O
6 O
7 O
14 O
genes O
or O
in O
the O
genes O
responsible O
for O
fried O
##re O
##ich O
s O
ata O
##xia O
and O
dent O
##ator O
##ub O
##ro O
pal O
##lid O
##o O
lu O
##ys O
##ian O
at O
##rop O
##hy O
electro O
##my O
##ography O
showed O
no O
signs O
of O
ne O
##uro O
##pathy O
or O
my O
##opa O
##thy O
ss O
##ep O
was O
not O
performed O
mri O
demonstrated O
subtle O
white O
matter O
lesions O
anterior O
##ly O
in O
both O
temporal O
lobes O
as O
well O
as O
mild O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bell O
##um O
brains O
##tem O
and O
cervical O
spinal O
cord O
on O
standard O
mri O
imaging O
fig O
1a O
c O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

as O
these O
combined O
clinical O
and O
imaging O
features O
were O
suggest O
##ive O
of O
alexander O
disease O
we O
sequence O
##d O
the O
g O
##fa O
##p O
gene O
and O
found O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
c O
69 O
##2 O
##t O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
4 O
predicting O
a O
p O
le O
##u O
##23 O
##1 O
##his O
amino O
acid O
change O
this O
mutation O
was O
not O
encountered O
in O
210 O
control O
chromosomes O
several O
cases O
of O
adult O
onset O
alexander O
disease O
have O
been O
reported O
mostly O
with O
an O
onset O
in O
the O
third O
or O
fourth O
decade O
of O
life O
ph O
##eno O
##typic O
het O
##ero O
##gen O
##eit O
##y O
is O
evident O
from O
the O
variable O
presence O
of O
bulb O
##ar O
symptoms O
ce O
##re O
##bella O
##r O
signs O
pal O
##atal O
tremor O
spa O
##stic O
par O
##esis O
and O
auto O
##no O
##mic O
dysfunction O

in O
conclusion O
we O
report O
two O
si O
##bs O
with O
late O
onset O
ata O
##xia O
due O
to O
alexander O
disease O
caused O
by O
a O
novel O
g O
##fa O
##p O
mutation O
alexander O
disease O
should O
thus O
be O
considered O
in O
the O
differential O
diagnosis O
of O
otherwise O
une O
##x O
##pl O
##aine O
##d O
hereditary O
late O
onset O
161 O
##3 O
161 O
##4 O
letters O
to O
the O
editor O

f O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
and O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
with O
spa O
##ring O
of O
the O
po O
##ns O
and O
cervical O
spinal O
cord O
a O
small O
les O
##ion O
in O
the O
anterior O
part O
of O
the O
corpus O
call O
##os O
##um O
there O
are O
in O
addition O
high O
signal O
par O
##en O
##chy O
##mal O
changes O
in O
the O
posterior O
med O
##ulla O
and O
ce O
##re O
##bella O
##r O
white O
matter O
sa O
##git O
##tal O
flair O
ata O
##xia O
additional O
yet O
not O
ob O
##liga O
##te O
clinical O
features O
pal O
##atal O
tremor O
ky O
##ph O
##os O
##col O
##ios O
##is O
and O
more O
or O
less O
distinctive O
mri O
ﬁ O
##nding O
##s O
subtle O
white O
matter O
changes O
marked O
at O
##rop O
##hy O
of O
brains O
##tem O
and O
spinal O
cord O
might O
constitute O
clues O
that O
hint O
towards O
this O
spec O
##i O
##ﬁ O
##c O
diagnosis O
legends O
to O
the O
video O

segment O
1 O
mild O
ata O
##xi O
##c O
and O
bouncing O
ga O
##it O
note O
the O
ﬂ O
##ex O
##ion O
contract O
##ures O
of O
the O
knees O
di O
##f O
##ﬁ O
##cu O
##lty O
tandem O
walking O
segment O
2 O
bent O
hip O
and O
bent O
knee O
posture O
segment O
3 O
o O
##cular O
pursuit O
showing O
jerk O
##y O
pursuit O
movements O
segment O
4 O
horizontal O
sac O
##cade O
##s O
showing O
multi O
step O
sac O
##cade O
##s O
and O
o O
##cular O
d O
##ys O
##met O
##ria O
both O
h O
##yp O
##ometric O
and O
hyper O
##metric O
segment O
5 O
ce O
##re O
##bella O
##r O
d O
##ys O
##arth O
##ria O
on O
repeating O
the O
dutch O
sentence O
rode O
ron O
##de O
app O
##els O
roll O
##en O
van O
de O
z O
##old O
##ert O
##ra O
##p O
and O
on O
repeating O
pat O
##aka O
segment O
6 O
mild O
decomposition O
of O
movement O
during O
ﬁ O
##nger O
to O
nose O
testing O
catherine O
c O
s O
del O
##no O
##oz O
md O
jurgen O
h O
sc O
##hel O
##ha O
##as O
md O
phd O

bart O
p O
c O
van O
de O
warren O
##burg O
md O
phd O
department O
of O
ne O
##uro O
##logy O
ra O
##db O
##oud O
university O
ni O
##jm O
##ege O
##n O
medical O
center O
ni O
##jm O
##ege O
##n O
the O
netherlands O
e O
mail O
b O
van O
##de O
##war O
##ren O
##burg O
ne O
##uro O
um O
##c O
##n O
nl O
robert O
jan O
de O
gr O
##aa O
##f O
md O
department O
of O
ne O
##uro O
##logy O
amp O
##hia O
hospital O
bred O
##a O
o O
##ost O
##er O
##ho O
##ut O
the O
netherlands O
ga O
##j O
##ja O
s O
sal O
##omo O
##ns O
phd O
department O
of O
clinical O
chemistry O
metabolic O
unit O
vu O
university O
medical O
center O
amsterdam O
the O
netherlands O
references O
johnson O
a O
alexander O
disease O
review O
of O
the O
gene O
int O
j O
dev O
ne O
##uro O
##sc O
##i O
2002 O
20 O
39 O
##1 O
39 O
##4 O

li O
r O
johnson O
ab O
sal O
##omo O
##ns O
g O
et O
al O
g O
##fa O
##p O
mutations O
in O
infant O
##ile O
juvenile O
and O
adult O
forms O
of O
alexander O
disease O
ann O
ne O
##uro O
##l O
2005 O
57 O
310 O
326 O
howard O
k O
##l O
hall O
da O
moon O
m O
ag O
##ar O
##wal O
p O
newman O
e O
br O
##enne O
##r O
m O
adult O
onset O
alexander O
disease O
with O
progressive O
ata O
##xia O
and O
pal O
##atal O
tremor O
mo O
##v O
di O
##s O
2008 O
23 O
118 O
122 O
de O
##pre O
##z O
m O
d O
ho O
##og O
##he O
m O
miss O
##on O
jp O
et O
al O
infant O
##ile O
and O
juvenile O
presentations O
of O
alexander O
disease O
a O
report O
of O
two O
cases O
act O
##a O
ne O
##uro O
##l O
scan O
##d O
1999 O
99 O
158 O
165 O

sal O
##ma O
##gg O
##i O
a O
bot O
##tur O
##i O
a O
lamp O
##ert O
##i O
e O
et O
al O
a O
novel O
mutation O
in O
the O
g O
##fa O
##p O
gene O
in O
a O
fa O
##mi O
##lia O
##l O
adult O
onset O
alexander O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
127 O
##8 O
128 O
##0 O
sc O
##hwa O
##nk O
##haus O
j O
paris O
##i O
je O
gu O
##lled O
##ge O
wr O
chin O
l O
currie O
##r O
rd O
hereditary O
adult O
onset O
alexander O
disease O
with O
pal O
##atal O
my O
##oc O
##lon O
##us O
spa O
##stic O
para O
##par O
##esis O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
ne O
##uro O
##logy O
1995 O
45 O
226 O
##6 O
227 O
##1 O
saw O
##ais O
##hi O
##i O
y O
hat O
##az O
##awa O
j O
och O
##i O
n O
et O
al O
pet O
in O
juvenile O
alexander O
disease O
j O
ne O
##uro O
##l O
sci O
1999 O
165 O
116 O
120 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##5 O

non O
##om O
##ura O
y O
shi O
##mi O
##zu O
k O
ni O
##shi O
##moto O
h O
ho O
##so O
##e O
h O
sa O
##ka O
##guchi O
y O
mi O
##yam O
##oto O
k O
sc O
##olio O
##sis O
in O
a O
patient O
with O
alexander O
disease O
j O
spin O
di O
##s O
2002 O
15 O
261 O
264 O
thy O
##aga O
##raj O
##an O
d O
chat O
##away O
t O
li O
r O
ga O
##i O
w O
##p O
br O
##enne O
##r O
m O
dominant O
##ly O
inherited O
adult O
onset O
le O
##uk O
##od O
##yst O
##rop O
##hy O
with O
pal O
##atal O
tremor O
caused O
by O
a O
mutation O
in O
the O
g O
##lia O
##l O
ﬁ O
##bri O
##llary O
acidic O
protein O
mo O
##v O
di O
##s O
2004 O
19 O
124 O
##4 O
124 O
##8 O
ok O
##amo O
##to O
y O
mit O
##su O
##yama O
h O
hi O
##rata O
k O
ari O
##mura O
k O
os O
##ame O
m O
nak O
##agawa O
m O
auto O
##som O
##al O
dominant O
pal O
##atal O
my O
##oc O
##lon O
##us O
and O
spinal O
cord O
at O
##rop O
##hy O
j O
ne O
##uro O
##l O
sci O
2002 O
195 O
71 O
76 O

stump O
##f O
e O
mass O
##on O
h O
du O
##quette O
a O
et O
al O
adult O
alexander O
disease O
with O
auto O
##som O
##al O
transmission O
arch O
ne O
##uro O
##l O
2003 O
60 O
130 O
##7 O
132 O
##0 O
bo O
##rret O
d O
becker O
le O
alexander O
disease O
of O
astro O
##cytes O
brain O
1985 O
108 O
36 O
##7 O
385 O
cole O
g O
de O
villiers O
f O
proctor O
ns O
fr O
##eim O
##an O
i O
bill O
p O
alexander O
disease O
case O
report O
including O
his O
##top O
##ath O
##ological O
and O
electron O
microscopic O
features O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
1979 O
42 O
61 O
##9 O
62 O
##4 O

ku O
##l O
##har O
##ni O
p O
mu O
##than O
##e O
u O
##b O
tal O
##y O
ab O
jaya O
##kumar O
p O
##n O
she O
##tty O
r O
sat O
##hya O
##nar O
##ayan O
##a O
swam O
##y O
h O
pal O
##atal O
tremor O
progressive O
multiple O
cr O
##anial O
nerve O
pal O
##sies O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
a O
case O
report O
and O
review O
of O
literature O
of O
pal O
##atal O
tremor O
##s O
in O
ne O
##uro O
##de O
##gen O
##erative O
disease O
mo O
##v O
di O
##s O
1999 O
14 O
68 O
##9 O
69 O
##3 O
samuel O
m O
tor O
##un O
n O
tu O
##ite O
p O
##j O
sharpe O
ja O
lang O
ae O
pa O
##pt O
clinical O
and O
mri O
assessment O
with O
review O
of O
pal O
##atal O
tremor O
brain O
2004 O
127 O
125 O
##2 O
126 O
##8 O
storey O
e O
knight O
ma O
forrest O
sm O
gardner O
r O
##j O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
type O
20 O
ce O
##re O
##bell O
##um O
2005 O
4 O
55 O
57 O

van O
der O
kn O
##aa O
##p O
ms O
na O
##id O
##u O
s O
br O
##eit O
##er O
s O
##n O
et O
al O
alexander O
disease O
diagnosis O
with O
mri O
am O
j O
ne O
##uro O
##rad O
##iol O
2001 O
22 O
54 O
##1 O
55 O
##2 O
anti O
##his O
##tam O
##ine O
associated O
my O
##oc O
##lon O
##us O
a O
case O
report O

five O
months O
later O
the O
patient O
suffered O
a O
rec O
##ur O
##rence O
of O
my O
##o O
cl O
##onus O
but O
it O
disappeared O
within O
several O
hours O
after O
oral O
administration O
of O
0 O
5 O
mg O
cl O
##ona O
##ze O
##pa O
##m O
all O
of O
the O
patient O
s O
medications O
were O
reviewed O
again O
the O
ﬁ O
##rst O
my O
##oc O
##lon O
##us O
occurred O
after O
18 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
the O
second O
occurred O
after O
8 O
days O
use O
of O
ox O
##ato O
##mide O
120 O
mg O
day O
and O
ep O
##inas O
##tine O
20 O
mg O
day O
for O
chronic O
pr O
##uri O
##go O
the O
my O
##oc O
##lon O
##us O
has O
not O
rec O
##ur O
##red O
since O
the O
patient O
stopped O
the O
anti O
##his O
##tam O
##ines O

movement O
disorders O
vol O
23 O
no O
11 O
2008 O
161 O
##6 O
letters O
to O
the O
editor O
fig O
1 O
electro O
##oc O
##ulo O
##graphy O
and O
surface O
electro O
##my O
##ography O
rhythmic O
o O
##cular O
movement O
of O
the O
left O
l O
eye O
in O
the O
vertical O
direction O
l O
om O
vertical O
was O
sync O
##hr O
##ono O
##us O
with O
my O
##oc O
##lon O
##us O
in O
the O
l O
orb O
##icular O
##is O
o O
##cu O
##li O
rhythmic O
sync O
##hr O
##ono O
##us O
my O
##oc O
##lon O
##ic O
discharge O
##s O
were O
also O
evident O
in O
the O
l O
ﬁ O
##rst O
dorsal O
inter O
##oss O
##eous O
f O
##di O
and O
l O
abd O
##uc O
##tor O
poll O
##ici O
##s O
br O
##ev O
##is O
ap O
##b O
cal O
##ib O
##ration O
100 O
l O
##v O
in O
each O
lane O
time O
constant O
0 O
1 O
s O
in O
the O
ﬁ O
##rst O
lane O
and O
0 O
001 O
s O
in O
other O
lanes O
black O
bar O
1 O
s O

tak O
##ashi O
ir O
##io O
##ka O
md O
phd O
akira O
mach O
##ida O
md O
tak O
##anor O
##i O
yoko O
##ta O
md O
phd O
hide O
##hiro O
mi O
##zu O
##sa O
##wa O
md O
phd O
department O
of O
ne O
##uro O
##logy O
and O
neurological O
science O
graduate O
school O
tokyo O
medical O
and O
dental O
university O
tokyo O
japan O
e O
mail O
t O
ir O
##io O
##ka O
nur O
##o O
t O
##md O
ac O
jp O
references O
ca O
##vine O
##ss O
j O
##n O
brown O
p O
my O
##oc O
##lon O
##us O
current O
concepts O
and O
recent O
advances O
lance O
##t O
ne O
##uro O
##l O
2004 O
3 O
59 O
##8 O
60 O
##7 O
gordon O
m O
##f O
toxin O
and O
drug O
induced O
my O
##oc O
##lon O
##us O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##l O
og O
##y O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
49 O
76 O

sc O
##hip O
##ior O
pg O
an O
unusual O
case O
of O
anti O
##his O
##tam O
##ine O
into O
##xi O
##cation O
j O
pediatric O
##s O
1967 O
71 O
58 O
##9 O
59 O
##1 O
hash O
##imo O
##to O
s O
ka O
##wa O
##mura O
j O
yamamoto O
t O
et O
al O
transient O
my O
##oc O
##lon O
##ic O
state O
with O
as O
##ter O
##ix O
##is O
in O
elderly O
patients O
a O
new O
syndrome O
j O
ne O
##uro O
##l O
sci O
1992 O
109 O
132 O
139 O
richards O
d O
##m O
bro O
##g O
##den O
rn O
heel O
rc O
sp O
##ei O
##ght O
t O
##m O
avery O
gs O
ox O
##ato O
##mide O
a O
review O
of O
its O
ph O
##arm O
##aco O
##dy O
##nami O
##c O
properties O
and O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
drugs O
1984 O
27 O
210 O
231 O
raj O
##put O
a O
bae O
##rg O
k O
ce O
##ti O
##riz O
##ine O
induced O
d O
##yst O
##onic O
movements O
ne O
##uro O
##logy O
2006 O
66 O
143 O
144 O

caste O
##els O
van O
da O
##ele O
m O
egg O
##er O
##mont O
e O
casa O
##er O
p O
van O
de O
cass O
##eye O
w O
de O
bo O
##eck O
k O
acute O
d O
##yst O
##onic O
reactions O
and O
long O
lasting O
impaired O
consciousness O
associated O
with O
ox O
##ato O
##mide O
in O
children O
lance O
##t O
1986 O
1 O
120 O
##4 O
120 O
##5 O
welsh O
jp O
pl O
##aca O
##nton O
##aki O
##s O
d O
##g O
wars O
##ets O
##ky O
si O
marquez O
r O
##g O
bernstein O
l O
ai O
##cher O
sa O
the O
ser O
##oton O
##in O
hypothesis O
of O
my O
##oc O
##lon O
##us O
from O
the O
perspective O
of O
ne O
##uron O
##al O
rhythmic O
##ity O
in O
fa O
##hn O
s O
fr O
##uch O
##t O
s O
##j O
halle O
##tt O
m O
tr O
##uo O
##ng O
dd O
editors O
advances O
in O
ne O
##uro O
##logy O
vol O
89 O
my O
##oc O
##lon O
##us O
and O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
307 O
329 O

do O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
differ O
by O
route O
of O
environmental O
pre O
##ci O
##pit O
##ant O
bra O
##ak O
and O
colleagues O
followed O
their O
groundbreaking O
staging O
class O
##i O
##ﬁ O
##cation O
for O
the O
brain O
ne O
##uro O
##path O
##ology O
of O
alzheimer O
s O
disease O
with O
the O
more O
recent O
one O
for O
sporadic O
parkinson O
s O
disease O
pd O
1 O
their O
new O
pd O
staging O
system O
has O
revolution O
##ized O
thinking O
about O
the O
topographic O
sequence O
of O
ne O
##uro O
##path O
##ological O
changes O
as O
the O
illness O
progresses O
generally O
in O
a O
ca O
##uda O
##l O
ro O
##stra O
##l O
direction O
from O
lower O
brains O
##tem O
to O
neo O
##cor O
##te O
##x O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##23 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##7 O

roger O
ku O
##rl O
##an O
md O
department O
of O
ne O
##uro O
##logy O
university O
of O
rochester O
school O
of O
medicine O
rochester O
new O
york O
usa O
references O
bra O
##ak O
h O
del O
tre O
##dic O
##i O
k O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
211 O
del O
tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
##e O
bra O
##ak O
h O
where O
does O
parkinson O
disease O
pathology O
begin O
in O
the O
brain O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2002 O
61 O
41 O
##3 O
42 O
##6 O

wa O
##ka O
##bay O
##ashi O
k O
takahashi O
h O
oh O
##ama O
e O
take O
##da O
s O
ik O
##uta O
f O
lew O
##y O
bodies O
in O
the O
vis O
##cera O
##l O
auto O
##no O
##mic O
nervous O
system O
in O
parkinson O
s O
disease O
in O
ik O
##uta O
f O
editor O
ne O
##uro O
##path O
##ology O
in O
brain O
research O
amsterdam O
london O
tokyo O
excerpt O
##a O
med O
##ica O
1991 O
p O
133 O
141 O
bra O
##ak O
h O
de O
vo O
##s O
rai O
bo O
##hl O
jr O
del O
tre O
##dic O
##i O
k O
gas O
##tric O
alpha O
##sy O
##nu O
##cle O
##in O
im O
##mun O
##ore O
##active O
inclusion O
##s O
in O
mei O
##ss O
##ner O
s O
and O
au O
##er O
##bach O
s O
pl O
##ex O
##uses O
in O
cases O
staged O
for O
parkinson O
s O
disease O
related O
brain O
pathology O
ne O
##uro O
##sc O
##i O
let O
##t O
2006 O
39 O
##6 O
67 O
72 O

ming O
##uez O
caste O
##llan O
##os O
a O
char O
##orro O
ce O
es O
##cam O
##illa O
sevilla O
f O
et O
al O
do O
a O
syn O
##uc O
##lein O
aggregate O
##s O
in O
auto O
##no O
##mic O
pl O
##ex O
##uses O
pre O
##date O
lew O
##y O
body O
disorders O
a O
co O
##hort O
study O
ne O
##uro O
##logy O
2007 O
68 O
2012 O
2018 O
bra O
##ak O
h O
sas O
##tre O
m O
bo O
##hl O
jr O
##e O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
parkinson O
s O
disease O
lesions O
in O
dorsal O
horn O
layer O
i O
involvement O
of O
para O
##sy O
##mp O
##ath O
##etic O
and O
sympathetic O
pre O
##and O
post O
##gang O
##lion O
##ic O
neurons O
act O
##a O
ne O
##uro O
##path O
##ol O
be O
##r O
2007 O
113 O
421 O
42 O
##9 O
obe O
##rdo O
##¨ O
##rst O
##er O
g O
sharp O
z O
at O
##ud O
##ore O
##i O
v O
et O
al O
trans O
##lo O
##cation O
of O
inhaled O
ultra O
##ﬁ O
##ne O
particles O
to O
the O
brain O
in O
##hal O
toxic O
##ol O
2004 O
16 O
43 O
##7 O
44 O
##5 O

rat O
##ner O
m O
##h O
feldman O
r O
##g O
environmental O
toxin O
##s O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
51 O
62 O
st O
##rick O
##land O
d O
rural O
environment O
and O
parkinson O
s O
disease O
in O
e O
##bad O
##i O
m O
p O
##fe O
##iff O
##er O
rf O
editors O
parkinson O
s O
disease O
boca O
rat O
##on O
fl O
cr O
##c O
press O
2005 O
p O
63 O
71 O
bra O
##ak O
h O
bo O
##hl O
jr O
mu O
##¨ O
##ller O
cm O
ru O
##¨ O
##b O
u O
de O
vo O
##s O
rai O
del O
tre O
##dic O
##i O
k O
stanley O
fa O
##hn O
lecture O
2005 O
the O
staging O
procedure O
for O
the O
inclusion O
body O
pathology O
associated O
with O
sporadic O
parkinson O
s O
disease O
rec O
##ons O
##ider O
##ed O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
204 O
##2 O
205 O
##1 O

klein O
c O
sc O
##hl O
##oss O
##mac O
##her O
mg O
parkinson O
s O
disease O
10 O
years O
after O
its O
genetic O
revolution O
multiple O
clues O
to O
a O
complex O
disorder O
ne O
##uro O
##logy O
2007 O
69 O
209 O
##3 O
210 O
##4 O
mc O
##kei O
##th O
i O
##g O
gala O
##sko O
d O
ko O
##saka O
k O
consensus O
guidelines O
for O
the O
clinical O
and O
path O
##olo O
##gic O
diagnosis O
of O
dementia O
with O
lew O
##y O
bodies O
dl O
##b O
report O
of O
the O
consortium O
on O
dl O
##b O
international O
workshop O
ne O
##uro O
##logy O
1996 O
47 O
111 O
##3 O
112 O
##4 O
richard O
i O
##h O
pa O
##p O
##ka O
m O
rub O
##io O
a O
et O
al O
parkinson O
s O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
one O
disease O
or O
two O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
116 O
##1 O
116 O
##5 O
d O
##yst O
##onia O
associated O
with O
hyper O
##int O
##ense O
basal O
gang O
##lia O
lesions O
on O
t O
##1 O
weighted O
brain O
mri O
video O

the O
initial O
ct O
was O
regular O
but O
the O
t O
##1 O
weighted O
mri O
without O
contrast O
demonstrated O
bilateral O
uniform O
area O
wide O
hyper O
##in O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##28 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
1618 O
letters O
to O
the O
editor O
fig O
1 O
a O
photograph O
of O
patient O
showing O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O

together O
the O
reasons O
for O
the O
initial O
t O
##1 O
hyper O
##int O
##ens O
##ities O
remain O
elusive O
theoretically O
besides O
intra O
##cellular O
met O
##hem O
##og O
##lo O
##bin O
in O
hem O
##or O
##rh O
##agi O
##c O
tissue O
and O
cal O
##ci O
##ﬁ O
##cation O
##s O
para O
##ma O
##gne O
##tic O
compounds O
including O
metal O
ions O
e O
g O
iron O
manga O
##nese O
and O
copper O
molecular O
oxygen O
or O
free O
radicals O
could O
lead O
to O
these O
legend O
to O
the O
full O
video O
time O
content O
00 O
00 O
00 O
00 O
00 O
15 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O
00 O
00 O
16 O
00 O
00 O
28 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O
forehead O
d O
##yst O
##onia O
00 O
00 O
29 O
00 O
00 O
37 O
listing O
the O
days O
of O
the O
week O
from O
monday O

to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O
00 O
00 O
38 O
00 O
00 O
47 O
patient O
closing O
and O
opening O
his O
eyes O
00 O
00 O
48 O
00 O
01 O
09 O
facial O
inner O
##vation O
mouth O
tongue O
and O
forehead O
00 O
01 O
10 O
00 O
01 O
31 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O
of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
01 O
32 O
00 O
02 O
01 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O
and O
pro O
##nation O
su O
##pina O
##tion O
test O
legend O
to O
the O
preview O
video O
time O
content O
00 O
00 O
00 O
00 O
00 O
03 O
patient O
sitting O
on O
chair O
brady O
##kin O
##es O
##ia O
and O
h O
##yp O
##omi O
##mia O
00 O
00 O
04 O
00 O
00 O
07 O
h O
##yp O
##omi O
##mia O
and O
reduced O
eye O
##lid O
movement O

forehead O
d O
##yst O
##onia O
00 O
00 O
08 O
00 O
00 O
15 O
listing O
the O
days O
of O
the O
week O
from O
monday O
to O
sunday O
d O
##ys O
##arth O
##rop O
##hon O
##ia O
and O
oro O
##man O
##di O
##bular O
d O
##yst O
##onia O
2 O
weeks O
after O
per O
##ior O
##al O
bot O
##ulin O
##um O
toxin O
type O
a O
injection O
##s O
00 O
00 O
16 O
00 O
00 O
33 O
facial O
inner O
##vation O
eyes O
mouth O
tongue O
and O
forehead O
00 O
00 O
34 O
00 O
00 O
46 O
patient O
putting O
his O
ﬁ O
##nger O
##s O
on O
nose O
d O
##yst O
##onia O
of O
the O
middle O
ﬁ O
##nger O
of O
the O
left O
hand O
00 O
00 O
47 O
00 O
00 O
59 O
hand O
##mo O
##ving O
brady O
##kin O
##etic O
hand O
gripping O
and O
pro O
##nation O
su O
##pina O
##tion O
test O

mri O
changes O
in O
our O
case O
we O
found O
no O
evidence O
of O
hem O
##or O
##rh O
##agi O
##c O
changes O
or O
cal O
##ci O
##ﬁ O
##cation O
##s O
so O
that O
reported O
t O
##1 O
weighted O
mri O
hyper O
##int O
##ens O
##ities O
may O
hypothetical O
##ly O
result O
from O
h O
##yp O
##ox O
##ic O
disruption O
of O
the O
cell O
mitochondrial O
heavy O
metal O
metabolism O
martin O
wo O
##lz O
md O
susan O
##n O
jung O
##han O
##ns O
md O
matthias O
lo O
##¨ O
##hl O
##e O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O
dresden O
germany O
ru O
##¨ O
##di O
##ger O
von O
ku O
##mmer O
md O
department O
of O
ne O
##uro O
##rad O
##iology O
technical O
university O
dresden O
dresden O
germany O
alexander O
st O
##or O
##ch O
md O
department O
of O
ne O
##uro O
##logy O
technical O
university O
dresden O
dresden O
germany O

e O
mail O
alexander O
st O
##or O
##ch O
ne O
##uro O
med O
tu O
dresden O
de O
references O
lin O
jj O
chang O
mk O
hem O
##iba O
##llis O
##m O
hem O
##ich O
##ore O
##a O
and O
non O
ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1994 O
57 O
74 O
##8 O
750 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
161 O
##9 O
oh O
sh O
lee O
ky O
im O
j O
##h O
lee O
ms O
cho O
##rea O
associated O
with O
non O
##ke O
##to O
##tic O
hyper O
##gly O
##ce O
##mia O
and O
hyper O
##int O
##ens O
##ity O
basal O
gang O
##lia O
les O
##ion O
on O
t O
##1 O
weighted O
brain O
mri O
study O
a O
meta O
analysis O
of O
53 O
cases O
including O
four O
present O
cases O
j O
ne O
##uro O
##l O
sci O
2002 O
200 O
57 O
62 O

fuji O
##oka O
m O
hiram O
##ats O
##u O
k O
sa O
##ka O
##ki O
t O
sa O
##ka O
##guchi O
s O
is O
##hi O
##i O
y O
spec O
##i O
##ﬁ O
##c O
changes O
in O
human O
brain O
after O
h O
##yp O
##og O
##ly O
##ce O
##mic O
injury O
stroke O
1997 O
28 O
58 O
##4 O
58 O
##7 O
k O
##rie O
##ger O
d O
k O
##rie O
##ger O
s O
jan O
##sen O
o O
gas O
##s O
p O
the O
##il O
##mann O
l O
li O
##cht O
##neck O
##er O
h O
manga O
##nese O
and O
chronic O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
lance O
##t O
1995 O
34 O
##6 O
270 O
274 O
oh O
##ara O
s O
nak O
##agawa O
s O
tab O
##ata O
k O
hash O
##imo O
##to O
t O
hem O
##iba O
##llis O
##m O
with O
hyper O
##gly O
##ce O
##mia O
and O
st O
##ria O
##tal O
t O
##1 O
mri O
hyper O
##int O
##ens O
##ity O
an O
autopsy O
report O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
521 O
525 O
shan O
de O
ho O
d O
##m O
chang O
c O
pan O
hc O
ten O
##g O
mm O
hem O
##ich O
##ore O
##ah O
##emi O
##ball O
##ism O
an O
explanation O
for O
mr O
signal O
changes O
am O
j O
ne O
##uro O
##rad O
##iol O
1998 O
19 O
86 O
##3 O
870 O

fuji O
##oka O
m O
tao O
##ka O
t O
mats O
##uo O
y O
hiram O
##ats O
##u O
ki O
sa O
##ka O
##ki O
t O
novel O
brain O
is O
##che O
##mic O
change O
on O
mri O
delayed O
is O
##che O
##mic O
hyper O
##int O
##ens O
##ity O
on O
t O
##1 O
weighted O
images O
and O
selective O
ne O
##uron O
##al O
death O
in O
the O
ca O
##ud O
##op O
##uta O
##men O
of O
rats O
after O
brief O
focal O
is O
##che O
##mia O
stroke O
1999 O
30 O
104 O
##3 O
104 O
##6 O
successful O
treatment O
of O
the O
mei O
##ge O
syndrome O
with O
oral O
z O
##ol O
##pid O
##em O
mono O
##therapy O
video O

z O
##ol O
##pid O
##em O
is O
an O
im O
##ida O
##zo O
##py O
##rid O
##ine O
ago O
##nist O
with O
a O
high O
af O
##ﬁ O
##nity O
for O
the O
benz O
##od O
##ia O
##ze O
##pine O
a1 O
subunit O
site O
1 O
it O
has O
been O
reported O
that O
this O
drug O
improves O
motor O
symptoms O
in O
patients O
with O
parkinson O
s O
disease O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
and O
xl O
##ink O
##ed O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
2 O
5 O
recently O
z O
##ol O
##pid O
##em O
has O
been O
shown O
to O
be O
effective O
in O
the O
treatment O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
the O
mei O
##ge O
syndrome O
in O
combination O
with O
bot O
##ulin O
##um O
toxin O
a O
6 O
here O
we O
report O
a O
patient O
with O
mei O
##ge O
syndrome O
non O
##res O
##pon O
##sive O
to O
bot O
##ulin O
##um O
toxin O
a O
but O
successfully O
treated O
with O
oral O
z O
##ol O
##pid O
##em O
administration O

additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##9 O
no O
exposure O
to O
ne O
##uro O
##le O
##ptic O
medications O
there O
was O
no O
family O
history O
of O
movement O
disorders O

in O
conclusion O
oral O
z O
##ol O
##pid O
##em O
may O
be O
a O
useful O
ph O
##arm O
##aco O
##logic O
alternative O
for O
patients O
with O
mei O
##ge O
syndrome O
who O
do O
not O
respond O
to O
bot O
##ulin O
##um O
toxin O
treatment O
however O
special O
precautions O
are O
necessary O
for O
long O
term O
management O
with O
this O
drug O
because O
of O
the O
risk O
of O
z O
##ol O
##pid O
##em O
abuse O
especially O
in O
patients O
with O
a O
previous O
history O
of O
substance O
abuse O
15 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
1620 O
letters O
to O
the O
editor O
legends O
to O
the O
video O

segment O
1 O
the O
patient O
shows O
a O
mixture O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
visual O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
facial O
grim O
##acing O
these O
movements O
were O
partially O
relieved O
by O
holding O
a O
pencil O
between O
the O
teeth O
segment O
2 O
one O
hour O
after O
oral O
z O
##ol O
##pid O
##em O
administration O
the O
symptoms O
were O
completely O
resolved O
in O
the O
resting O
state O
while O
showing O
his O
teeth O
as O
well O
as O
grim O
##acing O
and O
whistling O
jae O
young O
an O
md O
joo O
##ng O
seo O
##k O
kim O
md O
ye O
##ong O
in O
kim O
md O
kwan O
##g O
soo O
lee O
md O
department O
of O
ne O
##uro O
##logy O
the O
catholic O
university O
of O
korea O
seoul O
south O
korea O
e O
mail O
ne O
##uron O
##et O
catholic O
ac O
k O
##r O
references O

holm O
k O
##j O
goa O
k O
##l O
z O
##ol O
##pid O
##em O
an O
update O
of O
its O
ph O
##arm O
##aco O
##logy O
therapeutic O
e O
##f O
##ﬁ O
##ca O
##cy O
and O
to O
##ler O
##ability O
in O
the O
treatment O
of O
ins O
##om O
##nia O
drugs O
2000 O
59 O
86 O
##5 O
88 O
##9 O
daniel O
##e O
a O
alba O
##nese O
a O
gain O
##otti O
g O
gregor O
##i O
b O
bart O
##olo O
##meo O
p O
z O
##ol O
##pid O
##em O
in O
parkinson O
s O
disease O
lance O
##t O
1997 O
34 O
##9 O
122 O
##2 O
122 O
##3 O
daniel O
##e O
a O
mor O
##o O
e O
bent O
##ivo O
##glio O
ar O
z O
##ol O
##pid O
##em O
in O
progressive O
su O
##pr O
##anu O
##cle O
##ar O
pal O
##sy O
n O
eng O
##l O
j O
med O
1999 O
341 O
54 O
##3 O
54 O
##4 O
evident O
##e O
v O
##gh O
z O
##ol O
##pid O
##em O
improves O
d O
##yst O
##onia O
in O
lu O
##bag O
or O
x O
linked O
d O
##yst O
##onia O
parkinson O
##ism O
syndrome O
ne O
##uro O
##logy O
2002 O
58 O
66 O
##2 O
66 O
##3 O

ru O
##zic O
##ka O
e O
roth O
j O
je O
##ch O
r O
bus O
##ek O
p O
sub O
##hy O
##p O
##not O
##ic O
doses O
of O
z O
##ol O
##pid O
##em O
oppose O
do O
##pa O
##mine O
##rg O
##ic O
induced O
d O
##ys O
##kin O
##es O
##ia O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
73 O
##4 O
73 O
##5 O
garrett O
##o O
ns O
bu O
##eri O
ja O
rey O
rd O
ara O
##ka O
##ki O
t O
nano O
g O
##v O
man O
##cus O
##o O
m O
improvement O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
with O
z O
##ol O
##pid O
##em O
mo O
##v O
di O
##sor O
##d O
2004 O
19 O
96 O
##7 O
96 O
##8 O
jan O
##kovic O
j O
clinical O
features O
differential O
diagnosis O
and O
pathogen O
##esis O
of O
b O
##le O
##pha O
##ros O
##pas O
##m O
and O
cr O
##anial O
cervical O
d O
##yst O
##onia O
in O
bosnia O
##k O
l O
editor O
b O
##le O
##pha O
##ros O
##pas O
##m O
advances O
in O
op O
##ht O
##hal O
##mic O
plastic O
rec O
##ons O
##truct O
##ive O
surgery O
new O
york O
per O
##gam O
##on O
1985 O
p O
67 O
82 O

horn O
s O
come O
##lla O
c O
treatment O
of O
d O
##yst O
##onia O
in O
jan O
##kovic O
j O
to O
##los O
##a O
e O
editors O
parkinson O
s O
disease O
and O
movement O
disorders O
philadelphia O
lip O
##pin O
##cott O
williams O
wilkins O
2002 O
p O
35 O
##8 O
36 O
##4 O
ni O
##dda O
##m O
r O
dubois O
a O
sc O
##att O
##on O
b O
ar O
##bill O
##a O
s O
lange O
##r O
s O
##z O
auto O
##rad O
##io O
##graphic O
local O
##ization O
of O
3 O
##h O
z O
##ol O
##pid O
##em O
binding O
sites O
in O
the O
rat O
cn O
##s O
comparison O
with O
the O
distribution O
of O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
binding O
sites O
j O
ne O
##uro O
##che O
##m O
1987 O
49 O
89 O
##0 O
89 O
##9 O

dennis O
t O
dubois O
a O
ben O
##avi O
##des O
j O
sc O
##att O
##on O
b O
distribution O
of O
central O
omega O
1 O
benz O
##od O
##ia O
##ze O
##pine O
##1 O
and O
omega O
2 O
benz O
##od O
##ia O
##ze O
##pine O
##2 O
receptor O
sub O
##type O
##s O
in O
the O
monkey O
and O
human O
brain O
an O
auto O
##rad O
##io O
##graphic O
study O
with O
3 O
##h O
ﬂ O
##uni O
##tra O
##ze O
##pa O
##m O
and O
the O
omega O
1 O
selective O
ligand O
3 O
##h O
z O
##ol O
##pid O
##em O
j O
ph O
##arm O
##aco O
##l O
ex O
##p O
the O
##r O
1988 O
247 O
309 O
322 O
chen O
l O
xi O
##e O
j O
##x O
fun O
##g O
ks O
yun O
##g O
w O
##h O
z O
##ol O
##pid O
##em O
mod O
##ulates O
ga O
##ba O
##a O
receptor O
function O
in O
sub O
##thal O
##ami O
##c O
nucleus O
ne O
##uro O
##sc O
##i O
res O
2007 O
58 O
77 O
85 O
chen O
l O
sa O
##vio O
chang O
c O
yun O
##g O
w O
##h O
electro O
##phy O
##sio O
##logical O
and O
behavioral O
effects O
of O
z O
##ol O
##pid O
##em O
in O
rat O
g O
##lo O
##bus O
pal O
##lid O
##us O
ex O
##p O
ne O
##uro O
##l O
2004 O
186 O
212 O
220 O

pei O
##x O
##oto O
m O
##f O
ara O
##uj O
##o O
np O
silva O
r O
##h O
et O
al O
effects O
of O
ga O
##ba O
##er O
##gic O
drugs O
on O
res O
##er O
##pine O
induced O
oral O
d O
##ys O
##kin O
##es O
##ia O
be O
##ha O
##v O
brain O
res O
2005 O
160 O
51 O
59 O
ga O
##rc O
##´ O
##ı O
##a O
santos O
g O
herrera O
f O
mart O
##´ O
##ı O
##n O
v O
et O
al O
anti O
##ox O
##ida O
##nt O
activity O
and O
ne O
##uro O
##pro O
##tec O
##tive O
effects O
of O
z O
##ol O
##pid O
##em O
and O
several O
synthesis O
intermediate O
##s O
free O
ra O
##dic O
res O
2004 O
38 O
128 O
##9 O
129 O
##9 O
mad O
##rak O
l O
##n O
rosenberg O
m O
z O
##ol O
##pid O
##em O
abuse O
am O
j O
psychiatry O
2001 O
158 O
133 O
##0 O
133 O
##1 O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
induced O
by O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O

chronic O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
is O
effective O
in O
severe O
parkinson O
s O
disease O
pd O
1 O
however O
a O
few O
side O
effects O
especially O
o O
##cu O
##lom O
##oto O
##r O
manifestation O
##s O
have O
been O
reported O
2 O
understanding O
their O
mechanism O
may O
help O
to O
better O
de O
##ﬁ O
##ne O
functional O
anatomy O
of O
this O
region O
a O
66 O
year O
old O
woman O
was O
treated O
by O
bilateral O
st O
##n O
stimulation O
for O
pd O
a O
40 O
decrease O
of O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
followed O
st O
##n O
stimulation O
alone O
with O
the O
following O
parameters O
left O
contact O
2 O
3 O
5 O
v O
60 O
l O
second O
160 O
hz O
right O
contact O
7 O
3 O
5 O
v O
90 O
l O
second O
160 O
hz O

with O
right O
stimulation O
on O
contact O
6 O
3 O
5 O
v O
a O
counter O
##cl O
##ock O
##wise O
tn O
was O
found O
except O
for O
lower O
gain O
of O
vo O
##r O
eye O
movements O
were O
not O
mod O
##i O
##ﬁ O
##ed O
table O
2 O
vertical O
sac O
##cade O
##s O
could O
not O
be O
correctly O
recorded O
the O
sk O
##ew O
deviation O
increased O
sv O
##v O
slightly O
decreased O
12 O
04 O
##8 O
with O
left O
stimulation O
on O
contact O
1 O
4 O
5 O
v O
we O
noticed O
a O
clockwise O
tn O
ve O
##lo O
##cit O
##ies O
of O
downward O
sac O
##cade O
##s O
downward O
smooth O
pursuit O
gain O
and O
horizontal O
pen O
##du O
##lar O
vo O
##r O
gain O
decreased O
table O
2 O
the O
right O
sided O
sk O
##ew O
deviation O
decreased O
sv O
##v O
normal O
##ized O
10 O
48 O

previously O
reported O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
of O
st O
##n O
stimulation O
consisted O
of O
eye O
##lid O
apr O
##ax O
##ia O
bin O
##oc O
##ular O
dip O
##lo O
##pia O
my O
##osis O
my O
##dr O
##ias O
##is O
and O
contra O
##vers O
##ive O
eye O
deviation O
1 O
2 O
4 O
14 O
tn O
has O
been O
observed O
during O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
matter O
15 O
but O
not O
during O
st O
##n O
stimulation O
st O
##n O
is O
involved O
in O
sac O
##cade O
##s O
and O
smooth O
pursuit O
in O
primate O
##s O
and O
humans O
##16 O
23 O
and O
its O
stimulation O
could O
explain O
some O
o O
##cular O
motor O
side O
effects O
such O
as O
contra O
##vers O
##ive O
eye O
deviation O
10 O
however O
it O
is O
unlikely O
that O
st O
##n O
could O
have O
induced O
the O
tn O
as O
it O
was O
not O
observed O
at O
low O
intensity O
of O
stimulation O

published O
online O
10 O
july O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##51 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letter O
to O
the O
editor O
1621 O
table O
1 O
stimulation O
parameters O
and O
normal O
complaints O
v O
side O
effects O
contacts O
and O
voltage O
##s O
used O
for O
chronicle O
bilateral O
stimulation O
lc O
2 O
3 O
5 O
no O
visual O
complaint O
rc O
7 O
3 O
5 O
no O
visual O
complaint O
voltage O
##s O
giving O
a O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
lc O
rc O
7 O
3 O
5 O
slight O
cc O
##w O
tn O
6 O
3 O
5 O
marked O
cc O
##w O
tn O
nausea O
##s O
vertigo O
5 O
3 O
5 O
cc O
##w O
tn O
vertigo O
4 O
3 O
5 O
cc O
##w O
tn O
nausea O
##s O
vertigo O

lc O
left O
contacts O
0 O
is O
the O
deepest O
and O
3 O
is O
the O
upper O
rc O
right O
contacts O
4 O
is O
the O
deepest O
and O
7 O
is O
the O
upper O
v O
intensity O
of O
the O
stimulation O
expressed O
in O
vol O
##ts O
tn O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
cw O
clockwise O
cc O
##w O
counter O
##cl O
##ock O
##wise O
contacts O
on O
witch O
the O
ny O
##sta O
##gm O
##us O
was O
the O
more O
marked O
and O
used O
for O
the O
eyes O
movement O
recordings O
and O
as O
the O
contacts O
were O
medial O
to O
the O
st O
##n O
o O
##cu O
##lom O
##oto O
##r O
side O
effects O
can O
also O
be O
explained O
by O
intra O
##fa O
##sc O
##icular O
o O
##cu O
##lom O
##oto O
##r O
nerve O
stimulation O
but O
this O
could O
not O
explain O
bin O
##oc O
##ular O
ny O
##sta O
##gm O
##us O
24 O

1 O
14 O
5 O
right O
side O
4 O
9 O
6 O
5 O
7 O
5 O
9 O
5 O
5 O
8 O
6 O
10 O
3 O
9 O
5 O
7 O
11 O
1 O
11 O
rn O
red O
nucleus O
s O
##n O
sub O
##stan O
##tia O
ni O
##gra O
st O
##n O
sub O
##thal O
##ami O
##c O
nucleus O

according O
to O
the O
close O
relationship O
of O
ic O
rim O
##lf O
and O
stimulation O
contacts O
the O
contra O
##lateral O
tn O
reported O
here O
could O
be O
due O
to O
an O
activation O
of O
the O
ic O
or O
an O
inhibition O
of O
the O
rim O
##lf O
or O
both O
either O
due O
to O
a O
direct O
nucleus O
or O
an O
indirect O
in O
out O
connecting O
pathways O
modulation O
alice O
po O
##isson O
md O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##logie O
c O
lyon O
france O
caroline O
til O
##ike O
##te O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
unite O
##´ O
de O
ne O
##uro O
op O
##hta O
##lm O
##olo O
##gie O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O

if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O
lyon O
france O
patrick O
mer O
##tens O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##chi O
##ru O
##rg O
##ie O
a O
lyon O
france O
ye O
##ln O
##ik O
md O
phd O
ins O
##er O
##m O
u O
67 O
##9 O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
table O
2 O
eye O
movements O
recording O
with O
2d O
video O
o O
##cu O
##log O
##raphy O
200 O
hz O
frequency O
vis O
##uo O
##200 O
syn O
##ap O
##sy O
##s O
france O
bilateral O
stimulation O
no O
stimulation O

velocity O
ve O
##l O
and O
gain O
of O
horizontal O
158 O
and O
vertical O
108 O
visually O
guided O
sac O
##cade O
##s O
gain O
of O
smooth O
pursuit O
0 O
15 O
hz O
308 O
horizontal O
and O
208 O
vertical O
pen O
##du O
##lar O
vest O
##ib O
##ulo O
o O
##cular O
re O
##ﬂ O
##ex O
vo O
##r O
0 O
25 O
hz O
maximum O
amplitude O
of O
45 O
##8 O
and O
maximal O
velocity O
of O
head O
shaking O
ny O
##sta O
##gm O
##us O
hs O
##n O
mean O
frequency O
2 O
hz O
mean O
amplitude O
258 O
in O
horizontal O
and O
vertical O
directions O
were O
recorded O
letter O
to O
the O
editor O
1623 O
eric O
bard O
##ine O
##t O
phd O
cn O
##rs O
up O
##r O
640 O
up O
##mc O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O
centre O
de O
ne O
##uro O
image O
##rie O
de O
rec O
##her O
##che O
up O
##mc O
de O
la O
pit O
##ie O
##´ O
sal O
##pet O
##rie O
re O
paris O
france O

emmanuel O
bro O
##uss O
##oll O
##e O
md O
phd O
ste O
##´ O
##pha O
##ne O
tho O
##bo O
##is O
md O
phd O
universite O
##´ O
lyon O
i O
hospice O
##s O
civil O
##s O
de O
lyon O
ne O
##uro O
##log O
##ique O
pierre O
we O
##rth O
##eim O
##er O
ne O
##uro O
##logie O
c O
lyon O
france O
ins O
##er O
##m O
um O
##r O
s O
86 O
##4 O
if O
##r O
##19 O
institut O
fe O
##´ O
##de O
##´ O
##rat O
##if O
des O
neuroscience O
##s O
de O
lyon O
lyon O
france O
email O
stephane O
tho O
##bo O
##is O
chu O
lyon O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
promoted O
by O
the O
hospice O
##s O
civil O
##s O
de O
lyon O
project O
no O
hc O
##l O
p O
2002 O
303 O
references O
k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O

klein O
##er O
fis O
##man O
g O
her O
##zog O
j O
fis O
##man O
d O
##n O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
deep O
brain O
stimulation O
summary O
and O
meta O
analysis O
of O
outcomes O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
su O
##pp O
##l O
14 O
s O
##29 O
##0 O
s O
##30 O
##4 O
ye O
##ln O
##ik O
j O
bard O
##ine O
##t O
e O
dorm O
##ont O
d O
et O
al O
a O
three O
dimensional O
his O
##to O
##logical O
and O
def O
##or O
##mable O
atlas O
of O
the O
human O
basal O
gang O
##lia O
i O
atlas O
construction O
based O
on O
im O
##mun O
##oh O
##isto O
##chemical O
and O
mri O
data O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
61 O
##8 O
63 O
##8 O

ben O
##abi O
##d O
al O
ko O
##ud O
##sie O
a O
ben O
##az O
##zo O
##uz O
a O
et O
al O
deep O
brain O
stimulation O
of O
the O
corpus O
lu O
##ys O
##i O
sub O
##thal O
##ami O
##c O
nucleus O
and O
other O
targets O
in O
parkinson O
s O
disease O
extension O
to O
new O
indications O
such O
as O
d O
##yst O
##onia O
and O
ep O
##ile O
##psy O
j O
ne O
##uro O
##l O
2001 O
248 O
su O
##pp O
##l O
3 O
iii O
##37 O
iii O
##47 O
bro O
##gg O
##i O
g O
franz O
##ini O
a O
fe O
##rro O
##li O
p O
et O
al O
effect O
of O
bilateral O
sub O
##thal O
##ami O
##c O
electrical O
stimulation O
in O
parkinson O
s O
disease O
sur O
##g O
ne O
##uro O
##l O
2001 O
56 O
89 O
94 O
discussion O
94 O
86 O
her O
##zog O
j O
vol O
##km O
##ann O
j O
k O
##rac O
##k O
p O
et O
al O
two O
year O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2003 O
18 O
133 O
##2 O
133 O
##7 O

ian O
##se O
##k O
r O
rosen O
##feld O
j O
##v O
hu O
##x O
##ham O
fe O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
med O
j O
aus O
##t O
2002 O
177 O
142 O
146 O
os O
##ter O
##gaard O
k O
sun O
##de O
n O
dupont O
e O
effects O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
patients O
with O
severe O
parkinson O
s O
disease O
and O
motor O
ﬂ O
##uc O
##tua O
##tions O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
69 O
##3 O
700 O
rom O
##ito O
l O
##m O
sc O
##er O
##rat O
##i O
m O
con O
##tar O
##ino O
m O
##f O
bent O
##ivo O
##glio O
ar O
ton O
##ali O
p O
alba O
##nese O
a O
long O
term O
follow O
up O
of O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
ne O
##uro O
##logy O
2002 O
58 O
154 O
##6 O
1550 O

saul O
##eau O
p O
poll O
##ak O
p O
k O
##rac O
##k O
p O
et O
al O
contra O
##vers O
##ive O
eye O
deviation O
during O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
region O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
1810 O
1813 O
tam O
##ma O
f O
ramp O
##ini O
p O
e O
##gi O
##di O
m O
et O
al O
deep O
brain O
stimulation O
for O
parkinson O
s O
disease O
the O
experience O
of O
the O
pol O
##ic O
##lini O
##co O
san O
paolo O
group O
in O
milan O
ne O
##uro O
##l O
sci O
2003 O
24 O
su O
##pp O
##l O
1 O
s O
##41 O
s O
##42 O
ta O
##vel O
##la O
a O
berg O
##ama O
##sco O
b O
bo O
##stic O
##co O
e O
et O
al O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
parkinson O
s O
disease O
long O
term O
follow O
up O
ne O
##uro O
##l O
sci O
2002 O
23 O
su O
##pp O
##l O
2 O
s O
##11 O
##1 O
s O
##11 O
##2 O

tho O
##bo O
##is O
s O
mer O
##tens O
p O
gu O
##eno O
##t O
m O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
parkinson O
s O
disease O
clinical O
evaluation O
of O
18 O
patients O
j O
ne O
##uro O
##l O
2002 O
249 O
52 O
##9 O
53 O
##4 O
vol O
##km O
##ann O
j O
all O
##ert O
n O
vo O
##ges O
j O
weiss O
ph O
fr O
##eu O
##nd O
h O
##j O
stu O
##rm O
v O
safety O
and O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
pal O
##lid O
##al O
or O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
in O
advanced O
pd O
ne O
##uro O
##logy O
2001 O
56 O
54 O
##8 O
55 O
##1 O
lu O
##eck O
c O
##j O
has O
##ml O
##yn O
p O
crawford O
t O
##j O
levy O
is O
br O
##ind O
##ley O
gs O
watkins O
es O
ken O
##nard O
c O
a O
case O
of O
o O
##cular O
tilt O
reaction O
and O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
due O
to O
direct O
stimulation O
of O
the O
mid O
##bra O
##in O
in O
man O
brain O
1991 O
114 O
pt O
5 O
206 O
##9 O
207 O
##9 O

hue O
##rta O
m O
##f O
k O
##ru O
##bit O
##zer O
la O
ka O
##as O
j O
##h O
frontal O
eye O
ﬁ O
##eld O
as O
de O
##ﬁ O
##ned O
by O
intra O
##cor O
##tical O
micro O
##sti O
##mu O
##lation O
in O
squirrel O
monkeys O
owl O
monkeys O
and O
mac O
##aq O
##ue O
monkeys O
i O
sub O
##cor O
##tical O
connections O
j O
com O
##p O
ne O
##uro O
##l O
1986 O
253 O
415 O
43 O
##9 O
hue O
##rta O
m O
##f O
po O
##ns O
t O
##p O
primary O
motor O
cortex O
receives O
input O
from O
area O
3a O
in O
mac O
##aq O
##ues O
brain O
res O
1990 O
53 O
##7 O
36 O
##7 O
37 O
##1 O
stanton O
gb O
goldberg O
me O
bruce O
c O
##j O
frontal O
eye O
ﬁ O
##eld O
e O
##ffer O
##ents O
in O
the O
mac O
##aq O
##ue O
monkey O
ii O
topography O
of O
terminal O
ﬁ O
##eld O
##s O
in O
mid O
##bra O
##in O
and O
po O
##ns O
j O
com O
##p O
ne O
##uro O
##l O
1988 O
271 O
49 O
##3 O
50 O
##6 O

bass O
##o O
ma O
po O
##kor O
##ny O
jj O
liu O
p O
activity O
of O
sub O
##stan O
##tia O
ni O
##gra O
par O
##s O
re O
##tic O
##ulata O
neurons O
during O
smooth O
pursuit O
eye O
movements O
in O
monkeys O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2005 O
22 O
44 O
##8 O
46 O
##4 O
mats O
##um O
##ura O
m O
ko O
##jima O
j O
gardiner O
t O
##w O
hi O
##kos O
##aka O
o O
visual O
and O
o O
##cu O
##lom O
##oto O
##r O
functions O
of O
monkey O
sub O
##thal O
##ami O
##c O
nucleus O
j O
ne O
##uro O
##phy O
##sio O
##l O
1992 O
67 O
161 O
##5 O
1632 O
fa O
##wc O
##ett O
ap O
cu O
##nic O
d O
ham O
##ani O
c O
et O
al O
sac O
##cade O
related O
potential O
##s O
recorded O
from O
human O
sub O
##thal O
##ami O
##c O
nucleus O
cl O
##in O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
118 O
155 O
163 O

fa O
##wc O
##ett O
ap O
dos O
##tro O
##vsky O
jo O
lo O
##zano O
am O
hut O
##chison O
w O
##d O
eye O
movement O
related O
responses O
of O
neurons O
in O
human O
sub O
##thal O
##ami O
##c O
nucleus O
ex O
##p O
brain O
res O
2005 O
162 O
357 O
365 O
ri O
##va O
##ud O
pe O
##cho O
##ux O
s O
ve O
##rm O
##ers O
##ch O
ai O
gay O
##mar O
##d O
b O
et O
al O
improvement O
of O
memory O
guided O
sac O
##cade O
##s O
in O
parkinson O
##ian O
patients O
by O
high O
frequency O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2000 O
68 O
381 O
38 O
##4 O
be O
##j O
##jan O
##i O
bp O
ar O
##nu O
##lf O
i O
ho O
##uet O
##o O
j O
##l O
et O
al O
concurrent O
ex O
##cit O
##atory O
and O
inhibitor O
##y O
effects O
of O
high O
frequency O
stimulation O
an O
o O
##cu O
##lom O
##oto O
##r O
study O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2002 O
72 O
51 O
##7 O
52 O
##2 O

bu O
##ut O
##tner O
u O
bu O
##ut O
##tner O
en O
##ne O
##ver O
ja O
ram O
##bold O
h O
helm O
##chen O
c O
the O
contribution O
of O
mid O
##bra O
##in O
circuits O
in O
the O
control O
of O
gaze O
ann O
n O
y O
ac O
##ad O
sci O
2002 O
95 O
##6 O
99 O
110 O
k O
##rem O
##my O
##da O
o O
bu O
##¨ O
##tt O
##ner O
en O
##ne O
##ver O
ja O
bu O
##¨ O
##tt O
##ner O
u O
g O
##las O
##auer O
s O
tor O
##sion O
##al O
deviation O
##s O
with O
voluntary O
sac O
##cade O
##s O
caused O
by O
a O
un O
##ila O
##tera O
##l O
mid O
##bra O
##in O
les O
##ion O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2007 O
78 O
115 O
##5 O
115 O
##7 O
b O
##hid O
##aya O
##sir O
##i O
r O
plant O
gt O
leigh O
r O
##j O
a O
hypothetical O
scheme O
for O
the O
brains O
##tem O
control O
of O
vertical O
gaze O
ne O
##uro O
##logy O
2000 O
54 O
1985 O
1993 O

helm O
##chen O
c O
ram O
##bold O
h O
kemp O
##erman O
##n O
u O
butt O
##ner O
en O
##ne O
##ver O
ja O
butt O
##ner O
u O
local O
##izing O
value O
of O
tor O
##sion O
##al O
ny O
##sta O
##gm O
##us O
in O
small O
mid O
##bra O
##in O
lesions O
ne O
##uro O
##logy O
2002 O
59 O
1956 O
1964 O
rio O
##rdan O
eva O
p O
fa O
##ldon O
m O
butt O
##ner O
en O
##ne O
##ver O
ja O
gas O
##s O
a O
bro O
##nstein O
am O
gr O
##est O
##y O
ma O
abnormalities O
of O
tor O
##sion O
##al O
fast O
phase O
eye O
movements O
in O
un O
##ila O
##tera O
##l O
ro O
##stra O
##l O
mid O
##bra O
##in O
disease O
ne O
##uro O
##logy O
1996 O
47 O
201 O
207 O
far O
##sha O
##dman O
##esh O
f O
k O
##lier O
em O
chang O
p O
wang O
h O
crawford O
jd O
three O
dimensional O
eye O
head O
coordination O
after O
injection O
of O
mu O
##sc O
##imo O
##l O
into O
the O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
inc O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
232 O
##2 O
233 O
##8 O

k O
##lier O
em O
wang O
h O
crawford O
jd O
inter O
##sti O
##tial O
nucleus O
of O
ca O
##jal O
en O
##codes O
three O
dimensional O
head O
orientation O
##s O
in O
fi O
##ck O
like O
coordinates O
j O
ne O
##uro O
##phy O
##sio O
##l O
2007 O
97 O
60 O
##4 O
61 O
##7 O
dieter O
##ich O
m O
brandt O
t O
tha O
##lam O
##ic O
in O
##far O
##ctions O
differential O
effects O
on O
vest O
##ib O
##ular O
function O
in O
the O
roll O
plane O
35 O
patients O
ne O
##uro O
##logy O
1993 O
43 O
1732 O
1740 O
hal O
##ma O
##gy O
##i O
gm O
brandt O
t O
dieter O
##ich O
m O
curt O
##ho O
##ys O
is O
stark O
r O
##j O
ho O
##yt O
w O
##f O
tonic O
contra O
##vers O
##ive O
o O
##cular O
tilt O
reaction O
due O
to O
un O
##ila O
##tera O
##l O
me O
##so O
die O
##nce O
##pha O
##lic O
les O
##ion O
ne O
##uro O
##logy O
1990 O
40 O
150 O
##3 O
150 O
##9 O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
1624 O
letters O
to O
the O
editor O

but O
##son O
cr O
cooper O
se O
henderson O
j O
##m O
mcintyre O
cc O
patients O
##pe O
##ci O
##ﬁ O
##c O
analysis O
of O
the O
volume O
of O
tissue O
activated O
during O
deep O
brain O
stimulation O
ne O
##uro O
##ima O
##ge O
2007 O
34 O
66 O
##1 O
670 O
pal B-HPO_TERM
##atal I-HPO_TERM
tremor I-HPO_TERM
and O
facial B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
in O
a O
patient B-PATIENT
with O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O

intermittent O
as O
##ym O
##metric O
limb B-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
and I-HPO_TERM
sensory I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
signs O
of O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
with O
loss B-HPO_TERM
of I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
and O
sensory B-HPO_TERM
disturbance I-HPO_TERM
were O
also O
present O
muscle O
bulk O
tone O
and O
power O
appeared O
normal O
dna O
analysis O
con O
##ﬁ O
##rmed O
that O
she O
was O
homo O
##zy O
##go O
##us O
for O
the O
c B-GENE_VARIANT
224 I-GENE_VARIANT
##3 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
in O
pol B-GENE
##g I-GENE
##1 I-GENE
our O
patient B-PATIENT
demonstrates I-PATIENT
the O
typical O
features O
of O
msc O
##ae O
with O
the O
combination O
of O
focal B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
and O
ata B-HPO_TERM
##xia I-HPO_TERM
as O
well O
as O
sensitivity O
to O
sodium O
val O
##pro O
##ate O
3 O
10 O
the O
interesting O
features O
are O
the O
rhythmic O
##al O
facial B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
and O
the O
as O
##ym O
##p O

published O
online O
25 O
june O
2008 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
221 O
##7 O
##8 O
tom O
##atic O
pal B-HPO_TERM
##atal I-HPO_TERM
tremor I-HPO_TERM
with O
its O
structural O
co O
##rre O
##late O
of O
inferior B-HPO_TERM
ol I-HPO_TERM
##ivar I-HPO_TERM
##y I-HPO_TERM
nuclei I-HPO_TERM
involvement O

we O
present O
a O
case O
with O
the O
typical O
clinical O
features O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
and O
additional O
novel O
ﬁ O
##nding O
##s O
of O
pal B-HPO_TERM
##atal I-HPO_TERM
tremor I-HPO_TERM
with O
ho O
##d O
on O
mri O
and O
facial B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
these O
ﬁ O
##nding O
##s O
expand O
the O
clinical O
spectrum O
of O
the O
syndrome O
##s O
caused O
by O
mutation O
in O
this O
gene O
moreover O
since O
pal O
##atal O
tremor O
is O
a O
rare O
disorder O
and O
often O
reported O
as O
a O
sporadic O
entity O
we O
suggest O
that O
pol O
##g O
##1 O
mutation O
should O
be O
considered O
in O
patients O
with O
this O
disorder O
legends O
to O
the O
video O

segment O
1 O
the O
patient B-PATIENT
shows O
ga B-HPO_TERM
##it I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
mild B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
she O
has O
bilateral O
as O
##ym O
##metric O
##al O
rhythmic O
##al O
facial B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ias I-HPO_TERM
mainly O
in O
the O
per O
##ior O
##bit O
##al O
regions O
the O
as O
##ym O
##pt O
##oma O
##tic O
pal B-HPO_TERM
##atal I-HPO_TERM
tremor I-HPO_TERM
sound O
##less O
bilateral O
sync O
##hr O
##ono O
##us O
and O
symmetrical O
2 O
##h O
##z O
contraction O
##s O
of O
the O
soft O
pal O
##ate O
kris O
##z O
##tina O
k O
johan O
##sen O
md O
department O
of O
neuroscience O
norwegian O
university O
of O
science O
and O
technology O
trondheim O
norway O
movement O
disorders O
vol O
23 O
no O
11 O
2008 O
letters O
to O
the O
editor O
1625 O
fig O
1 O
marked B-HPO_TERM
hyper I-HPO_TERM
##tro I-HPO_TERM
##phic I-HPO_TERM
de I-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
inferior I-HPO_TERM
olive I-HPO_TERM
##s I-HPO_TERM
laurence O
a O
bind O
##off O
md O
phd O

department O
of O
ne O
##uro O
##logy O
ha O
##uke O
##land O
university O
hospital O
bergen O
institute O
of O
clinical O
medicine O
university O
of O
bergen O
norway O
jana O
ry O
##dl O
##and O
md O
department O
of O
radio O
##logy O
st O
ol O
##avs O
hospital O
trondheim O
norway O
jan O
o O
aa O
##sl O
##y O
md O
phd O
department O
of O
ne O
##uro O
##logy O
st O
ol O
##avs O
hospital O
trondheim O
department O
of O
neuroscience O
norwegian O
university O
of O
science O
and O
technology O
trondheim O
norway O
e O
mail O
jan O
aa O
##sl O
##y O
nt O
##nu O
no O
references O
van O
goethe O
##m O
g O
lu O
##oma O
p O
ran O
##tama O
##ki O
m O
et O
al O
pol O
##g O
mutations O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
with O
ata O
##xia O
but O
no O
muscle O
involvement O
ne O
##uro O
##logy O
2004 O
63 O
125 O
##1 O
125 O
##7 O

seizure O
18 O
2009 O
232 O
234 O
case B-PATIENT
report O
proof O
of O
progression O
over O
time O
finally O
fu O
##lm O
##ina O
##nt O
brain O
muscle O
and O
liver O
affection O
in O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
associated O
with O
the O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
m O
bo O
##es O
a O
j O
bauer O
a O
h O
ur O
##bach O
b O
c O
e O
el O
##ger O
a O
s O
frank O
c O
m O
baron O
a O
g O
z O
##sur O
##ka O
a O
w O
s O
kun O
##z O
a O
c O
ko O
##rn O
##bl O
##um O
d O
a O
department O
of O
ep O
##ile O
##pt O
##ology O
university O
hospital O
of O
bonn O
germany O
b O
department O
of O
radio O
##logy O
university O
hospital O
of O
bonn O
germany O
c O
department O
of O
ne O
##uro O
##path O
##ology O
university O
hospital O
of O
bonn O
germany O
d O
department O
of O
ne O
##uro O
##logy O
university O
hospital O
of O
bonn O
germany O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O

article O
history O
received O
14 O
april O
2008 O
received O
in O
revised O
form O
18 O
july O
2008 O
accepted O
8 O
august O
2008 O
key O
##words O
al O
##pers O
syndrome O
pol O
##g O
mutation O
ep O
##ile O
##ptic O
seizure O
brain O
mri O
a O
b O
s O
t O
r O
a O
c O
t O

this O
case B-PATIENT
concerns O
a O
17 B-AGE_DEATH
year O
old O
boy O
who O
was O
given O
the O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
only O
post O
##mo O
##rte O
##m O
when O
a O
homo O
##zy O
##go O
##us O
139 B-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
mutation O
was O
found O
in O
the O
link O
##er O
region O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
serial O
muscle O
and O
liver O
bio O
##ps O
##ies O
as O
well O
as O
brain O
mri O
scans O
in O
our O
patient O
ranging O
from O
early O
childhood O
to O
post O
##mo O
##rte O
##m O
analyses O
showed O
that O
i O
routine O
diagnostic O
procedures O
can O
be O
normal O
in O
the O
early O
stage O
of O
the O
disorder O
and O
that O
ii O
central O
nervous O
system O
and O
further O
organ O
affection O
may O
only O
develop O
in O
the O
time O
course O
of O
the O
disease O
consecutive O
diagnostic O
examinations O
clearly O
re O
##ﬂ O
##ect O
##ed O
the O
devastating O
clinical O
course O
and O
cerebral O
deterioration O
evolving O
over O
time O
in O
al O
##pers O
syndrome O

2008 O
british O
ep O
##ile O
##psy O
association O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
1 O
introduction O
infant O
##ile O
al O
##pers O
syndrome O
om O
##im O
203 O
##70 O
##0 O
is O
a O
severe O
ne O
##uro O
##de O
##gen O
##erative O
disorder O
frequently O
associated O
with O
mitochondrial O
dna O
polymer O
##ase O
g O
gene O
pol O
##g O
##1 O
mutations O
1 O
3 O
the O
syndrome O
is O
clinical O
##ly O
characterized O
by O
the O
triad O
of O
a O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
b O
developmental O
delay O
and O
c O
liver O
failure O
2 O
case O
report O

a O
17 B-AGE_DEATH
year O
old O
boy O
was O
referred O
to O
our O
department O
of O
ep O
##ile O
##pt O
##ology O
with O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
and O
died B-HPO_TERM
three O
months O
later O
in O
cerebral B-HPO_TERM
coma I-HPO_TERM
he O
had O
developed O
normal O
until O
the O
age O
of O
ﬁ B-AGE_ONSET
##ve I-AGE_ONSET
years O
when O
he O
was O
ﬁ O
##rst O
admitted O
to O
hospital O
for O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
weeks O
later O
he O
presented O
with O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
of O
the O
left O
arm O
evolving O
into O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
skeletal O
muscle O
bio O
##psy O
at O
that O
time O
was O
non O
contributor O
##y O
no O
ragged O
red O
or O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
negative O
ﬁ O
##bber O
##s O
however O
retrospective O
molecular O
##gen O
##etic O
work O
up O
of O
the O
muscle O
sample O
showed O
a O
low O
amount O
of O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
mt I-HPO_TERM
dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
5 O

corresponding O
author O
at O
university O
hospital O
of O
bonn O
department O
of O
ep O
##ile O
##pt O
##ology O
si O
##gm O
##und O
freud O
st O
##ras O
##se O
25 O
53 O
##10 O
##5 O
bonn O
germany O
tel O
49 O
228 O
287 O
157 O
##12 O
fa O
##x O
49 O
228 O
287 O
144 O
##86 O
e O
mail O
address O
mon O
##ika O
bo O
##es O
uk O
##b O
un O
##i O
bonn O
de O
m O
bo O
##es O

and O
considerable O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
the O
mean O
mt O
##dna O
content O
was O
reduced O
to O
55 O
of O
9 O
healthy O
controls O
aged O
20 O
1 O
10 O
3 O
years O
using O
long O
range O
and O
real O
time O
pc O
##r O
as O
previously O
described O
4 O
the O
patient O
s O
condition O
gradually B-HPO_TERM
deteriorated I-HPO_TERM
over O
the O
years O
with O
progressive B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
signs I-HPO_TERM
cognitive B-HPO_TERM
decline I-HPO_TERM
from O
the O
age O
of O
12 O
and O
worse B-HPO_TERM
##ning I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
from O
the O
age O
of O
15 O
years O
transient B-HPO_TERM
liver I-HPO_TERM
dysfunction I-HPO_TERM
occurred O
under O
intermittent O
anti O
##ep O
##ile O
##ptic O
treatment O
with O
sodium O
val O
##pro O
##ate O
however O
standard O
liver O
bio O
##psy O
and O
magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
at O
the O
age O
of O
15 O
years O
were O
normal O
at O
the O
age O
of O
17 O
years O
the O
patient O
developed O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
focal I-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
in O
association O
with O
pneumonia B-HPO_TERM
ﬁ O
##nally O
requiring O
vent B-HPO_TERM
##ila I-HPO_TERM
##tory I-HPO_TERM
assistance I-HPO_TERM
and O
admission O
to O
our O
hospital O
general O
ana O
##esthesia O
high O
dose O
benz O
##od O
##ia O
##ze O
##pine O
##s O
and O
ph O
##eno O
##bar O
##bit O
##ura O
##te O
did O
not O
interrupt O
the O
intra O
##ctable O
focal O
motor O
status O
for O
successful O
seizure O
control O
treatment O
with O
sodium O
val O
##pro O
##ate O
was O
ind O
##is O
##pen O
##sable O
over O
the O
following O
weeks O
blood O
chemist O
##ries O
showed O
persistent O
mild O
two O
##fold O
elevated B-HPO_TERM
liver I-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##se I-HPO_TERM
levels O
but O
no O
ja O
##und O
##ice O
hyper O
##am O
##mona O
##emia O
abnormalities O
of O
blood O
coa O
##gul O
##ation O
or O
other O
signs O
of O
he O
##pati O
##c O
failure O
after O
three O
months O
of O
int O
##uba O
##tion O
the O
patient O
remained O
in O
a O
ve B-HPO_TERM
##get I-HPO_TERM
##ative I-HPO_TERM
state I-HPO_TERM
after O
reduction O
of O
all O
ana O
##est O
##hetic O
##s O
maintaining O
sodium O
val O
##pro O
##ate O
a O
1 O
5 O
##t O
brain O
mri O
at O
that O
time O
showed O
symmetric O
hyper B-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
and I-HPO_TERM
swelling I-HPO_TERM
of I-HPO_TERM
deep I-HPO_TERM
grey I-HPO_TERM
matter I-HPO_TERM
nuclei I-HPO_TERM
as O
well O
as O
co O
##rti O
##cal O
grey O
and O
sub O
##cor O
##tical O
white O
matter O
with O
relative O
spa O
##ring O
of O
the O
frontal O
cortex O
fig O
1 O
in O
the O
further O
clinical O
course O
the O
patient O
developed O
brains O
##tem O
symptoms O
and O
died B-HPO_TERM
in O
coma B-HPO_TERM
one O
week O
after O
the O
ﬁ O
##nal O
brain O
mri O
examination O
autopsy O
showed O
a O
multi B-HPO_TERM
##org I-HPO_TERM
##an I-HPO_TERM
failure I-HPO_TERM

105 O
##9 O
131 O
##1 O
see O
front O
matter O
2008 O
british O
ep O
##ile O
##psy O
association O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
seizure O
2008 O
08 O
00 O
##3 O
m O
bo O
##es O
et O
al O
seizure O
18 O
2009 O
232 O
234 O
233 O
fig O
1 O
axial O
5 O
mm O
thick O
flair O
fast O
spin O
echo O
a O
t O
##1 O
weighted O
spin O
echo O
b O
and O
diffusion O
weighted O
spin O
echo O
ep O
##i O
c O
at O
the O
level O
of O
the O
basal B-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
show I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
and I-HPO_TERM
swollen I-HPO_TERM
deep I-HPO_TERM
grey I-HPO_TERM
matter I-HPO_TERM
nuclei I-HPO_TERM
as O
well O
as O
hyper B-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ity I-HPO_TERM
and I-HPO_TERM
swelling I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
grey I-HPO_TERM
and I-HPO_TERM
sub I-HPO_TERM
##cor I-HPO_TERM
##tical I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
note O
the O
nearly O
symmetric O
distribution O
and O
the O
fact O
that O
the O
frontal O
cortex O
is O
rather O
spared O
b O
d O

but O
no O
signs O
of O
liver O
ﬁ O
##bro O
##sis O
or O
ci O
##rr O
##hosis O
and O
no O
he O
##pati O
##c O
micro O
##ves O
##icular O
ste O
##ato O
##sis O
ne O
##uro O
##path O
##ological O
examinations O
revealed O
sp B-HPO_TERM
##ong I-HPO_TERM
##iform I-HPO_TERM
changes I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##br I-HPO_TERM
##um I-HPO_TERM
white B-HPO_TERM
matter I-HPO_TERM
sp I-HPO_TERM
##ong I-HPO_TERM
##ios I-HPO_TERM
##is I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
a O
brains B-HPO_TERM
##tem I-HPO_TERM
bleeding I-HPO_TERM
and O
multiple B-HPO_TERM
lac I-HPO_TERM
##una I-HPO_TERM
##r I-HPO_TERM
is I-HPO_TERM
##cha I-HPO_TERM
##emi I-HPO_TERM
##c I-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
in I-HPO_TERM
##far I-HPO_TERM
##cts I-HPO_TERM
post O
##mo O
##rte O
##m O
analyses O
of O
skeletal O
muscle O
and O
liver O
tissue O
revealed O
massive O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
the O
mean O
mt O
##dna O
content O
in O
muscle O
was O
reduced O
to O
16 O
of O
controls O
in O
liver O
to O
10 O
of O
5 O
normal O
controls O
aged O
53 O
5 O
1 O
years O
his O
##tology O
of O
post O
##mo O
##rte O
##m O
liver O
tissue O
showed O
abundant O
cox B-HPO_TERM
negative I-HPO_TERM
areas I-HPO_TERM
with O
only O
isolated O
ﬁ O
##eld O
##s O
of O
preserved O
cox O
activity O
5 O
the O
diagnosis O
of O
al O
##pers O
syndrome O
was O
given O
post O
##mo O
##rte O
##m O
when O
a O
homo O
##zy O
##go O
##us O
139 O
##9 O
##g O
a O
a O
##46 O
##7 O
##t O
mutation O
was O
found O
in O
the O
link O
##er O
region O
of O
pol O
##g O
##1 O

3 O
discussion O

the O
ph O
##eno O
##typic O
spectrum O
associated O
with O
pol O
##g O
##1 O
mutations O
is O
wide O
and O
comprises O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
6 O
ata O
##xi O
##c O
syndrome O
##s O
7 O
progressive O
neurological O
disorders O
8 O
9 O
and O
infant O
##ile O
al O
##pers O
syndrome O
with O
mitochondrial O
dna O
de O
##ple O
##tion O
1 O
4 O
according O
to O
recent O
data O
the O
a O
##46 O
##7 O
##t O
mutation O
can O
be O
detected O
in O
the O
majority O
of O
childhood O
onset O
cases O
associated O
with O
pol O
##g O
##1 O
mutations O
3 O
a O
##46 O
##7 O
##t O
was O
recently O
found O
in O
0 O
19 O
of O
german O
control O
all O
##eles O
providing O
a O
reservoir O
for O
recess O
##ive O
disease O
3 O
previous O
reports O
on O
cerebral O
mri O
in O
al O
##pers O
syndrome O
taken O
months O
to O
years O
before O
death O
revealed O
hyper O
##int O
##ens O
##ities O
frequently O
located O
in O
o O
##cci O
##pit O
##al O
lobes O
deep O
ce O
##re O
##bella O
##r O
nuclei O
tha O
##lam O
##us O
and O
basal O
gang O
##lia O
2 O
9 O
10 O
in O
contrast O

mri O
in O
our O
patient B-PATIENT
taken O
one O
week O
before O
death O
showed O
more O
pronounced O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
and I-HPO_TERM
sub I-HPO_TERM
##cor I-HPO_TERM
##tical I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
and O
swelling O
similarly O
including O
deep O
grey O
matter O
nuclei O
these O
ﬁ O
##nding O
##s O
were O
more O
pronounced O
and O
only O
partly O
in O
line O
compared O
with O
previously O
reported O
mri O
patterns O
in O
al O
##pers O
syndrome O
however O
this O
is O
the O
ﬁ O
##rst O
report O
on O
terminal O
brain O
mri O
ﬁ O
##nding O
##s O
in O
a O
fatal O
disease O
course O
it O
may O
be O
speculative O
if O
the O
more O
generalized O
and O
severe O
signal O
abnormalities O
in O
our O
patient O
are O
consequences O
of O
the O
natural O
history O
of O
the O
disorder O
itself O
or O
due O
to O
the O
characteristic O
complications O
of O
the O
disease O
like O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
involvement O
of O
the O
deep O
grey O
internal O
nuclei O
however O
is O
not O
consistent O
with O
prolonged O
status O
ep O
##ile O
##ptic O
##us O
therefore O
these O
ﬁ O
##nding O
##s O
can O
be O
interpreted O
as O
an O
expression O
of O
the O
terminal O
phase O
of O
en O
##ce O
##pha O
##lo O
##pathy O
in O
this O
distinct O
mitochondrial O
disorder O
differential O
diagnostic O
##ally O
pronounced O
tha O
##lam O
##ic O
signal O
changes O
in O
mri O
can O
be O
present O
in O
general O
cerebral O
h O
##yp O
##ox O
##ia O
the O
variant O
of O
cr O
##eu O
##tz O
##feld O
jakob O
disease O
deep O
cerebral O
vein O
th O
##rom O
##bos O
##is O
and O
various O
mitochondrial O
disorders O
like O
infant O
##ile O
leigh O
syndrome O
or O
ke O
##arns O
say O
##re O
syndrome O
however O
cerebral O
mri O
pathology O
is O
usually O
not O
restricted O
to O
deep O
grey O
internal O
or O
tha O
##lam O
##ic O
nuclei O
in O
these O
disorders O
which O
are O
usually O
easily O
to O
distinguish O
from O
al O
##pers O
syndrome O
by O
clinical O
signs O
and O
symptoms O

examination O
results O
of O
serial O
muscle O
samples O
taken O
at O
the O
age O
of O
5 O
years O
and O
post O
##mo O
##rte O
##m O
liver O
bio O
##ps O
##ies O
taken O
at O
the O
age O
of O
15 O
years O
and O
post O
##mo O
##rte O
##m O
and O
brain O
mri O
scans O
performed O
at O
15 O
and O
17 O
years O
of O
age O
prove O
the O
continuous O
and O
serious O
progress O
of O
cerebral O
234 O
m O
bo O
##es O
et O
al O
seizure O
18 O
2009 O
232 O
234 O

and O
multi O
##org O
##an O
affection O
in O
al O
##pers O
syndrome O
over O
time O
in O
detail O
our O
case O
demonstrates O
that O
brain O
mri O
abnormalities O
in O
al O
##pers O
syndrome O
may O
rapidly O
develop O
over O
a O
com O
##para O
##bly O
short O
time O
period O
and O
that O
muscle O
and O
liver O
bio O
##ps O
##ies O
following O
standard O
his O
##to O
##logical O
procedures O
can O
be O
normal O
particularly O
in O
the O
early O
course O
of O
the O
disease O
our O
experience O
under O
##lines O
the O
impact O
of O
serial O
mri O
scans O
and O
the O
need O
for O
spec O
##i O
##ﬁ O
##c O
bio O
##psy O
work O
up O
in O
clinical O
##ly O
suspect O
patients O
including O
qu O
##ali O
##tative O
and O
quantitative O
mt O
##dna O
examinations O
comprising O
analyses O
for O
multiple O
del O
##eti O
##ons O
and O
or O
de O
##ple O
##tion O
usually O
present O
in O
syndrome O
##s O
associated O
with O
pol O
##g O
##1 O
mutations O
as O
pol O
##g O
##1 O
mutations O
were O
only O
recently O
reported O
as O
frequent O
causes O
of O
infant O
##ile O
al O
##pers O
syndrome O
de O
##ﬁ O
##ni O
##te O
numbers O
of O
affected O
children O
are O
not O
known O
and O
the O
diagnosis O
may O
easily O
be O
overseen O
as O
many O
patients O
die O
at O
young O
age O

the O
severe O
ﬁ O
##nding O
##s O
in O
our O
patient O
clearly O
re O
##ﬂ O
##ect O
the O
devastating O
clinical O
course O
and O
cerebral O
deterioration O
that O
may O
evolve O
in O
al O
##pers O
syndrome O
our O
data O
indicate O
that O
not O
only O
liver O
failure O
but O
also O
severe O
brain O
damage O
may O
contribute O
to O
death O
in O
al O
##pers O
syndrome O
in O
patients O
with O
pol O
##g O
##1 O
mutations O
prolonged O
con O
##vu O
##ls O
##ive O
status O
ep O
##ile O
##ptic O
##us O
is O
a O
common O
and O
fatal O
com O
##plication O
and O
represents O
a O
major O
cause O
of O
death O
in O
these O
disease O
entities O
eng O
##els O
##en O
et O
al O
10 O
focal O
ep O
##ile O
##ptic O
seizures O
that O
often O
result O
in O
generalized O
status O
ep O
##ile O
##ptic O
##us O
are O
characteristic O
symptoms O
of O
brain O
affection O
in O
al O
##pers O
syndrome O
however O
they O
result O
in O
further O
cerebral O
damage O
themselves O
thus O
creating O
a O
vicious O
cycle O
of O
central O
nervous O
system O
pathology O
in O
our O
patient O
brains O
##tem O
affection O
may O
have O
further O
contributed O
to O
death O
potentially O
leading O
to O
central O
respiratory O
and O
auto O
##no O
##mic O
failure O
intriguing O
##ly O
his O
##to O
##chemical O
and O
molecular O
##gen O
##etic O
post O
##mo O
##rte O
##m O
analyses O
gave O
evidence O
of O
serious O
liver O
dysfunction O
without O
con O
##clusive O
clinical O
or O
morphological O
evidence O
for O
fatal O
liver O
failure O
like O
ﬁ O
##bro O
##sis O
ci O
##rr O
##hosis O
or O
he O
##pati O
##c O
micro O

ve O
##sic O
##ular O
ste O
##ato O
##sis O
as O
usually O
seen O
in O
he O
##pati O
##c O
failure O
due O
to O
val O
##pro O
##ate O
treatment O
we O
post O
##ulate O
that O
severe O
mt O
##dna O
de O
##ple O
##tion O
in O
liver O
tissue O
resulted O
in O
respiratory O
chain O
dysfunction O
which O
was O
re O
##ﬂ O
##ect O
##ed O
by O
severe O
cox O
ne O
##gat O
##ivity O
of O
the O
liver O
tissue O
bio O
##chemical O
liver O
dysfunction O
in O
our O
patient O
obviously O
did O
not O
yet O
lead O
to O
relevant O
clinical O
signs O
or O
severe O
morphological O
tissue O
changes O
references O
david O
##zon O
g O
man O
##cus O
##o O
m O
ferrari O
##s O
s O
qui O
##nz O
##ii O
c O
hi O
##rano O
m O
peters O
h O
##l O
et O
al O
pol O
##g O
mutations O
and O
al O
##pers O
syndrome O
ann O
ne O
##uro O
##l O
2005 O
57 O
92 O
##1 O
4 O

ferrari O
g O
lama O
##nte O
##a O
e O
dona O
##ti O
a O
fi O
##los O
##to O
m O
carr O
##ara O
f O
par O
##ini O
r O
et O
al O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
syndrome O
##s O
associated O
with O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
g O
a O
brain O
2005 O
128 O
72 O
##3 O
31 O
ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
fu O
##¨ O
tt O
##ere O
##r O
n O
ah O
##ola O
s O
lama O
##nte O
##a O
e O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
g O
gene O
brain O
2006 O
129 O
167 O
##4 O
84 O
baron O
m O
ku O
##din O
ap O
kun O
##z O
w O
##s O
mitochondrial O
dysfunction O
in O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
bio O
##che O
##m O
soc O
trans O
2007 O
35 O
122 O
##8 O
31 O

ko O
##rn O
##bl O
##um O
c O
baron O
m O
bo O
##es O
m O
z O
##sur O
##ka O
g O
kun O
##z O
w O
##s O
ph O
##eno O
##typic O
variations O
in O
patients O
with O
link O
##er O
region O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
gene O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2007 O
17 O
9 O
10 O
747 O
van O
goethe O
##m O
g O
der O
##ma O
##ut O
b O
lo O
##f O
##gren O
a O
martin O
jj O
van O
bro O
##eck O
##ho O
##ven O
c O
mutation O
of O
pol O
##g O
is O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
nat O
gene O
##t O
2001 O
28 O
211 O
2 O
van O
goethe O
##m O
g O
lu O
##oma O
p O
ran O
##tama O
##ki O
m O
al O
me O
##mar O
a O
ka O
##ako O
##la O
s O
hack O
##man O
p O
et O
al O
pol O
##g O
mutations O
in O
ne O
##uro O
##den O
##eger O
##ative O
disorders O
with O
ata O
##xia O
but O
no O
muscle O
involvement O
ne O
##uro O
##logy O
2004 O
63 O
125 O
##1 O
7 O

lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
ka O
##uk O
##one O
##n O
ja O
nu O
##pp O
##one O
##n O
n O
##n O
chalmers O
rm O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
82 O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
aa O
##sl O
##y O
j O
zev O
##iani O
m O
winter O
##th O
##un O
s O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutation O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
92 O
eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
lille O
##b O
##ø O
a O
la O
##eg O
##re O
##id O
l O
##m O
aa O
##sl O
##y O
j O
et O
al O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
2008 O
131 O
81 O
##8 O
28 O

ne O
##uro O
##path O
##ology O
and O
applied O
ne O
##uro O
##biology O
2009 O
35 O
120 O
124 O
doi O
10 O
111 O
##1 O
j O
136 O
##5 O
299 O
##0 O
2008 O
00 O
##9 O
##8 O
##1 O
x O
scientific O
correspondence O
published O
online O
article O
accepted O
on O
19th O
august O
2008 O
alpha O
syn O
##uc O
##lein O
pathology O
and O
parkinson O
##ism O
associated O
with O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
and O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O

mutations O
in O
the O
mitochondrial O
genome O
mt O
##dna O
accumulate O
in O
a O
variety O
of O
tissues O
with O
age O
1 O
it O
has O
been O
proposed O
that O
these O
so O
##matic O
mt O
##dna O
mutations O
play O
a O
role O
in O
age O
##ing O
and O
age O
related O
diseases O
such O
as O
parkinson O
s O
disease O
pd O
2 O
3 O
recently O
it O
was O
shown O
that O
high O
levels O
of O
deleted O
mt O
##dna O
are O
present O
in O
sub O
##stan O
##tia O
ni O
##gra O
s O
##n O
ne O
##uron O
##es O
from O
both O
aged O
controls O
and O
individuals O
with O
pd O
strengthening O
the O
suggestion O
that O
so O
##matic O
mt O
##dna O
del O
##eti O
##ons O
are O
involved O
in O
the O
selective O
ne O
##uron O
##al O
loss O
observed O
in O
brain O
age O
##ing O
and O
in O
pd O
2 O
4 O
to O
further O
investigate O
a O
possible O
association O
between O
multiple O
mt O
##dna O
del O
##eti O
##ons O
and O
age O
##ing O
we O
performed O
post O
mort O
##em O
examination O
of O
the O
brain O
from O
a O
patient O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
multiple O
mt O
##dna O
del O
##eti O
##ons O
usually O
develop O
secondary O
to O
a O
mutation O
in O
one O
of O
the O
enzymes O
involved O
in O
mt O
##dna O
maintenance O
e O
g O
polymer O
##ase O
gamma O
encoded O
by O
the O
nuclear O
gene O
pol O
##g O
##1 O
5 O
patients O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
show O
clinical O
het O
##ero O
##gen O
##eit O
##y O
6 O
although O
in O
our O
patient O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
and O
parkinson O
##ism O
were O
both O
prominent O
features O

the O
patient B-PATIENT
first O
presented O
at O
the O
age O
of O
22 B-AGE_ONSET
years O
with O

left B-HPO_TERM
sided I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
which O
slowly O
progressed B-HPO_TERM
over O
the O
next O
20 O
years O
to O
an O
almost O
complete B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
he O
developed O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
at O
age O
50 O
and O
his O
first O
parkinson B-HPO_TERM
##ian I-HPO_TERM
features O
at O
age O
51 O
the O
features O
including O
rigid B-HPO_TERM
##ity I-HPO_TERM
tremor B-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
and O
difficulty B-HPO_TERM
performing I-HPO_TERM
fine I-HPO_TERM
motor I-HPO_TERM
tasks I-HPO_TERM
were O
initially O
un O
##ila O
##tera O
##l O
and O
responded O
well O
to O
do O
##pa O
##mine O
ago O
##nist O
##s O
aged O
54 O
years O
he O
showed O
signs O
of O
cognitive B-HPO_TERM
impairment I-HPO_TERM
and O
increasing B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
his O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
my I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
also O
became O
more O
prominent O
and O
there O
was O
evidence O
of O
sensor B-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
at O
age O
57 O
do O
##pa O
##mine O
ago O
##nist O
##s O
became O
less O
effective O
but O
he O
responded O
well O
to O
ap O
##omo O
##rp O
##hine O
his O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
deteriorated O
and O
a O
peg B-HPO_TERM
tube I-HPO_TERM
was O
inserted O
because O
of O
rec B-HPO_TERM
##urrent I-HPO_TERM
as I-HPO_TERM
##piration I-HPO_TERM
the O
patient O
died O
aged O
59 B-AGE_DEATH
years O
because O
of O
pneumonia B-HPO_TERM
there O
was O
no O
family O
history O
of O
either O
mitochondrial O
disease O
or O
pd O

examination O
of O
a O
post O
mort O
##em O
skeletal O
muscle O
sample O
revealed O
features O
of O
mitochondrial B-HPO_TERM
my I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
with O
frequent O
muscle O
fibre O
##s O
def B-HPO_TERM
##icient I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
encoded I-HPO_TERM
cy I-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
some O
of O
which O
were O
hyper O
##active O
for O
nuclear O
dna O
n O
##dna O
encoded O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
figure O
1a O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
were O
detected O
both O
##on O
southern O
##bl O
##ot O
and O
##long O
range O
pc O
##r O
ass O
##ays O
of O
total O
muscle O
homo O
##gen O
##ate O
dna O
figure O
1b O
genetic O
analysis O
revealed O
that O
the O
patient O
was O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
mutations O
in O
the O
n O
##dna O
encoded O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
coding O
for O
the O
##cat O
##aly O
##tic O
subunit O
##of O
them O
##t O
##dna O
specific O
polymer O
##ase O
g O
7 O
these O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
were O
c B-GENE_VARIANT
331 I-GENE_VARIANT
##1 I-GENE_VARIANT
##c I-GENE_VARIANT
##g I-GENE_VARIANT
p I-GENE_VARIANT
s I-GENE_VARIANT
##11 I-GENE_VARIANT
##0 I-GENE_VARIANT
##4 I-GENE_VARIANT
##c I-GENE_VARIANT
and O
c B-GENE_VARIANT
254 I-GENE_VARIANT
##2 I-GENE_VARIANT
##ga I-GENE_VARIANT
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT

macro O
##scopic O
examination O
of O
the O
brain O
did O
not O
reveal O
any O
external O
abnormalities O
however O
the O
s B-HPO_TERM
##n I-HPO_TERM
was I-HPO_TERM
almost I-HPO_TERM
devoid I-HPO_TERM
of I-HPO_TERM
pigment I-HPO_TERM
throughout O
microscopic O
examination O
of O
the O
mid O
##bra O
##in O
revealed O
the O
extent O
of O
s B-HPO_TERM
##n I-HPO_TERM
ne I-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
loss I-HPO_TERM
which O
was O
severe O
in O
the O
lateral O
group O
moderately O
severe O
in O
the O
middle O
group O
and O
moderately O
severe O
in O
the O
medial O
group O
of O
the O
lower O
mid O
##bra O
##in O
and O
also O
uniformly O
moderate O
to O
moderately O
severe O
in O
the O
upper O
mid O
##bra O
##in O
with O
ha O
##ema O
##to O
##xy O
##lin O
and O
e O
##osi O
##n O
stain O
lew O
##y O
bodies O
lbs O
were O
seen O
in O
the O
surviving O
s O
##n O
ne O
##uron O
##es O
figure O
2a O
the O
red O
o O
##cu O
##lom O
##oto O
##r O
ed O
##inger O
west O
##pha O
##l O
and O
dorsal O
rap O
##he O
nuclei O
appeared O
unaffected O
within O
the O
po B-HPO_TERM
##ns I-HPO_TERM
there I-HPO_TERM
was I-HPO_TERM
mild I-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
ne I-HPO_TERM
##uron I-HPO_TERM
##es I-HPO_TERM
in O
the O
locus O
coe O
##ru O
##le O
##us O
and O
normal O
ne O
##uron O
##al O
population O
density O
n O
p O
d O
within O
the O
superior O
rap O
##he O
within O
the O
med O
##ulla O
the O
n O
p O
d O
of O
the O
dorsal O
nucleus O
of O
va O
##gus O
and O
of O
the O
ol O
##ivar O
##y O
nuclei O
were O
relatively O
intact O
the O
ce B-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
was I-HPO_TERM
affected I-HPO_TERM
with O
moderate O
focal O
loss B-HPO_TERM
of I-HPO_TERM
pu I-HPO_TERM
##rkin I-HPO_TERM
##je I-HPO_TERM
cells I-HPO_TERM
and O
focal O
mild O
ne B-HPO_TERM
##uron I-HPO_TERM
##e I-HPO_TERM
loss I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
dent I-HPO_TERM
##ate I-HPO_TERM
nucleus I-HPO_TERM
in O
the O
basal O
fore O
##bra O
##in O
the O
n O
p O
d O
of O
the O
nucleus O
of O
me O
##yne O
##rt O
appeared O
intact O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
using O
antibodies O
to O
alpha O
##sy O
##nu O
##cle O
##in O
revealed O
a O
high O
proportion O
of O
ne O
##uron O
##es O
with O
cy O
##top O
##las O
##mic O
im O
##mun O
##ore O
##act O
##ivity O
ne O
##uri O
##tes O
and O
im O
##mun O
##ore O
##act O
##ivity O
in O
the O
ne O
##uro O
##pi O
##l O
of O
the O
s O
##n O
figure O
2 O
##b O
and O
the O
nucleus O
of O
me O
##yne O
##rt O
the O
dorsal O
nucleus O
of O
va O
##gus O
and O
the O
other O
brains O
##tem O
and O
sub O
##cor O
##tical O
nuclei O
showed O
only O
mild O
lb O
pathology O
fewer O
than O
five O
alpha O
syn O
##uc O
##lein O
##im O
##mun O
##ore O
##active O
lbs O
were O
present O
in O
the O
anterior O
ci O
##ng O
##ulate O
and O
the O
frontal O
cortex O
but O
none O
in O
the O
trans O
##ent O
##or O
##hin O
##al O
lateral O
temporal O
or O
par O
##ie O
##tal O
cortex O
this O

120 O
2009 O
blackwell O
publishing O
ltd O
scientific O
correspondence O
121 O
a O
b O
1 O
kb O
control O
patient O
kb O
multiple O
mt O
##dna O
del O
##eti O
##ons O

dual O
cox O
sd O
##h O
his O
##to O
##chemist O
##ry O
revealed O
that O
21 O
2 O
of O
the O
remaining O
s O
##n O
ne O
##uron O
##es O
were O
cox B-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
figure O
2d O
this O
level O
of O
cox O
deficiency O
is O
higher O
than O
the O
levels O
recently O
observed O
in O
the O
s O
##n O
of O
age O
##ing O
controls O
1 O
and O
pd O
patients O
3 O
2 O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
for O
the O
mt O
##dna O
encoded O
cox O
subunit O
i O
revealed O
deficiency O
in O
individual O
ni O
##gra O
##l O
ne O
##uron O
##es O
figure O
2 O
##e O
while O
all O
ni O
##gra O
##l O
ne O
##uron O
##es O
showed O
normal O
activity O
for O
por O
##in O
a O
trans O
##me O
##mb O
##rane O
mitochondrial O
protein O
used O
as O
a O
reference O
marker O
for O
mitochondrial O
mass O
figure O
2 O
##f O
from O
the O
remaining O
s O
##n O
ne O
##uron O
##es O
five O
poole O
##d O
single O
ne O
##uron O
##es O
were O
laser O
micro O
##dis O
##se O
##cted O
and O
mt O
##dna O
del O
##eti O
##on O
load O
was O
assessed O
using O
a O
previously O
multiple O
##x O
real O
time O
pc O
##r O
9 O
the O
results O
confirmed O
high O
levels O
of O
mt O
##dna O
del O
##eti O
##ons O
in O
the O
s O
##n O
ne O
##uron O
##es O
65 O
n O
5 O

parkinson O
##ism O
has O
been O
previously O
described O
in O
pe O
##o O
patients O
with O
mt O
##dna O
del O
##eti O
##ons O
5 O
as O
has O
severe O
ne O
##uron O
##al O
loss O
from O
the O
s O
##n O
in O
patients O
with O
multiple O
mt O
##dna O
del O
##eti O
##on O
disorders O
10 O
11 O
however O
we O
believe O
this O
to O
be O
the O
first O
report O
of O
lb O
pathology O
in O
a O
patient B-PATIENT
with O
parkinson B-HPO_TERM
##ism I-HPO_TERM
pe B-HPO_TERM
##o I-HPO_TERM
and O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
secondary O
to O
a O
pol B-GENE
##g I-GENE
##1 I-GENE

figure O
1 O
his O
##to O
##chemical O
and O
mt O
##dna O
analyses O
a O
dual O
his O
##to O
##chemist O
##ry O
for O
the O
mt O
##dna O
encoded O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
and O
the O
n O
##dna O
encoded O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
on O
the O
patient B-PATIENT
s O
muscle O
bio O
##psy O
demonstrates O
cox B-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
ragged B-HPO_TERM
red I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
blue O
and O
muscle O
fibre O
##s O
expressing O
both O
cox O
and O
sd O
##h O
brown O
some O
freezing O
arte O
##fa O
##ct O
is O
apparent O
in O
this O
muscle O
sample O
but O
the O
mitochondrial O
abnormal O
##ity O
is O
clearly O
apparent O

available O
online O
at O
www O
science O
##di O
##re O
##ct O
com O
digest O
##ive O
and O
liver O
disease O
41 O
2009 O
49 O
##4 O
49 O
##9 O
liver O
pan O
##cre O
##as O
and O
bi O
##lia O
##ry O
tract O
two O
novel O
pol O
##g O
mutations O
causing O
he O
##pati O
##c O
mitochondrial O
dna O
de O
##ple O
##tion O
with O
rec O
##urrent O
h O
##yp O
##oke O
##to O
##tic O
h O
##yp O
##og O
##ly O
##ca O
##emia O
and O
fatal O
liver O
dysfunction O
b O
bo O
##rt O
##ot O
a O
c O
e O
bar O
##bi O
b O
s O
bi O
##ffi O
a O
d O
g O
luna O
##zzi O
a O
r O
bus O
##san O
##i O
e O
a O
bu O
##rlin O
##a O
f O
s O
nor O
##bedo O
b O
a O
ventura O
b O
m O
carr O
##oz O
##zi O
a O
g O
m O
se O
##ver O
##ini O
a O
c O
a O
children O
s O
ne O
##uro O
##logy O
and O
psychiatry O
unit O
institute O
of O
child O
health O
ir O
##cc O
##s O
bu O
##rl O
##o O
ga O
##ro O
##fo O
##lo O
via O
dell O
ist O
##ria O
trieste O
italy O

b O
department O
of O
pediatric O
##s O
university O
of O
trieste O
institute O
of O
child O
health O
ir O
##cc O
##s O
bu O
##rl O
##o O
ga O
##ro O
##fo O
##lo O
via O
dell O
ist O
##ria O
trieste O
italy O
c O
medical O
genetics O
unit O
institute O
of O
child O
health O
ir O
##cc O
##s O
bu O
##rl O
##o O
ga O
##ro O
##fo O
##lo O
via O
dell O
ist O
##ria O
trieste O
italy O
d O
optical O
imaging O
laboratory O
cb O
##m O
s O
c O
r O
l O
area O
science O
park O
bas O
##ov O
##iz O
##za O
ss O
14 O
km O
163 O
5 O
trieste O
italy O
e O
department O
of O
path O
##olo O
##gic O
anatomy O
os O
##ped O
##ale O
di O
cat O
##tina O
##ra O
st O
##rada O
di O
fi O
##ume O
trieste O
italy O
f O
division O
of O
metabolic O
disorders O
department O
of O
pediatric O
##s O
university O
hospital O
via O
gi O
##ust O
##inian O
##i O
padua O
italy O
received O
1 O
august O
2008 O
accepted O
13 O
november O
2008 O

available O
online O
4 O
february O
2009 O
abstract O
background O
inherited O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
##s O
md O
##s O
are O
a O
group O
of O
severe O
mitochondrial O
disorders O
resulting O
from O
defects O
in O
nucleus O
encoded O
factors O
and O
often O
associated O
with O
severe O
or O
fatal O
liver O
failure O
patient B-PATIENT
in O
this O
article O
we O
describe O
the O
case O
of O
an O
18 B-AGE_DEATH
month I-AGE_DEATH
old O
patient O
with O
rec B-HPO_TERM
##urrent I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oke I-HPO_TERM
##to I-HPO_TERM
##tic I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
and O
fatal B-HPO_TERM
he I-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
dysfunction I-HPO_TERM
with O
liver B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM

methods O
the O
assessment O
of O
mt O
##dna O
copy O
number O
was O
performed O
on O
le O
##uc O
##ocytes O
liver O
and O
muscle O
bio O
##psy O
by O
quantitative O
real O
time O
pc O
##r O
and O
total O
rna O
from O
liver O
bio O
##psy O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
the O
cd O
##na O
of O
the O
pol O
##g O
##1 O
gene O

results O
sequence O
analysis O
identified O
two O
previously O
und O
##es O
##cr O
##ibe O
##d O
mutations O
1868 B-GENE_VARIANT
##t I-GENE_VARIANT
g I-GENE_VARIANT
and O
226 B-GENE_VARIANT
##3 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT
located O
in O
the O
gene O
coding O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O
polymer O
##ase O
y O
pol B-GENE
##g I-GENE
predicting O
an O
l B-GENE_VARIANT
##6 I-GENE_VARIANT
##23 I-GENE_VARIANT
##w I-GENE_VARIANT
and O
k B-GENE_VARIANT
##75 I-GENE_VARIANT
##5 I-GENE_VARIANT
##e I-GENE_VARIANT
amino O
acid O
change O
respectively O
both O
mutations O
were O
located O
in O
the O
highly O
conserved O
link O
##er O
region O
of O
the O
protein O
and O
were O
absent O
in O
more O
than O
200 O
healthy O
unrelated O
control O
subjects O
the O
identification O
of O
these O
two O
mutations O
allowed O
us O
to O
perform O
genetic O
counsel O
##ling O
and O
pre O
##nat O
##al O
diagnosis O

conclusion O
our O
data O
further O
expand O
the O
spectrum O
of O
pol O
##g O
##1 O
gene O
mutations O
and O
the O
unique O
ph O
##eno O
##type O
reported O
late O
onset O
isolated O
liver O
disease O
without O
lac O
##tic O
acid O
##osis O
increase O
the O
variability O
of O
clinical O
presentations O
associated O
with O
mutations O
in O
this O
gene O
2008 O
edit O
##rice O
gas O
##tro O
##enter O
##olo O
##gic O
##a O
italiana O
s O
r O
l O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
key O
##words O
dna O
polymer O
##ase O
gamma O
late O
onset O
liver O
failure O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
introduction O

mt O
##dna O
de O
##ple O
##tion O
syndrome O
##s O
md O
##s O
are O
a O
group O
of O
severe O
mitochondrial O
disorders O
usually O
presenting O
in O
infancy O
or O
childhood O
due O
to O
tissue O
specific O
reduction O
of O
the O
mt O
##dna O
corresponding O
author O
at O
ne O
##uro O
##mus O
##cular O
disorders O
laboratory O
child O
ne O
##uro O
##logy O
and O
psychiatry O
unit O
institute O
of O
child O
health O
ir O
##cc O
##s O
bu O
##rl O
##o O
ga O
##ro O
##fo O
##lo O
via O
dell O
ist O
##ria O
trieste O
italy O
tel O
39 O
04 O
##0 O
37 O
##85 O
##42 O
##3 O
fa O
##x O
39 O
04 O
##0 O
37 O
##85 O
##21 O
##0 O
e O
mail O
address O
se O
##ver O
##ini O
bu O
##rl O
##o O
trieste O
it O
g O
m O
se O
##ver O
##ini O

copy O
number O
md O
##s O
is O
ph O
##eno O
##typical O
##ly O
het O
##ero O
##gen O
##eous O
manifest O
##ing O
either O
as O
a O
he O
##pa O
##to O
##cer O
##eb O
##ral O
en O
##ce O
##pha O
##lom O
##yo O
##pathic O
or O
my O
##opa O
##thic O
form O
1 O
all O
these O
syndrome O
##s O
result O
from O
defects O
in O
nucleus O
encoded O
factors O
and O
are O
mostly O
inherited O
as O
auto O
##som O
##al O
recess O
##ive O
traits O
2 O
the O
he O
##pa O
##to O
##cer O
##eb O
##ral O
form O
is O
probably O
the O
most O
common O
variant O
of O
md O
##s O
characterized O
by O
an O
infant O
##ile O
onset O
of O
acute O
liver O
failure O
and O
associated O
with O
let O
##har O
##gy O
h O
##yp O
##oton O
##ia O
vomiting O
seizures O
and O
h O
##yp O
##og O
##ly O
##ca O
##emia O
3 O
4 O
three O
genes O
have O
been O
identified O
as O
major O
cause O
of O
this O
md O
##s O
form O
d O
##gu O
##ok O
5 O
6 O
which O
en O
##codes O
the O
de O
##ox O
##y O
##gua O
##no O

159 O
##0 O
86 O
##58 O
30 O
2008 O
edit O
##rice O
gas O
##tro O
##enter O
##olo O
##gic O
##a O
italiana O
s O
r O
l O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
dl O
##d O
2008 O
11 O
01 O
##3 O

sin O
##e O
kinase O
d O
##g O
##k O
that O
together O
with O
t O
##k O
##2 O
maintains O
the O
supply O
of O
d O
##nt O
##ps O
for O
mt O
##dna O
synthesis O
2 O
mp O
##v O
##17 O
encoding O
a O
mitochondrial O
inner O
membrane O
protein O
of O
unknown O
function O
that O
seems O
to O
be O
involved O
in O
the O
mt O
##dna O
maintenance O
and O
regulation O
of O
protein O
ox O
##ph O
##os O
7 O
8 O
and O
pol O
##g O
##1 O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O
polymer O
##ase O
9 O
10 O
pol O
##g O
##1 O
is O
a O
major O
disease O
gene O
in O
mitochondrial O
disorders O
11 O
mutations O
in O
this O
gene O
can O
be O
associated O
with O
de O
##ple O
##tion O
but O
also O
with O
multiple O
del O
##eti O
##ons O
or O
point O
mutations O
of O
mitochondrial O
dna O
12 O
this O
genetic O
complexity O
is O
associated O
with O
an O
extremely O
het O
##ero O
##gen O
##eous O
clinical O
presentation O
with O
an O
overlapping O
ph O
##eno O
##typic O
spectrum O
ranging O
from O
severe O
and O
fatal O
childhood O
he O
##pa O
##to O
##ence O
##pha O
##lo O
##pathy O
to O
late O
onset O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ata O
##xia O
my O
##opa O
##thy O
and O
ep O
##ile O
##psy O
4 O
13 O
14 O

here O
we O
describe O
the O
case B-PATIENT
of O
an O
18 B-AGE_DEATH
month I-AGE_DEATH
old O
patient O
with O
rec B-HPO_TERM
##urrent I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oke I-HPO_TERM
##to I-HPO_TERM
##tic I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
and O
fatal B-HPO_TERM
liver I-HPO_TERM
dysfunction I-HPO_TERM
with O
tissue O
specific O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
due O
to O
mutations O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
case O
report O

an O
18 B-AGE_ONSET
month I-AGE_ONSET
old O
boy O
the O
second O
child O
to O
healthy O
unrelated O
parents O
was O
referred O
for O
a O
history O
of O
h B-HPO_TERM
##yp I-HPO_TERM
##oke I-HPO_TERM
##to I-HPO_TERM
##tic I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
he O
was O
born O
at O
term O
and O
his O
history O
was O
un O
##rem O
##ark O
##able O
until O
18 O
months O
of O
age O
when O
he O
was O
admitted O
for O
the O
first O
time O
to O
the O
local O
hospital O
due O
to O
an O
episode O
of O
let B-HPO_TERM
##har I-HPO_TERM
##gy I-HPO_TERM
which O
happened O
late O
in O
the O
morning O
the O
child O
had O
not O
had O
any O
breakfast O
g B-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
was O
19 O
mg O
dl O
with O
a O
mild B-HPO_TERM
ke I-HPO_TERM
##ton I-HPO_TERM
##uria I-HPO_TERM
1 O
at O
a O
comb O
##ur O
test O
urine O
st O
##ix O

laboratory O
tests O
showed O
raised B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##se I-HPO_TERM
alterations B-HPO_TERM
of I-HPO_TERM
coa I-HPO_TERM
##gul I-HPO_TERM
##ation I-HPO_TERM
and O
metabolic B-HPO_TERM
acid I-HPO_TERM
##osis I-HPO_TERM
see O
table O
1 O
ser O
##ological O
testing O
for O
par O
##vo O
##virus O
hepatitis O
b O
c O
a O
cy O
##tom O
##ega O
##lov O
##irus O
and O
e O
##bs O
##tein O
barr O
virus O
was O
negative O
he O
recovered O
in O
a O
few O
days O
clinical O
conditions O
were O
apparently O
normal O
so O
he O
was O
discharged O
with O
a O
program O
of O
further O
tests O
and O
follow O
up O
fundamental O
developmental O
milestone O
##s O
appeared O
normally O
acquired O
even O
though O
a O
brunette O
le O
##zine O
test O
showed O
a O
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
delay I-HPO_TERM
q O
##s O
79 O

after O
one O
month O
he O
was O
admitted O
again O
for O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
28 O
mg O
dl O
associated O
with O
let B-HPO_TERM
##har I-HPO_TERM
##gy I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
he O
was O
treated O
with O
intra O
##ven O
##ous O
glucose O
and O
was O
referred O
to O
our O
clinic O
again O
on O
that O
occasion O
ke O
##tones O
levels O
were O
low O
in O
urine O
1 O
at O
comb O
##ur O
st O
##ix O
and O
within O
normal O
range O
in O
blood O
2 O
5 O
mg O
dl O

on O
admission O
physical O
examination O
showed O
a O
let B-HPO_TERM
##har I-HPO_TERM
##gic I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ic I-HPO_TERM
child O
all O
the O
standard O
ha O
##ema O
##to O
##logical O
analyses O
were O
performed O
see O
table O
1 O
his O
weight B-HPO_TERM
was I-HPO_TERM
8 I-HPO_TERM
5 I-HPO_TERM
kg I-HPO_TERM
3rd I-HPO_TERM
cent I-HPO_TERM
##ile I-HPO_TERM
height B-HPO_TERM
was I-HPO_TERM
75 I-HPO_TERM
cm I-HPO_TERM
3rd I-HPO_TERM
cent I-HPO_TERM
##ile I-HPO_TERM
an O
ultrasound O
scan O
of O
the O
abdomen O
showed O
an O
un O
##hom O
##ogen O
##eous O
and O
hyper B-HPO_TERM
##ec I-HPO_TERM
##ogenic I-HPO_TERM
liver I-HPO_TERM
with O
normal O
intra O
##and O
extra O
##he O
##pati O
##c O
bi O
##lia O
##ry O
duct O
##s O
normal O
gall O
bladder O
and O
sp O
##leen O
ec O
##g O
and O
echo O
##card O
##io O
##gram O
were O
normal O
repeat O
surface O
ee O
##g O
recordings O
were O
performed O
according O
to O
the O
international O
10 O
20 O
system O
during O
wake O
##fulness O
dr O
##ows O
##iness O
and O
table O
1 O
hem O
##ato O
##chemical O
examinations O

analysis O
with O
normal O
results O
1st O
and O
2nd O
admission O
er O
##yt O
##hr O
##oc O
##yte O
sediment O
##ation O
rate O
c O
reactive O
protein O
electro O
##ly O
##tes O
album O
##in O
cr O
##ea O
##tin O
ph O
##os O
##ph O
##oki O
##nas O
##e O
im O
##mun O
##og O
##lo O
##bu O
##lins O
ammonia O
lac O
##tic O
acid O
insulin O
co O
##rti O
##sol O
##emia O
cho O
##lines O
##tera O
##se O
ce O
##ru O
##lo O
##pl O
##as O
##min O
auto O
##ant O
##ib O
##odies O
l O
##km O
lc O
##1 O
sm O
##a O
ac O
##yl O
##car O
##ni O
##tine O
amino O
acid O
organic O
acid O
l O
##km O
anti O
liver O
kidney O
micro O
##som O
##al O
antibodies O
lc O
##1 O
anti O
liver O
cy O
##tos O
##olic O
antigen O
type O
1 O
antibodies O
sm O
##a O
anti O
smooth O
muscle O
antibodies O

sleep O
which O
demonstrated O
slowing O
and O
high O
amplitude O
of O
background O
activity O
3 O
4 O
hz O
more O
evident O
on O
the O
right O
hemisphere O
lacking O
clear O
ep O
##ile O
##pt O
##iform O
abnormalities O
a O
liver O
bio O
##psy O
was O
performed O
see O
section O
4 O
and O
genetic O
testing O
for O
mitochondrial O
disease O
was O
started O
at O
the O
ne O
##uro O
##mus O
##cular O
disorders O
laboratory O
of O
our O
institute O

he O
was O
treated O
with O
intra O
##ven O
##ous O
glucose O
fresh O
plasma O
and O
enter O
##al O
feeding O
with O
progressive O
improvement O
up O
to O
a O
normal O
standard O
of O
behaviour O
and O
muscular O
tone O
without O
neurological O
abnormalities O
an O
apparent O
slow O
trend O
towards O
normal O
##ization O
of O
liver O
function O
tests O
was O
present O
and O
he O
was O
therefore O
discharged O
on O
nocturnal O
enter O
##al O
feeding O
while O
waiting O
for O
the O
missing O
laboratory O
tests O
after O
a O
few O
days O
he O
was O
read O
##mit O
##ted O
for O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
during O
acute B-HPO_TERM
dia I-HPO_TERM
##rr I-HPO_TERM
##hoe I-HPO_TERM
##a I-HPO_TERM
with O
fever B-HPO_TERM
laboratory O
tests O
showed O
a O
rot B-HPO_TERM
##avi I-HPO_TERM
##rus I-HPO_TERM
infection I-HPO_TERM
with O
liver B-HPO_TERM
failure I-HPO_TERM
his O
conditions O
progressively B-HPO_TERM
worsened I-HPO_TERM
and O
the O
patient O
died B-HPO_TERM

materials O
and O
methods O
respiratory O
chain O
enzymes O
were O
studied O
by O
spec O
##tro O
##ph O
##oto O
##metric O
ass O
##ays O
performed O
on O
super O
##nat O
##ants O
obtained O
from O
muscle O
and O
liver O
homo O
##gen O
##ates O
as O
previously O
described O
15 O
total O
dna O
was O
isolated O
from O
peripheral O
blood O
l O
##ym O
##ph O
##ocytes O
liver O
and O
muscle O
bio O
##psy O
by O
protein O
##ase O
k O
digest O
##ion O
followed O
by O
standard O
ph O
##eno O
##l O
ch O
##lor O
##of O
##or O
##m O
extraction O
and O
ethanol O
precipitation O
16 O

the O
presence O
of O
large O
scale O
mt O
##dna O
rear O
##rang O
##ement O
##s O
was O
investigated O
through O
an O
amp O
##li O
##fication O
of O
the O
complete O
mitochondrial O
genome O
16 O
6 O
kb O
using O
the O
gene O
##amp O
xl O
pc O
##r O
kit O
applied O
bio O
##systems O
foster O
city O
ca O
usa O
with O
prime O
##rs O

located O
in O
essential O
regions O
of O
the O
mitochondrial O
genome O
itself O
17 O
screening O
for O
mt O
##dna O
point O
mutations O
was O
performed O
by O
amp O
##li O
##fying O
the O
entire O
mt O
##dna O
in O
10 O
partially O
overlapping O
pc O
##r O
fragments O
which O
were O
then O
anal O
##yse O
##d O
with O
96 O
sequences O
using O
the O
sequencing O
kit O
ab O
##i O
prism O
dye O
term O
##inator O
cycle O
and O
the O
automatic O
sequencing O
system O
applied O
bio O
##systems O
310 O
##0 O
applied O
bio O
##systems O
foster O
city O
ca O
usa O
following O
standard O
procedures O

the O
measure O
of O
mt O
##dna O
copy O
number O
was O
performed O
on O
le O
##uc O
##ocytes O
liver O
and O
muscle O
bio O
##psy O
by O
quantitative O
real O
time O
pc O
##r O
q O
##rt O
pc O
##r O
based O
on O
sy O
##br O
green O
i O
flu O
##orescence O
in O
this O
analysis O
the O
amount O
of O
mt O
##dna O
was O
compared O
with O
the O
amount O
of O
the O
nuclear O
gene O
encoding O
the O
g O
##lo O
##bin O
gene O
contained O
in O
the O
same O
sample O
the O
fluorescent O
signal O
int O
##ens O
##ities O
were O
recorded O
and O
anal O
##yse O
##d O
during O
pc O
##r O
in O
an O
ab O
##i O
prism O
770 O
##0 O
sequence O
detector O
system O
applied O
bio O
##systems O
equipped O
with O
the O
770 O
##0 O
sequence O
detection O
system O
software O
ve O
##r O
1 O
7 O
18 O
the O
mt O
##dna O
g O
##lo O
##bin O
gene O
dna O
ratio O
obtained O
in O
the O
patient O
s O
samples O
was O
expressed O
as O
a O
percentage O
of O
the O
mean O
value O
obtained O
in O
control O
samples O
which O
represent O
the O
100 O
value O

total O
rna O
from O
liver O
bio O
##psy O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
the O
cd O
##na O
of O
the O
pol O
##g O
##1 O
gene O
dna O
obtained O
from O
l O
##ym O
##ph O
##ocytes O
was O
used O
to O
confirm O
mutations O
identified O
in O
the O
cd O
##na O
for O
pre O
##nat O
##al O
diagnosis O
total O
dna O
was O
extracted O
from O
am O
##nio O
##tic O
cells O
all O
pc O
##r O
fragments O
were O
anal O
##yse O
##d O
using O
the O
sequencing O
kit O
ab O
##i O
prism O
dye O
term O
##inator O
cycle O
and O
the O
automatic O
sequencing O
system O
applied O
bio O
##systems O
310 O
##0 O
applied O
bio O
##systems O
foster O
city O
ca O
usa O
results O

his O
##top O
##ath O
##ological O
examination O
of O
liver O
bio O
##psy O
showed O
macro B-HPO_TERM
10 O
and O
micro B-HPO_TERM
##ves I-HPO_TERM
##icular I-HPO_TERM
10 I-HPO_TERM
ste I-HPO_TERM
##ato I-HPO_TERM
##ses I-HPO_TERM
and O
some O
he O
##pa O
##to O
##cytes O
with O
intra B-HPO_TERM
##cy I-HPO_TERM
##top I-HPO_TERM
##las I-HPO_TERM
##mic I-HPO_TERM
micro I-HPO_TERM
##ves I-HPO_TERM
##icles I-HPO_TERM
hyper B-HPO_TERM
##pl I-HPO_TERM
##asia I-HPO_TERM
of I-HPO_TERM
ku I-HPO_TERM
##pf I-HPO_TERM
##fer I-HPO_TERM
cells I-HPO_TERM
portal B-HPO_TERM
and I-HPO_TERM
per I-HPO_TERM
##ip I-HPO_TERM
##ort I-HPO_TERM
##al I-HPO_TERM
fi I-HPO_TERM
##bro I-HPO_TERM
##sis I-HPO_TERM
fig O
1 O

bio O
##chemical O
studies O
of O
liver O
homo O
##gen O
##ate O
showed O
low B-HPO_TERM
activities I-HPO_TERM
30 I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
control I-HPO_TERM
values I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
mitochondrial I-HPO_TERM
##code I-HPO_TERM
##d I-HPO_TERM
complexes I-HPO_TERM
i O
ii O
nad O
##h O
cy O
##to O
##chrome O
c O
red O
##uc O
##tase O
rot O
##eno O
##ne O
sensitive O
and O
i O
iii O
su O
##cci O
##nate O
cy O
##to O
##chrome O
c O
red O
##uc O
##tase O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
activity I-HPO_TERM
was I-HPO_TERM
not I-HPO_TERM
detect I-HPO_TERM
##able I-HPO_TERM
while O
the O
nuclear O
coded O
subunit O
##s O
namely O
complex O
i O
nad O
##h O
de O
##hy O
##dro O
##genase O
ii O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
and O
ci O
##tra O
##te O
synth O
##ase O
showed O
activity O
within O
the O
normal O
range O
the O
studies O
performed O
on O
muscle O
homo O
##gen O
##ate O
showed O
only O
a O
reduction O
of O
the O
mitochondrial O
coded O
i O
iii O
complex O
70 O
of O
the O
control O
values O
while O
the O
other O
en O
##zy O
##matic O
activities O
were O
within O
the O
normal O
range O
this O
bio O
##chemical O
pattern O
suggested O
a O
mitochondrial B-HPO_TERM
dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM

xl O
pc O
##r O
amp O
##li O
##fication O
of O
mt O
##dna O
did O
not O
reveal O
any O
del O
##eti O
##ons O
in O
liver O
or O
muscle O
and O
sequencing O
of O
the O
entire O
mitochondrial O
genome O
in O
the O
liver O
dna O
did O
not O
reveal O
any O
pathogen O
##ic O
mutations O
the O
results O
of O
q O
##rt O
pc O
##r O
showed O
a O
fig O
1 O
diffuse B-HPO_TERM
ste I-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
of O
he O
##pa O
##to O
##cytes O
and O
ku O
##pf O
##fer O
cells O
moderate O
cellular O
infiltrate O
composed O
of O
mono O
##nu O
##cle O
##ar O
cells O
and O
plasma O
cells O
liver B-HPO_TERM
cells I-HPO_TERM
have I-HPO_TERM
foam I-HPO_TERM
##y I-HPO_TERM
cy I-HPO_TERM
##top I-HPO_TERM
##las I-HPO_TERM
##m I-HPO_TERM
h O
e O
40 O
##× O

reduction O
of O
the O
mt O
##dna O
g O
##lo O
##bin O
gene O
dna O
ratio O
of O
63 O
in O
different O
determination O
##s O
of O
the O
patient O
s O
post O
##mo O
##rte O
##m O
frozen O
liver O
sample O
compared O
with O
similar O
specimens O
from O
three O
age O
matched O
control O
individuals O
as O
suggested O
by O
mort O
##en O
et O
al O
19 O
mt O
##dna O
copy O
number O
in O
blood O
and O
muscle O
bio O
##psy O
were O
within O
the O
normal O
range O
but O
closed O
to O
the O
lower O
value O
mutations O
in O
the O
d O
##g O
##k O
t O
##k O
##2 O
and O
mp O
##v O
##17 O
genes O
which O
are O
known O
to O
be O
responsible O
for O
a O
number O
of O
cases O
of O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
##s O
md O
##s O
5 O
7 O
20 O
9 O
4 O
were O
first O
excluded O
after O
that O
as O
several O
authors O
identified O
pol O
##g O
##1 O
mutations O
causing O
al O
##pers O
he O
##pa O
##top O
##athic O
pol O
##io O
##dy O
##st O
##rop O
##hy O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
2 O
4 O
12 O
21 O
we O
decide O
to O
investigate O
the O
pol O
##g O
##1 O
gene O
also O
in O
our O
patient O

fig O
2 O
a O
sequence O
analysis O
showing O
the O
presence O
of O
the B-GENE_VARIANT
t I-GENE_VARIANT
##9 I-GENE_VARIANT
##25 I-GENE_VARIANT
##6 I-GENE_VARIANT
##g I-GENE_VARIANT
and O
the O
a1 B-GENE_VARIANT
##13 I-GENE_VARIANT
##90 I-GENE_VARIANT
##g I-GENE_VARIANT
mutations O
in O
pol B-GENE
##g I-GENE
gene O
b O
amino O
##ac O
##idi O
##c O
sequence O
comparison O
of O
both O
mutations O
in O
different O
species O
demonstrating O
that O
amino O
acids O
62 O
##3 O
and O
75 O
##5 O
are O
highly O
conserved O
in O
mammals O
and O
dr O
##oso O
##phila O

fig O
3 O
a O
human O
pol O
##g O
##1 O
cd O
##na O
showing O
the O
22 O
coding O
ex O
##ons O
2 O
23 O
a O
and O
the O
corresponding O
pol O
##g O
a O
primary O
sequence O
of O
123 O
##9 O
amino O
acids O
b O
vertical O
grey O
bars O
represent O
highly O
conserved O
ex O
##on O
##uc O
##lea O
##se O
and O
polymer O
##ase O
motifs O
in O
the O
family O
a O
polymer O
##ase O
##s O
the O
black O
boxes O
indicate O
the O
location O
of O
the O
four O
conserved O
space O
##r O
region O
blocks O
y O
##1 O
y O
##4 O
within O
amino O
acid O
boundaries O
441 O
82 O
##9 O
the O
substitution O
##s O
identified O
in O
this O
report O
are O
indicated O
with O
the O
orange O
and O
the O
green O
boxes O
and O
located O
in O
the O
y O
##3 O
and O
y O
##4 O
space O
##r O
region O
blocks O

the O
analysis O
performed O
on O
cd O
##na O
44 O
##65 O
bp O
and O
confirmed O
on O
gen O
##omic O
dna O
demonstrated O
that O
the O
patient O
was O
a O
compound O
het O
##ero O
##zy O
##go O
##te O
for O
a O
maternal O
1868 B-GENE_VARIANT
##t I-GENE_VARIANT
g I-GENE_VARIANT
mutation O
ex O
##on O
10 O
of O
the O
pol O
##g O
##1 O
gene O
predicting O
an O
l B-GENE_VARIANT
##6 I-GENE_VARIANT
##23 I-GENE_VARIANT
##w I-GENE_VARIANT
amino O
acid O
change O
and O
a O
paternal O
226 B-GENE_VARIANT
##3 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT
mutation O
ex O
##on O
13 O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
predicting O
a O
k B-GENE_VARIANT
##75 I-GENE_VARIANT
##5 I-GENE_VARIANT
##e I-GENE_VARIANT
amino O
acid O
change O
fig O
2a O
both O
mutations O
had O
never O
been O
previously O
reported O
and O
were O
absent O
in O
more O
than O
200 O
healthy O
unrelated O
control O
subjects O
l O
##6 O
##23 O
##w O
and O
k O
##75 O
##5 O
##e O
amino O
acid O
changes O
are O
located O
in O
the O
link O
##er O
region O
space O
##r O
between O
the O
n O
terminal O
proof O
##rea O
##ding O
domain O
and O
the O
c O
terminal O
polymer O
##ase O
domain O
of O
the O
protein O
fig O
3 O

moreover O
inter O
##sp O
##ec O
##ies O
comparison O
demonstrates O
that O
l O
##6 O
##23 O
and O
k O
##75 O
##5 O
residues O
are O
highly O
conserved O
in O
ve O
##rte O
##brates O
and O
in O
dr O
##oso O
##phila O
mel O
##ano O
##gas O
##ter O
fig O
2 O
##b O
after O
one O
year O
the O
mother O
reported O
being O
pregnant O
of O
another O
baby O
and O
a O
pre O
##nat O
##al O
diagnostic O
procedure O
starting O
from O
nuclear O
dna O
isolated O
from O
am O
##nio O
##tic O
fluid O
cells O
was O
carried O
out O
the O
new O
foe O
##tus O
tested O
het O
##ero O
##zy O
##go O
##te O
for O
the O
maternal O
mutation O
while O
the O
paternal O
all O
##ele O
was O
normal O
he O
was O
delivered O
uneven O
##tf O
##ull O
##y O
and O
is O
now O
a O
healthy O
baby O
of O
16 O
months O
of O
age O
fig O
4 O
fig O
4 O
pe O
##di O
##gree O
of O
family O
harbour O
##ing O
the O
newly O
identified O
mutations O

discussion O
mitochondrial O
disorders O
are O
often O
associated O
with O
liver O
dysfunction O
because O
of O
the O
high O
mitochondrial O
density O
in O
he O
##pa O
##to O
##cy O
##te O
and O
the O
need O
for O
high O
levels O
of O
atp O
for O
its O
bio O
##sy O
##nt O
##hetic O
and O
det O
##ox O
##ifying O
functions O
in O
this O
article O
we O
describe O
a O
patient O
affected O
by O
liver O
mitochondrial O
dna O
de O
##ple O
##tion O
with O
rec O
##urrent O
h O
##yp O
##oke O
##to O
##tic O
h O
##yp O
##og O
##ly O
##ca O
##emia O
and O
fatal O
liver O
failure O
the O
level O
of O
de O
##ple O
##tion O
is O
consistent O
with O
that O
observed O
in O
some O
patients O
showing O
a O
severe O
neon O
##atal O
onset O
liver O
involvement O
liver O
ins O
##uf O
##fi O
##ciency O
or O
he O
##pa O
##to O
##cellular O
dysfunction O
as O
described O
by O
other O
authors O
22 O

while O
it O
is O
well O
known O
that O
h O
##yp O
##oke O
##to O
##tic O
h O
##yp O
##og O
##ly O
##ca O
##emia O
is O
a O
common O
sy O
##mpt O
##om O
of O
beta O
oxidation O
deficit O
few O
cases O
have O
been O
reported O
of O
mit O
##ho O
##con O
##dr O
##ial O
dna O
de O
##ple O
##tion O
with O
isolated O
liver O
disease O
i O
e O
without O
evident O
muscle O
or O
cn O
##s O
involvement O
with O
a O
relatively O
late O
onset O
and O
without O
lac O
##tic O
acid O
##osis O
23 O
25 O
10 O
as O
a O
matter O
of O
fact O
some O
cases O
of O
al O
##per O
s O
syndrome O
with O
pol O
##g O
mutations O
have O
already O
been O
published O
but O
only O
few O
of O
them O
emphasize O
the O
possibility O
of O
a O
late O
onset O
after O
one O
year O
of O
age O
isolated O
liver O
disease O
moreover O
to O
the O
best O
of O
our O
knowledge O
none O
of O
these O
cases O
presented O
normal O
lac O
##tic O
acid O
levels O
as O
in O
our O
patient O

the O
molecular O
genetic O
analysis O
identified O
two O
previously O
und O
##es O
##cr O
##ibe O
##d O
mutations O
located O
in O
the O
gene O
encoding O
the O
catalytic O
subunit O
a O
subunit O
of O
the O
mitochondrial O
dna O
polymer O
##ase O
y O
pol O
##g O
these O
mutations O
are O
assumed O
to O
be O
pathogen O
##ic O
because O
they O
are O
not O
reported O
as O
poly O
##morphic O
changes O
are O
absent O
from O
more O
than O
400 O
control O
all O
##eles O
and O
can O
change O
highly O
conserved O
amino O
acids O
the O
le O
##uc O
##ine O
residue O
at O
cod O
##on O
62 O
##3 O
is O
located O
in O
a O
highly O
conserved O
region O
in O
ve O
##rte O
##brates O
fig O
2 O
##b O
and O
includes O
another O
pathogen O
##ic O
pol O
##g O
##1 O
mutation O
namely O
r O
##6 O
##27 O
##w O
26 O
the O
region O
containing O
the O
l O
##ys O
##ine O
residue O
at O
cod O
##on O
75 O
##5 O
is O
also O
conserved O
in O
dr O
##oso O
##phila O
fig O
2 O
##b O
and O
includes O
the O
pathogen O
##ic O
f O
##7 O
##49 O
##s O
pol O
##g O
##1 O
mutation O
27 O

dna O
polymer O
##ase O
y O
is O
composed O
of O
2 O
subunit O
##s O
a O
and O
and O
is O
necessary O
for O
replication O
and O
repair O
of O
the O
mt O
##dna O
presenting O
both O
dna O
polymer O
##ase O
and O
3 O
##∗ O
5 O
##∗ O
ex O
##on O
##uc O
##lea O
##se O
activity O
28 O
the O
region O
of O
pol O
##g O
a O
located O
between O
the O
ex O
##on O
##uc O
##lea O
##se O
and O
polymer O
##ase O
space O
##r O
has O
four O
pol O
##g O
a O
specific O
sequences O
y O
##1 O
y O
##4 O
fig O
3 O
29 O
which O
are O
highly O
conserved O
in O
species O
from O
dr O
##oso O
##phila O
to O
human O
the O
two O
mutations O
identified O
in O
our O
patient B-PATIENT
lead O
to O
the O
amino O
acids O
substitution O
##s O
in O
the O
y O
##3 O
l B-GENE_VARIANT
##6 I-GENE_VARIANT
##23 I-GENE_VARIANT
##w I-GENE_VARIANT
and O
y O
##4 O
k I-GENE_VARIANT
##75 I-GENE_VARIANT
##5 I-GENE_VARIANT
##e I-GENE_VARIANT
region O
of O
the O
pol B-PATIENT
##g I-PATIENT
a O
space O
##r O
fig O
3 O

up O
to O
date O
although O
the O
almost O
30 O
disease O
mutations O
located O
in O
the O
space O
##r O
region O
of O
the O
pol O
##g O
gene O
30 O
have O
been O
associated O
with O
the O
most O
severe O
clinical O
manifestation O
##s O
most O
of O
them O
have O
not O
been O
bio O
##chemical O
##ly O
characterized O
yet O
or O
linked O
to O
a O
specific O
ph O
##eno O
##type O
29 O
however O
mu O
##tage O
##nes O
##is O
in O
these O
conserved O
blocks O
y O
##3 O
and O
y O
##4 O
in O
dr O
##oso O
##phila O
protein O
seems O
to O
induce O
low O
dna O
polymer O
##ase O
activity O
y O
##3 O
and O
y O
##4 O
and O
decrease O
of O
interaction O
with O
pol O
##g O
subunit O
y O
##4 O
31 O
the O
strongest O
hypothesis O
during O
the O
initial O
diagnostic O
work O
up O
was O
that O
of O
a O
possible O
medium O
chain O
ac O
##yl O
coa O
deficiency O
mca O
##d O
the O
clinical O
and O
laboratory O
picture O
of O
mca O
##d O
can O
initially O
resemble O
a O
mitochondrial O
dna O
de O
##ple O
##tion O
and O
mca O
##d O
is O
by O
far O
more O
frequent O
than O
mitochondrial O
dna O
de O
##ple O
##tion O
furthermore O
normal O
lac O
##tate O
levels O
made O
unlikely O
the O
hypothesis O
of O
a O
mitochondrial O
dna O
de O
##ple O
##tion O
while O
waiting O
for O
the O
results O
of O
the O
ac O
##yl O
coa O
tests O
the O
child O
was O
put O
on O
continuous O
enter O
##al O
feeding O
to O
avoid O
h O
##yp O
##og O
##ly O
##ca O
##emia O
and O
further O
crises O
despite O
this O
he O
developed O
severe O
episodes O
of O
h O
##yp O
##og O
##ly O
##ca O
##emia O
and O
liver O
abnormalities O
we O
believe O
that O
in O
this O
setting O
the O
rec O
##ur O
##rence O
of O
h O
##yp O
##og O
##ly O
##ca O
##emia O
without O
fast O
##ing O
should O
have O
strongly O
induced O
the O
suspicion O
of O
a O
mitochondrial O
dna O
de O
##ple O
##tion O
this O
case O
is O
a O
further O
warning O
of O
the O
fact O
that O
even O
if O
this O
is O
a O
rare O
event O
it O
should O
be O
taken O
into O
account O
in O
differential O
dia O
##gno O
##ses O
a O
strong O
clinical O
suspicion O
could O
have O
accelerated O
diagnostic O
testing O
particularly O
in O
the O
perspective O
of O
a O
possible O
emergency O
liver O
transplant O
the O
issue O
of O
liver O
transplant O
in O
mitochondrial O
dna O
de O
##ple O
##tion O
has O
been O
debated O
without O
a O
definite O
consensus O
24 O
25 O
10 O
the O
possibility O
of O
a O
multi O
##vis O
##cera O
##l O
involvement O
muscle O
brain O
heart O
in O
the O
forthcoming O
years O
is O
an O
argument O
against O
transplant O
in O
our O
case O
the O
pro O
##tracted O
let O
##har O
##gy O
accompanying O
the O
critical O
episodes O
could O
suggest O
possible O
future O
brain O
involvement O

4 O
moreover O
we O
retain O
that O
this O
case O
is O
relevant O
also O
because O
it O
adds O
to O
the O
knowledge O
of O
two O
new O
mutations O
never O
reported O
before O
in O
literature O
allowing O
us O
to O
perform O
genetic O
counsel O
##ling O
and O
pre O
##nat O
##al O
diagnosis O

to O
our O
knowledge O
only O
two O
authors O
have O
reported O
pre O
##nat O
##al O
findings O
that O
were O
later O
confirmed O
as O
md O
##s O
22 O
29 O
in O
the O
first O
case O
pre O
##nat O
##al O
diagnosis O
was O
based O
on O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
stain O
##ing O
of O
an O
mt O
##dna O
encoded O
protein O
from O
culture O
##d O
am O
##nio O
##cytes O
and O
confirmed O
by O
the O
measurement O
of O
mt O
##dna O
in O
liver O
and O
muscle O
after O
birth O
32 O
however O
as O
measuring O
mt O
##dna O
levels O
from O
am O
##nio O
##cytes O
or O
from O
cho O
##rion O
##ic O
vi O
##llus O
is O
currently O
not O
a O
standard O
procedure O
this O
approach O
cannot O
be O
considered O
a O
valid O
option O
for O
pre O
##nat O
##al O
diagnosis O
more O
recently O
pre O
##nat O
##al O

diagnosis O
starting O
from O
nuclear O
dna O
isolated O
from O
am O
##nio O
##tic O
fluid O
has O
been O
reported O
in O
a O
family O
at O
risk O
for O
md O
##s O
due O
to O
d O
##g O
##k O
gene O
mutations O
13 O
in O
our O
case O
the O
identification O
of O
defined O
genetic O
mutations O
in O
the O
pol O
##g O
gene O
allowed O
us O
to O
perform O
accurate O
pre O
##nat O
##al O
testing O
by O
analyzing O
am O
##nio O
##cytes O
nuclear O
dna O
by O
pc O
##r O
and O
direct O
sequencing O

as O
a O
conclusion O
our O
data O
further O
expand O
the O
spectrum O
of O
pol O
##g O
##1 O
gene O
mutations O
and O
the O
unique O
ph O
##eno O
##type O
reported O
increase O
the O
variability O
of O
clinical O
presentations O
associated O
with O
mutations O
in O
this O
gene O
since O
an O
accurate O
molecular O
diagnosis O
is O
essential O
for O
proper O
genetic O
counsel O
##ling O
and O
pre O
##nat O
##al O
diagnostic O
##s O
we O
suggest O
performing O
pol O
##g O
##1 O
mutation O
analysis O
in O
children O
with O
a O
variety O
of O
clinical O
aspects O
of O
mitochondrial O
disorders O
including O
those O
showing O
late O
onset O
isolated O
liver O
disease O
without O
lac O
##tic O
acid O
##osis O
con O
##ﬂ O
##ic O
##t O
of O
interest O
statement O

journal O
of O
pediatric O
gas O
##tro O
##enter O
##ology O
and O
nutrition O
49 O
126 O
129 O
2009 O
by O
european O
society O
for O
pediatric O
gas O
##tro O
##enter O
##ology O
he O
##pa O
##tology O
and O
nutrition O
and O
north O
american O
society O
for O
pediatric O
gas O
##tro O
##enter O
##ology O
he O
##pa O
##tology O
and O
nutrition O
case O
report O
de O
novo O
mutations O
in O
pol B-GENE
##g I-GENE
presenting O
with O
acute O
liver O
failure O
or O
en O
##ce O
##pha O
##lo O
##pathy O
richard O
e O
lu O
##tz O
td O
##avi O
##d O
dim O
##mo O
##ck O
ter O
##ic O
s O
sc O
##hmi O
##tt O
tq O
##ing O
zhang O
t O
##lin O
ya O
tang O
z O
##christ O
##ine O
reyes O
edward O
true O
##mp O
##er O
y O
##rod O
##ney O
d O
mcc O
##om O
##b O
jj O
##ange O
##l O
hernandez O
alice O
basin O
##ger O
and O
t O
##lee O
jun O
c O
wong O

department O
of O
genetics O
end O
##oc O
##rino O
##logy O
and O
metabolism O
munro O
##e O
meyer O
institute O
department O
of O
pathology O
and O
micro O
##biology O
university O
of O
nebraska O
medical O
center O
department O
of O
pathology O
division O
of O
pediatric O
critical O
care O
children O
s O
hospital O
omaha O
td O
##ep O
##art O
##ment O
of O
molecular O
and O
human O
genetics O
baylor O
college O
of O
medicine O
houston O
tx O
jj O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
cook O
children O
s O
medical O
center O
and O
division O
of O
metabolic O
genetics O
cook O
children O
s O
physician O
network O
fort O
worth O
tx O

historically O
mitochondrial O
respiratory O
chain O
disorders O
have O
been O
recognized O
as O
a O
multi O
##sy O
##ste O
##mic O
disease O
with O
predominantly O
ne O
##uro O
##mus O
##cular O
dysfunction O
1 O
to O
date O
most O
patients O
with O
mutations O
in O
pol O
##g O
have O
presented O
with O
predominantly O
neurological O
features O
of O
headache O
##s O
or O
focal O
seizures O
2 O
3 O
in O
1 O
study O
end O
state O
he O
##pati O
##c O
disease O
developed O
in O
only O
2 O
of O
26 O
cases O
2 O
in O
another O
study O
the O
only O
patients O
who O
experienced O
he O
##pati O
##c O
disease O
had O
been O
exposed O
to O
sodium O
val O
##pro O
##ate O
3 O
4 O
viral O
infection O
may O
be O
temporal O
##ly O
associated O
with O
the O
development O
of O
acute O
liver O
failure O
in O
pediatric O
patients O
5 O
however O
the O
majority O
of O
children O
who O
contract O
viral O
infections O
do O
not O
experience O
liver O
failure O
this O
suggests O
that O
there O
must O
be O
host O
factors O
that O
differentiate O
those O
children O
who O
do O
experience O
liver O
failure O

case B-PATIENT
1 I-PATIENT
an O
infant O
girl O
was O
born O
at O
term O
with O
a O
normal O
birth O
weight O
to O
non O
##con O
##san O
##gui O
##neo O
##us O
white O
parents O
at O
2 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
she O
had O
feeding B-HPO_TERM
difficulties I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
consequently O
she O
underwent O
an O
extensive O
medical O
evaluation O
that O
included O
determination O
of O
plasma O
electro O
##ly O
##tes O
lac O
##tate O
p O
##yr O
##u O
##vate O
plasma O
amino O
acids O
urine O
organic O
acids O
chromosome O
ka O
##ry O
##ot O
##yp O
##ing O
flu O
##orescence O
in O
situ O
hybrid O
##ization O
for O
dig O
##eo O
##rge O
del O
##eti O
##on O
angel O
##man O
pr O
##ade O
##r O
##wil O
##li O
methyl O
##ation O
studies O
and O
magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
the O
results O
of O
these O
tests O
received O
february O
16 O
2008 O
accepted O
march O
28 O
2008 O

address O
correspondence O
and O
reprint O
requests O
to O
lee O
jun O
c O
wong O
phd O
department O
of O
molecular O
and O
human O
genetics O
baylor O
college O
of O
medicine O
one O
baylor O
plaza O
na O
##b O
2015 O
houston O
tx O
770 O
##30 O
e O
mail O
l O
##j O
##won O
##g O
bc O
##m O
ed O
##u O
dr O
##s O
lu O
##tz O
and O
dim O
##mo O
##ck O
contributed O
equally O
to O
this O
manuscript O
supported O
in O
part O
by O
a O
national O
institutes O
of O
health O
fellowship O
award O
k O
##12 O
rr O
##17 O
##66 O
##5 O
d O
d O
the O
authors O
report O
no O
conflicts O
of O
interest O
126 O
were O
normal O
although O
the O
result O
of O
her O
initial O
newborn O
hearing O
screening O
was O
normal O
subsequent O
testing O
showed O
her O
auditory O
brains O
##tem O
response O
to O
be O
abnormal O

at O
4 O
5 O
months O
of O
age O
the O
patient O
contracted O
an B-HPO_TERM
influenza I-HPO_TERM
a I-HPO_TERM
infection I-HPO_TERM
concurrently O
she O
experienced O
he B-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
associated O
with O
severe O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
and O
elevations B-HPO_TERM
of I-HPO_TERM
plasma I-HPO_TERM
ty I-HPO_TERM
##ros I-HPO_TERM
##ine I-HPO_TERM
203 O
mm O
##ol O
l O
normal O
range O
nr O
35 O
126 O
g B-HPO_TERM
##lu I-HPO_TERM
##tam I-HPO_TERM
##ine I-HPO_TERM
99 O
##4 O
mm O
##ol O
l O
nr O
35 O
##3 O
88 O
##3 O
and O
alan B-HPO_TERM
##ine I-HPO_TERM
104 O
##8 O
mm O
##ol O
l O
nr O
152 O
45 O
##9 O
her O
serum B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
to O
9 O
8 O
mm O
##ol O
l O
nr O
2 O
2 O
the O
markedly O
increased B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
to I-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
ratio I-HPO_TERM
43 O
9 O
nr O
15 O
suggested O
a O
defect O
in O
the O
electron O
transport O
chain O
or O
tri O
##car O
##box O
##yl O
##ic O
acid O
cycle O
6 O

abnormalities B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
synthetic I-HPO_TERM
function I-HPO_TERM
were O
demonstrated O
by O
an O
elevated B-HPO_TERM
pro I-HPO_TERM
##th I-HPO_TERM
##rom I-HPO_TERM
##bin I-HPO_TERM
time I-HPO_TERM
of O
23 O
seconds O
nr O
12 O
4 O
15 O
1 O
and O
a O
partial B-HPO_TERM
th I-HPO_TERM
##rom I-HPO_TERM
##bo I-HPO_TERM
##pl I-HPO_TERM
##ast I-HPO_TERM
##in I-HPO_TERM
time I-HPO_TERM
of I-HPO_TERM
58 I-HPO_TERM
seconds I-HPO_TERM
nr O
25 O
39 O
her O
con B-HPO_TERM
##ju I-HPO_TERM
##gated I-HPO_TERM
bi I-HPO_TERM
##li I-HPO_TERM
##ru I-HPO_TERM
##bin I-HPO_TERM
increased I-HPO_TERM
to O
1 O
89 O
mg O
dl O
nr O
0 O
0 O
0 O
3 O
suggesting O
a O
cho O
##les O
##tat O
##ic O
process O
conversely O
there O
were O
only O
modest O
elevations B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
he I-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
enzymes I-HPO_TERM
as O
##par O
##tate O
amino O
##tra O
##ns O
##fera O
##se O
as O
##t O
260 O
u O
l O
nr O
16 O
46 O
alan O
##ine O
trans O
##amina O
##se O
alt O
313 O
u O
l O
nr O
29 O
46 O
without O
significant O
elevations O
in O
cr O
##ea O
##tin O
##ine O
kinase O
ammonia O
was O
normal O
until O
the O
final O
stages O
of O
her O
illness O
when O
it O
rose O
to O
76 O
mm O
##ol O
l O
normal O

50 O

her O
neurological O
status O
did O
not O
show O
further O
decline O
she O
did O
not O
experience O
seizures O
or O
ny O
##sta O
##gm O
##us O
however O
a O
lu O
##mba O
##r O
pun O
##cture O
2 O
days O
after O
her O
second O
admission O
for O
worse B-HPO_TERM
##ning I-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
showed O
elevated B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
fluid I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
550 O
mg O
dl O
nr O
15 O
40 O
with O
a O
nearly O
ace O
##ll O
##ular O
tap O
13 O
white O
blood O
cells O
0 O
red O
blood O
cells O
mri O
of O
the O
brain O
showed O
non B-HPO_TERM
##sp I-HPO_TERM
##ec I-HPO_TERM
##ific I-HPO_TERM
extra I-HPO_TERM
##ax I-HPO_TERM
##ial I-HPO_TERM
fluid I-HPO_TERM
collection I-HPO_TERM
over O
the O
frontal O
cortex O
and O
also O
thick O
##ening O
and O
enhancement B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
nerve I-HPO_TERM
roots I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ca I-HPO_TERM
##uda I-HPO_TERM
e I-HPO_TERM
##quin I-HPO_TERM
##a I-HPO_TERM
these O
changes O
sometimes O
seen O
in O
dem O
##ye O
##lina O
##ting O
poly O
##ne O
##uro O
##path O
##ies O
suggested O
a O
possible O
ne B-HPO_TERM
##uro I-HPO_TERM
##de I-HPO_TERM
##gen I-HPO_TERM
##erative I-HPO_TERM
disorder I-HPO_TERM

de O
novo O
mutations O
in O
pol O
##g O
with O
liver O
failure O
or O
en O
##ce O
##pha O
##lo O
##pathy O
127 O
fig O
1 O
a O
liver O
shows O
marked O
accumulation O
of O
lip O
##id O
micro B-HPO_TERM
##ste I-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
tri O
##chrome O
stain O
original O
mag O
##ni O
##fication O
x O
##40 O
b O
longitudinal O
section O
of O
skeletal O
muscle O
shows O
marked O
accumulation B-HPO_TERM
of I-HPO_TERM
sub I-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
neutral I-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
mit O
##och O
##ond O
##ria O
are O
un O
##rem O
##ark O
##able O
electron O
microscopy O
bar O
equals O
1 O
mm O

the O
results O
of O
other O
studies O
including O
l O
##ys O
##osomal O
enzymes O
plasma O
very O
long O
chain O
fatty O
acids O
and O
screening O
for O
common O
mutations O
of O
mitochondrial O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##lei O
##c O
acid O
mt O
##dna O
were O
normal O
she O
showed O
signs O
of O
ongoing O
respiratory B-HPO_TERM
difficulty I-HPO_TERM
pan B-HPO_TERM
##cre I-HPO_TERM
##ati I-HPO_TERM
##tis I-HPO_TERM
and O
renal B-HPO_TERM
tub I-HPO_TERM
##ulo I-HPO_TERM
##pathy I-HPO_TERM
despite O
aggressive O
medical O
therapy O
the O
patient O
died B-HPO_TERM
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
months I-AGE_DEATH

liver O
bio O
##psy O
revealed O
marked O
pan O
##lo O
##bular O
accumulation O
of O
neutral B-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
within I-HPO_TERM
he I-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cytes I-HPO_TERM
with O
a O
predominantly O
micro B-HPO_TERM
##ves I-HPO_TERM
##icular I-HPO_TERM
pattern I-HPO_TERM
fig O
1a O
moderate O
sub O
##ac O
##ute O
portal O
inflammation O
mild O
canal O
##icular O
and O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
cho I-HPO_TERM
##les I-HPO_TERM
##tas I-HPO_TERM
##is I-HPO_TERM
and O
mild O
pseudo B-HPO_TERM
##ac I-HPO_TERM
##ina I-HPO_TERM
##r I-HPO_TERM
formation I-HPO_TERM
were O
also O
noted O
g O
##ly O
##co O
##gen O
stain O
##ing O
was O
normal O
electron O
microscopy O
confirmed O
the O
micro O
##ves O
##icular O
ste O
##ato O
##sis O
but O
did O
not O
demonstrate O
any O
structural O
abnormalities O
of O
mit O
##och O
##ond O
##ria O
the O
muscle O
bio O
##psy O
revealed O
prominent O
accumulation O
of O
neutral O
lip B-HPO_TERM
##id I-HPO_TERM
within I-HPO_TERM
my I-HPO_TERM
##ocytes I-HPO_TERM
especially O
in O
the O
sub O
##sar O
##col O
##em O
##mal O
region O
corresponding O
to O
a O
lip O
##id O

my O
##opa O
##thy O
fig O
1b O
the O
my B-HPO_TERM
##of I-HPO_TERM
##ibe I-HPO_TERM
##rs I-HPO_TERM
were I-HPO_TERM
abnormal I-HPO_TERM
##ly I-HPO_TERM
small I-HPO_TERM
measuring O
from O
5 O
to O
10 O
mm O
in O
cross O
sectional O
diameter O
there O
were O
no O
ragged O
red O
fibers O
or O
cy O
##cl O
##oo O
##xy O
##genase O
negative O
fibers O
g O
##ly O
##co O
##gen O
stain O
##ing O
was O
normal O
electron O
microscopy O
confirmed O
the O
excessive O
accumulation O
of O
lip O
##id O
and O
demonstrated O
small O
sub B-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
collections I-HPO_TERM
of I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
in O
occasional O
my O
##of O
##ibe O
##rs O
most O
mit O
##och O
##ond O
##ria O
in O
the O
specimen O
contained O
matrix O
gran O
##ules O
some O
cr O
##ista O
##e O
were O
slightly O
curved O
or O
dil O
##ated O
but O
there O
were O
no O
unique O
structural O
abnormalities O
and O
no O
para O
##cr O
##yst O
##all O
##ine O
inclusion O
##s O
the O
mit O
##och O
##ond O
##ria O
ranged O
from O
105 O
to O
510 O
mean O
262 O
nm O
in O
cross O
sectional O
diameter O
abnormal O
##ly O
enlarged O
mit O
##och O
##ond O
##ria O
were O
not O
present O
the O
lip O
##id O
droplets O
ranged O
from O
260 O
to O
146 O
##4 O
nm O
in O
diameter O
the O
activities O
of O
liver O
mitochondrial O
enzymes O
including O
respiratory O
chain O
complexes O
are O
summarized O
in O
table O
1 O

three O
het O
##ero O
##zy O
##go O
##us O
pol B-GENE
##g I-GENE
mutations O
c B-GENE_VARIANT
75 I-GENE_VARIANT
##2 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
c B-GENE_VARIANT
1760 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
and O
c B-GENE_VARIANT
357 I-GENE_VARIANT
##2 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT

p O
k O
##11 O
##9 O
##1 O
##r O
were O
identified O
the O
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
and O
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
miss O
##ense O
mutations O
have O
been O
frequently O
reported O
in O
cis O
7 O
9 O
the O
novel O
miss O
##ense O
variant O
c B-GENE_VARIANT
357 I-GENE_VARIANT
##2 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT
p B-GENE_VARIANT
k I-GENE_VARIANT
##11 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##r I-GENE_VARIANT
predict O
##s O
a O
relatively O
conservative O
change O
of O
l O
##ys O
##ine O
to O
ar O
##gin O
##ine O
however O
a O
p O
k O
##11 O
##9 O
##1 O
##n O
mutation O
at O
the O
same O
amino O
acid O
residue O
has O
been O
found O
in O
a O
patient O
with O
al O
##per O
syndrome O
2 O
thus O
the O
p O
k O
##11 O
##9 O
##1 O
##r O
alteration O
is O
likely O
to O
be O
pathogen O
##ic O
testing O
of O
the O
parents O
dna O
showed O
that O
the O
mother O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
p O
t O
##25 O
##1 O
##i O
and O
p O
p O
##58 O
##7 O
##l O
miss O
##ense O
mutations O
confirming O
her O
carrier O
status O
test O
results O
from O
the O
father O
were O
negative O
for O
all O
of O
the O
mutations O
pat O
##ern O
##ity O
was O
confirmed O
by O
comparative O
analysis O
using O
15 O
un O
##link O
##ed O
poly O
##morphic O
markers O
measurement O
of O
the O
mt O
##dna O
content O
in O
liver O
using O
q O
##pc O
##r O
revealed O
a O
severely O
reduced O
mt O
##dna O
3 O
of O
age O
matched O
mean O
consistent O
with O
2 O
mu O
##tated O
all O
##eles O
in O
the O
pol O
##g O
gene O

case B-PATIENT
2 I-PATIENT
a O
white O
infant O
boy O
was O
born O
to O
healthy O
unrelated O
parents O
at O
18 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
he O
had O
speech B-HPO_TERM
and O
motor B-HPO_TERM
delay I-HPO_TERM
he O
was O
able O
to O
crawl O
but O
not O
walk O
mri O
of O
the O
spinal O
cord O
showed O
an O
as O
##ym O
##pt O
##oma O
##tic O
sy B-HPO_TERM
##rin I-HPO_TERM
##x I-HPO_TERM
between O
t O
##11 O
and O
l O
##1 O
while O
at O
home O
with O
his O
family O
he O
had O
a O
new O
##ons O
##et O
seizure B-HPO_TERM
that O
included O
eye O
deviation O
jaw O
clenching O
and O
h O
##yp O
##oton O
##ia O
of O
the O
trunk O
and O
ex O
##tre O
##mit O
##ies O
he O
experienced O
repetitive B-HPO_TERM
generalized I-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
that O
evolved O
into O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
no O
pre O
##ci O
##pit O
##ating O
event O
or O
ing O
##est O
##ion O
was O
identified O
and O
he O
was O
not O
ill O
or O
feb O
##ril O
##e O
before O
the O
onset O
of O
seizures O

standard O
treatment O
with O
ph O
##eno O
##bar O
##bit O
##al O
f O
##os O
##ph O
##en O
##yt O
##oin O
mid O
##az O
##ola O
##m O
lo O
##raz O
##ep O
##am O
and O
diaz O
##ep O
##am O
was O
unsuccessful O
therefore O
the O
child O
underwent O
pen O
##to O
##bar O
##bit O
##al O
coma O
for O
seizure O
control O
he O
was O
not O
treated O
with O
val O
##pro O
##ic O
acid O
after O
30 O
days O
of O
this O
treatment O
his O
seizures O
resolved O
and O
the O
pen O
##to O
##bar O
##bit O
##al O
was O
discontinued O
he O
was O
left O
with O
a O
severe B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
characterized O
by O
cho B-HPO_TERM
##re I-HPO_TERM
##o I-HPO_TERM
at I-HPO_TERM
##het I-HPO_TERM
##oid I-HPO_TERM
j O
pe O
##dia O
##tr O
gas O
##tro O
##enter O
##ol O
nut O
##r O
vol O
49 O
no O
1 O
july O
2009 O
128 O
lu O
##tz O
et O
al O
table O
1 O
mitochondrial O
respiratory O
chain O
activity O
case O
1 O
ci O
##tra O
##te O
synth O
##ase O
activity O
nad O
##h O
fe O
##c O
##n O
red O
##uc O
##tase O
i O
##þ O
##iii O
rot O
##eno O
##ne O
sensitive O
su O
##cci O
##nate O

de O
##hy O
##dro O
##genase O
ii O
##þ O
##iii O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
iv O
liver O
232 O
pro O
##life O
##rated O
370 O
100 O
50 O
##9 O
206 O
56 O
30 O
16 O
4 O
65 O
36 O
##9 O
100 O
14 O
119 O
32 O
7 O
27 O
7 O
liver O
control O
mean O
sd O
62 O
7 O
25 O
8 O
247 O
127 O
188 O
58 O
7 O
17 O
6 O
5 O
3 O
11 O
8 O
3 O
2 O
26 O
4 O
10 O
8 O
range O
31 O
6 O
117 O
58 O
5 O
43 O
##8 O
84 O
5 O
281 O
11 O
1 O
26 O
5 O
4 O
8 O
15 O
7 O
7 O
5 O
42 O
8 O
muscle O
##y O
20 O
67 O
0 O
60 O
1 O
13 O
0 O
09 O
1 O
75 O
muscle O
reference O
range O
##y O
6 O
86 O
24 O
62 O
0 O
41 O
1 O
21 O
0 O
45 O
1 O
29 O
0 O
42 O
1 O
65 O
1 O
03 O
3 O
38 O

mitochondrial O
respiratory O
chain O
enzyme O
activities O
in O
liver O
and O
muscle O
showed O
significantly O
reduced B-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
and O
ii B-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
and O
iv B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
before O
and O
after O
correction O
for O
ci O
##tra O
##te O
synth O
##ase O
and O
significantly O
reduced B-HPO_TERM
complex I-HPO_TERM
ii I-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
ci O
##tra O
##te O
synth O
##ase O
and O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
activities O
which O
are O
not O
encoded O
by O
mt O
##dna O
were O
found O
to O
be O
increased O
in O
liver O
consistent O
with O
mitochondrial B-HPO_TERM
proliferation I-HPO_TERM
iv O
¼ O
##int O
##rave O
##nous O
nad O
##h O
¼ O
nico O
##tina O
##mide O
aden O
##ine O
din O
##uc O
##le O
##otide O

activities O
are O
expressed O
in O
nm O
##ol O
min O
1 O
mg O
1 O
of O
protein O
numbers O
in O
the O
parentheses O
represent O
percentage O
##s O
of O
the O
control O
mean O
before O
first O
number O
and O
after O
second O
number O
correction O
to O
ci O
##tra O
##te O
synth O
##ase O
activity O
control O
mean O
values O
were O
obtained O
from O
10 O
liver O
specimens O
with O
ur O
##ea O
cycle O
deficiency O
which O
may O
have O
below O
normal O
respiratory O
chain O
enzyme O
activities O
thus O
the O
patient O
values O
in O
this O
table O
may O
be O
over O
##est O
##imated O

journal O
of O
pediatric O
gas O
##tro O
##enter O
##ology O
and O
nutrition O
49 O
126 O
129 O
2009 O
by O
european O
society O
for O
pediatric O
gas O
##tro O
##enter O
##ology O
he O
##pa O
##tology O
and O
nutrition O
and O
north O
american O
society O
for O
pediatric O
gas O
##tro O
##enter O
##ology O
he O
##pa O
##tology O
and O
nutrition O
case O
report O
de O
novo O
mutations O
in O
pol B-GENE
##g I-GENE
presenting O
with O
acute O
liver O
failure O
or O
en O
##ce O
##pha O
##lo O
##pathy O
richard O
e O
lu O
##tz O
td O
##avi O
##d O
dim O
##mo O
##ck O
ter O
##ic O
s O
sc O
##hmi O
##tt O
tq O
##ing O
zhang O
t O
##lin O
ya O
tang O
z O
##christ O
##ine O
reyes O
edward O
true O
##mp O
##er O
y O
##rod O
##ney O
d O
mcc O
##om O
##b O
jj O
##ange O
##l O
hernandez O
alice O
basin O
##ger O
and O
t O
##lee O
jun O
c O
wong O

department O
of O
genetics O
end O
##oc O
##rino O
##logy O
and O
metabolism O
munro O
##e O
meyer O
institute O
department O
of O
pathology O
and O
micro O
##biology O
university O
of O
nebraska O
medical O
center O
department O
of O
pathology O
division O
of O
pediatric O
critical O
care O
children O
s O
hospital O
omaha O
td O
##ep O
##art O
##ment O
of O
molecular O
and O
human O
genetics O
baylor O
college O
of O
medicine O
houston O
tx O
jj O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
cook O
children O
s O
medical O
center O
and O
division O
of O
metabolic O
genetics O
cook O
children O
s O
physician O
network O
fort O
worth O
tx O

historically O
mitochondrial O
respiratory O
chain O
disorders O
have O
been O
recognized O
as O
a O
multi O
##sy O
##ste O
##mic O
disease O
with O
predominantly O
ne O
##uro O
##mus O
##cular O
dysfunction O
1 O
to O
date O
most O
patients O
with O
mutations O
in O
pol O
##g O
have O
presented O
with O
predominantly O
neurological O
features O
of O
headache O
##s O
or O
focal O
seizures O
2 O
3 O
in O
1 O
study O
end O
state O
he O
##pati O
##c O
disease O
developed O
in O
only O
2 O
of O
26 O
cases O
2 O
in O
another O
study O
the O
only O
patients O
who O
experienced O
he O
##pati O
##c O
disease O
had O
been O
exposed O
to O
sodium O
val O
##pro O
##ate O
3 O
4 O
viral O
infection O
may O
be O
temporal O
##ly O
associated O
with O
the O
development O
of O
acute O
liver O
failure O
in O
pediatric O
patients O
5 O
however O
the O
majority O
of O
children O
who O
contract O
viral O
infections O
do O
not O
experience O
liver O
failure O
this O
suggests O
that O
there O
must O
be O
host O
factors O
that O
differentiate O
those O
children O
who O
do O
experience O
liver O
failure O

case B-PATIENT
1 I-PATIENT
an O
infant O
girl O
was O
born O
at O
term O
with O
a O
normal O
birth O
weight O
to O
non O
##con O
##san O
##gui O
##neo O
##us O
white O
parents O
at O
2 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
she O
had O
feeding B-HPO_TERM
difficulties I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
consequently O
she O
underwent O
an O
extensive O
medical O
evaluation O
that O
included O
determination O
of O
plasma O
electro O
##ly O
##tes O
lac O
##tate O
p O
##yr O
##u O
##vate O
plasma O
amino O
acids O
urine O
organic O
acids O
chromosome O
ka O
##ry O
##ot O
##yp O
##ing O
flu O
##orescence O
in O
situ O
hybrid O
##ization O
for O
dig O
##eo O
##rge O
del O
##eti O
##on O
angel O
##man O
pr O
##ade O
##r O
##wil O
##li O
methyl O
##ation O
studies O
and O
magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
the O
results O
of O
these O
tests O
received O
february O
16 O
2008 O
accepted O
march O
28 O
2008 O

address O
correspondence O
and O
reprint O
requests O
to O
lee O
jun O
c O
wong O
phd O
department O
of O
molecular O
and O
human O
genetics O
baylor O
college O
of O
medicine O
one O
baylor O
plaza O
na O
##b O
2015 O
houston O
tx O
770 O
##30 O
e O
mail O
l O
##j O
##won O
##g O
bc O
##m O
ed O
##u O
dr O
##s O
lu O
##tz O
and O
dim O
##mo O
##ck O
contributed O
equally O
to O
this O
manuscript O
supported O
in O
part O
by O
a O
national O
institutes O
of O
health O
fellowship O
award O
k O
##12 O
rr O
##17 O
##66 O
##5 O
d O
d O
the O
authors O
report O
no O
conflicts O
of O
interest O
126 O
were O
normal O
although O
the O
result O
of O
her O
initial O
newborn O
hearing O
screening O
was O
normal O
subsequent O
testing O
showed O
her O
auditory O
brains O
##tem O
response O
to O
be O
abnormal O

at O
4 O
5 O
months O
of O
age O
the O
patient O
contracted O
an B-HPO_TERM
influenza I-HPO_TERM
a I-HPO_TERM
infection I-HPO_TERM
concurrently O
she O
experienced O
he B-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
associated O
with O
severe O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
and O
elevations B-HPO_TERM
of I-HPO_TERM
plasma I-HPO_TERM
ty I-HPO_TERM
##ros I-HPO_TERM
##ine I-HPO_TERM
203 O
mm O
##ol O
l O
normal O
range O
nr O
35 O
126 O
g B-HPO_TERM
##lu I-HPO_TERM
##tam I-HPO_TERM
##ine I-HPO_TERM
99 O
##4 O
mm O
##ol O
l O
nr O
35 O
##3 O
88 O
##3 O
and O
alan B-HPO_TERM
##ine I-HPO_TERM
104 O
##8 O
mm O
##ol O
l O
nr O
152 O
45 O
##9 O
her O
serum B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
to O
9 O
8 O
mm O
##ol O
l O
nr O
2 O
2 O
the O
markedly O
increased B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
to I-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
ratio I-HPO_TERM
43 O
9 O
nr O
15 O
suggested O
a O
defect O
in O
the O
electron O
transport O
chain O
or O
tri O
##car O
##box O
##yl O
##ic O
acid O
cycle O
6 O

abnormalities B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
synthetic I-HPO_TERM
function I-HPO_TERM
were O
demonstrated O
by O
an O
elevated B-HPO_TERM
pro I-HPO_TERM
##th I-HPO_TERM
##rom I-HPO_TERM
##bin I-HPO_TERM
time I-HPO_TERM
of O
23 O
seconds O
nr O
12 O
4 O
15 O
1 O
and O
a O
partial B-HPO_TERM
th I-HPO_TERM
##rom I-HPO_TERM
##bo I-HPO_TERM
##pl I-HPO_TERM
##ast I-HPO_TERM
##in I-HPO_TERM
time I-HPO_TERM
of I-HPO_TERM
58 I-HPO_TERM
seconds I-HPO_TERM
nr O
25 O
39 O
her O
con B-HPO_TERM
##ju I-HPO_TERM
##gated I-HPO_TERM
bi I-HPO_TERM
##li I-HPO_TERM
##ru I-HPO_TERM
##bin I-HPO_TERM
increased I-HPO_TERM
to O
1 O
89 O
mg O
dl O
nr O
0 O
0 O
0 O
3 O
suggesting O
a O
cho O
##les O
##tat O
##ic O
process O
conversely O
there O
were O
only O
modest O
elevations B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
he I-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
enzymes I-HPO_TERM
as O
##par O
##tate O
amino O
##tra O
##ns O
##fera O
##se O
as O
##t O
260 O
u O
l O
nr O
16 O
46 O
alan O
##ine O
trans O
##amina O
##se O
alt O
313 O
u O
l O
nr O
29 O
46 O
without O
significant O
elevations O
in O
cr O
##ea O
##tin O
##ine O
kinase O
ammonia O
was O
normal O
until O
the O
final O
stages O
of O
her O
illness O
when O
it O
rose O
to O
76 O
mm O
##ol O
l O
normal O

50 O

her O
neurological O
status O
did O
not O
show O
further O
decline O
she O
did O
not O
experience O
seizures O
or O
ny O
##sta O
##gm O
##us O
however O
a O
lu O
##mba O
##r O
pun O
##cture O
2 O
days O
after O
her O
second O
admission O
for O
worse B-HPO_TERM
##ning I-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
showed O
elevated B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
fluid I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
550 O
mg O
dl O
nr O
15 O
40 O
with O
a O
nearly O
ace O
##ll O
##ular O
tap O
13 O
white O
blood O
cells O
0 O
red O
blood O
cells O
mri O
of O
the O
brain O
showed O
non B-HPO_TERM
##sp I-HPO_TERM
##ec I-HPO_TERM
##ific I-HPO_TERM
extra I-HPO_TERM
##ax I-HPO_TERM
##ial I-HPO_TERM
fluid I-HPO_TERM
collection I-HPO_TERM
over O
the O
frontal O
cortex O
and O
also O
thick O
##ening O
and O
enhancement B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
nerve I-HPO_TERM
roots I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ca I-HPO_TERM
##uda I-HPO_TERM
e I-HPO_TERM
##quin I-HPO_TERM
##a I-HPO_TERM
these O
changes O
sometimes O
seen O
in O
dem O
##ye O
##lina O
##ting O
poly O
##ne O
##uro O
##path O
##ies O
suggested O
a O
possible O
ne B-HPO_TERM
##uro I-HPO_TERM
##de I-HPO_TERM
##gen I-HPO_TERM
##erative I-HPO_TERM
disorder I-HPO_TERM

de O
novo O
mutations O
in O
pol O
##g O
with O
liver O
failure O
or O
en O
##ce O
##pha O
##lo O
##pathy O
127 O
fig O
1 O
a O
liver O
shows O
marked O
accumulation O
of O
lip O
##id O
micro B-HPO_TERM
##ste I-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
tri O
##chrome O
stain O
original O
mag O
##ni O
##fication O
x O
##40 O
b O
longitudinal O
section O
of O
skeletal O
muscle O
shows O
marked O
accumulation B-HPO_TERM
of I-HPO_TERM
sub I-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
neutral I-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
mit O
##och O
##ond O
##ria O
are O
un O
##rem O
##ark O
##able O
electron O
microscopy O
bar O
equals O
1 O
mm O

the O
results O
of O
other O
studies O
including O
l O
##ys O
##osomal O
enzymes O
plasma O
very O
long O
chain O
fatty O
acids O
and O
screening O
for O
common O
mutations O
of O
mitochondrial O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##lei O
##c O
acid O
mt O
##dna O
were O
normal O
she O
showed O
signs O
of O
ongoing O
respiratory B-HPO_TERM
difficulty I-HPO_TERM
pan B-HPO_TERM
##cre I-HPO_TERM
##ati I-HPO_TERM
##tis I-HPO_TERM
and O
renal B-HPO_TERM
tub I-HPO_TERM
##ulo I-HPO_TERM
##pathy I-HPO_TERM
despite O
aggressive O
medical O
therapy O
the O
patient O
died B-HPO_TERM
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
months I-AGE_DEATH

liver O
bio O
##psy O
revealed O
marked O
pan O
##lo O
##bular O
accumulation O
of O
neutral B-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
within I-HPO_TERM
he I-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cytes I-HPO_TERM
with O
a O
predominantly O
micro B-HPO_TERM
##ves I-HPO_TERM
##icular I-HPO_TERM
pattern I-HPO_TERM
fig O
1a O
moderate O
sub O
##ac O
##ute O
portal O
inflammation O
mild O
canal O
##icular O
and O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
cho I-HPO_TERM
##les I-HPO_TERM
##tas I-HPO_TERM
##is I-HPO_TERM
and O
mild O
pseudo B-HPO_TERM
##ac I-HPO_TERM
##ina I-HPO_TERM
##r I-HPO_TERM
formation I-HPO_TERM
were O
also O
noted O
g O
##ly O
##co O
##gen O
stain O
##ing O
was O
normal O
electron O
microscopy O
confirmed O
the O
micro O
##ves O
##icular O
ste O
##ato O
##sis O
but O
did O
not O
demonstrate O
any O
structural O
abnormalities O
of O
mit O
##och O
##ond O
##ria O
the O
muscle O
bio O
##psy O
revealed O
prominent O
accumulation O
of O
neutral O
lip B-HPO_TERM
##id I-HPO_TERM
within I-HPO_TERM
my I-HPO_TERM
##ocytes I-HPO_TERM
especially O
in O
the O
sub O
##sar O
##col O
##em O
##mal O
region O
corresponding O
to O
a O
lip O
##id O

my O
##opa O
##thy O
fig O
1b O
the O
my B-HPO_TERM
##of I-HPO_TERM
##ibe I-HPO_TERM
##rs I-HPO_TERM
were I-HPO_TERM
abnormal I-HPO_TERM
##ly I-HPO_TERM
small I-HPO_TERM
measuring O
from O
5 O
to O
10 O
mm O
in O
cross O
sectional O
diameter O
there O
were O
no O
ragged O
red O
fibers O
or O
cy O
##cl O
##oo O
##xy O
##genase O
negative O
fibers O
g O
##ly O
##co O
##gen O
stain O
##ing O
was O
normal O
electron O
microscopy O
confirmed O
the O
excessive O
accumulation O
of O
lip O
##id O
and O
demonstrated O
small O
sub B-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
collections I-HPO_TERM
of I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
in O
occasional O
my O
##of O
##ibe O
##rs O
most O
mit O
##och O
##ond O
##ria O
in O
the O
specimen O
contained O
matrix O
gran O
##ules O
some O
cr O
##ista O
##e O
were O
slightly O
curved O
or O
dil O
##ated O
but O
there O
were O
no O
unique O
structural O
abnormalities O
and O
no O
para O
##cr O
##yst O
##all O
##ine O
inclusion O
##s O
the O
mit O
##och O
##ond O
##ria O
ranged O
from O
105 O
to O
510 O
mean O
262 O
nm O
in O
cross O
sectional O
diameter O
abnormal O
##ly O
enlarged O
mit O
##och O
##ond O
##ria O
were O
not O
present O
the O
lip O
##id O
droplets O
ranged O
from O
260 O
to O
146 O
##4 O
nm O
in O
diameter O
the O
activities O
of O
liver O
mitochondrial O
enzymes O
including O
respiratory O
chain O
complexes O
are O
summarized O
in O
table O
1 O

three O
het O
##ero O
##zy O
##go O
##us O
pol B-GENE
##g I-GENE
mutations O
c B-GENE_VARIANT
75 I-GENE_VARIANT
##2 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
c B-GENE_VARIANT
1760 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
and O
c B-GENE_VARIANT
357 I-GENE_VARIANT
##2 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT

p O
k O
##11 O
##9 O
##1 O
##r O
were O
identified O
the O
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
and O
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
miss O
##ense O
mutations O
have O
been O
frequently O
reported O
in O
cis O
7 O
9 O
the O
novel O
miss O
##ense O
variant O
c B-GENE_VARIANT
357 I-GENE_VARIANT
##2 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT
p B-GENE_VARIANT
k I-GENE_VARIANT
##11 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##r I-GENE_VARIANT
predict O
##s O
a O
relatively O
conservative O
change O
of O
l O
##ys O
##ine O
to O
ar O
##gin O
##ine O
however O
a O
p O
k O
##11 O
##9 O
##1 O
##n O
mutation O
at O
the O
same O
amino O
acid O
residue O
has O
been O
found O
in O
a O
patient O
with O
al O
##per O
syndrome O
2 O
thus O
the O
p O
k O
##11 O
##9 O
##1 O
##r O
alteration O
is O
likely O
to O
be O
pathogen O
##ic O
testing O
of O
the O
parents O
dna O
showed O
that O
the O
mother O
was O
het O
##ero O
##zy O
##go O
##us O
for O
the O
p O
t O
##25 O
##1 O
##i O
and O
p O
p O
##58 O
##7 O
##l O
miss O
##ense O
mutations O
confirming O
her O
carrier O
status O
test O
results O
from O
the O
father O
were O
negative O
for O
all O
of O
the O
mutations O
pat O
##ern O
##ity O
was O
confirmed O
by O
comparative O
analysis O
using O
15 O
un O
##link O
##ed O
poly O
##morphic O
markers O
measurement O
of O
the O
mt O
##dna O
content O
in O
liver O
using O
q O
##pc O
##r O
revealed O
a O
severely O
reduced O
mt O
##dna O
3 O
of O
age O
matched O
mean O
consistent O
with O
2 O
mu O
##tated O
all O
##eles O
in O
the O
pol O
##g O
gene O

case B-PATIENT
2 I-PATIENT
a O
white O
infant O
boy O
was O
born O
to O
healthy O
unrelated O
parents O
at O
18 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
he O
had O
speech B-HPO_TERM
and O
motor B-HPO_TERM
delay I-HPO_TERM
he O
was O
able O
to O
crawl O
but O
not O
walk O
mri O
of O
the O
spinal O
cord O
showed O
an O
as O
##ym O
##pt O
##oma O
##tic O
sy B-HPO_TERM
##rin I-HPO_TERM
##x I-HPO_TERM
between O
t O
##11 O
and O
l O
##1 O
while O
at O
home O
with O
his O
family O
he O
had O
a O
new O
##ons O
##et O
seizure B-HPO_TERM
that O
included O
eye O
deviation O
jaw O
clenching O
and O
h O
##yp O
##oton O
##ia O
of O
the O
trunk O
and O
ex O
##tre O
##mit O
##ies O
he O
experienced O
repetitive B-HPO_TERM
generalized I-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
that O
evolved O
into O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
no O
pre O
##ci O
##pit O
##ating O
event O
or O
ing O
##est O
##ion O
was O
identified O
and O
he O
was O
not O
ill O
or O
feb O
##ril O
##e O
before O
the O
onset O
of O
seizures O

standard O
treatment O
with O
ph O
##eno O
##bar O
##bit O
##al O
f O
##os O
##ph O
##en O
##yt O
##oin O
mid O
##az O
##ola O
##m O
lo O
##raz O
##ep O
##am O
and O
diaz O
##ep O
##am O
was O
unsuccessful O
therefore O
the O
child O
underwent O
pen O
##to O
##bar O
##bit O
##al O
coma O
for O
seizure O
control O
he O
was O
not O
treated O
with O
val O
##pro O
##ic O
acid O
after O
30 O
days O
of O
this O
treatment O
his O
seizures O
resolved O
and O
the O
pen O
##to O
##bar O
##bit O
##al O
was O
discontinued O
he O
was O
left O
with O
a O
severe B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
characterized O
by O
cho B-HPO_TERM
##re I-HPO_TERM
##o I-HPO_TERM
at I-HPO_TERM
##het I-HPO_TERM
##oid I-HPO_TERM
j O
pe O
##dia O
##tr O
gas O
##tro O
##enter O
##ol O
nut O
##r O
vol O
49 O
no O
1 O
july O
2009 O
128 O
lu O
##tz O
et O
al O
table O
1 O
mitochondrial O
respiratory O
chain O
activity O
case O
1 O
ci O
##tra O
##te O
synth O
##ase O
activity O
nad O
##h O
fe O
##c O
##n O
red O
##uc O
##tase O
i O
##þ O
##iii O
rot O
##eno O
##ne O
sensitive O
su O
##cci O
##nate O

de O
##hy O
##dro O
##genase O
ii O
##þ O
##iii O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
iv O
liver O
232 O
pro O
##life O
##rated O
370 O
100 O
50 O
##9 O
206 O
56 O
30 O
16 O
4 O
65 O
36 O
##9 O
100 O
14 O
119 O
32 O
7 O
27 O
7 O
liver O
control O
mean O
sd O
62 O
7 O
25 O
8 O
247 O
127 O
188 O
58 O
7 O
17 O
6 O
5 O
3 O
11 O
8 O
3 O
2 O
26 O
4 O
10 O
8 O
range O
31 O
6 O
117 O
58 O
5 O
43 O
##8 O
84 O
5 O
281 O
11 O
1 O
26 O
5 O
4 O
8 O
15 O
7 O
7 O
5 O
42 O
8 O
muscle O
##y O
20 O
67 O
0 O
60 O
1 O
13 O
0 O
09 O
1 O
75 O
muscle O
reference O
range O
##y O
6 O
86 O
24 O
62 O
0 O
41 O
1 O
21 O
0 O
45 O
1 O
29 O
0 O
42 O
1 O
65 O
1 O
03 O
3 O
38 O

mitochondrial O
respiratory O
chain O
enzyme O
activities O
in O
liver O
and O
muscle O
showed O
significantly O
reduced B-HPO_TERM
complex I-HPO_TERM
i I-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
and O
ii B-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
and O
iv B-HPO_TERM
in I-HPO_TERM
liver I-HPO_TERM
before O
and O
after O
correction O
for O
ci O
##tra O
##te O
synth O
##ase O
and O
significantly O
reduced B-HPO_TERM
complex I-HPO_TERM
ii I-HPO_TERM
##þ I-HPO_TERM
##iii I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
ci O
##tra O
##te O
synth O
##ase O
and O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
activities O
which O
are O
not O
encoded O
by O
mt O
##dna O
were O
found O
to O
be O
increased O
in O
liver O
consistent O
with O
mitochondrial B-HPO_TERM
proliferation I-HPO_TERM
iv O
¼ O
##int O
##rave O
##nous O
nad O
##h O
¼ O
nico O
##tina O
##mide O
aden O
##ine O
din O
##uc O
##le O
##otide O

activities O
are O
expressed O
in O
nm O
##ol O
min O
1 O
mg O
1 O
of O
protein O
numbers O
in O
the O
parentheses O
represent O
percentage O
##s O
of O
the O
control O
mean O
before O
first O
number O
and O
after O
second O
number O
correction O
to O
ci O
##tra O
##te O
synth O
##ase O
activity O
control O
mean O
values O
were O
obtained O
from O
10 O
liver O
specimens O
with O
ur O
##ea O
cycle O
deficiency O
which O
may O
have O
below O
normal O
respiratory O
chain O
enzyme O
activities O
thus O
the O
patient O
values O
in O
this O
table O
may O
be O
over O
##est O
##imated O

aa O
##mir O
bad O
##rud O
##din O
md O
ravi O
s O
menon O
md O
anthony O
t O
red O
##er O
md O
4 O
amino O
##py O
##rid O
##ine O
toxicity O
mimic O
##s O
auto O
##im O
##mun O
##e O
mediated O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
4 O
amino O
##py O
##rid O
##ine O
4 O
ap O
is O
a O
potassium O
channel O

block O
##er O
which O
increases O
motor O
performance O
and O
walking O
speed O
in O
multiple O
sc O
##ler O
##osis O
ms O
and O
spinal O
cord O
injury O
1 O
it O
enhance O
##s O
action O
potential O
##s O
by O
blocking O
open O
potassium O
channels O
4 O
ap O
toxicity O
can O
cause O
di O
##zziness O
nausea O
weakness O
psycho O
##sis O
and O
seizures O
2 O
in O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
antibodies O
bind O
voltage O
##gated O
potassium O
channels O
v O
##g O
##k O
##c O
and O
damage O
peripheral O
and O
central O
neurons O
3 O
v O
##g O
##k O
##c O
sub O
##type O
##s O
exist O
in O
brain O
peripheral O
nerves O
vascular O
end O
##oth O
##eli O
##um O
and O
all O
muscle O
types O
4 O
we O
document O
that O
severe O
4 O
ap O
overdose O
causes O
significant O
abu O
##lia O
cognitive O
impairment O
and O
prominent O
my O
##opa O
##thic O
changes O
in O
heart O
and O
skeletal O
muscle O
the O
temporal O
lobe O
mri O
signal O
and O
clinical O
presentation O
have O
parallels O
to O
the O
seem O

ing O
##ly O
distinct O
disease O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
case O
report O
a O
22 O
year O
old O
man O
with O
ms O
ing O
##ested O
30 O
10 O
mg O
tablets O
of O
4 O
ap O
he O
had O
agitated O
behavior O
but O
was O
oriented O
con O
##vers O
##ant O
and O
without O
focal O
ne O
##uro O
##logic O
deficit O
##s O
or O
muscle O
fi O
##bri O
##llation O
##s O
he O
had O
cool O
flushed O
dia O
##ph O
##ore O
##tic O
skin O
with O
temperature O
of O
38 O
9 O
##° O
##c O
blood O
pressure O
was O
209 O
108 O
mm O
h O
##g O
with O
runs O
of O
su O
##pr O
##ave O
##nt O
##ric O
##ular O
ta O
##chy O
##card O
##ia O
to O
170 O
beats O
per O
minute O
int O
##uba O
##tion O
for O
air O
##way O
protection O
led O
to O
intensive O
care O
unit O
admission O

ee O
##g O
exhibited O
frequent O
diffuse O
poly O
##sp O
##ike O
and O
spike O
wave O
discharge O
##s O
that O
normal O
##ized O
over O
time O
there O
were O
no O
electro O
##graphic O
or O
clinical O
seizures O
trans O
##thor O
##ac O
##ic O
echo O
##card O
##io O
##gram O
revealed O
diffuse O
h O
##yp O
##oki O
##nes O
##is O
and O
an O
e O
##ject O
##ion O
fraction O
of O
24 O
cs O
##f O
fluid O
on O
admission O
and O
4 O
days O
after O
overdose O
had O
normal O
cell O
count O
protein O
and O
glucose O
but O
contained O
cs O
##f O
ol O
##igo O
##cl O
##onal O
bands O
bilateral O
medial O
temporal O
lobe O
mri O
hyper O
##int O
##ens O
##ity O
figure O
on O
t O
##2 O
and O
fluid O
##att O
##en O
##uated O
inversion O
recovery O
did O
not O
enhance O
with O
ga O
##do O
##lini O
##um O
his O
mri O
before O
overdose O
did O
not O
show O
these O
signal O
abnormalities O

five O
days O
after O
overdose O
he O
was O
awake O
with O
spontaneous O
eye O
opening O
but O
had O
minimal O
awareness O
of O
the O
examiner O
and O
did O
not O
speak O
he O
displayed O
minimal O
brady O
##kin O
##etic O
movement O
to O
no O
##xious O
stimuli O
and O
had O
symmetric O
1 O
5 O
strength O
on O
ash O
##worth O
scale O
by O
the O
ninth O
day O
serum O
cp O
##k O
peaked O
at O
49 O
##4 O
i O
##u O
l O
he O
produced O
rare O
h O
##yp O
##op O
##hon O
##ic O
luc O
##id O
speech O
and O
followed O
simple O
commands O
ne O
##uro O
##psy O
##chia O
##tric O
evaluation O
revealed O
profound O
memory O
loss O

a O
right O
vent O
##ric O
##ular O
end O
##omy O
##oca O
##rdial O
bio O
##psy O
excluded O
inflammation O
fi O
##bro O
##sis O
or O
toxic O
inclusion O
##s O
on O
day O
12 O
the O
e O
##ject O
##ion O
fraction O
normal O
##ized O
57 O
nerve O
conduct O
##ion O
ve O
##lo O
##cit O
##ies O
were O
normal O
em O
##g O
demonstrated O
my O
##opa O
##thy O
in O
multiple O
my O
##oto O
##mes O
muscle O
bio O
##psy O
showed O
mild O
focal O
end O
##omy O
##sia O
##l O
inflammation O
with O
normal O
blood O
vessels O
and O
muscle O
architecture O

at O
27 O
days O
the O
patient O
s O
affect O
was O
brighter O
with O
rare O
h O
##yp O
##op O
##hon O
##ic O
speech O
he O
had O
3 O
5 O
anti O
##gra O
##vity O
limb O
movement O
over O
the O
next O
8 O
weeks O
his O
speech O
and O
language O
returned O
to O
normal O
and O
he O
walked O
independently O
despite O
3 O
months O
of O
cognitive O
rehabilitation O
he O
had O
significant O
ant O
##ero O
##grade O
and O
retro O
##grade O
memory O
dysfunction O
and O
in O
##ef O
##fi O
##cie O
##nt O
cognitive O
processing O
suggesting O
medial O
temporal O
lobe O
dysfunction O
mri O
signal O
abnormalities O
were O
no O
longer O
present O
at O
4 O
months O

one O
year O
after O
4 O
ap O
overdose O
spontaneous O
speech O
motor O
and O
verbal O
responses O
strength O
balance O
and O
ga O
##it O
had O
improved O
to O
baseline O
status O
he O
had O
difficulty O
with O
short O
term O
memory O
and O
learning O
new O
tasks O
discussion O
the O
cognitive O
deficit O
##s O
abu O
##lia O
and O
temporal O
lobe O
lesions O
on O
mri O
are O
striking O
##ly O
similar O
to O
findings O
in O
patients O
with O
hs O
##v O
or O
para O
##neo O
##pl O
##astic O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
5 O
clinical O
and O
radio O
##graphic O
findings O
likely O
resulted O
from O
direct O
high O
dose O
4 O
ap O
toxicity O
to O
cn O
##s O
neurons O
and O
cardiac O
and O
skeletal O
muscle O

an O
infectious O
et O
##iology O
is O
unlikely O
two O
cs O
##f O
studies O
showed O
no O
l O
##ym O
##ph O
##oc O
##yt O
##osis O
cs O
##f O
pc O
##r O
for O
hs O
##v O
and O
viral O
cultures O
were O
negative O
para O
##neo O
##pl O
##astic O
disease O
is O
unlikely O
because O
of O
the O
acute O
onset O
and O
lack O
of O
progression O
mor O
##van O
disease O
is O
unlikely O
in O
the O
absence O
of O
ne O
##uro O
##my O
##oton O
##ia O
and O
ins O
##idi O
##ous O
clinical O
course O
vs O
the O
acute O
onset O
in O
this O
patient O
6 O

v O
##g O
##k O
##c O
are O
present O
in O
brain O
and O
peripheral O
nerves O
6 O
there O
are O
antibodies O
to O
v O
##g O
##k O
##c O
in O
ne O
##uro O
##my O
##oton O
##ia O
a O
p O
##ns O
disease O
as O
well O
as O
in O
mor O
##van O
syndrome O
which O
involves O
cn O
##s O
peripheral O
nervous O
system O
and O
auto O
##no O
##mic O
nerves O
v O
##g O
##k O
##c O
block O
##age O
reduces O
glucose O
metabolism O
in O
the O
hip O
##po O
##camp O
##us O
and O
1100 O
ne O
##uro O
##logy O
72 O
march O
24 O
2009 O

channels O
could O
also O
reverse O
deficit O
##s O
in O
auto O
##im O
##mun O
##e O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
the O
similarity O
between O
antibody O
##media O
##ted O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
and O
ph O
##arm O
##aco O
##logical O
##ly O
induced O
en O
##ce O
##pha O
##lit O
##is O
suggests O
that O
an O
animal O
model O
for O
rev O
##ers O
##ible O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
could O
be O
developed O
using O
ph O
##arm O
##aco O
##logic O
blockade O
of O
v O
##g O
##k O
##c O
from O
the O
department O
of O
ne O
##uro O
##logy O
university O
of O
chicago O
medical O
center O
il O
disclosure O
the O
authors O
report O
no O
disclosure O
##s O
presented O
in O
part O
at O
the O
57th O
annual O
meeting O
of O
the O
american O
academy O
of O
ne O
##uro O
##logy O
miami O
beach O
fl O
april O
9 O
16 O
2005 O

received O
may O
20 O
2008 O
accepted O
in O
final O
form O
november O
20 O
2008 O
address O
correspondence O
and O
reprint O
requests O
to O
dr O
anthony O
red O
##er O
the O
university O
of O
chicago O
department O
of O
ne O
##uro O
##logy O
mc O
203 O
##0 O
58 O
##41 O
s O
maryland O
ave O
chicago O
il O
60 O
##6 O
##37 O
are O
##der O
ne O
##uro O
##logy O
bs O
##d O
uc O
##hic O
##ago O
ed O
##u O
copyright O
2009 O
by O
aa O
##n O
enterprises O
inc O

pa O
##pe O
##z O
circuit O
affecting O
memory O
and O
learning O
7 O
in O
mor O
##van O
syndrome O
and O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
antibodies O
to O
kv O
1 O
1 O
1 O
2 O
and O
1 O
6 O
in O
the O
molecular O
layer O
of O
the O
dent O
##ate O
g O
##yr O
##us O
are O
associated O
with O
memory O
disruption O
and O
agitation O
5 O
blockade O
of O
kv O
##1 O
1 O
and O
other O
kv O
##1 O
sub O
##type O
##s O
concentrated O
in O
the O
hip O
##po O
##camp O
##us O
and O
limb O
##ic O
circuit O
is O
likely O
in O
4 O
ap O
induced O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
and O
it O
could O
explain O
amnesia O
brady O
##kin O
##es O
##ia O
and O
impaired O
visual O
learning O

kv O
##1 O
5 O
v O
##g O
##k O
##c O
are O
present O
in O
skeletal O
muscles O
and O
the O
heart O
4 O
ap O
toxicity O
causes O
su O
##pr O
##ave O
##nt O
##ric O
##ular O
ta O
##chy O
##card O
##ias O
and O
at O
##rial O
fi O
##bri O
##llation O
2 O
here O
su O
##pr O
##ave O
##nt O
##ric O
##ular O
ta O
##chy O
##card O
##ia O
and O
severe O
contract O
##ile O
dysfunction O
resolved O
with O
time O
the O
cardiac O
dysfunction O
clinical O
weakness O
em O
##g O
abnormalities O
and O
skeletal O
muscle O
findings O
reflect O
a O
rev O
##ers O
##ible O
toxic O
my O
##opa O
##thy O
from O
direct O
4 O
ap O
toxicity O
as O
there O
was O
no O
history O
of O
prolonged O
muscle O
di O
##sus O
##e O
or O
ex O
##ert O
##ion O
clinical O
improvement O
as O
4 O
ap O
was O
meta O
##bol O
##ized O
suggests O
that O
early O
removal O
of O
antibodies O
to O
k O

davis O
fa O
ste O
##fo O
##ski O
d O
rush O
j O
oral O
##ly O
administered O
4 O
amino O
##py O
##rid O
##ine O
improves O
clinical O
signs O
in O
multiple O
sc O
##ler O
##osis O
ann O
ne O
##uro O
##l O
1990 O
27 O
186 O
192 O
johnson O
nc O
morgan O
mw O
an O
unusual O
case O
of O
4 O
amino O
##py O
##rid O
##ine O
toxicity O
j O
em O
##er O
##g O
med O
2006 O
30 O
175 O
177 O
vincent O
a O
buckley O
c O
sc O
##hot O
##t O
j O
##m O
et O
al O
potassium O
channel O
antibody O
associated O
en O
##ce O
##pha O
##lo O
##pathy O
a O
potentially O
im O
##mun O
##oth O
##era O
##py O
responsive O
form O
of O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
brain O
2004 O
127 O
70 O
##1 O
71 O
##2 O
judge O
si O
be O
##ver O
ct O
jr O
potassium O
channel O
block O
##ers O
in O
multiple O
sc O
##ler O
##osis O
ne O
##uron O
##al O
kv O
channels O
and O
effects O
of O
sy O
##mpt O
##oma O
##tic O
treatment O
ph O
##arm O
##aco O
##l O
the O
##r O
2006 O
111 O
224 O
259 O

buckley O
c O
og O
##er O
j O
clover O
l O
et O
al O
potassium O
channel O
antibodies O
in O
two O
patients O
with O
rev O
##ers O
##ible O
limb O
##ic O
en O
##ce O
##pha O
##lit O
##is O
ann O
ne O
##uro O
##l O
2001 O
50 O
73 O
78 O
li O
##gu O
##ori O
r O
vincent O
a O
clover O
l O
et O
al O
mor O
##van O
s O
syndrome O
peripheral O
and O
central O
nervous O
system O
and O
cardiac O
involvement O
with O
antibodies O
to O
voltage O
gate O
##d O
potassium O
channels O
brain O
2001 O
124 O
241 O
##7 O
242 O
##6 O
cochran O
sm O
harvey O
al O
pratt O
ja O
regional O
##ly O
selective O
alterations O
in O
local O
cerebral O
glucose O
utilization O
ev O
##oked O
by O
char O
##y O
##b O
##dot O
##ox O
##in O
a O
block O
##er O
of O
central O
voltage O
activated O
k O
channels O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2001 O
14 O
145 O
##5 O
146 O
##3 O
e O
c O
k O
##law O
##iter O
md O
e O
alvarez O
iii O
md O
phd O

j O
xu O
phd O
a O
r O
pac O
##ior O
##kowski O
md O
l O
zhu O
md O
phd O
b O
j O
parks O
md O
a O
h O
cross O
md O
r O
t O
na O
##ism O
##ith O
md O
nm O
##o O
i O
##gg O
detected O
in O
cs O
##f O
in O
ser O
##one O
##gative O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
nm O
##o O
is O
an O
inflammatory O

and O
dem O
##ye O
##lina O
##ting O
disease O
characterized O
by O
rec O
##urrent O
attacks O
of O
optic O
ne O
##uri O
##tis O
on O
and O
longitudinal O
##ly O
extensive O
transverse O
my O
##eli O
##tis O
let O
##m O
1 O
nm O
##o O
is O
associated O
with O
antibodies O
against O
the O
aqua O
##por O
##in O
4 O
a O
##q O
##p O
##4 O
water O
channel O
2 O
nm O
##o O
im O
##mun O
##og O
##lo O
##bu O
##lin O
g O
i O
##gg O
predict O
##s O
a O
re O
##la O
##ps O
##ing O
course O
and O
is O
a O
supportive O
criterion O
for O
nm O
##o O
3 O
5 O
the O
high O
risk O
of O
re O
##la O
##pse O
sometimes O
with O
devastating O
effects O
makes O
early O
diagnosis O
important O
early O
identification O
permits O
counseling O
and O
consideration O
for O
im O
##mun O
##os O
##up O
##pressive O
therapy O
the O
serum O
nm O
##o O
i O
##gg O
ass O
##ay O
using O
indirect O
im O
##mun O
##of O
##lu O
##orescence O
is O
73 O
sen O
##si O

ti O
##ve O
and O
91 O
specific O
for O
clinical O
##ly O
defined O
nm O
##o O
6 O
while O
helpful O
when O
positive O
the O
sensitivity O
is O
insufficient O
to O
exclude O
the O
diagnosis O
we O
describe O
3 O
of O
26 O
patients O
with O
nm O
##o O
at O
our O
institution O
with O
nm O
##o O
i O
##gg O
po O
##sit O
##ivity O
restricted O
to O
cs O
##f O
case O
reports O
case O
1 O
a O
25 O
year O
old O
african O
american O
woman O
presented O
with O
leg O
numb O
##ness O
and O
mild O
te O
##tra O
##par O
##esis O
that O
resolved O
over O
1 O
month O
two O
months O
later O
she O
developed O
a O
mid O
##thor O
##ac O
##ic O
sensory O
level O
again O
with O
recovery O
the O
next O
month O
bilateral O
leg O
weakness O
impaired O
her O
ability O
to O
am O
##bula O
##te O
mri O
figure O
a O
c O
demonstrated O
t O
##2 O
hyper O
##int O
##ens O
##i O

ne O
##uro O
##logy O
72 O
march O
24 O
2009 O
110 O
##1 O
treatment O
included O
iv O
g O
##lu O
##co O
##cor O
##tic O
##oids O
and O
ri O
##tu O
##xi O
##ma O
##b O
with O
no O
further O
ex O
##ace O
##rba O
##tions O
after O
8 O
months O
of O
disease O
expanded O
disability O
status O
scale O
eds O
##s O
was O
6 O
0 O

case O
2 O
a O
43 O
year O
old O
african O
american O
woman O
presented O
with O
right O
sided O
weakness O
and O
numb O
##ness O
mri O
demonstrated O
longitudinal O
##ly O
extensive O
t O
##2 O
##h O
with O
enhancement O
from O
the O
lower O
med O
##ulla O
through O
c O
##6 O
brain O
mri O
was O
non O
##dia O
##gno O
##stic O
serum O
nm O
##oi O
##gg O
was O
negative O
she O
recovered O
after O
iv O
g O
##lu O
##co O
##cor O
##tic O
##oids O
four O
months O
later O
she O
developed O
right O
sided O
weakness O
left O
sided O
numb O
##ness O
and O
difficulty O
am O
##bula O
##ting O
cervical O
spine O
mri O
figure O
d O
and O
e O
showed O
increased O
t O
##2 O
##h O
with O
enhancement O
ve O
##ps O
were O
normal O
repeat O
serum O
nm O
##o O
i O
##gg O
was O
negative O
cs O
##f O
nm O
##o O
i O
##gg O
was O
positive O
with O
1 O
8 O
ti O
##ter O
cs O
##f O
i O
##gg O
index O
was O
0 O
76 O
i O
##gg O
synthesis O
rate O
was O
6 O
5 O
with O
6 O
le O
##uk O
##ocytes O
µ O
##l O
o O
##cb O
##s O
and O
album O
##in O
index O
were O
normal O
serum O
ana O
was O
negative O
treatment O
has O
included O
monthly O
iv O
g O
##lu O
##co O
##cor O
##tic O
##oids O
with O
no O
ex O
##ace O
##rba O
##tions O
eds O
##s O
after O
5 O
months O
of O
disease O
was O
2 O
0 O

case O
3 O
a O
49 O
year O
old O
white O
woman O
presented O
with O
left O
upper O
ex O
##tre O
##mity O
par O
##esthesia O
##s O
and O
cl O
##ums O
##iness O
this O
improved O
but O
was O
followed O
2 O
months O
later O
by O
ascending O
bilateral O
numb O
##ness O
and O
weakness O
requiring O
a O
walker O
mri O
figure O
f O
h O
demonstrated O
enhancing O
ex O
##pan O
##sil O
##e O
t O
##2 O
hyper O
##int O
##ens O
##ity O
spanning O
c2 O
c O
##5 O
brain O
mri O
and O
ve O
##ps O
were O
normal O
she O
improved O
with O
iv O
g O
##lu O
##co O
##cor O
##tic O
##oids O
nm O
##o O
i O
##gg O
was O
negative O
in O
serum O
but O
positive O
in O
cs O
##f O
other O
cs O
##f O
parameters O
were O
normal O
serum O
ana O
was O
1 O
320 O
az O
##athi O
##op O
##rine O
was O
started O
with O
no O
further O
ex O
##ace O
##rba O
##tions O
after O
2 O
years O
of O
disease O
eds O
##s O
was O
2 O
0 O

case O
1 O
sa O
##git O
##tal O
t O
##2 O
weighted O
stir O
mri O
a O
shows O
hyper O
##int O
##ens O
##ity O
throughout O
the O
cervical O
and O
thor O
##ac O
##ic O
spinal O
cord O
axial O
t O
##1 O
weighted O
post O
##ga O
##do O
##lini O
##um O
mri O
at O
the O
level O
c2 O
b O
shows O
dorsal O
enhancement O
and O
at O
level O
c2 O
3 O
c O
shows O
peripheral O
enhancement O
and O
a O
central O
t O
##1 O
weighted O
h O
##yp O
##oint O
##ens O
##ity O
case O
2 O
sa O
##git O
##tal O
t O
##2 O
weighted O
stir O
mri O
d O
shows O
hyper O
##int O
##ens O
##ity O
from O
the O
lower O
med O
##ulla O
ca O
##uda O
##lly O
with O
enhancement O
on O
t O
##1 O
weighted O
post O
##ga O
##do O
##lini O
##um O
mri O
e O
case O
3 O
axial O
t O
##2 O
weighted O
mri O
at O
successive O
levels O
c2 O
f O
c O
##3 O
g O
and O
c O
##4 O
h O
show O
central O
gray O
matter O
involvement O

ties O
t O
##2 O
##h O
and O
patch O
##y O
enhancement O
spanning O
the O
med O
##ulla O
through O
c O
##7 O
and O
t O
##2 O
t O
##11 O
brain O
mri O
revealed O
a O
single O
non O
##sp O
##ec O
##ific O
t O
##2 O
##h O
visual O
ev O
##oked O
potential O
##s O
ve O
##ps O
were O
normal O
serum O
nm O
##o O
i O
##gg O
was O
negative O
but O
cs O
##f O
nm O
##o O
i O
##gg O
was O
positive O
i O
##gg O
index O
was O
elevated O
to O
0 O
79 O
cs O
##f O
le O
##uk O
##ocytes O
were O
24 O
µ O
##l O
but O
album O
##in O
index O
i O
##gg O
synthesis O
and O
ol O
##igo O
##cl O
##onal O
bands O
o O
##cb O
##s O
were O
normal O
serum O
anti O
##nu O
##cle O
##ar O
antibodies O
ana O
were O
negative O

discussion O
we O
report O
three O
cases O
of O
nm O
##o O
spectrum O
disorder O
with O
restriction O
of O
nm O
##o O
i O
##gg O
po O
##sit O
##ivity O
to O
the O
cs O
##f O
the O
cases O
presented O
with O
rapidly O
re O
##la O
##ps O
##ing O
let O
##m O
and O
a O
normal O
or O
non O
##dia O
##gno O
##stic O
brain O
mri O
while O
none O
showed O
evidence O
for O
on O
these O
individuals O
have O
been O
followed O
less O
than O
2 O
years O
in O
each O
case O
the O
second O
re O
##la O
##pse O
was O
severe O
and O
di O
##sa O
##bling O
occurring O
within O
months O
of O
onset O
in O
each O
patient O
serum O
nm O
##o O
i O
##gg O
testing O
was O
negative O
at O
a O
1 O
120 O
dil O
##ution O
and O
simultaneous O
cs O
##f O
nm O
##o O
i O
##gg O
was O
positive O
during O
an O
ex O
##ace O
##rba O
##tion O
before O
administration O
of O
co O
##rti O
##cos O
##ter O
##oids O
antibody O
testing O
was O
performed O
by O
the O
same O
laboratory O
mayo O
medical O
laboratories O
the O
cause O
of O
nm O
##o O
i O
##gg O
ser O
##one O
##gat O
##ivity O
in O
these O
three O
cs O
##fp O
##osi O
##tive O
patients O
is O
unknown O
the O
presence O
of O
a O
coe O
##xi O
##sti O
##ng O
interfering O
antibody O
may O
hind O
##er O
ser O
##olo O
##gic O
interpretation O
however O
only O
case O
3 O
was O
noted O
to O
have O
coe O
##xi O
##sti O
##ng O
ana O
the O
cs O
##f O
album O
##in O
indices O
indicated O
intact O
blood O
brain O
barriers O

110 O
##2 O
ne O
##uro O
##logy O
72 O
march O
24 O
2009 O

serum O
testing O
for O
nm O
##o O
i O
##gg O
remains O
the O
standard O
test O
for O
confirming O
a O
diagnosis O
of O
re O
##la O
##ps O
##ing O
nm O
##o O
spectrum O
disorder O
in O
our O
three O
ser O
##one O
##gative O
cases O
of O
re O
##la O
##ps O
##ing O
let O
##m O
detection O
of O
nm O
##oi O
##gg O
in O
the O
cs O
##f O
confirmed O
the O
diagnosis O
of O
an O
nm O
##o O
spectrum O
disorder O
and O
mandated O
initiation O
of O
im O
##mun O
##os O
##up O
##pressive O
the O
##ra O
##pies O
the O
potential O
value O
of O
early O
treatment O
emphasizes O
the O
importance O
of O
making O
the O
correct O
diagnosis O
7 O
if O
nm O
##o O
is O
strongly O
suspected O
and O
serum O
nm O
##o O
i O
##gg O
is O
negative O
measurement O
of O
cs O
##f O
nm O
##o O
i O
##gg O
is O
recommended O
and O
may O
add O
to O
the O
overall O
sensitivity O
of O
laboratory O
testing O
clinical O
scenarios O
that O
may O
warrant O
supplementary O
testing O
of O
cs O
##f O
include O
the O
following O
1 O
let O
##m O
2 O
re O
##la O
##ps O
##ing O
t O
##m O
3 O
severe O
and O
bilateral O
on O
4 O
on O
with O
poor O
recovery O
and O

5 O
rapidly O
re O
##la O
##ps O
##ing O
on O
cs O
##f O
studies O
should O
not O
be O
a O
substitute O
for O
serum O
testing O
larger O
systematic O
studies O
are O
required O
to O
determine O
the O
sensitivity O
and O
specific O
##ity O
of O
combined O
serum O
and O
cs O
##f O
testing O
whether O
distinct O
clinical O
characteristics O
exist O
for O
cases O
with O
cs O
##f O
restricted O
nm O
##o O
i O
##gg O
po O
##sit O
##ivity O
remains O
to O
be O
determined O
from O
washington O
university O
st O
louis O
mo O

supported O
by O
grant O
ul O
##1 O
rr O
##0 O
##24 O
##9 O
##9 O
##2 O
from O
the O
national O
center O
for O
research O
resources O
nc O
##rr O
a O
component O
of O
the O
ni O
##h O
and O
ni O
##h O
road O
##ma O
##p O
for O
medical O
research O
ni O
##h O
funding O
included O
ul O
##1 O
##rr O
##0 O
##24 O
##9 O
##9 O
##2 O
e O
c O
k O
k O
##23 O
##ns O
##0 O
##52 O
##43 O
##0 O
01 O
##a1 O
r O
t O
n O
k O
##12 O
##rr O
##0 O
##23 O
##24 O
##90 O
##2 O
r O
t O
n O
k O
##24 O
rr O
##01 O
##7 O
##100 O
a O
h O
c O
ca O
##10 O
##12 O
a O
h O
c O
american O
academy O
of O
ne O
##uro O
##logy O
foundation O
clinical O
research O
training O
fellowship O
e O
c O
k O
and O
national O
ms O
society O
f O
##g O
##17 O
##8 O
##2 O
##a1 O
j O
x O
dr O
cross O
was O
supported O
in O
part O
by O
the O
manny O
and O
rosa O
##lyn O
rosenthal O
dr O
john O
l O
tr O
##otte O
##r O
chair O
in O
ne O
##uro O
##im O
##mun O
##ology O

disclosure O
dr O
##s O
k O
##law O
##iter O
alvarez O
xu O
pac O
##ior O
##kowski O
and O
zhu O
have O
no O
disclosure O
##s O
to O
report O
dr O
parks O
is O
a O
participant O
in O
clinical O
trials O
for O
bio O
##ms O
and O
te O
##va O
neuroscience O
##s O
she O
has O
received O
consulting O
fees O
or O
speaking O
honor O
##aria O
from O
bio O
##gen O
id O
##ec O
bayer O
healthcare O
te O
##va O
neuroscience O
##s O
and O
p O
##fi O
##zer O
ser O
##ono O
dr O
cross O
has O
received O
research O
funding O
clinical O
trial O
funding O
honor O
##aria O
or O
consulting O
fees O
from O
the O
ni O
##h O
national O
ms O
society O
usa O
consortium O
of O
multiple O

sc O
##ler O
##osis O
centers O
gene O
##nte O
##ch O
inc O
be O
##rle O
##x O
now O
bayer O
healthcare O
bio O
##gen O
id O
##ec O
te O
##va O
neuroscience O
ac O
##ord O
##a O
therapeutic O
##s O
ser O
##ono O
p O
##fi O
##zer O
and O
bio O
##ms O
dr O
na O
##ism O
##ith O
is O
a O
participant O
in O
clinical O
trials O
for O
fa O
##mp O
##rid O
##ine O
sr O
by O
ac O
##ord O
##a O
therapeutic O
##s O
he O
has O
received O
consulting O
fees O
and O
speaking O
honor O
##aria O
from O
bayer O
healthcare O
bio O
##gen O
id O
##ec O
and O
te O
##va O
neuroscience O
##s O
research O
funding O
is O
through O
the O
ni O
##h O
and O
national O
ms O
society O

the O
corresponding O
author O
takes O
full O
responsibility O
for O
the O
data O
the O
analyses O
and O
interpretation O
and O
the O
conduct O
of O
the O
research O
the O
corresponding O
author O
has O
full O
access O
to O
all O
the O
data O
and O
has O
the O
right O
to O
publish O
any O
and O
all O
data O
separate O
and O
apart O
from O
the O
attitudes O
of O
the O
sponsor O
the O
contents O
are O
solely O
the O
responsibility O
of O
the O
authors O
and O
do O
not O
necessarily O
represent O
the O
official O
view O
of O
nc O
##rr O
or O
ni O
##h O
received O
september O
29 O
2008 O
accepted O
in O
final O
form O
november O
25 O
2008 O

address O
correspondence O
and O
reprint O
requests O
to O
dr O
eric O
k O
##law O
##iter O
ne O
##uro O
##logy O
box O
81 O
##11 O
660 O
s O
eu O
##cl O
##id O
ave O
washington O
university O
st O
louis O
mo O
63 O
##11 O
##0 O
k O
##law O
##iter O
##e O
ne O
##uro O
wu O
##st O
##l O
ed O
##u O
copyright O
2009 O
by O
aa O
##n O
enterprises O
inc O
winger O
##chuk O
d O
##m O
lennon O
va O
luc O
##chin O
##etti O
cf O
pitt O
##ock O
s O
##j O
wei O
##ns O
##hen O
##ker O
b O
##g O
the O
spectrum O
of O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
lance O
##t O
ne O
##uro O
##l O
2007 O
6 O
80 O
##5 O
81 O
##5 O
lennon O
va O
k O
##ry O
##zer O
t O
##j O
pitt O
##ock O
s O
##j O
ve O
##rk O
##man O
as O
hi O
##nson O
sr O
i O
##gg O
marker O
of O
optic O
spinal O
multiple O
sc O
##ler O
##osis O
binds O
to O
the O
aqua O
##por O
##in O
4 O
water O
channel O
j O
ex O
##p O
med O
2005 O
202 O
47 O
##3 O
47 O
##7 O

wei O
##ns O
##hen O
##ker O
b O
##g O
winger O
##chuk O
d O
##m O
vu O
##kus O
##ic O
s O
et O
al O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
i O
##gg O
predict O
##s O
re O
##la O
##pse O
after O
longitudinal O
##ly O
extensive O
transverse O
my O
##eli O
##tis O
ann O
ne O
##uro O
##l O
2006 O
59 O
56 O
##6 O
56 O
##9 O
mat O
##iel O
##lo O
m O
lennon O
va O
jacob O
a O
et O
al O
nm O
##o O
i O
##gg O
predict O
##s O
the O
outcome O
of O
rec O
##urrent O
optic O
ne O
##uri O
##tis O
ne O
##uro O
##logy O
2008 O
70 O
219 O
##7 O
220 O
##0 O
winger O
##chuk O
d O
##m O
lennon O
va O
pitt O
##ock O
s O
##j O
luc O
##chin O
##etti O
cf O
wei O
##ns O
##hen O
##ker O
b O
##g O
revised O
diagnostic O
criteria O
for O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
ne O
##uro O
##logy O
2006 O
66 O
148 O
##5 O
148 O
##9 O

lennon O
va O
winger O
##chuk O
d O
##m O
k O
##ry O
##zer O
t O
##j O
et O
al O
a O
serum O
auto O
##ant O
##ib O
##od O
##y O
marker O
of O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
distinction O
from O
multiple O
sc O
##ler O
##osis O
lance O
##t O
2004 O
36 O
##4 O
210 O
##6 O
211 O
##2 O
cree O
ba O
lamb O
s O
morgan O
k O
chen O
a O
wa O
##uba O
##nt O
e O
gen O
##ain O
c O
an O
open O
label O
study O
of O
the O
effects O
of O
ri O
##tu O
##xi O
##ma O
##b O
in O
ne O
##uro O
##my O
##eli O
##tis O
optic O
##a O
ne O
##uro O
##logy O
2005 O
64 O
127 O
##0 O
127 O
##2 O
c O
gi O
##ord O
##ano O
md O
phd O
h O
powell O
bsc O
m O
leo O
##pi O
##zzi O
bsc O
m O
de O
curtis O
md O
c O
tr O
##ava O
##gli O
##ni O
bsc O
m O
sebastian O
##i O
phd O
p O
gallo O
md O
r O
w O
taylor O
phd O
g O
d O
ama O
##ti O
md O
phd O
fatal O
congenital O
my O
##opa O
##thy O
and O
gas O
##tro O
##int O
##estinal O
pseudo O
obstruction O
due O
to O
pol O
##g O
##1 O
mutations O

mutations O
in O
the O
gene O
coding O
for O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
mt O
##dna O
polymer O
##ase O
y O
pol O
##g O
##1 O
are O
associated O
with O
a O
range O
of O
clinical O
syndrome O
##s O
characterized O
by O
secondary O
mt O
##dna O
defects O
including O
mt O
##dna O
de O
##ple O
##tion O
and O
multiple O
mt O
##dna O
del O
##eti O
##ons O
1 O
the O
ph O
##eno O
##typic O
spectrum O
of O
pol O
##g O
##1 O
associated O
disease O
ranges O
from O
fatal O
childhood O
en O
##ce O
##pha O
##lo O
##pathy O
with O
intra O
##ctable O
ep O
##ile O
##psy O
and O
liver O
failure O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
2 O
to O
late O
onset O
clinical O
disease O
affecting O
a O
single O
organ O
for O
a O
review O
see O
reference O
3 O
we O
describe O
a O
fatal O
skeletal O
and O
vis O
##cera O
##l O
my O
##op O

at O
##hy O
in O
the O
neon O
##atal O
period O
associated O
with O
recess O
##ive O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O

case B-PATIENT
report O
a O
newborn O
boy O
of O
healthy O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
was O
delivered O
at O
37 O
weeks O
ge O
##station O
by O
cesare O
##an O
section O
his O
mother O
pri O
##mi O
##para O
32 O
years O
old O
had O
been O
admitted O
to O
our O
hospital O
2 O
weeks O
previously O
because O
of O
reduced O
fetal O
intra O
##uter O
##ine O
movements O
and O
poly O
##hy O
##dra O
##m O
##nio O
##s O
the O
child O
s O
birth O
##weight O
was O
2 O
330 O
g O
10th O
percent O
##ile O
length O
47 O
cm O
and O
head O
ci O
##rc O
##um O
##ference O
33 O
2 O
cm O
25th O
percent O
##ile O
he O
had O
low B-HPO_TERM
set I-HPO_TERM
ears I-HPO_TERM
and O
bilateral B-HPO_TERM
club I-HPO_TERM
##foot I-HPO_TERM
ap O
##gar O
scores O
were O
2 O
6 O
and O
7 O
at O
1 O
5 O
and O
10 O
minutes O
the O
child O
presented O
with O
severe B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
generalized O
ne O
##uro O
##logy O
72 O
march O
24 O
2009 O
110 O
##3 O

a O
combined O
cox O
sd O
##h O
his O
##to O
##chemist O
##ry O
on O
skeletal O
muscle O
bio O
##psy O
showing O
numerous O
hyper O
##tro O
##phic O
cox B-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
muscle O
fibers O
blue O
b O
small O
int O
##est O
##ine O
wall O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
patient O
before O
i O
during O
ii O
and O
after O
iii O
laser O
micro O
##dis O
##section O
of O
cells O
from O
the O
external O
layer O
of O
muscular O
##is O
prop O
##ria O
his O
##to O
##logic O
features O
are O
un O
##rem O
##ark O
##able O
hem O
##ato O
##xy O
##lin O
e O
##osi O
##n O
x O
##20 O
c O
real O
time O
pc O
##r O
evaluation O
of O
mt O
##dna O
amount O
on O
micro O
##dis O
##se O
##cted O
tissue O
from O
gas O
##tro O
##int O
##estinal O
wall O
of O
patient O
white O
and O
one O
age O
matched O
autopsy O
control O
gray O
data O
are O
expressed O
as O
the O
mean O
value O
of O
three O
repeated O
measurements O
mp O
my O
##enter O
##ic O
pl O
##ex O
##us O
il O
internal O
layer O
el O
external O
layer O
of O
muscular O
##is O
prop O
##ria O

supplemental O
data O
at O
www O
ne O
##uro O
##logy O
org O

resident O
fellow O
section O
section O
editor O
mitchell O
s O
v O
elk O
##ind O
md O
ms O
clinical O
reasoning O
blurred O
vision O
and O
dancing O
feet O
restless O
legs O
syndrome O
presenting O
in O
mitochondrial O
disease O
h O
ai O
##t O
##ken O
g O
gorman O
mr O
##cp O
r O
mc O
##far O
##land O
mr O
##cp O
##ch O
m O
roberts O
fr O
##cp O
r O
w O
taylor O
fr O
##cp O
##at O
d O
m O
turnbull O
fr O
##cp O
address O
correspondence O
and O
reprint O
requests O
to O
professor O
d O
m O
turnbull O
mitochondrial O
research O
group O
4th O
floor O
the O
medical O
school O
newcastle O
university O
newcastle O
upon O
tyne O
ne O
##2 O
4 O
##hh O
uk O
d O
m O
turnbull O
nc O
##l O
ac O
uk O
section O
1 O

a O
58 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
presented O
to O
a O
ne O
##uro O
##op O
##ht O
##hal O
##mo O
##logist O
with O
a B-AGE_ONSET
5 I-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
progressively B-HPO_TERM
blurred I-HPO_TERM
vision I-HPO_TERM
dip B-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
and O
long O
##standing O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
she O
described O
occasional O
choking B-HPO_TERM
episodes I-HPO_TERM
after O
eating O
as O
well O
as O
fatigue B-HPO_TERM
and O
short B-HPO_TERM
##ness I-HPO_TERM
of I-HPO_TERM
breath I-HPO_TERM
after O
minimal O
ex O
##ert O
##ion O
her O
older O
sibling O
had O
received O
correct O
##ive O
eye O
##lid O
surgery O
for O
pt O
##osis O
and O
two O
niece O
##s O
had O
pt O
##osis O
and O
pro O
##xi O
##mal O
my O
##opa O
##thy O
and O
were O
being O
investigated O
in O
another O
center O
direct O
and O
con O
##sen O
##su O
##al O
pupil O
##lary O
light O
reflex O
##es O
were O
normal O
with O
no O
rapid O
alternating O
pupil O
##lary O
defect O

visual O
ac O
##uity O
was O
20 O
20 O
on O
the O
right O
and O
20 O
30 O
on O
the O
left O
she O
had O
bilateral O
symmetric B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
ob O
##scu O
##ring O
two O
thirds O
of O
the O
pupil O
and O
restriction B-HPO_TERM
of I-HPO_TERM
eye I-HPO_TERM
movements I-HPO_TERM
below O
60 O
of O
normal O
in O
all O
directions O
of O
gaze O
lower O
limb O
examination O
revealed O
symmetric O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
limb I-HPO_TERM
weakness I-HPO_TERM
medical O
research O
council O
grade O
4 O
with O
reduced B-HPO_TERM
reflex I-HPO_TERM
##es I-HPO_TERM
and O
flex O
##or O
plant O
##ars O
tandem O
ga O
##it O
was O
hesitant O
questions O
for O
consideration O
what O
are O
the O
possible O
dia O
##gno O
##ses O
what O
initial O
investigations O
would O
you O
recommend O
go O
to O
section O
2 O

from O
mitochondrial O
research O
group O
h O
a O
g O
g O
r O
m O
r O
w O
t O
d O
m O
t O
the O
medical O
school O
newcastle O
university O
newcastle O
upon O
tyne O
and O
department O
of O
ne O
##uro O
##logy O
m O
r O
hope O
hospital O
salford O
uk O
disclosure O
the O
authors O
report O
no O
disclosure O
##s O
e O
##86 O
copyright O
2009 O
by O
aa O
##n O
enterprises O
inc O

a O
sequential O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
his O
##to O
##chemist O
##ry O
in O
the O
muscle O
bio O
##psy O
from O
our O
patient O
reveals O
significant O
numbers O
13 O
of O
cox B-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibers I-HPO_TERM
some O
of O
which O
show O
clear O
sub B-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
abnormal I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
marked O
with O
an O
as O
##ter O
##isk O
b O
long O
range O
pc O
##r O
clearly O
demonstrates O
the O
presence O
of O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
in O
patient O
muscle O
dna O
lane O
4 O
compared O
to O
muscle O
dna O
extracted O
from O
two O
age O
##mat O
##ched O
controls O
lanes O
1 O
and O
2 O
lane O
3 O
shows O
muscle O
dna O
amplified O
from O
a O
patient O
with O
a O
single O
large O
scale O
mt O
##dna O
del O
##eti O
##on O
for O
comparison O
m O
size O
marker O

section O
2 O
the O
initial O
differential O
diagnosis O
included O
graves O
thyroid O
eye O
disease O
a O
ne O
##uro O
##mus O
##cular O
junction O
disorder O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
or O
bot O
##uli O
##sm O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
miller O
fisher O
variant O
of O
gui O
##lla O
##in O
barre O
##´ O
syndrome O
and O
progressive O
muscular O
d O
##yst O
##rop O
##hy O

free O
thy O
##ro O
##xin O
and O
thyroid O
stimulating O
hormone O
levels O
were O
normal O
thyroid O
antibodies O
were O
negative O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
antibody O
ass O
##ay O
was O
negative O
and O
repetitive O
nerve O
stimulation O
to O
exclude O
a O
ne O
##uro O
##mus O
##cular O
junction O
disorder O
was O
normal O
electro O
##my O
##ography O
of O
pro O
##xi O
##mal O
upper O
limb O
muscles O
revealed O
an O
increased O
number O
of O
short O
duration O
motor O
units O
consistent O
with O
border O
##line O
my B-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
nerve O
conduct O
##ion O
ve O
##lo O
##cit O
##ies O
were O
normal O
reducing O
the O
likelihood O
of O
an O
immune O
##media O
##ted O
inflammatory O
ne O
##uro O
##pathy O

due O
to O
the O
chronic O
##ity O
of O
symptoms O
presence O
of O
gaze B-HPO_TERM
par I-HPO_TERM
##esis I-HPO_TERM
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
findings O
on O
ne O
##uro O
##phy O
##sio O
##logic O
assessment O
and O
family O
history O
of O
o O
##cular O
complications O
suggest O
##ive O
of O
dominant O
inheritance O
a O
muscle O
bio O
##psy O
was O
performed O
poly O
##ade O
##ny O
##late O
binding O
protein O
nuclear O
1 O
pa O
##b O
##p O
##n O
##1 O
gene O
mutation O
analysis O
to O
exclude O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
was O
def O
##erre O
##d O
pending O
muscle O
bio O
##psy O
analysis O

the O
muscle O
bio O
##psy O
showed O
13 O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibers I-HPO_TERM
significant O
numbers O
of O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
but O
no O
excess O
of O
lip O
##id O
or O
g O
##ly O
##co O
##gen O
accumulation O
and O
sub B-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
abnormal I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
suggest O
##ive O
of O
a O
mitochondrial B-HPO_TERM
cy I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
figure O
1a O
testing O
for O
common O
mitochondrial O
dna O
mt O
##dna O
point O
mutations O
mel O
##as O
m O
324 O
##3 O
##a O
g O
mitochondrial O
en O
##ce O
##pha O
##lo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
like O
episodes O
mer O
##rf O
m O
83 O
##44 O
##a O
g O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
with O
ragged O
red O
fibers O
and O
na O
##rp O
m O
89 O
##9 O
##3 O
##t O
g O
c O
ne O
##uro O
##pathy O
ata O
##xia O
and O
re O
##tin O
##itis O
pigment O
##osa O
did O
not O
reveal O
any O
abnormalities O
long O
range O
pc O
##r O
however O
revealed O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
figure O
1b O

questions O
for O
consideration O
what O
is O
your O
differential O
diagnosis O
at O
this O
point O
what O
additional O
diagnostic O
tests O
would O
you O
consider O
at O
this O
time O
go O
to O
section O
3 O
ne O
##uro O
##logy O
72 O
may O
5 O
2009 O
e O
##8 O
##7 O
section O
3 O

j O
cell O
mo O
##l O
med O
vol O
15 O
no O
2 O
2011 O
pp O
44 O
##5 O
45 O
##6 O
mitochondrial O
dna O
de O
##ple O
##tion O
and O
fatal O
infant O
##ile O
he O
##pati O
##c O
failure O
due O
to O
mutations O
in O
the O
mitochondrial O
polymer O
##ase O
y O
pol O
##g O
gene O
a O
combined O
morphological O
enzyme O
his O
##to O
##chemical O
and O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
bio O
##chemical O
and O
molecular O
genetic O
study O
j O
muller O
hoc O
##ker O
a O
r O
ho O
##rva O
##th O
b O
s O
sc O
##ha O
##fer O
a O
h O
hesse O
##l O
a O
w O
muller O
fe O
##lb O
##er O
c O
j O
ku O
##hr O
d O
w O
c O
copeland O
e O
p O
se O
##ibe O
##l O
f O
a O
path O
##olo O
##gis O
##ches O
institut O
der O
ludwig O
maximilian O
##s O
un O
##iver O
##sit O
##at O
munchen O
germany O

b O
friedrich O
ba O
##ur O
institut O
department O
of O
ne O
##uro O
##logy O
ludwig O
maximilian O
##s O
university O
munich O
germany O
and O
mitochondrial O
research O
group O
institute O
for O
age O
##ing O
and O
health O
newcastle O
university O
newcastle O
upon O
tyne O
uk O
c O
friedrich O
ba O
##ur O
institut O
an O
der O
ne O
##uro O
##log O
##ischen O
k O
##lini O
##k O
und O
pol O
##ik O
##lini O
##k O
der O
ludwig O
maximilian O
##s O
un O
##iver O
##sit O
##at O
munchen O
germany O
d O
municipal O
hospital O
karlsruhe O
clinic O
for O
pediatric O
and O
adolescent O
medicine O
karlsruhe O
germany O
e O
national O
institute O
of O
environmental O
health O
sciences O
research O
triangle O
park O
nc O
usa O

f O
mole O
##ku O
##lar O
##e O
ze O
##ll O
##bio O
##logie O
bio O
##tech O
##no O
##log O
##isch O
bio O
##med O
##iz O
##ini O
##sche O
##s O
zen O
##trum O
un O
##iver O
##sit O
##at O
leipzig O
leipzig O
germany O
received O
december O
1 O
2008 O
accepted O
may O
6 O
2009 O
abstract O

combined O
morphological O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
bio O
##chemical O
and O
molecular O
genetic O
studies O
were O
performed O
on O
skeletal O
muscle O
heart O
muscle O
and O
liver O
tissue O
of O
a O
16 O
months O
boy O
with O
fatal O
liver O
failure O
the O
path O
##ological O
characterization O
of O
the O
tissues O
revealed O
a O
severe O
de O
##ple O
##tion O
of O
mt O
##dna O
mitochondrial O
dna O
that O
was O
most O
pronounced O
in O
liver O
followed O
by O
a O
less O
severe O
but O
still O
significant O
de O
##ple O
##tion O
in O
skeletal O
muscle O
and O
the O
heart O
the O
primary O
cause O
of O
the O
disease O
was O
linked O
to O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
the O
polymer O
##ase O
y O
pol B-GENE
##g I-GENE
gene O
dna B-GENE
polymer I-GENE
##ase I-GENE
y I-GENE
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
k B-GENE_VARIANT
##11 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##n I-GENE_VARIANT
we O
present O
evidence O
that O
compound O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
mutations O
lead O
to O
tissue O
selective O
impairment O
of O
mt O
##dna O
replication O
and O
thus O
to O
a O
mosaic O
defect O
pattern O
even O
in O
the O
severely O
affected O
liver O
a O
variable O
defect O
pattern O
was O
found O
in O
liver O
muscle O
and O
heart O
tissue O
as O
revealed O
by O
bio O
##chemical O
cy O
##to O
##chemical O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
and O
in O
situ O
hybrid O
##ization O
analysis O
functional O
##ly O
a O
severe O
deficiency O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
activity O
was O
seen O
in O
the O
liver O
although O
mt O
##dna O
de O
##ple O
##tion O
was O
detected O
in O
heart O
and O
skeletal O
muscle O
there O
was O
no O
cox O
deficiency O
in O
these O
tissues O
de O
##ple O
##tion O
of O
mt O
##dna O
and O
micro O
##dis O
##section O
of O
cox O
##po O
##sit O
##ive O
or O
negative O
areas O
correlated O
with O
the O
his O
##to O
##logical O
pattern O
in O
the O
liver O
interesting O
##ly O
the O
mosaic O
pattern O
detected O
for O
cox O
activity O
and O
mt O
##dna O
copy O
number O
fully O
aligned O
with O
the O
im O
##mun O
##oh O
##isto O
##logical O
##ly O
revealed O
defect O
pattern O
using O
pol O
y O
mt O
##ss O
##band O
mt O
##tf O
##a O
antibodies O
thus O
sub O
##stan O
##tia O
##ting O
the O
hypothesis O
that O
nuclear O
encoded O
proteins O
located O
within O
mit O
##och O
##ond O
##ria O
become O
unstable O
and O
are O
degraded O
when O
they O
are O
not O
actively O
bound O
to O
mt O
##dna O
their O
disappearance O
could O
also O
ag O
##gra O
##vate O
the O
mt O
##dna O
de O
##ple O
##tion O
and O
contribute O
to O
the O
non O
##hom O
##ogen O
##ous O
defect O
pattern O

key O
##words O
de O
##ple O
##tion O
of O
mt O
##dna O
polymer O
##ase O
y O
mitochondrial O
single O
stranded O
binding O
protein O
mt O
##ss O
##b O
mitochondrial O
transcription O
factor O
a O
mt O
##tf O
##a O
liver O
failure O
in O
situ O
hybrid O
##ization O
correspondence O
to O
j O
muller O
hoc O
##ker O
institute O
for O
pathology O
ludwig O
maximilian O
##s O
un O
##iver O
##sit O
##at O
munchen O
tha O
##lk O
##ir O
##chner O
##stra O
##sse O
36 O
80 O
##33 O
##7 O
munchen O
germany O
tel O
00 O
##49 O
##8 O
##9 O
##21 O
##80 O
##7 O
##36 O
##11 O
fa O
##x O
00 O
##49 O
##21 O
##80 O
##7 O
##36 O
##7 O
##1 O
e O
mail O
josef O
mueller O
ho O
##eck O
##er O
med O
un O
##i O
mu O
##en O
##chen O
de O
2011 O
the O
authors O
introduction O

mitochondrial O
diseases O
are O
a O
het O
##ero O
##gen O
##eous O
group O
of O
disorders O
caused O
by O
mutations O
in O
the O
mitochondrial O
dna O
mt O
##dna O
but O
also O
in O
nuclear O
genes O
1 O
3 O
these O
nuclear O
derived O
factors O
important O
for O
replication O
and O
transcription O
of O
the O
mt O
##dna O
include O
the O
human O
doi O
10 O
111 O
##1 O
j O
158 O
##2 O
49 O
##34 O
2009 O
00 O
##8 O
##19 O
x O
journal O
of O
cellular O
and O
molecular O
medicine O
2011 O
foundation O
for O
cellular O
and O
molecular O
medicine O
blackwell O
publishing O
ltd O

mitochondrial O
transcription O
factor O
a O
h O
mt O
##tf O
##a O
dna O
polymer O
##ase O
y O
pol O
y O
and O
mitochondrial O
single O
stranded O
binding O
protein O
mt O
##ss O
##b O
4 O
5 O
the O
disorders O
involve O
mostly O
skeletal O
muscle O
and O
brain O
but O
other O
organs O
may O
also O
be O
affected O
in O
this O
context O
liver O
failure O
due O
to O
de O
##ple O
##tion O
of O
mt O
##dna O
is O
relatively O
common O
6 O
11 O
de O
##ple O
##tion O
of O
mt O
##dna O
may O
be O
caused O
by O
mutations O
in O
different O
genes O
mutations O
in O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
polymer O
##ase O
y O
12 O
14 O
are O
associated O
with O
de O
##ple O
##tion O
of O
mt O
##dna O
and O
subsequently O
liver O
failure O
and O
have O
been O
described O
most O
often O
in O
al O
##pers O
hut O
##ten O
##lo O
##cher O
disease O
15 O
19 O
however O
these O
mutations O
were O
also O
found O
in O
a O
wide O
spectrum O
of O
other O
clinical O
disorders O
including O
auto O
##som O
##ally O
inherited O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sensory O
neural O
ne O
##uro O
##pathy O
ata O
##xia O
ep O
##ile O
##psy O
and O
parkinson O
##ism O
20 O
21 O
therefore O
an O
interesting O
question O
is O
how O
other O
coe O
##xi O
##sti O
##ng O
metabolic O
alterations O
might O
influence O
the O

clinical O
presentation O
22 O

in O
this O
study O
we O
describe O
the O
morphological O
cy O
##to O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
bio O
##chemical O
and O
molecular O
genetic O
results O
in O
a O
16 B-AGE_DEATH
months I-AGE_DEATH
old O
child B-PATIENT
who O
died O
of B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
due O
to O
mutations O
in O
the O
polymer B-GENE
##ase I-GENE
y I-GENE
pol B-GENE
##g I-GENE
gene O
our O
study O
showed O
het O
##ero O
##genic O
tissue O
involvement O
with O
a O
mosaic O
defect O
pattern O
in O
the O
liver O
probably O
related O
to O
con O
##com O
##itan O
##t O
secondary O
dysfunction O
of O
further O
proteins O
involved O
in O
mt O
##dna O
maintenance O
like O
mitochondrial O
single O
stranded O
binding O
protein O
mt O
##ss O
##b O
and O
mitochondrial O
transcription O
factor O
a O
mt O
##tf O
##a O
the O
results O
help O
to O
explain O
the O
occasionally O
observed O
recovery O
from O
mt O
##dna O
de O
##ple O
##tion O
and O
indicate O
also O
that O
a O
slight O
increase O
in O
the O
mt O
##dna O
copy O
number O
might O
be O
enough O
to O
retain O
the O
normal O
respiratory O
function O
which O
may O
open O
possibilities O
for O
therapeutic O
trials O
in O
the O
future O

materials O
and O
methods O
case O
report O
the O
patient B-PATIENT
a O
boy O
was O
the O
first O
child O
of O
healthy O
non O
con O
##san O
##gui O
##neo O
##us O
genetically O
unrelated O
parents O
there O
was O
no O
history O
of O
mis O
##carriage O
in O
the O
family O
and O
the O
history O
of O
the O
family O
was O
negative O
for O
liver O
disease O

pregnancy O
and O
delivery O
were O
normal O
birth O
weight O
39 O
##20 O
g O
ap O
##gar O
6 O
9 O
10 O
psycho O
##moto O
##r O
development O
was O
normal O
during O
the O
first O
4 O
months O
of O
life O
he O
started O
smiling O
at O
2 O
months O
and O
to O
grasp O
objects O
at O
4 O
months O
of O
age O
at O
the O
age O
of B-AGE_ONSET
5 I-AGE_ONSET
months I-AGE_ONSET
the O
patient O
developed O
rec B-HPO_TERM
##urrent I-HPO_TERM
vomiting I-HPO_TERM
and O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
liver O
enzymes O
at O
the O
age O
of O
6 O
months O
were O
200 B-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
for I-HPO_TERM
as I-HPO_TERM
##t I-HPO_TERM
107 B-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
for I-HPO_TERM
alt I-HPO_TERM
and O
50 B-HPO_TERM
##7 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
for I-HPO_TERM
y I-HPO_TERM
g I-HPO_TERM
##lu I-HPO_TERM
##tam I-HPO_TERM
##yl I-HPO_TERM
transfer I-HPO_TERM
##ase I-HPO_TERM
but O
total O
bi O
##li O
##ru O
##bin O
was O
normal O
in O
parallel O
with O
deterioration B-HPO_TERM
of I-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
re I-HPO_TERM
##tar I-HPO_TERM
##dation I-HPO_TERM
was O
noticed O
and O
the O
ability O
to O
grasp O
objects O
and O
to O
roll O
over O
was O
lost O
the O
muscle B-HPO_TERM
tone I-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
ee O
##g O
as O
well O
as O
mri O
and O
mr O
spectroscopy O
of O
the O
brain O
at O
the O
age O
of O
7 O
8 O
months O
were O
inc O
##ons O
##pic O
##uous O
ep O
##ile O
##ptic O
episodes O
have O
not O
been O
observed O
serum B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
elevated I-HPO_TERM
2 O
8 O
3 O
7 O
mm O
##ol O
l O
extensive O
clinical O
search O
did O
not O
reveal O
the O
et O
##iology O
of O
the O
liver O
disease O
there O
was O
a O
normal O
level O
of O
alpha O
1 O
anti O
##try O
##ps O
##ine O
coe O
##ru O
##lo O
##pl O
##as O
##min O
copper O
ser O
##ological O
test O
for O
hepatitis O
a O
b O
c O
cm O
##v O
ev O
##b O
rub O
##ella O
to O
##x O
##op O
##las O
##mos O
##is O
and O
hs O
##v O
##1 O
were O
negative O
im O
##mun O
##ological O
screening O
did O
not O
detect O
ana O
##s O
an O
##cas O
ds O
ana O
##s O
g O
##lia O
##din O
antibodies O
cy O
##stic O
fi O
##bro O
##sis O

was O
excluded O
by O
ion O
##top O
##hore O
##sis O
there O
were O
no O
clinical O
signs O
of O
a O
card O
##iom O
##yo O
##pathy O
and O
son O
##ography O
of O
the O
heart O
proved O
un O
##con O
##sp O
##ic O
##uous O
in O
the O
following O
months O
gas O
##tro O
##int O
##estinal O
problems O
rec O
##ur O
##red O
because O
of O
persist B-HPO_TERM
##ing I-HPO_TERM
vomiting I-HPO_TERM
and O
ref B-HPO_TERM
##lux I-HPO_TERM
ile B-HPO_TERM
##us I-HPO_TERM
due O
to O
small B-HPO_TERM
bow I-HPO_TERM
##el I-HPO_TERM
obstruction I-HPO_TERM
was O
suspected O
and O
parental O
feeding O
was O
necessary O
at O
the O
age O
of O
15 O
months O
as B-HPO_TERM
##t I-HPO_TERM
was I-HPO_TERM
still I-HPO_TERM
elevated I-HPO_TERM
48 O
##2 O
u O
l O
and O
total O
bi O
##li O
##ru O
##bin O
had O
risen O
to O
3 O
4 O
mg O
dl O
con O
##ju O
##gated O
2 O
mg O
dl O

at O
the O
age O
of O
16 O
months O
liver B-HPO_TERM
function I-HPO_TERM
rapidly I-HPO_TERM
det I-HPO_TERM
##orio I-HPO_TERM
##rated I-HPO_TERM
fi B-HPO_TERM
##bri I-HPO_TERM
##no I-HPO_TERM
##gen I-HPO_TERM
80 I-HPO_TERM
mg I-HPO_TERM
dl I-HPO_TERM
th B-HPO_TERM
##rom I-HPO_TERM
##bo I-HPO_TERM
##pl I-HPO_TERM
##ast I-HPO_TERM
##in I-HPO_TERM
time I-HPO_TERM
15 I-HPO_TERM
as B-HPO_TERM
##t I-HPO_TERM
up I-HPO_TERM
to I-HPO_TERM
about I-HPO_TERM
1900 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
alt B-HPO_TERM
up I-HPO_TERM
to I-HPO_TERM
350 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
total B-HPO_TERM
bi I-HPO_TERM
##li I-HPO_TERM
##ru I-HPO_TERM
##bin I-HPO_TERM
19 I-HPO_TERM
1 I-HPO_TERM
mg I-HPO_TERM
dl I-HPO_TERM
the O
con O
##ju O
##gated O
fraction O
being O
15 O
mg O
dl O
and O
as B-HPO_TERM
##cite I-HPO_TERM
##s I-HPO_TERM
developed O

he O
reacted O
well O
to O
acoustic O
stimuli O
but O
was O
unable O
to O
fix O
##ate O
objects O
and O
to O
sit O
without O
support O
an O
ee B-HPO_TERM
##g I-HPO_TERM
examination I-HPO_TERM
showed I-HPO_TERM
diffuse I-HPO_TERM
suppression I-HPO_TERM
of O
signals O
finally O
int I-HPO_TERM
##estinal I-HPO_TERM
bleeding I-HPO_TERM
led O
to O
ha B-HPO_TERM
##em I-HPO_TERM
##or I-HPO_TERM
##rh I-HPO_TERM
##agi I-HPO_TERM
##c I-HPO_TERM
shock I-HPO_TERM
and O
subsequent O
fatal B-HPO_TERM
multi I-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
an O
autopsy O
was O
not O
performed O
but O
in O
addition O
to O
bio O
##psy O
probe O
##s O
of O
the O
skeletal O
muscle O
and O
the O
liver O
nec O
##rop O
##sy O
probe O
##s O
were O
taken O
from O
the O
heart O
the O
patient O
was O
included O
in O
a O
previous O
study O
on O
the O
molecular O
genetic O
and O
clinical O
spectrum O
of O
pol O
##g O
mutations O
20 O

morphological O
bio O
##chemical O
and O
molecular O
genetic O
studies O
were O
performed O
the O
latter O
being O
restricted O
to O
analysis O
of O
mt O
##dna O
since O
the O
multi O
##sy O
##ste O
##mic O
clinical O
presentation O
pointed O
first O
of O
all O
to O
a O
mitochondrial O
disorder O
morphology O
cy O
##to O
##chemist O
##ry O
and O
biochemistry O

liver O
skeletal O
and O
heart O
muscle O
were O
fixed O
in O
4 O
buffer O
##ed O
formal O
##in O
and O
embedded O
for O
routine O
stain O
##ing O
procedures O
he O
pas O
van O
gi O
##eson O
prussian O
iron O
stain O
for O
electron O
microscopy O
tissues O
were O
fixed O
in O
6 O
25 O
g O
##lu O
##tara O
##lde O
##hy O
##de O
so O
##ere O
##nsen O
phosphate O
buffer O
for O
2 O
hr O
##s O
after O
washing O
in O
buffer O
##ed O
sac O
##cha O
##rose O
and O
os O
##mic O
##ation O
2 O
di O
##sti O
##lled O
water O
for O
1 O
hr O
tissues O
were O
de O
##hy O
##dra O
##ted O
in O
ace O
##tone O
and O
embedded O
in O
ep O
##on O
polymer O
##isation O
at O
78 O
##° O
##c O
overnight O
for O
the O
preparation O
of O
semi O
thin O
und O
ultra O
thin O
sections O
counters O
##tain O
##ing O
using O
ur O
##any O
##l O
ace O
##tate O
and O
lead O
ci O
##tra O
##te O
frozen O
tissue O
stored O
at O
80 O
##° O
##c O
was O
used O
for O
light O
microscopic O
##al O
and O
ultra O
cy O
##to O
##chemical O
detection O
of O
cy O
##to O
##chrome O
c O
oxide O
as O
previously O
described O
23 O
im O
##mun O
##o O
cy O
##to O
##chemist O
##ry O
using O
the O
abc O
elite O
kit O
da O
##ko O
was O
performed O
as O
previously O
described O
for O
the O
detection O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
subunit O
##s O
ii O
iii O
and O
va O
##b O
24 O
mt O
##tf O
##a O
dna O
polymer O
##ase O
y O
25 O
and O
mt O
##ss O
##b O
26 O
bio O
##chemical O
analysis O
of O
the O
respiratory O
chain O
enzymes O
was O
performed O
on O
homo O
##gen O
##ates O
of O
deep O
frozen O
muscle O
27 O
measurements O
were O
carried O
out O
for O
nad O
##h O
co O
##q O
ox O
##ido O
##red O
##uc O
##tase O
complex O
i O
and O
ii O
su O
##cci O
##nate O
ox O
##ido O
##red O
##uc O
##tase O
complex O
ii O
and O
iii O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
complex O
iv O
and O
ci O
##tra O
##te O
synth O
##ase O

dna O
analysis O

mt O
##dna O
and O
nuclear O
dna O
were O
extracted O
from O
skeletal O
muscle O
heart O
and O
liver O
and O
also O
from O
cox O
negative O
and O
cox O
positive O
areas O
and O
mt O
##dna O
copy O
number O
and O
mt O
##dna O
n O
##dna O
ratios O
were O
determined O
by O
real O
time O
pc O
##r O
using O
a O
fluorescent O
temperature O
cycle O
##r O
light O
cycle O
##r O
roche O
molecular O
bio O
##chemical O
##s O
mannheim O
germany O
the O
light O
cycle O
##r O
fast O
##star O
##t O
dna O
master O
sy O
##br O
green O
i O
kit O
roche O
molecular O
bio O
##chemical O
##s O
was O
used O
28 O
29 O
we O
amplified O
the O
mt O
##dna O
atp O
##6 O
gene O
with O
un O
##lab O
##elled O
prime O
##rs O
between O
nu O
##cle O
##otide O
positions O
89 O
##8 O
##1 O
and O
90 O
##6 O
##1 O
with O
the O
forward O
prime O
##r O
5 O
acc O
##aa O
##tag O
##cc O
##ct O
##gg O
##cc O
##gt O
##ac O
3 O
and O
the O
backward O
prime O
##r O
5 O
g O
##gt O
##gg O
##c O
##gc O
##tt O
##c O
ca O
##att O
##ag O
##gt O
3 O
for O
the O
detection O
of O
n O
##dna O
we O
selected O
ex O
##on O
number O
8 O
of O
the O
gap O
##dh O
gene O
between O
nu O
##cle O
##otide O
positions O
42 O
##80 O
43 O
##42 O
using O
the O
forward O
prime O
##r O
5 O
c O
##gg O
##gg O
##ct O
##ct O
##cca O
##ga O
##aca O
##tc O
3 O
and O
the O
backward O
prime O
##r O
5 O
at O
##ga O
##cc O
##tt O
##gc O
##cca O
##ca O
##gc O
##ct O
3 O
the O
control O
range O
was O

j O
cell O
mo O
##l O
med O
vol O
15 O
no O
2 O
2011 O
isolated O
human O
place O
##nta O
mt O
##dna O
the O
double O
stranded O
dna O
was O
pu O
##rified O
by O
cent O
##ric O
##on O
##™ O
100 O
micro O
##con O
##cent O
##rator O
##s O
ami O
##con O
beverly O
ma O
usa O
the O
pc O
##r O
dna O
fragments O
were O
labelled O
by O
random O
prime O
##d O
incorporation O
of O
dig O
##ox O
##igen O
##in O
labelled O
de O
##ox O
##yu O
##rid O
##ine O
trip O
##hos O
##phate O
applying O
the O
dig O
##ox O
##igen O
##in O
label O
##ling O
kit O
of O
bo O
##eh O
##ring O
##er O
mannheim O
results O
liver O

light O
microscopy O
of O
the O
liver O
fig O
1 O
showed O
a O
severe O
alteration O
of O
liver O
par O
##en O
##chy O
##ma O
with O
massive O
balloon O
##ing O
of O
liver O
cells O
that O
often O
formed O
giant B-HPO_TERM
cells I-HPO_TERM
the O
cy O
##top O
##las O
##m O
of O
the O
altered O
liver O
cells O
had O
a O
fine O
ve O
##sic O
##ular O
appearance O
fig O
1b O
often O
bi B-HPO_TERM
##li I-HPO_TERM
##ru I-HPO_TERM
##bino I-HPO_TERM
##sta I-HPO_TERM
##sis I-HPO_TERM
was O
present O
the O
portal B-HPO_TERM
tracts I-HPO_TERM
were I-HPO_TERM
enlarged I-HPO_TERM
showing O
regular O
pre O
existing O
bile O
duct O
##s O
and O
severe O
proliferation B-HPO_TERM
of I-HPO_TERM
bile I-HPO_TERM
duct I-HPO_TERM
##ules I-HPO_TERM
containing O
bile B-HPO_TERM
plug I-HPO_TERM
##s I-HPO_TERM
in O
the O
pas O
stain O
no O
g O
##lo O
##bular O
dia O
##sta O
##se O
resistant O
cy O
##top O
##las O
##mic O
inclusion O
##s O
were O
found O
besides O
the O
altered O
he O
##pa O
##to O
##cytes O
small O
islands O
of O
better O
preserved O
or O
normal O
looking O
he O
##pa O
##to O
##cytes O
were O
present O
fig O
1a O
a O
stain O
for O
iron O
per O
##l O
stain O
was O
negative O

fine O
structure O
most O
of O
the O
he O
##pa O
##to O
##cytes O
were O
stacked O
full O
with O
slightly O
enlarged B-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
these O
mit O
##och O
##ond O
##ria O
had O
a O
fl O
##oc O
##cular O
gran O
##ular O
matrix O
loss O
of O
matrix O
gran O
##ules O
and O
a O
reduced O
amount O
of O
cr O
##ista O
##e O
fig O
2a O
b O
occasionally O
mit B-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
with I-HPO_TERM
tubular I-HPO_TERM
cr I-HPO_TERM
##ista I-HPO_TERM
##e I-HPO_TERM
formations I-HPO_TERM
were O
also O
present O
fig O
2 O
##c O
deposits O
of O
bile O
and O
lip O
##id O
droplets O
were O
a O
constant O
feature O
corresponding O
to O
the O
light O
microscopic O
##al O
findings O
there O
were O
also O
he O
##pa O
##to O
##cytes O
with O
a O
normal O
content O
of O
mit O
##och O
##ond O
##ria O
and O
regular O
cr O
##ista O
##e O
fig O
2d O
the O
rough O
end O
##op O
##las O
##mic O
re O
##tic O
##ulum O
was O
inc O
##ons O
##pic O
##uous O

determined O
for O
skeletal O
muscle O
liver O
and O
heart O
using O
30 O
control O
muscle O
dna O
samples O
9 O
control O
liver O
dna O
samples O
and O
3 O
control O
heart O
dna O
samples O
sequencing O
of O
the O
nuclear O
encoded O
de O
##ox O
##y O
##gua O
##nos O
##ine O
kinase O
d O
##gu O
##ok O
30 O
and O
pol O
##g O
was O
performed O
as O
described O
20 O
micro O
##dis O
##section O
of O
frozen O
liver O
sections O
30 O
µ O
##m O
was O
performed O
after O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
stain O
##ing O
from O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
positive O
and O
negative O
areas O
by O
p O
a O
l O
m O
micro O
##lase O
##r O
technologies O
82 O
##34 O
##7 O
bern O
##ried O
germany O
for O
quantitative O
mt O
##dna O
##pc O
##r O
analysis O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O

in O
situ O
hybrid O
##ization O
was O
performed O
as O
previously O
described O
31 O
34 O
on O
formal O
##in O
fixed O
para O
##ffin O
embedded O
liver O
tissue O
as O
well O
as O
on O
skeletal O
and O
heart O
muscle O
using O
specific O
probe O
##s O
of O
mt O
##dna O
produced O
by O
pc O
##r O
from O
cy O
##to O
##chemist O
##ry O

in O
most O
of O
the O
he O
##pa O
##to O
##cytes O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
activity I-HPO_TERM
was I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fig O
3a O
however O
there O
were O
also O
small O
islands O
with O
preserved O
activity O
fig O
3 O
##b O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
was O
regularly O
detect O
##able O
both O
in O
the O
areas O
with O
and O
without O
deficiency O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
fig O
3 O
##c O
at O
the O
ultra O
##st O
##ru O
##ct O
##ural O
level O
occasionally O
a O
co O
existence O
of O
defective O
and O
normal O
reacting O
mit O
##och O
##ond O
##ria O
could O
be O
found O
not O
shown O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O

im O
##mun O
##oh O
##isto O
##chemist O
##ry O
disclosed O
a O
severe O
loss B-HPO_TERM
of I-HPO_TERM
cy I-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
cox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
subunit I-HPO_TERM
##s I-HPO_TERM
ii I-HPO_TERM
iii I-HPO_TERM
va O
##b O
spa O
##ring O
small O
islands O
of O
he O
##pa O
##to O
##cytes O
in O
contrast O
the O
bile O
duct O
##s O
reacted O
normally O
fig O
4a O
b O
there O
was O
also O
a O
severe O
defect O
of O
dna O
polymer O
##ase O
y O
spa O
##ring O
however O
small O
he O
##pa O
##to O
##cy O
##tic O
f O
##oc O
##i O
fig O
5 O
also O
mt O
##ss O
##b O
and O
mt O
##tf O
##a O
were O
partially O
def O
##icient O
leading O
to O
the O
coe O
##xi O
##sten O
##ce O
of O
both O
defective O
and O
normal O
reactive O
he O
##pa O
##to O
##cytes O
fig O
6 O
##a O
b O
j O
cell O
mo O
##l O
med O
vol O
15 O
no O
2 O
2011 O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O

in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
disclosed O
a O
severe O
reduction O
of O
mt O
##dna O
in O
the O
altered O
he O
##pa O
##to O
##cytes O
fig O
7 O
##a O
b O
but O
there O
were O
multiple O
small O
f O
##oc O
##i O
of O
he O
##pa O
##to O
##cytes O
with O
preserved O
stain O
##ing O
fig O
7 O
##a O
c O
no O
stain O
##ing O
defect O
could O
be O
found O
in O
the O
bile O
duct O
ep O
##ith O
##eli O
##um O
fig O
7 O
##b O
heart O
and O
skeletal O
muscle O

in O
the O
heart O
fig O
8 O
and O
skeletal O
muscle O
single O
cells O
fibre O
##s O
were O
present O
with O
an O
accumulation B-HPO_TERM
of I-HPO_TERM
lip I-HPO_TERM
##ids I-HPO_TERM
and O
mit O
##och O
##ond O
##ria O
the O
mit B-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
were I-HPO_TERM
enlarged I-HPO_TERM
and O
had O
irregular B-HPO_TERM
cr I-HPO_TERM
##ista I-HPO_TERM
##e I-HPO_TERM
of O
a O
tubular O
type O
however O
no O
defects O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
could O
be O
detected O
fig O
9 O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
was O
also O
normal O

furthermore O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
disclosed O
no O
defects O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
subunit O
##s O
ii O
iii O
va O
##b O
and O
of O
dna O
##pol O
##yme O
##rase O
y O
in O
the O
skeletal O
muscle O
also O
no O
defects O
were O
present O
for O
mt O
##tf O
##a O
and O
mt O
##ss O
##b O
in O
the O
heart O
in O
the O
skeletal O
muscle O
mt O
##tf O
##a O
and O
mt O
##ss O
##b O
could O
not O
be O
demonstrated O
with O
confidence O
even O
in O
controls O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
could O
not O
detect O
a O
clear O
reduction O
of O
mt O
##dna O
in O
the O
heart O
in O
the O
skeletal O
muscle O
the O
signal O
intensity O
was O
generally O
weak O
apparently O
because O
of O
artificial O
influences O
biochemistry O

analysis O
of O
the O
respiratory O
chain O
revealed O
a O
severely O
reduced O
activity O
of O
all O
mt O
##dna O
encoded O
enzyme O
complexes O
i O
iii O
iv O
in O
the O
liver O
table O
1 O
in O
the O
heart O
the O
enzyme O
activities O
were O
below O
the O
normal O
range O
however O
skeletal O
muscle O
showed O
normal O
respiratory O
chain O
activities O
table O
1 O
j O
cell O
mo O
##l O
med O
vol O
15 O
no O
2 O
2011 O
molecular O
genetics O
mt O
##dna O
quan O
##ti O
##fication O
a O
severe O
de O
##ple O
##tion O
of O
mt O
##dna O
was O
found O
in O
the O
liver O
and O
a O
less O
severe O
but O
still O
significant O
de O
##ple O
##tion O
was O
detected O
in O
skeletal O
muscle O
and O
in O
heart O
homo O
##gen O
##ates O
table O
2 O

the O
quantitative O
analysis O
of O
mt O
##dna O
in O
cox O
negative O
and O
cox O
##po O
##sit O
##ive O
he O
##pa O
##to O
##cytes O
revealed O
a O
very O
low O
copy O
number O
of O
mt O
##dna O
in O
cox O
negative O
and O
a O
significantly O
higher O
number O
in O
cox O
positive O
he O
##pa O
##to O
##cytes O
table O
2 O
but O
also O
in O
the O
cox O
positive O
cells O
the O
mt O
##dna O
copy O
number O
was O
lowered O
measuring O
only O
about O
24 O
of O
the O
lowest O
normal O
value O

molecular O
genetic O
analysis O
of O
dna O
isolated O
from O
blood O
cells O
of O
the O
index O
patient O
revealed O
two O
het O
##ero O
##zy O
##go O
##te O
miss O
##ense O
mutations O
in O
the O
pol B-GENE
##g I-GENE
gene O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
k B-GENE_VARIANT
##11 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##n I-GENE_VARIANT
the O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
mutation O
has O
been O
frequently O
described O
in O
patients O
with O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
but O
also O
in O
other O
pol O
##g O
ph O
##eno O
##type O
##s O
the O
other O
mutation O
k B-GENE_VARIANT
##11 I-GENE_VARIANT
##9 I-GENE_VARIANT
##1 I-GENE_VARIANT
##n I-GENE_VARIANT
affects O
a O
highly O
conserved O
amino O
acid O
in O
the O
polymer O
##ase O
domain O
in O
trans O
with O
the O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
mutation O
20 O
both O
parents O
harbour O
##ed O
one O
of O
the O
two O
mutations O
found O
in O
the O
child O
proving O
compound O
het O
##ero O
##zy O
##gos O
##ity O
discussion O

mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
affecting O
either O
selective O
##ly O
or O
in O
combinations O
various O
organs O
especially O
the O
liver O
heart O
kidney O
##s O
skeletal O
muscle O
and O
brain O
in O
contrast O
to O
other O
mitochondrial O
diseases O
severe O
de O
##ple O
##tion O
of O
mt O
##dna O
often O
affects O
the O
liver O
and O
can O
lead O
to O
liver O
failure O
6 O
11 O
de O
##ple O
##tion O
of O
mt O
##dna O
in O
the O
liver O
has O
also O
been O
found O
in O
on O
##co O
##cy O
##tic O
he O
##pa O
##to O
##cytes O
35 O
associated O
with O
defects O
of O
the O
respiratory O
chain O
25 O
most O
probably O
as O
an O
effect O
of O
cellular O
age O
##ing O
31 O

the O
enzyme O
responsible O
for O
mt O
##dna O
replication O
is O
pol O
y O
which O
consists O
of O
a O
140 O
k O
##d O
catalytic O
poly O
##pe O
##pt O
##ide O
encoded O
by O
pol O
##g O
or O
pol O
##g O
##1 O
and O
two O
identical O
55 O
k O
##d O
accessory O
subunit O
##s O
encoded O
by O
pol O
##g O
##2 O
that O
are O
required O
for O
an O
increased O
dna O
affinity O
and O
highly O
process O
##ive O
dna O
synthesis O
12 O
14 O
36 O
37 O
the O
majority O
of O
mutations O
involved O
with O
pol O
y O
have O
been O
genetically O
linked O
to O
the O
pol O
##g O
gene O
15 O
19 O
while O
mutations O
in O
pol O
##g O
##2 O
are O
rare O
38 O

over O
150 O
disease O
causing O
mutations O
have O
been O
reported O
in O
pol O
##g O
where O
the O
a O
##46 O
##7 O
##t O
mutation O
of O
pol O
##g O
has O
been O
observed O
to O
be O
the O
most O
frequent O
12 O
20 O
21 O
see O
also O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
the O
a O
##46 O
##7 O
##t O
mutation O
compromise O
##s O
the O
interaction O
with O
the O
accessory O
subunit O
and O
decreases O
polymer O
##ase O
activity O
12 O
patients O
het O
##ero O
##zy O
##go O
##us O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
like O
the O
patient O
described O
here O
are O
usually O
more O
severely O
affected O
than O
a O
##46 O
##7 O
##t O
homo O
##zy O
##go O
##tes O
20 O
39 O
patients O
with O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
involving O
a O
##46 O
##7 O
##t O
display O
a O
wide O
clinical O
ph O
##eno O
##type O
from O
pe O
##o O
to O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
but O
in O
general O
mutations O
in O
the O
polymer O
##ase O
domain O
such O
as O
the O
k O
##11 O
##9 O
##1 O
##n O
are O
associated O
with O
al O
##pers O
syndrome O
40 O
the O
fatal O
liver O
failure O
in O
our O
patient O
was O
comparable O
with O
the O
liver O
fail O

ur O
##e O
seen O
in O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
however O
the O
lack O
of O
ep O
##ile O
##psy O
makes O
the O
clinical O
presentation O
at O
##yp O
##ical O
although O
clinical O
##ly O
silent O
the O
child O
also O
had O
mitochondrial B-HPO_TERM
card I-HPO_TERM
##iom I-HPO_TERM
##yo I-HPO_TERM
##pathy I-HPO_TERM
thus O
our O
studies O
provide O
evidence O
that O
the O
heart O
muscle O
might O
also O
be O
affected O
by O
mutations O
in O
pol O
##g O

furthermore O
our O
study O
confirms O
the O
occurrence O
of O
tissue O
dependent O
defects O
19 O
41 O
44 O
whereas O
only O
a O
mild O
mitochondrial O
cy O
##top O
##athy O
of O
the O
heart O
and O
skeletal O
muscle O
was O
seen O
on O
single O
cells O
fibre O
level O
a O
severe O
but O
nevertheless O
non O
homo O
##gen O
##ous O
defect O
was O
detected O
in O
the O
liver O
the O
finding O
of O
non O
homo O
##gen O
##ous O
liver O
involvement O
has O
been O
previously O
reported O
in O
three O
studies O
10 O
11 O
63 O
the O
underlying O
pathogen O
##ic O
mechanisms O
were O
however O
not O
further O
el O
##uc O
##ida O
##ted O
in O
the O
present O
study O
we O
analyzed O
the O
defect O
pattern O
by O
cy O
##to O
##chemical O
and O
im O
##mun O
##oc O
##yt O
##oche O
##mic O
##al O
detection O
of O
cy O
##to O
##chrome O
cox O
##ida O
##se O
and O
for O
the O
first O
time O
combined O
the O
findings O
with O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
and O
additional O
quantitative O
pc O
##r O
analysis O
of O
mt O
##dna O
on O
isolated O
cox O
positive O
and O
cox O
negative O
liver O
cells O

in O
whole O
liver O
preparations O
the O
mt O
##dna O
copy O
number O
proved O
to O
be O
80 O
reduced O
referred O
to O
the O
lowest O
normal O
value O
in O
isolated O
cox O
positive O
liver O
cells O
mt O
##dna O
was O
similarly O
depleted O
cox O
negative O
liver O
cells O
however O
exhibited O
an O
even O
more O
severe O
de O
##ple O
##tion O
their O
mt O
##dna O
content O
was O
about O
9 O
times O
lower O
than O
that O
of O

cox O
positive O
liver O
cells O
this O
quantitative O
analysis O
correlated O
well O
with O
the O
results O
obtained O
by O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
interesting O
##ly O
no O
defect O
could O
be O
localized O
in O
the O
bi O
##lia O
##ry O
duct O
cell O
system O
thus O
our O
findings O
suggest O
that O
even O
when O
mt O
##dna O
is O
depleted O
in O
liver O
the O
amount O
of O
de O
##ple O
##tion O
has O
to O
reach O
a O
critical O
threshold O
in O
single O
cells O
in O
order O
to O
express O
the O
bio O
##chemical O
defect O
and O
this O
may O
be O
variable O
within O
single O
cells O
thereby O
similar O
to O
the O
skeletal O
muscle O
45 O
46 O
a O
mosaic O
defect O
pattern O
may O
result O
63 O
in O
the O
skeletal O
muscle O
0 O
01 O
mt O
##dna O
µ O
##m O
##3 O
has O
been O
found O
sufficient O
for O
residual O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
activity O
46 O
therefore O
a O
slight O
increase O
in O
the O
mt O
##dna O
copy O
number O
might O
be O
enough O
to O
traverse O
the O
threshold O
value O
to O
regain O
the O
normal O
respiratory O
function O
this O
observation O
may O
open O
new O
possibilities O
for O
further O
therapy O
trials O
and O
may O
explain O
the O
occasionally O
observed O
rev O
##ers O
##ibility O
of O
mt O
##dna O
de O
##ple O
##tion O
47 O
49 O
the O
mechanisms O
however O
underlying O
the O
expression O
of O
tissue O
select O
##ivity O
and O
the O
rev O
##ers O
##ibility O
remain O
still O
unclear O
50 O
51 O

besides O
tissue O
specific O
iso O
##forms O
of O
enzymes O
enrolled O
in O
dna O
replication O
and O
maintenance O
ox O
##ida O
##tive O
damage O
from O
free O
radicals O
might O
be O
a O
ca O
##usa O
##tive O
factor O
since O
pol O
y O
is O
susceptible O
to O
ox O
##ida O
##tive O
damage O
in O
vitro O
52 O
53 O
in O
the O
present O
case O
the O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
pol O
##g O
presented O
as O
im O
##mun O
##oh O
##isto O
##chemical O
##ly O
j O
cell O
mo O
##l O
med O
vol O
15 O
no O
2 O
2011 O
severely O
reduced O
pol O
y O
protein O
and O
a O
mosaic O
pattern O
of O
cox O
stain O
##ing O
and O
mt O
##dna O
levels O
in O
a O
previous O
case O
with O
dna O
de O
##ple O
##tion O
caused O
by O
a O
homo O
##zy O
##go O
##us O
de O
##ox O
##y O
##gua O
##nos O
##ine O
kinase O
gene O
d O
##gu O
##ok O
mutation O

54 O
expression O
of O
pol O
y O
was O
shown O
to O
be O
normal O
11 O

in O
our O
study O
we O
also O
tested O
the O
expression O
of O
mitochondrial O
transcription O
factor O
mt O
##tf O
##a O
and O
of O
mitochondrial O
single O
stranded O
protein O
mt O
##ss O
##b O
which O
both O
are O
involved O
in O
mt O
##dna O
replication O
h O
mt O
##tf O
##a O
is O
a O
25 O
k O
##d O
protein O
ind O
##is O
##pen O
##sable O
for O
transcription O
and O
replication O
of O
mt O
##dna O
55 O
the O
protein O
bends O
and O
un O
##wind O
##s O
mt O
##dna O
thus O
pri O
##ming O
transcription O
and O
replication O
5 O
56 O
in O
the O
liver O
of O
the O
present O
patient O
a O
mosaic O
defect O
pattern O
of O
both O
proteins O
existed O
in O
a O
previously O
described O
case O
11 O
with O
a O
he O
##pati O
##c O
form O
of O
mt O
##dna O
de O
##ple O
##tion O
caused O
by O
a O
homo O
##zy O
##go O
##us O
d O
##gu O
##ok O
gene O
mutation O

54 O
mt O
##tf O
##a O
and O
mt O
##ss O
##b O
were O
also O
defective O
the O
latter O
however O
only O
in O
single O
abnormal O
he O
##pa O
##to O
##cytes O
in O
a O
previous O
study O
on O
para O
##thy O
##roids O
with O
defects O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
both O
mt O
##tf O
##a O
and O
polymer O
##ase O
y O
were O
regularly O
expressed O
57 O
it O
is O
generally O
accepted O
that O
h O
mt O
##tf O
##a O
mirrors O
the O
mt O
##dna O
status O
of O
the O
cell O
but O
it O
is O
most O
likely O
that O
reduction O
of O
h O
mt O
##tf O
##a O
represents O
a O
secondary O
phenomenon O
as O
it O
is O
also O
reduced O
in O
cell O
lines O
where O
mt O
##dna O
copy O
number O
was O
experimental O
##ly O
reduced O
58 O
59 O
therefore O
it O
appears O
that O
similar O
as O
in O
sac O
##cha O
##rom O
##yce O
##s O
ce O
##re O
##vis O
##iae O

60 O
in O
the O
liver O
mitochondrial O
proteins O
are O
soon O
degraded O
when O
they O
are O
not O
properly O
assembled O
e O
g O
because O
of O
reduced O
binding O
sites O
a O
similar O
observation O
concerns O
the O
single O
strand O
binding O
protein O
mt O
##ss O
##b O
as O
mt O
##ss O
##b O
is O
essential O
for O
mt O
##dna O
replication O
and O
thus O
the O
maintenance O
of O
the O
dna O
its O
amount O
directly O
co O
##rre O
##lates O
with O
the O
mt O
##dna O
content O
61 O
consequently O
it O
may O
be O
assumed O
that O
the O
reduced O
appearance O
of O
mt O
##tf O
##a O
and O
mt O
##ss O
##b O
mirrors O
the O
replica O
##tive O
failure O
of O
mt O
##dna O
it O
therefore O
appears O
that O
de O
##ple O
##tion O

represents O
a O
dynamic O
process O
leading O
to O
additional O
secondary O
alterations O
in O
the O
mt O
##dna O
replica O
##tive O
machinery O
which O
might O
also O
ag O
##gra O
##vate O
the O
degree O
of O
mt O
##dna O
de O
##ple O
##tion O
and O
be O
a O
contributor O
##y O
cause O
of O
the O
mosaic O
defect O
pattern O
in O
the O
liver O
we O
also O
addressed O
the O
question O
of O
como O
##rb O
##iti O
##ty O
with O
other O
chronic O
liver O
diseases O
22 O
but O
there O
was O
no O
evidence O
for O
infectious O
liver O
disease O
pau O
##city O
of O
intra O
##he O
##pati O
##c O
bile O
duct O
##s O
fetal O
hem O
##och O
##rom O
##ato O
##sis O
a O
1 O
anti O
##try O
##ps O
##in O
deficiency O
or O
cy O
##stic O
fi O
##bro O
##sis O
as O
potential O
contributing O
factors O

in O
conclusion O
the O
presented O
results O
illustrate O
that O
morphological O
cy O
##to O
##chemical O
data O
and O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
provide O
valuable O
information O
in O
dia O
##gno O
##sing O
mt O
##dna O
de O
##ple O
##tion O
mt O
##dna O
de O
##ple O
##tion O
in O
the O
liver O
should O
be O
suspected O
on O
light O
microscopy O
when O
severe O
balloon O
##ing O
bi O
##lu O
##ru O
##bino O
##sta O
##sis O
and O
ste O
##ato O
##sis O
and O
giant O
he O
##pa O
##to O
##cytes O
are O
present O
on O
electron O
microscopy O
the O
most O
characteristic O
signs O
for O
mt O
##dna O
de O
##ple O
##tion O
are O
the O
accumulation O
of O
abnormal O
mit O
##och O
##ond O
##ria O
with O
tubular O
cr O
##ista O
##e O
or O
lack O
of O
cr O
##ista O
##e O
11 O
62 O
cy O
##to O
##chemist O
##ry O
im O
##mun O
##oc O
##yt O
##oche O
##mist O
##ry O
combined O
with O
in O
situ O
hybrid O
##ization O
of O
mt O
##dna O
are O
especially O
suited O
for O
the O
detection O
of O
mosaic O
tissue O
involvement O
if O
bio O
##chemical O
evidence O
decreased O
activity O
of O
respiratory O
chain O
complexes O
i O
iii O
and O
iv O
in O
liver O
also O

supports O
the O
mitochondrial O
origin O
it O
can O
give O
further O
support O
for O
the O
de O
##ple O
##tion O
if O
molecular O
genetic O
data O
are O
in O
the O
border O
line O
range O
our O
data O
show O
that O
mutations O
in O
pol O
##g O
lead O
to O
het O
##ero O
##gen O
##ous O
de O
##ple O
##tion O
of O
mt O
##dna O
in O
liver O
skeletal O
and O
heart O
and O
to O
a O
mosaic O
defect O
pattern O
even O
in O
the O
severely O
affected O
liver O
secondary O
d O
##ys O
##re O
##gul O
##ation O
of O
other O
proteins O
involved O
in O
mt O
##dna O
maintenance O
like O
mt O
##tf O
##a O
and O
mt O
##ss O
##b O
probably O
ag O
##gra O
##vate O
the O
defect O
and O
may O
thereby O
promote O
the O
development O
of O
a O
mosaic O
defect O
pattern O
the O
results O
help O
to O
explain O
the O
occasionally O
observed O
recovery O
from O
mt O
##dna O
de O
##ple O
##tion O

acknowledge O
##ments O
the O
authors O
are O
ind O
##eb O
##ted O
to O
mrs O
diane O
ra O
##abe O
and O
mrs O
mon O
##ika O
at O
##tman O
##sp O
##ache O
##r O
for O
in O
##val O
##ua O
##ble O
help O
in O
preparing O
the O
manuscript O
funding O
information O
w O
c O
c O
is O
funded O
by O
intra O
##mura O
##l O
funds O
from O
the O
national O
institutes O
of O
health O
ni O
##eh O
##s O
this O
work O
was O
in O
part O
p O
s O
supported O
by O
the O
sachs O
##ische O
minister O
##ium O
fur O
wi O
##ssen O
##schaft O
und O
kunst O
r O
##h O
is O
supported O
by O
the O
deutsche O
for O
##sch O
##ung O
##sg O
##eme O
##ins O
##chaft O
ho O
250 O
##5 O
2 O
1 O
references O
dim O
##aur O
##o O
s O
sc O
##hon O
ea O
mitochondrial O
respiratory O
chain O
diseases O
n O
eng O
##l O
j O
med O
2003 O
34 O
##8 O
265 O
##6 O
68 O

wallace O
dc O
diseases O
of O
the O
mitochondrial O
dna O
ann O
##u O
rev O
bio O
##che O
##m O
1992 O
61 O
117 O
##5 O
212 O
zev O
##iani O
m O
di O
dona O
##to O
s O
mitochondrial O
disorders O
brain O
2004 O
127 O
215 O
##3 O
72 O
graz O
##ie O
##wicz O
ma O
long O
##ley O
m O
##j O
copeland O
wc O
dna O
polymer O
##ase O
gamma O
in O
mitochondrial O
dna O
replication O
and O
repair O
che O
##m O
rev O
2006 O
106 O
38 O
##3 O
405 O
shade O
##l O
gs O
clayton O
da O
mitochondrial O
dna O
maintenance O
in O
ve O
##rte O
##brates O
ann O
##u O
rev O
bio O
##che O
##m O
1997 O
66 O
40 O
##9 O
35 O
ba O
##kker O
hd O
sc O
##hol O
##te O
hr O
ding O
##eman O
##s O
k O
##p O
et O
al O
de O
##ple O
##tion O
of O
mitochondrial O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##lei O
##c O
acid O
in O
a O
family O
with O
fatal O
neon O
##atal O
liver O
disease O
j O
pe O
##dia O
##tr O
1996 O
128 O
68 O
##3 O
7 O

duc O
##lu O
##ze O
##au O
ph O
lac O
##ha O
##ux O
a O
bo O
##u O
##vier O
r O
et O
al O
de O
##ple O
##tion O
of O
mitochondrial O
dna O
associated O
with O
infant O
##ile O
cho O
##les O
##tas O
##is O
and O
progressive O
liver O
fi O
##bro O
##sis O
j O
he O
##pa O
##to O
##l O
1999 O
30 O
149 O
55 O
ma O
##as O
##win O
##kel O
mo O
##oi O
##j O
pd O
van O
den O
bog O
##ert O
c O
sc O
##hol O
##te O
hr O
et O
al O
de O
##ple O
##tion O
of O
mitochondrial O
dna O
in O
the O
liver O
of O
a O
patient O
with O
lac O
##tic O
acid O
##emia O
and O
h O
##yp O
##oke O
##to O
##tic O
h O
##yp O
##og O
##ly O
##ce O
##mia O
j O
pe O
##dia O
##tr O
1996 O
128 O
67 O
##9 O
83 O
ma O
##zzi O
##ott O
##a O
mr O
ric O
##ci O
e O
bert O
##ini O
e O
et O
al O
fatal O
infant O
##ile O
liver O
failure O
associated O
with O
mitochondrial O
dna O
de O
##ple O
##tion O
j O
pe O
##dia O
##tr O
1992 O
121 O
89 O
##6 O
90 O
##1 O

morris O
aa O
ta O
##an O
##man O
j O
##w O
blake O
j O
et O
al O
liver O
failure O
associated O
with O
mitochondrial O
dna O
de O
##ple O
##tion O
j O
he O
##pa O
##to O
##l O
1998 O
28 O
55 O
##6 O
63 O
muller O
hoc O
##ker O
j O
mu O
##nta O
##u O
a O
sc O
##ha O
##fer O
s O
et O
al O
de O
##ple O
##tion O
of O
mitochondrial O
dna O
in O
the O
liver O
of O
an O
infant O
with O
neon O
##atal O
giant O
cell O
hepatitis O
hum O
path O
##ol O
2002 O
33 O
247 O
53 O
chan O
ss O
long O
##ley O
m O
##j O
copeland O
wc O
the O
common O
a O
##46 O
##7 O
##t O
mutation O
in O
the O
human O
mitochondrial O
dna O
polymer O
##ase O
pol O
##g O
compromise O
##s O
catalytic O
efficiency O
and O
interaction O
with O
the O
accessory O
subunit O
j O
bio O
##l O
che O
##m O
2005 O
280 O
313 O
##41 O
6 O

molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
and O
cn O
##s O
in O
##ﬂ O
##am O
##mat O
##ory O
markers O
in O
al O
##pers O
disease O
oswald O
has O
##sel O
##mann O
a O
ne O
##nad O
b O
##lau O
b O
vincent O
t O
rama O
##eke O
##rs O
c O
edward O
v O
quad O
##ros O
d O
j O
m O
se O
##que O
##ira O
d O
markus O
weiss O
##ert O
a O
a O
department O
of O
pediatric O
ne O
##uro O
##logy O
os O
##ts O
##ch O
##wei O
##zer O
kind O
##ers O
##pit O
##al O
claudius O
##stra O
##sse O
6 O
ch O
900 O
##6 O
st O
gall O
##en O
switzerland O
b O
division O
of O
clinical O
chemistry O
and O
biochemistry O
university O
children O
s O
hospital O
zurich O
switzerland O
c O
department O
of O
pediatric O
ne O
##uro O
##logy O
university O
hospital O
liege O
belgium O

d O
departments O
of O
medicine O
and O
cell O
biology O
sun O
##y O
downs O
##tate O
medical O
centre O
brooklyn O
ny O
usa O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
2 O
august O
2009 O
received O
in O
revised O
form O
19 O
august O
2009 O
accepted O
19 O
august O
2009 O
available O
online O
22 O
august O
2009 O
key O
##words O
mit O
##och O
##ond O
##ria O
f O
##olate O
antibodies O
ep O
##ile O
##psy O
neo O
##pt O
##erin O
cy O
##tok O
##ines O
pol O
##g O
a O
b O
s O
t O
r O
a O
c O
t O

we O
describe O
a O
3 B-AGE_FOLLOWUP
5 I-AGE_FOLLOWUP
year O
old O
female B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
with O
a O
pol B-GENE
##g I-GENE
gen O
##otype O
of O
p B-GENE
a I-GENE
##46 I-GENE
##7 I-GENE
##t I-GENE
p B-GENE
g I-GENE
##8 I-GENE
##48 I-GENE
##s I-GENE
and O
with O
a O
lethal O
outcome O
laboratory O
investigation O
revealed O
elevated B-HPO_TERM
cs B-HPO_TERM
##f I-HPO_TERM
neo I-HPO_TERM
##pt I-HPO_TERM
##erin I-HPO_TERM
il B-HPO_TERM
6 I-HPO_TERM
il B-HPO_TERM
8 I-HPO_TERM
if B-HPO_TERM
##n I-HPO_TERM
c I-HPO_TERM
reduced B-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
5 I-HPO_TERM
methyl I-HPO_TERM
##tet I-HPO_TERM
##rah I-HPO_TERM
##yd I-HPO_TERM
##ro I-HPO_TERM
##fo I-HPO_TERM
##late I-HPO_TERM
5 O
##mt O
##h O
##f O
and O
increased O
serum O
as O
well O
as O
cs O
##f O
f O
##olate O
receptor O
blocking O
auto O
##ant O
##ib O
##odies O
treatment O
with O
oral O
le O
##uc O
##ovo O
##rine O
5 O
form O
##yl O
te O
##tra O
##hy O
##dro O
##fo O
##late O
was O
initiated O
at O

0 O
25 O
mg O
kg O
bid O
and O
later O
increased O
to O
4 O
mg O
kg O
bid O
under O
treatment O
cs O
##f O
levels O
of O
5 O
##mt O
##h O
##f O
seizure B-HPO_TERM
frequency O
and O
com O
##mun O
##icative O
abilities O
improved O
over O
a O
time O
span O
of O
17 O
months O
cs O
##f O
levels O
of O
il O
6 O
and O
if O
##n O
c O
decreased O
levels O
of O
f O
##olate O
receptor O
blocking O
auto O
##ant O
##ib O
##odies O
continued O
to O
raise O
whereas O
cs O
##f O
il O
8 O
remained O
elevated O
1500 O
fold O
above O
normal O
the O
child O
died B-HPO_TERM
without O
apparent O
stress O
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
years O

al O
##pers O
disease O
a O
ne O
##uro O
##de O
##gen O
##erative O
disease O
usually O
presents O
in O
the O
ﬁ O
##rst O
years O
of O
life O
as O
a O
progressive O
en O
##ce O
##pha O
##lo O
##pathy O
with O
multi O
##fo O
##cal O
my O
##oc O
##lon O
##ic O
seizures O
developmental O
regression O
co O
##rti O
##cal O
blindness O
and O

early O
death O
the O
underlying O
genetic O
defect O
has O
been O
attributed O
to O
mutations O
of O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
polymer O
##ase O
c O
leading O
to O
an O
organ O
spec O
##i O
##ﬁ O
##c O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
with O
reduced O
activity O
of O
respiratory O
chain O
enzyme O
complexes O
in O
the O
brain O
and O
the O
liver O
a O
cu O
##rative O
therapy O
is O
not O
available O
this O
case O
report O
of O
al O
##pers O
disease O
provides O
new O
insights O
into O
the O
path O
##op O
##hy O
##sio O
##logy O

of O
al O
##pers O
disease O
where O
mitochondrial O
dysfunction O
in O
conjunction O
with O
in O
##ﬂ O
##am O
##mat O
##ory O
cy O
##tok O
##ines O
and O
blocking O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
may O
lead O
to O
a O
secondary O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
syndrome O
the O
treatment O
of O
the O
latter O
provides O
relief O
to O
the O
patient O
without O
stopping O
the O
underlying O
disease O
2009 O
else O
##vier O
inc O
all O
rights O
reserved O
introduction O

al O
##pers O
disease O
om O
##im O
203 O
##70 O
##0 O
1 O
a O
sp O
##ong O
##iform O
cerebral O
de O
##gen O
##erative O
disease O
affects O
the O
cerebral O
cortex O
the O
ce O
##re O
##bell O
##um O
the O
basal O
gang O
##lia O
and O
the O
brain O
stem O
the O
incidence O
of O
al O
##pers O
disease O
is O
estimated O
between O
1 O
100 O
000 O
and O
1 O
250 O
000 O
the O
affected O
patients O
present O
with O
a O
developmental O
re O
##tar O
##dation O
followed O
by O
regression O
intra O
##ctable O
ep O
##ile O
##psy O
movement O
disorders O
abnormal O
res O
##piration O
and O
at O
times O
co O
##rti O
##cal O
at O
##rop O
##hy O
and O
liver O
dysfunction O
2 O
bio O
##chemical O
ﬁ O
##nding O
##s O
can O
disclose O
a O
dysfunction O
of O
the O
ci O
##tric O
acid O
cycle O
due O
to O
reduced O
activity O
of O
respiratory O
chain O
enzymes O
at O
##tri O
##bu O
##table O
to O
mutations O
of O
the O
gene O
encoding O
the O
mitochondrial O
dna O
polymer O
##ase O
enzyme O
pol O
##g O
1 O
3 O
there O
are O
so O
far O
no O
bio O
##che O
##m O

corresponding O
authors O
fa O
##x O
41 O
71 O
243 O
73 O
67 O
o O
has O
##sel O
##mann O
e O
mail O
addresses O
oswald O
has O
##sel O
##mann O
ki O
##sp O
##is O
##g O
ch O
o O
has O
##sel O
##mann O
ne O
##nad O
b O
##lau O
ki O
##sp O
##i O
u O
##zh O
ch O
n O
b O
##lau O
1 O
abbreviation O
##s O
used O
ee O
##g O
electro O
##ence O
##pha O
##log O
##raphy O
il O
6 O
inter O
##le O
##uki O
##n O
6 O
il O
8 O
inter O
##le O
##uki O
##n O
8 O
if O
##n O
c O
inter O
##fer O
##on O
gamma O
mt O
##dna O
mitochondrial O
dna O
5 O
##mt O
##h O
##f O
5 O
methyl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
mt O
##h O
##fr O
methyl O
##ene O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
red O
##uc O
##tase O
pol O
##g O
polymer O
##ase O
gamma O

ic O
##als O
or O
in O
##ﬂ O
##am O
##mat O
##ory O
markers O
reported O
and O
there O
is O
no O
known O
effective O
therapy O
val O
##pro O
##ate O
as O
an O
anti O
##con O
##vu O
##ls O
##ant O
drug O
should O
be O
avoided O
since O
it O
is O
known O
to O
induce O
he O
##pati O
##c O
failure O
here O
we O
report O
on O
novel O
bio O
##chemical O
ﬁ O
##nding O
##s O
in O
a O
girl B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
complicated O
by O
cerebral B-HPO_TERM
f I-HPO_TERM
##olate I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
and O
potential O
treatment O
options O
with O
f O
##olin O
##ic O
acid O
materials O
and O
methods O
case O
report O

a O
3 O
##½ O
year O
old O
girl B-PATIENT
presented O
with O
acute O
onset O
of O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
and O
so B-HPO_TERM
##m I-HPO_TERM
##no I-HPO_TERM
##lence I-HPO_TERM
ee B-HPO_TERM
##g I-HPO_TERM
activity I-HPO_TERM
was I-HPO_TERM
severely I-HPO_TERM
suppressed I-HPO_TERM
with O
focal B-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
over O
the O
temporal O
regions O
the O
status O
was O
initially O
interrupted O
by O
the O
use O
of O
a O
combination O
of O
anti O
##con O
##vu O
##ls O
##ant O
drugs O
but O
re O
emerged O
in O
the O
following O
days O
and O
months O
and O
could O
at O
times O
only O
be O
suppressed O
by O
an O
##est O
##hetic O
agents O
the O
girl O
is O
the O
only O
child O
of O
healthy O
unrelated O
parents O
no O
progressive O
neurological O
diseases O
are O
known O
in O
the O
wider O
family O
at O
the O
age O
of O
30 B-AGE_ONSET
months I-AGE_ONSET
the O
girl O
was O
diagnosed O
with O
mental O
and O

109 O
##6 O
71 O
##9 O
##2 O
see O
front O
matter O
2009 O
else O
##vier O
inc O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
y O
##mg O
##me O
2009 O
08 O
00 O
##5 O
o O
has O
##sel O
##mann O
et O
al O
molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O
59 O

motor B-HPO_TERM
re I-HPO_TERM
##tar I-HPO_TERM
##dation I-HPO_TERM
of O
about O
8 O
12 O
months O
a O
video O
taken O
by O
the O
local O
pediatric O
##ian O
at O
age O
2 O
##½ O
years O
showed O
an O
ata B-HPO_TERM
##xia I-HPO_TERM
with O
d B-HPO_TERM
##ys I-HPO_TERM
##met I-HPO_TERM
##ria I-HPO_TERM
and O
muscular B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
her O
iq O
was O
estimated O
at O
a O
value O
of O
75 O
at O
the O
age O
of O
2 B-AGE_ONSET
years O
she O
had O
developed O
simple O
speech O
her O
weight O
and O
height O
curves O
never B-HPO_TERM
surpassed I-HPO_TERM
the I-HPO_TERM
3rd I-HPO_TERM
percent I-HPO_TERM
##ile I-HPO_TERM
she O
had O
no O
spec O
##i O
##ﬁ O
##c O
d O
##ys O
##morphic O
features O
nor O
increased O
su O
##sc O
##ept O
##ibility O
to O
infectious O
diseases O
the O
child O
died B-HPO_TERM
without O
apparent O
ne O
##uro O
##de O
##gen O
##eration O
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
years I-AGE_DEATH
an O
autopsy O
was O
not O
obtained O
ne O
##uro O
##ima O
##ging O

cr O
##anial O
computer O
tom O
##ography O
cc O
##t O
on O
day O
two O
of O
the O
acute O
disease O
was O
compatible O
with O
a O
generalized B-HPO_TERM
brain I-HPO_TERM
ed I-HPO_TERM
##ema I-HPO_TERM
whereas O
magnetic O
resonance O
imaging O
mri O
of O
the O
cn O
##s O
at O
the O
same O
time O
showed O
no O
abnormalities O
of O
either O
white O
or O
grey O
matter O
a O
second O
mri O
3 O
months O
after O
disease O
onset O
showed O
mild O
cerebral B-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
and O
an O
8 O
x O
11 O
mm O
is B-HPO_TERM
##che I-HPO_TERM
##mic I-HPO_TERM
les I-HPO_TERM
##ion I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
laboratory O
investigations O

laboratory O
or O
skin O
examinations O
excluded O
the O
following O
diseases O
sp O
##hing O
##oli O
##pid O
##oses O
gang O
##lio O
##si O
##dos O
##es O
disorders O
of O
g O
##ly O
##col O
##ys O
##ation O
ce O
##roid O
lip O
##of O
##us O
##cino O
##sis O
type O
1 O
and O
2 O
la O
##for O
##a O
disease O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
with O
ragged O
red O
ﬁ O
##bers O
and O
p O
##yr O
##ido O
##xin O
##e O
p O
##yr O
##ido O
##xa O
##l O
50 O
ph O
##os O
##pha O
##t O
dependent O
ep O
##ile O
##psy O
normal O
laboratory O
values O
were O
obtained O
for O
liver O
enzymes O
coa O
##gul O
##ation O
parameters O
lac O
##tate O
lac O
##tate O
p O
##yr O
##u O
##vate O
ratio O
vitamin O
b1 O
##2 O
homo O
##cy O
##stein O
##e O
f O
##olic O
acid O
serum O
organic O
acids O
urine O
amino O
acids O
urine O
serum O
ac O
##yl O
##car O
##ni O
##tine O
##s O
dried O
blood O
neo O
##pt O
##erin O
and O
bio O
##pt O
##erin O
urine O
ammonia B-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
intermittent I-HPO_TERM
##ly I-HPO_TERM
up O
to O
three O
times O
the O
normal O
values O

143 O
l O
##mo O
##l O
l O
normal O
10 O
48 O
l O
##mo O
##l O
l O
cerebral O
spinal O
ﬂ O
##uid O
cs O
##f O
analysis O
was O
normal O
for O
white O
blood O
count O
amino O
acids O
bacterial O
or O
viral O
infections O
lac B-HPO_TERM
##tate I-HPO_TERM
and O
protein B-HPO_TERM
were O
elevated O
lac O
##tate O
3 O
1 O
mm O
##ol O
l O
normal O
0 O
8 O
2 O
3 O
mm O
##ol O
l O
protein O
2 O
9 O
g O
l O
normal O
0 O
1 O
0 O
3 O
g O
l O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
meta O
##bol O
##ites O
and O
f O
##olate O
##s O
in O
cs O
##f O
were O
investigated O
as O
described O
previously O
4 O
cs O
##f O
and O
f O
##olate O
receptor O
fr O
auto O
##ant O
##ib O
##odies O
of O
the O
blocking O
type O
were O
measured O
in O
cs O
##f O
and O
plasma O
5 O
results O
cs O
##f O
investigations O

ne O
##uro O
##tra O
##ns O
##mit O
##ter O
and O
f O
##olate O
analysis O
of O
cs O
##f O
showed O
a O
markedly O
decreased B-HPO_TERM
5 I-HPO_TERM
methyl I-HPO_TERM
##tet I-HPO_TERM
##rah I-HPO_TERM
##yd I-HPO_TERM
##ro I-HPO_TERM
##fo I-HPO_TERM
##late I-HPO_TERM
5 I-HPO_TERM
##mt I-HPO_TERM
##h I-HPO_TERM
##f I-HPO_TERM
concentration I-HPO_TERM
in O
the O
presence O
of O
increased O
neo O
##pt O
##erin O
inter O
##le O
##uki O
##n O
6 O
il O
6 O
inter O
##le O
##uki O
##n O
8 O
il O
8 O
and O
inter O
##fer O
##on O
c O
if O
##n O
c O
table O
1 O
f O
##olate O
receptor O
fr O
auto O
##ant O
##ib O
##odies O
of O
the O
blocking O
type O
were O
present O
at O
week O
32 O
and O
week O
52 O
in O
serum O
0 O
34 O
pm O
##ol O
ml O
0 O
98 O
pm O
##ol O
ml O
normal O
0 O
2 O
pm O
##ol O
ml O
and O
at O
52 O
weeks O
in O
cs O
##f O
1 O
2 O
pm O
##ol O
ml O
normal O
0 O
2 O
pm O
##ol O
ml O
table O
1 O
the O
two O
meta O
##bo O

lit O
##es O
of O
do O
##pa O
##mine O
and O
ser O
##oton O
##in O
homo O
##vani O
##lli O
##c O
acid O
h O
##va O
and O
5 O
##hy O
##dro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
5 O
##hia O
##a O
as O
well O
as O
3 O
o O
methyl O
do O
##pa O
3 O
##om O
##d O
were O
at O
the O
upper O
normal O
range O
or O
even O
increased O
at O
all O
times O
independently O
of O
the O
5 O
##mt O
##f O
##h O
therapy O
protein O
content O
in O
cs O
##f O
wars O
repeatedly O
above O
expected O
values O
1 O
3 O
1 O
9 O
2 O
9 O
normal O
0 O
1 O
0 O
3 O
g O
l O
muscle O
bio O
##psy O

respiratory O
chain O
enzyme O
analysis O
performed O
on O
quad O
##rice O
##ps O
muscle O
showed O
normal O
activities O
of O
complexes O
i O
ii O
ii O
iii O
iii O
and O
iv O
compared O
to O
the O
mitochondrial O
marker O
enzyme O
ci O
##tra O
##te O
synth O
##ase O
friedrich O
ba O
##ur O
institute O
university O
of O
munich O
germany O
mitochondrial O
dna O
mt O
##dna O
quan O
##ti O
##ﬁ O
##cation O
performed O
on O
the O
muscle O
bio O
##psy O
material O
was O
not O
done O
ep O
##ile O
##psy O
and O
electro O
##ence O
##pha O
##logram O

repeated B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
required O
invasive B-HPO_TERM
ventilation I-HPO_TERM
and O
at O
times O
the O
use O
of O
more O
than O
four O
anti O
##con O
##vu O
##ls O
##ant O
drugs O
simultaneously O
val O
##pro O
##ic O
acid O
as O
an O
anti O
##con O
##vu O
##ls O
##ant O
agent O
was O
not O
administered O
since O
an O
underlying O
metabolic O
disturbances O
could O
not O
be O
excluded O
and O
the O
ee B-HPO_TERM
##g I-HPO_TERM
pattern I-HPO_TERM
with O
un O
##ila O
##tera O
##l O
o B-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
rhythmic I-HPO_TERM
high I-HPO_TERM
amplitude I-HPO_TERM
delta I-HPO_TERM
with O
super B-HPO_TERM
##im I-HPO_TERM
##posed I-HPO_TERM
poly I-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
##s I-HPO_TERM
was O
suggest O
##ive O
of O
for O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
6 O
molecular O
examination O

molecular O
testing O
revealed O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
the O
pol B-GENE
##g I-GENE
1 I-GENE
gene O
on O
chromosome O
15 O
##q O
##25 O
a O
miss O
##ense O
mutation O
in O
the O
polymer O
##ase O
domain O
in O
ex O
##on O
16 O
leading O
to O
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
exchange O
c B-GENE_VARIANT
254 I-GENE_VARIANT
##2 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
and O
a O
miss O
##ense O
mutation O
in O
the O
link O
##er O
region O
in O
ex O
##on O
7 O
leading O
to O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
exchange O
c B-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
was O
id O
##ent O
##i O
##ﬁ O
##ed O
the O
ﬁ O
##rst O
mutation O
was O
derived O
from O
the O
mother O
the O
latter O
from O
the O
father O
of O
the O
child O
both O
being O
healthy O
both O
mutations O
have O
previously O
been O
described O
as O
compound O
het O
##ero O
##zy O
##gos O
##ity O
in O
patients O
with O
al O
##pers O
disease O
3 O
treatment O

faced O
with O
the O
deteriorating B-HPO_TERM
clinical I-HPO_TERM
situation O
of O
an O
intra B-HPO_TERM
##ctable I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
syndrome O
impress O
##ing O
as O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
ref O
##rac O
##tory O
to O
common O
anti O
##ep O
##ile O
##ptic O
drugs O
we O
asked O
for O
parental O
consent O
to O
administer O
ph O
##arm O
##aco O
##logic O
doses O
of O
f O
##olin O
##ic O
acid O
5 O
form O
##yl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
le O
##uc O
##ovo O
##rine O
in O
order O
to O
compensate O
for O
the O
intra O
##cer O
##eb O
##ral O
f O
##olate O
de O
##ﬁ O
##ciency O
treatment O
was O
started O
with O
a O
daily O
oral O
dose O
of O
2 O
x O
0 O
25 O
mg O
kg O
body O
weight O
and O
later O
increased O
to O
2 O
x O
4 O
mg O
kg O
body O
weight O

a O
remarkable O
clinical O
improvement O
could O
be O
observed O
thereafter O
after O
2 O
weeks O
we O
could O
start O
to O
reduce O
the O
anti O
##con O
##vu O
##ls O
##ant O
treatment O
from O
four O
to O
two O
drugs O
for O
17 O
months O
under O
a O
combined O
anti O
##con O
##vu O
##ls O
##ant O
drug O
regime O
with O
ph O
##eno O
##bar O
##bit O
##one O
and O
vi O
##ga O
table O
1 O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
meta O
##bol O
##ites O
f O
##olate O
##s O
cy O
##tok O
##ines O
in O
cs O
##f O
and O
auto O
##ant O
##ib O
##odies O
against O
f O
##olate O
receptor O
in O
serum O
and O
cs O
##f O
of O
a O
patient O
with O
al O
##pers O
disease O

under O
f O
##olin O
##ic O
acid O
substitution O
n O
d O
not O
determined O
5 O
##hia O
##a O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
h O
##va O
homo O
##vani O
##lli O
##c O
acid O
3 O
##om O
##d O
3 O
o O
methyl O
do O
##pa O
5 O
##mt O
##f O
##h O
5 O
methyl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
neo O
neo O
##pt O
##erin O
bio O
bio O
##pt O
##erin O
il O
6 O
inter O
##le O
##uki O
##n O
6 O
il O
8 O
inter O
##le O
##uki O
##n O
8 O
if O
##n O
c O
inter O
##fer O
##on O
gamma O
fra O
##a O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
60 O
o O
has O
##sel O
##mann O
et O
al O
molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O

bat O
##rin O
no O
more O
status O
ep O
##ile O
##ptic O
##us O
and O
a O
marked O
reduction O
of O
focal B-HPO_TERM
seizures I-HPO_TERM
could O
be O
witnessed O
during O
the O
months O
of O
f O
##olin O
##ic O
acid O
substitution O
therapy O
the O
ee O
##g O
remained O
highly O
path O
##ological O
although O
high O
amplitude O
slow O
waves O
decreased O
and O
spec O
##i O
##ﬁ O
##c O
ep O
##ile O
##ptic O
activity O
appeared O
less O
pronounced O

on O
the O
clinical O
side O
we O
witnessed O
an O
improvement O
of O
communication O
skills O
of O
the O
child O
whereas O
before O
there O
was O
no O
interaction O
possible O
between O
the O
parents O
and O
their O
daughter O
a O
prompt O
response O
of O
the O
child O
could O
be O
observed O
when O
the O
child O
was O
spoken O
to O
or O
touched O
by O
the O
parents O
the O
girl O
was O
able O
to O
indicate O
physical O
discomfort O
such O
as O
a O
full O
bladder O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
seemed O
much O
less O
apparent O
swallowing B-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lt I-HPO_TERM
##ies I-HPO_TERM
were O
diminished O
at O
the O
age O
of O
5 B-AGE_DEATH
##½ I-AGE_DEATH
the O
girl O
passed O
away O
without O
an O
apparent O
deterioration O

during O
f O
##olin O
##ic O
acid O
supplement O
##ation O
follow O
up O
investigations O
showed O
a O
rise O
in O
cs O
##f O
fr O
auto O
##ant O
##ib O
##od O
##y O
ti O
##ters O
coin O
##ci O
##ding O
with O
a O
decrease O
of O
5 O
##mt O
##h O
##f O
levels O
prompting O
us O
to O
increase O
the O
f O
##olin O
##ic O
acid O
doses O
at O
disease O
onset O
il O
6 O
was O
increased O
3000 O
times O
the O
expected O
value O
and O
almost O
approached O
normal O
values O
in O
the O
course O
of O
the O
disease O
whereas O
il O
8 O
still O
remained O
elevated O
with O
an O
inc O
##rem O
##ent O
at O
1500 O
times O
the O
expected O
value O
table O
1 O
discussion O

although O
the O
understanding O
of O
the O
molecular O
defects O
of O
al O
##pers O
disease O
has O
increased O
over O
recent O
years O
the O
exact O
relationship O
between O
the O
molecular O
defect O
and O
the O
ph O
##eno O
##type O
remains O
very O
complex O
clayton O
described O
in O
1982 O
how O
the O
1656 O
##9 O
bp O
human O
mitochondrial O
genome O
is O
replicate O
##d O
and O
repaired O
by O
dna O
polymer O
##ase O
c O
pol O
##g O
7 O
the O
ﬁ O
##rst O
pathogen O
##ic O
mutations O
of O
pol O
##g O
were O
described O
in O
2001 O
in O
families O
with O
auto O
##som O
##al O
dominant O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
8 O
tissue O
spec O
##i O
##ﬁ O
##c O
mt O
##dna O
del O
##eti O
##ons O
were O
later O
id O
##ent O
##i O
##ﬁ O
##ed O
as O
causes O
of O
de O
##ﬁ O
##cie O
##ncies O
in O
mitochondrial O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
9 O

different O
and O
overlapping O
disease O
entities O
ranging O
from O
psychiatric O
disturbances O
to O
primary O
neurological O
diseases O
and O
end O
##oc O
##rine O
disturbances O
have O
been O
associated O
with O
pol O
##g O
mutation O
mutations O
in O
pol O
##g O
gene O
account O
for O
approximately O
90 O
of O
the O
classical O
ph O
##eno O
##type O
of O
al O
##pers O
disease O
10 O
one O
in O
50 O
people O
are O
thought O
to O
be O
silent O
het O
##ero O
##zy O
##go O
##te O
carriers O
of O
pol O
##g O
mutations O

most O
cases O
with O
childhood O
onset O
al O
##pers O
disease O
are O
associated O
with O
at O
least O
one O
mutation O
in O
the O
link O
##er O
region O
of O
the O
pol O
##g O
gene O
and O
one O
in O
the O
polymer O
##ase O
domain O
the O
most O
common O
disease O
mutation O
in O
pol O
##g O
associated O
with O
al O
##pers O
disease O
as O
in O
our O
patient O
is O
the O
g O
to O
a O
mutation O
at O
nu O
##cle O
##otide O
139 O
##9 O
in O
ex O
##on O
7 O
of O
pol O
##g O
causing O
an O
alan O
##ine O
to O
th O
##re O
##oni O
##ne O
amino O
acid O
substitution O
at O
cod O
##on O
46 O
##7 O
in O
the O
belgian O
population O
the O
p O
a O
##46 O
##7 O
##t O
mutation O
has O
been O
observed O
at O
a O
frequency O
of O
0 O
6 O
without O
showing O
clinical O
signs O
6 O

molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
and O
cn O
##s O
in O
##ﬂ O
##am O
##mat O
##ory O
markers O
in O
al O
##pers O
disease O
oswald O
has O
##sel O
##mann O
a O
ne O
##nad O
b O
##lau O
b O
vincent O
t O
rama O
##eke O
##rs O
c O
edward O
v O
quad O
##ros O
d O
j O
m O
se O
##que O
##ira O
d O
markus O
weiss O
##ert O
a O
a O
department O
of O
pediatric O
ne O
##uro O
##logy O
os O
##ts O
##ch O
##wei O
##zer O
kind O
##ers O
##pit O
##al O
claudius O
##stra O
##sse O
6 O
ch O
900 O
##6 O
st O
gall O
##en O
switzerland O
b O
division O
of O
clinical O
chemistry O
and O
biochemistry O
university O
children O
s O
hospital O
zurich O
switzerland O
c O
department O
of O
pediatric O
ne O
##uro O
##logy O
university O
hospital O
liege O
belgium O

d O
departments O
of O
medicine O
and O
cell O
biology O
sun O
##y O
downs O
##tate O
medical O
centre O
brooklyn O
ny O
usa O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
2 O
august O
2009 O
received O
in O
revised O
form O
19 O
august O
2009 O
accepted O
19 O
august O
2009 O
available O
online O
22 O
august O
2009 O
key O
##words O
mit O
##och O
##ond O
##ria O
f O
##olate O
antibodies O
ep O
##ile O
##psy O
neo O
##pt O
##erin O
cy O
##tok O
##ines O
pol O
##g O
a O
b O
s O
t O
r O
a O
c O
t O

we O
describe O
a O
3 B-AGE_FOLLOWUP
5 I-AGE_FOLLOWUP
year O
old O
female B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
with O
a O
pol B-GENE
##g I-GENE
gen O
##otype O
of O
p B-GENE
a I-GENE
##46 I-GENE
##7 I-GENE
##t I-GENE
p B-GENE
g I-GENE
##8 I-GENE
##48 I-GENE
##s I-GENE
and O
with O
a O
lethal O
outcome O
laboratory O
investigation O
revealed O
elevated B-HPO_TERM
cs B-HPO_TERM
##f I-HPO_TERM
neo I-HPO_TERM
##pt I-HPO_TERM
##erin I-HPO_TERM
il B-HPO_TERM
6 I-HPO_TERM
il B-HPO_TERM
8 I-HPO_TERM
if B-HPO_TERM
##n I-HPO_TERM
c I-HPO_TERM
reduced B-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
5 I-HPO_TERM
methyl I-HPO_TERM
##tet I-HPO_TERM
##rah I-HPO_TERM
##yd I-HPO_TERM
##ro I-HPO_TERM
##fo I-HPO_TERM
##late I-HPO_TERM
5 O
##mt O
##h O
##f O
and O
increased O
serum O
as O
well O
as O
cs O
##f O
f O
##olate O
receptor O
blocking O
auto O
##ant O
##ib O
##odies O
treatment O
with O
oral O
le O
##uc O
##ovo O
##rine O
5 O
form O
##yl O
te O
##tra O
##hy O
##dro O
##fo O
##late O
was O
initiated O
at O

0 O
25 O
mg O
kg O
bid O
and O
later O
increased O
to O
4 O
mg O
kg O
bid O
under O
treatment O
cs O
##f O
levels O
of O
5 O
##mt O
##h O
##f O
seizure B-HPO_TERM
frequency O
and O
com O
##mun O
##icative O
abilities O
improved O
over O
a O
time O
span O
of O
17 O
months O
cs O
##f O
levels O
of O
il O
6 O
and O
if O
##n O
c O
decreased O
levels O
of O
f O
##olate O
receptor O
blocking O
auto O
##ant O
##ib O
##odies O
continued O
to O
raise O
whereas O
cs O
##f O
il O
8 O
remained O
elevated O
1500 O
fold O
above O
normal O
the O
child O
died B-HPO_TERM
without O
apparent O
stress O
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
years O

al O
##pers O
disease O
a O
ne O
##uro O
##de O
##gen O
##erative O
disease O
usually O
presents O
in O
the O
ﬁ O
##rst O
years O
of O
life O
as O
a O
progressive O
en O
##ce O
##pha O
##lo O
##pathy O
with O
multi O
##fo O
##cal O
my O
##oc O
##lon O
##ic O
seizures O
developmental O
regression O
co O
##rti O
##cal O
blindness O
and O

early O
death O
the O
underlying O
genetic O
defect O
has O
been O
attributed O
to O
mutations O
of O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
polymer O
##ase O
c O
leading O
to O
an O
organ O
spec O
##i O
##ﬁ O
##c O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
with O
reduced O
activity O
of O
respiratory O
chain O
enzyme O
complexes O
in O
the O
brain O
and O
the O
liver O
a O
cu O
##rative O
therapy O
is O
not O
available O
this O
case O
report O
of O
al O
##pers O
disease O
provides O
new O
insights O
into O
the O
path O
##op O
##hy O
##sio O
##logy O

of O
al O
##pers O
disease O
where O
mitochondrial O
dysfunction O
in O
conjunction O
with O
in O
##ﬂ O
##am O
##mat O
##ory O
cy O
##tok O
##ines O
and O
blocking O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
may O
lead O
to O
a O
secondary O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
syndrome O
the O
treatment O
of O
the O
latter O
provides O
relief O
to O
the O
patient O
without O
stopping O
the O
underlying O
disease O
2009 O
else O
##vier O
inc O
all O
rights O
reserved O
introduction O

al O
##pers O
disease O
om O
##im O
203 O
##70 O
##0 O
1 O
a O
sp O
##ong O
##iform O
cerebral O
de O
##gen O
##erative O
disease O
affects O
the O
cerebral O
cortex O
the O
ce O
##re O
##bell O
##um O
the O
basal O
gang O
##lia O
and O
the O
brain O
stem O
the O
incidence O
of O
al O
##pers O
disease O
is O
estimated O
between O
1 O
100 O
000 O
and O
1 O
250 O
000 O
the O
affected O
patients O
present O
with O
a O
developmental O
re O
##tar O
##dation O
followed O
by O
regression O
intra O
##ctable O
ep O
##ile O
##psy O
movement O
disorders O
abnormal O
res O
##piration O
and O
at O
times O
co O
##rti O
##cal O
at O
##rop O
##hy O
and O
liver O
dysfunction O
2 O
bio O
##chemical O
ﬁ O
##nding O
##s O
can O
disclose O
a O
dysfunction O
of O
the O
ci O
##tric O
acid O
cycle O
due O
to O
reduced O
activity O
of O
respiratory O
chain O
enzymes O
at O
##tri O
##bu O
##table O
to O
mutations O
of O
the O
gene O
encoding O
the O
mitochondrial O
dna O
polymer O
##ase O
enzyme O
pol O
##g O
1 O
3 O
there O
are O
so O
far O
no O
bio O
##che O
##m O

corresponding O
authors O
fa O
##x O
41 O
71 O
243 O
73 O
67 O
o O
has O
##sel O
##mann O
e O
mail O
addresses O
oswald O
has O
##sel O
##mann O
ki O
##sp O
##is O
##g O
ch O
o O
has O
##sel O
##mann O
ne O
##nad O
b O
##lau O
ki O
##sp O
##i O
u O
##zh O
ch O
n O
b O
##lau O
1 O
abbreviation O
##s O
used O
ee O
##g O
electro O
##ence O
##pha O
##log O
##raphy O
il O
6 O
inter O
##le O
##uki O
##n O
6 O
il O
8 O
inter O
##le O
##uki O
##n O
8 O
if O
##n O
c O
inter O
##fer O
##on O
gamma O
mt O
##dna O
mitochondrial O
dna O
5 O
##mt O
##h O
##f O
5 O
methyl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
mt O
##h O
##fr O
methyl O
##ene O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
red O
##uc O
##tase O
pol O
##g O
polymer O
##ase O
gamma O

ic O
##als O
or O
in O
##ﬂ O
##am O
##mat O
##ory O
markers O
reported O
and O
there O
is O
no O
known O
effective O
therapy O
val O
##pro O
##ate O
as O
an O
anti O
##con O
##vu O
##ls O
##ant O
drug O
should O
be O
avoided O
since O
it O
is O
known O
to O
induce O
he O
##pati O
##c O
failure O
here O
we O
report O
on O
novel O
bio O
##chemical O
ﬁ O
##nding O
##s O
in O
a O
girl B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
complicated O
by O
cerebral B-HPO_TERM
f I-HPO_TERM
##olate I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
and O
potential O
treatment O
options O
with O
f O
##olin O
##ic O
acid O
materials O
and O
methods O
case O
report O

a O
3 O
##½ O
year O
old O
girl B-PATIENT
presented O
with O
acute O
onset O
of O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
and O
so B-HPO_TERM
##m I-HPO_TERM
##no I-HPO_TERM
##lence I-HPO_TERM
ee B-HPO_TERM
##g I-HPO_TERM
activity I-HPO_TERM
was I-HPO_TERM
severely I-HPO_TERM
suppressed I-HPO_TERM
with O
focal B-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
over O
the O
temporal O
regions O
the O
status O
was O
initially O
interrupted O
by O
the O
use O
of O
a O
combination O
of O
anti O
##con O
##vu O
##ls O
##ant O
drugs O
but O
re O
emerged O
in O
the O
following O
days O
and O
months O
and O
could O
at O
times O
only O
be O
suppressed O
by O
an O
##est O
##hetic O
agents O
the O
girl O
is O
the O
only O
child O
of O
healthy O
unrelated O
parents O
no O
progressive O
neurological O
diseases O
are O
known O
in O
the O
wider O
family O
at O
the O
age O
of O
30 B-AGE_ONSET
months I-AGE_ONSET
the O
girl O
was O
diagnosed O
with O
mental O
and O

109 O
##6 O
71 O
##9 O
##2 O
see O
front O
matter O
2009 O
else O
##vier O
inc O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
y O
##mg O
##me O
2009 O
08 O
00 O
##5 O
o O
has O
##sel O
##mann O
et O
al O
molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O
59 O

motor B-HPO_TERM
re I-HPO_TERM
##tar I-HPO_TERM
##dation I-HPO_TERM
of O
about O
8 O
12 O
months O
a O
video O
taken O
by O
the O
local O
pediatric O
##ian O
at O
age O
2 O
##½ O
years O
showed O
an O
ata B-HPO_TERM
##xia I-HPO_TERM
with O
d B-HPO_TERM
##ys I-HPO_TERM
##met I-HPO_TERM
##ria I-HPO_TERM
and O
muscular B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
her O
iq O
was O
estimated O
at O
a O
value O
of O
75 O
at O
the O
age O
of O
2 B-AGE_ONSET
years O
she O
had O
developed O
simple O
speech O
her O
weight O
and O
height O
curves O
never B-HPO_TERM
surpassed I-HPO_TERM
the I-HPO_TERM
3rd I-HPO_TERM
percent I-HPO_TERM
##ile I-HPO_TERM
she O
had O
no O
spec O
##i O
##ﬁ O
##c O
d O
##ys O
##morphic O
features O
nor O
increased O
su O
##sc O
##ept O
##ibility O
to O
infectious O
diseases O
the O
child O
died B-HPO_TERM
without O
apparent O
ne O
##uro O
##de O
##gen O
##eration O
at O
the O
age O
of O
5 B-AGE_DEATH
5 I-AGE_DEATH
years I-AGE_DEATH
an O
autopsy O
was O
not O
obtained O
ne O
##uro O
##ima O
##ging O

cr O
##anial O
computer O
tom O
##ography O
cc O
##t O
on O
day O
two O
of O
the O
acute O
disease O
was O
compatible O
with O
a O
generalized B-HPO_TERM
brain I-HPO_TERM
ed I-HPO_TERM
##ema I-HPO_TERM
whereas O
magnetic O
resonance O
imaging O
mri O
of O
the O
cn O
##s O
at O
the O
same O
time O
showed O
no O
abnormalities O
of O
either O
white O
or O
grey O
matter O
a O
second O
mri O
3 O
months O
after O
disease O
onset O
showed O
mild O
cerebral B-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
and O
an O
8 O
x O
11 O
mm O
is B-HPO_TERM
##che I-HPO_TERM
##mic I-HPO_TERM
les I-HPO_TERM
##ion I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
laboratory O
investigations O

laboratory O
or O
skin O
examinations O
excluded O
the O
following O
diseases O
sp O
##hing O
##oli O
##pid O
##oses O
gang O
##lio O
##si O
##dos O
##es O
disorders O
of O
g O
##ly O
##col O
##ys O
##ation O
ce O
##roid O
lip O
##of O
##us O
##cino O
##sis O
type O
1 O
and O
2 O
la O
##for O
##a O
disease O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
with O
ragged O
red O
ﬁ O
##bers O
and O
p O
##yr O
##ido O
##xin O
##e O
p O
##yr O
##ido O
##xa O
##l O
50 O
ph O
##os O
##pha O
##t O
dependent O
ep O
##ile O
##psy O
normal O
laboratory O
values O
were O
obtained O
for O
liver O
enzymes O
coa O
##gul O
##ation O
parameters O
lac O
##tate O
lac O
##tate O
p O
##yr O
##u O
##vate O
ratio O
vitamin O
b1 O
##2 O
homo O
##cy O
##stein O
##e O
f O
##olic O
acid O
serum O
organic O
acids O
urine O
amino O
acids O
urine O
serum O
ac O
##yl O
##car O
##ni O
##tine O
##s O
dried O
blood O
neo O
##pt O
##erin O
and O
bio O
##pt O
##erin O
urine O
ammonia B-HPO_TERM
was I-HPO_TERM
increased I-HPO_TERM
intermittent I-HPO_TERM
##ly I-HPO_TERM
up O
to O
three O
times O
the O
normal O
values O

143 O
l O
##mo O
##l O
l O
normal O
10 O
48 O
l O
##mo O
##l O
l O
cerebral O
spinal O
ﬂ O
##uid O
cs O
##f O
analysis O
was O
normal O
for O
white O
blood O
count O
amino O
acids O
bacterial O
or O
viral O
infections O
lac B-HPO_TERM
##tate I-HPO_TERM
and O
protein B-HPO_TERM
were O
elevated O
lac O
##tate O
3 O
1 O
mm O
##ol O
l O
normal O
0 O
8 O
2 O
3 O
mm O
##ol O
l O
protein O
2 O
9 O
g O
l O
normal O
0 O
1 O
0 O
3 O
g O
l O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
meta O
##bol O
##ites O
and O
f O
##olate O
##s O
in O
cs O
##f O
were O
investigated O
as O
described O
previously O
4 O
cs O
##f O
and O
f O
##olate O
receptor O
fr O
auto O
##ant O
##ib O
##odies O
of O
the O
blocking O
type O
were O
measured O
in O
cs O
##f O
and O
plasma O
5 O
results O
cs O
##f O
investigations O

ne O
##uro O
##tra O
##ns O
##mit O
##ter O
and O
f O
##olate O
analysis O
of O
cs O
##f O
showed O
a O
markedly O
decreased B-HPO_TERM
5 I-HPO_TERM
methyl I-HPO_TERM
##tet I-HPO_TERM
##rah I-HPO_TERM
##yd I-HPO_TERM
##ro I-HPO_TERM
##fo I-HPO_TERM
##late I-HPO_TERM
5 I-HPO_TERM
##mt I-HPO_TERM
##h I-HPO_TERM
##f I-HPO_TERM
concentration I-HPO_TERM
in O
the O
presence O
of O
increased O
neo O
##pt O
##erin O
inter O
##le O
##uki O
##n O
6 O
il O
6 O
inter O
##le O
##uki O
##n O
8 O
il O
8 O
and O
inter O
##fer O
##on O
c O
if O
##n O
c O
table O
1 O
f O
##olate O
receptor O
fr O
auto O
##ant O
##ib O
##odies O
of O
the O
blocking O
type O
were O
present O
at O
week O
32 O
and O
week O
52 O
in O
serum O
0 O
34 O
pm O
##ol O
ml O
0 O
98 O
pm O
##ol O
ml O
normal O
0 O
2 O
pm O
##ol O
ml O
and O
at O
52 O
weeks O
in O
cs O
##f O
1 O
2 O
pm O
##ol O
ml O
normal O
0 O
2 O
pm O
##ol O
ml O
table O
1 O
the O
two O
meta O
##bo O

lit O
##es O
of O
do O
##pa O
##mine O
and O
ser O
##oton O
##in O
homo O
##vani O
##lli O
##c O
acid O
h O
##va O
and O
5 O
##hy O
##dro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
5 O
##hia O
##a O
as O
well O
as O
3 O
o O
methyl O
do O
##pa O
3 O
##om O
##d O
were O
at O
the O
upper O
normal O
range O
or O
even O
increased O
at O
all O
times O
independently O
of O
the O
5 O
##mt O
##f O
##h O
therapy O
protein O
content O
in O
cs O
##f O
wars O
repeatedly O
above O
expected O
values O
1 O
3 O
1 O
9 O
2 O
9 O
normal O
0 O
1 O
0 O
3 O
g O
l O
muscle O
bio O
##psy O

respiratory O
chain O
enzyme O
analysis O
performed O
on O
quad O
##rice O
##ps O
muscle O
showed O
normal O
activities O
of O
complexes O
i O
ii O
ii O
iii O
iii O
and O
iv O
compared O
to O
the O
mitochondrial O
marker O
enzyme O
ci O
##tra O
##te O
synth O
##ase O
friedrich O
ba O
##ur O
institute O
university O
of O
munich O
germany O
mitochondrial O
dna O
mt O
##dna O
quan O
##ti O
##ﬁ O
##cation O
performed O
on O
the O
muscle O
bio O
##psy O
material O
was O
not O
done O
ep O
##ile O
##psy O
and O
electro O
##ence O
##pha O
##logram O

repeated B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
required O
invasive B-HPO_TERM
ventilation I-HPO_TERM
and O
at O
times O
the O
use O
of O
more O
than O
four O
anti O
##con O
##vu O
##ls O
##ant O
drugs O
simultaneously O
val O
##pro O
##ic O
acid O
as O
an O
anti O
##con O
##vu O
##ls O
##ant O
agent O
was O
not O
administered O
since O
an O
underlying O
metabolic O
disturbances O
could O
not O
be O
excluded O
and O
the O
ee B-HPO_TERM
##g I-HPO_TERM
pattern I-HPO_TERM
with O
un O
##ila O
##tera O
##l O
o B-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
rhythmic I-HPO_TERM
high I-HPO_TERM
amplitude I-HPO_TERM
delta I-HPO_TERM
with O
super B-HPO_TERM
##im I-HPO_TERM
##posed I-HPO_TERM
poly I-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
##s I-HPO_TERM
was O
suggest O
##ive O
of O
for O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
6 O
molecular O
examination O

molecular O
testing O
revealed O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
the O
pol B-GENE
##g I-GENE
1 I-GENE
gene O
on O
chromosome O
15 O
##q O
##25 O
a O
miss O
##ense O
mutation O
in O
the O
polymer O
##ase O
domain O
in O
ex O
##on O
16 O
leading O
to O
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
exchange O
c B-GENE_VARIANT
254 I-GENE_VARIANT
##2 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
and O
a O
miss O
##ense O
mutation O
in O
the O
link O
##er O
region O
in O
ex O
##on O
7 O
leading O
to O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
exchange O
c B-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
was O
id O
##ent O
##i O
##ﬁ O
##ed O
the O
ﬁ O
##rst O
mutation O
was O
derived O
from O
the O
mother O
the O
latter O
from O
the O
father O
of O
the O
child O
both O
being O
healthy O
both O
mutations O
have O
previously O
been O
described O
as O
compound O
het O
##ero O
##zy O
##gos O
##ity O
in O
patients O
with O
al O
##pers O
disease O
3 O
treatment O

faced O
with O
the O
deteriorating B-HPO_TERM
clinical I-HPO_TERM
situation O
of O
an O
intra B-HPO_TERM
##ctable I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
syndrome O
impress O
##ing O
as O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
ref O
##rac O
##tory O
to O
common O
anti O
##ep O
##ile O
##ptic O
drugs O
we O
asked O
for O
parental O
consent O
to O
administer O
ph O
##arm O
##aco O
##logic O
doses O
of O
f O
##olin O
##ic O
acid O
5 O
form O
##yl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
le O
##uc O
##ovo O
##rine O
in O
order O
to O
compensate O
for O
the O
intra O
##cer O
##eb O
##ral O
f O
##olate O
de O
##ﬁ O
##ciency O
treatment O
was O
started O
with O
a O
daily O
oral O
dose O
of O
2 O
x O
0 O
25 O
mg O
kg O
body O
weight O
and O
later O
increased O
to O
2 O
x O
4 O
mg O
kg O
body O
weight O

a O
remarkable O
clinical O
improvement O
could O
be O
observed O
thereafter O
after O
2 O
weeks O
we O
could O
start O
to O
reduce O
the O
anti O
##con O
##vu O
##ls O
##ant O
treatment O
from O
four O
to O
two O
drugs O
for O
17 O
months O
under O
a O
combined O
anti O
##con O
##vu O
##ls O
##ant O
drug O
regime O
with O
ph O
##eno O
##bar O
##bit O
##one O
and O
vi O
##ga O
table O
1 O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
meta O
##bol O
##ites O
f O
##olate O
##s O
cy O
##tok O
##ines O
in O
cs O
##f O
and O
auto O
##ant O
##ib O
##odies O
against O
f O
##olate O
receptor O
in O
serum O
and O
cs O
##f O
of O
a O
patient O
with O
al O
##pers O
disease O

under O
f O
##olin O
##ic O
acid O
substitution O
n O
d O
not O
determined O
5 O
##hia O
##a O
5 O
hydro O
##xy O
##ind O
##ole O
##ace O
##tic O
acid O
h O
##va O
homo O
##vani O
##lli O
##c O
acid O
3 O
##om O
##d O
3 O
o O
methyl O
do O
##pa O
5 O
##mt O
##f O
##h O
5 O
methyl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
neo O
neo O
##pt O
##erin O
bio O
bio O
##pt O
##erin O
il O
6 O
inter O
##le O
##uki O
##n O
6 O
il O
8 O
inter O
##le O
##uki O
##n O
8 O
if O
##n O
c O
inter O
##fer O
##on O
gamma O
fra O
##a O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
60 O
o O
has O
##sel O
##mann O
et O
al O
molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O

bat O
##rin O
no O
more O
status O
ep O
##ile O
##ptic O
##us O
and O
a O
marked O
reduction O
of O
focal B-HPO_TERM
seizures I-HPO_TERM
could O
be O
witnessed O
during O
the O
months O
of O
f O
##olin O
##ic O
acid O
substitution O
therapy O
the O
ee O
##g O
remained O
highly O
path O
##ological O
although O
high O
amplitude O
slow O
waves O
decreased O
and O
spec O
##i O
##ﬁ O
##c O
ep O
##ile O
##ptic O
activity O
appeared O
less O
pronounced O

on O
the O
clinical O
side O
we O
witnessed O
an O
improvement O
of O
communication O
skills O
of O
the O
child O
whereas O
before O
there O
was O
no O
interaction O
possible O
between O
the O
parents O
and O
their O
daughter O
a O
prompt O
response O
of O
the O
child O
could O
be O
observed O
when O
the O
child O
was O
spoken O
to O
or O
touched O
by O
the O
parents O
the O
girl O
was O
able O
to O
indicate O
physical O
discomfort O
such O
as O
a O
full O
bladder O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
seemed O
much O
less O
apparent O
swallowing B-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lt I-HPO_TERM
##ies I-HPO_TERM
were O
diminished O
at O
the O
age O
of O
5 B-AGE_DEATH
##½ I-AGE_DEATH
the O
girl O
passed O
away O
without O
an O
apparent O
deterioration O

during O
f O
##olin O
##ic O
acid O
supplement O
##ation O
follow O
up O
investigations O
showed O
a O
rise O
in O
cs O
##f O
fr O
auto O
##ant O
##ib O
##od O
##y O
ti O
##ters O
coin O
##ci O
##ding O
with O
a O
decrease O
of O
5 O
##mt O
##h O
##f O
levels O
prompting O
us O
to O
increase O
the O
f O
##olin O
##ic O
acid O
doses O
at O
disease O
onset O
il O
6 O
was O
increased O
3000 O
times O
the O
expected O
value O
and O
almost O
approached O
normal O
values O
in O
the O
course O
of O
the O
disease O
whereas O
il O
8 O
still O
remained O
elevated O
with O
an O
inc O
##rem O
##ent O
at O
1500 O
times O
the O
expected O
value O
table O
1 O
discussion O

although O
the O
understanding O
of O
the O
molecular O
defects O
of O
al O
##pers O
disease O
has O
increased O
over O
recent O
years O
the O
exact O
relationship O
between O
the O
molecular O
defect O
and O
the O
ph O
##eno O
##type O
remains O
very O
complex O
clayton O
described O
in O
1982 O
how O
the O
1656 O
##9 O
bp O
human O
mitochondrial O
genome O
is O
replicate O
##d O
and O
repaired O
by O
dna O
polymer O
##ase O
c O
pol O
##g O
7 O
the O
ﬁ O
##rst O
pathogen O
##ic O
mutations O
of O
pol O
##g O
were O
described O
in O
2001 O
in O
families O
with O
auto O
##som O
##al O
dominant O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
8 O
tissue O
spec O
##i O
##ﬁ O
##c O
mt O
##dna O
del O
##eti O
##ons O
were O
later O
id O
##ent O
##i O
##ﬁ O
##ed O
as O
causes O
of O
de O
##ﬁ O
##cie O
##ncies O
in O
mitochondrial O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
9 O

different O
and O
overlapping O
disease O
entities O
ranging O
from O
psychiatric O
disturbances O
to O
primary O
neurological O
diseases O
and O
end O
##oc O
##rine O
disturbances O
have O
been O
associated O
with O
pol O
##g O
mutation O
mutations O
in O
pol O
##g O
gene O
account O
for O
approximately O
90 O
of O
the O
classical O
ph O
##eno O
##type O
of O
al O
##pers O
disease O
10 O
one O
in O
50 O
people O
are O
thought O
to O
be O
silent O
het O
##ero O
##zy O
##go O
##te O
carriers O
of O
pol O
##g O
mutations O

most O
cases O
with O
childhood O
onset O
al O
##pers O
disease O
are O
associated O
with O
at O
least O
one O
mutation O
in O
the O
link O
##er O
region O
of O
the O
pol O
##g O
gene O
and O
one O
in O
the O
polymer O
##ase O
domain O
the O
most O
common O
disease O
mutation O
in O
pol O
##g O
associated O
with O
al O
##pers O
disease O
as O
in O
our O
patient O
is O
the O
g O
to O
a O
mutation O
at O
nu O
##cle O
##otide O
139 O
##9 O
in O
ex O
##on O
7 O
of O
pol O
##g O
causing O
an O
alan O
##ine O
to O
th O
##re O
##oni O
##ne O
amino O
acid O
substitution O
at O
cod O
##on O
46 O
##7 O
in O
the O
belgian O
population O
the O
p O
a O
##46 O
##7 O
##t O
mutation O
has O
been O
observed O
at O
a O
frequency O
of O
0 O
6 O
without O
showing O
clinical O
signs O
6 O

in O
al O
##pers O
disease O
the O
p O
a O
##46 O
##7 O
##t O
mutation O
is O
either O
homo O
##zy O
##go O
##us O
or O
paired O
in O
trans O
with O
other O
mutations O
in O
pol O
##g O
in O
the O
case O
of O
compound O
het O
##ero O
##zy O
##gos O
##ity O
there O
is O
a O
polymer O
##ase O
activity O
of O
only O
4 O
comparing O
to O
the O
wild O
type O
dna O
11 O
it O
is O
thus O
the O
nature O
of O
the O
mutation O
in O
the O
second O
pol O
##g O
all O
##ele O
in O
compound O
het O
##ero O
##zy O
##go O
##us O
patients O
that O
in O
##ﬂ O
##uen O
##ces O
the O
severity O
and O
type O
of O
the O
disease O
more O
prolonged O
disease O
courses O
with O
less O
severe O
symptoms O
have O
been O
described O
and O
seemed O
to O
be O
associated O
with O
a O
homo O
##zy O
##go O
##us O
mutation O
10 O
12 O

the O
sy O
##mpt O
##oma O
##tic O
ep O
##ile O
##psy O
in O
al O
##pers O
disease O
is O
usually O
ref O
##rac O
##tory O
to O
common O
anti O
##ep O
##ile O
##ptic O
drug O
treatment O
ep O
##ile O
##ptic O
status O
is O
often O
the O
terminating O
event O
the O
use O
of O
val O
##pro O
##ic O
acid O
as O
an O
anti O
##con O
##vu O
##ls O
##ant O
drug O
has O
repeatedly O
led O
to O
a O
terminal O
he O
##pati O
##c O
failure O
and O
should O
be O
avoided O
13 O
the O
natural O
course O
of O
the O
disease O
is O
progressive O
with O
death O
occurring O
in O
most O
cases O
within O
6 O
12 O
months O
after O
the O
onset O
of O
the O
disease O
a O
gene O
dos O
##age O
effect O
is O
thought O
to O
be O
an O
important O
deter O
##mina O
##nt O
for O
age O
of O
onset O
the O
severity O
and O
course O
of O
the O
disease O

we O
just O
##i O
##ﬁ O
##ed O
giving O
5 O
form O
##yl O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
calcium O
f O
##olin O
##ate O
in O
the O
form O
of O
le O
##uc O
##ovo O
##rin O
taking O
the O
following O
into O
consideration O
f O
##olic O
acid O
is O
a O
water O
soluble O
vitamin O
that O
is O
converted O
into O
various O
reduced O
forms O
involved O
in O
synthesis O
of O
pu O
##rine O
and O
p O
##yr O
##imi O
##dine O
bases O
methyl O
##ation O
of O
gen O
##omic O
dna O
conversion O
of O
homo O
##cy O
##stein O
##e O
to O
met O
##hi O
##oni O
##ne O
transfer O
of O
methyl O
groups O
and O
formation O
of O
the O
active O
methyl O
group O
donor O
s O
aden O
##os O
##yl O
##met O
##hi O
##oni O
##ne O
used O
in O
various O
methyl O
##ation O
reactions O
furthermore O
f O
##olate O
##s O
ex O
##ert O
a O
direct O
in O
##ﬂ O
##uen O
##ce O
on O
brain O
function O
through O
the O
enhanced O
bio O
##sy O
##nt O
##hesis O
of O
ph O
##os O
##ph O
##oli O
##pid O
##s O
and O
hence O
my O
##elin O
##ation O

the O
physiological O
plasma O
f O
##olate O
form O
5 O
##mt O
##h O
##f O
is O
actively O
transferred O
across O
the O
blood O
brain O
barrier O
by O
a O
f O
##olate O
receptor O
mediated O
end O
##oc O
##yt O
##otic O
process O
in O
cho O
##roid O
ep O
##ith O
##elial O
cells O
and O
reaches O
2 O
4 O
fold O
higher O
concentration O
in O
the O
spinal O
ﬂ O
##uid O
as O
compared O
to O
serum O

a O
balanced O
diet O
usually O
provides O
su O
##f O
##ﬁ O
##cie O
##nt O
quantities O
of O
f O
##olate O
to O
the O
cn O
##s O
however O
the O
presence O
of O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
ox O
##ida O
##tive O
stress O
and O
secondary O
in O
##ﬂ O
##am O
##mat O
##ory O
responses O
are O
able O
to O
block O
f O
##olate O
transfer O
across O
the O
cho O
##roid O
pl O
##ex O
##us O
to O
the O
cn O
##s O
such O
primary O
and O
secondary O
forms O
of O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
cf O
##d O
with O
an O
en O
##ce O
##pha O
##lo O
##pathic O
sy O
##mpt O
##oma O
##tology O
have O
extensively O
been O
described O
in O
the O
infant O
##ile O
onset O
cf O
##d O
syndrome O
14 O
mitochondrial O
en O
##ce O
##pha O
##lo O
##path O
##ies O
15 O
ke O
##arns O
say O
##re O
syndrome O
16 O
re O
##tt O
syndrome O
17 O
18 O
and O
ai O
##card O
##i O
go O
##uti O
##eres O
syndrome O
19 O
the O
use O
of O
anti O
##fo O
##late O
drugs O
in O
rare O
in O
##born O
errors O
of O
metabolism O
like O
de O
##ﬁ O
##ciency O
of O
di O
##hy O
##drop O
##ter O
##idi O
##ne O
red O
##uc O
##tase O
methyl O
##ene O
##tet O
##rah O
##yd O
##ro O
##fo O
##late O
red O
##uc O
##tase O
aromatic O
amino O
##ac O
##id O
dec O
##ar O
##box O
##yla O
##se O
and O
3 O
ph O
##os O
##ph O
##og O
##ly O
##cera O
##te O
de O
##hy O
##dro O
##genase O
should O
be O
excluded O
14 O

the O
low O
cs O
##f O
levels O
of O
5 O
##mt O
##h O
##f O
in O
our O
patient O
can O
be O
explained O
by O
blocked O
transport O
across O
the O
blood O
brain O
barrier O
due O
to O
the O
presence O
of O
fr O
auto O
##ant O
##ib O
##odies O
as O
well O
as O
by O
increased O
utilization O
and O
cat O
##ab O
##olis O
##m O
of O
5 O
##mt O
##h O
##f O
due O
to O
ox O
##ida O
##tive O
stress O
16 O
another O
explanation O
may O
be O
a O
defective O
transport O
due O
to O
atp O
de O
##ple O
##tion O
in O
the O
cho O
##roid O
pl O
##ex O
##us O
as O
seen O
in O
ke O
##arns O
say O
##re O
syndrome O

of O
interest O
are O
the O
relative O
high O
concentrations O
of O
ne O
##uro O
##tra O
##ns O
##mit O
##ter O
meta O
##bol O
##ites O
5 O
##hia O
##a O
h O
##va O
and O
3 O
##om O
##d O
in O
cs O
##f O
both O
ser O
##oton O
##in O
and O
cat O
##ech O
##ola O
##mine O
##s O
metabolism O
are O
intimately O
tied O
to O
both O
mit O
##och O
##ond O
##ria O
and O
in O
##ﬂ O
##am O
##mation O
an O
in O
##ﬂ O
##am O
##mat O
##ory O
event O
with O
if O
##n O
c O
stimulation O
is O
known O
to O
lead O
to O
both O
increased O
try O
##pt O
##op O
##han O
de O
##gra O
dat O
##ion O
via O
indo O
##lea O
##mine O
di O
##ox O
##y O
##genase O
and O
neo O
##pt O
##erin O
production O
via O
gt O
##p O
cy O
##cl O
##oh O
##yd O
##rol O
##ase O
i O
20 O

the O
substitution O
with O
high O
doses O
of O
f O
##olin O
##ic O
acid O
will O
increase O
5 O
##mt O
##h O
##f O
plasma O
concentrations O
even O
in O
the O
presence O
of O
blocking O
fr O
auto O
##ant O
##ib O
##odies O
facilitating O
thereby O
an O
increased O
up O
##take O
of O
5 O
##mt O
##h O
##f O
into O
the O
cs O
##f O
compartment O
via O
the O
f O
##olate O
carrier O
to O
treat O
the O
cerebral O
f O
##olate O
de O
##ﬁ O
##ciency O
we O
have O
chosen O
an O
initial O
oral O
dose O
of O
2 O
x O
0 O
25 O
mg O
kg O
body O
weight O
le O
##uc O
##ovo O
##rine O
and O
later O
adapted O
the O
dose O
to O
reach O
age O
spec O
##i O
##ﬁ O
##c O
levels O
of O
cs O
##f O
5 O
##mt O
##h O
##f O
we O
refrain O
##ed O
from O
further O
aug O
##ment O
##ing O
the O
dose O
since O
it O
is O
known O
that O
high O
f O
##olic O
acid O
doses O
can O
decrease O
blood O
levels O
of O
anti O
##con O
##vu O
##ls O
##ant O
drugs O
such O
as O
ph O
##eno O
##bar O
##bit O
##al O
and O
thereby O
potentially O
interfere O
with O
seizure O
control O
21 O
the O
medication O
was O
well O
tolerated O
and O
followed O
by O
a O
marked O
improvement O
of O
the O
child O
though O
high O
cs O
##f O
il O
8 O
levels O
reminded O
of O
the O
persist O
##ing O
pro O
in O
##ﬂ O
##am O
##mat O
##ory O
process O

considering O
the O
possible O
mechanism O
of O
the O
observed O
effects O
we O
spec O
##ulate O
that O
rep O
##let O
##ion O
of O
f O
##olate O
##s O
within O
the O
cn O
##s O
could O
lead O
to O
a O
partial O
repair O
of O
previously O
der O
##ange O
##d O
f O
##olate O
depend O
##ant O
pathways O
and O
mitochondrial O
dysfunction O
to O
our O
knowledge O
in O
disorders O
of O
mt O
##dna O
del O
##eti O
##ons O
the O
role O
of O
f O
##olin O
##ic O
acid O
substitution O
has O
not O
been O
evaluated O
at O
the O
moment O
we O
do O
not O
know O
to O
what O
extent O
the O
production O
of O
f O
##olate O
receptor O
auto O
##ant O
##ib O
##odies O
in O
al O
##pers O
disease O
contribute O
to O
its O
path O
##op O
##hy O
##sio O
##logy O
whether O
it O
represents O
a O
consistent O
ﬁ O
##nding O
or O
it O
is O
merely O
an O
ep O
##ip O
##hen O
##ome O
##non O
of O
the O
cerebral O
in O
##ﬂ O
##am O
##mat O
##ory O
response O

o O
has O
##sel O
##mann O
et O
al O
molecular O
genetics O
and O
metabolism O
99 O
2010 O
58 O
61 O
61 O

movement O
disorders O
vol O
25 O
no O
2 O
2010 O
pp O
243 O
251 O
2009 O
movement O
disorder O
society O
letters O
to O
the O
editor O
related O
to O
new O
topics O
sustained O
do O
##pa O
##mine O
##rg O
##ic O
response O
of O
parkinson O
##ism O
and O
depression O
in O
pol O
##g O
associated O
parkinson O
##ism O

parkinson O
##ism O
with O
##1 O
2 O
or O
without O
##3 O
chronic O
progressive O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
cp O
##eo O
can O
be O
caused O
by O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
g O
pol O
##g O
pol O
##g O
associated O
parkinson O
##ism O
pol O
##g O
p O
is O
at O
least O
partially O
responsive O
to O
lev O
##od O
##opa O
1 O
2 O
but O
predict O
##ors O
of O
do O
##pa O
##mine O
response O
have O
not O
been O
reported O
of O
the O
pl O
##eth O
##ora O
of O
different O
syndrome O
##s O
associated O
with O
pol O
##g O
mutations O
depression O
and O
anxiety O
present O
common O
major O
therapeutic O
problems O
4 O
patients O
with O
id O
##io O
##pathic O
parkinson O
s O
disease O
ip O
##d O
frequently O
show O
improvement O
not O
only O
of O
motor O
symptoms O
but O
also O
of O
depression O
and O
anxiety O
after O
initiation O
of O
treatment O
with O
lev O
##od O
##opa O
or O
do O
##pa O
##mine O
ago O
##nist O
##s O
here O
we O
present O
a O
patient B-PATIENT
with O
pol B-GENE
##g I-GENE
p O
whose O
parkinson B-HPO_TERM
##ism I-HPO_TERM
and O
depression B-HPO_TERM
showed O
sustained O
excellent O
response O
to O
do O
##pa O
##mine O
##rg O
##ic O
treatment O

a O
55 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
of O
croatian O
origin O
presented O
with O
a O
3 O
year O
history O
of O
slowly O
progressive B-HPO_TERM
facial I-HPO_TERM
mask I-HPO_TERM
##ing I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##op I-HPO_TERM
##hon I-HPO_TERM
##ia I-HPO_TERM
symmetric B-HPO_TERM
co I-HPO_TERM
##g I-HPO_TERM
##wheel I-HPO_TERM
##ing I-HPO_TERM
of O
the O
wrists O
shu B-HPO_TERM
##f I-HPO_TERM
##ﬂ I-HPO_TERM
##ing I-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
marked O
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
and O
positive B-HPO_TERM
pull I-HPO_TERM
test I-HPO_TERM
yielding O
47 O
108 O
points O
in O
the O
up O
##dr O
##s O
motor O
score O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
incomplete B-HPO_TERM
cp I-HPO_TERM
##eo I-HPO_TERM
and O
exercise B-HPO_TERM
into I-HPO_TERM
##ler I-HPO_TERM
##ance I-HPO_TERM
had O
been O
present B-AGE_ONSET
for I-AGE_ONSET
10 I-AGE_ONSET
years I-AGE_ONSET
and O
had O
led O
to O
the O
previous O
mis O
##dia O
##gno O
##sis O
of O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
severe B-HPO_TERM
depression I-HPO_TERM
indicated O
by O
43 O
63 O
points O
on O
the O
beck O
depression O
inventory O
had O
been O
noted O
for O
3 O
years O
family O
history O
on O
the O
paternal O
side O
was O
positive O
for O
cp O
##eo O
and O
pt O
##osis O
and O
both O
sons O
of O
the O
patient O
aged O
28 O
and O
25 O
years O
were O
suffering O
from O
pt O
##osis O
depression O
and O
anxiety O
but O
had O
no O
extra O
##py O
##ram O
##idal O
movement O
abnormalities O
two O
consecutive O
sub O
##cut O
##aneous O
injection O
##s O
of O
ap O
##omo O
##rp O
##hine O
markedly O
reduced O
up O
##dr O
##s O
motor O
scores O
from O
47 O
to O
27 O
points O
243 O
on O
2 O
5 O
mg O
ap O
##omo O
##rp O
##hine O
and O
from O
55 O
to O
26 O
points O

253 O
on O
5 O
mg O
ap O
##omo O
##rp O
##hine O
supporting O
table O
1 O
the O
injection O
##s O
also O
lead O
to O
a O
rapid O
and O
marked O
am O
##eli O
##oration O
of O
depressed O
mood O
a O
long O
term O
medication O
was O
initiated O
with O
extended O
release O
formulation O
##s O
of O
ro O
##pin O
##iro O
##le O
6 O
mg O
d O
and O
lev O
##od O
##opa O
100 O
mg O
d O

at O
10 O
months O
follow O
up O
the O
patient O
presented O
with O
a O
sustained O
improvement O
of O
parkinson O
##ism O
and O
mood O
as O
evidenced O
by O
a O
decrease O
down O
to O
20 O
points O
in O
the O
up O
##dr O
##s O
motor O
score O
257 O
and O
to O
4 O
points O
on O
the O
beck O
depression O
inventory O
291 O
testing O
was O
done O
by O
an O
examiner O
blind O
to O
the O
results O
of O
the O
ap O
##omo O
##rp O
##hine O
tests O
for O
details O
see O
supporting O
tables O
1 O
and O
2 O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
7 O
december O
2009 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
228 O
##65 O

123 O
##i O
f O
##p O
ci O
##t O
dat O
##scan O
demonstrated O
a O
severe O
symmetric B-HPO_TERM
reduction I-HPO_TERM
of I-HPO_TERM
ni I-HPO_TERM
##gr I-HPO_TERM
##ost I-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
do I-HPO_TERM
##pa I-HPO_TERM
##mine I-HPO_TERM
transport I-HPO_TERM
##ers I-HPO_TERM
similar O
to O
advanced O
ip O
##d O
fig O
1b O
and O
ruled O
out O
a O
depression O
induced O
pseudo O
parkinson O
##ism O
in O
addition O
trans O
##cr O
##anial O
son O
##ography O
performed O
by O
an O
examiner O
blind O
to O
the O
history O
and O
clinical O
examination O
of O
the O
patient O
revealed O
a O
hyper O
##ech O
##ogenic O
sub O
##stan O
##tia O
ni O
##gra O
and O
a O
h O
##yp O
##oe O
##cho O
##genic O
rap O
##he O
fig O
1 O
##d O
thus O
resembling O
the O
characteristic O
son O
##ography O
mid O
##bra O
##in O
ﬁ O
##nding O
##s O
of O
ip O
##d O
with O
depression O
5 O
because O
of O
the O
suggest O
##ive O
ph O
##eno O
##type O
and O
family O
history O
a O
genetic O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
was O
initiated O
revealing O
a O
het O
##ero O
##zy O
##go O
##us O
ty B-GENE_VARIANT
##r I-GENE_VARIANT
##9 I-GENE_VARIANT
##55 I-GENE_VARIANT
##cy I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
which O
is O
known O
to O
present O
inter O
##alia O
as O
pol O
##g O
p O
with O
auto O
##som O
##al O
dominant O
inheritance O
1 O

our O
ﬁ O
##nding O
##s O
present O
close O
similarities O
between O
ip O
##d O
and O
pol O
##g O
p O
in O
contrast O
to O
other O
at O
##yp O
##ical O
parkinson O
diseases O
like O
ms O
##a O
p O
or O
ps O
##p O
p O
both O
entities O
feature O
predominant O
de O
##gen O
##eration O
of O
ni O
##gr O
##o O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
neurons O
respond O
well O
not O
only O
to O
lev O
##od O
##opa O
but O
also O
to O
do O
##pa O
##mine O
ago O
##nist O
##s O
and O
display O
hyper O
##ech O
##ogenic O
##ity O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O

these O
similarities O
are O
particularly O
interesting O
as O
increased O
levels O
of O
mt O
##dna O
del O
##eti O
##on O
and O
respiratory O
chain O
de O
##ﬁ O
##ciency O
have O
been O
found O
in O
sub O
##stan O
##tia O
ni O
##gra O
neurons O
of O
ip O
##d O
patients O
6 O
thus O
suggesting O
mitochondrial O
dysfunction O
as O
part O
of O
the O
complex O
pathogen O
##etic O
pathway O
of O
sub O
##stan O
##tia O
ni O
##gra O
de O
##gen O
##eration O
in O
ip O
##d O
as O
pol O
##g O
mutations O
lead O
to O
elevated O
levels O
of O
ox O
##ida O
##tive O
stress O
and O
mt O
##dna O
damage O
7 O
patients O
harbor O
##ing O
these O
mutations O
might O
be O
at O
particular O
risk O
for O
ip O
##d O
like O
sub O
##stan O
##tia O
ni O
##gra O
de O
##gen O
##eration O

anti O
##de O
##press O
##ant O
effects O
of O
lev O
##od O
##opa O
and O
do O
##pa O
##mine O
ago O
##nist O
##s O
especially O
of O
d O
##4 O
d O
##5 O
ago O
##nist O
##s O
like O
ro O
##pin O
##iro O
##le O
have O
been O
shown O
consistently O
in O
patients O
with O
ip O
##d O
8 O
almost O
complete O
re O
##mission O
of O
depression O
in O
our O
patient O
might O
be O
partially O
attributed O
to O
her O
dramatic O
motor O
improvement O
but O
it O
is O
likely O
that O
spec O
##i O
##ﬁ O
##c O
do O
##pa O
##mine O
##rg O
##ic O
effects O
like O
in O
ip O
##d O
are O
also O
involved O
future O
studies O
are O
warrant O
##ed O
to O
test O
whether O
depression O
in O
pol O
##g O
patients O
without O
parkinson O
##ism O
is O
also O
associated O
with O
a O
h O
##yp O
##oe O
##cho O
##genic O
rap O
##he O
and O
responds O
to O
do O
##pa O
##mine O
##rg O
##ic O
treatment O
as O
well O

in O
conclusion O
the O
large O
ben O
##e O
##ﬁ O
##t O
from O
do O
##pa O
##mine O
##rg O
##ic O
therapy O
emphasizes O
the O
need O
to O
identify O
motor O
and O
non O
##moto O
##r O
parkinson O
##ian O
features O
also O
in O
the O
large O
majority O
of O
those O
pol O
##gp O
##ati O
##ents O
that O
present O
with O
a O
multi O
##face O
##ted O
ph O
##eno O
##type O
moreover O
different O
##iating O
pol O
##g O
p O
from O
other O
forms O
of O
at O
##yp O
##ical O
parkinson O
##ism O
is O
of O
great O
importance O
because O
of O
the O
potential O
excellent O
response O
to O
do O
##pa O
##mine O
##rg O
##ic O
medication O
trans O
##cr O
##anial O
son O
##ography O
and O
ap O
##op O
##mo O
##rp O
##hine O
testing O
could O
serve O
as O
inexpensive O
easily O
available O
tests O
for O
facilitating O
a O
differential O
diagnosis O
and O
to O
predict O
treatment O
response O
of O
both O
motor O
and O
non O
##moto O
##r O
symptoms O

ac O
##k O
##now O
##led O
##gm O
##ents O
l O
##s O
was O
supported O
by O
a O
grant O
from O
the O
german O
ministry O
for O
education O
and O
research O
b O
##mb O
##f O
to O
mit O
##one O
##t O
01 O
##gm O
##0 O
##86 O
##4 O
243 O
244 O
letters O
to O
the O
editor O

fig O
1 O
ni O
##gr O
##ost O
##ria O
##tal O
and O
mid O
##bra O
##in O
pathology O
in O
pol O
##g O
associated O
parkinson O
##ism O
visual O
##ized O
by O
dat O
##scan O
and O
trans O
##cr O
##anial O
son O
##ography O
tc O
##s O
a O
and O
b O
compared O
with O
a O
healthy O
control O
a O
trans O
##ax O
##ial O
123 O
##i O
f O
##p O
ci O
##t O
spec O
##t O
images O
of O
the O
pol O
##g O
patient B-PATIENT
b O
show O
markedly O
reduced B-HPO_TERM
do I-HPO_TERM
##pa I-HPO_TERM
##mine I-HPO_TERM
transport I-HPO_TERM
##er I-HPO_TERM
levels I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
put I-HPO_TERM
##amen I-HPO_TERM
and O
to O
a O
lesser O
extent O
in O
the O
ca O
##uda O
##te O
c O
e O
tc O
##s O
of O
the O
mid O
##bra O
##in O
in O
the O
me O
##sen O
##ce O
##pha O
##lic O
scanning O
plane O
ex O
##em O
##pl O
##ari O
##ly O
depicted O
in O
e O
demonstrates O
an O
enlarged O
area O
of O
hyper O
##ech O
##ogenic O
##ity O
line O
ip O
##sil O
##ater O
##al O
to O
the O
probe O
white O
arrows O
contra O
##lateral O
side O
at O
the O
anatomical O
site O
of O
the O
s O
##n O
within O
the O
h O
##yp O
##oe O
##cho O
##genic O
butter O
##ﬂ O
##y O
shaped O
me O
##sen O
##ce O
##pha O
##lic O
brains O
##tem O
dotted O
lines O
in O
the O
pol O
##g O
patient O
d O
in O
a O
control O
only O
small O
dots O
of O
hyper O
##ech O
##ogenic O
##ity O
are O
visible O
at O
this O
site O
white O
arrows O
c O
the O
mid O
##line O
rap O
##he O
un O
##ﬁ O
##lled O
arrow O
is O
interrupted O
in O
the O
patient O
d O
whereas O
it O
is O
continuous O
in O
the O
control O
person O
c O
red O
nucleus O
color O
ﬁ O
##gur O
##e O
can O
be O
viewed O
in O
the O
online O
issue O
which O
is O
available O
at O
www O
inter O
##sc O
##ience O
wiley O
com O

financial O
disclosure O
##s O
dr O
syn O
##of O
##zi O
##k O
received O
a O
research O
grant O
by O
the O
volkswagen O
foundation O
european O
platform O
project O
and O
a O
travel O
grant O
by O
act O
##eli O
##on O
pharmaceuticals O
dr O
as O
##mus O
has O
received O
speakers O
honor O
##aria O
and O
travel O
grants O
from O
ip O
##sen O
ph O
##arm O
##a O
all O
##er O
##gan O
and O
mer O
##z O
pharmaceuticals O
dr O
rei O
##mo O
##ld O
received O
grants O
from O
the O
deutsche O
for O
##sch O
##ung O
##ge O
##mei O
##ns O
##chaft O
re O
##14 O
##7 O
##2 O
62 O
dr O
sc O
##ho O
##¨ O
##ls O
served O
as O
an O
editorial O
board O
member O
of O
movement O
disorders O
and O
was O
a O
member O
of O
the O
sci O
##ent O
##i O
##ﬁ O
##c O
advisory O
board O
for O
take O
##da O
ph O
##arm O
##a O
as O
participant O
of O
the O
mic O
##ono O
##s O
trial O
dr O
sc O
##ho O
##¨ O
##ls O
received O
fees O
from O
sant O
##her O
##a O
pharmaceuticals O
dr O
sc O
##ho O
##¨ O
##ls O
received O
research O
grants O
of O
the O
deutsche O
for O
##sch O
##ung O
##sg O
##eme O
##ins O
##chaft O
sc O
##ho O
##75 O
##4 O
3 O
1 O
and O
sc O
##ho O
##75 O
##4 O
4 O
1 O
grants O
of O
the O
german O
research O
council O
b O
##mb O
##f O
to O
le O
##uk O
##one O
##t O
01 O
##gm O
##0 O
##64 O
##4 O
and O
gene O
##mo O
##ve O
01 O
##gm O
##0 O
##60 O
##3 O
funding O
from O
the O
eu O
for O
euros O
##ca O
l O
##sh O
##mc O
##t O
2004 O
50 O
##33 O
##0 O
##4 O
and O
e O
rare O
grants O
to O
euros O
##pa O

01 O
##gm O
##0 O
##80 O
##7 O
and O
ri O
##sca O
01 O
##gm O
##0 O
##8 O
##20 O
as O
well O
as O
a O
grant O
of O
the O
volkswagen O
foundation O
i O
80 O
##7 O
##11 O
he O
further O
received O
funding O
from O
the O
hs O
##p O
se O
##lb O
##st O
##hil O
##fe O
##gr O
##uppe O
deutschland O
ev O
dr O
berg O
received O
research O
grants O
from O
the O
bun O
##des O
##mini O
##ster O
##ium O
fu O
##¨ O
##r O
bi O
##ld O
##ung O
und O
for O
##sch O
##ung O
b O
##mb O
##f O
the O
german O
parkinson O
association O
as O
well O
as O
from O
nova O
##rti O
##s O
gmbh O
and O
johnson O
johnson O
she O
received O
honor O
##aria O
for O
talks O
from O
uc O
##b O
schwarz O

ph O
##arm O
##a O
g O
##la O
##x O
##os O
##mith O
##k O
##line O
te O
##va O
lund O
##beck O
nova O
##rti O
##s O
and O
mer O
##ck O
ser O
##ono O
she O
served O
as O
a O
pi O
of O
a O
multi O
##cent O
##er O
study O
of O
nova O
##rti O
##s O
gmbh O
and O
as O
a O
ci O
of O
multi O
##cent O
##er O
trials O
of O
bo O
##eh O
##ring O
##er O
te O
##va O
and O
e O
##isa O
##i O
she O
served O
on O
advisory O
boards O
for O
nova O
##rti O
##s O
g O
##la O
##x O
##os O
##mith O
##k O
##line O
te O
##va O
lund O
##beck O
and O
uc O
##b O
schwarz O
##pha O
##rma O

author O
roles O
syn O
##of O
##zi O
##k O
conception O
organization O
and O
execution O
of O
research O
project O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
manuscript O
as O
##mus O
execution O
of O
research O
project O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
manuscript O
rei O
##mo O
##ld O
execution O
of O
research O
project O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
manuscript O
sc O
##ho O
##¨ O
##ls O
conception O
and O
organization O
of O
research O
project O
review O
and O
critique O
of O
manuscript O
berg O
organization O
and O
execution O
of O
research O
project O
review O
and O
critique O
of O
manuscript O
matt O
##his O
syn O
##of O
##zi O
##k O
md O
department O
of O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
her O
##tie O
institute O
for O
clinical O
brain O
research O

university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
movement O
disorders O
vol O
25 O
no O
2 O
2010 O
letters O
to O
the O
editor O
245 O
friedrich O
as O
##mus O
md O
department O
of O
general O
ne O
##uro O
##logy O
her O
##tie O
institute O
for O
clinical O
brain O
research O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
matthias O
rei O
##mo O
##ld O
md O
department O
of O
nuclear O
medicine O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
lu O
##dge O
##r O
sc O
##ho O
##¨ O
##ls O
md O
daniela O
berg O
md O
department O
of O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
her O
##tie O
institute O
for O
clinical O
brain O
research O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
e O
mail O
lu O
##dge O
##r O
sc O
##hoe O
##ls O
un O
##i O
tu O
##eb O
##ingen O
de O
references O

lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
88 O
##2 O
in O
##vern O
##iz O
##zi O
f O
var O
##ane O
##se O
s O
thomas O
a O
carr O
##ara O
f O
ono O
##fr O
##j O
m O
zev O
##iani O
m O
two O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
lev O
##od O
##opa O
responsive O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
460 O
46 O
##4 O
david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O

sc O
##hul O
##te O
c O
syn O
##of O
##zi O
##k O
m O
gas O
##ser O
t O
sc O
##ho O
##¨ O
##ls O
l O
ata O
##xia O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
or O
sensory O
ne O
##uro O
##pathy O
is O
frequently O
caused O
by O
pol O
##g O
mutations O
ne O
##uro O
##logy O
2009 O
73 O
89 O
##8 O
900 O
walter O
u O
ho O
##ep O
##p O
##ner O
j O
pr O
##ude O
##nte O
morris O
##sey O
l O
ho O
##row O
##ski O
s O
her O
##per O
##tz O
sc O
ben O
##eck O
##e O
r O
parkinson O
s O
disease O
like O
mid O
##bra O
##in O
son O
##ography O
abnormalities O
are O
frequent O
in O
de O
##pressive O
disorders O
brain O
2007 O
130 O
part O
7 O
1799 O
1807 O
bender O
a O
krishna O
##n O
k O
##j O
morris O
cm O
et O
al O
high O
levels O
of O
mitochondrial O
dna O
del O
##eti O
##ons O
in O
sub O
##stan O
##tia O
ni O
##gra O
neurons O
in O
aging O
and O
parkinson O
disease O
nat O
gene O
##t O
2006 O
38 O
51 O
##5 O
51 O
##7 O

graz O
##ie O
##wicz O
ma O
bien O
##stock O
r O
##j O
copeland O
wc O
the O
dna O
polymer O
##ase O
gamma O
y O
##9 O
##55 O
##c O
disease O
variant O
associated O
with O
pe O
##o O
and O
parkinson O
##ism O
media O
##tes O
the O
incorporation O
and O
trans O
##les O
##ion O
synthesis O
opposite O
7 O
8 O
di O
##hy O
##dro O
8 O
ox O
##o O
2 O
de O
##ox O
##y O
##gua O
##nos O
##ine O
hum O
mo O
##l O
gene O
##t O
2007 O
16 O
272 O
##9 O
273 O
##9 O
re O
##kt O
##oro O
##va O
i O
bala O
##z O
m O
sv O
##ato O
##va O
j O
et O
al O
effects O
of O
ro O
##pin O
##iro O
##le O
on O
non O
##moto O
##r O
symptoms O
of O
parkinson O
disease O
a O
prospective O
multi O
##cent O
##er O
study O
cl O
##in O
ne O
##uro O
##pha O
##rma O
##col O
2008 O
31 O
261 O
266 O
novel O
pan O
##k O
##2 O
gene O
mutations O
in O
korean O
patient O
with O
pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
presenting O
un O
##ila O
##tera O
##l O
d O
##yst O
##onic O
tremor O
video O

pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
p O
##kan O
mi O
##m O
234 O
##200 O
is O
a O
rare O
auto O
##som O
##al O
recess O
##ive O
disorder O
with O
iron O
accumulation O
in O
the O
basal O
gang O
##lia O
due O
to O
mutations O
in O
the O
pan O
##to O
##the O
##nate O
kinase O
2 O
pan O
##k O
##2 O
gene O
on O
chromosome O
20 O
##p O
##13 O
1 O
the O
ph O
##eno O
##type O
of O
p O
##kan O
is O
widely O
variable O
and O
overlap O
##s O
with O
a O
wide O
spectrum O
of O
disorders O
characterized O
by O
ne O
##uro O
##de O
##gen O
##eration O
with O
brain O
iron O
accumulation O
formerly O
known O
as O
halle O
##r O
##vor O
##den O
spat O
##z O
syndrome O
2 O

a O
55 O
year O
old O
korean O
man O
visited O
our O
movement O
disorder O
clinic O
due O
to O
tre O
##mu O
##lous O
movement O
in O
the O
right O
arm O
and O
hand O
he O
was O
healthy O
until O
his O
late O
thirties O
but O
he O
felt O
unpleasant O
movements O
on O
the O
right O
hand O
while O
doing O
ﬁ O
##ne O
actions O
and O
then O
he O
had O
slowly O
progressive O
di O
##f O
##ﬁ O
##cu O
##lty O
in O
writing O
and O
manipulation O
with O
right O
hand O
for O
7 O
years O
there O
was O
no O
history O
of O
drug O
exposure O
trauma O
or O
other O
medical O
problems O
but O
family O
history O
was O
positive O
for O
his O
brother O
who O
had O
similar O
symptoms O
initial O
neurological O
examination O
revealed O
the O
post O
##ural O
and O
kinetic O
tre O
##mu O
##lous O
movements O
in O
the O
right O
arm O
and O
hand O
video O
segment O
1 O
he O
had O
no O
problem O
in O
the O
left O
upper O
and O
both O
lower O
ex O
##tre O
##mit O
##ies O
and O
his O
ga O
##it O
and O
balance O
were O
normal O
there O
was O
no O
other O
focal O
ne O
##uro O
##logic O
sign O
he O
did O
not O
have O
any O
cognitive O
or O
psychiatric O
problems O
like O
depression O
or O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
the O
score O
of O
mini O
##mental O
st O
##a O

tu O
##s O
examination O
was O
30 O

initial O
routine O
blood O
tests O
including O
thyroid O
and O
para O
##thy O
##roid O
hormone O
test O
peripheral O
blood O
sm O
##ear O
test O
and O
gene O
studies O
for O
huntington O
s O
disease O
and O
tor O
##sion O
d O
##yst O
##onia O
d O
##yt O
##1 O
gene O
were O
not O
remarkable O
cervical O
spine O
magnetic O
resonance O
images O
mri O
was O
normal O
brain O
t O
##2 O
weighted O
ﬂ O
##uid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
mri O
showed O
symmetrical O
low O
signal O
intensity O
in O
the O
pal O
##lid O
##um O
with O
a O
slight O
ant O
##ero O
##media O
##l O
core O
of O
high O
signal O
intensity O
as O
the O
so O
called O
eye O
of O
##the O
tiger O
sign O
fig O
1a O
although O
he O
had O
un O
##ila O
##tera O
##l O
symptoms O
in O
the O
right O
upper O
ex O
##tre O
##mity O
there O
was O
no O
difference O
in O
size O
and O
intensity O
between O
bilateral O
brain O
lesions O
furthermore O
brain O
per O
##fusion O
single O
photon O
emission O
computed O
tom O
##ography O
spec O
##t O
showed O
no O
sign O
##i O
##ﬁ O
##can O
##t O
per O
##fusion O
as O
##ym O
##metry O
in O
this O
patient O
fig O
1b O

genetic O
studies O
of O
the O
pan O
##k O
##2 O
gene O
gen O
##bank O
id O
nm O
153 O
##6 O
##38 O
2 O
examined O
by O
dna O
sequence O
analyses O
revealed O
the O
two O
het O
##ero O
##zy O
##go O
##us O
mutations O
one O
mutation O
was O
1 O
bp O
nu O
##cle O
##otide O
del O
##eti O
##on O
of O
c O
and O
insertion O
of O
tt O
in O
ex O
##on O
3 O
c O
115 O
##3d O
##el O
##cin O
##st O
##t O
resulting O
in O
frame O
shift O
and O
generation O
of O
a O
premature O
stop O
cod O
##on O
p O
le O
##u O
##38 O
##5 O
##ph O
##ef O
##s O
##x O
##11 O
fig O
2a O
another O
mutation O
was O
a O
single O
nu O
##cle O
##otide O
substitution O
c O
131 O
##9 O
##g O
c O
in O
ex O
##on O
4 O
which O
was O
predicted O
to O
replace O
ar O
##gin O
##ine O
residue O
at O
cod O
##on O
440 O
with O
pro O
##line O
p O
ar O
##g O
##44 O
##0 O
##pro O
fig O
2 O
##b O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O

published O
online O
11 O
december O
2009 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
228 O
##9 O
##1 O
movement O
disorders O
vol O
25 O
no O
2 O
2010 O
246 O
letters O
to O
the O
editor O
fig O
1 O
bilateral O
h O
##yp O
##oint O
##ens O
##ity O
with O
central O
region O
of O
hyper O
##int O
##ens O
##ity O
in O
the O
medial O
g O
##lo O
##bus O
pal O
##lid O
##us O
or O
the O
so O
called O
eye O
of O
the O
tiger O
sign O
in O
the O
t O
##2 O
weighted O
flair O
mri O
a O
brain O
per O
##fusion O
spec O
##t O
showed O
no O
sign O
##i O
##ﬁ O
##can O
##t O
per O
##fusion O
as O
##ym O
##metry O
b O

his O
d O
##yst O
##onic O
tremor O
in O
the O
right O
arm O
did O
not O
respond O
to O
anti O
##cho O
##liner O
##gic O
##s O
beta O
block O
##ers O
and O
muscle O
relax O
##ants O
but O
had O
a O
partial O
response O
to O
the O
additional O
lev O
##od O
##opa O
car O
##bid O
##opa O
250 O
25 O
mg O
three O
times O
a O
day O
treatment O
video O
segment O
2 O
during O
medical O
treatment O
his O
disability O
had O
been O
in O
stationary O
state O
over O
the O
following O
3 O
years O
and O
was O
restricted O
to O
his O
right O
arm O
and O
hand O

for O
now O
we O
report O
a O
korean O
patient O
with O
p O
##kan O
presenting O
at O
##yp O
##ical O
ph O
##eno O
##type O
that O
included O
late O
onset O
lev O
##od O
##opa O
responsive O
d O
##yst O
##onic O
tremor O
in O
the O
mainly O
un O
##ila O
##tera O
##l O
upper O
ex O
##tre O
##mity O
and O
id O
##ent O
##i O
##ﬁ O
##ed O
two O
novel O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
ex O
##on O
3 O
le O
##u O
##38 O
##5 O
##ph O
##ef O
##s O
##x O
##11 O
and O
ex O
##on O
4 O
ar O
##g O
##44 O
##0 O
##pro O
of O
the O
pan O
##k O
##2 O
gene O
to O
our O
knowledge O
these O
two O
mutations O
have O
not O
been O
reported O
previously O
although O
we O
recommended O
further O
genetic O
study O
for O
his O
brother O
with O
similar O
ne O
##uro O
##logic O
symptoms O
and O
other O
as O
##ym O
##pt O
##oma O
##tic O
family O
members O
they O
denied O
the O
further O
genetic O
studies O

to O
date O
numerous O
mutations O
underlying O
p O
##kan O
have O
been O
reported O
patients O
with O
nonsense O
mutations O
show O
typical O
ph O
##eno O
##type O
while O
those O
with O
miss O
##ense O
mutations O
tend O
to O
show O
at O
##yp O
##ical O
clinical O
manifestation O
##s O
2 O
4 O
in O
one O
latest O
report O
about O
at O
##yp O
##ical O
p O
##kan O
there O
are O
many O
differences O
of O
ph O
##eno O
##type O
between O
two O
siblings O
with O
same O
gen O
##otype O
5 O

similar O
to O
our O
patient O
some O
reports O
about O
p O
##kan O
have O
presented O
focal O
or O
un O
##ila O
##tera O
##l O
ph O
##eno O
##type O
at O
early O
stage O
however O
many O
of O
those O
cases O
had O
progressed O
within O
several O
years O
and O
then O
eventually O
had O
been O
aggravated O
presenting O
multi O
focal O
variable O
motor O
symptoms O
6 O
8 O
these O
clinical O
courses O
are O
different O
from O
that O
of O
our O
patient O
whose O
disability O
had O
been O
in O
stationary O
state O
over O
7 O
years O
and O
was O
steadily O
restricted O
to O
his O
right O
arm O
and O
hand O
interesting O
##ly O
our O
case O
showed O
an O
un O
##ila O
##tera O
##l O
d O
##yst O
##onic O
tremor O
even O
though O
his O
brain O
mri O
revealed O
symmetrical O
eye O
of O
the O
tiger O
sign O
in O
the O
basal O
gang O
##lia O
furthermore O
in O
contrast O
with O
our O
expectation O
his O
brain O
per O
##fusion O
spec O
##t O
showed O
no O
sign O
##i O
##ﬁ O
##can O
##t O
per O
##fusion O
as O
##ym O
##metry O

because O
one O
reported O
case O
and O
our O
case O
have O
showed O
some O
improvement O
by O
lev O
##od O
##opa O
treatment O
6 O
it O
should O
be O
considered O
lev O
##od O
##opa O
treatment O
to O
patients O
with O
the O
late O
onset O
at O
##yp O
##ical O
p O
##kan O
presenting O
d O
##yst O
##onic O
symptoms O
legends O
to O
the O
video O
segment O
1 O
the O
patient O
shows O
un O
##ila O
##tera O
##l O
tre O
##mu O
##lous O
movements O
in O
right O
upper O
ex O
##tre O
##mity O
and O
intermittent O
pro O
##nat O
##ing O
fig O
2 O
sequence O
analysis O
of O
the O
patient O
showed O
two O
novel O
mutations O
they O
included O
a O
del O
##eti O
##on O
insertion O
and O
frame O
shift O
mutation O
c O
115 O
##3d O
##el O
##cin O
##st O
##t O
p O
le O
##u O
##38 O
##5 O
##ph O
##ef O
##s O
##x O
##11 O
in O
ex O
##on O
3 O
a O
and O
a O
miss O
##ense O
mutation O
c O
131 O
##9 O
##g O
c O
p O
ar O
##g O
##44 O
##0 O
##pro O
in O
ex O
##on O
4 O
b O

contraction O
##s O
while O
raising O
his O
arm O
straight O
##ly O
he O
was O
unable O
to O
write O
leg O
##ibly O
and O
draw O
the O
spiral O
of O
arch O
##ime O
##des O
with O
the O
right O
hand O
but O
could O
do O
well O
the O
same O
task O
with O
the O
left O
hand O
segment O
2 O
his O
d O
##yst O
##onia O
and O
d O
##yst O
##onic O
tremor O
in O
the O
right O
arm O
had O
partially O
improved O
after O
additional O
lev O
##od O
##opa O
car O
##bid O
##opa O
treatment O
author O
roles O
w O
##t O
yoon O
execution O
of O
project O
and O
writing O
ﬁ O
##rst O
draft O
of O
manuscript O
w O
##y O
lee O
conception O
organization O
of O
the O
project O
and O
manuscript O
review O
h O
##y O
shin O
manuscript O
review O
and O
critique O
st O
lee O
execution O
of O
gene O
study O
cs O
ki O
manuscript O
review O
and O
critique O

won O
tae O
yoon O
md O
won O
yong O
lee O
md O
phd O
hee O
young O
##shin O
md O
department O
of O
ne O
##uro O
##logy O
samsung O
medical O
center O
sung O
##kyu O
##nk O
##wan O
university O
school O
of O
medicine O
seoul O
korea O
e O
mail O
ne O
##uro O
##l O
##wy O
sk O
##ku O
ed O
##u O
se O
##ung O
tae O
lee O
md O
phd O
chang O
seo O
##k O
ki O
md O
phd O
department O
of O
laboratory O
medicine O
samsung O
medical O
center O
sung O
##kyu O
##nk O
##wan O
university O
school O
of O
medicine O
seoul O
korea O
references O
zhou O
b O
west O
##away O
sk O
levin O
##son O
b O
johnson O
ma O
gi O
##ts O
##chi O
##er O
j O
hay O
##ﬂ O
##ick O
s O
##j O
a O
novel O
pan O
##to O
##the O
##nate O
kinase O
gene O
pan O
##k O
##2 O
is O
defective O
in O
halle O
##r O
##vor O
##den O
spat O
##z O
syndrome O
nat O
gene O
##t O
2001 O
28 O
345 O
34 O
##9 O
movement O
disorders O
vol O
25 O
no O
2 O
2010 O

letters O
to O
the O
editor O
247 O
hart O
##ig O
mb O
ho O
##rt O
##nage O
##l O
k O
ga O
##ra O
##va O
##glia O
b O
et O
al O
gen O
##ot O
##yp O
##ic O
and O
ph O
##eno O
##typic O
spectrum O
of O
pan O
##k O
##2 O
mutations O
in O
patients O
with O
ne O
##uro O
##de O
##gen O
##eration O
with O
brain O
iron O
accumulation O
ann O
ne O
##uro O
##l O
2006 O
59 O
248 O
256 O
hay O
##ﬂ O
##ick O
s O
##j O
west O
##away O
sk O
levin O
##son O
b O
et O
al O
genetic O
clinical O
and O
radio O
##graphic O
del O
##ine O
##ation O
of O
halle O
##r O
##vor O
##den O
spat O
##z O
syndrome O
n O
eng O
##l O
j O
med O
2003 O
34 O
##8 O
33 O
40 O
pe O
##lle O
##cchi O
##a O
mt O
vale O
##nte O
em O
ci O
##f O
l O
et O
al O
the O
diverse O
ph O
##eno O
##type O
and O
gen O
##otype O
of O
pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
ne O
##uro O
##logy O
2005 O
64 O
1810 O
1812 O

wu O
y O
##r O
chen O
cm O
chao O
cy O
l O
##yu O
r O
##k O
lee O
chen O
g O
##j O
pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
in O
two O
taiwanese O
siblings O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
a O
novel O
pan O
##k O
##2 O
gene O
mutation O
mo O
##v O
di O
##sor O
##d O
2009 O
24 O
94 O
##0 O
94 O
##1 O
ya O
##mas O
##hita O
s O
mae O
##da O
y O
oh O
##mori O
h O
et O
al O
pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
initially O
presenting O
as O
post O
##ural O
tremor O
alone O
in O
a O
japanese O
family O
with O
homo O
##zy O
##go O
##us O
n O
##24 O
##5 O
##s O
substitution O
##s O
in O
the O
pan O
##to O
##the O
##nate O
kinase O
gene O
j O
ne O
##uro O
##l O
sci O
2004 O
225 O
129 O
133 O

anton O
##ini O
a O
gold O
##wu O
##rm O
s O
bent O
##i O
r O
et O
al O
genetic O
clinical O
and O
imaging O
characterization O
of O
one O
patient O
with O
late O
onset O
slowly O
progressive O
pan O
##to O
##the O
##nate O
kinase O
associated O
ne O
##uro O
##de O
##gen O
##eration O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
417 O
41 O
##8 O
chung O
s O
##j O
lee O
j O
##h O
lee O
mc O
yoo O
h O
##w O
kim O
g O
##h O
focal O
hand O
d O
##yst O
##onia O
in O
a O
patient O
with O
pan O
##k O
##2 O
mutation O
mo O
##v O
di O
##sor O
##d O
2008 O
23 O
46 O
##6 O
46 O
##8 O
backpack O
treatment O
for O
camp O
##to O
##cor O
##mia O
video O

camp O
##to O
##cor O
##mia O
also O
called O
bent O
spine O
syndrome O
is O
an O
extreme O
ﬂ O
##ex O
##ion O
of O
the O
trunk O
during O
walking O
that O
resolve O
##s O
in O
the O
su O
##pine O
position O
treatment O
attempts O
for O
this O
di O
##sa O
##bling O
condition O
are O
often O
unsuccessful O
we O
describe O
a O
case O
of O
markedly O
improved O
camp O
##to O
##cor O
##mia O
with O
the O
simple O
intervention O
of O
wearing O
a O
backpack O

a O
69 O
year O
old O
man O
with O
parkinson O
s O
disease O
pd O
presented O
with O
progressive O
camp O
##to O
##cor O
##mia O
for O
the O
prior O
1 O
5 O
years O
he O
had O
been O
diagnosed O
with O
pd O
5 O
years O
earlier O
after O
the O
onset O
of O
left O
upper O
ex O
##tre O
##mity O
resting O
tremor O
shoulder O
pain O
and O
brady O
##kin O
##es O
##ia O
he O
had O
no O
discomfort O
when O
seated O
or O
su O
##pine O
but O
with O
walking O
he O
developed O
dramatic O
thor O
##aco O
##lum O
##bar O
ﬂ O
##ex O
##ion O
associated O
with O
pain O
in O
the O
lower O
abdomen O
and O
back O
the O
camp O
##to O
##cor O
##mia O
was O
worse O
in O
the O
evenings O
he O
reported O
ﬂ O
##ex O
##ion O
approaching O
90 O
##8 O
at O
night O
compared O
with O
only O
slight O
ﬂ O
##ex O
##ion O
in O
the O
mornings O
the O
severity O
of O
camp O
##to O
##cor O
##mia O
was O
unrelated O
to O
pd O
medication O
dos O
##ing O
although O
his O
other O
pd O
motor O
symptoms O
responded O
well O
to O
do O
##pa O
##mine O
##rg O
##ic O
therapy O
it O
was O
ex O
##ace O
##rba O
##ted O
by O
carrying O
weight O
in O
front O
of O
him O
it O
was O
alleviate O
##d O
by O
using O
a O
walker O
and O
with O
pressure O
on O
his O
lower O
back O
a O
possible O
sensory O
trick O
magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
was O
un O
##rem O
##ark O
##able O
and O
mri O
##s O
of O
thor O
##ac O
##ic O
and O
lu O
##mba O
##r O
spine O
were O
notable O
for O
mild O
de O
##gen O
##erative O
changes O
bot O
##ulin O
##um O
toxin O
a O
injection O
##s O
to O
the O
rec O
##tus O
abd O
##omi O
##nis O
muscles O
ﬁ O
##rst O
with O
180 O
units O
and O
later O
with O
360 O
units O
were O
ineffective O
muscle O
relax O
##ants O
were O
also O
ineffective O
additional O
lev O
##od O
##opa O
improved O
his O
pd O
symptoms O
and O
produced O
mild O
d O
##ys O
##kin O
##es O
##ias O
but O
did O
not O
improve O
the O
camp O
##to O
##cor O
##mia O

potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
13 O
january O
2010 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
229 O
##0 O
##9 O

ne O
##uro O
##logic O
exam O
performed O
while O
pd O
medications O
were O
active O
revealed O
normal O
muscle O
tone O
throughout O
mild O
as O
##ym O
##metric O
brady O
##kin O
##es O
##ia O
absence O
of O
tremor O
and O
mild O
cho O
##re O
##iform O
d O
##ys O
##kin O
##es O
##ias O
he O
had O
mild O
age O
appropriate O
thor O
##ac O
##ic O
ky O
##ph O
##osis O
while O
seated O
and O
standing O
but O
otherwise O
no O
abnormal O
anterior O
or O
lateral O
ﬂ O
##ex O
##ion O
he O
was O
examined O
in O
the O
morning O
a O
time O
when O
he O
reported O
his O
tr O
##un O
##cal O
ﬂ O
##ex O
##ion O
was O
relatively O
mild O
after O
walking O
for O
about O
30 O
s O
he O
had O
onset O
of O
thor O
##aco O
##lum O
##bar O
ﬂ O
##ex O
##ion O
that O
progressed O
for O
another O
30 O
s O
to O
reach O
a O
maximum O
of O
40 O
##8 O
this O
degree O
of O
ﬂ O
##ex O
##ion O
was O
into O
##ler O
##ably O
painful O
caused O
him O
to O
stop O
walking O
and O
forced O
his O
trunk O
upright O
he O
would O
then O
resume O
walking O
and O
the O
pattern O
would O
repeat O
the O
rec O
##tus O
abd O
##omi O
##nis O
muscles O
were O
pal O
##pa O
##bly O
tight O
during O
ﬂ O
##ex O
##ion O
the O
camp O
##to O
##cor O
##mia O
was O
completely O
relieved O
when O
wearing O
a O
low O
slung O
backpack O
weighing O
6 O
kg O
video O
and O
returned O
upon O
removal O
it O
was O
also O
improved O
by O
using O
a O
wheeled O
walker O
or O
by O
pressing O
his O
back O
against O
the O
hallway O
hand O
##rail O
he O
found O
the O
backpack O
less O
cum O
##bers O
##ome O
and O
embarrassing O
than O
using O
a O
walker O

in O
follow O
up O
clinic O
visits O
he O
reported O
a O
consistent O
immediate O
ben O
##e O
##ﬁ O
##t O
each O
time O
a O
backpack O
was O
worn O
the O
ben O
##e O
##ﬁ O
##t O
was O
sustained O
without O
dec O
##rem O
##ent O
for O
long O
duration O
##s O
hours O
and O
was O
terminated O
only O
by O
removal O
of O
the O
backpack O
however O
prolonged O
use O
of O
a O
backpack O
was O
limited O
by O
discomfort O
from O
the O
backpack O
itself O
changing O
to O
a O
smaller O
size O
backpack O
ti O
##tra O
##ting O
the O
weight O
it O
contained O
and O
adjusting O
it O
to O
hang O
lower O
partially O
alleviate O
##d O
this O
discomfort O

camp O
##to O
##cor O
##mia O
is O
associated O
with O
het O
##ero O
##gen O
##eous O
et O
##iol O
##og O
##ies O
including O
parkinson O
##ism O
primary O
and O
secondary O
d O
##yst O
##onia O
##s O
spinal O
def O
##or O
##mit O
##ies O
ne O
##uro O
##mus O
##cular O
disorders O
psycho O
##genic O
causes O
and O
others O
1 O
among O
pd O
patients O
camp O
##to O
##cor O
##mia O
has O
a O
reported O
prevalence O
of O
7 O
2 O
and O
is O
associated O
with O
greater O
discomfort O
and O
disability O
3 O
it O
has O
features O
of O
a O
tr O
##un O
##cal O
kin O
##es O
##ogenic O
d O
##yst O
##onia O
many O
patients O
have O
pal O
##pa O
##ble O
contraction O
of O
the O
rec O
##tus O
abd O
##omi O
##nis O
improvement O
with O
sensory O
tricks O
and O
a O
di O
##urn O
##al O
pattern O
of O
ex O
##ace O
##rba O
##tion O
1 O
4 O
like O
other O
axial O
manifestation O
##s O
of O
pd O
it O
responds O
poorly O
to O
lev O
##od O
##opa O
1 O
4 O
other O
treatments O
including O
muscle O
relax O
##ants O
bot O
##ulin O
##um O
toxin O
and O
deep O
brain O
stimulation O
have O
been O
attempted O
but O
are O
un O
##sat O
##is O
##factory O
in O
many O
cases O
1 O
5 O
thor O
##aco O
##lum O
##bar O
or O
##th O
##oses O
have O
been O
tried O
but O
some O
are O
poorly O
tolerated O
and O
others O
while O
ben O
##e O
##ﬁ O
##cial O
require O
custom O
design O
and O
in O
##patient O
rehabilitation O
training O
6 O

we O
spec O
##ulate O
that O
the O
backpack O
may O
have O
acted O
as O
a O
counter O
##weight O
to O
help O
correct O
posture O
as O
well O
as O
stimulated O
a O
sensory O
trick O
to O
our O
knowledge O
backpack O
therapy O
has O
not O
previously O
been O
reported O
in O
camp O
##to O
##cor O
##mia O
and O
we O
suggest O
it O
as O
an O
inexpensive O
non O
##in O
##vas O
##ive O
option O
for O
this O
di O
##sa O
##bling O
condition O
legends O
to O
the O
video O

segment O
1 O
the O
patient O
is O
shown O
walking O
down O
a O
hallway O
with O
camp O
##to O
##cor O
##mia O
building O
up O
gradually O
over O
about O
60 O
s O
a O
backpack O
is O
then O
worn O
which O
resolve O
##s O
the O
camp O
##to O
##cor O
##mia O
the O
camp O
##to O
##cor O
##mia O
is O
also O
relieved O
when O
using O
a O
walker O
or O
when O
standing O
with O
his O
back O
against O
a O
hand O
##rail O
thor O
##aco O
##lum O
##bar O
ﬂ O
##ex O
##ion O
is O
absent O
when O
su O
##pine O
on O
the O
examination O
table O
the O
video O
is O
intentionally O
mute O
to O
avoid O
distracting O
background O
noise O
author O
roles O
brooke O
ge O
##rton O
was O
involved O
in O
the O
clinical O
observations O
writing O
of O
ﬁ O
##rst O
draft O
manuscript O
review O
and O
critique O
brett O
thee O
##ler O
was O
involved O
in O
the O
clinical O
observations O

movement O
disorders O
vol O
25 O
no O
2 O
2010 O
248 O
letters O
to O
the O
editor O
manuscript O
review O
and O
critique O
ali O
sami O
##i O
was O
involved O
in O
the O
clinical O
observations O
manuscript O
review O
and O
critique O
brooke O
k O
ge O
##rton O
md O
department O
of O
ne O
##uro O
##logy O
parkinson O
s O
disease O
research O
education O
and O
clinical O
centers O
veteran O
s O
affairs O
puget O
sound O
health O
care O
system O
and O
university O
of O
washington O
seattle O
washington O
usa O
e O
mail O
b O
##ger O
##ton O
u O
washington O
ed O
##u O
brett O
thee O
##ler O
md O
department O
of O
medicine O
mad O
##igan O
army O
medical O
center O
ne O
##uro O
##logy O
service O
tacoma O
washington O
usa O

ali O
sami O
##i O
md O
department O
of O
ne O
##uro O
##logy O
parkinson O
s O
disease O
research O
education O
and O
clinical O
centers O
veteran O
s O
affairs O
puget O
sound O
health O
care O
system O
and O
university O
of O
washington O
seattle O
washington O
usa O
references O
az O
##her O
s O
##n O
jan O
##kovic O
j O
camp O
##to O
##cor O
##mia O
pathogen O
##esis O
class O
##i O
##ﬁ O
##cation O
and O
response O
to O
therapy O
ne O
##uro O
##logy O
2005 O
65 O
355 O
35 O
##9 O
tip O
##le O
d O
fa O
##bb O
##rini O
g O
col O
##osi O
##mo O
c O
et O
al O
camp O
##to O
##cor O
##mia O
in O
parkinson O
disease O
an O
ep O
##ide O
##mi O
##ological O
and O
clinical O
study O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2009 O
80 O
145 O
148 O

bloc O
##h O
f O
ho O
##uet O
##o O
j O
##l O
te O
##zen O
##as O
du O
mont O
##cel O
s O
et O
al O
parkinson O
s O
disease O
with O
camp O
##to O
##cor O
##mia O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2006 O
77 O
122 O
##3 O
122 O
##8 O
dj O
##ald O
##etti O
r O
mo O
##sberg O
gal O
##ili O
r O
sr O
##oka O
h O
mer O
##im O
##s O
d O
mel O
##ame O
##d O
e O
camp O
##to O
##cor O
##mia O
bent O
spine O
in O
patients O
with O
parkinson O
s O
disease O
characterization O
and O
possible O
pathogen O
##esis O
of O
an O
unusual O
phenomenon O
mo O
##v O
di O
##sor O
##d O
1999 O
14 O
44 O
##3 O
44 O
##7 O
mel O
##ame O
##d O
e O
dj O
##ald O
##etti O
r O
camp O
##to O
##cor O
##mia O
in O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
2006 O
253 O
su O
##pp O
##l O
7 O
vii O
##14 O
vii O
##16 O

de O
se O
##ze O
mp O
cr O
##eu O
##ze O
a O
de O
se O
##ze O
m O
ma O
##za O
##ux O
j O
##m O
an O
or O
##th O
##osis O
and O
ph O
##ys O
##iot O
##her O
##ap O
##y O
programme O
for O
camp O
##to O
##cor O
##mia O
a O
prospective O
case O
study O
j O
rehab O
##il O
med O
2008 O
40 O
76 O
##1 O
76 O
##5 O
deep O
brain O
stimulation O
in O
a O
patient O
with O
isolated O
mixed O
tremor O
isolated O
mixed O
tremor O
##s O
are O
characterized O
by O
the O
presence O
of O
post O
##ural O
and O
resting O
tremor O
in O
the O
absence O
of O
other O
ne O
##uro O
##logic O
signs O
such O
as O
brady O
##kin O
##es O
##ia O
or O
rigid O
##ity O
1 O
a O
recent O
study O
has O
demonstrated O
that O
about O
half O
of O
the O
patients O
with O
isolated O
mixed O
tremor O
and O
intact O
ni O
##gr O
##ost O
##ria O
##tal O
pathway O
at O
baseline O
developed O
parkinson O
s O
disease O
pd O
2 O
years O
later O
whereas O

potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
11 O
december O
2009 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
md O
##s O
229 O
##01 O
movement O
disorders O
vol O
25 O
no O
2 O
2010 O

the O
remaining O
patients O
continued O
to O
present O
only O
mixed O
tremor O
at O
a O
2 O
year O
follow O
up O
1 O
it O
is O
still O
unknown O
however O
whether O
these O
latter O
patients O
will O
develop O
pd O
over O
time O
or O
will O
remain O
consistent O
with O
a O
diagnosis O
of O
et O
with O
resting O
tremor O
deep O
brain O
stimulation O
db O
##s O
of O
the O
ventral O
intermediate O
tha O
##lam O
##ic O
nucleus O
vi O
##m O
is O
an O
effective O
treatment O
option O
for O
et O
patients O
with O
medication O
resistant O
tremor O
##s O
2 O
here O
we O
describe O
a O
patient O
with O
di O
##sa O
##bling O
isolated O
mixed O
tremor O
and O
intact O
ni O
##gr O
##ost O
##ria O
##tal O
pathway O
resistant O
to O
ph O
##arm O
##aco O
##logic O
treatment O
who O
ben O
##e O
##ﬁ O
##ted O
from O
surgery O

a O
57 O
year O
old O
woman O
had O
a O
1 O
year O
history O
of O
tremor O
affecting O
her O
arms O
legs O
trunk O
and O
head O
with O
increasing O
disability O
in O
the O
last O
5 O
months O
her O
tremor O
was O
present O
at O
rest O
in O
the O
maintenance O
of O
posture O
and O
on O
standing O
secondary O
causes O
of O
tremor O
were O
excluded O
there O
was O
no O
fa O
##mi O
##lia O
##l O
history O
of O
neurological O
disorders O
when O
she O
was O
ﬁ O
##rst O
admitted O
to O
our O
clinic O
her O
neurological O
examination O
showed O
head O
and O
trunk O
tremor O
along O
with O
a O
moderate O
resting O
and O
post O
##ural O
tremor O
in O
the O
four O
limbs O
predominant O
on O
the O
right O
side O
and O
severe O
legs O
tremor O
during O
standing O
electro O
##phy O
##sio O
##logical O
studies O
revealed O
involvement O
of O
ago O
##nist O
antagonist O
distal O
muscles O
of O
upper O
and O
lower O
limbs O
at O
a O
frequency O
of O
4 O
to O
5 O
hz O
at O
rest O
and O
in O
the O
maintenance O
of O
posture O
fig O
1a O
on O
standing O
a O
rhythmic O
legs O
tremor O
at O
a O
frequency O
of O
5 O
hz O
sync O
##hr O
##ono O
##us O
in O
pro O
##xi O
##mal O
muscles O
and O
as O
##yn O
##ch O
##ron O
##ous O
in O
distal O
muscles O
was O
recorded O
fig O
1 O
##c O
mri O
scan O
of O
the O
brain O
was O
normal O
123 O
##i O
f O
##p O
ci O
##t O
spec O
##t O
revealed O
integrity O
of O
the O
ni O
##gr O
##ost O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
system O
the O
patient O
had O
received O
various O
treatments O
cl O
##ona O
##ze O
##pa O
##m O
prop O
##rano O
##lo O
##l O
pri O
##mi O
##don O
##e O
etc O
in O
adequate O
dos O
##age O
but O
these O
did O
not O
result O
in O
any O
sign O
##i O
##ﬁ O
##can O
##t O
improvement O
she O
complained O
of O
increased O
disability O
for O
daily O
life O
activities O
and O
was O
assessed O
for O
surgery O
at O
the O
clinical O
follow O
up O
18 O
months O
after O
baseline O
evaluation O
the O
patient O
showed O
as O
##ym O
##metric O
post O
##ural O
and O
resting O
tremor O
of O
the O
upper O
and O
lower O
limbs O
and O
marked O
tremor O
of O
the O
trunk O
and O
lower O
limbs O
on O
standing O
position O
a O
second O
123 O
##i O
f O
##p O
ci O
##t O
spec O
##t O
performed O
18 O
months O
after O
the O
ﬁ O
##rst O
examination O
was O
normal O
both O
pre O
##and O
post O
operative O
##ly O
fa O
##hn O
to O
##los O
##a O
marin O
tremor O
rating O
scale O
was O
performed O
see O
table O
1 O
after O
written O
consent O
was O
obtained O
she O
underwent O
mono O
##pol O
##ar O
bilateral O
micro O
##ele O
##ct O
##rod O
##e O
guided O
vi O
##m O
db O
##s O
after O
the O
usual O
pre O
##oper O
##ative O
ct O
mri O
local O
##ization O
of O
the O
target O
coordinate O
the O
vi O
##m O
coordinates O
were O
4 O
mm O
posterior O
to O
the O
mid O
com O
##mis O
##sur O
##al O
point O
3 O
mm O
above O
and O
13 O
mm O
lateral O
to O
the O
com O
##mis O
##sur O
##al O
plane O
with O
active O
contacts O
1 O
and O
5 O
the O
patient O
remained O
conscious O
the O
db O
##s O
setting O
had O
a O
frequency O
of O
130 O
hz O
a O
pulse O
width O
of O
250 O
l O
##s O
and O
a O
amplitude O
of O
1 O
ma O

post O
operative O
##ly O
the O
ben O
##e O
##ﬁ O
##t O
was O
rapidly O
evident O
with O
marked O
improvement O
of O
tremor O
of O
head O
trunk O
and O
limbs O
comparison O
of O
pre O
##and O
post O
operative O
video O
segments O
depicts O
the O
improvement O
quite O
clearly O
in O
on O
stimulation O
condition O
resting O
and O
post O
##ural O
tremor O
completely O
disappeared O
in O
distal O
muscles O
of O
upper O
and O
lower O
limbs O
fig O
1b O
on O
standing O
only O
an O
as O
##yn O
##ch O
##ron O
##ous O
tremor O
was O
recorded O
in O
the O
distal O
muscles O
of O
the O
legs O
with O
substantially O
more O
than O
50 O
of O
baseline O
decreased O
amplitude O
fig O
1 O
##d O
at O
the O
follow O
up O
visit O
12 O
months O
after O
surgery O
db O
##s O
was O
still O
effective O
and O
the O
patient O
showed O
no O
tremor O
in O
her O
four O
limbs O
trunk O
and O
head O
her O
quality O
of O
life O
substantially O
improved O
and O
she O
remained O
off O
medication O

the O
vi O
##m O
nucleus O
is O
the O
primary O
surgical O
target O
for O
the O
treatment O
of O
tremor O
3 O
the O
ben O
##e O
##ﬁ O
##cial O
effect O
of O
vi O
##m O
db O
##s O
on O
letters O
to O
the O
editor O
249 O

fig O
1 O
em O
##g O
recording O
of O
leg O
muscles O
in O
a O
patient O
with O
isolated O
mixed O
tremor O
at O
rest O
at O
the O
pre O
operative O
evaluation O
rhythmic O
and O
as O
##yn O
##ch O
##ron O
##ous O
4 O
to O
5 O
hz O
em O
##g O
activity O
involving O
ta O
and O
gm O
a O
in O
on O
stimulation O
condition O
tremor O
completely O
disappeared O
in O
distal O
muscles O
b O
on O
standing O
at O
the O
pre O
operative O
evaluation O
a O
rhythmic O
5 O
hz O
tremor O
developed O
in O
all O
leg O
muscles O
sync O
##hr O
##ono O
##us O
in O
v O
##m O
and O
bf O
as O
##yn O
##ch O
##ron O
##ous O
in O
ta O
and O
gm O
c O
in O
on O
stimulation O
condition O
em O
##g O
amplitude O
decreased O
in O
ta O
and O
gm O
whereas O
tremor O
disappeared O
in O
v O
##m O
and O
bf O
muscles O
d O
v O
##m O
vast O
##us O
medial O
##is O
muscle O
bf O
biceps O
fe O
##mori O
##s O
muscle O
ta O
ti O
##bial O
##is O
anterior O
muscle O
gm O
medial O
gas O
##tro O
##c O
##nem O
##ius O
muscle O

et O
has O
been O
well O
documented O
several O
studies O
have O
demonstrated O
that O
about O
80 O
of O
patients O
experience O
sign O
##i O
##ﬁ O
##can O
##t O
overall O
tremor O
relief O
4 O
6 O
no O
report O
of O
vi O
##m O
db O
##s O
procedure O
in O
patients O
with O
isolated O
mixed O
tremor O
and O
intact O
do O
##pa O
##mine O
##rg O
##ic O
ni O
##gr O
##ost O
##ria O
##tal O
system O
has O
been O
documented O
until O
now O
interesting O
##ly O
in O
our O
patient O
vi O
##m O
db O
##s O
produced O
the O
clinical O
disappearance O
not O
only O
of O
the O
axial O
tremor O
##s O
along O
with O
the O
post O
##ural O
tremor O
of O
the O
limbs O
but O
also O
of O
the O
resting O
tremor O

in O
conclusion O
we O
described O
the O
ﬁ O
##rst O
reported O
patient O
with O
isolated O
mixed O
tremor O
ref O
##rac O
##tory O
to O
medications O
who O
was O
successfully O
treated O
with O
vi O
##m O
db O
##s O
this O
case O
suggests O
that O
vi O
##m O
table O
1 O
fa O
##hn O
to O
##los O
##a O
marin O
tremor O
rating O
scale O
ft O
##mt O
##rs O
before O
and O
after O
db O
##s O
ae O
##val O
##uation O
performed O
after O
a O
12 O
months O
period O
of O
follow O
up O
db O
##s O
may O
be O
an O
effective O
target O
for O
the O
treatment O
of O
patients O
with O
isolated O
mixed O
tremor O
##s O
and O
intact O
ni O
##gr O
##ost O
##ria O
##tal O
system O
legends O
to O
the O
video O

segment O
1 O
pre O
##oper O
##ative O
video O
clip O
of O
the O
patient O
showing O
marked O
tremor O
of O
head O
trunk O
and O
lower O
limbs O
on O
standing O
position O
as O
##ym O
##metric O
post O
##ural O
and O
resting O
tremor O
of O
the O
upper O
and O
the O
lower O
limbs O
are O
also O
depicted O
in O
the O
video O
segment O
2 O
post O
##oper O
##ative O
st O
##im O
##ulator O
off O
video O
clip O
showing O
tremor O
of O
head O
trunk O
and O
lower O
limbs O
on O
standing O
position O
with O
markedly O
as O
##ym O
##metric O
##al O
post O
##ural O
tremor O
of O
upper O
and O
lower O
limbs O

segment O
3 O
post O
##oper O
##ative O
st O
##im O
##ulator O
on O
video O
clip O
head O
trunk O
and O
lower O
limbs O
tremor O
on O
standing O
along O
with O
resting O
and O
post O
##ural O
tremor O
of O
the O
upper O
and O
lower O
limbs O
completely O
disappeared O
segment O
4 O
at O
the O
follow O
up O
visit O
12 O
months O
after O
surgery O
st O
##im O
##ulator O
off O
video O
clip O
showed O
tremor O
of O
head O
trunk O
and O
four O
limbs O
predominant O
on O
the O
right O
side O
movement O
disorders O
vol O
25 O
no O
2 O
2010 O
250 O
letters O
to O
the O
editor O
segment O
5 O
at O
the O
follow O
up O
visit O
12 O
months O
after O
surgery O
st O
##im O
##ulator O
on O
patient O
showed O
no O
tremor O
in O
her O
four O
limbs O
trunk O
and O
head O

author O
roles O
s O
pa O
##glio O
##nic O
##o O
organization O
and O
execution O
of O
research O
project O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
of O
the O
manuscript O
g O
arabia O
execution O
of O
research O
project O
review O
and O
critique O
of O
the O
manuscript O
a O
lava O
##no O
organization O
of O
research O
project O
review O
and O
critique O
of O
the O
manuscript O
m O
d O
rose O
review O
and O
critique O
of O
the O
manuscript O
d O
pi O
##rri O
##tan O
##o O
organization O
of O
research O
project O
review O
and O
critique O
of O
the O
manuscript O
a O
qu O
##att O
##rone O
conception O
and O
organization O
of O
research O
project O
review O
and O
critique O
of O
the O
manuscript O

sandra O
pa O
##glio O
##nic O
##o O
md O
gen O
##nar O
##ina O
arabia O
md O
msc O
domenico O
pi O
##rri O
##tan O
##o O
md O
aldo O
qu O
##att O
##rone O
md O
angelo O
lava O
##no O
md O
maris O
##a O
de O
rose O
md O
department O
of O
medical O
sciences O
institute O
of O
ne O
##uro O
##logy O
university O
magna O
gr O
##æ O
##cia O
cat O
##anza O
##ro O
italy O
e O
mail O
a O
qu O
##att O
##rone O
isn O
cn O
##r O
it O
references O
ce O
##ra O
##vo O
##lo O
r O
anton O
##ini O
a O
vol O
##ter O
##rani O
d O
et O
al O
predict O
##ive O
value O
of O
ni O
##gr O
##ost O
##ria O
##tal O
dysfunction O
in O
isolated O
tremor O
a O
clinical O
and O
spec O
##t O
study O
mo O
##v O
di O
##sor O
##d O
2008 O
21 O
204 O
##9 O
205 O
##4 O
lyons O
ke O
pa O
##hwa O
r O
deep O
brain O
stimulation O
and O
tremor O
ne O
##uro O
##ther O
##ape O
##uti O
##cs O
2008 O
5 O
331 O
338 O

is O
it O
ad O
##em O
pol O
##g O
or O
both O
mandy O
o O
harris O
md O
laurence O
e O
walsh O
md O
e O
##yas O
m O
hat O
##ta O
##b O
md O
meredith O
r O
go O
##lom O
##b O
md O
msc O
objective O
to O
describe O
a O
child O
with O
apparent O
brain O
bio O
##psy O
confirmed O
acute B-HPO_TERM
di I-HPO_TERM
##sse I-HPO_TERM
##minated I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lom I-HPO_TERM
##ye I-HPO_TERM
##lit I-HPO_TERM
##is I-HPO_TERM
ad B-HPO_TERM
##em I-HPO_TERM
but O
genetic O
confirmation O
of O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
dna O
mutations O
of O
the O
polymer B-GENE
##ase I-GENE
y I-GENE
pol B-GENE
##g I-GENE
gene O
design O
case O
report O
setting O
tertiary O
refer O
##ral O
center O
patient B-PATIENT
a O
4 B-AGE_ONSET
year O
old O
boy O
presented O
with O
ata B-HPO_TERM
##xia I-HPO_TERM
and O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM

results O
magnetic O
resonance O
imaging O
demonstrated O
multiple B-HPO_TERM
focal I-HPO_TERM
areas I-HPO_TERM
of I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
pro I-HPO_TERM
##long I-HPO_TERM
##ation I-HPO_TERM
the O
patient O
s O
family O
refused O
ste O
##roid O
treatment O
his O
symptoms O
improved O
then O
progressed O
magnetic O
resonance O
imaging O
findings O
also O
progressed O
a O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
specimen O
revealed O
my B-HPO_TERM
##elin I-HPO_TERM
basic I-HPO_TERM
protein I-HPO_TERM
and O
ol B-HPO_TERM
##igo I-HPO_TERM
##cl I-HPO_TERM
##onal I-HPO_TERM
bands I-HPO_TERM
a O
brain O
bio O
##psy O

specimen O
demonstrated O
dem B-HPO_TERM
##ye I-HPO_TERM
##lina I-HPO_TERM
##tion I-HPO_TERM
suggesting O
progression O
of O
ad O
##em O
however O
polymer O
##ase O
chain O
reaction O
amp O
##li O
##fication O
and O
sequencing O
revealed O
2 O
het O
##ero O
##zy O
##go O
##us O
mutations O
of O
the O
pol B-GENE
##g I-GENE
gene O
suggesting O
mitochondrial O
disease O
the O
patient O
died O
9 B-AGE_DEATH
months I-AGE_DEATH
after I-AGE_DEATH
his O
initial O
presentation O

conclusions O
this O
case O
raises O
interesting O
questions O
about O
whether O
ad O
##em O
triggered O
severe O
ne B-HPO_TERM
##uro I-HPO_TERM
##logic I-HPO_TERM
de I-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
in O
a O
patient O
with O
mitochondrial O
disease O
whether O
mitochondrial O
disease O
pre O
##dis O
##posed O
to O
a O
path O
##olo O
##gic O
immune O
response O
or O
whether O
mitochondrial O
disease O
can O
mimic O
an O
auto O
##im O
##mun O
##e O
disease O
mitochondrial O
disease O
causing O
mutations O
may O
help O
explain O
the O
poor O
outcome O
in O
some O
cases O
of O
apparent O
auto O
##im O
##mun O
##e O
central O
nervous O
system O
disease O
arch O
ne O
##uro O
##l O
2010 O
67 O
4 O
49 O
##3 O
49 O
##6 O

author O
affiliation O
##s O
department O
of O
ne O
##uro O
##logy O
division O
of O
pediatric O
ne O
##uro O
##logy O
dr O
##s O
harris O
walsh O
and O
go O
##lom O
##b O
and O
department O
of O
pathology O
and O
laboratory O
medicine O
dr O
hat O
##ta O
##b O
indiana O
university O
school O
of O
medicine O
indianapolis O
mp O
##roved O
genetic O
and O
radio O
graphic O
testing O
techniques O
have O
blurred O
the O
borders O
between O
auto O
##im O
##mun O
##e O
and O
ne O
##uro O
##gen O
##etic O
disease O
several O
patients O
who O
cl O
##ini O

call O
##y O
appeared O
to O
have O
multiple O
sc O
##ler O
##osis O
or O
variations O
of O
auto O
##im O
##mun O
##e O
dem O
##ye O
##lina O
##tion O
but O
carried O
variants O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
1 O
pl O
##p O
##1 O
gene O
have O
been O
described O
in O
the O
literature O
the O
pl O
##p O
##1 O
gene O
usually O
causes O
pe O
##li O
##za O
##eus O
mer O
##z O
##bach O
##er O
disease O
or O
hereditary O
spa O
##stic O
para O
##par O
##esis O
type O

2 O
it O
was O
unclear O
whether O
the O
cases O
were O
unusual O
presentations O
of O
a O
ne O
##uro O
##gen O
##etic O
disease O
or O
whether O
the O
mutation O
induced O
an O
abnormal O
auto O
##im O
##mun O
##e O
response O
1 O
2 O
mouse O
studies O
of O
juvenile O
bat O
##ten O
disease O
another O
ne O
##uro O
##gen O
##etic O
disease O
have O
revealed O
an O
auto O
##im O
##mun O
##e O
attack O
against O
g O
##lu O
##tam O
##ic O
acid O
dec O
##ar O
##box O
##yla O
##se O
65 O
the O
authors O
speculated O
that O
the O
ca O
##usa O
##tive O
gene O
might O
affect O
g O
##lu O
##tam O
##ic O
acid O
dec O
##ar O
##box O
##yla O
##se O
65 O
in O
a O
way O
that O
induce O
##s O
the O
abnormal O
auto O
##im O
##mun O
##e O
response O
3 O
in O
duc O
##hen O
##ne O
muscular O
d O
##yst O
##rop O
##hy O
d O
##yst O
##rop O
##hin O
##opa O
##thy O
appears O
to O
induce O
a O
secondary O
auto O
##im O
##mun O
##e O
response O
##4 O
pre O
##d O
##nis O
##one O
has O
become O
a O
stan O

dar O
##d O
part O
of O
therapy O
in O
these O
cases O
5 O
we O
describe O
a O
patient O
with O
apparent O
brain O
bio O
##psy O
proved O
progressive O
acute O
di O
##sse O
##minated O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
ad O
##em O
in O
whom O
genetic O
testing O
supported O
mitochondrial O
disease O
due O
to O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
the O
polymer O
##ase O
y O
pol O
##g O
gene O

a O
4 B-AGE_ONSET
year O
old O
boy O
presented O
with O
1 O
week O
of O
ata B-HPO_TERM
##xia I-HPO_TERM
after O
an O
ot B-HPO_TERM
##itis I-HPO_TERM
media I-HPO_TERM
infection O
his O
birth O
and O
developmental O
and O
medical O
histories O
were O
un O
##rem O
##ark O
##able O
his O
family O
history O
revealed O
only O
1 O
relative O
with O
cerebral O
pal O
##sy O
due O
to O
h O
##yp O
##ox O
##ia O
further O
details O
not O
available O
initial O
brain O
magnetic O
resonance O
imaging O
in O
this O
case O
revealed O
multiple B-HPO_TERM
focal I-HPO_TERM
areas I-HPO_TERM
of I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
pro I-HPO_TERM
##long I-HPO_TERM
##ation I-HPO_TERM
with O
ga B-HPO_TERM
##do I-HPO_TERM
##lini I-HPO_TERM
##um I-HPO_TERM
enhancement I-HPO_TERM
the O
affected O
regions O
included O
the O
left O
par B-HPO_TERM
##ie I-HPO_TERM
##tal I-HPO_TERM
lobe I-HPO_TERM
the O
internal B-HPO_TERM
capsule I-HPO_TERM
and O
head B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ca I-HPO_TERM
##uda I-HPO_TERM
##te I-HPO_TERM
and O
the O
right O
middle B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
pe I-HPO_TERM
##dun I-HPO_TERM
##cle I-HPO_TERM
figure O
1a O
the O
findings O
were O
thought O
to O
be O
most O
compatible O
with O
ad O
##em O
the O

figure O
1 O
the O
findings O
of O
magnetic O
resonance O
imaging O
are O
consistent O
with O
acute B-HPO_TERM
di I-HPO_TERM
##sse I-HPO_TERM
##minated I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lom I-HPO_TERM
##ye I-HPO_TERM
##lit I-HPO_TERM
##is I-HPO_TERM
a O
and O
b O
and O
then O
suggest O
##ive O
of O
aggressive O
tumor O
c O
a O
initial O
fluid O
at O
##ten O
##uated O
inversion O
recovery O
magnetic O
resonance O
imaging O
demonstrates O
involvement O
of O
the O
left O
internal O
capsule O
and O
ca O
##uda O
##te O
b O
subsequent O
fluid O
at O
##ten O
##uated O
inversion O
recovery O
magnetic O
resonance O
imaging O
3 O
months O
later O
demonstrates O
increased O
involvement O
c O
magnetic O
resonance O
spectroscopy O
on O
the O
second O
admission O
demonstrates O
an O
elevated B-HPO_TERM
level I-HPO_TERM
of I-HPO_TERM
cho I-HPO_TERM
##line I-HPO_TERM
arrow O
1 O
a O
depressed B-HPO_TERM
level I-HPO_TERM
of I-HPO_TERM
n I-HPO_TERM
ace I-HPO_TERM
##ty I-HPO_TERM
##las I-HPO_TERM
##par I-HPO_TERM
##tate I-HPO_TERM
arrow O
2 O
and O
an O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
double I-HPO_TERM
##t I-HPO_TERM
arrow O
3 O
in O
the O
left O
basal B-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM

family O
declined O
treatment O
with O
ste O
##roids O
and O
the O
patient O
improved O
during O
hospital O
##ization O
after O
discharge O
the O
family O
failed O
to O
appear O
for O
routine O
follow O
up O
appointments O
but O
brought O
the O
child O
to O
the O
emergency O
department O
several O
times O
for O
worse B-HPO_TERM
##ning I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
each O
time O
they O
refused O
admission O
with O
the O
help O
of O
social O
services O
the O
patient O
was O
read O
##mit O
##ted O
3 O
months O
after O
his O
initial O
presentation O

at O
read O
##mission O
he O
was O
so B-HPO_TERM
##m I-HPO_TERM
##no I-HPO_TERM
##lent I-HPO_TERM
and O
responded O
only O
to O
ta O
##ct O
##ile O
stimuli O
with O
loss B-HPO_TERM
of I-HPO_TERM
extra I-HPO_TERM
##oc I-HPO_TERM
##ular I-HPO_TERM
movement I-HPO_TERM
on O
the O
right O
and O
right O
arm O
and O
leg O
spa B-HPO_TERM
##stic I-HPO_TERM
##ity I-HPO_TERM
and O
hyper B-HPO_TERM
##re I-HPO_TERM
##fle I-HPO_TERM
##xia I-HPO_TERM
magnetic O
resonance O
imaging O
revealed O
en O
##lar O
##gement O
of O
previously O
identified O
lesions O
and O
new O
f O
##oc O
##i O
of O
t O
##2 O
pro O
##long O
##ation O
in O
the O
left O
front B-HPO_TERM
##opa I-HPO_TERM
##rie I-HPO_TERM
##tal I-HPO_TERM
sub I-HPO_TERM
##cor I-HPO_TERM
##tical I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
gen B-HPO_TERM
##u I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
corpus I-HPO_TERM
call I-HPO_TERM
##os I-HPO_TERM
##um I-HPO_TERM
gen O
##u O
of O
the O
right B-HPO_TERM
internal I-HPO_TERM
capsule I-HPO_TERM
anterior B-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and O
bilateral B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
hemisphere I-HPO_TERM
##s I-HPO_TERM
with O
extension O
into O
the O
bilateral B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
pe I-HPO_TERM
##dun I-HPO_TERM
##cles I-HPO_TERM
sub B-HPO_TERM
##ac I-HPO_TERM
##ute I-HPO_TERM
hem I-HPO_TERM
##or I-HPO_TERM
##rh I-HPO_TERM
##age I-HPO_TERM
was O
present O
in O
the O
left O
tha B-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and O
put B-HPO_TERM
##amen I-HPO_TERM
figure O
1b O
magnetic O
resonance O
spectroscopy O
showed O
an O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
level I-HPO_TERM
a O
markedly O
depressed B-HPO_TERM
n I-HPO_TERM
ace I-HPO_TERM
##ty I-HPO_TERM
##las I-HPO_TERM
##par I-HPO_TERM
##tate I-HPO_TERM
level I-HPO_TERM
and O
a O
markedly O
elevated B-HPO_TERM
cho I-HPO_TERM
##line I-HPO_TERM
level I-HPO_TERM
in O
the O
left O
basal B-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
findings O
most O
compatible O
with O
an O
aggressive O
tumor O
such O
as O
g O
##lio O
##bla O
##sto O
##ma O
multi O
##form O
##e O
figure O
1 O
##c O
however O
magnetic O
resonance O
per O
##fusion O
studies O
showed O
no O
evidence O
of O
increased O
per O
##fusion O
in O
the O
lesions O
findings O
more O
consistent O
with O
a O
fu O
##lm O
##ina O
##nt O
inflammatory O
process O
such O
as O
tu O
##me O
##fa O
##ctive O
dem O
##ye O
##lina O
##tion O
than O
with O
neo O
##pl O
##as O
##m O
bio O
##psy O
of O
the O
deep O
left O
frontal O
les O
##ion O
revealed O
multiple O
fragments O
of O
heavily O
g B-HPO_TERM
##lio I-HPO_TERM
##tic I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
diffuse O
##ly O
infiltrate O
##d O
by O
abundant O
foam B-HPO_TERM
##y I-HPO_TERM
his I-HPO_TERM
##ti I-HPO_TERM
##ocytes I-HPO_TERM
scattered O
l B-HPO_TERM
##ym I-HPO_TERM
##ph I-HPO_TERM
##ocytes I-HPO_TERM
and O
occasional O
plasma B-HPO_TERM
cells I-HPO_TERM
figure O
2a O
a O
my O
##elin O
stain O
showed O
remarkable O
loss B-HPO_TERM
of I-HPO_TERM
my I-HPO_TERM
##elin I-HPO_TERM
with O
macro O
##pha O
##ges O
containing O
my O
##elin O
particles O
figure O
2 O
##b O
as O
expected O
the O
reactive B-HPO_TERM
astro I-HPO_TERM
##cytes I-HPO_TERM
were O
intensely O
highlighted O
by O
g B-HPO_TERM
##lia I-HPO_TERM
##l I-HPO_TERM
fi I-HPO_TERM
##bri I-HPO_TERM
##llary I-HPO_TERM
acidic I-HPO_TERM
protein I-HPO_TERM
figure O
2 O
##c O
and O
the O
macro O
##pha O
##ges O
stained O
for O
the O
macro O
##pha O
##ge O
marker O
cd O
##6 O
##8 O
figure O
2d O
no O
micro O
##org O
##ani O
##sms O
were O
identified O
and O
there O
was O
no O
evidence O
of O
a O
neo O
##pl O
##as O
##m O
these O
findings O
were O
most O
consistent O
with O
an O
active B-HPO_TERM
dem I-HPO_TERM
##ye I-HPO_TERM
##lina I-HPO_TERM
##ting I-HPO_TERM
process I-HPO_TERM

the O
patient O
was O
treated O
with O
30 O
mg O
kg O
of O
methyl O
##pre O
##d O
##nis O
##olo O
##ne O
sodium O
su O
##cci O
##nate O
sol O
##u O
med O
##rol O
for O
5 O
daily O
doses O
followed O
by O
an O
oral O
pre O
##d O
##nis O
##olo O
##ne O
tape O
##r O
with O
only O
minimal O
clinical O
improvement O
his O
hospital O
##ization O
was O
complicated O
by O
ste O
##roid O
induced O
hyper O
##gly O
##ce O
##mia O
and O
witnessed O
physical O
abuse O
by O
his O
mother O
he O
was O
subsequently O
placed O
in O
state O
custody O
he O
eventually O
required O
per B-HPO_TERM
##cut I-HPO_TERM
##aneous I-HPO_TERM
gas I-HPO_TERM
##tro I-HPO_TERM
##sto I-HPO_TERM
##my I-HPO_TERM
tube I-HPO_TERM
placement O
for O
feeding O
and O
was O
discharged O
to O
a O
long O
term O
care O
facility O
he O
died B-HPO_TERM
9 B-AGE_DEATH
months I-AGE_DEATH
after I-AGE_DEATH
his O
initial O
presentation O

after O
his O
discharge O
but O
before O
his O
death O
several O
of O
his O
laboratory O
test O
results O
returned O
and O
were O
reviewed O
ur O
##ina O
##ry O
organic O
acids O
demonstrated O
a O
mild O
increase B-HPO_TERM
in I-HPO_TERM
vanilla I-HPO_TERM
##te I-HPO_TERM
levels I-HPO_TERM
presumably O
from O
diet O
levels O
of O
serum O
amino O
acids O
very O
long O
chain O
fatty O
acids O
and O
plasma O
car O
##ni O
##tine O
were O
normal O
as O
were O
the O
results O
of O
an O
ac O
##yl O
car O
##ni O
##tine O
profile O
the O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
specimen O
demonstrated O
normal O
levels O
of O
protein O
but O
the O
my B-HPO_TERM
##elin I-HPO_TERM
basic I-HPO_TERM
protein I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
higher I-HPO_TERM
than I-HPO_TERM
1000 I-HPO_TERM
ng I-HPO_TERM
ml I-HPO_TERM
and O
ol B-HPO_TERM
##igo I-HPO_TERM
##cl I-HPO_TERM
##onal I-HPO_TERM
bands I-HPO_TERM
were I-HPO_TERM
present I-HPO_TERM
no O
at O
##yp O
##ical O
cells O
were O
present O
on O
cy O
##to O
##logic O
examination O
epstein O
barr O
virus O
cy O
##tom O
##ega O
##lov O
##irus O
and O
human O
her O
##pes O
##virus O
6 O
were O
not O
detected O
by O
polymer O
##ase O
chain O
reaction O
the O
serum B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
high I-HPO_TERM
at O
23 O
4 O
mg O
dl O
reference O
range O
4 O
5 O
19 O
8 O
mg O
dl O
to O
convert O
to O
mill O
##imo O
##les O
per O
liter O
multi O
##ply O
by O
0 O
111 O
however O
the O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
lac O
##tate O
level O
was O
normal O
dna O
pol B-GENE
##g I-GENE
sequencing O
revealed O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
c B-GENE_VARIANT
##75 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
and O
c1 B-GENE_VARIANT
##7 I-GENE_VARIANT
##60 I-GENE_VARIANT
##t I-GENE_VARIANT
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT

dna O
pol O
##g O
is O
the O
nuclear O
encoded O
polymer O
##ase O
that O
is O
responsible O
for O
replication O
of O
the O
mitochondrial O
genome O
it O
consists O
of O
2 O
subunit O
##s O
a O
catalytic O
subunit O
encoded O
by O
pol O
##g O
##1 O
now O
known O
as O
pol O
##g O
and O
an O
accessory O
subunit O
encoded O
by O
pol O
##g O
##2 O
pol O
##g O
is O
located O
on O

figure O
2 O
path O
##olo O
##gic O
findings O
of O
a O
brain O
bio O
##psy O
are O
consistent O
with O
acute B-HPO_TERM
di I-HPO_TERM
##sse I-HPO_TERM
##minated I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lom I-HPO_TERM
##ye I-HPO_TERM
##lit I-HPO_TERM
##is I-HPO_TERM
a O
a O
stereo O
##ta O
##ctic O
bio O
##psy O
specimen O
from O
the O
left O
frontal O
lobe O
shows O
diffuse B-HPO_TERM
in I-HPO_TERM
##filtration I-HPO_TERM
by I-HPO_TERM
reactive I-HPO_TERM
astro I-HPO_TERM
##cytes I-HPO_TERM
arrows O
and O
foam B-HPO_TERM
##y I-HPO_TERM
macro I-HPO_TERM
##pha I-HPO_TERM
##ges I-HPO_TERM
arrow O
##heads O
hem O
##ato O
##xy O
##lin O
e O
##osi O
##n O
original O
mag O
##ni O
##fication O
x O
##500 O
b O
a O
my O
##elin O
stain O
shows O
severe O
pal O
##lor O
of O
white O
matter O
loss O
of O
blue O
stain O
##ing O
my O
##elin O
note O
the O
my O
##elin O
particles O
engulfed O
by O
macro O
##pha O
##ges O
arrows O
lux O
##ol O
fast O
blue O
original O
mag O
##ni O
##fication O
x O
##500 O
c O
an O
im O
##mun O
##osta O
##in O
for O
poly O
##cl O
##onal O
g O
##lia O
##l O
fi O
##bri O
##llary O
acidic O
protein O
da O
##ko O
carp O
##int O
##eria O
california O
intensely O
highlights O
reactive O
astro O
##cytes O
arrows O
while O
leaving O
macro O
##pha O
##ges O
un O
##sta O
##ined O
original O
mag O
##ni O
##fication O
x O
##500 O
d O
conversely O
the O
macro O
##pha O
##ge O
marker O
cd O
##6 O
##8 O
da O
##ko O
positively O
stains O
macro O
##pha O
##ges O
arrows O
note O
the O
per O
##iva O
##scu O
##lar O
aggregate O
##s O
of O
macro O
##pha O
##ges O
arrow O
##heads O
reactive O
astro O
##cytes O
are O
non O
##rea O
##ctive O
original O
mag O
##ni O
##fication O
x O
##500 O

chromosome O
15 O
##q O
##25 O
6 O
homo O
##zy O
##gos O
##ity O
for O
the O
a O
##46 O
##7 O
##t O
mutation O
and O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
in O
pol O
##g O
are O
most O
commonly O
associated O
with O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
and O
al O
##pers O
syndrome O
which O
is O
characterized O
by O
a O
clinical O
triad O
of O
psycho O
##moto O
##r O
re O
##tar O
##dation O
intra O
##ctable O
ep O
##ile O
##psy O
and O
liver O
failure O
in O
infants O
and O
young O
children O
7 O
our O
patient O
s O
pol O
##g O
sequencing O
revealed O
compound O
het O
##ero O
##zy O
##gos O
##ity O
at O
t O
##25 O
##1 O
##i O
and O
p O
##58 O
##7 O
##l O
ho O
##rva O
##th O
et O
al O
##8 O
described O
8 O
patients O
with O
this O
combination O
of O
mutations O
all O
were O
adults O
and O
7 O
of O
the O
8 O
had O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
six O
patients O
also O
had O
my O
##opa O
##thy O
1 O
had O
ata O
##xia O
and O
1 O
had O
ne O
##uro O
##pathy O
one O
patient O
had O
only O
isolated O
my O
##opa O
##thy O
this O
combination O
of O
mutations O
was O
also O
described O
in O
2 O
sisters O
with O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
syndrome O
but O
no O
le O
##uk O
##oe O
##nce O
##pha O
##lo O
##pathy O
9 O
10 O
also O
3 O
families O
with O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
were O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
the O
t O
##25 O
##1 O
##i O
and O
the O
p O
##58 O
##7 O
##l O
gene O
mutations O
11 O
our O
patient B-PATIENT
had O
progressive B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
as B-HPO_TERM
##ym I-HPO_TERM
##metric I-HPO_TERM
##al I-HPO_TERM
right I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
seizures B-HPO_TERM
and O
brain O
bio O
##psy O
findings O
that O
were O
consistent O
with O
rapidly B-HPO_TERM
progressive I-HPO_TERM
dem I-HPO_TERM
##y I-HPO_TERM

eli B-HPO_TERM
##nation I-HPO_TERM
suggesting O
a O
wider O
ph O
##eno O
##typic O
spectrum O
associated O
with O
pol B-GENE
##g I-GENE
mutations O

dem O
##ye O
##lina O
##ting O
disease O
or O
what O
appears O
to O
be O
dem O
##ye O
##lina O
##ting O
disease O
has O
been O
reported O
previously O
in O
patients O
carrying O
other O
mutations O
associated O
with O
mitochondrial O
disease O
there O
is O
a O
le O
##ber O
plus O
ph O
##eno O
##type O
that O
has O
a O
radio O
##graphic O
appearance O
suggest O
##ive O
of O
multiple O
sc O
##ler O
##osis O
##12 O
however O
most O
patients O
with O
multiple O
sc O
##ler O
##osis O
do O
not O
carry O
le O
##ber O
mitochondrial O
dna O
mutations O
13 O
an O
adult O
man O
with O
a O
multiple O
sc O
##ler O
##osis O
like O
clinical O
presentation O
compatible O
radio O
##graphic O
imaging O
results O
and O
ol O
##igo O
##cl O
##onal O
bands O
in O
a O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
specimen O
had O
a O
het O
##ero O
##zy O
##go O
##us O
s O
##64 O
##6 O
##l O
mutation O
in O
the O
optic O
at O
##rop O
##hy O
1 O
op O
##a1 O
gene O
which O
codes O
for O
a O
mitochondrial O
protein O
and O
is O
associated O
with O
auto O
##som O
##al O
dominant O
optic O
at O
##rop O
##hy O
14 O
care O
##lli O
and O
bella O
##n O
##15 O
suggested O
that O
mitochondrial O
dysfunction O
in O
le O
##ber O
and O
op O
##a1 O
mutations O
may O
induce O
an O
auto O
##im O
##mun O
##e O
response O
conversely O
mitochondrial O
dysfunction O
has O
been O
proposed O
as O
a O
contributor O
to O
ax O
##onal O
de O
##gen O
##eration O
in O
multiple O
sc O
##ler O
##osis O
although O
the O
initial O
trigger O
of O
this O
dysfunction O
remains O
unclear O
16 O
our O
patient O
s O
presentation O
ant O
##ece O
##dent O
infectious O
pro O
##drome O
and O
radio O

graphic O
laboratory O
and O
path O
##olo O
##gic O
evidence O
were O
all O
consistent O
with O
acute O
auto O
##im O
##mun O
##e O
dem O
##ye O
##lina O
##ting O
disease O
but O
the O
subsequent O
de O
##gen O
##erative O
course O
was O
unusual O
for O
ad O
##em O
and O
triggered O
the O
search O
for O
mitochondrial O
causes O
we O
wonder O
whether O
the O
underlying O
pol O
##g O
mutation O
triggered O
an O
auto O
##im O
##mun O
##e O
reaction O
as O
suggested O
by O
care O
##lli O
and O
bella O
##n O
##15 O
for O
other O
mitochondrial O
mutations O
or O
whether O
the O
stress O
of O
ad O
##em O
triggered O
severe O
mitochondrial O
dysfunction O
leading O
to O
our O
patient O
s O
decline O
and O
death O

compound O
het O
##ero O
##zy O
##go O
##us O
polymer B-GENE
##ase I-GENE
gamma I-GENE
gene O
mutation O
in O
a O
patient B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
javier O
f O
card O
##enas O
md O
and O
r O
stephen O
ama O
##to O
md O

al O
##pers O
disease O
is O
a O
mitochondrial O
de O
##ple O
##tion O
syndrome O
characterized O
by O
psycho O
##moto O
##r O
re O
##tar O
##dation O
intra O
##ctable O
ep O
##ile O
##psy O
and O
liver O
failure O
polymer O
##ase O
gamma O
pol O
##g O
gene O
mutations O
are O
a O
known O
cause O
of O
the O
disease O
we O
describe O
a O
case B-PATIENT
in O
which O
a O
14 B-AGE_ONSET
month I-AGE_ONSET
old O
female O
presented O
with O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
evolving O
into O
generalized B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
treatment O
with O
multiple O
anti O
##ep O
##ile O
##ptic O
medications O
and O
the O
ke O
##to O
##genic O
diet O
eliminated O
her O
seizures B-HPO_TERM
but O
she O
remained O
severely B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
magnetic O
resonance O
imaging O
showed O
diffuse B-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
of I-HPO_TERM
gray I-HPO_TERM
matter I-HPO_TERM
structures I-HPO_TERM
she O
ultimately O
developed O
liver B-HPO_TERM
failure I-HPO_TERM
and O
died O
mitochondrial O
analysis O
revealed O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
3 O
pol B-GENE
##g I-GENE
gene O
mutations O
2 O
of O
which O
were O
previously O
un O
##re O
##port O
##ed O

semi O
##n O
pe O
##dia O
##tr O
ne O
##uro O
##l O
17 O
62 O
64 O
2010 O
else O
##vier O
inc O
all O
rights O
reserved O

14 B-AGE_ONSET
month I-AGE_ONSET
old O
female O
with O
a O
history O
of O
poor B-HPO_TERM
weight I-HPO_TERM
gain I-HPO_TERM
and O
persistent B-HPO_TERM
##ly I-HPO_TERM
loose I-HPO_TERM
stool I-HPO_TERM
##s I-HPO_TERM
presented O
with O
new O
onset O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
her O
parents O
reported O
ir B-HPO_TERM
##rita I-HPO_TERM
##bility I-HPO_TERM
several O
days O
before O
admission O
but O
denied O
symptoms O
of O
illness O
she O
was O
initially O
noted O
to O
have O
intermittent O
rhythmic O
jerking O
of O
her O
left O
arm O
with O
a O
clenched O
left O
hand O
she O
was O
alert O
and O
af O
##eb O
##ril O
##e O
but O
was O
taken O
to O
an O
urgent O
care O
center O
where O
she O
was O
described O
as O
having O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerking I-HPO_TERM
of O
her O
bilateral O
upper O
ex O
##tre O
##mit O
##ies O
upon O
arrival O
to O
the O
intensive O
care O
unit O
she O
had O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
jerking I-HPO_TERM
she O
was O
treated O
with O
anti O
##ep O
##ile O
##ptic O
drugs O
and O
int O
##uba O
##ted O
the O
initial O
evaluation O
revealed O
a O
weight O
greater O
than O
2 O
standard O
deviation O
##s O
below O
the O
mean O
with O
height O
and O
head O
ci O
##rc O
##um O
##ference O
measurements O
in O
the O
40th O
and O
25th O
percent O
##ile O
##s O
respectively O
the O
initial O
laboratory O
and O
ne O
##uro O
##ima O
##ging O
studies O
were O
un O
##re O
##ve O
##aling O
for O
infectious O
inflammatory O
or O
metabolic O
causes O
ce O
##re O
##bro O
##sp O
##inal O
fluid O

revealed O
an O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
of O
4 O
0 O
me O
##q O
l O

a O
trend O
electro B-HPO_TERM
##ence I-HPO_TERM
##pha I-HPO_TERM
##logram I-HPO_TERM
showed I-HPO_TERM
persistent I-HPO_TERM
generalized I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##pt I-HPO_TERM
##iform I-HPO_TERM
discharge I-HPO_TERM
##s I-HPO_TERM
and O
anti O
##ep O
##ile O
##ptic O
therapy O
was O
escalated O
to O
the O
point O
of O
pen O
##to O
##bar O
##bit O
##al O
suppression O
val O
##pro O
##ate O
was O
deliberately O
avoided O
because O
of O
a O
concern O
for O
a O
possible O
mitochondrial O
et O
##iology O
of O
disease O
the O
patient O
ultimately O
responded O
to O
multi O
##dr O
##ug O
therapy O
that O
included O
the O
ke O
##to O
##genic O
diet O
after O
ex O
##tub O
##ation O
the O
patient O
was O
severely B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
and O
unable O
to O
communicate O
feed O
or O
dress O
herself O
she O
had O
persistent O
episodes O
of O
as B-HPO_TERM
##ym I-HPO_TERM
##metric I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
activity O
of O
the O
upper O
ex O
##tre O
##mit O
##ies O
that O
did O
not O
correspond O
with O
an O
el O
##ec O

from O
the O
division O
of O
child O
ne O
##uro O
##logy O
barrow O
neurological O
institute O
and O
st O
joseph O
s O
hospital O
and O
medical O
center O
phoenix O
az O
address O
reprint O
requests O
to O
javier O
f O
card O
##enas O
md O
500 O
west O
thomas O
road O
suite O
400 O
phoenix O
az O
850 O
##13 O
e O
mail O
javier O
card O
##enas O
ch O
##w O
ed O
##u O
tr O
##oe O
##nce O
##pha O
##log O
##raphic O
change O
repeated O
ne O
##uro O
##ima O
##ging O
revealed O
global O
cerebral B-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
involving O
both O
the O
cortex O
and O
basal B-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
fig O
1 O

the O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
disease I-HPO_TERM
was O
finalized O
based O
on O
muscle O
bio O
##psy O
and O
genetic O
testing O
electron O
microscopy O
showed O
reduced B-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
with O
abnormal B-HPO_TERM
cr I-HPO_TERM
##ista I-HPO_TERM
##e I-HPO_TERM
and I-HPO_TERM
va I-HPO_TERM
##cu I-HPO_TERM
##oli I-HPO_TERM
##zation I-HPO_TERM
fig O
2 O
mitochondrial O
analysis O
revealed O
a O
dna O
polymer B-GENE
##ase I-GENE
gamma I-GENE
##1 I-GENE
pol B-GENE
##g I-GENE
het O
##ero O
##zy O
##go O
##us O
mutation O
a O
previously O
reported O
c B-GENE
##9 I-GENE
##11 I-GENE
##t I-GENE
g I-GENE
p B-GENE
l I-GENE
##30 I-GENE
4 I-GENE
##r I-GENE
mutation O
was O
accompanied O
by O
an O
unknown O
mutation B-GENE
c I-GENE
117 I-GENE
##4 I-GENE
##c I-GENE
g I-GENE
pl B-GENE
##39 I-GENE
2 I-GENE
##v I-GENE
and O
a O
324 B-GENE
##0 I-GENE
324 I-GENE
##2 I-GENE
du I-GENE
##plication I-GENE
pr B-GENE
##10 I-GENE
##8 I-GENE
##1 I-GENE
##du I-GENE
##p I-GENE
parental O
testing O
revealed O
paternal O
presence O
of O
the O
known O
mutation O
and O
the O
existence O
of O
both O
unknown O
pol O
##g O
mutations O
in O
the O
mother O

the O
patient O
was O
discharged O
after O
prolonged O
hospital O
##ization O
she O
remained O
at O
home O
for O
several O
weeks O
with O
continuous O
care O
but O
was O
read O
##mit O
##ted O
with O
coa B-HPO_TERM
##gul I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
and O
elevated B-HPO_TERM
liver I-HPO_TERM
enzymes I-HPO_TERM
her O
seizures B-HPO_TERM
returned O
and O
she O
was O
found O
to O
be O
unable O
to O
make O
ke O
##tones O
in O
her O
urine O
she O
died B-HPO_TERM
approximately I-HPO_TERM
5 I-HPO_TERM
months I-HPO_TERM
after I-HPO_TERM
her O
initial O
presentation O
al O
##pers O
disease O

al O
##pers O
disease O
also O
known O
as O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
and O
progressive O
ne O
##uron O
##al O
de O
##gen O
##eration O
of O
childhood O
with O
liver O
disease O
was O
initially O
described O
by O
bernard O
al O
##pers O
in O
1931 O
1 O
3 O
he O
detailed O
the O
ne O
##uro O
##path O
##ological O
de O
##gen O
##eration O
of O
cerebral O
gray O
matter O
in O
a O
4 O
month O
old O
female O
with O
intra O
##ctable O
ep O
##ile O
##psy O
1 O
hut O
##ten O
##lo O
##cher O
et O
al O
##3 O
reported O
similar O
path O
##olo O
##gic O
findings O
in O
2 O
children O
who O
also O
developed O
liver O
failure O
and O
death O
by O
3 O
years O
of O
age O
in O
1976 O
3 O
harding O
##2 O
detailed O
the O
ce O
##re O
62 O
107 O
##1 O
90 O
##9 O
##1 O
10 O
see O
front O
matter O
2010 O
else O
##vier O
inc O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
sp O
##en O
2010 O
02 O
01 O
##2 O

diagnosis O
it O
is O
common O
for O
a O
patient O
with O
my O
##opa O
##thy O
to O
show O
liver O
enzyme O
abnormalities O
therefore O
it O
is O
important O
to O
check O
muscle O
enzymes O
in O
patients O
when O
the O
diagnosis O
and O
cause O
of O
abnormal O
liver O
enzymes O
is O
uncertain O

in O
conclusion O
we O
have O
demonstrated O
the O
absence O
of O
lamp O
2 O
expression O
in O
skeletal O
muscles O
from O
a O
female O
patient O
with O
early O
onset O
over O
##t O
pro O
##xi O
##mal O
weakness O
many O
va O
##cu O
##olate O
##d O
ﬁ O
##bers O
and O
a O
de O
novo O
novel O
mutation O
in O
the O
lamp O
##2 O
gene O
we O
strongly O
suggest O
that O
the O
pathogen O
##esis O
of O
pro O
##xi O
##mal O
weakness O
is O
more O
related O
to O
auto O
##pha O
##gic O
va O
##cu O
##oles O
than O
primary O
lamp O
2 O
expression O
we O
also O
believe O
that O
there O
may O
be O
other O
factors O
that O
cause O
card O
##iom O
##yo O
##pathy O
in O
dan O
##on O
disease O

this O
study O
was O
supported O
by O
a O
grant O
from O
the O
korea O
healthcare O
technology O
r O
d O
project O
ministry O
for O
health O
welfare O
and O
family O
affairs O
republic O
of O
korea O
grant O
no O
a O
##0 O
##80 O
##58 O
##8 O
the O
authors O
thank O
mis O
##un O
park O
for O
her O
english O
correction O
of O
the O
manuscript O
references O
ni O
##shin O
##o O
i O
fu O
j O
tank O
##i O
k O
ya O
##mada O
t O
shi O
##mo O
##jo O
s O
ko O
##or O
##l O
t O
et O
al O
primary O
lamp O
2 O
de O
##ﬁ O
##ciency O
causes O
x O
linked O
va O
##cu O
##olar O
card O
##iom O
##yo O
##pathy O
and O
my O
##opa O
##thy O
dan O
##on O
disease O
nature O
2000 O
406 O
90 O
##6 O
910 O
ni O
##shin O
##o O
i O
auto O
##pha O
##gic O
va O
##cu O
##olar O
my O
##opa O
##thy O
semi O
##n O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2006 O
13 O
90 O
95 O

su O
##gie O
k O
no O
##guchi O
s O
ko O
##zuka O
y O
ari O
##kawa O
hi O
##ras O
##awa O
e O
tanaka O
m O
yan O
c O
et O
al O
auto O
##pha O
##gic O
va O
##cu O
##oles O
with O
sar O
##col O
##em O
##mal O
features O
del O
##ine O
##ate O
dan O
##on O
disease O
and O
related O
my O
##opa O
##thi O
##es O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2005 O
64 O
51 O
##3 O
52 O
##2 O
mali O
##cd O
##an O
mc O
no O
##guchi O
s O
non O
##aka O
i O
sa O
##ft O
##ig O
p O
ni O
##shin O
##o O
i O
l O
##ys O
##osomal O
my O
##opa O
##thi O
##es O
an O
excessive O
build O
up O
in O
auto O
##pha O
##gos O
##ome O
##s O
is O
too O
much O
to O
handle O
ne O
##uro O
##mus O
##c O
di O
##sor O
##d O
2008 O
18 O
521 O
52 O
##9 O
su O
##gie O
k O
yamamoto O
a O
mu O
##raya O
##ma O
bs O
oh O
s O
##j O
takahashi O
m O
mora O
m O
et O
al O
clinic O
##opa O
##th O
##ological O
features O
of O
genetically O
con O
##ﬁ O
##rmed O
dan O
##on O
disease O
ne O
##uro O
##logy O
2002 O
58 O
1773 O
1778 O

fan O
##in O
m O
nas O
##ci O
##mbe O
##ni O
ac O
fu O
##li O
##zio O
l O
spin O
##az O
##zi O
m O
mel O
##ac O
##ini O
p O
angel O
##ini O
c O
generalized O
l O
##ys O
##oso O
##me O
associated O
membrane O
protein O
2 O
defect O
explains O
multi O
##sy O
##ste O
##m O
clinical O
involvement O
and O
allows O
le O
##uk O
##oc O
##yte O
diagnostic O
screening O
in O
dan O
##on O
disease O
am O
j O
path O
##ol O
2006 O
168 O
130 O
##9 O
132 O
##0 O
su O
##gie O
k O
ko O
##ori O
t O
yamamoto O
a O
og O
##awa O
m O
hi O
##rano O
m O
in O
##oue O
k O
et O
al O
characterization O
of O
dan O
##on O
disease O
in O
a O
male O
patient O
and O
his O
affected O
mother O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2003 O
13 O
70 O
##8 O
71 O
##1 O

byrne O
e O
den O
##nett O
x O
cr O
##ott O
##y O
b O
tr O
##oun O
##ce O
i O
sands O
j O
##m O
hawkins O
r O
et O
al O
dominant O
##ly O
inherited O
card O
##ios O
##kel O
##eta O
##l O
my O
##opa O
##thy O
with O
l O
##ys O
##osomal O
g O
##ly O
##co O
##gen O
storage O
and O
normal O
acid O
malta O
##se O
levels O
brain O
1986 O
109 O
52 O
##3 O
53 O
##6 O
d O
##wo O
##rza O
##k O
f O
casa O
##zza O
f O
mora O
m O
de O
maria O
r O
gr O
##onda O
e O
bar O
##old O
##i O
g O
et O
al O
l O
##ys O
##osomal O
g O
##ly O
##co O
##gen O
storage O
with O
normal O
acid O
malta O
##se O
a O
fa O
##mi O
##lia O
##l O
study O
with O
successful O
heart O
transplant O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
1994 O
4 O
243 O
247 O

t O
guerrero O
d O
ur O
##cha O
##ga O
a O
ni O
##shin O
##o O
i O
a O
##yu O
##so O
t O
mats O
##uda O
y O
et O
al O
dan O
##on O
disease O
a O
novel O
lamp O
2 O
gene O
mutation O
in O
a O
family O
with O
four O
affected O
members O
ne O
##uro O
##mus O
##c O
di O
##sor O
##d O
2008 O
18 O
167 O
174 O
tanaka O
y O
gu O
##hd O
##e O
g O
su O
##ter O
a O
es O
##kel O
##inen O
el O
hartman O
##n O
d O
lu O
##¨ O
ll O
##mann O
##ra O
##uch O
r O
et O
al O
accumulation O
of O
auto O
##pha O
##gic O
va O
##cu O
##oles O
and O
card O
##iom O
##yo O
##pathy O
in O
lamp O
2 O
de O
##ﬁ O
##cie O
##nt O
mice O
nature O
2000 O
406 O
90 O
##2 O
90 O
##6 O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
in O
late O
life O
due O
to O
compound O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
mutations O
michael O
d O
weiss O
md O
1 O
and O
russell O
p O
sane O
##to O
do O
phd O
##2 O

1 O
department O
of O
ne O
##uro O
##logy O
university O
of O
washington O
medical O
center O
box O
356 O
##11 O
##5 O
1959 O
ne O
pac O
##i O
##ﬁ O
##c O
street O
seattle O
washington O
98 O
##19 O
##5 O
usa O
2 O
division O
of O
pediatric O
ne O
##uro O
##logy O
seattle O
children O
s O
hospital O
seattle O
washington O
usa O
accepted O
24 O
november O
2009 O

abstract O
miss O
##ense O
mutations O
in O
the O
gene O
for O
polymer O
##ase O
c O
1 O
pol O
##g O
##1 O
cause O
a O
number O
of O
ph O
##eno O
##typical O
##ly O
het O
##ero O
##gen O
##eous O
mitochondrial O
diseases O
most O
commonly O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
are O
characterized O
by O
the O
accumulation O
of O
multiple O
large O
scale O
del O
##eti O
##ons O
of O
mitochondrial O
dna O
the O
triad O
of O
sensory B-HPO_TERM
ata I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
sand O
##o O
has O
been O
demonstrated O
in O
a O
small O
subset O
of O
patients O
with O
pol O
##g O
##1 O
mutations O
we O
report O
a O
sporadic O
case B-PATIENT
of O
an O
80 O
year O
old O
compound O
het O
##ero O
##zy O
##go O
##te O
man O
who O
presented O
with O
sand B-HPO_TERM
##o I-HPO_TERM
and O
was O
found O
to O
have O
three O
known O
pathogen O
##ic O
mutations O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
to O
our O
knowledge O
none O
of O
these O
mutations O
have O
been O
demonstrated O
previously O
in O
sand O
##o O
this O
patient O
s O
late O
presentation O
illustrates O
that O
a O
mitochondrial O
disorder O
should O
be O
considered O
regardless O
of O
age O
if O
the O
clinical O
symptoms O
warrant O

muscle O
nerve O
41 O
88 O
##2 O
88 O
##5 O
2010 O
abbreviation O
##s O
ana O
anti O
##nu O
##cle O
##ar O
antibodies O
ant O
##1 O
aden O
##ine O
nu O
##cle O
##otide O
trans O
##lo O
##cat O
##or O
1 O
cox O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
em O
##g O
electro O
##my O
##ography O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
mira O
##s O
mitochondrial O
ata O
##xi O
##c O
syndrome O
without O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
mt O
##dna O
mitochondrial O
dna O
pol O
##g O
##1 O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
sand O
##o O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
snap O
sensory O
nerve O
action O
potential O
key O
words O
d O
##ys O
##arth O
##ria O
polymer O
##ase O
c O
mitochondrial O
my O
##opa O
##thy O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O

correspondence O
to O
m O
d O
weiss O
e O
mail O
md O
##wei O
##ss O
u O
washington O
ed O
##u O
vc O
2010 O
wiley O
periodicals O
inc O
published O
online O
15 O
may O
2010 O
in O
wiley O
inter O
##sc O
##ience O
www O
inter O
##sc O
##ience O
wiley O
com O
doi O
10 O
100 O
##2 O
mu O
##s O
216 O
##36 O

mutations O
in O
polymer O
##ase O
c O
1 O
pol O
##g O
##1 O
lead O
to O
a O
number O
of O
mitochondrial O
disease O
ph O
##eno O
##type O
##s O
associated O
with O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
such O
mutations O
present O
clinical O
##ly O
in O
a O
het O
##ero O
##gen O
##eous O
manner O
and O
include O
both O
auto O
##som O
##al O
dominant O
and O
recess O
##ive O
forms O
of O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
mitochondrial O
ata O
##xi O
##c O
syndrome O
without O
opt O
##hal O
##mo O
##ple O
##gia O
mira O
##s O
and O
the O
clinical O
triad O
of O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
1 O
2 O
there O
is O
no O
spec O
##i O
##ﬁ O
##c O
treatment O
for O
diseases O
related O
to O
pol O
##g O
##1 O
mutations O
although O
val O
##pro O
##ic O
acid O
is O
contra O
##ind O
##icated O
as O
it O
may O
pre O
##ci O
##pate O
fu O
##lm O
##ina O
##nt O
liver O
disease O
only O
a O
few O
cases O
of O
sand O
##o O
associated O
with O
pol O
##g O
##1 O
mutations O
have O
been O
reported O
3 O
8 O
we O
report O
a O
case B-PATIENT
of O
sand B-HPO_TERM
##o I-HPO_TERM
associated O
with O
known O
pathogen O
##ic O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
that O
presented O
in O
late O
life O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##te O
male O

case B-PATIENT
report O
an O
80 B-AGE_ONSET
year I-AGE_ONSET
old I-AGE_ONSET
man I-AGE_ONSET
presented I-AGE_ONSET
with I-AGE_ONSET
a I-AGE_ONSET
7 I-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
progressively B-HPO_TERM
dr I-HPO_TERM
##oop I-HPO_TERM
##y I-HPO_TERM
eyelids I-HPO_TERM
a O
4 O
year O
history O
of O
double B-HPO_TERM
vision I-HPO_TERM
and O
3 O
years O
of O
an O
increasingly B-HPO_TERM
nasal I-HPO_TERM
88 O
##2 O
sand O
##o O
from O
pol O
##g O
mutations O
muscle O
nerve O
june O
2010 O

figure O
1 O
left O
del O
##to O
##id O
muscle O
bio O
##psy O
a O
modified O
go O
##mori O
tri O
##chrome O
stain O
##ing O
reveals O
a O
single O
ragged B-HPO_TERM
red I-HPO_TERM
fiber I-HPO_TERM
arrow O
b O
two O
ragged B-HPO_TERM
blue I-HPO_TERM
fibers I-HPO_TERM
are O
noted O
with O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
stain O
##ing O
arrows O
c O
a O
number O
of O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
negative I-HPO_TERM
fibers I-HPO_TERM
are O
shown O
arrows O
d O
on O
ultra O
##st O
##ru O
##ct O
##ural O
analysis O
para B-HPO_TERM
##cr I-HPO_TERM
##yst I-HPO_TERM
##all I-HPO_TERM
##ine I-HPO_TERM
parking I-HPO_TERM
lot I-HPO_TERM
inclusion I-HPO_TERM
##s I-HPO_TERM
are I-HPO_TERM
noted I-HPO_TERM
within I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
arrows O
as O
are O
me O
##mb O
##rano O
##us O
w O
##hir O
##ls O
as O
##ter O
##isk O
and O
debris O

voice O
as O
well O
as O
more O
recent O
ga B-HPO_TERM
##it I-HPO_TERM
instability I-HPO_TERM
with O
near B-HPO_TERM
falls I-HPO_TERM
and O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
arm I-HPO_TERM
weakness I-HPO_TERM
he O
denied O
any O
family O
history O
of O
a O
similar O
disorder O
a O
previous O
work O
##up O
earlier O
in O
the O
year O
by O
another O
physician O
had O
included O
negative O
ser O
##olo O
##gic O
and O
electro O
##phy O
##sio O
##logic O
testing O
for O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
along O
with O
normal O
but O
limited O
needle O
electro O
##my O
##ography O
a O
bio O
##psy O
of O
the O
left O
del O
##to O
##id O
muscle O
demonstrated O
non O
##sp O
##ec O
##i O
##ﬁ O
##c O
changes O
including O
ﬁ B-HPO_TERM
##ber I-HPO_TERM
size I-HPO_TERM
variability I-HPO_TERM
and O
central B-HPO_TERM
nuclei I-HPO_TERM
there O
were O
also O
ragged B-HPO_TERM
red I-HPO_TERM
and O
ragged B-HPO_TERM
blue I-HPO_TERM
su I-HPO_TERM
##cci I-HPO_TERM
##nate I-HPO_TERM
de I-HPO_TERM
##hy I-HPO_TERM
##dro I-HPO_TERM
##genase I-HPO_TERM
positive I-HPO_TERM
ﬁ I-HPO_TERM
##bers I-HPO_TERM
in O
about O
3 O
and O
6 O
of O
all O
muscle O
ﬁ O
##bers O
respectively O
both O
sign O
##ifying O
increased O
mitochondrial O
numbers O
and O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bers I-HPO_TERM
in O
about O
6 O
of O
all O
ﬁ O
##bers O
there O
were O
also O
ultra O
##st O
##ru O
##ct O
##ural O
changes O
of O
abnormal B-HPO_TERM
##ly I-HPO_TERM
swollen I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
and I-HPO_TERM
para I-HPO_TERM
##cr I-HPO_TERM
##yst I-HPO_TERM
##all I-HPO_TERM
##ine I-HPO_TERM
inclusion I-HPO_TERM
##s I-HPO_TERM
fig O
1 O
respiratory O
chain O
complex O
activity O
showed O
an O
increase B-HPO_TERM
in I-HPO_TERM
ci I-HPO_TERM
##tra I-HPO_TERM
##te I-HPO_TERM
synth I-HPO_TERM
##ase I-HPO_TERM
levels I-HPO_TERM
consistent O
with O
increased B-HPO_TERM
mitochondrial I-HPO_TERM
content I-HPO_TERM
but O
it O
was O
otherwise O
normal O

on O
ne O
##uro O
##logic O
examination O
at O
presentation O
the O
patient O
had O
moderate O
to O
severe B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
lateral B-HPO_TERM
rec I-HPO_TERM
##tus I-HPO_TERM
pal I-HPO_TERM
##sies I-HPO_TERM
with O
associated O
horizontal O
dip B-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
his O
also O
had O
a O
moderately O
severe O
nasal B-HPO_TERM
ﬂ I-HPO_TERM
##ac I-HPO_TERM
##ci I-HPO_TERM
##d I-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
moderate B-HPO_TERM
facial I-HPO_TERM
weakness I-HPO_TERM
and O
mild O
tongue B-HPO_TERM
weakness I-HPO_TERM
without O
any O
at O
##rop O
##hy O
his O
power B-HPO_TERM
was I-HPO_TERM
reduced I-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
del I-HPO_TERM
##to I-HPO_TERM
##id I-HPO_TERM
muscles I-HPO_TERM
4 O
##þ O
5 O
medical O
research O
council O
scale O
but O
was O
other O

wise O
5 O
5 O
his O
sensory O
examination O
showed O
mild B-HPO_TERM
stock I-HPO_TERM
##ing I-HPO_TERM
loss I-HPO_TERM
to I-HPO_TERM
light I-HPO_TERM
touch I-HPO_TERM
and O
pin O
prick O
absent B-HPO_TERM
vi I-HPO_TERM
##bra I-HPO_TERM
##tory I-HPO_TERM
sensation I-HPO_TERM
and O
impaired B-HPO_TERM
joint I-HPO_TERM
position I-HPO_TERM
sense I-HPO_TERM
at O
the O
toes O
and O
decreased B-HPO_TERM
vi I-HPO_TERM
##bra I-HPO_TERM
##tory I-HPO_TERM
sensation I-HPO_TERM
at O
the O
ankles O
he O
had O
a O
positive B-HPO_TERM
rom I-HPO_TERM
##berg I-HPO_TERM
sign I-HPO_TERM
his O
deep B-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
absent I-HPO_TERM
at I-HPO_TERM
the I-HPO_TERM
ankles I-HPO_TERM
his O
ga B-HPO_TERM
##it I-HPO_TERM
was I-HPO_TERM
mildly I-HPO_TERM
wide I-HPO_TERM
based I-HPO_TERM

repeat O
nerve O
conduct O
##ion O
studies O
of O
the O
right O
arm O
and O
leg O
demonstrated O
absent B-HPO_TERM
right I-HPO_TERM
sur I-HPO_TERM
##al I-HPO_TERM
and I-HPO_TERM
per I-HPO_TERM
##one I-HPO_TERM
##al I-HPO_TERM
sensory I-HPO_TERM
nerve I-HPO_TERM
action I-HPO_TERM
potential I-HPO_TERM
##s I-HPO_TERM
snap O
and O
a O
moderately O
reduced B-HPO_TERM
super I-HPO_TERM
##ﬁ I-HPO_TERM
##cial I-HPO_TERM
radial I-HPO_TERM
snap I-HPO_TERM
amplitude O
of O
7 O
l O
##v O
normal O
12 O
l O
##v O
with O
a O
normal O
conduct O
##ion O
velocity O
of O
63 O
m O
s O
consistent O
with O
a O
sensory B-HPO_TERM
ax I-HPO_TERM
##ono I-HPO_TERM
##pathy I-HPO_TERM
right O
per O
##one O
##al O
motor O
nerve O
conduct O
##ion O
and O
minimum O
f O
wave O
late O
##ncies O
were O
normal O
needle O
electro O
##my O
##ographic O
em O
##g O
study O
of O
the O
right O
arm O
and O
leg O
demonstrated O
an O
excess O
of O
low O
amplitude O
short O
duration O
occasionally O
poly O
##pha O
##sic O
motor O
unit O
action O
potential O
##s O
without O
ﬁ O
##bri O
##llation O
potential O
##s O
or O
positive O
sharp O
waves O
and O
early O
recruitment O
in O
the O
right O
il O
##iac O
##us O
and O
biceps O
bra O
##chi O
##i O
muscles O
consistent O
with O
a O
non B-HPO_TERM
ir I-HPO_TERM
##rita I-HPO_TERM
##tive I-HPO_TERM
my I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
involving I-HPO_TERM
the I-HPO_TERM
pro I-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
limbs I-HPO_TERM
quantitative O
motor O
unit O
analysis O
was O
performed O
on O
the O
right O
orb O
##icular O
##is O
or O
##is O
muscle O
employing O
the O
technique O
described O
by O
far O
##rug O
##ia O
and O
ken O
##nett O
9 O
it O
showed O
a O
mean O
motor O
unit O
action O
potential O
duration O
of O
3 O
5 O
ms O
normal O
range O
7 O
2 O
11 O
0 O
ms O
which O
was O
indicative O
of O
my B-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
involving I-HPO_TERM
the I-HPO_TERM
facial I-HPO_TERM
muscles I-HPO_TERM

sand O
##o O
from O
pol B-GENE
##g I-GENE
mutations O
muscle O
nerve O
june O
2010 O
88 O
##3 O
figure O
2 O
location O
of O
miss O
##ense O
mutations O
in O
the O
polymer O
##ase O
c O
gene O
in O
sand O
##o O
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##i I-GENE_VARIANT
##1 I-GENE_VARIANT
and O
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
mutations O
were O
identified O
in O
cis O
in O
the O
ex O
##on O
##uc O
##lea O
##se O
motif O
and O
link O
##er O
regions O
of O
the O
gene O
respectively O
in O
addition O
the O
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
was O
found O
in O
the O
polymer O
##ase O
motif O
these O
mutations O
have O
been O
seen O
in O
other O
mitochondrial O
ph O
##eno O
##type O
##s O
such O
as O
al O
##pers O
syndrome O
and O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
both O
individually O
and O
in O
combination O
but O
not O
with O
sand O
##o O
courtesy O
of O
dr O
robert O
na O
##via O
##ux O

the O
patient B-PATIENT
had O
a O
normal O
metabolic O
panel O
liver O
function O
pro O
##ﬁ O
##le O
sediment O
##ation O
rate O
thyroid O
function O
vitamin O
b1 O
##2 O
methyl O
##mal O
##onic O
acid O
serum O
protein O
and O
im O
##mun O
##o O
##ﬁ O
##xa O
##tion O
electro O
##ph O
##ores O
##is O
serum O
amino O
acid O
urine O
organic O
pro O
##ﬁ O
##le O
lac O
##tic O
acid O
ammonia O
and O
cr O
##ea O
##tine O
ph O
##os O
##ph O
##oki O
##nas O
##e O
and O
negative O
antibodies O
to O
extract O
##able O
nuclear O
antigen O
and O
to O
ro O
and O
la O
he O
had O
a O
mildly B-HPO_TERM
elevated I-HPO_TERM
g I-HPO_TERM
##ly I-HPO_TERM
##cos I-HPO_TERM
##yla I-HPO_TERM
##ted I-HPO_TERM
hem I-HPO_TERM
##og I-HPO_TERM
##lo I-HPO_TERM
##bin I-HPO_TERM
level I-HPO_TERM
of O
6 O
2 O
and O
positive B-HPO_TERM
anti I-HPO_TERM
##nu I-HPO_TERM
##cle I-HPO_TERM
##ar I-HPO_TERM
antibodies I-HPO_TERM
ana O
of O
1 O
160 O
showing O
a O
spec O
##kled O
pattern O
his O
free B-HPO_TERM
car I-HPO_TERM
##ni I-HPO_TERM
##tine I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
mildly I-HPO_TERM
elevated I-HPO_TERM
at O
67 O
2 O
l O
##mo O
##l O
l O
normal O
16 O
65 O
l O
##mo O
##l O
l O
short B-HPO_TERM
chain I-HPO_TERM
ac I-HPO_TERM
##yl I-HPO_TERM
car I-HPO_TERM
##ni I-HPO_TERM
##tine I-HPO_TERM
level I-HPO_TERM
moderately I-HPO_TERM
increased I-HPO_TERM
at O
46 O
1 O
l O
##mo O
##l O
l O
normal O
1 O
24 O
l O
##mo O
##l O
l O
and O
ac O
##yl O
free O
ratio O
modest O
##ly O
increased O
at O
0 O
73 O
l O
##mo O
##l O
l O
normal O
0 O
7 O
l O
##mo O
##l O
l O
testing O
of O
the O
genes O
for O
poly O
##ade O
##ny O
##late O
binding O
protein O
nuclear O
1 O
for O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
ant O
##1 O
and O
twinkle O
pe O
##o O
##1 O
demonstrated O
normal O
coding O
sequences O
direct O
sequencing O
of O
the O
coding O
ex O
##ons O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
showed O
that O
the O
patient O
had O
three O
known O
del O
##eter O
##ious O
het O
##ero O
##zy O
##go O
##us O
miss O
##ense O
mutations O
c B-GENE_VARIANT
75 I-GENE_VARIANT
##2 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
c I-GENE_VARIANT
1760 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p O
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
and O
c B-GENE_VARIANT
254 I-GENE_VARIANT
##2 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
p O
g B-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
located O
in O
ex O
##ons O
2 O
9 O
and O
15 O
respectively O
all O
have O
previously O
been O
associated O
with O
disease O
fig O
2 O

mit O
##och O
##ond O
##rion O
11 O
2011 O
223 O
227 O
short O
communication O
pol B-GENE
##g I-GENE
ex O
##on O
22 O
skipping O
induced O
by O
different O
mechanisms O
in O
two O
unrelated O
cases O
of O
al O
##pers O
syndrome O
benedict O
##e O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
a O
mai O
##te O
cha O
##ssa O
##gne O
a O
martin O
##e O
may O
##en O
##con O
a O
sylvie O
pad O
##et O
a O
her O
##ve O
cr O
##eh O
##ale O
##t O
b O
pascal O
##e O
cl O
##er O
##c O
ren O
##aud O
a O
isabelle O
ro O
##uve O
##t O
c O
marie O
therese O
za O
##bot O
c O
francois O
ri O
##vier O
d O
pierre O
sar O
##da O
e O
vincent O
des O
porte O
##s O
f O
dominique O
bo O
##zon O
b O
a O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
service O
des O
mala O
##dies O
here O
##dit O
##aire O
##s O
du O
metabolism O
##e O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O

b O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
unite O
de O
card O
##io O
##gen O
##eti O
##que O
mole O
##cula O
##ire O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
c O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
centre O
de O
bio O
##tech O
##no O
##logie O
cell O
##ula O
##ire O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
d O
hop O
##ital O
gui O
de O
cha O
##ulia O
##c O
service O
de O
ne O
##uro O
##ped O
##ia O
##tri O
##e O
chu O
montpellier O
34 O
##29 O
##5 O
montpellier O
france O
e O
hop O
##ital O
ar O
##naud O
de O
ville O
##neuve O
service O
de O
gene O
##tique O
medical O
##e O
chu O
montpellier O
34 O
##29 O
##5 O
montpellier O
france O
f O
hop O
##ital O
femme O
mere O
en O
##fan O
##t O
service O
de O
ne O
##uro O
##logie O
pe O
##dia O
##tri O
##que O
and O
universite O
lyon O
1 O
chu O
lyon O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O

received O
30 O
march O
2010 O
received O
in O
revised O
form O
29 O
june O
2010 O
accepted O
23 O
july O
2010 O
available O
online O
4 O
august O
2010 O
key O
##words O
pol O
##g O
variation O
al O
##pers O
syndrome O
rna O
sp O
##lic O
##ing O
ex O
##on O
skipping O
dna O
polymer O
##ase O
γ O
a O
b O
s O
t O
r O
a O
c O
t O

the O
pol O
##g O
genes O
were O
sequence O
##d O
in O
two O
unrelated O
patients O
presenting O
with O
al O
##pers O
syndrome O
the O
novel O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
c O
36 O
##43 O
2 O
##t O
##n O
c O
all O
##eles O
were O
associated O
in O
trans O
with O
p O
a O
##46 O
##7 O
##t O
and O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
respectively O
pol B-GENE
##g I-GENE
transcript O
##s O
from O
skin O
ﬁ O
##bro O
##bla O
##sts O
showed O
complete O
ex B-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
2 I-PATIENT
but O
surprisingly O
partial B-GENE_VARIANT
ex I-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
from O
the O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
for O
patient B-PATIENT
1 I-PATIENT
the O
creation O
of O
a O
put O
##ative O
ex O
##onic O
sp O
##lic O
##ing O
silence O
##r O
could O
be O
responsible O
for O
the O
sp O
##lic O
##ing O
anomaly O
observed O
in O
patient O
1 O
both O
c O
36 O
##43 O
2 O
##t O
##nc O
and O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
create O
a O
premature O
termination O
cod O
##on O
and O
a O
low O
polymer O
##ase O
γ O
activity O
in O
skin O
ﬁ O
##bro O
##bla O
##sts O
is O
responsible O
for O
the O
severe O
ph O
##eno O
##type O
in O
these O
patients O

2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
introduction O

al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
ah O
##s O
om O
##im O
203 O
##70 O
##0 O
is O
a O
rare O
auto O
##som O
##al O
recess O
##ive O
disease O
associated O
with O
mitochondrial O
mt O
dna O
de O
##ple O
##tion O
and O
mutations O
in O
the O
pol O
##g O
gene O
ah O
##s O
is O
usually O
characterized O
by O
a O
clinical O
te O
##tra O
##d O
of O
psycho O
##moto O
##r O
regression O
intra O
##ctable O
ep O
##ile O
##psy O
co O
##rti O
##cal O
blindness O
and O
liver O
disease O
in O
infants O
and O
young O
children O
harding O
1990 O
na O
##via O
##ux O
and O
nguyen O
2004 O
kurt O
et O
al O
2010 O
replication O
of O
mt O
##dna O
involves O
a O
complex O
machinery O
called O
mt O
##dna O
rep O
##lis O
##ome O
including O
the O
mt O
##dna O
polymer O
##ase O
γ O
pol O
γ O
and O
the O
twinkle O
he O
##lica O
##se O
far O
##ge O
et O
al O
2007 O
it O
was O
established O
that O
the O
ho O
##loe O
##nz O
##yme O
pol O
γ O
is O
a O
het O
##ero O
##tri O
##mer O
consisting O
of O
one O
catalytic O
pol O
##g O
##1 O
subunit O
and O
a O
homo O
##dim O
##er O
of O
the O
pol O
##g O
##2 O
accessory O
subunit O
ya O
##ku O
##bo O
##vs O
##kaya O
et O
al O
2007 O
recently O
the O
crystal O
structure O
of O
the O
human O
ho O
##loe O
##nz O
##yme O
pol O
γ O
has O
been O
reported O
providing O
a O
structural O
basis O
for O
understanding O
interactions O
between O
catalytic O
and O
accessory O
subunit O
##s O
lee O
et O
al O
2009 O

corresponding O
author O
service O
des O
mala O
##dies O
here O
##dit O
##aire O
##s O
du O
metabolism O
##e O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
group O
##ement O
hospital O
##ier O
est O
chu O
lyon O
59 O
boulevard O
pine O
##l O
69 O
##6 O
##7 O
##7 O
bro O
##n O
ce O
##de O
##x O
france O
tel O
33 O
4 O
72 O
12 O
96 O
82 O
fa O
##x O
33 O
4 O
72 O
12 O
97 O
20 O
e O
mail O
address O
benedict O
##e O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
chu O
lyon O
fr O
b O
mo O
##uss O
##on O
de O
cam O
##are O
##t O

the O
human O
pol O
##g O
also O
known O
as O
pol O
##g O
##1 O
or O
pol O
γ O
##a O
is O
localized O
on O
chromosome O
band O
15 O
##q O
##25 O
and O
spans O
nearly O
18 O
5 O
kb O
with O
23 O
ex O
##ons O
the O
44 O
##64 O
bp O
transcript O
nm O
00 O
##26 O
##9 O
##3 O
en O
##codes O
the O
123 O
##9 O
amino O
##ac O
##id O
pol O
##g O
##1 O
protein O
the O
mature O
protein O
is O
a O
135 O
k O
##da O
poly O
##pe O
##pt O
##ide O
composed O
of O
three O
functional O
domains O
an O
amino O
terminal O
3 O
5 O
ex O
##on O
##uc O
##lea O
##se O
ex O
##o O
domain O
responsible O
for O
the O
ﬁ O
##del O
##ity O
of O
mt O
##dna O
replication O
long O
##ley O
et O
al O
2001 O
a O
link O
##er O
domain O
and O
a O
car O
##box O
##y O
terminal O
polymer O
##ase O
pol O

domain O
ro O
##pp O
and O
copeland O
1996 O
le O
##cre O
##nier O
et O
al O
1997 O
the O
50 O
k O
##da O
pol O
##g O
##2 O
or O
pol O
γ O
##b O
subunit O
encoded O
by O
the O
pol O
##g O
##2 O
gene O
ch O
##r O
17 O
##q O
##21 O
acts O
as O
a O
process O
##ivity O
factor O
accelerating O
polymer O
##isation O
rate O
in O
addition O
to O
increasing O
af O
##ﬁ O
##nity O
of O
pol O
γ O
for O
dna O
lim O
et O
al O
1999 O
far O
##ge O
et O
al O
2007 O

human O
dna O
pol O
γ O
is O
known O
to O
be O
an O
effective O
in O
vitro O
reverse O
transcript O
##ase O
rna O
directed O
dna O
polymer O
##ase O
and O
a O
possible O
physiological O
role O
for O
this O
reverse O
transcript O
##ase O
activity O
has O
been O
suggested O
mu O
##rak O
##ami O
et O
al O
2003 O
the O
most O
sensitive O
ass O
##ays O
developed O
to O
date O
for O
the O
measurement O
of O
pol O
##g O
γ O
activity O
used O
homo O
##pol O
##yme O
##ric O
rna O
template O
##s O
clinical O
ass O
##ays O
were O
performed O
on O
mit O
##och O
##ond O
##ria O
isolated O
from O
skeletal O
muscle O
na O
##via O
##ux O
et O
al O
1999 O
or O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
ta O
##an O
##man O
et O
al O
2009 O
characterization O
of O
the O
enzyme O
has O
been O
assessed O
in O
vitro O
with O
pu O
##ri O
##ﬁ O
##ed O
or O
rec O
##om O
##bina O
##nt O
pol O
γ O
carr O
##ode O
##gua O
##s O
et O
al O
1999 O
far O
##r O
et O
al O
1999 O
lee O
and O
johnson O
2007 O
or O
in O
vivo O
by O
expressing O
a O
pol O
##g O
##1 O
fusion O
protein O
in O
human O
culture O
##d O
cells O
sp O
##el O
##bri O
##nk O
et O
al O
2000 O

156 O
##7 O
72 O
##49 O
see O
front O
matter O
2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
mit O
##o O
2010 O
07 O
01 O
##1 O
to O
date O
more O
than O
150 O
different O
pol O
##g O
variations O
have O
been O
reported O
in O
a O
broad O
range O
of O
clinical O
ph O
##eno O
##type O
##s O
in O
children O
and O
adults O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
ah O
##s O
is O
one O
of O
the O
six O
major O
groups O
of O
pol O
##g O
disease O
de O
##ﬁ O
##ned O
by O
wong O
et O
al O
2008 O

in O
this O
study O
we O
investigated O
pol O
##g O
in O
two O
unrelated O
patients O
presenting O
with O
infant B-AGE_ONSET
##ile I-AGE_ONSET
onset I-AGE_ONSET
ah O
##s O
a O
novel O
ga O
##ta O
du O
##plication O
in O
ex O
##on O
22 O
and O
a O
yet O
reported O
donor O
sp O
##lice O
site O
alteration O
in O
intro O
##n O
22 O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##ty O
with O
the O
most O
common O
variation O
p O
a O
##46 O
##7 O
##t O
and O
the O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
respectively O
for O
both O
patients O
cd O
##na O
study O
showed O
that O
both O
the O
ga O
##ta O
du O
##plication O
and O
the O
donor O
sp O
##lice O
site O
alteration O
cause O
a O
sp O
##lic O
##ing O
defect O
leading O
to O
partial O
or O
complete O
skipping O
of O
ex O
##on O
22 O
the O
mechanisms O
inducing O
ex O
##on O
22 O
skipping O
in O
these O
patients O
are O
discussed O

to O
ﬁ O
##nd O
out O
if O
these O
pol O
##g O
mutants O
could O
be O
responsible O
for O
the O
ah O
##s O
ph O
##eno O
##type O
we O
performed O
ass O
##ays O
of O
pol O
γ O
activity O
in O
mit O
##och O
##ond O
##ria O
from O
ﬁ O
##bro O
##bla O
##sts O
we O
showed O
a O
sign O
##i O
##ﬁ O
##can O
##t O
decrease O
of O
polymer O
##ase O
activity O
in O
organ O
##ello O
for O
both O
patients O
providing O
evidence O
that O
these O
pol O
##g O
variations O
affect O
enzyme O
cat O
##aly O
##sis O
and O
play O
a O
major O
role O
in O
the O
ah O
##s O
ph O
##eno O
##type O
subjects O
and O
methods O
case O
reports O
patient B-PATIENT
1 I-PATIENT

this B-PATIENT
girl I-PATIENT
was O
the O
second O
child O
of O
non O
con O
##san O
##gui O
##neo O
##us O
french O
parents O
with O
no O
clinical O
relevant O
family O
history O
height O
and O
weight O
growth B-PATIENT
decreased I-PATIENT
at O
6 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
at O
1 O
year O
of O
age O
she O
presented O
a O
rights B-HPO_TERM
##ided I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
resistant O
to O
multiple O
anti O
##ep O
##ile O
##ptic O
drugs O
car O
##ba O
##ma O
##ze O
##pine O
worsened O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
a O
ke O
##to O
##genic O
diet O
was O
well O
tolerated O
but O
was O
ineffective O
o O
##cci O
##pit O
##al O
frontal O
ci O
##rc O
##um O
##ference O
was O
normal O
ee O
##g O
showed O
sub B-HPO_TERM
##con I-HPO_TERM
##tin I-HPO_TERM
##uous I-HPO_TERM
discharge I-HPO_TERM
##s I-HPO_TERM
of I-HPO_TERM
ry I-HPO_TERM
##th I-HPO_TERM
##mic I-HPO_TERM
slow I-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
on I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
hemisphere I-HPO_TERM
related O
to O
right O
hand O
and O
foot O
cl O
##onic O
jerk O
##s O
brain O
magnetic O
resonance O
imaging O
mri O
at O
12 O
months O
of O
age O
was O
normal O
at O
the O
same O
time O
a O
dramatic O
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
regression I-HPO_TERM
was O
observed O
with O
poor B-HPO_TERM
interaction I-HPO_TERM
major O
global B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
no B-HPO_TERM
eye I-HPO_TERM
contact I-HPO_TERM
due O
to O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
mild O
lac B-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
##osis I-HPO_TERM
and O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
ratio I-HPO_TERM
were O
documented O
in O
blood O
lac O
##tate O
2 O
8 O
mm O
##ol O
l O

normal O
0 O
5 O
2 O
0 O
lac O
##tate O
p O
##yr O
##u O
##vate O
ratio O
31 O
normal O
b O
20 O
elevation B-HPO_TERM
of I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
ﬂ I-HPO_TERM
##uid I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
was O
noticed O
twice O
2 O
8 O
and O
2 O
2 O
mm O
##ol O
l O
normal O
1 O
4 O
2 O
0 O
cs O
##f O
protein O
content O
was O
normal O
content B-HPO_TERM
of I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
reduced I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
62 O
of O
age O
matched O
control O
mean O
with O
no O
major O
abnormalities O
of O
the O
mitochondrial O
respiratory O
chain O
activities O
a O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
was O
suggested O
in O
the O
following O
months O
her O
neurological O
condition O
evolved O
into O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM

reinforced O
by O
rec B-HPO_TERM
##urrent I-HPO_TERM
episodes I-HPO_TERM
of I-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
at O
16 O
months O
of O
age O
liver B-HPO_TERM
en I-HPO_TERM
##lar I-HPO_TERM
##gement I-HPO_TERM
was O
noticed O
associated O
with O
mild O
cy O
##to O
##lysis O
asa O
##t O
90 O
i O
##u O
l O
normal O
b O
50 O
and O
increased B-HPO_TERM
level I-HPO_TERM
of I-HPO_TERM
gamma I-HPO_TERM
g I-HPO_TERM
##lu I-HPO_TERM
##tam I-HPO_TERM
##yl I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
g O
##gt O
138 O
i O
##u O
l O
normal O
5 O
25 O
the O
pro B-HPO_TERM
##th I-HPO_TERM
##rom I-HPO_TERM
##bine I-HPO_TERM
time I-HPO_TERM
and I-HPO_TERM
the I-HPO_TERM
cl I-HPO_TERM
##otti I-HPO_TERM
##ng I-HPO_TERM
factors I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
ii O
36 O
v O
39 O
vii O
59 O
and O
pro O
##th O
##rom O
##bine O
time O
48 O
the O
patient O
died O
at O
27 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
of O
respiratory B-HPO_TERM
failure I-HPO_TERM
informed O
parental O
consent O
was O
obtained O
in O
agreement O
with O
the O
french O
recommendations O
for O
genetic O
analysis O
patient B-PATIENT
2 I-PATIENT

this O
boy B-PATIENT
was O
the O
ﬁ O
##rst O
child O
of O
healthy O
young O
unrelated O
french O
parents O
without O
relevant O
family O
history O
at O
16 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
he O
started O
a O
severe O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
cs B-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
0 O
78 O
g O
l O
normal O
0 O
15 O
0 O
35 O
cerebral O
mri O
showed O
brain B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
with O
symmetrical B-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
and I-HPO_TERM
flair I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
signals I-HPO_TERM
associated O
with O
cy B-HPO_TERM
##to I-HPO_TERM
##to I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
o I-HPO_TERM
##ede I-HPO_TERM
##ma I-HPO_TERM
within I-HPO_TERM
basal I-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
on O
diffusion O
sequences O
then O
he O
developed O
intra B-HPO_TERM
##ctable I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
associated O
with O
gene O
##r O

ali O
##zed O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
at O
24 O
months O
of O
age O
a O
new O
cerebral O
mri O
con O
##ﬁ O
##rmed O
brain B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
associated O
with O
marked O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
signals I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
dent I-HPO_TERM
##ate I-HPO_TERM
nuclei I-HPO_TERM
and O
of O
posterior O
per O
##ive O
##nt O
##ric O
##ular O
white O
matter O
at O
a O
less O
extent O
proton O
magnetic O
resonance O
spec B-HPO_TERM
##trom I-HPO_TERM
##et I-HPO_TERM
##ry I-HPO_TERM
revealed I-HPO_TERM
an I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
lac I-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
in I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
and O

per O
##ive O
##nt O
##ric O
##ular O
regions O
one O
month O
later O
a O
new O
acute O
episode O
occurred O
with O
diffuse B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
let B-HPO_TERM
##har I-HPO_TERM
##gy I-HPO_TERM
and O
vomiting B-HPO_TERM
lac B-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
mild I-HPO_TERM
elevated I-HPO_TERM
in O
plasma O
2 O
8 O
mm O
##ol O
l O
normal O
0 O
5 O
2 O
0 O
mm O
##ol O
l O
and O
in O
cs O
##f O
3 O
2 O
mm O
##ol O
l O
normal O
1 O
4 O
2 O
0 O
mm O
##ol O
l O
cs B-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
at O
0 O
59 O
g O
l O
normal O
0 O
15 O
0 O
35 O
g O
l O
en O
##zy O
##matic O
measurements O
of O
the O

respiratory O
chain O
complexes O
of O
a O
muscle O
bio O
##psy O
revealed O
a O
partial O
defect B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
complexes I-HPO_TERM
i O
ii O
iii O
and O
iv O
44 O
52 O
and O
63 O
of O
the O
mean O
control O
values O
respectively O
during O
the O
two O
following O
years O
ep O
##ile O
##psy O
was O
always O
very O
active O
including O
spa B-HPO_TERM
##sms I-HPO_TERM
and O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
at O
46 O
months O
val O
##pro O
##ate O
therapy O
was O
started O
because O
of O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
seizures I-HPO_TERM
at O
the O
beginning O
val O
##pro O
##ate O
was O
clinical O
##ly O
well O
tolerated O
but O
no O
clear O
improvement O
of O
seizure O
frequency O
was O
noticed O
leading O
to O
the O
introduction O
of O
a O
ke O
##to O
##genic O
diet O
this O
last O
therapy O
was O
stopped O
after O
6 O
weeks O
because O
of O
int O
##estinal O
into O
##ler O
##ance O
despite O
stopping O
val O
##pro O
##ate O
a O
rapidly O
progressive B-HPO_TERM
he I-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
with O
increasing B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##ses I-HPO_TERM
and O
am B-HPO_TERM
##mon I-HPO_TERM
##ie I-HPO_TERM
##mia I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##oa I-HPO_TERM
##lb I-HPO_TERM
##umi I-HPO_TERM
##nae I-HPO_TERM
##mia I-HPO_TERM
and O
decrease B-HPO_TERM
of I-HPO_TERM
cl I-HPO_TERM
##otti I-HPO_TERM
##ng I-HPO_TERM
factors I-HPO_TERM
led O
to O
the O
death B-HPO_TERM
of O
the O
child O
at O
50 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
the O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
was O
proposed O
and O
then O
con O
##ﬁ O
##rmed O
by O
the O
following O
analysis O
de B-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
of I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
in O
liver O
86 O
was O
demonstrated O
associated O
with O
the O
defects O
of O
mt O
##dna O
related O
respiratory O
chain O
complexes O
17 O
65 O
and O
25 O
of O
the O
mean O
control O
values O
for O
the O
complexes O
i O
iii O
and O
iv O
respectively O
informed O
parental O
consent O
was O
obtained O
for O
this O
study O

cell O
cultures O
and O
mit O
##och O
##ond O
##ria O
enriched O
preparations O

der O
##mal O
ﬁ O
##bro O
##bla O
##st O
and O
am O
##nio O
##tic O
ﬂ O
##uid O
cells O
were O
obtained O
from O
cbc O
bio O
##tec O
cr O
##b O
hc O
##l O
shortly O
ﬁ O
##bro O
##bla O
##sts O
from O
forearm O
skin O
ex O
##pl O
##ants O
obtained O
from O
patients O
family O
members O
and O
controls O
were O
culture O
##d O
in O
ham O
f1 O
##0 O
medium O
supplemented O
with O
12 O
of O
fetal O
calf O
serum O
with O
pen O
##ici O
##llin O
st O
##re O
##pt O
##omy O
##cin O
and O
amp O
##hot O
##eric O
##in O
b O
and O
50 O
mg O
l O
of O
ur O
##idi O
##ne O
cells O
were O
routinely O
culture O
##d O
in O
plastic O
ﬂ O
##ask O
##s O
t O
##17 O
##5 O
at O
37 O
in O
a O
humid O
##i O
##ﬁ O
##ed O
atmosphere O
of O
5 O
co O
##2 O
in O
air O
cultures O
were O
checked O
for O
my O
##co O
##pl O
##as O
##ma O
infection O
prior O
to O
all O
experiments O
mit O
##och O
##ond O
##ria O
##en O
##rich O
##ed O
preparations O
from O
three O
t O
##17 O
##5 O
ﬂ O
##ask O
##s O
of O
cell O
lines O
were O
obtained O
as O
described O
previously O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
et O
al O
2007 O
the O
pe O
##llet O
##ed O
mit O
##och O
##ond O
##ria O
were O
res O
##us O
##pen O
##ded O
to O
an O
approximate O
concentration O
of O
10 O
g O
l O
and O
kept O
in O
ali O
##qu O
##ots O
at O
##80 O
protein O
concentration O
was O
measured O
by O
the O
bi O
##cin O
##chon O
##ini O
##c O
acid O
method O

molecular O
investigations O
for O
mt O
##dna O
quan O
##ti O
##ﬁ O
##cation O
continuous O
real O
time O
quantitative O
pc O
##r O
with O
the O
ﬂ O
##uo O
##res O
##cent O
sy O
##br O
green O
i O
double O
strand O
dna O
spec O
##i O
##ﬁ O
##c O
dye O
was O
used O
to O
determine O
the O
copy O
number O
for O
three O
mitochondrial O
genes O
n O
##d O
##2 O
n O
##d O
##5 O
and O
16 O
s O
and O
a O
nuclear O
gene O
atp O
##sy O
##n O
##β O
as O
described O
previously O
cha O
##bi O
et O
al O
2002 O
pol O
##g O
ex O
##ons O
2 O
23 O
and O
intro O
##n O
ex O
##on O
boundaries O
were O
amp O
##li O
##ﬁ O
##ed O
and O

sequence O
##d O
from O
the O
gen O
##omic O
dna O
of O
both O
patients O
and O
their O
parents O
total O
rna O
was O
isolated O
from O
culture O
##d O
skin O
ﬁ O
##bro O
##bla O
##sts O
using O
the O
rn O
##ea O
##sy O
mini O
kit O
qi O
##age O
##n O
rna O
samples O
were O
free O
of O
any O
con O
##tam O
##inating O
dna O
by O
treatment O
with O
the O
dna O
free O
##tm O
kit O
am O
##bio O
##n O
inc O
reverse O
transcription O
of O
rna O
was O
performed O
with O
the O
gene O
##amp O
##® O
rna O
pc O
##r O
core O
kit O
applied O
bio O
##systems O
as O
recommended O
by O
the O
supplier O
amp O
##li O
##ﬁ O
##cation O
and O
sequencing O
of O
pol O
##g O
cd O
##na O
were O
performed O
to O
assess O
ex O
##on O
22 O
skipping O
pc O
##r O
products O
with O
ex O
##on O
21 O
and O
23 O
prime O
##rs O
were O
pu O
##ri O
##ﬁ O
##ed O
by O
ag O
##aro O
##se O
gel O
electro O
##ph O
##ores O
##is O
and O
extracted O
by O
the O
dna O
and O
gel O
band O
pu O
##ri O
##ﬁ O
##cation O
kit O
ge O
healthcare O
and O
sequence O
##d O
results O
were O
compared O
with O
the O
gene O
##bank O
reference O
sequences O

nc O
000 O
##01 O
##5 O
8 O
range O
87 O
##6 O
##7 O
##90 O
##30 O
87 O
##66 O
##0 O
##55 O
##4 O
complement O
and O
nm O
00 O
##26 O
##9 O
##3 O
2 O
en O
##zy O
##matic O
measurements O
the O
dna O
pol O
γ O
activity O
was O
measured O
in O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
using O
the O
rna O
directed O
dna O
polymer O
##ase O
ass O
##ay O
with O
a O
procedure O
based O
on O
that O
described O
previously O
na O
##via O
##ux O
et O
al O
1999 O
tha O
##wed O
mit O
##och O
##ond O
##ria O
were O
l O
##yse O
##d O
as O
reported O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
et O
al O
2007 O
serial O
dil O
##ution O
##s O
of O
l O
##yse O
##d O
mit O
##och O
##ond O
##ria O
were O
prepared O
to O
obtain O
ﬁ O
##nal O
concentration O
of O
0 O
15 O
0 O
25 O
0 O
5 O
1 O
0 O
and O
1 O
5 O
μ O
##g O
per O
ass O
##ay O
the O
standard O
reaction O
mixture O

contained O
50 O
mm O
tri O
##s O
hc O
##l O
ph O
8 O
0 O
50 O
mm O
na O
##cl O
5 O
mm O
kc O
##l O
5 O
mm O
mg O
##cl O
##2 O
and O
0 O
5 O
mm O
mn O
##cl O
##2 O
10 O
mm O
dt O
##t O
10 O
mg O
l O
poly O
ra O
and O
5 O
mg O
l O
ol O
##igo O
##dt O
##12 O
18 O
am O
##ers O
##ham O
bio O
##sc O
##ience O
##s O
5 O
μ O
##m O
dt O
##tp O
and O
50 O
μ O
##ci O
ml O
of O
α O
32 O
##p O
dt O
##tp O
per O
##kin O
elmer O
10 O
μ O
##ci O
μ O
##l O
3000 O
ci O
mm O
##ol O
0 O
01 O
##7 O
μ O
##m O
ﬁ O
##nal O
concentration O
in O
a O
ﬁ O
##nal O
volume O
of O
20 O
μ O
##l O
ass O
##ays O
were O
initiated O
by O
addition O
of O
0 O
15 O
to O
1 O
5 O
μ O
##g O
of O
mitochondrial O
protein O
per O
ass O
##ay O
and O
conducted O
at O
37 O
during O
30 O
min O
the O
reaction O
was O
stopped O
at O
4 O

and O
the O
amount O
of O
the O
reaction O
products O
was O
determined O
by O
spotting O
ali O
##qu O
##ots O
of O
4 O
μ O
##l O
on O
what O
##man O
de O
81 O
an O
##ion O
exchange O
papers O
fischer O
bio O
##block O
the O
papers O
were O
then O
washed O
as O
described O
na O
##via O
##ux O
et O
al O
1999 O
for O
each O
dil O
##ution O
of O
mit O
##och O
##ond O
##ria O
a O
parallel O
ass O
##ay O
was O
performed O
with O
5 O
μ O
##m O
2 O
3 O
did O
##eo O
##xy O
##thy O
##mi O
##dine O
5 O
trip O
##hos O
##phate O
dd O
##tt O
##p O
data O
obtained O
from O
each O
dil O
##ution O
were O
used O
to O
establish O
a O
regression O
line O
for O
each O
sample O
regression O
analysis O
was O
used O
to O
calculate O
spec O
##i O
##ﬁ O
##c O
activity O
according O
to O
na O
##via O
##ux O
et O
al O
1999 O
dna O
pol O
γ O
spec O
##i O
##ﬁ O
##c O
activity O
dd O
##tt O
##p O
sensitive O
was O
obtained O
as O
the O
difference O

between O
the O
two O
parallel O
ass O
##ays O
measured O
with O
and O
without O
dd O
##tt O
##p O
one O
unit O
of O
spec O
##i O
##ﬁ O
##c O
activity O
u O
is O
given O
as O
the O
incorporation O
of O
one O
pic O
##omo O
##le O
of O
dt O
##tp O
per O
min O
per O
mg O
of O
protein O
results O
molecular O
investigations O
pol B-GENE
##g I-GENE
sequence O
variations O
patient B-PATIENT
1 I-PATIENT
is O
a O
compound O
het O
##ero O
##zy O
##go O
##te O
for O
two O
sequence O
variations O
i O
the O
common B-GENE_VARIANT
c I-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##gna I-GENE_VARIANT
in O
ex O
##on O
7 O
which O
predict O
##s O
a O
substitution O
of O
ala O
with O
th O
##r O
at O
cod O
##on O
46 O
##7 O
p B-GENE_VARIANT
ala I-GENE_VARIANT
##46 I-GENE_VARIANT
##7th I-GENE_VARIANT
##r I-GENE_VARIANT
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
in O
the O
thumb O
sub O
##dom O
##ain O
of O
the O
protein O
pol O
domain O
na O
##via O
##ux O
and O
nguyen O
2004 O
lee O
et O

al O
2009 O
ii O
a O
novel O
ga O
##ta O
du O
##plication O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
located O
14 O
nt O
before O
the O
3 O
end O
of O
ex O
##on O
22 O
this O
du O
##plication O
creates O
a O
premature O
termination O
cod O
##on O
pt O
##c O
located O
17 O
nt O
upstream O
from O
the O
intro O
##n O
22 O
the O
mother O
was O
the O
carrier O
of O
the O
a O
##46 O
##7 O
##t O
and O
the O
father O
of O
the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
not O
shown O

patient B-PATIENT
2 O
pol B-GENE
##g I-GENE
of O
patient O
2 O
harbor O
##ed O
two O
het O
##ero O
##zy O
##go O
##us O
base O
changes O
i O
the O
previously O
reported O
combination O
in O
cis B-GENE_VARIANT
p I-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e B-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
van O
goethe O
##m O
et O
al O
2004 O
ferrari O
et O
al O
2005 O
ii O
the O
recently O
reported O
t O
to O
c O
substitution O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
##t I-GENE_VARIANT
##nc I-GENE_VARIANT
ab O
##olis O
##hing O
the O
in O
##var O
##iable O
consensus O
gt O
sp O
##lice O
donor O
site O
of O
intro O
##n O
22 O
roe O
##ls O
et O
al O
2009 O
patient B-PATIENT
2 I-PATIENT
inherited O
the O
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e I-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
from O
his O
mother O
and O
the O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
tn I-GENE_VARIANT
##c I-GENE_VARIANT
from O
his O
father O
not O
shown O
rt O
pc O
##r O
analysis O

to O
identify O
the O
impact O
of O
these O
variations O
on O
sp O
##lic O
##ing O
cd O
##nas O
from O
both O
patients O
and O
a O
control O
were O
amp O
##li O
##ﬁ O
##ed O
with O
prime O
##rs O
located O
in O
ex O
##ons O
21 O
and O
23 O
as O
expected O
for O
patient O
2 O
two O
different O
amp O
##li O
##ﬁ O
##cation O
products O
were O
revealed O
an O
approx O
49 O
##6 O
bp O
band O
of O
expected O
size O
and O
a O
336 O
bp O
shorter O
one O
fig O
1 O
lane O
3 O
sequencing O
of O
these O
pu O
##ri O
##ﬁ O
##ed O

products O
demonstrated O
that O
the O
49 O
##6 O
bp O
fragment O
corresponded O
to O
ex O
##ons O
21 O
22 O
23 O
from O
the O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
all O
##ele O
while O
the O
shorter O
one O
corresponded O
to O
ex O
##on O
21 O
directly O
linked O
to O
ex O
##on O
23 O
fig O
2 O
thus O
the O
c O
36 O
##43 O
2 O
##t O
##nc O
variation O
in O
patient O
2 O
causes O
complete O
skipping O
of O
ex O
##on O
22 O
furthermore O
ex O
##on O
22 O
skipping O
introduces O
a O
pt O
##c O
located O
one O
cod O
##on O
into O
the O
last O
ex O
##on O
23 O
resulting O
in O
a O
c O
terminal O
78 O
amino O
acid O
tr O
##un O
##cation O
of O
the O
protein O

for O
patient O
1 O
surprisingly O
the O
same O
pattern O
of O
amp O
##li O
##ﬁ O
##cation O
products O
was O
obtained O
fig O
1 O
lane O
1 O
but O
the O
intensity O
of O
the O
336 O
bp O
product O
was O
faint O
##er O
than O
for O
patient O
2 O
sequencing O
of O
the O
normal O
size O
49 O
##6 O
bp O
product O
showed O
two O
different O
species O
one O
bearing O
the O
ga O
##ta O
du O
##plication O
and O
the O
other O
bearing O
the O
wild O
type O
ga O
##ta O
sequence O
and O
sequencing O
of O
the O
336 O
bp O
shorter O
product O
showed O
ex O
##on O
22 O
skipping O

fig O
1 O
amp O
##li O
##ﬁ O
##cation O
of O
ex O
##ons O
21 O
23 O
from O
cd O
##nas O
of O
patients O
ex O
##ons O
21 O
23 O
of O
cd O
##nas O
were O
amp O
##li O
##ﬁ O
##ed O
using O
the O
ex O
##on O
21 O
forward O
prime O
##r O
nt O
335 O
##6 O
337 O
##5 O
and O
the O
ex O
##on O
23 O
reverse O
prime O
##r O
nt O
385 O
##1 O
38 O
##32 O
nu O
##cle O
##otide O
numbering O
uses O
the O
a O
of O
the O
ﬁ O
##rst O
at O
##g O
translation O
initiation O
start O
cod O
##on O
as O
nu O
##cle O
##otide O
1 O
lanes O
1 O
and O
2 O
cd O
##na O
from O
ﬁ O
##bro O
##bla O
##sts O
of O
patient O
1 O
and O
a O
control O
respectively O
lanes O
3 O
4 O
5 O
and O
6 O
cd O
##na O
from O
ﬁ O
##bro O
##bla O
##sts O
of O
patient O
2 O
a O
control O
his O
mother O
and O
his O
father O
respectively O
lanes O
7 O
and O
8 O
cd O
##na O
from O
am O
##nio O
##tic O
cells O
patient O
2 O
family O
and O
a O
control O
respectively O
m O
is O
a O
100 O
bp O
ladder O

fig O
2 O
this O
cd O
##na O
study O
showed O
an O
unexpected O
sp O
##lic O
##ing O
defect O
for O
patient O
1 O
as O
two O
kinds O
of O
transcript O
##s O
were O
produced O
from O
the O
ga O
##ta O
duplicate O
##d O
all O
##ele O
one O
containing O
ex O
##on O
22 O
with O
the O
ga O
##ta O
du O
##plication O
and O
one O
with O
ex O
##on O
22 O
skipping O
dna O
pol O
γ O
measurements O
to O
assess O
the O
pathogen O
##ici O
##ty O
of O
the O
pol O
##g O
gene O
variations O
in O
both O
patients O
we O
used O
a O
rna O
directed O
dna O
polymer O
##ase O
ass O
##ay O
for O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
the O

dd O
##tt O
##p O
sensitive O
incorporation O
of O
dt O
##tp O
was O
used O
to O
calculate O
dna O
polymer O
##ase O
γ O
activity O
a O
85 O
95 O
dd O
##tt O
##p O
sensitivity O
of O
the O
total O
dt O
##tp O
incorporation O
was O
obtained O
in O
control O
and O
patients O
mit O
##och O
##ond O
##ria O
similar O
results O
of O
dd O
##tt O
##p O
sensitivity O
were O
reported O
elsewhere O
na O
##via O
##ux O
et O
al O
1999 O
sp O
##el O
##bri O
##nk O
et O
al O
2000 O
ta O
##an O
##man O
et O
al O
2009 O

a O
low O
level O
of O
enzyme O
activity O
was O
measured O
in O
the O
mit O
##och O
##ond O
##ria O
of O
both O
patients O
table O
1 O
18 O
8 O
u O
for O
patient O
1 O
and O
15 O
8 O
u O
for O
patient O
2 O
compared O
to O
the O
controls O
56 O
6 O
u O
##± O
17 O
8 O
n O
8 O
range O
36 O
6 O
91 O
0 O
residual O
activities O
were O
33 O
and O
28 O
of O
the O
mean O
control O
value O
for O
patients O
1 O
and O
2 O
respectively O
discussion O

we O
investigated O
pol O
##g O
in O
two O
unrelated O
children O
presenting O
with O
al O
##pers O
syndrome O
patient B-GENE_VARIANT
1 I-GENE_VARIANT
harbor O
##ed O
the O
novel O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
in O
ex O
##on O
22 O
in O
trans O
with O
the O
common O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
patient B-PATIENT
2 I-PATIENT
the O
recently O
reported O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
##t I-GENE_VARIANT
##nc I-GENE_VARIANT
in O
trans O
with O
the O
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e I-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
in O
order O
to O
evaluate O
the O
consequences O
of O
the O
mutant O
all O
##eles O
on O
pol O
##g O
##1 O
bio O
##chemical O
function O
catalytic O
activity O
of O
dna O
pol O
γ O
was O
assessed O
in O
organ O
##ello O
on O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
the O
a O
##46 O
##7 O
##t O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
c O
36 O
##43 O
2 O
##t O
##nc O
enzymes O
showed O
a O
decreased O
catalytic O
rate O
33 O
and O
28 O
of O
the O
mean O
control O
activity O
for O
patients O
1 O
and O
2 O

respectively O

as O
both O
the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
c O
36 O
##43 O
2 O
##t O
##nc O
create O
a O
pt O
##c O
and O
probably O
inactive O
proteins O
the O
level O
of O
residual O
activity O
for O
each O
patient O
is O
to O
be O
likely O
the O
re O
##ﬂ O
##ect O
of O
the O
a O
##46 O
##7 O
##t O
or O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
mutant O
proteins O
it O
has O
been O
established O
that O
either O
the O
a O
##46 O
##7 O
##t O
or O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
rec O
##om O
##bina O
##nt O
proteins O
harbor O
##ed O
decreased O
activity O
chan O
et O
al O
2005 O
##a O
2006 O
recently O
disease O
associated O
pol O
γ O
variations O
have O
been O
divided O
into O
three O
classes O
lee O
et O
al O
2009 O
w O
##7 O
##48 O
##s O
and O
a O
##46 O
##7 O
##t O
are O
included O
into O
class O
ii O
and O
class O
iii O
respectively O
the O
class O
ii O
variations O
are O
located O
in O
the O
dna O
binding O
channel O
leading O
to O
reduced O
dna O
binding O
and O
lower O
polymer O
##ase O
activity O
the O
most O

mit O
##och O
##ond O
##rion O
11 O
2011 O
223 O
227 O
short O
communication O
pol B-GENE
##g I-GENE
ex O
##on O
22 O
skipping O
induced O
by O
different O
mechanisms O
in O
two O
unrelated O
cases O
of O
al O
##pers O
syndrome O
benedict O
##e O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
a O
mai O
##te O
cha O
##ssa O
##gne O
a O
martin O
##e O
may O
##en O
##con O
a O
sylvie O
pad O
##et O
a O
her O
##ve O
cr O
##eh O
##ale O
##t O
b O
pascal O
##e O
cl O
##er O
##c O
ren O
##aud O
a O
isabelle O
ro O
##uve O
##t O
c O
marie O
therese O
za O
##bot O
c O
francois O
ri O
##vier O
d O
pierre O
sar O
##da O
e O
vincent O
des O
porte O
##s O
f O
dominique O
bo O
##zon O
b O
a O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
service O
des O
mala O
##dies O
here O
##dit O
##aire O
##s O
du O
metabolism O
##e O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O

b O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
unite O
de O
card O
##io O
##gen O
##eti O
##que O
mole O
##cula O
##ire O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
c O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
chu O
lyon O
centre O
de O
bio O
##tech O
##no O
##logie O
cell O
##ula O
##ire O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
d O
hop O
##ital O
gui O
de O
cha O
##ulia O
##c O
service O
de O
ne O
##uro O
##ped O
##ia O
##tri O
##e O
chu O
montpellier O
34 O
##29 O
##5 O
montpellier O
france O
e O
hop O
##ital O
ar O
##naud O
de O
ville O
##neuve O
service O
de O
gene O
##tique O
medical O
##e O
chu O
montpellier O
34 O
##29 O
##5 O
montpellier O
france O
f O
hop O
##ital O
femme O
mere O
en O
##fan O
##t O
service O
de O
ne O
##uro O
##logie O
pe O
##dia O
##tri O
##que O
and O
universite O
lyon O
1 O
chu O
lyon O
69 O
##6 O
##7 O
##7 O
bro O
##n O
france O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O

received O
30 O
march O
2010 O
received O
in O
revised O
form O
29 O
june O
2010 O
accepted O
23 O
july O
2010 O
available O
online O
4 O
august O
2010 O
key O
##words O
pol O
##g O
variation O
al O
##pers O
syndrome O
rna O
sp O
##lic O
##ing O
ex O
##on O
skipping O
dna O
polymer O
##ase O
γ O
a O
b O
s O
t O
r O
a O
c O
t O

the O
pol O
##g O
genes O
were O
sequence O
##d O
in O
two O
unrelated O
patients O
presenting O
with O
al O
##pers O
syndrome O
the O
novel O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
c O
36 O
##43 O
2 O
##t O
##n O
c O
all O
##eles O
were O
associated O
in O
trans O
with O
p O
a O
##46 O
##7 O
##t O
and O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
respectively O
pol B-GENE
##g I-GENE
transcript O
##s O
from O
skin O
ﬁ O
##bro O
##bla O
##sts O
showed O
complete O
ex B-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
2 I-PATIENT
but O
surprisingly O
partial B-GENE_VARIANT
ex I-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
from O
the O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
for O
patient B-PATIENT
1 I-PATIENT
the O
creation O
of O
a O
put O
##ative O
ex O
##onic O
sp O
##lic O
##ing O
silence O
##r O
could O
be O
responsible O
for O
the O
sp O
##lic O
##ing O
anomaly O
observed O
in O
patient O
1 O
both O
c O
36 O
##43 O
2 O
##t O
##nc O
and O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
create O
a O
premature O
termination O
cod O
##on O
and O
a O
low O
polymer O
##ase O
γ O
activity O
in O
skin O
ﬁ O
##bro O
##bla O
##sts O
is O
responsible O
for O
the O
severe O
ph O
##eno O
##type O
in O
these O
patients O

2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
introduction O

al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
ah O
##s O
om O
##im O
203 O
##70 O
##0 O
is O
a O
rare O
auto O
##som O
##al O
recess O
##ive O
disease O
associated O
with O
mitochondrial O
mt O
dna O
de O
##ple O
##tion O
and O
mutations O
in O
the O
pol O
##g O
gene O
ah O
##s O
is O
usually O
characterized O
by O
a O
clinical O
te O
##tra O
##d O
of O
psycho O
##moto O
##r O
regression O
intra O
##ctable O
ep O
##ile O
##psy O
co O
##rti O
##cal O
blindness O
and O
liver O
disease O
in O
infants O
and O
young O
children O
harding O
1990 O
na O
##via O
##ux O
and O
nguyen O
2004 O
kurt O
et O
al O
2010 O
replication O
of O
mt O
##dna O
involves O
a O
complex O
machinery O
called O
mt O
##dna O
rep O
##lis O
##ome O
including O
the O
mt O
##dna O
polymer O
##ase O
γ O
pol O
γ O
and O
the O
twinkle O
he O
##lica O
##se O
far O
##ge O
et O
al O
2007 O
it O
was O
established O
that O
the O
ho O
##loe O
##nz O
##yme O
pol O
γ O
is O
a O
het O
##ero O
##tri O
##mer O
consisting O
of O
one O
catalytic O
pol O
##g O
##1 O
subunit O
and O
a O
homo O
##dim O
##er O
of O
the O
pol O
##g O
##2 O
accessory O
subunit O
ya O
##ku O
##bo O
##vs O
##kaya O
et O
al O
2007 O
recently O
the O
crystal O
structure O
of O
the O
human O
ho O
##loe O
##nz O
##yme O
pol O
γ O
has O
been O
reported O
providing O
a O
structural O
basis O
for O
understanding O
interactions O
between O
catalytic O
and O
accessory O
subunit O
##s O
lee O
et O
al O
2009 O

corresponding O
author O
service O
des O
mala O
##dies O
here O
##dit O
##aire O
##s O
du O
metabolism O
##e O
centre O
de O
bio O
##logie O
et O
de O
path O
##olo O
##gie O
est O
group O
##ement O
hospital O
##ier O
est O
chu O
lyon O
59 O
boulevard O
pine O
##l O
69 O
##6 O
##7 O
##7 O
bro O
##n O
ce O
##de O
##x O
france O
tel O
33 O
4 O
72 O
12 O
96 O
82 O
fa O
##x O
33 O
4 O
72 O
12 O
97 O
20 O
e O
mail O
address O
benedict O
##e O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
chu O
lyon O
fr O
b O
mo O
##uss O
##on O
de O
cam O
##are O
##t O

the O
human O
pol O
##g O
also O
known O
as O
pol O
##g O
##1 O
or O
pol O
γ O
##a O
is O
localized O
on O
chromosome O
band O
15 O
##q O
##25 O
and O
spans O
nearly O
18 O
5 O
kb O
with O
23 O
ex O
##ons O
the O
44 O
##64 O
bp O
transcript O
nm O
00 O
##26 O
##9 O
##3 O
en O
##codes O
the O
123 O
##9 O
amino O
##ac O
##id O
pol O
##g O
##1 O
protein O
the O
mature O
protein O
is O
a O
135 O
k O
##da O
poly O
##pe O
##pt O
##ide O
composed O
of O
three O
functional O
domains O
an O
amino O
terminal O
3 O
5 O
ex O
##on O
##uc O
##lea O
##se O
ex O
##o O
domain O
responsible O
for O
the O
ﬁ O
##del O
##ity O
of O
mt O
##dna O
replication O
long O
##ley O
et O
al O
2001 O
a O
link O
##er O
domain O
and O
a O
car O
##box O
##y O
terminal O
polymer O
##ase O
pol O

domain O
ro O
##pp O
and O
copeland O
1996 O
le O
##cre O
##nier O
et O
al O
1997 O
the O
50 O
k O
##da O
pol O
##g O
##2 O
or O
pol O
γ O
##b O
subunit O
encoded O
by O
the O
pol O
##g O
##2 O
gene O
ch O
##r O
17 O
##q O
##21 O
acts O
as O
a O
process O
##ivity O
factor O
accelerating O
polymer O
##isation O
rate O
in O
addition O
to O
increasing O
af O
##ﬁ O
##nity O
of O
pol O
γ O
for O
dna O
lim O
et O
al O
1999 O
far O
##ge O
et O
al O
2007 O

human O
dna O
pol O
γ O
is O
known O
to O
be O
an O
effective O
in O
vitro O
reverse O
transcript O
##ase O
rna O
directed O
dna O
polymer O
##ase O
and O
a O
possible O
physiological O
role O
for O
this O
reverse O
transcript O
##ase O
activity O
has O
been O
suggested O
mu O
##rak O
##ami O
et O
al O
2003 O
the O
most O
sensitive O
ass O
##ays O
developed O
to O
date O
for O
the O
measurement O
of O
pol O
##g O
γ O
activity O
used O
homo O
##pol O
##yme O
##ric O
rna O
template O
##s O
clinical O
ass O
##ays O
were O
performed O
on O
mit O
##och O
##ond O
##ria O
isolated O
from O
skeletal O
muscle O
na O
##via O
##ux O
et O
al O
1999 O
or O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
ta O
##an O
##man O
et O
al O
2009 O
characterization O
of O
the O
enzyme O
has O
been O
assessed O
in O
vitro O
with O
pu O
##ri O
##ﬁ O
##ed O
or O
rec O
##om O
##bina O
##nt O
pol O
γ O
carr O
##ode O
##gua O
##s O
et O
al O
1999 O
far O
##r O
et O
al O
1999 O
lee O
and O
johnson O
2007 O
or O
in O
vivo O
by O
expressing O
a O
pol O
##g O
##1 O
fusion O
protein O
in O
human O
culture O
##d O
cells O
sp O
##el O
##bri O
##nk O
et O
al O
2000 O

156 O
##7 O
72 O
##49 O
see O
front O
matter O
2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
mit O
##o O
2010 O
07 O
01 O
##1 O
to O
date O
more O
than O
150 O
different O
pol O
##g O
variations O
have O
been O
reported O
in O
a O
broad O
range O
of O
clinical O
ph O
##eno O
##type O
##s O
in O
children O
and O
adults O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
ah O
##s O
is O
one O
of O
the O
six O
major O
groups O
of O
pol O
##g O
disease O
de O
##ﬁ O
##ned O
by O
wong O
et O
al O
2008 O

in O
this O
study O
we O
investigated O
pol O
##g O
in O
two O
unrelated O
patients O
presenting O
with O
infant B-AGE_ONSET
##ile I-AGE_ONSET
onset I-AGE_ONSET
ah O
##s O
a O
novel O
ga O
##ta O
du O
##plication O
in O
ex O
##on O
22 O
and O
a O
yet O
reported O
donor O
sp O
##lice O
site O
alteration O
in O
intro O
##n O
22 O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
a O
compound O
het O
##ero O
##zy O
##go O
##ty O
with O
the O
most O
common O
variation O
p O
a O
##46 O
##7 O
##t O
and O
the O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
respectively O
for O
both O
patients O
cd O
##na O
study O
showed O
that O
both O
the O
ga O
##ta O
du O
##plication O
and O
the O
donor O
sp O
##lice O
site O
alteration O
cause O
a O
sp O
##lic O
##ing O
defect O
leading O
to O
partial O
or O
complete O
skipping O
of O
ex O
##on O
22 O
the O
mechanisms O
inducing O
ex O
##on O
22 O
skipping O
in O
these O
patients O
are O
discussed O

to O
ﬁ O
##nd O
out O
if O
these O
pol O
##g O
mutants O
could O
be O
responsible O
for O
the O
ah O
##s O
ph O
##eno O
##type O
we O
performed O
ass O
##ays O
of O
pol O
γ O
activity O
in O
mit O
##och O
##ond O
##ria O
from O
ﬁ O
##bro O
##bla O
##sts O
we O
showed O
a O
sign O
##i O
##ﬁ O
##can O
##t O
decrease O
of O
polymer O
##ase O
activity O
in O
organ O
##ello O
for O
both O
patients O
providing O
evidence O
that O
these O
pol O
##g O
variations O
affect O
enzyme O
cat O
##aly O
##sis O
and O
play O
a O
major O
role O
in O
the O
ah O
##s O
ph O
##eno O
##type O
subjects O
and O
methods O
case O
reports O
patient B-PATIENT
1 I-PATIENT

this B-PATIENT
girl I-PATIENT
was O
the O
second O
child O
of O
non O
con O
##san O
##gui O
##neo O
##us O
french O
parents O
with O
no O
clinical O
relevant O
family O
history O
height O
and O
weight O
growth B-PATIENT
decreased I-PATIENT
at O
6 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
at O
1 O
year O
of O
age O
she O
presented O
a O
rights B-HPO_TERM
##ided I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
resistant O
to O
multiple O
anti O
##ep O
##ile O
##ptic O
drugs O
car O
##ba O
##ma O
##ze O
##pine O
worsened O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
a O
ke O
##to O
##genic O
diet O
was O
well O
tolerated O
but O
was O
ineffective O
o O
##cci O
##pit O
##al O
frontal O
ci O
##rc O
##um O
##ference O
was O
normal O
ee O
##g O
showed O
sub B-HPO_TERM
##con I-HPO_TERM
##tin I-HPO_TERM
##uous I-HPO_TERM
discharge I-HPO_TERM
##s I-HPO_TERM
of I-HPO_TERM
ry I-HPO_TERM
##th I-HPO_TERM
##mic I-HPO_TERM
slow I-HPO_TERM
spike I-HPO_TERM
waves I-HPO_TERM
on I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
hemisphere I-HPO_TERM
related O
to O
right O
hand O
and O
foot O
cl O
##onic O
jerk O
##s O
brain O
magnetic O
resonance O
imaging O
mri O
at O
12 O
months O
of O
age O
was O
normal O
at O
the O
same O
time O
a O
dramatic O
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
regression I-HPO_TERM
was O
observed O
with O
poor B-HPO_TERM
interaction I-HPO_TERM
major O
global B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
no B-HPO_TERM
eye I-HPO_TERM
contact I-HPO_TERM
due O
to O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
mild O
lac B-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
##osis I-HPO_TERM
and O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
ratio I-HPO_TERM
were O
documented O
in O
blood O
lac O
##tate O
2 O
8 O
mm O
##ol O
l O

normal O
0 O
5 O
2 O
0 O
lac O
##tate O
p O
##yr O
##u O
##vate O
ratio O
31 O
normal O
b O
20 O
elevation B-HPO_TERM
of I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
ﬂ I-HPO_TERM
##uid I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
was O
noticed O
twice O
2 O
8 O
and O
2 O
2 O
mm O
##ol O
l O
normal O
1 O
4 O
2 O
0 O
cs O
##f O
protein O
content O
was O
normal O
content B-HPO_TERM
of I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
was I-HPO_TERM
slightly I-HPO_TERM
reduced I-HPO_TERM
in I-HPO_TERM
muscle I-HPO_TERM
62 O
of O
age O
matched O
control O
mean O
with O
no O
major O
abnormalities O
of O
the O
mitochondrial O
respiratory O
chain O
activities O
a O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
was O
suggested O
in O
the O
following O
months O
her O
neurological O
condition O
evolved O
into O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM

reinforced O
by O
rec B-HPO_TERM
##urrent I-HPO_TERM
episodes I-HPO_TERM
of I-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
at O
16 O
months O
of O
age O
liver B-HPO_TERM
en I-HPO_TERM
##lar I-HPO_TERM
##gement I-HPO_TERM
was O
noticed O
associated O
with O
mild O
cy O
##to O
##lysis O
asa O
##t O
90 O
i O
##u O
l O
normal O
b O
50 O
and O
increased B-HPO_TERM
level I-HPO_TERM
of I-HPO_TERM
gamma I-HPO_TERM
g I-HPO_TERM
##lu I-HPO_TERM
##tam I-HPO_TERM
##yl I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
g O
##gt O
138 O
i O
##u O
l O
normal O
5 O
25 O
the O
pro B-HPO_TERM
##th I-HPO_TERM
##rom I-HPO_TERM
##bine I-HPO_TERM
time I-HPO_TERM
and I-HPO_TERM
the I-HPO_TERM
cl I-HPO_TERM
##otti I-HPO_TERM
##ng I-HPO_TERM
factors I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
ii O
36 O
v O
39 O
vii O
59 O
and O
pro O
##th O
##rom O
##bine O
time O
48 O
the O
patient O
died O
at O
27 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
of O
respiratory B-HPO_TERM
failure I-HPO_TERM
informed O
parental O
consent O
was O
obtained O
in O
agreement O
with O
the O
french O
recommendations O
for O
genetic O
analysis O
patient B-PATIENT
2 I-PATIENT

this O
boy B-PATIENT
was O
the O
ﬁ O
##rst O
child O
of O
healthy O
young O
unrelated O
french O
parents O
without O
relevant O
family O
history O
at O
16 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
he O
started O
a O
severe O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
cs B-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
0 O
78 O
g O
l O
normal O
0 O
15 O
0 O
35 O
cerebral O
mri O
showed O
brain B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
with O
symmetrical B-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
and I-HPO_TERM
flair I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
signals I-HPO_TERM
associated O
with O
cy B-HPO_TERM
##to I-HPO_TERM
##to I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
o I-HPO_TERM
##ede I-HPO_TERM
##ma I-HPO_TERM
within I-HPO_TERM
basal I-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
on O
diffusion O
sequences O
then O
he O
developed O
intra B-HPO_TERM
##ctable I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
associated O
with O
gene O
##r O

ali O
##zed O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
blindness I-HPO_TERM
at O
24 O
months O
of O
age O
a O
new O
cerebral O
mri O
con O
##ﬁ O
##rmed O
brain B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
associated O
with O
marked O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
signals I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
dent I-HPO_TERM
##ate I-HPO_TERM
nuclei I-HPO_TERM
and O
of O
posterior O
per O
##ive O
##nt O
##ric O
##ular O
white O
matter O
at O
a O
less O
extent O
proton O
magnetic O
resonance O
spec B-HPO_TERM
##trom I-HPO_TERM
##et I-HPO_TERM
##ry I-HPO_TERM
revealed I-HPO_TERM
an I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
lac I-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
in I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
and O

per O
##ive O
##nt O
##ric O
##ular O
regions O
one O
month O
later O
a O
new O
acute O
episode O
occurred O
with O
diffuse B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
let B-HPO_TERM
##har I-HPO_TERM
##gy I-HPO_TERM
and O
vomiting B-HPO_TERM
lac B-HPO_TERM
##tate I-HPO_TERM
was I-HPO_TERM
mild I-HPO_TERM
elevated I-HPO_TERM
in O
plasma O
2 O
8 O
mm O
##ol O
l O
normal O
0 O
5 O
2 O
0 O
mm O
##ol O
l O
and O
in O
cs O
##f O
3 O
2 O
mm O
##ol O
l O
normal O
1 O
4 O
2 O
0 O
mm O
##ol O
l O
cs B-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
content I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
at O
0 O
59 O
g O
l O
normal O
0 O
15 O
0 O
35 O
g O
l O
en O
##zy O
##matic O
measurements O
of O
the O

respiratory O
chain O
complexes O
of O
a O
muscle O
bio O
##psy O
revealed O
a O
partial O
defect B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
complexes I-HPO_TERM
i O
ii O
iii O
and O
iv O
44 O
52 O
and O
63 O
of O
the O
mean O
control O
values O
respectively O
during O
the O
two O
following O
years O
ep O
##ile O
##psy O
was O
always O
very O
active O
including O
spa B-HPO_TERM
##sms I-HPO_TERM
and O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
at O
46 O
months O
val O
##pro O
##ate O
therapy O
was O
started O
because O
of O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
seizures I-HPO_TERM
at O
the O
beginning O
val O
##pro O
##ate O
was O
clinical O
##ly O
well O
tolerated O
but O
no O
clear O
improvement O
of O
seizure O
frequency O
was O
noticed O
leading O
to O
the O
introduction O
of O
a O
ke O
##to O
##genic O
diet O
this O
last O
therapy O
was O
stopped O
after O
6 O
weeks O
because O
of O
int O
##estinal O
into O
##ler O
##ance O
despite O
stopping O
val O
##pro O
##ate O
a O
rapidly O
progressive B-HPO_TERM
he I-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
with O
increasing B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##ses I-HPO_TERM
and O
am B-HPO_TERM
##mon I-HPO_TERM
##ie I-HPO_TERM
##mia I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##oa I-HPO_TERM
##lb I-HPO_TERM
##umi I-HPO_TERM
##nae I-HPO_TERM
##mia I-HPO_TERM
and O
decrease B-HPO_TERM
of I-HPO_TERM
cl I-HPO_TERM
##otti I-HPO_TERM
##ng I-HPO_TERM
factors I-HPO_TERM
led O
to O
the O
death B-HPO_TERM
of O
the O
child O
at O
50 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
the O
diagnosis O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
was O
proposed O
and O
then O
con O
##ﬁ O
##rmed O
by O
the O
following O
analysis O
de B-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
of I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
in O
liver O
86 O
was O
demonstrated O
associated O
with O
the O
defects O
of O
mt O
##dna O
related O
respiratory O
chain O
complexes O
17 O
65 O
and O
25 O
of O
the O
mean O
control O
values O
for O
the O
complexes O
i O
iii O
and O
iv O
respectively O
informed O
parental O
consent O
was O
obtained O
for O
this O
study O

cell O
cultures O
and O
mit O
##och O
##ond O
##ria O
enriched O
preparations O

der O
##mal O
ﬁ O
##bro O
##bla O
##st O
and O
am O
##nio O
##tic O
ﬂ O
##uid O
cells O
were O
obtained O
from O
cbc O
bio O
##tec O
cr O
##b O
hc O
##l O
shortly O
ﬁ O
##bro O
##bla O
##sts O
from O
forearm O
skin O
ex O
##pl O
##ants O
obtained O
from O
patients O
family O
members O
and O
controls O
were O
culture O
##d O
in O
ham O
f1 O
##0 O
medium O
supplemented O
with O
12 O
of O
fetal O
calf O
serum O
with O
pen O
##ici O
##llin O
st O
##re O
##pt O
##omy O
##cin O
and O
amp O
##hot O
##eric O
##in O
b O
and O
50 O
mg O
l O
of O
ur O
##idi O
##ne O
cells O
were O
routinely O
culture O
##d O
in O
plastic O
ﬂ O
##ask O
##s O
t O
##17 O
##5 O
at O
37 O
in O
a O
humid O
##i O
##ﬁ O
##ed O
atmosphere O
of O
5 O
co O
##2 O
in O
air O
cultures O
were O
checked O
for O
my O
##co O
##pl O
##as O
##ma O
infection O
prior O
to O
all O
experiments O
mit O
##och O
##ond O
##ria O
##en O
##rich O
##ed O
preparations O
from O
three O
t O
##17 O
##5 O
ﬂ O
##ask O
##s O
of O
cell O
lines O
were O
obtained O
as O
described O
previously O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
et O
al O
2007 O
the O
pe O
##llet O
##ed O
mit O
##och O
##ond O
##ria O
were O
res O
##us O
##pen O
##ded O
to O
an O
approximate O
concentration O
of O
10 O
g O
l O
and O
kept O
in O
ali O
##qu O
##ots O
at O
##80 O
protein O
concentration O
was O
measured O
by O
the O
bi O
##cin O
##chon O
##ini O
##c O
acid O
method O

molecular O
investigations O
for O
mt O
##dna O
quan O
##ti O
##ﬁ O
##cation O
continuous O
real O
time O
quantitative O
pc O
##r O
with O
the O
ﬂ O
##uo O
##res O
##cent O
sy O
##br O
green O
i O
double O
strand O
dna O
spec O
##i O
##ﬁ O
##c O
dye O
was O
used O
to O
determine O
the O
copy O
number O
for O
three O
mitochondrial O
genes O
n O
##d O
##2 O
n O
##d O
##5 O
and O
16 O
s O
and O
a O
nuclear O
gene O
atp O
##sy O
##n O
##β O
as O
described O
previously O
cha O
##bi O
et O
al O
2002 O
pol O
##g O
ex O
##ons O
2 O
23 O
and O
intro O
##n O
ex O
##on O
boundaries O
were O
amp O
##li O
##ﬁ O
##ed O
and O

sequence O
##d O
from O
the O
gen O
##omic O
dna O
of O
both O
patients O
and O
their O
parents O
total O
rna O
was O
isolated O
from O
culture O
##d O
skin O
ﬁ O
##bro O
##bla O
##sts O
using O
the O
rn O
##ea O
##sy O
mini O
kit O
qi O
##age O
##n O
rna O
samples O
were O
free O
of O
any O
con O
##tam O
##inating O
dna O
by O
treatment O
with O
the O
dna O
free O
##tm O
kit O
am O
##bio O
##n O
inc O
reverse O
transcription O
of O
rna O
was O
performed O
with O
the O
gene O
##amp O
##® O
rna O
pc O
##r O
core O
kit O
applied O
bio O
##systems O
as O
recommended O
by O
the O
supplier O
amp O
##li O
##ﬁ O
##cation O
and O
sequencing O
of O
pol O
##g O
cd O
##na O
were O
performed O
to O
assess O
ex O
##on O
22 O
skipping O
pc O
##r O
products O
with O
ex O
##on O
21 O
and O
23 O
prime O
##rs O
were O
pu O
##ri O
##ﬁ O
##ed O
by O
ag O
##aro O
##se O
gel O
electro O
##ph O
##ores O
##is O
and O
extracted O
by O
the O
dna O
and O
gel O
band O
pu O
##ri O
##ﬁ O
##cation O
kit O
ge O
healthcare O
and O
sequence O
##d O
results O
were O
compared O
with O
the O
gene O
##bank O
reference O
sequences O

nc O
000 O
##01 O
##5 O
8 O
range O
87 O
##6 O
##7 O
##90 O
##30 O
87 O
##66 O
##0 O
##55 O
##4 O
complement O
and O
nm O
00 O
##26 O
##9 O
##3 O
2 O
en O
##zy O
##matic O
measurements O
the O
dna O
pol O
γ O
activity O
was O
measured O
in O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
using O
the O
rna O
directed O
dna O
polymer O
##ase O
ass O
##ay O
with O
a O
procedure O
based O
on O
that O
described O
previously O
na O
##via O
##ux O
et O
al O
1999 O
tha O
##wed O
mit O
##och O
##ond O
##ria O
were O
l O
##yse O
##d O
as O
reported O
mo O
##uss O
##on O
de O
cam O
##are O
##t O
et O
al O
2007 O
serial O
dil O
##ution O
##s O
of O
l O
##yse O
##d O
mit O
##och O
##ond O
##ria O
were O
prepared O
to O
obtain O
ﬁ O
##nal O
concentration O
of O
0 O
15 O
0 O
25 O
0 O
5 O
1 O
0 O
and O
1 O
5 O
μ O
##g O
per O
ass O
##ay O
the O
standard O
reaction O
mixture O

contained O
50 O
mm O
tri O
##s O
hc O
##l O
ph O
8 O
0 O
50 O
mm O
na O
##cl O
5 O
mm O
kc O
##l O
5 O
mm O
mg O
##cl O
##2 O
and O
0 O
5 O
mm O
mn O
##cl O
##2 O
10 O
mm O
dt O
##t O
10 O
mg O
l O
poly O
ra O
and O
5 O
mg O
l O
ol O
##igo O
##dt O
##12 O
18 O
am O
##ers O
##ham O
bio O
##sc O
##ience O
##s O
5 O
μ O
##m O
dt O
##tp O
and O
50 O
μ O
##ci O
ml O
of O
α O
32 O
##p O
dt O
##tp O
per O
##kin O
elmer O
10 O
μ O
##ci O
μ O
##l O
3000 O
ci O
mm O
##ol O
0 O
01 O
##7 O
μ O
##m O
ﬁ O
##nal O
concentration O
in O
a O
ﬁ O
##nal O
volume O
of O
20 O
μ O
##l O
ass O
##ays O
were O
initiated O
by O
addition O
of O
0 O
15 O
to O
1 O
5 O
μ O
##g O
of O
mitochondrial O
protein O
per O
ass O
##ay O
and O
conducted O
at O
37 O
during O
30 O
min O
the O
reaction O
was O
stopped O
at O
4 O

and O
the O
amount O
of O
the O
reaction O
products O
was O
determined O
by O
spotting O
ali O
##qu O
##ots O
of O
4 O
μ O
##l O
on O
what O
##man O
de O
81 O
an O
##ion O
exchange O
papers O
fischer O
bio O
##block O
the O
papers O
were O
then O
washed O
as O
described O
na O
##via O
##ux O
et O
al O
1999 O
for O
each O
dil O
##ution O
of O
mit O
##och O
##ond O
##ria O
a O
parallel O
ass O
##ay O
was O
performed O
with O
5 O
μ O
##m O
2 O
3 O
did O
##eo O
##xy O
##thy O
##mi O
##dine O
5 O
trip O
##hos O
##phate O
dd O
##tt O
##p O
data O
obtained O
from O
each O
dil O
##ution O
were O
used O
to O
establish O
a O
regression O
line O
for O
each O
sample O
regression O
analysis O
was O
used O
to O
calculate O
spec O
##i O
##ﬁ O
##c O
activity O
according O
to O
na O
##via O
##ux O
et O
al O
1999 O
dna O
pol O
γ O
spec O
##i O
##ﬁ O
##c O
activity O
dd O
##tt O
##p O
sensitive O
was O
obtained O
as O
the O
difference O

between O
the O
two O
parallel O
ass O
##ays O
measured O
with O
and O
without O
dd O
##tt O
##p O
one O
unit O
of O
spec O
##i O
##ﬁ O
##c O
activity O
u O
is O
given O
as O
the O
incorporation O
of O
one O
pic O
##omo O
##le O
of O
dt O
##tp O
per O
min O
per O
mg O
of O
protein O
results O
molecular O
investigations O
pol B-GENE
##g I-GENE
sequence O
variations O
patient B-PATIENT
1 I-PATIENT
is O
a O
compound O
het O
##ero O
##zy O
##go O
##te O
for O
two O
sequence O
variations O
i O
the O
common B-GENE_VARIANT
c I-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##gna I-GENE_VARIANT
in O
ex O
##on O
7 O
which O
predict O
##s O
a O
substitution O
of O
ala O
with O
th O
##r O
at O
cod O
##on O
46 O
##7 O
p B-GENE_VARIANT
ala I-GENE_VARIANT
##46 I-GENE_VARIANT
##7th I-GENE_VARIANT
##r I-GENE_VARIANT
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
in O
the O
thumb O
sub O
##dom O
##ain O
of O
the O
protein O
pol O
domain O
na O
##via O
##ux O
and O
nguyen O
2004 O
lee O
et O

al O
2009 O
ii O
a O
novel O
ga O
##ta O
du O
##plication O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
located O
14 O
nt O
before O
the O
3 O
end O
of O
ex O
##on O
22 O
this O
du O
##plication O
creates O
a O
premature O
termination O
cod O
##on O
pt O
##c O
located O
17 O
nt O
upstream O
from O
the O
intro O
##n O
22 O
the O
mother O
was O
the O
carrier O
of O
the O
a O
##46 O
##7 O
##t O
and O
the O
father O
of O
the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
not O
shown O

patient B-PATIENT
2 O
pol B-GENE
##g I-GENE
of O
patient O
2 O
harbor O
##ed O
two O
het O
##ero O
##zy O
##go O
##us O
base O
changes O
i O
the O
previously O
reported O
combination O
in O
cis B-GENE_VARIANT
p I-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e B-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
van O
goethe O
##m O
et O
al O
2004 O
ferrari O
et O
al O
2005 O
ii O
the O
recently O
reported O
t O
to O
c O
substitution O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
##t I-GENE_VARIANT
##nc I-GENE_VARIANT
ab O
##olis O
##hing O
the O
in O
##var O
##iable O
consensus O
gt O
sp O
##lice O
donor O
site O
of O
intro O
##n O
22 O
roe O
##ls O
et O
al O
2009 O
patient B-PATIENT
2 I-PATIENT
inherited O
the O
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e I-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
from O
his O
mother O
and O
the O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
tn I-GENE_VARIANT
##c I-GENE_VARIANT
from O
his O
father O
not O
shown O
rt O
pc O
##r O
analysis O

to O
identify O
the O
impact O
of O
these O
variations O
on O
sp O
##lic O
##ing O
cd O
##nas O
from O
both O
patients O
and O
a O
control O
were O
amp O
##li O
##ﬁ O
##ed O
with O
prime O
##rs O
located O
in O
ex O
##ons O
21 O
and O
23 O
as O
expected O
for O
patient O
2 O
two O
different O
amp O
##li O
##ﬁ O
##cation O
products O
were O
revealed O
an O
approx O
49 O
##6 O
bp O
band O
of O
expected O
size O
and O
a O
336 O
bp O
shorter O
one O
fig O
1 O
lane O
3 O
sequencing O
of O
these O
pu O
##ri O
##ﬁ O
##ed O

products O
demonstrated O
that O
the O
49 O
##6 O
bp O
fragment O
corresponded O
to O
ex O
##ons O
21 O
22 O
23 O
from O
the O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
all O
##ele O
while O
the O
shorter O
one O
corresponded O
to O
ex O
##on O
21 O
directly O
linked O
to O
ex O
##on O
23 O
fig O
2 O
thus O
the O
c O
36 O
##43 O
2 O
##t O
##nc O
variation O
in O
patient O
2 O
causes O
complete O
skipping O
of O
ex O
##on O
22 O
furthermore O
ex O
##on O
22 O
skipping O
introduces O
a O
pt O
##c O
located O
one O
cod O
##on O
into O
the O
last O
ex O
##on O
23 O
resulting O
in O
a O
c O
terminal O
78 O
amino O
acid O
tr O
##un O
##cation O
of O
the O
protein O

for O
patient O
1 O
surprisingly O
the O
same O
pattern O
of O
amp O
##li O
##ﬁ O
##cation O
products O
was O
obtained O
fig O
1 O
lane O
1 O
but O
the O
intensity O
of O
the O
336 O
bp O
product O
was O
faint O
##er O
than O
for O
patient O
2 O
sequencing O
of O
the O
normal O
size O
49 O
##6 O
bp O
product O
showed O
two O
different O
species O
one O
bearing O
the O
ga O
##ta O
du O
##plication O
and O
the O
other O
bearing O
the O
wild O
type O
ga O
##ta O
sequence O
and O
sequencing O
of O
the O
336 O
bp O
shorter O
product O
showed O
ex O
##on O
22 O
skipping O

fig O
1 O
amp O
##li O
##ﬁ O
##cation O
of O
ex O
##ons O
21 O
23 O
from O
cd O
##nas O
of O
patients O
ex O
##ons O
21 O
23 O
of O
cd O
##nas O
were O
amp O
##li O
##ﬁ O
##ed O
using O
the O
ex O
##on O
21 O
forward O
prime O
##r O
nt O
335 O
##6 O
337 O
##5 O
and O
the O
ex O
##on O
23 O
reverse O
prime O
##r O
nt O
385 O
##1 O
38 O
##32 O
nu O
##cle O
##otide O
numbering O
uses O
the O
a O
of O
the O
ﬁ O
##rst O
at O
##g O
translation O
initiation O
start O
cod O
##on O
as O
nu O
##cle O
##otide O
1 O
lanes O
1 O
and O
2 O
cd O
##na O
from O
ﬁ O
##bro O
##bla O
##sts O
of O
patient O
1 O
and O
a O
control O
respectively O
lanes O
3 O
4 O
5 O
and O
6 O
cd O
##na O
from O
ﬁ O
##bro O
##bla O
##sts O
of O
patient O
2 O
a O
control O
his O
mother O
and O
his O
father O
respectively O
lanes O
7 O
and O
8 O
cd O
##na O
from O
am O
##nio O
##tic O
cells O
patient O
2 O
family O
and O
a O
control O
respectively O
m O
is O
a O
100 O
bp O
ladder O

fig O
2 O
this O
cd O
##na O
study O
showed O
an O
unexpected O
sp O
##lic O
##ing O
defect O
for O
patient O
1 O
as O
two O
kinds O
of O
transcript O
##s O
were O
produced O
from O
the O
ga O
##ta O
duplicate O
##d O
all O
##ele O
one O
containing O
ex O
##on O
22 O
with O
the O
ga O
##ta O
du O
##plication O
and O
one O
with O
ex O
##on O
22 O
skipping O
dna O
pol O
γ O
measurements O
to O
assess O
the O
pathogen O
##ici O
##ty O
of O
the O
pol O
##g O
gene O
variations O
in O
both O
patients O
we O
used O
a O
rna O
directed O
dna O
polymer O
##ase O
ass O
##ay O
for O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
the O

dd O
##tt O
##p O
sensitive O
incorporation O
of O
dt O
##tp O
was O
used O
to O
calculate O
dna O
polymer O
##ase O
γ O
activity O
a O
85 O
95 O
dd O
##tt O
##p O
sensitivity O
of O
the O
total O
dt O
##tp O
incorporation O
was O
obtained O
in O
control O
and O
patients O
mit O
##och O
##ond O
##ria O
similar O
results O
of O
dd O
##tt O
##p O
sensitivity O
were O
reported O
elsewhere O
na O
##via O
##ux O
et O
al O
1999 O
sp O
##el O
##bri O
##nk O
et O
al O
2000 O
ta O
##an O
##man O
et O
al O
2009 O

a O
low O
level O
of O
enzyme O
activity O
was O
measured O
in O
the O
mit O
##och O
##ond O
##ria O
of O
both O
patients O
table O
1 O
18 O
8 O
u O
for O
patient O
1 O
and O
15 O
8 O
u O
for O
patient O
2 O
compared O
to O
the O
controls O
56 O
6 O
u O
##± O
17 O
8 O
n O
8 O
range O
36 O
6 O
91 O
0 O
residual O
activities O
were O
33 O
and O
28 O
of O
the O
mean O
control O
value O
for O
patients O
1 O
and O
2 O
respectively O
discussion O

we O
investigated O
pol O
##g O
in O
two O
unrelated O
children O
presenting O
with O
al O
##pers O
syndrome O
patient B-GENE_VARIANT
1 I-GENE_VARIANT
harbor O
##ed O
the O
novel O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##26 I-GENE_VARIANT
36 I-GENE_VARIANT
##29 I-GENE_VARIANT
##du I-GENE_VARIANT
##pg I-GENE_VARIANT
##ata I-GENE_VARIANT
in O
ex O
##on O
22 O
in O
trans O
with O
the O
common O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
patient B-PATIENT
2 I-PATIENT
the O
recently O
reported O
c B-GENE_VARIANT
36 I-GENE_VARIANT
##43 I-GENE_VARIANT
2 I-GENE_VARIANT
##t I-GENE_VARIANT
##nc I-GENE_VARIANT
in O
trans O
with O
the O
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
e I-GENE_VARIANT
##11 I-GENE_VARIANT
##43 I-GENE_VARIANT
##g I-GENE_VARIANT
in O
order O
to O
evaluate O
the O
consequences O
of O
the O
mutant O
all O
##eles O
on O
pol O
##g O
##1 O
bio O
##chemical O
function O
catalytic O
activity O
of O
dna O
pol O
γ O
was O
assessed O
in O
organ O
##ello O
on O
mit O
##och O
##ond O
##ria O
enriched O
preparations O
from O
culture O
##d O
ﬁ O
##bro O
##bla O
##sts O
the O
a O
##46 O
##7 O
##t O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
c O
36 O
##43 O
2 O
##t O
##nc O
enzymes O
showed O
a O
decreased O
catalytic O
rate O
33 O
and O
28 O
of O
the O
mean O
control O
activity O
for O
patients O
1 O
and O
2 O

respectively O

as O
both O
the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
and O
the O
c O
36 O
##43 O
2 O
##t O
##nc O
create O
a O
pt O
##c O
and O
probably O
inactive O
proteins O
the O
level O
of O
residual O
activity O
for O
each O
patient O
is O
to O
be O
likely O
the O
re O
##ﬂ O
##ect O
of O
the O
a O
##46 O
##7 O
##t O
or O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
mutant O
proteins O
it O
has O
been O
established O
that O
either O
the O
a O
##46 O
##7 O
##t O
or O
the O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
rec O
##om O
##bina O
##nt O
proteins O
harbor O
##ed O
decreased O
activity O
chan O
et O
al O
2005 O
##a O
2006 O
recently O
disease O
associated O
pol O
γ O
variations O
have O
been O
divided O
into O
three O
classes O
lee O
et O
al O
2009 O
w O
##7 O
##48 O
##s O
and O
a O
##46 O
##7 O
##t O
are O
included O
into O
class O
ii O
and O
class O
iii O
respectively O
the O
class O
ii O
variations O
are O
located O
in O
the O
dna O
binding O
channel O
leading O
to O
reduced O
dna O
binding O
and O
lower O
polymer O
##ase O
activity O
the O
most O

fig O
2 O
sequence O
analysis O
of O
cd O
##na O
fragments O
left O
panel O
sequences O
from O
the O
approx O
49 O
##6 O
bp O
band O
found O
in O
lanes O
2 O
8 O
showing O
only O
the O
wild O
type O
ex O
##on O
21 O
22 O
junction O
middle O
panel O
sequences O
from O
the O
approx O
49 O
##6 O
bp O
band O
found O
in O
lane O
1 O
corresponding O
to O
both O
the O
c O
36 O
##26 O
36 O
##29 O
du O
##pg O
##ata O
and O
non O
duplicate O
##d O
sequences O
right O
panel O
sequences O
from O
the O
approx O
336 O
bp O
band O
found O
in O
lanes O
1 O
3 O
6 O
and O
7 O
showing O
the O
ex O
##on O
21 O
23 O
junction O
and O
the O
skipping O
of O
ex O
##on O
22 O
ex O
##on O
22 O
skipping O
produces O
a O
t O
##ga O
termination O
cod O
##on O
at O
the O
ﬁ O
##rst O
coding O
position O
of O
ex O
##on O
23 O
under O
##lined O

common O
substitution O
a O
##46 O
##7 O
##t O
falls O
into O
class O
iii O
containing O
mutants O
that O
are O
located O
along O
the O
subunit O
interface O
between O
pol O
##g O
##1 O
and O
pol O
##g O
##2 O
reducing O
both O
process O
##ivity O
of O
pol O
γ O
and O
dna O
binding O

the O
c O
36 O
##43 O
2 O
##t O
##nc O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
pol O
##g O
gene O
from O
patient O
2 O
induce O
##s O
complete O
ex O
##on O
22 O
skipping O
from O
the O
transcript O
substitution O
affecting O
the O
invariant O
gt O
din O
##uc O
##le O
##otide O
at O
the O
donor O
sp O
##lice O
results O
either O
in O
the O
use O
of O
a O
pre O
##ex O
##ist O
##ing O
but O
weaker O
cryptic O
donor O
site O
or O
in O
ex O
##on O
skipping O
k O
##ra O
##wc O
##zak O
et O
al O
1992 O
the O
transcript O
lacking O
ex O
##on O
22 O
has O
a O
pt O
##c O
in O
ex O
##on O
23 O
and O
is O
not O
destroyed O
by O
the O
nonsense O
mediated O
mrna O
decay O
nm O
##d O
pathway O
as O
this O
pt O
##c O
is O
in O
the O
last O
ex O
##on O
the O
truncated O
protein O
encoded O
by O
this O
abnormal O
transcript O
would O
have O
only O
46 O
of O
the O
c O
terminal O
pol O
sub O
##dom O
##ain O
lee O
et O
al O
2009 O
and O
could O
be O
mis O
##fold O
##ed O
and O
sent O
for O
degradation O

the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
all O
##ele O
has O
two O
different O
transcript O
##s O
both O
containing O
a O
pt O
##c O
and O
both O
escaping O
nm O
##d O
1 O
a O
full O
length O
carrying O
the O
du O
##plication O
resulting O
in O
a O
pt O
##c O
in O
ex O
##on O
22 O
and O
2 O
a O
transcript O
with O
a O
skipped O
ex O
##on O
22 O
the O
pt O
##c O
created O
by O
the O
du O
##plication O
17 O
nt O
upstream O
from O
the O
last O
ex O
##on O
junction O
complex O
e O
##j O
##c O
is O
not O
located O
at O
least O
50 O
55 O
nt O
upstream O
from O
at O
least O
one O
e O
##j O
##c O
as O
described O
previously O
in O
the O
87 O
##3 O
x O
all O
##ele O
chan O
et O
al O
2005 O
##b O
this O
pt O
##c O
results O
in O
a O
truncated O
protein O

lacking O
the O
last O
31 O
amino O
##ac O
##ids O
and O
removing O
21 O
of O
the O
c O
terminal O
pol O
sub O
##dom O
##ain O
lee O
et O
al O
2009 O
and O
probably O
sent O
for O
degradation O
these O
two O
abnormal O
transcript O
##s O
arising O
from O
the O
duplicate O
##d O
all O
##ele O
are O
not O
targets O
for O
nm O
##d O
as O
described O
for O
other O
pol O
##g O
transcript O
##s O
containing O
pt O
##c O
chan O
et O
al O
2005 O
##b O
2009 O
whatever O
the O
relative O
amount O
of O
these O
two O
abnormal O
transcript O
##s O
they O
lead O
obviously O
to O
truncated O
proteins O
and O
ha O
##pl O
##oin O
##su O
##f O
##ﬁ O
##ciency O

sp O
##lic O
##ing O
is O
a O
highly O
regulated O
mechanism O
and O
variations O
affecting O
sp O
##lic O
##ing O
regulatory O
elements O
sr O
##e O
can O
disrupt O
sp O
##lic O
##ing O
cart O
##eg O
##ni O
et O
al O
2002 O
ex O
##onic O
sr O
##e O
promoting O
ex O
##on O
inclusion O
are O
referred O
to O
as O
ex O
##onic O
sp O
##lic O
##ing O
enhance O
##rs O
es O
##e O
and O
those O
inhibit O
##ing O
ex O
##on O
inclusion O
are O
ex O
##onic O
table O
1 O

dna O
polymer O
##ase O
γ O
activity O
of O
human O
wild O
type O
and O
mutant O
enzymes O
samples O
were O
measured O
under O
standard O
conditions O
see O
subjects O
and O
methods O
for O
patients O
and O
controls O
two O
different O
ali O
##qu O
##ots O
of O
mit O
##och O
##ond O
##ria O
were O
submitted O
to O
serial O
dil O
##ution O
##s O
0 O
15 O
to O
1 O
5 O
μ O
##g O
of O
proteins O
per O
ass O
##ay O
each O
dil O
##ution O
was O
measured O
twice O
and O
data O
are O
averaged O
spec O
##i O
##ﬁ O
##c O
activity O
u O
was O
calculated O
as O
described O
in O
subjects O
and O
methods O
for O
patients O
u O
values O
are O
the O
mean O
of O
two O
independent O
measurements O
with O
each O
value O
in O
parentheses O
for O
controls O
u O
value O
is O
the O
mean O
for O
eight O
control O
lines O
within O
the O
age O
range O
of O
patients O
sd O
standard O
deviation O
n O
number O
of O
samples O
percentage O
of O
the O
mean O
control O
value O

sp O
##lic O
##ing O
silence O
##rs O
es O
##s O
ex O
##on O
inclusion O
skipping O
is O
a O
result O
of O
a O
ﬁ O
##ne O
balance O
between O
enhance O
##rs O
and O
silence O
##rs O
both O
in O
con O
##sti O
##tu O
##tive O
and O
alternative O
sp O
##lic O
##ing O
these O
sequences O
are O
bound O
by O
ser O
##ine O
ar O
##gin O
##ine O
rich O
sr O
proteins O
for O
many O
es O
##e O
and O
het O
##ero O
##gen O
##eous O
nuclear O
rib O
##on O
##uc O
##le O
##op O
##rot O
##ein O
##s O
h O
##nr O
##np O
for O
es O
##s O
ju O
##rica O
and O
moore O
2003 O
to O
test O
the O
hypothesis O
that O
the O
c O
36 O
##26 O
36 O
##29 O
##du O
##pg O
##ata O
could O
involve O
a O
sr O
##e O
the O
normal O
and O
duplicate O
##d O
sequences O
were O
submitted O
to O
search O
for O
es O
##e O
es O
##s O
motifs O
with O
human O
sp O
##lic O
##ing O
find O
##er O
hs O
##f O
website O
des O
##met O
et O
al O
2009 O
no O
sign O
##i O
##ﬁ O
##can O
##t O
change O
of O
the O
motif O
scores O
for O
four O
sr O
proteins O
sf O
##2 O
as O
##f O
sc O
##35 O
sr O
##p O
##40 O
and O
sr O
##p O
##55 O
was O
observed O
in O
the O
ga O
##ta O
duplicate O
##d O
sequence O
compared O
with O
the O
wild O
type O
sequence O
but O
when O
screening O
for O
es O
##s O
motifs O
it O
appears O
that O
the O
ga O
##ta O
du O
##plication O
creates O
a O
new O
binding O
site O
tag O
##ata O
for O
h O
##nr O
##np O
a1 O
with O
a O
sign O
##i O
##ﬁ O
##can O
##t O
strength O
binding O
of O
h O
##nr O
##np O
a1 O
on O
a O
fraction O
of O
the O
transcript O
with O
the O
duplicate O
##d O
sequence O
could O
be O
responsible O
for O
the O
partial O
ex O
##on O
22 O
skipping O
observed O
in O
cd O
##na O
from O
patient O
1 O
although O
this O
should O
be O
experimental O
##ly O
demonstrated O
a O
recent O
paper O
woolf O
##e O
et O
al O
2010 O
showed O
a O
clear O
enrichment O
for O
silence O
##r O
creation O
in O
sp O
##lice O
affecting O
genome O
variants O

in O
conclusion O
two O
different O
mechanisms O
are O
involved O
in O
the O
ha O
##pl O
##oin O
##su O
##f O
##ﬁ O
##ciency O
in O
these O
patients O
i O
e O
pt O
##c O
and O
partial B-GENE_VARIANT
ex I-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
1 I-PATIENT
complete B-GENE_VARIANT
ex I-GENE_VARIANT
##on I-GENE_VARIANT
22 I-GENE_VARIANT
skipping I-GENE_VARIANT
for O
patient B-PATIENT
2 I-PATIENT
and O
the O
severe B-HPO_TERM
ah I-HPO_TERM
##s I-HPO_TERM
ph O
##eno O
##type O
in O
these O
patients O
was O
a O
consequence O
of O
a O
single O
copy O
gene O
dose O
of O
the O
p O
a O
##46 O
##7 O
##t O
or O
the O
p O
w O
##7 O
##48 O
##s O
e O
##11 O
##43 O
##g O
all O
##ele O
ac O
##k O
##now O
##led O
##gm O
##ents O
this O
work O
was O
supported O
by O
the O
hospice O
##s O
civil O
##s O
de O
lyon O
and O
by O
the O
minister O
##e O
de O
la O
sant O
##e O
references O

carr O
##ode O
##gua O
##s O
j O
a O
kobayashi O
r O
lim O
s O
e O
copeland O
w O
c O
bog O
##en O
##ha O
##gen O
d O
f O
1999 O
the O
accessory O
subunit O
of O
x O
##eno O
##pus O
la O
##ev O
##is O
mitochondrial O
dna O
polymer O
##ase O
γ O
increases O
process O
##ivity O
of O
the O
catalytic O
subunit O
of O
human O
dna O
polymer O
##ase O
γ O
and O
is O
related O
to O
class O
ii O
amino O
##acy O
##l O
tr O
##na O
synth O
##eta O
##ses O
mo O
##l O
cell O
bio O
##l O
19 O
403 O
##9 O
404 O
##6 O
cart O
##eg O
##ni O
l O
chew O
s O
l O
k O
##raine O
##r O
a O
r O
2002 O
listening O
to O
silence O
and O
understanding O
nonsense O
ex O
##onic O
mutations O
that O
affect O
sp O
##lic O
##ing O
nat O
rev O
gene O
##t O
3 O
285 O
298 O

published O
in O
final O
edited O
form O
as O
fe O
##rti O
##l O
ste O
##ril O
2010 O
december O
94 O
7 O
293 O
##2 O
293 O
##4 O
doi O
10 O
1016 O
j O
fe O
##rt O
##nst O
##ert O
2010 O
06 O
04 O
##9 O
five O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
pol O
##g O
are O
not O
a O
prevalent O
et O
##iology O
for O
spontaneous O
46 O
xx O
primary O
o O
##var O
##ian O
ins O
##uf O
##fi O
##ciency O
sp O
##oi O
z O
##hi O
bin O
tong O
md O
shannon O
d O
sullivan O
md O
phd O
lindsey O
m O
law O
##less O
bs O
vie O
##n O
van O
##der O
##ho O
##of O
cr O
##np O
keith O
zach O
##man O
ms O
and O
lawrence O
m O
nelson O
md O

int O
##eg O
##rative O
reproductive O
medicine O
group O
intra O
##mura O
##l O
research O
program O
on O
reproductive O
and O
adult O
end O
##oc O
##rino O
##logy O
eun O
##ice O
kennedy O
shri O
##ver O
national O
institute O
of O
child O
health O
and O
human O
development O
national O
institutes O
of O
health O
beth O
##es O
##da O
maryland O
abstract O

the O
et O
##iology O
of O
most O
cases O
of O
spontaneous O
46 O
xx O
primary O
o O
##var O
##ian O
ins O
##uf O
##fi O
##ciency O
sp O
##oi O
is O
unknown O
however O
associations O
have O
been O
made O
between O
mitochondrial O
diseases O
due O
to O
mu O
##tated O
mitochondrial O
dna O
polymer O
##ase O
gamma O
pol O
##g O
and O
sp O
##oi O
here O
we O
show O
that O
in O
201 O
women O
with O
46 O
xx O
sp O
##oi O
rf O
##lp O
analysis O
of O
gen O
##omic O
dna O
shows O
only O
one O
case O
0 O
5 O
95 O
ci O
3 O
of O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
mt O
##dna O
pol O
##g O
mutation O
suggesting O
that O
this O
is O
not O
a O
common O
genetic O
et O
##iology O
for O
this O
form O
of O
in O
##fer O
##tility O

spontaneous O
46 O
xx O
primary O
o O
##var O
##ian O
ins O
##uf O
##fi O
##ciency O
sp O
##oi O
also O
known O
as O
premature O
o O
##var O
##ian O
failure O
po O
##f O
affects O
1 O
of O
women O
before O
age O
40 O
sp O
##oi O
is O
characterized O
by O
abnormal O
men O
##ses O
men O
##opa O
##usa O
##l O
f O
##sh O
and O
est O
##rogen O
deficiency O
due O
to O
primary O
o O
##var O
##ian O
dysfunction O
in O
90 O
of O
cases O
the O
et O
##iology O
is O
unknown O
recently O
several O
genetic O
abnormalities O
have O
been O
highly O
associated O
with O
sp O
##oi O
including O
mutations O
in O
mitochondrial O
dna O
polymer O
##ase O
γ O
pol O
##g O
1 O
4 O

pol O
##g O
is O
the O
only O
dna O
polymer O
##ase O
responsible O
for O
mitochondrial O
dna O
mt O
##dna O
replication O
and O
repair O
thus O
it O
is O
essential O
for O
mitochondrial O
function O
several O
pol O
##g O
mutations O
have O
been O
described O
resulting O
in O
del O
##eti O
##ons O
or O
point O
mutations O
in O
mt O
##dna O
and O
decreased O
polymer O
##ase O
activity O
although O
there O
is O
a O
spectrum O
in O
the O
degree O
of O
ins O
##uf O
##fi O
##ciency O
in O
polymer O
##ase O
activity O
the O
most O
severe O
mutations O
lead O
to O
loss O
of O
99 O
of O
polymer O
##ase O
function O
and O
cell O
death O
due O
to O
insufficient O
cellular O
energy O
production O
5 O
auto O
##som O
##al O
dominant O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
was O
the O
first O
disease O
associated O
with O
pol O
##g O
mutations O
3 O
6 O
additional O
pol O
##g O
driven O
mitochondrial O
diseases O
include O
parkinson O
s O
disease O
pd O
ep O
##ile O
##psy O
ata O
##xia O
psychiatric O
illnesses O
1 O
6 O
9 O
and O
primary O
go O
##nad O
##al O
ins O
##uf O
##fi O
##ciency O
in O
both O
men O
and O
women O
1 O
4 O
in O
women O
sp O
##oi O
co O
se O
##gre O
##gate O
##s O
with O
pe O
##o O
and O
parkinson O
s O
in O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
mutation O
carriers O
suggesting O
mt O
##dna O
polymer O
##ase O
activity O
is O
required O
for O
both O
normal O
ne O
##uro O
##logic O
and O
o O
##var O
##ian O
function O
1 O
several O
described O
pol O
##g O
mutations O
are O
associated O
with O
pe O
##o O
y O
##9 O
##55 O
##c O
indicating O
change O
from O
ty O
##ros O
##ine O
y O
to O

reprint O
requests O
shannon O
d O
sullivan O
md O
phd O
national O
institutes O
of O
health O
cr O
##c O
1 O
314 O
##0 O
10 O
center O
drive O
msc O
110 O
##9 O
beth O
##es O
##da O
md O
208 O
##9 O
##2 O
110 O
##3 O
usa O
fa O
##x O
301 O
402 O
08 O
##8 O
##4 O
sul O
##li O
##vs O
##h O
mail O
ni O
##h O
gov O

publisher O
s O
disc O
##lai O
##mer O
this O
is O
a O
pdf O
file O
of O
an O
une O
##dit O
##ed O
manuscript O
that O
has O
been O
accepted O
for O
publication O
as O
a O
service O
to O
our O
customers O
we O
are O
providing O
this O
early O
version O
of O
the O
manuscript O
the O
manuscript O
will O
undergo O
copy O
##ed O
##iting O
types O
##etti O
##ng O
and O
review O
of O
the O
resulting O
proof O
before O
it O
is O
published O
in O
its O
final O
ci O
##table O
form O
please O
note O
that O
during O
the O
production O
process O
errors O
may O
be O
discovered O
which O
could O
affect O
the O
content O
and O
all O
legal O
disc O
##lai O
##mers O
that O
apply O
to O
the O
journal O
per O
##tain O
tong O
et O
al O
page O
2 O

cy O
##sti O
##ne O
c O
at O
the O
95 O
##5 O
##th O
peptide O
residue O
r O
##9 O
##43 O
##h O
g O
##9 O
##23 O
##d O
a O
##9 O
##57 O
##s O
and O
r O
##9 O
##53 O
##c O
5 O
10 O
of O
these O
r O
##9 O
##43 O
##h O
has O
also O
been O
associated O
with O
sp O
##oi O
3 O

to O
determine O
if O
pol O
##g O
mutations O
known O
to O
be O
associated O
with O
pe O
##o O
are O
also O
associated O
with O
sp O
##oi O
we O
screened O
the O
gen O
##omic O
dna O
of O
women O
with O
46 O
xx O
sp O
##oi O
for O
the O
5 O
pol O
##g O
mutations O
described O
above O
g O
##9 O
##23 O
##d O
r O
##9 O
##43 O
##h O
r O
##9 O
##53 O
##c O
y O
##9 O
##55 O
##c O
and O
a O
##9 O
##57 O
##s O
women O
aged O
18 O
42 O
with O
46 O
xx O
sp O
##oi O
n O
201 O
were O
recruited O
between O
august O
2004 O
and O
march O
2006 O
as O
part O
of O
an O
ongoing O
cross O
sectional O
study O
evaluating O
the O
health O
of O
women O
with O
sp O
##oi O
11 O
women O
with O
known O
ia O
##tro O
##genic O
cause O
of O
po O
##i O
were O
excluded O
46 O
xx O
sp O
##oi O
was O
defined O
as O
abnormal O
men O
##ses O
for O
at O
least O
four O
months O
men O
##opa O
##usa O
##l O
range O
f O
##sh O
levels O
confirmed O
on O
two O
occasions O
at O
least O
one O
month O
apart O
and O
age O
less O
than O
40 O
at O
the O
time O
of O
diagnosis O
this O
study O
was O
approved O
by O
the O
institutional O
review O
board O
of O
the O
national O
institute O
of O
child O
health O
and O
human O
development O

demographics O
of O
this O
group O
was O
similar O
to O
that O
seen O
in O
other O
published O
groups O
of O
women O
with O
46 O
xx O
sp O
##oi O
12 O
82 O
caucasian O
164 O
201 O
9 O
black O
19 O
201 O
5 O
hispanic O
11 O
201 O
and O
2 O
asian O
5 O
201 O
f O
##sh O
was O
elevated O
into O
the O
men O
##opa O
##usa O
##l O
range O
in O
all O
women O
mean O
f O
##sh O
77 O
4 O
37 O
8 O
u O
l O
with O
corresponding O
low O
serum O
est O
##rad O
##iol O
levels O
mean O
e O
##2 O
44 O
5 O
42 O
7 O
pg O
ml O
112 O
56 O
women O
were O
tested O
for O
a O
prem O
##utation O
in O
the O
fragile O
x O
fm O
##r O
##1 O
gene O
3 O
of O
these O
women O
3 O
carry O
the O
fm O
##r O
##1 O
prem O
##utation O
defined O
as O
55 O
199 O
c O
##gg O
repeats O
on O
the O
fm O
##r O
##1 O
gene O
which O
itself O
in O
##fers O
approximately O
a O
20 O
risk O
of O
developing O
sp O
##oi O

13 O
1 O
woman O
0 O
5 O
had O
ste O
##roid O
##ogenic O
cell O
auto O
##ant O
##ib O
##odies O
indicating O
auto O
##im O
##mun O
##e O
o O
##op O
##hor O
##itis O
as O
the O
primary O
cause O
of O
her O
sp O
##oi O
45 O
women O
22 O
reported O
a O
family O
history O
of O
sp O
##oi O
or O
po O
##f O
or O
premature O
men O
##opa O
##use O
several O
patients O
reported O
a O
family O
history O
of O
ne O
##uro O
##logic O
disorders O
parkinson O
s O
disease O
4 O
5 O
tremor O
10 O
ata O
##xia O
4 O
early O
onset O
hearing O
loss O
3 O
5 O
learning O
disability O
14 O
4 O
and O
mental O
re O
##tar O
##dation O
1 O

gen O
##omic O
dna O
from O
each O
patient O
was O
isolated O
using O
a O
rapid O
non O
en O
##zy O
##matic O
method O
and O
amplified O
using O
pc O
##r O
as O
previously O
described O
14 O
15 O
we O
performed O
dna O
mu O
##tage O
##nes O
##is O
on O
a O
pl O
##as O
##mi O
##d O
with O
the O
pc O
##r O
products O
460 O
bp O
containing O
normal O
sequences O
of O
ex O
##on O
18 O
of O
the O
pol O
##g O
using O
qui O
##k O
##chang O
##e O
ii O
xl O
site O
directed O
mu O
##tage O
##nes O
##is O
kit O
strata O
##gen O
##e O
and O
confirmed O
the O
expected O
mutant O
pl O
##as O
##mi O
##ds O
with O
the O
pol O
##g O
mutations O
c2 O
##7 O
##6 O
##7 O
##g O
a O
c2 O
##8 O
##28 O
##g O
a O
c2 O
##85 O
##7 O
##c O
t O
c2 O
##86 O
##4 O
##a O
g O
and O
c2 O
##86 O
##9 O
##g O
t O
individually O
these O
mutant O
pl O
##as O
##mi O
##ds O
were O
used O
as O
template O
##s O
for O
pc O
##r O
reactions O
for O
positive O
controls O
of O
such O
dna O
mutations O
in O
rf O
##lp O
analysis O
as O
shown O
in O
table O
1 O
the O
restriction O
enzymes O
mw O
##oi O
ms O
##li O
ea O
##gi O
al O
##wn O
##i O
and O
bs O
##ey O
##i O
were O
used O
and O
the O
resultant O
dna O
fragments O
were O
separated O
by O
gel O
electro O
##ph O
##ores O
##is O
to O
screen O
for O
the O
pol O
##g O
mutations O
c2 O
##7 O
##6 O
##7 O
##g O
a O
c2 O
##8 O
##28 O
##g O
a O
c2 O
##85 O
##7 O
##c O
t O
c2 O
##86 O
##4 O
##a O
g O
and O
c2 O
##86 O
##9 O
##g O
t O
respectively O

these O
nu O
##cle O
##otide O
changes O
lead O
to O
the O
pol O
##g O
mutations O
of O
the O
peptide O
residues O
with O
g O
##9 O
##23 O
##d O
r O
##9 O
##43 O
##h O
r O
##9 O
##53 O
##c O
y O
##9 O
##55 O
##c O
and O
a O
##9 O
##57 O
##s O
respectively O

mitochondrial O
dna O
pol O
##g O
mutations O
are O
associated O
with O
sp O
##oi O
in O
combination O
with O
other O
mitochondrial O
diseases O
particularly O
pe O
##o O
we O
screened O
201 O
women O
with O
46 O
xx O
sp O
##oi O
for O
five O
pol O
##g O
mutations O
with O
known O
association O
with O
pe O
##o O
including O
y O
##9 O
##55 O
##c O
and O
r O
##9 O
##43 O
##h O
which O
have O
also O
been O
associated O
with O
sp O
##oi O
1 O
3 O
4 O
only O
1 O
of O
the O
201 O
women O
we O
screened O
0 O
5 O
demonstrated O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
single O
pol B-GENE
##g I-GENE
mutation O
c2 B-GENE_VARIANT
##85 I-GENE_VARIANT
##7 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
r B-GENE_VARIANT
##9 I-GENE_VARIANT
##53 I-GENE_VARIANT
##c I-GENE_VARIANT
table O
1 O
based O
on O
this O
observation O
95 O
confidence O
level O
indicates O
the O
frequency O
of O
these O
pol O
##g O
mutations O
accounts O
for O
3 O
of O
cases O
of O
46 O
xx O
sp O
##oi O

the O
woman B-PATIENT
found O
to O
have O
a O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
mutation O
was O
an O
otherwise O
healthy O
28 B-AGE_ONSET
##year I-AGE_ONSET
old O
caucasian O
she O
had O
men O
##ar O
##che O
at O
age O
11 O
and O
normal O
monthly O
men O
##ses O
until O
age O
28 B-AGE_ONSET
at O
which O
time O
she O
developed O
ol B-HPO_TERM
##igo I-HPO_TERM
##men I-HPO_TERM
##or I-HPO_TERM
##rh I-HPO_TERM
##ea I-HPO_TERM
men O
##ses O
every O
3 O
to O
4 O
months O
she O
was O
diagnosed O
with O
sp O
##oi O
after O
fertility O
work O
##up O
showed O
men O
##opa O
##usa O
##l O
range O
f O
##sh O
she O
had O
been O
attempting O
pregnancy O
for O
approximately O
5 O
years O
without O
success O
in O
addition O
to O
sp O
##oi O
she O
had O
one O
co O
tong O
et O
al O
page O
3 O

mor O
##bid O
medical O
condition O
men B-HPO_TERM
##iere I-HPO_TERM
s I-HPO_TERM
syndrome I-HPO_TERM
characterized O
by O
ep B-HPO_TERM
##iso I-HPO_TERM
##dic I-HPO_TERM
vertigo I-HPO_TERM
tin B-HPO_TERM
##ni I-HPO_TERM
##tus I-HPO_TERM
and O
hearing B-HPO_TERM
loss I-HPO_TERM
due O
to O
damage O
to O
the O
inner O
ear O
she O
had O
no O
current O
or O
past O
history O
of O
anxiety O
or O
depression O
and O
no O
auto O
##im O
##mun O
##e O
disorders O
family O
history O
was O
negative O
for O
in O
##fer O
##tility O
sp O
##oi O
or O
other O
men O
##st O
##ru O
##al O
irregular O
##ity O
ne O
##uro O
##logic O
disorders O
including O
pe O
##o O
or O
pd O
and O
except O
for O
al O
##ope O
##cia O
in O
a O
maternal O
grandmother O
negative O
for O
auto O
##im O
##mun O
##e O
disease O
at O
the O
ni O
##h O
this O
patient O
s O
mean O
serum O
f O
##sh O
was O
72 O
7 O
u O
l O
l O
##h O
53 O
7 O
u O
l O
est O
##rad O
##iol O
58 O
2 O
pg O
ml O
and O
pro O
##ges O
##ter O
##one O
0 O
5 O
ng O
ml O
anti O
ad O
##ren O
##al O
and O
21 O
hydro O
##xy O
##lase O
antibodies O
were O
negative O
fm O
##r O
##1 O
prem O
##utation O
testing O
was O
normal O
ruling O
out O
fragile O
x O
associated O
po O
##i O
trans O
##va O
##ginal O
ultrasound O
showed O
an O
8 O
mm O
end O
##ome O
##tri O
##al O
stripe O
a O
2 O
4 O
##× O
##2 O
5 O
##× O
##0 O
9 O
cm O
left O
o O
##vary O
without O
evident O
f O
##oll O
##icles O
and O
a O
2 O
7 O
##× O
##1 O
0 O
##× O
##2 O
3 O
cm O
right O
o O
##vary O
with O
one O
9 O
mm O
f O
##oll O
##icle O

the O
pol B-GENE
##g I-GENE
r B-GENE_VARIANT
##9 I-GENE_VARIANT
##53 I-GENE_VARIANT
##c I-GENE_VARIANT
mutation O
has O
not O
been O
definitive O
##ly O
associated O
with O
sp O
##oi O
although O
such O
a O
relationship O
has O
been O
suggested O
by O
its O
association O
with O
a O
parkinson O
s O
like O
syndrome O
that O
co O
##se O
##gre O
##gate O
##s O
with O
po O
##i O
within O
families O
1 O
thus O
the O
pol O
##g O
r O
##9 O
##53 O
##c O
mutation O
may O
be O
a O
rare O
cause O
of O
sp O
##oi O
due O
to O
mitochondrial O
dysfunction O
a O
direct O
relationship O
between O
the O
r O
##9 O
##53 O
##c O
mutation O
and O
sp O
##oi O
cannot O
be O
determined O
from O
this O
study O
however O
previous O
work O
has O
shown O
that O
neither O
the O
r O
##9 O
##53 O
##c O
nor O
any O
other O
pol O
##g O
mutations O
were O
present O
among O
1640 O
healthy O
controls O
1 O
suggesting O
the O
possibility O
of O
a O
causal O
association O
with O
this O
fertility O
disorder O
however O
whether O
r O
##9 O
##53 O
##c O
is O
a O
rare O
dna O
sequence O
variant O
or O
a O
true O
functional O
mutation O
cannot O
be O
determined O
from O
this O
study O
or O
previous O
studies O
given O
that O
impaired O
function O
due O
to O
the O
mutation O
has O
not O
been O
demonstrated O
in O
vitro O
further O
investigation O
is O
needed O
to O
clarify O
this O

together O
these O
data O
demonstrate O
that O
these O
five O
pol O
##g O
mutations O
are O
not O
a O
prevalent O
et O
##iology O
of O
sp O
##oi O
this O
is O
in O
agreement O
with O
similar O
studies O
in O
in O
##fer O
##tile O
males O
in O
which O
patients O
were O
screened O
for O
pol O
##g O
ca O
##g O
repeat O
poly O
##morphism O
##s O
that O
had O
previously O
been O
associated O
with O
primary O
go O
##nad O
##al O
ins O
##uf O
##fi O
##ciency O
14 O
15 O
only O
3 O
of O
in O
##fer O
##tile O
males O
screened O
were O
found O
to O
be O
homo O
##zy O
##go O
##us O
carriers O
of O
the O
mutations O
and O
half O
of O
these O
reported O
successful O
pre O
##gnan O
##cies O
despite O
presence O
of O
the O
mutation O
in O
addition O
1 O
of O
fertile O
males O
were O
found O
to O
be O
homo O
##zy O
##go O
##us O
carriers O
providing O
further O
evidence O
that O
pol O
##g O
dysfunction O
may O
not O
be O
a O
factor O
in O
primary O
go O
##nad O
##al O
ins O
##uf O
##fi O
##ciency O
in O
men O
16 O

the O
pol O
##g O
mutations O
most O
commonly O
associated O
with O
sp O
##oi O
to O
date O
y O
##9 O
##55 O
##c O
and O
r O
##9 O
##43 O
##h O
1 O
3 O
4 O
were O
not O
seen O
in O
any O
of O
the O
women O
we O
screened O
the O
prevalence O
of O
pol O
##g O
mutations O
is O
estimated O
to O
be O
as O
high O
as O
1 O
in O
certain O
populations O
including O
the O
u O
s O
17 O
we O
cannot O
exclude O
the O
possibility O
that O
screening O
a O
larger O
number O
of O
patients O
would O
have O
shown O
more O
cases O
of O
pol O
##g O
mutations O
associated O
with O
sp O
##oi O
further O
we O
only O
tested O
for O
5 O
of O
the O
20 O
described O
pol O
##g O
mutations O
thus O
we O
are O
unable O
to O
exclude O
the O
possibility O
that O
mutations O
other O
than O
those O
we O
tested O
associate O
with O
sp O
##oi O

whether O
o O
##var O
##ian O
dysfunction O
due O
to O
pol O
##g O
mutations O
is O
due O
to O
f O
##oll O
##icle O
de O
##ple O
##tion O
or O
f O
##oll O
##icle O
dysfunction O
is O
not O
known O
o O
##ocytes O
have O
the O
highest O
mt O
##dna O
copy O
number O
of O
all O
cells O
18 O
which O
increases O
their O
su O
##sc O
##ept O
##ibility O
to O
mt O
##dna O
de O
##ple O
##tion O
and O
suggests O
a O
role O
for O
f O
##oll O
##icular O
de O
##ple O
##tion O
on O
the O
other O
hand O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
and O
thus O
mt O
##dna O
is O
required O
for O
f O
##oll O
##icular O
development O
19 O
suggesting O
f O
##oll O
##icle O
dysfunction O
may O
be O
responsible O
indeed O
in O
##fer O
##tility O
in O
men O
believed O
to O
be O
due O
to O
pol O
##g O
mutations O
is O
never O
due O
to O
az O
##oo O
##sper O
##mia O
but O
seems O
to O
be O
associated O
with O
defective O
sperm O
##ato O
##genesis O
and O
or O
ste O
##roid O
##ogen O
##esis O
14 O

mit O
##och O
##ond O
##rion O
11 O
2011 O
104 O
107 O
application O
of O
ol O
##igo O
##nu O
##cle O
##otide O
array O
c O
##gh O
in O
the O
detection O
of O
a O
large O
intra O
##genic O
del O
##eti O
##on O
in O
pol B-GENE
##g I-GENE
associated O
with O
al O
##pers O
syndrome O
alison O
g O
compton O
a O
christopher O
tr O
##oed O
##son O
b O
meredith O
wilson O
c O
peter O
g O
pro O
##co O
##pis O
b O
fang O
yuan O
li O
d O
ellen O
k O
br O
##unda O
##ge O
d O
tar O
##o O
ya O
##ma O
##zaki O
a O
e O
david O
r O
thor O
##burn O
a O
f O
lee O
jun O
c O
wong O
d O
a O
murdoch O
children O
##s O
research O
institute O
and O
genetic O
health O
services O
victoria O
royal O
children O
s O
hospital O
melbourne O
australia O
b O
ty O
nelson O
department O
of O
ne O
##uro O
##logy O
the O
children O
s O
hospital O
at O
west O
##me O
##ad O
sydney O
australia O

c O
western O
sydney O
genetics O
program O
the O
children O
s O
hospital O
at O
west O
##me O
##ad O
and O
disciplines O
of O
pa O
##ed O
##ia O
##trics O
and O
child O
health O
genetic O
medicine O
university O
of O
sydney O
sydney O
australia O
d O
department O
of O
molecular O
and O
human O
genetics O
baylor O
college O
of O
medicine O
houston O
usa O
e O
department O
of O
pediatric O
##s O
school O
of O
medicine O
sai O
##tama O
medical O
university O
sai O
##tama O
japan O
f O
department O
of O
pa O
##ed O
##ia O
##trics O
university O
of O
melbourne O
melbourne O
australia O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
18 O
june O
2010 O
received O
in O
revised O
form O
23 O
july O
2010 O
accepted O
23 O
july O
2010 O
available O
online O
12 O
august O
2010 O
key O
##words O
pol O
##g O

array O
c O
##gh O
intra O
##genic O
del O
##eti O
##on O
al O
##pers O
syndrome O
a O
b O
s O
t O
r O
a O
c O
t O
mutations O
in O
the O
polymer O
##ase O
γ O
pol O
##g O
gene O
are O
among O
the O
most O
common O
causes O
of O
mitochondrial O
disease O
and O
more O
than O
160 O
pol O
##g O
mutations O
have O
been O
reported O
however O
a O
large O
proportion O
of O
patients O
suspected O
of O
having O
pol O
##g O
mutations O
only O
have O
one O
het O
##ero O
##zy O
##go O
##us O
de O
##ﬁ O
##ni O
##tive O
pathogen O
##ic O
mutation O
id O
##ent O
##i O
##ﬁ O
##ed O
using O
ol O
##igo O
##nu O
##cle O
##otide O
array O
c O
##gh O
we O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
large O
intra O
##genic O
del B-GENE_VARIANT
##eti I-GENE_VARIANT
##on I-GENE_VARIANT
encompassing I-GENE_VARIANT
ex I-GENE_VARIANT
##ons I-GENE_VARIANT
15 I-GENE_VARIANT
21 I-GENE_VARIANT
of O
this O
gene O
in O
a O
child B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
due O
to O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
this O
is O
the O
ﬁ O
##rst O
large O
pol B-GENE
##g I-GENE

del O
##eti O
##on O
reported O
and O
the O
ﬁ O
##nding O
##s O
show O
the O
clinical O
utility O
of O
using O
array O
c O
##gh O
in O
cases O
where O
a O
single O
het O
##ero O
##zy O
##go O
##us O
mutation O
has O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
pol O
##g O
2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
introduction O

dna O
polymer O
##ase O
γ O
pol O
##g O
encoded O
by O
the O
nuclear O
pol O
##g O
gene O
mi O
##m O
1747 O
##6 O
##3 O
is O
the O
only O
known O
dna O
polymer O
##ase O
in O
human O
mit O
##och O
##ond O
##ria O
it O
possesses O
both O
polymer O
##ase O
and O
3 O
5 O
ex O
##on O
##uc O
##lea O
##se O
activities O
and O
is O
essential O
for O
mitochondrial O
dna O
mt O
##dna O
replication O
and O
repair O
more O
than O
160 O
coding O
variations O
in O
this O
gene O
have O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
since O
its O
id O
##ent O
##i O
##ﬁ O
##cation O
as O
a O
disease O
gene O
in O
2001 O
http O
www O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
mutations O
in O
this O
gene O
cause O
sec O

on O
##dar O
##y O
defects O
in O
mt O
##dna O
maintenance O
leading O
to O
respiratory O
chain O
dysfunction O
the O
current O
diagnostic O
sequencing O
techniques O
only O
allow O
the O
detection O
of O
point O
mutations O
small O
del O
##eti O
##ons O
or O
du O
##plication O
##s O
and O
several O
reports O
have O
commented O
on O
identifying O
only O
a O
single O
het O
##ero O
##zy O
##go O
##us O
auto O
##som O
##al O
recess O
##ive O
pol O
##g O
mutation O
in O
multiple O
suspected O
pol O
##g O
patients O
ago O
##sti O
##no O
et O
al O
2003 O
b O
##lok O
et O
al O
2009 O
fi O
##los O
##to O
et O
al O
2003 O
wong O
et O
al O
2008 O
##b O

here O
we O
describe O
a O
patient B-PATIENT
with O
a O
common O
pol B-GENE
##g I-GENE
disease O
presentation O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
mi O
##m O
203 O
##70 O
##0 O
characterized O
by O
early B-HPO_TERM
age I-HPO_TERM
of I-HPO_TERM
onset I-HPO_TERM
fatal B-HPO_TERM
intra B-HPO_TERM
##ctable I-HPO_TERM
seizures I-HPO_TERM
he B-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
and O
global B-HPO_TERM
neurological I-HPO_TERM
deterioration I-HPO_TERM
na O
##via O
##ux O
and O
nguyen O
2004 O
she O
was O
corresponding O
author O
the O
murdoch O
children O
##s O
research O
institute O
royal O
children O
s O
hospital O
fleming O
##ton O
rd O
park O
##ville O
305 O
##2 O
melbourne O
australia O
tel O
61 O
3 O
83 O
##41 O
62 O
##35 O
fa O
##x O
61 O
3 O
83 O
##41 O
62 O
##12 O
e O
mail O
address O
david O
thor O
##burn O
mc O
##ri O
ed O
##u O
au O
d O
r O
thor O
##burn O

compound O
het O
##ero O
##zy O
##go O
##us O
for O
the O
common O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
pol B-GENE
##g I-GENE
mutation O
and O
a O
novel O
large O
intra B-GENE_VARIANT
##genic I-GENE_VARIANT
del I-GENE_VARIANT
##eti I-GENE_VARIANT
##on I-GENE_VARIANT
of I-GENE_VARIANT
4 I-GENE_VARIANT
7 I-GENE_VARIANT
kb I-GENE_VARIANT
length O
to O
our O
knowledge O
this O
is O
the O
ﬁ O
##rst O
reported O
case O
of O
a O
large O
del O
##eti O
##on O
in O
pol O
##g O
illustrating O
the O
necessity O
of O
testing O
for O
intra O
##genic O
del O
##eti O
##ons O
in O
all O
patients O
with O
a O
single O
het O
##ero O
##zy O
##go O
##us O
mutation O
id O
##ent O
##i O
##ﬁ O
##ed O
methods O
respiratory O
chain O
enzyme O
and O
mt O
##dna O
analysis O

respiratory O
chain O
enzyme O
activities O
and O
relative O
abundance O
of O
mt O
##dna O
were O
ass O
##ay O
##ed O
as O
described O
previously O
kirby O
et O
al O
1999 O
pa O
##gna O
##ment O
##a O
et O
al O
2006 O
all O
enzyme O
and O
molecular O
investigations O
were O
performed O
as O
part O
of O
the O
diagnostic O
investigations O
for O
this O
patient O
with O
informed O
consent O
from O
the O
parents O
and O
in O
compliance O
with O
ethics O
approval O
by O
the O
human O
research O
ethics O
committee O
of O
the O
royal O
children O
s O
hospital O
melbourne O
mutation O
analysis O

mutation O
analysis O
was O
performed O
on O
gen O
##omic O
dna O
using O
prime O
##rs O
designed O
to O
amp O
##li O
##fy O
the O
coding O
ex O
##ons O
and O
the O
ex O
##on O
intro O
##n O
boundaries O
of O
pol O
##g O
nm O
00 O
##26 O
##9 O
##3 O
2 O
d O
##gu O
##ok O
nm O
08 O
##0 O
##9 O
##16 O
1 O
and O
nm O
08 O
##0 O
##9 O
##18 O
1 O
mp O
##v O
##17 O
nm O
00 O
##24 O
##37 O
4 O
and O
c1 O
##0 O
##orf O
##2 O
pe O
##o O
##1 O
twinkle O
nm O
02 O
##18 O
##30 O
156 O
##7 O
72 O
##49 O
see O
front O
matter O
2010 O
else O
##vier O
b O
v O
and O
mit O
##och O
##ond O
##ria O
research O
society O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
mit O
##o O
2010 O
07 O
01 O
##2 O
a O
g O
compton O
et O
al O
mit O
##och O
##ond O
##rion O
11 O
2011 O
104 O
107 O
105 O
fragments O
were O
anal O
##yse O
##d O
by O
direct O
sequencing O
using O
ab O
##i O
313 O
##0 O
##x O
##l O
applied O
bio O
##systems O
melbourne O
vic O
australia O
rna O
analysis O

primary O
ﬁ O
##bro O
##bla O
##sts O
were O
culture O
##d O
in O
media O
with O
or O
without O
100 O
ng O
μ O
##l O
cy O
##cl O
##oh O
##ex O
##imi O
##de O
ch O
##x O
for O
24 O
h O
prior O
to O
preparation O
of O
rna O
in O
order O
to O
minimize O
nonsense O
mediated O
decay O
lama O
##nde O
et O
al O
1998 O
before O
total O
rna O
was O
extracted O
using O
ill O
##ust O
##ra O
rna O
##sp O
##in O
mini O
kit O
ge O
healthcare O
ry O
##dal O
##mere O
nsw O
australia O
pc O
##r O
prime O
##rs O
were O
designed O
to O
amp O
##li O
##fy O
the O
entire O
cd O
##na O
in O
one O
or O
two O
fragments O
analysis O
of O
del O
##eti O
##on O
and O
break O
##points O

a O
custom O
designed O
clinical O
ol O
##igo O
##nu O
##cle O
##otide O
comparative O
gen O
##omic O
hybrid O
##ization O
c O
##gh O
array O
with O
complete O
coverage O
of O
the O
mitochondrial O
genome O
and O
about O
160 O
nuclear O
genes O
related O
to O
mitochondrial O
functions O
and O
metabolic O
diseases O
including O
the O
pol O
##g O
gene O
china O
##ult O
et O
al O
2009 O
wong O
et O
al O
2008 O
##a O
was O
manufactured O
using O
the O
agile O
##nt O
micro O
##ar O
##ray O
platform O
agile O
##nt O
technologies O
santa O
clara O
ca O
analysis O
of O
the O
del O
##eti O
##on O
break O
##points O
was O
performed O
by O
pc O
##r O
of O
the O
del O
##eti O
##on O
junction O
detected O
by O
array O
c O
##gh O
results O
case O
report O

this O
patient B-PATIENT
was O
the O
ﬁ O
##rst O
child O
of O
non O
con O
##san O
##gui O
##neo O
##us O
caucasian O
parents O
her O
birth O
and O
per O
##ina O
##tal O
history O
were O
un O
##rem O
##ark O
##able O
she O
presented O
at O
12 B-PATIENT
months I-PATIENT
of O
age O
with O
acute O
partial B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
initial O
tests O
demonstrated O
mildly O
abnormal B-HPO_TERM
liver I-HPO_TERM
function I-HPO_TERM
tests I-HPO_TERM
and O
normal O
blood O
lac O
##tate O
an O
mri O
performed O
10 O
h O
after O
the O
event O
demonstrated O
a O
focal B-HPO_TERM
area I-HPO_TERM
of I-HPO_TERM
restricted I-HPO_TERM
diffusion I-HPO_TERM
with O
overly O
##ing O
subtle B-HPO_TERM
g I-HPO_TERM
##yra I-HPO_TERM
##l I-HPO_TERM
swelling I-HPO_TERM
in O
the O
right O
o O
##cci O
##pit O
##al O
lobe O
acute O
##ly O
the O
ee O
##g O
demonstrated O
almost O
continuous B-HPO_TERM
par I-HPO_TERM
##ox I-HPO_TERM
##ys I-HPO_TERM
##mal I-HPO_TERM
lateral I-HPO_TERM
##izing I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##pt I-HPO_TERM
##iform I-HPO_TERM
discharge I-HPO_TERM
##s I-HPO_TERM
over O
the O
right O
hemisphere O
she O
remained O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
for O
24 O
h O
on O
day O
3 O
she O
had O
a O
further O
episode O
of O
focal B-HPO_TERM
status I-HPO_TERM
despite O
a O
therapeutic O
level O
of O
ph O
##en O
##yt O
##oin O
seizures B-HPO_TERM
continued O
after O
ph O
##eno O
##bar O
##bit O
##one O
loading O
and O
she O
was O
commenced O
on O
a O
mid O
##az O
##ola O
##m O
in O
##fusion O
her O
seizures O
settled O
and O
she O
was O
discharged O
home O
on O
ph O
##eno O
##bar O
##bit O
##one O
after O
a O
2 O
##½ O
##week O
admission O

the O
patient B-PATIENT
had I-PATIENT
further O
admissions O
between O
18 O
and O
36 O
months O
with O
repeated O
mri O
showing O
progressively O
more O
extensive O
right B-PATIENT
sided I-PATIENT
diffusion I-PATIENT
changes I-PATIENT
involving O
the O
right B-PATIENT
o I-PATIENT
##cci I-PATIENT
##pit I-PATIENT
##al I-PATIENT
and O
par B-PATIENT
##ie I-PATIENT
##tal I-PATIENT
lobes I-PATIENT
plus O
the O
right B-PATIENT
posterior I-PATIENT
tha I-PATIENT
##lam I-PATIENT
##us I-PATIENT
at O
2 O
years O
the O
patient O
was O
admitted O
with O
left B-PATIENT
sided I-PATIENT
ep I-PATIENT
##ile I-PATIENT
##ps I-PATIENT
##ia I-PATIENT
partial I-PATIENT
##is I-PATIENT
con I-PATIENT
##tin I-PATIENT
##ua I-PATIENT
which O
was O
resistant O
to O
multiple O

fig O
1 O
gen O
##omic O
dna O
del O
##eti O
##on O
analyses O
a O
ol O
##igo O
##nu O
##cle O
##otide O
array O
c O
##gh O
analysis O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
het O
##ero O
##zy O
##go O
##us O
loss O
of O
4 O
5 O
kb O
nu O
##cle O
##otide O
position O
87 O
66 O
##2 O
154 O
to O
87 O
66 O
##6 O
650 O
in O
the O
long O
arm O
of O
chromosome O
15 O
spanning O
from O
intro O
##n O
14 O
to O
intro O
##n O
21 O
of O
the O
pol O
##g O
gene O
in O
the O
patient O
each O
dot O
indicates O
an O
ol O
##igo O
##nu O
##cle O
##otide O
probe O
green O
dots O
represent O
copy O
number O
loss O
the O
del O
##eti O
##on O
region O
is O
boxed O
and O
the O
numbers O
are O
the O
coordinates O
of O
the O
estimated O
break O
points O
according O
to O
the O
reference O
sequence O
in O
the O
en O
##se O
##mb O
##l O
database O
en O
##sg O
##00 O
##00 O
##01 O
##40 O
##52 O
##1 O
in O
version O
54 O
black O
dots O
represent O
no O
copy O
number O
changes O
and O
the O
red O
dots O
represent O
gain O
of O
copy O
number O
the O
corresponding O
gen O
##omic O
structure O
of O
the O
pol O
##g O
gene O
is O
on O
the O
right O
b O
long O
range O
pc O
##r O
analysis O
of O
the O
pol O
##g O
gene O
using O
prime O
##rs O
located O
in O
intro O
##ns O
13 O
and O
22 O
showed O
that O
a O
full O
length O
product O
56 O
##75 O
bp O
could O
be O
detected O
in O
the O
father O
f O
mother O
m O

and O
patient O
p O
however O
a O
del O
##eti O
##on O
product O
of O
93 O
##5 O
bp O
was O
also O
detected O
in O
a O
het O
##ero O
##zy O
##go O
##us O
state O
in O
both O
the O
patient O
and O
her O
mother O
prime O
##rs O
forward O
5 O
g O
##ca O
##gg O
##ta O
##ct O
##ca O
##c O
##gt O
##t O
##gg O
##tt O
##c O
3 O
and O
reverse O
5 O
ct O
##gt O
##tc O
##tc O
##ca O
##aga O
##cc O
##ca O
##ct O
##t O
3 O
c O
sequencing O
of O
the O
gen O
##omic O
pc O
##r O
del O
##eti O
##on O
product O
id O
##ent O
##i O
##ﬁ O
##ed O
the O
del O
##eti O
##on O
break O
##points O
106 O
a O
g O
compton O
et O
al O
mit O
##och O
##ond O
##rion O
11 O
2011 O
104 O
107 O

medications O
including O
top O
##ira O
##mate O
lev O
##eti O
##race O
##tam O
and O
cl O
##ob O
##az O
##am O
a O
ke O
##to O
##genic O
diet O
z O
##onis O
##ami O
##de O
and O
a O
mitochondrial O
cocktail O
and O
no O
new O
developmental O
milestone O
##s O
were O
gained O
over O
the O
next O
12 O
months O
liver O
function O
tests O
indicated O
a O
progressive B-PATIENT
he I-PATIENT
##pa I-PATIENT
##top I-PATIENT
##athy I-PATIENT
from O
age O
2 O
year O
10 O
months O
at O
36 O
months O
she O
had O
a O
catastrophic O
deterioration O
and O
was O
found O
un B-PATIENT
##res I-PATIENT
##pon I-PATIENT
##sive I-PATIENT
with O
right B-PATIENT
arm I-PATIENT
tonic I-PATIENT
cl I-PATIENT
##onic I-PATIENT
jerking I-PATIENT
and O
right O
leg O

stiff O
##ness O
mri O
brain O
and O
ee O
##g O
demonstrated O
new O
extensive B-PATIENT
left I-PATIENT
hem I-PATIENT
##is I-PATIENT
##pher I-PATIENT
##ic I-PATIENT
involvement I-PATIENT
further O
neurological B-PATIENT
deterioration I-PATIENT
continued O
her O
seizures B-PATIENT
were I-PATIENT
intra I-PATIENT
##ctable I-PATIENT
she O
required O
tube B-PATIENT
feeding I-PATIENT
and O
was O
co B-PATIENT
##rti I-PATIENT
##cal I-PATIENT
##ly I-PATIENT
blind I-PATIENT
she O
died O
at O
age O
3 B-AGE_DEATH
years I-AGE_DEATH
6 I-AGE_DEATH
months I-AGE_DEATH
mitochondrial O
enzyme O
and O
molecular O
studies O

liver O
respiratory O
chain O
enzymes O
showed O
complex B-HPO_TERM
i I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
16 O
of O
normal O
control O
mean O
relative O
to O
complex O
ii O
with O
an O
overall O
pro O
##ﬁ O
##le O
suggest O
##ive O
of O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
which O
was O
con O
##ﬁ O
##rmed O
by O
q O
##pc O
##r O
8 O
of O
the O
mean O
normal O
control O
amount O
of O
mt O
##dna O
relative O
to O
nuclear O
dna O
residual O
enzyme O
activities O
relative O
to O
protein O
were O
53 O
complex O
i O
330 O
complex O
ii O
117 O
complex O
iii O
110 O
complex O
iv O
and O
221 O
ci O
##tra O
##te O
synth O
##ase O

sequence O
analysis O
of O
gen O
##omic O
dna O
for O
the O
three O
most O
common O
pathogen O
##ic O
pol B-GENE
##g I-GENE
mutations O
in O
the O
australian O
population O
ha O
##kon O
##en O
et O
al O
2007 O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
het B-GENE_VARIANT
##ero I-GENE_VARIANT
##zy I-GENE_VARIANT
##go I-GENE_VARIANT
##us I-GENE_VARIANT
p I-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
c B-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##gna I-GENE_VARIANT
mutation O
full O
pol O
##g O
sequencing O
did O
not O
reveal O
any O
other O
mutations O
other O
genes O
associated O
with O
he O
##pati O
##c O
mt O
##dna O
de O
##ple O
##tion O
mp O
##v O
##17 O
c1 O
##0 O
##orf O
##2 O
and O
d O
##gu O
##ok O
were O
also O
sequence O
##d O
no O
potentially O
pathogen O
##ic O
mutations O
were O
found O
in O
mp O
##v O
##17 O
or O
c1 O
##0 O
##orf O
##2 O
however O
a O
het O
##ero O
##zy O
##go O
##us O
c O
50 O
##9 O
##ang O
p O
q O
##17 O
##0 O
##r O
sequence O
variant O
was O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
d O
##gu O
##ok O
this O
variant O
had O
been O
reported O
previously O
in O
a O
patient O
with O
he O
##pati O
##c O
mt O
##dna O
de O
##ple O
##tion O
fr O
##eis O
##inger O
et O
al O
2006 O
but O
is O
now O
regarded O
as O
a O
poly O
##morphism O
sequence O
analysis O
of O
parental O
dna O
demonstrated O
that O
her O
father O
carried O
both O
the O
pol O
##g O
p O
a O
##46 O
##7 O
##t O
mutation O
and O
the O
d O
##gu O
##ok O
sequence O
variant O
making O
dig O
##eni O
##c O
inheritance O
unlikely O
cd O
##na O
sequencing O
of O
ex O
##ons O
5 O
to O
8 O
of O
pol O
##g O
from O
ﬁ O
##bro O
##bla O
##sts O
grown O
##± O
##ch O
##x O
showed O
the O
presence O
of O
the O
het O
##ero O
##zy O
##go O
##us O
c O
139 O
##9 O
##gna O
pol O
##g O
mutation O
indicating O
that O
both O
all O
##eles O
are O
expressed O
and O
that O
nonsense O
mediated O
mrna O
decay O
was O
not O
occurring O
array O
c O
##gh O
analysis O
on O
patient O
l O
##ym O
##ph O
##oc O
##yte O
dna O
revealed O
a O
het O
##ero O
##zy O
##go O
##us O
loss O
of O
approximately O
4 O
5 O
kb O
nu O
##cle O
##otide O
positions O

doi O
10 O
100 O
##7 O
s O
##00 O
##41 O
##5 O
01 O
##0 O
57 O
##21 O
2 O
magnesium O
treatment O
for O
patients O
with O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
due O
to O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
nora O
a O
vis O
##ser O
ke O
##es O
p O
j O
braun O
fran O
##s O
s O
s O
lei O
##j O
##ten O
on O
##no O
van O
ni O
##eu O
##wen O
##hui O
##zen O
john O
h O
j O
wo O
##kk O
##e O
walter O
m O
van O
den O
berg O
##h O
received O
25 O
may O
2010 O
revised O
9 O
august O
2010 O
accepted O
13 O
august O
2010 O
published O
online O
29 O
august O
2010 O
the O
author O
s O
2010 O
this O
article O
is O
published O
with O
open O
access O
at O
springer O
##link O
com O

abstract O
mutations O
in O
the O
gene O
encoding O
of O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
can O
cause O
typical O
al O
##pers O
syndrome O
recently O
a O
new O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
was O
described O
the O
so O
called O
juvenile O
onset O
al O
##pers O
syndrome O
this O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
is O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
with O
rec O
##urrent O
status O
ep O
##ile O
##ptic O
##us O
and O
episodes O
of O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
which O
often O
nec O
##ess O
##itate O
admission O
to O
the O
intensive O
care O
unit O
ic O
##u O
and O
pose O
an O
important O
mortality O
risk O
we O
describe O
two O
previously O
healthy O
unrelated O
teenage O
girls O
who O
both O
were O
admitted O
with O
generalized O
tonic O
cl O
##onic O
seizures O
and O
visual O
symptoms O
leading O
to O
a O
dna O
supported O
diagnosis O
of O
juvenile O
onset O
al O
##pers O
syndrome O
despite O
combined O
treatment O
with O
anti O
ep O
##ile O
##ptic O
drugs O
both O
patients O
developed O
status O
ep O
##ile O
##ptic O
##us O
requiring O
admission O
to O
the O
ic O
##u O
intra O
##ven O
##ous O
magnesium O
as O
anti O
con O
##vu O
##ls O
##ant O
therapy O
was O
initiated O
resulting O
in O
clinical O
and O
ne O
##uro O
##phy O
##sio O
##logical O
improvement O
and O
rapid O
ex O
##tub O
##ation O
of O
both O
patients O
treating O
status O
ep O
##ile O
##ptic O
##us O
in O
juvenile O
onset O
al O
##pers O
syndrome O
with O
magnesium O
has O
not O
been O
described O
previously O
given O
the O
difficulties O

n O
a O
vis O
##ser O
f O
s O
s O
lei O
##j O
##ten O
j O
h O
j O
wo O
##kk O
##e O
rudolf O
magnus O
institute O
of O
neuroscience O
department O
of O
ne O
##uro O
##logy O
university O
medical O
centre O
utrecht O
po O
box O
85 O
##500 O
350 O
##8 O
ga O
utrecht O
the O
netherlands O
e O
mail O
n O
a O
vis O
##ser O
3 O
um O
##cut O
##recht O
nl O
k O
p O
j O
braun O
o O
van O
ni O
##eu O
##wen O
##hui O
##zen O
rudolf O
magnus O
institute O
of O
neuroscience O
department O
of O
child O
ne O
##uro O
##logy O
university O
medical O
centre O
utrecht O
po O
box O
85 O
##500 O
350 O
##8 O
ga O
utrecht O
the O
netherlands O
w O
m O
van O
den O
berg O
##h O
department O
of O
intensive O
care O
academic O
medical O
centre O
amsterdam O
the O
netherlands O

encountered O
while O
treating O
ep O
##ile O
##psy O
in O
patients O
with O
this O
syndrome O
magnesium O
therapy O
might O
be O
considered O
key O
##words O
al O
##pers O
syndrome O
pol O
##g O
##1 O
magnesium O
status O
ep O
##ile O
##ptic O
##us O
adolescence O
introduction O

polymer O
##ase O
gamma O
is O
essential O
for O
mitochondrial O
dna O
replication O
mutations O
in O
the O
nuclear O
gene O
encoding O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
are O
associated O
with O
mitochondrial O
diseases O
1 O
pol O
##g O
##1 O
mutations O
have O
been O
implicated O
in O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
2 O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
3 O
parkinson O
##ism O
4 O
premature O
men O
##opa O
##use O
4 O
al O
##pers O
syndrome O
5 O
6 O
and O
mixed O
ph O
##eno O
##type O
##s O
7 O
8 O
there O
appears O
no O
strict O
relationship O
between O
ph O
##eno O
##type O
and O
gen O
##otype O
in O
patients O
with O
pathogen O
##ic O
mutations O
in O
the O
gene O
that O
en O
##codes O
for O
pol O
##g O
##1 O
8 O

al O
##pers O
syndrome O
usually O
presents O
in O
early O
childhood O
with O
the O
classical O
triad O
of O
developmental O
delay O
intra O
##ctable O
seizures O
and O
he O
##pati O
##c O
failure O
which O
may O
be O
pre O
##ci O
##pit O
##ated O
by O
val O
##pro O
##ic O
acid O
3 O
5 O
8 O
in O
2008 O
a O
new O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
was O
described O
features O
of O
which O
are O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
and O
visual O
symptoms O
in O
previously O
healthy O
adolescents O
or O
young O
adults O
the O
so O
called O
juvenile O
onset O
al O
##pers O
syndrome O
9 O
10 O
both O
al O
##pers O
ph O
##eno O
##type O
##s O
are O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
with O
rec O
##urrent O
status O
ep O
##ile O
##ptic O
##us O
and O
episodes O
of O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
which O
often O
nec O
##ess O
##itate O
admission O
to O
the O
intensive O
care O
unit O
ic O
##u O
and O
pose O
an O
important O
mortality O
risk O
10 O

intra O
##ven O
##ous O
magnesium O
is O
the O
first O
choice O
agent O
in O
treating O
con O
##vu O
##ls O
##ions O
in O
ec O
##lam O
##ps O
##ia O
11 O
and O
may O
be O
effective O
in O
status O
ep O
##ile O
##ptic O
##us O
of O
other O
origin O
although O
reports O
on O
this O
topic O
are O
sparse O
12 O
14 O
we O
present O
two O
cases O
of O
non O
related O
teenage O
girls O
with O
juvenile O
onset O
al O
##pers O
syndrome O
due O
to O
pol O
##g O
##1 O
mutations O
who O
presented O
with O
ref O
##rac O
##tory O
seizures O
that O
originated O
in O
the O
o O
##cci O
##pit O
##al O
lobe O
and O
were O
eventually O
successfully O
treated O
with O
magnesium O
case B-PATIENT
1 I-PATIENT

a O
previously O
healthy O
19 B-AGE_ONSET
year O
old O
woman B-PATIENT
was O
admitted O
to O
our O
tertiary O
care O
center O
after O
two O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
in O
a O
fort O
##night O
since O
the O
first O
seizure O
she O
complained O
of O
seeing O
bright O
spots O
routine O
neurological O
examination O
and O
brain O
ct O
at O
admission O
showed O
no O
abnormalities O
visual O
field O
examination O
revealed O
a O
rights B-HPO_TERM
##ided I-HPO_TERM
homo I-HPO_TERM
##ny I-HPO_TERM
##mous I-HPO_TERM
para I-HPO_TERM
##cent I-HPO_TERM
##ral I-HPO_TERM
sc I-HPO_TERM
##oto I-HPO_TERM
##ma I-HPO_TERM
flair O
and O
t O
##2 O
##weight O
##ed O
mri O
showed O
bilateral B-HPO_TERM
lesions I-HPO_TERM
with I-HPO_TERM
increased I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
cortex I-HPO_TERM
most O
prominent O
in O
the O
left O
hemisphere O
with O
areas O
of O
both O
increased O
and O
decreased O
diffusion O
on O
ad O
##c O
maps O
ee B-HPO_TERM
##g I-HPO_TERM
showed I-HPO_TERM
slowing I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
background I-HPO_TERM
activity I-HPO_TERM
and O
continuous B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
activity I-HPO_TERM
over I-HPO_TERM
the I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
areas I-HPO_TERM
also O
most O
prominent O
in O
the O
left O
hemisphere O
her O
visual O
symptoms O
were O
therefore O
interpreted O
as O
focal B-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
treatment O
with O
ph O
##en O
##yt O
##oin O
and O
continuous O
intra O
##ven O
##ous O
in O
##fusion O
of O

cl O
##ona O
##ze O
##pa O
##m O
were O
initiated O
this O
improved O
the O
visual O
complaints O
but O
they O
did O
not O
resolve O
completely O

five O
weeks O
after O
the O
first O
seizure O
while O
still O
on O
ph O
##en O
##yt O
##oin O
and O
cl O
##ona O
##ze O
##pa O
##m O
she O
experienced O
right B-HPO_TERM
sided I-HPO_TERM
focal I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
that O
only O
partially O
responded O
to O
additional O
therapy O
with O
cl O
##ob O
##az O
##am O
and O
lev O
##eti O
##race O
##tam O
since O
a O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
syndrome O
was O
suspected O
val O
##pro O
##ic O
acid O
was O
avoided O
treatment O
with O
mid O
##az O
##ola O
##m O
resulted O
in O
temporary O
resolution O
of O
focal O
con O
##vu O
##ls O
##ions O
but O
her O
visual O
complaints O
did O
not O
improve O
and O
ict O
##al O
activity O
persisted O
on O
ee O
##g O
with O
right B-HPO_TERM
sided I-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
her O
mental B-HPO_TERM
status I-HPO_TERM
deteriorated I-HPO_TERM
as O
she O
became O
di B-HPO_TERM
##sor I-HPO_TERM
##iente I-HPO_TERM
##d I-HPO_TERM
with O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
and O
ac B-HPO_TERM
##al I-HPO_TERM
##cu I-HPO_TERM
##lia I-HPO_TERM
repeated O
mri O
showed O
an O
increase O
in O
the O
extent O
and O
number O
of O
the O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lesions I-HPO_TERM
now O
including O
left B-HPO_TERM
##side I-HPO_TERM
##d I-HPO_TERM
pu I-HPO_TERM
##l I-HPO_TERM
##vina I-HPO_TERM
##r I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
abnormalities I-HPO_TERM
urgent O
dna O
analysis O
indeed O
revealed O
a O
homo O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t O
mutation O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
confirming O
the O
diagnosis O
of O
juvenile O
##ons O
##et O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM

her O
condition B-HPO_TERM
worsened I-HPO_TERM
as O
she O
developed O
frequent O
simple B-HPO_TERM
left I-HPO_TERM
sided I-HPO_TERM
partial I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
which O
gradually O
transformed O
into O
generalized B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
she O
was O
admitted O
to O
the O
ic O
##u O
and O
treated O
with O
high O
dose O
intra O
##ven O
##ous O
mid O
##az O
##ola O
##m O
0 O
4 O
mg O
kg O
h O
and O
a O
combination O
of O
ph O
##en O
##yt O
##oin O
300 O
mg O
day O
i O
v O
cl O
##ona O
##ze O
##pa O
##m O
3 O
mg O
day O
i O
v O
and O
lev O
##eti O
##race O
##tam O
1 O
500 O
mg O
day O
i O
v O
and O
vent O
##ila O
##tory O
support O
fig O
1 O
timetable O
with O
overview O
of O
anti O
ep O
##ile O
##ptic O
drugs O
d O
discharge O
from O
hospital O

fe O
focal O
ep O
##ile O
##pt O
##iform O
discharge O
##s O
f O
##se O
focal O
status O
ep O
##ile O
##ptic O
##us O
gs O
##e O
generalized O
status O
ep O
##ile O
##ptic O
##us O
vs O
vent O
##ila O
##tory O
support O
improved O
compared O
to O
previous O
ee O
##g O
td O
##ied O
days O
after O
onset O
ep O
##ile O
##psy O
37 O
38 O
39 O
40 O
41 O
42 O
43 O
44 O
45 O
46 O
47 O
48 O
49 O
50 O
51 O
days O
after O
onset O
ep O
##ile O
##psy O
4 O
5 O
6 O
7 O
8 O
9 O
10 O
11 O
12 O
13 O
14 O
15 O
16 O
31 O
d O

fig O
1 O
when O
se O
##dation O
was O
tempered O
the O
seizures O
immediately O
returned O
high O
dose O
oral O
top O
##ira O
##mate O
1 O
000 O
mg O
day O
somewhat O
decreased O
the O
frequency O
of O
the O
seizures O
but O
the O
ee B-HPO_TERM
##gs I-HPO_TERM
remained I-HPO_TERM
highly I-HPO_TERM
abnormal I-HPO_TERM
showing O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
changes I-HPO_TERM
with O
continuous B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
activity I-HPO_TERM
magnesium O
in O
##fusion O
was O
then O
introduced O
aiming O
to O
increase O
serum O
levels O
from O
0 O
81 O
mm O
##ol O
l O
to O
approximately O
3 O
5 O
mm O
##ol O
l O
leading O
almost O
instantly O
to O
complete O
ab O
##olis O
##hm O
##ent O
of O
her O
clinical O
seizures O
mid O
##az O
##ola O
##m O
was O
tape O
##red O
and O
she O
was O
ex O
##tub O
##ated O
the O
following O
day O
at O
time O
of O
ex O
##tub O
##ation O
serum O
magnesium O
level O
was O
3 O
8 O
mm O
##ol O
l O
after O
ex O
##tub O
##ation O
she O
was O
able O
to O
communicate O
although O
she O
remained O
so B-HPO_TERM
##m I-HPO_TERM
##no I-HPO_TERM
##lent I-HPO_TERM

although O
clinical O
signs O
of O
seizures O
remained O
absent O
the O
patient O
developed O
sep B-HPO_TERM
##sis I-HPO_TERM
probably O
due O
to O
vent B-HPO_TERM
##ila I-HPO_TERM
##tor I-HPO_TERM
associated I-HPO_TERM
pneumonia I-HPO_TERM
leading O
to O
multi B-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
and O
death B-HPO_TERM
2 B-AGE_DEATH
weeks I-AGE_DEATH
after I-AGE_DEATH
admission O
to O
the O
ic O
##u O
case B-PATIENT
2 I-PATIENT

in O
december O
2008 O
a O
previously O
healthy O
17 B-AGE_ONSET
year O
old O
girl B-PATIENT
complained O
of O
impaired B-HPO_TERM
vision I-HPO_TERM
and O
light O
flashes O
for O
several O
weeks O
she O
was O
evaluated O
in O
another O
hospital O
after O
a O
15 O
min O
episode O
of O
confusion B-HPO_TERM
and O
suspected B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
she O
fully O
recovered O
and O
was O
diagnosed O
with O
mig B-HPO_TERM
##raine I-HPO_TERM
two O
days O
later O
she O
had O
two O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
and O
was O
admitted O
to O
our O
hospital O
neurological O
examination O
revealed O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
right B-HPO_TERM
sided I-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
and O
intermittent O
partial B-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
of O
her O
right O
leg O
t O
##2 O
and O
flair O
mri O
showed O
hyper B-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
lesions I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
cortex I-HPO_TERM
tha B-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and O
me B-HPO_TERM
##sia I-HPO_TERM
##l I-HPO_TERM
temporal I-HPO_TERM
lobe I-HPO_TERM
one O
week O
after O
admission O
dna O
analysis O
revealed O
a O
homo O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
mutation O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
confirming O
the O
suspected O
diagnosis O
of O
juvenile O
onset O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome O
fourteen O
years O
earlier O
her O
teenage O
sister O
had O
generalized O
status O
ep O
##ile O
##ptic O
##us O
she O
died O
without O
an O
established O
diagnosis O
after O
a O
complicated O
brain O
bio O
##psy O

while O
being O
treated O
with O
ph O
##en O
##yt O
##oin O
fig O
1 O
her O
ee O
##g O
showed O
a O
continuing B-HPO_TERM
focal I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
of O
the O
left O
o O
##cci O
##pit O
##al O
region O
spreading O
anterior O
##ly O
continuous O
intra O
##ven O
##ous O
in O
##fusion O
of O
mid O
##az O
##ola O
##m O
and O
lev O
##eti O
##race O
##tam O
were O
added O
and O
she O
was O
admitted O
to O
the O
ic O
##u O
for O
vent O
##ila O
##tory O
support O
when O
high O
dose O
mid O
##az O
##ola O
##m O
0 O
3 O
mg O
kg O
h O
lev O
##eti O
##race O
##tam O
2 O
000 O
mg O
day O
i O
v O
and O
ph O
##en O
##yt O
##oin O
300 O
mg O
day O
i O
v O
could O
not O
ab O
##olis O
##h O
focal B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
magnesium O
in O
##fusion O
was O
started O
aiming O
to O
increase O
serum O
levels O
from O

0 O
85 O
mm O
##ol O
l O
to O
approximately O
3 O
5 O
mm O
##ol O
l O
par B-HPO_TERM
##esis I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
both O
gradually O
improved O
within O
hours O
after O
the O
start O
of O
magnesium O
in O
##fusion O
and O
within O
12 O
h O
mid O
##az O
##ola O
##m O
was O
tape O
##red O
and O
she O
was O
ex O
##tub O
##ated O
with O
at O
that O
time O
a O
serum O
magnesium O
level O
of O
2 O
0 O
mm O
##ol O
l O
ee O
##g O
after O
ex O
##tub O
##ation O
showed O
improvement O
although O
there O
was O
still O
a O
focal B-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
fig O
2 O

when O
magnesium O
was O
tape O
##red O
and O
mid O
##az O
##ola O
##m O
was O
discontinued O
focal B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
of O
her O
right O
arm O
rec O
##ur O
##red O
for O
which O
mid O
##az O
##ola O
##m O
0 O
1 O
mg O
kg O
h O
was O
restarted O
in O
addition O
to O
magnesium O
ph O
##en O
##yt O
##oin O
and O
cl O
##ob O
##az O
##am O
con B-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
ceased O
and O
the O
right O
sided O
post B-HPO_TERM
ict I-HPO_TERM
##al I-HPO_TERM
par I-HPO_TERM
##esis I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
disappeared O
gradually O
mid O
##az O
##ola O
##m O
and O
magnesium O
were O
stopped O
and O
oral O
ph O
##en O
##yt O
##oin O
cl O
##ob O
##az O
##am O
and O
lev O
##eti O
##race O
##tam O
were O
continued O
the O
patient O
could O
be O
discharged O
1 O
month O
after O
admission O
and O
she O
remains O
without O
seizures O
up O
to O
now O
8 B-AGE_FOLLOWUP
months I-AGE_FOLLOWUP
after I-AGE_FOLLOWUP
discharge O
her O
ee O
##g O
at O
discharge O
showed O
subtle O
focal O
o O
##cci O
##pit O
##al O
ep O
##ile O
##ptic O
discharge O
##s O
although O
there O
was O
an O
obvious O
improvement O
compared O
to O
previous O
ee O
##gs O

discussion O

juvenile O
onset O
al O
##pers O
syndrome O
is O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
pre O
##dom O
##inating O
in O
the O
o O
##cci O
##pit O
##al O
lobe O
with O
frequent O
episodes O
of O
spreading O
and O
status O
ep O
##ile O
##ptic O
##us O
for O
which O
a O
combination O
of O
several O
anti O
ep O
##ile O
##ptic O
drugs O
ae O
##ds O
is O
often O
required O
10 O
benz O
##od O
##ia O
##ze O
##pine O
##s O
are O
the O
main O
stay O
in O
the O
treatment O
of O
status O
ep O
##ile O
##ptic O
##us O
but O
often O
nec O
##ess O
##itate O
vent O
##ila O
##tory O
support O
importantly O
val O
##pro O
##ic O
acid O
should O
be O
avoided O
since O
it O
carries O
a O
high O
risk O
of O
inducing O
he O
##pati O
##c O
failure O
in O
our O
own O
experience O
prop O
##of O
##ol O
and O
th O
##io O
##pen O
##tal O
may O
also O
lead O
to O
he O
##pati O
##c O
failure O
and O
rapid O
neurological O
deterioration O
in O
children O
with O
al O
##pers O
syndrome O
in O
juvenile O
onset O
patients O
with O
pol O
##g O
##1 O
mutations O
these O
drugs O
should O
perhaps O
also O
be O
avoided O
when O
the O
combination O
of O
several O
high O
dose O
ae O
##ds O
could O
not O
stop O
focal O
or O
generalized O
status O
ep O
##ile O
##ptic O
##us O
in O
our O
two O
patients O
we O
chose O
to O
add O
magnesium O
according O
to O
the O
use O
in O
pre O
ec O
##lam O
##ps O
##ia O
11 O
the O
anti O
##con O
##vu O
##ls O
##ive O
effect O
of O
magnesium O
has O
been O
well O
established O
in O
pre O
ec O
##lam O
##ps O
##ia O
but O
it O
is O
rarely O
used O
in O
the O
treatment O
of O
ep O
##ile O
##psy O
of O
other O
origin O
in O
pre O
ec O
##lam O
##ps O
##ia O
an O
immediate O
effect O
is O
pursued O
by O
a O
loading O
dose O
of O
magnesium O
sul O
##phate O
followed O
by O
continuous O
in O
##fusion O
for O
24 O
h O
resulting O
in O
serum O
magnesium O
levels O
of O
1 O
7 O
3 O
5 O
mm O
##ol O
l O
15 O
but O
even O
at O
these O
high O
doses O
side O
effects O
are O
mild O
and O
sparse O
11 O
16 O
in O
particular O
renal O
or O
he O
##pati O
##c O
failure O
due O
to O
high O
dose O
magnesium O
therapy O
have O
not O
been O
described O
although O
magnesium O
is O
effective O
in O
preventing O
and O
treating O
ec O
##lam O
##ps O
##ia O
its O
mechanism O
of O
action O
remains O
unclear O
one O
of O
the O
suggested O
anti O
##con O
##vu O
##ls O
##ant O
mechanisms O
is O
its O
action O
as O
a O
n O
methyl O
d O
as O
##par O
##tic O
acid O
nm O
##da O
receptor O
antagonist O
the O
nm O
##da O
receptor O
is O
a O
g O
##lu O
##tama O
##te O
receptor O
which O
when O
activated O
leads O
to O
a O
massive O
de O
##pol O
##ari O
##zation O
of O
ne O
##uron O
##al O
networks O
and O
bursts O
of O
action O
potential O
##s O
magnesium O
may O
act O
to O
increase O
the O
seizure O
threshold O
by O
blocking O
the O
nm O
##da O
receptors O
15 O
animal O
models O
suggest O
that O
ae O
##ds O
enhancing O
ga O
##ba O
receptor O
activation O
e O
g O
bar O
##bit O
##ura O
##tes O
and O
benz O
##od O
##ia O
##ze O
##pine O
##s O
are O
effective O
in O
the O

doi O
10 O
100 O
##7 O
s O
##00 O
##41 O
##5 O
01 O
##0 O
57 O
##21 O
2 O
magnesium O
treatment O
for O
patients O
with O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
due O
to O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
nora O
a O
vis O
##ser O
ke O
##es O
p O
j O
braun O
fran O
##s O
s O
s O
lei O
##j O
##ten O
on O
##no O
van O
ni O
##eu O
##wen O
##hui O
##zen O
john O
h O
j O
wo O
##kk O
##e O
walter O
m O
van O
den O
berg O
##h O
received O
25 O
may O
2010 O
revised O
9 O
august O
2010 O
accepted O
13 O
august O
2010 O
published O
online O
29 O
august O
2010 O
the O
author O
s O
2010 O
this O
article O
is O
published O
with O
open O
access O
at O
springer O
##link O
com O

abstract O
mutations O
in O
the O
gene O
encoding O
of O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
can O
cause O
typical O
al O
##pers O
syndrome O
recently O
a O
new O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
was O
described O
the O
so O
called O
juvenile O
onset O
al O
##pers O
syndrome O
this O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
is O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
with O
rec O
##urrent O
status O
ep O
##ile O
##ptic O
##us O
and O
episodes O
of O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
which O
often O
nec O
##ess O
##itate O
admission O
to O
the O
intensive O
care O
unit O
ic O
##u O
and O
pose O
an O
important O
mortality O
risk O
we O
describe O
two O
previously O
healthy O
unrelated O
teenage O
girls O
who O
both O
were O
admitted O
with O
generalized O
tonic O
cl O
##onic O
seizures O
and O
visual O
symptoms O
leading O
to O
a O
dna O
supported O
diagnosis O
of O
juvenile O
onset O
al O
##pers O
syndrome O
despite O
combined O
treatment O
with O
anti O
ep O
##ile O
##ptic O
drugs O
both O
patients O
developed O
status O
ep O
##ile O
##ptic O
##us O
requiring O
admission O
to O
the O
ic O
##u O
intra O
##ven O
##ous O
magnesium O
as O
anti O
con O
##vu O
##ls O
##ant O
therapy O
was O
initiated O
resulting O
in O
clinical O
and O
ne O
##uro O
##phy O
##sio O
##logical O
improvement O
and O
rapid O
ex O
##tub O
##ation O
of O
both O
patients O
treating O
status O
ep O
##ile O
##ptic O
##us O
in O
juvenile O
onset O
al O
##pers O
syndrome O
with O
magnesium O
has O
not O
been O
described O
previously O
given O
the O
difficulties O

n O
a O
vis O
##ser O
f O
s O
s O
lei O
##j O
##ten O
j O
h O
j O
wo O
##kk O
##e O
rudolf O
magnus O
institute O
of O
neuroscience O
department O
of O
ne O
##uro O
##logy O
university O
medical O
centre O
utrecht O
po O
box O
85 O
##500 O
350 O
##8 O
ga O
utrecht O
the O
netherlands O
e O
mail O
n O
a O
vis O
##ser O
3 O
um O
##cut O
##recht O
nl O
k O
p O
j O
braun O
o O
van O
ni O
##eu O
##wen O
##hui O
##zen O
rudolf O
magnus O
institute O
of O
neuroscience O
department O
of O
child O
ne O
##uro O
##logy O
university O
medical O
centre O
utrecht O
po O
box O
85 O
##500 O
350 O
##8 O
ga O
utrecht O
the O
netherlands O
w O
m O
van O
den O
berg O
##h O
department O
of O
intensive O
care O
academic O
medical O
centre O
amsterdam O
the O
netherlands O

encountered O
while O
treating O
ep O
##ile O
##psy O
in O
patients O
with O
this O
syndrome O
magnesium O
therapy O
might O
be O
considered O
key O
##words O
al O
##pers O
syndrome O
pol O
##g O
##1 O
magnesium O
status O
ep O
##ile O
##ptic O
##us O
adolescence O
introduction O

polymer O
##ase O
gamma O
is O
essential O
for O
mitochondrial O
dna O
replication O
mutations O
in O
the O
nuclear O
gene O
encoding O
the O
catalytic O
subunit O
of O
mt O
##dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
are O
associated O
with O
mitochondrial O
diseases O
1 O
pol O
##g O
##1 O
mutations O
have O
been O
implicated O
in O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
2 O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
3 O
parkinson O
##ism O
4 O
premature O
men O
##opa O
##use O
4 O
al O
##pers O
syndrome O
5 O
6 O
and O
mixed O
ph O
##eno O
##type O
##s O
7 O
8 O
there O
appears O
no O
strict O
relationship O
between O
ph O
##eno O
##type O
and O
gen O
##otype O
in O
patients O
with O
pathogen O
##ic O
mutations O
in O
the O
gene O
that O
en O
##codes O
for O
pol O
##g O
##1 O
8 O

al O
##pers O
syndrome O
usually O
presents O
in O
early O
childhood O
with O
the O
classical O
triad O
of O
developmental O
delay O
intra O
##ctable O
seizures O
and O
he O
##pati O
##c O
failure O
which O
may O
be O
pre O
##ci O
##pit O
##ated O
by O
val O
##pro O
##ic O
acid O
3 O
5 O
8 O
in O
2008 O
a O
new O
pol O
##g O
##1 O
mutation O
ph O
##eno O
##type O
was O
described O
features O
of O
which O
are O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
and O
visual O
symptoms O
in O
previously O
healthy O
adolescents O
or O
young O
adults O
the O
so O
called O
juvenile O
onset O
al O
##pers O
syndrome O
9 O
10 O
both O
al O
##pers O
ph O
##eno O
##type O
##s O
are O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
with O
rec O
##urrent O
status O
ep O
##ile O
##ptic O
##us O
and O
episodes O
of O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
which O
often O
nec O
##ess O
##itate O
admission O
to O
the O
intensive O
care O
unit O
ic O
##u O
and O
pose O
an O
important O
mortality O
risk O
10 O

intra O
##ven O
##ous O
magnesium O
is O
the O
first O
choice O
agent O
in O
treating O
con O
##vu O
##ls O
##ions O
in O
ec O
##lam O
##ps O
##ia O
11 O
and O
may O
be O
effective O
in O
status O
ep O
##ile O
##ptic O
##us O
of O
other O
origin O
although O
reports O
on O
this O
topic O
are O
sparse O
12 O
14 O
we O
present O
two O
cases O
of O
non O
related O
teenage O
girls O
with O
juvenile O
onset O
al O
##pers O
syndrome O
due O
to O
pol O
##g O
##1 O
mutations O
who O
presented O
with O
ref O
##rac O
##tory O
seizures O
that O
originated O
in O
the O
o O
##cci O
##pit O
##al O
lobe O
and O
were O
eventually O
successfully O
treated O
with O
magnesium O
case B-PATIENT
1 I-PATIENT

a O
previously O
healthy O
19 B-AGE_ONSET
year O
old O
woman B-PATIENT
was O
admitted O
to O
our O
tertiary O
care O
center O
after O
two O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
in O
a O
fort O
##night O
since O
the O
first O
seizure O
she O
complained O
of O
seeing O
bright O
spots O
routine O
neurological O
examination O
and O
brain O
ct O
at O
admission O
showed O
no O
abnormalities O
visual O
field O
examination O
revealed O
a O
rights B-HPO_TERM
##ided I-HPO_TERM
homo I-HPO_TERM
##ny I-HPO_TERM
##mous I-HPO_TERM
para I-HPO_TERM
##cent I-HPO_TERM
##ral I-HPO_TERM
sc I-HPO_TERM
##oto I-HPO_TERM
##ma I-HPO_TERM
flair O
and O
t O
##2 O
##weight O
##ed O
mri O
showed O
bilateral B-HPO_TERM
lesions I-HPO_TERM
with I-HPO_TERM
increased I-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
cortex I-HPO_TERM
most O
prominent O
in O
the O
left O
hemisphere O
with O
areas O
of O
both O
increased O
and O
decreased O
diffusion O
on O
ad O
##c O
maps O
ee B-HPO_TERM
##g I-HPO_TERM
showed I-HPO_TERM
slowing I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
background I-HPO_TERM
activity I-HPO_TERM
and O
continuous B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
activity I-HPO_TERM
over I-HPO_TERM
the I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
areas I-HPO_TERM
also O
most O
prominent O
in O
the O
left O
hemisphere O
her O
visual O
symptoms O
were O
therefore O
interpreted O
as O
focal B-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
treatment O
with O
ph O
##en O
##yt O
##oin O
and O
continuous O
intra O
##ven O
##ous O
in O
##fusion O
of O

cl O
##ona O
##ze O
##pa O
##m O
were O
initiated O
this O
improved O
the O
visual O
complaints O
but O
they O
did O
not O
resolve O
completely O

five O
weeks O
after O
the O
first O
seizure O
while O
still O
on O
ph O
##en O
##yt O
##oin O
and O
cl O
##ona O
##ze O
##pa O
##m O
she O
experienced O
right B-HPO_TERM
sided I-HPO_TERM
focal I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
that O
only O
partially O
responded O
to O
additional O
therapy O
with O
cl O
##ob O
##az O
##am O
and O
lev O
##eti O
##race O
##tam O
since O
a O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
syndrome O
was O
suspected O
val O
##pro O
##ic O
acid O
was O
avoided O
treatment O
with O
mid O
##az O
##ola O
##m O
resulted O
in O
temporary O
resolution O
of O
focal O
con O
##vu O
##ls O
##ions O
but O
her O
visual O
complaints O
did O
not O
improve O
and O
ict O
##al O
activity O
persisted O
on O
ee O
##g O
with O
right B-HPO_TERM
sided I-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
her O
mental B-HPO_TERM
status I-HPO_TERM
deteriorated I-HPO_TERM
as O
she O
became O
di B-HPO_TERM
##sor I-HPO_TERM
##iente I-HPO_TERM
##d I-HPO_TERM
with O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
and O
ac B-HPO_TERM
##al I-HPO_TERM
##cu I-HPO_TERM
##lia I-HPO_TERM
repeated O
mri O
showed O
an O
increase O
in O
the O
extent O
and O
number O
of O
the O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lesions I-HPO_TERM
now O
including O
left B-HPO_TERM
##side I-HPO_TERM
##d I-HPO_TERM
pu I-HPO_TERM
##l I-HPO_TERM
##vina I-HPO_TERM
##r I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
abnormalities I-HPO_TERM
urgent O
dna O
analysis O
indeed O
revealed O
a O
homo O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t O
mutation O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
confirming O
the O
diagnosis O
of O
juvenile O
##ons O
##et O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM

her O
condition B-HPO_TERM
worsened I-HPO_TERM
as O
she O
developed O
frequent O
simple B-HPO_TERM
left I-HPO_TERM
sided I-HPO_TERM
partial I-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
which O
gradually O
transformed O
into O
generalized B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
she O
was O
admitted O
to O
the O
ic O
##u O
and O
treated O
with O
high O
dose O
intra O
##ven O
##ous O
mid O
##az O
##ola O
##m O
0 O
4 O
mg O
kg O
h O
and O
a O
combination O
of O
ph O
##en O
##yt O
##oin O
300 O
mg O
day O
i O
v O
cl O
##ona O
##ze O
##pa O
##m O
3 O
mg O
day O
i O
v O
and O
lev O
##eti O
##race O
##tam O
1 O
500 O
mg O
day O
i O
v O
and O
vent O
##ila O
##tory O
support O
fig O
1 O
timetable O
with O
overview O
of O
anti O
ep O
##ile O
##ptic O
drugs O
d O
discharge O
from O
hospital O

fe O
focal O
ep O
##ile O
##pt O
##iform O
discharge O
##s O
f O
##se O
focal O
status O
ep O
##ile O
##ptic O
##us O
gs O
##e O
generalized O
status O
ep O
##ile O
##ptic O
##us O
vs O
vent O
##ila O
##tory O
support O
improved O
compared O
to O
previous O
ee O
##g O
td O
##ied O
days O
after O
onset O
ep O
##ile O
##psy O
37 O
38 O
39 O
40 O
41 O
42 O
43 O
44 O
45 O
46 O
47 O
48 O
49 O
50 O
51 O
days O
after O
onset O
ep O
##ile O
##psy O
4 O
5 O
6 O
7 O
8 O
9 O
10 O
11 O
12 O
13 O
14 O
15 O
16 O
31 O
d O

fig O
1 O
when O
se O
##dation O
was O
tempered O
the O
seizures O
immediately O
returned O
high O
dose O
oral O
top O
##ira O
##mate O
1 O
000 O
mg O
day O
somewhat O
decreased O
the O
frequency O
of O
the O
seizures O
but O
the O
ee B-HPO_TERM
##gs I-HPO_TERM
remained I-HPO_TERM
highly I-HPO_TERM
abnormal I-HPO_TERM
showing O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
changes I-HPO_TERM
with O
continuous B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
activity I-HPO_TERM
magnesium O
in O
##fusion O
was O
then O
introduced O
aiming O
to O
increase O
serum O
levels O
from O
0 O
81 O
mm O
##ol O
l O
to O
approximately O
3 O
5 O
mm O
##ol O
l O
leading O
almost O
instantly O
to O
complete O
ab O
##olis O
##hm O
##ent O
of O
her O
clinical O
seizures O
mid O
##az O
##ola O
##m O
was O
tape O
##red O
and O
she O
was O
ex O
##tub O
##ated O
the O
following O
day O
at O
time O
of O
ex O
##tub O
##ation O
serum O
magnesium O
level O
was O
3 O
8 O
mm O
##ol O
l O
after O
ex O
##tub O
##ation O
she O
was O
able O
to O
communicate O
although O
she O
remained O
so B-HPO_TERM
##m I-HPO_TERM
##no I-HPO_TERM
##lent I-HPO_TERM

although O
clinical O
signs O
of O
seizures O
remained O
absent O
the O
patient O
developed O
sep B-HPO_TERM
##sis I-HPO_TERM
probably O
due O
to O
vent B-HPO_TERM
##ila I-HPO_TERM
##tor I-HPO_TERM
associated I-HPO_TERM
pneumonia I-HPO_TERM
leading O
to O
multi B-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
and O
death B-HPO_TERM
2 B-AGE_DEATH
weeks I-AGE_DEATH
after I-AGE_DEATH
admission O
to O
the O
ic O
##u O
case B-PATIENT
2 I-PATIENT

in O
december O
2008 O
a O
previously O
healthy O
17 B-AGE_ONSET
year O
old O
girl B-PATIENT
complained O
of O
impaired B-HPO_TERM
vision I-HPO_TERM
and O
light O
flashes O
for O
several O
weeks O
she O
was O
evaluated O
in O
another O
hospital O
after O
a O
15 O
min O
episode O
of O
confusion B-HPO_TERM
and O
suspected B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
she O
fully O
recovered O
and O
was O
diagnosed O
with O
mig B-HPO_TERM
##raine I-HPO_TERM
two O
days O
later O
she O
had O
two O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
and O
was O
admitted O
to O
our O
hospital O
neurological O
examination O
revealed O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
right B-HPO_TERM
sided I-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
and O
intermittent O
partial B-HPO_TERM
motor I-HPO_TERM
seizures I-HPO_TERM
of O
her O
right O
leg O
t O
##2 O
and O
flair O
mri O
showed O
hyper B-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
lesions I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
cortex I-HPO_TERM
tha B-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and O
me B-HPO_TERM
##sia I-HPO_TERM
##l I-HPO_TERM
temporal I-HPO_TERM
lobe I-HPO_TERM
one O
week O
after O
admission O
dna O
analysis O
revealed O
a O
homo O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
mutation O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
confirming O
the O
suspected O
diagnosis O
of O
juvenile O
onset O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome O
fourteen O
years O
earlier O
her O
teenage O
sister O
had O
generalized O
status O
ep O
##ile O
##ptic O
##us O
she O
died O
without O
an O
established O
diagnosis O
after O
a O
complicated O
brain O
bio O
##psy O

while O
being O
treated O
with O
ph O
##en O
##yt O
##oin O
fig O
1 O
her O
ee O
##g O
showed O
a O
continuing B-HPO_TERM
focal I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
of O
the O
left O
o O
##cci O
##pit O
##al O
region O
spreading O
anterior O
##ly O
continuous O
intra O
##ven O
##ous O
in O
##fusion O
of O
mid O
##az O
##ola O
##m O
and O
lev O
##eti O
##race O
##tam O
were O
added O
and O
she O
was O
admitted O
to O
the O
ic O
##u O
for O
vent O
##ila O
##tory O
support O
when O
high O
dose O
mid O
##az O
##ola O
##m O
0 O
3 O
mg O
kg O
h O
lev O
##eti O
##race O
##tam O
2 O
000 O
mg O
day O
i O
v O
and O
ph O
##en O
##yt O
##oin O
300 O
mg O
day O
i O
v O
could O
not O
ab O
##olis O
##h O
focal B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
magnesium O
in O
##fusion O
was O
started O
aiming O
to O
increase O
serum O
levels O
from O

0 O
85 O
mm O
##ol O
l O
to O
approximately O
3 O
5 O
mm O
##ol O
l O
par B-HPO_TERM
##esis I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
both O
gradually O
improved O
within O
hours O
after O
the O
start O
of O
magnesium O
in O
##fusion O
and O
within O
12 O
h O
mid O
##az O
##ola O
##m O
was O
tape O
##red O
and O
she O
was O
ex O
##tub O
##ated O
with O
at O
that O
time O
a O
serum O
magnesium O
level O
of O
2 O
0 O
mm O
##ol O
l O
ee O
##g O
after O
ex O
##tub O
##ation O
showed O
improvement O
although O
there O
was O
still O
a O
focal B-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
fig O
2 O

when O
magnesium O
was O
tape O
##red O
and O
mid O
##az O
##ola O
##m O
was O
discontinued O
focal B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
of O
her O
right O
arm O
rec O
##ur O
##red O
for O
which O
mid O
##az O
##ola O
##m O
0 O
1 O
mg O
kg O
h O
was O
restarted O
in O
addition O
to O
magnesium O
ph O
##en O
##yt O
##oin O
and O
cl O
##ob O
##az O
##am O
con B-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ions I-HPO_TERM
ceased O
and O
the O
right O
sided O
post B-HPO_TERM
ict I-HPO_TERM
##al I-HPO_TERM
par I-HPO_TERM
##esis I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
disappeared O
gradually O
mid O
##az O
##ola O
##m O
and O
magnesium O
were O
stopped O
and O
oral O
ph O
##en O
##yt O
##oin O
cl O
##ob O
##az O
##am O
and O
lev O
##eti O
##race O
##tam O
were O
continued O
the O
patient O
could O
be O
discharged O
1 O
month O
after O
admission O
and O
she O
remains O
without O
seizures O
up O
to O
now O
8 B-AGE_FOLLOWUP
months I-AGE_FOLLOWUP
after I-AGE_FOLLOWUP
discharge O
her O
ee O
##g O
at O
discharge O
showed O
subtle O
focal O
o O
##cci O
##pit O
##al O
ep O
##ile O
##ptic O
discharge O
##s O
although O
there O
was O
an O
obvious O
improvement O
compared O
to O
previous O
ee O
##gs O

discussion O

juvenile O
onset O
al O
##pers O
syndrome O
is O
characterized O
by O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
pre O
##dom O
##inating O
in O
the O
o O
##cci O
##pit O
##al O
lobe O
with O
frequent O
episodes O
of O
spreading O
and O
status O
ep O
##ile O
##ptic O
##us O
for O
which O
a O
combination O
of O
several O
anti O
ep O
##ile O
##ptic O
drugs O
ae O
##ds O
is O
often O
required O
10 O
benz O
##od O
##ia O
##ze O
##pine O
##s O
are O
the O
main O
stay O
in O
the O
treatment O
of O
status O
ep O
##ile O
##ptic O
##us O
but O
often O
nec O
##ess O
##itate O
vent O
##ila O
##tory O
support O
importantly O
val O
##pro O
##ic O
acid O
should O
be O
avoided O
since O
it O
carries O
a O
high O
risk O
of O
inducing O
he O
##pati O
##c O
failure O
in O
our O
own O
experience O
prop O
##of O
##ol O
and O
th O
##io O
##pen O
##tal O
may O
also O
lead O
to O
he O
##pati O
##c O
failure O
and O
rapid O
neurological O
deterioration O
in O
children O
with O
al O
##pers O
syndrome O
in O
juvenile O
onset O
patients O
with O
pol O
##g O
##1 O
mutations O
these O
drugs O
should O
perhaps O
also O
be O
avoided O
when O
the O
combination O
of O
several O
high O
dose O
ae O
##ds O
could O
not O
stop O
focal O
or O
generalized O
status O
ep O
##ile O
##ptic O
##us O
in O
our O
two O
patients O
we O
chose O
to O
add O
magnesium O
according O
to O
the O
use O
in O
pre O
ec O
##lam O
##ps O
##ia O
11 O
the O
anti O
##con O
##vu O
##ls O
##ive O
effect O
of O
magnesium O
has O
been O
well O
established O
in O
pre O
ec O
##lam O
##ps O
##ia O
but O
it O
is O
rarely O
used O
in O
the O
treatment O
of O
ep O
##ile O
##psy O
of O
other O
origin O
in O
pre O
ec O
##lam O
##ps O
##ia O
an O
immediate O
effect O
is O
pursued O
by O
a O
loading O
dose O
of O
magnesium O
sul O
##phate O
followed O
by O
continuous O
in O
##fusion O
for O
24 O
h O
resulting O
in O
serum O
magnesium O
levels O
of O
1 O
7 O
3 O
5 O
mm O
##ol O
l O
15 O
but O
even O
at O
these O
high O
doses O
side O
effects O
are O
mild O
and O
sparse O
11 O
16 O
in O
particular O
renal O
or O
he O
##pati O
##c O
failure O
due O
to O
high O
dose O
magnesium O
therapy O
have O
not O
been O
described O
although O
magnesium O
is O
effective O
in O
preventing O
and O
treating O
ec O
##lam O
##ps O
##ia O
its O
mechanism O
of O
action O
remains O
unclear O
one O
of O
the O
suggested O
anti O
##con O
##vu O
##ls O
##ant O
mechanisms O
is O
its O
action O
as O
a O
n O
methyl O
d O
as O
##par O
##tic O
acid O
nm O
##da O
receptor O
antagonist O
the O
nm O
##da O
receptor O
is O
a O
g O
##lu O
##tama O
##te O
receptor O
which O
when O
activated O
leads O
to O
a O
massive O
de O
##pol O
##ari O
##zation O
of O
ne O
##uron O
##al O
networks O
and O
bursts O
of O
action O
potential O
##s O
magnesium O
may O
act O
to O
increase O
the O
seizure O
threshold O
by O
blocking O
the O
nm O
##da O
receptors O
15 O
animal O
models O
suggest O
that O
ae O
##ds O
enhancing O
ga O
##ba O
receptor O
activation O
e O
g O
bar O
##bit O
##ura O
##tes O
and O
benz O
##od O
##ia O
##ze O
##pine O
##s O
are O
effective O
in O
the O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
pp O
246 O
##1 O
247 O
##7 O
2010 O
movement O
disorder O
society O
letters O
to O
the O
editor O
related O
to O
new O
topics O
re O
##tina O
thickness O
in O
parkinson O
s O
disease O
and O
essential O
tremor O
visual O
symptoms O
particularly O
impaired O
f O
##ove O
##al O
vision O
are O
common O
among O
the O
non O
##moto O
##r O
phenomena O
in O
parkinson O
s O
disease O
pd O
experimental O
evidence O
from O
humans O
and O
monkeys O
shows O
that O
there O
are O
do O
##pa O
##mine O
##rg O
##ic O
cells O
in O
the O
re O
##tina O
including O
the O
ama O
##cr O
##ine O
sub O
##type O
a1 O
##8 O
with O
d O
##1 O
and O
d O
##2 O
receptors O
and O
inter O
##plex O
##iform O
cells O

post O
##mo O
##rte O
##m O
studies O
have O
shown O
that O
pd O
eyes O
have O
lower O
do O
##pa O
##mine O
content O
1 O
compared O
with O
healthy O
controls O
likewise O
a O
loss O
in O
the O
sensitivity O
to O
contrast O
and O
color O
vision O
altered O
visual O
ev O
##oked O
potential O
and O
electro O
##ret O
##ino O
##graphic O
measurements O
have O
been O
observed O
indicating O
f O
##ove O
##al O
re O
##tina O
##l O
gang O
##lion O
cells O
damage O
in O
pd O
2 O

quantitative O
morphology O
of O
gross O
re O
##tina O
##l O
his O
##tology O
in O
humans O
can O
be O
measured O
in O
vivo O
using O
time O
domain O
optical O
co O
##her O
##ence O
tom O
##ography O
oct O
in O
pd O
a O
thin O
##ning O
of O
the O
per O
##ip O
##ap O
##illa O
##ry O
re O
##tina O
##l O
nerve O
ﬁ O
##ber O
layer O
which O
represents O
ax O
##ons O
of O
the O
gang O
##lion O
cells O
and O
mac O
##ula O
have O
been O
shown O
supporting O
the O
hypothesis O
that O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
in O
the O
re O
##tina O
can O
cause O
structural O
changes O
2 O
5 O
however O
the O
useful O
##ness O
of O
measuring O
f O
##ove O
##al O
thickness O
by O
oct O
as O
a O
diagnostic O
tool O
to O
differentiate O
pd O
from O
other O
tremor O
disease O
such O
as O
essential O
tremor O
et O
remains O
unknown O
therefore O
the O
main O
purpose O
of O
this O
pilot O
study O
was O
to O
measure O
f O
##ove O
##al O
thickness O
in O
patients O
with O
pd O
and O
to O
compare O
it O
against O
a O
normal O
population O
and O
patients O
with O
et O

we O
designed O
a O
cross O
sectional O
pilot O
study O
that O
included O
a O
consecutive O
sample O
of O
out O
##patient O
##s O
diagnosed O
with O
id O
##io O
##pathic O
pd O
in O
accordance O
with O
the O
uk O
parkinson O
s O
disease O
society O
brain O
bank O
and O
et O
based O
on O
clinical O
criteria O
patients O
with O
any O
coe O
##xi O
##sti O
##ng O
o O
##cular O
disease O
were O
excluded O
this O
study O
was O
approved O
by O
the O
ethics O
committee O
of O
the O
general O
ya O
##gu O
##¨ O
##e O
hospital O
bu O
##rgos O
spain O
and O
all O
patients O
signed O
the O
informed O
consent O
before O
being O
enrolled O
control O
subjects O
were O
matched O
for O
age O
6 O
5 O
years O
and O
gender O
to O
pd O
patients O
demographic O
and O
pd O
et O
lateral O
##ity O
data O
were O
collected O
oct O
was O
acquired O
through O
a O
dil O
##ated O
pupil O
by O
an O
experienced O
operator O
using O
the O
oct O
##3 O
carl O
ze O
##iss O
med O
##ite O
##c O
dublin O
cal O
##if O
with O
axial O
resolution O
of O
10 O
l O
##m O
the O
mac O
##ular O
thickness O
map O
analysis O
and O
the O
center O
f O
##ove O
##al O
thickness O
was O
automatically O
determined O
by O
the O
oct O
##3 O
software O
6 O
images O
were O
considered O
to O
be O
of O
good O
quality O
if O
the O
signal O
to O
noise O
ratio O
was O
greater O
than O
30 O
##db O
or O
had O
more O
than O
95 O
sweeps O
accepted O

data O
analysis O
was O
performed O
from O
an O
ex O
##pl O
##ora O
##tory O
point O
of O
view O
using O
the O
statistical O
package O
sp O
##ss O
program O
sp O
##ss O
17 O
sp O
##ss O
chicago O
only O
descriptive O
analysis O
was O
used O
owing O
to O
the O
small O
sample O
size O
data O
were O
summarized O
as O
mean O
6 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
28 O
july O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##15 O
standard O
deviation O
and O
median O
range O
to O
maintain O
independence O
of O
all O
observations O
right O
eye O
re O
versus O
left O
eye O
le O
were O
analyzed O
for O
each O
patient O

fifty O
two O
eyes O
from O
9 O
patients O
with O
pd O
5 O
men O
and O
4 O
women O
with O
a O
mean O
age O
of O
64 O
1 O
12 O
years O
and O
disease O
duration O
of O
8 O
4 O
6 O
1 O
9 O
years O
8 O
patients O
with O
et O
4 O
men O
and O
4 O
women O
with O
a O
mean O
age O
of O
67 O
8 O
6 O
4 O
8 O
years O
and O
disease O
duration O
of O
23 O
7 O
6 O
18 O
3 O
years O
and O
9 O
controls O
were O
included O
the O
mean O
f O
##ove O
##al O
thickness O
was O
thinner O
in O
the O
pd O
group O
compared O
with O
the O
et O
group O
and O
controls O
table O
1 O
for O
the O
pd O
and O
et O
groups O
the O
mean O
f O
##ove O
##al O
thickness O
was O
also O
thinner O
in O
the O
contra O
lateral O
eye O
of O
the O
most O
affected O
side O
table O
1 O

in O
this O
pilot O
study O
based O
on O
the O
oct O
imaging O
the O
f O
##ove O
##a O
was O
thinner O
in O
the O
pd O
group O
compared O
with O
the O
et O
group O
and O
controls O
interesting O
##ly O
whereas O
inter O
##oc O
##ular O
mac O
##ular O
symmetry O
has O
been O
found O
in O
the O
normal O
population O
7 O
we O
found O
that O
the O
f O
##ove O
##al O
thickness O
was O
as O
##ym O
##metric O
and O
thinner O
in O
the O
eye O
contra O
##lateral O
to O
the O
side O
more O
affected O
by O
tremor O
and O
parkinson O
##ism O
in O
the O
et O
and O
pd O
groups O
respectively O
ha O
##jee O
et O
al O
also O
found O
the O
correlation O
between O
thin O
##ning O
in O
the O
left O
and O
the O
right O
eye O
of O
the O
same O
was O
not O
perfect O
7 O
hence O
this O
inter O
##oc O
##ular O
f O
##ove O
##al O
as O
##ym O
##metry O
should O
be O
considered O
in O
interpretation O
except O
that O
for O
et O
although O
mild O
tremor O
as O
##ym O
##metry O
has O
been O
documented O
as O
a O
fundamental O
characteristic O
of O
et O
there O
is O
no O
published O
information O
regarding O
f O
##ove O
##al O
thickness O
in O
patients O
with O
et O
the O
similar O
as O
##ym O
##metry O
ﬁ O
##nding O
in O
et O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
understand O
and O
we O
cannot O
obviously O
explain O
it O
based O
on O
our O
preliminary O
data O
however O
abnormal O
oct O
measures O
have O
also O
been O
found O
in O
other O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
such O
as O
alzheimer O
s O
disease O
multiple O
sc O
##ler O
##osis O
and O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
##s O
most O
likely O
related O
to O
the O
loss O
of O
re O
##tina O
##l O
gang O
##lion O
cells O
and O
ax O
##ons O
8 O
therefore O
further O
studies O
are O
required O
to O
establish O
whether O
oct O
measures O
contribute O
for O
a O
sensitive O
and O
spec O
##i O
##ﬁ O
##c O
diagnosis O
of O
pd O
and O
to O
differentiate O
it O
from O
other O
conditions O
we O
recognize O
our O
results O
cannot O
be O
compared O
with O
prior O
oct O
reports O
in O
pd O
because O
of O
the O
different O
imaging O
map O
protocol O
and O
equipment O
we O
are O
also O
aware O
that O
because O
of O
the O
small O
sample O
size O
used O
these O
results O
need O
to O
be O
repeated O
in O
larger O
co O
##hort O
##s O
to O
ensure O
rep O
##rod O
##uc O
##ibility O

with O
regards O
to O
technical O
feasibility O
the O
oct O
compared O
with O
other O
expensive O
ones O
such O
as O
the O
single O
photon O
emission O
computed O
tom O
##ography O
spec O
##t O
studies O
using O
123 O
##i O
f O
##p O
ci O
##t O
dat O
scan O
is O
widely O
available O
fast O
as O
it O
only O
takes O
a O
few O
minutes O
to O
perform O
and O
relatively O
inexpensive O
based O
on O
our O
preliminary O
data O
and O
in O
accordance O
with O
other O
authors O
2 O
5 O
we O
believe O
that O
f O
##ove O
##al O
thickness O
measured O
by O
the O
oct O
could O
be O
a O
promising O
feasible O
bio O
##mark O
##er O
of O
pd O
by O
quan O
##tify O
##ing O
the O
morphological O
changes O
of O
re O
##tina O
##l O
do O
##pa O
##mine O
##rg O
##ic O
neurons O

ac O
##k O
##now O
##led O
##gm O
##ent O
this O
study O
was O
supported O
by O
a O
grant O
from O
ca O
##ja O
bu O
##rgos O
2009 O
financial O
disclosure O
##s O
cub O
##o O
e O
honor O
##aria O
bo O
##eh O
##ring O
##er O
ing O
##el O
##heim O
g O
##la O
##x O
##o O
smith O
k O
##line O
lund O
##beck O
grant O
michael O
j O
246 O
##1 O
fox O
fis O
sac O
##yl O
pri O
##eto O
ted O
##ej O
##o O
r O
none O
rodriguez O
mendez O
v O
none O
lo O
##´ O
##pe O
##z O
pu O
##ey O
##o O
m O
##j O
none O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
j O
##m O
honor O
##aria O
p O
##ﬁ O
##zer O
grants O
ser O
##vier O
san O
##o O
##ﬁ O
este O
##ve O
sac O
##yl O
michael O
j O
fox O

author O
roles O
cub O
##o O
e O
research O
project O
conception O
and O
organization O
statistical O
analysis O
design O
and O
execution O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
the O
manuscript O
pri O
##eto O
ted O
##ej O
##o O
r O
research O
project O
organization O
and O
execution O
rodriguez O
mendez O
v O
research O
project O
organization O
lo O
##´ O
##pe O
##z O
pu O
##ey O
##o O
m O
##j O
review O
and O
critique O
of O
statistical O
analysis O
and O
manuscript O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
j O
##m O
review O
and O
critique O
of O
statistical O
analysis O
and O
manuscript O
esther O
cub O
##o O
md O
phd O
rosa O
pri O
##eto O
ted O
##ej O
##o O
ne O
##uro O
##logy O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
e O
mail O
esther O
##cu O
##bo O
gma O
##il O
com O

ve O
##ro O
##´ O
##nica O
rodriguez O
mendez O
md O
mar O
##´ O
##ı O
##a O
je O
##su O
##´s O
lo O
##´ O
##pe O
##z O
md O
phd O
op O
##ht O
##hal O
##mology O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
jose O
##´ O
mar O
##´ O
##ı O
##a O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
md O
phd O
ne O
##uro O
##logy O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
references O
ha O
##rno O
##is O
c O
dip O
##ao O
##lo O
t O
decreased O
do O
##pa O
##mine O
in O
the O
re O
##tina O
of O
patients O
with O
parkinson O
s O
disease O
invest O
op O
##ht O
##hal O
##mo O
##l O
1990 O
31 O
247 O
##3 O
247 O
##5 O
bo O
##dis O
wo O
##ll O
##ner O
i O
re O
##tino O
##pathy O
in O
parkinson O
s O
disease O
j O
neural O
trans O
##m O
2009 O
116 O
149 O
##3 O
150 O
##1 O

ha O
##jee O
me O
march O
w O
##f O
la O
##zza O
##ro O
dr O
wo O
##lin O
##tz O
ah O
shri O
##er O
em O
g O
##la O
##zman O
s O
bo O
##dis O
wo O
##ll O
##ner O
i O
##g O
inner O
re O
##tina O
##l O
layer O
thin O
##ning O
in O
parkinson O
disease O
arch O
op O
##ht O
##hal O
##mo O
##l O
2009 O
127 O
737 O
74 O
##1 O
o O
p O
oz O
##kan O
b O
y O
correlation O
between O
re O
##tina O
##l O
morphological O
and O
functional O
ﬁ O
##nding O
##s O
and O
clinical O
severity O
in O
parkinson O
s O
disease O
doc O
op O
##ht O
##hal O
##mo O
##l O
2008 O
116 O
137 O
146 O
in O
##zel O
##berg O
r O
ramirez O
ja O
ni O
##si O
##pe O
##anu O
p O
op O
##hir O
a O
re O
##tina O
##l O
nerve O
ﬁ O
##ber O
be O
##rish O
##a O
f O
fe O
##ke O
gt O
tre O
##mp O
##e O
cl O
mc O
##me O
##el O
j O
##w O
sc O
##he O
##pen O
##s O
cl O
re O
##tina O
##l O
abnormalities O
in O
early O
alzheimer O
s O
disease O
invest O
op O
##ht O
##hal O
##mo O
##l O
vis O
sci O
2007 O
48 O
228 O
##5 O
228 O
##9 O

lam O
##ire O
##l O
c O
newman O
n O
bio O
##uss O
##e O
v O
the O
use O
of O
optical O
co O
##her O
##ence O
tom O
##ography O
in O
ne O
##uro O
##logy O
rev O
ne O
##uro O
##l O
di O
##s O
2009 O
6 O
105 O
120 O
acute O
renal O
failure O
in O
patients O
with O
bilateral O
deep O
brain O
stimulation O
the O
management O
of O
parkinson O
s O
disease O
is O
mainly O
ph O
##arm O
##aco O
##logical O
with O
lev O
##od O
##opa O
but O
in O
recent O
years O
surgery O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
has O
been O
rev O
##ital O
##ized O
for O
the O
treatment O
of O
patients O
with O
un O
##con O
##tro O
##lla O
##ble O
motor O
complications O
1 O

a O
large O
proportion O
of O
patients O
suffering O
from O
parkinson O
s O
disease O
presents O
with O
ur O
##ina O
##ry O
dysfunction O
described O
as O
urgency O
increased O
frequency O
or O
inc O
##ont O
##inen O
##ce O
as O
predominant O
symptoms O
##2 O
3 O
and O
also O
st O
##n O
db O
##s O
has O
proven O
to O
improve O
ur O
##ina O
##ry O
function O
4 O
data O
from O
experimental O
ur O
##od O
##yna O
##mic O
measures O
in O
men O
and O
animal O
models O
have O
demonstrated O
a O
sign O
##i O
##ﬁ O
##can O
##t O
in O
##ﬂ O
##uen O
##ce O
of O
st O
##n O
db O
##s O
on O
ur O
##ina O
##ry O
bladder O
function O
5 O
6 O
in O
these O
studies O
the O
main O
effect O
of O
st O
##n O
db O
##s O
appeared O
to O
be O
a O
normal O
##ization O
of O
ur O
##od O
##yna O
##mic O
parameters O
but O
there O
is O
no O
data O
reported O
about O
kidney O
function O
in O
these O
patients O
7 O
despite O
its O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
the O
manifold O
physiological O
consequences O
of O
st O
##n O
db O
##s O
are O
to O
date O
poorly O
understood O

acute O
renal O
failure O
ar O
##f O
de O
##ﬁ O
##ned O
as O
an O
abrupt O
or O
rapid O
decline O
in O
renal O
ﬁ O
##lt O
##ration O
function O
and O
cr O
##ea O
##tin O
##ine O
clearance O
cc O
is O
used O
to O
estimate O
the O
g O
##lom O
##er O
##ular O
ﬁ O
##lt O
##ration O
rate O
g O
##fr O
the O
cc O
test O
compares O
the O
level O
of O
cr O
##ea O
##tin O
##ine O
in O
urine O
with O
the O
cr O
##ea O
##tin O
##ine O
level O
in O
the O
blood O
usually O
based O
on O
measurements O
of O
a O
24 O
hour O
urine O
sample O
g O
##fr O
has O
never O
been O
studied O
in O
parkinson O
patients O
with O
normal O
pre O
##oper O
##ative O
renal O
function O
immediately O
after O
st O
##n O
db O
##s O
here O
we O
report O
a O
decline O
in O
renal O
ﬁ O
##lt O
##ration O
function O
after O
st O
##n O
db O
##s O

nineteen O
patients O
15 O
men O
and O
four O
women O
with O
a O
mean O
6 O
##sd O
age O
of O
63 O
6 O
7 O
years O
at O
the O
time O
of O
surgery O
and O
a O
mean O
duration O
of O
disease O
of O
16 O
6 O
9 O
years O
were O
selected O
for O
implant O
##ation O
of O
electrode O
##s O
in O
the O
st O
##n O
the O
selection O
criteria O
were O
clinical O
##ly O
diagnosed O
parkinson O
s O
disease O
severe O
lev O
##od O
##opa O
related O
motor O
complications O
despite O
optimal O
adjustment O
of O
anti O
##park O
##ins O
##onia O
##n O
medication O
an O
age O
under O
70 O
years O
no O
layer O
thin O
##ning O
in O
parkinson O
disease O
vision O
res O
2004 O
44 O
279 O
##3 O
279 O
##7 O

el O
ash O
##ry O
m O
he O
##g O
##de O
v O
james O
p O
pa O
##glia O
##rini O
s O
analysis O
of O
mac O
##ular O
thickness O
in O
british O
population O
using O
optical O
co O
##her O
##ence O
tom O
##ography O
oct O
an O
emphasis O
on O
inter O
##oc O
##ular O
symmetry O
cu O
##rr O
eye O
res O
2008 O
33 O
69 O
##3 O
69 O
##9 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
there O
is O
no O
potential O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
from O
each O
author O
that O
relate O
to O
the O
research O
covered O
in O
the O
article O
submitted O
published O
online O
28 O
july O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##28 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##3 O
fig O
1 O
cr O
##ea O
##tin O
##ine O
clearance O
before O
and O
after O
st O
##n O
db O
##s O

surgical O
contra O
##ind O
##ication O
##s O
and O
no O
dementia O
or O
major O
ongoing O
psychiatric O
illness O
electrode O
##s O
were O
implant O
##ed O
bilateral O
##ly O
under O
local O
an O
##esthesia O
as O
described O
previously O
8 O
patients O
were O
evaluated O
pre O
##oper O
##ative O
##ly O
1 O
week O
after O
surgery O
and O
post O
##oper O
##ative O
##ly O
1 O
week O
after O
surgery O
evaluation O
##s O
included O
1 O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
parts O
iii O
motor O
2 O
mean O
dose O
of O
lev O
##od O
##opa O
3 O
all O
medical O
manifestation O
##s O
4 O
24 O
hours O
urine O
5 O
urine O
ion O
##og O
##ram O
and O
biochemistry O
6 O
blood O
ion O
##og O
##ram O
and O
7 O
cc O

cc O
and O
fraction O
##al O
ex O
##cre O
##tion O
of O
sodium O
potassium O
and O
phosphate O
were O
calculated O
as O
previously O
reported O
5 O
ur O
##ea O
was O
measured O
by O
an O
en O
##zy O
##matic O
test O
and O
cr O
##ea O
##tin O
##ine O
by O
the O
ja O
##ffe O
##´ O
method O
ion O
selective O
electrode O
##s O
performed O
the O
quan O
##ti O
##ﬁ O
##cation O
##s O
of O
sodium O
and O
potassium O
in O
urine O
samples O
phosphate O
was O
determined O
by O
a O
direct O
photo O
##metric O
method O
all O
ass O
##ays O
were O
performed O
by O
co O
##bas O
mira O
plus O
anal O
##yse O
##r O
ab O
##x O
diagnostic O
##s O
geneva O
switzerland O
urine O
and O
plasma O
os O
##mo O
##lal O
##ity O
were O
determined O
by O
means O
of O
an O
os O
changes O
were O
observed O
in O
urine O
and O
blood O
ion O
##og O
##ram O
before O
and O
after O
surgery O
table O
1 O

st O
##n O
db O
##s O
has O
been O
shown O
to O
am O
##eli O
##ora O
##te O
bladder O
dysfunction O
increases O
bladder O
capacity O
in O
patients O
with O
parkinson O
s O
disease O
by O
modulation O
of O
sensory O
processing O
9 O
it O
appears O
to O
be O
a O
normal O
##ization O
of O
ur O
##od O
##yna O
##mic O
parameters O
but O
there O
is O
no O
data O
reported O
about O
kidney O
function O
in O
these O
patients O

in O
our O
patients O
kidney O
function O
was O
altered O
immediately O
after O
surgery O
a O
decline O
in O
ﬁ O
##lt O
##ration O
function O
developed O
after O
st O
##n O
db O
##s O
and O
some O
patients O
without O
pre O
##oper O
##ative O
ri O
developed O
acute O
ri O
post O
##oper O
##ative O
##ly O
in O
these O
patients O
no O
ur O
##ina O
##ry O
retention O
occurred O
ur O
##ina O
##ry O
volume O
was O
similar O
before O
and O
after O
surgery O
no O
pre O
##oper O
##ative O
hem O
##od O
##yna O
##mic O
complications O
as O
de O
##hy O
##dra O
##tion O
occurred O
like O
other O
series O
ne O
##uro O
##sti O
##mu O
##lat O
##or O
implant O
##ation O
an O
##est O
##hetic O
technique O
is O
not O
associated O
with O
major O
hem O
##od O
##yna O
##mic O
adverse O
effects O
10 O

a O
recent O
study O
of O
experimental O
##ly O
induced O
ar O
##f O
showed O
that O
there O
is O
a O
close O
interaction O
between O
the O
kidney O
and O
the O
central O
nervous O
system O
11 O
sympathetic O
in O
##ﬂ O
##uen O
##ce O
in O
kidney O
functions O
is O
under O
control O
of O
brains O
##tem O
bio O
##genic O
amin O
##e O
cell O
groups O
and O
h O
##yp O
##oth O
##ala O
##mic O
nuclei O
12 O
13 O
it O
cannot O
be O
excluded O
that O
there O
may O
be O
regional O
effects O
of O
db O
##s O
st O
##n O
on O
h O
##yp O
##oth O
##ala O
##mic O
centers O
depending O
on O
the O
exact O
location O
of O
the O
contacts O
in O
the O
st O
##n O
area O

effect O
of O
db O
##s O
st O
##n O
in O
h O
##yp O
##oth O
##ala O
##mic O
centers O
remains O
a O
valid O
hypothesis O
which O
could O
explain O
an O
altered O
kidney O
function O
immediately O
after O
surgery O
but O
further O
investigations O
are O
required O
to O
explore O
this O
possible O
mechanism O
with O
these O
preliminary O
results O
the O
authors O
suggest O
that O
it O
is O
necessary O
to O
evaluate O
cc O
before O
and O
after O
surgery O
for O
early O
orientation O
of O
patients O
with O
ri O
ac O
##k O
##now O
##led O
##gm O
##ents O
we O
thank O
the O
clinical O
investigation O
center O
of O
hospital O
de O

financial O
disclosure O
##s O
the O
authors O
have O
no O
ﬁ O
##nan O
##cial O
disclosure O
##s O
or O
nothing O
to O
disclose O
financial O
disclosure O
##s O
of O
all O
authors O
for O
the O
past O
year O
none O
of O
the O
authors O
have O
received O
table O
1 O
urine O
and O
blood O
ion O
##og O
##ram O
before O
and O
after O
surgery O
mom O
##eter O
model O
3 O
mo O
advanced O
instruments O
wilcox O
##on O
signed O
rank O
test O
and O
spear O
##man O
test O
were O
used O
for O
statistical O
parkinson O
patient O
experimental O
conditions O
st O
##n O
db O
##s O
before O
st O
##n O
db O
##s O
after O
analysis O
24 O
hours O
urine O
volume O
ml O
1 O
60 O
##1 O
6 O
56 O
##2 O
1 O
521 O
6 O
58 O
##3 O
after O
surgery O
db O
##s O
st O
##n O
produced O
a O
statistical O
##ly O
and O
cl O
##ini O

call O
##y O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
in O
mean O
un O
##i O
##ﬁ O
##ed O
park O
##ison O
s O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
scores O
up O
##rs O
##s O
iii O
was O
sign O
##i O
##ﬁ O
g O
##lom O
##er O
##ular O
ﬁ O
##lt O
##ration O
rate O
ml O
min O
blood O
ion O
##og O
##ram O
78 O
2 O
6 O
31 O
1 O
69 O
3 O
6 O
27 O
9 O
can O
##tly O
improved O
after O
db O
##s O
st O
##n O
p O
0 O
00 O
##5 O
52 O
6 O
8 O
3 O
before O
surgery O
and O
16 O
5 O
6 O
8 O
4 O
1 O
week O
after O
surgery O
as O
well O
as O
a O
ma O
red O
49 O
sodium O
me O
##q O
l O
139 O
6 O
2 O
2 O
136 O
6 O
2 O
1 O
potassium O
me O
##q O
l O
4 O
1 O
6 O
0 O
1 O
4 O
0 O
6 O
0 O
1 O
mean O
estimated O
g O
##fr O
calculated O
by O
cc O
ml O
min O
declined O
sign O
##i O
##ﬁ O
##can O
##tly O
p O
0 O
00 O
##5 O
after O
st O
##n O
db O
##s O
from O
78 O
2 O
6 O
31 O
1 O

to O
69 O
3 O
6 O
27 O
9 O
fig O
1 O
moreover O
three O
patients O
without O
pre O
##oper O
##ative O
renal O
ins O
##uf O
##ﬁ O
##ciency O
ri O
cc O
90 O
ml O
min O
developed O
acute O
ri O
post O
##oper O
##ative O
##ly O
stage O
2 O
ri O
in O
two O
patients O
and O
stage O
3 O
ri O
in O
one O
patient O
three O
patients O
with O
pre O
##oper O
##ative O
ri O
ex O
##ace O
##rba O
##ted O
stage O
2 O
into O
stage O
3 O
in O
one O
patient O
and O
stage O
3 O
into O
stage O
4 O
in O
two O
patients O
mean O
ur O
##ina O
##ry O
volume O
in O
ml O
day O
were O
similar O
pre O
##oper O
##ative O
##ly O
1 O
60 O
##1 O
6 O
56 O
##2 O
and O
post O
##oper O
##ative O
##ly O
1 O
521 O
6 O
58 O
##3 O
no O
urine O
ion O
##og O
##ram O
sodium O
mmm O
##ol O
l O
109 O
6 O
40 O
123 O
6 O
67 O
potassium O
mmm O
##ol O
l O
33 O
7 O
6 O
11 O
3 O
33 O
7 O
6 O
10 O
4 O
calcium O
mg O
dl O
8 O
2 O
6 O
4 O
2 O
7 O
7 O
6 O
4 O
3 O

ph O
##os O
##por O
##um O
mg O
dl O
59 O
8 O
6 O
26 O
1 O
55 O
1 O
6 O
27 O
9 O
ur O
##ic O
acid O
mg O
dl O
6 O
4 O
6 O
5 O
3 O
10 O
3 O
6 O
7 O
6 O
urine O
biochemistry O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##4 O
letters O
to O
the O
editor O
ﬁ O
##nan O
##cial O
support O
and O
funding O
for O
the O
preceding O
12 O
months O
of O
the O
listed O
sources O
regardless O
of O
relationship O
to O
current O
manuscript O

author O
roles O
joan O
##a O
research O
project O
conception O
organization O
execution O
statistical O
analysis O
design O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
augusta O
vie O
##ira O
coe O
##lho O
research O
project O
conception O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
maria O
jose O
##´ O
rosa O
##s O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
eduardo O
mo O
##ura O
research O
project O
execution O
statistical O
analysis O
design O
execution O
review O
and O
critique O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
ru O
##i O
va O
##z O
research O
project O
conception O
organization O
manuscript O
review O
and O
critique O
carolina O
garrett O
research O
project O
conception O
organization O

joan O
##a O
md O
ne O
##uro O
##logy O
department O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
e O
mail O
j O
##gui O
##m O
##rae O
##s O
##9 O
hot O
##mail O
com O
augusta O
vie O
##ira O
coe O
##lho O
md O
phd O
institute O
of O
ph O
##arm O
##aco O
##logy O
and O
therapeutic O
##s O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
maria O
jose O
##´ O
rosa O
##s O
md O
ne O
##uro O
##logy O
department O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O

eduardo O
mo O
##ura O
md O
phd O
institute O
of O
ph O
##arm O
##aco O
##logy O
and O
therapeutic O
##s O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
ru O
##i O
va O
##z O
md O
phd O
carolina O
garrett O
md O
phd O
ne O
##uro O
##sur O
##ger O
##y O
department O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
references O

k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O
le O
##mack O
ge O
dewey O
rb O
jr O
roe O
##hr O
##born O
c O
##g O
o O
sui O
##lle O
##ab O
##hai O
##n O
pe O
z O
##im O
##mer O
##n O
pe O
question O
##naire O
based O
assessment O
of O
bladder O
dysfunction O
in O
patients O
with O
mild O
to O
moderate O
parkinson O
s O
disease O
ur O
##ology O
2000 O
56 O
250 O
254 O
wing O
##e O
k O
fowler O
c O
##j O
bladder O
dysfunction O
in O
parkinson O
##ism O
mechanisms O
prevalence O
symptoms O
and O
management O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
737 O
74 O
##5 O

her O
##zog O
j O
weiss O
ph O
ass O
##mus O
a O
et O
al O
improved O
sensory O
ga O
##ting O
of O
ur O
##ina O
##ry O
bladder O
af O
##fer O
##ents O
in O
parkinson O
s O
disease O
following O
sub O
##thal O
##ami O
##c O
stimulation O
brain O
2008 O
131 O
pt O
1 O
132 O
145 O
k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O
se O
##if O
c O
her O
##zog O
j O
van O
der O
horst O
c O
et O
al O
effect O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
on O
the O
function O
of O
the O
ur O
##ina O
##ry O
bladder O
ann O
ne O
##uro O
##l O
2004 O
55 O
118 O
120 O

her O
##zog O
j O
weiss O
ph O
ass O
##mus O
a O
et O
al O
sub O
##thal O
##ami O
##c O
stimulation O
mod O
##ulates O
co O
##rti O
##cal O
control O
of O
ur O
##ina O
##ry O
bladder O
in O
parkinson O
s O
disease O
brain O
2006 O
129 O
336 O
##6 O
337 O
##5 O
le O
##ma O
##ire O
jj O
cost O
##e O
j O
ou O
##ch O
##chan O
##e O
l O
et O
al O
brain O
mapping O
in O
stereo O
##ta O
##ctic O
surgery O
a O
brief O
overview O
from O
the O
pro O
##ba O
##bilis O
##tic O
targeting O
to O
the O
patient O
based O
ana O
##tom O
##ic O
mapping O
ne O
##uro O
##ima O
##ge O
2007 O
37 O
su O
##pp O
##l O
1 O
s O
##10 O
##9 O
s O
##11 O
##5 O
karim O
##i O
m O
go O
##lch O
##in O
n O
tab O
##bal O
sd O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
induced O
regional O
blood O
ﬂ O
##ow O
responses O
co O
##rre O
##late O
with O
improvement O
of O
motor O
signs O
in O
parkinson O
disease O
brain O
2008 O
131 O
271 O
##0 O
271 O
##9 O

po O
##on O
cc O
irwin O
mg O
ana O
##esthesia O
for O
deep O
brain O
stimulation O
and O
in O
patients O
with O
implant O
##ed O
ne O
##uro O
##sti O
##mu O
##lat O
##or O
devices O
br O
j O
ana O
##est O
##h O
2009 O
103 O
152 O
165 O
pal O
##kov O
##its O
m O
se O
##bek O
##ova O
k O
gall O
##atz O
k O
et O
al O
ne O
##uron O
##al O
activation O
in O
the O
cn O
##s O
during O
different O
forms O
of O
acute O
renal O
failure O
in O
rats O
neuroscience O
2009 O
159 O
86 O
##2 O
88 O
##2 O
turner O
ms O
gray O
ts O
mick O
##ie O
##wicz O
al O
napier O
tc O
f O
##os O
expression O
following O
activation O
of O
the O
ventral O
pal O
##lid O
##um O
in O
normal O
rats O
and O
in O
a O
model O
of O
parkinson O
s O
disease O
implications O
for O
limb O
##ic O
system O
and O
basal O
gang O
##lia O
interactions O
brain O
st O
##ru O
##ct O
fun O
##ct O
2008 O
213 O
197 O
213 O

kit O
##ta O
t O
mats O
##um O
##oto O
m O
tanaka O
h O
mit O
##su O
##i O
t O
yo O
##shi O
##oka O
m O
non O
##om O
##ura O
k O
ga O
##ba O
##er O
##gic O
mechanism O
mediated O
via O
d O
receptors O
in O
the O
rat O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
participates O
in O
the O
mic O
##tur O
##ition O
re O
##ﬂ O
##ex O
an O
in O
vivo O
micro O
##dial O
##ysis O
study O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2008 O
27 O
321 O
##6 O
322 O
##5 O
ad O
##em O
presenting O
as O
a O
movement O
disorder O
video O
acute O
di O
##sse O
##minated O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
ad O
##em O
is O
a O
dem O
##ye O
##lina O
##ting O
disease O
of O
the O
central O
nervous O
system O
characterized O
by O
multi O
##fo O
##cal O
neurological O
de O
##ﬁ O
##cit O
##s O
and O
en O
##ce O
##pha O
##lo O
##pathy O
1 O
we O
report O
a O
patient O
with O
ad O
##em O
who O
presented O
with O
a O
movement O
disorder O

a O
44 O
year O
old O
woman O
was O
admitted O
with O
cho O
##re O
##iform O
movements O
her O
medications O
included O
sodium O
val O
##pro O
##ate O
400 O
mg O
th O
##rice O
daily O
for O
mig O
##raine O
and O
ph O
##ene O
##lz O
##ine O
30 O
mg O
twice O
daily O
for O
sc O
##hi O
##zo O
##af O
##fect O
##ive O
disorder O
the O
patient O
had O
developed O
involuntary O
movements O
in O
her O
left O
leg O
3 O
days O
following O
an O
upper O
respiratory O
tract O
infection O
the O
movements O
progressed O
to O
involve O
both O
upper O
and O
lower O
limbs O
ph O
##ene O
##lz O
##ine O
was O
ceased O
with O
no O
improvement O
examination O
revealed O
cho O
##re O
##iform O
movements O
affecting O
the O
upper O
limb O
and O
lower O
limb O
particularly O
on O
the O
left O
the O
movements O
were O
continuous O
with O
intermittent O
brief O
jerk O
##s O
see O
video O
1 O

ct O
brain O
was O
un O
##rem O
##ark O
##able O
blood O
glucose O
was O
normal O
the O
cr O
##ea O
##tine O
kinase O
ck O
was O
elevated O
at O
98 O
##8 O
##2 O
l O
##mo O
##l O
l O
decreasing O
to O
83 O
##5 O
l O
##mo O
##l O
l O
by O
day O
5 O
sodium O
val O
##pro O
##ate O
level O
was O
106 O
l O
##mo O
##l O
l O
therapeutic O
range O
350 O
700 O
l O
##mo O
##l O
l O
the O
as O
##ot O
was O
elevated O
at O
47 O
##3 O
i O
##u O
ml O
and O
increased O
to O
83 O
##7 O
i O
##u O
ml O
after O
2 O
weeks O
anti O
dna O
##se O
b O
ti O
##tre O
remained O
negative O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
24 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##29 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##5 O
fig O
1 O
a O
axial O
ﬂ O
##uid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
mri O
brain O
multiple O
f O
##oc O
##i O
of O
hyper O
##int O
##ens O
##ti O
##y O
in O
the O
sub O
##thal O
##ami O
##c O
regions O
brains O
##tem O
ce O
##re O
##bell O
##um O
not O
shown O
left O
o O
##cci O
##pit O
##al O
white O
matter O
and O
left O
lent O
##iform O
nucleus O
b O
repeat O
axial O
ﬂ O
##uid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
mri O
brain O
three O
months O
after O
onset O
showing O
resolution O
of O
lesions O

the O
patient O
was O
commenced O
on O
benz O
##yl O
##pen O
##ici O
##llin O
and O
cl O
##ona O
##ze O
##pa O
##m O
ph O
##ene O
##lz O
##ine O
was O
rec O
##om O
##men O
##ced O
her O
movement O
disorder O
improved O
within O
a O
few O
days O
and O
resolved O
over O
the O
following O
several O
days O
on O
the O
5th O
day O
the O
patient O
developed O
a O
fever O
and O
left O
sided O
6th O
nerve O
pal O
##sy O
the O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
showed O
normal O
protein O
and O
glucose O
and O
one O
mono O
##nu O
##cle O
##ar O
cell O
ol O
##igo O
##cl O
##onal O
bands O
were O
not O
present O
mri O
brain O
revealed O
multiple O
none O
##nh O
##an O
##cing O
f O
##oc O
##i O
of O
hyper O
##int O
##ens O
##ity O
in O
the O
sub O
##thal O
##ami O
##c O
regions O
bilateral O
##ly O
brains O
##tem O
ce O
##re O
##bell O
##um O
left O
lent O
##iform O
nucleus O
and O
left O
o O
##cci O
##pit O
##al O
white O
matter O
fig O
1a O

the O
patient O
then O
deteriorated O
with O
del O
##iri O
##um O
ata O
##xia O
ny O
##sta O
##gm O
##us O
a O
left O
horne O
##r O
s O
syndrome O
and O
bilateral O
sixth O
nerve O
pal O
##sies O
repeat O
cerebral O
mri O
showed O
progression O
of O
the O
previous O
ﬁ O
##nding O
##s O
with O
patch O
##y O
areas O
of O
enhancement O
methyl O
##pre O
##d O
##nis O
##one O
was O
commenced O
repeat O
cs O
##f O
examination O
2 O
days O
later O
showed O
12 O
mono O
##nu O
##cle O
##ar O
cells O
but O
remained O
otherwise O
normal O
tests O
for O
hiv O
bo O
##rre O
##lia O
bu O
##rg O
##dorf O
##eri O
b O
hen O
##sel O
##ae O
b O
per O
##tus O
##sis O
e O
##b O
##v O
cm O
##v O
my O
##co O
##pl O
##as O
##ma O
to O
##x O
##op O
##las O
##mos O
##is O
crypt O
##oco O
##cca O
##l O
antigen O
q O
fever O
bar O
##mah O
forest O
hs O
##v O
1 O
and O
2 O
in O
##ﬂ O
##uen O
##za O
a O
and O
b O
fl O
##avi O
##virus O
ross O
river O
h O
##h O
##v O
6 O
v O
##z O
me O
##as O
##les O
and O

rick O
##ett O
##sia O
ser O
##ology O
were O
negative O
testing O
for O
metabolic O
diseases O
as O
well O
as O
auto O
##im O
##mun O
##e O
markers O
including O
anti O
g O
##q O
##1 O
##b O
i O
##gg O
antibodies O
were O
negative O
by O
day O
17 O
the O
patient O
gradually O
improved O
and O
was O
discharged O
to O
rehabilitation O
at O
3 O
month O
follow O
up O
the O
patient O
had O
experienced O
complete O
resolution O
of O
her O
symptoms O
and O
mri O
changes O
fig O
1b O

the O
clinical O
and O
radio O
##logical O
ﬁ O
##nding O
##s O
in O
our O
patient O
were O
consistent O
with O
ad O
##em O
although O
lesions O
in O
ad O
##em O
typically O
enhance O
with O
ga O
##do O
##lini O
##um O
schwarz O
et O
al O
reported O
patch O
##y O
enhancement O
in O
24 O
of O
cases O
with O
no O
enhancement O
in O
4 O
1 O
similarly O
although O
cs O
##f O
ol O
##igo O
##cl O
##onal O
bands O
were O
negative O
the O
reported O
percentage O
in O
ad O
##em O
varies O
from O
0 O
to O
58 O
in O
contrast O
to O
multiple O
sc O
##ler O
##osis O
where O
ol O
##igo O
##cl O
##onal O
bands O
are O
detected O
in O
90 O
95 O
of O
cases O
2 O
this O
lower O
percentage O
may O
be O
explained O
by O
poly O
##cl O
##onal O
rather O
than O
ol O
##igo O
##cl O
##onal O
activation O
in O
ad O
##em O
in O
response O
to O
an O
antigen O
##ic O
challenge O

it O
is O
likely O
that O
the O
bilateral O
sub O
##thal O
##ami O
##c O
lesions O
and O
possibly O
also O
the O
left O
lent O
##iform O
nucleus O
les O
##ion O
resulted O
in O
the O
development O
of O
cho O
##rea O
in O
our O
patient O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##6 O
letters O
to O
the O
editor O
the O
ﬁ O
##nding O
of O
an O
elevated O
as O
##ot O
raises O
the O
possibility O
of O
sy O
##den O
##ham O
s O
cho O
##rea O
but O
in O
the O
setting O
of O
a O
persistent O
##ly O
negative O
anti O
dna O
##se O
b O
is O
ins O
##uf O
##ﬁ O
##cie O
##nt O
evidence O
to O
support O
a O
recent O
st O
##re O
##pt O
##oco O
##cca O
##l O
infection O
a O
normal O
value O
for O
anti O
st O
##re O
##pt O
##oco O
##cca O
##l O
antibody O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
de O
##ﬁ O
##ne O
owing O
to O
di O
##spar O
##ities O
due O
to O
age O
geography O
and O
seasonal O
variation O
3 O

reports O
of O
cho O
##re O
##iform O
movements O
associated O
with O
sodium O
val O
##pro O
##ate O
have O
been O
described O
4 O
however O
our O
patient O
improved O
despite O
continuation O
of O
this O
medication O
we O
have O
found O
one O
report O
of O
cho O
##rea O
associated O
with O
mono O
##amine O
ox O
##ida O
##se O
inhibitors O
5 O
however O
the O
patient O
also O
improved O
despite O
rec O
##om O
##men O
##ce O
##ment O
and O
maintenance O
of O
her O
mono O
##amine O
ox O
##ida O
##se O
inhibitor O
an O
adverse O
reaction O
to O
this O
medication O
such O
as O
ser O
##oton O
##in O
syndrome O
is O
therefore O
also O
unlikely O
the O
elevation O
in O
ck O
is O
presumably O
related O
to O
muscle O
damage O
in O
the O
setting O
of O
intense O
and O
prolonged O
involuntary O
movements O

intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
has O
been O
used O
for O
treatment O
of O
ste O
##roid O
resistant O
ad O
##em O
with O
success O
in O
a O
few O
cases O
however O
it O
is O
unclear O
whether O
the O
improvement O
was O
co O
incident O
##al O
with O
the O
self O
limiting O
nature O
of O
the O
disease O
6 O
reports O
regarding O
the O
effectiveness O
of O
plasma O
##pher O
##esis O
have O
been O
inconsistent O
7 O
in O
conclusion O
we O
describe O
an O
adult O
patient O
who O
presented O
with O
an O
involuntary O
movement O
disorder O
and O
subsequently O
went O
on O
to O
develop O
a O
typical O
clinical O
course O
and O
radio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
ad O
##em O
legend O
to O
the O
video O

video O
clip O
of O
initial O
examination O
showing O
cho O
##re O
##iform O
movements O
affecting O
upper O
limbs O
and O
lower O
limbs O
particularly O
on O
the O
left O
financial O
disclosure O
##s O
nothing O
to O
disclose O
author O
roles O
ain O
##hi O
ha O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
of O
manuscript O
carolyn O
sue O
conception O
organization O
execution O
of O
research O
project O
design O
execution O
review O
and O
critique O
of O
statistical O
analysis O
and O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
of O
manuscript O
ain O
##hi O
d O
ha O
mb O
##bs O
department O
of O
ne O
##uro O
##logy O
royal O
north O
shore O
hospital O
sydney O

carolyn O
sue O
mb O
##bs O
phd O
fra O
##cp O
medicine O
northern O
clinical O
school O
ko O
##lling O
institute O
of O
medical O
research O
royal O
north O
shore O
hospital O
the O
university O
of O
sydney O
new O
south O
wales O
2006 O
australia O
e O
mail O
cs O
##ue O
med O
us O
##yd O
ed O
##u O
au O
references O
schwarz O
s O
mo O
##hr O
a O
kn O
##au O
##th O
m O
wilde O
##mann O
b O
st O
##or O
##ch O
hagen O
##lo O
##cher O
b O
acute O
di O
##sse O
##minated O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
a O
follow O
up O
study O
of O
40 O
adult O
patients O
ne O
##uro O
##logy O
2001 O
56 O
131 O
##3 O
131 O
##8 O
cia O
##n O
or O
primary O
care O
physician O
pe O
##dia O
##tr O
in O
##fect O
di O
##s O
j O
2002 O
21 O
420 O
45 O
##6 O
quiz O
42 O
##7 O
430 O
gun O
##al O
di O
gu O
##ler O
##yu O
##z O
m O
bingo O
##l O
ca O
rev O
##ers O
##ible O
val O
##pro O
##ate O
induced O
cho O
##re O
##iform O
movements O
seizure O
2002 O
11 O
205 O
206 O

macleod O
d O
##m O
cho O
##rea O
induced O
by O
tran O
##quil O
##lis O
##ers O
lance O
##t O
1964 O
1 O
38 O
##8 O
38 O
##9 O
ra O
##va O
##glia O
s O
piccolo O
g O
ce O
##ron O
##i O
m O
et O
al O
severe O
ste O
##roid O
resistant O
post O
infectious O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
general O
features O
and O
effects O
of O
iv O
##ig O
j O
ne O
##uro O
##l O
2007 O
254 O
151 O
##8 O
152 O
##3 O
kay O
##nar O
l O
alt O
##unt O
##as O
f O
a O
##yd O
##og O
##du O
i O
et O
al O
therapeutic O
plasma O
exchange O
in O
patients O
with O
ne O
##uro O
##logic O
diseases O
retrospective O
multi O
##cent O
##er O
study O
trans O
##fus O
ap O
##her O
sci O
2008 O
38 O
109 O
115 O
pet O
findings O
in O
rev O
##ers O
##ible O
improvement O
of O
ol O
##factory O
dysfunction O
after O
st O
##n O
stimulation O
in O
a O
parkinson O
s O
disease O
patient O

ol O
##factory O
dysfunction O
o O
##d O
is O
one O
of O
the O
earliest O
non O
##moto O
##r O
symptoms O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
pd O
1 O
h O
##yp O
##os O
##mia O
in O
pd O
is O
generally O
bilateral O
and O
remains O
unaffected O
by O
parkinson O
##ian O
medication O
1 O
despite O
of O
its O
high O
occurrence O
little O
is O
really O
known O
about O
the O
mechanisms O
of O
ol O
##factory O
loss O
2 O
most O
h O
##yp O
##oth O
##eses O
raised O
to O
explain O
this O
phenomenon O
involve O
ne O
##uro O
##de O
##gen O
##erative O
processes O
of O
ol O
##factory O
structures O
3 O
the O
authors O
report O
a O
case O
and O
the O
ﬂ O
##uo O
##rod O
##eo O
##xy O
##gl O
##uc O
##ose O
f O
##d O
##g O
pet O
ﬁ O
##nding O
##s O
of O
a O
patient O
who O
underwent O
bilateral O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
and O
subsequently O
developed O
a O
great O
improvement O
in O
motor O
symptoms O
parallel O
##ed O
by O
an O
impressive O
recovery O
of O
ol O
##fa O
##ction O
after O
surgery O

a O
51 O
year O
old O
man O
with O
advanced O
pd O
severe O
motor O
ﬂ O
##uc O
##tua O
##tions O
and O
inca O
##pac O
##itating O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
underwent O
bilateral O
st O
##n O
db O
##s O
he O
presented O
early O
onset O
of O
pd O
symptoms O
35 O
years O
old O
eight O
years O
ago O
he O
started O
complaining O
of O
severe O
loss O
of O
ol O
##fa O
##ction O
discrimination O
he O
seldom O
perceived O
very O
intense O
and O
unpleasant O
fragrance O
##s O
and O
loss O
of O
li O
##bid O
##o O
his O
motor O
scores O
on O
the O
up O
##dr O
##s O
part O
iii O
in O
on O
medication O
were O
35 O
and O
74 O
in O
off O
medication O
condition O
chronic O
mono O
##pol O
##ar O
stimulation O
was O
applied O
on O
the O
contacts O
corresponding O
to O
the O
st O
##n O
two O
distal O
contacts O
on O
each O
side O
as O
the O
cat O
##ho O
##des O
1 O
7 O
v O
right O
2 O
0 O
v O
left O
pulse O
width O
210 O
l O
##s O
and O
frequency O
of O
130 O
hz O
at O
ﬁ O
##ve O
months O
on O
post O
##oper O
##ative O
follow O
up O
the O
patient O
had O
experienced O
improvement O
in O
the O
up O
##dr O
##s O
part O
iii O
score O
16 O
on O
##med O
on O
##sti O
##m O
vs O
39 O
off O
##med O
on O
##sti O
##m O
during O
a O
routine O
visit O
the O
patient O
spontaneously O
reported O
marked O
improvement O
in O
his O
ol O
##factory O
function O
ol O
##fa O
##ction O
was O
assessed O
using O
the O
brief O
smell O
id O
##ent O
##i O
##ﬁ O
##cation O
test O
12 O
items O
b O
sit O
4 O
he O
recognized O
the O
odor O
of O
eight O
of O
twelve O
substances O
score O
considered O
normal O
ol O
##fa O
##ction O
for O
someone O
his O
age O
according O
to O
the O
dot O
##y O
s O
values O
1 O

six O
months O
after O
surgery O
under O
informed O
consent O
the O
patient O
underwent O
f O
##d O
##g O
pet O
scan O
study O
in O
the O
on O
##sti O
##m O
on O
##med O
vs O
the O
offs O
##ti O
##m O
on O
##med O
conditions O
the O
ﬁ O
##rst O
study O
was O
performed O
with O
the O
st O
##im O
##ulator O
on O
and O
under O
routine O
medication O
best O
functional O
condition O
the O
radio O
##tra O
##cer O
was O
injected O
at O
rest O
in O
a O
dark O
and O
quiet O
room O
during O
odor O
expo O
##si O
fran O
##cio O
##tta O
d O
col O
##umb O
##a O
cab O
##eza O
##s O
s O
andre O
##oni O
l O
et O
al O
ol O
##igo O
##cl O
##onal O
i O
##gg O
band O
patterns O
in O
in O
##ﬂ O
##am O
##mat O
##ory O
dem O
##ye O
##lina O
##ting O
human O
and O
mouse O
diseases O
j O
ne O
##uro O
##im O
##mun O
##ol O
2008 O
200 O
125 O
128 O

she O
##t O
a O
kaplan O
el O
clinical O
use O
and O
interpretation O
of O
group O
a O
st O
##re O
##pt O
##oco O
##cca O
##l O
antibody O
tests O
a O
practical O
approach O
for O
the O
pe O
##dia O
##tri O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
the O
authors O
report O
no O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
published O
online O
4 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##53 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##7 O

fig O
1 O
results O
of O
regional O
brain O
activation O
related O
to O
the O
ol O
##factory O
paradigm O
during O
bilateral O
st O
##n O
stimulation O
images O
corresponding O
to O
on O
and O
off O
conditions O
were O
compared O
through O
computer O
##ized O
vox O
##el O
based O
image O
sub O
##tra O
##ction O
mat O
##lab O
##1 O
image O
##j O
##1 O
fused O
onto O
the O
mri O
os O
##iri O
##x O
##1 O
and O
plotted O
into O
the O
tail O
##ara O
##ch O
atlas O
brains O
##ight O
##1 O
the O
image O
shows O
in O
red O
and O
yellow O
the O
greater O
activation O
areas O
tha O
##lam O
##us O
st O
##ria O
##tum O
nucleus O
acc O
##umb O
##ens O
and O
amy O
##g O
##dal O
##oid O
complex O
bilateral O
##ly O
and O
the O
left O
g O
##yr O
##us O
rec O
##tus O
at O
the O
bottom O
z O
shows O
the O
brain O
slice O
distance O
from O
the O
ac O
pc O
line O
coordinates O
of O
tal O
##air O
##ach O
atlas O
color O
ﬁ O
##gur O
##e O
can O
be O
viewed O
in O
the O
online O
issue O
which O
is O
available O
at O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O

ti O
##on O
to O
one O
of O
the O
substances O
b O
sit O
the O
second O
pet O
study O
was O
performed O
under O
the O
same O
conditions O
but O
the O
st O
##im O
##ulator O
had O
been O
turned O
off O
for O
seven O
days O
at O
this O
time O
the O
patient O
experienced O
return O
of O
h O
##yp O
##os O
##mia O
as O
he O
observed O
and O
reported O
spontaneously O
the O
o O
##d O
at O
this O
point O
corresponded O
to O
the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
2 O
12 O
fragrance O
##s O
in O
b O
sit O
the O
results O
of O
pet O
images O
revealed O
sign O
##i O
##ﬁ O
##can O
##t O
metabolic O
activation O
of O
tha O
##lam O
##us O
st O
##ria O
##tum O
nucleus O
acc O
##umb O
##ens O
and O
amy O
##g O
##dal O
##oid O
complex O
bilateral O
##ly O
as O
well O
as O
the O
left O
g O
##yr O
##us O
rec O
##tus O
the O
tissue O
around O
the O
electrode O
also O
revealed O
metabolic O
activation O
from O
deep O
st O
##n O
extending O
to O
ventral O
tha O
##lam O
##us O
fig O
1 O

previous O
reports O
have O
stated O
that O
odor O
discrimination O
improves O
after O
st O
##n O
db O
##s O
in O
pd O
patients O
while O
ol O
##factory O
detection O
threshold O
does O
not O
these O
results O
suggest O
that O
st O
##nd O
##bs O
might O
mod O
##ulate O
cognitive O
processing O
of O
ol O
##factory O
information O
5 O
the O
return O
to O
h O
##yp O
##os O
##mia O
after O
the O
stimulation O
was O
turned O
off O
favors O
the O
hypothesis O
that O
functional O
changes O
in O
st O
##ria O
##tum O
tha O
##lam O
##us O
co O
##rti O
##cal O
networks O
rather O
than O
ir O
##re O
##vers O
##ible O
de O
##gen O
##eration O
of O
ol O
##factory O
structures O
only O
are O
responsible O
for O
o O
##d O
observed O
in O
pd O
patients O
the O
progressive O
ne O
##uron O
##al O
loss O
throughout O
the O
brain O
generates O
dysfunction O
in O
the O
ch O
##ron O
##ome O
##try O
of O
circuits O
of O
the O
basal O
gang O
##lia O
affecting O
different O
systems O
interpreted O
clinical O
##ly O
as O
various O
symptoms O
of O
pd O
once O
the O
hyper O
activation O
of O
st O
##n O
is O
reversed O
by O
the O
onset O
of O
local O
electrical O
stimulation O
its O
in O
##ﬂ O
##uen O
##ce O
spreads O
out O
to O
other O
neural O
circuits O
correct O
##ing O
dysfunction O
##s O
of O
mod O
##ulator O
##y O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
which O
in O
turn O
is O
related O
to O
the O
temporary O
improvement O
of O
motor O
and O
non O
##moto O
##r O
symptoms O
although O
data O
in O
previous O
studies O
##6 O
suggest O
that O
the O
motor O
effect O
obtained O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
and O
by O
st O
##n O
stimulation O
shares O
the O
same O
activated O
brain O
areas O
this O
is O
not O
likely O
to O
happen O
with O
ol O
##factory O
function O
because O
do O
##pa O
##mine O
##rg O
##ic O
rep O
##osition O
has O
no O
effect O
on O
h O
##yp O
##os O
##mia O
1 O

in O
line O
with O
previous O
reports O
pet O
signs O
of O
motor O
improvement O
at O
##ten O
##uation O
of O
the O
parkinson O
disease O
related O
pattern O
pd O
##rp O
6 O
was O
expressed O
except O
for O
a O
residual O
hyper O
##met O
##ab O
##olis O
##m O
in O
left O
st O
##ria O
##tum O
observed O
in O
the O
present O
study O
although O
a O
remarkable O
motor O
improvement O
was O
observed O
in O
this O
patient O
the O
expected O
abolition O
of O
pd O
##rp O
was O
not O
fully O

expressed O
this O
apparent O
inc O
##ons O
##iste O
##ncy O
may O
be O
related O
to O
individual O
variability O
in O
a O
single O
subject O
analysis O
or O
it O
may O
suggest O
the O
participation O
of O
left O
st O
##ria O
##tum O
in O
the O
ol O
##factory O
information O
processing O
network O
in O
this O
patient O
also O
a O
substantial O
increase O
in O
metabolism O
in O
the O
vicinity O
of O
the O
sub O
##thal O
##ami O
##c O
target O
site O
extending O
ro O
##stra O
##lly O
into O
the O
ventral O
tha O
##lam O
##us O
was O
observed O
since O
the O
f O
##d O
##g O
hyper O
##met O
##ab O
##olis O
##m O
was O
highly O
coincide O
##nt O
with O
the O
location O
of O
electrode O
##s O
this O
component O
is O
probably O
related O
to O
the O
direct O
effects O
of O
electrical O
stimulation O
of O
st O
##n O
inhibit O
##ing O
de O
##pol O
##ari O
##zation O
on O
the O
cell O
membrane O
6 O
the O
electrode O
trajectory O
performed O
in O
this O
patient O
includes O
the O
motor O
anterior O
ventral O
##is O
oral O
##is O
nucleus O
of O
tha O
##lam O
##us O
posterior O
ventral O
##is O
oral O
##is O
nucleus O
of O
tha O
##lam O
##us O
vo O
##a O
vo O
##p O
as O
observed O
in O
the O
post O
##oper O
##ative O
mri O
the O
upper O
contact O
is O
located O
within O
the O
ventral O
portion O
of O
tha O
##lam O
##us O
besides O
the O
activation O
of O
amy O
##g O
##dal O
##oid O
complex O
hip O
##po O
##camp O
##us O
orbit O
##of O
##ron O
##tal O
cortex O
st O
##ria O
##tum O
tha O
##lam O
##us O
mid O
##bra O
##in O
and O
ce O
##re O
##bell O
##um O
related O
to O
ol O
##factory O
stimulation O
in O
pd O
patients O
as O
shown O
by O
west O
##erman O
##n O
et O
al O
7 O
also O
observed O
in O
this O
case O
there O
was O
additional O
activation O
of O
bilateral O
nucleus O
acc O
##umb O
##ens O
and O
left O
g O
##yr O
##us O
rec O
##tus O
although O
further O
studies O
are O
required O
for O
more O
robust O
conclusions O
the O
present O
ﬁ O
##nding O
##s O
suggest O
that O
the O
activated O
areas O
may O
media O
##te O
the O
odor O
discrimination O
improvement O
after O
bilateral O
st O
##n O
db O
##s O
the O
stimulation O
of O
tha O
##lam O
##ic O
region O
in O
this O
case O
might O
also O
have O
activated O
tha O
##lam O
##ic O
nuclei O
related O
to O
ol O
##factory O
function O
e O
g O
nucleus O
para O
##ta O
##enia O
##lis O
of O
tha O
##lam O
##us O
pt O
the O
connections O
of O
the O
pt O
nucleus O
arise O
from O
the O
secondary O
ol O
##factory O
centers O
through O
st O
##ria O
med O
##ulla O
##ris O
of O
tha O
##lam O
##us O
8 O
the O
activation O
of O
this O
nucleus O
could O
in O
##ﬂ O
##uen O
##ce O
the O
ol O
##factory O
circuit O
##ry O
at O
distant O
sites O
once O
reports O
of O
ol O
##factory O
sensation O
were O
observed O
by O
direct O
electrical O
stimulation O
of O
this O
region O
9 O

these O
preliminary O
observations O
suggest O
that O
o O
##d O
in O
pd O
may O
rather O
be O
a O
circuit O
##ry O
dysfunction O
and O
not O
only O
a O
ne O
##uro O
##de O
##gen O
##erative O
process O
in O
ol O
##factory O
structures O
a O
dysfunction O
of O
cognitive O
processing O
involved O
in O
odor O
discrimination O
might O
explain O
this O
phenomenon O
there O
are O
multiple O
levels O
of O
integration O
of O
ol O
##factory O
information O
and O
the O
st O
##n O
db O
##s O
seems O
to O
in O
##ﬂ O
##uen O
##ce O
the O
circuit O
involving O
the O
primary O
ol O
##factory O
areas O
limb O
##ic O
areas O
as O
the O
ventral O
st O
##ria O
##tum O
and O
basal O
frontal O
cortex O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##8 O
letters O
to O
the O
editor O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fa O
##pes O
##p O
03 O
117 O
##9 O
##4 O
6 O
and O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
of O
hospital O
das O
cl O
##´ O
##ı O
##nica O
##s O

author O
roles O
dr O
f O
##ono O
##ff O
was O
involved O
in O
conception O
and O
design O
acquisition O
of O
data O
analysis O
and O
interpretation O
of O
data O
drafting O
the O
article O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
and O
administrative O
technical O
material O
support O
dr O
te O
##ix O
##eira O
was O
involved O
in O
conception O
and O
design O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
and O
administrative O
technical O
material O
support O
dr O
almeida O
was O
involved O
in O
acquisition O
analysis O
and O
interpretation O
of O
data O
drafting O
the O
article O
and O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
dr O
ga O
##rri O
##do O
was O
involved O
in O
analysis O
and O
interpretation O
of O
data O
dr O
salle O
##m O
was O
involved O
in O
drafting O
and O
critically O
rev O
##ising O
the O
article O
dr O
and O
##rade O
was O
involved O
in O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
dr O
bar O
##bos O
##a O
was O
involved O
in O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O

erich O
tal O
##amo O
##ni O
f O
##ono O
##ff O
md O
phd O
y O
##w O
##zh O
##e O
si O
##fu O
##entes O
almeida O
de O
oliveira O
md O
santiago O
dr O
##iol O
##let O
md O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
e O
mail O
f O
##ono O
##ffe O
##t O
us O
##p O
br O
gr O
##ise O
##lda O
jar O
##ra O
ga O
##rri O
##do O
phd O
inform O
##atics O
division O
heart O
institute O
school O
of O
medicine O
university O
of O
sao O
paulo O
sao O
paulo O
brazil O
daniel O
cia O
##mp O
##i O
de O
and O
##rade O
md O
fl O
##a O
##´ O
##vio O
salle O
##m O
md O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
e O
##gb O
##ert O
##o O
rei O
##s O
bar O
##bos O
##a O
md O
phd O

department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
man O
##oe O
##l O
jacobs O
##en O
te O
##ix O
##eira O
md O
phd O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
references O
dot O
##y O
r O
##l O
dee O
##ms O
d O
ste O
##ller O
s O
ol O
##factory O
dysfunction O
in O
parkinson O
s O
disease O
a O
general O
de O
##ﬁ O
##cit O
unrelated O
to O
ne O
##uro O
##logic O
signs O
di O
##s O
bra O
##ak O
h O
del O
##tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
210 O

double O
k O
##l O
rowe O
db O
hayes O
m O
chan O
d O
##ky O
black O
##ie O
j O
identifying O
the O
pattern O
of O
ol O
##factory O
de O
##ﬁ O
##cit O
##s O
in O
parkinson O
disease O
using O
the O
brief O
smell O
id O
##ent O
##i O
##ﬁ O
##cation O
test O
arch O
ne O
##uro O
##l O
2003 O
60 O
54 O
##5 O
54 O
##9 O
hum O
##mel O
t O
ja O
##hn O
##ke O
u O
somme O
##r O
u O
reich O
##mann O
h O
mu O
##¨ O
##ller O
a O
ol O
##factory O
function O
in O
patients O
with O
id O
##io O
##pathic O
parkinson O
s O
disease O
effects O
of O
deep O
brain O
stimulation O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
j O
neural O
trans O
##m O
2005 O
112 O
66 O
##9 O
67 O
##6 O
asa O
##num O
##a O
k O
tang O
c O
ma O
y O
dh O
##awan O
v O
matt O
##is O
p O
edwards O
c O
ka O
##pl O
##itt O
mg O
fei O
##gin O
a O
e O
##ide O
##lberg O
d O
network O
modulation O
in O
the O
treatment O
of O
parkinson O
s O
disease O
brain O
2006 O
129 O
266 O
##7 O
267 O
##8 O

west O
##erman O
##n O
b O
watt O
##end O
##orf O
e O
sc O
##h O
##wer O
##dt O
##fe O
##ger O
u O
hu O
##sner O
a O
fu O
##hr O
p O
gr O
##atz O
##l O
o O
hum O
##mel O
t O
bile O
##cen O
d O
we O
##lge O
lu O
##¨ O
##ssen O
a O
functional O
imaging O
of O
the O
cerebral O
ol O
##factory O
system O
in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O
##tr O
2008 O
79 O
19 O
24 O
sc O
##hal O
##ten O
##brand O
g O
walker O
e O
has O
##sler O
r O
nara O
##bay O
##ashi O
h O
ri O
##eche O
##rt O
t O
editors O
stereo O
##ta O
##xy O
of O
the O
human O
brain O
second O
ed O
new O
york O
th O
##ie O
##me O
st O
##rat O
##ton O
inc O
1982 O
153 O
##p O
nash O
##old O
bs O
wilson O
w O
##p O
ol O
##factory O
hall O
##uc O
##inations O
ev O
##oked O
from O
stimulation O
of O
human O
tha O
##lam O
##us O
con O
##ﬁ O
##n O
ne O
##uro O
##l O
1970 O
32 O
298 O
306 O

fa O
##mi O
##lia O
##l O
non O
##kin O
##es O
##igen O
##ic O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ia O
and O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O
a O
new O
syndrome O

par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
p O
##nk O
##d O
refers O
to O
a O
clinical O
syndrome O
characterized O
by O
attacks O
of O
involuntary O
movements O
including O
d O
##yst O
##onia O
cho O
##rea O
at O
##het O
##osis O
or O
ball O
##ism O
occurring O
at O
rest O
1 O
2 O
p O
##nk O
##d O
is O
associated O
to O
a O
wide O
range O
of O
ae O
##ti O
##ologies O
for O
example O
auto O
##im O
##mun O
##e O
vascular O
traumatic O
in O
##fect O
##ive O
and O
end O
##oc O
##rine O
disorders O
1 O
however O
most O
cases O
of O
p O
##nk O
##d O
are O
id O
##io O
##pathic O
and O
ne O
##uro O
##ima O
##ging O
is O
usually O
un O
##rem O
##ark O
##able O
1 O
2 O
we O
report O
a O
p O
##nk O
##d O
family O
whose O
computed O
tom O
##ography O
ct O
scan O
revealed O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O

this O
four O
generation O
family O
includes O
5 O
one O
deceased O
patients O
table O
1 O
fig O
1 O
the O
pro O
##band O
individual O
iv O
2 O
is O
7 O
##year O
old O
girl O
who O
experienced O
at O
age O
of O
9 O
months O
a O
ﬁ O
##rst O
attack O
of O
d O
##yst O
##onic O
posture O
of O
the O
head O
with O
con O
##com O
##itan O
##t O
ballistic O
and O
cho O
##re O
##ic O
movements O
of O
upper O
and O
lower O
ex O
##tre O
##mit O
##ies O
this O
event O
lasted O
30 O
minutes O
without O
alteration O
of O
consciousness O
and O
was O
followed O
by O
prompt O
recovery O
one O
month O
later O
the O
girl O
experienced O
a O
similar O
episode O
pre O
##ci O
##pit O
##ated O
by O
fever O
and O
resolving O
spontaneously O
neurological O
examination O
between O
attacks O
was O
normal O
laboratory O
investigations O
serum O
and O
urine O
copper O
calcium O
phosphorus O
vitamin O
d O
ce O
##ru O
##lo O
##pl O
##as O
##min O
fe O
##rri O
##tin O
transfer O
##rin O
serum O
iron O
thyroid O
para O
##thy O
##roid O
and O
ad O
##ren O
##oco O
##rti O
##cot O
##rop O
##ic O
hormones O
anti O
trans O
##gl O
##uta O
##mina O
##se O
antibodies O
serum O
lip O
##op O
##rot O
##ein O
##s O
and O
lip O
##id O
pro O
##ﬁ O
##le O
lac O
##tate O
p O
##yr O
##u O
##vate O
amino O
acids O
and O
urine O
organic O
acids O
were O
normal O
brain O
magnetic O
resonance O
imaging O
mri O
was O
un O
##rem O
##ark O
##able O
mutations O
in O
mr O
1 O
my O
##o O
##ﬁ O
##bri O
##llo O
##genesis O
regulator O
1 O
3 O
and O
sl O
##c O
##2 O
##a1 O
g O
##lu O
##t O
1 O
4 O
genes O
were O
excluded O
as O
well O
as O
and O
family O
link O
##age O
to O
chromosome O
14 O
##q O
##5 O
lo O
##d O
score O
22 O
y O
5 O
0 O
in O
the O
following O
years O
the O
girl O
continued O
to O
experience O
similar O
episodes O
at O
the O
frequency O
of O
about O
one O
per O
year O
in O
one O
o O
##cca O

ease O
stage O
or O
disease O
duration O
ne O
##uro O
##logy O
1988 O
38 O
123 O
##7 O
124 O
##4 O
take O
##da O
a O
ki O
##ku O
##chi O
a O
mats O
##uz O
##aki O
kobayashi O
m O
su O
##gen O
##o O
n O
ito O
##yama O
y O
ol O
##factory O
dysfunction O
in O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
iv O
2 O
iv O
7 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
27 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##6 O
##7 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##9 O
table O
1 O
clinical O
features O
of O
the O
p O
##nk O
##d O
patients O
trunk O
20 O
300 O
cerebral O
white O
matter O
re O
##mission O
at O
33 O
years O
iii O
3 O
37 O
m O
6 O
years O
fever O
emotional O
stress O

head O
limbs O
20 O
300 O
normal O
basal O
gang O
##lia O
yearly O
persist O
iv O
2 O
7 O
f O
9 O
months O
fever O
head O
limbs O
5 O
300 O
normal O
absent O
sporadic O
persist O
and O
not O
done O
si O
##on O
ict O
##al O
electro O
##ence O
##pha O
##log O
##raphy O
ee O
##g O
recording O
excluded O
the O
ep O
##ile O
##ptic O
nature O
of O
the O
event O
at O
the O
age O
of O
7 O
years O
a O
new O
ct O
scan O
was O
un O
##rem O
##ark O
##able O

individual O
iii O
2 O
is O
a O
39 O
year O
old O
man O
suffering O
from O
rec O
##urrent O
attacks O
of O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
involving O
the O
head O
limbs O
and O
trunk O
from O
4 O
years O
of O
life O
pre O
##ci O
##pit O
##ated O
by O
emotional O
stress O
at O
age O
33 O
years O
brain O
ct O
and O
mri O
revealed O
basal O
gang O
##lia O
and O
cerebral O
white O
matter O
cal O
##ci O
##ﬁ O
##cation O
##s O
extensive O
laboratory O
screening O
and O
neurological O
examination O
were O
un O
##rem O
##ark O
##able O
no O
further O
attacks O
were O
reported O
during O
the O
last O
6 O
years O

individual O
iii O
3 O
is O
a O
37 O
year O
old O
man O
experiencing O
yearly O
attacks O
of O
sudden O
onset O
d O
##yst O
##onia O
and O
cho O
##re O
##ic O
movements O
of O
the O
head O
and O
limbs O
from O
age O
6 O
to O
30 O
years O
related O
to O
physical O
or O
emotional O
stress O
neurological O
examination O
was O
un O
##rem O
##ark O
##able O
laboratory O
investigations O
and O
ee O
##g O
were O
normal O
brain O
ct O
at O
age O
30 O
years O
showed O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
##s O

individual O
ii O
3 O
is O
a O
70 O
year O
old O
woman O
presenting O
her O
ﬁ O
##rst O
attack O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
involving O
the O
head O
and O
the O
four O
limbs O
at O
the O
age O
of O
4 O
years O
subsequently O
these O
manifestation O
##s O
occurred O
regularly O
at O
the O
frequency O
of O
one O
per O
year O
in O
association O
with O
fast O
##ing O
or O
stress O
laboratory O
investigations O
and O
neurological O
examination O
were O
normal O
at O
the O
age O
of O
65 O
years O
brain O
ct O
revealed O
basal O
gang O
##lia O
and O
ce O
##re O
##bella O
##r O
cal O
##ci O
##ﬁ O
##cation O
##s O
the O
patient O
still O
experiences O
yearly O
episodes O
and O
in O
the O
last O
few O
years O
developed O
post O
##ural O
and O
kinetic O
tremor O
responding O
to O
alcohol O
intake O

individual O
i O
2 O
experienced O
a O
single O
episode O
of O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
of O
the O
head O
at O
the O
age O
of O
75 O
years O
pre O
##ci O
##pit O
##ated O
by O
fever O
and O
lasting O
about O
20 O
minutes O

this O
family O
shows O
typical O
clinical O
features O
of O
p O
##nk O
##d O
1 O
2 O
all O
patients O
showed O
a O
typical O
pattern O
and O
duration O
of O
the O
episodes O
not O
activated O
by O
movement O
and O
showed O
normal O
neurological O
status O
between O
attacks O
except O
for O
the O
oldest O
living O
individual O
ii O
3 O
who O
developed O
late O
onset O
post O
##ural O
and O
kinetic O
tremor O
responding O
to O
alcohol O
intake O
individual O
i O
1 O
who O
experienced O
a O
single O
attack O
at O
age O
75 O
years O
related O
to O
feb O
##ril O
##e O
illness O
was O
considered O
as O
probably O
affected O
considering O
the O
transit O
##ory O
nature O
of O
his O
manifestation O
and O
the O
fact O
that O
fever O
was O
a O
pre O
##ci O
##pit O
##ating O
factor O
also O
in O
other O
affected O
members O
as O
reported O
in O
p O
##nk O
##d O
6 O
the O
course O
of O
the O
disease O
was O
relatively O
benign O
and O
affected O
individuals O
achieved O
spontaneous O
re O
##mission O
or O
continued O
to O
have O
about O
yearly O
episodes O
without O
treatment O
mutations O
in O
mr O
1 O
the O
only O
gene O
associated O
with O
fa O
##mi O
##lia O
##l O
p O
##nk O
##d O
3 O
7 O
were O
excluded O

fig O
1 O
pe O
##di O
##gree O
and O
ct O
scans O
of O
affected O
family O
members O
see O
the O
text O
for O
details O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##0 O
letters O
to O
the O
editor O

indeed O
the O
most O
distinctive O
feature O
in O
our O
family O
was O
the O
ﬁ O
##nding O
of O
symmetrical O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O
primarily O
affecting O
the O
basal O
gang O
##lia O
which O
has O
been O
previously O
reported O
in O
few O
isolated O
cases O
8 O
11 O
hereditary O
brain O
cal O
##cino O
##sis O
may O
be O
found O
in O
several O
different O
conditions O
12 O
for O
example O
disorders O
of O
para O
##thy O
##roid O
hormone O
or O
calcium O
regulation O
mitochondrial O
diseases O
and O
defects O
of O
organic O
or O
amino O
acid O
metabolism O
however O
all O
these O
ae O
##ti O
##ologies O
were O
ruled O
out O
in O
our O
family O
link O
##age O
to O
14 O
##q O
described O
in O
families O
with O
fa O
##hr O
disease O
and O
neurological O
symptoms O
5 O
was O
excluded O
con O
##ﬁ O
##rmin O
##g O
that O
this O
condition O
is O
genetically O
het O
##ero O
##gen O
##eous O
13 O
14 O
moreover O
the O
pathogen O
##etic O
role O
of O
cal O
##ci O
##ﬁ O
##cation O
##s O
remains O
unclear O
as O
the O
youngest O
patient O
showed O
un O
##rem O
##ark O
##able O
ne O
##uro O
##ima O
##ging O
despite O
full O
ph O
##eno O
##typical O
presentation O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
further O
families O
could O
shed O
light O
on O
the O
pathogen O
##esis O
of O
p O
##nk O
##d O

author O
roles O
conception O
and O
design O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
and O
p O
st O
##rian O
##o O
data O
acquisition O
and O
analysis O
p O
st O
##rian O
##o O
pat O
##riz O
##ia O
acc O
##ors O
##i O
lorenzo O
pine O
##lli O
francesca O
far O
##ave O
##lli O
and O
luc O
##io O
gi O
##ord O
##ano O
drafting O
editing O
and O
rev O
##ising O
of O
the O
text O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
p O
st O
##rian O
##o O
federico O
za O
##ra O
and O
carlo O
mine O
##tti O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
md O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
armenian O
republican O
ep O
##ile O
##psy O
center O
er O
##eb O
##oun O
##i O
yerevan O
state O
medical O
university O
yerevan O
armenia O
e O
mail O
y O
##nu O
##ne O
yahoo O
com O
nun O
##ep O
##ile O
##psy O
gma O
##il O
com O
pas O
##qual O
##e O
st O
##rian O
##o O
md O
phd O

muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
pat O
##riz O
##ia O
acc O
##ors O
##i O
md O
pediatric O
ne O
##uro O
##psy O
##chia O
##tric O
division O
sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
lorenzo O
pine O
##lli O
md O
ne O
##uro O
##rad O
##iology O
department O
sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
francesca O
far O
##ave O
##lli O
md O
laboratory O
of O
human O
genetics O
gall O
##ier O
##a O
hospital O
gen O
##ova O
italy O
federico O
za O
##ra O
phd O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
carlo O
mine O
##tti O
md O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
luc O
##io O
gi O
##ord O
##ano O
md O
pediatric O
ne O
##uro O
##psy O
##chia O
##tric O
division O

sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
references O
demi O
##rk O
##ira O
##n O
m O
jan O
##kovic O
j O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
clinical O
features O
and O
class O
##i O
##ﬁ O
##cation O
ann O
ne O
##uro O
##l O
1995 O
38 O
57 O
##1 O
57 O
##9 O
b O
##hat O
##ia O
k O
##p O
the O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
j O
ne O
##uro O
##l O
1999 O
246 O
149 O
155 O
lee O
h O
##y O
xu O
y O
huang O
y O
et O
al O
the O
gene O
for O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
en O
##codes O
an O
enzyme O
in O
a O
stress O
response O
pathway O
hum O
mo O
##l O
gene O
##t O
2004 O
13 O
316 O
##1 O
317 O
##0 O
sul O
##s O
a O
de O
##dek O
##en O
p O
go O
##f O
##ﬁ O
##n O
k O
et O
al O
par O
##ox O
##ys O
##mal O
exercise O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ia O
and O
ep O
##ile O
##psy O
is O
due O
to O
mutations O
in O
sl O
##c O
##2 O
##a1 O
encoding O
the O
glucose O
transport O
##er O
g O
##lu O
##t O
##1 O
brain O
2008 O
131 O
1831 O
1844 O

ge O
##sch O
##wind O
dh O
log O
##ino O
##v O
m O
stern O
j O
##m O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
a O
locus O
on O
chromosome O
14 O
##q O
for O
id O
##io O
##pathic O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
fa O
##hr O
disease O
am O
j O
hum O
gene O
##t O
1999 O
65 O
76 O
##4 O
77 O
##7 O
harbor O
##d O
mg O
kobayashi O
j O
##s O
fever O
producing O
ball O
##ism O
##us O
in O
patients O
with O
cho O
##re O
##oat O
##het O
##osis O
j O
child O
ne O
##uro O
##l O
1991 O
6 O
49 O
52 O
stefano O
##va O
e O
dj O
##arm O
##ati O
a O
mom O
##ci O
##lovic O
d O
et O
al O
clinical O
characteristics O
of O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
in O
serbian O
family O
with O
my O
##o O
##ﬁ O
##bri O
##llo O
##genesis O
regulator O
1 O
gene O
mutation O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
2010 O
2015 O

michel O
##i O
f O
fernandez O
par O
##dal O
mm O
casa O
##s O
par O
##era O
i O
gia O
##nna O
##ula O
r O
sporadic O
par O
##ox O
##ys O
##mal O
d O
##yst O
##onic O
cho O
##re O
##oat O
##het O
##osis O
associated O
with O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
##s O
ann O
ne O
##uro O
##l O
1986 O
20 O
750 O
yamamoto O
k O
ka O
##wa O
##zawa O
s O
basal O
gang O
##lion O
cal O
##ci O
##ﬁ O
##cation O
in O
par O
##ox O
##ys O
##mal O
d O
##yst O
##onic O
cho O
##re O
##oat O
##het O
##osis O
ann O
ne O
##uro O
##l O
1987 O
22 O
55 O
##6 O
klein O
c O
vie O
##re O
##gg O
##e O
p O
ko O
##¨ O
##mp O
##f O
d O
par O
##ox O
##ys O
##mal O
cho O
##re O
##oat O
##het O
##osis O
in O
a O
patient O
with O
id O
##io O
##pathic O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
cho O
##rea O
and O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
1997 O
12 O
254 O
255 O

ale O
##md O
##ar O
m O
se O
##le O
##k O
a O
p O
e O
##fen O
##di O
h O
ko O
##ms O
##uo O
##gl O
##u O
ss O
fa O
##hr O
s O
disease O
presenting O
with O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
a O
case O
report O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2008 O
14 O
69 O
71 O
baba O
y O
bro O
##der O
##ick O
d O
##f O
ui O
##tti O
r O
##j O
hutton O
ml O
w O
##sz O
##ole O
##k O
z O
##k O
here O
##do O
##fa O
##mi O
##lia O
##l O
brain O
cal O
##cino O
##sis O
syndrome O
mayo O
cl O
##in O
pro O
##c O
2005 O
80 O
64 O
##1 O
65 O
##1 O
space O
##y O
sd O
adams O
p O
##j O
lam O
pc O
mater O
##ek O
la O
st O
##oes O
##sl O
aj O
s O
##nut O
##ch O
t O
##p O
hs O
##iu O
##ng O
g O
##y O
genetic O
het O
##ero O
##gen O
##eit O
##y O
in O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
ne O
##uro O
##logy O
2006 O
66 O
158 O
##8 O
159 O
##0 O

bruno O
mk O
lee O
h O
##y O
au O
##burg O
##er O
g O
##w O
et O
al O
gen O
##otype O
ph O
##eno O
##type O
correlation O
of O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
ne O
##uro O
##logy O
2007 O
68 O
1782 O
1789 O
dramatic O
response O
of O
facial O
stereo O
##type O
ti O
##c O
to O
te O
##tra O
##ben O
##azi O
##ne O
in O
the O
first O
reported O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
the O
united O
states O
video O

ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
is O
a O
rare O
ne O
##uro O
##de O
##gen O
##erative O
disease O
associated O
with O
brain O
iron O
deposition O
caused O
by O
mutations O
in O
gene O
encoding O
the O
fe O
##rri O
##tin O
light O
poly O
##pe O
##pt O
##ide O
ft O
##l O
a O
460 O
##du O
##pa O
ft O
##l O
was O
ﬁ O
##rst O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
patients O
in O
northern O
england O
1 O
since O
then O
several O
different O
mutations O
of O
fl O
##t O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
japanese O
and O
french O
and O
french O
canadian O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
3 O
september O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##9 O
##9 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##1 O
fig O
1 O
top O
row O
of O
mri O
##s O
various O
sequences O
of O
the O
father O
age O
74 O
and O
bottom O
role O
shows O
mri O
##s O
of O
son O
age O
49 O

dutch O
2 O
6 O
but O
the O
original O
mutation O
which O
accounts O
for O
the O
majority O
of O
documented O
cases O
has O
not O
been O
reported O
outside O
the O
united O
kingdom O
we O
report O
the O
ﬁ O
##rst O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
north O
america O
and O
the O
ﬁ O
##rst O
cases O
showing O
the O
460 O
##du O
##pa O
ft O
##l O
mutation O
originating O
from O
outside O
the O
united O
kingdom O
in O
an O
american O
family O
of O
german O
ancestry O
one O
patient O
presented O
with O
oral O
ti O
##cs O
stereo O
##ty O
##pies O
most O
ph O
##eno O
##typical O
##ly O
similar O
to O
those O
seen O
in O
front O
##ote O
##mp O
##ora O
##l O
dementia O
or O
tour O
##ette O
s O
these O
completely O
resolved O
with O
low O
dose O
te O
##tra O
##ben O
##azi O
##ne O
tb O
##z O
his O
father O
who O
demonstrated O
facial O
and O
app O
##end O
##icular O
cho O
##rea O
marked O
bulb O
##ar O
dysfunction O
ata O
##xia O
and O
dementia O
also O
improved O
with O
tb O
##z O

a O
49 O
year O
old O
right O
handed O
man O
presented O
with O
a O
2 O
year O

history O
of O
varied O
involuntary O
facial O
movements O
including O
as O
##ym O
##metric O
facial O
grim O
##acing O
symmetric O
lip O
pu O
##rs O
##ing O
tongue O
biting O
and O
teeth O
clicking O
parana O
##sal O
contraction O
##s O
touching O
his O
mouth O
with O
his O
hand O
and O
vocal O
##izations O
including O
throat O
clearing O
coughing O
and O
a O
t O
##z O
sound O
these O
were O
partially O
suppress O
##ible O
but O
there O
was O
no O
clear O
urge O
to O
move O
these O
movements O
worsened O
while O
on O
es O
##cit O
##alo O
##pr O
##am O
despite O
improvement O
of O
mood O
no O
other O
ex O
##ace O
##rba O
##ting O
or O
all O
##ev O
##iating O
factors O
were O
noted O
his O
other O
subjective O
complaints O
were O
of O
mild O
worse O
##ning O
of O
balance O
mild O
decreased O
dexter O
##ity O
manifest O
only O
while O
typing O
and O
general O
fatigue O
past O
medical O
and O
social O
histories O
were O
un O
##re O
##ve O
##aling O
the O
patient O
s O
father O
is O
affected O
and O
is O
presented O
below O
his O
paternal O
grandfather O
was O
diagnosed O
with O
huntington O
s O
disease O
and O
bulb O
##ar O
pal O
##sy O
and O
had O
cho O
##rea O
two O
of O
the O
grandfather O
s O
brothers O
were O
diagnosed O
with O
parkinson O
s O
disease O
but O
we O
have O
no O
actual O
clinical O
descriptions O

formal O
neurological O
examination O
was O
largely O
normal O
mm O
##se O
was O
29 O
30 O
cr O
##anial O
nerves O
were O
intact O
motor O
testing O
showed O
normal O
strength O
bulk O
and O
tone O
and O
a O
trace O
action O
tremor O
sensory O
ce O
##re O
##bella O
##r O
and O
ga O
##it O
examinations O
were O
normal O
re O
##ﬂ O
##ex O
##es O
were O
modest O
##ly O
depressed O
throughout O
the O
patient O
had O
frequent O
mouth O
touching O
right O
facial O
grim O
##acing O
and O
ﬁ O
##nger O
rubbing O
which O
was O
partially O
suppress O
##ible O
supporting O
information O
video O
segment O
1 O
patients O
provided O
informed O
consent O
for O
the O
videos O

fe O
##rri O
##tin O
was O
22 O
l O
##g O
ml O
and O
iron O
binding O
percentage O
was O
28 O
a O
lower O
than O
typical O
fe O
##rri O
##tin O
iron O
binding O
ratio O
thyroid O
test O
and O
electro O
##ly O
##tes O
were O
normal O
ac O
##ant O
##ho O
##cy O
##te O
sm O
##ear O
huntington O
s O
testing O
ce O
##ru O
##lo O
##pl O
##as O
##min O
and O
cho O
##re O
##in O
vp O
##s O
##13 O
##a O
testing O
were O
normal O
em O
##g O
nc O
##v O
was O
normal O
brain O
mri O
showed O
t O
##2 O
and O
flair O
lesions O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
and O
to O
a O
lesser O
extent O
in O
the O
ce O
##re O
##bell O
##i O
fig O
1 O

the O
patient O
was O
placed O
on O
tb O
##z O
which O
was O
eventually O
maintained O
on O
37 O
5 O
mg O
day O
25 O
mg O
in O
a O
m O
and O
12 O
5 O
mg O
in O
p O
m O
resulting O
in O
complete O
ce O
##ssa O
##tion O
of O
the O
movements O
after O
6 O
months O
he O
reported O
some O
subjective O
worse O
##ning O
in O
balance O
without O
falls O
tb O
##z O
withdrawal O
did O
not O
alter O
the O
balance O
complaint O
but O
did O
result O
in O
rec O
##rud O
##escence O
of O
the O
same O
movements O
within O
24 O
hours O
the O
tb O
##z O
was O
reins O
##tituted O
at O
the O
same O
dose O
without O
any O
other O
adverse O
events O

the O
father O
of O
case O
1 O
ﬁ O
##rst O
appreciated O
involuntary O
movements O
of O
the O
hand O
around O
age O
50 O
upon O
presentation O
to O
us O
at O
age O
69 O
he O
had O
oral O
and O
app O
##end O
##icular O
movements O
a O
4 O
year O
history O
of O
progressive O
d O
##ys O
##arth O
##ria O
and O
d O
##ys O
##pha O
##gia O
marked O
si O
##alo O
##rr O
##hea O
a O
2 O
year O
history O
of O
ga O
##it O
and O
balance O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
several O
falls O
and O
recent O
mild O
cognitive O
slowing O
examination O
showed O
a O
mm O
##se O
of O
29 O
30 O
cr O
##anial O
nerves O
showed O
gut O
##tura O
##l O
more O
than O
ling O
##ual O
or O
lab O
##ial O
d O
##ys O
##arth O
##ria O
and O
h O
##yp O
##omi O
##mia O
but O
were O
otherwise O
normal O
strength O
was O
normal O
but O
there O
were O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##2 O
letters O
to O
the O
editor O

some O
fa O
##sc O
##ic O
##ulation O
##s O
and O
distal O
at O
##rop O
##hy O
sensory O
examination O
showed O
decreased O
distal O
vibration O
and O
prop O
##rio O
##ception O
ga O
##it O
was O
modest O
##ly O
wide O
based O
and O
un O
##stead O
##y O
but O
not O
parkinson O
##ian O
re O
##ﬂ O
##ex O
##es O
were O
normal O
with O
down O
##going O
toes O
and O
positive O
frontal O
release O
signs O
the O
involuntary O
movements O
were O
complex O
and O
best O
described O
as O
a O
mix O
of O
stereo O
##type O
mouth O
and O
hands O
and O
cho O
##rea O
with O
oral O
movements O
most O
prominent O
supporting O
information O
video O
segment O
2 O
age O
74 O

over O
the O
next O
6 O
years O
the O
d O
##ys O
##pha O
##gia O
d O
##ys O
##arth O
##ria O
ga O
##it O
and O
cognition O
gradually O
progressed O
at O
age O
75 O
he O
was O
ana O
##rth O
##ric O
unable O
to O
vol O
##ition O
##ally O
move O
the O
tongue O
despite O
lack O
of O
peripheral O
involvement O
per O
em O
##g O
and O
wheelchair O
bound O
un O
##re O
##ve O
##aling O
evaluation O
##s O
were O
similar O
to O
case O
1 O
but O
also O
showed O
normal O
cs O
##f O
studies O
including O
a O
normal O
14 O
3 O
3 O
protein O
and O
a O
normal O
ata O
##xia O
panel O
including O
dent O
##ator O
##ub O
##ral O
pal O
##lid O
##ol O
##uy O
##sian O
at O
##rop O
##hy O
mri O
showed O
t O
##2 O
lesions O
throughout O
the O
st O
##ria O
##tum O
and O
g O
##lo O
##bus O
pal O
##lid O
##us O
fig O
1 O
tb O
##z O
did O
help O
the O
cho O
##rea O
and O
stereo O
##type O
but O
was O
poorly O
tolerated O
at O
higher O
doses O
due O
to O
se O
##dation O
and O
parkinson O
##ism O
tb O
##z O
withdrawal O
on O
several O
occasions O
resulted O
in O
increased O
movements O
he O
remains O
on O
25 O
mg O
day O
with O
continued O
ben O
##e O
##ﬁ O
##t O

we O
report O
the O
ﬁ O
##rst O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
the O
united O
states O
the O
mutation O
was O
identical O
to O
the O
original O
one O
which O
until O
now O
was O
isolated O
only O
in O
cases O
originating O
in O
the O
united O
kingdom O
the O
family O
denies O
any O
known O
ancestry O
from O
that O
area O
on O
examination O
the O
father O
appears O
to O
have O
a O
classic O
ph O
##eno O
##type O
of O
cho O
##rea O
prominently O
in O
the O
lower O
face O
with O
later O
onset O
of O
ga O
##it O
disorder O
and O
dementia O
however O
we O
feel O
that O
the O
ph O
##eno O
##men O
##ology O
of O
the O
son O
is O
best O
described O
as O
ti O
##cs O
or O
possibly O
stereo O
##type O
potentially O
expanding O
the O
ph O
##eno O
##type O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
he O
had O
a O
complete O
resolution O
of O
symptoms O
on O
tb O
##z O
whereas O
his O
father O
had O
fair O
control O
of O
the O
cho O
##rea O
movements O
but O
was O
limited O
by O
side O
effects O

legends O
to O
the O
video O
segment O
1 O
patient O
showing O
facial O
stereo O
##type O
ti O
##cs O
segment O
2 O
patient O
showing O
constant O
facial O
stereo O
##type O
diffuse O
slow O
cho O
##rea O
and O
mild O
ata O
##xia O
ac O
##k O
##now O
##led O
##gm O
##ents O
we O
would O
like O
to O
acknowledge O
the O
assistance O
of O
joseph O
m O
ferrara O
md O
for O
assistance O
with O
the O
mri O
ﬁ O
##gur O
##e O

financial O
disclosure O
##s O
dr O
on O
##do O
has O
received O
speaker O
fees O
from O
lund O
##beck O
all O
##er O
##gan O
ip O
##sen O
te O
##va O
and O
gs O
##k O
has O
received O
consulting O
fees O
from O
te O
##va O
mer O
##z O
and O
lund O
##beck O
and O
has O
received O
grant O
support O
from O
te O
##va O
ip O
##sen O
all O
##er O
##gan O
and O
bayer O
dr O
jan O
##kovic O
has O
received O
con O
##su O
##tl O
##ting O
fees O
from O
lund O
##beck O
research O
support O
from O
all O
##er O
##gan O
inc O
bo O
##eh O
##ring O
##er O
ing O
##eh O
##eim O
inc O
ce O
##re O
##gen O
##e O
inc O
chelsea O
therapeutic O
##s O
he O
##lis O
foundation O
huntington O
s O
disease O
society O
of O
america O
huntington O
study O
group O
imp O
##ax O
pharmaceuticals O
ip O
##sen O
ltd O
lund O
##beck O
inc O
med O
##tron O
##ic O
mer O
##z O
ph O
##arm O
##ce O
##uti O
##cal O
##s O
ni O
##h O
national O
parkinson O
foundation O
ne O
##uro O
##gen O
st O
jude O
medical O
te O
##va O
university O
of O
rochester O
and O
the O
parkinson O
study O
group O
has O
been O
consultant O
and O
or O
advisory O
committee O
me O
##me O
##ber O
for O
all O
##er O
##gan O
inc O
bio O
##va O
##il O
the O
michael O
j O
fox O
foundation O
for O
parkinson O
research O
mer O
##z O

william O
g O
on O
##do O
md O
department O
of O
ne O
##uro O
##logy O
baylor O
college O
of O
medicine O
houston O
texas O
usa O
e O
mail O
won O
##do O
bc O
##m O
t O
##mc O
ed O
##u O
oct O
##avian O
r O
adam O
md O
department O
of O
ne O
##uro O
##logy O
university O
of O
texas O
medical O
branch O
galveston O
texas O
usa O
joseph O
jan O
##kovic O
md O
department O
of O
ne O
##uro O
##logy O
baylor O
college O
of O
medicine O
houston O
texas O
usa O
patrick O
f O
chin O
##nery O
mb O
##bs O
phd O
fr O
##cp O
institute O
of O
human O
genetics O
newcastle O
university O
newcastle O
uk O
references O
curtis O
ar O
fey O
c O
morris O
cm O
et O
al O
mutation O
in O
the O
gene O
encoding O
fe O
##rri O
##tin O
light O
poly O
##pe O
##pt O
##ide O
causes O
dominant O
adult O
onset O
basal O
gang O
##lia O
disease O
nat O
gene O
##t O
2001 O
28 O
350 O
354 O

dev O
##os O
d O
tc O
##hof O
##o O
p O
##j O
vu O
##illa O
##ume O
i O
et O
al O
clinical O
features O
and O
natural O
history O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
caused O
by O
the O
45 O
##8 O
##du O
##pa O
ft O
##l O
mutation O
brain O
2009 O
132 O
1 O
3 O
e O
##10 O
##9 O
oh O
##ta O
e O
naga O
##saka O
t O
shin O
##do O
k O
et O
al O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
a O
japanese O
family O
with O
a O
du O
##plication O
in O
the O
fe O
##rri O
##tin O
light O
chain O
gene O
ne O
##uro O
##logy O
2008 O
70 O
part O
2 O
149 O
##3 O
149 O
##4 O
mac O
##iel O
p O
cruz O
vt O
constant O
##e O
m O
et O
al O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
miss O
##ense O
mutation O
in O
ft O
##l O
causing O
early O
onset O
bilateral O
pal O
##lid O
##al O
involvement O
ne O
##uro O
##logy O
2005 O
65 O
60 O
##3 O
60 O
##5 O
levi O
s O
co O
##zzi O
a O
ar O
##osi O
##o O
p O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
a O
ne O
##uro O
##de O
##ge O

ne O
##rative O
disorder O
associated O
with O
l O
fe O
##rri O
##tin O
mutation O
best O
pr O
##act O
res O
cl O
##in O
ha O
##ema O
##to O
##l O
2005 O
18 O
265 O
276 O
man O
##cus O
##o O
m O
david O
##zon O
g O
ku O
##rl O
##an O
rm O
et O
al O
hereditary O
fe O
##rri O
##tino O
##pathy O
a O
novel O
mutation O
its O
cellular O
pathology O
and O
pathogen O
##etic O
insights O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2005 O
64 O
280 O
294 O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
associated O
with O
pol O
##g O
mutations O
video O
patients O
presenting O
with O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
remain O
a O
major O
diagnostic O
challenge O
due O
to O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
clinical O
class O
##i O
##ﬁ O
##cation O
and O
an O
increasing O
number O
of O
associated O
mono O
##gen O
##etic O
diseases O
1 O

mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
pol O
##g O
have O
been O
described O
to O
cause O
a O
broad O
variety O
of O
ph O
##eno O
##type O
##s O
2 O
but O
cho O
##rea O
d O
##yst O
##onia O
and O
my O
##oc O
##lon O
##us O
have O
only O
pharmaceuticals O
lund O
##beck O
inc O
and O
te O
##va O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
author O
roles O
dr O
on O
##do O
inception O
data O
collection O
draft O
ing O
and O
reviewing O
of O
the O
article O
dr O
adam O
critical O
review O
dr O
jan O
##kovic O
critical O
review O
dr O
chin O
##nery O
data O
collection O
analysis O
and O
critical O
review O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O

published O
online O
3 O
september O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
233 O
##0 O
##7 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##3 O

fig O
1 O
pe O
##di O
##gree O
and O
characteristic O
mri O
ﬁ O
##nding O
##s O
in O
two O
patients O
with O
a O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
pol O
##g O
mutation O
two O
affected O
sicilian O
siblings O
of O
con O
##san O
##gui O
##neo O
##us O
parents O
a O
were O
investigated O
by O
magnetic O
resonance O
imaging O
mr O
t O
##2 O
weighted O
images O
in O
patient O
1 O
b O
e O
reveal O
an O
enlarged O
ce O
##re O
##bella O
##r O
primary O
ﬁ O
##ss O
##ure O
b O
beginning O
bilateral O
hyper O
##int O
##ense O
lesions O
in O
the O
ce O
##re O
##bella O
##r O
white O
matter O
c O
and O
the O
tha O
##lam O
##us O
e O
the O
brain O
stem O
and O
po O
##ns O
appeared O
normal O
in O
patient O
1 O
d O
t O
##2 O
weighted O
images O
in O
patient O
2 O
f O
i O
show O
ce O
##re O
##bella O
##r O
and O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
at O
##rop O
##hy O
f O
and O
like O
in O
patient O
1 O
and O
similar O
to O
other O
pol O
##g O
patients O
5 O
symmetric O
hyper O
##int O
##ense O
lesions O
in O
the O
ce O
##re O
##bella O
##r O
white O
matter O
g O
and O
the O
tha O
##lam O
##us O
i O
and O
additionally O
in O
the O
po O
##ns O
h O
magnetic O
resonance O
spectroscopy O
of O
the O
ce O
##re O
##bella O
##r O
white O
matter O
lesions O
revealed O
normal O
levels O
of O
cho O
##line O
and O
cr O
##ea O
##tine O
but O
reduced O
levels O
of O
n O
ace O
##ty O
##l O
as O
##par O
##tate O
indicating O
chronic O
ne O
##uron O
##al O
loss O
not O
shown O

been O
mentioned O
as O
parts O
of O
a O
pl O
##eth O
##ora O
of O
pol O
##g O
associated O
symptoms O
2 O
3 O
not O
as O
the O
only O
presenting O
sy O
##mpt O
##om O
here O
we O
report O
on O
two O
siblings O
from O
a O
con O
##san O
##gui O
##neo O
##us O
sicilian O
family O
with O
a O
homo O
##zy O
##go O
##us O
pol O
##g O
mutation O
the O
index B-PATIENT
patient I-PATIENT
presented O
with O
a O
complex O
hyper B-HPO_TERM
##kin I-HPO_TERM
##etic I-HPO_TERM
movement I-HPO_TERM
disorder I-HPO_TERM
as O
initial O
sy O
##mpt O
##om O
whereas O
other O
common O
pol O
##g O
associated O
symptoms O
did O
not O
evolve O
until O
three O
years O
later O

the O
index O
patient O
patient B-PATIENT
1 I-PATIENT
underwent O
un O
##com O
##pl O
##icated O
surgery O
of O
a O
right O
sided O
carp B-HPO_TERM
##al I-HPO_TERM
tunnel I-HPO_TERM
syndrome I-HPO_TERM
at O
32 B-AGE_ONSET
years O
of O
age O
two O
weeks O
later O
she O
developed O
complex B-HPO_TERM
regional I-HPO_TERM
pain I-HPO_TERM
syndrome I-HPO_TERM
of O
the O
operated O
limb O
with O
severe B-HPO_TERM
pain I-HPO_TERM
and O
all B-HPO_TERM
##od I-HPO_TERM
##yn I-HPO_TERM
##ia I-HPO_TERM
another O
two O
weeks O
later O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
post I-HPO_TERM
##uring I-HPO_TERM
of O
the O
right O
hand O
with O
rapid O
jerk O
##y O
wrist O
and O
ﬁ O
##nger O
movements O
manifested O
these O
jerk O
##s O
consisted O
of O
a O
complex O
mixture O
of O
ph O
##asi O
##c O
d O
##yst O
##onic O
wrist O
ﬂ O
##ex O
##ions O
and O
small O
amplitude O
ﬁ O
##nger O
movements O
poly B-HPO_TERM
##mini I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
in O
addition O
continuous O
jerk O
##y O
movements O
of O
her O
feet O
at O
rest O
were O
observed O
supporting O
information O
video O
segment O
1 O
which O
were O
presumably O
pre O
##ex O
##ist O
##ing O
but O
un O
##re O
##co O
##gni O
##zed O
by O
the O
patient O
herself O
these O
movements O
were O
un O
##pa O
##tter O
##ned O
and O
similar O
to O
limb O
movements O
seen O
in O
patients O
with O
benign O
hereditary O
cho O
##rea O
1 O
4 O
ee O
##g O
and O
sep O
recordings O
showed O
no O
co O
##rti O
##cal O
co O
##rre O
##lates O
of O
the O
limb O
jerk O
##s O
but O
tempo O
##ro O
par O
##ie O
##tal O
focal O
slowing O
and O
intermittent O
temporal O
sharp O
slow O
waves O
as O
the O
forceful O
wrist O
and O
ﬁ O
##nger O
movements O
triggered O
pain O
attacks O
injection O
##s O
to O
wrist O
and O
ﬁ O
##nger O
ex O
##tens O
##ors O
and O
ﬂ O
##ex O
##ors O
were O
given O
with O
a O
total O
dose O
of O
800 O
u O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
a O
bon O
##ta O
d O
##ys O
##port O
ip O
##sen O
ph O
##arm O
##a O

injection O
##s O
dramatically O
reduced O
movement B-HPO_TERM
induced I-HPO_TERM
pain I-HPO_TERM
attacks O
and O
were O
repeated O
every O
3 O
month O
since O
then O
supporting O
information O
video O
segment O
2 O
severe B-HPO_TERM
depression I-HPO_TERM
with O
rec B-HPO_TERM
##urrent I-HPO_TERM
anxiety I-HPO_TERM
attacks I-HPO_TERM
necessitated O
admission O
to O
the O
local O
psychiatric O
hospital O
secondary B-HPO_TERM
generalized I-HPO_TERM
seizures I-HPO_TERM
and O
premature B-HPO_TERM
am I-HPO_TERM
##eno I-HPO_TERM
##rr I-HPO_TERM
##hoe I-HPO_TERM
##a I-HPO_TERM
started O
at O
the O
age O
of O
33 O
years O
comprehensive O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
revealed O
below B-HPO_TERM
average I-HPO_TERM
cognitive I-HPO_TERM
capacities O
at O
the O
age O
of O
35 O
years O
she O
started O
to O
develop O
sensory B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
mild O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
subtle O
ga B-HPO_TERM
##it I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
yet O
without O
leading O
to O
inca O
##pac O
##itation O
##s O
in O
daily O
life O
supporting O
information O
video O
segment O
3 O
for O
mri O
images O
see O
fig O
1 O

patient B-PATIENT
2 I-PATIENT
the O
index O
patient O
s O
sister O
manifested O
with O
slowly O
progressive B-HPO_TERM
cognitive I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
##s I-HPO_TERM
during O
primary B-AGE_ONSET
school I-AGE_ONSET
leading O
to O
severe B-HPO_TERM
cognitive I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
##s I-HPO_TERM
at O
the O
age O
of O
40 O
at O
age O
13 O
years O
ep B-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
seizures I-HPO_TERM
rec B-HPO_TERM
##urrent I-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
and O
mild O
personality B-HPO_TERM
changes I-HPO_TERM
started O
the O
movement B-HPO_TERM
disorder I-HPO_TERM
was O
similar O
to O
her O
sister O
s O
action B-HPO_TERM
triggered I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
started O
at O
the O
left O
arm O
at O
age O
14 O
years O
and O
generalized O
afterwards O
whereas O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
hand O
with O
ﬂ O
##ex O
##ion O
of O
the O
ﬁ O
##nger O
##s O
iii O
v O
was O
ﬁ O
##rst O
noticed O
at O
age O
20 O
years O
since O
then O
she O
also O
developed O
progressive B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
became O
wheel B-HPO_TERM
chair I-HPO_TERM
bound I-HPO_TERM
at O
the O
age O
of O
31 O
at O
the O
last O
examination O
age O
40 O
years O
incomplete O
chronic B-HPO_TERM
progressive I-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
pe O
##o O
supporting O
information O
video O
segment O
5 O
and O
severe B-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
sensor I-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
were O
detected O
as O
her O
ph O
##eno O
##type O
suggested O
mitochondrial B-HPO_TERM
recess I-HPO_TERM
##ive I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
syndrome I-HPO_TERM
mira O
##s O
6 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##4 O
letters O
to O
the O
editor O
genetic O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
was O
initiated O
revealing O
a O
homo O
##zy O
##go O
##us O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
in O
both O
patients O
gen O
##ot O
##yp O
##ing O
of O
intra O
##genic O
single O
nu O
##cle O
##otide O
poly O
##morphism O
s O
##np O
##s O
rs O
##20 O
##7 O
##22 O
##6 O
##7 O
rs O
##23 O
##0 O
##7 O
##43 O
##3 O
rs O
##22 O
##46 O
##90 O
##0 O
rs O
##23 O
##0 O
##20 O
##8 O
##4 O
and O
rs O
##23 O
##0 O
##7 O
##43 O
##8 O
showed O
a O
homo O
##zy O
##go O
##us O
c O
insertion O
g O
c O
g O
ha O
##pl O
##otype O
which O
is O
identical O
to O
the O
ha O
##pl O
##otype O
common O
in O
north O
european O
w O
##7 O
##48 O
##s O
mutation O
carriers O
##6 O
and O
thus O
suggests O
a O
relation O
between O
an O
ancient O
founder O
from O
north O
europe O
and O
these O
sicilian O
patients O

our O
ﬁ O
##nding O
##s O
demonstrate O
that O
pol O
##g O
mutations O
should O
be O
considered O
in O
the O
work O
##up O
of O
progressive O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
as O
of O
yet O
hyper O
##kin O
##etic O
movements O
like O
my O
##oc O
##lon O
##us O
and O
cho O
##rea O
have O
been O
mentioned O
in O
pol O
##g O
patients O
mainly O
as O
part O
of O
a O
pl O
##eth O
##ora O
of O
pol O
##g O
associated O
symptoms O
2 O
3 O
as O
shown O
in O
patient B-PATIENT
1 I-PATIENT
complex O
hyper B-HPO_TERM
##kin I-HPO_TERM
##etic I-HPO_TERM
movements I-HPO_TERM
presenting O
with O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
d B-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
and O
possibly O
also O
cho B-HPO_TERM
##re I-HPO_TERM
##ic I-HPO_TERM
elements O
may O
be O
the O
only O
feature O
seen O
for O
several O
years O
this O
ﬁ O
##nding O
moreover O
demonstrates O
that O
not O
only O
apr O
##ax O
##ia O
of O
eye O
lid O
opening O
##7 O
and O
d O
##yst O
##onic O
toe O
curling O
8 O
but O
also O
upper O
limb O
d O
##yst O
##onia O
is O
part O
of O
the O
spectrum O
of O
pol O
##g O
associated O
d O
##yst O
##onia O

interesting O
##ly O
the O
disease O
course O
in O
patient O
1 O
shows O
that O
ce O
##re O
##bella O
##r O
ata O
##xia O
sensory O
ne O
##uro O
##pathy O
and O
or O
pe O
##o O
are O
not O
necessarily O
presenting O
or O
early O
features O
of O
auto O
##som O
##al O
recess O
##ive O
pol O
##g O
ar O
pol O
##g O
mutations O
a O
family O
history O
with O
con O
##san O
##gui O
##neo O
##us O
marriage O
and O
or O
recess O
##ive O
inheritance O
like O
in O
our O
pe O
##di O
##gree O
or O
pol O
##g O
characteristic O
features O
in O
the O
disease O
course O
like O
in O
patient O
1 O
may O
support O
the O
decision O
for O
pol O
##g O
sequencing O
in O
und O
##ia O
##gno O
##sed O
patients O
with O
hyper O
##kin O
##etic O
movement O
disorders O
legends O
to O
the O
video O
patient O
1 O

segment O
1 O
at O
the O
age O
of O
33 O
years O
patient B-PATIENT
1 I-PATIENT
showed O
d B-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
of O
both O
arms O
with O
predominant O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
upper O
limb O
with O
jerk B-HPO_TERM
##y I-HPO_TERM
wrist I-HPO_TERM
and I-HPO_TERM
ﬁ I-HPO_TERM
##nger I-HPO_TERM
movements O
which O
had O
started O
four O
weeks O
after O
carp O
##al O
tunnel O
surgery O
induced O
cr O
##ps O
distal O
ﬁ O
##nger O
movements O
have O
smaller O
amplitude O
##s O
characteristic O
of O
poly B-HPO_TERM
##mini I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
also O
her O
feet O
show O
un O
##pa O
##tter O
##end O
jerk O
##y O
movements O
which O
may O
be O
class O
##i O
##ﬁ O
##ed O
as O
my O
##oc O
##lon O
##us O
but O
are O
also O
similar O
to O
limb O
movements O
in O
benign O
hereditary O
cho O
##rea O
1 O
4 O

segment O
2 O
bot O
##ulin O
##um O
toxin O
treatment O
of O
ex O
##tens O
##or O
and O
ﬂ O
##ex O
##or O
muscles O
of O
the O
right O
forearm O
markedly O
reduced O
hyper O
##kin O
##etic O
movements O
the O
main O
therapeutic O
goal O
remained O
pain O
reduction O
apart O
from O
the O
bot O
##ulin O
##um O
toxin O
effect O
also O
intermittent O
mirror O
movements O
can O
be O
observed O
in O
this O
segment O
segment O
3 O
at O
the O
age O
of O
35 O
years O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
slowing O
of O
voluntary O
sac O
##cade O
##s O
and O
ga O
##it O
ata O
##xia O
started O
also O
a O
reduced O
arm O
swing O
on O
the O
right O
side O
was O
ﬁ O
##rst O
noticed O
patient O
2 O

segment O
4 O
at O
the O
age O
of O
40 O
years O
patient B-PATIENT
2 I-PATIENT
displayed O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
left O
upper O
limb O
with O
distal O
pre O
##dom O
##ina O
##nce O
she O
showed O
intermittent B-HPO_TERM
facial I-HPO_TERM
and I-HPO_TERM
jaw I-HPO_TERM
opening I-HPO_TERM
d I-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
at O
rest O
she O
had O
marked O
post B-HPO_TERM
##ural I-HPO_TERM
instability I-HPO_TERM
caused O
by O
trunk B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
which O
is O
aggravated O
by O
motor O
actions O
like O
e O
g O
lifting O
the O
upper O
limbs O
segment O
5 O
in O
patient O
2 O
severe B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
incomplete O
horizontal B-HPO_TERM
and I-HPO_TERM
vertical I-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
ata B-HPO_TERM
##xia I-HPO_TERM
were O
observed O
as O
clinical O
features O
of O
mira O
##s O
patient O
2 O
was O
only O
able O
to O
stand B-HPO_TERM
assisted I-HPO_TERM
for O
a O
few O
seconds O

author O
roles O
syn O
##of O
##zi O
##k O
was O
involved O
in O
the O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
sc O
##hu O
##¨ O
##le O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
sc O
##hul O
##te O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
lin O
##di O
##g O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
k O
##ru O
##¨ O
##ger O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
sc O
##ho O
##¨ O
##ls O
was O
involved O
in O
the O
research O
project O
organization O
manuscript O
review O
and O
critique O
as O
##mus O
was O
involved O
in O
the O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O

financial O
disclosure O
##s O
dr O
syn O
##of O
##zi O
##k O
received O
a O
research O
grant O
by O
the O
volkswagen O
foundation O
european O
platform O
project O
and O
a O
travel O
grant O
by O
act O
##eli O
##on O
pharmaceuticals O
dr O
k O
##ru O
##¨ O
##ger O
received O
research O
grants O
of O
the O
german O
research O
council O
d O
##f O
##g O
k O
##r O
##21 O
##19 O
3 O
1 O
and O
the O
federal O
ministry O
for O
education O
and O
research O
b O
##mb O
##f O
ng O
##f O
##np O
##lus O
01 O
##gs O
##0 O
##8 O
##13 O
##4 O
as O
well O
as O
speakers O
honor O
##aria O
and O
travel O
grants O
from O
uc O
##b O
ph O
##arm O
##a O
sol O
##va O
##y O
ph O
##arm O
##a O
and O
med O
##tron O
##ic O
dr O
lin O
##di O
##g O
has O
received O
travel O
grants O
from O
ip O
##sen O
ph O
##arm O
##a O
all O
##er O
##gan O
and O
mer O
##z O
pharmaceuticals O
dr O
sc O
##ho O
##¨ O
##ls O
served O
as O
an O
editorial O
board O
member O
of O
movement O
disorders O
and O
was O
a O
member O
of O
the O
sci O
##ent O
##i O
##ﬁ O
##c O
advisory O
board O
for O
take O
##da O
ph O
##arm O
##a O
as O
participant O
of O
the O
mic O
##ono O
##s O
trial O
dr O
sc O
##ho O
##¨ O
##ls O
received O
fees O
from O
sant O
##her O
##a O
pharmaceuticals O
dr O
sc O
##ho O
##¨ O
##ls O
received O
research O
grants O
of O
the O
deutsche O
for O
##sch O
##ung O
##sg O
##eme O
##ins O
##chaft O
sc O
##ho O
##75 O
##4 O
3 O
1 O
and O
sc O
##ho O
##75 O
##4 O
4 O
1 O
grants O
of O
the O
german O
research O
council O
b O
##mb O
##f O
to O
le O
##uk O
##one O
##t O
01 O
##gm O
##0 O
##64 O
##4 O
gene O
##mo O
##ve O
01 O
##gm O
##0 O
##60 O
##3 O
and O
mit O
##one O
##t O
01 O
##gm O
##0 O
##86 O
##4 O
funding O
from O
the O
eu O
for O
euros O
##ca O
l O
##sh O
##m O
ct O
2004 O
50 O
##33 O
##0 O
##4 O
and O
e O
rare O
grants O
to O
euros O
##pa O
01 O
##gm O
##0 O
##80 O
##7 O
and O
ri O
##sca O
01 O
##gm O
##0 O
##8 O
##20 O
as O
well O
as O
a O

grant O
of O
the O
volkswagen O
foundation O
i O
80 O
##7 O
##11 O
he O
further O
received O
funding O
from O
the O
hs O
##p O
se O
##lb O
##st O
##hil O
##fe O
##gr O
##uppe O
deutschland O
ev O
dr O
as O
##mus O
has O
received O
speakers O
honor O
##aria O
and O
travel O
grants O
from O
ip O
##sen O
ph O
##arm O
##a O
all O
##er O
##gan O
and O
mer O
##z O
pharmaceuticals O
ac O
##k O
##now O
##led O
##gm O
##ents O
l O
##s O
was O
supported O
by O
a O
grant O
from O
the O
german O
ministry O
for O
education O
and O
research O
b O
##mb O
##f O
to O
mit O
##one O
##t O
01 O
##gm O
##0 O
##86 O
##4 O
fa O
and O
ms O
were O
supported O
by O
grants O
of O
the O
german O
center O
for O
ne O
##uro O
##den O
##erative O
diseases O
d O
##z O
##ne O
matt O
##his O
syn O
##of O
##zi O
##k O
md O
rebecca O
sc O
##hu O
##¨ O
##le O
md O
claudia O
sc O
##hul O
##te O
phd O
re O
##jk O
##o O
k O
##ru O
##¨ O
##ger O
md O
tobias O
lin O
##di O
##g O
md O
lu O
##dge O
##r O
sc O
##ho O
##¨ O
##ls O
md O

department O
of O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
her O
##tie O
institute O
for O
clinical O
brain O
research O
german O
research O
center O
for O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
friedrich O
as O
##mus O
md O
department O
of O
general O
ne O
##uro O
##logy O
her O
##tie O
institute O
for O
clinical O
brain O
research O
german O
research O
center O
for O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
e O
mail O
friedrich O
as O
##mus O
d O
##yst O
##onia O
genetics O
com O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##5 O
references O

as O
##mus O
f O
lang O
##set O
##h O
a O
doherty O
e O
et O
al O
jerk O
##y O
d O
##yst O
##onia O
in O
children O
spectrum O
of O
ph O
##eno O
##type O
##s O
and O
genetic O
testing O
mo O
##v O
di O
##sor O
##d O
2009 O
24 O
70 O
##2 O
70 O
##9 O
b O
##lok O
m O
##j O
van O
den O
bosch O
b O
##j O
jong O
##en O
e O
et O
al O
the O
un O
##folding O
clinical O
spectrum O
of O
pol O
##g O
mutations O
j O
med O
gene O
##t O
2009 O
46 O
77 O
##6 O
78 O
##5 O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
part O
7 O
1685 O
1692 O
sc O
##hra O
##g O
a O
quinn O
np O
b O
##hat O
##ia O
k O
##p O
marsden O
cd O
benign O
hereditary O
cho O
##rea O
entity O
or O
syndrome O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
280 O
288 O

eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
et O
al O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
2008 O
131 O
part O
3 O
81 O
##8 O
82 O
##8 O
ha O
##kon O
##en O
ah O
david O
##zon O
g O
salem O
##i O
r O
et O
al O
abundance O
of O
the O
pol O
##g O
disease O
mutations O
in O
europe O
australia O
new O
zealand O
and O
the O
united O
states O
explained O
by O
single O
ancient O
european O
founders O
eu O
##r O
j O
hum O
gene O
##t O
2007 O
15 O
77 O
##9 O
78 O
##3 O
pau O
##s O
s O
z O
##sur O
##ka O
g O
baron O
m O
et O
al O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
mo O
##v O
di O
##sor O
##d O
2008 O
23 O
128 O
##6 O
128 O
##8 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
with O
ari O
##pi O
##pr O
##az O
##ole O
in O
huntington O
s O
disease O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
pp O
246 O
##1 O
247 O
##7 O
2010 O
movement O
disorder O
society O
letters O
to O
the O
editor O
related O
to O
new O
topics O
re O
##tina O
thickness O
in O
parkinson O
s O
disease O
and O
essential O
tremor O
visual O
symptoms O
particularly O
impaired O
f O
##ove O
##al O
vision O
are O
common O
among O
the O
non O
##moto O
##r O
phenomena O
in O
parkinson O
s O
disease O
pd O
experimental O
evidence O
from O
humans O
and O
monkeys O
shows O
that O
there O
are O
do O
##pa O
##mine O
##rg O
##ic O
cells O
in O
the O
re O
##tina O
including O
the O
ama O
##cr O
##ine O
sub O
##type O
a1 O
##8 O
with O
d O
##1 O
and O
d O
##2 O
receptors O
and O
inter O
##plex O
##iform O
cells O

post O
##mo O
##rte O
##m O
studies O
have O
shown O
that O
pd O
eyes O
have O
lower O
do O
##pa O
##mine O
content O
1 O
compared O
with O
healthy O
controls O
likewise O
a O
loss O
in O
the O
sensitivity O
to O
contrast O
and O
color O
vision O
altered O
visual O
ev O
##oked O
potential O
and O
electro O
##ret O
##ino O
##graphic O
measurements O
have O
been O
observed O
indicating O
f O
##ove O
##al O
re O
##tina O
##l O
gang O
##lion O
cells O
damage O
in O
pd O
2 O

quantitative O
morphology O
of O
gross O
re O
##tina O
##l O
his O
##tology O
in O
humans O
can O
be O
measured O
in O
vivo O
using O
time O
domain O
optical O
co O
##her O
##ence O
tom O
##ography O
oct O
in O
pd O
a O
thin O
##ning O
of O
the O
per O
##ip O
##ap O
##illa O
##ry O
re O
##tina O
##l O
nerve O
ﬁ O
##ber O
layer O
which O
represents O
ax O
##ons O
of O
the O
gang O
##lion O
cells O
and O
mac O
##ula O
have O
been O
shown O
supporting O
the O
hypothesis O
that O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
in O
the O
re O
##tina O
can O
cause O
structural O
changes O
2 O
5 O
however O
the O
useful O
##ness O
of O
measuring O
f O
##ove O
##al O
thickness O
by O
oct O
as O
a O
diagnostic O
tool O
to O
differentiate O
pd O
from O
other O
tremor O
disease O
such O
as O
essential O
tremor O
et O
remains O
unknown O
therefore O
the O
main O
purpose O
of O
this O
pilot O
study O
was O
to O
measure O
f O
##ove O
##al O
thickness O
in O
patients O
with O
pd O
and O
to O
compare O
it O
against O
a O
normal O
population O
and O
patients O
with O
et O

we O
designed O
a O
cross O
sectional O
pilot O
study O
that O
included O
a O
consecutive O
sample O
of O
out O
##patient O
##s O
diagnosed O
with O
id O
##io O
##pathic O
pd O
in O
accordance O
with O
the O
uk O
parkinson O
s O
disease O
society O
brain O
bank O
and O
et O
based O
on O
clinical O
criteria O
patients O
with O
any O
coe O
##xi O
##sti O
##ng O
o O
##cular O
disease O
were O
excluded O
this O
study O
was O
approved O
by O
the O
ethics O
committee O
of O
the O
general O
ya O
##gu O
##¨ O
##e O
hospital O
bu O
##rgos O
spain O
and O
all O
patients O
signed O
the O
informed O
consent O
before O
being O
enrolled O
control O
subjects O
were O
matched O
for O
age O
6 O
5 O
years O
and O
gender O
to O
pd O
patients O
demographic O
and O
pd O
et O
lateral O
##ity O
data O
were O
collected O
oct O
was O
acquired O
through O
a O
dil O
##ated O
pupil O
by O
an O
experienced O
operator O
using O
the O
oct O
##3 O
carl O
ze O
##iss O
med O
##ite O
##c O
dublin O
cal O
##if O
with O
axial O
resolution O
of O
10 O
l O
##m O
the O
mac O
##ular O
thickness O
map O
analysis O
and O
the O
center O
f O
##ove O
##al O
thickness O
was O
automatically O
determined O
by O
the O
oct O
##3 O
software O
6 O
images O
were O
considered O
to O
be O
of O
good O
quality O
if O
the O
signal O
to O
noise O
ratio O
was O
greater O
than O
30 O
##db O
or O
had O
more O
than O
95 O
sweeps O
accepted O

data O
analysis O
was O
performed O
from O
an O
ex O
##pl O
##ora O
##tory O
point O
of O
view O
using O
the O
statistical O
package O
sp O
##ss O
program O
sp O
##ss O
17 O
sp O
##ss O
chicago O
only O
descriptive O
analysis O
was O
used O
owing O
to O
the O
small O
sample O
size O
data O
were O
summarized O
as O
mean O
6 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
28 O
july O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##15 O
standard O
deviation O
and O
median O
range O
to O
maintain O
independence O
of O
all O
observations O
right O
eye O
re O
versus O
left O
eye O
le O
were O
analyzed O
for O
each O
patient O

fifty O
two O
eyes O
from O
9 O
patients O
with O
pd O
5 O
men O
and O
4 O
women O
with O
a O
mean O
age O
of O
64 O
1 O
12 O
years O
and O
disease O
duration O
of O
8 O
4 O
6 O
1 O
9 O
years O
8 O
patients O
with O
et O
4 O
men O
and O
4 O
women O
with O
a O
mean O
age O
of O
67 O
8 O
6 O
4 O
8 O
years O
and O
disease O
duration O
of O
23 O
7 O
6 O
18 O
3 O
years O
and O
9 O
controls O
were O
included O
the O
mean O
f O
##ove O
##al O
thickness O
was O
thinner O
in O
the O
pd O
group O
compared O
with O
the O
et O
group O
and O
controls O
table O
1 O
for O
the O
pd O
and O
et O
groups O
the O
mean O
f O
##ove O
##al O
thickness O
was O
also O
thinner O
in O
the O
contra O
lateral O
eye O
of O
the O
most O
affected O
side O
table O
1 O

in O
this O
pilot O
study O
based O
on O
the O
oct O
imaging O
the O
f O
##ove O
##a O
was O
thinner O
in O
the O
pd O
group O
compared O
with O
the O
et O
group O
and O
controls O
interesting O
##ly O
whereas O
inter O
##oc O
##ular O
mac O
##ular O
symmetry O
has O
been O
found O
in O
the O
normal O
population O
7 O
we O
found O
that O
the O
f O
##ove O
##al O
thickness O
was O
as O
##ym O
##metric O
and O
thinner O
in O
the O
eye O
contra O
##lateral O
to O
the O
side O
more O
affected O
by O
tremor O
and O
parkinson O
##ism O
in O
the O
et O
and O
pd O
groups O
respectively O
ha O
##jee O
et O
al O
also O
found O
the O
correlation O
between O
thin O
##ning O
in O
the O
left O
and O
the O
right O
eye O
of O
the O
same O
was O
not O
perfect O
7 O
hence O
this O
inter O
##oc O
##ular O
f O
##ove O
##al O
as O
##ym O
##metry O
should O
be O
considered O
in O
interpretation O
except O
that O
for O
et O
although O
mild O
tremor O
as O
##ym O
##metry O
has O
been O
documented O
as O
a O
fundamental O
characteristic O
of O
et O
there O
is O
no O
published O
information O
regarding O
f O
##ove O
##al O
thickness O
in O
patients O
with O
et O
the O
similar O
as O
##ym O
##metry O
ﬁ O
##nding O
in O
et O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
understand O
and O
we O
cannot O
obviously O
explain O
it O
based O
on O
our O
preliminary O
data O
however O
abnormal O
oct O
measures O
have O
also O
been O
found O
in O
other O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
such O
as O
alzheimer O
s O
disease O
multiple O
sc O
##ler O
##osis O
and O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
##s O
most O
likely O
related O
to O
the O
loss O
of O
re O
##tina O
##l O
gang O
##lion O
cells O
and O
ax O
##ons O
8 O
therefore O
further O
studies O
are O
required O
to O
establish O
whether O
oct O
measures O
contribute O
for O
a O
sensitive O
and O
spec O
##i O
##ﬁ O
##c O
diagnosis O
of O
pd O
and O
to O
differentiate O
it O
from O
other O
conditions O
we O
recognize O
our O
results O
cannot O
be O
compared O
with O
prior O
oct O
reports O
in O
pd O
because O
of O
the O
different O
imaging O
map O
protocol O
and O
equipment O
we O
are O
also O
aware O
that O
because O
of O
the O
small O
sample O
size O
used O
these O
results O
need O
to O
be O
repeated O
in O
larger O
co O
##hort O
##s O
to O
ensure O
rep O
##rod O
##uc O
##ibility O

with O
regards O
to O
technical O
feasibility O
the O
oct O
compared O
with O
other O
expensive O
ones O
such O
as O
the O
single O
photon O
emission O
computed O
tom O
##ography O
spec O
##t O
studies O
using O
123 O
##i O
f O
##p O
ci O
##t O
dat O
scan O
is O
widely O
available O
fast O
as O
it O
only O
takes O
a O
few O
minutes O
to O
perform O
and O
relatively O
inexpensive O
based O
on O
our O
preliminary O
data O
and O
in O
accordance O
with O
other O
authors O
2 O
5 O
we O
believe O
that O
f O
##ove O
##al O
thickness O
measured O
by O
the O
oct O
could O
be O
a O
promising O
feasible O
bio O
##mark O
##er O
of O
pd O
by O
quan O
##tify O
##ing O
the O
morphological O
changes O
of O
re O
##tina O
##l O
do O
##pa O
##mine O
##rg O
##ic O
neurons O

ac O
##k O
##now O
##led O
##gm O
##ent O
this O
study O
was O
supported O
by O
a O
grant O
from O
ca O
##ja O
bu O
##rgos O
2009 O
financial O
disclosure O
##s O
cub O
##o O
e O
honor O
##aria O
bo O
##eh O
##ring O
##er O
ing O
##el O
##heim O
g O
##la O
##x O
##o O
smith O
k O
##line O
lund O
##beck O
grant O
michael O
j O
246 O
##1 O
fox O
fis O
sac O
##yl O
pri O
##eto O
ted O
##ej O
##o O
r O
none O
rodriguez O
mendez O
v O
none O
lo O
##´ O
##pe O
##z O
pu O
##ey O
##o O
m O
##j O
none O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
j O
##m O
honor O
##aria O
p O
##ﬁ O
##zer O
grants O
ser O
##vier O
san O
##o O
##ﬁ O
este O
##ve O
sac O
##yl O
michael O
j O
fox O

author O
roles O
cub O
##o O
e O
research O
project O
conception O
and O
organization O
statistical O
analysis O
design O
and O
execution O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
the O
manuscript O
pri O
##eto O
ted O
##ej O
##o O
r O
research O
project O
organization O
and O
execution O
rodriguez O
mendez O
v O
research O
project O
organization O
lo O
##´ O
##pe O
##z O
pu O
##ey O
##o O
m O
##j O
review O
and O
critique O
of O
statistical O
analysis O
and O
manuscript O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
j O
##m O
review O
and O
critique O
of O
statistical O
analysis O
and O
manuscript O
esther O
cub O
##o O
md O
phd O
rosa O
pri O
##eto O
ted O
##ej O
##o O
ne O
##uro O
##logy O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
e O
mail O
esther O
##cu O
##bo O
gma O
##il O
com O

ve O
##ro O
##´ O
##nica O
rodriguez O
mendez O
md O
mar O
##´ O
##ı O
##a O
je O
##su O
##´s O
lo O
##´ O
##pe O
##z O
md O
phd O
op O
##ht O
##hal O
##mology O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
jose O
##´ O
mar O
##´ O
##ı O
##a O
tre O
##jo O
gabriel O
y O
gala O
##´ O
##n O
md O
phd O
ne O
##uro O
##logy O
department O
hospital O
general O
ya O
##gu O
##¨ O
##e O
bu O
##rgos O
spain O
references O
ha O
##rno O
##is O
c O
dip O
##ao O
##lo O
t O
decreased O
do O
##pa O
##mine O
in O
the O
re O
##tina O
of O
patients O
with O
parkinson O
s O
disease O
invest O
op O
##ht O
##hal O
##mo O
##l O
1990 O
31 O
247 O
##3 O
247 O
##5 O
bo O
##dis O
wo O
##ll O
##ner O
i O
re O
##tino O
##pathy O
in O
parkinson O
s O
disease O
j O
neural O
trans O
##m O
2009 O
116 O
149 O
##3 O
150 O
##1 O

ha O
##jee O
me O
march O
w O
##f O
la O
##zza O
##ro O
dr O
wo O
##lin O
##tz O
ah O
shri O
##er O
em O
g O
##la O
##zman O
s O
bo O
##dis O
wo O
##ll O
##ner O
i O
##g O
inner O
re O
##tina O
##l O
layer O
thin O
##ning O
in O
parkinson O
disease O
arch O
op O
##ht O
##hal O
##mo O
##l O
2009 O
127 O
737 O
74 O
##1 O
o O
p O
oz O
##kan O
b O
y O
correlation O
between O
re O
##tina O
##l O
morphological O
and O
functional O
ﬁ O
##nding O
##s O
and O
clinical O
severity O
in O
parkinson O
s O
disease O
doc O
op O
##ht O
##hal O
##mo O
##l O
2008 O
116 O
137 O
146 O
in O
##zel O
##berg O
r O
ramirez O
ja O
ni O
##si O
##pe O
##anu O
p O
op O
##hir O
a O
re O
##tina O
##l O
nerve O
ﬁ O
##ber O
be O
##rish O
##a O
f O
fe O
##ke O
gt O
tre O
##mp O
##e O
cl O
mc O
##me O
##el O
j O
##w O
sc O
##he O
##pen O
##s O
cl O
re O
##tina O
##l O
abnormalities O
in O
early O
alzheimer O
s O
disease O
invest O
op O
##ht O
##hal O
##mo O
##l O
vis O
sci O
2007 O
48 O
228 O
##5 O
228 O
##9 O

lam O
##ire O
##l O
c O
newman O
n O
bio O
##uss O
##e O
v O
the O
use O
of O
optical O
co O
##her O
##ence O
tom O
##ography O
in O
ne O
##uro O
##logy O
rev O
ne O
##uro O
##l O
di O
##s O
2009 O
6 O
105 O
120 O
acute O
renal O
failure O
in O
patients O
with O
bilateral O
deep O
brain O
stimulation O
the O
management O
of O
parkinson O
s O
disease O
is O
mainly O
ph O
##arm O
##aco O
##logical O
with O
lev O
##od O
##opa O
but O
in O
recent O
years O
surgery O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
has O
been O
rev O
##ital O
##ized O
for O
the O
treatment O
of O
patients O
with O
un O
##con O
##tro O
##lla O
##ble O
motor O
complications O
1 O

a O
large O
proportion O
of O
patients O
suffering O
from O
parkinson O
s O
disease O
presents O
with O
ur O
##ina O
##ry O
dysfunction O
described O
as O
urgency O
increased O
frequency O
or O
inc O
##ont O
##inen O
##ce O
as O
predominant O
symptoms O
##2 O
3 O
and O
also O
st O
##n O
db O
##s O
has O
proven O
to O
improve O
ur O
##ina O
##ry O
function O
4 O
data O
from O
experimental O
ur O
##od O
##yna O
##mic O
measures O
in O
men O
and O
animal O
models O
have O
demonstrated O
a O
sign O
##i O
##ﬁ O
##can O
##t O
in O
##ﬂ O
##uen O
##ce O
of O
st O
##n O
db O
##s O
on O
ur O
##ina O
##ry O
bladder O
function O
5 O
6 O
in O
these O
studies O
the O
main O
effect O
of O
st O
##n O
db O
##s O
appeared O
to O
be O
a O
normal O
##ization O
of O
ur O
##od O
##yna O
##mic O
parameters O
but O
there O
is O
no O
data O
reported O
about O
kidney O
function O
in O
these O
patients O
7 O
despite O
its O
clinical O
e O
##f O
##ﬁ O
##ca O
##cy O
the O
manifold O
physiological O
consequences O
of O
st O
##n O
db O
##s O
are O
to O
date O
poorly O
understood O

acute O
renal O
failure O
ar O
##f O
de O
##ﬁ O
##ned O
as O
an O
abrupt O
or O
rapid O
decline O
in O
renal O
ﬁ O
##lt O
##ration O
function O
and O
cr O
##ea O
##tin O
##ine O
clearance O
cc O
is O
used O
to O
estimate O
the O
g O
##lom O
##er O
##ular O
ﬁ O
##lt O
##ration O
rate O
g O
##fr O
the O
cc O
test O
compares O
the O
level O
of O
cr O
##ea O
##tin O
##ine O
in O
urine O
with O
the O
cr O
##ea O
##tin O
##ine O
level O
in O
the O
blood O
usually O
based O
on O
measurements O
of O
a O
24 O
hour O
urine O
sample O
g O
##fr O
has O
never O
been O
studied O
in O
parkinson O
patients O
with O
normal O
pre O
##oper O
##ative O
renal O
function O
immediately O
after O
st O
##n O
db O
##s O
here O
we O
report O
a O
decline O
in O
renal O
ﬁ O
##lt O
##ration O
function O
after O
st O
##n O
db O
##s O

nineteen O
patients O
15 O
men O
and O
four O
women O
with O
a O
mean O
6 O
##sd O
age O
of O
63 O
6 O
7 O
years O
at O
the O
time O
of O
surgery O
and O
a O
mean O
duration O
of O
disease O
of O
16 O
6 O
9 O
years O
were O
selected O
for O
implant O
##ation O
of O
electrode O
##s O
in O
the O
st O
##n O
the O
selection O
criteria O
were O
clinical O
##ly O
diagnosed O
parkinson O
s O
disease O
severe O
lev O
##od O
##opa O
related O
motor O
complications O
despite O
optimal O
adjustment O
of O
anti O
##park O
##ins O
##onia O
##n O
medication O
an O
age O
under O
70 O
years O
no O
layer O
thin O
##ning O
in O
parkinson O
disease O
vision O
res O
2004 O
44 O
279 O
##3 O
279 O
##7 O

el O
ash O
##ry O
m O
he O
##g O
##de O
v O
james O
p O
pa O
##glia O
##rini O
s O
analysis O
of O
mac O
##ular O
thickness O
in O
british O
population O
using O
optical O
co O
##her O
##ence O
tom O
##ography O
oct O
an O
emphasis O
on O
inter O
##oc O
##ular O
symmetry O
cu O
##rr O
eye O
res O
2008 O
33 O
69 O
##3 O
69 O
##9 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
there O
is O
no O
potential O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
from O
each O
author O
that O
relate O
to O
the O
research O
covered O
in O
the O
article O
submitted O
published O
online O
28 O
july O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##28 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##3 O
fig O
1 O
cr O
##ea O
##tin O
##ine O
clearance O
before O
and O
after O
st O
##n O
db O
##s O

surgical O
contra O
##ind O
##ication O
##s O
and O
no O
dementia O
or O
major O
ongoing O
psychiatric O
illness O
electrode O
##s O
were O
implant O
##ed O
bilateral O
##ly O
under O
local O
an O
##esthesia O
as O
described O
previously O
8 O
patients O
were O
evaluated O
pre O
##oper O
##ative O
##ly O
1 O
week O
after O
surgery O
and O
post O
##oper O
##ative O
##ly O
1 O
week O
after O
surgery O
evaluation O
##s O
included O
1 O
the O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
parts O
iii O
motor O
2 O
mean O
dose O
of O
lev O
##od O
##opa O
3 O
all O
medical O
manifestation O
##s O
4 O
24 O
hours O
urine O
5 O
urine O
ion O
##og O
##ram O
and O
biochemistry O
6 O
blood O
ion O
##og O
##ram O
and O
7 O
cc O

cc O
and O
fraction O
##al O
ex O
##cre O
##tion O
of O
sodium O
potassium O
and O
phosphate O
were O
calculated O
as O
previously O
reported O
5 O
ur O
##ea O
was O
measured O
by O
an O
en O
##zy O
##matic O
test O
and O
cr O
##ea O
##tin O
##ine O
by O
the O
ja O
##ffe O
##´ O
method O
ion O
selective O
electrode O
##s O
performed O
the O
quan O
##ti O
##ﬁ O
##cation O
##s O
of O
sodium O
and O
potassium O
in O
urine O
samples O
phosphate O
was O
determined O
by O
a O
direct O
photo O
##metric O
method O
all O
ass O
##ays O
were O
performed O
by O
co O
##bas O
mira O
plus O
anal O
##yse O
##r O
ab O
##x O
diagnostic O
##s O
geneva O
switzerland O
urine O
and O
plasma O
os O
##mo O
##lal O
##ity O
were O
determined O
by O
means O
of O
an O
os O
changes O
were O
observed O
in O
urine O
and O
blood O
ion O
##og O
##ram O
before O
and O
after O
surgery O
table O
1 O

st O
##n O
db O
##s O
has O
been O
shown O
to O
am O
##eli O
##ora O
##te O
bladder O
dysfunction O
increases O
bladder O
capacity O
in O
patients O
with O
parkinson O
s O
disease O
by O
modulation O
of O
sensory O
processing O
9 O
it O
appears O
to O
be O
a O
normal O
##ization O
of O
ur O
##od O
##yna O
##mic O
parameters O
but O
there O
is O
no O
data O
reported O
about O
kidney O
function O
in O
these O
patients O

in O
our O
patients O
kidney O
function O
was O
altered O
immediately O
after O
surgery O
a O
decline O
in O
ﬁ O
##lt O
##ration O
function O
developed O
after O
st O
##n O
db O
##s O
and O
some O
patients O
without O
pre O
##oper O
##ative O
ri O
developed O
acute O
ri O
post O
##oper O
##ative O
##ly O
in O
these O
patients O
no O
ur O
##ina O
##ry O
retention O
occurred O
ur O
##ina O
##ry O
volume O
was O
similar O
before O
and O
after O
surgery O
no O
pre O
##oper O
##ative O
hem O
##od O
##yna O
##mic O
complications O
as O
de O
##hy O
##dra O
##tion O
occurred O
like O
other O
series O
ne O
##uro O
##sti O
##mu O
##lat O
##or O
implant O
##ation O
an O
##est O
##hetic O
technique O
is O
not O
associated O
with O
major O
hem O
##od O
##yna O
##mic O
adverse O
effects O
10 O

a O
recent O
study O
of O
experimental O
##ly O
induced O
ar O
##f O
showed O
that O
there O
is O
a O
close O
interaction O
between O
the O
kidney O
and O
the O
central O
nervous O
system O
11 O
sympathetic O
in O
##ﬂ O
##uen O
##ce O
in O
kidney O
functions O
is O
under O
control O
of O
brains O
##tem O
bio O
##genic O
amin O
##e O
cell O
groups O
and O
h O
##yp O
##oth O
##ala O
##mic O
nuclei O
12 O
13 O
it O
cannot O
be O
excluded O
that O
there O
may O
be O
regional O
effects O
of O
db O
##s O
st O
##n O
on O
h O
##yp O
##oth O
##ala O
##mic O
centers O
depending O
on O
the O
exact O
location O
of O
the O
contacts O
in O
the O
st O
##n O
area O

effect O
of O
db O
##s O
st O
##n O
in O
h O
##yp O
##oth O
##ala O
##mic O
centers O
remains O
a O
valid O
hypothesis O
which O
could O
explain O
an O
altered O
kidney O
function O
immediately O
after O
surgery O
but O
further O
investigations O
are O
required O
to O
explore O
this O
possible O
mechanism O
with O
these O
preliminary O
results O
the O
authors O
suggest O
that O
it O
is O
necessary O
to O
evaluate O
cc O
before O
and O
after O
surgery O
for O
early O
orientation O
of O
patients O
with O
ri O
ac O
##k O
##now O
##led O
##gm O
##ents O
we O
thank O
the O
clinical O
investigation O
center O
of O
hospital O
de O

financial O
disclosure O
##s O
the O
authors O
have O
no O
ﬁ O
##nan O
##cial O
disclosure O
##s O
or O
nothing O
to O
disclose O
financial O
disclosure O
##s O
of O
all O
authors O
for O
the O
past O
year O
none O
of O
the O
authors O
have O
received O
table O
1 O
urine O
and O
blood O
ion O
##og O
##ram O
before O
and O
after O
surgery O
mom O
##eter O
model O
3 O
mo O
advanced O
instruments O
wilcox O
##on O
signed O
rank O
test O
and O
spear O
##man O
test O
were O
used O
for O
statistical O
parkinson O
patient O
experimental O
conditions O
st O
##n O
db O
##s O
before O
st O
##n O
db O
##s O
after O
analysis O
24 O
hours O
urine O
volume O
ml O
1 O
60 O
##1 O
6 O
56 O
##2 O
1 O
521 O
6 O
58 O
##3 O
after O
surgery O
db O
##s O
st O
##n O
produced O
a O
statistical O
##ly O
and O
cl O
##ini O

call O
##y O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
in O
mean O
un O
##i O
##ﬁ O
##ed O
park O
##ison O
s O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
scores O
up O
##rs O
##s O
iii O
was O
sign O
##i O
##ﬁ O
g O
##lom O
##er O
##ular O
ﬁ O
##lt O
##ration O
rate O
ml O
min O
blood O
ion O
##og O
##ram O
78 O
2 O
6 O
31 O
1 O
69 O
3 O
6 O
27 O
9 O
can O
##tly O
improved O
after O
db O
##s O
st O
##n O
p O
0 O
00 O
##5 O
52 O
6 O
8 O
3 O
before O
surgery O
and O
16 O
5 O
6 O
8 O
4 O
1 O
week O
after O
surgery O
as O
well O
as O
a O
ma O
red O
49 O
sodium O
me O
##q O
l O
139 O
6 O
2 O
2 O
136 O
6 O
2 O
1 O
potassium O
me O
##q O
l O
4 O
1 O
6 O
0 O
1 O
4 O
0 O
6 O
0 O
1 O
mean O
estimated O
g O
##fr O
calculated O
by O
cc O
ml O
min O
declined O
sign O
##i O
##ﬁ O
##can O
##tly O
p O
0 O
00 O
##5 O
after O
st O
##n O
db O
##s O
from O
78 O
2 O
6 O
31 O
1 O

to O
69 O
3 O
6 O
27 O
9 O
fig O
1 O
moreover O
three O
patients O
without O
pre O
##oper O
##ative O
renal O
ins O
##uf O
##ﬁ O
##ciency O
ri O
cc O
90 O
ml O
min O
developed O
acute O
ri O
post O
##oper O
##ative O
##ly O
stage O
2 O
ri O
in O
two O
patients O
and O
stage O
3 O
ri O
in O
one O
patient O
three O
patients O
with O
pre O
##oper O
##ative O
ri O
ex O
##ace O
##rba O
##ted O
stage O
2 O
into O
stage O
3 O
in O
one O
patient O
and O
stage O
3 O
into O
stage O
4 O
in O
two O
patients O
mean O
ur O
##ina O
##ry O
volume O
in O
ml O
day O
were O
similar O
pre O
##oper O
##ative O
##ly O
1 O
60 O
##1 O
6 O
56 O
##2 O
and O
post O
##oper O
##ative O
##ly O
1 O
521 O
6 O
58 O
##3 O
no O
urine O
ion O
##og O
##ram O
sodium O
mmm O
##ol O
l O
109 O
6 O
40 O
123 O
6 O
67 O
potassium O
mmm O
##ol O
l O
33 O
7 O
6 O
11 O
3 O
33 O
7 O
6 O
10 O
4 O
calcium O
mg O
dl O
8 O
2 O
6 O
4 O
2 O
7 O
7 O
6 O
4 O
3 O

ph O
##os O
##por O
##um O
mg O
dl O
59 O
8 O
6 O
26 O
1 O
55 O
1 O
6 O
27 O
9 O
ur O
##ic O
acid O
mg O
dl O
6 O
4 O
6 O
5 O
3 O
10 O
3 O
6 O
7 O
6 O
urine O
biochemistry O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##4 O
letters O
to O
the O
editor O
ﬁ O
##nan O
##cial O
support O
and O
funding O
for O
the O
preceding O
12 O
months O
of O
the O
listed O
sources O
regardless O
of O
relationship O
to O
current O
manuscript O

author O
roles O
joan O
##a O
research O
project O
conception O
organization O
execution O
statistical O
analysis O
design O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
augusta O
vie O
##ira O
coe O
##lho O
research O
project O
conception O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
maria O
jose O
##´ O
rosa O
##s O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
eduardo O
mo O
##ura O
research O
project O
execution O
statistical O
analysis O
design O
execution O
review O
and O
critique O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
ru O
##i O
va O
##z O
research O
project O
conception O
organization O
manuscript O
review O
and O
critique O
carolina O
garrett O
research O
project O
conception O
organization O

joan O
##a O
md O
ne O
##uro O
##logy O
department O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
e O
mail O
j O
##gui O
##m O
##rae O
##s O
##9 O
hot O
##mail O
com O
augusta O
vie O
##ira O
coe O
##lho O
md O
phd O
institute O
of O
ph O
##arm O
##aco O
##logy O
and O
therapeutic O
##s O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
maria O
jose O
##´ O
rosa O
##s O
md O
ne O
##uro O
##logy O
department O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O

eduardo O
mo O
##ura O
md O
phd O
institute O
of O
ph O
##arm O
##aco O
##logy O
and O
therapeutic O
##s O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
ru O
##i O
va O
##z O
md O
phd O
carolina O
garrett O
md O
phd O
ne O
##uro O
##sur O
##ger O
##y O
department O
faculty O
of O
medicine O
university O
of O
porto O
hospital O
de O
hospital O
de O
alam O
##eda O
professor O
monte O
##iro O
porto O
420 O
##0 O
portugal O
references O

k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O
le O
##mack O
ge O
dewey O
rb O
jr O
roe O
##hr O
##born O
c O
##g O
o O
sui O
##lle O
##ab O
##hai O
##n O
pe O
z O
##im O
##mer O
##n O
pe O
question O
##naire O
based O
assessment O
of O
bladder O
dysfunction O
in O
patients O
with O
mild O
to O
moderate O
parkinson O
s O
disease O
ur O
##ology O
2000 O
56 O
250 O
254 O
wing O
##e O
k O
fowler O
c O
##j O
bladder O
dysfunction O
in O
parkinson O
##ism O
mechanisms O
prevalence O
symptoms O
and O
management O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
737 O
74 O
##5 O

her O
##zog O
j O
weiss O
ph O
ass O
##mus O
a O
et O
al O
improved O
sensory O
ga O
##ting O
of O
ur O
##ina O
##ry O
bladder O
af O
##fer O
##ents O
in O
parkinson O
s O
disease O
following O
sub O
##thal O
##ami O
##c O
stimulation O
brain O
2008 O
131 O
pt O
1 O
132 O
145 O
k O
##rac O
##k O
p O
bat O
##ir O
a O
van O
b O
##ler O
##com O
n O
et O
al O
five O
year O
follow O
up O
of O
bilateral O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
in O
advanced O
parkinson O
s O
disease O
n O
eng O
##l O
j O
med O
2003 O
34 O
##9 O
1925 O
1934 O
se O
##if O
c O
her O
##zog O
j O
van O
der O
horst O
c O
et O
al O
effect O
of O
sub O
##thal O
##ami O
##c O
deep O
brain O
stimulation O
on O
the O
function O
of O
the O
ur O
##ina O
##ry O
bladder O
ann O
ne O
##uro O
##l O
2004 O
55 O
118 O
120 O

her O
##zog O
j O
weiss O
ph O
ass O
##mus O
a O
et O
al O
sub O
##thal O
##ami O
##c O
stimulation O
mod O
##ulates O
co O
##rti O
##cal O
control O
of O
ur O
##ina O
##ry O
bladder O
in O
parkinson O
s O
disease O
brain O
2006 O
129 O
336 O
##6 O
337 O
##5 O
le O
##ma O
##ire O
jj O
cost O
##e O
j O
ou O
##ch O
##chan O
##e O
l O
et O
al O
brain O
mapping O
in O
stereo O
##ta O
##ctic O
surgery O
a O
brief O
overview O
from O
the O
pro O
##ba O
##bilis O
##tic O
targeting O
to O
the O
patient O
based O
ana O
##tom O
##ic O
mapping O
ne O
##uro O
##ima O
##ge O
2007 O
37 O
su O
##pp O
##l O
1 O
s O
##10 O
##9 O
s O
##11 O
##5 O
karim O
##i O
m O
go O
##lch O
##in O
n O
tab O
##bal O
sd O
et O
al O
sub O
##thal O
##ami O
##c O
nucleus O
stimulation O
induced O
regional O
blood O
ﬂ O
##ow O
responses O
co O
##rre O
##late O
with O
improvement O
of O
motor O
signs O
in O
parkinson O
disease O
brain O
2008 O
131 O
271 O
##0 O
271 O
##9 O

po O
##on O
cc O
irwin O
mg O
ana O
##esthesia O
for O
deep O
brain O
stimulation O
and O
in O
patients O
with O
implant O
##ed O
ne O
##uro O
##sti O
##mu O
##lat O
##or O
devices O
br O
j O
ana O
##est O
##h O
2009 O
103 O
152 O
165 O
pal O
##kov O
##its O
m O
se O
##bek O
##ova O
k O
gall O
##atz O
k O
et O
al O
ne O
##uron O
##al O
activation O
in O
the O
cn O
##s O
during O
different O
forms O
of O
acute O
renal O
failure O
in O
rats O
neuroscience O
2009 O
159 O
86 O
##2 O
88 O
##2 O
turner O
ms O
gray O
ts O
mick O
##ie O
##wicz O
al O
napier O
tc O
f O
##os O
expression O
following O
activation O
of O
the O
ventral O
pal O
##lid O
##um O
in O
normal O
rats O
and O
in O
a O
model O
of O
parkinson O
s O
disease O
implications O
for O
limb O
##ic O
system O
and O
basal O
gang O
##lia O
interactions O
brain O
st O
##ru O
##ct O
fun O
##ct O
2008 O
213 O
197 O
213 O

kit O
##ta O
t O
mats O
##um O
##oto O
m O
tanaka O
h O
mit O
##su O
##i O
t O
yo O
##shi O
##oka O
m O
non O
##om O
##ura O
k O
ga O
##ba O
##er O
##gic O
mechanism O
mediated O
via O
d O
receptors O
in O
the O
rat O
per O
##ia O
##que O
##du O
##cta O
##l O
gray O
participates O
in O
the O
mic O
##tur O
##ition O
re O
##ﬂ O
##ex O
an O
in O
vivo O
micro O
##dial O
##ysis O
study O
eu O
##r O
j O
ne O
##uro O
##sc O
##i O
2008 O
27 O
321 O
##6 O
322 O
##5 O
ad O
##em O
presenting O
as O
a O
movement O
disorder O
video O
acute O
di O
##sse O
##minated O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
ad O
##em O
is O
a O
dem O
##ye O
##lina O
##ting O
disease O
of O
the O
central O
nervous O
system O
characterized O
by O
multi O
##fo O
##cal O
neurological O
de O
##ﬁ O
##cit O
##s O
and O
en O
##ce O
##pha O
##lo O
##pathy O
1 O
we O
report O
a O
patient O
with O
ad O
##em O
who O
presented O
with O
a O
movement O
disorder O

a O
44 O
year O
old O
woman O
was O
admitted O
with O
cho O
##re O
##iform O
movements O
her O
medications O
included O
sodium O
val O
##pro O
##ate O
400 O
mg O
th O
##rice O
daily O
for O
mig O
##raine O
and O
ph O
##ene O
##lz O
##ine O
30 O
mg O
twice O
daily O
for O
sc O
##hi O
##zo O
##af O
##fect O
##ive O
disorder O
the O
patient O
had O
developed O
involuntary O
movements O
in O
her O
left O
leg O
3 O
days O
following O
an O
upper O
respiratory O
tract O
infection O
the O
movements O
progressed O
to O
involve O
both O
upper O
and O
lower O
limbs O
ph O
##ene O
##lz O
##ine O
was O
ceased O
with O
no O
improvement O
examination O
revealed O
cho O
##re O
##iform O
movements O
affecting O
the O
upper O
limb O
and O
lower O
limb O
particularly O
on O
the O
left O
the O
movements O
were O
continuous O
with O
intermittent O
brief O
jerk O
##s O
see O
video O
1 O

ct O
brain O
was O
un O
##rem O
##ark O
##able O
blood O
glucose O
was O
normal O
the O
cr O
##ea O
##tine O
kinase O
ck O
was O
elevated O
at O
98 O
##8 O
##2 O
l O
##mo O
##l O
l O
decreasing O
to O
83 O
##5 O
l O
##mo O
##l O
l O
by O
day O
5 O
sodium O
val O
##pro O
##ate O
level O
was O
106 O
l O
##mo O
##l O
l O
therapeutic O
range O
350 O
700 O
l O
##mo O
##l O
l O
the O
as O
##ot O
was O
elevated O
at O
47 O
##3 O
i O
##u O
ml O
and O
increased O
to O
83 O
##7 O
i O
##u O
ml O
after O
2 O
weeks O
anti O
dna O
##se O
b O
ti O
##tre O
remained O
negative O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
24 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##29 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##5 O
fig O
1 O
a O
axial O
ﬂ O
##uid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
mri O
brain O
multiple O
f O
##oc O
##i O
of O
hyper O
##int O
##ens O
##ti O
##y O
in O
the O
sub O
##thal O
##ami O
##c O
regions O
brains O
##tem O
ce O
##re O
##bell O
##um O
not O
shown O
left O
o O
##cci O
##pit O
##al O
white O
matter O
and O
left O
lent O
##iform O
nucleus O
b O
repeat O
axial O
ﬂ O
##uid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
mri O
brain O
three O
months O
after O
onset O
showing O
resolution O
of O
lesions O

the O
patient O
was O
commenced O
on O
benz O
##yl O
##pen O
##ici O
##llin O
and O
cl O
##ona O
##ze O
##pa O
##m O
ph O
##ene O
##lz O
##ine O
was O
rec O
##om O
##men O
##ced O
her O
movement O
disorder O
improved O
within O
a O
few O
days O
and O
resolved O
over O
the O
following O
several O
days O
on O
the O
5th O
day O
the O
patient O
developed O
a O
fever O
and O
left O
sided O
6th O
nerve O
pal O
##sy O
the O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
showed O
normal O
protein O
and O
glucose O
and O
one O
mono O
##nu O
##cle O
##ar O
cell O
ol O
##igo O
##cl O
##onal O
bands O
were O
not O
present O
mri O
brain O
revealed O
multiple O
none O
##nh O
##an O
##cing O
f O
##oc O
##i O
of O
hyper O
##int O
##ens O
##ity O
in O
the O
sub O
##thal O
##ami O
##c O
regions O
bilateral O
##ly O
brains O
##tem O
ce O
##re O
##bell O
##um O
left O
lent O
##iform O
nucleus O
and O
left O
o O
##cci O
##pit O
##al O
white O
matter O
fig O
1a O

the O
patient O
then O
deteriorated O
with O
del O
##iri O
##um O
ata O
##xia O
ny O
##sta O
##gm O
##us O
a O
left O
horne O
##r O
s O
syndrome O
and O
bilateral O
sixth O
nerve O
pal O
##sies O
repeat O
cerebral O
mri O
showed O
progression O
of O
the O
previous O
ﬁ O
##nding O
##s O
with O
patch O
##y O
areas O
of O
enhancement O
methyl O
##pre O
##d O
##nis O
##one O
was O
commenced O
repeat O
cs O
##f O
examination O
2 O
days O
later O
showed O
12 O
mono O
##nu O
##cle O
##ar O
cells O
but O
remained O
otherwise O
normal O
tests O
for O
hiv O
bo O
##rre O
##lia O
bu O
##rg O
##dorf O
##eri O
b O
hen O
##sel O
##ae O
b O
per O
##tus O
##sis O
e O
##b O
##v O
cm O
##v O
my O
##co O
##pl O
##as O
##ma O
to O
##x O
##op O
##las O
##mos O
##is O
crypt O
##oco O
##cca O
##l O
antigen O
q O
fever O
bar O
##mah O
forest O
hs O
##v O
1 O
and O
2 O
in O
##ﬂ O
##uen O
##za O
a O
and O
b O
fl O
##avi O
##virus O
ross O
river O
h O
##h O
##v O
6 O
v O
##z O
me O
##as O
##les O
and O

rick O
##ett O
##sia O
ser O
##ology O
were O
negative O
testing O
for O
metabolic O
diseases O
as O
well O
as O
auto O
##im O
##mun O
##e O
markers O
including O
anti O
g O
##q O
##1 O
##b O
i O
##gg O
antibodies O
were O
negative O
by O
day O
17 O
the O
patient O
gradually O
improved O
and O
was O
discharged O
to O
rehabilitation O
at O
3 O
month O
follow O
up O
the O
patient O
had O
experienced O
complete O
resolution O
of O
her O
symptoms O
and O
mri O
changes O
fig O
1b O

the O
clinical O
and O
radio O
##logical O
ﬁ O
##nding O
##s O
in O
our O
patient O
were O
consistent O
with O
ad O
##em O
although O
lesions O
in O
ad O
##em O
typically O
enhance O
with O
ga O
##do O
##lini O
##um O
schwarz O
et O
al O
reported O
patch O
##y O
enhancement O
in O
24 O
of O
cases O
with O
no O
enhancement O
in O
4 O
1 O
similarly O
although O
cs O
##f O
ol O
##igo O
##cl O
##onal O
bands O
were O
negative O
the O
reported O
percentage O
in O
ad O
##em O
varies O
from O
0 O
to O
58 O
in O
contrast O
to O
multiple O
sc O
##ler O
##osis O
where O
ol O
##igo O
##cl O
##onal O
bands O
are O
detected O
in O
90 O
95 O
of O
cases O
2 O
this O
lower O
percentage O
may O
be O
explained O
by O
poly O
##cl O
##onal O
rather O
than O
ol O
##igo O
##cl O
##onal O
activation O
in O
ad O
##em O
in O
response O
to O
an O
antigen O
##ic O
challenge O

it O
is O
likely O
that O
the O
bilateral O
sub O
##thal O
##ami O
##c O
lesions O
and O
possibly O
also O
the O
left O
lent O
##iform O
nucleus O
les O
##ion O
resulted O
in O
the O
development O
of O
cho O
##rea O
in O
our O
patient O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##6 O
letters O
to O
the O
editor O
the O
ﬁ O
##nding O
of O
an O
elevated O
as O
##ot O
raises O
the O
possibility O
of O
sy O
##den O
##ham O
s O
cho O
##rea O
but O
in O
the O
setting O
of O
a O
persistent O
##ly O
negative O
anti O
dna O
##se O
b O
is O
ins O
##uf O
##ﬁ O
##cie O
##nt O
evidence O
to O
support O
a O
recent O
st O
##re O
##pt O
##oco O
##cca O
##l O
infection O
a O
normal O
value O
for O
anti O
st O
##re O
##pt O
##oco O
##cca O
##l O
antibody O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
de O
##ﬁ O
##ne O
owing O
to O
di O
##spar O
##ities O
due O
to O
age O
geography O
and O
seasonal O
variation O
3 O

reports O
of O
cho O
##re O
##iform O
movements O
associated O
with O
sodium O
val O
##pro O
##ate O
have O
been O
described O
4 O
however O
our O
patient O
improved O
despite O
continuation O
of O
this O
medication O
we O
have O
found O
one O
report O
of O
cho O
##rea O
associated O
with O
mono O
##amine O
ox O
##ida O
##se O
inhibitors O
5 O
however O
the O
patient O
also O
improved O
despite O
rec O
##om O
##men O
##ce O
##ment O
and O
maintenance O
of O
her O
mono O
##amine O
ox O
##ida O
##se O
inhibitor O
an O
adverse O
reaction O
to O
this O
medication O
such O
as O
ser O
##oton O
##in O
syndrome O
is O
therefore O
also O
unlikely O
the O
elevation O
in O
ck O
is O
presumably O
related O
to O
muscle O
damage O
in O
the O
setting O
of O
intense O
and O
prolonged O
involuntary O
movements O

intra O
##ven O
##ous O
im O
##mun O
##og O
##lo O
##bu O
##lin O
has O
been O
used O
for O
treatment O
of O
ste O
##roid O
resistant O
ad O
##em O
with O
success O
in O
a O
few O
cases O
however O
it O
is O
unclear O
whether O
the O
improvement O
was O
co O
incident O
##al O
with O
the O
self O
limiting O
nature O
of O
the O
disease O
6 O
reports O
regarding O
the O
effectiveness O
of O
plasma O
##pher O
##esis O
have O
been O
inconsistent O
7 O
in O
conclusion O
we O
describe O
an O
adult O
patient O
who O
presented O
with O
an O
involuntary O
movement O
disorder O
and O
subsequently O
went O
on O
to O
develop O
a O
typical O
clinical O
course O
and O
radio O
##logical O
ﬁ O
##nding O
##s O
consistent O
with O
ad O
##em O
legend O
to O
the O
video O

video O
clip O
of O
initial O
examination O
showing O
cho O
##re O
##iform O
movements O
affecting O
upper O
limbs O
and O
lower O
limbs O
particularly O
on O
the O
left O
financial O
disclosure O
##s O
nothing O
to O
disclose O
author O
roles O
ain O
##hi O
ha O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
of O
manuscript O
carolyn O
sue O
conception O
organization O
execution O
of O
research O
project O
design O
execution O
review O
and O
critique O
of O
statistical O
analysis O
and O
writing O
of O
the O
ﬁ O
##rst O
draft O
review O
and O
critique O
of O
manuscript O
ain O
##hi O
d O
ha O
mb O
##bs O
department O
of O
ne O
##uro O
##logy O
royal O
north O
shore O
hospital O
sydney O

carolyn O
sue O
mb O
##bs O
phd O
fra O
##cp O
medicine O
northern O
clinical O
school O
ko O
##lling O
institute O
of O
medical O
research O
royal O
north O
shore O
hospital O
the O
university O
of O
sydney O
new O
south O
wales O
2006 O
australia O
e O
mail O
cs O
##ue O
med O
us O
##yd O
ed O
##u O
au O
references O
schwarz O
s O
mo O
##hr O
a O
kn O
##au O
##th O
m O
wilde O
##mann O
b O
st O
##or O
##ch O
hagen O
##lo O
##cher O
b O
acute O
di O
##sse O
##minated O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
a O
follow O
up O
study O
of O
40 O
adult O
patients O
ne O
##uro O
##logy O
2001 O
56 O
131 O
##3 O
131 O
##8 O
cia O
##n O
or O
primary O
care O
physician O
pe O
##dia O
##tr O
in O
##fect O
di O
##s O
j O
2002 O
21 O
420 O
45 O
##6 O
quiz O
42 O
##7 O
430 O
gun O
##al O
di O
gu O
##ler O
##yu O
##z O
m O
bingo O
##l O
ca O
rev O
##ers O
##ible O
val O
##pro O
##ate O
induced O
cho O
##re O
##iform O
movements O
seizure O
2002 O
11 O
205 O
206 O

macleod O
d O
##m O
cho O
##rea O
induced O
by O
tran O
##quil O
##lis O
##ers O
lance O
##t O
1964 O
1 O
38 O
##8 O
38 O
##9 O
ra O
##va O
##glia O
s O
piccolo O
g O
ce O
##ron O
##i O
m O
et O
al O
severe O
ste O
##roid O
resistant O
post O
infectious O
en O
##ce O
##pha O
##lom O
##ye O
##lit O
##is O
general O
features O
and O
effects O
of O
iv O
##ig O
j O
ne O
##uro O
##l O
2007 O
254 O
151 O
##8 O
152 O
##3 O
kay O
##nar O
l O
alt O
##unt O
##as O
f O
a O
##yd O
##og O
##du O
i O
et O
al O
therapeutic O
plasma O
exchange O
in O
patients O
with O
ne O
##uro O
##logic O
diseases O
retrospective O
multi O
##cent O
##er O
study O
trans O
##fus O
ap O
##her O
sci O
2008 O
38 O
109 O
115 O
pet O
findings O
in O
rev O
##ers O
##ible O
improvement O
of O
ol O
##factory O
dysfunction O
after O
st O
##n O
stimulation O
in O
a O
parkinson O
s O
disease O
patient O

ol O
##factory O
dysfunction O
o O
##d O
is O
one O
of O
the O
earliest O
non O
##moto O
##r O
symptoms O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
pd O
1 O
h O
##yp O
##os O
##mia O
in O
pd O
is O
generally O
bilateral O
and O
remains O
unaffected O
by O
parkinson O
##ian O
medication O
1 O
despite O
of O
its O
high O
occurrence O
little O
is O
really O
known O
about O
the O
mechanisms O
of O
ol O
##factory O
loss O
2 O
most O
h O
##yp O
##oth O
##eses O
raised O
to O
explain O
this O
phenomenon O
involve O
ne O
##uro O
##de O
##gen O
##erative O
processes O
of O
ol O
##factory O
structures O
3 O
the O
authors O
report O
a O
case O
and O
the O
ﬂ O
##uo O
##rod O
##eo O
##xy O
##gl O
##uc O
##ose O
f O
##d O
##g O
pet O
ﬁ O
##nding O
##s O
of O
a O
patient O
who O
underwent O
bilateral O
deep O
brain O
stimulation O
of O
the O
sub O
##thal O
##ami O
##c O
nucleus O
st O
##n O
db O
##s O
and O
subsequently O
developed O
a O
great O
improvement O
in O
motor O
symptoms O
parallel O
##ed O
by O
an O
impressive O
recovery O
of O
ol O
##fa O
##ction O
after O
surgery O

a O
51 O
year O
old O
man O
with O
advanced O
pd O
severe O
motor O
ﬂ O
##uc O
##tua O
##tions O
and O
inca O
##pac O
##itating O
lev O
##od O
##opa O
induced O
d O
##ys O
##kin O
##es O
##ias O
underwent O
bilateral O
st O
##n O
db O
##s O
he O
presented O
early O
onset O
of O
pd O
symptoms O
35 O
years O
old O
eight O
years O
ago O
he O
started O
complaining O
of O
severe O
loss O
of O
ol O
##fa O
##ction O
discrimination O
he O
seldom O
perceived O
very O
intense O
and O
unpleasant O
fragrance O
##s O
and O
loss O
of O
li O
##bid O
##o O
his O
motor O
scores O
on O
the O
up O
##dr O
##s O
part O
iii O
in O
on O
medication O
were O
35 O
and O
74 O
in O
off O
medication O
condition O
chronic O
mono O
##pol O
##ar O
stimulation O
was O
applied O
on O
the O
contacts O
corresponding O
to O
the O
st O
##n O
two O
distal O
contacts O
on O
each O
side O
as O
the O
cat O
##ho O
##des O
1 O
7 O
v O
right O
2 O
0 O
v O
left O
pulse O
width O
210 O
l O
##s O
and O
frequency O
of O
130 O
hz O
at O
ﬁ O
##ve O
months O
on O
post O
##oper O
##ative O
follow O
up O
the O
patient O
had O
experienced O
improvement O
in O
the O
up O
##dr O
##s O
part O
iii O
score O
16 O
on O
##med O
on O
##sti O
##m O
vs O
39 O
off O
##med O
on O
##sti O
##m O
during O
a O
routine O
visit O
the O
patient O
spontaneously O
reported O
marked O
improvement O
in O
his O
ol O
##factory O
function O
ol O
##fa O
##ction O
was O
assessed O
using O
the O
brief O
smell O
id O
##ent O
##i O
##ﬁ O
##cation O
test O
12 O
items O
b O
sit O
4 O
he O
recognized O
the O
odor O
of O
eight O
of O
twelve O
substances O
score O
considered O
normal O
ol O
##fa O
##ction O
for O
someone O
his O
age O
according O
to O
the O
dot O
##y O
s O
values O
1 O

six O
months O
after O
surgery O
under O
informed O
consent O
the O
patient O
underwent O
f O
##d O
##g O
pet O
scan O
study O
in O
the O
on O
##sti O
##m O
on O
##med O
vs O
the O
offs O
##ti O
##m O
on O
##med O
conditions O
the O
ﬁ O
##rst O
study O
was O
performed O
with O
the O
st O
##im O
##ulator O
on O
and O
under O
routine O
medication O
best O
functional O
condition O
the O
radio O
##tra O
##cer O
was O
injected O
at O
rest O
in O
a O
dark O
and O
quiet O
room O
during O
odor O
expo O
##si O
fran O
##cio O
##tta O
d O
col O
##umb O
##a O
cab O
##eza O
##s O
s O
andre O
##oni O
l O
et O
al O
ol O
##igo O
##cl O
##onal O
i O
##gg O
band O
patterns O
in O
in O
##ﬂ O
##am O
##mat O
##ory O
dem O
##ye O
##lina O
##ting O
human O
and O
mouse O
diseases O
j O
ne O
##uro O
##im O
##mun O
##ol O
2008 O
200 O
125 O
128 O

she O
##t O
a O
kaplan O
el O
clinical O
use O
and O
interpretation O
of O
group O
a O
st O
##re O
##pt O
##oco O
##cca O
##l O
antibody O
tests O
a O
practical O
approach O
for O
the O
pe O
##dia O
##tri O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
the O
authors O
report O
no O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
published O
online O
4 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##53 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##7 O

fig O
1 O
results O
of O
regional O
brain O
activation O
related O
to O
the O
ol O
##factory O
paradigm O
during O
bilateral O
st O
##n O
stimulation O
images O
corresponding O
to O
on O
and O
off O
conditions O
were O
compared O
through O
computer O
##ized O
vox O
##el O
based O
image O
sub O
##tra O
##ction O
mat O
##lab O
##1 O
image O
##j O
##1 O
fused O
onto O
the O
mri O
os O
##iri O
##x O
##1 O
and O
plotted O
into O
the O
tail O
##ara O
##ch O
atlas O
brains O
##ight O
##1 O
the O
image O
shows O
in O
red O
and O
yellow O
the O
greater O
activation O
areas O
tha O
##lam O
##us O
st O
##ria O
##tum O
nucleus O
acc O
##umb O
##ens O
and O
amy O
##g O
##dal O
##oid O
complex O
bilateral O
##ly O
and O
the O
left O
g O
##yr O
##us O
rec O
##tus O
at O
the O
bottom O
z O
shows O
the O
brain O
slice O
distance O
from O
the O
ac O
pc O
line O
coordinates O
of O
tal O
##air O
##ach O
atlas O
color O
ﬁ O
##gur O
##e O
can O
be O
viewed O
in O
the O
online O
issue O
which O
is O
available O
at O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O

ti O
##on O
to O
one O
of O
the O
substances O
b O
sit O
the O
second O
pet O
study O
was O
performed O
under O
the O
same O
conditions O
but O
the O
st O
##im O
##ulator O
had O
been O
turned O
off O
for O
seven O
days O
at O
this O
time O
the O
patient O
experienced O
return O
of O
h O
##yp O
##os O
##mia O
as O
he O
observed O
and O
reported O
spontaneously O
the O
o O
##d O
at O
this O
point O
corresponded O
to O
the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
2 O
12 O
fragrance O
##s O
in O
b O
sit O
the O
results O
of O
pet O
images O
revealed O
sign O
##i O
##ﬁ O
##can O
##t O
metabolic O
activation O
of O
tha O
##lam O
##us O
st O
##ria O
##tum O
nucleus O
acc O
##umb O
##ens O
and O
amy O
##g O
##dal O
##oid O
complex O
bilateral O
##ly O
as O
well O
as O
the O
left O
g O
##yr O
##us O
rec O
##tus O
the O
tissue O
around O
the O
electrode O
also O
revealed O
metabolic O
activation O
from O
deep O
st O
##n O
extending O
to O
ventral O
tha O
##lam O
##us O
fig O
1 O

previous O
reports O
have O
stated O
that O
odor O
discrimination O
improves O
after O
st O
##n O
db O
##s O
in O
pd O
patients O
while O
ol O
##factory O
detection O
threshold O
does O
not O
these O
results O
suggest O
that O
st O
##nd O
##bs O
might O
mod O
##ulate O
cognitive O
processing O
of O
ol O
##factory O
information O
5 O
the O
return O
to O
h O
##yp O
##os O
##mia O
after O
the O
stimulation O
was O
turned O
off O
favors O
the O
hypothesis O
that O
functional O
changes O
in O
st O
##ria O
##tum O
tha O
##lam O
##us O
co O
##rti O
##cal O
networks O
rather O
than O
ir O
##re O
##vers O
##ible O
de O
##gen O
##eration O
of O
ol O
##factory O
structures O
only O
are O
responsible O
for O
o O
##d O
observed O
in O
pd O
patients O
the O
progressive O
ne O
##uron O
##al O
loss O
throughout O
the O
brain O
generates O
dysfunction O
in O
the O
ch O
##ron O
##ome O
##try O
of O
circuits O
of O
the O
basal O
gang O
##lia O
affecting O
different O
systems O
interpreted O
clinical O
##ly O
as O
various O
symptoms O
of O
pd O
once O
the O
hyper O
activation O
of O
st O
##n O
is O
reversed O
by O
the O
onset O
of O
local O
electrical O
stimulation O
its O
in O
##ﬂ O
##uen O
##ce O
spreads O
out O
to O
other O
neural O
circuits O
correct O
##ing O
dysfunction O
##s O
of O
mod O
##ulator O
##y O
ne O
##uro O
##tra O
##ns O
##mit O
##ters O
which O
in O
turn O
is O
related O
to O
the O
temporary O
improvement O
of O
motor O
and O
non O
##moto O
##r O
symptoms O
although O
data O
in O
previous O
studies O
##6 O
suggest O
that O
the O
motor O
effect O
obtained O
by O
do O
##pa O
##mine O
##rg O
##ic O
medication O
and O
by O
st O
##n O
stimulation O
shares O
the O
same O
activated O
brain O
areas O
this O
is O
not O
likely O
to O
happen O
with O
ol O
##factory O
function O
because O
do O
##pa O
##mine O
##rg O
##ic O
rep O
##osition O
has O
no O
effect O
on O
h O
##yp O
##os O
##mia O
1 O

in O
line O
with O
previous O
reports O
pet O
signs O
of O
motor O
improvement O
at O
##ten O
##uation O
of O
the O
parkinson O
disease O
related O
pattern O
pd O
##rp O
6 O
was O
expressed O
except O
for O
a O
residual O
hyper O
##met O
##ab O
##olis O
##m O
in O
left O
st O
##ria O
##tum O
observed O
in O
the O
present O
study O
although O
a O
remarkable O
motor O
improvement O
was O
observed O
in O
this O
patient O
the O
expected O
abolition O
of O
pd O
##rp O
was O
not O
fully O

expressed O
this O
apparent O
inc O
##ons O
##iste O
##ncy O
may O
be O
related O
to O
individual O
variability O
in O
a O
single O
subject O
analysis O
or O
it O
may O
suggest O
the O
participation O
of O
left O
st O
##ria O
##tum O
in O
the O
ol O
##factory O
information O
processing O
network O
in O
this O
patient O
also O
a O
substantial O
increase O
in O
metabolism O
in O
the O
vicinity O
of O
the O
sub O
##thal O
##ami O
##c O
target O
site O
extending O
ro O
##stra O
##lly O
into O
the O
ventral O
tha O
##lam O
##us O
was O
observed O
since O
the O
f O
##d O
##g O
hyper O
##met O
##ab O
##olis O
##m O
was O
highly O
coincide O
##nt O
with O
the O
location O
of O
electrode O
##s O
this O
component O
is O
probably O
related O
to O
the O
direct O
effects O
of O
electrical O
stimulation O
of O
st O
##n O
inhibit O
##ing O
de O
##pol O
##ari O
##zation O
on O
the O
cell O
membrane O
6 O
the O
electrode O
trajectory O
performed O
in O
this O
patient O
includes O
the O
motor O
anterior O
ventral O
##is O
oral O
##is O
nucleus O
of O
tha O
##lam O
##us O
posterior O
ventral O
##is O
oral O
##is O
nucleus O
of O
tha O
##lam O
##us O
vo O
##a O
vo O
##p O
as O
observed O
in O
the O
post O
##oper O
##ative O
mri O
the O
upper O
contact O
is O
located O
within O
the O
ventral O
portion O
of O
tha O
##lam O
##us O
besides O
the O
activation O
of O
amy O
##g O
##dal O
##oid O
complex O
hip O
##po O
##camp O
##us O
orbit O
##of O
##ron O
##tal O
cortex O
st O
##ria O
##tum O
tha O
##lam O
##us O
mid O
##bra O
##in O
and O
ce O
##re O
##bell O
##um O
related O
to O
ol O
##factory O
stimulation O
in O
pd O
patients O
as O
shown O
by O
west O
##erman O
##n O
et O
al O
7 O
also O
observed O
in O
this O
case O
there O
was O
additional O
activation O
of O
bilateral O
nucleus O
acc O
##umb O
##ens O
and O
left O
g O
##yr O
##us O
rec O
##tus O
although O
further O
studies O
are O
required O
for O
more O
robust O
conclusions O
the O
present O
ﬁ O
##nding O
##s O
suggest O
that O
the O
activated O
areas O
may O
media O
##te O
the O
odor O
discrimination O
improvement O
after O
bilateral O
st O
##n O
db O
##s O
the O
stimulation O
of O
tha O
##lam O
##ic O
region O
in O
this O
case O
might O
also O
have O
activated O
tha O
##lam O
##ic O
nuclei O
related O
to O
ol O
##factory O
function O
e O
g O
nucleus O
para O
##ta O
##enia O
##lis O
of O
tha O
##lam O
##us O
pt O
the O
connections O
of O
the O
pt O
nucleus O
arise O
from O
the O
secondary O
ol O
##factory O
centers O
through O
st O
##ria O
med O
##ulla O
##ris O
of O
tha O
##lam O
##us O
8 O
the O
activation O
of O
this O
nucleus O
could O
in O
##ﬂ O
##uen O
##ce O
the O
ol O
##factory O
circuit O
##ry O
at O
distant O
sites O
once O
reports O
of O
ol O
##factory O
sensation O
were O
observed O
by O
direct O
electrical O
stimulation O
of O
this O
region O
9 O

these O
preliminary O
observations O
suggest O
that O
o O
##d O
in O
pd O
may O
rather O
be O
a O
circuit O
##ry O
dysfunction O
and O
not O
only O
a O
ne O
##uro O
##de O
##gen O
##erative O
process O
in O
ol O
##factory O
structures O
a O
dysfunction O
of O
cognitive O
processing O
involved O
in O
odor O
discrimination O
might O
explain O
this O
phenomenon O
there O
are O
multiple O
levels O
of O
integration O
of O
ol O
##factory O
information O
and O
the O
st O
##n O
db O
##s O
seems O
to O
in O
##ﬂ O
##uen O
##ce O
the O
circuit O
involving O
the O
primary O
ol O
##factory O
areas O
limb O
##ic O
areas O
as O
the O
ventral O
st O
##ria O
##tum O
and O
basal O
frontal O
cortex O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
246 O
##8 O
letters O
to O
the O
editor O

ac O
##k O
##now O
##led O
##gm O
##ents O
this O
study O
was O
supported O
by O
fa O
##pes O
##p O
03 O
117 O
##9 O
##4 O
6 O
and O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
of O
hospital O
das O
cl O
##´ O
##ı O
##nica O
##s O

author O
roles O
dr O
f O
##ono O
##ff O
was O
involved O
in O
conception O
and O
design O
acquisition O
of O
data O
analysis O
and O
interpretation O
of O
data O
drafting O
the O
article O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
and O
administrative O
technical O
material O
support O
dr O
te O
##ix O
##eira O
was O
involved O
in O
conception O
and O
design O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
and O
administrative O
technical O
material O
support O
dr O
almeida O
was O
involved O
in O
acquisition O
analysis O
and O
interpretation O
of O
data O
drafting O
the O
article O
and O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
dr O
ga O
##rri O
##do O
was O
involved O
in O
analysis O
and O
interpretation O
of O
data O
dr O
salle O
##m O
was O
involved O
in O
drafting O
and O
critically O
rev O
##ising O
the O
article O
dr O
and O
##rade O
was O
involved O
in O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O
dr O
bar O
##bos O
##a O
was O
involved O
in O
critically O
rev O
##ising O
the O
article O
review O
of O
ﬁ O
##nal O
version O
of O
the O
manuscript O
and O
approval O
for O
submission O

erich O
tal O
##amo O
##ni O
f O
##ono O
##ff O
md O
phd O
y O
##w O
##zh O
##e O
si O
##fu O
##entes O
almeida O
de O
oliveira O
md O
santiago O
dr O
##iol O
##let O
md O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
e O
mail O
f O
##ono O
##ffe O
##t O
us O
##p O
br O
gr O
##ise O
##lda O
jar O
##ra O
ga O
##rri O
##do O
phd O
inform O
##atics O
division O
heart O
institute O
school O
of O
medicine O
university O
of O
sao O
paulo O
sao O
paulo O
brazil O
daniel O
cia O
##mp O
##i O
de O
and O
##rade O
md O
fl O
##a O
##´ O
##vio O
salle O
##m O
md O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
e O
##gb O
##ert O
##o O
rei O
##s O
bar O
##bos O
##a O
md O
phd O

department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
man O
##oe O
##l O
jacobs O
##en O
te O
##ix O
##eira O
md O
phd O
division O
of O
functional O
ne O
##uro O
##sur O
##ger O
##y O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
paulo O
paulo O
brazil O
references O
dot O
##y O
r O
##l O
dee O
##ms O
d O
ste O
##ller O
s O
ol O
##factory O
dysfunction O
in O
parkinson O
s O
disease O
a O
general O
de O
##ﬁ O
##cit O
unrelated O
to O
ne O
##uro O
##logic O
signs O
di O
##s O
bra O
##ak O
h O
del O
##tre O
##dic O
##i O
k O
rub O
u O
de O
vo O
##s O
rai O
jan O
##sen O
ste O
##ur O
en O
##h O
bra O
##ak O
e O
staging O
of O
brain O
pathology O
related O
to O
sporadic O
parkinson O
s O
disease O
ne O
##uro O
##bio O
##l O
aging O
2003 O
24 O
197 O
210 O

double O
k O
##l O
rowe O
db O
hayes O
m O
chan O
d O
##ky O
black O
##ie O
j O
identifying O
the O
pattern O
of O
ol O
##factory O
de O
##ﬁ O
##cit O
##s O
in O
parkinson O
disease O
using O
the O
brief O
smell O
id O
##ent O
##i O
##ﬁ O
##cation O
test O
arch O
ne O
##uro O
##l O
2003 O
60 O
54 O
##5 O
54 O
##9 O
hum O
##mel O
t O
ja O
##hn O
##ke O
u O
somme O
##r O
u O
reich O
##mann O
h O
mu O
##¨ O
##ller O
a O
ol O
##factory O
function O
in O
patients O
with O
id O
##io O
##pathic O
parkinson O
s O
disease O
effects O
of O
deep O
brain O
stimulation O
in O
the O
sub O
##thal O
##ami O
##c O
nucleus O
j O
neural O
trans O
##m O
2005 O
112 O
66 O
##9 O
67 O
##6 O
asa O
##num O
##a O
k O
tang O
c O
ma O
y O
dh O
##awan O
v O
matt O
##is O
p O
edwards O
c O
ka O
##pl O
##itt O
mg O
fei O
##gin O
a O
e O
##ide O
##lberg O
d O
network O
modulation O
in O
the O
treatment O
of O
parkinson O
s O
disease O
brain O
2006 O
129 O
266 O
##7 O
267 O
##8 O

west O
##erman O
##n O
b O
watt O
##end O
##orf O
e O
sc O
##h O
##wer O
##dt O
##fe O
##ger O
u O
hu O
##sner O
a O
fu O
##hr O
p O
gr O
##atz O
##l O
o O
hum O
##mel O
t O
bile O
##cen O
d O
we O
##lge O
lu O
##¨ O
##ssen O
a O
functional O
imaging O
of O
the O
cerebral O
ol O
##factory O
system O
in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
ps O
##ych O
##ia O
##tr O
2008 O
79 O
19 O
24 O
sc O
##hal O
##ten O
##brand O
g O
walker O
e O
has O
##sler O
r O
nara O
##bay O
##ashi O
h O
ri O
##eche O
##rt O
t O
editors O
stereo O
##ta O
##xy O
of O
the O
human O
brain O
second O
ed O
new O
york O
th O
##ie O
##me O
st O
##rat O
##ton O
inc O
1982 O
153 O
##p O
nash O
##old O
bs O
wilson O
w O
##p O
ol O
##factory O
hall O
##uc O
##inations O
ev O
##oked O
from O
stimulation O
of O
human O
tha O
##lam O
##us O
con O
##ﬁ O
##n O
ne O
##uro O
##l O
1970 O
32 O
298 O
306 O

fa O
##mi O
##lia O
##l O
non O
##kin O
##es O
##igen O
##ic O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ia O
and O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O
a O
new O
syndrome O

par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
p O
##nk O
##d O
refers O
to O
a O
clinical O
syndrome O
characterized O
by O
attacks O
of O
involuntary O
movements O
including O
d O
##yst O
##onia O
cho O
##rea O
at O
##het O
##osis O
or O
ball O
##ism O
occurring O
at O
rest O
1 O
2 O
p O
##nk O
##d O
is O
associated O
to O
a O
wide O
range O
of O
ae O
##ti O
##ologies O
for O
example O
auto O
##im O
##mun O
##e O
vascular O
traumatic O
in O
##fect O
##ive O
and O
end O
##oc O
##rine O
disorders O
1 O
however O
most O
cases O
of O
p O
##nk O
##d O
are O
id O
##io O
##pathic O
and O
ne O
##uro O
##ima O
##ging O
is O
usually O
un O
##rem O
##ark O
##able O
1 O
2 O
we O
report O
a O
p O
##nk O
##d O
family O
whose O
computed O
tom O
##ography O
ct O
scan O
revealed O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O

this O
four O
generation O
family O
includes O
5 O
one O
deceased O
patients O
table O
1 O
fig O
1 O
the O
pro O
##band O
individual O
iv O
2 O
is O
7 O
##year O
old O
girl O
who O
experienced O
at O
age O
of O
9 O
months O
a O
ﬁ O
##rst O
attack O
of O
d O
##yst O
##onic O
posture O
of O
the O
head O
with O
con O
##com O
##itan O
##t O
ballistic O
and O
cho O
##re O
##ic O
movements O
of O
upper O
and O
lower O
ex O
##tre O
##mit O
##ies O
this O
event O
lasted O
30 O
minutes O
without O
alteration O
of O
consciousness O
and O
was O
followed O
by O
prompt O
recovery O
one O
month O
later O
the O
girl O
experienced O
a O
similar O
episode O
pre O
##ci O
##pit O
##ated O
by O
fever O
and O
resolving O
spontaneously O
neurological O
examination O
between O
attacks O
was O
normal O
laboratory O
investigations O
serum O
and O
urine O
copper O
calcium O
phosphorus O
vitamin O
d O
ce O
##ru O
##lo O
##pl O
##as O
##min O
fe O
##rri O
##tin O
transfer O
##rin O
serum O
iron O
thyroid O
para O
##thy O
##roid O
and O
ad O
##ren O
##oco O
##rti O
##cot O
##rop O
##ic O
hormones O
anti O
trans O
##gl O
##uta O
##mina O
##se O
antibodies O
serum O
lip O
##op O
##rot O
##ein O
##s O
and O
lip O
##id O
pro O
##ﬁ O
##le O
lac O
##tate O
p O
##yr O
##u O
##vate O
amino O
acids O
and O
urine O
organic O
acids O
were O
normal O
brain O
magnetic O
resonance O
imaging O
mri O
was O
un O
##rem O
##ark O
##able O
mutations O
in O
mr O
1 O
my O
##o O
##ﬁ O
##bri O
##llo O
##genesis O
regulator O
1 O
3 O
and O
sl O
##c O
##2 O
##a1 O
g O
##lu O
##t O
1 O
4 O
genes O
were O
excluded O
as O
well O
as O
and O
family O
link O
##age O
to O
chromosome O
14 O
##q O
##5 O
lo O
##d O
score O
22 O
y O
5 O
0 O
in O
the O
following O
years O
the O
girl O
continued O
to O
experience O
similar O
episodes O
at O
the O
frequency O
of O
about O
one O
per O
year O
in O
one O
o O
##cca O

ease O
stage O
or O
disease O
duration O
ne O
##uro O
##logy O
1988 O
38 O
123 O
##7 O
124 O
##4 O
take O
##da O
a O
ki O
##ku O
##chi O
a O
mats O
##uz O
##aki O
kobayashi O
m O
su O
##gen O
##o O
n O
ito O
##yama O
y O
ol O
##factory O
dysfunction O
in O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
2007 O
254 O
iv O
2 O
iv O
7 O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
27 O
august O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##6 O
##7 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
246 O
##9 O
table O
1 O
clinical O
features O
of O
the O
p O
##nk O
##d O
patients O
trunk O
20 O
300 O
cerebral O
white O
matter O
re O
##mission O
at O
33 O
years O
iii O
3 O
37 O
m O
6 O
years O
fever O
emotional O
stress O

head O
limbs O
20 O
300 O
normal O
basal O
gang O
##lia O
yearly O
persist O
iv O
2 O
7 O
f O
9 O
months O
fever O
head O
limbs O
5 O
300 O
normal O
absent O
sporadic O
persist O
and O
not O
done O
si O
##on O
ict O
##al O
electro O
##ence O
##pha O
##log O
##raphy O
ee O
##g O
recording O
excluded O
the O
ep O
##ile O
##ptic O
nature O
of O
the O
event O
at O
the O
age O
of O
7 O
years O
a O
new O
ct O
scan O
was O
un O
##rem O
##ark O
##able O

individual O
iii O
2 O
is O
a O
39 O
year O
old O
man O
suffering O
from O
rec O
##urrent O
attacks O
of O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
involving O
the O
head O
limbs O
and O
trunk O
from O
4 O
years O
of O
life O
pre O
##ci O
##pit O
##ated O
by O
emotional O
stress O
at O
age O
33 O
years O
brain O
ct O
and O
mri O
revealed O
basal O
gang O
##lia O
and O
cerebral O
white O
matter O
cal O
##ci O
##ﬁ O
##cation O
##s O
extensive O
laboratory O
screening O
and O
neurological O
examination O
were O
un O
##rem O
##ark O
##able O
no O
further O
attacks O
were O
reported O
during O
the O
last O
6 O
years O

individual O
iii O
3 O
is O
a O
37 O
year O
old O
man O
experiencing O
yearly O
attacks O
of O
sudden O
onset O
d O
##yst O
##onia O
and O
cho O
##re O
##ic O
movements O
of O
the O
head O
and O
limbs O
from O
age O
6 O
to O
30 O
years O
related O
to O
physical O
or O
emotional O
stress O
neurological O
examination O
was O
un O
##rem O
##ark O
##able O
laboratory O
investigations O
and O
ee O
##g O
were O
normal O
brain O
ct O
at O
age O
30 O
years O
showed O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
##s O

individual O
ii O
3 O
is O
a O
70 O
year O
old O
woman O
presenting O
her O
ﬁ O
##rst O
attack O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
involving O
the O
head O
and O
the O
four O
limbs O
at O
the O
age O
of O
4 O
years O
subsequently O
these O
manifestation O
##s O
occurred O
regularly O
at O
the O
frequency O
of O
one O
per O
year O
in O
association O
with O
fast O
##ing O
or O
stress O
laboratory O
investigations O
and O
neurological O
examination O
were O
normal O
at O
the O
age O
of O
65 O
years O
brain O
ct O
revealed O
basal O
gang O
##lia O
and O
ce O
##re O
##bella O
##r O
cal O
##ci O
##ﬁ O
##cation O
##s O
the O
patient O
still O
experiences O
yearly O
episodes O
and O
in O
the O
last O
few O
years O
developed O
post O
##ural O
and O
kinetic O
tremor O
responding O
to O
alcohol O
intake O

individual O
i O
2 O
experienced O
a O
single O
episode O
of O
cho O
##re O
##ic O
d O
##yst O
##onic O
posture O
##s O
of O
the O
head O
at O
the O
age O
of O
75 O
years O
pre O
##ci O
##pit O
##ated O
by O
fever O
and O
lasting O
about O
20 O
minutes O

this O
family O
shows O
typical O
clinical O
features O
of O
p O
##nk O
##d O
1 O
2 O
all O
patients O
showed O
a O
typical O
pattern O
and O
duration O
of O
the O
episodes O
not O
activated O
by O
movement O
and O
showed O
normal O
neurological O
status O
between O
attacks O
except O
for O
the O
oldest O
living O
individual O
ii O
3 O
who O
developed O
late O
onset O
post O
##ural O
and O
kinetic O
tremor O
responding O
to O
alcohol O
intake O
individual O
i O
1 O
who O
experienced O
a O
single O
attack O
at O
age O
75 O
years O
related O
to O
feb O
##ril O
##e O
illness O
was O
considered O
as O
probably O
affected O
considering O
the O
transit O
##ory O
nature O
of O
his O
manifestation O
and O
the O
fact O
that O
fever O
was O
a O
pre O
##ci O
##pit O
##ating O
factor O
also O
in O
other O
affected O
members O
as O
reported O
in O
p O
##nk O
##d O
6 O
the O
course O
of O
the O
disease O
was O
relatively O
benign O
and O
affected O
individuals O
achieved O
spontaneous O
re O
##mission O
or O
continued O
to O
have O
about O
yearly O
episodes O
without O
treatment O
mutations O
in O
mr O
1 O
the O
only O
gene O
associated O
with O
fa O
##mi O
##lia O
##l O
p O
##nk O
##d O
3 O
7 O
were O
excluded O

fig O
1 O
pe O
##di O
##gree O
and O
ct O
scans O
of O
affected O
family O
members O
see O
the O
text O
for O
details O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##0 O
letters O
to O
the O
editor O

indeed O
the O
most O
distinctive O
feature O
in O
our O
family O
was O
the O
ﬁ O
##nding O
of O
symmetrical O
intra O
##cr O
##anial O
cal O
##ci O
##ﬁ O
##cation O
##s O
primarily O
affecting O
the O
basal O
gang O
##lia O
which O
has O
been O
previously O
reported O
in O
few O
isolated O
cases O
8 O
11 O
hereditary O
brain O
cal O
##cino O
##sis O
may O
be O
found O
in O
several O
different O
conditions O
12 O
for O
example O
disorders O
of O
para O
##thy O
##roid O
hormone O
or O
calcium O
regulation O
mitochondrial O
diseases O
and O
defects O
of O
organic O
or O
amino O
acid O
metabolism O
however O
all O
these O
ae O
##ti O
##ologies O
were O
ruled O
out O
in O
our O
family O
link O
##age O
to O
14 O
##q O
described O
in O
families O
with O
fa O
##hr O
disease O
and O
neurological O
symptoms O
5 O
was O
excluded O
con O
##ﬁ O
##rmin O
##g O
that O
this O
condition O
is O
genetically O
het O
##ero O
##gen O
##eous O
13 O
14 O
moreover O
the O
pathogen O
##etic O
role O
of O
cal O
##ci O
##ﬁ O
##cation O
##s O
remains O
unclear O
as O
the O
youngest O
patient O
showed O
un O
##rem O
##ark O
##able O
ne O
##uro O
##ima O
##ging O
despite O
full O
ph O
##eno O
##typical O
presentation O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
further O
families O
could O
shed O
light O
on O
the O
pathogen O
##esis O
of O
p O
##nk O
##d O

author O
roles O
conception O
and O
design O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
and O
p O
st O
##rian O
##o O
data O
acquisition O
and O
analysis O
p O
st O
##rian O
##o O
pat O
##riz O
##ia O
acc O
##ors O
##i O
lorenzo O
pine O
##lli O
francesca O
far O
##ave O
##lli O
and O
luc O
##io O
gi O
##ord O
##ano O
drafting O
editing O
and O
rev O
##ising O
of O
the O
text O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
p O
st O
##rian O
##o O
federico O
za O
##ra O
and O
carlo O
mine O
##tti O
nun O
##e O
s O
ye O
##ghi O
##az O
##ary O
##an O
md O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
armenian O
republican O
ep O
##ile O
##psy O
center O
er O
##eb O
##oun O
##i O
yerevan O
state O
medical O
university O
yerevan O
armenia O
e O
mail O
y O
##nu O
##ne O
yahoo O
com O
nun O
##ep O
##ile O
##psy O
gma O
##il O
com O
pas O
##qual O
##e O
st O
##rian O
##o O
md O
phd O

muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
pat O
##riz O
##ia O
acc O
##ors O
##i O
md O
pediatric O
ne O
##uro O
##psy O
##chia O
##tric O
division O
sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
lorenzo O
pine O
##lli O
md O
ne O
##uro O
##rad O
##iology O
department O
sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
francesca O
far O
##ave O
##lli O
md O
laboratory O
of O
human O
genetics O
gall O
##ier O
##a O
hospital O
gen O
##ova O
italy O
federico O
za O
##ra O
phd O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
carlo O
mine O
##tti O
md O
muscular O
and O
ne O
##uro O
##de O
##gen O
##erative O
disease O
unit O
institute O
g O
gas O
##lini O
gen O
##ova O
italy O
luc O
##io O
gi O
##ord O
##ano O
md O
pediatric O
ne O
##uro O
##psy O
##chia O
##tric O
division O

sped O
##ali O
ri O
##uni O
##ti O
br O
##es O
##cia O
italy O
references O
demi O
##rk O
##ira O
##n O
m O
jan O
##kovic O
j O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
clinical O
features O
and O
class O
##i O
##ﬁ O
##cation O
ann O
ne O
##uro O
##l O
1995 O
38 O
57 O
##1 O
57 O
##9 O
b O
##hat O
##ia O
k O
##p O
the O
par O
##ox O
##ys O
##mal O
d O
##ys O
##kin O
##es O
##ias O
j O
ne O
##uro O
##l O
1999 O
246 O
149 O
155 O
lee O
h O
##y O
xu O
y O
huang O
y O
et O
al O
the O
gene O
for O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
en O
##codes O
an O
enzyme O
in O
a O
stress O
response O
pathway O
hum O
mo O
##l O
gene O
##t O
2004 O
13 O
316 O
##1 O
317 O
##0 O
sul O
##s O
a O
de O
##dek O
##en O
p O
go O
##f O
##ﬁ O
##n O
k O
et O
al O
par O
##ox O
##ys O
##mal O
exercise O
##ind O
##uce O
##d O
d O
##ys O
##kin O
##es O
##ia O
and O
ep O
##ile O
##psy O
is O
due O
to O
mutations O
in O
sl O
##c O
##2 O
##a1 O
encoding O
the O
glucose O
transport O
##er O
g O
##lu O
##t O
##1 O
brain O
2008 O
131 O
1831 O
1844 O

ge O
##sch O
##wind O
dh O
log O
##ino O
##v O
m O
stern O
j O
##m O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
a O
locus O
on O
chromosome O
14 O
##q O
for O
id O
##io O
##pathic O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
fa O
##hr O
disease O
am O
j O
hum O
gene O
##t O
1999 O
65 O
76 O
##4 O
77 O
##7 O
harbor O
##d O
mg O
kobayashi O
j O
##s O
fever O
producing O
ball O
##ism O
##us O
in O
patients O
with O
cho O
##re O
##oat O
##het O
##osis O
j O
child O
ne O
##uro O
##l O
1991 O
6 O
49 O
52 O
stefano O
##va O
e O
dj O
##arm O
##ati O
a O
mom O
##ci O
##lovic O
d O
et O
al O
clinical O
characteristics O
of O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
in O
serbian O
family O
with O
my O
##o O
##ﬁ O
##bri O
##llo O
##genesis O
regulator O
1 O
gene O
mutation O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
2010 O
2015 O

michel O
##i O
f O
fernandez O
par O
##dal O
mm O
casa O
##s O
par O
##era O
i O
gia O
##nna O
##ula O
r O
sporadic O
par O
##ox O
##ys O
##mal O
d O
##yst O
##onic O
cho O
##re O
##oat O
##het O
##osis O
associated O
with O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
##s O
ann O
ne O
##uro O
##l O
1986 O
20 O
750 O
yamamoto O
k O
ka O
##wa O
##zawa O
s O
basal O
gang O
##lion O
cal O
##ci O
##ﬁ O
##cation O
in O
par O
##ox O
##ys O
##mal O
d O
##yst O
##onic O
cho O
##re O
##oat O
##het O
##osis O
ann O
ne O
##uro O
##l O
1987 O
22 O
55 O
##6 O
klein O
c O
vie O
##re O
##gg O
##e O
p O
ko O
##¨ O
##mp O
##f O
d O
par O
##ox O
##ys O
##mal O
cho O
##re O
##oat O
##het O
##osis O
in O
a O
patient O
with O
id O
##io O
##pathic O
basal O
gang O
##lia O
cal O
##ci O
##ﬁ O
##cation O
cho O
##rea O
and O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
1997 O
12 O
254 O
255 O

ale O
##md O
##ar O
m O
se O
##le O
##k O
a O
p O
e O
##fen O
##di O
h O
ko O
##ms O
##uo O
##gl O
##u O
ss O
fa O
##hr O
s O
disease O
presenting O
with O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
a O
case O
report O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2008 O
14 O
69 O
71 O
baba O
y O
bro O
##der O
##ick O
d O
##f O
ui O
##tti O
r O
##j O
hutton O
ml O
w O
##sz O
##ole O
##k O
z O
##k O
here O
##do O
##fa O
##mi O
##lia O
##l O
brain O
cal O
##cino O
##sis O
syndrome O
mayo O
cl O
##in O
pro O
##c O
2005 O
80 O
64 O
##1 O
65 O
##1 O
space O
##y O
sd O
adams O
p O
##j O
lam O
pc O
mater O
##ek O
la O
st O
##oes O
##sl O
aj O
s O
##nut O
##ch O
t O
##p O
hs O
##iu O
##ng O
g O
##y O
genetic O
het O
##ero O
##gen O
##eit O
##y O
in O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
ne O
##uro O
##logy O
2006 O
66 O
158 O
##8 O
159 O
##0 O

bruno O
mk O
lee O
h O
##y O
au O
##burg O
##er O
g O
##w O
et O
al O
gen O
##otype O
ph O
##eno O
##type O
correlation O
of O
par O
##ox O
##ys O
##mal O
non O
##kin O
##es O
##igen O
##ic O
d O
##ys O
##kin O
##es O
##ia O
ne O
##uro O
##logy O
2007 O
68 O
1782 O
1789 O
dramatic O
response O
of O
facial O
stereo O
##type O
ti O
##c O
to O
te O
##tra O
##ben O
##azi O
##ne O
in O
the O
first O
reported O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
the O
united O
states O
video O

ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
is O
a O
rare O
ne O
##uro O
##de O
##gen O
##erative O
disease O
associated O
with O
brain O
iron O
deposition O
caused O
by O
mutations O
in O
gene O
encoding O
the O
fe O
##rri O
##tin O
light O
poly O
##pe O
##pt O
##ide O
ft O
##l O
a O
460 O
##du O
##pa O
ft O
##l O
was O
ﬁ O
##rst O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
patients O
in O
northern O
england O
1 O
since O
then O
several O
different O
mutations O
of O
fl O
##t O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
japanese O
and O
french O
and O
french O
canadian O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
3 O
september O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
232 O
##9 O
##9 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##1 O
fig O
1 O
top O
row O
of O
mri O
##s O
various O
sequences O
of O
the O
father O
age O
74 O
and O
bottom O
role O
shows O
mri O
##s O
of O
son O
age O
49 O

dutch O
2 O
6 O
but O
the O
original O
mutation O
which O
accounts O
for O
the O
majority O
of O
documented O
cases O
has O
not O
been O
reported O
outside O
the O
united O
kingdom O
we O
report O
the O
ﬁ O
##rst O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
north O
america O
and O
the O
ﬁ O
##rst O
cases O
showing O
the O
460 O
##du O
##pa O
ft O
##l O
mutation O
originating O
from O
outside O
the O
united O
kingdom O
in O
an O
american O
family O
of O
german O
ancestry O
one O
patient O
presented O
with O
oral O
ti O
##cs O
stereo O
##ty O
##pies O
most O
ph O
##eno O
##typical O
##ly O
similar O
to O
those O
seen O
in O
front O
##ote O
##mp O
##ora O
##l O
dementia O
or O
tour O
##ette O
s O
these O
completely O
resolved O
with O
low O
dose O
te O
##tra O
##ben O
##azi O
##ne O
tb O
##z O
his O
father O
who O
demonstrated O
facial O
and O
app O
##end O
##icular O
cho O
##rea O
marked O
bulb O
##ar O
dysfunction O
ata O
##xia O
and O
dementia O
also O
improved O
with O
tb O
##z O

a O
49 O
year O
old O
right O
handed O
man O
presented O
with O
a O
2 O
year O

history O
of O
varied O
involuntary O
facial O
movements O
including O
as O
##ym O
##metric O
facial O
grim O
##acing O
symmetric O
lip O
pu O
##rs O
##ing O
tongue O
biting O
and O
teeth O
clicking O
parana O
##sal O
contraction O
##s O
touching O
his O
mouth O
with O
his O
hand O
and O
vocal O
##izations O
including O
throat O
clearing O
coughing O
and O
a O
t O
##z O
sound O
these O
were O
partially O
suppress O
##ible O
but O
there O
was O
no O
clear O
urge O
to O
move O
these O
movements O
worsened O
while O
on O
es O
##cit O
##alo O
##pr O
##am O
despite O
improvement O
of O
mood O
no O
other O
ex O
##ace O
##rba O
##ting O
or O
all O
##ev O
##iating O
factors O
were O
noted O
his O
other O
subjective O
complaints O
were O
of O
mild O
worse O
##ning O
of O
balance O
mild O
decreased O
dexter O
##ity O
manifest O
only O
while O
typing O
and O
general O
fatigue O
past O
medical O
and O
social O
histories O
were O
un O
##re O
##ve O
##aling O
the O
patient O
s O
father O
is O
affected O
and O
is O
presented O
below O
his O
paternal O
grandfather O
was O
diagnosed O
with O
huntington O
s O
disease O
and O
bulb O
##ar O
pal O
##sy O
and O
had O
cho O
##rea O
two O
of O
the O
grandfather O
s O
brothers O
were O
diagnosed O
with O
parkinson O
s O
disease O
but O
we O
have O
no O
actual O
clinical O
descriptions O

formal O
neurological O
examination O
was O
largely O
normal O
mm O
##se O
was O
29 O
30 O
cr O
##anial O
nerves O
were O
intact O
motor O
testing O
showed O
normal O
strength O
bulk O
and O
tone O
and O
a O
trace O
action O
tremor O
sensory O
ce O
##re O
##bella O
##r O
and O
ga O
##it O
examinations O
were O
normal O
re O
##ﬂ O
##ex O
##es O
were O
modest O
##ly O
depressed O
throughout O
the O
patient O
had O
frequent O
mouth O
touching O
right O
facial O
grim O
##acing O
and O
ﬁ O
##nger O
rubbing O
which O
was O
partially O
suppress O
##ible O
supporting O
information O
video O
segment O
1 O
patients O
provided O
informed O
consent O
for O
the O
videos O

fe O
##rri O
##tin O
was O
22 O
l O
##g O
ml O
and O
iron O
binding O
percentage O
was O
28 O
a O
lower O
than O
typical O
fe O
##rri O
##tin O
iron O
binding O
ratio O
thyroid O
test O
and O
electro O
##ly O
##tes O
were O
normal O
ac O
##ant O
##ho O
##cy O
##te O
sm O
##ear O
huntington O
s O
testing O
ce O
##ru O
##lo O
##pl O
##as O
##min O
and O
cho O
##re O
##in O
vp O
##s O
##13 O
##a O
testing O
were O
normal O
em O
##g O
nc O
##v O
was O
normal O
brain O
mri O
showed O
t O
##2 O
and O
flair O
lesions O
in O
the O
g O
##lo O
##bus O
pal O
##lid O
##us O
and O
to O
a O
lesser O
extent O
in O
the O
ce O
##re O
##bell O
##i O
fig O
1 O

the O
patient O
was O
placed O
on O
tb O
##z O
which O
was O
eventually O
maintained O
on O
37 O
5 O
mg O
day O
25 O
mg O
in O
a O
m O
and O
12 O
5 O
mg O
in O
p O
m O
resulting O
in O
complete O
ce O
##ssa O
##tion O
of O
the O
movements O
after O
6 O
months O
he O
reported O
some O
subjective O
worse O
##ning O
in O
balance O
without O
falls O
tb O
##z O
withdrawal O
did O
not O
alter O
the O
balance O
complaint O
but O
did O
result O
in O
rec O
##rud O
##escence O
of O
the O
same O
movements O
within O
24 O
hours O
the O
tb O
##z O
was O
reins O
##tituted O
at O
the O
same O
dose O
without O
any O
other O
adverse O
events O

the O
father O
of O
case O
1 O
ﬁ O
##rst O
appreciated O
involuntary O
movements O
of O
the O
hand O
around O
age O
50 O
upon O
presentation O
to O
us O
at O
age O
69 O
he O
had O
oral O
and O
app O
##end O
##icular O
movements O
a O
4 O
year O
history O
of O
progressive O
d O
##ys O
##arth O
##ria O
and O
d O
##ys O
##pha O
##gia O
marked O
si O
##alo O
##rr O
##hea O
a O
2 O
year O
history O
of O
ga O
##it O
and O
balance O
di O
##f O
##ﬁ O
##cu O
##lty O
with O
several O
falls O
and O
recent O
mild O
cognitive O
slowing O
examination O
showed O
a O
mm O
##se O
of O
29 O
30 O
cr O
##anial O
nerves O
showed O
gut O
##tura O
##l O
more O
than O
ling O
##ual O
or O
lab O
##ial O
d O
##ys O
##arth O
##ria O
and O
h O
##yp O
##omi O
##mia O
but O
were O
otherwise O
normal O
strength O
was O
normal O
but O
there O
were O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##2 O
letters O
to O
the O
editor O

some O
fa O
##sc O
##ic O
##ulation O
##s O
and O
distal O
at O
##rop O
##hy O
sensory O
examination O
showed O
decreased O
distal O
vibration O
and O
prop O
##rio O
##ception O
ga O
##it O
was O
modest O
##ly O
wide O
based O
and O
un O
##stead O
##y O
but O
not O
parkinson O
##ian O
re O
##ﬂ O
##ex O
##es O
were O
normal O
with O
down O
##going O
toes O
and O
positive O
frontal O
release O
signs O
the O
involuntary O
movements O
were O
complex O
and O
best O
described O
as O
a O
mix O
of O
stereo O
##type O
mouth O
and O
hands O
and O
cho O
##rea O
with O
oral O
movements O
most O
prominent O
supporting O
information O
video O
segment O
2 O
age O
74 O

over O
the O
next O
6 O
years O
the O
d O
##ys O
##pha O
##gia O
d O
##ys O
##arth O
##ria O
ga O
##it O
and O
cognition O
gradually O
progressed O
at O
age O
75 O
he O
was O
ana O
##rth O
##ric O
unable O
to O
vol O
##ition O
##ally O
move O
the O
tongue O
despite O
lack O
of O
peripheral O
involvement O
per O
em O
##g O
and O
wheelchair O
bound O
un O
##re O
##ve O
##aling O
evaluation O
##s O
were O
similar O
to O
case O
1 O
but O
also O
showed O
normal O
cs O
##f O
studies O
including O
a O
normal O
14 O
3 O
3 O
protein O
and O
a O
normal O
ata O
##xia O
panel O
including O
dent O
##ator O
##ub O
##ral O
pal O
##lid O
##ol O
##uy O
##sian O
at O
##rop O
##hy O
mri O
showed O
t O
##2 O
lesions O
throughout O
the O
st O
##ria O
##tum O
and O
g O
##lo O
##bus O
pal O
##lid O
##us O
fig O
1 O
tb O
##z O
did O
help O
the O
cho O
##rea O
and O
stereo O
##type O
but O
was O
poorly O
tolerated O
at O
higher O
doses O
due O
to O
se O
##dation O
and O
parkinson O
##ism O
tb O
##z O
withdrawal O
on O
several O
occasions O
resulted O
in O
increased O
movements O
he O
remains O
on O
25 O
mg O
day O
with O
continued O
ben O
##e O
##ﬁ O
##t O

we O
report O
the O
ﬁ O
##rst O
cases O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
the O
united O
states O
the O
mutation O
was O
identical O
to O
the O
original O
one O
which O
until O
now O
was O
isolated O
only O
in O
cases O
originating O
in O
the O
united O
kingdom O
the O
family O
denies O
any O
known O
ancestry O
from O
that O
area O
on O
examination O
the O
father O
appears O
to O
have O
a O
classic O
ph O
##eno O
##type O
of O
cho O
##rea O
prominently O
in O
the O
lower O
face O
with O
later O
onset O
of O
ga O
##it O
disorder O
and O
dementia O
however O
we O
feel O
that O
the O
ph O
##eno O
##men O
##ology O
of O
the O
son O
is O
best O
described O
as O
ti O
##cs O
or O
possibly O
stereo O
##type O
potentially O
expanding O
the O
ph O
##eno O
##type O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
he O
had O
a O
complete O
resolution O
of O
symptoms O
on O
tb O
##z O
whereas O
his O
father O
had O
fair O
control O
of O
the O
cho O
##rea O
movements O
but O
was O
limited O
by O
side O
effects O

legends O
to O
the O
video O
segment O
1 O
patient O
showing O
facial O
stereo O
##type O
ti O
##cs O
segment O
2 O
patient O
showing O
constant O
facial O
stereo O
##type O
diffuse O
slow O
cho O
##rea O
and O
mild O
ata O
##xia O
ac O
##k O
##now O
##led O
##gm O
##ents O
we O
would O
like O
to O
acknowledge O
the O
assistance O
of O
joseph O
m O
ferrara O
md O
for O
assistance O
with O
the O
mri O
ﬁ O
##gur O
##e O

financial O
disclosure O
##s O
dr O
on O
##do O
has O
received O
speaker O
fees O
from O
lund O
##beck O
all O
##er O
##gan O
ip O
##sen O
te O
##va O
and O
gs O
##k O
has O
received O
consulting O
fees O
from O
te O
##va O
mer O
##z O
and O
lund O
##beck O
and O
has O
received O
grant O
support O
from O
te O
##va O
ip O
##sen O
all O
##er O
##gan O
and O
bayer O
dr O
jan O
##kovic O
has O
received O
con O
##su O
##tl O
##ting O
fees O
from O
lund O
##beck O
research O
support O
from O
all O
##er O
##gan O
inc O
bo O
##eh O
##ring O
##er O
ing O
##eh O
##eim O
inc O
ce O
##re O
##gen O
##e O
inc O
chelsea O
therapeutic O
##s O
he O
##lis O
foundation O
huntington O
s O
disease O
society O
of O
america O
huntington O
study O
group O
imp O
##ax O
pharmaceuticals O
ip O
##sen O
ltd O
lund O
##beck O
inc O
med O
##tron O
##ic O
mer O
##z O
ph O
##arm O
##ce O
##uti O
##cal O
##s O
ni O
##h O
national O
parkinson O
foundation O
ne O
##uro O
##gen O
st O
jude O
medical O
te O
##va O
university O
of O
rochester O
and O
the O
parkinson O
study O
group O
has O
been O
consultant O
and O
or O
advisory O
committee O
me O
##me O
##ber O
for O
all O
##er O
##gan O
inc O
bio O
##va O
##il O
the O
michael O
j O
fox O
foundation O
for O
parkinson O
research O
mer O
##z O

william O
g O
on O
##do O
md O
department O
of O
ne O
##uro O
##logy O
baylor O
college O
of O
medicine O
houston O
texas O
usa O
e O
mail O
won O
##do O
bc O
##m O
t O
##mc O
ed O
##u O
oct O
##avian O
r O
adam O
md O
department O
of O
ne O
##uro O
##logy O
university O
of O
texas O
medical O
branch O
galveston O
texas O
usa O
joseph O
jan O
##kovic O
md O
department O
of O
ne O
##uro O
##logy O
baylor O
college O
of O
medicine O
houston O
texas O
usa O
patrick O
f O
chin O
##nery O
mb O
##bs O
phd O
fr O
##cp O
institute O
of O
human O
genetics O
newcastle O
university O
newcastle O
uk O
references O
curtis O
ar O
fey O
c O
morris O
cm O
et O
al O
mutation O
in O
the O
gene O
encoding O
fe O
##rri O
##tin O
light O
poly O
##pe O
##pt O
##ide O
causes O
dominant O
adult O
onset O
basal O
gang O
##lia O
disease O
nat O
gene O
##t O
2001 O
28 O
350 O
354 O

dev O
##os O
d O
tc O
##hof O
##o O
p O
##j O
vu O
##illa O
##ume O
i O
et O
al O
clinical O
features O
and O
natural O
history O
of O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
caused O
by O
the O
45 O
##8 O
##du O
##pa O
ft O
##l O
mutation O
brain O
2009 O
132 O
1 O
3 O
e O
##10 O
##9 O
oh O
##ta O
e O
naga O
##saka O
t O
shin O
##do O
k O
et O
al O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
in O
a O
japanese O
family O
with O
a O
du O
##plication O
in O
the O
fe O
##rri O
##tin O
light O
chain O
gene O
ne O
##uro O
##logy O
2008 O
70 O
part O
2 O
149 O
##3 O
149 O
##4 O
mac O
##iel O
p O
cruz O
vt O
constant O
##e O
m O
et O
al O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
miss O
##ense O
mutation O
in O
ft O
##l O
causing O
early O
onset O
bilateral O
pal O
##lid O
##al O
involvement O
ne O
##uro O
##logy O
2005 O
65 O
60 O
##3 O
60 O
##5 O
levi O
s O
co O
##zzi O
a O
ar O
##osi O
##o O
p O
ne O
##uro O
##fer O
##rit O
##ino O
##pathy O
a O
ne O
##uro O
##de O
##ge O

ne O
##rative O
disorder O
associated O
with O
l O
fe O
##rri O
##tin O
mutation O
best O
pr O
##act O
res O
cl O
##in O
ha O
##ema O
##to O
##l O
2005 O
18 O
265 O
276 O
man O
##cus O
##o O
m O
david O
##zon O
g O
ku O
##rl O
##an O
rm O
et O
al O
hereditary O
fe O
##rri O
##tino O
##pathy O
a O
novel O
mutation O
its O
cellular O
pathology O
and O
pathogen O
##etic O
insights O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2005 O
64 O
280 O
294 O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
associated O
with O
pol O
##g O
mutations O
video O
patients O
presenting O
with O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
remain O
a O
major O
diagnostic O
challenge O
due O
to O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
clinical O
class O
##i O
##ﬁ O
##cation O
and O
an O
increasing O
number O
of O
associated O
mono O
##gen O
##etic O
diseases O
1 O

mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
pol O
##g O
have O
been O
described O
to O
cause O
a O
broad O
variety O
of O
ph O
##eno O
##type O
##s O
2 O
but O
cho O
##rea O
d O
##yst O
##onia O
and O
my O
##oc O
##lon O
##us O
have O
only O
pharmaceuticals O
lund O
##beck O
inc O
and O
te O
##va O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
author O
roles O
dr O
on O
##do O
inception O
data O
collection O
draft O
ing O
and O
reviewing O
of O
the O
article O
dr O
adam O
critical O
review O
dr O
jan O
##kovic O
critical O
review O
dr O
chin O
##nery O
data O
collection O
analysis O
and O
critical O
review O
version O
of O
this O
article O
potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O

published O
online O
3 O
september O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
233 O
##0 O
##7 O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##3 O

fig O
1 O
pe O
##di O
##gree O
and O
characteristic O
mri O
ﬁ O
##nding O
##s O
in O
two O
patients O
with O
a O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
pol O
##g O
mutation O
two O
affected O
sicilian O
siblings O
of O
con O
##san O
##gui O
##neo O
##us O
parents O
a O
were O
investigated O
by O
magnetic O
resonance O
imaging O
mr O
t O
##2 O
weighted O
images O
in O
patient O
1 O
b O
e O
reveal O
an O
enlarged O
ce O
##re O
##bella O
##r O
primary O
ﬁ O
##ss O
##ure O
b O
beginning O
bilateral O
hyper O
##int O
##ense O
lesions O
in O
the O
ce O
##re O
##bella O
##r O
white O
matter O
c O
and O
the O
tha O
##lam O
##us O
e O
the O
brain O
stem O
and O
po O
##ns O
appeared O
normal O
in O
patient O
1 O
d O
t O
##2 O
weighted O
images O
in O
patient O
2 O
f O
i O
show O
ce O
##re O
##bella O
##r O
and O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
at O
##rop O
##hy O
f O
and O
like O
in O
patient O
1 O
and O
similar O
to O
other O
pol O
##g O
patients O
5 O
symmetric O
hyper O
##int O
##ense O
lesions O
in O
the O
ce O
##re O
##bella O
##r O
white O
matter O
g O
and O
the O
tha O
##lam O
##us O
i O
and O
additionally O
in O
the O
po O
##ns O
h O
magnetic O
resonance O
spectroscopy O
of O
the O
ce O
##re O
##bella O
##r O
white O
matter O
lesions O
revealed O
normal O
levels O
of O
cho O
##line O
and O
cr O
##ea O
##tine O
but O
reduced O
levels O
of O
n O
ace O
##ty O
##l O
as O
##par O
##tate O
indicating O
chronic O
ne O
##uron O
##al O
loss O
not O
shown O

been O
mentioned O
as O
parts O
of O
a O
pl O
##eth O
##ora O
of O
pol O
##g O
associated O
symptoms O
2 O
3 O
not O
as O
the O
only O
presenting O
sy O
##mpt O
##om O
here O
we O
report O
on O
two O
siblings O
from O
a O
con O
##san O
##gui O
##neo O
##us O
sicilian O
family O
with O
a O
homo O
##zy O
##go O
##us O
pol O
##g O
mutation O
the O
index B-PATIENT
patient I-PATIENT
presented O
with O
a O
complex O
hyper B-HPO_TERM
##kin I-HPO_TERM
##etic I-HPO_TERM
movement I-HPO_TERM
disorder I-HPO_TERM
as O
initial O
sy O
##mpt O
##om O
whereas O
other O
common O
pol O
##g O
associated O
symptoms O
did O
not O
evolve O
until O
three O
years O
later O

the O
index O
patient O
patient B-PATIENT
1 I-PATIENT
underwent O
un O
##com O
##pl O
##icated O
surgery O
of O
a O
right O
sided O
carp B-HPO_TERM
##al I-HPO_TERM
tunnel I-HPO_TERM
syndrome I-HPO_TERM
at O
32 B-AGE_ONSET
years O
of O
age O
two O
weeks O
later O
she O
developed O
complex B-HPO_TERM
regional I-HPO_TERM
pain I-HPO_TERM
syndrome I-HPO_TERM
of O
the O
operated O
limb O
with O
severe B-HPO_TERM
pain I-HPO_TERM
and O
all B-HPO_TERM
##od I-HPO_TERM
##yn I-HPO_TERM
##ia I-HPO_TERM
another O
two O
weeks O
later O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
post I-HPO_TERM
##uring I-HPO_TERM
of O
the O
right O
hand O
with O
rapid O
jerk O
##y O
wrist O
and O
ﬁ O
##nger O
movements O
manifested O
these O
jerk O
##s O
consisted O
of O
a O
complex O
mixture O
of O
ph O
##asi O
##c O
d O
##yst O
##onic O
wrist O
ﬂ O
##ex O
##ions O
and O
small O
amplitude O
ﬁ O
##nger O
movements O
poly B-HPO_TERM
##mini I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
in O
addition O
continuous O
jerk O
##y O
movements O
of O
her O
feet O
at O
rest O
were O
observed O
supporting O
information O
video O
segment O
1 O
which O
were O
presumably O
pre O
##ex O
##ist O
##ing O
but O
un O
##re O
##co O
##gni O
##zed O
by O
the O
patient O
herself O
these O
movements O
were O
un O
##pa O
##tter O
##ned O
and O
similar O
to O
limb O
movements O
seen O
in O
patients O
with O
benign O
hereditary O
cho O
##rea O
1 O
4 O
ee O
##g O
and O
sep O
recordings O
showed O
no O
co O
##rti O
##cal O
co O
##rre O
##lates O
of O
the O
limb O
jerk O
##s O
but O
tempo O
##ro O
par O
##ie O
##tal O
focal O
slowing O
and O
intermittent O
temporal O
sharp O
slow O
waves O
as O
the O
forceful O
wrist O
and O
ﬁ O
##nger O
movements O
triggered O
pain O
attacks O
injection O
##s O
to O
wrist O
and O
ﬁ O
##nger O
ex O
##tens O
##ors O
and O
ﬂ O
##ex O
##ors O
were O
given O
with O
a O
total O
dose O
of O
800 O
u O
bot O
##ulin O
##um O
ne O
##uro O
##to O
##xin O
a O
bon O
##ta O
d O
##ys O
##port O
ip O
##sen O
ph O
##arm O
##a O

injection O
##s O
dramatically O
reduced O
movement B-HPO_TERM
induced I-HPO_TERM
pain I-HPO_TERM
attacks O
and O
were O
repeated O
every O
3 O
month O
since O
then O
supporting O
information O
video O
segment O
2 O
severe B-HPO_TERM
depression I-HPO_TERM
with O
rec B-HPO_TERM
##urrent I-HPO_TERM
anxiety I-HPO_TERM
attacks I-HPO_TERM
necessitated O
admission O
to O
the O
local O
psychiatric O
hospital O
secondary B-HPO_TERM
generalized I-HPO_TERM
seizures I-HPO_TERM
and O
premature B-HPO_TERM
am I-HPO_TERM
##eno I-HPO_TERM
##rr I-HPO_TERM
##hoe I-HPO_TERM
##a I-HPO_TERM
started O
at O
the O
age O
of O
33 O
years O
comprehensive O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
revealed O
below B-HPO_TERM
average I-HPO_TERM
cognitive I-HPO_TERM
capacities O
at O
the O
age O
of O
35 O
years O
she O
started O
to O
develop O
sensory B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
mild O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
subtle O
ga B-HPO_TERM
##it I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
yet O
without O
leading O
to O
inca O
##pac O
##itation O
##s O
in O
daily O
life O
supporting O
information O
video O
segment O
3 O
for O
mri O
images O
see O
fig O
1 O

patient B-PATIENT
2 I-PATIENT
the O
index O
patient O
s O
sister O
manifested O
with O
slowly O
progressive B-HPO_TERM
cognitive I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
##s I-HPO_TERM
during O
primary B-AGE_ONSET
school I-AGE_ONSET
leading O
to O
severe B-HPO_TERM
cognitive I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
##s I-HPO_TERM
at O
the O
age O
of O
40 O
at O
age O
13 O
years O
ep B-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
seizures I-HPO_TERM
rec B-HPO_TERM
##urrent I-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
and O
mild O
personality B-HPO_TERM
changes I-HPO_TERM
started O
the O
movement B-HPO_TERM
disorder I-HPO_TERM
was O
similar O
to O
her O
sister O
s O
action B-HPO_TERM
triggered I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
started O
at O
the O
left O
arm O
at O
age O
14 O
years O
and O
generalized O
afterwards O
whereas O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
hand O
with O
ﬂ O
##ex O
##ion O
of O
the O
ﬁ O
##nger O
##s O
iii O
v O
was O
ﬁ O
##rst O
noticed O
at O
age O
20 O
years O
since O
then O
she O
also O
developed O
progressive B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
became O
wheel B-HPO_TERM
chair I-HPO_TERM
bound I-HPO_TERM
at O
the O
age O
of O
31 O
at O
the O
last O
examination O
age O
40 O
years O
incomplete O
chronic B-HPO_TERM
progressive I-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
pe O
##o O
supporting O
information O
video O
segment O
5 O
and O
severe B-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
sensor I-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
were O
detected O
as O
her O
ph O
##eno O
##type O
suggested O
mitochondrial B-HPO_TERM
recess I-HPO_TERM
##ive I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
syndrome I-HPO_TERM
mira O
##s O
6 O

movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##4 O
letters O
to O
the O
editor O
genetic O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
was O
initiated O
revealing O
a O
homo O
##zy O
##go O
##us O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
in O
both O
patients O
gen O
##ot O
##yp O
##ing O
of O
intra O
##genic O
single O
nu O
##cle O
##otide O
poly O
##morphism O
s O
##np O
##s O
rs O
##20 O
##7 O
##22 O
##6 O
##7 O
rs O
##23 O
##0 O
##7 O
##43 O
##3 O
rs O
##22 O
##46 O
##90 O
##0 O
rs O
##23 O
##0 O
##20 O
##8 O
##4 O
and O
rs O
##23 O
##0 O
##7 O
##43 O
##8 O
showed O
a O
homo O
##zy O
##go O
##us O
c O
insertion O
g O
c O
g O
ha O
##pl O
##otype O
which O
is O
identical O
to O
the O
ha O
##pl O
##otype O
common O
in O
north O
european O
w O
##7 O
##48 O
##s O
mutation O
carriers O
##6 O
and O
thus O
suggests O
a O
relation O
between O
an O
ancient O
founder O
from O
north O
europe O
and O
these O
sicilian O
patients O

our O
ﬁ O
##nding O
##s O
demonstrate O
that O
pol O
##g O
mutations O
should O
be O
considered O
in O
the O
work O
##up O
of O
progressive O
complex O
hyper O
##kin O
##etic O
movement O
disorders O
as O
of O
yet O
hyper O
##kin O
##etic O
movements O
like O
my O
##oc O
##lon O
##us O
and O
cho O
##rea O
have O
been O
mentioned O
in O
pol O
##g O
patients O
mainly O
as O
part O
of O
a O
pl O
##eth O
##ora O
of O
pol O
##g O
associated O
symptoms O
2 O
3 O
as O
shown O
in O
patient B-PATIENT
1 I-PATIENT
complex O
hyper B-HPO_TERM
##kin I-HPO_TERM
##etic I-HPO_TERM
movements I-HPO_TERM
presenting O
with O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
d B-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
and O
possibly O
also O
cho B-HPO_TERM
##re I-HPO_TERM
##ic I-HPO_TERM
elements O
may O
be O
the O
only O
feature O
seen O
for O
several O
years O
this O
ﬁ O
##nding O
moreover O
demonstrates O
that O
not O
only O
apr O
##ax O
##ia O
of O
eye O
lid O
opening O
##7 O
and O
d O
##yst O
##onic O
toe O
curling O
8 O
but O
also O
upper O
limb O
d O
##yst O
##onia O
is O
part O
of O
the O
spectrum O
of O
pol O
##g O
associated O
d O
##yst O
##onia O

interesting O
##ly O
the O
disease O
course O
in O
patient O
1 O
shows O
that O
ce O
##re O
##bella O
##r O
ata O
##xia O
sensory O
ne O
##uro O
##pathy O
and O
or O
pe O
##o O
are O
not O
necessarily O
presenting O
or O
early O
features O
of O
auto O
##som O
##al O
recess O
##ive O
pol O
##g O
ar O
pol O
##g O
mutations O
a O
family O
history O
with O
con O
##san O
##gui O
##neo O
##us O
marriage O
and O
or O
recess O
##ive O
inheritance O
like O
in O
our O
pe O
##di O
##gree O
or O
pol O
##g O
characteristic O
features O
in O
the O
disease O
course O
like O
in O
patient O
1 O
may O
support O
the O
decision O
for O
pol O
##g O
sequencing O
in O
und O
##ia O
##gno O
##sed O
patients O
with O
hyper O
##kin O
##etic O
movement O
disorders O
legends O
to O
the O
video O
patient O
1 O

segment O
1 O
at O
the O
age O
of O
33 O
years O
patient B-PATIENT
1 I-PATIENT
showed O
d B-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
of O
both O
arms O
with O
predominant O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
right O
upper O
limb O
with O
jerk B-HPO_TERM
##y I-HPO_TERM
wrist I-HPO_TERM
and I-HPO_TERM
ﬁ I-HPO_TERM
##nger I-HPO_TERM
movements O
which O
had O
started O
four O
weeks O
after O
carp O
##al O
tunnel O
surgery O
induced O
cr O
##ps O
distal O
ﬁ O
##nger O
movements O
have O
smaller O
amplitude O
##s O
characteristic O
of O
poly B-HPO_TERM
##mini I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
also O
her O
feet O
show O
un O
##pa O
##tter O
##end O
jerk O
##y O
movements O
which O
may O
be O
class O
##i O
##ﬁ O
##ed O
as O
my O
##oc O
##lon O
##us O
but O
are O
also O
similar O
to O
limb O
movements O
in O
benign O
hereditary O
cho O
##rea O
1 O
4 O

segment O
2 O
bot O
##ulin O
##um O
toxin O
treatment O
of O
ex O
##tens O
##or O
and O
ﬂ O
##ex O
##or O
muscles O
of O
the O
right O
forearm O
markedly O
reduced O
hyper O
##kin O
##etic O
movements O
the O
main O
therapeutic O
goal O
remained O
pain O
reduction O
apart O
from O
the O
bot O
##ulin O
##um O
toxin O
effect O
also O
intermittent O
mirror O
movements O
can O
be O
observed O
in O
this O
segment O
segment O
3 O
at O
the O
age O
of O
35 O
years O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
slowing O
of O
voluntary O
sac O
##cade O
##s O
and O
ga O
##it O
ata O
##xia O
started O
also O
a O
reduced O
arm O
swing O
on O
the O
right O
side O
was O
ﬁ O
##rst O
noticed O
patient O
2 O

segment O
4 O
at O
the O
age O
of O
40 O
years O
patient B-PATIENT
2 I-PATIENT
displayed O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
ul I-HPO_TERM
##nar I-HPO_TERM
deviation I-HPO_TERM
of O
the O
left O
upper O
limb O
with O
distal O
pre O
##dom O
##ina O
##nce O
she O
showed O
intermittent B-HPO_TERM
facial I-HPO_TERM
and I-HPO_TERM
jaw I-HPO_TERM
opening I-HPO_TERM
d I-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
at O
rest O
she O
had O
marked O
post B-HPO_TERM
##ural I-HPO_TERM
instability I-HPO_TERM
caused O
by O
trunk B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
which O
is O
aggravated O
by O
motor O
actions O
like O
e O
g O
lifting O
the O
upper O
limbs O
segment O
5 O
in O
patient O
2 O
severe B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
incomplete O
horizontal B-HPO_TERM
and I-HPO_TERM
vertical I-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
ata B-HPO_TERM
##xia I-HPO_TERM
were O
observed O
as O
clinical O
features O
of O
mira O
##s O
patient O
2 O
was O
only O
able O
to O
stand B-HPO_TERM
assisted I-HPO_TERM
for O
a O
few O
seconds O

author O
roles O
syn O
##of O
##zi O
##k O
was O
involved O
in O
the O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O
sc O
##hu O
##¨ O
##le O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
sc O
##hul O
##te O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
lin O
##di O
##g O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
k O
##ru O
##¨ O
##ger O
was O
involved O
in O
the O
research O
project O
execution O
manuscript O
review O
and O
critique O
sc O
##ho O
##¨ O
##ls O
was O
involved O
in O
the O
research O
project O
organization O
manuscript O
review O
and O
critique O
as O
##mus O
was O
involved O
in O
the O
research O
project O
conception O
organization O
execution O
manuscript O
writing O
of O
the O
ﬁ O
##rst O
draft O

financial O
disclosure O
##s O
dr O
syn O
##of O
##zi O
##k O
received O
a O
research O
grant O
by O
the O
volkswagen O
foundation O
european O
platform O
project O
and O
a O
travel O
grant O
by O
act O
##eli O
##on O
pharmaceuticals O
dr O
k O
##ru O
##¨ O
##ger O
received O
research O
grants O
of O
the O
german O
research O
council O
d O
##f O
##g O
k O
##r O
##21 O
##19 O
3 O
1 O
and O
the O
federal O
ministry O
for O
education O
and O
research O
b O
##mb O
##f O
ng O
##f O
##np O
##lus O
01 O
##gs O
##0 O
##8 O
##13 O
##4 O
as O
well O
as O
speakers O
honor O
##aria O
and O
travel O
grants O
from O
uc O
##b O
ph O
##arm O
##a O
sol O
##va O
##y O
ph O
##arm O
##a O
and O
med O
##tron O
##ic O
dr O
lin O
##di O
##g O
has O
received O
travel O
grants O
from O
ip O
##sen O
ph O
##arm O
##a O
all O
##er O
##gan O
and O
mer O
##z O
pharmaceuticals O
dr O
sc O
##ho O
##¨ O
##ls O
served O
as O
an O
editorial O
board O
member O
of O
movement O
disorders O
and O
was O
a O
member O
of O
the O
sci O
##ent O
##i O
##ﬁ O
##c O
advisory O
board O
for O
take O
##da O
ph O
##arm O
##a O
as O
participant O
of O
the O
mic O
##ono O
##s O
trial O
dr O
sc O
##ho O
##¨ O
##ls O
received O
fees O
from O
sant O
##her O
##a O
pharmaceuticals O
dr O
sc O
##ho O
##¨ O
##ls O
received O
research O
grants O
of O
the O
deutsche O
for O
##sch O
##ung O
##sg O
##eme O
##ins O
##chaft O
sc O
##ho O
##75 O
##4 O
3 O
1 O
and O
sc O
##ho O
##75 O
##4 O
4 O
1 O
grants O
of O
the O
german O
research O
council O
b O
##mb O
##f O
to O
le O
##uk O
##one O
##t O
01 O
##gm O
##0 O
##64 O
##4 O
gene O
##mo O
##ve O
01 O
##gm O
##0 O
##60 O
##3 O
and O
mit O
##one O
##t O
01 O
##gm O
##0 O
##86 O
##4 O
funding O
from O
the O
eu O
for O
euros O
##ca O
l O
##sh O
##m O
ct O
2004 O
50 O
##33 O
##0 O
##4 O
and O
e O
rare O
grants O
to O
euros O
##pa O
01 O
##gm O
##0 O
##80 O
##7 O
and O
ri O
##sca O
01 O
##gm O
##0 O
##8 O
##20 O
as O
well O
as O
a O

grant O
of O
the O
volkswagen O
foundation O
i O
80 O
##7 O
##11 O
he O
further O
received O
funding O
from O
the O
hs O
##p O
se O
##lb O
##st O
##hil O
##fe O
##gr O
##uppe O
deutschland O
ev O
dr O
as O
##mus O
has O
received O
speakers O
honor O
##aria O
and O
travel O
grants O
from O
ip O
##sen O
ph O
##arm O
##a O
all O
##er O
##gan O
and O
mer O
##z O
pharmaceuticals O
ac O
##k O
##now O
##led O
##gm O
##ents O
l O
##s O
was O
supported O
by O
a O
grant O
from O
the O
german O
ministry O
for O
education O
and O
research O
b O
##mb O
##f O
to O
mit O
##one O
##t O
01 O
##gm O
##0 O
##86 O
##4 O
fa O
and O
ms O
were O
supported O
by O
grants O
of O
the O
german O
center O
for O
ne O
##uro O
##den O
##erative O
diseases O
d O
##z O
##ne O
matt O
##his O
syn O
##of O
##zi O
##k O
md O
rebecca O
sc O
##hu O
##¨ O
##le O
md O
claudia O
sc O
##hul O
##te O
phd O
re O
##jk O
##o O
k O
##ru O
##¨ O
##ger O
md O
tobias O
lin O
##di O
##g O
md O
lu O
##dge O
##r O
sc O
##ho O
##¨ O
##ls O
md O

department O
of O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
her O
##tie O
institute O
for O
clinical O
brain O
research O
german O
research O
center O
for O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
friedrich O
as O
##mus O
md O
department O
of O
general O
ne O
##uro O
##logy O
her O
##tie O
institute O
for O
clinical O
brain O
research O
german O
research O
center O
for O
ne O
##uro O
##de O
##gen O
##erative O
diseases O
university O
of O
tu O
##eb O
##ingen O
tu O
##eb O
##ingen O
germany O
e O
mail O
friedrich O
as O
##mus O
d O
##yst O
##onia O
genetics O
com O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
letters O
to O
the O
editor O
247 O
##5 O
references O

as O
##mus O
f O
lang O
##set O
##h O
a O
doherty O
e O
et O
al O
jerk O
##y O
d O
##yst O
##onia O
in O
children O
spectrum O
of O
ph O
##eno O
##type O
##s O
and O
genetic O
testing O
mo O
##v O
di O
##sor O
##d O
2009 O
24 O
70 O
##2 O
70 O
##9 O
b O
##lok O
m O
##j O
van O
den O
bosch O
b O
##j O
jong O
##en O
e O
et O
al O
the O
un O
##folding O
clinical O
spectrum O
of O
pol O
##g O
mutations O
j O
med O
gene O
##t O
2009 O
46 O
77 O
##6 O
78 O
##5 O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
part O
7 O
1685 O
1692 O
sc O
##hra O
##g O
a O
quinn O
np O
b O
##hat O
##ia O
k O
##p O
marsden O
cd O
benign O
hereditary O
cho O
##rea O
entity O
or O
syndrome O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
280 O
288 O

eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
et O
al O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
2008 O
131 O
part O
3 O
81 O
##8 O
82 O
##8 O
ha O
##kon O
##en O
ah O
david O
##zon O
g O
salem O
##i O
r O
et O
al O
abundance O
of O
the O
pol O
##g O
disease O
mutations O
in O
europe O
australia O
new O
zealand O
and O
the O
united O
states O
explained O
by O
single O
ancient O
european O
founders O
eu O
##r O
j O
hum O
gene O
##t O
2007 O
15 O
77 O
##9 O
78 O
##3 O
pau O
##s O
s O
z O
##sur O
##ka O
g O
baron O
m O
et O
al O
apr O
##ax O
##ia O
of O
lid O
opening O
mimic O
##king O
pt O
##osis O
in O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
##1 O
mutations O
mo O
##v O
di O
##sor O
##d O
2008 O
23 O
128 O
##6 O
128 O
##8 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
with O
ari O
##pi O
##pr O
##az O
##ole O
in O
huntington O
s O
disease O

the O
at O
##yp O
##ical O
anti O
##psy O
##cho O
##tic O
drug O
ari O
##pi O
##pr O
##az O
##ole O
is O
a O
partial O
do O
##pa O
##mine O
d O
##2 O
and O
ser O
##oton O
##in O
5 O
h O
##t O
##1 O
##a O
receptor O
ago O
##nist O
and O
an O
antagonist O
at O
ser O
##oton O
##in O
5 O
h O
##t O
##2 O
##a O
receptors O
it O
is O
a O
promising O
agent O
for O
patients O
with O
schizophrenia O
but O
also O
for O
those O
with O
huntington O
s O
disease O
hd O
who O
may O
suffer O
from O
psycho O
##sis O
aggression O
cognitive O
decline O
and O
movement O
disorder O
recent O
reports O
##1 O
2 O
and O
clinical O
observations O
suggest O
that O
ari O
##pi O
##pr O
##az O
##ole O
improves O
cho O
##rea O
and O
functional O
disability O
with O
an O
effect O
comparable O
with O
te O
##tra O
##ben O
##azi O
##ne O
but O
with O
less O
se O
##dation O
and O
better O
to O
##ler O
##ability O
thus O
ari O
##pi O
##pr O
##az O
##ole O
may O
be O
an O
attractive O
treatment O
option O
in O
hd O
in O
particular O
for O
patients O
with O
psycho O
##sis O
and O
cho O
##rea O
or O
those O
not O
responding O
to O
other O
cho O
##rea O
treatments O
in O
schizophrenia O
however O
ari O
##pi O
##pr O
##az O
##ole O
was O
associated O
with O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
nm O
##s O
3 O
4 O
patients O
with O
hd O
may O
have O
an O
increased O
risk O
for O
developing O
nm O
##s O
although O
the O
occurrence O
of O
nm O
##s O
in O
hd O
is O
rarely O
reported O
5 O
here O
we O
present O
a O
case O
of O
mn O
##s O
in O
a O
hd O
patient O
treated O
with O
ari O
##pi O
##pr O
##az O
##ole O

the O
patient O
a O
55 O
year O
old O
retired O
engineering O
technician O
presented O
with O
increasingly O
severe O
behavioral O
disorders O
including O
ir O
##rita O
##bility O
and O
violent O
behavior O
une O
##qui O
##vo O
##cal O
motor O
signs O
of O
hd O
cho O
##rea O
had O
been O
observed O
for O
the O
ﬁ O
##rst O
time O
10 O
years O
before O
the O
father O
and O
brother O
of O
the O
patients O
had O
died O
of O
hd O
the O
clinical O
diagnosis O
of O
hd O
was O
con O
##ﬁ O
##rmed O
with O
molecular O
genetic O
testing O
ca O
##g O
repeat O
expansion O
with O
43 O
triple O
##ts O
an O
mri O
scan O
of O
the O
brain O
at O
the O
time O
of O
diagnosis O
showed O
normal O
cerebral O
morphology O
recent O
mri O
scans O
revealed O
hd O
typical O
morphological O
alterations O
symmetric O
at O
##rop O
##hy O
of O
the O
st O
##ria O
##tum O
and O
widening O
of O
the O
lateral O
vent O
##ric O
##les O
subsequently O
the O
patient O
developed O
severe O
cho O
##rea O
of O
arms O
and O
legs O
head O
and O
trunk O
together O
with O
moderate O
cognitive O

potential O
con O
##ﬂ O
##ic O
##t O
of O
interest O
nothing O
to O
report O
published O
online O
28 O
july O
2010 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
233 O
##32 O
impairment O
he O
lost O
25 O
kg O
of O
weight O
because O
of O
cho O
##rea O
##ind O
##uce O
##d O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
with O
eating O
on O
admission O
he O
presented O
with O
severe O
d O
##ys O
##arth O
##ria O
generalized O
cho O
##rea O
slowing O
of O
sac O
##ca O
##dic O
eye O
movements O
severely O
un O
##stead O
##y O
ga O
##it O
and O
post O
##ural O
instability O
cognitive O
de O
##ﬁ O
##cit O
##s O
comprised O
several O
domains O
including O
attention O
memory O
and O
executive O
functions O

initially O
the O
patient O
had O
been O
treated O
for O
cho O
##rea O
with O
per O
##ph O
##ena O
##zine O
and O
tia O
##pr O
##ide O
because O
of O
increasingly O
aggressive O
behavior O
ri O
##sper O
##idon O
##e O
was O
initiated O
and O
considered O
effective O
over O
4 O
years O
ser O
##tral O
##ine O
was O
added O
to O
treat O
de O
##pressive O
symptoms O
upon O
admission O
the O
patient O
was O
treated O
with O
ri O
##sper O
##idon O
##e O
3 O
mg O
d O
ser O
##tral O
##ine O
50 O
mg O
d O
and O
tia O
##pr O
##ide O
700 O
mg O
d O
trim O
##ip O
##ram O
##ine O
50 O
mg O
and O
mel O
##per O
##one O
50 O
mg O
had O
been O
tried O
unsuccessfully O
to O
am O
##eli O
##ora O
##te O
ins O
##om O
##nia O
we O
considered O
a O
connection O
between O
ri O
##sper O
##idon O
##e O
and O
aggravated O
agitation O
and O
restless O
##ness O
in O
terms O
of O
an O
extra O
##py O
##ram O
##idal O
side O
effect O
withdrawing O
ri O
##sper O
##idon O
##e O
we O
added O
ari O
##pi O
##pr O
##az O
##ole O
10 O
mg O
to O
tia O
##pr O
##ide O
and O
mel O
##per O
##one O
to O
treat O
the O
patient O
s O
aggressive O
behavior O
because O
ari O
##pi O
##pr O
##az O
##ole O
is O
known O
to O
reduce O
aggressive O
symptoms O
in O
other O
psychiatric O
disorders O
6 O
within O
2 O
days O
the O
patient O
attracted O
attention O
because O
of O
ap O
##athy O
muscular O
rigid O
##ity O
and O
fever O
together O
with O
ta O
##chy O
##card O
##ia O
and O
ta O
##chy O
##p O
##nea O
peak O
cr O
##ea O
##tine O
kinase O
levels O
were O
339 O
##80 O
u O
l O
le O
##uc O
##oc O
##yt O
##osis O
reached O
levels O
of O

19 O
5 O
g O
l O
upon O
immediate O
withdrawal O
of O
all O
do O
##pa O
##mine O
antagonist O
##s O
tia O
##pr O
##ide O
mel O
##per O
##one O
ari O
##pi O
##pr O
##az O
##ole O
parent O
##eral O
hydra O
##tion O
and O
treatment O
with O
di O
##ure O
##tics O
clinical O
symptoms O
and O
laboratory O
abnormalities O
resolved O
within O
2 O
weeks O
because O
of O
rec O
##urrent O
symptoms O
of O
cho O
##rea O
ir O
##rita O
##bility O
and O
disturbed O
sleep O
we O
initiated O
te O
##tra O
##ben O
##azi O
##ne O
up O
to O
112 O
5 O
mg O
and O
que O
##tia O
##pine O
50 O
mg O
together O
with O
ser O
##tral O
##ine O
150 O
mg O
and O
mir O
##ta O
##za O
##pine O
45 O
mg O
resulting O
in O
adequate O
sy O
##mpt O
##om O
control O
without O
rec O
##ur O
##rence O
of O
nm O
##s O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
ﬁ O
##rst O
report O
of O
nm O
##s O
in O
hd O
with O
ari O
##pi O
##pr O
##az O
##ole O
treatment O
the O
application O
of O
conventional O
clinical O
doses O
of O
ari O
##pi O
##pr O
##az O
##ole O
such O
as O
in O
our O
case O
leads O
to O
a O
nearly O
complete O
sat O
##uration O
of O
d O
##2 O
like O
do O
##pa O
##mine O
receptors O
7 O
high O
do O
##pa O
##mine O
d O
##2 O
receptor O
af O
##ﬁ O
##nity O
has O
been O
suggested O
as O
one O
of O
the O
bases O
of O
nm O
##s O
particularly O
of O
note O
when O
adding O
ari O
##pi O
##pr O
##az O
##ole O
to O
other O
do O
##pa O
##mine O
receptor O
antagonist O
##s O
##3 O
as O
in O
our O
case O
blocking O
st O
##ria O
##tal O
and O
h O
##yp O
##oth O
##ala O
##mic O
do O
##pa O
##mine O
transmission O
may O
have O
contributed O
to O
muscular O
rigid O
##ity O
and O
dysfunction O
##al O
the O
##rm O
##ore O
##gul O
##ation O
7 O
although O
a O
poly O
##pha O
##rma O
##col O
##og O
##ic O
cause O
of O
nm O
##s O
has O
to O
be O
considered O
in O
our O
patient O
the O
proportional O
##ly O
low O
af O
##ﬁ O
##nity O
of O
tia O
##pr O
##ide O
and O
mel O
##per O
##one O
to O
d O
##2 O
like O
do O
##pa O
##mine O
receptors O
suggests O
that O
ari O
##pi O
##pr O
##az O
##ole O
may O
have O
been O
the O
main O
cu O
##lp O
##rit O
in O
conclusion O
when O
using O
ari O
##pi O
##pr O
##az O
##ole O
in O
hd O
one O
needs O
to O
be O
aware O
of O
the O
risk O
for O
nm O
##s O
in O
particular O
if O
patients O
take O
other O
do O
##pa O
##mine O
receptor O
antagonist O
##s O

author O
roles O
b O
able O
##r O
was O
involved O
in O
clinical O
management O
of O
the O
patient O
including O
diagnostic O
##s O
and O
treatment O
and O
review O
and O
critique O
of O
the O
manuscript O
m O
ga O
##hr O
was O
involved O
in O
writing O
of O
the O
ﬁ O
##rst O
draft O
of O
the O
manuscript O
m O
or O
##th O
was O
involved O
in O
review O
and O
critique O
of O
the O
manuscript O
maximilian O
ga O
##hr O
phd O
department O
of O
psychiatry O
university O
of O
ul O
##m O
lei O
##mg O
##ru O
##ben O
##we O
##g O
12 O
14 O
ul O
##m O
89 O
##0 O
##75 O
germany O
e O
mail O
maximilian O
ga O
##hr O
un O
##i O
ul O
##m O
de O
movement O
disorders O
vol O
25 O
no O
14 O
2010 O
247 O
##6 O
letters O
to O
the O
editor O
michael O
or O
##th O
phd O
department O
of O
ne O
##uro O
##logy O
university O
of O
ul O
##m O
lei O
##mg O
##ru O
##ben O
##we O
##g O
12 O
14 O
ul O
##m O
89 O
##0 O
##75 O
germany O

bi O
##rg O
##it O
able O
##r O
phd O
department O
of O
psychiatry O
university O
of O
ul O
##m O
lei O
##mg O
##ru O
##ben O
##we O
##g O
12 O
14 O
ul O
##m O
89 O
##0 O
##75 O
germany O
references O
br O
##usa O
l O
or O
##la O
##cchi O
##o O
a O
mo O
##sche O
##lla O
v O
ian O
##i O
c O
bernard O
##i O
g O
mer O
##cu O
##ri O
n O
##b O
treatment O
of O
the O
symptoms O
of O
huntington O
s O
disease O
preliminary O
results O
comparing O
ari O
##pi O
##pr O
##az O
##ole O
and O
te O
##tra O
##ben O
##azi O
##ne O
mo O
##v O
di O
##sor O
##d O
2009 O
24 O
126 O
129 O
lin O
wc O
cho O
##u O
y O
##h O
ari O
##pi O
##pr O
##az O
##ole O
effects O
on O
psycho O
##sis O
and O
cho O
##rea O
in O
a O
patient O
with O
huntington O
s O
disease O
am O
j O
ps O
##ych O
##ia O
##tr O
2008 O
165 O
120 O
##7 O
120 O
##8 O

marshall O
p O
##b O
mel O
##lman O
ta O
nguyen O
s O
##x O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
with O
the O
addition O
of O
ari O
##pi O
##pr O
##az O
##ole O
to O
ol O
##anza O
##pine O
am O
j O
ps O
##ych O
##ia O
##tr O
2008 O
165 O
148 O
##8 O
148 O
##9 O
molina O
d O
tingle O
le O
lu O
x O
ari O
##pi O
##pr O
##az O
##ole O
as O
the O
ca O
##usa O
##tive O
agent O
of O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
a O
case O
report O
pri O
##m O
care O
companion O
j O
cl O
##in O
ps O
##ych O
##ia O
##tr O
2007 O
9 O
148 O
150 O
gaa O
##sb O
##ee O
##k O
d O
na O
##arding O
p O
st O
##or O
t O
k O
##rem O
##er O
hp O
drug O
induced O
hyper O
##ther O
##mia O
in O
huntington O
s O
disease O
j O
ne O
##uro O
##l O
2004 O
251 O
45 O
##4 O
45 O
##7 O
green O
##away O
m O
el O
##be O
d O
focus O
on O
ari O
##pi O
##pr O
##az O
##ole O
a O
review O
on O
its O
use O
in O
child O
and O
adolescent O
psychiatry O
j O
can O
ac O
##ad O
child O
ad O
##oles O
##c O
ps O
##ych O
##ia O
##tr O
2009 O
18 O
250 O
260 O

lie O
##berman O
##n O
ja O
ari O
##pi O
##pr O
##az O
##ole O
in O
sc O
##hat O
##z O
##berg O
af O
ne O
##mer O
##off O
cb O
editors O
the O
american O
psychiatric O
publishing O
textbook O
of O
psycho O
##pha O
##rma O
##cology O
third O
ed O
washington O
dc O
and O
london O
uk O
american O
psychiatric O
publishing O
2004 O
p O
407 O
49 O
##7 O
electro O
##phy O
##sio O
##logical O
evaluation O
of O
tha O
##lam O
##ic O
db O
##s O
for O
or O
##th O
##osta O
##tic O
tremor O

skip O
to O
navigation O
top O
of O
form O
jam O
##a O
ne O
##uro O
##logy O
bottom O
of O
form O
top O
of O
form O
sign O
in O
trend O
##ing O
ne O
##uro O
##mo O
##du O
##lation O
for O
children O
with O
hem O
##ip O
##ares O
##is O
and O
per O
##ina O
##tal O
stroke O
research O
february O
3 O
202 O
##5 O
pain O
ph O
##eno O
##type O
##s O
and O
multi O
##mo O
##rb O
##idi O
##ty O
in O
medicare O
ben O
##ef O
##icia O
##ries O
with O
cerebral O
pal O
##sy O
research O
august O
5 O
202 O
##4 O
more O
this O
issue O
citations O
16 O
observation O
september O
2010 O
isolated O
distal O
my O
##opa O
##thy O
of O
the O
upper O
limbs O
associated O
with O
mitochondrial O
dna O
de O
##ple O
##tion O
and O
polymer O
##ase O
γ O
mutations O

carla O
gi O
##ord O
##ano O
md O
phd O
florian O
##a O
pic O
##hi O
##or O
##ri O
md O
emma O
l O
blake O
##ly O
phd O
et O
al O
elena O
per O
##li O
bsc O
ma O
##uri O
##zia O
or O
##land O
##i O
bsc O
pietro O
gallo O
md O
robert O
w O
taylor O
phd O
fr O
##cp O
##ath O
ma O
##uri O
##zio O
ing O
##hill O
##eri O
md O
gi O
##ulia O
d O
ama O
##ti O
md O
phd O
author O
affiliation O
##s O
article O
information O
arch O
ne O
##uro O
##l O
2010 O
67 O
9 O
114 O
##4 O
114 O
##6 O
doi O
10 O
100 O
##1 O
arch O
##ne O
##uro O
##l O
2010 O
200 O
abstract O
objective O
to O
describe O
an O
unusual O
clinical O
ph O
##eno O
##type O
in O
an O
adult O
harbor O
##ing O
2 O
compound O
het O
##ero O
##zy O
##go O
##us O
polymer O
##ase O
γ O
pol O
##g O
mutations O
design O
case O
report O
setting O
university O
based O
out O
##patient O
ne O
##uro O
##logy O
clinic O
and O
pathology O
and O
genetics O
laboratory O

patient B-PATIENT
a O
27 B-AGE_FOLLOWUP
year O
old O
man O
presenting O
with O
isolated O
distal B-HPO_TERM
my I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
of O
the O
upper O
ex O
##tre O
##mit O
##ies O
in O
the O
absence O
of O
sensory O
disturbances O

results O
his O
##to O
##chemical O
analysis O
of O
a O
muscle O
bio O
##psy O
specimen O
showed O
numerous O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibers I-HPO_TERM
molecular O
analysis O
revealed O
marked O
de B-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
of I-HPO_TERM
muscle I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
in O
the O
absence O
of O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
sequence O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
revealed O
het O
##ero O
##zy O
##go O
##us O
sequence O
variants O
in O
compound O
c B-GENE_VARIANT
115 I-GENE_VARIANT
##6 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
r I-GENE_VARIANT
##38 I-GENE_VARIANT
##6 I-GENE_VARIANT
##c I-GENE_VARIANT
and O
c B-GENE_VARIANT
279 I-GENE_VARIANT
##4 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
h I-GENE_VARIANT
##9 I-GENE_VARIANT
##32 I-GENE_VARIANT
##y I-GENE_VARIANT
se O
##gre O
##gating O
with O
clinical O
disease O
in O
the O
family O
the O
p O
r O
##38 O
##6 O
##c O
change O
appears O
to O
be O
a O
novel O
mutation O

conclusion O
our O
case O
broad O
##ens O
the O
ph O
##eno O
##typic O
spectrum O
of O
disorders O
associated O
with O
pol O
##g O
mutations O
and O
highlights O
the O
complex O
relationship O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
in O
pol O
##g O
related O
disease O

mutations O
in O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
mt O
##dna O
polymer O
##ase O
γ O
gene O
pol O
##g O
are O
associated O
with O
a O
variety O
of O
disorders O
characterized O
by O
secondary O
defects O
of O
the O
mitochondrial O
genome O
and O
respiratory O
chain O
dysfunction O
1 O
the O
ph O
##eno O
##typic O
spectrum O
of O
pol O
##g O
related O
disease O
is O
extremely O
het O
##ero O
##gen O
##eous O
ranging O
from O
late O
onset O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
om O
##im O
157 O
##64 O
##0 O
to O
fatal O
infant O
##ile O
disorders O
such O
as O
the O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
usually O
associated O
with O
profound O
mt O
##dna O
de O
##ple O
##tion O
in O
affected O
tissues O
2 O
3 O
here O
##in O
we O
describe O
the O
unusual O
association O
of O
distal O
my O
##opa O
##thy O
of O
the O
upper O
limbs O
and O
marked O
mt O
##dna O
de O
##ple O
##tion O
in O
skeletal O
muscle O
of O
an O
adult O
patient O
due O
to O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
pol O
##g O

report O
of O
a O
case O
case O

a O
27 B-AGE_FOLLOWUP
year O
old O
man B-PATIENT
born O
to O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
presented O
with O
a O
3 B-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
progressive B-HPO_TERM
weakness I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
distal I-HPO_TERM
upper I-HPO_TERM
limbs I-HPO_TERM
in O
the O
absence O
of O
sensory O
disturbances O
he O
used O
to O
be O
an O
amateur O
tennis O
player O
but O
had O
to O
stop O
this O
activity O
on O
account O
of O
his O
reduced B-HPO_TERM
muscle I-HPO_TERM
strength I-HPO_TERM
he O
reported O
normal O
motor O
development O
and O
there O
was O
no O
family O
history O
suggest O
##ive O
of O
ne O
##uro O
##mus O
##cular O
disease O
clinical O
examination O
showed O
as O
##ym O
##metric O
moderate O
weakness O
of O
wrist O
extension O
medical O
research O
council O
scale O
score O
3 O
5 O
on O
the O
right O
side O
and O
4 O
5 O
on O
the O
left O
and O
elbow O
flex O
##ion O
and O
finger O
extension O
medical O
research O
council O
scale O
score O
4 O
5 O
there O
was O
no O
muscle O
at O
##rop O
##hy O
deep B-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
reflex I-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
reduced I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
upper I-HPO_TERM
ex I-HPO_TERM
##tre I-HPO_TERM
##mit I-HPO_TERM
##ies I-HPO_TERM
corresponding O
with O
strength O
reduction O
muscle O
strength O
of O
the O
lower O
ex O
##tre O
##mit O
##ies O
was O
normal O
and O
he O
had O
no O
evidence O
of O
pt O
##osis O
or O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
his O
cr B-HPO_TERM
##ea I-HPO_TERM
##tine I-HPO_TERM
kinase I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
mildly I-HPO_TERM
increased I-HPO_TERM
39 O
##6 O
u O
l O
reference O
range O
22 O
269 O
u O
l O
to O
convert O
to O
micro O
##kata O
##ls O
per O
liter O
multi O
##ply O
by O
0 O
01 O
##6 O
##7 O
whereas O
his O
serum O
lac O
##tate O
level O
was O
normal O
17 O
02 O
mg O
dl O
reference O
range O
4 O
5 O
20 O
mg O
dl O
to O
convert O
to O
mill O
##imo O
##les O
per O
liter O
multi O
##ply O
by O
0 O
111 O
radial O
ul O
##nar O
and O
posterior O
ti O
##bial O
##is O
nerve O
conduct O
##ion O
studies O
were O
performed O
to O
rule O
out O
motor O
ne O
##uro O
##path O
##ies O
and O
results O
were O
repeatedly O
normal O
electro B-HPO_TERM
##my I-HPO_TERM
##ography I-HPO_TERM
consistently I-HPO_TERM
showed I-HPO_TERM
my I-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
features O
characterized O
by O
early O
interference O
pattern O
and O
small O
poly O
##pha O
##sic O
motor O
unit O
potential O
##s O
in O
the O
biceps O
bra O
##chi O
##i O
wrist O
ex O
##tens O
##ors O
and O
finger O
ex O
##tens O
##ors O
bilateral O
##ly O
although O
no O
electro O
##my O
##ography O
abnormalities O
were O
observed O
in O
the O
trunk O
or O
lower O
limb O
muscles O
renal O
and O
he O
##pati O
##c O
profiles O
and O
thyroid O
pan O
##cre O
##atic O
and O
cardiac O
function O
were O
all O
un O
##rem O
##ark O
##able O
he O
subsequently O
underwent O
an O
open O
bio O
##psy O
of O
the O
del O
##to O
##id O
muscle O
for O
diagnostic O
purposes O

analysis O

standard O
his O
##to O
##logical O
and O
his O
##to O
##chemical O
analyses O
were O
performed O
on O
fresh O
frozen O
muscle O
sections O
10 O
μ O
##m O
total O
dna O
was O
extracted O
from O
blood O
and O
whole O
muscle O
homo O
##gen O
##ates O
by O
standard O
procedures O
single O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
positive O
and O
cox O
def O
##icient O
skeletal O
muscle O
cells O
were O
separately O
obtained O
by O
laser O
capturing O
micro O
##dis O
##section O
with O
the O
mm O
##i O
uv O
cut O
system O
nik O
##on O
instruments O
kingston O
england O
4 O
the O
total O
amount O
of O
mt O
##dna O
was O
measured O
by O
quantitative O
real O
time O
polymer O
##ase O
chain O
reaction O
as O
previously O
described O
5 O
briefly O
an O
mt O
##dna O
fragment O
nu O
##cle O
##otide O
46 O
##25 O
47 O
##14 O
and O
a O
nuclear O
dna O
fragment O
fa O
##sl O
gene O
were O
coa O
##mp O
##li O
##fied O
using O
a O
multiple O
##x O
ta O
##q O
##man O
polymer O
##ase O
chain O
reaction O
ass O
##ay O
in O
##vi O
##tro O
##gen O
life O
technologies O
par O
##sley O
england O
for O
each O
ass O
##ay O
a O
standard O
curve O
for O
mt O
##dna O
and O
nuclear O
dna O
was O
generated O
using O
serial O
dil O
##ution O
##s O
of O
a O
vector O
kind O
gift O
from O
andrea O
co O
##ssar O
##iz O
##za O
md O
phd O
in O
which O
the O
regions O
used O
as O
the O
template O
for O
the O
2 O
amp O
##li O
##fication O
##s O
were O
clone O
##d O
tail O
to O
tail O
to O
have O
a O
ratio O
of O
1 O
1 O
of O
the O
reference O
molecules O
the O
absolute O
mt O
##dna O
copy O
number O
per O
nucleus O
was O
obtained O
by O
multi O
##ply O
##ing O
the O
ratio O
of O
mt O
##dna O
to O
nuclear O
dna O
values O
by O
2 O
because O
2 O
copies O
of O
the O
nuclear O
gene O
are O
present O
in O
a O
cell O
screening O
for O
mt O
##dna O
large O
scale O
rear O
##rang O
##ement O
##s O
was O
carried O
out O
by O
real O
time O
polymer O
##ase O
chain O
reaction O
##6 O
and O
conventional O
polymer O
##ase O
chain O
reaction O
using O
shifted O
prime O
##r O
sets O
within O
the O
major O
arc O
of O
human O
mt O
##dna O
##7 O
both O
on O
muscle O
homo O
##gen O
##ate O
dna O
and O
on O
micro O
##dis O
##se O
##cted O
cells O
the O
entire O
coding O
region O
and O
intro O
##n O
ex O
##on O
boundaries O
of O
pol O
##g O
were O
amplified O
and O
directly O
sequence O
##d O
as O
previously O
reported O
1 O

m O
i O
t O
o O
c O
h O
o O
n O
d O
r O
i O
a O
l O
m O
i O
m O
i O
c O
r O
y O
o O
f O
m O
s O
a O
c O
jan O
##kovic O
j O
schwartz O
k O
response O
and O
im O
##mun O
##ores O
##istan O
##ce O
to O
bot O
##ulin O
##um O
toxin O
injection O
##s O
ne O
##uro O
##logy O
1995 O
45 O
1743 O
1746 O
halle O
##tt O
m O
ben O
##eck O
##e O
r O
blitz O
##er O
a O
come O
##lla O
cl O
toxic O
##on O
2009 O
54 O
5 O
62 O
##8 O
63 O
##3 O
jan O
##kovic O
j O
bot O
##ulin O
##um O
toxin O
therapy O
for O
cervical O
d O
##yst O
##onia O
ne O
##uro O
##to O
##x O
res O
2006 O
9 O
145 O
148 O
mitochondrial O
mimic O
##ry O
of O
multiple O
system O
at O
##rop O
##hy O
of O
the O
ce O
##re O
##bella O
##r O
sub O
##type O
ar O
##pan O
r O
me O
##hta O
b O
a O
b O
m O
b O
ch O
1 O
susan O
h O
fox O
m O
r O
c O
p O
ph O
d O
1 O
mark O
tar O
##no O
##pol O
##sky O
m O
d O
ph O
d O
f O
r O
c O
p O
2 O
and O
grace O
yoon O
m O
d O
f O
r O
c O
p O
f O
c O
c O
m O
g O
3 O

1 O
##mo O
##ve O
##ment O
disorder O
clinic O
toronto O
western O
hospital O
university O
of O
toronto O
toronto O
canada O
2d O
##ivision O
of O
ne O
##uro O
##mus O
##cular O
and O
ne O
##uro O
##met O
##ab O
##olic O
disease O
mc O
##master O
university O
medical O
center O
hamilton O
canada O
3d O
##ivision O
##s O
of O
clinical O
metabolic O
genetics O
and O
ne O
##uro O
##logy O
the O
hospital O
for O
sick O
children O
university O
of O
toronto O
toronto O
canada O
patients O
with O
diverse O
clinical O
presentations O
that O
include O
parkinson O
##ism O
and O
ce O
##re O
##bella O
##r O
ata O
##xia O
2 O

here O
for O
the O
ﬁ O
##rst O
time O
we O
describe O
a O
patient B-PATIENT
who O
presented O
with O
clinical O
and O
radio O
##logical O
ﬁ O
##nding O
##s O
suggest O
##ive O
of O
multiple B-HPO_TERM
system I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
ms O
##a O
of O
the O
ce O
##re O
##bella O
##r O
sub O
##type O
ms O
##a O
c O
but O
was O
shown O
to O
have O
mutations O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
this O
case O
highlights O
the O
importance O
of O
considering O
primary O
mitochondrial O
disorders O
in O
the O
differential O
diagnosis O
of O
parkinson O
##ian O
syndrome O
##s O
3 O
4 O
case O
report O
written O
informed O
consent O
was O
obtained O
from O
the O
patient O
to O
publish O
both O
video O
and O
brain O
imaging O
results O
for O
this O
case O
report O
this O
58 B-AGE_FOLLOWUP
year O
old O
woman O
had O
a O
progressive B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
syndrome I-HPO_TERM
her O
symptoms O
had O
started O

9 B-AGE_ONSET
years I-AGE_ONSET
prior I-AGE_ONSET
with O
im B-HPO_TERM
##balance I-HPO_TERM
when O
getting O
out O
of O
a O
canoe O
or O
when O
walking O
up O
and O
down O
stairs O
she O
also O
noted O
poor B-HPO_TERM
handwriting I-HPO_TERM
and O
mild O
inc B-HPO_TERM
##oor I-HPO_TERM
##dina I-HPO_TERM
##tion I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
hands I-HPO_TERM
her O
speech B-HPO_TERM
had I-HPO_TERM
become I-HPO_TERM
sl I-HPO_TERM
##ur I-HPO_TERM
##red I-HPO_TERM
her O
symptoms O
worsened O
toward O
the O
end O
of O
the O
day O
or O
when O
she O
was O
fatigue B-HPO_TERM
##d I-HPO_TERM
in O
addition O
the O
symptoms O
partially O
improved O
after O
excluding O
dietary O
g O
##lu O
##ten O
and O
she O
had O
lost B-HPO_TERM
18 I-HPO_TERM
kg I-HPO_TERM
over O
the O
previous O
year O
she O
had O
mild O
ur O
##ina O
##ry O
inc B-HPO_TERM
##ont I-HPO_TERM
##inen I-HPO_TERM
##ce I-HPO_TERM
when I-HPO_TERM
coughing I-HPO_TERM
she O
has O
type B-HPO_TERM
ii I-HPO_TERM
diabetes I-HPO_TERM
mel I-HPO_TERM
##lit I-HPO_TERM
##us I-HPO_TERM
treated O
with O
pi O
##og O
##lita O
##zone O
there O
is O
no O
history O
of O
ep O
##ile O
##psy O
cognitive O
problems O
visual O
problems O
stroke O
like O
episodes O
hearing O
problems O
or O
men O
##st O
##ru O
##al O
disturbances O
her O
family O
history O
revealed O
that O
she O
had O
a O
sister O
who O
died O
at O
2 O
years O
of O
age O
this O
child O
who O
was O
blind O
was O
never O
able O
to O
roll O
sit O
or O
walk O
independently O
and O
she O
also O
had O
intra O
##ctable O
seizures O
no O
diagnosis O
was O
ever O
established O
the O
pro O
##band O
s O
brother O
has O
sensor O
##ine O
##ural O
hearing O
loss O
g O
##lau O
##com O
##a O
and O
adult O
onset O
diabetes O
mel O
##lit O
##us O
requiring O
treatment O
with O
insulin O

on O
initial O
examination O
4 O
years O
after O
the O
onset O
of O
her O
symptoms O
she O
had O
slight O
slowing B-HPO_TERM
of I-HPO_TERM
vertical I-HPO_TERM
sac I-HPO_TERM
##cade I-HPO_TERM
##s I-HPO_TERM
but O
a O
full O
range O
of O
eye O
movements O
and O
normal O
fund O
##i O
she O
had O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
mild O
limb B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##met I-HPO_TERM
##ria I-HPO_TERM
that O
was O
worse O
on O
the O
left O
mild O
slowing B-HPO_TERM
of I-HPO_TERM
foot I-HPO_TERM
taps I-HPO_TERM
bilateral I-HPO_TERM
##ly I-HPO_TERM
and O
a O
mildly O
impaired B-HPO_TERM
tandem I-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
tone O
and O
re O
##ﬂ O
##ex O
##es O
were O
normal O
with O
ﬂ O
##ex O
##or O
plant O
##ar O
responses O
see O
supporting O
information O
video O
investigations O
for O
coe O
##lia O
##c O

mitochondrial O
disorders O
can O
result O
from O
either O
primary O
defects O
in O
the O
mitochondrial O
dna O
mt O
##dna O
or O
defects O
in O
nuclear O
encoded O
proteins O
that O
affect O
mt O
##dna O
structure O
or O
function O
the O
maintenance O
of O
mt O
##dna O
replication O
is O
critically O
dependent O
upon O
mt O
##dna O
polymer O
##ase O
c O
1 O
encoded O
by O
the O
nuclear O
genes O
pol O
##g O
##1 O
and O
pol O
##g O
##2 O
mutations O
in O
pol O
##g O
##1 O
have O
been O
described O
in O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

correspondence O
to O
dr O
grace O
yoon O
divisions O
of O
clinical O
metabolic O
genetics O
and O
ne O
##uro O
##logy O
the O
hospital O
for O
sick O
children O
university O
of O
toronto O
555 O
university O
avenue O
toronto O
ontario O
m O
##5 O
##g O
1 O
##x O
##8 O
canada O
grace O
yoon O
ut O
##oro O
##nto O
ca O
relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
nothing O
to O
report O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
received O
23 O
july O
2010 O
revised O
22 O
september O
2010 O
accepted O
11 O
october O
2010 O
published O
online O
21 O
january O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
235 O
##10 O

movement O
disorders O
vol O
26 O
no O
4 O
2011 O
75 O
##3 O
m O
e O
h O
t O
a O
e O
t O
a O
l O
fig O
1 O
a O
mri O
flair O
brain O
scan O
showing O
an O
enlarged O
fourth O
vent O
##ric O
##le O
because O
of O
pont O
##ine O
and O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
in O
association O
with O
hyper O
##int O
##ens O
##ities O
in O
the O
middle O
ce O
##re O
##bella O
##r O
pe O
##dun O
##cles O
bilateral O
##ly O
b O
mri O
t O
##2 O
weighted O
brain O
scan O
demonstrating O
the O
hot O
cross O
bun O
sign O
classical O
##ly O
associated O
with O
ms O
##a O

disease O
including O
a O
small O
bow O
##el O
bio O
##psy O
were O
negative O
sensory O
testing O
was O
normal O
and O
nerve O
conduct O
##ion O
studies O
were O
normal O
in O
view O
of O
the O
sign B-HPO_TERM
##i I-HPO_TERM
##ﬁ I-HPO_TERM
##can I-HPO_TERM
##t I-HPO_TERM
weight I-HPO_TERM
loss I-HPO_TERM
investigations O
for O
a O
para O
##neo O
##pl O
##astic O
process O
were O
performed O
and O
the O
anti O
pu O
##rkin O
##je O
cell O
antibody O
was O
negative O
computed O
tom O
##ography O
of O
thor O
##ax O
and O
ma O
##mm O
##og O
##ram O
were O
normal O
her O
vitamin O
b1 O
##2 O
and O
e O
levels O
were O
normal O
metabolic O
studies O
including O
plasma O
amino O
acids O
urine O
organic O
acids O
car O
##ni O
##tine O
pro O
##ﬁ O
##le O
lac O
##tate O
ammonia O
and O
le O
##uk O
##oc O
##yte O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
activity O
were O
all O
normal O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
sc O
##a O
types O
1 O
2 O
3 O
6 O
and O
7 O
testing O
were O
negative O
she O
was O
found O
to O
have O
an O
intermediate O
range O
expansion O
of O
the O
ct O
##g O
repeat O
of O
the O
sc O
##a O
type O
8 O
sc O
##a O
8 O
gene O
with O
all O
##ele O
sizes O
of O
75 O
and O
26 O
ct O
##g O
repeats O
which O
were O
not O
felt O
to O
be O
clinical O
##ly O
sign O
##i O
##ﬁ O
##can O
##t O
her O
magnetic O
resonance O
imaging O
mri O
brain O
scan O
showed O
pont B-HPO_TERM
##ine I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
with O
some O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
middle I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
pe I-HPO_TERM
##dun I-HPO_TERM
##cles I-HPO_TERM
fig O
1 O

her O
symptoms O
continued O
to O
progress O
and O
7 O
years O
after O
sy O
##mpt O
##om O
onset O
her O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
had O
sign O
##i O
##ﬁ O
##can O
##tly O
worsened O
despite O
using O
a O
walker O
she O
fell B-HPO_TERM
and O
sustained O
a O
right O
hip B-HPO_TERM
fracture I-HPO_TERM
she O
developed O
post B-HPO_TERM
##ural I-HPO_TERM
di I-HPO_TERM
##zziness I-HPO_TERM
owing O
to O
or B-HPO_TERM
##th I-HPO_TERM
##osta I-HPO_TERM
##tic I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##ote I-HPO_TERM
##ns I-HPO_TERM
##ion I-HPO_TERM
moreover O
her O
ur B-HPO_TERM
##ina I-HPO_TERM
##ry I-HPO_TERM
urgency I-HPO_TERM
worsened O
and O
she O
developed O
no B-HPO_TERM
##ct I-HPO_TERM
##uria I-HPO_TERM
she O
had O
dr B-HPO_TERM
##ool I-HPO_TERM
##ing I-HPO_TERM
of I-HPO_TERM
saliva I-HPO_TERM
and O
intermittent B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
for O
liquids O
examination O
revealed O
a O
su O
##pine O
blood O
pressure O
of O
110 O
60 O
and O
90 O
40 O
mm O
h O
##g O
after O
standing O
for O
3 O
minutes O
with O
no O
corresponding O
change O
in O
pulse O
rate O
she O
had O
poly B-HPO_TERM
##mini I-HPO_TERM
##my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
of O
her O
outstretched O
hands O
a O
positive B-HPO_TERM
g I-HPO_TERM
##lab I-HPO_TERM
##ella I-HPO_TERM
##r I-HPO_TERM
tap I-HPO_TERM
and O
brisk B-HPO_TERM
deep I-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
with O
ﬂ O
##ex O
##or O
plant O
##ar O
responses O
she O
was O
unable B-HPO_TERM
to I-HPO_TERM
walk I-HPO_TERM
una I-HPO_TERM
##ided I-HPO_TERM
and O
required O
a O
wheelchair O
on O
recent O
examination O
9 O
years O
after O
onset O
she O
had O
jerk B-HPO_TERM
##y I-HPO_TERM
sac I-HPO_TERM
##cade I-HPO_TERM
##s I-HPO_TERM
marked O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM

ep O
##ile O
##psy O
behavior O
21 O
2011 O
206 O
210 O
case B-PATIENT
report O
par B-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lobe I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
caused O
by O
a O
pol B-GENE
##g I-GENE
##1 I-GENE
compound O
het O
##ero O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
gen O
##otype O
david O
ro O
##sha O
##l O
david O
gloss O
##er O
and O
##ro O
za O
##nga O
##lad O
##ze O
department O
of O
ne O
##uro O
##logy O
thomas O
jefferson O
university O
hospital O
philadelphia O
pa O
usa O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
22 O
december O
2010 O
revised O
3 O
march O
2011 O
accepted O
4 O
march O
2011 O
available O
online O
22 O
april O
2011 O
key O
##words O
pol O
##g O
##1 O
gene O
mutation O
mit O
##ho O
##chon O
##dr O
##ial O
disorder O
a O
##46 O
##7 O
##t O
w O
##7 O
##48 O
##s O
gen O
##otype O
so O
##mat O
##ose O
##nsor O
##y O
seizures O
status O
ep O
##ile O
##ptic O
##us O
a O
b O
s O
t O
r O
a O
c O
t O

we O
describe O
a O
16 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
with O
a O
rare O
pol B-GENE
##g I-GENE
##1 I-GENE
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
gen O
##otype O
with O
a O
wide O
range O
of O
neurological O
manifestation O
##s O
including O
focal B-HPO_TERM
par I-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lobe I-HPO_TERM
seizures I-HPO_TERM
mig B-HPO_TERM
##raine I-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
sensory B-HPO_TERM
motor I-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
and O
impairment B-HPO_TERM
of I-HPO_TERM
visual I-HPO_TERM
perception I-HPO_TERM
and O
cognitive O
function O
treatment O
of O
ep O
##ile O
##psy O
in O
patients O
with O
a O
pol B-GENE
##g I-GENE
##1 I-GENE
compound O
het O
##ero O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
gen O
##otype O
is O
very O
challenging O
the O
ep O
##ile O
##psy O
may O
prefer O
##ential O
##ly O
respond O
to O
sodium O
channel O
block O
##ers O
the O
pol O
##g O
##1 O
related O
syndrome O
has O
a O
variable O
clinical O
course O
and O
disease O
mor O
##bid O
##ity O
and O
mortality O
may O
be O
correlated O
with O
the O
gen O
##otype O

2011 O
else O
##vier O
inc O
all O
rights O
reserved O
introduction O
the O
pol O
##g O
##1 O
gene O
mutation O
is O
a O
commonly O
reported O
gene O
defect O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O
1 O
pol O
##g O
##1 O
gene O
located O
on O
chromosome O
15 O
##q O
##25 O
en O
##codes O
for O
the O
140 O
k O
##da O
catalytic O
subunit O
of O
dna O
polymer O
##ase O
γ O
which O
is O
responsible O
for O
mitochondrial O
dna O
replication O
1 O
dna O
polymer O
##ase O
γ O
also O
consists O
of O
a O

55 O
k O
##da O
accessory O
subunit O
which O
is O
encoded O
by O
the O
pol O
##g O
##2 O
gene O
on O
chromosome O
17 O
##q O
##23 O
24 O
and O
is O
responsible O
for O
tight O
binding O
to O
doubles O
##tra O
##nded O
dna O
2 O
the O
pol O
##g O
##1 O
gene O
mutation O
was O
id O
##ent O
##i O
##ﬁ O
##ed O
as O
a O
genetic O
substrate O
in O
al O
##pers O
disease O
3 O
which O
was O
described O
in O
the O
early O
1930s O
by O
bernard O
al O
##pers O
as O
diffuse O
progressive O
de O
##gen O
##eration O
of O
the O
gray O
matter O
in O
children O
4 O
since O
that O
time O
many O
more O
pol O
##g O
##1 O
gen O
##otype O
##s O
causing O
al O
##pers O
disease O
have O
been O
discovered O
5 O
more O
than O
150 O
different O
homo O
##zy O
##go O
##us O
and O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
have O
been O
reported O
in O
the O
literature O
2 O
4 O
6 O
8 O
they O
have O
variable O
ph O
##eno O
##type O
##s O
clinical O
spectra O
and O
natural O
histories O
which O
depend O
on O
the O
spec O
##i O
##ﬁ O
##c O
pol O
##g O
##1 O
gene O
mutation O
mitochondrial O
disorders O
can O
have O
a O
very O
ins O
##idi O
##ous O
clinical O
course O
which O
can O
make O
the O
diagnosis O
di O
##f O
##ﬁ O
##cu O
##lt O
especially O
if O
the O
genetic O
work O
##up O
for O
routinely O
tested O
mitochondrial O
disorders O
is O
negative O
treatment O
of O
ep O
##ile O
##psy O
in O
patients O
with O
pol O
##g O
##1 O
gene O
mutations O
spec O
##i O
##ﬁ O
##cal O
##ly O
the O
compound O
het O
##ero O
##zy O
##go O
##us O
a O
##46 O
##7 O
##t O
w O
##7 O
##48 O
##s O
gen O
##otype O
is O
very O
challenging O
and O
the O
ep O
##ile O
##psy O
may O
selective O
##ly O
respond O
to O
only O
certain O
anti O
##ep O
##ile O
##ptic O
drugs O
7 O

we O
describe O
here O
a O
patient B-PATIENT
with O
a O
rare O
pol B-GENE
##g I-GENE
##1 I-GENE
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
compound O
het O
##ero O
##zy O
##go O
##us O
gen O
##otype O
with O
a O
wide O
range O
of O
neurological O
and O
non O
##ne O
##uro O
##logical O
manifestation O
##s O
including O
focal B-HPO_TERM
seizures I-HPO_TERM
mig B-HPO_TERM
##raine I-HPO_TERM
corresponding O
author O
at O
900 O
walnut O
street O
suite O
200 O
philadelphia O
pa O
1910 O
##7 O
usa O
fa O
##x O
1 O
215 O
50 O
##3 O
259 O
##8 O
e O
mail O
address O
and O
##ro O
za O
##nga O
##lad O
##ze O
jefferson O
ed O
##u O
a O
za O
##nga O
##lad O
##ze O

headache B-HPO_TERM
##s I-HPO_TERM
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
sensory B-HPO_TERM
motor I-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
and O
de B-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
##s I-HPO_TERM
in I-HPO_TERM
visual I-HPO_TERM
perception I-HPO_TERM
and O
other B-HPO_TERM
cognitive I-HPO_TERM
domains I-HPO_TERM
we O
discuss O
the O
2 O
year O
clinical O
course O
of O
this O
condition O
as O
well O
as O
the O
focal O
seizure O
treatment O
failures O
and O
responses O
case O
report O

a O
16 B-AGE_FOLLOWUP
year O
old O
right O
handed O
woman O
who O
was O
an O
ex O
pre O
##emi O
##e O
ge B-AGE_FOLLOWUP
##station I-AGE_FOLLOWUP
##al I-AGE_FOLLOWUP
age I-AGE_FOLLOWUP
36 I-AGE_FOLLOWUP
weeks I-AGE_FOLLOWUP
born O
to O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
developed O
over O
a O
1 O
year O
period O
progressively O
worse O
##ning O
focal B-AGE_FOLLOWUP
seizures I-AGE_FOLLOWUP
ref I-AGE_FOLLOWUP
##rac I-AGE_FOLLOWUP
##tory I-AGE_FOLLOWUP
to O
multiple O
anti O
##ep O
##ile O
##ptic O
drugs O
the O
patient O
had O
daily O
seizures O
of O
different O
semi O
##ology O
sign O
##ifying O
the O
multi B-AGE_FOLLOWUP
##fo I-AGE_FOLLOWUP
##cal I-AGE_FOLLOWUP
##ity I-AGE_FOLLOWUP
of I-AGE_FOLLOWUP
her I-AGE_FOLLOWUP
seizures I-AGE_FOLLOWUP
the O
ﬁ O
##rst O
was O
a O
focal B-AGE_FOLLOWUP
motor I-AGE_FOLLOWUP
seizure I-AGE_FOLLOWUP
with O
right O
face O
arm O
and O
leg O
twitching O
in O
##fr O
##e O
##quent O
##ly O
evolving O
into O
con O
##vu O
##ls O
##ions O
the O
second O
type O
was O
a O
visual B-AGE_FOLLOWUP
sensory I-AGE_FOLLOWUP
seizure I-AGE_FOLLOWUP
which O
was O
described O
as O
either O
a O
right B-AGE_FOLLOWUP
homo I-AGE_FOLLOWUP
##ny I-AGE_FOLLOWUP
##mous I-AGE_FOLLOWUP
hem I-AGE_FOLLOWUP
##iano I-AGE_FOLLOWUP
##ps I-AGE_FOLLOWUP
##ia I-AGE_FOLLOWUP
or O
colored O
spheres O
in O
the O
right O
visual O
ﬁ O
##eld O
and O
the O
third O
type O
of O
seizure O
was O
a O
so B-AGE_FOLLOWUP
##mat I-AGE_FOLLOWUP
##ose I-AGE_FOLLOWUP
##nsor I-AGE_FOLLOWUP
##y I-AGE_FOLLOWUP
seizure I-AGE_FOLLOWUP
of O
spreading O
numb O
##ness O
and O
tingling O
sensation O
on O
the O
right O
side O
of O
the O
body O
she O
was O
ref O
##rac O
##tory O
to O
ox O
##car O
##ba O
##ze O
##pine O
lev O
##eti O
##race O
##tam O
and O
z O
##onis O
##ami O
##de O
at O
which O
point O
top O
##ira O
##mate O
was O
started O
but O
the O
patient O
developed O
cognitive B-AGE_FOLLOWUP
side I-AGE_FOLLOWUP
effects I-AGE_FOLLOWUP
and O
therefore O
top O
##ira O
##mate O
was O
discontinued O
val O
##pro O
##ic O
acid O
was O
initiated O
which O
made O
the O
patient O
s O
cognitive O
symptoms O
and O
seizures O
worse O
at O
which O
time O
the O
patient O
was O
brought O
to O
thomas O
jefferson O
university O
ep O
##ile O
##psy O
monitoring O
unit O
with O
focal B-AGE_FOLLOWUP
status I-AGE_FOLLOWUP
ep I-AGE_FOLLOWUP
##ile I-AGE_FOLLOWUP
##ptic I-AGE_FOLLOWUP
##us I-AGE_FOLLOWUP
for O
video O
ee O
##g O
ve O
##eg O
monitoring O

on O
admission O
ve O
##eg O
demonstrated O
multiple O
focal O
so O
##mat O
##ose O
##nsor O
##y O
and O
visual B-AGE_FOLLOWUP
seizures I-AGE_FOLLOWUP
without O
impairment O
of O
consciousness O
the O
majority O
of O
the O
seizures O
em O
##ana O
##ted O
from O
the O
left O
par O
##ie O
##tal O
p O
##3 O
region O
with O
a O
tendency O
to O
spread O
within O
the O
ip O
##sil O
##ater O
##al O
hemisphere O
fig O
1 O
few O
seizures O
em O
##ana O
##ted O
from O
the O
left O
posterior O
temporal O
t O
##5 O
region O
and O
most O
of O
those O
showed O
no O
spread O
to O
the O
other O
leads O
inter O
##ic O
##tal O
##ly O
the O
152 O
##5 O
505 O
##0 O
see O
front O
matter O
2011 O
else O
##vier O
inc O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
ye O
##be O
##h O
2011 O
03 O
00 O
##3 O
d O
ro O
##sha O
##l O
et O
al O
ep O
##ile O
##psy O
behavior O
21 O
2011 O
206 O
210 O
207 O

fig O
1 O
electro O
##ence O
##pha O
##log O
##raphy O
a O
scalp O
ee B-AGE_FOLLOWUP
##g I-AGE_FOLLOWUP
with I-AGE_FOLLOWUP
inter I-AGE_FOLLOWUP
##ic I-AGE_FOLLOWUP
##tal I-AGE_FOLLOWUP
left I-AGE_FOLLOWUP
par I-AGE_FOLLOWUP
##ie I-AGE_FOLLOWUP
##to I-AGE_FOLLOWUP
o I-AGE_FOLLOWUP
##cci I-AGE_FOLLOWUP
##pit I-AGE_FOLLOWUP
##al I-AGE_FOLLOWUP
sharp I-AGE_FOLLOWUP
waves I-AGE_FOLLOWUP
b O
scalp O
ee O
##g O
with O
left O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
seizure O
patient O
had O
frequent O
par B-AGE_FOLLOWUP
##ie I-AGE_FOLLOWUP
##to I-AGE_FOLLOWUP
o I-AGE_FOLLOWUP
##cci I-AGE_FOLLOWUP
##pit I-AGE_FOLLOWUP
##al I-AGE_FOLLOWUP
sharp I-AGE_FOLLOWUP
waves I-AGE_FOLLOWUP
in O
wake O
##fulness O
and O
sleep O
in O
addition O
to O
seizures O
the O
patient O
also O
had O
frequent B-AGE_FOLLOWUP
mig I-AGE_FOLLOWUP
##raine I-AGE_FOLLOWUP
headache I-AGE_FOLLOWUP
##s I-AGE_FOLLOWUP
which O
were O
often O
preceded O
by O
a O
visual B-AGE_FOLLOWUP
aura I-AGE_FOLLOWUP
making O
it O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
differentiate O
the O
mig O
##raine O
aura O
from O
a O
visual O
sensory O
seizure O
non O
##ne O
##uro O
##logical O
chronic O
symptoms O
included O
pal O
##pit O
##ations O
with O
a O
baseline O
heart O
rate O
of O
120 O
bp O
##m O
and O
abdominal O
discomfort O
with O
irregular O
bow O
##el O
movements O

general O
physical O
examination O
revealed O
moderate B-AGE_FOLLOWUP
obesity I-AGE_FOLLOWUP
with O
abdominal B-AGE_FOLLOWUP
st I-AGE_FOLLOWUP
##ria I-AGE_FOLLOWUP
##e I-AGE_FOLLOWUP
ne O
##uro O
##psy O
##cho O
##logical O
assessment O
was O
undertaken O
during O
in O
##patient O
ve O
##eg O
monitoring O
though O
she O
had O
an O
average O
full O

scale O
iq O
88 O
a O
sign O
##i O
##ﬁ O
##can O
##t O
difference O
prevailed O
between O
her O
verbal O
iq O
of O
112 O
and O
performance O
iq O
of O
70 O
she O
demonstrated O
a O
lexi B-AGE_FOLLOWUP
##cal I-AGE_FOLLOWUP
retrieval I-AGE_FOLLOWUP
defect I-AGE_FOLLOWUP
on O
the O
boston O
naming O
test O
and O
was O
at O
only O
the O
1st O
percent O
##ile O
semantic O
and O
ﬁ O
##rst O
letter O
ﬂ O
##uen O
##cy O
were O
at O
the O
3rd O
and O
10th O
percent O
##ile O
##s O
respectively O
vis O
##uo O
##con O
##st O
##ru O
##ction O
##al O
dominant O
par O
##ie O
##tal O
function O
was O
assessed O
with O
block O
design O
and O
matrix O
reasoning O
sub O
##test O
##s O
of O
the O
we O
##chs O
##ler O
abbreviated O
scale O
of O
intelligence O
was O
##i O
and O
was O
completed O
at O
the O
1st O
and O
9th O
percent O
##ile O
##s O
respectively O
on O
a O
test O
of O
visual O
scanning O
and O
cancellation O
she O
made O
predominantly O
right O
sided O
om O
##iss O
##ion O
errors O
prose O
passage O
recall O
immediately O
and O
on O
delay O
dominant O

cell O
count O
with O
differential O
white O
blood O
cells O
8 O
0 O
5 O
with O
65 O
l O
##ym O
##ph O
##ocytes O
red O
blood O
cells O
9 O
0 O
5 O
glucose O
56 O
50 O
80 O
protein O
85 O
15 O
45 O
protein O
electro O
##ph O
##ores O
##is O
and O
serum O
protein O
electro O
##ph O
##ores O
##is O
normal O
with O
no O
ol O
##igo O
##cl O
##onal O
bands O
my O
##elin O
basic O
protein O
5 O
6 O
0 O
07 O
4 O
10 O
human O
t O
l O
##ym O
##ph O
##ot O
##rop O
##ic O
virus O
1 O
l O
##yme O
antibody O
her O
##pes O
pc O
##r O
normal O
p O
##yr O
##u O
##vate O
0 O
03 O
0 O
06 O
0 O
19 O
lac O
##tate O
de O
##hy O
##dro O
##genase O
46 O
11 O
22 O
lac O
##tate O
normal O
cad O
##asi O
##l O
a O
f O
##hm O
auto O
##som O
##al O
dominant O
ata O
##xia O
panel O
negative O
mitochondrial O
disorders O
athena O
panel O
normal O
vitamin O
b1 O
##2 O
163 O
180 O
900 O
methyl O
##mal O
##onic O
acid O
normal O
25 O
hydro O
##xy O
##vita O
##min O
d O
8 O
4 O
32 O
100 O

vitamin O
##s O
a O
k O
e O
normal O
celia O
##c O
antibody O
panel O
normal O
pan O
##cre O
##atic O
enzymes O
normal O
homo O
##cy O
##stein O
##e O
normal O
cr O
##ea O
##tine O
ph O
##os O
##ph O
##oki O
##nas O
##e O
and O
aldo O
##lase O
normal O
muscle O
bio O
##psy O
normal O
without O
ragged O
red O
ﬁ O
##bers O
ga O
##d O
v O
##g O
##k O
##c O
hu O
ri O
yo O
and O
nm O
##da O
antibodies O
normal O
urine O
sul O
##fat O
##ides O
normal O
ana O
es O
##r O
en O
##a O
can O
##ca O
and O
pan O
##ca O
normal O
echo O
##card O
##io O
##gram O
normal O
dual O
energy O
x O
ray O
abs O
##ort O
##iom O
##et O
##ry O
dex O
##a O
scan O
os O
##te O
##op O
##oro O
##sis O
electro O
##my O
##ography O
nerve O
conduct O
##ion O
tests O
sensory O
ax O
##onal O
ne O
##uro O
##pathy O
ca O
125 O
tumor O
marker O
normal O
ee O
##g O
fig O
1 O
mri O
brain O
scan O
fig O
2 O
pol B-GENE
##g I-GENE
##1 I-GENE
genetic O
testing O
patient O
compound O
het O
##ero O
##zy O
##go O
##us O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O

father O
het O
##ero O
##zy O
##go O
##us O
a O
##46 O
##7 O
##t O
mutation O
mother O
het O
##ero O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutation O
a O
cad O
##asi O
##l O
cerebral O
auto O
##som O
##al O
dominant O
arte O
##rio O
##pathy O
with O
sub O
##cor O
##tical O
in O
##far O
##cts O
and O
le O
##uk O
##oe O
##nce O
##pha O
##lo O
##pathy O
f O
##hm O
fa O
##mi O
##lia O
##l O
hem O
##ip O
##leg O
##ic O
mig O
##raine O
ga O
##d O
g O
##lu O
##tam O
##ic O
acid O
dec O
##ar O
##box O
##yla O
##se O
v O
##g O
##k O
##c O
voltage O
gate O
##d O
potassium O
channel O
nm O
##da O
n O
methyl O
d O
as O
##par O
##tate O
ana O
anti O
##nu O
##cle O
##ar O
antibodies O
en O
##a O
extract O
##able O
nuclear O
antigen O
##s O
es O
##r O
er O
##yt O
##hr O
##oc O
##yte O
sediment O
##ation O
rate O

temporal O
lobe O
dependent O
was O
solid O
##ly O
average O
but O
delayed O
free O
recall O
on O
su O
##pr O
##as O
##pan O
verbal O
list O
learning O
california O
verbal O
learning O
test O
ii O
was O
at O
only O
the O
10th O
percent O
##ile O
facial O
recognition O
memory O
right O
posterior O
temporal O
dependent O
was O
at O
the O
2nd O
and O
10th O
percent O
##ile O
##s O
relative O
to O
age O
matched O
norms O
on O
tests O
of O
writing O
and O
ﬁ O
##nger O
dexter O
##ity O
she O
demonstrated O
per O
##vas O
##ive O
graph O
##omo O
##tor O
control O
problems O
single O
##word O
reading O
recognition O
was O
at O
the O
95 O
##th O
percent O
##ile O
she O
also O
had O

di O
##f O
##ﬁ O
##cu O
##lty O
with O
calculations O
using O
single O
##and O
double O
digit O
numbers O
as O
well O
as O
right O
left O
confusion O
overall O
the O
ne O
##uro O
##psy O
##cho O
##logical O
testing O
was O
consistent O
with O
a O
multi B-HPO_TERM
##fo I-HPO_TERM
##cal I-HPO_TERM
cognitive I-HPO_TERM
dysfunction I-HPO_TERM

cr O
##anial O
nerve O
examination O
was O
noteworthy O
for O
down B-HPO_TERM
##beat I-HPO_TERM
and I-HPO_TERM
horizontal I-HPO_TERM
ny I-HPO_TERM
##sta I-HPO_TERM
##gm I-HPO_TERM
##us I-HPO_TERM
o B-HPO_TERM
##cular I-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##met I-HPO_TERM
##ria I-HPO_TERM
right B-HPO_TERM
homo I-HPO_TERM
##ny I-HPO_TERM
##mous I-HPO_TERM
hem I-HPO_TERM
##iano I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
bilateral O
tilted O
and O
at B-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
optic I-HPO_TERM
nerves I-HPO_TERM
and O
a O
mild O
right B-HPO_TERM
central I-HPO_TERM
facial I-HPO_TERM
nerve I-HPO_TERM
pal I-HPO_TERM
##sy I-HPO_TERM
with O
the O
rest O
of O
the O
cr O
##anial O
nerves O
being O
gross O
##ly O
intact O
on O
motor O
testing O
there O
was O
a O
right O
upper O
ex O
##tre O
##mity O
drift O
with O
strength O
of O
4 O
5 O
and O
bilateral B-HPO_TERM
weakness I-HPO_TERM
of I-HPO_TERM
foot I-HPO_TERM
do I-HPO_TERM
##rs I-HPO_TERM
##i I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##ion I-HPO_TERM
at O
4 O
5 O
with O
normal O
strength O
in O
the O
rest O
of O
her O
muscles O
sensation B-HPO_TERM
was I-HPO_TERM
diminished I-HPO_TERM
to O
pain O
temperature O
vibration O
and O
prop O
##rio O
##ception O
in O
all O
four O
ex O
##tre O
##mit O
##ies O
on O
coordination O
testing O
the O
patient O
was O
unable B-HPO_TERM
to I-HPO_TERM
perform I-HPO_TERM
ﬁ I-HPO_TERM
##nger I-HPO_TERM
to I-HPO_TERM
nose I-HPO_TERM
or O
heel O
to O
shin O
and O
had O
a O
positive B-HPO_TERM
rom I-HPO_TERM
##berg I-HPO_TERM
sign I-HPO_TERM
ga B-HPO_TERM
##it I-HPO_TERM
was I-HPO_TERM
un I-HPO_TERM
##stead I-HPO_TERM
##y I-HPO_TERM
wide I-HPO_TERM
based I-HPO_TERM
and O
ata B-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
with O
the O
patient O
leaning O
more O
to O
the O
right O
re B-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oa I-HPO_TERM
##ctive I-HPO_TERM
at O
1 O
4 O
in O
the O
upper O
and O
lower O
ex O
##tre O
##mit O
##ies O
plant O
##ar O
cut O
##aneous O
responses O
were O
ﬂ O
##ex O
##or O
bilateral O
##ly O
with O
no O
cl O
##onus O
or O
path O
##ological O
spread O

on O
the O
basis O
of O
the O
patient O
s O
clinical O
history O
of O
worse B-HPO_TERM
##ning I-HPO_TERM
seizures I-HPO_TERM
and O
cognitive O
function O
on O
val O
##pro O
##ate O
and O
because O
of O
evidence O
of O

multi O
##sy O
##ste O
##mic O
involvement O
a O
mitochondrial O
cy O
##top O
##athy O
was O
suspected O
though O
the O
differential O
also O
included O
cerebral O
auto O
##som O
##al O
dominant O
arte O
##rio O
##pathy O
with O
sub O
##cor O
##tical O
in O
##far O
##cts O
and O
le O
##uk O
##oe O
##nce O
##pha O
##lo O
##pathy O
cad O
##asi O
##l O
fa O
##mi O
##lia O
##l O
hem O
##ip O
##leg O
##ic O
mig O
##raine O
f O
##hm O
auto O
##som O
##al O
dominant O
ata O
##xia O
##s O
le O
##uk O
##od O
##yst O
##rop O
##hy O
and O
para O
##neo O
##pl O
##astic O
disorder O
as O
well O
as O
diseases O
of O
infectious O
auto O
##im O
##mun O
##e O
and O
ne O
##uro O
##de O
##gen O
##erative O
et O
##iology O
val O
##pro O
##ate O
was O
immediately O
switched O
to O
ph O
##en O
##yt O
##oin O
and O
10 O
dex O
##tro O
##se O
intra O
##ven O
##ously O
with O
l O
car O
##ni O
##tine O
and O
coe O
##nz O
##yme O
q O
10 O
was O
started O
which O
resulted O
in O
rapid O
resolution O
of O
the O
ep O
##ile O
##ptic O
status O
and O
subsequent O
improvement O
of O
the O
patient O
s O
neurological O
function O
diagnostic O
work O
##up O
in O
addition O
to O
scalp O
ve O
##eg O
monitoring O
included O
comprehensive O
blood O
and O
spinal O
ﬂ O
##uid O
testing O
table O
1 O
ne O
##uro O
##ima O
##ging O
echo O
##card O
##io O
##gram O
muscle O
bio O
##psy O
genetic O
testing O
for O
mitochondrial O
disorders O
such O
as O
mitochondrial O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
##like O
episodes O
mel O
##as O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
with O
ragged O
red O
ﬁ O
##bers O
mer O
##rf O
and O
genetic O
testing O
for O
cad O
##asi O
##l O
and O
f O
##hm O
all O
laboratory O
tests O
table O
1 O
except O
for O
the O
high B-HPO_TERM
serum I-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
and I-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
levels O
low B-HPO_TERM
vitamin I-HPO_TERM
b1 I-HPO_TERM
##2 I-HPO_TERM
and I-HPO_TERM
25 I-HPO_TERM
hydro I-HPO_TERM
##xy I-HPO_TERM
##vita I-HPO_TERM
##min I-HPO_TERM
d I-HPO_TERM
levels I-HPO_TERM
brain O
mri O
and O
ee O
##g O
were O
normal O
mri O
of O
the O
brain O
fig O
2 O
revealed O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in O
the O
left O
tha O
##lam O
##us O
left O
par O
##ie O
##tal O
and O
left O
o O
##cci O
##pit O
##al O
co O
##rti O
##cal O
regions O
and O
right O
ce O
##re O
##bella O
##r O
white O
matter O
with O
corresponding O
restricted O
diffusion O
on O
d O
##wi O
as O
well O
as O
associated O
at B-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
left I-HPO_TERM
par I-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lobe I-HPO_TERM
over O
a O
period O
of O
several O
months O
the O
hyper O
##int O
##ense O
lesions O
on O
the O
mri O
resolved O
which O
correlated O
with O
improvement O
of O
the O
patient O
s O
seizures O
and O
neurological O
function O
the O
patient O
was O
discharged O
from O
the O
ep O
##ile O
##psy O
monitoring O
unit O
after O
her O
seizures O
had O
stopped O
and O
she O
was O
periodically O
followed O
in O
the O
out O
##patient O
clinic O

d O
ro O
##sha O
##l O
et O
al O
ep O
##ile O
##psy O
behavior O
21 O
2011 O
206 O
210 O
209 O
fig O
2 O
magnetic O
resonance O
imaging O
left O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
lobe O
hyper O
##int O
##ens O
##ity O
on O
axial O
t O
##2 O
mri O
scan O
of O
brain O
a O
with O
corresponding O
restricted O
diffusion O
signal O
abnormal O
##ity O
b O
during O
the O
initial O
hospital O
stay O
left O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
lobe O
at O
##rop O
##hy O
on O
sa O
##git O
##tal O
t O
##1 O
mri O
scan O
of O
brain O
c O
on O
follow O
up O
imaging O

rev O
##ers O
##ible O
parkinson O
##ism O
due O
to O
involvement O
of O
sub O
##stan O
##tia O
ni O
##gra O
in O
epstein O
barr O
virus O
en O
##ce O
##pha O
##lit O
##is O
although O
the O
prevalence O
of O
epstein O
barr O
virus O
e O
##b O
##v O
infection O
in O
general O
population O
is O
high O
it O
is O
uncommon O
that O
e O
##b O
##v O
infection O
causes O
parkinson O
##ism O
especially O
injuring O
sub O
##stan O
##tia O
ni O
##gra O
directly O
we O
report O
a O
case O
of O
rev O
##ers O
##ible O
parkinson O
##ism O
due O
to O
involvement O
of O
sub O
##stan O
##tia O
ni O
##gra O
in O
e O
##b O
##vre O
##lated O
en O
##ce O
##pha O
##lit O
##is O
case O
report O

a O
24 O
year O
old O
female O
teacher O
presented O
with O
fever O
headache O
and O
vomiting O
then O
an O
akin O
##etic O
rigid O
syndrome O
with O
tremor O
developed O
several O
days O
later O
there O
was O
no O
family O
or O
personal O
history O
of O
movement O
disorders O
or O
other O
neurological O
or O
psychiatric O
diseases O
exposure O
to O
toxic O
substances O
or O
illicit O
drugs O
was O
denied O
the O
ce O
##re O
##bro O
##sp O
##inal O
ﬂ O
##uid O
cs O
##f O
examination O
showed O
normal O
ch O
##lor O
##ine O
and O
glucose O
content O
but O
there O
were O
50 O
white O
blood O
cells O
per O
cubic O
mill O
##ime O
##tre O
and O
slightly O
elevated O
protein O
content O
cs O
##f O
culture O
did O
not O
grow O
any O
organisms O
im O
##mun O
##og O
##lo O
##bu O
##lin O
m O
i O
##gm O
levels O
of O
anti O
##eb O
##v O
viral O
caps O
##id O
antigen O
vc O
##a O
were O
remarkably O
increased O
in O
serum O
and O
cs O
##f O
i O
##gg O
levels O
of O
anti O
e O
##b O
##v O
vc O
##a O
were O
increased O
in O
serum O
but O
not O
detect O
##able O
in O
cs O
##f O
anti O
epstein O
##bar O
##r O
nuclear O
antigen O
e O
##bn O
##a O
antibodies O
were O
not O
detect O
##able O
in O
either O
serum O
or O
cs O
##f O
magnetic O
resonance O
imaging O
mri O
showed O
bilateral O
sub O
##stan O
##tia O
ni O
##gra O
lesions O
on O
admission O
after O
a O
2 O
month O
treatment O
with O
mad O
##opa O
##r O
the O
patient O
recovered O
completely O
without O
any O
sequel O
##ae O
mad O
##opa O
##r O
was O
slowly O
tape O
##red O
off O
and O
withdrawn O
a O
repeated O
mri O
after O
3 O
months O
showed O
resolution O
of O
the O
lesions O
fig O
1 O

discussion O
this O
patient O
ﬁ O
##rst O
presented O
with O
fever O
headache O
and O
vomiting O
followed O
by O
an O
akin O
##etic O
rigid O
syndrome O
with O
tremor O
developing O
several O
days O
later O
clinical O
historical O
and O
investigative O
data O
ruled O
out O
ia O
##tro O
##genic O
toxic O
genetic O
and O
other O
secondary O
causes O
although O
no O
virus O
has O
been O
isolated O
from O
our O
patient O
we O
believe O
that O
she O
had O
post O
##ence O
##pha O
##lit O
##ic O
parkinson O
##ism O
as O
suggested O
by O
a O
history O
and O
ser O
##olo O
##gic O
and O
cs O
##f O
evidence O
the O
mri O
showed O
isolated O
involvement O
of O
the O
sub O

correspondence O
to O
dr O
jing O
##xia O
gu O
##an O
department O
of O
ne O
##uro O
##logy O
ren O
##min O
hospital O
of O
wu O
##han O
university O
no O
238 O
ji O
##ef O
##ang O
road O
wu O
##chang O
district O
wu O
##han O
430 O
##0 O
##60 O
p O
r O
china O
gu O
##an O
##jing O
##xia O
yahoo O
com O
cn O
relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
nothing O
to O
report O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
11 O
october O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##35 O

stan O
##tia O
ni O
##gra O
and O
no O
lesions O
or O
signs O
of O
dem O
##ye O
##lina O
##tion O
elsewhere O
in O
the O
brain O
thus O
it O
was O
con O
##ﬁ O
##rmed O
that O
damage O
to O
the O
sub O
##stan O
##tia O
ni O
##gra O
alone O
could O
produce O
clinical O
features O
of O
pd O
although O
several O
viruses O
are O
known O
to O
cause O
parkinson O
##ism O
1 O
it O
is O
uncommon O
that O
a O
virus O
could O
have O
produced O
lesions O
predominantly O
in O
the O
sub O
##stan O
##tia O
ni O
##gra O
and O
have O
caused O
rev O
##ers O
##ible O
parkinson O
##ism O
such O
selective O
lesions O
have O
demonstrated O
with O
toxin O
##s O
such O
as O
1 O
methyl O
4 O
ph O
##en O
##yl O
##1 O
2 O
3 O
6 O
te O
##tra O
##hy O
##drop O
##yr O
##idi O
##ne O
mp O
##tp O
2 O
however O
the O
current O
study O
demonstrates O
the O
capability O
of O
a O
virus O
to O
do O
so O
hs O
##ie O
##h O
et O
al O
3 O
reported O
the O
case O
of O
a O
boy O
who O
presented O
with O
rev O
##ers O
##ible O
parkinson O
##ism O
as O
the O
major O
sy O
##mpt O
##om O
of O
e O
##b O
##v O
en O
##ce O
##pha O
##lit O
##is O
brain O
single O
photon O
emission O
computed O
tom O
##ography O
spec O
##t O
showed O
diminished O
per O
##fusion O
in O
the O
region O
of O
the O
right O
ca O
##uda O
##te O
nucleus O
and O
no O
abnormalities O
in O
sub O
##stan O
##tia O
ni O
##gra O
rose O
##lli O
et O
al O
4 O
also O
reported O
a O
case O
of O
rev O
##ers O
##ible O
parkinson O
##ism O
associated O
with O
e O
##b O
##v O
en O
##ce O
##pha O
##lit O
##is O
and O
anti O
##ne O
##uron O
##al O
antibodies O
detected O
in O
a O
human O
ne O
##uro O
##bla O
##sto O
##ma O
cell O
line O
which O
suggests O
that O
an O
auto O
##im O
##mun O
##e O
mechanism O
may O
play O
an O
important O
path O
##op O
##hy O
##sio O
##logical O
role O
however O
mri O
showed O
no O
abnormalities O
in O
sub O
##stan O
##tia O
ni O
##gra O
in O
these O
2 O
cases O
which O
was O
different O
from O
our O
case O
our O
observation O
indicates O
a O
direct O
acute O
ne O
##uro O
##tro O
##pic O
effect O
of O
e O
##b O
##v O
on O
ni O
##gra O
##l O
do O
##pa O
##mine O
##rg O
##ic O
cells O
the O
patient O
showed O
a O
substantial O
response O
in O
the O
acute O
phase O
to O
do O
##pa O
##mine O
##rg O
##ic O
medication O
during O
the O
treatment O
this O
patient O
did O
not O
develop O
l O
do O
##pa O
related O
d O
##ys O
##kin O
##es O
##ias O
or O
wearing O
off O
we O
will O
follow O
this O
patient O
to O
observe O
whether O
she O
develops O
pd O
later O

fig O
1 O
mri O
showed O
symmetric O
a O
h O
##yp O
##oint O
##ens O
##ity O
signal O
on O
t O
##1 O
##weight O
##ed O
imaging O
and O
b O
hyper O
##int O
##ens O
##ity O
signal O
on O
t O
##2 O
weighted O
imaging O
in O
bilateral O
sub O
##stan O
##tia O
ni O
##gra O
on O
admission O
a O
repeated O
mri O
after O
3 O
months O
showed O
resolution O
of O
the O
lesions O
on O
c O
t O
##2 O
weighted O
imaging O
and O
d O
t O
##1 O
weighted O
imaging O
156 O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O

in O
conclusion O
our O
report O
indicates O
that O
e O
##b O
##v O
infection O
can O
in O
##jure O
sub O
##stan O
##tia O
ni O
##gra O
directly O
and O
cause O
rev O
##ers O
##ible O
parkinson O
##ism O
nevertheless O
given O
the O
high O
prevalence O
of O
e O
##b O
##v O
infection O
in O
the O
general O
population O
e O
##b O
##v O
testing O
can O
be O
worth O
##while O
in O
acute O
onset O
movement O
disorders O
especially O
those O
manifest O
##ing O
with O
parkinson O
##ism O
jing O
##xia O
gu O
##an O
md O
zu O
##nen O
##g O
lu O
md O
and O
qin O
zhou O
md O
department O
of O
ne O
##uro O
##logy O
ren O
##min O
hospital O
of O
wu O
##han O
university O
wu O
##han O
china O
references O
jang O
h O
bolt O
##z O
da O
webster O
r O
##g O
et O
al O
viral O
parkinson O
##ism O
bio O
##chi O
##m O
bio O
##phy O
##s O
act O
##a O
2009 O
1792 O
71 O
##4 O
72 O
##1 O

burns O
rs O
chi O
##ue O
##h O
cc O
mark O
##ey O
sp O
et O
al O
a O
primate O
model O
of O
parkinson O
##ism O
selective O
destruction O
of O
do O
##pa O
##mine O
##rg O
##ic O
neurons O
in O
the O
par O
##s O
compact O
##a O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
by O
n O
methyl O
4 O
ph O
##en O
##yl O
##1 O
2 O
3 O
6 O
te O
##tra O
##hy O
##drop O
##yr O
##idi O
##ne O
pro O
##c O
nat O
##l O
ac O
##ad O
sci O
u O
s O
a O
1983 O
80 O
45 O
##46 O
45 O
##50 O
hs O
##ie O
##h O
jc O
lu O
##e O
k O
##h O
lee O
y O
##l O
parkinson O
like O
syndrome O
as O
the O
major O
presenting O
sy O
##mpt O
##om O
of O
epstein O
barr O
virus O
en O
##ce O
##pha O
##lit O
##is O
arch O
di O
##s O
child O
2002 O
87 O
35 O
##8 O
rose O
##lli O
f O
russo O
i O
fra O
##dd O
##osi O
##o O
a O
et O
al O
rev O
##ers O
##ible O
parkinson O
##ian O
syndrome O
associated O
with O
anti O
ne O
##uron O
##al O
antibodies O
in O
acute O
e O
##b O
##v O
en O
##ce O
##pha O
##lit O
##is O
a O
case O
report O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2006 O
12 O
257 O
260 O

the O
new O
brady O
##kin O
##es O
##ia O
akin O
##es O
##ia O
inc O
##oor O
##dina O
##tion O
brain O
test O
preliminary O
data O
from O
an O
online O
test O
of O
upper O
limb O
movement O

the O
brady O
##kin O
##es O
##ia O
akin O
##es O
##ia O
inc O
##oor O
##dina O
##tion O
brain O
test O
is O
computer O
software O
based O
on O
the O
alternate O
ﬁ O
##nger O
tap O
test O
1 O
3 O
it O
detect O
##s O
motor O
features O
of O
parkinson O
s O
disease O
pd O
and O
co O
##rre O
##lates O
with O
the O
gold O
standard O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
2 O
3 O
users O
alternately O
tap O
2 O
keys O
15 O
cm O
apart O
on O
a O
standard O
u O
s O
or O
u O
k O
computer O
keyboard O
as O
fast O
and O
accurately O
as O
possible O
for O
60 O
seconds O
the O
original O
version O
ran O
in O
ms O
dos O
and O
testing O
was O
performed O
observed O
under O
experimental O
conditions O
2 O
3 O
we O
have O
produced O
a O
new O
online O
version O
of O
the O
brain O
test O
written O
in O
java O
##script O
that O
can O
be O
self O
administered O
in O
all O
mainstream O
internet O
browser O
##s O
data O
are O
stored O
in O
a O
secure O
online O
database O

nineteen O
pd O
patients O
uk O
brain O
bank O
criteria O
from O
the O
movement O
disorder O
clinic O
at O
the O
royal O
london O
hospital O
consent O
##ed O
to O
participate O
age O
mean O
67 O
years O
disease O
du O
##ra O
correspondence O
to O
dr O
ala O
##sta O
##ir O
j O
no O
##yce O
re O
##ta O
lila O
weston O
institute O
of O
neurological O
studies O
uc O
##l O
institute O
of O
ne O
##uro O
##logy O
1 O
wake O
##ﬁ O
##eld O
street O
london O
uk O
wc O
##1 O
##n O
1 O
##p O
##j O
ala O
##sta O
##ir O
no O
##yce O
mac O
com O
relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
connor O
tre O
##acy O
is O
a O
ben O
##e O
##ﬁ O
##cia O
##ry O
of O
departmental O
funds O
allocated O
to O
rec O
##ode O
and O
deploy O
the O
brain O
test O
online O
all O
other O
authors O
report O
no O
relevant O
ﬁ O
##nan O
##cial O
disclosure O
##s O
or O
con O
##ﬂ O
##ic O
##ts O
of O
interest O

full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
24 O
august O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##47 O
ti O
##on O
mean O
9 O
7 O
years O
hand O
dominance O
17 O
right O
handed O
medication O
16 O
on O
l O
do O
##pa O
2 O
on O
do O
##pa O
##mine O
ago O
##nist O
mono O
##therapy O
1 O
newly O
diagnosed O
motor O
ﬂ O
##uc O
##tua O
##tions O
present O
in O
10 O
and O
on O
off O
status O
10 O
tested O
while O
on O
were O
recorded O
patients O
followed O
on O
screen O
instructions O
and O
were O
not O
assisted O
both O
hands O
were O
tested O
for O
each O
patient O
total O
tests O

¼ O
38 O
patients O
were O
examined O
according O
to O
the O
motor O
section O
of O
the O
up O
##dr O
##s O
full O
ethical O
approval O
was O
granted O
statistics O
were O
performed O
in O
graph O
##pad O
prism O
v O
##5 O
for O
windows O
descriptive O
statistics O
and O
normal O
##ity O
testing O
were O
performed O
for O
all O
variables O
log O
##ari O
##th O
##mic O
transformations O
were O
made O
where O
necessary O
to O
normal O
##ize O
the O
data O

the O
brain O
test O
reports O
4 O
variables O
kin O
##es O
##ia O
score O
ks O
number O
of O
alternating O
key O
taps O
in O
60 O
seconds O
akin O
##es O
##ia O
time O
at O
mean O
dwell O
time O
on O
each O
key O
in O
mill O
##ise O
##con O
##ds O
ms O
d O
##ys O
##met O
##ria O
score O
ds O
weighted O
index O
using O
the O
number O
of O
incorrectly O
hit O
keys O
corrected O
for O
speed O
and O
ar O
##rh O
##yt O
##hmi O
##a O
score O
as O
variance O
of O
the O
time O
interval O
between O
keys O
##tro O
##kes O
our O
preliminary O
results O
give O
the O
following O
means O
with O
25th O
and O
75th O
percent O
##ile O
##s O
for O
pd O
patients O
n O
¼ O
38 O
tests O
ks O
91 O
6 O
taps O
73 O
5 O
110 O
8 O
at O
169 O
ms O
86 O
237 O
ds O
2 O
88 O
2 O
39 O
3 O
34 O
and O
as O
4 O
45 O
4 O
17 O
4 O
79 O

in O
the O
previous O
version O
of O
the O
brain O
test O
the O
variable O
that O
correlated O
best O
with O
the O
up O
##dr O
##s O
was O
ks O
using O
2 O
tailed O
pearson O
s O
tests O
and O
linear O
regression O
on O
the O
current O
data O
sign O
##i O
##ﬁ O
##can O
##t O
correlation O
##s O
were O
seen O
between O
up O
##dr O
##s O
and O
ks O
and O
component O
up O
##dr O
##s O
scores O
and O
ks O
fig O
1a O
e O
these O
correlation O
##s O
are O
comparable O
to O
those O
seen O
with O
the O
previous O
observed O
version O
of O
the O
brain O
test O
2 O

ks O
scores O
were O
analyzed O
for O
number O
of O
taps O
in O
the O
ﬁ O
##rst O
30 O
seconds O
and O
last O
30 O
seconds O
of O
the O
timed O
minute O
in O
test O
runs O
that O
had O
low O
ds O
scores O
ie O
most O
accurate O
n O
¼ O
14 O
there O
was O
no O
difference O
in O
the O
mean O
number O
of O
taps O
43 O
6 O
and O
fig O
1 O
correlation O
between O
total O
up O
##dr O
##s O
motor O
score O
and O
ks O
in O
dominant O
hand O
a O
non O
##dom O
##ina O
##nt O
hand O
b O
and O
most O
affected O
hand O
c O
correlation O
between O
finger O
tapping O
score O
and O
ks O
d O
and O
total O
up O
##dr O
##s O
motor O
score O
in O
1 O
upper O
limb O
and O
ks O
e O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
157 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O

44 O
0 O
taps O
respectively O
paired O
t O
test O
p O
¼ O
0 O
74 O
this O
observation O
supports O
the O
future O
use O
of O
a O
30 O
second O
test O

the O
brain O
test O
is O
a O
quick O
and O
now O
widely O
available O
objective O
test O
of O
upper O
limb O
movement O
making O
it O
an O
attractive O
option O
for O
use O
in O
the O
out O
##patient O
clinic O
and O
in O
clinical O
drug O
trials O
we O
are O
valid O
##ating O
this O
online O
test O
to O
con O
##ﬁ O
##rm O
the O
normal O
range O
of O
the O
4 O
variables O
in O
pd O
and O
matched O
controls O
and O
to O
evaluate O
whether O
at O
ds O
and O
as O
co O
##rre O
##late O
with O
disease O
severity O
scales O
we O
will O
also O
further O
develop O
the O
brain O
test O
to O
operate O
with O
other O
language O
depend O
##ant O
keyboard O
layout O
##s O
non O
##u O
s O
non O
u O
k O
to O
enable O
more O
widespread O
use O
the O
brain O
test O
can O
be O
found O
at O
http O
www O
predict O
##pd O
com O
token O

ala O
##sta O
##ir O
j O
no O
##yce O
b O
##med O
##sc O
##i O
mr O
##cp O
1 O
4 O
connor O
tre O
##acy O
ben O
##g O
msc O
2 O
caroline O
bud O
##u O
bsc O
dip O
##psy O
3 O
julian O
fear O
##nl O
##ey O
md O
fr O
##cp O
3 O
andrew O
j O
lee O
##s O
md O
fr O
##cp O
1 O
and O
gavin O
gi O
##ova O
##nn O
##oni O
phd O
fr O
##cp O
##4 O
1 O
##ret O
##a O
lila O
weston O
institute O
of O
neurological O
studies O
uc O
##l O
institute O
of O
ne O
##uro O
##logy O
london O
uk O
2 O
##grass O
roots O
group O
plc O
hertfordshire O
uk O
3 O
##bar O
##ts O
and O
the O
london O
nhs O
trust O
london O
uk O
4 O
##bl O
##iza O
##rd O
institute O
of O
cell O
and O
molecular O
science O
bart O
##s O
and O
the O
london O
school O
of O
medicine O
and O
dentistry O
queen O
mary O
university O
of O
london O
london O
uk O
references O

burns O
b O
##d O
de O
jong O
jd O
a O
preliminary O
report O
on O
the O
measurement O
of O
parkinson O
s O
disease O
ne O
##uro O
##logy O
1960 O
10 O
109 O
##6 O
110 O
##2 O
gi O
##ova O
##nn O
##oni O
g O
van O
sc O
##hal O
##k O
##wy O
##k O
j O
fritz O
vu O
lee O
##s O
aj O
brady O
##kin O
##es O
##ia O
akin O
##es O
##ia O
inc O
##o O
ordination O
test O
brain O
test O
an O
objective O
computer O
##ized O
assessment O
of O
upper O
limb O
motor O
function O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1999 O
67 O
62 O
##4 O
62 O
##9 O
ho O
##mann O
cn O
su O
##ppa O
##n O
k O
wen O
##zel O
k O
et O
al O
the O
brady O
##kin O
##es O
##ia O
akin O
##es O
##ia O
inc O
##oor O
##dina O
##tion O
test O
brain O
test O
an O
objective O
and O
user O
##fr O
##ien O
##dly O
means O
to O
evaluate O
patients O
with O
parkinson O
##ism O
mo O
##v O
di O
##sor O
##d O
2000 O
15 O
64 O
##1 O
64 O
##7 O

g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
gene O
mutations O
are O
associated O
with O
parkinson O
s O
disease O
in O
russia O
mutations O
in O
the O
gene O
encoding O
g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
gb O
##a O
the O
enzyme O
de O
##ﬁ O
##cie O
##nt O
in O
the O
l O
##ys O
##osomal O
storage O
disorder O
ga O
##ucher O
disease O
g O
##d O
have O
been O
associated O
with O
par O
correspondence O
to O
so O
##fy O
##a O
pc O
##hel O
##ina O
petersburg O
nuclear O
physics O
institute O
ras O
st O
petersburg O
russia O
so O
##pc O
##hel O
##ina O
hot O
##mail O
com O
funding O
agencies O
this O
work O
was O
supported O
by O
a O
grant O
of O
the O
russian O
fund O
of O
fundamental O
investigations O
n O
09 O
04 O
00 O
##9 O
##34 O
a O

relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
nothing O
to O
report O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
13 O
september O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##50 O
this O
article O
originally O
published O
online O
ahead O
of O
print O
on O
13 O
september O
2011 O
dr O
dr O
##oz O
##do O
##va O
s O
was O
miss O
##pel O
##led O
in O
the O
original O
and O
has O
since O
been O
updated O

kin O
##son O
s O
disease O
pd O
in O
different O
ethnic O
populations O
1 O
2 O
to O
date O
almost O
300 O
mutations O
have O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
gb O
##a O
gene O
of O
which O
the O
n O
##37 O
##0s O
l O
##44 O
##4 O
##p O
mutations O
are O
the O
most O
common O
1 O
at O
the O
same O
time O
the O
n O
##37 O
##0s O
and O
l O
##44 O
##4 O
##p O
variants O
are O
the O
most O
frequent O
mutations O
in O
the O
gb O
##a O
gene O
among O
g O
##d O
patients O
in O
russia O
accounting O
for O
45 O
and O
23 O
of O
the O
mutant O
all O
##eles O
respectively O
3 O
gb O
##a O
mutation O
frequency O
among O
pd O
patients O
in O
russia O
has O
not O
yet O
been O
investigated O

here O
we O
examined O
a O
possible O
association O
of O
l O
##44 O
##4 O
##p O
n O
##37 O
##0s O
mutations O
with O
pd O
in O
russia O
the O
study O
was O
approved O
by O
the O
local O
ethics O
committee O
the O
data O
set O
was O
composed O
of O
330 O
unrelated O
pd O
cases O
mean O
age O
63 O
8 O
6 O
9 O
8 O
years O
and O
240 O
controls O
mean O
age O
67 O
7 O
6 O
8 O
8 O
years O
all O
subjects O
were O
residents O
of O
the O
northwestern O
region O
of O
russia O
one O
hundred O
patients O
had O
fa O
##mi O
##lia O
##l O
pd O
mean O
age O
62 O
7 O
6 O
10 O
3 O
years O
eighty O
ﬁ O
##ve O
patients O
had O
early O
onset O
pd O
50 O
years O
old O
mean O
age O
55 O
5 O
6 O
11 O
1 O
years O
mean O
age O
of O
onset O

43 O
6 O
6 O
5 O
8 O
years O
to O
screen O
n O
##37 O
##0s O
l O
##44 O
##4 O
##p O
mutations O
in O
patients O
and O
controls O
pair O
prime O
##rs O
and O
corresponding O
restriction O
enzymes O
were O
used O
as O
previously O
described O
4 O
all O
found O
mutations O
were O
ve O
##ri O
##ﬁ O
##ed O
by O
direct O
sequencing O
of O
pc O
##r O
products O
mutation O
frequencies O
in O
patients O
and O
controls O
were O
compared O
using O
chi O
square O
adjustment O
odds O
ratios O
with O
95 O
con O
##ﬁ O
##den O
##ce O
intervals O
were O
calculated O
to O
test O
the O
association O
between O
the O
gb O
##a O
mutations O
and O
pd O

the O
distributions O
and O
association O
of O
gb O
##a O
mutations O
in O
patients O
and O
controls O
are O
shown O
in O
table O
1 O
het O
##ero O
##zy O
##go O
##us O
gb O
##a O
mutations O
were O
detected O
in O
9 O
pd O
patients O
2 O
7 O
and O
1 O
subject O
in O
the O
control O
group O
0 O
4 O
p O
¼ O
03 O
##8 O
the O
l O
##44 O
##4 O
##p O
mutation O
was O
more O
common O
in O
our O
sample O
of O
pd O
patients O
than O
the O
n O
##37 O
##0s O
as O
was O
previously O
shown O
for O
other O
non O
jewish O
co O
##hort O
##s O
1 O
inverse O
##ly O
the O
n O
##37 O
##0s O
mutation O
dominated O
among O
g O
##d O
patients O
in O
russia O
3 O
to O
date O
several O
studies O
have O
reported O
full O
gb O
##a O
sequencing O
est O
##imating O
the O
odds O
ratio O
for O
carrying O
a O
gb O
##a O
mutation O
in O
a O
subject O
with O
pd O
as O
5 O
43 O
95 O
ci O
3 O
89 O
7 O
57 O
2 O
which O
is O
compatible O
with O
the O
six O
##fold O
increase O
of O
pd O
in O
l O
##44 O
##4 O
##p O
n O
##37 O
##0s O
carriers O
revealed O
in O
our O
study O

most O
published O
studies O
spec O
##i O
##ﬁ O
##cal O
##ly O
investigated O
sporadic O
pd O
in O
our O
study O
we O
showed O
the O
increased O
frequency O
of O
the O
l O
##44 O
##4 O
##p O
mutation O
in O
fa O
##mi O
##lia O
##l O
pd O
the O
association O
of O
gb O
##a O
variants O
with O
fa O
##mi O
##lia O
##l O
pd O
was O
also O
reported O
in O
the O
pro O
##gen O
##i O
study O
5 O
it O
was O
established O
earlier O
that O
parkinson O
##ism O
associated O
with O
a O
gb O
##a O
mutation O
appears O
to O
ph O
##eno O
##typical O
##ly O
resemble O
sporadic O
pd O
but O
an O
early O
disease O
onset O
was O
reported O
1 O
in O
our O
study O
the O
frequency O
of O
the O
l O
##44 O
##4 O
##p O
mutation O
in O
patients O
with O
early O
onset O
50 O
years O
old O
pd O
was O
the O
highest O
among O
the O
studied O
groups O

in O
summary O
we O
have O
demonstrated O
that O
gb O
##a O
l O
##44 O
##4 O
##p O
n O
##37 O
##0s O
mutations O
are O
found O
in O
russian O
pd O
patients O
at O
the O
same O
frequencies O
as O
mutations O
in O
the O
l O
##rr O
##k O
##2 O
gene O
6 O
7 O
our O
data O
indicate O
that O
the O
gb O
##a O
l O
##44 O
##4 O
##p O
n O
##37 O
##0s O
mutations O
are O
genetic O
su O
##sc O
##ept O
##ibility O
factors O
for O
parkinson O
s O
disease O
in O
russia O
anton O
em O
##ely O
##anov O
ms O
1 O
2 O
3 O
ta O
##tya O
##na O
bo O
##uki O
##na O
phd O
4 O
andrey O
ya O
##kim O
##ov O
##ski O
##i O
md O
phd O
2 O
ta O
##tya O
##na O
use O
##nko O
ms O
1 O
2 O
ale O
##sy O
##a O
dr O
##oz O
##do O
##va O
ms O
1 O
andrey O
za O
##khar O
##chuk O
md O
phd O
5 O
pavel O
and O
##os O
##kin O
ms O
1 O
michael O
dub O
##ina O
md O
phd O
ds O
##ci O
cm O
of O
ras O
2 O
3 O
alexander O
schwarz O
##man O
phd O
ds O
##ci O
1 O
and O
so O
##fy O
##a O
pc O
##hel O
##ina O
phd O
##1 O
2 O
3 O

158 O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O
table O
1 O
distributions O
and O
association O
of O
l O
##44 O
##4 O
##p O
n O
##37 O
##0s O
gb O
##a O
mutations O
in O
patients O
and O
controls O
6 O
7 O
1 O
05 O
42 O
4 O
p O
¼ O
03 O
##8 O
##a O
ao O
##dd O
##s O
ratio O
95 O
con O
##ﬁ O
##den O
##ce O
interval O
p O
value O
1 O
##pet O
##ers O
##burg O
nuclear O
physics O
institute O
ras O
st O
petersburg O
russia O
2 O
##pa O
##v O
##lov O
s O
state O
medical O
university O
of O
saint O
petersburg O
st O
petersburg O
russia O
3 O
##st O
petersburg O
academic O
university O
nano O
##tech O
##nology O
research O
and O
education O
centre O
ras O
st O
petersburg O
russia O
4 O
##res O
##ear O
##ch O
centre O
for O
medical O
genetics O
rams O
moscow O
russia O

5 O
##st O
petersburg O
state O
university O
st O
petersburg O
russia O
references O
ve O
##laya O
##ti O
a O
yu O
w O
##h O
sid O
##ran O
##sky O
e O
the O
role O
of O
g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
mutations O
in O
parkinson O
disease O
and O
lew O
##y O
body O
disorders O
cu O
##rr O
ne O
##uro O
##l O
ne O
##uro O
##sc O
##i O
rep O
2010 O
10 O
190 O
198 O
de O
##pa O
##olo O
j O
go O
##ker O
al O
##pan O
o O
sam O
##ad O
##dar O
t O
lopez O
g O
sid O
##ran O
##sky O
e O
the O
association O
between O
mutations O
in O
the O
l O
##ys O
##osomal O
protein O
g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
and O
parkinson O
##ism O
mo O
##v O
di O
##sor O
##d O
2009 O
24 O
157 O
##1 O
157 O
##8 O

bu O
##kin O
##a O
t O
##m O
ts O
##vet O
##kova O
iv O
distribution O
of O
mutations O
of O
acid O
beta O
d O
g O
##lu O
##cos O
##ida O
##se O
gene O
gb O
##a O
among O
68 O
russian O
patients O
with O
ga O
##ucher O
s O
disease O
in O
russian O
bio O
##med O
k O
##him O
2007 O
53 O
59 O
##3 O
60 O
##2 O
ah O
##aro O
##n O
pere O
##tz O
j O
rosen O
##baum O
h O
ge O
##rs O
##hon O
##i O
bar O
##uch O
r O
mutations O
in O
the O
g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
gene O
and O
parkinson O
s O
disease O
in O
ash O
##ken O
##azi O
jews O
n O
eng O
##l O
j O
med O
2004 O
351 O
1972 O
1977 O
nichols O
wc O
pan O
##kra O
##tz O
n O
marek O
d O
##k O
et O
al O
parkinson O
study O
group O
pro O
##gen O
##i O
investigators O
mutations O
in O
gb O
##a O
are O
associated O
with O
fa O
##mi O
##lia O
##l O
parkinson O
disease O
su O
##sc O
##ept O
##ibility O
and O
age O
at O
onset O
ne O
##uro O
##logy O
2009 O
72 O
310 O
316 O

pc O
##hel O
##ina O
s O
##n O
ya O
##kim O
##ov O
##ski O
##i O
af O
ivanov O
##a O
on O
em O
##elia O
##nov O
ak O
za O
##khar O
##chuk O
ah O
schwarz O
##man O
al O
g O
##20 O
##19 O
##s O
l O
##rr O
##k O
##2 O
mutation O
in O
fa O
##mi O
##lia O
##l O
and O
sporadic O
parkinson O
s O
disease O
in O
russia O
mo O
##v O
di O
##sor O
##d O
2006 O
21 O
223 O
##4 O
223 O
##6 O
pc O
##hel O
##ina O
s O
##n O
ya O
##kim O
##ov O
##ski O
##i O
af O
em O
##ely O
##anov O
ak O
ivanov O
##a O
on O
schwarz O
##man O
al O
singleton O
ab O
screening O
for O
l O
##rr O
##k O
##2 O
mutations O
in O
patients O
with O
parkinson O
s O
disease O
in O
russia O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
a O
novel O
l O
##rr O
##k O
##2 O
variant O
eu O
##r O
j O
ne O
##uro O
##l O
2008 O
15 O
69 O
##2 O
69 O
##6 O
a O
stimulus O
sensitive O
ti O
##c O
disorder O
characterized O
by O
echo O
##ph O
##eno O
##men O
##a O
and O
cop O
##rol O
##alia O

the O
coe O
##xi O
##sten O
##ce O
of O
echo O
##pr O
##ax O
##ia O
echo O
##lal O
##ia O
cop O
##rol O
##alia O
and O
force O
obedience O
were O
ﬁ O
##rst O
studied O
by O
george O
beard O
and O
labeled O
as O
the O
jumping O
french O
##men O
of O
maine O
1 O
similar O
but O
culturally O
distinct O
phenomenon O
was O
later O
described O
from O
siberia O
mir O
##ya O
##chi O
##t O
2 O
and O
in O
malay O
##ian O
women O
la O
##ta O
##h O
3 O
gilles O
de O
la O
tour O
##ette O
##4 O
described O
mala O
##die O
des O
ti O
##cs O
con O
##vu O
##ls O
##if O
##s O
and O
considered O
this O
new O
disorder O
to O
be O
similar O
in O
ca O
##usa O
##tion O
to O
the O
culturally O
determined O
start O
##le O
syndrome O
##s O
more O
recent O
studies O
have O
distance O
##d O
these O
disorders O
from O
gilles O
de O
la O
tour O
##ette O
syndrome O
despite O
the O
publication O
of O
some O
cases O
with O
stimulus O
##ind O
##uce O
##d O
ti O
##cs O
##5 O
and O
considered O
them O
to O
be O
fact O
##iti O
##ous O
psycho O
##genic O
or O
psychotic O
in O
origin O
6 O
it O
was O
later O
proposed O
that O
there O
is O
a O
universal O
tendency O
to O
exaggerated O
start O
##le O
in O
some O
individuals O
which O
may O
be O
more O
or O
less O
exaggerated O
7 O

our O
patient O
was O
a O
41 O
year O
old O
man O
from O
istanbul O
whose O
symptoms O
began O
at O
the O
age O
of O
8 O
years O
shortly O
after O
a O
rat O
had O
jumped O
onto O
him O
following O
this O
frightening O
episode O
he O
reacted O
with O
ti O
##c O
like O
grimace O
##s O
neck O
turning O
to O
the O
left O
and O
the O
utter O
##ance O
of O
a O
single O
stereo O
##type O
##d O
ob O
##sc O
##enity O
every O
time O
he O
looked O
at O
an O
animal O
someone O
uttered O
the O
name O
of O
a O
furry O
animal O
or O
someone O
used O
the O
word O
furry O
in O
conversation O
he O
also O
developed O
severe O
echo O
##pr O
##ax O
##ia O
which O
he O
could O
only O
br O
##ie O
##ﬂ O
##y O
suppress O
voluntarily O
and O
at O
the O
expense O
of O
chest O
pain O
he O
in O
##vo O
##lun O
##tar O
##ily O
concentrate O
##s O
on O
the O
gestures O
of O
the O
person O
he O
talks O
to O
rather O
than O
the O
content O
of O
the O
conversation O
he O
cannot O
watch O
television O
because O
he O
becomes O
extremely O
exhausted O
by O
echo O
##pr O
##ax O
##ia O
there O
were O
no O
spontaneously O
occurring O
ti O
##cs O
and O
no O
forced O
obedience O

he O
completed O
primary O
school O
with O
di O
##f O
##ﬁ O
##cu O
##lty O
and O
experienced O
great O
stress O
during O
military O
service O
he O
was O
married O
but O
divorced O
due O
to O
his O
imitation O
behaviors O
he O
was O
a O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
correspondence O
to O
dr O
hu O
##ly O
##a O
ap O
##ay O
##din O
ad O
##nan O
men O
##der O
##es O
bu O
##lva O
##ri O
em O
##lak O
##bank O
ev O
##ler O
##i O
d O
##3 O
b O
##lok O
d O
30 O
fat O
##ih O
34 O
##25 O
##0 O
istanbul O
turkey O
ap O
##ay O
##din O
hu O
##ly O
##a O
hot O
##mail O
com O
relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
nothing O
to O
report O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

published O
online O
13 O
september O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##52 O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
159 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O

security O
guard O
at O
night O
to O
avoid O
social O
contact O
but O
was O
then O
offered O
a O
well O
paid O
job O
by O
a O
rich O
employer O
to O
entertain O
clients O
with O
his O
antics O
he O
refused O
treatment O
despite O
having O
a O
my O
##oca O
##rdial O
in O
##far O
##ction O
after O
pronounced O
teasing O
by O
his O
neighbors O
he O
had O
never O
received O
psycho O
##tro O
##pic O
medication O
including O
ne O
##uro O
##le O
##ptic O
##s O
there O
is O
no O
family O
history O
for O
ti O
##cs O
tour O
##ette O
s O
syndrome O
or O
any O
other O
psychiatric O
and O
ne O
##uro O
##logic O
disorder O

the O
neurological O
examination O
was O
normal O
except O
he O
displayed O
echo O
##pr O
##ax O
##ia O
echo O
##lal O
##ia O
and O
cop O
##rol O
##alia O
see O
video O
he O
displayed O
a O
short O
start O
##le O
response O
upon O
auditory O
or O
ta O
##ct O
##ile O
stimulus O
and O
after O
the O
start O
##le O
he O
im O
##itated O
behavior O
shouting O
or O
clapping O
or O
touching O
the O
person O
who O
touched O
him O
in O
the O
ﬁ O
##rst O
place O
he O
had O
severe O
ob O
##ses O
##sive O
com O
##pu O
##ls O
##ive O
disorder O
depression O
claus O
##tro O
##phobia O
and O
nyc O
##top O
##ho O
##bia O
but O
there O
was O
no O
evidence O
of O
schizophrenia O
and O
he O
had O
rational O
insight O
into O
his O
behavior O

we O
described O
this O
patient O
as O
hu O
##yl O
##u O
of O
turkey O
which O
means O
te O
##tch O
##y O
we O
believe O
that O
he O
has O
a O
ne O
##uro O
##psy O
##chia O
##tric O
disorder O
akin O
to O
culturally O
related O
start O
##le O
syndrome O
##s O
and O
stimulus O
induced O
ti O
##cs O
because O
of O
the O
striking O
imitation O
behavior O
and O
echo O
##ph O
##eno O
##men O
##a O
stimulus O
sensitivity O
to O
animals O
dominating O
the O
clinical O
picture O
and O
the O
lack O
of O
abnormal O
movements O
spontaneously O
under O
situations O
of O
stress O
or O
boredom O
we O
think O
this O
condition O
is O
not O
a O
variant O
of O
gilles O
de O
la O
tour O
##ette O
syndrome O
but O
much O
more O
closely O
linked O
to O
la O
##ta O
##h O
and O
jumping O
french O
##men O
video O
legend O

video O
the O
patient O
displayed O
echo O
##pr O
##ax O
##ia O
echo O
##lal O
##ia O
and O
cop O
##rol O
##alia O
upon O
stimuli O
given O
by O
our O
staff O
in O
segment O
1 O
the O
patient O
tries O
to O
duplicate O
every O
movement O
made O
by O
our O
staff O
in O
segment O
2 O
the O
television O
is O
turned O
on O
and O
the O
patient O
ﬁ O
##rst O
shows O
an O
attempt O
to O
im O
##itate O
what O
he O
sees O
however O
he O
cannot O
duplicate O
many O
movements O
and O
shows O
signs O
of O
anxiety O
and O
avoids O
looking O
at O
the O
screen O
in O
segment O
3 O
the O
patient O
immediately O
repeats O
the O
name O
of O
a O
furry O
animal O
pronounced O
by O
the O
doctor O
and O
then O
swear O
##s O
a O
few O
times O
he O
uses O
the O
same O
swearing O
words O
each O
time O
and O
turns O
his O
head O
to O
the O
left O
with O
mouth O
##ing O
and O
anxiety O

hu O
##ly O
##a O
ap O
##ay O
##din O
md O
1 O
ben O
##bir O
md O
1 O
and O
andrew O
lee O
##s O
md O
##2 O
1 O
##de O
##par O
##tment O
of O
ne O
##uro O
##logy O
ce O
##rra O
##hp O
##asa O
medical O
school O
istanbul O
university O
istanbul O
turkey O
2 O
##ret O
##a O
lila O
weston O
institute O
of O
neurological O
studies O
university O
college O
london O
and O
national O
hospital O
for O
ne O
##uro O
##logy O
and O
ne O
##uro O
##sur O
##ger O
##y O
queen O
square O
london O
uk O
references O
beard O
g O
experiments O
with O
the O
jumper O
##s O
or O
jumping O
french O
##men O
of O
maine O
j O
ne O
##r O
##v O
men O
##t O
di O
##st O
1886 O
7 O
48 O
##7 O
490 O
hammond O
w O
mir O
##ya O
##chi O
##t O
a O
newly O
described O
disease O
of O
the O
nervous O
system O
and O
its O
analogue O
##s O
n O
y O
med O
j O
1884 O
39 O
191 O
192 O

o O
brien O
ha O
la O
##ta O
##h O
journal O
of O
the O
straits O
of O
branch O
of O
the O
royal O
asia O
##te O
society O
of O
great O
britain O
and O
ireland O
1883 O
11 O
143 O
153 O
de O
la O
tour O
##ette O
g O
jumping O
la O
##ta O
##h O
my O
##ria O
##chi O
##t O
archives O
de O
ne O
##uro O
##logie O
paris O
1884 O
8 O
68 O
74 O
ti O
##js O
##sen O
ma O
brown O
p O
morris O
hr O
lee O
##s O
a O
late O
onset O
start O
##le O
induced O
ti O
##cs O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1999 O
67 O
78 O
##2 O
78 O
##4 O
van O
lo O
##on O
f O
##hg O
am O
##ok O
and O
la O
##ta O
##h O
j O
abnormal O
soc O
ps O
##ych O
1927 O
21 O
43 O
##4 O
44 O
##4 O
ea O
##pen O
v O
lee O
##s O
aj O
la O
##kk O
##e O
jp O
trim O
##ble O
mr O
robertson O
mm O
adult O
##ons O
##et O
ti O
##c O
disorders O
mo O
##v O
di O
##sor O
##d O
2002 O
17 O
73 O
##5 O
740 O
generalized O
d O
##yst O
##onia O
at O
##het O
##osis O
and O
parkinson O
##ism O
associated O
with O
fox O
##g O
##1 O
mutation O

fox O
##g O
##1 O
ha O
##pl O
##oin O
##su O
##f O
##ﬁ O
##ciency O
is O
a O
rare O
cause O
of O
complex O
developmental O
en O
##ce O
##pha O
##lo O
##pathy O
due O
to O
de O
novo O
intra O
##genic O
mutations O
of O
the O
fork O
##head O
box O
g O
##1 O
fox O
##g O
##1 O
gene O
large O
del O
##eti O
##ons O
encompassing O
the O
gene O
or O
disruption O
of O
cis O
regulatory O
elements O
1 O
the O
typical O
fox O
##g O
##1 O
syndrome O
a O
key O
differential O
diagnosis O
of O
re O
##tt O
syndrome O
is O
one O
of O
early O
onset O
severe O
en O
##ce O
##pha O
##lo O
##pathy O
with O
micro O
##ce O
##pha O
##ly O
and O
hand O
and O
tongue O
stereo O
##ty O
##pies O
less O
than O
10 O
of O
the O
fox O
##g O
##1 O
patients O
are O
able O
to O
walk O
1 O
mixed O
hyper O
##kin O
##etic O
early O
onset O
movement O
disorders O
are O
also O
a O
hallmark O
of O
the O
syndrome O
they O
are O
characterized O
by O
various O
combinations O
of O
cho O
##rea O
d O
##yst O
##onia O
and O
at O
##het O
##osis O
clinical O
spectrum O
and O
disease O
s O
course O
in O
adulthood O
are O
poorly O
known O
1 O
3 O

a O
38 O
year O
old O
female O
had O
no O
fa O
##mi O
##lia O
##l O
history O
of O
ne O
##uro O
##logic O
or O
psychiatric O
disorder O
pregnancy O
delivery O
and O
per O
##ina O
##tal O
period O
were O
normal O
she O
had O
severe O
psycho O
##moto O
##r O
re O
##tar O
##dation O
from O
age O
3 O
months O
micro O
##ce O
##pha O
##ly O
was O
noted O
from O
age O
11 O
months O
2 O
standard O
deviation O
##s O
sd O
and O
gradually O
worsened O
she O
walked O
at O
age O
5 O
years O
and O
never O
acquired O
language O
social O
interactions O
were O
very O
poor O
she O
had O
ph O
##arm O
##aco O
##res O
##pon O
##sive O
ep O
##ile O
##psy O
with O
tonic O
cl O
##onic O
seizures O
and O
stereo O
##ty O
##pies O
since O
childhood O
around O
the O
age O
of O
30 O
years O
according O
to O
the O
mother O
although O
the O
date O
of O
onset O
could O
not O
be O
ve O
##ri O
##ﬁ O
##ed O
she O
developed O
d O
##ys O
##kin O
##etic O
movement O
disorders O
with O
gradual O
worse O
##ning O
of O
walking O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
at O
age O
38 O
she O
was O
treated O
with O
val O
##pro O
##ate O
for O
20 O
years O
and O
lam O
##ot O
##ri O
##gin O
##e O
for O
2 O
years O
for O
ep O
##ile O
##psy O
she O
had O
micro O
##ce O
##pha O
##ly O
head O
ci O
##rc O
##um O
##ference O
3 O
5 O
sd O
and O
converge O
##nt O
st O
##ra O
##bis O
##mus O
she O
had O
stereo O
##ty O
##pies O
with O
frequent O
rubbing O
t O
##wi O
##ddling O
hand O
movements O
and O
occasional O
episodes O
of O
trunk O
rocking O
see O
video O
she O
also O
had O
generalized O
d O
##yst O
##onia O
with O
predominant O
cr O
##ani O
##of O
##ac O
##ial O
involvement O
at O
##het O
##oid O
movements O
of O
the O
4 O
limbs O
and O
akin O
##etic O
rigid O
parkinson O
##ism O
without O
tremor O
see O
video O
there O
was O
no O
manifestation O
of O
ve O
##get O
##ative O
dysfunction O
at O
the O
last O
follow O
up O
at O
age O
41 O
years O
the O
patient O
could O
still O
walk O
una O
##ided O
brain O
magnetic O
resonance O
imaging O
mri O
showed O
sim O
##pl O
##i O
##ﬁ O
##ed O
g O
##yra O
##l O
pattern O
and O
reduced O
white O
matter O
volume O
fig O
1 O
do O
##pa O
##mine O
transport O
##er O
imaging O
with O
123 O
##i O
f O
##p O
ci O
##t O
dat O
##scan O
showed O
a O
moderate O
as O
##ym O
##metric O
##al O
reduction O
in O
st O
##ria O
##tal O
up O
##take O
pre O
##dom O
##inating O
in O
put O
##amina O
array O
comparative O
gen O
##omic O
hybrid O
##ization O
found O
no O
ch O
##rom O
##osomal O
abnormal O
##ity O
and O
sequencing O
of O
the O
me O
##cp O
##2 O
gene O
was O
normal O
molecular O
studies O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
new O
mutation O
c O
610 O
##c O
t O
in O

additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
correspondence O
to O
emmanuel O
ro O
##ze O
le O
des O
mala O
##dies O
du O
sy O
##ste O
me O
nerve O
##ux O
group O
##e O
hospital O
##ier O
pit O
##ie O
##´ O
tri O
##e O
re O
47 O
83 O
boulevard O
de O
l O
pit O
##al O
75 O
##65 O
##1 O
paris O
ce O
##de O
##x O
13 O
france O
emmanuel O
ﬂ O
##aman O
##d O
ro O
##ze O
ps O
##l O
ap O
##hp O
fr O
relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
none O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O

published O
online O
23 O
september O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##56 O
160 O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O
fig O
1 O
axial O
and O
para O
##sa O
##git O
##tal O
brain O
mri O
showing O
frontal O
h O
##yp O
##ogen O
##esis O
simplified O
g O
##yra O
##l O
pattern O
and O
globally O
reduced O
white O
matter O
volume O
mri O
magnetic O
resonance O
imaging O
fox O
##g O
##1 O
resulting O
in O
the O
p O
le O
##u O
##20 O
##4 O
##ph O
##e O
change O
at O
the O
amino O
acid O
level O

the O
fox O
##g O
##1 O
mutation O
was O
absent O
in O
her O
mother O
but O
its O
de O
novo O
origin O
could O
not O
be O
as O
##cer O
##tained O
because O
of O
the O
father O
s O
death O
however O
its O
ca O
##usa O
##tive O
role O
is O
highly O
probable O
1 O
it O
lies O
in O
the O
functional O
##ly O
critical O
dna O
binding O
fork O
##head O
domain O
of O
the O
protein O
2 O
it O
involves O
a O
residue O
highly O
conserved O
in O
different O
species O
and O
3 O
it O
was O
never O
found O
in O
200 O
control O
females O

four O
adult O
fox O
##g O
##1 O
patients O
have O
been O
previously O
reported O
aged O
18 O
31 O
years O
1 O
3 O
none O
of O
them O
had O
been O
able O
to O
walk O
and O
there O
is O
no O
detailed O
information O
on O
the O
characteristics O
and O
course O
of O
their O
movement O
disorders O
our O
patient O
is O
the O
oldest O
reported O
fox O
##g O
##1 O
case O
which O
con O
##ﬁ O
##rm O
##s O
that O
prolonged O
survival O
into O
adulthood O
is O
possible O
she O
has O
original O
ph O
##eno O
##typic O
characteristics O
1 O
she O
was O
able O
to O
walk O
accounting O
for O
a O
rare O
mild O
ph O
##eno O
##type O
of O
the O
disorder O
2 O
d O
##yst O
##onia O
and O
at O
##het O
##oid O
movements O
started O
later O
in O
life O
than O
in O
other O
reported O
fox O
##g O
##1 O
patients O
##1 O
5 O
3 O
she O
had O
late O
onset O
a O
kinetic O
rigid O
parkinson O
##ism O
similar O
to O
what O
has O
been O
reported O
in O
patients O
with O
re O
##tt O
syndrome O
6 O
anti O
##ep O
##ile O
##ptic O
drugs O
might O
have O
contributed O
to O
the O
movement O
disorders O
but O
the O
absence O
of O
a O
temporal O
link O
between O
drugs O
intake O
and O
their O
development O
and O
the O
dat O
##scan O
abnormalities O
do O
not O
favor O
this O
hypothesis O
although O
we O
cannot O
exclude O
a O
co O
occurrence O
of O
early O
onset O
parkinson O
s O
disease O
and O
fox O
##g O
##1 O
syndrome O
our O
ﬁ O
##nding O
##s O
based O
on O
this O
single O
case O
suggest O
that O
dysfunction O
of O
the O
ni O
##gr O
##ost O
##ria O
##tal O
pathway O
can O
result O
from O
fox O
##g O
##1 O
mutations O
a O
similar O
alteration O
has O
been O
evidenced O
in O
rt O
##t O
patients O
7 O

this O
report O
further O
expands O
the O
clinical O
spectrum O
of O
fox O
##g O
##1 O
mutations O
it O
also O
emphasizes O
the O
diagnostic O
value O
of O
movement O
disorders O
including O
d O
##yst O
##onia O
at O
##het O
##osis O
and O
or O
parkinson O
##ism O
associated O
with O
stereo O
##ty O
##pies O
in O
adult O
patients O
with O
early O
onset O
en O
##ce O
##pha O
##lo O
##pathy O
and O
micro O
##ce O
##pha O
##ly O
legends O
to O
the O
video O
video O
mixed O
movement O
disorders O
due O
to O
fox O
##g O
##1 O
syndrome O
segment O
1 O
the O
patient O
is O
able O
to O
walk O
una O
##ided O
note O
the O
d O
##yst O
##onic O
posture O
of O
the O
4 O
limbs O
distal O
more O
than O
pro O
##xi O
##mal O

segment O
2 O
the O
d O
##yst O
##onic O
posture O
of O
the O
upper O
limbs O
interfere O
##s O
with O
voluntary O
movements O
note O
the O
at O
##het O
##oid O
movements O
of O
the O
hands O
and O
feet O
segment O
3 O
note O
the O
severe O
oro O
##fa O
##cial O
involvement O
with O
mobile O
d O
##yst O
##onia O
segment O
4 O
rubbing O
and O
t O
##wi O
##ddling O
hand O
stereo O
##ty O
##pies O
au O
##re O
##´ O
##lie O
me O
##´ O
##ner O
##et O
md O
1 O
cyril O
mig O
##not O
md O
phd O
2 O
3 O
isabelle O
an O
md O
phd O
4 O
marie O
odi O
##le O
ha O
##bert O
md O
5 O
au O
##re O
##´ O
##lia O
ja O
##c O
##quette O
md O
2 O
3 O
marie O
vida O
##il O
##het O
md O
1 O
6 O
thierry O
bien O
##ven O
##u O
phd O
7 O
and O
emmanuel O
ro O
##ze O
md O
phd O
##1 O
6 O

1 O
##de O
##´ O
##par O
##tem O
##ent O
de O
ne O
##uro O
##logie O
le O
des O
mala O
##dies O
du O
sy O
##ste O
me O
nerve O
##ux O
group O
##e O
hospital O
##ier O
pit O
##ie O
##´ O
re O
universite O
##´ O
pierre O
et O
marie O
cu O
##rie O
paris O
vi O
paris O
france O
2 O
##uni O
##te O
##´ O
f O
##on O
##ction O
##nell O
##e O
de O
ge O
##´ O
##ne O
##´ O
##tique O
cl O
##ini O
##que O
group O
##e O
hospital O
##ier O
pit O
##ie O
##´ O
re O
ap O
##hp O
paris O
france O
3 O
##cent O
##re O
de O
re O
##´ O
##fe O
##´ O
##rence O
des O
de O
##´ O
##ﬁ O
##cie O
##nce O
##s O
intellect O
##uel O
##les O
de O
causes O
rare O
##s O
ap O
##hp O
paris O
france O
4 O
##ser O
##vic O
##e O
de O
ne O
##uro O
##logie O
1 O
le O
des O
mala O
##dies O
du O
sy O
##ste O
me O
nerve O
##ux O
group O
##e O
hospital O
##ier O
pit O
##ie O
##´ O
re O
universite O
##´ O
pierre O
et O
marie O
cu O
##rie O
paris O
vi O
paris O
france O

5 O
##ser O
##vic O
##e O
de O
me O
##´ O
##de O
##cine O
nu O
##cle O
##´ O
##aire O
group O
##e O
hospital O
##ier O
pit O
##ie O
##´ O
re O
universite O
##´ O
pierre O
et O
marie O
cu O
##rie O
paris O
vi O
paris O
france O
6 O
##cr O
##ic O
##m O
up O
##mc O
ins O
##er O
##m O
um O
##r O
s O
##9 O
##75 O
cn O
##rs O
um O
##r O
##7 O
##22 O
##5 O
paris O
france O
7 O
##ins O
##ti O
##tu O
##t O
cochin O
universite O
##´ O
paris O
des O
##car O
##tes O
cn O
##rs O
um O
##r O
81 O
##0 O
##4 O
ins O
##er O
##m O
u O
##10 O
##16 O
paris O
france O
references O
ko O
##rt O
##u O
##¨ O
m O
f O
das O
s O
fl O
##ind O
##t O
m O
et O
al O
the O
core O
fox O
##g O
##1 O
syndrome O
ph O
##eno O
##type O
consists O
of O
post O
##nat O
##al O
micro O
##ce O
##pha O
##ly O
severe O
mental O
re O
##tar O
##dation O
absent O
language O
d O
##ys O
##kin O
##es O
##ia O
and O
corpus O
call O
##os O
##um O
h O
##yp O
##ogen O
##esis O
j O
med O
gene O
##t O
2011 O
48 O
39 O
##6 O
406 O

aria O
##ni O
f O
hay O
##ek O
g O
ron O
##dine O
##lla O
d O
et O
al O
fox O
##g O
##1 O
is O
responsible O
for O
the O
congenital O
variant O
of O
re O
##tt O
syndrome O
am O
j O
hum O
gene O
##t O
2008 O
83 O
89 O
93 O
philippe O
c O
am O
##sal O
##lem O
d O
fran O
##can O
##net O
c O
et O
al O
ph O
##eno O
##typic O
variability O
in O
re O
##tt O
syndrome O
associated O
with O
fox O
##g O
##1 O
mutations O
in O
females O
j O
med O
gene O
##t O
2010 O
47 O
59 O
65 O
jacob O
f O
##d O
rama O
##sw O
##amy O
v O
andersen O
j O
bold O
##uc O
f O
##v O
at O
##yp O
##ical O
re O
##tt O
syndrome O
with O
selective O
fox O
##g O
##1 O
del O
##eti O
##on O
detected O
by O
comparative O
gen O
##omic O
hybrid O
##ization O
case O
report O
and O
review O
of O
literature O
eu O
##r O
j O
hum O
gene O
##t O
2009 O
17 O
157 O
##7 O
158 O
##1 O

men O
##care O
##lli O
ma O
span O
##hol O
ross O
##eto O
a O
art O
##uso O
r O
et O
al O
novel O
fox O
##g O
##1 O
mutations O
associated O
with O
the O
congenital O
variant O
of O
re O
##tt O
syndrome O
j O
med O
gene O
##t O
2010 O
47 O
49 O
53 O
ro O
##ze O
e O
co O
##chen O
v O
sang O
##la O
s O
et O
al O
re O
##tt O
syndrome O
an O
overlooked O
diagnosis O
in O
women O
with O
stereo O
##typic O
hand O
movements O
psycho O
##moto O
##r O
re O
##tar O
##dation O
parkinson O
##ism O
and O
d O
##yst O
##onia O
mo O
##v O
di O
##sor O
##d O
2007 O
22 O
38 O
##7 O
38 O
##9 O
dunn O
h O
##g O
st O
##oes O
##sl O
aj O
ho O
h O
##h O
et O
al O
re O
##tt O
syndrome O
investigation O
of O
nine O
patients O
including O
pet O
scan O
can O
j O
ne O
##uro O
##l O
sci O
2002 O
29 O
345 O
357 O
movement O
disorders O
vol O
27 O
no O
1 O
2012 O
161 O
l O
e O
t O
t O
e O
r O
s O
n O
e O
w O
o O
b O
s O
e O
r O
v O
a O
t O
i O
o O
n O
s O

d O
##yst O
##onia O
in O
mitochondrial O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
and O
ep O
##ile O
##psy O
syndrome O
associated O
with O
novel O
recess O
##ive O
pol B-GENE
##g I-GENE
mutations O
mutations O
in O
the O
polymer O
##ase O
c O
pol O
##g O
gene O
cause O
a O
growing O
spectrum O
of O
auto O
##som O
##al O
dominant O
and O
recess O
##ive O
ph O
##eno O
##type O
##s O
cho O
##rea O
my O
##oc O
##lon O
##us O
ata O
##xia O
and O
parkinson O
##ism O
can O
be O
observed O
d O
##yst O
##onia O
has O
been O
rarely O
described O
1 O
we O
present O
a O
girl B-PATIENT
with O
mitochondrial B-HPO_TERM
spin I-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
msc O
##ae O
2 O
who O
developed O
d B-HPO_TERM
##yst I-HPO_TERM
##onia I-HPO_TERM
and O
is O
compound O
het O
##ero O
##zy O
##go O
##te O
for O
a O
novel O
combination O
of O
pol O
##g O
mutations O

our O
patient B-PATIENT
presented O
elsewhere O
at O
age O
15 B-AGE_ONSET
years O
with O
generalized B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
and O
mild O
long B-HPO_TERM
standing I-HPO_TERM
learning I-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lt I-HPO_TERM
##ies I-HPO_TERM
requiring O
special O
education O
while O
taking O
val O
##pro O
##ate O
she O
developed O
acute B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
a O
mitochondrial O
disorder O
was O
suspected O
in O
light O
of O
an O
older O
brother O
with O
infant O
##ile O
onset O
seizures O
and O
developmental O
delay O
who O
died O
at O
age O
18 O
months O
from O
val O
##pro O
##ate O
associated O
liver O
failure O
laboratory O
investigations O
including O
muscle O
bio O
##psy O
for O
respiratory O
chain O
enzymes O
and O
mitochondrial O
dna O
analysis O
were O
normal O
nuclear O
dna O
genetic O
analysis O
revealed O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
pol B-GENE
##g I-GENE
gene O
mutation O
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
and O
pt B-GENE_VARIANT
##9 I-GENE_VARIANT
##14 I-GENE_VARIANT
##p I-GENE_VARIANT
variant O
at O
16 O
years O
she O
developed O
mig B-HPO_TERM
##raine I-HPO_TERM
##s I-HPO_TERM
right O
sided O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
arm I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
a O
pan B-HPO_TERM
##cer I-HPO_TERM
##eb I-HPO_TERM
##ella I-HPO_TERM
##r I-HPO_TERM
syndrome I-HPO_TERM
and O
progressive B-HPO_TERM
cognitive I-HPO_TERM
impairment I-HPO_TERM
at O
18 O
years O
she O
noted O
ep O
##iso O
##dic O
involuntary O
right O
foot O
in O
turning O
she O
developed O
head O
left O
neck O
and O
left O
shoulder O
tremor B-HPO_TERM
at O
age O
20 O
and O
was O
referred O
to O
our O
service O
for O
treatment O

examination O
revealed O
mild O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
sac B-HPO_TERM
##ca I-HPO_TERM
##dic I-HPO_TERM
pursuit I-HPO_TERM
writhing B-HPO_TERM
tongue I-HPO_TERM
movements I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
bilateral O
d B-HPO_TERM
##ys I-HPO_TERM
##dia I-HPO_TERM
##do I-HPO_TERM
##cho I-HPO_TERM
##kin I-HPO_TERM
##esis I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##met I-HPO_TERM
##ria I-HPO_TERM
and O
poor O
heel B-HPO_TERM
toe I-HPO_TERM
walking I-HPO_TERM
a O
mild O
left O
later B-HPO_TERM
##oco I-HPO_TERM
##llis I-HPO_TERM
tremor B-HPO_TERM
of O
the O
left O
neck O
and O
a O
no O
no O
head O
tremor O
improved O
with O
a O
sensory O
trick O
she O
had O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
and O
cho B-HPO_TERM
##re I-HPO_TERM
##ic I-HPO_TERM
ﬁ O
##nger O
and O
arm O
movements O
d B-HPO_TERM
##yst I-HPO_TERM
##onic I-HPO_TERM
post I-HPO_TERM
##uring I-HPO_TERM
of O
hands O
and O
feet O
while O
walking O
and O
st B-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
toes I-HPO_TERM
more O
evident O
on O
the O
right O
she O
had O
features O
of O
mild O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
plant O
##ar O
responses O
were O
ﬂ O
##ex O
##or O
see O
video O

brain O
mri O
at O
age O
15 O
fig O
1a O
b O
was O
compared O
to O
age O
20 O
fig O
1 O
##c O
d O
which O
showed O
persistent O
tha B-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
and I-HPO_TERM
dent I-HPO_TERM
##ate I-HPO_TERM
nuclei I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ity I-HPO_TERM
and O
increased O
signal O
change O
in O
the O
ce O
##re O
##bella O
##r O
hemisphere O
##s O
nerve O
conduct O
##ion O
studies O
con O
##ﬁ O
##rmed O
mild O
sensory B-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
peripheral I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
surface O
electro O
##my O
##ography O
of O
the O
left O
stern O
##oc O
##lei O
##dom O
##ast O
##oid O
fig O
1 O
##e O
showed O
a O
rhythmic O
5 O
##to O
6 O
hz O
tremor O
without O
ee O
##g O
co O
##rre O
##late O
back O
correspondence O
to O
michael O
samuel O
king O
s O
college O
hospital O
department O
of O
ne O
##uro O
##logy O
london O
united O
kingdom O
m O
samuel O
nhs O
net O

relevant O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
ﬁ O
##nan O
##cial O
disclosure O
##s O
nothing O
to O
report O
full O
ﬁ O
##nan O
##cial O
disclosure O
##s O
and O
author O
roles O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
published O
online O
28 O
september O
2011 O
in O
wiley O
online O
library O
wiley O
##on O
##line O
##lib O
##rar O
##y O
com O
doi O
10 O
100 O
##2 O
md O
##s O
239 O
##60 O
averaging O
was O
not O
performed O
the O
tremor O
responded O
to O
bot O
##ulin O
##um O
toxin O
injection O
##s O

mutations O
in O
the O
pol O
##g O
gene O
are O
an O
uncommon O
but O
important O
cause O
of O
movement O
disorders O
our O
case O
demonstrates O
typical O
features O
of O
msc O
##ae O
adolescent B-HPO_TERM
onset I-HPO_TERM
ata B-HPO_TERM
##xia I-HPO_TERM
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
mig B-HPO_TERM
##raine I-HPO_TERM
ep B-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
and O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
pt O
##osis O
are O
reported O
in O
msc O
##ae O
and O
other O
pol O
##g O
mutations O
but O
tend O
to O
occur O
later O
3 O
severe O
liver O
disease O
can O
occur O
secondary O
to O
val O
##pro O
##ate O
treatment O
4 O
our O
patient O
s O
tremor B-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
signs I-HPO_TERM
are O
possibly O
explained O
by O
ce O
##re O
##bella O
##r O
and O
tha O
##lam O
##ic O
involvement O
seen O
on O
mri O
however O
the O
path O
##op O
##hy O
##sio O
##logy O
mri O
co O
##rre O
##late O
of O
d O
##yst O
##onia O
is O
not O
clear O
it O
is O
also O
possible O
that O
other O
normal O
appearing O
tissue O
is O
involved O

eu O
##r O
o O
pea O
n O
journal O
o O
f O
p O
ae O
##di O
at O
##ric O
n O
euro O
##log O
y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O
original O
article O
polymer B-GENE
##ase I-GENE
gamma I-GENE
deficiency O
pol B-GENE
##g I-GENE
clinical O
course O
in O
a O
child B-PATIENT
with O
a O
two O
stage O
evolution O
from O
infant B-HPO_TERM
##ile I-HPO_TERM
my B-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bro I-HPO_TERM
##he I-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
spectrum O
to O
an O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
and O
ne O
##uro O
##path O
##ological O
findings O
of O
leigh B-HPO_TERM
s I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
emmanuel O
scala O
##is O
a O
ba O
##ud O
##ouin O
francois O
b O
patrick O
sc O
##hl O
##ess O
##er O
c O
rene O
stevens O
c O
christian O
nut O
##tin O
a O
jean O
jacques O
martin O
d O
rudy O
van O
cost O
##er O
e O
sara O
seneca O
f O
frank O
roe O
##ls O
g O
ge O
##rt O
van O
goethe O
##m O
h O
i O
ann O
lo O
##¨ O
##f O
##gren O
h O
linda O
de O
mei O
##rle O
##ir O
j O

a O
division O
of O
pa O
##ed O
##ia O
##tric O
ne O
##uro O
##logy O
centre O
hospital O
##ier O
de O
luxembourg O
luxembourg O
b O
centre O
pin O
##oc O
##chio O
ch O
##c O
cl O
##ini O
##que O
de O
l O
es O
##pe O
##´ O
##rance O
monte O
##gne O
##´ O
##e O
belgium O
c O
department O
of O
pediatric O
##s O
ch O
##c O
cl O
##ini O
##que O
de O
l O
es O
##pe O
##´ O
##rance O
monte O
##gne O
##´ O
##e O
belgium O
d O
laboratory O
of O
ultra O
##st O
##ru O
##ct O
##ural O
ne O
##uro O
##path O
##ology O
institute O
born O
bun O
##ge O
university O
of O
antwerp O
antwerp O
belgium O
e O
department O
of O
pediatric O
##s O
division O
of O
pediatric O
ne O
##uro O
##logy O
ghent O
university O
hospital O
ghent O
belgium O
f O
center O
for O
medical O
genetics O
u O
##z O
br O
##uss O
##el O
vr O
##ij O
##e O
universite O
##it O
br O
##uss O
##el O
brussels O
belgium O

g O
department O
of O
pathology O
ghent O
university O
hospital O
block O
a O
de O
pin O
##tel O
##aan O
185 O
900 O
##0 O
gen O
##t O
belgium O
h O
ne O
##uro O
##gen O
##etic O
##s O
group O
department O
of O
molecular O
genetics O
vi O
##b O
university O
of O
antwerp O
antwerp O
##en O
belgium O
i O
department O
of O
ne O
##uro O
##logy O
and O
ne O
##uro O
##mus O
##cular O
reference O
center O
university O
hospital O
of O
antwerp O
antwerp O
##en O
belgium O
j O
department O
of O
pediatric O
##s O
division O
of O
pediatric O
ne O
##uro O
##logy O
u O
##z O
brussels O
vr O
##ij O
##e O
universite O
##it O
brussels O
brussels O
belgium O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
17 O
august O
2011 O
received O
in O
revised O
form O
11 O
january O
2012 O
accepted O
26 O
january O
2012 O
key O
##words O

polymer O
##ase O
gamma O
deficiency O
mitochondrial O
dna O
de O
##ple O
##tion O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
al O
##pers O
syndrome O
leigh O
syndrome O
features O
long O
chain O
tri O
##gly O
##cer O
##ide O
toxicity O
a O
b O
s O
t O
r O
a O
c O
t O
aims O
description O
of O
the O
clinical O
course O
in O
a O
child O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
pol O
##g O
##1 O
mutations O
ne O
##uro O
##path O
##ology O
findings O
and O
results O
of O
dietary O
treatment O
based O
on O
fast O
##ing O
avoidance O
and O
long O
chain O
tri O
##gly O
##cer O
##ides O
lc O
##t O
restriction O

results O
at O
31 B-AGE_ONSET
2 I-AGE_ONSET
months I-AGE_ONSET
of O
age O
the O
patient B-PATIENT
presented O
with O
severe B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
hyper B-HPO_TERM
##la I-HPO_TERM
##cta I-HPO_TERM
##tem I-HPO_TERM
##ia I-HPO_TERM
moderate B-HPO_TERM
ke I-HPO_TERM
##tosis I-HPO_TERM
and O
he B-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
fast B-HPO_TERM
##ing I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
occurred O
8 O
h O
after O
meals O
the O
h O
##yp O
##og O
##ly O
##ce O
##mia O
did O
not O
respond O
to O
g O
##lu O
##ca O
##gon O
she O
was O
supplemented O
with O
iv O
glucose O
and O
or O
frequent O
feeding O
##s O
but O
developed O
liver B-HPO_TERM
ins I-HPO_TERM
##uf I-HPO_TERM
##fi I-HPO_TERM
##ciency I-HPO_TERM
which O
was O
reversed O
by O
long O
chain O
tri O
##gly O
##cer O
##ide O
lc O
##t O
restriction O
alpha B-HPO_TERM
foe I-HPO_TERM
##to I-HPO_TERM
protein I-HPO_TERM
af I-HPO_TERM
##p I-HPO_TERM
levels I-HPO_TERM
were I-HPO_TERM
elevated I-HPO_TERM
and O
returned O
to O
low O
values O
after O
dietary O
treatment O
liver O
bio O
##psy O
displayed O
ci B-HPO_TERM
##rr I-HPO_TERM
##hosis I-HPO_TERM
bile B-HPO_TERM
duct I-HPO_TERM
##ular I-HPO_TERM
proliferation I-HPO_TERM
ste B-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
isolated B-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
defect I-HPO_TERM
in O
part O
of O
the O
liver O
mit O
##och O
##ond O
##ria O
and O
mitochondrial B-HPO_TERM
dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
27 O
of O
control O
values O
two O
het O
##ero O
##zy O
##go O
##us O
mutations O
p B-GENE_VARIANT
ala I-GENE_VARIANT
##46 I-GENE_VARIANT
##7th I-GENE_VARIANT
##r I-GENE_VARIANT
þ O
p B-GENE_VARIANT
g I-GENE_VARIANT
##ly I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##ser I-GENE_VARIANT
were O
found O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
at O
3 O
years O
of O
age O
she O
progressively O
developed O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
mixed I-HPO_TERM
type I-HPO_TERM
seizures I-HPO_TERM
including O
a O
focal O
component O
and O
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
regression I-HPO_TERM
which O
fulfilled O
the O
criteria O
of O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
as O
although O
the O
initial O
presentation O
was O
compatible O
with O
infant B-HPO_TERM
##ile I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bro I-HPO_TERM
##he I-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
spectrum O
mc O
##hs O
she O
died O
at O
5 B-AGE_DEATH
years O
of O
age O
of O
respiratory B-HPO_TERM
ins I-HPO_TERM
##uf I-HPO_TERM
##fi I-HPO_TERM
##ciency I-HPO_TERM
ne O
##uro O
##path O
##olo O
##gic O

corresponding O
author O
centre O
hospital O
##ier O
de O
luxembourg O
division O
of O
pa O
##ed O
##ia O
##tric O
ne O
##uro O
##logy O
bar O
##ble O
no O
4 O
l O
##12 O
##10 O
luxembourg O
luxembourg O
tel O
þ O
##35 O
##2 O
441 O
##1 O
318 O
##1 O
fa O
##x O
þ O
##35 O
##2 O
441 O
##1 O
64 O
##66 O
e O
mail O
address O
scala O
##is O
emmanuel O
ch O
##l O
lu O
e O
scala O
##is O
109 O
##0 O
37 O
##9 O
##8 O
e O
see O
front O
matter O
ª O
2012 O
european O
pa O
##ed O
##ia O
##tric O
ne O
##uro O
##logy O
society O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
e O
##j O
##p O
##n O
2012 O
01 O
01 O
##3 O
european O
j O
o O
ur O
##nal O
o O
f O
p O
ae O
##dia O
##tric O
n O
euro O
log O
##y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O
54 O
##3 O
investigation O
revealed O
lesions B-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
right I-HPO_TERM
st I-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
area I-HPO_TERM
and O
the O
inferior B-HPO_TERM
col I-HPO_TERM
##lic I-HPO_TERM
##uli I-HPO_TERM
typical O
for O
leigh B-HPO_TERM
s I-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM

conclusion O
the O
present O
patient O
showed O
an O
evolution O
from O
infant O
##ile O
mc O
##hs O
to O
as O
and O
dietary O
treatment O
seemed O
to O
slow O
the O
progression O
of O
liver O
failure O
in O
spite O
of O
the O
late O
clinical O
features O
of O
as O
it O
extends O
the O
ne O
##uro O
##path O
##ological O
spectrum O
of O
as O
and O
polymer O
##ase O
gamma O
deficiency O
pol O
##g O
to O
leigh O
syndrome O
lesions O
ª O
2012 O
european O
pa O
##ed O
##ia O
##tric O
ne O
##uro O
##logy O
society O
published O
by O
else O
##vier O
ltd O
all O
rights O
reserved O
introduction O

mitochondrial O
dna O
mt O
##dna O
de O
##ple O
##tions O
##yn O
##drome O
##s O
md O
##ds O
mi O
##m O
251 O
##8 O
##80 O
first O
described O
in O
1991 O
by O
mora O
##es O
et O
al O
1 O
are O
het O
##ero O
##gen O
##eous O
auto O
##som O
##al O
recess O
##ive O
disorders O
sharing O
marked O
reduction O
in O
mt O
##dna O
copy O
number O
in O
one O
##or O
more O
tissues O
generally O
md O
##ds O
have O
an O
infant O
##ile O
or O
childhood O
onset O
with O
tissue O
specific O
features O
the O
pol O
##g O
##1 O
gene O
mi O
##m O
1747 O
##6 O
##3 O
is O
one O
of O
the O
several O
md O
##ds O
nuclear O
genes O
encoding O
proteins O
involved O
in O
the O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##le O
##otide O
trip O
##hos O
##phate O
metabolism O
and O
in O
mt O
##dna O
maintenance O
early O
onset O
usually O
presents O
either O
an O
infant O
##ile O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
mc O
##hs O
or O
al O
##pers O
syndrome O
as O
2 O
an O
increasing O
number O
of O
pol O
##g O
##1 O
mutations O
have O
been O
reported O
as O
a O
cause O
of O
as O
2 O
##e O
##11 O
combined O
en O
##ce O
##pha O
##lo O
##pathy O
and O
liver O
failure O
with O
md O
##ds O
can O
also O
be O
due O
to O
mutations O
in O
other O
md O
##ds O
nuclear O
genes O
such O
as O
pe O
##o O
##1 O
twinkle O
mi O
##m O
60 O
##6 O
##75 O
d O
##gu O
##ok O
mi O
##m O
60 O
##14 O
##65 O
mp O
##v O
##17 O
mi O
##m O
256 O
##8 O
##10 O
and O
su O
##cl O
##g O
##11 O
##2 O
mi O
##m O
245 O
##400 O

in O
this O
paper O
we O
report O
the O
clinical O
bio O
##chemical O
radio O
##logical O
and O
ne O
##uro O
##path O
##ological O
features O
of O
a O
31 B-AGE_ONSET
2 I-AGE_ONSET
month I-AGE_ONSET
old O
patient O
with O
two O
different O
pol B-GENE
##g I-GENE
mutations O
who O
first O
met O
the O
diagnostic O
criteria O
for O
mc O
##hs O
subsequently O
for O
as O
and O
then O
with O
leigh O
syndrome O
##ne O
##uro O
##path O
##ological O
##fe O
##at O
##ures O
we O
##com O
##par O
##ed O
##the O
##cl O
##ini O
##cal O
presentation O
##with O
##the O
##pres O
##entation O
##so O
##fo O
##ther O
md O
##ds O
nuclear O
##gen O
##e O
defects O
combining O
en O
##ce O
##pha O
##lo O
##pathy O
and O
liver O
failure O
and O
report O
the O
effects O
of O
dietary O
treatment O
on O
##li O
##ver O
disease O
progression O
the O
liver O
ana O
##tom O
##opa O
##th O
##ological O
and O
en O
##zy O
##matic O
features O
of O
the O
present O
patient O
have O
been O
previously O
reported O
13 O

case O
report O

the O
present O
patient O
was O
born O
at O
term O
after O
an O
uneven O
##tf O
##ul O
pregnancy O
from O
healthy O
non O
con O
##san O
##gui O
##neo O
##us O
parents O
birth O
weight O
was O
297 O
##0 O
g O
and O
length O
50 O
cm O
by O
the O
age O
of O
31 B-AGE_ONSET
2 I-AGE_ONSET
months I-AGE_ONSET
following O
an O
overnight O
fast O
##ing O
with O
mild O
feb O
##ril O
##e O
illness O
she O
presented O
with O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
lac B-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
##osis I-HPO_TERM
moderate B-HPO_TERM
ke I-HPO_TERM
##tosis I-HPO_TERM
and O
liver B-HPO_TERM
dysfunction I-HPO_TERM
on O
admission O
physical O
examination O
was O
normal O
except O
a O
liver B-HPO_TERM
edge I-HPO_TERM
pal I-HPO_TERM
##pa I-HPO_TERM
##ble I-HPO_TERM
at O
3 O
cm O
below O
the O
right O
costa O
##l O
margin O
and O
a O
generalized B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
with O
preserved O
deep O
tend O
##on O
reflex O
##es O
weight O
was O
45 O
##60 O
g O
p O
##10 O
length O
59 O
cm O
p O
##25 O
and O
head O
ci O
##rc O
##um O
##ference O
38 O
5 O
cm O
p O
##10 O
she O
developed O
progressive B-HPO_TERM
ja I-HPO_TERM
##und I-HPO_TERM
##ice I-HPO_TERM
and O
abdominal B-HPO_TERM
di I-HPO_TERM
##sten I-HPO_TERM
##sion I-HPO_TERM
with O
as B-HPO_TERM
##cite I-HPO_TERM
##s I-HPO_TERM
and O
increased B-HPO_TERM
liver I-HPO_TERM
echo I-HPO_TERM
##genic I-HPO_TERM
##ity I-HPO_TERM
at O
ultrasound O
plasma O
amino O
acid O
ch O
##rom O
##ato O
##graphy O
showed O
increased B-HPO_TERM
alan I-HPO_TERM
##ine I-HPO_TERM
132 O
##6 O
mm O
##ol O
l O
normal O
128 O
##e O
##44 O
##1 O
level O
iso O
##ele O
##ct O
##ro O
##fo O
##cus O
##ing O
of O
serum O
si O
##alo O
##tra O
##ns O
##fer O
##rin O
##s O
was O
normal O
alpha B-HPO_TERM
foe I-HPO_TERM
##top I-HPO_TERM
##rot I-HPO_TERM
##ein I-HPO_TERM
levels I-HPO_TERM
were I-HPO_TERM
increased I-HPO_TERM
from O
311 O
to O
38 O
##70 O
0 O
ng O
ml O
normal O
0 O
##e O
##15 O
0 O
ng O
ml O
ur O
##ina O
##ry O
adi O
##pic O
acid O
202 O
##5 O
mm O
##ol O
g O
cr O
##ea O
##tin O
##ine O
normal O
30 O
##e O
##44 O
##0 O
and O
hydro O
##xy O
##dic O
##ar O
##box O
##yl O
##ic O
acids O

were O
increased O
ur O
##ina O
##ry O
amino O
acids O
were O
normal O
cs B-HPO_TERM
##f I-HPO_TERM
analysis O
showed O
slight O
increased B-HPO_TERM
protein I-HPO_TERM
0 O
5 O
g O
l O
normal O
0 O
4 O
g O
l O
and O
lac B-HPO_TERM
##tate I-HPO_TERM
2 O
92 O
mm O
##ol O
l O
normal O
1 O
20 O
##e O
##2 O
10 O
levels O
table O
1 O
shows O
laboratory O
data O
at O
different O
periods O
at O
onset O
after O
continuous O
iv O
glucose O
administration O
nas O
##oga O
##st O
##ric O
fraction O
##al O
meal O
supplemented O
with O
raw O
corn O
star O
##ch O
lc O
##t O
and O
or O
medium O
chain O
tri O
##gly O
##cer O
##ide O
mc O
##t O
intake O
following O
lc O
##t O
restriction O
at O
days O
55 O
and O
63 O
after O
onset O
post O
##pr O
##and O
##ial O
lac O
##tate O
was O
normal O
in O
contrast O
h B-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
and O
hyper B-HPO_TERM
##la I-HPO_TERM
##cta I-HPO_TERM
##cide I-HPO_TERM
##mia I-HPO_TERM
were O
induced B-HPO_TERM
by I-HPO_TERM
fast I-HPO_TERM
##ing I-HPO_TERM
periods I-HPO_TERM
of O
8 O
h O
and O
did O
not O
respond O
to O
im O
g O
##lu O
##ca O
##gon O
lc O
##t O
restriction O
induced O
a O
decreased O
of O
abdominal O
di O
##sten O
##sion O
and O
ja O
##und O
##ice O
associated O
with O
bio O
##chemical O
improvement O
of O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
cy I-HPO_TERM
##to I-HPO_TERM
##lysis I-HPO_TERM
and O
cho B-HPO_TERM
##les I-HPO_TERM
##tas I-HPO_TERM
##is I-HPO_TERM
later O
alpha O
foe O
##to O
protein O
levels O
also O
decreased O
to O
lower O
levels O
35 O
2 O
ng O
ml O
normal O
0 O
##e O
##15 O
0 O
ng O
ml O
at O
18 O
months O
of O
age O
she O
was O
able O
to O
walk O
by O
shuffling O
she O
could O
speak O
approximately O
20 O
words O
combine O
two O
words O
together O
but O
not O
handle O
three O
word O
sentences O
few O
episodes O
of O
at B-HPO_TERM
##yp I-HPO_TERM
##ical I-HPO_TERM
absence I-HPO_TERM
##s I-HPO_TERM
followed O
by O
a O
drop B-HPO_TERM
attack I-HPO_TERM
were O
observed O
but O
there O
was O
no O
psycho O
##moto O
##r O
regression O
both O
ee O
##g O
and O
brain O
mri O
were O
normal O
at O
the O
age O
of O
three O
years O
her O
developmental B-HPO_TERM
quo I-HPO_TERM
##tie I-HPO_TERM
##nt I-HPO_TERM
was I-HPO_TERM
62 I-HPO_TERM
harvey O
test O
a O
few O
months O
later O
she O
was O
admitted O
in O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
with O
generalized B-HPO_TERM
tonic I-HPO_TERM
##o I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
she O
had O
an O
intermittent B-HPO_TERM
tremor I-HPO_TERM
moderate B-HPO_TERM
tr I-HPO_TERM
##un I-HPO_TERM
##cal I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
with O
a O
wide B-HPO_TERM
based I-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
between O
4 O
and O
49 O
12 O
years O
of O
age O
she O
suffered O
2 O
more O
episodes O
of O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
requiring O
artificial B-HPO_TERM
ventilation I-HPO_TERM
and O
was O
treated O
with O
different O
anti O
ep O
##ile O
##ptic O
drugs O
except O
val O
##pro O
##ate O
developmental B-HPO_TERM
regression I-HPO_TERM
occurred O
with O
loss B-HPO_TERM
of I-HPO_TERM
walking I-HPO_TERM
ability I-HPO_TERM
and O
right O
hand O
use O
additional O
seizure O
types O
appeared O
consisting O
of O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
seizures I-HPO_TERM
and O
ep B-HPO_TERM
##ile I-HPO_TERM
##ps I-HPO_TERM
##ia I-HPO_TERM
partial I-HPO_TERM
##is I-HPO_TERM
con I-HPO_TERM
##tin I-HPO_TERM
##ua I-HPO_TERM
ee B-HPO_TERM
##g I-HPO_TERM
disclosed I-HPO_TERM
spike I-HPO_TERM
wave I-HPO_TERM
complexes I-HPO_TERM
and O
par B-HPO_TERM
##ox I-HPO_TERM
##ys I-HPO_TERM
##mal I-HPO_TERM
delta I-HPO_TERM
and I-HPO_TERM
sharp I-HPO_TERM
waves I-HPO_TERM
predominantly O
in O
the O
right O
and O
left O
o O
##cci O
##pit O
##al O
area O
sensory B-HPO_TERM
conduct I-HPO_TERM
##ion I-HPO_TERM
velocity I-HPO_TERM
sc I-HPO_TERM
##v I-HPO_TERM
was I-HPO_TERM
decreased I-HPO_TERM
left O
median O
nerve O
wrist O
25 O
3 O
m O
s O
normal O
range O
48 O
6 O
3 O
0 O
left O
superficial O
per O
##one O
##al O
nerve O
not O
obtained O
late O
mri O
disclosed O
on O
t O
##2 O
sequence O
a O
high B-HPO_TERM
signal I-HPO_TERM
abnormal I-HPO_TERM
##ity I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
right I-HPO_TERM
inferior I-HPO_TERM
col I-HPO_TERM
##lic I-HPO_TERM
##ulus I-HPO_TERM
as O
shown O
in O
fig O
1 O
at O
that O
time O
the O
clinical O
diagnosis O
of O
as O
was O
made O
although O
the O
initial O
clinical O
feature O
was O
compatible O
with O
infant O
##ile O
mc O
##hs O
she O
died B-HPO_TERM
of O
respiratory B-HPO_TERM
ins I-HPO_TERM
##uf I-HPO_TERM
##fi I-HPO_TERM
##ciency I-HPO_TERM
at O
the O
age O
of O
5 B-AGE_DEATH
years O
autopsy O
of O
both O
brain O
and O
med O
##ulla O
were O
performed O

investigations O
and O
results O
the O
oxidation O
of O
14 O
##c O
##1 O
oct O
##ano O
##ate O
14 O
##c O
##1 O
##e O
##8 O
14 O
##c O
##1 O
palm O
##itate O
14 O
##c O
##1 O
##e O
##16 O
and O
14 O
##c O
##1 O
su O
##cci O
##nate O
14 O
##c O
##1 O
##e O
##4 O
in O
fi O
##bro O
##bla O
##sts O
was O
normal O
at O
the O
age O
of O
8 O
months O
a O
liver O
bio O
##psy O
showed O
micro B-HPO_TERM
##no I-HPO_TERM
##du I-HPO_TERM
##lar I-HPO_TERM
ci I-HPO_TERM
##rr I-HPO_TERM
##hosis I-HPO_TERM
with O
ann B-HPO_TERM
##ular I-HPO_TERM
type I-HPO_TERM
fi I-HPO_TERM
##bro I-HPO_TERM
##sis I-HPO_TERM
bile O
duct O
##ular O
54 O
##4 O
eu O
##r O
o O
pea O
n O
journal O
o O
f O
p O
ae O
##di O
at O
##ric O
n O
euro O
##log O
y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O

proliferation O
was O
observed O
but O
no O
ste O
##ato O
##sis O
im O
##mun O
##o O
stain O
##ing O
with O
a O
specific O
antibody O
against O
alpha O
1 O
anti O
##try O
##ps O
##in O
showed O
a O
normal O
pattern O
activities O
of O
fr O
##uc O
##tose O
1 O
##ph O
##os O
##phate O
aldo O
##lase O
aldo O
##lase O
b O
fr O
##uc O
##tose O
1 O
6 O
bi O
##ph O
##os O
##pha O
##tase O
and O
glucose O
6 O
##ph O
##os O
##pha O
##tase O
in O
liver O
tissue O
were O
normal O
at O
17 O
months O
of O
age O
his O
##top O
##ath O
##ological O
analysis O
of O
a O
muscle O
bio O
##psy O
was O
normal O
including O
the O
absence O
of O
ragged O
red O
fibre O
##s O
as O
well O
as O
ox O
##ph O
##os O
activities O
the O
results O
of O
the O
second O
liver O
bio O
##psy O
have O
been O
reported O
elsewhere O
##13 O
most O
striking O
was O
a O
mosaic O
distribution O
of O
cy O
##to O
##chrome O
ox O
##ida O
##se O
activity O
as O
well O
as O
its O
im O
##mun O
##olo O
##cal O
##isation O
in O
liver O
mit O
##och O
##ond O
##ria O
blue O
native O
page O
of O
liver O
tissue O
showed O
a O
decreased B-HPO_TERM
activity I-HPO_TERM
of I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
the O
amount O
of O
mt O
##dna O
was O
21 O
in O
muscle O
27 O
in O
liver O
and O
98 O
in O
blood O
sequencing O
analysis O
of O
the O
de O
##ox O
##y O
##gua O
##nos O
##ine O
kinase O
gene O
d O
##gu O
##ok O
was O
normal O
mutation O
analysis O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
blood O
cells O
revealed O
two O
miss O
##ense O
mutations O
c I-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT

fig O
1 O
e O
late O
brain O
imaging O
performed O
at O
410 O
12 O
years O
of O
age O
corona O
##l O
t O
##2 O
image O
at O
the O
level O
of O
the O
inferior O
and O
superior O
col O
##lic O
##uli O
shows O
abnormal O
increased O
signal B-HPO_TERM
intensity I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
right I-HPO_TERM
inferior I-HPO_TERM
col I-HPO_TERM
##lic I-HPO_TERM
##ulus I-HPO_TERM
predicting B-GENE_VARIANT
p I-GENE_VARIANT
ala I-GENE_VARIANT
##46 I-GENE_VARIANT
##7th I-GENE_VARIANT
##r I-GENE_VARIANT
substitution O
paternal O
and O
c B-GENE_VARIANT
254 I-GENE_VARIANT
##2 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
predicting O
p B-GENE_VARIANT
g I-GENE_VARIANT
##ly I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##ser I-GENE_VARIANT
substitution O
maternal O

microscopic O
examination O
of O
the O
brain O
revealed O
a O
widespread O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
in O
the O
right O
st O
##ria O
##te O
cortex O
primary O
visual O
cortex O
associated O
with O
cap O
##illa O
##ry O
end O
##oth O
##elial O
cell O
swelling O
congestion O
and O
sp B-HPO_TERM
##ong I-HPO_TERM
##ios I-HPO_TERM
##is I-HPO_TERM
involving O
layer O
ii O
and O
iv O
with O
relative O
preservation O
of O
neurons O
fig O
2a O
reactive B-HPO_TERM
gem I-HPO_TERM
##isto I-HPO_TERM
##cy I-HPO_TERM
##tic I-HPO_TERM
astro I-HPO_TERM
##cytes I-HPO_TERM
were O
observed O
in O
the O
middle O
and O
deep O
co O
##rti O
##cal O
layers O
astro B-HPO_TERM
##glio I-HPO_TERM
##sis I-HPO_TERM
was O
also O
present O
in O
the O
superior O
frontal O
ci O
##ng O
##ulate O
para O
##hip O
##po O
##camp O
##al O
o O
##cci O
##pit O
##ote O
##mp O
##ora O
##l O
g O
##yr O
##i O
in O
the O
neo O
##st O
##ria O
##tum O
ca O
##uda O
##te O
nucleus O
and O
put O
##amen O
ne B-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
cell I-HPO_TERM
drop I-HPO_TERM
##out I-HPO_TERM
ch B-HPO_TERM
##rom I-HPO_TERM
##ato I-HPO_TERM
##lysis I-HPO_TERM
fi B-HPO_TERM
##bri I-HPO_TERM
##llary I-HPO_TERM
g I-HPO_TERM
##lio I-HPO_TERM
##sis I-HPO_TERM
and O
pal B-HPO_TERM
##lor I-HPO_TERM
within I-HPO_TERM
the I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pi I-HPO_TERM
##l I-HPO_TERM
were O
visual O
##ized O
the O
hip O
##po O
##camp O
##us O
was O
well O
preserved O
as O
well O
as O
the O
para O
##hip O
##po O
##camp O
##al O
g O
##yr O
##us O
in O
the O
tha O
##lam O
##us O
only O
one O
area O
of O
the O
par O
##s O
lateral O
##is O
of O
the O
pu O
##l O
##vina O
##r O
showed O
a O
focal B-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
large I-HPO_TERM
size I-HPO_TERM
neurons I-HPO_TERM
associated O
with O
cap O
##illa O
##ry O
end O
##oth O
##elial O
cell O
swelling O
and O
congestion O
va O
##cu O
##oles O
as O
well O
as O
astro B-HPO_TERM
##glio I-HPO_TERM
##sis I-HPO_TERM
in O
the O
brains O
##tem O
the O
inferior B-HPO_TERM
col I-HPO_TERM
##lic I-HPO_TERM
##uli I-HPO_TERM
displayed I-HPO_TERM
symmetric I-HPO_TERM
peculiar I-HPO_TERM
nec I-HPO_TERM
##rot I-HPO_TERM
##izing I-HPO_TERM
lesions I-HPO_TERM
cap O
##illa O
##ry O
end O
##oth O
##elial O
cell O
hyper O
##tro O
##phy O
causing O
lu O
##mina O
##l O
narrowing O
and O
relative O
preservation O
of O
neurons O
with O
prominent O
ni O
##ss O
##l O
end O
##op O
##las O
##mic O
re O
##tic O
##ulum O
fig O
2 O
##b O
in O
the O
me O
##sen O
##ce O
##pha O
##lic O
re O
##tic O
##ular O
formation O
and O
the O
par O
##s O
compact O
##a O
of O
the O
sub O
##stan O
##tia O
ni O
##gra O
there O
was O
only O
sp B-HPO_TERM
##ong I-HPO_TERM
##ios I-HPO_TERM
##is I-HPO_TERM
the O
ce O
##re O
##bella O
##r O
cortex O
showed O
mild O
focal B-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
pu I-HPO_TERM
##rkin I-HPO_TERM
##je I-HPO_TERM
cells I-HPO_TERM
with O
pal B-HPO_TERM
##lor I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
internal I-HPO_TERM
gran I-HPO_TERM
##ular I-HPO_TERM
cell I-HPO_TERM
layer I-HPO_TERM
the O
dent B-HPO_TERM
##ate I-HPO_TERM
nucleus I-HPO_TERM
showed I-HPO_TERM
ne I-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
with O
va O
##cu O
##oli O
##zation O
within O
the O
ne O
##uro O
##pi O
##l O
in O
the O
spinal B-HPO_TERM
cord I-HPO_TERM
my I-HPO_TERM
##elin I-HPO_TERM
pal I-HPO_TERM
##lor I-HPO_TERM
indicating O
fibre O
loss O
was O
observed O
in O
the O
posterior O
column O
as O
well O
as O
in O
the O
posterior O
spin O
##oc O
##ere O
##bella O
##r O
tract O
associated O
with O
mild O
astro B-HPO_TERM
##glio I-HPO_TERM
##sis I-HPO_TERM
also O
clarke O
s O
column O
showed O
ne O
##uron O
##al O
loss O
but O
anterior O
horn O
neurons O
and O
inter O
##med O
##iol O
##ater O
##al O
cell O
columns O
seemed O
preserved O

discussion O
at O
31 B-AGE_ONSET
2 I-AGE_ONSET
months I-AGE_ONSET
of O
age O
the O
present O
patient O
presented O
an O
acute O
episode O
of O
fast B-HPO_TERM
##ing I-HPO_TERM
induced I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oke I-HPO_TERM
##to I-HPO_TERM
##tic I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ce I-HPO_TERM
##mia I-HPO_TERM
with O
hyper B-HPO_TERM
##la I-HPO_TERM
##cta I-HPO_TERM
##tem I-HPO_TERM
##ia I-HPO_TERM
and O
liver B-HPO_TERM
dysfunction I-HPO_TERM
plasma O
lac O
##tate O
reached O
its O
maximum O
levels O
when O
she O
was O
fast O
##ing O
and O
h O
##yp O
##og O
##ly O
##ce O
##mic O
as O
it O
can O
occur O
in O
g O
##lu O
##con O
##eo O
##genesis O
disorders O
14 O
in O
the O
present O
case O
glucose O
6 O
ph O
##os O
##pha O
##tase O
and O
fr O
##uc O
##tose O
1 O
6 O
bi O
##ph O
##os O
##pha O
##tase O
european O
j O
o O
ur O
##nal O
o O
f O
p O
ae O
##dia O
##tric O
n O
euro O
log O
##y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O
54 O
##5 O
fig O
2 O
e O
a O
right O
area O
st O
##ria O
##ta O
showing O
cap O
##illa O
##ry O
end O
##oth O
##elial O
cell O
swelling O
and O
congestion O
astro O
##cy O
##tic O
g O
##lio O
##sis O
with O

a O
conservation O
of O
ne O
##uron O
##al O
per O
##ika O
##rya O
para O
##ffin O
em O
##bed O
##ding O
k O
##lu O
##¨ O
ve O
##r O
barre O
##ra O
method O
b O
similar O
lesions O
in O
the O
inferior O
col O
##lic O
##uli O
para O
##ffin O
em O
##bed O
##ding O
k O
##lu O
##¨ O
ve O
##r O
barre O
##ra O
method O

activities O
were O
normal O
the O
clinical O
triad O
of O
mc O
##hs O
defined O
by O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
developmental B-HPO_TERM
delay I-HPO_TERM
and O
he B-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
was O
found O
in O
the O
present O
patient O
additional O
diagnostic O
findings O
such O
as O
elevated B-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
were O
found O
and O
later O
at O
the O
age O
of O
18 O
months O
an O
onset O
of O
seizures B-HPO_TERM
and O
at O
41 O
2 O
years O
a O
decreased O
sc O
##v O
also O
the O
characteristic O
features O
of O
the O
first O
liver O
bio O
##psy O
performed O
at O
91 O
2 O
months O
of O
age O
did O
not O
meet O
the O
criteria O
for O
the O
diagnosis O
of O
as O
9 O
of O
the O
8 O
characteristic O
his O
##to O
##logical O
findings O
only O
micro B-HPO_TERM
##no I-HPO_TERM
##du I-HPO_TERM
##lar I-HPO_TERM
ci I-HPO_TERM
##rr I-HPO_TERM
##hosis I-HPO_TERM
and O
bile B-HPO_TERM
duct I-HPO_TERM
##ular I-HPO_TERM
proliferation I-HPO_TERM
were O
identified O
early O
dietary O
regime O
##n O
initiated O
in O
the O
present O
patient O
with O
frequent O
nas B-HPO_TERM
##oga I-HPO_TERM
##st I-HPO_TERM
##ric I-HPO_TERM
feeding I-HPO_TERM
and O
lc O
##t O
restriction O
could O
have O
modified O
the O
fatty O
change O
like O
ste O
##ato O
##sis O
nevertheless O
after O
the O
age O
of O
41 O
2 O
years O
the O
clinical O
triad O
of O
as O
was O
present O
with O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
mixed I-HPO_TERM
type I-HPO_TERM
seizures I-HPO_TERM
including O
a O
focal O
component O
psycho B-HPO_TERM
##moto I-HPO_TERM
##r I-HPO_TERM
regression I-HPO_TERM
ep O
##iso O
##dic O
and O
he B-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
with O
acute O
liver O
failure O
9 O
three O
other O
additional O
clinical O
or O
laboratory O
features O
for O
as O
were O
found O
including O
elevated B-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
protein I-HPO_TERM
abnormal B-HPO_TERM
ee I-HPO_TERM
##g I-HPO_TERM
with O
as O
##ym O
##metric O
and O
high B-HPO_TERM
amplitude I-HPO_TERM
slow I-HPO_TERM
wave I-HPO_TERM
activity I-HPO_TERM
inter O
##mi O
##xed O
with O
poly B-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
discharge I-HPO_TERM
##s I-HPO_TERM
and O
liver B-HPO_TERM
en I-HPO_TERM
##zy I-HPO_TERM
##matic I-HPO_TERM
respiratory I-HPO_TERM
chain I-HPO_TERM
defects I-HPO_TERM
in O
liver O
tissue O
only O
complex B-HPO_TERM
iv I-HPO_TERM
showed I-HPO_TERM
a I-HPO_TERM
decreased I-HPO_TERM
activity I-HPO_TERM
suggesting O
that O
in O
this O

case O
complex O
iv O
was O
the O
most O
vulnerable O
as O
seen O
in O
other O
md O
##ds O
10 O
the O
finding O
of O
normal O
muscle O
his O
##to O
##chemical O
and O
ox O
##ph O
##os O
activities O
emphasis O
##ed O
the O
need O
to O
investigate O
several O
primary O
tissues O
as O
muscle O
analysis O
in O
the O
present O
case O
gave O
misleading O
results O
in O
the O
present O
patient O
under O
iv O
glucose O
and O
frequent O
feeding O
##s O
with O
lc O
##t O
we O
found O
a O
severe B-HPO_TERM
he I-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
dysfunction I-HPO_TERM
including O
cy O
##to O
##lysis O
cho B-HPO_TERM
##les I-HPO_TERM
##tat I-HPO_TERM
##ic I-HPO_TERM
ja I-HPO_TERM
##und I-HPO_TERM
##ice I-HPO_TERM
as B-HPO_TERM
##cite I-HPO_TERM
##s I-HPO_TERM
like O
in O
long O
chain O
3 O
hydro O
##xy O
##acy O
##l O
coa O
de O
##hy O
##dro O
##gens O
##ase O
lc O
##had O
while O
mc O
##t O
dietary O
fat O
had O
a O
beneficial O
effect O
in O
lc O
##had O
deficiency O
liver O
ci O
##rr O
##hot O
##ic O
changes O
are O
presumed O
to O
be O
a O
toxic O
effect O
of O
the O
acc O
##um O
##ulating O
3 O
hydro O
##xy O
fatty O
acids O
15 O
in O
the O
same O
way O
in O
children O
harbour O
##ing O
pol O
##g O
mutations O
val O
##pro O
##ic O
acid O
which O
is O
a O
branched O
chain O
car O
##box O
##yl O
##ic O
acid O
has O
been O
reported O
as O
very O
he O
##pa O
##to O
##to O
##xi O
##c O
in O
as O
16 O
in O
some O
of O
the O
md O
##ds O
patients O
an O
elevation O
of O
af O
##p O
levels O
can O
be O
a O
helpful O
diagnostic O
clue O
in O
the O
present O
patient O
af O
##p O
levels O
were O
initially O
markedly O
increased O
and O
subsequently O
returned O
to O
lower O
values O
35 O
2 O
ng O
ml O
normal O
0 O
##e O
##15 O
0 O
ng O
ml O
increased O
serum O
af O
##p O
level O
has O
been O
reported O
in O
d O
##gu O
##ok O
deficiency O
##17 O
##e O
##20 O
and O
in O
mvp O
##17 O
deficiency O
21 O
the O
gen O
##otype O
of O
the O
present O
patient O
has O
been O
reported O
in O
as O
most O
of O
as O
affected O
patients O
carry O
the O
link O
##er O
p O
ala O
##46 O
##7th O
##r O
mutation O
mostly O
associated O
with O
p O
tr O
##p O
##7 O
##48 O
##ser O
another O
link O
##er O
mutation O
or O
p O
g O
##ly O
##8 O
##48 O
##ser O
mutation O
located O
in O
the O
polymer O
##ase O
domain O
2 O
5 O
6 O
22 O
in O
most O
patients O
with O
features O
of O
as O
the O
most O
prominent O
sy O
##mpt O
##om O
is O
intra O
##ctable O
progressive O
ep O
##ile O
##psy O
while O
he O
##pa O
##top O
##athy O
develops O
later O
in O
the O
course O
of O
the O
disease O
the O
pol O
##g O
##1 O
gene O
om O
##im O
1747 O
##6 O
##3 O
is O
one O
of O
the O
nine O
md O
##ds O
nuclear O
genes O
six O
of O
them O
t O
##k O
##2 O
23 O
24 O
rr O
##m O
##2 O
##b O
25 O
d O
##gu O
##ok O
18 O
su O
##cl O
##g O
##1 O

su O
##cl O
##a O
##2 O
12 O
26 O
27 O
ty O
##mp O
##28 O
supply O
the O
mit O
##och O
##ond O
##ria O
with O
nu O
##cle O
##o O

tide O
pools O
needed O
for O
dna O
replication O
pol O
##g O
##2 O
and O
twinkle O
##29 O
products O
function O
directly O
at O
the O
mt O
##dna O
replication O
fork O
mp O
##v O
##17 O
##30 O
en O
##codes O
an O
inner O
membrane O
mitochondrial O
protein O
of O
unknown O
function O
combined O
en O
##ce O
##pha O
##lo O
##pathy O
and O
liver O
failure O
can O
also O
be O
a O
feature O
of O
other O
md O
##ds O
nuclear O
genes O
such O
as O
twinkle O
d O
##gu O
##ok O
mp O
##v O
##17 O
and O
su O
##cl O
##g O
##1 O
mutations O
patients O
with O
twinkle O
mutation O
have O
liver O
ins O
##uf O
##fi O
##ciency O
major O
tr O
##un O
##cal O
h O
##yp O
##oton O
##ia O
seizures O
peripheral O
sensitive O
ne O
##uro O
##pathy O
growth O
re O
##tar O
##dation O
abnormal O
eye O
movements O
and O
hyper O
##la O
##cta O
##tem O
##ia O
29 O
in O
d O
##gu O
##ok O
deficiency O
18 O
the O
majority O
of O
infants O
have O
cho O
##les O
##tas O
##is O
subsequently O
ne O
##uro O
##logic O
dysfunction O
with O
severe O
h O
##yp O
##oton O
##ia O
developmental O
regression O
and O
ny O
##sta O
##gm O
##us O
but O
no O
seizures O
or O
ee O
##g O
abnormalities O
in O
mp O
##v O
##17 O
defects O
the O
patients O
are O
characterized O
by O
a O
variable O
neurological O
involvement O
at O
onset O
absent O
or O
mild O
hyper O
##la O
##cta O
##tem O
##ia O
consistently O
severe O
h O
##yp O
##og O
##ly O
##ca O
##emia O
3 O
##e O
##4 O
h O
after O
meals O
no O
hyper O
##la O
##cta O
##tem O
##ia O
after O
glucose O
loading O
and O
beneficial O
effect O
of O
iv O
glucose O
and O
frequent O
feeding O
on O
liver O
function O
tests O
31 O
mutations O
in O
su O
##cl O
##g O
##1 O
were O
found O
in O
a O
patient O
with O
both O
leigh O
disease O
and O
rec O
##urrent O
he O
##pati O
##c O
failure O
but O
also O
severe O
my O
##opa O
##thy O
12 O

table O
2 O
emphasizes O
the O
ne O
##uro O
##path O
##olo O
##gic O
microscopic O
features O
of O
patients O
with O
as O
or O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
ph O
##eno O
##type O
associated O
with O
pol O
##g O
mutations O
in O
pol O
##g O
##1 O
gene O
reported O
in O
the O
literature O
and O
those O
of O
the O
index O
patient O
harbour O
##ing O
the O
p O
ala O
##46 O
##7th O
##r O
p O
g O
##ly O
##8 O
##48 O
##ser O
sub O
##ti O
##tu O
##tions O
2 O
3 O
5 O
7 O
32 O
##e O
##34 O

although O
the O
late O
clinical O
features O
of O
the O
present O
patient O
corresponded O
to O
as O
she O
particularly O
exhibited O
lesions O
in O
the O
dorsal O
part O
of O
the O
mid O
brain O
and O
to O
a O
lesser O
extent O
in O
the O
deep O
grey O
structures O
and O
spinal O
cord O
which O
were O
striking O
##ly O
reminiscent O
of O
those O
that O
occur O
in O
l O
##s O
also O
if O
the O
right O
cal O
##car O
##ine O
les O
##ion O
observed O
in O
the O
present O
patient O
belongs O
to O
the O
54 O
##6 O
eu O
##r O
o O
pea O
n O
journal O
o O
f O
p O
ae O
##di O
at O
##ric O
n O
euro O
##log O
y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O

topography O
of O
as O
the O
relative O
preservation O
of O
neurons O
with O
cap O
##illa O
##ry O
wall O
swelling O
is O
more O
typical O
of O
l O
##s O
in O
fact O
both O
al O
##pers O
and O
leigh O
syndrome O
##s O
are O
characterized O
by O
prominent O
grey O
matter O
involvement O
but O
each O
of O
these O
syndrome O
##s O
generally O
has O
different O
les O
##ion O
topography O
and O
his O
##to O
##logical O
characteristics O
in O
leigh O
syndrome O
lesions O
tend O
to O
be O
symmetrical O
and O

pre O
##dom O
##inate O
as O
in O
the O
present O
patient O
in O
the O
dorsal O
part O
of O
the O
brain O
stem O
but O
also O
in O
the O
neo O
##st O
##ria O
##tum O
the O
ce O
##re O
##bella O
##r O
nuclei O
the O
tha O
##lam O
##us O
and O
the O
spinal O
cord O
35 O
however O
in O
both O
tha O
##lam O
##i O
and O
sub O
##stan O
##tia O
ni O
##gra O
such O
lesions O
were O
not O
observed O
in O
the O
index O
patient O
but O
for O
the O
lateral O
part O
of O
the O
pu O
##l O
##vina O
##r O
in O
contrast O
in O
as O
selective O
involvement O
of O
the O
cal O
##car O
##ine O
cortex O
european O
j O
o O
ur O
##nal O
o O
f O
p O
ae O
##dia O
##tric O
n O
euro O
log O
##y O
16 O
2012 O
54 O
##2 O
e O
##54 O
##8 O
54 O
##7 O

with O
patch O
##y O
ne O
##uron O
##al O
loss O
and O
g O
##lio O
##sis O
is O
typical O
although O
all O
co O
##rti O
##cal O
areas O
may O
be O
affected O
white O
matter O
changes O
are O
usually O
slight O
in O
both O
as O
and O
leigh O
s O
en O
##ce O
##pha O
##lo O
##pathy O
but O
may O
pre O
##dom O
##inate O
table O
2 O
reference O
7 O
patient O
7 O
the O
lesions O
could O
correspond O
to O
energy O
im O
##balance O
in O
ne O
##uron O
##es O
or O
astro O
##cytes O
in O
areas O
inc O
##ong O
##ru O
##ent O
to O
a O
vascular O
territory O
or O
sul O
##cal O
topography O
36 O

in O
conclusion O
this O
case O
report O
particularly O
highlights O
the O
change O
from O
infant O
##ile O
mc O
##hs O
to O
as O
and O
the O
effects O
of O
dietary O
treatment O
in O
slowing O
the O
progression O
of O
liver O
failure O
therefore O
we O
suggest O
to O
study O
the O
effect O
of O
lc O
##t O
dietary O
restriction O
on O
liver O
function O
in O
other O
patients O
with O
as O
or O
pol O
##g O
associated O
he O
##pa O
##top O
##athy O
finally O
this O
report O
extends O
the O
ne O
##uro O
##path O
##ological O
spectrum O
of O
as O
to O
leigh O
s O
lesions O
acknowledge O
##ment O
the O
authors O
are O
most O
grateful O
to O
the O
parents O
for O
their O
collaboration O
on O
this O
report O
in O
particular O
for O
their O
agreeing O
to O
the O
autopsy O
and O
brain O
studies O
refer O
##en O
c O
es O

mora O
##es O
ct O
shan O
##ske O
s O
tri O
##ts O
##ch O
##ler O
h O
##j O
et O
al O
mt O
##dna O
de O
##ple O
##tion O
with O
variable O
tissue O
expression O
a O
novel O
genetic O
abnormal O
##ity O
in O
mitochondrial O
diseases O
am O
j O
hum O
gene O
##t O
1991 O
48 O
3 O
49 O
##2 O
##e O
##50 O
##1 O
na O
##via O
##ux O
r O
##k O
nguyen O
kv O
pol O
##g O
mutations O
associated O
with O
al O
##pers O
syndrome O
and O
mitochondrial O
dna O
de O
##ple O
##tion O
ann O
ne O
##uro O
##l O
2004 O
55 O
5 O
70 O
##6 O
##e O
##12 O
david O
##zon O
g O
man O
##cus O
##o O
m O
ferrari O
##s O
s O
et O
al O
pol O
##g O
mutations O
and O
al O
##pers O
syndrome O
ann O
ne O
##uro O
##l O
2005 O
57 O
6 O
92 O
##1 O
##e O
##3 O

de O
vr O
##ies O
mc O
rode O
##nburg O
r O
##j O
mora O
##va O
e O
et O
al O
multiple O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
def O
##iciencies O
in O
severe O
childhood O
multi O
##sy O
##ste O
##m O
disorders O
due O
to O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
mutations O
eu O
##r O
j O
pe O
##dia O
##tr O
2007 O
166 O
3 O
229 O
##e O
##34 O
ferrari O
g O
lama O
##nte O
##a O
e O
dona O
##ti O
a O
et O
al O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
syndrome O
##s O
associated O
with O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
brain O
2005 O
128 O
pt O
4 O
72 O
##3 O
##e O
##31 O
ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
pt O
7 O
167 O
##4 O
##e O
##8 O
##4 O

available O
online O
at O
www O
science O
##di O
##re O
##ct O
com O
ne O
##uro O
##mus O
##cular O
disorders O
22 O
2012 O
401 O
405 O
case O
report O
www O
else O
##vier O
com O
locate O
nm O
##d O
a O
case O
of O
my O
##elo O
##pathy O
my O
##opa O
##thy O
peripheral O
ne O
##uro O
##pathy O
and O
sub O
##cor O
##tical O
grey O
matter O
de O
##gen O
##eration O
associated O
with O
recess O
##ive O
compound O
het O
##ero O
##zy O
##go O
##us O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
p O
mc O
##kel O
##vie O
a O
r O
mar O
##ott O
##a O
b O
d O
r O
thor O
##burn O
c O
j O
chin O
b O
s O
punch O
##ih O
##ew O
##a O
b O
s O
collins O
b O
d O
a O
department O
of O
anatomical O
pathology O
st O
vincent O
s O
hospital O
melbourne O
australia O
b O
st O
vincent O
s O
melbourne O
ne O
##uro O
##mus O
##cular O
diagnostic O
laboratory O
department O
of O
clinical O
neuroscience O
##s O
st O
vincent O
s O
hospital O
australia O

c O
murdoch O
children O
s O
research O
institute O
and O
university O
of O
melbourne O
department O
of O
pa O
##ed O
##ia O
##trics O
the O
royal O
children O
s O
hospital O
park O
##ville O
victoria O
australia O
d O
university O
of O
melbourne O
australia O
received O
21 O
may O
2011 O
received O
in O
revised O
form O
6 O
october O
2011 O
accepted O
26 O
october O
2011 O
abstract O

this O
54 O
year O
old O
woman B-PATIENT
presented O
with O
symptoms O
of O
sensory B-HPO_TERM
ata I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
with O
ce O
##re O
##bella O
##r O
features O
she O
developed O
further O
weakness B-HPO_TERM
visual B-HPO_TERM
disturbances I-HPO_TERM
with O
dip B-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##sia I-HPO_TERM
after O
her O
death O
at O
66 B-AGE_DEATH
years O
she O
was O
found O
to O
have O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
of O
pol B-AGE_DEATH
##g I-AGE_DEATH
##1 I-AGE_DEATH
gene O
in O
muscle O
and O
southern O
b O
##lot O
showed O
low O
levels O
of O
multiple B-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
of I-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
ne O
##uro O
##path O
##ological O
examination O
showed O
profound O
dorsal O
column O
and O
dorsal B-HPO_TERM
spin I-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
tract I-HPO_TERM
de I-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
de B-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
of I-HPO_TERM
dorsal I-HPO_TERM
root I-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
and O
clarke O
s O
nucleus O
in O
spinal O
cord O
and O
severe O
predominantly O
sensory B-HPO_TERM
peripheral I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
the O
brain O
showed O
severe O
ne B-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
loss I-HPO_TERM
and O
g B-HPO_TERM
##lio I-HPO_TERM
##sis I-HPO_TERM
in I-HPO_TERM
sub I-HPO_TERM
##stan I-HPO_TERM
##tia I-HPO_TERM
ni I-HPO_TERM
##gra I-HPO_TERM
medial O
posterior O
tha O
##lam O
##us O
and O
head O
of O
ca O
##uda O
##te O
excess O
numbers O
of O
cox B-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
and O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
were O
found O
in O
ﬁ O
##ve O
skeletal O
muscles O
sampled O

2011 O
else O
##vier O
b O
v O
all O
rights O
reserved O
key O
##words O
compound O
het O
##ero O
##zy O
##go O
##us O
polymer O
##ase O
gamma O
pol O
##g O
mutations O
spinal O
cord O
de O
##gen O
##eration O
dorsal O
column O
and O
dorsal O
spin O
##oc O
##ere O
##bella O
##r O
tract O
de O
##gen O
##eration O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
peripheral O
ne O
##uro O
##pathy O
mitochondrial O
my O
##opa O
##thy O
cox O
negative O
ﬁ O
##bre O
##s O
ragged O
red O
ﬁ O
##bre O
##s O
sub O
##stan O
##tia O
ni O
##gra O
de O
##gen O
##eration O
tha O
##lam O
##ic O
de O
##gen O
##eration O
sand O
##o O
introduction O

mitochondrial O
dna O
polymer O
##ase O
c O
pol O
##g O
is O
a O
nuclear O
encoded O
protein O
involved O
in O
mitochondrial O
dna O
replication O
and O
the O
only O
dna O
polymer O
##ase O
functional O
in O
animal O
mit O
##och O
##ond O
##ria O
1 O
2 O
in O
humans O
the O
195 O
k O
##da O
het O
##ero O
##tri O
##mer O
consists O
of O
one O
catalytic O
subunit O
which O
is O
encoded O
by O
pol O
##g O
##1 O
located O
on O
chromosome O
15 O
##q O
##25 O
and O
two O
accessory O
subunit O
##s O
encoded O
by O
pol O
##g O
##2 O
located O
on O
chromosome O
17 O
##q O
##23 O
24 O
corresponding O
author O
address O
anatomical O
pathology O
st O
vincent O
s O
hospital O
melbourne O
p O
o O
box O
290 O
##0 O
fitzroy O
vic O
306 O
##5 O
australia O
tel O
61 O
3 O
92 O
##8 O
##8 O
45 O
##58 O
fa O
##x O
61 O
3 O
92 O
##8 O
##8 O
45 O
##80 O

e O
mail O
address O
penny O
mc O
##kel O
##vie O
sv O
##hm O
org O
au O
p O
mc O
##kel O
##vie O
pol O
##g O
##1 O
has O
23 O
ex O
##ons O
and O
the O
ﬁ O
##rst O
pathogen O
##ic O
mutations O
of O
pol O
##g O
##1 O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
auto O
##som O
##al O
dominant O
syndrome O
chronic O
progressive O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ad O
##cp O
##eo O
3 O
this O
is O
characterized O
by O
multiple O
secondary O
mt O
##dna O
del O
##eti O
##ons O
in O
skeletal O
muscle O
causing O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
defects O
in O
some O
families O
transmitting O
dominant O
pol O
##g O
##1 O
mutations O
a O
high O
incidence O
of O
psychiatric O
disease O
a O
parkinson O
##ian O
syndrome O
and O
primary O
go O
##nad O
##al O
failure O
have O
also O
been O
reported O
4 O
5 O

compound O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
have O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
the O
auto O
##som O
##al O
recess O
##ive O
syndrome O
##s O
in O
patients O
with O
sporadic O
and O
recess O
##ive O
pe O
##o O
which O
are O
also O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
4 O
subsequently O
mutations O
in O
pol O
##g O
##1 O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
patients O
with O
al O
##pers O
syndrome O
ata O
##xia O
ne O
##uro O
##pathy O
syndrome O
##s O
id O
##io O
##pathic O
parkinson O
##ism O
09 O
##60 O
89 O
##66 O
see O
front O
matter O
2011 O
else O
##vier O
b O
v O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
nm O
##d O
2011 O
10 O
01 O
##7 O
402 O
p O
mc O
##kel O
##vie O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
22 O
2012 O
401 O
405 O

and O
others O
all O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
or O
de O
##ple O
##tions O
in O
sy O
##mpt O
##oma O
##tic O
tissues O
2 O
to O
date O
about O
150 O
disease O
mutations O
have O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
2 O
studies O
have O
indicated O
that O
sand O
##o O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
is O
a O
variant O
of O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
arc O
##pe O
##o O
in O
sand O
##o O
o O
##cular O
manifest O
##ions O
occur O
at O
a O
later O
stage O
of O
disease O
progression O
and O
are O
less O
prominent O
than O
the O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
which O
is O
distinguish O
##able O
from O
the O
mild O
generalized O
sensor O
##imo O
##tor O
peripheral O
ne O
##uro O
##pathy O
in O
cp O
##eo O
patients O
5 O
7 O

we O
present O
a O
case B-PATIENT
study O
showing O
spinal O
cord O
peripheral O
nerve O
and O
selective O
nuclear O
de B-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
brain I-HPO_TERM
due O
to O
recess O
##ive O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
case O
report O
a B-AGE_FOLLOWUP
54 I-AGE_FOLLOWUP
year O
old O
woman O
ﬁ O
##rst O
presented O
with O
an O
eight B-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
symptoms O
including O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
features I-HPO_TERM
with O
ata B-HPO_TERM
##xia I-HPO_TERM
in O
all O
limbs O
a O
moderate O
ne B-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
with O
depressed B-HPO_TERM
and I-HPO_TERM
absent I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
in I-HPO_TERM
all I-HPO_TERM
limbs I-HPO_TERM
distal B-HPO_TERM
weakness I-HPO_TERM
and O
distal B-HPO_TERM
sensory I-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
prop I-HPO_TERM
##rio I-HPO_TERM
##ception I-HPO_TERM
and I-HPO_TERM
vibration I-HPO_TERM
a O
tentative O
diagnosis O
of O
hereditary O
spin O
##oc O
##ere O
##bella O
##r O
de O
##gen O
##eration O
and O
peripheral O
ne O
##uro O
##pathy O
was O
made O

progression O
of O
symptoms O
since O
initial O
presentation O
included O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
slowing B-HPO_TERM
with I-HPO_TERM
fat I-HPO_TERM
##iga I-HPO_TERM
##bility I-HPO_TERM
ur B-HPO_TERM
##ina I-HPO_TERM
##ry I-HPO_TERM
stress I-HPO_TERM
inc I-HPO_TERM
##ont I-HPO_TERM
##inen I-HPO_TERM
##ce I-HPO_TERM
and O
dip B-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
leading O
to O
prism O
lenses O
she O
underwent O
bilateral B-HPO_TERM
total I-HPO_TERM
hip I-HPO_TERM
replacements I-HPO_TERM

investigations O
included O
normal O
serum O
ph O
##yt O
##ani O
##c O
acid O
and O
lac O
##tate O
negative O
screening O
for O
peripheral O
le O
##uk O
##oc O
##yte O
l O
##ys O
##osomal O
storage O
disorders O
in O
1994 O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
tests O
for O
sc O
##a1 O
2 O
3 O
6 O
and O
7 O
were O
all O
negative O
fried O
##re O
##ich O
s O
ata O
##xia O
screen O
was O
negative O
serum O
vitamin O
e O
was O
within O
normal O
limits O
ec O
##g O
showed O
p O
pu O
##lm O
##onale O
and O
an O
ace O
inhibitor O
was O
given O
an O
echo O
##card O
##io O
##gram O
showed O
no O
card O
##iom O
##yo O
##pathy O
sleep O
studies O
revealed O
moderate O
sleep B-HPO_TERM
ap I-HPO_TERM
##no I-HPO_TERM
##ea I-HPO_TERM
but O
the O
patient O
did O
not O
tolerate O
cp O
##ap O
brain O
mri O
in O
2007 O
revealed O
mild O
at B-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
superior I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ve I-HPO_TERM
##rmi I-HPO_TERM
##s I-HPO_TERM
a O
swallowing O
assessment O
revealed O
a O
delayed B-HPO_TERM
ph I-HPO_TERM
##ary I-HPO_TERM
##nge I-HPO_TERM
##al I-HPO_TERM
phase I-HPO_TERM

subsequent O
examination O
showed O
reduced B-HPO_TERM
upward I-HPO_TERM
gaze I-HPO_TERM
but O
good O
bin O
##oc O
##ular O
vision O
on O
lateral O
gaze O
lower O
limb O
hip O
ﬂ O
##ex O
##ion O
and O
extension O
were O
grade O
4 O
5 O
medical O
research O
council O
scale O
and O
she O
had O
sign O
##i O
##ﬁ O
##can O
##t O
distal B-HPO_TERM
weakness I-HPO_TERM
upper O
limbs O
were O
normal O
the O
patient O
was O
are B-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##ic I-HPO_TERM
and O
used O
an O
electric O
chair O
for O
mobilization O
over O
six O
years O

during O
her O
last O
admission O
a O
general O
deterioration O
of O
health O
had O
occurred O
with O
increasing B-HPO_TERM
sac I-HPO_TERM
##ral I-HPO_TERM
pains I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
increased B-HPO_TERM
dr I-HPO_TERM
##ows I-HPO_TERM
##iness I-HPO_TERM
intermittent B-HPO_TERM
nausea I-HPO_TERM
worse B-HPO_TERM
##ning I-HPO_TERM
mobility I-HPO_TERM
and O
coping I-HPO_TERM
she O
became O
progressively O
dr B-HPO_TERM
##ows I-HPO_TERM
##y I-HPO_TERM
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathic I-HPO_TERM
and O
feb B-HPO_TERM
##ril I-HPO_TERM
##e I-HPO_TERM
she O
died B-HPO_TERM
aged O
66 B-AGE_DEATH
years O

a O
family O
history O
of O
ne O
##uro O
##psy O
##chia O
##tric O
illness O
in O
a O
deceased O
39 O
year O
old O
sister O
was O
recorded O
the O
sister O
from O
a O
nervous O
breakdown O
and O
underwent O
electro O
##con O
##vu O
##ls O
##ive O
therapy O
she O
had O
decreased O
memory O
mobility O
lower O
limb O
wasting O
and O
weakness O
and O
decreased O
sensation O
in O
distal O
upper O
and O
lower O
limbs O
she O
may O
have O
also O
from O
d O
##ys O
##arth O
##ria O
and O
d O
##ys O
##pha O
##sia O
and O
was O
wheelchair O
##and O
frame O

bound O
the O
sister O
s O
muscle O
bio O
##psy O
revealed O
a O
number O
of O
cy O
##to O
##chrome O
ox O
##ida O
##se O
negative O
ﬁ O
##bre O
##s O
genetic O
studies O
were O
not O
pursued O
at O
the O
time O
and O
post O
mort O
##em O
tissue O
was O
not O
available O
for O
further O
analysis O
on O
the O
patient O
s O
sister O
his O
##to O
##logical O
examination O
muscle O
bio O
##psy O
in O
1994 O
age O
52 O
years O
showed O
extensive B-HPO_TERM
type I-HPO_TERM
grouping I-HPO_TERM
of I-HPO_TERM
type I-HPO_TERM
1 I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
with O
severely O
at B-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
type I-HPO_TERM
2 I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
and O
increased B-HPO_TERM
sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
nuclear I-HPO_TERM
aggregate I-HPO_TERM
##s I-HPO_TERM
some O
cox B-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
were O
noted O
post O
##mo O
##rte O
##m O
post O
##mo O
##rte O
##m O
delay O
was O
24 O
h O
the O
general O
autopsy O
showed O
bilateral O
acute B-HPO_TERM
bro I-HPO_TERM
##nch I-HPO_TERM
##op I-HPO_TERM
##ne I-HPO_TERM
##um I-HPO_TERM
##onia I-HPO_TERM
muscle O

quad O
##rice O
##ps O
gas O
##tro O
##c O
##nem O
##ius O
del O
##to O
##id O
pe O
##ctor O
##alis O
major O
ps O
##oa O
##s O
inter O
##cos O
##tal O
and O
dia O
##ph O
##rag O
##m O
muscles O
all O
showed O
an O
excess O
number O
5 O
of O
cox B-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
and O
ragged B-HPO_TERM
##red I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
3 O
scattered O
de O
##gen O
##era O
##ting O
and O
reg O
##ener O
##ating O
ﬁ O
##bre O
##s O
and O
increased O
numbers O
of O
sar B-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
nuclear I-HPO_TERM
aggregate I-HPO_TERM
##s I-HPO_TERM
were O
noted O
in O
all O
muscles O
group O
at O
##rop O
##hy O
of O
ﬁ O
##bre O
##s O
in O
the O
quad O
##rice O
##ps O
muscle O
and O
marked O
at O
##rop O
##hy O
and O
almost O
end B-HPO_TERM
stage I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
in I-HPO_TERM
gas I-HPO_TERM
##tro I-HPO_TERM
##c I-HPO_TERM
##nem I-HPO_TERM
##ius I-HPO_TERM
poor O
ﬁ O
##bre O
typing O
was O
seen O
with O
atp O
##ase O
stains O
in O
all O
muscles O
except O
the O
del O
##to O
##id O
which O
showed O
type O
grouping O
of O
type O
1 O
and O
type O
2 O
ﬁ O
##bre O
##s O
peripheral O
nerves O

the O
sur O
##al O
nerve O
showed O
severe B-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
my I-HPO_TERM
##elin I-HPO_TERM
##ated I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
of O
all O
diameter O
##s O
with O
only O
some O
residual O
small O
diameter O
ﬁ O
##bre O
##s O
fig O
1a O
electron O
microscopy O
revealed O
small O
numbers O
of O
thin O
##ly O
my O
##elin O
##ated O
ax O
##ons O
some O
ax B-HPO_TERM
##onal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
scattered O
clusters O
of O
reg O
##ener O
##ating O
ﬁ O
##bre O
##s O
but O
no O
onion O
bulbs O
or O
waller O
##ian O
de O
##gen O
##eration O
fe O
##moral O
nerve O
showed O
mild O
loss O
fig O
1 O
a O
sur O
##al O
nerve O
stained O
with O
os O
##mium O
te O
##tro O
##xide O
showing O
very O
few O
residual O
my O
##elin O
##ated O
ax O
##ons O
mag O
##ni O
##ﬁ O
##cation O
x O
##200 O
p O
mc O
##kel O
##vie O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
22 O
2012 O
401 O
405 O
403 O

of O
my O
##elin O
##ated O
ﬁ O
##bre O
##s O
especially O
larger O
diameter O
ﬁ O
##bre O
##s O
electron O
microscopy O
showed O
similar O
changes O
to O
those O
in O
sur O
##al O
nerve O
but O
less O
severe O
brain O

there O
was O
prominent O
loss B-HPO_TERM
of I-HPO_TERM
pigment I-HPO_TERM
##ed I-HPO_TERM
neurons I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
sub I-HPO_TERM
##stan I-HPO_TERM
##tia I-HPO_TERM
ni I-HPO_TERM
##gra I-HPO_TERM
bilateral O
##ly O
fig O
2 O
with O
no O
lew O
##y O
bodies O
or O
ne O
##uro O
##ﬁ O
##bri O
##llary O
tangle O
##s O
and O
negative O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
for O
tau O
u O
##bi O
##qui O
##tin O
and O
alpha O
syn O
##uc O
##lein O
mild O
ne B-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
loss I-HPO_TERM
and O
g B-HPO_TERM
##lio I-HPO_TERM
##sis I-HPO_TERM
was O
noted O
in O
the O
vest O
##ib O
##ular O
nuclei O
there O
was O
severe O
ne O
##uron O
##al O
loss O
and O
g B-HPO_TERM
##lio I-HPO_TERM
##sis I-HPO_TERM
in O
the O
vent B-HPO_TERM
##rol I-HPO_TERM
##ater I-HPO_TERM
##al I-HPO_TERM
posterior I-HPO_TERM
nuclei I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
ne O
##uron O
##al O
loss O
and O
at B-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
was O
seen O
in O
the O
head O
of O
the O
ca B-HPO_TERM
##uda I-HPO_TERM
##te I-HPO_TERM
nucleus I-HPO_TERM
without O
over O
##t O
in O
##far O
##ction O
there O
was O
minimal O
loss B-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
pu I-HPO_TERM
##rkin I-HPO_TERM
##je I-HPO_TERM
cells I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
superior I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
ve I-HPO_TERM
##rmi I-HPO_TERM
##s I-HPO_TERM
dent O
##ate O
nucleus O
and O
ce O
##re O
##bell O
##um O
were O
otherwise O
normal O

spinal O
cord O

there O
was O
prominent O
at B-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
gr I-HPO_TERM
##ac I-HPO_TERM
##ile I-HPO_TERM
and I-HPO_TERM
cu I-HPO_TERM
##nea I-HPO_TERM
##te I-HPO_TERM
nuclei I-HPO_TERM
posterior O
columns O
at O
all O
levels O
and O
the O
dorsal O
spin O
##oc O
##ere O
##bella O
##r O
tract O
with O
very O
at B-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
dorsal I-HPO_TERM
nerve I-HPO_TERM
roots I-HPO_TERM
fig O
##s O
3a O
and O
3 O
##b O
lux O
##ol O
fast O
blue O
and O
ne O
##uro O
##ﬁ O
##lam O
##ent O
stains O
con O
##ﬁ O
##rmed O
that O
there O
was O
both O
severe O
ax B-HPO_TERM
##onal I-HPO_TERM
and I-HPO_TERM
my I-HPO_TERM
##elin I-HPO_TERM
loss I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
dorsal I-HPO_TERM
columns I-HPO_TERM
clarke O
s O
nucleus O
showed O
moderate O
de O
##ple O
##tion O
of O
large O
neurons O
and O
reduced O
size O
and O
numbers O
of O
residual O
neurons O
dorsal O
root O
gang O
##lia O
showed O
de O
##gen O
##eration O
with O
loss O
of O
neurons O
with O
residual O
islands O
of O
satellite O
cells O
and O
a O
number O
of O
de O
##gen O
##era O
##ting O
and O
at O
##rop O
##hic O
neurons O
fig O
3 O
##c O
the O
anterior B-HPO_TERM
nerve I-HPO_TERM
roots I-HPO_TERM
also I-HPO_TERM
appeared I-HPO_TERM
mildly I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
with O
some O
loss O
of O
neurons O
in O
the O
anterior O
horns O
in O
lu O
##mba O
##r O
cord O

bio O
##chemical O
studies O
the O
results O
for O
skeletal O
muscle O
respiratory O
chain O
enzymes O
were O
e O
##qui O
##vo O
##cal O
showing O
border O
##line O
low O
activities O
fig O
3a O
low O
power O
photo O
##mic O
##ro O
##graph O
of O
cervical O
spinal O
cord O
showing O
severe B-HPO_TERM
ax I-HPO_TERM
##onal I-HPO_TERM
loss I-HPO_TERM
in I-HPO_TERM
dorsal I-HPO_TERM
columns I-HPO_TERM
ne O
##uro O
##ﬁ O
##lam O
##ent O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
mag O
##ni O
##ﬁ O
##cation O
x O
##25 O
fig O
3 O
##b O
high O
power O
photo O
##mic O
##ro O
##graph O
of O
spinal O
cord O
showing O
severe O
ax O
##onal O
loss O
in O
dorsal O
spin O
##oc O
##ere O
##bella O
##r O
tract O
indicated O
by O
an O
arrow O
ne O
##uro O
##ﬁ O
##lam O
##ent O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
mag O
##ni O
##ﬁ O
##cation O
x O
##400 O

fig O
2 O
high O
power O
photo O
##mic O
##ro O
##graph O
of O
sub B-HPO_TERM
##stan I-HPO_TERM
##tia I-HPO_TERM
ni I-HPO_TERM
##gra I-HPO_TERM
showing I-HPO_TERM
severe I-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
pigment I-HPO_TERM
##ed I-HPO_TERM
neurons I-HPO_TERM
and I-HPO_TERM
g I-HPO_TERM
##lio I-HPO_TERM
##sis I-HPO_TERM
but O
no O
lew O
##y O
bodies O
or O
ne O
##uro O
##ﬁ O
##bri O
##llary O
tangle O
##s O
in O
residual O
pigment O
##ed O
neurons O
h O
e O
mag O
##ni O
##ﬁ O
##cation O
x O
##200 O
fig O
3 O
##c O
high O
power O
photo O
##mic O
##ro O
##graph O
of O
dorsal O
root O
gang O
##lia O
with O
va O
##cu O
##olar O
de O
##gen O
##eration O
and O
f O
##oc O
##i O
of O
ne O
##uron O
##al O
drop O
##out O
with O
proliferation O
of O
satellite O
cells O
on O
right O
arrows O
mag O
##ni O
##ﬁ O
##cation O
x O
##400 O
404 O
p O
mc O
##kel O
##vie O
et O
al O
ne O
##uro O
##mus O
##cular O
disorders O
22 O
2012 O
401 O
405 O
for O
the O
complexes O
with O
subunit O
##s O
encoded O
by O
mitochondrial O
dna O
mt O
##dna O
genetic O
studies O

the O
common O
point O
mutations O
for O
mel O
##as O
mt O
##tl O
##1 O
##m O
324 O
##3 O
##a O
g O
mer O
##rf O
mt O
t O
##k O
m O
83 O
##44 O
##a O
g O
l O
##hon O
mt O
n O
##d O
##1 O
##m O
34 O
##60 O
##a O
g O
and O
m O
117 O
##7 O
##8 O
##g O
a O
were O
not O
detected O
in O
the O
primary O
muscle O
bio O
##psy O
a O
southern O
b O
##lot O
showed O
no O
mt O
##dna O
del O
##eti O
##ons O
on O
the O
primary O
muscle O
bio O
##psy O
screening O
for O
the O
common O
point O
mutation O
for O
na O
##rp O
l O
##s O
mt O
atp O
##6 O
##m O
89 O
##9 O
##3 O
##t O
c O
g O
on O
blood O
dna O
from O
a O
guthrie O
card O
was O
negative O
the O
tests O
for O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
sc O
##a O
1 O
2 O
3 O
6 O
and O
7 O
showed O
normal O
results O
fried O
##re O
##ich O
s O
ata O
##xia O
screen O
and O
the O
peripheral O
le O
##uc O
##oc O
##yte O
l O
##ys O
##osomal O
storage O
disorder O
screen O
were O
also O
negative O
post O
##mo O
##rte O
##m O
genetic O
studies O

a O
mitochondrial O
mutation O
screen O
was O
again O
carried O
out O
on O
post O
##mo O
##rte O
##m O
del O
##to O
##id O
muscle O
the O
common O
point O
mutations O
for O
mel O
##as O
mt O
t O
##l O
##1 O
##m O
324 O
##3 O
##a O
g O
mer O
##rf O
mt O
##t O
##k O
m O
83 O
##44 O
##a O
g O
na O
##rp O
l O
##s O
mt O
atp O
##6 O
##m O
89 O
##9 O
##3 O
##t O
c O
g O
and O
l O
##hon O
mt O
n O
##d O
##1 O
##m O
34 O
##60 O
##a O
g O
m O
117 O
##7 O
##8 O
##g O
a O
and O
m O
144 O
##8 O
##4 O
##t O
c O
were O
not O
detected O
in O
the O
muscle O
bio O
##psy O
the O
rare O
##r O
mutations O
for O
mel O
##as O
mt O
t O
##l O
##1 O
##m O
327 O
##1 O
##t O
c O
and O
mt O
n O
##d O
##5 O
##m O
135 O
##13 O
##g O
a O
were O
also O
not O
detected O
sequencing O
of O
the O
mitochondrial O
##en O
##code O
##d O
cox O
i O
ii O
and O
iii O
genes O
only O
revealed O
reported O
poly O
##morphism O
##s O
not O
associated O
with O
pathogen O
##ici O
##ty O

a O
southern O
b O
##lot O
on O
post O
##mo O
##rte O
##m O
ps O
##oa O
##s O
pe O
##ctor O
##alis O
inter O
##cos O
##tal O
gas O
##tro O
##c O
##nem O
##ius O
dia O
##ph O
##rag O
##m O
del O
##to O
##id O
and O
quad O
##rice O
##ps O
muscles O
revealed O
low O
levels O
of O
multiple O
mt O
##dna O
del O
##eti O
##ons O
analysis O
of O
quad O
##rice O
##ps O
muscle O
dna O
by O
q O
##pc O
##r O
revealed O
a O
decreased O
amount O
of O
mt O
##dna O
in O
relative O
to O
nuclear O
dna O
corresponding O
to O
28 O
and O
32 O
of O
the O
normal O
mean O
ratio O
in O
two O
independent O
experiments O

sequencing O
of O
pol B-GENE
##g I-GENE
http O
www O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
ex O
##ons O
in O
gen O
##omic O
dna O
did O
not O
detect O
the O
3 O
common O
pathogen O
##ic O
variants O
of O
european O
origin O
p B-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
p B-GENE_VARIANT
w I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
and O
p B-GENE_VARIANT
g I-GENE_VARIANT
##8 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
however O
two O
reported O
het O
##ero O
##zy O
##go O
##us O
sequence O
variants O
in O
the O
polymer O
##ase O
domain O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
were O
id O
##ent O
##i O
##ﬁ O
##ed O
the O
ﬁ O
##rst O
was O
a O
het O
##ero O
##zy O
##go O
##us O
mutation O
c B-GENE_VARIANT
258 I-GENE_VARIANT
##4 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
in O
ex O
##on O
16 O
predicting O
a O
p B-GENE_VARIANT
a I-GENE_VARIANT
##86 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
change O
the O
second O
het O
##ero O
##zy O
##go O
##us O
mutation O
was O
in O
ex O
##on O
3 O
a O
c B-GENE_VARIANT
83 I-GENE_VARIANT
##0 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
predicting O
a O
p B-GENE_VARIANT
h I-GENE_VARIANT
##27 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
change O
the O
a O
86 O
##2 O
nu O
##cle O
##otide O
and O
the O
277 O
amino O
acid O
his O
##ti O
##dine O
are O
highly O
conserved O
from O
humans O
to O
ne O
##uro O
##sp O
##ora O
genetic O
studies O
in O
family O
members O

further O
studies O
were O
carried O
out O
on O
two O
other O
siblings O
and O
the O
daughter O
with O
no O
manifestation O
of O
disease O
only O
the O
c O
83 O
##0 O
##a O
t O
mutation O
was O
found O
in O
het O
##ero O
##zy O
##go O
##us O
form O
in O
the O
patient O
s O
36 O
year O
old O
daughter O
and O
the O
patient O
s O
72 O
year O
old O
sister O
the O
two O
variants O
described O
in O
the O
patient O
were O
not O
detected O
in O
the O
second O
sibling O
of O
80 O
years O
of O
age O
discussion O

this O
woman B-PATIENT
presented O
in O
middle O
age O
with O
a O
progressive B-HPO_TERM
sensory I-HPO_TERM
ata I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
with O
later O
development O
of O
pt B-HPO_TERM
##osis I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
and O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
no O
de O
##ﬁ O
##ni O
##te O
diagnosis O
was O
made O
prior O
to O
autopsy O
but O
a O
form O
of O
hereditary O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
with O
peripheral O
ne O
##uro O
##pathy O
was O
favoured O
mitochondrial O
cy O
##top O
##athy O
was O
suspected O
in O
view O
of O
the O
previous O
changes O
of O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
and O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
on O
two O
muscle O
bio O
##ps O
##ies O
performed O
20 O
and O
14 O
years O
prior O
to O
death O

autopsy O
con O
##ﬁ O
##rmed O
that O
the O
patient O
had O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
associated O
with O
compound O
het O
##ero O
##zy O
##go O
##us O
pol B-GENE
##g I-GENE
mutations O
p B-GENE_VARIANT
a I-GENE_VARIANT
##86 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
p B-GENE_VARIANT
h I-GENE_VARIANT
##27 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
in O
skeletal O
muscle O
the O
p O
a O
##86 O
##2 O
##t O
mutation O
has O
been O
reported O
previously O
as O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
a O
man O
with O
late O
onset O
pe O
##o O
and O
ata O
##xia O
with O
a O
sc O
##a O
like O
illness O
in O
siblings O
8 O
the O
p O
h O
##27 O
##7 O
##l O
mutation O
has O
only O
been O
very O
recently O
reported O
as O
a O
compound O
het O
##ero O
##zy O
##go O
##us O
mutation O
in O
a O
man O
with O
late O
onset O
pe O
##o O
and O
parkinson O
##ism O
9 O
detailed O
ne O
##uro O
##path O
##ological O
examination O
in O
our O
case O
con O
##ﬁ O
##rmed O
features O
of O
mitochondrial O
my O
##opa O
##thy O
in O
multiple O
skeletal O
muscles O
severe O
predominantly O
sensory O
peripheral O
ne O
##uro O
##pathy O
but O
also O
profound O
dorsal O
column O
and O
dorsal O
spin O
##oc O
##ere O
##bella O
##r O
tract O
de O
##gen O
##eration O
in O
the O
spinal O
cord O
which O
has O
not O
previously O
been O
reported O
in O
patients O
with O
documented O
pol O
##g O
mutations O
or O
sand O
##o O
dorsal O
root O
gang O
##lion O
cells O
were O
reduced O
in O
number O
and O
size O
with O
evidence O
of O
drop O
##out O
and O
ongoing O
de O
##gen O
##eration O
clarke O
s O
nucleus O
also O
showed O
loss O
of O
large O
neurons O
and O
reduced O
size O
and O
numbers O
of O
residual O
neurons O
however O
spinal O
cord O
involvement O
dorsal O
column O
and O
dorsal O
spin O
##oc O
##ere O
##bella O
##r O
tract O
de O
##gen O
##eration O
has O
been O
noted O
in O
patients O
with O
mitochondrial O
cy O
##top O
##athy O
with O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
and O
pe O
##o O
10 O
another O
adult O
case O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
published O
prior O
to O
the O
id O
##ent O
##i O
##ﬁ O
##cation O
of O
pol O
##g O
3 O
but O
who O
is O
likely O
to O
have O
pol O
##g O
mutation O
s O
and O
the O
clinical O
scenario O
of O
ata O
##xia O
pe O
##o O
pt O
##osis O
peripheral O
ne O
##uro O
##pathy O
d O
##ys O
##pha O
##gia O
and O
extra O
##py O
##ram O
##idal O
movement O
disorder O
also O
had O
dorsal O
column O
and O
dorsal O
root O
gang O
##lia O
de O
##gen O
##eration O
at O
autopsy O
11 O
posterior O
column O
de O
##gen O
##eration O
has O
been O
reported O
in O
a O
family O
with O
a O
rare O
auto O
##som O
##al O
dominant O
pol O
##g O
##1 O
mutation O
with O
metabolic O
strokes O
and O
multi O
##end O
##oc O
##rine O
disease O
12 O

unusual O
association O
of O
diseases O
symptoms O
novel O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
in O
a O
patient B-PATIENT
with O
adult B-HPO_TERM
onset I-HPO_TERM
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
mika O
h O
mart O
##ika O
##inen O
1 O
re O
##etta O
hint O
##tal O
##a O
2 O
kari O
maj O
##ama O
##a O
##2 O
1 O
department O
of O
ne O
##uro O
##logy O
turk O
##u O
university O
hospital O
turk O
##u O
finland O
2 O
department O
of O
ne O
##uro O
##logy O
institute O
of O
clinical O
medicine O
university O
of O
ou O
##lu O
ou O
##lu O
finland O
correspondence O
to O
kari O
maj O
##ama O
##a O
kari O
maj O
##ama O
##a O
ou O
##lu O
fi O
summary O

mutations O
in O
pol O
##g O
##1 O
are O
an O
important O
cause O
of O
human O
mitochondrial O
disease O
we O
describe O
a O
woman B-PATIENT
who O
presented O
with O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
at O
64 B-AGE_ONSET
years O
of O
age O
neurological O
examination O
revealed O
symptoms O
of O
diffuse B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
the O
symptoms B-HPO_TERM
were I-HPO_TERM
progressive I-HPO_TERM
and O
at O
67 O
years O
she O
was O
severely B-HPO_TERM
cognitive I-HPO_TERM
##ly I-HPO_TERM
impaired I-HPO_TERM
had O
severe B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
complete B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
frequent O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
negative I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
were O
detected O
in O
muscle O
electro O
##phy O
##sio O
##logical O
examination O
revealed O
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
changes O
and O
ax B-HPO_TERM
##onal I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
standard O
laboratory O
tests O
were O
normal O
brain O
ct O
showed O
general O
moderate B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
molecular O
analysis O
of O
muscle O
dna O
revealed O
multiple B-HPO_TERM
mitochondrial I-HPO_TERM
dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
sequencing O
of O
the O
entire O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
revealed O
two O
changes O
c B-GENE_VARIANT
299 I-GENE_VARIANT
##3 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
99 I-GENE_VARIANT
##8 I-GENE_VARIANT
##s I-GENE_VARIANT
l I-GENE_VARIANT
and O
c B-GENE_VARIANT
355 I-GENE_VARIANT
##0 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
p B-GENE_VARIANT
118 I-GENE_VARIANT
##4 I-GENE_VARIANT
##d I-GENE_VARIANT
h I-GENE_VARIANT
both O
mutations O
are O
previously O
un O
##re O
##port O
##ed O
and O
confirmed O
to O
be O
compound O
het O
##ero O
##zy O
##go O
##us O
late O
onset O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
with O
severe O
en O
##ce O
##pha O
##lo O
##pathy O
is O
an O
unusual O
combination O
in O
patients O
with O
pol O
##g O
##1 O
mutations O
pol O
##g O
associated O
disease O
should O
be O
considered O
in O
any O
patient O
with O
une O
##x O
##pl O
##aine O
##d O
or O
unusual O
neurological O
features O

background O
this O
case B-PATIENT
represents O
two O
novel O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
causing O
an O
uncommon O
ph O
##eno O
##type O
with O
adult B-HPO_TERM
onset I-HPO_TERM
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
pe B-HPO_TERM
##o I-HPO_TERM
and O
progressive B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
as O
dominant O
features O
the O
case O
depicts O
the O
clinical O
symptoms O
caused O
by O
these O
novel O
mutations O
and O
further O
confirms O
that O
the O
possibility O
of O
a O
pol O
##g O
associated O
disease O
should O
be O
considered O
in O
any O
patient O
with O
une O
##x O
##pl O
##aine O
##d O
or O
unusual O
neurological O
features O
case O
presentation O

the O
patient B-PATIENT
is O
a O
woman O
with O
an O
uneven O
##tf O
##ul O
medical O
history O
until O
the O
age O
of O
50 O
years O
when O
she O
had O
a O
breast B-HPO_TERM
cancer I-HPO_TERM
operation O
ax O
##illa O
##ry O
l O
##ym O
##ph O
node O
evacuation O
and O
post O
##oper O
##ative O
radiation O
treatment O
was O
performed O
at O
age O
54 O
years O
she O
also O
had O
a O
history O
of O
psychiatric B-HPO_TERM
symptoms I-HPO_TERM
of O
unknown O
quality O
and O
she O
had O
been O
on O
anti O
##de O
##pressive O
medication O
her O
parents O
had O
had O
no O
known O
medical O
conditions O
her O
father O
had O
died O
at O
age O
75 O
years O
and O
her O
mother O
at O
age O
85 O
years O
the O
patient O
was O
her O
parents O
only O
child O
she O
had O
two O
adult O
daughters O
who O
were O
healthy O

at O
age O
64 B-AGE_ONSET
years O
she O
was O
referred O
to O
an O
op O
##ht O
##hal O
##mo O
##logist O
for O
consideration O
of O
surgical O
treatment O
of O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
there O
was O
no O
history O
of O
dip O
##lo O
##pia O
headache O
or O
difficulties O
with O
swallowing O
at O
that O
time O
her O
medication O
consisted O
of O
bis O
##op O
##rol O
##ol O
los O
##art O
##an O
que O
##tia O
##pine O
and O
es O
##cit O
##alo O
##pr O
##am O
the O
op O
##ht O
##hal O
##mo O
##logist O
confirmed O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
but O
diagnosed O
also O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
neurological O
examination O
revealed O
symptoms O
of O
diffuse B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
echo B-HPO_TERM
##lal I-HPO_TERM
##ia I-HPO_TERM
automatic B-HPO_TERM
laughter I-HPO_TERM
depression B-HPO_TERM
general B-HPO_TERM
cognitive I-HPO_TERM
slow I-HPO_TERM
##ness I-HPO_TERM
problems B-HPO_TERM
in I-HPO_TERM
understanding I-HPO_TERM
and I-HPO_TERM
following I-HPO_TERM
commands I-HPO_TERM
in O
clinical O
examination O
confusion B-HPO_TERM
and O
di B-HPO_TERM
##sor I-HPO_TERM
##ient I-HPO_TERM
##ation I-HPO_TERM
as O
well O
as O
general O
cl B-HPO_TERM
##ums I-HPO_TERM
##iness I-HPO_TERM
there O
were O
no O
signs O
of O
hem O
##ip O
##ares O
##is O

tend B-HPO_TERM
##on I-HPO_TERM
reflex I-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
weak I-HPO_TERM
but O
symmetric O
and O
she O
had O
flex O
##or O
plant O
##ar O
responses O
the O
disease O
history O
and O
the O
clinical O
assessment O
were O
not O
suggest O
##ive O
of O
dementia O
of O
alzheimer O
type O
the O
patient O
had O
no O
history O
of O
seizures O
or O
other O
symptoms O
suggest O
##ive O
of O
ep O
##ile O
##psy O
her O
mini O
mental O
state O
examination O
mm O
##se O
score O
at O
age O
64 O
years O
was O
27 O
points O
out O
of O
30 O
which O
is O
decreased O
but O
not O
indicative O
of O
dementia O
mm O
##se O
was O
not O
repeated O
but O
later O
clinical O
notes O
indicate O
definite B-HPO_TERM
progression I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
cognitive I-HPO_TERM
problems O
leading O
to O
dementia B-HPO_TERM
at O
age O
67 O
years O
the O
patient O
had O
slowly O
progressive B-HPO_TERM
symmetric I-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
she O
was O
not B-HPO_TERM
able I-HPO_TERM
to I-HPO_TERM
move I-HPO_TERM
una I-HPO_TERM
##ided I-HPO_TERM
and O
was O
not O
able O
to O
live O
independently O
she O
had O
severe B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
complete B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
she O
died B-HPO_TERM
from O
pneumonia B-HPO_TERM
at O
age O
67 B-AGE_DEATH
years O
in O
a O
nursing O
home O

investigations O

his O
##to O
##logical O
examination O
of O
a O
sample O
from O
the O
right O
vast O
##us O
lateral O
##is O
muscle O
showed O
abnormal O
##ly O
frequent O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
negative I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
at O
the O
age O
of O
64 O
years O
figure O
1a O
electro O
##phy O
##sio O
##logical O
examination O
revealed O
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
changes O
and O
they O
were O
most O
prominent O
in O
facial B-HPO_TERM
muscles I-HPO_TERM
furthermore O
sensory O
more O
than O
motor O
ax B-HPO_TERM
##onal I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
was O
observed O
facial O
nerve O
conduct O
##ion O
was O
not O
studied O
an O
aero O
##bic O
exercise O
test O
was O
not O
performed O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
antibodies O
were O
not O
detected O
fast O
##ing O
blood O
glucose O
trans O
##amina O
##se O
values O
cr O
##ea O
##tin O
##ine O
cr O
##ea O
##tine O
kinase O
thyroid O
function O
tests O
and O
serum O
sodium O
and O
potassium O
were O
normal O
blood B-HPO_TERM
p I-HPO_TERM
##yr I-HPO_TERM
##u I-HPO_TERM
##vate I-HPO_TERM
was I-HPO_TERM
172 I-HPO_TERM
μ I-HPO_TERM
##mo I-HPO_TERM
##l I-HPO_TERM
litre I-HPO_TERM
laboratory O
reference O
40 O
70 O
μ O
##mo O
##l O
litre O
blood O
lac O
##tate O
was O
not O
determined O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
analysis O
was O
not O
performed O
brain O
ct O
and O
mri O
showed O
general O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
that O
was O
not O
particularly O
prominent O
in O
tempo O
##ro O
par O
##ie O
##tal O
structures O
and O
no O
focal O
abnormalities O
there O
were O
no O
signs O

figure O
1 O
a O
dual O
his O
##to O
##chemist O
##ry O
for O
the O
mitochondrial O
dna O
encoded O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
and O
the O
nuclear O
dna O
encoded O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
on O
the O
patient O
s O
vast O
##us O
lateral O
##is O
muscle O
bio O
##psy O
demonstrates O
cox B-HPO_TERM
def I-HPO_TERM
##icient I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
blue O
and O
muscle O
fibre O
##s O
expressing O
both O
cox O
and O
sd O
##h O
brown O
scale O
bar O
100 O
μ O
##m O

long O
range O
pc O
##r O
amp O
##li O
##fication O
of O
mt O
##dna O
from O
skeletal O
muscle O
lane O
##1 O
1 O
kb O
ladder O
new O
england O
bio O
##lab O
##s O
ipswich O
massachusetts O
usa O
lane O
2 O
the O
pro O
##band O
lane O
3 O
patient O
with O
a O
sporadic O
mt O
##dna O
del O
##eti O
##on O
lane O
4 O
mt O
##dna O
from O
a O
healthy O
control O
lane O
5 O
mix O
ladder O
fe O
##rm O
##ent O
##as O
finland O
helsinki O
finland O
white O
arrow O
head O
the O
full O
size O
16 O
5 O
kb O
amp O
##lic O
##on O
black O
arrow O
head O
small O
sized O
amp O
##lic O
##ons O
on O
lane O
2 O

sequence O
ch O
##rom O
##ato O
##gram O
showing O
het O
##ero O
##zy O
##go O
##us O
changes O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
above O
the O
ser B-GENE_VARIANT
##9 I-GENE_VARIANT
##9 I-GENE_VARIANT
##8 I-GENE_VARIANT
##le I-GENE_VARIANT
##u I-GENE_VARIANT
change O
c B-GENE_VARIANT
299 I-GENE_VARIANT
##3 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
tc O
##g O
tt O
##g O
detected O
with O
forward O
prime O
##r O
below O
the O
as B-GENE_VARIANT
##p I-GENE_VARIANT
##11 I-GENE_VARIANT
##8 I-GENE_VARIANT
##4 I-GENE_VARIANT
##his I-GENE_VARIANT
change O
c B-GENE_VARIANT
355 I-GENE_VARIANT
##0 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
ga O
##t O
cat O
detected O
with O
reverse O
prime O
##r O
of O
vascular O
lesions O
or O
hydro O
##ce O
##pha O
##lus O
additional O
central O
nervous O
system O
examinations O
were O
not O
performed O

total O
dna O
was O
extracted O
from O
muscle O
tissue O
homo O
##gen O
##ate O
using O
the O
standard O
sodium O
dod O
##ec O
##yl O
sul O
##phate O
##pro O
##tein O
##ase O
k O
method O
and O
from O
blood O
using O
qi O
##aa O
##mp O
dna O
blood O
mini O
kit O
qi O
##age O
##n O
valencia O
california O
usa O
mitochondrial O
dna O
mt O
##dna O
del O
##eti O
##ons O
were O
anal O
##yse O
##d O
by O
long O
pc O
##r O
expand O
long O
template O
pc O
##r O
system O
kit O
roche O
mannheim O
germany O
blood O
dna O
was O
used O
as O
a O
template O
to O
amp O
##li O
##fy O
and O
sequence O
the O
23 O
coding O
ex O
##ons O
of O
the O
pol O
##g O
##1 O
gene O
nm O
00 O
##26 O
##9 O
##3 O
in O
the O
pro O
##band O
by O
automated O
sequencing O
ab O
##i O
prism O
310 O
##0 O
genetic O
analyze O
##r O
applied O
bio O
##systems O
foster O
city O
california O
usa O
using O
the O
big O
##dy O
##e O
term O
##inator O
v O
##1 O
1 O
cycle O
sequencing O
kit O
applied O
bio O
##systems O
after O
treatment O
with O
ex O
##on O
##uc O
##lea O
##se O
i O
and O
shrimp O
al O
##kali O
##ne O
ph O
##os O
##pha O
##tase O
the O
novel O
sequence O
variants O
found O
in O
pol O
##g O
##1 O
were O
confirmed O
using O
restriction O
fragment O
length O
poly O
##morphism O
analysis O
the O
p O
118 O
##4 O
##d O
h O
substitution O
destroys O
a O
recognition O
site O
for O
ta O
##qi O
leading O
to O
an O
und O
##ige O
##sted O
pc O
##r O
product O
of O
289 O
bp O
in O
size O
the O
p O
99 O
##8 O
##s O
l O
substitution O
destroys O
a O
recognition O
site O
for O
hp O
##y O
##11 O
##8 O
##i O
leading O
to O
an O
und O
##ige O
##sted O
pc O
##r O
product O
of O
277 O
bp O
in O
size O

outcome O
and O
follow O
up O
initial O
analysis O
for O
the O
common O
mt O
##dna O
point O
mutations O
m O
324 O
##3 O
##a O
g O
m O
83 O
##44 O
##a O
g O
and O
m O
89 O
##9 O
##3 O
##t O
c O
as O
well O
as O
southern O
b O
##lot O
analysis O
to O
demonstrate O
large O
mt O
##dna O
del O
##eti O
##ons O
were O
negative O
further O
molecular O
analysis O
revealed O
multiple O
mt O
##dna O
del O
##eti O
##ons O
confirming O
mitochondrial O
disease O
figure O
1b O
sequencing O
of O
the O
entire O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
revealed O
two O
het O
##ero O
##zy O
##go O
##us O
nu O
##cle O
##otide O
substitution O
##s O
c B-GENE_VARIANT
299 I-GENE_VARIANT
##3 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
99 I-GENE_VARIANT
##8 I-GENE_VARIANT
##s I-GENE_VARIANT
l I-GENE_VARIANT
and O
c B-GENE_VARIANT
355 I-GENE_VARIANT
##0 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
p B-GENE_VARIANT
118 I-GENE_VARIANT
##4 I-GENE_VARIANT
##d I-GENE_VARIANT
h I-GENE_VARIANT
fig O
ur O
##e O
1 O
##c O
both O
are O
previously O
un O
##re O
##port O
##ed O
the O
two O
da O
##ugh O

ter O
##s O
of O
the O
pro O
##band O
as O
well O
as O
one O
child O
of O
the O
elder O
daughter O
harbour O
##ed O
het O
##ero O
##zy O
##go O
##us O
p O
118 O
##4 O
##d O
h O
but O
p O
99 O
##8 O
##s O
l O
was O
found O
only O
in O
the O
pro O
##band O
these O
findings O
confirm O
that O
the O
two O
novel O
base O
exchanges O
in O
the O
pro O
##band O
were O
het O
##ero O
##zy O
##go O
##us O
in O
trans O
discussion O
since O
1989 O
nuclear O
defects O
have O
been O
implicated O
as O
possible O
ae O
##ti O
##ologies O
of O
mitochondrial O
disease O
1 O
pol O
##g O
##1 O
gene O
en O
##codes O
the O
catalytic O
subunit O
of O
pol O
the O
only O
dna O
polymer O
##ase O
in O
human O
mit O
##och O
##ond O
##ria O
and O
its O
mutations O
have O
emerged O
as O
an O
important O
ae O
##ti O
##ology O
of O
human O
mitochondrial O
disease O
2 O
5 O

pe O
##o O
and O
en O
##ce O
##pha O
##lo O
##pathy O
are O
both O
frequent O
ph O
##eno O
##typic O
features O
in O
mitochondrial O
diseases O
but O
in O
patients O
with O
pol O
##g O
##1 O
mutations O
en O
##ce O
##pha O
##lo O
##pathic O
ph O
##eno O
##type O
##s O
present O
most O
often O
in O
childhood O
the O
combination O
of O
adult O
onset O
pe O
##o O
and O
en O
##ce O
##pha O
##lo O
##pathy O
is O
uncommon O
56 O

our O
patient B-PATIENT
had O
a O
pe B-HPO_TERM
##o I-HPO_TERM
plus O
ph O
##eno O
##type O
consisting O
of O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
progressive B-HPO_TERM
en I-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
as O
dominant O
features O
muscle O
his O
##tology O
showed O
cox B-HPO_TERM
negative I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
that O
were O
abnormal O
##ly O
frequent O
to O
the O
age O
of O
the O
patient O
molecular O
genetic O
analysis O
revealed O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
in O
muscle O
and O
het O
##ero O
##zy O
##go O
##us O
in O
trans O
mutations O
p B-GENE_VARIANT
99 I-GENE_VARIANT
##8 I-GENE_VARIANT
##s I-GENE_VARIANT
l I-GENE_VARIANT
and O
p B-GENE_VARIANT
118 I-GENE_VARIANT
##4 I-GENE_VARIANT
##d I-GENE_VARIANT
h I-GENE_VARIANT
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
neither O
of O
them O
has O
been O
described O
previously O
but O
another O
pathogen O
##ic O
mutation O
p O
118 O
##4 O
##d O
n O
has O
previously O
been O
described O
in O
the O
position O
118 O
##4 O
the O
p O
118 O
##4 O
##d O
n O
mutation O
has O
been O
described O
in O
trans O
with O
the O
ex O
##on O
##uc O
##lea O
##se O
domain O
mutation O
p O
227 O
##r O
w O
in O
children O
with O
failure O
to O
thrive O
mental O
re O
##tar O
##dation O
and O
h O
##yp O
##oton O
##ia O
7 O
and O
in O
adults O
with O
a O
link O
##er O
region O
mutation O
p O
46 O
##8 O
##n O
d O
with O
pe O
##o O
and O
te O
##tra O
##par O
##esis O
8 O
both O
p O
99 O
##8 O
##s O
l O
and O
p O
118 O
##4 O
##d O
h O
mutations O
are O
located O
in O
the O
polymer O
##ase O
domain O
of O
pol O
in O
positions O
that O
are O
evolution O
##ari O
##ly O
conserved O
suggesting O
that O
the O
mutations O
are O
pathogen O
##ic O

our O
patient B-PATIENT
harbour O
##ed O
two O
novel O
pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
her O
clinical O
features O
a O
relatively O
late O
adult B-HPO_TERM
onset I-HPO_TERM
sy O
##mpt O
##om O
combination O
of O
pe B-HPO_TERM
##o I-HPO_TERM
and O
prominent O
dem B-HPO_TERM
##enting I-HPO_TERM
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
demonstrate O
the O
wide O
ph O
##eno O
##typic O
variety O
of O
the O
pol O
##g O
##1 O
mutations O
the O
possibility O
of O
a O
pol O
##g O
associated O
disease O
should O
be O
considered O
in O
any O
patient O
with O
une O
##x O
##pl O
##aine O
##d O
or O
unusual O
neurological O
features O
9 O

acknowledge O
##ments O
the O
authors O
thank O
ms O
an O
##ja O
he O
##ik O
##kin O
##en O
and O
ms O
pi O
##r O
##jo O
ke O
##rone O
##n O
for O
their O
expert O
assistance O
the O
work O
was O
supported O
by O
the O
research O
council O
for O
health O
at O
the O
academy O
of O
finland O
the O
si O
##gr O
##id O
ju O
##sel O
##ius O
foundation O
the O
national O
graduate O
school O
of O
clinical O
investigation O
cl O
##ig O
##s O
and O
the O
north O
os O
##tro O
##bot O
##hn O
##ia O
regional O
fund O
of O
the O
finnish O
cultural O
foundation O
competing O
interests O
none O
patient O
consent O
obtained O
references O
zev O
##iani O
m O
ser O
##vid O
##ei O
s O
gel O
##ler O
##a O
c O
et O
al O
an O
auto O
##som O
##al O
dominant O
disorder O
with O
multiple O
del O
##eti O
##ons O
of O
mitochondrial O
dna O
starting O
at O
the O
d O
loop O
region O
nature O
1989 O
339 O
309 O
11 O

van O
goethe O
##m O
g O
der O
##ma O
##ut O
b O
l O
f O
##gren O
a O
et O
al O
mutation O
of O
pol O
##g O
is O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
nat O
gene O
##t O
2001 O
28 O
211 O
12 O
lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
et O
al O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O
2002 O
52 O
211 O
19 O
hudson O
g O
chin O
##nery O
p O
##f O
mitochondrial O
dna O
polymer O
##ase O
gamma O
and O
human O
disease O
hum O
mo O
##l O
gene O
##t O
2006 O
15 O
r O
##24 O
##4 O
52 O

ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
et O
al O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
167 O
##4 O
84 O
wong O
l O
##j O
na O
##via O
##ux O
r O
##k O
br O
##une O
##tti O
pier O
##ri O
n O
et O
al O
molecular O
and O
clinical O
genetics O
of O
mitochondrial O
diseases O
due O
to O
pol O
##g O
mutations O
hum O
mu O
##tat O
2008 O
29 O
e O
##15 O
##0 O
72 O
de O
vr O
##ies O
mc O
rode O
##nburg O
r O
##j O
mora O
##va O
e O
et O
al O
multiple O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
def O
##iciencies O
in O
severe O
childhood O
multi O
system O
disorders O
due O
to O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
mutations O
eu O
##r O
j O
pe O
##dia O
##tr O
2007 O
166 O
229 O
34 O
gonzalez O
vi O
##o O
##que O
e O
b O
##la O
##zquez O
a O
fernandez O
more O
##ira O
d O
et O
al O
association O
of O

novel O
pol O
##g O
mutations O
and O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
with O
variable O
clinical O
ph O
##eno O
##type O
##s O
in O
a O
spanish O
population O
arch O
ne O
##uro O
##l O
2006 O
63 O
107 O
111 O
chin O
##nery O
p O
##f O
zev O
##iani O
m O
155 O
##th O
en O
##mc O
workshop O
polymer O
##ase O
gamma O
and O
disorders O
of O
mitochondrial O
dna O
synthesis O
21 O
23 O
september O
2007 O
na O
##ard O
##en O
the O
netherlands O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
259 O
67 O

auto O
##no O
##mic O
neuroscience O
basic O
and O
clinical O
170 O
2012 O
70 O
72 O
short O
communication O
novel O
mutation O
in O
space O
##r O
region O
of O
pol B-GENE
##g I-GENE
associated O
with O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
and O
gas O
##tro O
##par O
##esis O
ali O
##on O
##ka O
bo O
##stan O
a O
gerald O
g O
##lib O
##ert O
a O
bernard O
da O
##chy O
a O
bernard O
dan O
b O
a O
department O
of O
ne O
##uro O
##logy O
chu O
br O
##ug O
##mann O
universite O
libre O
de O
br O
##ux O
##elles O
place O
a O
van O
ge O
##hu O
##cht O
##en O
4 O
brussels O
b O
102 O
##0 O
belgium O
b O
department O
of O
ne O
##uro O
##logy O
hop O
##ital O
un O
##iver O
##sit O
##aire O
des O
en O
##fan O
##ts O
rein O
##e O
fabio O
##la O
universite O
libre O
de O
br O
##ux O
##elles O
ul O
##b O
brussels O
belgium O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
17 O
november O
2011 O

received O
in O
revised O
form O
15 O
june O
2012 O
accepted O
17 O
june O
2012 O
key O
##words O
polymer O
##ase O
gamma O
mitochondrial O
dna O
poly O
##ne O
##uro O
##pathy O
gas O
##tro O
##par O
##esis O
a O
b O
s O
t O
r O
a O
c O
t O
clinical O
expression O
of O
pol O
##g O
mutations O
is O
largely O
variable O
we O
present O
a O
patient B-PATIENT
with O
a O
new O
mutation O
in O
space O
##r O
region O
of O
mitochondrial O
polymer B-GENE
##ase I-GENE
gamma I-GENE
protein I-GENE
p B-GENE_VARIANT
##7 I-GENE_VARIANT
##65 I-GENE_VARIANT
##t I-GENE_VARIANT
the O
clinical O
picture O
is O
characterized O
by O
the O
presence O
of O
sensory B-HPO_TERM
ata I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
gas B-HPO_TERM
##tro I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
which O
had O
not O
been O
previously O
observed O
in O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
2012 O
else O
##vier O
b O
v O
all O
rights O
reserved O
introduction O

dna O
polymer O
##ase O
gamma O
pol O
##g O
the O
only O
dna O
polymer O
##ase O
found O
in O
mit O
##och O
##ond O
##ria O
is O
entirely O
responsible O
for O
all O
dna O
synthetic O
reactions O
including O
mt O
##dna O
replication O
and O
repair O
han O
##ce O
et O
al O
2005 O
pol O
##g O
is O
a O
het O
##ero O
##dim O
##eric O
enzyme O
containing O
a O
pol O
i O
like O
catalytic O
core O
pol O
##ga O
and O
an O
accessory O
subunit O
pol O
##gb O
encoded O
by O
pol O
##g O
at O
locus O
15 O
##q O
##25 O
and O
pol O
##g O
##2 O
at O
locus O
17 O
##q O
##24 O
1 O
respectively O
chan O
and O
copeland O
2009 O
pol O
##ga O
possesses O
both O
polymer O
##ase O
and O
proof O
##rea O
##ding O
ex O
##on O
##uc O
##lea O
##se O
activities O
pol O
##gb O
increases O
enzyme O
s O
process O
##ivity O
lee O
et O
al O
2009 O
mutations O
in O
the O
catalytic O
subunit O
of O
pol O
##g O
can O
cause O
mt O
##dna O
instability O
inducing O
its O
del O
##eti O
##on O
and O
or O
de O
##ple O
##tion O
mutation O
database O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
currently O
lists O
more O
than O
150 O
pol O
##g O
mutations O
which O
are O
evenly O
distributed O
over O
the O
protein O
sequence O
in O
addition O
to O
the O
clinical O
het O
##ero O
##gen O
##eit O
##y O
pol O
##g O
mutations O
can O
be O
either O
dominant O
or O
recess O
##ive O
posing O
a O
great O
diagnostic O
challenge O
for O
the O
clinic O
##ian O

the O
ph O
##eno O
##typic O
spectrum O
is O
wide O
including O
en O
##ce O
##pha O
##lo O
##pathy O
ep O
##ile O
##psy O
ata O
##xia O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
my O
##opa O
##thy O
and O
he O
##pa O
##top O
##athy O
among O
neurological O
features O
of O
pol O
##g O
related O
disorders O
the O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
an O
##s O
has O
been O
de O
##ﬁ O
##ned O
comprising O
mitochondrial O
recess O
##ive O
ata O
##xia O
syndrome O
mira O
##s O
and O
sensory O
ata O
##xia O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sand O
##o O
we O
report O
a O
p O
##7 O
##65 O
##t O
pol O
##g O
miss O
##ense O
mutation O
in O
a O
patient O
with O
sensory O

ata O
##xi O
##c O
ne O
##uro O
##pathy O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
d O
##ys O
##arth O
##ria O
and O
gas O
##tro O
##par O
##esis O
to O
our O
knowledge O
this O
mutation O
of O
pol O
##g O
coding O
region O
has O
not O
been O
reported O
previously O
cohen O
and O
na O
##via O
##ux O
2010 O
corresponding O
author O
at O
ne O
##uro O
##logy O
department O
chu O
br O
##ug O
##mann O
universite O
libre O
de O
br O
##ux O
##elles O
place O
a O
van O
ge O
##hu O
##cht O
##en O
4 O
102 O
##0 O
brussels O
belgium O
tel O
32 O
2 O
47 O
##7 O
24 O
49 O
e O
mail O
address O
ab O
##osta O
##n O
ul O
##b O
ac O
be O
a O
bo O
##stan O
case O
report O

a O
52 B-AGE_FOLLOWUP
year O
old O
moroccan B-PATIENT
woman I-PATIENT
presented O
with O
a O
10 B-AGE_ONSET
year I-AGE_ONSET
history I-AGE_ONSET
of O
dr B-HPO_TERM
##ooping I-HPO_TERM
eyelids I-HPO_TERM
without O
daytime O
ﬂ O
##uc O
##tua O
##tion O
and O
sl B-HPO_TERM
##ur I-HPO_TERM
##red I-HPO_TERM
speech I-HPO_TERM
she O
developed O
over O
the O
past O
six O
months O
progressive B-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
instability I-HPO_TERM
leg B-HPO_TERM
numb I-HPO_TERM
##ness I-HPO_TERM
and O
inability B-HPO_TERM
to I-HPO_TERM
feel I-HPO_TERM
the I-HPO_TERM
ground I-HPO_TERM
under O
her O
feet O
several O
weeks O
prior O
to O
admission O
she O
suffered O
from O
an B-HPO_TERM
##ore I-HPO_TERM
##xia I-HPO_TERM
and O
had O
a O
dramatic B-HPO_TERM
weight I-HPO_TERM
loss I-HPO_TERM
she O
lost O
15 O
kg O
over O
past O
two O
months O
she O
was O
complaining O
of O
early B-HPO_TERM
sat I-HPO_TERM
##ie I-HPO_TERM
##ty I-HPO_TERM
b B-HPO_TERM
##lo I-HPO_TERM
##ating I-HPO_TERM
upper B-HPO_TERM
abdominal I-HPO_TERM
discomfort I-HPO_TERM
and O
tendency O
to O
con B-HPO_TERM
##sti I-HPO_TERM
##pati I-HPO_TERM
##on I-HPO_TERM
the O
patient O
s O
deceased O
mother O
had O
a O
similar O
bilateral O
pt O
##osis O
without O
any O
other O
o O
##cular O
signs O
her O
parents O
were O
not O
con O
##san O
##gui O
##neo O
##us O
the O
patient O
has O
one O
healthy O
daughter O

on O
neurological O
examination O
she O
had O
una O
##lter O
##ed O
mental O
status O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
complete B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
optic B-HPO_TERM
discs I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
pupils O
were O
equally O
reactive O
a O
ﬂ B-HPO_TERM
##ac I-HPO_TERM
##ci I-HPO_TERM
##d I-HPO_TERM
type I-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
was O
noted O
she O
had O
mild O
upper O
and O
lower B-HPO_TERM
limb I-HPO_TERM
muscle I-HPO_TERM
weakness I-HPO_TERM
with O
distal O
pre O
##dom O
##ina O
##nce O
deep B-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
were I-HPO_TERM
absent I-HPO_TERM
plant O
##ar O
responses O
were O
ﬂ O
##ex O
##or O
muscular O
tone O
was O
normal O
no O
d O
##ys O
##met O
##ria O
was O
observed O
sensation O
to O
touch O
and O
pin O
prick O
was O
normal O
she O
had O
impaired B-HPO_TERM
vi I-HPO_TERM
##bra I-HPO_TERM
##tory I-HPO_TERM
and I-HPO_TERM
position I-HPO_TERM
sensation I-HPO_TERM
in O
both O
feet O
ga B-HPO_TERM
##it I-HPO_TERM
was I-HPO_TERM
staggering I-HPO_TERM
and I-HPO_TERM
wide I-HPO_TERM
based I-HPO_TERM
which O
made O
the O
rom O
##berg O
test O
imp O
##rac O
##tica O
##ble O
general O
examination O
was O
otherwise O
un O
##rem O
##ark O
##able O

the O
patient O
had O
normal O
liver O
renal O
and O
thyroid O
functions O
normal O
electro O
##ly O
##tes O
sediment O
##ation O
rate O
cr O
##ea O
##tine O
kinase O
serum O
protein O
electro O
##ph O
##ores O
##is O
serum O
lac O
##tate O
and O
urine O
organic O
acid O
pro O
##ﬁ O
##le O
a O
1 O
5 O
tesla O
brain O
mri O
showed O
mild O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
sub I-HPO_TERM
##cor I-HPO_TERM
##tical I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
without O
any O
other O
par O
##en O
##chy O
##mal O
abnormalities O
sensory O
nerve O
conduct O
##ion O
studies O
showed O
low O
amplitude O
radial O
sensory O
nerve O
action O
potential O
snap O
4 O
8 O
μ O
##v O
normal O
20 O
μ O
##v O
and O
absent B-HPO_TERM
sur I-HPO_TERM
##al I-HPO_TERM
snap I-HPO_TERM
motor B-HPO_TERM
conduct I-HPO_TERM
##ion I-HPO_TERM
ve I-HPO_TERM
##lo I-HPO_TERM
##cit I-HPO_TERM
##ies I-HPO_TERM
were I-HPO_TERM
decreased I-HPO_TERM
in O
the O
median O
nerve O

156 O
##6 O
07 O
##0 O
##2 O
see O
front O
matter O
2012 O
else O
##vier O
b O
v O
all O
rights O
reserved O
doi O
10 O
1016 O
j O
au O
##t O
##ne O
##u O
2012 O
06 O
00 O
##2 O
a O
bo O
##stan O
et O
al O
auto O
##no O
##mic O
neuroscience O
basic O
and O
clinical O
170 O
2012 O
70 O
72 O
71 O
fig O
1 O
a O
iso O
##top O
##ic O
gas O
##tric O
empty O
##ing O
study O
showing O
markedly B-HPO_TERM
delayed I-HPO_TERM
gas I-HPO_TERM
##tric I-HPO_TERM
empty I-HPO_TERM
##ing I-HPO_TERM
with O
clearance O
time O
t O
½ O
or O
t O
##50 O
of O
100 O
minutes O
normal O
range O
is O
50 O
##± O
##15 O
minutes O
b O
x O
ray O
study O
showing O
important O
gas B-HPO_TERM
##tric I-HPO_TERM
and I-HPO_TERM
bow I-HPO_TERM
##el I-HPO_TERM
di I-HPO_TERM
##sten I-HPO_TERM
##tion I-HPO_TERM

44 O
m O
s O
normal O
48 O
m O
s O
and O
the O
ti O
##bial O
nerve O
35 O
m O
s O
normal O
40 O
m O
s O
f O
wave O
late O
##ncies O
were O
mildly O
prolonged O
in O
the O
ti O
##bial O
nerve O
minimal O
late O
##ncy O
58 O
8 O
ms O
normal O
##b O
##58 O
ms O
this O
is O
suggest O
##ive O
of O
an O
ax B-HPO_TERM
##onal I-HPO_TERM
sensor I-HPO_TERM
##i I-HPO_TERM
motor I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
with O
sensory O
pre O
##dom O
##ina O
##nce O
needle O
electro O
##my O
##ographic O
studies O
em O
##g O
showed O
some O
poly B-HPO_TERM
##pha I-HPO_TERM
##sic I-HPO_TERM
motor I-HPO_TERM
unit I-HPO_TERM
action I-HPO_TERM
potential I-HPO_TERM
##s I-HPO_TERM
in I-HPO_TERM
upper I-HPO_TERM
and I-HPO_TERM
lower I-HPO_TERM
ex I-HPO_TERM
##tre I-HPO_TERM
##mit I-HPO_TERM
##ies I-HPO_TERM
these O
were O
also O
found O
in O
the O
orb O
##icular O
##is O
or O
##is O
orb O
##icular O
##is O
o O
##cu O
##li O
and O
stern O
##oc O
##lei O
##dom O
##ast O
##oid O
muscles O
which O
also O
showed O
a O
my B-HPO_TERM
##ogenic I-HPO_TERM
em I-HPO_TERM
##g I-HPO_TERM
pattern I-HPO_TERM
with O
short O
low O
amplitude O
motor O
unit O
action O
potential O
##s O
brains O
##tem O
auditory O
ev O
##oked O
potential O
##s O
and O
blink O
re O
##ﬂ O
##ex O
were O
normal O
ne O
##uro O
op O
##ht O
##hal O
##mo O
##logic O
examination O
including O
electro O
re O
##tino O
##graphy O
suggested O
chronic O
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
without O
re O
##tino O
##pathy O
x O
ray O
studies O
demonstrated O
gas B-HPO_TERM
##tric I-HPO_TERM
and I-HPO_TERM
bow I-HPO_TERM
##el I-HPO_TERM
di I-HPO_TERM
##sten I-HPO_TERM
##tion I-HPO_TERM
isotope O
gas O
##tric O
empty O
##ing O
showed O
markedly O
delayed O
empty O
##ing O
consistent O
with O
gas B-HPO_TERM
##tro I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
fig O
1 O

del O
##to O
##id O
muscle O
im O
##mun O
##oh O
##isto O
##chemist O
##ry O
showed O
changes O
characteristic O
of O
a O
muscular O
d O
##yst O
##rop O
##hy O
with O
cox B-HPO_TERM
negative I-HPO_TERM
ﬁ I-HPO_TERM
##bers I-HPO_TERM
suggesting O
mitochondrial O
disorder O
electron O
microscopy O
showed O
para B-HPO_TERM
##cr I-HPO_TERM
##yst I-HPO_TERM
##all I-HPO_TERM
##ine I-HPO_TERM
mitochondrial I-HPO_TERM
inclusion I-HPO_TERM
##s I-HPO_TERM
fig O
2 O
all O
ox B-HPO_TERM
##ida I-HPO_TERM
##tive I-HPO_TERM
ph I-HPO_TERM
##os I-HPO_TERM
##ph I-HPO_TERM
##ory I-HPO_TERM
##lation I-HPO_TERM
enzyme I-HPO_TERM
complexes I-HPO_TERM
were I-HPO_TERM
diminished I-HPO_TERM
on O
mitochondrial O
en O
##zy O
##matic O
activity O
ass O
##ays O
analysis O
of O
ty O
##mp O
gene O
demonstrated O
normal O
coding O
sequences O
direct O
sequencing O
of O
pol B-GENE
##g I-GENE
gene O
ex O
##ons O
showed O
a O
homo O
##or O
hem O
##iz O
##y O
##go O
##us O

point O
mutation O
in O
76 O
##5 O
cod O
##on O
p B-GENE_VARIANT
##7 I-GENE_VARIANT
##65 I-GENE_VARIANT
##t I-GENE_VARIANT
located O
in O
ex O
##on O
14 O
which O
is O
an O
evolutionary O
conserved O
amino O
acid O
the O
ml O
##pa O
analysis O
performed O
indicates O
the O
mutation O
at O
homo O
##zy O
##go O
##us O
state O
in O
our O
patient O
the O
patient O
s O
daughter O
carries O
the O
same O
mutation O
at O
het O
##ero O
##zy O
##go O
##us O
state O
discussion O

we O
report O
a O
patient B-PATIENT
with O
dramatic B-HPO_TERM
weight I-HPO_TERM
loss I-HPO_TERM
gas B-HPO_TERM
##tro I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
pt B-HPO_TERM
##osis I-HPO_TERM
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
peripheral B-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
the O
latter O
caused O
sign O
##i O
##ﬁ O
##can O
##t O
sensory B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
the O
absence O
of O
d O
##ys O
##met O
##ria O
and O
the O
ﬂ O
##ac O
##ci O
##d O
character O
of O
the O
d O
##ys O
##arth O
##ria O
were O
inconsistent O
with O
additional O
ce O
##re O
##bella O
##r O
involvement O
muscular O
involvement O
was O
proven O
by O
the O
bio O
##psy O
suggest O
##ive O
of O
mitochondrial O
disorder O
most O
of O
our O
patient O
s O
features O
and O
particularly O
sensory B-HPO_TERM
ata I-HPO_TERM
##xi I-HPO_TERM
##c I-HPO_TERM
ne I-HPO_TERM
##uro I-HPO_TERM
##pathy I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
ﬁ O
##t O
best O

with O
sand O
##o O
of O
the O
an O
##s O
typically O
associated O
with O
pol O
##g O
mutations O
van O
goethe O
##m O
et O
al O
2001 O
santo O
##ro O
et O
al O
2006 O
our O
patient O
s O
clinical O
picture O
may O
be O
also O
ev O
##oca O
##tive O
of O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lo O
##pathy O
mn O
##gie O
ni O
##shin O
##o O
et O
al O
2000 O
but O
was O
excluded O
by O
the O
absence O
of O
white O
matter O
abnormalities O
on O
mri O
and O
normal O
ty O
##mp O
sequencing O
the O
pol O
##g O
protein O
maintains O
mitochondrial O
dna O
integrity O
and O
replication O
ka O
##si O
##vis O
##wana O
##than O
et O
al O
2010 O
its O
catalytic O
subunit O
contains O
ex O
##on O
##uc O
##lea O
##se O
and O

fig O
2 O
a O
cox O
sd O
##h O
stain O
##ing O
showing O
cox B-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
ﬁ I-HPO_TERM
##bers I-HPO_TERM
arrow O
in O
del O
##to O
##id O
muscle O
bio O
##psy O
b O
electron O
microscopy O
showing O
para O
##cr O
##yst O
##all O
##ine O
inclusion O
##s O
arrow O
72 O
a O
bo O
##stan O
et O
al O
auto O
##no O
##mic O
neuroscience O
basic O
and O
clinical O
170 O
2012 O
70 O
72 O

polymer O
##ase O
domains O
separated O
by O
space O
##r O
lee O
et O
al O
2009 O
this O
has O
two O
sub O
##dom O
##ains O
involved O
in O
intrinsic O
process O
##ivity O
and O
dna O
protein O
interaction O
respectively O
lee O
et O
al O
2009 O
our O
patient O
s O
p O
##7 O
##65 O
##t O
mutation O
is O
situated O
in O
the O
intrinsic O
process O
##ivity O
sub O
##dom O
##ain O
thought O
to O
imp O
##art O
additional O
enzyme O
process O
##ivity O
through O
additional O
prime O
##r O
template O
interactions O
mutations O
in O
the O
space O
##r O
region O
induce O
varied O
bio O
##chemical O

abnormalities O
and O
associated O
clinical O
manifestation O
##s O
wong O
et O
al O
2008 O
our O
patient O
shows O
features O
described O
in O
other O
mutations O
in O
pol O
##g O
space O
##r O
unit O
g O
##7 O
##6 O
##3 O
##r O
pol O
##g O
mutation O
was O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
sensor O
##imo O
##tor O
ne O
##uro O
##pathy O
santo O
##ro O
et O
al O
2006 O
and O
a O
##7 O
##6 O
##7 O
##d O
mutation O
with O
ep O
##ile O
##psy O
without O
any O
peripheral O
nervous O
system O
involvement O
ho O
##rva O
##th O
et O
al O
2006 O
in O
our O
patient O
a O
novel O
pol O
##g O
mutation O
is O
associated O
with O
an O
##s O
plus O
gas O
##tro O
##par O
##esis O
which O
has O
not O
been O
observed O
previously O
the O
digest O
##ive O
d O
##ys O
##re O
##gul O
##ation O
could O
be O
the O
result O
of O
energy O
deprivation O
following O
mitochondrial O
loss O
of O
function O
due O
to O
accumulation O
of O
mt O
##dna O
mutations O
del O
##eti O
##ons O
and O
decline O
of O
respiratory O
chain O
function O
with O
severe O
consequences O
for O
all O
energy O
dependent O
cellular O
functions O
including O
gas O
##tric O
nerve O
cells O
our O
report O
illustrates O
clinical O
variability O
of O
pol O
##g O
mutations O
and O
under O
##lines O
the O
importance O
of O
further O
bio O
##chemical O
and O
translation O
##al O
research O
to O
better O
address O
the O
pathogen O
##ici O
##ty O
of O
pol O
##g O
dysfunction O
in O
addition O
gas O
##tric O
d O
##ys O
##mot O
##ility O
should O
be O
more O
readily O
searched O
for O
in O
this O
clinical O
con O
##jun O
##cture O

acknowledge O
##ments O
we O
thank O
prof O
h O
ka O
##dhi O
##m O
for O
performing O
the O
path O
##ological O
studies O
and O
prof O
g O
van O
goethe O
##m O
for O
genetic O
studies O
references O
chan O
s O
s O
copeland O
w O
c O
2009 O
dna O
polymer O
##ase O
gamma O
and O
mitochondrial O
disease O
understanding O
the O
consequence O
of O
pol O
##g O
mutations O
bio O
##chi O
##m O
bio O
##phy O
##s O
act O
##a O
1787 O
312 O
319 O
cohen O
b O
h O
na O
##via O
##ux O
r O
k O
2010 O
the O
clinical O
diagnosis O
of O
pol O
##g O
disease O
and O
other O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O
methods O
51 O
36 O
##4 O
37 O
##3 O

han O
##ce O
n O
ek O
##stra O
##nd O
m O
tri O
##fu O
##nov O
##ic O
a O
2005 O
mitochondrial O
dna O
polymer O
##ase O
gamma O
is O
essential O
for O
mammalian O
embryo O
##genesis O
hum O
mo O
##l O
gene O
##t O
14 O
1775 O
1783 O
ho O
##rva O
##th O
r O
et O
al O
2006 O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
129 O
167 O
##4 O
168 O
##4 O
ka O
##si O
##vis O
##wana O
##than O
r O
long O
##ley O
m O
j O
young O
m O
j O
copeland O
w O
c O
2010 O
pu O
##ri O
##ﬁ O
##cation O
and O
functional O
characterization O
of O
human O
mitochondrial O
dna O
polymer O
##ase O
gamma O
harbor O
##ing O
disease O
mutations O
methods O
51 O
4 O
37 O
##9 O
38 O
##4 O

lee O
y O
s O
kennedy O
w O
d O
yin O
y O
w O
2009 O
structural O
insight O
into O
process O
##ive O
human O
mitochondrial O
dna O
synthesis O
and O
disease O
related O
polymer O
##ase O
mutations O
cell O
139 O
2 O
312 O
324 O
ni O
##shin O
##o O
i O
et O
al O
2000 O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
due O
to O
thy O
##mi O
##dine O
ph O
##os O
##ph O
##ory O
##lase O
mutations O
ann O
ne O
##uro O
##l O
47 O
79 O
##2 O
800 O
santo O
##ro O
l O
et O
al O
2006 O
a O
new O
pol O
##g O
##1 O
mutation O
with O
pe O
##o O
and O
severe O
ax O
##onal O
and O
dem O
##ye O
##lina O
##ting O
sensory O
motor O
ne O
##uro O
##pathy O
j O
ne O
##uro O
##l O
253 O
86 O
##9 O
87 O
##4 O

van O
goethe O
##m O
g O
der O
##ma O
##ut O
b O
lo O
##f O
##gren O
a O
martin O
j O
j O
van O
bro O
##eck O
##ho O
##ven O
c O
2001 O
mutation O
of O
pol O
##g O
is O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
nat O
gene O
##t O
28 O
211 O
212 O
wong O
l O
j O
et O
al O
2008 O
molecular O
and O
clinical O
genetics O
of O
mitochondrial O
diseases O
due O
to O
pol O
##g O
mutations O
hum O
mu O
##tat O
29 O
9 O
e O
##15 O
##0 O
72 O

case B-PATIENT
report O
case O
series O
early O
onset O
ata B-HPO_TERM
##xia I-HPO_TERM
with O
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
associated O
with O
pol B-GENE
##g I-GENE
mutation O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
or O
sand O
##o O
mario O
ha O
##bek O
md O
phd O
w O
barbara O
bar O
##un O
md O
w O
ivan O
adam O
##ec O
md O
z O
##oran O
mit O
##rov O
##ic O
##´ O
md O
david O
oz O
##ret O
##ic O
##´ O
md O
z O
and O
ve O
##s O
##na O
v O
br O
##ina O
##r O
md O
phd O
w O

abstract O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
##s O
caused O
by O
mutations O
of O
the O
polymer O
##ase O
g O
pol O
##g O
gene O
make O
an O
important O
group O
of O
progressive O
ata O
##xia O
##s O
accompanied O
by O
a O
diverse O
spectrum O
of O
neurological O
disorders O
because O
the O
clinical O
picture O
can O
be O
quite O
miscellaneous O
it O
is O
challenging O
to O
ass O
##ort O
patients O
to O
any O
of O
the O
currently O
described O
syndrome O
##s O
therefore O
to O
provide O
such O
a O
patient O
with O
a O
con O
##clusive O
diagnosis O
can O
be O
challenging O
for O
the O
ne O
##uro O
##logist O
a O
typical O
magnetic O
resonance O
imaging O
finding O
is O
probably O
the O
most O
useful O
landmark O
in O
the O
diagnostic O
process O
which O
will O
steer O
the O
clinic O
##ian O
toward O
pol O
##g O
gene O
testing O
to O
illustrate O
this O
we O
present O
a O
case B-PATIENT
of O
progressive B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
caused O
by O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutations O
of O
pol B-GENE
##g I-GENE
gene O
who O
presented O
with O
overlapping O
symptoms O
of O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
and O
sand O
##o O
as O
well O
as O
cho B-HPO_TERM
##re I-HPO_TERM
##oat I-HPO_TERM
##het I-HPO_TERM
##otic I-HPO_TERM
movements O
and O
d B-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
after O
lengthy O
investigations O
magnetic O
resonance O
imaging O
showed O
t O
##2 O
and O
flair O
hyper B-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
inferior B-HPO_TERM
olive I-HPO_TERM
##s I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
which O
led O
us O
to O
the O
analysis O
of O
pol O
##g O
mutations O

key O
words O
ata O
##xia O
auto O
##som O
##al O
recess O
##ive O
mri O
pol O
##g O
cho O
##re O
##oat O
##het O
##otic O
movements O
d O
##ys O
##phon O
##ia O
the O
ne O
##uro O
##logist O
2012 O
18 O
287 O
289 O
ro O
##gre O
##ssi O
##ve O
loss O
of O
balance O
followed O
by O
other O
het O
##ero O
##gen O
##ous O
neurological O
symptoms O
is O
usually O
challenging O
for O
physicians O
due O
to O
the O
spectrum O
of O
hereditary O
and O
acquired O
disorders O
that O
should O
be O
taken O
into O
consideration O
depending O
on O
the O
mode O
of O
inheritance O
hereditary O
ata O
##xia O
can O
be O
divided O
into O
auto O
##som O
##al O
dominant O
auto O
##som O
##al O
recess O
##ive O
x O
linked O
and O
mitochondrial O
ata O
##xia O
##s O

many O
patients O
with O
auto O
##som O
##al O
recess O
##ive O
disorders O
have O
negative O
family O
history O
but O
the O
presence O
of O
additional O
characteristic O
ph O
##eno O
##typic O
features O
makes O
it O
obligatory O
to O
include O
these O
disorders O
into O
differential O
##s O
these O
include O
the O
onset O
of O
symptoms O
before O
the O
age O
of O
20 O
peripheral O
sensor O
##imo O
##tor O
received O
for O
publication O
august O
9 O
2010 O
accepted O
may O
30 O
2012 O

from O
the O
department O
of O
ne O
##uro O
##logy O
school O
of O
medicine O
university O
of O
zagreb O
wu O
##ni O
##vers O
##ity O
department O
of O
ne O
##uro O
##logy O
zagreb O
university O
hospital O
center O
refer O
##ral O
center O
for O
dem O
##ye O
##lina O
##ting O
diseases O
of O
the O
central O
nervous O
system O
and O
zu O
##ni O
##vers O
##ity O
department O
of O
radio O
##logy O
zagreb O
university O
hospital O
center O
zagreb O
croatia O

m O
h O
and O
v O
v O
b O
study O
concept O
and O
design O
m O
h O
z O
m O
d O
o O
and O
v O
v O
b O
acquisition O
of O
data O
m O
h O
b O
b O
i O
a O
z O
m O
d O
o O
and O
v O
v O
b O
analysis O
and O
interpretation O
of O
data O
m O
h O
b O
b O
and O
i O
a O
drafting O
of O
the O
manuscript O
m O
h O
b O
b O
i O
a O
z O
m O
d O
o O
and O
v O
v O
b O
critical O
revision O
of O
the O
manuscript O
for O
important O
intellectual O
content O
m O
h O
b O
b O
i O
a O
and O
d O
o O
administrative O
technical O
and O
material O
support O
the O
authors O
declare O
no O
conflict O
of O
interest O

reprint O
##s O
mario O
ha O
##bek O
md O
university O
department O
of O
ne O
##uro O
##logy O
zagreb O
school O
of O
medicine O
and O
university O
hospital O
center O
12 O
zagreb O
hr O
1000 O
##0 O
croatia O
e O
mail O
m O
##hab O
##ek O
me O
##f O
hr O
copyright O
r O
2012 O
by O
lip O
##pin O
##cott O
williams O
wilkins O
issn O
107 O
##4 O
79 O
##31 O
12 O
1805 O
02 O
##8 O
##7 O
doi O
10 O
109 O
##7 O
nrl O
0 O
##b O
##01 O
##3 O
##e O
##31 O
##8 O
##26 O
##6 O
##f O
##5 O
##a O
##6 O

ne O
##uro O
##pathy O
with O
loss O
of O
prop O
##rio O
##ception O
and O
vibration O
sense O
as O
prominent O
signs O
absence O
of O
deep O
tend O
##on O
reflex O
##es O
and O
involvement O
of O
other O
systems O
besides O
the O
nervous O
system O
1 O
it O
is O
clinical O
##ly O
useful O
to O
divide O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
##s O
into O
2 O
groups O
in O
one O
group O
there O
are O
disorders O
in O
which O
the O
ph O
##eno O
##type O
resembles O
fried O
##re O
##ich O
ata O
##xia O
including O
polymer O
##ase O
g O
pol O
##g O
mutations O
ph O
##eno O
##type O
whereas O
the O
other O
group O
includes O
early O
onset O
ata O
##xia O
##s O
with O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
this O
emphasizes O
magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
as O
an O
important O
diagnostic O
tool O
1 O

defects O
in O
mitochondrial O
dna O
mt O
##dna O
may O
be O
a O
product O
of O
mutations O
of O
mitochondrial O
or O
nuclear O
genome O
involved O
in O
mt O
##dna O
home O
##osta O
##sis O
2 O
mutations O
of O
nuclear O
genes O
such O
as O
mt O
##dna O
polymer O
##ase O
pol O
##g O
3 O
aden O
##ine O
nu O
##cle O
##otide O
transport O
##er O
4 O
and O
twinkle O
a O
mitochondrial O
he O
##lica O
##se O
##5 O
cause O
mt O
##dna O
del O
##eti O
##ons O
or O
a O
quantitative O
loss O
called O
mt O
##dna O
de O
##ple O
##tion O
although O
most O
common O
ph O
##eno O
##typic O
presentation O
of O
these O
nuclear O
genome O
defects O
is O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
3 O
other O
manifestation O
##s O
have O
been O
described O
particularly O
in O
patients O
with O
mutations O
affecting O
pol O
##g O
many O
mitochondrial O
disorders O
may O
include O
ata O
##xia O
as O
an O
additional O
sign O
but O
only O
disorders O
associated O
with O
pol O
##g O
mutation O
and O
infant O
##ile O
onset O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
caused O
by O
mutation O
of O
the O
c1 O
##0 O
##orf O
##2 O
gene O
that O
en O
##codes O
for O
twinkle O
proteins O
a O
mitochondrial O
he O
##lica O
##se O
have O
ata O
##xia O
as O
a O
defining O
feature O
1 O

we O
report O
on O
a O
patient B-PATIENT
with O
pol B-GENE
##g I-GENE
mutations O
presenting O
with O
ata B-HPO_TERM
##xia I-HPO_TERM
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
and O
some O
additional O
features O
who O
was O
diagnosed O
on O
the O
basis O
of O
mri O
findings O
case O
report O

a O
32 B-AGE_FOLLOWUP
year O
old O
woman O
was O
referred O
to O
our O
center O
for O
evaluation O
of O
ata B-HPO_TERM
##xia I-HPO_TERM
symptoms O
started O
at O
the O
age O
of O
13 B-AGE_ONSET
years O
with O
difficulties B-HPO_TERM
in I-HPO_TERM
balancing I-HPO_TERM
with O
closed O
eyes O
at O
the O
age O
of O
24 O
during O
pregnancy O
she O
developed O
broad B-HPO_TERM
based I-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
and O
par B-HPO_TERM
##esthesia I-HPO_TERM
##s I-HPO_TERM
in O
the O
feet O
during O
the O
next O
2 O
years O
she O
started O
to O
develop O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
in O
an O
out O
##patient O
clinic O
she O
underwent O
electron O
##eur O
##ography O
which O
showed O
mild B-HPO_TERM
slowing I-HPO_TERM
of I-HPO_TERM
nerve I-HPO_TERM
conduct I-HPO_TERM
##ion I-HPO_TERM
ve I-HPO_TERM
##lo I-HPO_TERM
##cit I-HPO_TERM
##ies I-HPO_TERM
and O
absent B-HPO_TERM
sensory I-HPO_TERM
potential I-HPO_TERM
##s I-HPO_TERM
in I-HPO_TERM
hands I-HPO_TERM
and I-HPO_TERM
feet I-HPO_TERM
brain O
mri O
showed O
increased B-HPO_TERM
signal I-HPO_TERM
intensity I-HPO_TERM
in O
both O
tha B-HPO_TERM
##lam I-HPO_TERM
##i I-HPO_TERM
and O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
hemisphere I-HPO_TERM
##s I-HPO_TERM
extensive O
genetic O
work O
##up O
for O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
##s O
1 O
2 O
3 O
6 O
7 O
12 O
17 O
d O
##pr O
##la O
and O
mitochondrial O
transfer O
rna O
le O
##uc O
##ine O
was O
negative O
studies O
for O
ce O
##ru O
##lo O
##pl O
##as O
##min O
vitamin O
e O
a O
fe O
##top O
##rot O
##ein O
am O
##monium O
lac O
##tate O
p O
##yr O
##u O
##vate O
car O
##ni O
##tine O
fatty O
acids O
organic O
acids O
ph O
##yt O
##ani O
##c O
acid O
very O
long O
fatty O
acids O
b O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
gala O
##ct O
##oc O
##ere O
##bro O
##si O
##das O
##e O
congenital O
disorders O
of O
g O
##ly O
##cos O
##yla O
##tion O
ne O
##uron O
##al O
lip O
##of O
##us O
##cino O
##sis O
ol O
##igo O
##sa O
##cc O
##hari O
##des O
and O
mu O
##co O
##pol O
##ys O
##ac O
##cha O
##ride O
##s O
in O
urine O
were O
negative O

neurological O
examination O
performed O
on O
the O
patient O
s O
initial O
presentation O
revealed O
almost O
complete B-HPO_TERM
horizontal I-HPO_TERM
gaze I-HPO_TERM
pal I-HPO_TERM
##sy I-HPO_TERM
only O
minimal O
add O
##uc O
##tion O
of O
the O
right O
eye O
was O
possible O
she O
had O
severe B-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
of O
all O
4 O
limbs O
and O
ga O
##it O
reflex B-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
absent I-HPO_TERM
and O
cho B-HPO_TERM
##re I-HPO_TERM
##oat I-HPO_TERM
##het I-HPO_TERM
##otic I-HPO_TERM
movements O
of O
the O
hands O
were O
noted O
complete B-HPO_TERM
absence I-HPO_TERM
of I-HPO_TERM
prop I-HPO_TERM
##rio I-HPO_TERM
##ceptive I-HPO_TERM
sensation I-HPO_TERM
of O
the O
legs O
was O
present O
cognitive O
examination O
was O
normal O
the O
ne O
##uro O
##logist O
volume O
18 O
number O
5 O
september O
2012 O
www O
then O
##eur O
##ologist O
org O
287 O
ha O
##bek O
et O
al O
the O
ne O
##uro O
##logist O
volume O
18 O
number O
5 O
september O
2012 O

figure O
1 O
magnetic O
resonance O
imaging O
of O
the O
brain O
showing O
t O
##2 O
and O
flair O
hyper B-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
c O
e O
inferior O
olive O
##s O
a O
c O
and O
ce O
##re O
##bell O
##um O
d O
repeat O
brain O
mri O
is O
shown O
in O
figure O
1 O
on O
the O
basis O
of O
mri O
findings O
we O
performed O
analysis O
for O
pol B-GENE
##g I-GENE
mutations O
which O
revealed O
2 O
mutations O
in O
the O
pol O
##g O
gene O
139 B-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and O
224 B-GENE_VARIANT
##3 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
both O
in O
trans O
position O
the O
patient O
was O
prescribed O
vitamin O
c O
1 O
g O
qi O
##d O
coe O
##nz O
##yme O
q O
##10 O
100 O
mg O
ti O
##d O
l O
car O
##ni O
##tine O
500 O
mg O
qi O
##d O
and O
lam O
##ot O
##ri O
##gin O
##e O
25 O
mg O
bid O
discussion O

differential O
diagnosis O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
##s O
is O
wide O
broadly O
they O
can O
be O
divided O
into O
3 O
groups O
1 O
fried O
##re O
##ich O
ata O
##xia O
like O
2 O
fried O
##re O
##ich O
ata O
##xia O
like O
with O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
and O
3 O
early O
onset O
ata O
##xia O
with O
ce O
##re O
##bella O
##r O
at O
##rop O
##hy O
1 O
the O
second O
group O
of O
ata O
##xia O
##s O
includes O
4 O
diseases O
late O
onset O
tay O
sachs O
disease O
ce O
##re O
##bro O
##ten O
##din O
##ous O
x O
##ant O
##hom O
##ato O
##sis O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
with O
ax O
##onal O
ne O
##uro O
##pathy O
and O
dna O
pol O
##g O
disorders O
mitochondrial O
recess O
##ive O
ata O
##xia O
syndrome O

the O
human O
mt O
##dna O
polymer O
##ase O
a O
crucial O
enzyme O
for O
mt O
##dna O
replication O
and O
repair O
is O
a O
het O
##ero O
##tri O
##mer O
consisting O
of O
a O
catalytic O
subunit O
pol O
##g O
containing O
the O
polymer O
##ase O
and O
ex O
##on O
##uc O
##lea O
##se O
activities O
and O
2 O
accessory O
subunit O
##s O
pol O
##g O
##2 O
6 O
and O
is O
encoded O
by O
nuclear O
pol O
##g O
gene O
located O
on O
chromosome O
15 O
##q O
##25 O
7 O
the O
consequence O
of O
pol O
##g O
mutation O
is O
the O
accumulation O
of O
multiple O
mt O
##dna O
del O
##eti O
##ons O
in O
post O
##mit O
##otic O
tissues O
such O
as O
muscle O
and O
brain O
a O
great O
majority O
of O
the O
mu O
##tated O
all O
##eles O
are O
miss O
##ense O
mutations O
whereas O
frames O
##hi O
##ft O
and O
nonsense O
mutations O
account O
for O
a O
smaller O
portion O
8 O
numerous O
mutations O
of O
pol O
##g O
gene O
have O
been O
identified O
to O
cause O
a O
broad O
spectrum O
of O
disorders O
inherited O
in O
auto O
##som O
##al O
dominant O
or O
auto O
##som O
##al O
recess O
##ive O
manner O
including O
the O
auto O
##som O
##al O
dominant O
and O
recess O
##ive O
forms O
of O
pe O
##o O
3 O
9 O
10 O
the O
auto O
##som O
##al O
recess O
##ive O
lethal O
al O
##pers O
syndrome O
11 O
12 O
the O
mitochondrial O
recess O
##ive O
ata O
##xia O
syndrome O
with O
##13 O
and O
without O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
14 O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
15 O
parkinson O
##ism O
16 O
and O
male O
in O
##fer O
##tility O
17 O
as O
reported O
by O
wong O
et O
al O
8 O
in O
a O
co O
##hort O
of O
350 O
patients O
the O
most O
common O
pol O
##g O
mutation O
in O
patients O
with O
auto O
##som O
##al O
recess O
##ive O
inheritance O
al O
##pers O
disease O
ata O
##xia O
sensory O
ne O
##uro O
##pathy O
and O
pe O
##o O
syndrome O
##s O
was O
a O
##46 O
##7 O
##t O
followed O
by O
g O
##8 O
##48 O
##s O
and O
t O
##25 O
##1 O
##i O
p O
##58 O
##7 O
##l O
in O
cis O
w O
##7 O
##48 O
##s O
and O
t O
##9 O
##14 O
##p O
our O
patient O
was O
found O
to O
be O
compound O
het O
##ero O
##zy O
##go O
##us O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
mutations O

clinical O
presentation O
of O
recess O
##ive O
pol O
##g O
mutations O
is O
expanded O
by O
ata O
##xia O
and O
the O
ne O
##uro O
##pathy O
spectrum O
8 O
combined O
with O
variable O
features O
of O
involvement O
of O
central O
nervous O
system O
and O
other O
organs O
our O
patient O
presented O
with O
ata O
##xi O
##c O
syndrome O
which O
includes O
an O
overlapping O
spectrum O
of O
disorders O
organized O
around O
the O
finding O
of O
ata O
##xia O
demonstrating O
recess O
##ive O
inheritance O
primarily O
due O
to O
its O
onset O
before O
the O
age O
of O
20 O
and O
presence O
of O
peripheral O
sensory O
ne O
##uro O
##pathy O
most O
patients O
have O

additional O
symptoms O
which O
may O
include O
pe O
##o O
ne O
##uro O
##pathy O
and O
d O
##ys O
##arth O
##ria O
mri O
is O
very O
helpful O
in O
deciding O
when O
to O
order O
genetic O
testing O
for O
pol O
##g O
mutations O
as O
mri O
shows O
characteristic O
lesions O
that O
are O
hyper O
##int O
##ense O
relative O
to O
gray O
matter O
typically O
these O
are O
seen O
centrally O
in O
the O
posterior O
part O
of O
the O
tha O
##lam O
##us O
dent O
##ate O
nuclei O
and O
inferior O
olive O
##s O
and O
probably O
are O
caused O
by O
ne O
##uron O
##al O
loss O
with O
secondary O
g O
##lio O
##sis O
12 O
18 O
these O
mri O
findings O
after O
lengthy O
investigations O
revealed O
the O
true O
et O
##iology O
of O
symptoms O
in O
our O
patient O
the O
involvement O
of O
these O
particular O
brain O
areas O
can O
be O
explained O
not O
just O
with O
high O
##ener O
##gy O
demands O
of O
the O
brain O
region O
involved O
but O
also O
with O
secondary O
vascular O
effects O
due O
to O
ph O
changes O
12 O

taking O
into O
account O
the O
genetic O
clinical O
and O
ne O
##uro O
##rad O
##iol O
##og O
##ic O
findings O
sand O
##o O
or O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
due O
to O
mitochondrial O
pol O
##g O
mutations O
were O
the O
2 O
syndrome O
##s O
considered O
in O
our O
patient O
sand O
##o O
comprises O
of O
a O
triad O
of O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
19 O
pal O
##atal O
tremor O
and O
memory O
loss O
have O
been O
reported O
as O
additional O
symptoms O
13 O
besides O
pol O
##g O
mutations O
other O
gene O
mutations O
can O
cause O
this O
syndrome O
as O
it O
is O
a O
genetically O
het O
##ero O
##gen O
##ous O
disease O
20 O
pol O
##g O
mutations O
that O
are O
reported O
to O
be O
the O
cause O
of O
sand O
##o O
include O
a O
##46 O
##7 O
##t O
r O
##6 O
##27 O
##w O
h O
##9 O
##32 O
##y O
and O
g O
##10 O
##51 O
##r O
10 O
21 O
23 O

auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
is O
characterized O
by O
ga O
##it O
and O
limb O
ata O
##xia O
d O
##ys O
##arth O
##ria O
poly O
##ne O
##uro O
##pathy O
h O
##yp O
##ore O
##fle O
##xia O
ny O
##sta O
##gm O
##us O
cognitive O
impairment O
ep O
##ile O
##psy O
and O
in O
some O
cases O
op O
##ht O
##hal O
##mo O
##par O
##esis O
pol O
##g O
mutations O
have O
been O
found O
in O
a O
##46 O
##7 O
##t O
and O
t O
##7 O
##48 O
##s O
1 O
14 O

we O
present O
a O
case O
exhibiting O
features O
of O
both O
sand O
##o O
and O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
recently O
some O
authors O
were O
inclined O
to O
include O
these O
2 O
syndrome O
##s O
as O
well O
as O
spin O
##oc O
##ere O
##bella O
##r O
ata O
##xia O
with O
ep O
##ile O
##psy O
into O
the O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
or O
syndrome O
23 O
24 O
in O
addition O
our B-PATIENT
patient I-PATIENT
presented O
with O
cho B-HPO_TERM
##re I-HPO_TERM
##oat I-HPO_TERM
##het I-HPO_TERM
##otic I-HPO_TERM
movements I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
as O
there O
is O
a O
huge O
inc O
##ons O
##iste O
##ncy O
in O
muscle O
bio O
##psy O
and O
bio O
##chemical O
findings O
in O
patients O
with O
pol O
##g O
mutations O
13 O
brain O
mri O
is O
the O
diagnostic O
procedure O
of O
choice O
that O
can O
lead O
to O
molecular O
analysis O
of O
pol O
##g O
gene O
thus O
yielding O
definitive O
diagnosis O
because O
there O
is O
no O
clear O
correlation O
between O
gen O
##otype O
and O
ph O
##eno O
##type O
in O
patients O
with O
pol O
##g O
mutations O
we O
believe O
it O
to O
be O
clinical O
##ly O
more O
useful O
to O
consider O
pol O
##g O
mutation O
related O
ph O
##eno O
##type O
as O
a O
clinical O
entity O
with O
a O
diverse O
sy O
##mpt O
##oma O
##tic O
presentation O

references O
fog O
##el O
b O
##l O
per O
##lman O
s O
clinical O
features O
and O
molecular O
genetics O
of O
auto O
##som O
##al O
recess O
##ive O
ce O
##re O
##bella O
##r O
ata O
##xia O
##s O
lance O
##t O
ne O
##uro O
##l O
2007 O
6 O
245 O
257 O
288 O
www O
then O
##eur O
##ologist O
org O
r O
2012 O
lip O
##pin O
##cott O
williams O
wilkins O
the O
ne O
##uro O
##logist O
volume O
18 O
number O
5 O
september O
2012 O
ata O
##xia O
with O
pe O
##o O
associated O
with O
pol O
##g O
mutation O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
1692 O

van O
goethe O
##m O
g O
der O
##ma O
##ut O
b O
lo O
##f O
##gren O
a O
et O
al O
mutation O
of O
pol O
##g O
is O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
nat O
gene O
##t O
2001 O
28 O
211 O
212 O
ka O
##uk O
##one O
##n O
j O
ju O
##sel O
##ius O
j O
##k O
ti O
##rant O
##i O
v O
et O
al O
role O
of O
aden O
##ine O
nu O
##cle O
##otide O
trans O
##lo O
##cat O
##or O
1 O
in O
mt O
##dna O
maintenance O
science O
2000 O
289 O
78 O
##2 O
78 O
##5 O
sp O
##el O
##bri O
##nk O
j O
##n O
li O
f O
##y O
ti O
##rant O
##i O
v O
et O
al O
human O
mitochondrial O
dna O
del O
##eti O
##ons O
associated O
with O
mutations O
in O
the O
gene O
encoding O
twinkle O
a O
ph O
##age O
t O
##7 O
gene O
4 O
like O
protein O
localized O
in O
mit O
##och O
##ond O
##ria O
nat O
gene O
##t O
2001 O
28 O
223 O
231 O

ya O
##ku O
##bo O
##vs O
##kaya O
e O
chen O
z O
carr O
##ode O
##gua O
##s O
ja O
et O
al O
functional O
human O
mitochondrial O
dna O
polymer O
##ase O
gamma O
forms O
a O
het O
##ero O
##tri O
##mer O
j O
bio O
##l O
che O
##m O
2005 O
281 O
37 O
##4 O
38 O
##2 O
ro O
##pp O
pa O
copeland O
wc O
cl O
##oning O
and O
characterization O
of O
the O
human O
mitochondrial O
dna O
polymer O
##ase O
dna O
polymer O
##ase O
gamma O
gen O
##omics O
1996 O
36 O
44 O
##9 O
45 O
##8 O
wong O
l O
##j O
na O
##via O
##ux O
r O
##k O
br O
##une O
##tti O
pier O
##ri O
n O
et O
al O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
a O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O
2002 O
52 O
211 O
219 O

van O
goethe O
##m O
g O
martin O
jj O
der O
##ma O
##ut O
b O
et O
al O
recess O
##ive O
pol O
##g O
mutations O
presenting O
with O
sensory O
and O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
in O
compound O
het O
##ero O
##zy O
##go O
##te O
patients O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2003 O
13 O
133 O
142 O
black O
##wood O
w O
bu O
##xton O
ph O
cum O
##ings O
j O
##n O
et O
al O
diffuse O
cerebral O
de O
##gen O
##eration O
in O
infancy O
al O
##pers O
disease O
arch O
di O
##s O
child O
1963 O
38 O
193 O
204 O
hut O
##ten O
##lo O
##cher O
pr O
sol O
##ita O
##re O
gb O
adams O
g O
infant O
##ile O
diffuse O
cerebral O
de O
##gen O
##eration O
with O
he O
##pati O
##c O
ci O
##rr O
##hosis O
arch O
ne O
##uro O
##l O
1976 O
33 O
186 O
192 O

winter O
##th O
##un O
s O
ferrari O
g O
he O
l O
et O
al O
auto O
##som O
##al O
recess O
##ive O
mitochondrial O
ata O
##xi O
##c O
syndrome O
due O
to O
mitochondrial O
polymer O
##ase O
g O
mutations O
ne O
##uro O
##logy O
2005 O
64 O
120 O
##4 O
120 O
##8 O
milo O
##ne O
m O
br O
##une O
##tti O
pier O
##ri O
n O
tang O
l O
##y O
et O
al O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
op O
##ht O
##hal O
##mo O
##par O
##esis O
caused O
by O
pol O
##g O
mutations O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
62 O
##6 O
63 O
##2 O
ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
441 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
85 O
##9 O
86 O
##2 O
ro O
##vio O
at O
marching O
##ton O
dr O
dona O
##t O
s O
et O
al O
mutations O
at O
the O
mitochondrial O
dna O
polymer O
##ase O
pol O
##g O
locus O
associated O
with O
male O
in O
##fer O
##tility O
nat O
gene O
##t O
2001 O
29 O
261 O
262 O
ran O
##tama O
##ki O
m O
k O
##rah O
##e O
r O
pa O
##eta O
##u O
a O
et O
al O
adult O
onset O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
tha O
##lam O
##ic O
lesions O
in O
a O
finnish O
family O
ne O
##uro O
##logy O
2001 O
57 O
104 O
##3 O
104 O
##9 O
fa O
##dic O
r O
russell O
ja O
ve O
##dana O
##raya O
##nan O
v O
##v O
et O
al O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
as O
the O
presenting O
feature O
of O
a O
novel O
mitochondrial O
disease O
ne O
##uro O
##logy O
1997 O
49 O
239 O
245 O

hudson O
g O
des O
##cha O
##uer O
m O
bus O
##se O
k O
et O
al O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
due O
to O
a O
novel O
c1 O
##0 O
##orf O
##2 O
mutation O
with O
probable O
ge O
##rm O
##line O
mosaic O
##ism O
ne O
##uro O
##logy O
2005 O
64 O
37 O
##1 O
37 O
##3 O
di O
f O
##onzo O
a O
bo O
##rdon O
##i O
a O
cr O
##imi O
m O
et O
al O
pol O
##g O
mutations O
in O
sporadic O
mitochondrial O
disorders O
with O
multiple O
mt O
##dna O
del O
##eti O
##ons O
hum O
mu O
##tat O
2003 O
22 O
49 O
##8 O
49 O
##9 O
man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
oh O
s O
##j O
et O
al O
a O
novel O
polymer O
##ase O
gamma O
mutation O
in O
a O
family O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O
2004 O
61 O
1777 O
1779 O

man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
bella O
##n O
m O
et O
al O
pol O
##g O
mutations O
causing O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sensor O
##imo O
##tor O
poly O
##ne O
##uro O
##pathy O
ata O
##xia O
and O
deaf O
##ness O
ne O
##uro O
##logy O
2004 O
62 O
316 O
318 O
milo O
##ne O
m O
mass O
##ie O
r O
polymer O
##ase O
gamma O
1 O
mutations O
clinical O
correlation O
##s O
ne O
##uro O
##logist O
2010 O
16 O
84 O
91 O
cohen O
b O
##h O
na O
##via O
##ux O
r O
##k O
the O
clinical O
diagnosis O
of O
pol O
##g O
disease O
and O
other O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O
methods O
2010 O
51 O
36 O
##4 O
37 O
##3 O
r O
2012 O
lip O
##pin O
##cott O
williams O
wilkins O
www O
then O
##eur O
##ologist O
org O
289 O

ep O
##ile O
##ptic O
di O
##sor O
##d O
2012 O
14 O
4 O
43 O
##8 O
41 O
successful O
treatment O
of O
pol B-GENE
##g I-GENE
related O
mitochondrial O
ep O
##ile O
##psy O
with O
anti O
##ep O
##ile O
##ptic O
drugs O
and O
low O
g O
##ly O
##ca O
##emi O
##c O
index O
diet O
mika O
h O
mart O
##ika O
##inen O
1 O
mark O
##ku O
pa O
##ivar O
##int O
##a O
1 O
sat O
##u O
ja O
##ask O
##ela O
##inen O
2 O
kari O
maj O
##ama O
##a O
3 O
1 O
department O
of O
ne O
##uro O
##logy O
2 O
department O
of O
clinical O
ne O
##uro O
##phy O
##sio O
##logy O
university O
of O
turk O
##u O
and O
turk O
##u O
university O
hospital O
turk O
##u O
3 O
university O
of O
ou O
##lu O
department O
of O
clinical O
medicine O
and O
ne O
##uro O
##logy O
and O
ou O
##lu O
university O
hospital O
department O
of O
ne O
##uro O
##logy O
ou O
##lu O
finland O
received O
june O
29 O
2012 O
accepted O
october O
22 O
2012 O
correspondence O
kari O
maj O
##ama O
##a O

abstract O
ep O
##ile O
##psy O
is O
a O
common O
manifestation O
of O
mitochondrial O
disease O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
y O
pol B-GENE
##g I-GENE
pro O
##gno O
##sis O
of O
mitochondrial O
ep O
##ile O
##psy O
is O
often O
poor O
and O
there O
are O
few O
reports O
of O
successful O
treatment O
of O
pol O
##g O
related O
ep O
##ile O
##psy O
we O
describe O
a O
26 B-AGE_FOLLOWUP
year O
old O
woman B-PATIENT
who O
experienced O
severe B-HPO_TERM
headache I-HPO_TERM
during O
a O
three O
day O
period O
followed O
by O
symptoms O
of O
visual B-HPO_TERM
ﬂ I-HPO_TERM
##ashi I-HPO_TERM
##ng I-HPO_TERM
speech B-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lty I-HPO_TERM
and O
general B-HPO_TERM
##ised I-HPO_TERM
seizures I-HPO_TERM
ee O
##g O
recording O
showed O
non B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ive I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
left O
o O
##cci O
##pit O
##al O
area O
and O
brain O
mri O
revealed O
par B-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
visual B-HPO_TERM
aura I-HPO_TERM
and O
ap B-HPO_TERM
##has I-HPO_TERM
##ia I-HPO_TERM
persisted O
despite O
anti O
##ep O
##ile O
##ptic O
medication O
with O
ph O
##en O
##yt O
##oin O
ox O
##car O
##ba O
##ze O
##pine O
and O
lev O
##eti O
##race O
##tam O
mitochondrial O
disorder O
was O
clinical O
##ly O
suspected O
and O
a O
homo B-GENE_VARIANT
##zy I-GENE_VARIANT
##go I-GENE_VARIANT
##us I-GENE_VARIANT
c I-GENE_VARIANT
224 I-GENE_VARIANT
##3 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
mutation O
p B-GENE_VARIANT
tr I-GENE_VARIANT
##p I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##ser I-GENE_VARIANT
was O
discovered O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
the O
patient O
was O
then O
set O
on O
a O
low O
g O
##ly O
##ca O
##emi O
##c O
index O
treatment O
l O
##git O
variant O
of O
the O
ke O
##to O
##genic O
diet O
after O
which O
the O
headache O
##s O
ap O
##has O
##ia O
and O
visual O
aura O
progressively O
improved O
and O
disappeared O
she O
returned O
home O
two O
weeks O
after O
onset O
of O
symptoms O
and O
has O
not O
had O
further O
seizures O
she O
continues O
to O
receive O
lev O
##eti O
##race O
##tam O
mono O
##therapy O
and O
l O
##git O
we O
conclude O
that O
at O
least O
for O
this O
patient O
the O
combination O
of O
three O
anti O
##ep O
##ile O
##ptic O
drugs O
and O
l O
##git O
is O
effective O
and O
well O
tolerated O
as O
treatment O
for O
severe O
episodes O
of O
pol O
##g O
related O
mitochondrial O
ep O
##ile O
##psy O

key O
words O
ep O
##ile O
##psy O
ke O
##to O
##genic O
diet O
low O
g O
##ly O
##ce O
##mic O
index O
treatment O
mitochondrial O
disease O
pol O
##g O
university O
of O
ou O
##lu O
department O
of O
clinical O
medicine O
and O
ne O
##uro O
##logy O
po O
box O
5000 O
fin O
900 O
##14 O
ou O
##lu O
finland O
kari O
maj O
##ama O
##a O
ou O
##lu O
ﬁ O
ep O
##ile O
##psy O
is O
a O
prevalent O
feature O
of O
disease O
related O
to O
mutations O
in O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
human O
mitochondrial O
dna O
polymer O
##ase O
y O
pol O
##g O
t O
##zo O
##uli O
##s O
et O
al O
2006 O
pro O
##gno O
##sis O
of O
mitochondrial O
ep O
##ile O
##psy O
is O
often O
poor O
and O
there O
are O
only O
few O
reports O
of O
successful O
treatment O
of O
pol O
##g O
related O
ep O
##ile O
##psy O
the O
ke O
##to O
##genic O
diet O
k O
##d O
is O
used O
as O
treatment O

for O
intra O
##ctable O
ep O
##ile O
##psy O
and O
ben O
##e O
##ﬁ O
##cial O
effect O
of O
k O
##d O
in O
severe O
pol O
##g O
related O
ep O
##ile O
##psy O
in O
children O
has O
been O
previously O
reported O
joshi O
et O
al O
2009 O
here O
we O
describe O
successful O
treatment O
of O
a O
26 B-AGE_FOLLOWUP
year O
old O
woman O
with O
severe O
episodes O
of O
pol B-GENE
##g I-GENE
associated O
ep B-HPO_TERM
##ile I-HPO_TERM
##psy I-HPO_TERM
non B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ive I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
nc O
##se O
using O
ph O
##en O
##yt O
##oin O
ox O
##car O
##ba O
##ze O
##pine O
and O
lev O
##eti O
##race O
##tam O
medications O
with O
a O
low O
g O
##ly O
##ca O
##emi O
##c O
index O
treatment O
l O
##git O
a O
mod O
##i O
##ﬁ O
##ed O
k O
##d O
case O
report O

the O
patient B-PATIENT
was O
investigated O
as O
a O
result O
of O
severe B-HPO_TERM
headache I-HPO_TERM
##s I-HPO_TERM
at O
the O
age O
of O
22 B-PATIENT
years O
brain O
mri O
revealed O
non O
spec O
##i O
##ﬁ O
##c O
white O
matter O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##es I-HPO_TERM
##ities I-HPO_TERM
in I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
hemisphere I-HPO_TERM
##s I-HPO_TERM
clinical O
##ly O
horizontal B-HPO_TERM
ny I-HPO_TERM
##sta I-HPO_TERM
##gm I-HPO_TERM
##us I-HPO_TERM
and O
slight O
problems B-HPO_TERM
with I-HPO_TERM
balance I-HPO_TERM
were O
noted O
the O
diagnosis O
of O
multiple O
sc O
##ler O
##osis O
was O
entertained O
but O
not O
supported O
by O
her O
medical O
history O
and O
cs O
##f O
examination O
no O
further O
investigations O
were O
performed O
at O
age O
26 B-AGE_FOLLOWUP
years O
she O
experienced O
a O
severe B-HPO_TERM
headache I-HPO_TERM
during O
a O
3 O
day O
period O
on O
day O
4 O
after O
sy O
##mpt O
##om O
onset O
she O
presented O
to O
the O
emergency O
unit O
after O
having O
two O
general B-HPO_TERM
##ised I-HPO_TERM
seizures I-HPO_TERM
she O
also O
had O
symptoms O
of O
visual B-HPO_TERM
ﬂ I-HPO_TERM
##ashi I-HPO_TERM
##ng I-HPO_TERM
ﬂ B-HPO_TERM
##uc I-HPO_TERM
##tua I-HPO_TERM
##ting I-HPO_TERM
visual I-HPO_TERM
blur I-HPO_TERM
##ring I-HPO_TERM
and O
ﬁ B-HPO_TERM
##eld I-HPO_TERM
defects I-HPO_TERM
and O
speech B-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lty I-HPO_TERM
there O
was O
no O
previous O
history O
of O
such O
symptoms O
at O
presentation O
she O
was O

slightly B-HPO_TERM
confused I-HPO_TERM
but O
the O
neurological O
examination O
was O
otherwise O
normal O
no O
signs O
of O
men O
##inge O
##al O
irritation O
were O
noted O
white B-HPO_TERM
cell I-HPO_TERM
count I-HPO_TERM
my B-HPO_TERM
##og I-HPO_TERM
##lo I-HPO_TERM
##bin I-HPO_TERM
and O
cr B-HPO_TERM
##ea I-HPO_TERM
##tine I-HPO_TERM
kinase I-HPO_TERM
values I-HPO_TERM
were I-HPO_TERM
elevated I-HPO_TERM
but O
other O
routine O
investigations O
including O
cs O
##f O
were O
normal O
head O
ct O
was O
normal O
men O
##ing O
##oe O
##nce O
##pha O
##lit O
##is O
or O
cerebral O
sin O
##us O
th O
##rom O
##bos O
##is O
were O
not O
considered O
likely O
the O
patient O
was O
admitted O
to O
the O
neurological O
ward O
for O
follow O
up O
but O
no O
anti O
##ep O
##ile O
##ptic O
medication O
was O
started O

on O
day O
5 O
the O
patient O
had O
yet O
another O
seizure B-HPO_TERM
and O
intra O
##ven O
##ous O
ph O
##en O
##yt O
##oin O
was O
initiated O
she O
had O
severe B-HPO_TERM
headache I-HPO_TERM
with O
persistent B-HPO_TERM
visual I-HPO_TERM
aura I-HPO_TERM
despite O
treatment O
with O
conventional O
anal O
##ges O
##ics O
and O
a O
right B-HPO_TERM
homo I-HPO_TERM
##ny I-HPO_TERM
##mous I-HPO_TERM
hem I-HPO_TERM
##iano I-HPO_TERM
##pia I-HPO_TERM
she O
had O
word B-HPO_TERM
ﬁ I-HPO_TERM
##nding I-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lt I-HPO_TERM
##ies I-HPO_TERM
but O
normal O
comprehension O
and O
she O
was O
not O
able O
to O
perform O
simple O
numerical O
tasks O
e O
g O
counting O
down O
from O
100 O
on O
day O
6 O
ee O
##g O
revealed O
slight O
slowing O
down O
of O
background O
and O
continuous B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##pt I-HPO_TERM
##iform I-HPO_TERM
poly I-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
and I-HPO_TERM
slow I-HPO_TERM
wave I-HPO_TERM
complexes I-HPO_TERM
occurring O
pseudo O
periodically O
at O
0 O
5 O
to O
2 O
second O
intervals O
within O
the O
left O
tempo O
##ro O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
region O
with O
negative O
maximum O
at O
the O
o O
##cci O
##pit O
##al O
electrode O
o O
##1 O
these O
complexes O
were O
very O
similar O
to O
the O
rhythmic O
high O
##amp O
##lit O
##ude O
delta O
activity O
with O
poly O
##sp O
##ike O
##s O
r O
##had O
##s O
previously O
reported O
in O
children O
with O
pol O
##g O
related O
status O
ep O
##ile O
##ptic O
##us O
wolf O
et O
al O
2009 O
however O
in O
this O
adult O
patient O
the O
amplitude O
of O
the O
delta O
waves O
only O
reached O
130 O
µ O
##v O
ﬁ O
##gur O
##e O
1 O
the O
clinical O
condition O
and O

figure O
1 O
twenty O
three O
channel O
ee O
##g O
recording O
obtained O
during O
non B-HPO_TERM
con I-HPO_TERM
##vu I-HPO_TERM
##ls I-HPO_TERM
##ive I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
day O
6 O
continuous O
quasi O
rhythmic O
poly B-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
and I-HPO_TERM
delta I-HPO_TERM
wave I-HPO_TERM
activity O
was O
present O
within O
the O
left O
o O
##cci O
##pit O
##al O
region O
maximum O
at O
o O
##1 O
electrode O
recording O
was O
performed O
with O
nicole O
##tone O
ee O
##g O
ne O
##r O
##vus O
device O
ce O
##pha O
##lon O
ltd O
n O
##ø O
##rre O
##sund O
##by O
denmark O
electro O
##cap O
with O
ag O
ag O
##cle O
##le O
##ct O
##rod O
##es O
and O
standard O
international O
10 O
20 O
electrode O
placement O
the O
space O
between O
each O
vertical O
line O
represents O
one O
second O
and O
a O
bar O
of O
100 O
µ O
##v O
is O
depicted O
above O
the O
e O
##og O
channel O
on O
the O
right O
hand O
side O

ee O
##g O
ﬁ O
##nding O
##s O
were O
compatible O
with O
nc O
##se O
on O
the O
same O
day O
brain O
mri O
revealed O
new O
t B-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
o I-HPO_TERM
##ede I-HPO_TERM
##mic I-HPO_TERM
lesions I-HPO_TERM
in O
the O
left O
tha B-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and O
left O
par B-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
region I-HPO_TERM
ﬁ O
##gur O
##e O
2 O
ox O
##car O
##ba O
##ze O
##pine O
and O
lev O
##eti O
##race O
##tam O
were O
added O
to O
anti O
##ep O
##ile O
##ptic O
medication O
pol O
##g O
related O
mitochondrial O
disorder O
was O
now O
suspected O
based O
on O
clinical O
symptoms O
as O
well O
as O
ee O
##g O
and O
mri O
ﬁ O
##nding O
##s O
u O
##us O
##ima O
##a O
et O
al O
2008 O
wolf O
et O
al O
2009 O
and O
genetic O
testing O
was O
requested O
on O
day O
7 O
she O
was O
given O
l O
##git O
for O
details O
see O
p O
##fe O
##ifer O
and O
th O
##iel O
##e O
2005 O
which O
has O
been O
reported O
to O
be O
useful O
in O
patients O
with O
intra O
##ctable O
ep O
##ile O
##psy O
ko O
##sso O
##ff O
and O
hartman O
2012 O
p O
##fe O
##ifer O
and O
th O
##iel O
##e O
2005 O
the O
diet O
was O
well O
tolerated O
with O
no O
sign O
##i O
##ﬁ O
##can O
##t O
side O
effects O
the O
patient O
s O
condition O
improved O
such O
that O
the O
headache B-HPO_TERM
##s I-HPO_TERM
ap B-HPO_TERM
##has I-HPO_TERM
##ia I-HPO_TERM
and O
visual B-HPO_TERM
aura I-HPO_TERM
gradually O
disappeared O
during O
the O
following O
four O
days O
there O
were O
no O
further O
seizures O
at O
discharge O
on O
day O
12 O
she O
still O
had O
homo B-HPO_TERM
##ny I-HPO_TERM
##mous I-HPO_TERM
right I-HPO_TERM
sided I-HPO_TERM
visual I-HPO_TERM
ﬁ I-HPO_TERM
##eld I-HPO_TERM
defect I-HPO_TERM
which O
resolved O
slowly O
two O
months O
later O
the O
visual O
ﬁ O
##eld O
##s O
were O
normal O
during O
the O
follow O
up O
the O
patient O
did O
not O
have O
further O
seizures O
ph O
##en O
##yt O
##oin O
and O
ox O
##car O
##ba O
##ze O
##pine O
were O
gradually O
discontinued O
and O
she O
continues O
to O
receive O
lev O
##eti O
##race O
##tam O
mono O
##therapy O
and O
l O
##git O
genetic O
testing O
revealed O
a O
homo O
##zy O
##go O
##us O
c B-GENE_VARIANT
224 I-GENE_VARIANT
##3 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
mutation O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
leading O
to B-GENE_VARIANT
p I-GENE_VARIANT
tr I-GENE_VARIANT
##p I-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##ser I-GENE_VARIANT

discussion O
figure O
2 O
3 O
##t O
brain O
mri O
a O
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
lesions I-HPO_TERM
in O
t O
##2 O
weighted O
sequence O
three O
years O
prior O
to O
the O
ep O
##ile O
##ptic O
episode O
b O
t O
##2 O
hyper O
##int O
##ense O
lesions O
in O
fluid O
at O
##ten O
##uated O
inversion O
recovery O
flair O
sequence O
in O
the O
left O
tha O
##lam O
##us O
and O
the O
left O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
region O
at O
the O
time O
of O
the O
ep O
##ile O
##ptic O
episode O
day O
6 O
c O
resolution O
of O
tha B-HPO_TERM
##lam I-HPO_TERM
##ic I-HPO_TERM
and I-HPO_TERM
par I-HPO_TERM
##ie I-HPO_TERM
##to I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lesions I-HPO_TERM
in I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
weighted O
sequence O
during O
treatment O
with O
anti O
##ep O
##ile O
##ptic O
drugs O
and O
ke O
##to O
##genic O
diet O
day O
74 O

the O
ke O
##to O
##genic O
diet O
including O
l O
##git O
has O
several O
plausible O
anti O
##con O
##vu O
##ls O
##ant O
mechanisms O
such O
as O
increased O
energy O
production O
and O
increased O
y O
amino O
##bu O
##ty O
##ric O
acid O
ga O
##ba O
synthesis O
in O
the O
brain O
bo O
##ugh O
and O
r O
##ho O
2007 O
ko O
##sso O
##ff O
and O
hartman O
2012 O
in O
addition O
recent O
animal O
study O
data O
suggest O
that O
a O
ke O
##to O
##genic O
diet O
may O
have O
ben O
##e O
##ﬁ O
##cial O
effects O
for O
mitochondrial O
disorders O
ah O
##ola O
er O
##kki O
##la O
et O
al O
2010 O
pol O
##g O
related O
mitochondrial O
disease O
is O
common O
in O
the O
population O
e O
g O
in O
finland O
the O
carrier O
frequency O
of O
the O
p O
tr O
##p O
##7 O
##48 O
##ser O
all O
##ele O
is O
estimated O
to O
be O
1 O
125 O
ha O
##kon O
##en O
et O
al O
2005 O
in O
pol O
##g O
related O
mitochondrial O
ep O
##ile O
##psy O
progression O
to O
status O
ep O
##ile O
##ptic O
##us O
is O
common O
and O
this O
condition O
may O
be O
highly O
resistant O
to O
treatment O
t O
##zo O
##uli O
##s O
et O
al O
2006 O
ben O
##e O
##ﬁ O
##t O
of O
magnesium O
treatment O
has O
recently O
been O
reported O
in O
two O
patients O
with O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
and O
another O
homo O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutation O
p O
ala O
##46 O
##7th O
##r O
vis O
##ser O
et O
al O
2011 O
magnesium O
treatment O
was O
however O
not O
applied O
for O
the O
treatment O
of O
the O
patient O
reported O
here O
we O
conclude O
that O
the O
combination O
of O
ph O
##en O
##yt O
##oin O
ox O
##car O
##ba O
##ze O
##pine O
lev O
##eti O
##race O
##tam O
and O
l O
##git O
was O
effective O
and O
well O
tolerated O
in O
a O
patient O
with O
severe O
episodes O
of O
pol O
##g O
related O
mitochondrial O
ep O
##ile O
##psy O
manifest O
##ing O
as O
nc O
##se O
we O
suggest O
that O
combining O
l O
##git O
to O
anti O
##ep O
##ile O
##ptic O
drug O
treatment O
should O
be O
considered O
in O
this O
potentially O
life O
threatening O
condition O

disclosure O
##s O
none O
of O
the O
authors O
has O
any O
con O
##ﬂ O
##ic O
##t O
of O
interests O
to O
disclose O
references O
ah O
##ola O
er O
##kki O
##la O
s O
carroll O
c O
##j O
pe O
##lto O
##la O
m O
##jos O
##und O
k O
et O
al O
ke O
##to O
##genic O
diet O
slow O
##s O
down O
mitochondrial O
my O
##opa O
##thy O
progression O
in O
mice O
hum O
mo O
##l O
gene O
##t O
2010 O
19 O
1974 O
84 O
bo O
##ugh O
k O
##j O
r O
##ho O
j O
##m O
anti O
##con O
##vu O
##ls O
##ant O
mechanisms O
of O
the O
ke O
##to O
##genic O
diet O
ep O
##ile O
##ps O
##ia O
2007 O
48 O
43 O
58 O
ha O
##kon O
##en O
ah O
he O
##isk O
##ane O
##n O
s O
ju O
##von O
##en O
v O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
w O
##7 O
##48 O
##s O
mutation O
a O
common O
cause O
of O
auto O
##som O
##al O
recess O
##ive O
ata O
##xia O
with O
ancient O
european O
origin O
am O
j O
hum O
gene O
##t O
2005 O
77 O
430 O
41 O

joshi O
cn O
greenberg O
cr O
m O
##han O
##ni O
aa O
salman O
ms O
ke O
##to O
##genic O
diet O
in O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2009 O
40 O
314 O
6 O
ko O
##sso O
##ff O
eh O
hartman O
al O
ke O
##to O
##genic O
diet O
##s O
new O
advances O
for O
metabolism O
based O
the O
##ra O
##pies O
cu O
##rr O
op O
##in O
ne O
##uro O
##l O
2012 O
25 O
173 O
8 O
p O
##fe O
##ifer O
h O
##h O
th O
##iel O
##e O
ea O
low O
g O
##ly O
##ce O
##mic O
index O
treatment O
a O
liberal O
##ized O
ke O
##to O
##genic O
diet O
for O
treatment O
of O
intra O
##ctable O
ep O
##ile O
##psy O
ne O
##uro O
##logy O
2005 O
65 O
1810 O
2 O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
1685 O
92 O

u O
##us O
##ima O
##a O
j O
hint O
##tal O
##a O
r O
ran O
##tal O
##a O
h O
et O
al O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutation O
in O
the O
pol O
##g O
##1 O
gene O
in O
patients O
with O
juvenile O
##ons O
##et O
al O
##pers O
syndrome O
and O
status O
ep O
##ile O
##ptic O
##us O
ep O
##ile O
##ps O
##ia O
2008 O
49 O
103 O
##8 O
45 O
vis O
##ser O
na O
braun O
k O
##p O
lei O
##j O
##ten O
f O
##s O
et O
al O
magnesium O
treatment O
for O
patients O
with O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
due O
to O
pol O
##g O
##1 O
mutations O
j O
ne O
##uro O
##l O
2011 O
258 O
218 O
22 O
wolf O
ni O
rahman O
s O
sc O
##hmi O
##tt O
b O
et O
al O
status O
ep O
##ile O
##ptic O
##us O
in O
children O
with O
al O
##pers O
disease O
caused O
by O
pol O
##g O
##1 O
mutations O
ee O
##g O
and O
mri O
features O
ep O
##ile O
##ps O
##ia O
2009 O
50 O
159 O
##6 O
60 O
##7 O

pol B-GENE
##g I-GENE
##1 I-GENE
mutations O
and O
stroke O
like O
episodes O
a O
distinct O
clinical O
entity O
rather O
than O
an O
at O
##yp O
##ical O
mel O
##as O
syndrome O
anton O
##ella O
che O
##ld O
##i O
##1 O
dario O
ron O
##chi O
##2 O
andrei O
##na O
bo O
##rdon O
##i O
##2 O
bianca O
bo O
##rdo O
##1 O
silvia O
lan O
##fra O
##nco O
##ni O
##2 O
maria O
graz O
##ia O
bell O
##otti O
##1 O
stefan O
##ia O
co O
##rti O
##2 O
vale O
##ria O
luc O
##chin O
##i O
##3 O
monica O
sci O
##ac O
##co O
##3 O
ma O
##uri O
##zio O
mo O
##ggio O
##3 O
pier O
##lu O
##ig O
##i O
baron O
##2 O
giacomo O
pietro O
com O
##i O
##2 O
antonio O
colombo O
##1 O
anna O
be O
##rsa O
##no O
##4 O
and O
on O
behalf O
of O
lombard O
##ia O
gen O
##s O
collaborators O
background O

mitochondrial O
my O
##opa O
##thy O
en O
##ce O
##pha O
##lo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
like O
episodes O
mel O
##as O
syndrome O
is O
a O
ph O
##eno O
##typical O
##ly O
and O
genetically O
het O
##ero O
##gen O
##eous O
mitochondrial O
disorder O
stroke O
like O
episodes O
which O
are O
usually O
transient O
and O
not O
di O
##sa O
##bling O
represent O
the O
clinical O
hallmark O
##s O
additional O
features O
include O
seizures O
cognitive O
decline O
psycho O
##sis O
lac O
##tic O
acid O
##osis O
mig O
##raine O
visual O
impairment O
hearing O
loss O
short O
stature O
diabetes O
and O
my O
##opa O
##thy O
mri O
shows O
hyper O
##int O
##ens O
##ities O
on O
t O
##2 O
weighted O
and O
d O
##wi O
sequences O
mostly O
over O
the O
temporal O
par O
##ie O
##tal O
and O
o O
##cci O
##pit O
##al O
regions O
not O
confined O
to O
a O
vascular O
territory O
muscle O
bio O
##psy O
typically O
shows O
ragged O
##red O
and O
cox O
negative O
fibers O
sd O
##h O
hyper O
##rea O
##ct O
##ivity O
and O
at O
ultra O
##st O
##ru O
##ct O
##ural O
level O
abnormal O
##ly O
shaped O
mit O
##och O
##ond O
##ria O
with O

correspondence O
anna O
be O
##rsa O
##no O
gma O
##il O
com O
4 O
##cer O
##eb O
##rov O
##as O
##cular O
unit O
ir O
##cc O
##s O
foundation O
neurological O
institute O
c O
best O
##a O
via O
ce O
##lor O
##ia O
23 O
2013 O
##5 O
milan O
italy O
full O
list O
of O
author O
information O
is O
available O
at O
the O
end O
of O
the O
article O

para O
##cr O
##ista O
##llin O
##e O
inclusion O
##s O
mel O
##as O
results O
in O
80 O
of O
cases O
from O
a O
point O
mutation O
m O
324 O
##3 O
##a O
g O
in O
the O
mitochondrial O
tr O
##nal O
##eu O
u O
##ur O
gene O
mt O
##tl O
##1 O
1 O
2 O
other O
mitochondrial O
dna O
mt O
##dna O
mutations O
in O
mt O
##tl O
##1 O
gene O
and O
other O
transfer O
rna O
genes O
mt O
##tf O
mt O
##tv O
mt O
##t O
##q O
as O
well O
as O
mutations O
in O
other O
subunit O
##s O
of O
complex O
1 O
such O
as O
mt O
##nd O
##1 O
mt O
##nd O
##5 O
and O
mt O
##nd O
##6 O
have O
been O
also O
identified O
as O
cause O
of O
mel O
##as O
3 O
6 O
indeed O
mutations O
in O
nuclear O
genes O
leading O
to O
secondary O
mt O
##dna O
changes O
de O
##ple O
##tions O
and O
multiple O
del O
##eti O
##ons O
have O
been O
described O
as O
emerging O
causes O
of O
mel O
##as O
7 O
recently O
des O
##cha O
##uer O
et O
al O
described O
a O
patient O
showing O
stroke O
like O
episodes O
and O
a O
right O
o O
##cci O
##pit O
##al O
les O
##ion O
headache O
seizures O
elevated O
cs O
##f O
lac O
##tate O
ragged O
red O
fibers O
and O
carrying O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
mt O
##dna O
polymer O
##ase O
gene O
pol O
##g O
##1 O
arguing O
that O
mel O
##as O
could O
be O
included O
in O
pol O
##g O
##1 O
spectrum O
ph O
##eno O
##type O
7 O
pol O
##g O
##1 O
mutations O
were O
described O
so O
far O
in O
families O
with O
auto O
##som O
##al O
dominant O
and O
recess O
##ive O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O

2013 O
che O
##ld O
##i O
et O
al O
license O
##e O
bio O
##med O
central O
ltd O
this O
is O
an O
open O
access O
article O
distributed O
under O
the O
terms O
of O
the O
creative O
commons O
at O
##tri O
##bution O
license O
http O
creative O
##com O
##mons O
org O
licenses O
by O
2 O
0 O
which O
permits O
unrest O
##ricted O
use O
distribution O
and O
reproduction O
in O
any O
medium O
provided O
the O
original O
work O
is O
properly O
cited O

pe O
##o O
al O
##pers O
syndrome O
parkinson O
##ism O
optic O
ne O
##uri O
##tis O
and O
late O
onset O
ata O
##xia O
8 O
9 O
we O
previously O
reported O
a O
co O
##hort O
of O
67 O
patients O
affected O
by O
my O
##opa O
##thy O
with O
or O
without O
pe O
##o O
in O
which O
19 O
4 O
of O
patients O
carried O
pol O
##g O
##1 O
mutations O
10 O
here O
##in O
we O
report O
the O
2 O
year O
neurological O
follow O
up O
of O
one O
of O
these O
patients O
disc O
##los O
##ing O
over O
time O
a O
clinical O
ph O
##eno O
##type O
highly O
consistent O
with O
mel O
##as O
case O
presentation O
patient B-PATIENT
s O
history O

a O
74 B-AGE_FOLLOWUP
year O
old O
man O
was O
admitted O
to O
the O
neurological O
unit O
of O
des O
##io O
hospital O
in O
september O
2004 O
for O
sudden O
onset O
of O
a O
speech B-HPO_TERM
disorder I-HPO_TERM
and O
left B-HPO_TERM
side I-HPO_TERM
weakness I-HPO_TERM
over O
the O
past B-AGE_ONSET
ten I-AGE_ONSET
years I-AGE_ONSET
he O
developed O
a O
progressive B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
hearing B-HPO_TERM
loss I-HPO_TERM
and O
difficulties B-HPO_TERM
in I-HPO_TERM
swallowing I-HPO_TERM
for O
these O
symptoms O
he O
was O
hospitalized O
in O
1996 O
elsewhere O
the O
neurological O
examination O
performed O
at O
that O
time O
revealed O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
bilateral B-HPO_TERM
hearing I-HPO_TERM
loss I-HPO_TERM
and O
mild B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
the O
ne O
##uro O
##phy O
##sio O
##logical O
examination O
performed O
in O
1996 O
revealed O
a O
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
pattern I-HPO_TERM
however O
at O
that O
time O
the O
patient O
refused O
any O
further O
investigation O
including O
muscle O
bio O
##psy O
the O
remaining O
patient O
s O
past O
history O
was O
un O
##rem O
##ark O
##able O
in O
particular O
except O
for O
a O
mild B-HPO_TERM
increase I-HPO_TERM
in I-HPO_TERM
cho I-HPO_TERM
##les I-HPO_TERM
##terol I-HPO_TERM
levels I-HPO_TERM
ce O
##re O
##bro O
##vas O
##cular O
risk O
factors O
were O
absent O
family O
history O
was O
negative O
for O
muscular O
disorders O
stroke O
hearing O
loss O
diabetes O
short O
stature O
headache O
mental O
re O
##tar O
##dation O
or O
dementia O
neurological O
examination O
performed O
on O
admission O
in O
2004 O
revealed O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
severe B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
hearing B-HPO_TERM
loss I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
left B-HPO_TERM
facial I-HPO_TERM
nerve I-HPO_TERM
pal I-HPO_TERM
##sy I-HPO_TERM
and O
mild B-HPO_TERM
left I-HPO_TERM
side I-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
acute O
phase O
ni O
##hs O
##s O
score O
was O
4 O
fat O
##iga O
##bility O
and O
my O
##oton O
##ic O
phenomena O
were O
absent O
acute O
phase O
cerebral O
ct O
scan O
was O
negative O
for O
acute O
is O
##che O
##mic O
lesions O
cerebral O
mri O
performed O
two O
days O
later O
showed O
a O
right B-HPO_TERM
pre I-HPO_TERM
roland I-HPO_TERM
##ic I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ity I-HPO_TERM
on I-HPO_TERM
t I-HPO_TERM
##2 I-HPO_TERM
##weight I-HPO_TERM
##ed I-HPO_TERM
sequence O
not O
confined O
to O
a O
specific O
vascular O
territory O
with O
a O
slight O
enhancement O
after O
ga O
##do O
##lini O
##um O
consistent O
with O
an O
acute O
is O
##cha O
##emi O
##c O
les O
##ion O
other O
bilateral B-HPO_TERM
focal I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
mostly O
in O
the O
posterior O
circulation O
territory O
ce O
##re O
##bella O
##r O
bilateral O
left O
tempo O
##ro O
o O
##cci O
##pit O
##al O
and O
frontal O
consistent O
with O
stabilized B-HPO_TERM
is I-HPO_TERM
##cha I-HPO_TERM
##emi I-HPO_TERM
##c I-HPO_TERM
lesions I-HPO_TERM
were O
also O
found O
figure O
1 O
biochemistry O
was O
normal O
except O
for O
increased B-HPO_TERM
level I-HPO_TERM
of I-HPO_TERM
serum I-HPO_TERM
cr I-HPO_TERM
##ea I-HPO_TERM
##tine I-HPO_TERM
kinase I-HPO_TERM
189 O
##→ O
##64 O
##3 O
n O
v O
38 O
174 O
u O
l O
inflammatory O
and O
auto O
##im O
##mun O
##e O
markers O
were O
normal O
as O
well O
as O
lac O
##tate O
serum O
level O
1 O
7 O
n O
v O
0 O
51 O
8 O
mm O
##ol O
l O
electro O
##card O
##io O
##gram O
echo O
##card O
##iography O
and O
abdominal O
ultra O
##son O
##ography O
were O
negative O
audio O
##metry O
revealed O
a O
moderate B-HPO_TERM
sensor I-HPO_TERM
##imo I-HPO_TERM
##tor I-HPO_TERM
bilateral I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oa I-HPO_TERM
##cus I-HPO_TERM
##ia I-HPO_TERM
op O
##ht O
##hal O
##mo O
##logical O
examination O
including O
flu O
##oro O
##ang O
##iography O
excluded O
a O
pigment O
##ary O
re O
##tino O
##pathy O
electro O
##ence O
##pha O
##log O
##raphy O
was O
normal O
too O
ne O
##uro O
##phy O
##sio O
##logical O
examination O
demonstrated O
my O
##opa O
##thic O
signs O
in O
frontal O
mass O
##eter O
##s O
orb O
##icular O
##is O
o O
##cu O
##li O
and O
mouth O
muscles O
without O
den O
##er O
##vation O
and O
normal O
findings O
in O
the O
other O
examined O
muscles O
right O
biceps O
tri O
##ce O
##ps O
inter O
##oss O
##eous O
and O
left O
and O
right O
quad O
##rice O
##ps O

ti O
##bial O
##is O
anterior O
medial O
gem O
##ell O
##us O
no O
signs O
of O
poly O
##ne O
##uro O
##pathy O
were O
detected O
ti O
##cl O
##op O
##idi O
##ne O
250 O
mg O
twice O
daily O
was O
started O
left O
hem O
##ip O
##ares O
##is O
resolved O
completely O
within O
7 O
days O
during O
the O
following O
years O
a O
progressive B-HPO_TERM
worse I-HPO_TERM
##ning I-HPO_TERM
of I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
hearing B-HPO_TERM
loss I-HPO_TERM
and O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
was O
observed O
cognitive O
impairment O
was O
not O
detected O
at O
mm O
##se O
headache O
and O
seizures O
were O
not O
referred O
too O
in O
november O
2008 B-AGE_FOLLOWUP
the O
patient O
was O
hospitalized O
again O
for O
a O
sudden B-HPO_TERM
onset I-HPO_TERM
of I-HPO_TERM
ap I-HPO_TERM
##has I-HPO_TERM
##ia I-HPO_TERM
no O
other O
new O
onset O
neurological O
symptoms O
were O
referred O
the O
neurological O
examination O
performed O
at O
that O
time O
showed O
global B-HPO_TERM
ap I-HPO_TERM
##has I-HPO_TERM
##ia I-HPO_TERM
and O
a O
right B-HPO_TERM
hem I-HPO_TERM
##ip I-HPO_TERM
##ares I-HPO_TERM
##is I-HPO_TERM
with O
right B-HPO_TERM
ba I-HPO_TERM
##bin I-HPO_TERM
##ski I-HPO_TERM
sign I-HPO_TERM
the O
ni O
##hs O
##s O
score O
was O
4 O
residual O
signs O
such O
as O
severe B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
bilateral B-HPO_TERM
opt I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
bilateral B-HPO_TERM
hearing I-HPO_TERM
loss I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
solid O
food B-HPO_TERM
d I-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
were O
unchanged O
fat O
##iga O
##bility O
ce O
##re O
##bella O
##r O
ata O
##xia O
or O
sensitive O
deficit O
##s O
were O
absent O
biochemistry O
echo O
##card O
##iography O
ep O
##ia O
##ort O
##ic O
vessel O
do O
##pp O
##ler O
ultrasound O
were O
normal O
cerebral O
ct O
scan O
performed O
in O
the O
acute O
phase O
was O
un O
##mo O
##di O
##fied O
in O
comparison O
to O
the O
previous O
ones O
cerebral O
mri O
at O
day O
3 O
demonstrated O
a O
small B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
##su I-HPO_TERM
##bc I-HPO_TERM
##ort I-HPO_TERM
##ical I-HPO_TERM
left I-HPO_TERM
tempo I-HPO_TERM
##ro I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
les I-HPO_TERM
##ion I-HPO_TERM
with I-HPO_TERM
d I-HPO_TERM
##wi I-HPO_TERM
restriction I-HPO_TERM
figure O
1 O
the O
strength O
deficit O
resolved O
in O
a O
few O
days O
whereas O
a O
language O
rehabilitation O
was O
necessary O
ap O
##has O
##ia O
progressively O
recovered O
and O
was O
not O
present O
at O
the O
three O
months O
follow O
up O
the O
patient O
continued O
to O
assume O
ti O
##cl O
##op O
##idi O
##ne O

genetic O
analysis O

total O
dna O
was O
extracted O
from O
peripheral O
blood O
and O
muscle O
pc O
##r O
rf O
##lp O
analysis O
did O
not O
reveal O
m O
324 O
##3 O
##a O
g O
mutation O
southern O
b O
##lot O
analysis O
of O
muscle O
mt O
##dna O
11 O
revealed O
the O
presence O
of O
several O
bands O
compatible O
with O
mt O
##dna O
multiple O
del O
##eti O
##ons O
figure O
2 O
a O
specific O
pc O
##r O
ass O
##ay O
identified O
mt O
##dna O
multiple O
del O
##eti O
##ons O
using O
two O
prime O
##rs O
forward O
74 O
##40 O
74 O
##65 O
and O
reverse O
complement O
161 O
##35 O
1611 O
##0 O
and O
the O
following O
amp O
##li O
##fication O
protocol O
an O
initial O
den O
##at O
##uration O
at O
94 O
##° O
##c O
for O
2 O
min O
followed O
by O
25 O
cycles O
94 O
##° O
##c O
for O
30 O
s O
55 O
##° O
##c O
for O
30 O
s O
and O
68 O
##° O
##c O
for O
90 O
s O
and O
a O
final O
extension O
for O
2 O
min O
at O
72 O
##° O
##c O
platinum O
hi O
##fi O
ta O
##q O
polymer O
##ase O
by O
in O
##vi O
##tro O
##gen O
carl O
##sb O
##ad O
ca O
the O
entire O
coding O
sequence O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
nm O
00 O
##26 O
##9 O
##3 O
1 O
was O
pc O
##r O
amplified O
and O
directly O
sequence O
##d O
disc O
##los O
##ing O
the O
presence O
of O
three O
het O
##ero O
##zy O
##go O
##us O
variants O
the O
c B-GENE_VARIANT
75 I-GENE_VARIANT
##2 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
ex O
##on O
3 O
p B-GENE_VARIANT
t I-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
c B-GENE_VARIANT
1760 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
ex O
##on O
10 O
p B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
and O
c B-GENE_VARIANT
355 I-GENE_VARIANT
##6 I-GENE_VARIANT
##g I-GENE_VARIANT
c I-GENE_VARIANT
ex O
##on O
22 O
p B-GENE_VARIANT
d I-GENE_VARIANT
##11 I-GENE_VARIANT
##86 I-GENE_VARIANT
##h I-GENE_VARIANT
we O
did O
not O
test O
any O
other O
family O
member O
for O
pol O
##g O
mutations O
since O
parents O
are O
not O
alive O
and O
siblings O
are O
not O
available O
both O
the O
mutations O
p O
t O
##25 O
##1 O
##i O
and O
p O
p O
##58 O
##7 O
##l O
were O
reported O
several O
times O
in O
subjects O
showing O
multiple O
clinical O
ph O
##eno O
##type O
##s O
according O
to O
the O
human O
dna O
polymer O
##ase O
gamma O
mutation O
database O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
the O
miss O
##ense O
mutation O
c O
355 O
##6 O
##g O
c O
was O
not O
listed O
in O
the O
db O
##s O
##np O
database O
http O
www O
nc O
##bi O
nl O
##m O
ni O
##h O
gov O
projects O
s O
##np O
as O
well O
as O
in O
the O
pol O
##g O
mutation O
database O
and O
it O
was O
not O

figure O
1 O
a O
d O
skeletal O
muscle O
bio O
##psy O
showing O
one O
ragged B-HPO_TERM
red I-HPO_TERM
fiber I-HPO_TERM
with O
his O
##to O
##logical O
methods O
a O
b O
h O
e O
10 O
##x O
b O
gt O
40 O
##x O
his O
##to O
##chemical O
reactions O
for O
cox O
c O
10 O
##x O
and O
cox O
sd O
##h O
d O
10 O
##x O
in O
cross O
serial O
sections O
show O
lack B-HPO_TERM
of I-HPO_TERM
cox I-HPO_TERM
activity I-HPO_TERM
in O
several O
skeletal O
muscle O
fibers O
c O
many O
of O
which O
also O
show O
increased O
sd O
##h O
activity O
d O
e O
h O
axial O
t O
##2 O
weighted O
cerebral O
mri O
sequences O
showing O
a O
co B-HPO_TERM
##rti I-HPO_TERM
##co I-HPO_TERM
sub I-HPO_TERM
##cor I-HPO_TERM
##tical I-HPO_TERM
front I-HPO_TERM
##opa I-HPO_TERM
##rie I-HPO_TERM
##tal I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ity I-HPO_TERM
with O
restricted O
diffusion O
not O
shown O
consistent O
with O
acute B-HPO_TERM
is I-HPO_TERM
##cha I-HPO_TERM
##emi I-HPO_TERM
##c I-HPO_TERM
les I-HPO_TERM
##ion I-HPO_TERM
and O
bilateral B-HPO_TERM
old I-HPO_TERM
is I-HPO_TERM
##cha I-HPO_TERM
##emi I-HPO_TERM
##c I-HPO_TERM
lesions I-HPO_TERM
in O
the O
right O
o O
##cci O
##pit O
##al O
and O
left O
temporal O
lobe O

found O
in O
more O
than O
200 O
italian O
healthy O
controls O
the O
affected O
residue O
position O
118 O
##6 O
is O
evolution O
##ari O
##ly O
conserved O
across O
species O
three O
software O
programs O
were O
used O
to O
predict O
the O
overall O
severity O
of O
this O
variant O
according O
poly O
##ph O
##en O
2 O
http O
genetics O
b O
##w O
##h O
harvard O
ed O
##u O
pp O
##h O
##2 O
si O
##ft O
sorting O
into O
##ler O
##ant O
from O
tolerant O
http O
si O
##ft O
bi O
##i O
a O
star O
ed O
##u O
sg O
and O
pm O
##ut O
http O
mm O
##b O
pc O
##b O
u O
##b O
es O
pm O
##ut O
the O
p O
d O
##11 O
##86 O
##h O
change O
is O
predicted O
to O
be O
highly O
del O
##eter O
##ious O
skeletal O
muscle O
and O
nerve O
his O
##top O
##ath O
##ology O

in O
2004 O
the O
patient O
underwent O
a O
left O
biceps O
skeletal O
muscle O
bio O
##psy O
cry O
##osta O
##tic O
cross O
sections O
were O
processed O
according O
to O
standard O
his O
##to O
##logical O
and O
his O
##to O
##chemical O
techniques O
including O
ha O
##ema O
##to O
##xy O
##lin O
e O
##osi O
##n O
h O
e O
go O
##mori O
tri O
##chrome O
gt O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
and O
double O
reaction O
for O
cox O
and O
sd O
##h O
12 O
electron O
microscopy O
studies O
were O
performed O
as O
described O
13 O

his O
##to O
##logical O
examination O
of O
muscle O
specimen O
showed O
slight B-HPO_TERM
fiber I-HPO_TERM
size I-HPO_TERM
variability I-HPO_TERM
some O
nuclear B-HPO_TERM
central I-HPO_TERM
##izations I-HPO_TERM
and O
several B-HPO_TERM
fiber I-HPO_TERM
splitting I-HPO_TERM
##s I-HPO_TERM
along O
with O
a O
consistent O
number O
n O
10 O
of O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
rr O
##f O
nec B-HPO_TERM
##rosis I-HPO_TERM
was I-HPO_TERM
observed I-HPO_TERM
in I-HPO_TERM
a I-HPO_TERM
few I-HPO_TERM
fibers I-HPO_TERM
his O
##to O
##chemical O
##ly O
several O
fibers O
were O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
negative I-HPO_TERM
many O
of O
these O
fibers O
were O
also O
intensely O
sd O
##h O
positive O
figure O
1 O

dna O
sample O
and O
muscle O
bio O
##psy O
were O
collected O
after O
obtaining O
patient O
informed O
consent O
according O
to O
the O
local O
ethics O
and O
privacy O
and O
human O
subjects O
protection O
regulations O
and O
were O
taken O
as O
part O
of O
standard O
patient O
care O
conclusion O

the O
human O
mitochondrial O
genome O
is O
replicate O
##d O
by O
the O
dna O
polymer O
##ase O
γ O
pol O
γ O
which O
is O
encoded O
by O
pol O
##g O
##1 O
which O
is O
a O
23 O
ex O
##ons O
nuclear O
gene O
located O
on O
chromosome O
15 O
##q O
##25 O
het O
##ero O
##zy O
##go O
##us O
and O
homo O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
have O
been O
typically O
associated O
with O
het O
##ero O
##gen O
##eous O
and O
severe O
clinical O
ph O
##eno O
##type O
##s O
of O
pe O
##o O
both O
in O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
form O
they O
can O
also O
result O
in O
adult O
onset O
ce O
##re O
##bella O
##r O
ata O
##xia O
with O
mt O
##dna O
multiple O
del O
##eti O
##ons O
and O
al O
##pers O
syndrome O
an O
auto O
##som O
##al O
recess O
##ive O
he O
##pa O
##to O
##cer O
##eb O
##ral O
disease O
characterized O
by O
severe O
developmental O
delay O
intra O
##ctable O
seizures O
liver O
failure O
and O
death O
in O
childhood O
moreover O
throughout O
the O
years O
a O
wide O
spectrum O
of O
clinical O
findings O
including O
parkinson O
##ism O
ne O
##uro O
##pathy O
optic O
ne O
##uri O
##tis O
psychiatric O
disorders O
has O
been O
described O
in O
pol O
##g O
##1 O
mutations O
carriers O
12 O
14 O
19 O
des O
##cha O
##uer O
et O
al O
2007 O
described O
a O
patient O
presenting O
with O
o O
##cci O
##pit O
##al O
seizures O
and O
residual O
homo O
##ny O
##mous O
hem O
##iano O
##ps O
##ia O
headache O
and O
ata O
##xia O
and O
carrying O
two O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
7 O
the O
presence O
of O
o O
##cci O
##pit O
##al O
symptoms O
and O
lesions O
interpreted O
as O
stroke O
like O
episodes O
together O
with O
elevated O
cs O
##f O
lac O
##tate O
and O
ragged O
red O
fibers O
posed O
the O
suspicion O
of O
mel O
##as O
raising O
the O
question O
whether O
pol O
##g O
##1 O
mutations O
could O
be O
associated O
with O
a O
mel O
##as O
like O
ph O
##eno O
##type O
7 O
20 O
however O
given O
several O
clinical O
differences O
between O
pol O
##g O
##1 O
patient O
characteristics O
and O
mel O
##as O
it O
has O
been O
supposed O
that O
despite O
some O
overlapping O
symptoms O
pol O
##g O
##1 O
represent O
a O
distinct O
clinical O
and O
genetic O
entity O
pol O
##g O
associated O
en O
##ce O
##pha O
##lo O
##pathy O
has O
been O
post O
##ulated O
to O
give O
rise O
to O
a O
distinct O
ph O
##eno O
##type O
including O
variable O
age O
at O
onset O
either O
recess O
##ive O
or O
dominant O
inheritance O
pattern O
and O
peculiar O
ne O
##uro O
##ima O
##ging O

findings O
characterized O
by O
predominant O
posterior O
is O
##che O
##mic O
lesions O
and O
lack O
of O
cerebral O
cal O
##ci O
##fication O
21 O

our O
case O
had O
some O
at O
##yp O
##ical O
aspects O
for O
mel O
##as O
such O
as O
late O
onset O
lack O
of O
cerebral O
cal O
##ci O
##fication O
and O
presence O
of O
frontal O
and O
o O
##cci O
##pit O
##al O
mri O
lesions O
better O
consistent O
with O
the O
pol O
##g O
associated O
en O
##ce O
##pha O
##lo O
##pathy O
spectrum O
however O
it O
is O
difficult O
to O
assess O
with O
certainty O
whether O
our O
patient O
could O
be O
classified O
as O
mel O
##as O
like O
or O
pol O
##gas O
##so O
##cia O
##ted O
en O
##ce O
##pha O
##lo O
##pathy O
moreover O
although O
the O
patient O
did O
not O
present O
any O
vascular O
risk O
factor O
given O
the O
elderly O
age O
a O
co O
incidence O
between O
a O
pol O
##g O
my O
##opa O
##thy O
and O
a O
ce O
##re O
##bro O
##vas O
##cular O
disease O
can O
not O
be O
excluded O
at O
all O
however O
it O
is O
difficult O
to O
compare O
mel O
##as O
which O
is O
a O
clearly O
defined O
clinical O
syndrome O
with O
pol O
##g O
##1 O
associated O
en O
##ce O
##pha O
##lo O
##pathy O
which O
is O
so O
far O
a O
purely O
molecular O
##ly O
defined O
syndrome O
with O
a O
quite O
het O
##ero O
##gen O
##eous O
clinical O
picture O
in O
addition O
although O
140 O
pol O
##g O
mutations O
have O
been O
described O
in O
patients O
with O
symptoms O
that O
suggest O
mitochondrial O
disease O
most O
of O
mutations O
are O
reported O
in O
het O
##ero O
##zy O
##go O
##us O
in O
whom O
each O
pol O
##g O
all O
##ele O
can O
be O
one O
or O
more O
different O
mutations O
and O
only O
few O
of O
these O
has O
been O
replicate O
##d O
in O
not O
related O
families O
this O
makes O
difficult O
a O
clear O
definition O
of O
ph O
##eno O
##type O
and O
in O
providing O
evidence O
of O

the O
disease O
causing O
nature O
of O
these O
mutations O
22 O

our O
patient B-PATIENT
harbour O
##ed O
the O
ha O
##pl O
##otype O
p O
t O
##25 O
##1 O
##i O
p O
##58 O
##7 O
##l O
in O
combination O
with O
d B-GENE_VARIANT
##11 I-GENE_VARIANT
##86 I-GENE_VARIANT
##h I-GENE_VARIANT
located O
in O
polymer O
##ase O
domain O
the O
ha O
##pl O
##otype O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
and O
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
has O
been O
already O
described O
but O
it O
is O
currently O
not O
possible O
to O
know O
whether O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
or O
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
is O
the O
primary O
pathogen O
##ic O
all O
##ele O
or O
whether O
both O
mutations O
are O
necessary O
to O
cause O
disease O
nevertheless O
both O
variants O
have O
also O
been O
reported O
in O
trans O
one O
each O
other O
in O
affected O
subjects O
notably O
both O
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
and O
d B-GENE_VARIANT
##11 I-GENE_VARIANT
##86 I-GENE_VARIANT
residues O
are O
located O
in O
the O
dna O
binding O
channel O
of O
pol O
##g O
enzyme O
thus O
the O
substitution O
##s O
found O
in O
our O
patient O
could O
be O
consistent O
with O
a O
reduced O
dna O
binding O
capacity O

jim O
##d O
reports O
doi O
10 O
100 O
##7 O
89 O
##0 O
##4 O
2011 O
73 O
complete O
del O
##eti O
##on O
of O
a O
pol B-GENE
##g I-GENE
##1 I-GENE
all O
##ele O
in O
a O
patient B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
karin O
na O
##ess O
michel O
##a O
bar O
##bar O
##o O
helene O
br O
##uh O
##n O
rolf O
wi O
##bo O
##m O
ing O
##er O
ne O
##nne O
##smo O
ul O
##rika O
von O
d O
##€ O
##obe O
##ln O
nils O
g O
##€ O
##oran O
lars O
##son O
ant O
##al O
ne O
##met O
##h O
nicole O
les O
##ko O
received O
28 O
march O
2011 O
revised O
10 O
june O
2011 O
accepted O
21 O
june O
2011 O
published O
online O
20 O
october O
2011 O
ss O
##ie O
##m O
and O
springer O
verlag O
berlin O
heidelberg O
2011 O

abstract O
mutations O
in O
the O
gene O
encoding O
the O
catalytic O
subunit O
of O
polymer O
##ase O
g O
pol O
##g O
##1 O
are O
a O
major O
cause O
of O
human O
mitochondrial O
disease O
more O
than O
150 O
different O
point O
mutations O
in O
the O
gene O
have O
been O
reported O
to O
be O
disease O
causing O
resulting O
in O
a O
large O
range O
of O
clinical O
symptoms O
depending O
on O
the O
mutation O
or O
combination O
of O
mutations O
disease O
onset O
can O
occur O
in O
early O
infancy O
or O
late O
in O
adult O
life O
here O
we O
describe O
the O
use O
of O
multiple O
##x O
liga O
##tion O
dependent O
probe O
amp O
##li O
##fication O
ml O
##pa O
analysis O
to O
detect O
del O
##eti O
##ons O
within O
pol O
##g O
##1 O
which O
could O
otherwise O
go O
und O
##ete O
##cted O
by O
solely O
sequencing O
of O
the O
gene O
we O
present O
a O
case B-PATIENT
where O
an O
entire O
pol B-GENE
##g I-GENE
##1 I-GENE
all O
##ele O
is O
deleted B-GENE_VARIANT
with O
a O
known O
pathogen O
##ic O
mutation O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
on O
the O
remaining O
all O
##ele O
the O
del O
##eti O
##on O
was O
found O
in O
a O
boy O
with B-HPO_TERM
al I-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
presenting O
at O
18 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
with O
slightly B-HPO_TERM
re I-HPO_TERM
##tar I-HPO_TERM
##ded I-HPO_TERM
motor I-HPO_TERM
development I-HPO_TERM
balance B-HPO_TERM
problems I-HPO_TERM
and O
seizures B-HPO_TERM
administration O
of O
val O
##pro O
##ic O
acid O
vp O
##a O
led O
to O

rapidly O
progressive B-HPO_TERM
fatal I-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
in O
our O
patient B-PATIENT
and O
we O
would O
like O
to O
highlight O
the O
need O
to O
carry O
out O
complete O
pol O
##g O
##1 O
gene O
analysis O
before O
administration O
of O
vp O
##a O
in O
cases O
of O
pediatric O
seizure O
disorders O
of O
unknown O
origin O
debut O
and O
severity O
of O
the O
disease O
in O
this O
patient O
was O
unique O
when O
compared O
to O
homo O
##zy O
##go O
##us O
or O
het O
##ero O
##zy O
##go O
##us O
patients O
with O
the O
w O
##7 O
##48 O
##s O
mutation O
leading O
to O
the O
conclusion O
that O
gene O
dos O
##age O
plays O
a O
role O
in O
the O
clinical O
ph O
##eno O
##type O
of O
this O
disease O
introduction O

the O
nuclear O
encoded O
dna O
polymer O
##ase O
g O
pol O
##g O
is O
the O
sole O
polymer O
##ase O
replica O
##ting O
mitochondrial O
dna O
mt O
##dna O
clayton O
1982 O
this O
ho O
##loe O
##nz O
##yme O
is O
a O
het O
##ero O
##tri O
##mer O
made O
up O
of O
one O
catalytic O
subunit O
pol O
##g O
##1 O
and O
two O
accessory O
subunit O
##s O
pol O
##g O
##2 O
ya O
##ku O
##bo O
##vs O
##kaya O
et O
al O
2006 O
pol O
##g O
##1 O
communicated O
by O
wolfgang O
sp O
##er O
##l O
competing O
interests O
none O
declared O
k O
na O
##ess O
h O
br O
##uh O
##n O
r O
wi O
##bo O
##m O
i O
ne O
##nne O
##smo O
u O
von O
d O
##€ O
##obe O
##ln O
n O
les O
##ko O

department O
of O
laboratory O
medicine O
division O
of O
metabolic O
diseases O
ka O
##rol O
##ins O
##ka O
institute O
##t O
cm O
##ms O
c2 O
71 O
ka O
##rol O
##ins O
##ka O
university O
hospital O
hu O
##dding O
##e O
141 O
86 O
stockholm O
sweden O
e O
mail O
nicole O
les O
##ko O
ka O
##rol O
##ins O
##ka O
se O
k O
na O
##ess O
a O
ne O
##met O
##h O
department O
of O
clinical O
sciences O
pediatric O
division O
ka O
##rol O
##ins O
##ka O
institute O
##t O
141 O
86 O
stockholm O
sweden O
m O
bar O
##bar O
##o O
department O
of O
molecular O
medicine O
and O
surgery O
ka O
##rol O
##ins O
##ka O
institute O
##t O
stockholm O
sweden O
n O
g O
lars O
##son O
max O
planck O
institute O
for O
biology O
of O
age O
##ing O
g O
##le O
##uel O
##er O
st O
##ras O
##se O
50 O
##a O
50 O
##9 O
##31 O
cologne O
germany O

consists O
of O
an O
ex O
##on O
##uc O
##lea O
##se O
domain O
at O
its O
n O
terminal O
and O
a O
polymer O
##ase O
domain O
at O
its O
c O
terminal O
which O
are O
separated O
by O
a O
link O
##er O
region O
the O
crystalline O
structure O
of O
pol O
##g O
has O
revealed O
that O
this O
link O
##er O
region O
is O
where O
interaction O
between O
pol O
##g O
##1 O
and O
pol O
##g O
##2 O
occurs O
leading O
to O
increased O
process O
##ivity O
and O
substrate O
binding O
lee O
et O
al O
2009 O

mutations O
in O
the O
gene O
for O
pol O
##g O
##1 O
are O
major O
causes O
of O
human O
mitochondrial O
disease O
the O
first O
pol O
##g O
##1 O
mutation O
associated O
with O
disease O
was O
described O
in O
2001 O
van O
goethe O
##m O
et O
al O
2001 O
since O
then O
approximately O
150 O
pathogen O
##ic O
mutations O
have O
been O
identified O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
and O
linked O
to O
a O
wide O
spectrum O
of O
clinical O
ph O
##eno O
##type O
##s O
ranging O
from O
severe O
progressive O
ne O
##uro O
##de O
##gen O
##erative O
disorders O
in O
early O
childhood O
to O
mild O
##er O
syndrome O
##s O
with O
onset O
in O
adult O
age O
some O
major O
groups O
of O
different O
clinical O
ph O
##eno O
##type O
##s O
are O
seen O
1 O
my O
##o O
ce O
##re O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
disorders O
2 O
al O
##pers O
syndrome O

68 O
jim O
##d O
reports O
3 O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
disorders O
4 O
my O
##oc O
##lon O
##us O
ep O
##ile O
##psy O
my O
##opa O
##thy O
sensory O
ata O
##xia O
spectrum O
disorders O
5 O
auto O
##som O
##al O
dominant O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ad O
##pe O
##o O
and O
6 O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ar O
##pe O
##o O
wong O
et O
al O
2008 O
however O
many O
additional O
symptoms O
have O
been O
reported O
and O
cat O
##ego O
##rization O
of O
patients O
into O
specific O
clinical O
groups O
is O
not O
always O
straightforward O

here O
we O
report O
the O
finding O
of O
a O
complete O
del B-GENE_VARIANT
##eti I-GENE_VARIANT
##on I-GENE_VARIANT
of O
one O
pol B-GENE
##g I-GENE
##1 I-GENE
all O
##ele O
in O
a O
patient B-PATIENT
with O
al B-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
and O
acute B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
induced B-HPO_TERM
by I-HPO_TERM
treatment I-HPO_TERM
with O
vp O
##a O
the O
del B-GENE_VARIANT
##eti I-GENE_VARIANT
##on I-GENE_VARIANT
comprises I-GENE_VARIANT
the I-GENE_VARIANT
entire I-GENE_VARIANT
pol I-GENE_VARIANT
##g I-GENE_VARIANT
##1 I-GENE_VARIANT
gene I-GENE_VARIANT
and O
the O
adjacent O
fan O
##ci O
gene O
om O
##im O
61 O
##13 O
##60 O
on O
the O
retained O
pol O
##g O
##1 O
all O
##ele O
we O
found O
the O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
previously O
reported O
to O
be O
associated O
with O
al O
##pers O
syndrome O
patient O
and O
methods O
patient B-PATIENT
the O
patient O
a O
boy O
was O
the O
second O
child O
of O
healthy O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
of O
swedish O
origin O
an O
older O
brother O
is O
healthy O
pregnancy O
was O
uneven O
##tf O
##ul O
and O
the O
patient O
was O
born O
at O
term O

the O
boy O
showed O
normal O
mental O
development O
however O
his O
motor B-HPO_TERM
development I-HPO_TERM
was I-HPO_TERM
delayed I-HPO_TERM
he O
was O
able O
to O
roll O
over O
from O
9 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
and O
started O
to O
crawl O
on O
his O
knees O
at O
18 O
months O
of O
age O
by O
the O
age O
of O
2 O
years O
he O
was O
able O
to O
walk O
independently O
but O
his O
ga B-HPO_TERM
##it I-HPO_TERM
was I-HPO_TERM
wide I-HPO_TERM
based I-HPO_TERM
and O
un B-HPO_TERM
##stead I-HPO_TERM
##y I-HPO_TERM
with O
frequent B-HPO_TERM
falls I-HPO_TERM
ep B-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
seizures I-HPO_TERM
mainly O
absence B-HPO_TERM
##s I-HPO_TERM
were O
observed O
from O
around O
18 O
months O
of O
age O
electro O
##ence O
##pha O
##log O
##raphy O
demonstrated O
both O
generalized B-HPO_TERM
spike I-HPO_TERM
and I-HPO_TERM
slow I-HPO_TERM
waves I-HPO_TERM
and O
focal B-HPO_TERM
sharp I-HPO_TERM
waves I-HPO_TERM
in I-HPO_TERM
frontal I-HPO_TERM

regions O
a O
computed O
tom O
##ography O
of O
the O
brain O
at O
27 O
months O
of O
age O
showed O
normal O
findings O
routine O
blood O
parameters O
including O
liver O
function O
values O
were O
normal O
treatment O
with O
val O
##pro O
##ic O
acid O
vp O
##a O
was O
started O
from O
28 O
months O
of O
age O
with O
the O
patient O
responding O
well O
to O
treatment O
there O
were O
no O
further O
seizures O
blood O
concentration O
of O
vp O
##a O
was O
700 O
870 O
mm O
##ol O
l O

three O
months O
later O
the O
boy O
was O
hospitalized O
because O
of O
generalized B-HPO_TERM
fatigue I-HPO_TERM
and O
vomiting B-HPO_TERM
laboratory O
investigations O
revealed O
liver O
involvement O
with O
increased B-HPO_TERM
serum I-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##ses I-HPO_TERM
g O
g O
##lu O
##tam O
##yl O
trans O
##pe O
##pt O
##ida O
##se O
pro O
##th O
##rom O
##bin O
in O
##r O
international O
normal O
##ized O
ratio O
and O
ammonia B-HPO_TERM
he O
had B-HPO_TERM
elevated I-HPO_TERM
blood I-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
2 O
8 O
3 O
9 O
mm O
##ol O
l O
normal O
2 O
3 O
although O
vp O
##a O
was O
stopped O
within O
a O
few O
days O
from O
admission O
his O
liver O
disease O
progressed O
and O
he O
developed O
an O
acute B-HPO_TERM
fu I-HPO_TERM
##lm I-HPO_TERM
##ina I-HPO_TERM
##nt I-HPO_TERM
and I-HPO_TERM
non I-HPO_TERM
##cho I-HPO_TERM
##les I-HPO_TERM
##tat I-HPO_TERM
##ic I-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
with O
severe B-HPO_TERM
coa I-HPO_TERM
##gul I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
liver O
bio O
##psy O
could O
not O
be O
performed O
due O
to O
the O
tendency O
of O
bleeding O

magnetic O
resonance O
imaging O
mri O
of O
the O
brain O
showed O
abnormalities B-HPO_TERM
in I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and I-HPO_TERM
basal I-HPO_TERM
gang I-HPO_TERM
##lia I-HPO_TERM
signs O
of O
at O
##rop O
##hy O
were O
seen O
fig O
1 O
the O
clinical O
picture O
was O
consistent O
with B-HPO_TERM
al I-HPO_TERM
##pers I-HPO_TERM
syndrome I-HPO_TERM
a O
muscle O
bio O
##psy O
was O
performed O
and O
dna O
analysis O
of O
the O
pol O
##g O
##1 O
gene O
was O
started O
the O
boy O
deteriorated O
further O
and O
died O
at O
the O
age O
of O
32 B-AGE_DEATH
months I-AGE_DEATH
due O
to O
he B-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
autopsy O
was O
not O
carried O
out O
mitochondrial O
atp O
production O
respiratory O
chain O
enzyme O
activities O
and O
morphological O
analysis O

a O
muscle O
specimen O
was O
obtained O
from O
ti O
##bial O
##is O
anterior O
at O
30 O
months O
of O
age O
mit O
##och O
##ond O
##ria O
were O
isolated O
from O
muscle O
and O
mitochondrial O
atp O
production O
rate O
and O
respiratory O
fig O
1 O
magnetic O
resonance O
imaging O
of O
the O
brain O
performed O
at O
32 O
months O
of O
age O
a O
axial O
t O
##2 O
weighted O
images O
show O
symmetrical O
bilateral O
high O
signaling O
abnormalities O
and O
ed B-HPO_TERM
##ema I-HPO_TERM
of I-HPO_TERM
tha I-HPO_TERM
##lam I-HPO_TERM
##us I-HPO_TERM
and I-HPO_TERM
cap I-HPO_TERM
##ut I-HPO_TERM
nucleus I-HPO_TERM
ca I-HPO_TERM
##uda I-HPO_TERM
##tus I-HPO_TERM
signal O
changes B-HPO_TERM
also I-HPO_TERM
present I-HPO_TERM
in I-HPO_TERM
g I-HPO_TERM
##lo I-HPO_TERM
##bus I-HPO_TERM
pal I-HPO_TERM
##lid I-HPO_TERM
##us I-HPO_TERM

bilateral O
##ly O
seen O
in O
other O
slices O
of O
the O
examination O
signs B-HPO_TERM
of I-HPO_TERM
frontal I-HPO_TERM
and I-HPO_TERM
temporal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
ce B-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
also O
present O
not O
included O
in O
this O
image O
b O
diffusion O
images O
show O
increased O
diffusion O
in O
tha O
##lam O
##ic O
regions O
jim O
##d O
reports O
69 O
chain O
enzyme O
activities O
were O
determined O
as O
previously O
described O
wi O
##bo O
##m O
et O
al O
2002 O
in O
addition O
standard O
techniques O
were O
applied O
for O
routine O
and O
enzyme O
his O
##to O
##chemical O
stain O
##ings O
of O
cry O
##osta O
##t O
sections O
and O
for O
electron O
microscopy O
lars O
##son O
and O
old O
##for O
##s O
2001 O
sequence O
analysis O
of O
the O
pol O
##g O
##1 O
gene O
and O
break O
##point O

total O
dna O
was O
isolated O
from O
whole O
blood O
using O
qi O
##aa O
##mp O
dna O
mini O
kit O
qi O
##age O
##n O
ex O
##ons O
2 O
to O
23 O
of O
pol O
##g O
##1 O
were O
amplified O
by O
pc O
##r O
using O
intro O
##nic O
prime O
##rs O
sequencing O
reactions O
were O
carried O
out O
on O
the O
pc O
##r O
products O
followed O
by O
sequencing O
on O
a O
313 O
##0 O
##x O
##l O
dna O
sequence O
##r O
applied O
bio O
##systems O
foster O
city O
ca O
for O
sequencing O
of O
the O
del O
##eti O
##on O
break O
##point O
a O
forward O
prime O
##r O
50 O
aa O
##gg O
##gc O
##t O
##ga O
##gat O
##gg O
##cat O
##ct O
##c O
30 O
was O
designed O
within O
the O
multiple O
##x O
liga O
##tion O
dependent O
probe O
amp O
##li O
##fication O
ml O
##pa O
probe O
c1 O
##5 O
##ig O
##s O
##7 O
and O
reverse O
50 O
ag O
##aga O
##ag O
##t O
##gt O
##gt O
##t O
##ga O
##cat O
##gc O
##c O
30 O
within O
the O
ml O
##pa O
probe O
c1 O
##5 O
##ig O
##s O
##6 O
as O
both O
probe O
##s O
were O
known O
to O
lie O
outside O
of O
the O
del O
##eti O
##on O
table O
1 O
the O
expand O
long O
template O
pc O
##r O
system O
roche O
mannheim O
germany O
was O
used O
to O
amp O
##li O
##fy O
the O
junction O
break O
##point O
using O
these O
prime O
##rs O
and O
successful O
amp O
##lic O
##ons O
were O
sequence O
##d O

multiple O
##x O
liga O
##tion O
dependent O
probe O
amp O
##li O
##fication O
analysis O

ml O
##pa O
analysis O
using O
kit O
p O
##01 O
##0 O
mr O
##c O
holland O
amsterdam O
the O
netherlands O
for O
detection O
of O
del O
##eti O
##ons O
or O
du O
##plication O
##s O
of O
each O
ex O
##on O
of O
the O
pol O
##g O
##1 O
gene O
was O
performed O
according O
to O
the O
manufacturer O
s O
protocol O
starting O
from O
100 O
ng O
dna O
the O
pc O
##r O
products O
were O
separated O
by O
cap O
##illa O
##ry O
electro O
##ph O
##ores O
##is O
on O
an O
ab O
##i O
313 O
##0 O
##x O
##l O
genetic O
analyze O
##r O
trace O
data O
was O
analyzed O
using O
the O
gene O
##ma O
##pper O
v O
##3 O
7 O
software O
and O
the O
integrated O
peak O
heights O
were O
exported O
to O
an O
excel O
spreads O
##hee O
##t O
microsoft O
for O
further O
calculations O
for O
each O
sample O
the O
peak O
heights O
were O
first O
normal O
##ized O
to O
the O
average O
peak O
height O
of O
the O
control O
probe O
##s O
followed O
by O
normal O
##ization O
to O
the O
average O
peak O
height O
of O
the O
control O
samples O
included O
in O
the O
run O
the O
analysis O
was O
considered O
acceptable O
if O
the O
ratio O
for O
the O
internal O
control O
was O
between O
0 O
8 O
and O
1 O
2 O
threshold O
values O
for O
del O
##eti O
##ons O
and O
du O
##plication O
##s O
were O
set O
at O
0 O
7 O
and O
1 O
3 O
respectively O

synthetic O
probe O
##s O
to O
narrow O
down O
the O
break O
##point O
regions O
were O
designed O
as O
previously O
described O
bar O
##bar O
##o O
et O
al O
2008 O
stern O
et O
al O
2004 O
different O
probe O
combinations O
together O
with O
the O
ek O
##1 O
re O
##age O
##nt O
kit O
mr O
##c O
holland O
were O
used O
for O
the O
ml O
##pa O
reactions O
quan O
##ti O
##fication O
analysis O
was O
performed O
as O
described O
above O
synthetic O
probe O
sequences O
together O
with O
their O
results O
are O
summarized O
in O
table O
1 O
results O

morphological O
studies O
of O
the O
muscle O
bio O
##psy O
showed O
a O
slightly O
increased B-HPO_TERM
amount I-HPO_TERM
of I-HPO_TERM
fat I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
muscle I-HPO_TERM
but O
no O
other O
abnormalities O
mitochondrial O
atp O
production O
rate O
and O
respiratory O
chain O
enzyme O
activities O
were O
normal O

sequencing O
of O
all O
coding O
ex O
##ons O
and O
ex O
##on O
intro O
##n O
boundaries O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
revealed O
that O
the O
patient O
was O
homo O
##zy O
##go O
##us O
for O
the O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
the O
father O
was O
shown O
to O
be O
a O
het O
##ero O
##zy O
##go O
##te O
carrier O
whilst O
the O
mother O
lacked O
the O
mutation O
completely O
interesting O
##ly O
the O
mother O
was O
homo O
##zy O
##go O
##us O
for O
an O
intro O
##nic O
change O
c O
207 O
##4 O
22 O
##t O
which O
the O
patient O
had O
not O
inherited O
this O
led O
us O
to O
believe O
that O
the O
patient O
had O
a O
del O
##eti O
##on O
in O
one O
of O
his O
pol O
##g O
##1 O
all O
##eles O
either O
a O
spontaneous O
del O
##eti O
##on O
or O
one O
inherited O
from O
his O
mother O

ml O
##pa O
analysis O
revealed O
that O
the O
entire O
pol B-GENE_VARIANT
##g I-GENE_VARIANT
##1 I-GENE_VARIANT
gene I-GENE_VARIANT
was I-GENE_VARIANT
deleted I-GENE_VARIANT
on I-GENE_VARIANT
one I-GENE_VARIANT
all I-GENE_VARIANT
##ele I-GENE_VARIANT
in O
both O
the O
patient O
and O
the O
mother O
by O
designing O
synthetic O
probe O
##s O
for O
ml O
##pa O
we O
could O
narrow O
down O
the O
break O
##point O
region O
and O
determine O
that O
the O
centro O
##meric O
and O
tel O
##ome O
##ric O
break O
##points O
lie O
between O
probe O
##s O
c1 O
##5 O
##ig O
##s O
##7 O
c1 O
##5 O
##ig O
##s O
##13 O
and O
probe O
##s O
c1 O
##5 O
##ig O
##s O
##11 O
c1 O
##5 O
##ig O
##s O
##6 O
respectively O
fig O
2 O
following O
this O
the O
break O
##point O
region O
was O
amplified O
by O
extra O
long O
pc O
##r O
and O
sequence O
##d O
establishing O
that O
the O
del O
##eti O
##on O
was O
almost O
118 O
kb O
in O
length O
the O
presence O
of O
a O
4 O
bp O
micro O
##hom O
##ology O
region O
at O
the O
break O
##point O
junction O
indicates O
that O
the O
del O
##eti O
##on O
was O
created O
by O
a O
non O
##hom O
##olo O
##go O
##us O
end O
joining O
mechanism O
in O
addition O
to O
the O
del O
##eti O
##on O
of O
pol O
##g O
##1 O
an O
adjacent O
gene O
fan O
##ci O
was O
also O
completely O
deleted O

discussion O

al O
##pers O
syndrome O
is O
a O
disease O
in O
the O
severe O
end O
of O
the O
pol O
##g O
disease O
spectrum O
clinical O
##ly O
characterized O
by O
intra O
##ctable O
ep O
##ile O
##psy O
psycho O
##moto O
##r O
regression O
and O
he O
##pa O
##top O
##athy O
with O
or O
without O
liver O
failure O
om O
##im O
203 O
##70 O
##0 O
additional O
symptoms O
such O
as O
ata O
##xia O
h O
##yp O
##oton O
##ia O
and O
co O
##rti O
##cal O
blindness O
are O
frequently O
seen O
mc O
##far O
##land O
et O
al O
2008 O
onset O
is O
usually O
in O
early O
childhood O
although O
later O
forms O
exist O
u O
##us O
##ima O
##a O
et O
al O
2008 O
skeletal O
muscle O
is O
not O
always O
affected O
and O
a O
muscle O
bio O
##psy O
often O
turns O
out O
to O
be O
normal O
in O
children O
with O
al O
##pers O
syndrome O
bi O
##ck O
##nese O
et O
al O
described O
vp O
##a O
induced O
liver O
toxicity O
in O
children O
with O
al O
##pers O
syndrome O
already O
in O
1992 O
since O
then O
several O
cases O
have O
been O
reported O
often O
with O
fatal O
outcome O
kay O
##ih O
##an O
et O
al O
2000 O
the O
mechanism O
of O
vp O
##a O
induced O
liver O
failure O
in O
pol O
##g O
disease O
is O
not O
clear O
however O
vp O
##a O
is O
known O
to O
affect O
the O
mitochondrial O
respiratory O
chain O
function O
among O
other O
ways O
by O
inhibition O
of O
mitochondrial O
fatty O
acid O
oxidation O
silva O
et O
al O
2008 O
its O
effect O
on O
pol O
##g O
and O
mt O
##dna O
replication O
has O
not O
been O
investigated O
this O
case O

table O
1 O
probe O
##s O
used O
for O
ml O
##pa O
analysis O
to O
narrow O
down O
the O
break O
##point O
a O
the O
50 O
half O
probe O
##s O
are O
preceded O
by O
the O
universal O
tag O
sequence O
g O
##gg O
##tt O
##cc O
##cta O
##ag O
##gg O
##tt O
##gga O
b O
the O
30 O
half O
probe O
##s O
are O
preceded O
by O
the O
universal O
tag O
sequence O
tc O
##tag O
##att O
##gga O
##tc O
##tt O
##gc O
##t O
##gg O
##ca O
##c O
and O
are O
ph O
##os O
##ph O
##ory O
##lated O
at O
the O
50 O
end O
c O
plus O
and O
minus O
signs O
indicate O
non O
deleted O
and O
deleted O
regions O
respectively O
jim O
##d O
reports O
71 O
fig O
2 O
fine O
mapping O
of O
the O
pol O
##g O
##1 O
locus O
del O
##eti O
##on O
using O
ml O
##pa O
a O
representation O
from O
the O
uc O
##sc O
database O
march O
2006 O
assembly O
of O
the O
pol O
##g O
##1 O
and O
fan O
##ci O
lo O
##ci O
on O
15 O
##q O
##26 O
1 O
probe O
##s O
used O
to O
narrow O
down O

the O
del O
##eti O
##on O
are O
represented O
by O
red O
vertical O
lines O
and O
the O
dark O
green O
horizontal O
line O
is O
showing O
the O
span O
of O
the O
deleted O
dna O
b O
del O
##eti O
##on O
junction O
alignment O
with O
the O
4 O
bp O
micro O
##hom O
##ology O
boxed O
further O
emphasizes O
the O
importance O
of O
considering O
the O
possibility O
of O
pol O
##g O
disease O
and O
liberal O
##ly O
performing O
pol O
##g O
##1 O
dna O
testing O
in O
pediatric O
seizure O
disorders O
of O
unknown O
et O
##iology O
especially O
if O
a O
psycho O
##moto O
##r O
regression O
is O
also O
seen O

the O
reported O
del O
##eti O
##on O
also O
comprised O
the O
adjacent O
fan O
##ci O
gene O
mutations O
in O
fan O
##ci O
cause O
fan O
##con O
##is O
an O
##emia O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
affecting O
all O
bone O
marrow O
elements O
and O
associated O
with O
cardiac O
renal O
and O
limb O
mal O
##form O
##ations O
our O
patient O
had O
no O
symptoms O
of O
fan O
##con O
##is O
an O
##emia O

the O
association O
between O
al O
##pers O
syndrome O
and O
pol O
##g O
##1 O
mutations O
is O
well O
established O
long O
##ley O
et O
al O
2005 O
the O
gen O
##otype O
can O
vary O
but O
most O
cases O
of O
al O
##pers O
syndrome O
carry O
either O
of O
the O
two O
link O
##er O
mutations O
a O
##46 O
##7 O
##t O
or O
w O
##7 O
##48 O
##s O
in O
compound O
het O
##ero O
##zy O
##go O
##us O
with O
another O
pol O
##g O
##1 O
mutation O
nguyen O
et O
al O
2005 O
recent O
crystal O
##lization O
of O
pol O
##g O
has O
shown O
that O
the O
w O
##7 O
##48 O
##s O
mutation O
is O
located O
in O
a O
g O
##lo O
##bular O
sub O
##dom O
##ain O
of O
the O
link O
##er O
region O
which O
contacts O
the O
prime O
##rte O
##mp O
##late O
dna O
complex O
to O
promote O
intrinsic O
process O
##ivity O
of O
pol O
##g O
lee O
et O
al O
2009 O
fa O
##lke O
##nberg O
and O
lars O
##son O
2009 O

in O
our O
patient O
co O
##hort O
we O
have O
diagnosed O
four O
children O
compound O
het O
##ero O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
they O
all O
had O
early O
onset O
of O
symptoms O
including O
intra O
##ctable O
ep O
##ile O
##psy O
and O
died O
before O
16 O
months O
of O
life O
in O
addition O
we O
have O
diagnosed O
three O
patients O
who O
are O
homo O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
the O
first O
patient O
had O
mild O
cognitive O
problems O
ata O
##xia O
and O
ny O
##sta O
##gm O
##us O
with O
the O
onset O
of O
ep O
##ile O
##psy O
at O
16 O
years O
of O
age O
vp O
##a O
treatment O
was O
started O
and O
within O
a O
few O
months O
she O
developed O
a O
rapidly O
progressing O
liver O
disease O
and O
died O
2 O
months O
later O
the O
second O
patient O
is O
a O
girl O
with O
mild O
mental O
re O
##tar O
##dation O
attention O
deficit O
motor O
difficulties O
and O
ny O
##sta O
##gm O
##us O
ep O
##ile O
##psy O
started O
at O
11 O
years O
of O

age O
and O
is O
successfully O
treated O
with O
lam O
##ot O
##ri O
##gin O
##e O
and O
top O
##ira O
##mate O
with O
no O
progress O
in O
her O
disease O
the O
younger O
brother O
of O
this O
girl O
has O
a O
slight O
developmental O
re O
##tar O
##dation O
but O
no O
other O
symptoms O
at O
his O
current O
age O
of O
3 O
years O
these O
observations O
are O
consistent O
with O
previous O
reports O
that O
patients O
homo O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
have O
a O
mild O
##er O
disease O
with O
onset O
in O
later O
childhood O
or O
even O
adult O
age O
u O
##us O
##ima O
##a O
et O
al O
2008 O
the O
patient B-PATIENT
we O
report O
here O
has O
one B-GENE_VARIANT
deleted I-GENE_VARIANT
pol I-GENE_VARIANT
##g I-GENE_VARIANT
##1 I-GENE_VARIANT
all I-GENE_VARIANT
##ele I-GENE_VARIANT
and O
the O
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
mutation O
on O
the O
retained O
pol B-GENE
##g I-GENE
##1 I-GENE
all O
##ele O
in O
contrast O
to O
previously O
described O
patients O
homo O
##zy O
##go O
##us O
for O
the O
w O
##7 O
##48 O
##s O
mutation O
the O
patient O
of O
this O
report O
had O
a O
relatively O
early O
onset O
of O
disease O
at O

novel O
polymer O
##ase O
gamma O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
mutation O
in O
the O
link O
##er O
domain O
associated O
with O
parkinson O
##ism O
rachel O
do O
##l O
##hun O
erin O
m O
pre O
##sant O
and O
peter O
he O
##der O
##a O
background O

mitochondrial O
dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
is O
a O
nuclear O
encoded O
protein O
critical O
for O
the O
synthesis O
replication O
and O
repair O
of O
mitochondrial O
dna O
mt O
##dna O
abnormal O
function O
of O
this O
sole O
mt O
##dna O
polymer O
##ase O
leads O
to O
defective O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
and O
atp O
production O
impaired O
integrity O
of O
mt O
##dna O
with O
its O
de O
##ple O
##tion O
or O
del O
##eti O
##on O
causes O
a O
broad O
spectrum O
of O
both O
non O
neurological O
and O
neurological O
ph O
##eno O
##type O
##s O
1 O
greater O
than O
one O
hundred O
pathogen O
##ic O
mutations O
in O
this O
enzyme O
have O
been O
found O
since O
it O
was O
first O
described O
2 O
these O
include O
but O
are O
not O
limited O
to O
parkinson O
##ism O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
cp O
##eo O
ce O
##re O
##bella O
##r O
ata O
##xia O
sensory O
poly O
##ne O
##uro O
##pathy O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
which O
is O
characterized O
by O
progressive O
en O
##ce O
##pha O
##lo O
##pathy O
with O
seizures O
and O
he O
##pati O
##c O
failure O
isolated O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
or O
non O
syn O
##dro O
##mic O
liver O
failure O
2 O
6 O
this O
wide O
variety O
of O
distinct O
and O
seemingly O
unrelated O
clinical O
problems O
with O
both O
auto O
##som O
##al O
dominant O
ad O
or O
recess O
##ive O
ar O

correspondence O
peter O
he O
##der O
##a O
vanderbilt O
ed O
##u O
department O
of O
ne O
##uro O
##logy O
vanderbilt O
university O
46 O
##5 O
21st O
avenue O
south O
61 O
##40 O
mr O
##b O
iii O
nashville O
tn O
usa O
inheritance O
presents O
a O
significant O
challenge O
to O
clinic O
##ians O
and O
a O
high O
degree O
of O
clinical O
suspicion O
is O
typically O
crucial O
for O
the O
recognition O
of O
the O
underlying O
genetic O
mechanism O
here O
we O
report O
a O
novel O
mutation O
in O
pol O
##g O
##1 O
located O
in O
the O
link O
##er O
domain O
of O
this O
gene O
in O
a O
patient O
with O
parkinson O
##ism O
and O
cp O
##eo O
case O
presentation O

presented O
patient B-PATIENT
is O
a O
79 B-AGE_FOLLOWUP
year O
old O
caucasian O
who O
developed O
first O
ne O
##uro O
##logic O
problems O
in O
his O
thirties B-PATIENT
with O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
double B-HPO_TERM
vision I-HPO_TERM
the O
op O
##ht O
##hal O
##mo O
##logic O
examination O
showed O
a O
progressive B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
he O
required O
several O
correct O
##ive O
eye O
##lid O
surge O
##ries O
to O
mit O
##igate O
his O
pt B-HPO_TERM
##osis I-HPO_TERM
shortly O
thereafter O
he O
developed O
a O
shuffling B-HPO_TERM
ga I-HPO_TERM
##it I-HPO_TERM
and O
overall O
slow B-HPO_TERM
##ness I-HPO_TERM
of I-HPO_TERM
movements I-HPO_TERM
he O
experienced O
a O
gradual O
progression B-HPO_TERM
of I-HPO_TERM
his I-HPO_TERM
rigid I-HPO_TERM
##ity I-HPO_TERM
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
without O
any O
significant O
as O
##ym O
##metry O
h B-HPO_TERM
##yp I-HPO_TERM
##op I-HPO_TERM
##hon I-HPO_TERM
##ia I-HPO_TERM
and O
within O
10 O
15 O
years O
he O
also O
developed O
camp B-HPO_TERM
##to I-HPO_TERM
##cor I-HPO_TERM
##mia I-HPO_TERM
with O
subsequent O
post B-HPO_TERM
##ural I-HPO_TERM
instability I-HPO_TERM
additional O
file O
1 O

parkinson B-HPO_TERM
##ism I-HPO_TERM
was O
partially O
responsive O
to O
do O
##pa O
##mine O
##rg O
##ic O
replacement O
with O
car O
##bid O
##opa O
lev O
##od O
##opa O
with O
the O
highest O
used O
dose O
of O
125 O
##0 O
mg O
per O
day O
later O
ama O
##nta O
##dine O
at O
the O
dose O
of O
300 O
mg O
day O
was O
added O
for O
his O
ga O
##it O
difficulties O
2013 O
do O
##l O
##hun O
et O
al O
license O
##e O
bio O
##med O
central O
ltd O
this O
is O
an O
open O
access O
article O
distributed O
under O
the O
terms O
of O
the O
creative O
commons O
at O
##tri O
##bution O
license O
http O
creative O
##com O
##mons O
org O
licenses O
by O
2 O
0 O
which O
permits O
unrest O
##ricted O
use O
distribution O
and O
reproduction O
in O
any O
medium O
provided O
the O
original O
work O
is O
properly O
cited O

with O
reported O
improvement O
both O
medications O
were O
later O
reduced O
because O
of O
hall O
##uc O
##inations O
dementia B-HPO_TERM
treated O
with O
me O
##man O
##tine O
and O
done O
##pe O
##zi O
##l O
was O
diagnosed O
at O
the O
age O
of O
75 B-AGE_FOLLOWUP
years O
family O
history O
was O
positive O
for O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
s O
disease O
diagnosed O
in O
his O
father O
and O
brother O
we O
could O
not O
personally O
examine O
his O
brother O
but O
available O
history O
indicated O
that O
he O
was O
diagnosed O
with O
parkinson O
s O
disease O
and O
reported O
a O
good O
response O
to O
600 O
mg O
of O
lev O
##od O
##opa O
per O
day O

we O
performed O
muscle O
bio O
##psy O
because O
of O
suspicion O
for O
a O
mitochondrial O
disorder O
at O
the O
age O
of O
70 O
years O
muscle O
bio O
##psy O
obtained O
from O
the O
vast O
##us O
lateral O
##is O
muscle O
revealed O
non O
##sp O
##ec O
##ific O
changes O
with O
some O
irregularities O
of O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
stain O
##ing O
but O
ragged O
red O
fibers O
were O
not O
seen O
these O
changes O
alone O
were O
not O
sufficient O
for O
the O
definite O
diagnosis O
of O
a O
mitochondrial O
my O
##opa O
##thy O
repeat O
bio O
##psy O
was O
considered O
with O
sampling O
of O
additional O
muscles O
but O
the O
patient O
declined O
brain O
mri O
showed O
only O
mild O
scattered B-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
abnormalities I-HPO_TERM

sequencing O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
was O
done O
by O
sang O
##er O
sequencing O
dna O
extraction O
from O
blood O
was O
carried O
out O
using O
standard O
procedures O
all O
ex O
##ons O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
were O
amplified O
by O
pc O
##r O
reaction O
with O
previously O
published O
intro O
##n O
based O
prime O
##rs O
7 O
bid O
##ire O
##ction O
##al O
sang O
##er O
sequencing O
was O
performed O
for O
each O
amp O
##lic O
##on O
and O
detected O
single O
nu O
##cle O
##otide O
poly O
##morphism O
##s O
s O
##np O
were O
compared O
with O
available O
public O
domain O
databases O
we O
identified O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
p B-GENE_VARIANT
k I-GENE_VARIANT
##51 I-GENE_VARIANT
##2 I-GENE_VARIANT
##m I-GENE_VARIANT
mutation O
c B-GENE_VARIANT
153 I-GENE_VARIANT
##5 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
figure O
1 O
in O
si O
##lic O
##o O
analysis O
of O
this O
single O
nu O
##cle O
##otide O
poly O
##morphism O

using O
poly O
##ph O
##en O
2 O
software O
http O
genetics O
b O
##w O
##h O
harvard O
ed O
##u O
pp O
##h O
##2 O
predicted O
that O
this O
change O
is O
possibly O
damaging O
with O
a O
score O
of O
0 O
90 O
##6 O
sensitivity O
0 O
82 O
and O
specific O
##ity O
0 O
94 O
this O
is O
a O
highly O
conserved O
position O
in O
the O
link O
##er O
region O
of O
the O
pol O
##g O
##1 O
protein O
figure O
2 O
and O
sequencing O
of O
100 O
normal O
ethnic O
##ally O
matched O
control O
individuals O
did O
not O
identify O
this O
sequence O
changes O
further O
supporting O
its O
role O
as O
a O
disease O
causing O
mutation O

mutations O
in O
the O
aden O
##osi O
##ne O
nu O
##cle O
##otide O
trans O
##lo O
##cat O
##or O
1 O
ant O
##1 O
and O
twinkle O
c1 O
##0 O
##orf O
##2 O
genes O
have O
also O
been O
associated O
with O
cp O
##eo O
and O
additional O
ne O
##uro O
##logic O
problems O
including O
parkinson O
##ism O
8 O
9 O
we O
also O
sequence O
##d O
all O
coding O
ex O
##ons O
of O
these O
genes O
using O
the O
same O
approach O
as O
for O
pol O
##g O
##1 O
analysis O
but O
no O
put O
##ative O
mutations O
were O
identified O
conclusions O

european O
journal O
of O
ne O
##uro O
##logy O
2014 O
21 O
124 O
##2 O
124 O
##6 O
doi O
10 O
111 O
##1 O
en O
##e O
123 O
##64 O
short O
communication O
rec O
##urrent O
and O
fatal O
akin O
##etic O
crisis O
in O
genetic O
mitochondrial O
parkinson O
##isms O
l O
bon O
##ann O
##ia O
b O
m O
ono O
##fr O
##ja O
b O
e O
m O
vale O
##nte O
##c O
l O
man O
##zo O
##lid O
e O
m O
v O
de O
angel O
##isa O
m O
cap O
##ass O
##oa O
and O
a O
thomas O
##a O
b O

an O
##eur O
##ology O
clinic O
os O
##ped O
##ale O
clinic O
##iz O
##za O
##to O
chi O
##eti O
b O
##de O
##par O
##tment O
of O
neuroscience O
and O
imaging O
aging O
research O
center O
university O
g O
d O
ann O
##un O
##zio O
of O
chi O
##eti O
pe O
##sca O
##ra O
chi O
##eti O
cc O
##asa O
sol O
##lie O
##vo O
della O
hospital O
men O
##del O
institute O
rome O
ds O
##ection O
of O
ep O
##ide O
##mi O
##ology O
department O
of O
medicine O
and O
aging O
university O
g O
d O
ann O
##un O
##zio O
of O
chi O
##eti O
pe O
##sca O
##ra O
chi O
##eti O
and O
er O
##eg O
##ional O
healthcare O
agency O
of O
ab O
##ru O
##zzo O
ab O
##ru O
##zzo O
italy O
key O
##words O
akin O
##etic O
crisis O
genetic O
parkinson O
##ism O
mali O
##gnant O
syndrome O
mit O
##och O
##ond O
##ria O
received O
30 O
august O
2013 O
accepted O
17 O
december O
2013 O

background O
and O
purpose O
akin O
##etic O
crisis O
ac O
is O
the O
most O
severe O
and O
possibly O
lethal O
com O
##plication O
of O
parkinson O
##ism O
it O
occurs O
with O
an O
incidence O
of O
3 O
parkinson O
s O
disease O
patients O
per O
year O
but O
it O
is O
not O
known O
whether O
genetically O
determined O
parkinson O
##ism O
is O
more O
or O
less O
susceptible O
to O
this O
com O
##plication O

methods O
in O
a O
co O
##hort O
of O
75 O
##6 O
parkinson O
##ian O
patients O
the O
incidence O
and O
outcome O
of O
ac O
was O
prospective O
##ly O
assessed O
a O
total O
of O
142 O
of O
the O
parkinson O
##ian O
patients O
were O
tested O
for O
genetic O
mutations O
because O
of O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
and O
20 O
patients O
resulted O
positive O
in O
four O
the O
mutation O
de O
##ﬁ O
##ni O
##tel O
##y O
involved O
mitochondrial O
functions O
pol O
##g O
##1 O
pink O
##1 O
two O
presented O
with O
l O
##rr O
##k O
##2 O
mutation O
nine O
presented O
with O
gb O
##a O
mutation O
and O
ﬁ O
##ve O
presented O
with O
park O
4 O
mutations O

results O
akin O
##etic O
crisis O
occurred O
in O
30 O
patients O
for O
an O
incidence O
of O
2 O
8 O
persons O
year O
and O
was O
lethal O
in O
seven O
23 O
not O
di O
##ssi O
##mi O
##lar O
##ly O
from O
known O
incidence O
##s O
of O
this O
com O
##plication O
yet O
six O
of O
30 O
patients O
were O
carriers O
of O
genetic O
mutations O
one O
gb O
##a O
one O
l O
##rr O
##k O
##2 O
one O
pol O
##g O
##1 O
and O
three O
pink O
##1 O
in O
pol O
##g O
##1 O
and O
pink O
##1 O
carriers O
the O
syndrome O
was O
rec O
##urrent O
and O
was O
fatal O
in O
three O
incidence O
of O
ac O
was O
3 O
0 O
in O
familiar O
parkinson O
##ism O
21 O
2 O
in O
genetic O
parkinson O
##isms O
conclusions O
our O
preliminary O
ﬁ O
##nding O
##s O
suggest O
that O
the O
incidence O
of O
ac O
is O
remarkably O
increased O
in O
carriers O
of O
these O
genetic O
mutations O
introduction O

akin O
##etic O
crisis O
ac O
also O
termed O
mali O
##gnant O
syndrome O
or O
parkinson O
hyper O
##pire O
##xia O
syndrome O
ne O
##uro O
##le O
##ptic O
like O
mali O
##gnant O
syndrome O
or O
acute O
akin O
##es O
##ia O
is O
a O
com O
##plication O
that O
appears O
in O
parkinson O
##ism O
because O
of O
treatment O
manipulation O
##s O
or O
withdrawal O
infectious O
diseases O
trauma O
or O
gas O
##tro O
##int O
##estinal O
tract O
diseases O
1 O
ac O
is O
the O
most O
severe O
com O
##plication O
of O
pd O
occurring O
with O
an O
annual O
incidence O
of O
three O
cases O
per O
1000 O
parkinson O
##ian O
patients O
and O
consists O
of O
acute O
motor O
sy O
##mpt O
##om O
worse O
##ning O
characterized O
by O
an O
akin O
##etic O
state O
with O
d O
##ys O
##pha O
##gia O
hyper O
##ther O
##mia O
inc O
##rem O
##ent O
of O
serum O
cp O
##k O
and O
my O
##og O
##lo O
##bin O
d O
##ys O
##au O
##ton O
##omi O
##a O
and O
transient O
un O
##res O
##pon O
##sive O
##ness O
to O
current O
anti O
##park O
##ins O
##onia O
##n O
treatment O
or O
to O
an O
inc O
##rem O
##ent O
of O
do O
##pa O
##mine O
##rg O
##ic O
drug O
doses O
1 O
its O
symptoms O
are O
identical O
to O
symptoms O
of O
ne O
##uro O
##le O
##ptic O
mali O
##g O

correspondence O
a O
thomas O
department O
of O
neuroscience O
and O
imaging O
university O
g O
d O
ann O
##un O
##zio O
of O
chi O
##eti O
pe O
##sca O
##ra O
via O
dei O
vest O
##ini O
66 O
##100 O
chi O
##eti O
italy O
tel O
390 O
##8 O
##7 O
##13 O
##58 O
##52 O
##5 O
fa O
##x O
390 O
##8 O
##7 O
##15 O
##6 O
##20 O
##19 O
e O
mail O
at O
##hom O
##as O
un O
##ich O
it O
nan O
##t O
syndrome O
2 O
3 O
and O
it O
was O
h O
##yp O
##oth O
##es O
##ized O
that O
both O
represent O
id O
##ios O
##yn O
##cratic O
severe O
complications O
induced O
by O
het O
##ero O
##gen O
##eous O
causes O
4 O

co O
##hort O
or O
multi O
##cent O
##er O
studies O
highlighted O
the O
relevance O
of O
this O
com O
##plication O
of O
parkinson O
##ism O
1 O
5 O
an O
operating O
de O
##ﬁ O
##ni O
##tion O
of O
ac O
was O
also O
provided O
in O
order O
to O
facilitate O
diagnosis O
in O
patients O
already O
followed O
for O
their O
pd O
sudden O
worse O
##ning O
of O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
up O
##dr O
##s O
motor O
score O
by O
20 O
or O
more O
points O
accompanied O
by O
three O
or O
more O
days O
of O
un O
##res O
##pon O
##sive O
##ness O
to O
the O
same O
drug O
regime O
##n O
that O
adequately O
corrected O
symptoms O
before O
the O
appearance O
of O
akin O
##es O
##ia O
or O
of O
un O
##res O
##pon O
##sive O
##ness O
to O
rescue O
drugs O
i O
e O
in O
##ject O
##able O
ap O
##omo O
##rp O
##hine O
ama O
##nta O
##dine O
lev O
##od O
##opa O
este O
##rs O
1 O

yet O
in O
the O
last O
two O
decades O
several O
genetic O
mutations O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
patients O
by O
clinical O
pd O
leading O
to O
a O
red O
##e O
##ﬁ O
##ni O
##tion O
of O
pd O
as O
a O
syndrome O
6 O
including O
et O
##iol O
##og O
##ies O
and O
some O
common O
clinical O
features O
no O
evidence O
was O
presented O
however O
on O
of O
ac O
prevalence O
in O
genetic O
rather O
than O
in O
id O
##io O
##pathic O
124 O
##2 O
2014 O
the O
author O
s O
european O
journal O
of O
ne O
##uro O
##logy O
2014 O
ea O
##n O
akin O
##etic O
crisis O
in O
genetic O
mitochondrial O
parkinson O
##ism O
124 O
##3 O
parkinson O
##isms O
yet O
such O
information O
might O
be O
of O
relevance O
for O
an O
understanding O
of O
the O
mechanism O
of O
ac O

the O
occurrence O
of O
ac O
in O
six O
patients O
by O
genetic O
parkinson O
##ism O
due O
to O
mutations O
possibly O
or O
de O
##ﬁ O
##ni O
##tel O
##y O
involving O
mitochondrial O
function O
are O
described O
methods O
the O
study O
is O
the O
pro O
##long O
##ation O
of O
a O
previous O
study O
describing O
the O
incidence O
of O
ac O
in O
a O
co O
##hort O
of O
75 O
##6 O
pd O
patients O
admitting O
only O
patients O
who O
were O
put O
##ative O
##ly O
diagnosed O
as O
by O
pd O
according O
to O
uk O
brain O
bank O
criteria O
7 O
with O
the O
exception O
of O
the O
patient O
by O
pol O
##g O
##1 O
mutation O
who O
were O
regularly O
followed O
in O
our O
clinic O
who O
were O
responsive O
to O
l O
do O
##pa O

8 O
and O
who O
received O
evaluation O
assessments O
every O
4 O
5 O
months O
including O
treatment O
ti O
##tra O
##tion O
ho O
##eh O
##n O
and O
ya O
##hr O
h O
y O
staging O
ud O
##pr O
##s O
total O
score O
mini O
mental O
state O
examination O
the O
present O
study O
is O
an O
incident O
##al O
prospective O
co O
##hort O
study O
where O
incidence O
of O
ac O
and O
of O
genetic O
mutations O
were O
eventually O
matched O
the O
study O
was O
approved O
by O
our O
local O
ethical O
committee O
com O
##ita O
##to O
di O
et O
##ica O
delle O
province O
di O
chi O
##eti O
##pes O
##car O
##a O

in O
order O
to O
reduce O
at O
##tri O
##tion O
due O
to O
drop O
outs O
only O
patients O
who O
could O
be O
followed O
for O
at O
last O
10 O
years O
were O
considered O
for O
the O
study O
during O
the O
2005 O
2013 O
time O
period O
620 O
patients O
were O
occasionally O
addressed O
to O
our O
clinic O
but O
were O
not O
followed O
regularly O
during O
follow O
up O
255 O
of O
the O
75 O
##6 O
patients O
died O
and O
86 O
patients O
were O
lost O
after O
the O
10th O
year O
patient O
year O
p O
##y O
incidence O
calculations O
are O
added O
in O
the O
present O
study O

of O
the O
75 O
##6 O
co O
##hort O
patients O
142 O
presented O
with O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
76 O
with O
a O
ﬁ O
##rst O
degree O
relative O
involved O
genetic O
testing O
was O
performed O
in O
all O
the O
142 O
fa O
##mi O
##lia O
##l O
parkinson O
##isms O
and O
in O
two O
juvenile O
patients O
with O
no O
known O
fa O
##mi O
##lia O
##l O
transmission O
yet O
both O
were O
tested O
negative O

genetic O
testing O
was O
targeted O
according O
to O
the O
possible O
mode O
of O
inheritance O
age O
at O
onset O
and O
clinical O
presentation O
of O
patients O
on O
the O
following O
possible O
gene O
mutations O
park O
8 O
l O
##rr O
##k O
##2 O
ex O
##ons O
29 O
31 O
35 O
41 O
g O
##20 O
##19 O
##s O
and O
i O
##20 O
##20 O
##t O
and O
48 O
gb O
##a O
p O
l O
##44 O
##4 O
##p O
c O
144 O
##8 O
t O
c O
p O
n O
##37 O
##0s O
c O
1926 O
a O
g O
e O
##32 O
##6 O
##k O
c O
109 O
##3 O
g O
a O
park O
4 O
s O
##nca O
p O
a O
##53 O
##t O
s O
##nc O
##b O
p O
l O
##44 O
##4 O
##p O
path O
##oge O

net O
##ic O
mutations O
were O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
20 O
patients O
from O
19 O
families O
including O
pol B-GENE
##g I-GENE
##1 I-GENE
c B-GENE_VARIANT
128 I-GENE_VARIANT
##8 I-GENE_VARIANT
##a I-GENE_VARIANT
t I-GENE_VARIANT
trans O
##version O
c B-GENE_VARIANT
275 I-GENE_VARIANT
##2 I-GENE_VARIANT
##t I-GENE_VARIANT
c I-GENE_VARIANT
transition O
mutation O
n O
1 O
s O
##nca O
du O
##plication O
n O
2 O
s O
##nca O
trip O
##lica O
##tion O
n O
3 O
pink O
##1 O
p O
g O
##40 O
##9 O
##v O
het O
##ero O
##zy O
##go O
##us O
mutations O
n O
3 O
l O
##rr O
##k O
##2 O
p O
g O
##20 O
##19 O
##s O
mutation O
n O
2 O
gb O
##a O
p O
l O
##48 O
##3 O
##p O
p O
n O
##40 O
##9 O
##s O
and O
p O
e O
##36 O
##5 O
##k O
het O
##ero O
##zy O
##go O
##us O
mutations O
respectively O

n O
3 O
n O
4 O
and O
n O
2 O
genetic O
diagnosis O
was O
obtained O
5 O
2 O
years O
after O
admission O
to O
the O
ac O
co O
##hort O
using O
standardized O
protocols O
9 O
14 O
the O
patient B-PATIENT
with O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
is O
included O
in O
the O
study O
despite O
the O
ambiguity O
of O
class O
##i O
##ﬁ O
##cation O
because O
of O
the O
potential O
sign O
##i O
##ﬁ O
##can O
##ce O
for O
the O
present O
report O
he O
had O
been O
described O
in O
a O
previous O
paper O
9 O
and O
had O
been O
followed O
for O
10 O
years O
for O
progressive B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁ I-HPO_TERM
##ber I-HPO_TERM
my B-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
9 O
l O
do I-HPO_TERM
##pa I-HPO_TERM
responsive I-HPO_TERM
parkinson I-HPO_TERM
##ism I-HPO_TERM
appeared O
15 O
years O
before O
death O
the O
genetic O
diagnosis O
was O
provided O
5 O
years O
before O
death O
due O
to O
ac O

post O
hoc O
analysis O
evaluated O
whether O
ph O
##eno O
##typic O
variables O
up O
##dr O
##s O
at O
admission O
h O
y O
stage O
at O
admission O
treatments O
or O
presence O
of O
genetic O
mutations O
in O
##ﬂ O
##uen O
##ced O
the O
occurrence O
of O
ac O
and O
whether O
the O
same O
variables O
in O
##ﬂ O
##uen O
##ced O
the O
outcome O
of O
ac O
i O
e O
fatal O
##ity O
or O
recovery O
ac O
occurrence O

as O
reported O
in O
the O
previous O
study O
only O
ac O
duration O
in O
days O
could O
predict O
the O
outcome O
the O
longer O
the O
duration O
of O
ac O
the O
higher O
the O
probability O
of O
fatal O
outcome O
other O
variables O
such O
as O
up O
##dr O
##s O
scores O
como O
##rb O
##idi O
##ties O
at O
admission O
and O
during O
ac O
progression O
of O
disease O
disease O
stage O
were O
equally O
distributed O
in O
patients O
with O
and O
without O
ac O
table O
1 O
disease O
duration O
was O
also O
similar O
probably O
because O
of O
the O
method O
used O
to O
reduce O
at O
##tri O
##tion O
bias O
##es O

table O
2 O
shows O
that O
ac O
was O
observed O
in O
30 O
of O
75 O
##6 O
co O
##hort O
patients O
after O
a O
mean O
of O
14 O
3 O
2 O
7 O
years O
of O
follow O
up O
for O
a O
total O
of O
10 O
82 O
##8 O
p O
##ys O
overall O
incidence O
2 O
8 O
9 O
1000 O
p O
##ys O
of O
the O
30 O
ac O
cases O
24 O
occurred O
amongst O
the O
61 O
##4 O
patients O
with O
non O
fa O
##mi O
##lia O
##l O
pd O
2 O
7 O
9 O
1000 O
p O
##ys O
and O
six O
in O
the O
142 O
patients O
with O
fa O
##mi O
##lia O
##l O
pd O
3 O
0 O
9 O
1000 O
p O
##ys O
the O
latter O
six O
cases O
were O
all O
diagnosed O
amongst O
the O
20 O
patients O
with O
a O
genetic O
mutation O
21 O
2 O
9 O
1000 O
p O
##ys O
four O
were O
carriers O
of O
genetic O
mutations O
involving O
the O
mitochondrial O
functions O
one O
pol O
##g O
##1 O
three O
pink O
##1 O
one O
had O
l O
##rr O
##k O
##2 O
mutation O
and O
one O
was O
a O
carrier O
of O
gb O
##a O
mutation O
the O
incidence O
of O
ac O
in O
non O
genetically O
determined O
pd O
was O
24 O
out O
of O
73 O
##6 O
patients O
2 O
3 O
9 O
1000 O
p O
##ys O

fatalities O
due O
to O
ac O
occurred O
in O
seven O
of O
the O
30 O
patients O
23 O
in O
three O
of O
the O
seven O
patients O
no O
genetic O
inheritance O
was O
in O
evidence O
four O
of O
the O
seven O
were O
by O
pol O
##g O
##1 O
pink O
##1 O
two O
patients O
and O
l O
##rr O
##k O
##2 O
mutations O
one O
patient B-PATIENT
by O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
had O
three O
previous O
episodes O
of B-HPO_TERM
ac I-HPO_TERM
before O
the O
fatal O
last O
one O
all O
the O
patients O
by O
pink O
##1 O
had O
two O
or O
three O
episodes O
of O
ac O
two O
died O
in O
the O
last O
crisis O
2014 O
the O
author O
s O
european O
journal O
of O
ne O
##uro O
##logy O
2014 O
ea O
##n O
table O
1 O
demographic O
and O
clinical O
data O
in O
pd O
patients O
with O
and O
without O
ac O
h O
y O
mean O
sd O
mm O
##se O
mean O
sd O
como O
##rb O
##idi O
##ties O
co O
##hort O

sample O
n O
age O
years O
mean O
sd O
disease O
duration O
admission O
last O
assessment O
up O
##dr O
##s O
mean O
sd O
admission O
last O
assessment O
cardiovascular O
no O
of O
patients O
metabolic O
no O
of O
patients O
auto O
##im O
##mun O
##e O
no O
of O
patients O

ac B-HPO_TERM
akin I-HPO_TERM
##etic I-HPO_TERM
crisis I-HPO_TERM
h O
y O
ho O
##eh O
##n O
and O
ya O
##hr O
stage O
up O
##dr O
##s O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
mm O
##se O
mini O
mental O
state O
examination O
cardiovascular O
hyper O
##tension O
heart O
disease O
ve O
##nous O
disease O
arte O
##rio O
##pathy O
auto O
##im O
##mun O
##e O
thyroid O
##itis O
r O
##he O
##uma O
##to O
##id O
arthritis O
metabolic O
diabetes O
d O
##ys O
##lip O
##ide O
##mia O
blood O
ur O
##ea O
nitrogen O
20 O
mg O
dl O
h O
y O
and O
up O
##dr O
##s O
are O
rated O
during O
opt O
##imi O
##zed O
treatment O
according O
to O
need O
when O
not O
stated O
results O
refer O
to O
baseline O
condition O
for O
ac O
patients O
disease O
duration O
is O
considered O
before O
ac O
table O
2 O
incidence O
of O
akin O
##etic O
crisis O
ac O
in O
the O
study O
population O

ac O
akin O
##etic O
crisis O
up O
##dr O
##s O
ci O
con O
##ﬁ O
##den O
##ce O
interval O
un O
##i O
##ﬁ O
##ed O
parkinson O
s O
disease O
rating O
scale O
part O
iii O
p O
##y O
person O
year O
the O
study O
was O
prospective O
genetic O
id O
##ent O
##i O
##ﬁ O
##cation O
##s O
were O
obtained O
3 O
13 O
years O
after O
disease O
onset O
akin O
##etic O
crisis O
in O
genetic O
mitochondrial O
parkinson O
##ism O
124 O
##5 O

the O
pre O
##ci O
##pit O
##ating O
event O
for O
ac B-HPO_TERM
were O
infections B-HPO_TERM
pneumonia B-HPO_TERM
gas B-HPO_TERM
##tro I-HPO_TERM
##enter I-HPO_TERM
##itis I-HPO_TERM
in O
all O
episodes O
in O
the O
patient B-PATIENT
with O
pol B-GENE
##g I-GENE
##1 I-GENE
mutation O
infections O
in O
three O
episodes O
of O
patients O
with O
pink O
##1 O
mutations O
surgical O
procedure O
in O
one O
episode O
of O
a O
patient O
with O
pink O
##1 O
mutation O
bone O
trauma O
with O
fracture O
in O
the O
patient O
with O
gb O
##a O
mutation O
and O
infection O
gas O
##tro O
##enter O
##itis O
in O
the O
patient O
with O
l O
##rr O
##k O
##2 O
mutation O

the O
pre O
##ci O
##pit O
##ating O
event O
for O
pd O
patients O
who O
were O
non O
carriers O
of O
genetic O
mutations O
were O
infections O
in O
14 O
of O
24 O
bone O
trauma O
fracture O
in O
four O
of O
24 O
surgical O
procedure O
in O
one O
of O
24 O
treatment O
withdrawal O
in O
two O
of O
24 O
exposition O
to O
anti O
##do O
##pa O
##mine O
##rg O
##ic O
drugs O
cl O
##eb O
##op O
##ride O
in O
one O
ri O
##sper O
##idon O
##e O
and O
ami O
##sul O
##pr O
##ide O
in O
two O
in O
three O
the O
website O
material O
describes O
in O
detail O
each O
single O
genetically O
de O
##ﬁ O
##ned O
case O
and O
two O
representative O
cases O
by O
id O
##io O
##pathic O
pd O
discussion O

ac O
is O
a O
relatively O
rare O
critical O
condition O
and O
only O
few O
studies O
could O
present O
data O
on O
more O
than O
25 O
cases O
1 O
5 O
although O
our O
co O
##hort O
of O
patients O
was O
wide O
and O
intensive O
##ly O
studied O
15 O
16 O
an O
outline O
of O
ep O
##ide O
##mi O
##ological O
distributions O
in O
an O
ethnic O
##ally O
and O
ph O
##eno O
##men O
##ological O
##ly O
homogeneous O
population O
the O
ra O
##rity O
of O
the O
syndrome O
and O
the O
numerical O
##ly O
modest O
results O
of O
genetic O
testing O
probably O
due O
to O
under O
##est O
##ima O
##tion O
of O
recess O
##ive O
and O
low O
pen O
##et O
##rance O
mutations O
resulted O
in O
a O
small O
number O
of O
patients O
six O
patients O
by O
ac O
out O
of O
20 O
genetically O
id O
##ent O
##i O
##ﬁ O
##ed O
parkinson O
##isms O
in O
a O
co O
##hort O
of O
75 O
##6 O
patients O
followed O
for O
10 O
years O
table O
2 O
therefore O
a O
possible O
criticism O
is O
that O
statistical O
inference O
##s O
may O
be O
de O
##bat O
##able O
however O
the O
striking O
coincidence O
of O
ac O
with O
the O
genetic O
dia O
##gno O
##ses O
obtained O
in O
six O
patients O
indicates O
a O
di O
##sp O
##rop O
##ort O
##ion O
##ate O
prevalence O
of O
this O
crisis O
in O
comparison O
with O
the O
population O
of O
pd O
patients O
the O
incidence O
of O
ac O
in O
the O
described O
genetic O
mutation O
carriers O
pol O
##g O
##1 O
pink O
##1 O
l O
##rr O
##k O
##2 O
gb O
##a O
was O
a O
multiple O
i O
e O
21 O
2 O
vs O
3 O
0 O
of O
the O
known O
inc O
##i O

den O
##ce O
of O
ac O
in O
parkinson O
##ian O
populations O
moreover O
ac O
episodes O
were O
rec O
##urrent O
in O
four O
out O
of O
the O
six O
patients O
and O
all O
four O
were O
carriers O
of O
mutations O
involving O
mitochondrial O
functions O
pol O
##g O
##1 O
found O
in O
one O
of O
the O
four O
is O
the O
gene O
that O
codes O
for O
the O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
polymer O
##ase O
pink O
##1 O
three O
patients O
is O
the O
gene O
encoding O
a O
mitochondrial O
ser O
##ine O
th O
##re O
##oni O
##ne O
protein O
kinase O
three O
of O
the O
four O
patients O
died O
in O
the O
last O
crisis O

this O
ﬁ O
##nding O
suggests O
that O
mitochondrial O
dysfunction O
may O
represent O
a O
pre O
##dis O
##position O
to O
ac O
and O
to O
its O
possible O
lethal O
outcome O
this O
assumption O
is O
challenged O
by O
the O
occurrence O
of O
ac O
in O
a O
carrier O
of O
l O
##rr O
##k O
##2 O
mutation O
with O
lethal O
outcome O
and O
in O
a O
carrier O
of O
gb O
##a O
mutation O
suggesting O
that O
mitochondrial O
dysfunction O
cannot O
be O
the O
only O
explanation O

l O
##rr O
##k O
##2 O
is O
a O
member O
of O
the O
le O
##uc O
##ine O
rich O
repeat O
kinase O
family O
involved O
in O
ve O
##sic O
##ular O
expression O
of O
l O
##rr O
##k O
##2 O
mutants O
in O
experimental O
models O
increases O
the O
presence O
of O
auto O
##pha O
##gic O
compartments O
17 O
however O
the O
pathogen O
##ic O
gain O
of O
function O
mutant O
form O
of O
l O
##rr O
##k O
##2 O
g O
##20 O
##19 O
##s O
can O
cause O
defects O
in O
the O
morphology O
and O
dynamics O
ﬁ O
##ssion O
of O
mit O
##och O
##ond O
##ria O
18 O

also O
in O
the O
gb O
##a O
mutation O
mostly O
leading O
to O
l O
##ys O
##osomal O
storage O
disorders O
some O
recent O
evidence O
showed O
that O
mit O
##och O
##ond O
##ria O
were O
dysfunction O
##al O
and O
fragmented O
with O
impaired O
res O
##piration O
and O
reduced O
respiratory O
chain O
complex O
including O
atp O
synth O
##ase O
activities O
19 O
therefore O
the O
main O
conclusion O
is O
that O
our O
ﬁ O
##nding O
##s O
point O
to O
mitochondrial O
genetically O
driven O
dysfunction O
as O
one O
of O
the O
most O
probable O
underlying O
causes O
of O
ac O

it O
is O
suggested O
that O
in O
a O
cell O
environment O
where O
mitochondrial O
power O
is O
defective O
stress O
##ful O
conditions O
such O
as O
the O
pre O
##ci O
##pit O
##ating O
events O
described O
in O
our O
case O
co O
##hort O
infections O
trauma O
##s O
etc O
could O
activate O
a O
stress O
cascade O
altering O
the O
cellular O
energy O
state O
by O
inhibit O
##ing O
the O
electron O
transport O
chain O
it O
is O
therefore O
suggested O
that O
the O
deter O
##mina O
##nt O
factor O
in O
ac O
might O
be O
akin O
to O
inhibition O
of O
complex O
i O
activity O
observed O
in O
brain O
mit O
##och O
##ond O
##ria O
of O
rats O
exposed O
to O
ne O
##uro O
##le O
##ptic O
##s O
20 O
or O
in O
post O
##mo O
##rte O
##m O
evaluation O
##s O
of O
patients O
by O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
21 O
which O
is O
a O
disorder O
similar O
to O
ac O
4 O

in O
order O
to O
con O
##ﬁ O
##rm O
debate O
the O
hypothesis O
suggested O
by O
our O
preliminary O
ﬁ O
##nding O
##s O
further O
studies O
will O
be O
needed O
considering O
wider O
populations O
assessing O
all O
cases O
of O
ac O
for O
genetic O
mutations O
and O
considering O
the O
risk O
of O
under O
##est O
##ima O
##tion O
of O
genetic O
mutations O
because O
of O
reduced O
pen O
##et O
##rance O
or O
recess O
##ive O
inheritance O
it O
is O
suggested O
that O
the O
construction O
of O
an O
observation O
##al O
network O
might O
answer O
the O
question O
asked O
by O
our O
report O
and O
might O
help O
further O
the O
search O
for O
the O
mechanism O
of O
ac O
and O
for O
its O
treatment O
disclosure O
of O
conflicts O
of O
interest O

the O
authors O
declare O
no O
ﬁ O
##nan O
##cial O
or O
other O
con O
##ﬂ O
##ic O
##ts O
of O
interest O
supporting O
information O
additional O
supporting O
information O
may O
be O
found O
in O
the O
online O
version O
of O
this O
article O
data O
s O
##1 O
case O
descriptions O
of O
genetic O
and O
id O
##io O
##pathic O
park O
##is O
##non O
##ian O
patients O
experiencing O
ac O
2014 O
the O
author O
s O
european O
journal O
of O
ne O
##uro O
##logy O
2014 O
ea O
##n O
124 O
##6 O
l O
bon O
##ann O
##i O
et O
al O
references O
ono O
##fr O
##j O
m O
thomas O
a O
acute O
akin O
##es O
##ia O
in O
parkinson O
disease O
ne O
##uro O
##logy O
2005 O
64 O
116 O
##2 O
1629 O
u O
##eda O
m O
ham O
##amo O
##to O
m O
naga O
##yama O
h O
et O
al O
su O
##sc O
##ept O
##ibility O
to O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
in O
parkinson O
s O
disease O
ne O
##uro O
##logy O
1999 O
52 O
77 O
##7 O
78 O
##1 O

thomas O
a O
ono O
##fr O
##j O
m O
akin O
##etic O
crisis O
acute O
akin O
##es O
##ia O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
like O
syndrome O
parkinson O
##ism O
##hy O
##per O
##py O
##re O
##xia O
syndrome O
and O
mali O
##gnant O
syndrome O
are O
the O
same O
entity O
and O
are O
often O
independent O
of O
treatment O
withdrawal O
mo O
##v O
di O
##sor O
##d O
2005 O
20 O
167 O
##1 O
author O
reply O
167 O
##1 O
1672 O
marge O
##ti O
c O
b O
au O
##ks O
##t O
marge O
##ti O
c O
b O
ne O
##uro O
##le O
##ptic O
mali O
##gnant O
syndrome O
and O
its O
controversies O
ph O
##arm O
##aco O
##ep O
##ide O
##mi O
##ol O
drug O
sa O
##f O
2010 O
19 O
42 O
##9 O
435 O
tak O
##ub O
##o O
h O
hara O
##da O
t O
hash O
##imo O
##to O
t O
et O
al O
a O
collaborative O
study O
on O
the O
mali O
##gnant O
syndrome O
in O
parkinson O
s O
disease O
and O
related O
disorders O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2003 O
9 O
su O
##pp O
##l O
1 O
s O
##31 O
s O
##41 O

al O
##bin O
r O
##l O
da O
##uer O
w O
##t O
parkinson O
syndrome O
het O
##ero O
##gen O
##eit O
##y O
of O
et O
##iology O
het O
##ero O
##gen O
##eit O
##y O
of O
pathogen O
##esis O
ne O
##uro O
##logy O
2012 O
79 O
202 O
203 O
hughes O
aj O
daniel O
se O
ki O
##lford O
l O
lee O
##s O
aj O
accuracy O
of O
clinical O
diagnosis O
of O
id O
##io O
##pathic O
parkinson O
s O
disease O
a O
clinic O
path O
##ological O
study O
of O
100 O
cases O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
1992 O
55 O
181 O
184 O
alba O
##nese O
a O
bon O
##uc O
##cel O
##li O
u O
br O
##efe O
##l O
c O
et O
al O
consensus O
statement O
on O
the O
role O
of O
acute O
do O
##pa O
##mine O
##rg O
##ic O
challenge O
in O
parkinson O
s O
disease O
mo O
##v O
di O
##sor O
##d O
2001 O
16 O
197 O
201 O

in O
##vern O
##iz O
##zi O
f O
var O
##ane O
##se O
s O
thomas O
a O
carr O
##ara O
f O
ono O
##fr O
##j O
m O
zev O
##iani O
m O
two O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
lev O
##od O
##opa O
responsive O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
460 O
46 O
##4 O
singleton O
ab O
far O
##rer O
m O
johnson O
j O
et O
al O
a O
syn O
##uc O
##lein O
locus O
trip O
##lica O
##tion O
cause O
parkinson O
s O
disease O
science O
2003 O
302 O
84 O
##1 O
bon O
##if O
##ati O
v O
ro O
##h O
e O
cf O
breed O
##vel O
##d O
g O
##j O
et O
al O
early O
onset O
parkinson O
##ism O
associated O
with O
pink O
##1 O
mutations O
frequency O
gen O
##otype O
##s O
and O
ph O
##eno O
##type O
##s O
ne O
##uro O
##logy O
2005 O
65 O
87 O
95 O

vale O
##nte O
em O
ab O
##ou O
sl O
##eim O
##an O
pm O
cap O
##uto O
v O
et O
al O
hereditary O
early O
onset O
parkinson O
s O
disease O
caused O
by O
mutations O
in O
pink O
##1 O
science O
2004 O
304 O
115 O
##8 O
116 O
##0 O
fun O
##aya O
##ma O
m O
has O
##ega O
##wa O
k O
ko O
##wa O
h O
sai O
##to O
m O
ts O
##uj O
##i O
s O
ob O
##ata O
f O
a O
new O
locus O
for O
parkinson O
s O
disease O
park O
##8 O
maps O
to O
chromosome O
12 O
##p O
##11 O
2 O
q O
##13 O
1 O
ann O
ne O
##uro O
##l O
2002 O
51 O
296 O
301 O
neumann O
j O
bra O
##s O
j O
dea O
##s O
e O
et O
al O
g O
##lu O
##co O
##cer O
##eb O
##ros O
##ida O
##se O
mutations O
in O
clinical O
and O
path O
##ological O
##ly O
proven O
parkinson O
s O
disease O
brain O
2009 O
132 O
1783 O
1794 O

ono O
##fr O
##j O
m O
bon O
##ann O
##i O
l O
man O
##zo O
##li O
l O
thomas O
a O
co O
##hort O
study O
on O
so O
##mat O
##of O
##or O
##m O
disorders O
in O
parkinson O
disease O
and O
dementia O
with O
lew O
##y O
bodies O
ne O
##uro O
##logy O
2010 O
74 O
159 O
##8 O
160 O
##6 O
ono O
##fr O
##j O
m O
var O
##ane O
##se O
s O
bon O
##ann O
##i O
l O
et O
al O
co O
##hort O
study O
of O
prevalence O
and O
ph O
##eno O
##men O
##ology O
of O
tremor O
in O
dementia O
with O
lew O
##y O
bodies O
j O
ne O
##uro O
##l O
2013 O
260 O
1731 O
1742 O
ore O
##nstein O
s O
##j O
ku O
##o O
sh O
ta O
##sse O
##t O
i O
et O
al O
inter O
##play O
of O
l O
##rr O
##k O
##2 O
with O
cha O
##per O
##one O
mediated O
auto O
##pha O
##gy O
nat O
ne O
##uro O
##sc O
##i O
2013 O
16 O
39 O
##4 O
406 O
ni O
##u O
j O
yu O
m O
wang O
c O
xu O
z O
le O
##uc O
##ine O
rich O
repeat O
kinase O
2 O
disturb O
##s O
mitochondrial O
dynamics O
via O
d O
##yna O
##min O
like O
protein O
j O
ne O
##uro O
##che O
##m O
2012 O
122 O
650 O
65 O
##8 O

os O
##ella O
##me O
ld O
ra O
##him O
aa O
ha O
##rg O
##rea O
##ves O
ip O
et O
al O
mit O
##och O
##ond O
##ria O
and O
quality O
control O
defects O
in O
a O
mouse O
model O
of O
ga O
##ucher O
disease O
links O
to O
parkinson O
s O
disease O
cell O
meta O
##b O
2013 O
17 O
94 O
##1 O
95 O
##3 O
bu O
##rk O
##hardt O
c O
kelly O
jp O
lim O
y O
##h O
et O
al O
ne O
##uro O
##le O
##ptic O
medications O
inhibit O
complex O
i O
of O
the O
electron O
transport O
chain O
ann O
ne O
##uro O
##l O
1993 O
33 O
512 O
51 O
##7 O
ma O
##urer O
i O
mo O
##ller O
h O
##j O
inhibition O
of O
complex O
i O
by O
ne O
##uro O
##le O
##ptic O
##s O
in O
normal O
human O
brain O
cortex O
parallels O
the O
extra O
##py O
##ram O
##idal O
toxicity O
of O
ne O
##uro O
##le O
##ptic O
##s O
mo O
##l O
cell O
bio O
##che O
##m O
1997 O
174 O
255 O
259 O
2014 O
the O
author O
s O
european O
journal O
of O
ne O
##uro O
##logy O
2014 O
ea O
##n O

case O
reports O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
causing O
liver O
failure O
sun O
##ita O
bi O
##jar O
##nia O
maha O
##y O
nee O
##lam O
mohan O
deep O
##ak O
go O
##yal O
and O
ic O
ve O
##rma O
from O
center O
of O
medical O
genetics O
sir O
ganga O
ram O
hospital O
new O
delhi O
and O
department O
of O
pediatric O
gas O
##tro O
##enter O
##ology O
he O
##pa O
##tology O
and O
liver O
transplant O
##ation O
med O
##anta O
the O
medici O
##ty O
gu O
##rga O
##on O
correspondence O
to O
dr O
sun O
##ita O
bi O
##jar O
##nia O
maha O
##y O
senior O
consultant O
center O
of O
medical O
genetics O
sir O
ganga O
ram O
hospital O
raj O
##ind O
##er O
nagar O
new O
delhi O
110 O
06 O
##0 O
india O
bi O
##jar O
##nia O
gma O
##il O
com O
received O
february O
06 O
2014 O
initial O
review O
march O
31 O
2014 O
accepted O
june O
11 O
2014 O
m O

background O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
##s O
are O
disorders O
of O
mitochondrial O
dna O
maintenance O
causing O
varied O
manifestation O
##s O
including O
fu O
##lm O
##ina O
##nt O
liver O
failure O
case O
characteristics O
two O
infants O
presenting O
with O
severe O
fatal B-HPO_TERM
he B-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
observation O
raised O
serum O
lac O
##tate O
positive O
family O
history O
in O
first O
case O
and O
absence O
of O
other O
causes O
of O
acute O
liver O
failure O
outcome O
case B-PATIENT
1 I-PATIENT
with O
homo O
##zy O
##go O
##us O
mutation O
c B-GENE_VARIANT
328 I-GENE_VARIANT
##6 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
ar I-GENE_VARIANT
##g I-GENE_VARIANT
##10 I-GENE_VARIANT
##9 I-GENE_VARIANT
##6 I-GENE_VARIANT
##cy I-GENE_VARIANT
##s I-GENE_VARIANT
in O
pol B-GENE
##g I-GENE
gene O
and O
case O
2 O
with O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
novel O
c O
40 O
##8 O
##t O
g O
p O
ty O
##r O
##13 O
##6 O
##x O
and O
previously O
reported O
c O
293 O
##c O
t O
p O
pro O
##9 O
##8 O
##le O
##u O
in O
mp O
##v O
##17 O
gene O
message O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
is O
a O
rare O
cause O
of O
severe O
acute O
liver O
failure O
in O
children O

key O
##words O
acute O
liver O
failure O
genetic O
diagnosis O
he O
##pa O
##to O
##cer O
##eb O
##ral O
mit O
##och O
##ond O
##rio O
##pathy O
metabolic O
disorders O
ito O
##chon O
##dr O
##ial O
disorders O
are O
inherited O
disorders O
of O
energy O
metabolism O
caused O
by O
mutations O
either O
in O
mitochondrial O
genome O
mt O
##dna O
or O
in O
nuclear O
genes O
encoding O

proteins O
used O
either O
in O
the O
respiratory O
chain O
enzyme O
complexes O
or O
regulating O
the O
mt O
##dna O
functioning O
1 O
in O
childhood O
most O
of O
the O
disorders O
occur O
due O
to O
mutations O
in O
the O
nuclear O
genes O
inherited O
in O
auto O
##som O
##al O
recess O
##ive O
or O
x O
linked O
recess O
##ive O
j O
##mann O
##er O
over O
the O
last O
decade O
a O
growing O
number O
of O
syndrome O
##s O
associated O
with O
mitochondrial O
dysfunction O
resulting O
from O
tissue O
specific O
de O
##ple O
##tion O
of O
mt O
##dna O
have O
been O
reported O
in O
infants O
2 O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
##s O
are O
transmitted O
as O
an O
auto O
##som O
##al O
recess O
##ive O
trait O
and O
cause O
respiratory O
chain O
dysfunction O
with O
prominent O
neurological O
muscular O
and O
he O
##pati O
##c O
involvement O
3 O
4 O
acute O
he O
##pati O
##c O
failure O
is O
usually O
a O
sporadic O
phenomenon O
mitochondrial O
disorders O
are O
usually O
not O
considered O
in O
diagnosis O
due O
to O
lack O
of O
awareness O
and O
resources O
to O
prove O
it O
although O
there O
are O
no O
specific O
pointer O
##s O
to O
mitochondrial O
et O
##iology O
but O
it O
should O
be O
suspected O
whenever O
there O
is O
a O
family O
history O
of O
similar O
occurrence O
or O
parental O
con O
##san O
##gui O
##nity O
une O
##x O
##pl O
##aine O
##d O
elevated O
plasma O
lac O
##tate O
##s O
also O
provide O
useful O
clues O
we O
report O
mitochondrial O
disorders O
causing O
acute O
he O
##pati O
##c O
failure O
in O
two O
infants O

case O
reports O
case B-PATIENT
1 I-PATIENT
an O
8 B-AGE_DEATH
month I-AGE_DEATH
old O
boy O
from O
af O
##gan O
##istan O
presented O
with O
progressive B-HPO_TERM
he I-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
and O
en B-HPO_TERM
##ce I-HPO_TERM
##pha I-HPO_TERM
##lo I-HPO_TERM
##pathy I-HPO_TERM
for O
4 O
6 O
weeks O
the O
boy O
was O
the O
third O
child O
born O
to O
con O
##san O
##gui O
##neo O
##us O
couple O
with O
a O
previous O
child O
death O
at O
18 O
months O
of O
age O
with O
similar O
illness O
the O
present O
child O
s O
illness O
started O
at O
four B-AGE_ONSET
months I-AGE_ONSET
of O
age O
with O
mild O
he B-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
and O
der B-HPO_TERM
##ange I-HPO_TERM
##ment I-HPO_TERM
of I-HPO_TERM
liver I-HPO_TERM
enzymes I-HPO_TERM
noted O
during O
episode O
of O
gas B-HPO_TERM
##tro I-HPO_TERM
##enter I-HPO_TERM
##itis I-HPO_TERM
at O
presentation O
to O
us O

main O
clinical O
features O
were O
altered B-HPO_TERM
sensor I-HPO_TERM
##ium I-HPO_TERM
seizures B-HPO_TERM
requiring B-HPO_TERM
ventilation I-HPO_TERM
and O
critical O
care O
management O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
mild B-HPO_TERM
he I-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
relevant O
results O
on O
investigations O
are O
included O
in O
table O
i O
child O
deteriorated B-HPO_TERM
rapidly I-HPO_TERM
because O
of O
liver B-HPO_TERM
failure I-HPO_TERM
and O
died B-HPO_TERM
within O
two O
weeks O
of O
admission O

in O
view O
of O
classical O
features O
mainly O
he O
##pati O
##c O
failure O
and O
central O
nervous O
system O
cn O
##s O
involvement O
en O
##ce O
##pha O
##lo O
##pathy O
seizures O
high O
plasma O
lac O
##tate O
levels O
and O
family O
history O
a O
clinical O
diagnosis O
of O
mitochondrial O
disorder O
of O
the O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
al B-HPO_TERM
##pers I-HPO_TERM
hut I-HPO_TERM
##ten I-HPO_TERM
##lo I-HPO_TERM
##cher I-HPO_TERM
syndrome I-HPO_TERM
or O
p O
##yr O
##u O
##vate O
car O
##box O
##yla O
##se O
deficiency O
was O
made O
liver O
and O
skin O
bio O
##ps O
##ies O
were O
sent O
for O
mitochondrial O
electron O
transport O
chain O
etc O
en O
##zy O
##mology O
p O
##yr O
##u O
##vate O
car O
##box O
##yla O
##se O
enzyme O
ass O
##ay O
and O
mt O
##dna O
de O
##ple O
##tion O
studies O
the O
en O
##zy O
##mology O
in O
liver O
revealed O
significant O
reduction B-HPO_TERM
in I-HPO_TERM
activity I-HPO_TERM
in I-HPO_TERM
complexes I-HPO_TERM
i I-HPO_TERM
and I-HPO_TERM
iii I-HPO_TERM
1 O
and O
border O
##line O
low B-HPO_TERM
activity I-HPO_TERM
in I-HPO_TERM
complex I-HPO_TERM
iv I-HPO_TERM
15 O
whereas O
it O
was O
normal O
in O
all O
complexes O
studied O
i O
iii O
and O
iv O
in O
culture O
##d O
skin O
fi O
##bro O
##bla O
##sts O
simultaneous O
measurement O
of O
control O
enzyme O
ci O
##tra O
##te O
synth O
##ase O
in O
both O
liver O
and O
culture O
##d O
fi O
##bro O
##bla O
##sts O
was O
normal O
indicating O
good O
quality O
of O
sample O
p O
##yr O
##u O
##vate O
car O
##box O
##yla O
##se O
enzyme O
activity O
was O
normal O

next O
generation O
sequencing O
ng O
##s O
was O
performed O
for O
four O
genes O
implicated O
in O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
##s O
pol O
##g O
mp O
##v O
##17 O
d O
##gu O
##ok O
and O
twinkle O
the O
ng O
##s O
followed O
by O
sang O
##er O
sequencing O
in O
the O
patient O
revealed O
a O
previously O
reported O
homo O
##zy O
##go O
##us O
mutation O
c I-GENE_VARIANT
328 I-GENE_VARIANT
##6 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
ar I-GENE_VARIANT
##g I-GENE_VARIANT
##10 I-GENE_VARIANT
##9 I-GENE_VARIANT
##6 I-GENE_VARIANT
##cy I-GENE_VARIANT
##s I-GENE_VARIANT
in O
pol B-GENE
##g I-GENE
gene O
thus O
confirming O
diagnosis O
of O
pol O
##g O
related O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
cerebral I-HPO_TERM
form O
of O
mt B-HPO_TERM
##dna I-HPO_TERM
de I-HPO_TERM
##ple I-HPO_TERM
##tion I-HPO_TERM
syndrome O
overlapping O
with O
al O
##pers O
##hu O
##tten O
##lo O
##cher O
syndrome O
case O
2 O
this O
6 O
##½ O
month O
old O
boy O
born O
to O
a O
non O
case O
reports O

con O
##san O
##gui O
##neo O
##us O
couple O
presented O
with O
persistent O
ja O
##und O
##ice O
and O
abdominal O
di O
##sten O
##sion O
since O
four O
months O
of O
age O
he O
##pa O
##tom O
##ega O
##ly O
without O
as O
##cite O
##s O
was O
noted O
by O
pediatric O
##ian O
along O
with O
ja O
##und O
##ice O
cho O
##les O
##tas O
##is O
and O
coa O
##gul O
##opa O
##thy O
at O
five O
months O
of O
age O
there O
was O
poor O
weight O
gain O
since O
three O
months O
of O
age O
there O
was O
no O
history O
of O
rash O
##es O
it O
##ching O
and O
clay O
colored O
stool O
##s O
loose O
stool O
##s O
or O
vomiting O
history O
of O
ir O
##rita O
##bility O
seizures O
or O
altered O
consciousness O
was O
also O
about O
there O
was O
no O
bleeding O
or O
any O
he O
##pa O
##to O
##to O
##xi O
##c O
drug O
intake O

on O
examination O
the O
baby O
had O
ict O
##erus O
without O
any O
pal O
##lor O
ed O
##ema O
or O
scratch O
marks O
his O
weight O
was O
6 O
kg O
and O
height O
was O
60 O
cm O
both O
3rd O
cent O
##ile O
abdomen O
was O
soft O
and O
di O
##sten O
##ded O
liver O
was O
pal O
##pa O
##ble O
7 O
5 O
cm O
below O
right O
costa O
##l O
margin O
firm O
with O
smooth O
surface O
sp O
##leen O
was O
not O
pal O
##pa O
##ble O
and O
there O
was O
no O
as O
##cite O
##s O
rest O
of O
the O
systemic O
examination O
was O
normal O

his O
metabolic O
work O
##up O
including O
screening O
for O
gala O
##ct O
##ose O
##mia O
ty O
##ros O
##ine O
##mia O
type O
1 O
amino O
acids O
organic O
acids O
and O
fatty O
acid O
oxidation O
defects O
was O
normal O
plasma O
lac O
##tate O
was O
elevated O
on O
several O
occasions O
fast O
##ing O
ultrasound O
abdomen O
revealed O
enlarged O
liver O
with O
increased O
echo O
##genic O
##ity O
and O
partially O
di O
##sten O
##ded O
gall O
bladder O
with O
wall O
ed O
##ema O
sp O
##leen O
and O
kidney O
##s O
were O
normal O
his O
liver O
bio O
##psy O
showed O
mild O
bi O
##lia O
##ry O
duct O
proliferation O
intra O
##he O
##pati O
##c O
cho O
##les O
##tas O
##is O
pan O
lo O
##bular O
ste O
##ato O
##sis O
micro O
and O
macro O
##ves O
##icular O
and O
fi O
##bro O
##sis O
echo O
##card O
##io O
##gram O
revealed O
dil O
##ated O
left O
vent O
##ric O
##le O
with O
normal O
e O
##ject O
##ion O
fraction O
ec O
##g O
was O
normal O
other O
relevant O
investigations O
are O
provided O
in O
table O
i O
ne O
##uro O
##ima O
##ging O
showed O
non O
specific O
changes O
related O
to O
liver O
dysfunction O
and O
hyper O
##am O
##mon O
##emia O
in O
view O

facilities O
respiratory O
chain O
en O
##zy O
##mology O
and O
blue O
native O
gel O
electro O
##ph O
##ores O
##is O
and O
molecular O
studies O
with O
increasing O
availability O
and O
feasibility O
of O
genetic O
testing O
gene O
sequencing O
either O
single O
or O
panel O
testing O
using O
ng O
##s O
it O
is O
now O
becoming O
possible O
to O
confirm O
these O
dia O
##gno O
##ses O
to O
guide O
for O
further O
management O
of O
the O
child O
as O
well O
as O
for O
accurate O
counseling O
and O
pre O
##nat O
##al O
diagnosis O
in O
future O
pre O
##gnan O
##cies O
in O
the O
families O
ng O
##s O
helped O
in O
making O
diagnosis O
of O
mp O
##v O
##17 O
related O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
in O
case O
2 O
similar O
to O
reports O
earlier O
5 O
awareness O
of O
these O
disorders O
is O
essential O
as O
there O
are O
no O
specific O
pointer O
##s O
other O
than O
raised O
lac O
##tate O
along O
with O
organ O
specific O
dysfunction O
an O
index O
of O
suspicion O
should O
be O
raised O
whenever O
any O
child O
is O
noted O
to O
have O
the O
constellation O
of O
symptoms O
of O
he O
##pa O
##to O
cerebral O
or O
my O
##opa O
##thic O
form O
or O
even O
with O
isolated O
liver O
disease O
along O
with O
positive O
family O
history O
or O
con O
##san O
##gui O
##nity O
accurate O
diagnosis O
can O
guide O
pe O
##dia O
tri O
##cian O
##s O
for O
appropriate O
management O
and O
pro O
##gno O
##sis O
of O
the O
disease O
in O
our O
cases O
both O
children O
were O
candidates O
for O
liver O
transplant O
##ation O
but O
diagnosis O
of O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
with O
multiple O
organ O
involvement O
led O
to O
avoidance O
of O
the O
transplant O
the O
decision O
of O
avoiding O
transplant O
was O
based O
on O
poor O
outcomes O
55 O
mortality O
and O
progression O
of O
disease O
post O
transplant O
6 O
patients O
with O
md O
##s O
also O
need O
to O
be O
advised O
against O
val O
##pro O
##ate O
therapy O
as O
it O
may O
trigger O
a O
crisis O
and O
fu O
##lm O
##ina O
##nt O
he O
##pati O
##c O
failure O
in O
children O
who O
may O
not O
have O
had O
he O
##pati O
##c O
involvement O
7 O
8 O
pre O
##nat O
##al O
diagnosis O
is O
now O
feasible O
in O
future O
pre O
##gnan O
##cies O
to O
rule O
out O
25 O
risk O
of O
rec O
##ur O
##rence O
in O
siblings O

table O
i O
bio O
##chemical O
profile O
in O
the O
two O
children O
of O
a O
progressive O
cho O
##les O
##tat O
##ic O
liver O
disease O
and O
failure O
to O
thrive O
having O
excluded O
many O
of O
the O
metabolic O
and O

infectious O
causes O
molecular O
genetic O
studies O
were O
performed O
keeping O
in O
mind O
the O
high O
index O
of O
suspicion O
of O
a O
mitochondrial O
disorder O
ng O
##s O
was O
carried O
out O
for O
a O
panel O
of O
51 O
##4 O
genes O
causing O
childhood O
onset O
recess O
##ive O
disorders O
the O
ng O
##s O
panel O
results O
were O
further O
confirmed O
by O
sang O
##er O
sequencing O
in O
our O
laboratory O
the O
results O
revealed O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
mp O
##v O
##17 O
gene O
one O
novel O
c O
40 O
##8 O
##t O
g O
p O
ty O
##r O
##13 O
##6 O
##x O
and O
another O
previously O
reported O
c O
293 O
##c O
t O
p O
pro O
##9 O
##8 O
##le O
##u O
thus O
confirming O
the O
diagnosis O
of O
he O
##pa O
##to O
cerebral O
type O
of O
md O
##s O
parents O
were O
tested O
further O
and O
detected O
to O
carry O
one O
mutation O
each O
in O
het O
##ero O
##zy O
##go O
##us O
form O
the O
child O
died O
few O
months O
later O
because O
of O
progressive O
liver O
failure O
liver O
transplant O
was O
not O
performed O
in O
view O
of O
mitochondrial O
et O
##iology O
and O
neurological O
involvement O
as O
evident O
on O
ne O
##uro O
##ima O
##ging O

discussion O
mitochondrial O
disorders O
are O
in O
##fr O
##e O
##quent O
##ly O
diagnosed O
in O
india O
mainly O
because O
of O
lack O
of O
advanced O
diagnostic O
value O
in O
mm O
##ol O
l O
plasma O
values O
t O
total O
d O
direct O
case O
reports O
acknowledge O
##ments O
dr O
douglas O
s O
kerr O
and O
dr O
charles O
l O
hop O
##pel O
at O
cid O
##em O
cleveland O
usa O
and O
dr O
lauren O
c O
h O
##yam O
##s O
and O
dr O
john O
sho O
##ff O
##ner O
medical O
ne O
##uro O
##gen O
##etic O
##s O
lab O
atlanta O
usa O
for O
carrying O
out O
enzyme O
and O
gene O
analysis O
respectively O
for O
the O
patient O
dr O
stephen O
kings O
##more O
and O
dr O
emily O
far O
##row O
at O
center O
of O
pediatric O
gen O
##omic O
medicine O
children O
s O
mercy O
hospitals O
and O
clinics O
kansas O
city O
usa O
for O
genetic O
testing O
by O
ng O
##s O

contributors O
sb O
##m O
wrote O
the O
manuscript O
contributed O
in O
making O
clinical O
diagnosis O
of O
children O
and O
facilitating O
genetic O
testing O
nm O
contributed O
to O
management O
of O
both O
cases O
and O
provided O
critical O
comments O
on O
manuscript O
d O
##g O
contributed O
in O
management O
of O
case O
2 O
and O
assisted O
in O
writing O
manuscript O
and O
ic O
##v O
provided O
critical O
revision O
of O
manuscript O
for O
important O
intellectual O
content O
funding O
none O
competing O
interests O
none O
stated O
references O
sc O
##ag O
##lia O
f O
nuclear O
gene O
defects O
in O
mitochondrial O
disorders O
methods O
mo O
##l O
bio O
##l O
2012 O
83 O
##7 O
17 O
34 O

no O
##gue O
##ira O
c O
carr O
##oz O
##zo O
r O
vila O
##rin O
##ho O
l O
santo O
##relli O
fm O
infant O
##ile O
onset O
disorders O
of O
mitochondrial O
replication O
and O
protein O
synthesis O
j O
child O
ne O
##uro O
##l O
2011 O
26 O
86 O
##6 O
75 O
su O
##oma O
##lain O
##en O
a O
iso O
##han O
##ni O
p O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
##s O
many O
genes O
common O
mechanisms O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2010 O
20 O
42 O
##9 O
37 O
el O
hat O
##ta O
##b O
aw O
sc O
##ag O
##lia O
f O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
##s O
review O
and O
updates O
of O
genetic O
basis O
manifestation O
##s O
and O
therapeutic O
options O
ne O
##uro O
##ther O
##ape O
##uti O
##cs O
2013 O
10 O
186 O
98 O

ron O
##chi O
d O
ga O
##rone O
c O
bo O
##rdon O
##i O
a O
gutierrez O
rios O
p O
cal O
##vo O
se O
rip O
##olo O
##ne O
m O
et O
al O
next O
generation O
sequencing O
reveals O
d O
##gu O
##ok O
mutations O
in O
adult O
patients O
with O
mitochondrial O
dna O
multiple O
del O
##eti O
##ons O
brain O
2012 O
135 O
340 O
##4 O
15 O
de O
gr O
##ee O
##f O
e O
christ O
##od O
##ou O
##lou O
j O
alexander O
ie O
shu O
##n O
a O
o O
lough O
##lin O
ev O
thor O
##burn O
dr O
et O
al O
mitochondrial O
respiratory O
chain O
he O
##pa O
##top O
##athi O
##es O
role O
of O
liver O
transplant O
##ation O
a O
case O
series O
of O
five O
patients O
jim O
##d O
rep O
2012 O
4 O
5 O
11 O

cohen O
b O
##h O
chin O
##nery O
p O
##f O
copeland O
wc O
pol O
##g O
related O
disorders O
2010 O
mar O
16 O
updated O
2012 O
oct O
11 O
in O
pa O
##gon O
ra O
adam O
mp O
bird O
td O
et O
al O
editors O
gene O
##re O
##view O
##s O
##™ O
internet O
seattle O
wa O
university O
of O
washington O
seattle O
1993 O
2013 O
del O
##aru O
##e O
a O
pau O
##t O
o O
guys O
j O
##m O
mont O
##fort O
m O
##f O
let O
##hel O
v O
ro O
##quel O
##aur O
##e O
b O
et O
al O
inappropriate O
liver O
transplant O
##ation O
in O
a O
child O
with O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
mis O
##dia O
##gno O
##sed O
as O
val O
##pro O
##ate O
induced O
acute O
liver O
failure O
pe O
##dia O
##tr O
transplant O
2000 O
4 O
67 O
71 O
immune O
rec O
##ons O
##ti O
##tu O
##tion O
inflammatory O
syndrome O
in O
cn O
##s O
tuberculosis O
ke O
elizabeth O
and O
k O
ju O
##bin O

from O
department O
of O
pediatric O
##s O
sat O
hospital O
government O
medical O
college O
th O
##ir O
##u O
##vana O
##nt O
##ha O
##puram O
kerala O
india O
correspondence O
to O
dr O
ke O
elizabeth O
professor O
of O
pediatric O
##s O
and O
superintendent O
sat O
hospital O
government O
medical O
college O
th O
##ir O
##u O
##vana O
##nt O
##ha O
##puram O
kerala O
india O
69 O
##5 O
01 O
##1 O
eliza O
##ke O
hot O
##mail O
com O
received O
march O
05 O
2014 O
initial O
review O
may O
09 O
2014 O
accepted O
july O
02 O
2014 O
i O

background O
immune O
rec O
##ons O
##ti O
##tu O
##tion O
inflammatory O
syndrome O
iris O
an O
exaggerated O
inflammatory O
response O
with O
clinical O
worse O
##ning O
due O
to O
immune O
recovery O
during O
treatment O
is O
rare O
in O
the O
immune O
competent O
population O
case O
characteristics O
a O
5 O
½ O
year O
old O
immune O
##com O
##pet O
##ent O
girl O
with O
cn O
##s O
tuberculosis O
without O
hiv O
who O
developed O
paradox O
##ical O
iris O
outcome O
response O
to O
supportive O
care O
along O
with O
anti O
tuberculosis O
treatment O
message O
iris O
can O
occur O
in O
tuberculosis O
even O
in O
the O
im O
##mun O
##o O
competent O
key O
##words O
hyper O
##sen O
##sit O
##ivity O
immunity O
tuberculosis O

mm O
##une O
rec O
##ons O
##ti O
##tu O
##tion O
inflammatory O
syndrome O
iris O
is O
a O
heightened O
inflammatory O
response O
to O
a O
pathogen O
in O
the O
setting O
of O
im O
##mun O
##olo O
##gic O
recovery O
after O
im O
##mun O
##os O
##up O
##press O
##ion O
it O
occurs O
in O
those O
who O
have O
undergone O
a O
rec O
##ons O
##ti O
##tu O
##tion O
of O
the O
immune O
responses O
against O
an O
antigen O
it O
is O
mostly O
described O
in O
hiv O
infected O
patients O
initiated O
on O
highly O
active O
anti O
##ret O
##rov O
##ira O
##l O
therapy O
ha O
##art O
it O
can O
also O
occur O
in O
patients O
with O
solid O
organ O
transplant O
bone O
marrow O
transplant O
cy O
##tore O
##ductive O
chemotherapy O
and O
rarely O
in O
tuberculosis O
1 O
2 O
iris O

includes O
increased O
l O
##ym O
##ph O
##op O
##rol O
##ifer O
##ative O
response O
to O
my O
##co O
##ba O
##cter O
##ium O
antigen O
##s O
restoration O
of O
cut O
##aneous O
response O
to O
tube O
##rc O
##ulin O
and O
increased O
activation O
markers O
like O
cd O
##38 O
tn O
##fa O
308 O
1 O
and O
il O
##6 O
174 O
g O
3 O
we O
report O
a O
girl O
who O
developed O
iris O
after O
initiating O
anti O
tuberculosis O
treatment O
at O
##t O
case O
report O
a O
5 O
##½ O
year O
old O
girl O
was O
admitted O
with O
low O
grade O
fever O
of O
1 O
week O
duration O
dr O
##ows O
##iness O
of O
two O
days O
signs O
of O

pediatric O
ne O
##uro O
##logy O
51 O
2014 O
73 O
##4 O
##e O
##7 O
##36 O
clinical O
observations O
cr O
##anial O
nerve O
and O
cervical O
root O
enhancement O
in O
an O
infant O
with O
polymer O
##ase O
gamma O
mutation O
mitochondrial O
disease O
dean O
##na O
m O
horst O
a O
lynne O
rue O
##ss O
md O
a O
b O
jerome O
a O
rus O
##in O
md O
a O
b O
dennis O
w O
bartholomew O
md O
c O
d O
a O
department O
of O
radio O
##logy O
nationwide O
children O
s O
hospital O
columbus O
ohio O
b O
department O
of O
radio O
##logy O
the O
ohio O
state O
university O
college O
of O
medicine O
and O
public O
health O
columbus O
ohio O
c O
center O
for O
molecular O
and O
human O
genetics O
nationwide O
children O
s O
hospital O
research O
institute O
columbus O
ohio O

d O
department O
of O
pediatric O
##s O
the O
ohio O
state O
university O
college O
of O
medicine O
and O
public O
health O
columbus O
ohio O
abstract O

background O
nuclear O
polymer O
##ase O
gamma O
pol O
##g O
mutations O
are O
the O
most O
common O
cause O
of O
inherited O
mitochondrial O
disease O
pol O
##g O
mutation O
diseases O
have O
a O
broad O
spectrum O
of O
clinical O
manifestation O
##s O
the O
lethal O
infant O
##ile O
form O
is O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
patient I-PATIENT
a O
4 O
month O
old O
boy O
was O
referred O
for O
poor B-HPO_TERM
feeding I-HPO_TERM
em B-HPO_TERM
##esis I-HPO_TERM
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
results O
brain O
computed O
tom O
##ography O
was O
normal O
brain O
magnetic O
resonance O
imaging O
with O
and O
without O
contrast O
demonstrated O
bilateral B-HPO_TERM
enhancement I-HPO_TERM
of I-HPO_TERM
cr I-HPO_TERM
##anial I-HPO_TERM
nerves I-HPO_TERM
iii O
v O
x O
and O
the O
upper O
and O
mid O
##cer O
##vic O
##al O
nerve O
roots O
liver O
bio O
##psy O
revealed O
early B-HPO_TERM
ci I-HPO_TERM
##rr I-HPO_TERM
##hosis I-HPO_TERM
ste B-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
and O
focal B-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
muscle O
bio O
##psy O
did O
not O
demonstrate O
spec O
##i O
##ﬁ O
##c O
abnormalities O
of O
mitochondrial O
morphology O
or O
number O
electron O
transport O
chain O
analysis O
of O
both O
ﬁ O
##bro O
##bla O
##sts O
and O
muscle O
demonstrated O
de O
##ﬁ O
##cie O
##ncies O
because O
of O
suspected O
mitochondrial O
de O
##ple O
##tion O
disorder O
testing O
was O
performed O
for O
mitochondrial O
abnormalities O
including O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
which O
revealed O
two O
pathogen O
##ic O
mutations O
c B-GENE
139 I-GENE
##9 I-GENE
##g I-GENE
a I-GENE
p B-GENE
a I-GENE
##46 I-GENE
##7 I-GENE
##t I-GENE
and O
c B-GENE
328 I-GENE
##5 I-GENE
##c I-GENE
g I-GENE
p B-GENE
s I-GENE
##10 I-GENE
##9 I-GENE
##5 I-GENE
##r I-GENE
conclusions O
we O
report O
abnormal O
ga O
##do O
##lini O
##um O
enhancement O
of O
multiple O
cr O
##anial O
nerves O
and O
cervical O
nerve O
roots O
in O
an O
infant O
with O
my B-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bro I-HPO_TERM
##he I-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
spectrum O
disease O
whose O
brain O
mri O
otherwise O
revealed O
only O
mild B-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
mitochondrial O
disease O
should O
be O
included O
in O
the O
differential O
diagnosis O
of O
cr O
##anial O
nerve O
enhancement O
contrast O
enhanced O
mri O
aids O
in O
the O
diagnostic O
evaluation O
of O
infants O
with O
developmental O
delay O
and O
suspected O
neurological O
disease O

key O
##words O
mitochondrial O
disease O
infant O
imaging O
mri O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2014 O
51 O
73 O
##4 O
73 O
##6 O
2014 O
else O
##vier O
inc O
all O
rights O
reserved O
introduction O
inherited O
mitochondrial O
diseases O
are O
most O
commonly O
associated O
with O
mutations O
in O
the O
mitochondrial O
dna O
mt O
##dna O
polymer O
##ase O
polymer O
##ase O
gamma O
1 O
pol O
##g O
gene O
1 O
more O
than O
160 O
pathogen O
##ic O
mutations O
in O
the O
pol O
##g O
gene O
have O
been O
id O
##ent O
##i O
##ﬁ O
##ed O
2 O
inheritance O
is O
usually O
auto O
##som O
##al O
recess O
##ive O
however O
auto O
##som O
##al O
dominant O
forms O
exist O
pol O
##g O
disease O
may O
present O
in O
children O
or O
adults O
at O
least O
six O
distinct O
ph O
##eno O
##type O
##s O
with O
varying O
he O
##pati O
##c O
mu O
##scu O
##los O
##kel O
##eta O
##l O

presented O
at O
the O
annual O
meeting O
for O
the O
society O
for O
pediatric O
radio O
##logy O
may O
13 O
17 O
2014 O
washington O
dc O
article O
history O
received O
april O
18 O
2014 O
accepted O
in O
ﬁ O
##nal O
form O
june O
22 O
2014 O
communications O
should O
be O
addressed O
to O
dr O
rue O
##ss O
department O
of O
radio O
##logy O
nationwide O
children O
s O
hospital O
columbus O
ohio O
43 O
##20 O
##5 O
e O
mail O
address O
lynne O
rue O
##ss O
nationwide O
##child O
##ren O
##s O
org O
and O
central O
and O
peripheral O
nervous O
system O
involvement O
are O
currently O
recognized O
1 O
more O
severe O
and O
lethal O
forms O
of O
pol O
##g O
disease O
present O
in O
infancy O

we O
describe O
abnormal O
ga O
##do O
##lini O
##um O
enhancement O
of O
multiple O
cr O
##anial O
nerves O
in O
an O
infant O
with O
pol O
##g O
disease O
who O
otherwise O
had O
only O
mild O
signs O
of O
co O
##rti O
##cal O
and O
white O
matter O
at O
##rop O
##hi O
##es O
on O
magnetic O
resonance O
imaging O
mri O
this O
child O
expands O
the O
differential O
diagnosis O
of O
cr O
##anial O
nerve O
enhancement O
in O
infants O
with O
neurological O
disease O
and O
should O
prompt O
evaluation O
for O
pol O
##g O
mutations O
in O
the O
appropriate O
clinical O
setting O
patient O
description O

a O
4 B-AGE_ONSET
month I-AGE_ONSET
old O
boy O
was O
referred O
for O
poor B-HPO_TERM
feeding I-HPO_TERM
em B-HPO_TERM
##esis I-HPO_TERM
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
elevated B-HPO_TERM
trans I-HPO_TERM
##amina I-HPO_TERM
##ses I-HPO_TERM
he O
was O
the O
ﬁ O
##rst O
child O
of O
non O
##con O
##san O
##gui O
##neo O
##us O
parents O
born O
at O
39 O
weeks O
of O
ge O
##station O
by O
va O
##ginal O
delivery O
without O
sign O
##i O
##ﬁ O
##can O
##t O
pre O
##nat O
##al O
complications O
he O
weighed O
08 O
##8 O
##7 O
89 O
##9 O
##4 O
see O
front O
matter O
2014 O
else O
##vier O
inc O
all O
rights O
reserved O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
pe O
##dia O
##tr O
##ne O
##uro O
##l O
2014 O
06 O
01 O
##5 O
d O
m O
horst O
et O
al O
pediatric O
ne O
##uro O
##logy O
51 O
2014 O
73 O
##4 O
##e O
##7 O
##36 O
73 O
##5 O

3 O
209 O
kg O
with O
head O
ci O
##rc O
##um O
##ference O
in O
the O
eighty O
eighth O
percent O
##ile O
ap O
##gar O
scores O
were O
9 O
and O
9 O
at O
1 O
and O
5 O
minutes O
newborn O
screening O
test O
results O
were O
negative O
per O
##ina O
##tal O
course O
was O
uneven O
##tf O
##ul O
except O
hyper B-HPO_TERM
##bil I-HPO_TERM
##ir I-HPO_TERM
##ub I-HPO_TERM
##ine I-HPO_TERM
##mia I-HPO_TERM
at O
1 O
week O
of O
age O
treated O
with O
photo O
##therapy O
family O
history O
was O
non O
##con O
##tri O
##bu O
##tory O

examination O
on O
admission O
demonstrated O
an O
ir B-HPO_TERM
##rita I-HPO_TERM
##ble I-HPO_TERM
non O
##dy O
##smo O
##rp O
##hic O
child O
with O
mild B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
poor B-HPO_TERM
head I-HPO_TERM
control I-HPO_TERM
pal B-HPO_TERM
##pa I-HPO_TERM
##ble I-HPO_TERM
liver I-HPO_TERM
edge I-HPO_TERM
3 O
cm O
below O
the O
costa O
##l O
margin O
decreased B-HPO_TERM
muscle I-HPO_TERM
mass I-HPO_TERM
central B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
absent B-HPO_TERM
deep I-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
head B-HPO_TERM
ci I-HPO_TERM
##rc I-HPO_TERM
##um I-HPO_TERM
##ference I-HPO_TERM
had I-HPO_TERM
decreased I-HPO_TERM
to O
the O
thirteenth O
percent O
##ile O
initial O
laboratory O
tests O
demonstrated O
elevated B-HPO_TERM
levels I-HPO_TERM
of I-HPO_TERM
direct I-HPO_TERM
bi I-HPO_TERM
##li I-HPO_TERM
##ru I-HPO_TERM
##bin I-HPO_TERM
2 O
8 O
mg O
dl O
normal O
nl O
0 O
6 O
mg O
dl O
indirect O
bi O
##li O
##ru O
##bin O

1 O
3 O
mg O
dl O
nl O
0 O
1 O
1 O
0 O
mg O
dl O
as B-HPO_TERM
##par I-HPO_TERM
##tate I-HPO_TERM
amino I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
44 I-HPO_TERM
##8 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
nl O
510 O
##5 O
u O
l O
alan B-HPO_TERM
##ine I-HPO_TERM
amino I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
167 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
nl O
7 O
110 O
u O
l O
and O
lac B-HPO_TERM
##tate I-HPO_TERM
de I-HPO_TERM
##hy I-HPO_TERM
##dro I-HPO_TERM
##genase I-HPO_TERM
222 I-HPO_TERM
##1 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
nl O
600 O
1400 O
u O
l O
the O
plasma B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
level I-HPO_TERM
peaked I-HPO_TERM
at I-HPO_TERM
12 I-HPO_TERM
3 I-HPO_TERM
mm I-HPO_TERM
##ol I-HPO_TERM
l O
nl O
0 O
5 O
2 O
2 O
mm O
##ol O
l O
the O
ce B-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
ﬂ I-HPO_TERM
##uid I-HPO_TERM
protein I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
111 I-HPO_TERM
##3 I-HPO_TERM
mg I-HPO_TERM
dl I-HPO_TERM
nl O
15 O
45 O
mg O
dl O
an O
abdominal O
ultra O
##son O
##ography O
demonstrated O
gall B-HPO_TERM
##bla I-HPO_TERM
##dder I-HPO_TERM
sl I-HPO_TERM
##udge I-HPO_TERM
non O
##con O
##tra O
##st O
brain O
computed O
tom O
##ography O
scan O
was O
normal O

the O
clinical O
ph O
##eno O
##type O
of O
poor O
head O
control O
and O
progressive O
weakness O
of O
the O
upper O
ex O
##tre O
##mit O
##ies O
suggested O
a O
mitochondrial O
disorder O
and O
prompted O
a O
brain O
mri O
to O
investigate O
the O
possibility O
of O
metabolic O
stroke O
or O
basal O
gang O
##lia O
abnormalities O
the O
mri O
with O
and O
without O
intra O
##ven O
##ous O
contrast O
demonstrated O
bilateral B-HPO_TERM
enhancement I-HPO_TERM
of I-HPO_TERM
cr I-HPO_TERM
##anial I-HPO_TERM
nerves I-HPO_TERM
cn I-HPO_TERM
iii I-HPO_TERM
and I-HPO_TERM
v I-HPO_TERM
x I-HPO_TERM
as O
well O
as O
dorsal B-HPO_TERM
nerve I-HPO_TERM
root I-HPO_TERM
enhancement I-HPO_TERM
in O
the O
visual O
##ized O
portion O
of O
the O
cervical O
spine O
figure O
a O
e O
dedicated O
spine O
imaging O
was O
not O
performed O
the O
mri O
also O
revealed O
prominent B-HPO_TERM
sub I-HPO_TERM
##ara I-HPO_TERM
##ch I-HPO_TERM
##no I-HPO_TERM
##id I-HPO_TERM
spaces I-HPO_TERM
and O
vent O
##ric O
##le O
size O
indicative O
of O
co B-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
and I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
figure O
f O
in O
the O
setting O
of O
a O
small O
and O
decreasing B-HPO_TERM
head I-HPO_TERM
ci I-HPO_TERM
##rc I-HPO_TERM
##um I-HPO_TERM
##ference I-HPO_TERM
no O
additional O
mri O
abnormalities O
were O
observed O
the O
my O
##elin O
##ation O
pattern O
was O
normal O
for O
age O
figure O
f O
g O
gala O
##ct O
##oc O
##ere O
##bro O
##si O
##das O
##e O
and O
ar O
##yl O
##sul O
##fat O
##ase O

a O
activities O
were O
normal O
testing O
for O
spinal O
muscular O
at O
##rop O
##hy O
ty O
##ros O
##ine O
##mia O
type O
1 O
gala O
##ct O
##ose O
##mia O
mitochondrial O
genome O
mutations O
p O
##yr O
##u O
##vate O
disorders O
ni O
##emann O
pick O
disease O
and O
per O
##ox O
##iso O
##mal O
defects O
were O
also O
un O
##rem O
##ark O
##able O

three O
weeks O
after O
admission O
the O
child O
worsened O
he O
developed O
h B-HPO_TERM
##yp I-HPO_TERM
##ox I-HPO_TERM
##ia I-HPO_TERM
as B-HPO_TERM
##cite I-HPO_TERM
##s I-HPO_TERM
ta B-HPO_TERM
##chy I-HPO_TERM
##card I-HPO_TERM
##ia I-HPO_TERM
intermittent B-HPO_TERM
fever I-HPO_TERM
##s I-HPO_TERM
and O
sep B-HPO_TERM
##sis I-HPO_TERM
liver O
bio O
##psy O
revealed O
ﬁ O
##nding O
##s O
of O
early O
ci B-HPO_TERM
##rr I-HPO_TERM
##hosis I-HPO_TERM
ste B-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
and O
focal B-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
electron O
transport O
chain O
etc O
analysis O
of O
ﬁ O
##bro O
##bla O
##sts O
was O
consistent O
with O
complex B-HPO_TERM
iii I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
muscle O
bio O
##psy O
did O
not O
demonstrate O
spec O
##i O
##ﬁ O
##c O
abnormalities O
of O
mitochondrial O
morphology O
or O
number O
type O
1 O
muscle O
ﬁ O
##bers O
were O
predominant O
and O
shorter O
than O
expected O
some O
severely B-HPO_TERM
cy I-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cie I-HPO_TERM
##nt I-HPO_TERM
muscle I-HPO_TERM
ﬁ I-HPO_TERM
##bers I-HPO_TERM
were O
present O
no O
mt O
##dna O
mutations O
or O
del O
##eti O
##ons O
were O
observed O
however O
muscle O
etc O
analysis O
revealed O
de B-HPO_TERM
##ﬁ I-HPO_TERM
##cie I-HPO_TERM
##ncies I-HPO_TERM
in I-HPO_TERM
all I-HPO_TERM
etc I-HPO_TERM
complexes I-HPO_TERM
except O
complex O
ii O
in O
particular O
de O
##ﬁ O
##cie O
##ncies O
in O
complexes O
i O
and O
iv O
met O
major O
mod O
##i O
##ﬁ O
##ed O
walker O
criterion O
because O
of O
suspicion O
for O
a O
mitochondrial O
de O
##ple O
##tion O
disorder O
testing O
to O
include O
analysis O
of O
the O
pol B-GENE
##g I-GENE
gene O
revealed O
two O
pathogen O
##ic O
mutations O
c B-GENE_VARIANT
139 I-GENE_VARIANT
##9 I-GENE_VARIANT
##g I-GENE_VARIANT
a I-GENE_VARIANT
p I-GENE_VARIANT
a I-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
and B-GENE_VARIANT
c I-GENE_VARIANT
328 I-GENE_VARIANT
##5 I-GENE_VARIANT
##c I-GENE_VARIANT
g I-GENE_VARIANT
p B-GENE_VARIANT
s I-GENE_VARIANT
##10 I-GENE_VARIANT
##9 I-GENE_VARIANT
##5 I-GENE_VARIANT
##r I-GENE_VARIANT

the O
patient O
died O
at O
7 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
because O
of O
respiratory B-HPO_TERM
failure I-HPO_TERM
discussion O
polymer O
##ase O
gamma O
1 O
pol O
##g O
is O
a O
nuclear O
encoded O
enzyme O
responsible O
for O
the O
replication O
and O
maintenance O
of O
the O
mt O
##dna O
genome O
faulty O
pol O
##g O
activity O
induce O
##s O
mutations O
within O
the O
mt O
##dna O
that O
translate O
into O
de O
##ple O
##tions O
of O
mt O
##dna O
copy O
number O
single O
nu O
##cle O
##otide O
substitution O
##s O
and O
multiple O
##nu O
##cle O
##otide O
del O
##eti O
##ons O
2 O
these O
alterations O
co O
##rre O
##late O
with O
figure O

magnetic O
resonance O
images O
obtained O
at O
4 O
months O
of O
age O
a O
d O
ga O
##do O
##lini O
##um O
enhanced O
t O
##1 O
weighted O
axial O
images O
with O
abnormal O
bilateral B-HPO_TERM
enhancement I-HPO_TERM
of I-HPO_TERM
cn I-HPO_TERM
##s I-HPO_TERM
iii I-HPO_TERM
v I-HPO_TERM
vi I-HPO_TERM
vii I-HPO_TERM
viii I-HPO_TERM
and I-HPO_TERM
x I-HPO_TERM
arrows O
patient O
also O
had O
bilateral B-HPO_TERM
cn I-HPO_TERM
ix I-HPO_TERM
enhancement I-HPO_TERM
not O
shown O
e O
ga O
##do O
##lini O
##um O
enhanced O
t O
##1 O
weighted O
corona O
##l O
image O
also O
reveals O
abnormal O
bilateral B-HPO_TERM
enhancement I-HPO_TERM
of I-HPO_TERM
multiple I-HPO_TERM
dorsal I-HPO_TERM
cervical I-HPO_TERM
nerve I-HPO_TERM
roots I-HPO_TERM
arrows O
f O
axial O
t O
##2 O
weighted O
image O
reveals O
mild B-HPO_TERM
co I-HPO_TERM
##rti I-HPO_TERM
##cal I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
g O
axial O
t O
##2 O
weighted O
image O
with O
prominent O
lateral O
vent O
##ric O
##les O
and O
mild B-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
with O
appropriate O
my O
##elin O
##ation O
for O
age O
cn O
¼ O
cr O
##anial O
nerve O

73 O
##6 O
d O
m O
horst O
et O
al O
pediatric O
ne O
##uro O
##logy O
51 O
2014 O
73 O
##4 O
##e O
##7 O
##36 O

severe O
de O
##ﬁ O
##cit O
##s O
in O
functioning O
of O
the O
etc O
complex O
the O
fa O
##ci O
##lita O
##tor O
of O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
all O
the O
known O
pathogen O
##ic O
mutations O
in O
the O
pol O
##g O
gene O
have O
been O
compiled O
into O
a O
national O
institutes O
of O
health O
database O
http O
tools O
ni O
##eh O
##s O
ni O
##h O
gov O
pol O
##g O
the O
most O
common O
mutation O
responsible O
for O
pol O
##g O
associated O
mitochondrial O
disease O
is O
c O
139 O
##9 O
##g O
a O
p O
a O
##46 O
##7 O
##t O
either O
homo O
##zy O
##go O
##us O
or O
compound O
het O
##ero O
##zy O
##go O
##us O
with O
another O
mutation O
1 O
tang O
et O
al O
2 O
catalogue O
##d O
a O
large O
series O
of O
patients O
with O
pol O
##g O
mutations O
and O
only O
our O
patient O
had O
compound O
het O
##ero O
##zy O
##gos O
##ity O
for O
c O
139 O
##9 O
##g O
a O
p O
a O
##46 O
##7 O
##t O
and O
c O
328 O
##5 O
##c O
g O
p O
s O
##10 O
##9 O
##5 O
##r O
the O
latter O
has O
previously O
been O
reported O
as O
pathogen O
##ic O
con O
##ﬁ O
##rmin O
##g O
the O
clinical O
impression O
of O
pol O
##g O
de O
##ﬁ O
##ciency O
1 O

pol O
##g O
mutations O
have O
a O
broad O
spectrum O
of O
clinical O
manifestation O
##s O
and O
age O
of O
onset O
liver O
brain O
and O
muscle O
are O
most O
commonly O
affected O
at O
least O
six O
distinct O
ph O
##eno O
##type O
##s O
are O
recognized O
1 O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
mc O
##hs O
2 O
al O
##pers O
syndrome O
3 O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
4 O
my O
##oc O
##lon O
##us O
ep O
##ile O
##psy O
my O
##opa O
##thy O
sensory O
ata O
##xia O
5 O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
opt O
##hal O
##mo O
##ple O
##gia O
and O
6 O
auto O
##som O
##al O
dominant O
progressive O
external O
opt O
##hal O
##mo O
##ple O
##gia O
1 O
the O
mc O
##hs O
ph O
##eno O
##type O
describes O
the O
clinical O
picture O
of O
our O
patient O
infant O
##ile O
presentation O
of O
h O
##yp O
##oton O
##ia O
my O
##opa O
##thy O
developmental O
delay O
en O
##ce O
##pha O
##lo O
##pathy O
and O
liver O
dysfunction O
and O
is O
the O
form O
of O
pol O
##g O
disease O
with O
the O
earliest O
age O
of O
onset O
1 O
mc O
##hs O
can O
be O
distinguished O
from O
the O
more O
common O
al O
##pers O
syndrome O
by O
the O
lack O
of O
seizures O
liver O
pathology O
and O
more O
severe O
my O
##opa O
##thy O
3 O
mc O
##hs O
disease O
has O
also O
been O
attributed O
to O
other O
mitochondrial O
gene O
mutations O
not O
solely O
pol O
##g O
mutations O
3 O

generally O
infant O
##ile O
mitochondrial O
diseases O
have O
extensive O
white O
matter O
abnormalities O
including O
dem O
##ye O
##lina O
##tion O
or O
delayed O
my O
##elin O
##ation O
le O
##uk O
##od O
##yst O
##rop O
##hy O
and O
co O
##rti O
##cal O
at O
##rop O
##hy O
with O
or O
without O
gray O
matter O
nuclei O
abnormalities O
4 O
ferrari O
et O
al O
3 O
reported O
a O
series O
of O
nine O
infants O
with O
pol O
##g O
disease O
the O
eight O
patients O
with O
al O
##pers O
syndrome O
had O
non O
##sp O
##ec O
##i O
##ﬁ O
##c O
white O
and O
gray O
matter O
mr O
abnormalities O
one O
girl O
with O
a O
clinical O
picture O
of O
mc O
##hs O
and O
multiple O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
gene O
mutations O
presented O
at O
3 O
months O
of O
age O
and O
died O
at O
6 O
months O
her O
brain O
mri O
was O
reportedly O
normal O

abnormal O
cr O
##anial O
nerve O
enhancement O
has O
not O
been O
reported O
in O
a O
pol O
##g O
associated O
mitochondrial O
disease O
cr O
##anial O
nerve O
enhancement O
has O
been O
reported O
along O
with O
widespread O
cerebral O
white O
matter O
abnormalities O
in O
adult O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
5 O
and O
in O
childhood O
metabolic O
diseases O
including O
k O
##ra O
##bbe O
disease O
and O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
both O
cr O
##anial O
nerve O
and O
ca O
##uda O
e O
##quin O
##a O
enhancement O
have O
been O
observed O
6 O
9 O
isolated O
cr O
##anial O
nerve O
enhancement O
signaled O
early O
infant O
##ile O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
in O
one O
child O
10 O

the O
mechanism O
behind O
enhancing O
cr O
##anial O
nerves O
has O
yet O
to O
be O
el O
##uc O
##ida O
##ted O
speculation O
##s O
include O
the O
breakdown O
of O
the O
blood O
nerve O
barrier O
because O
of O
per O
##iva O
##scu O
##lar O
in O
##ﬂ O
##am O
##mation O
or O
in O
##ﬁ O
##lt O
##ration O
and O
areas O
of O
active O
dem O
##ye O
##lina O
##tion O
6 O
nerve O
enhancement O
could O
also O
originate O
from O
the O
cy O
##to O
##to O
##xi O
##c O
build O
##up O
of O
meta O
##bol O
##ites O
that O
prevent O
normal O
my O
##elin O
##ation O
and O
facilitate O
dem O
##ye O
##lina O
##tion O
in O
diseases O
such O
as O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
8 O

most O
articles O
describe O
mri O
without O
contrast O
this O
may O
explain O
the O
patient O
with O
mc O
##hs O
who O
had O
a O
normal O
mri O
in O
the O
study O
by O
ferrari O
et O
al O
3 O
gan O
##eson O
et O
al O
7 O
advocated O
using O
contrast O
in O
the O
routine O
evaluation O
of O
infants O
with O
early O
onset O
of O
developmental O
delay O
when O
they O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
patient O
with O
early O
infant O
##ile O
k O
##ra O
##bbe O
disease O
who O
had O
multiple O
enhancing O
cr O
##anial O
nerves O
along O
with O
non O
##sp O
##ec O
##i O
##ﬁ O
##c O
white O
matter O
changes O
at O
mri O
we O
are O
in O
agreement O
with O
moran O
##a O
et O
al O
9 O
in O
h O
##yp O
##oth O
##es O
##izing O
that O
abnormal O
cr O
##anial O
nerve O
enhancement O
goes O
largely O
und O
##ete O
##cted O
because O
of O
the O
lack O
of O
administration O
of O
mri O
contrast O
when O
evaluating O
infants O

in O
conclusion O
the O
differential O
diagnosis O
of O
abnormal O
cr O
##anial O
nerve O
enhancement O
should O
be O
expanded O
to O
include O
pol O
##g O
mutations O
and O
more O
generally O
mitochondrial O
diseases O
if O
the O
appropriate O
clinical O
signs O
are O
present O
we O
have O
mod O
##i O
##ﬁ O
##ed O
our O
mr O
protocols O
to O
include O
contrast O
enhancement O
for O
infants O
with O
suspected O
ne O
##uro O
##met O
##ab O
##olic O
disease O
references O
wong O
l O
##j O
na O
##via O
##ux O
r O
##k O
br O
##une O
##tti O
pier O
##ri O
n O
et O
al O
molecular O
and O
clinical O
genetics O
of O
mitochondrial O
disease O
due O
to O
pol O
##g O
mutations O
hum O
mu O
##tat O
2008 O
29 O
e O
##15 O
##0 O
e O
##17 O
##2 O

tang O
s O
wang O
j O
lee O
n O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
an O
ever O
expanding O
molecular O
and O
clinical O
spectrum O
j O
med O
gene O
##t O
2011 O
48 O
66 O
##9 O
68 O
##1 O
ferrari O
g O
lama O
##nte O
##a O
e O
dona O
##ti O
a O
et O
al O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
syndrome O
##s O
associated O
with O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
brain O
2005 O
128 O
72 O
##3 O
73 O
##1 O
munoz O
a O
mateo O
##s O
f O
simon O
r O
garcia O
silva O
mt O
cab O
##ello O
s O
arenas O
j O
mitochondrial O
diseases O
in O
children O
ne O
##uro O
##rad O
##iol O
##ogical O
and O
clinical O
features O
in O
17 O
patients O
ne O
##uro O
##rad O
##iology O
1999 O
41 O
92 O
##0 O
92 O
##8 O

pet O
##cha O
##run O
##pa O
##isan O
s O
castillo O
m O
multiple O
cr O
##anial O
nerve O
enhancement O
in O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
j O
com O
##put O
assist O
tom O
##og O
##r O
2010 O
34 O
247 O
248 O
bern O
##al O
og O
len O
##n O
n O
multiple O
cr O
##anial O
nerve O
enhancement O
in O
early O
infant O
##ile O
k O
##ra O
##bbe O
s O
disease O
ne O
##uro O
##logy O
2000 O
54 O
234 O
##8 O
234 O
##9 O
gan O
##esa O
##n O
k O
des O
##ai O
s O
he O
##g O
##de O
a O
multiple O
cr O
##anial O
nerve O
enhancement O
uncommon O
imaging O
ﬁ O
##nding O
in O
early O
infant O
##ile O
k O
##ra O
##bbe O
s O
disease O
j O
ne O
##uro O
##ima O
##ging O
2010 O
20 O
195 O
197 O

maia O
jr O
ac O
da O
roc O
##ha O
aj O
da O
silva O
c O
##j O
rose O
##mberg O
s O
multiple O
cr O
##anial O
nerve O
enhancement O
a O
new O
mr O
imaging O
ﬁ O
##nding O
in O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
aj O
##nr O
am O
j O
ne O
##uro O
##rad O
##iol O
2007 O
28 O
999 O
moran O
##a O
g O
bi O
##an O
##cher O
##i O
r O
dir O
##oc O
##co O
m O
et O
al O
enhancing O
cr O
##anial O
nerves O
and O
ca O
##uda O
e O
##quin O
##a O
an O
emerging O
magnetic O
resonance O
imaging O
pattern O
in O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
and O
k O
##ra O
##bbe O
disease O
ne O
##uro O
##ped O
##ia O
##trics O
2009 O
40 O
291 O
294 O
singh O
r O
##k O
les O
##hner O
rt O
ka O
##dom O
n O
van O
##der O
##ver O
al O
isolated O
cr O
##anial O
nerve O
enhancement O
in O
meta O
##ch O
##romatic O
le O
##uk O
##od O
##yst O
##rop O
##hy O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2009 O
40 O
380 O
38 O
##2 O

brain O
development O
37 O
2015 O
71 O
##9 O
72 O
##4 O
case O
report O
www O
else O
##vier O
com O
locate O
brain O
##dev O
my B-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bro I-HPO_TERM
##he I-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
spectrum O
disorder O
due O
to O
pol B-GENE
##g I-GENE
mutations O
a O
clinic O
##opa O
##th O
##ological O
report O
he O
##sham O
mont O
##ass O
##ir O
a O
b O
yo O
##shi O
##hiro O
mae O
##ga O
##ki O
a O
kei O
mu O
##raya O
##ma O
c O
tar O
##o O
ya O
##ma O
##zaki O
d O
mas O
##aka O
##zu O
ko O
##hd O
##a O
e O
akira O
oh O
##take O
d O
hi O
##roy O
##as O
##u O
i O
##was O
##a O
e O
yuki O
##ko O
ya O
##tsu O
##ka O
f O
ya O
##sus O
##hi O
ok O
##az O
##aki O
e O
f O
chi O
##tose O
su O
##gi O
##ura O
a O
ik O
##uo O
naga O
##ta O
g O
mit O
##su O
##o O
toy O
##oshi O
##ma O
h O
yo O
##shi O
##aki O
sai O
##to O
a O
mas O
##ay O
##uki O
ito O
##h O
i O
ich O
##iz O
##o O
ni O
##shin O
##o O
j O
ko O
##usa O
##ku O
oh O
##no O
a O
a O
division O
of O
child O
ne O
##uro O
##logy O
faculty O
of O
medicine O
to O
##tto O
##ri O
university O
yo O
##na O
##go O
japan O

b O
department O
of O
family O
medicine O
faculty O
of O
medicine O
cairo O
university O
cairo O
egypt O
c O
department O
of O
metabolism O
chiba O
children O
s O
hospital O
chiba O
japan O
d O
department O
of O
pediatric O
##s O
school O
of O
medicine O
sai O
##tama O
medical O
university O
sai O
##tama O
japan O
e O
division O
of O
translation O
##al O
research O
research O
center O
for O
gen O
##omic O
medicine O
sai O
##tama O
medical O
university O
hid O
##aka O
japan O
f O
division O
of O
functional O
gen O
##omics O
systems O
medicine O
research O
center O
for O
gen O
##omic O
medicine O
sai O
##tama O
medical O
university O
hid O
##aka O
japan O
g O
division O
of O
pediatric O
##s O
and O
per O
##ina O
##tology O
faculty O
of O
medicine O
to O
##tto O
##ri O
university O
yo O
##na O
##go O
japan O

h O
department O
of O
pediatric O
##s O
graduate O
school O
of O
medical O
and O
dental O
sciences O
ka O
##gos O
##hima O
university O
ka O
##gos O
##hima O
japan O
i O
department O
of O
mental O
re O
##tar O
##dation O
and O
birth O
defect O
research O
national O
center O
of O
ne O
##uro O
##logy O
and O
psychiatry O
tokyo O
japan O
j O
department O
of O
ne O
##uro O
##mus O
##cular O
research O
national O
institute O
of O
neuroscience O
national O
center O
of O
ne O
##uro O
##logy O
and O
psychiatry O
tokyo O
japan O
received O
8 O
august O
2014 O
received O
in O
revised O
form O
6 O
october O
2014 O
accepted O
26 O
october O
2014 O
abstract O

we O
report O
on O
the O
clinical O
ne O
##uro O
##path O
##ological O
and O
genetic O
ﬁ O
##nding O
##s O
of O
a O
japanese O
case B-PATIENT
with O
my B-HPO_TERM
##oc I-HPO_TERM
##ere I-HPO_TERM
##bro I-HPO_TERM
##he I-HPO_TERM
##pa I-HPO_TERM
##top I-HPO_TERM
##athy I-HPO_TERM
spectrum O
mc O
##hs O
disorder O
due O
to O
polymer B-GENE
##ase I-GENE
gamma I-GENE
pol B-GENE
##g I-GENE
mutations O
a O
girl O
manifested O
poor B-HPO_TERM
sucking I-HPO_TERM
and O
failure B-HPO_TERM
to I-HPO_TERM
thrive I-HPO_TERM
since O
4 B-AGE_ONSET
months I-AGE_ONSET
of O
age O
and O
had O
frequent B-HPO_TERM
vomiting I-HPO_TERM
and O
developmental B-HPO_TERM
regression I-HPO_TERM
at O
5 O
months O
of O
age O
she O
showed O
sign B-HPO_TERM
##i I-HPO_TERM
##ﬁ I-HPO_TERM
##can I-HPO_TERM
##t I-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
he B-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
laboratory O
tests O
showed O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
dysfunction I-HPO_TERM
and O
elevated B-HPO_TERM
protein I-HPO_TERM
and O
lac B-HPO_TERM
##tate I-HPO_TERM
levels I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
ﬂ O
##uid O
her O
liver O
function O
and O
ne B-HPO_TERM
##uro I-HPO_TERM
##logic I-HPO_TERM
condition I-HPO_TERM
ex I-HPO_TERM
##ace I-HPO_TERM
##rba I-HPO_TERM
##ted I-HPO_TERM
and O
she O
died O
at O
8 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
at O
autopsy O
fatty B-HPO_TERM
de I-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
and O
ﬁ B-HPO_TERM
##bro I-HPO_TERM
##sis I-HPO_TERM
were I-HPO_TERM
observed I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
liver I-HPO_TERM
ne O
##uro O
##path O
##ological O
examination O
revealed O
white O
matter O
predominant O
sp O
##ong O
##y O
changes O
with O
alzheimer B-HPO_TERM
type I-HPO_TERM
ii I-HPO_TERM
g I-HPO_TERM
##lia I-HPO_TERM
and I-HPO_TERM
loss I-HPO_TERM
of I-HPO_TERM
my I-HPO_TERM
##elin I-HPO_TERM
enzyme O
activities O
of O
the O
respiratory O
chain O
complex O
i O
iii O
and O
iv O
relative O
to O
ci O
##tra O
##te O
synth O
##ase O
in O
the O
muscle O
were O
normal O
in O
the O
bio O
##ps O
##ied O
muscle O
tissue O
but O
they O
were O
reduced O
in O
the O
liver O
to O
0 O
10 O
and O
14 O
of O
normal O
values O
respectively O
in O
the O
liver O
the O
copy O
number O
of O
mitochondrial O
dna O
compared O
to O
nuclear O
dna O
was O
reduced O
to O
3 O
3 O
of O
normal O
values O
as O
evaluated O
by O
quantitative O
polymer O
##ase O
chain O
reaction O
genetic O
analysis O
revealed O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
for O
pol B-GENE
##g I-GENE
i B-GENE_VARIANT
##11 I-GENE_VARIANT
##85 I-GENE_VARIANT
##t I-GENE_VARIANT
a B-GENE_VARIANT
##9 I-GENE_VARIANT
##57 I-GENE_VARIANT
##v I-GENE_VARIANT
this O
case O
represents O
the O
involvement O
of O
multiple O
organs O
and O
ph O
##eno O
##type O
spec O
##i O
##ﬁ O
##c O
distribution O
of O
brain O
lesions O
in O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O

2014 O
the O
japanese O
society O
of O
child O
ne O
##uro O
##logy O
published O
by O
else O
##vier O
b O
v O
all O
rights O
reserved O
key O
##words O
al O
##pers O
syndrome O
mitochondrial O
dna O
de O
##ple O
##tion O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
disorder O
pol O
##g O
corresponding O
author O
at O
division O
of O
child O
ne O
##uro O
##logy O
faculty O
of O
medicine O
to O
##tto O
##ri O
university O
36 O
1 O
ni O
##shi O
cho O
yo O
##na O
##go O
68 O
##3 O
850 O
##4 O
japan O
tel O
81 O
85 O
##9 O
38 O
67 O
##7 O
##7 O
fa O
##x O
81 O
85 O
##9 O
38 O
67 O
##7 O
##9 O
e O
mail O
address O
mae O
##ga O
##ki O
med O
to O
##tto O
##ri O
u O
ac O
jp O
y O
mae O
##ga O
##ki O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
brain O
##dev O
2014 O
10 O
01 O
##3 O
03 O
##8 O
##7 O
760 O
##4 O
2014 O
the O
japanese O
society O
of O
child O
ne O
##uro O
##logy O
published O
by O
else O
##vier O
b O
v O
all O
rights O
reserved O

introduction O

mitochondrial O
dna O
mt O
##dna O
de O
##ple O
##tion O
syndrome O
md O
##ds O
ﬁ O
##rst O
described O
in O
1991 O
is O
de O
##ﬁ O
##ned O
as O
a O
reduction O
in O
the O
mt O
##dna O
copy O
number O
in O
tissues O
leading O
to O
synthesis O
of O
respiratory O
chain O
complexes O
rc O
##c O
1 O
clinical O
manifestation O
##s O
of O
md O
##ds O
involve O
many O
organ O
systems O
including O
the O
central O
and O
peripheral O
nervous O
system O
liver O
muscle O
and O
gas O
##tro O
##int O
##estinal O
tract O
2 O
human O
polymer O
##ase O
gamma O
pol O
##g O
is O
the O
common O
ca O
##usa O
##tive O
gene O
involved O
in O
md O
##ds O
whose O
mutations O
result O
in O
a O
diverse O
group O
of O
ph O
##eno O
##type O
##s O
such O
as O
al O
##pers O
syndrome O
and O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
mc O
##hs O
disorders O
which O
typically O
show O
disease O
onset O
during O
early O
childhood O
further O
several O
pol O
##g O
related O
ph O
##eno O
##type O
##s O
manifest O
##ing O
during O
adolescence O
and O
adulthood O
are O
recognized O
including O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
disorders O
my O
##oc O
##lon O
##us O
ep O
##ile O
##psy O
my O
##opa O
##thy O
sensory O
ata O
##xia O
and O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
d O
##ys O
##arth O
##ria O
d O
##ys O
##pha O
##gia O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
some O
overlap O
##s O
in O
the O
symptoms O
between O
these O
adult O
ph O
##eno O
##type O
##s O
exist O
and O
can O
be O
additionally O
accompanied O
by O
tremor O
parkinson O
##ism O
hearing O
loss O
stroke O
like O
episodes O
and O
gas O
##tro O
##int O
##estinal O
symptoms O
which O
are O
reminiscent O
of O
symptoms O
of O
mitochondrial O
diseases O
with O
path O
##ome O
##chan O
##isms O
other O
than O
md O
##ds O
3 O
4 O

mc O
##hs O
the O
most O
severe O
ph O
##eno O
##type O
of O
pol O
##g O
disorders O
was O
recently O
id O
##ent O
##i O
##ﬁ O
##ed O
and O
is O
de O
##ﬁ O
##ned O
by O
the O
clinical O
triad O
of O
1 O
my O
##opa O
##thy O
or O
h O
##yp O
##oton O
##ia O
2 O
developmental O
delay O
or O
dementia O
and O
3 O
liver O
dysfunction O
3 O
5 O
severe O
intra O
##ctable O
ep O
##ile O
##psy O
is O
included O
in O
the O
diagnostic O
hallmark O
##s O
of O
al O
##pers O
syndrome O
but O
is O
not O
characteristic O
of O
mc O
##hs O
as O
the O
number O
of O
patients O
with O
mc O
##hs O
disorders O
is O
small O
and O
detailed O
clinic O
##opa O
##th O
##ological O
ﬁ O
##nding O
##s O
are O
unavailable O
we O
here O
##in O
report O
the O
case O
of O
a O
girl O
with O
mc O
##hs O
disorders O
due O
to O
pol O
##g O
mutations O
as O
far O
as O
we O
know O
this O
is O
the O
ﬁ O
##rst O
japanese O
case O
of O
mc O
##hs O
disorders O
with O
pol O
##g O
mutation O

case B-PATIENT
report O
a O
girl O
was O
born O
at O
40 O
weeks O
of O
ge O
##station O
to O
healthy O
non O
con O
##san O
##gui O
##neo O
##us O
parents O
without O
any O
abnormalities O
the O
birth O
weight O
height O
and O
head O
ci O
##rc O
##um O
##ference O
were O
norma O
##tive O
early O
development O
and O
growth O
were O
un O
##rem O
##ark O
##able O
at B-AGE_ONSET
4 I-AGE_ONSET
months I-AGE_ONSET
of O
age O
she O
developed O
poor B-HPO_TERM
weight I-HPO_TERM
gain I-HPO_TERM
em B-HPO_TERM
##esis I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
developmental B-HPO_TERM
delay I-HPO_TERM
and O
let B-HPO_TERM
##har I-HPO_TERM
##gy I-HPO_TERM
she O
was O
admitted O
to O
our O
hospital O
because O
of O
rec B-HPO_TERM
##urrent I-HPO_TERM
vomiting I-HPO_TERM
at O
6 O
months O
of O
age O

on O
admission O
body O
length O
was O
60 O
9 O
cm O
2 O
2 O
standard O
deviation O
sd O
body O
weight O
was O
560 O
##0 O
g O
2 O
3 O
sd O
and O
head O
ci O
##rc O
##um O
##ference O
was O
42 O
cm O
0 O
2 O
sd O
he B-HPO_TERM
##pa I-HPO_TERM
##tom I-HPO_TERM
##ega I-HPO_TERM
##ly I-HPO_TERM
of O
a O
hard O
consistency O
was O
observed O
approximately O
3 O
cm O
under O
the O
costa O
##l O
margin O
with O
no O
associated O
sp O
##len O
##ome O
##gal O
##y O
she O
was O
alert O
and O
could O
establish O
good O
eye O
contact O
and O
smile O
she O
showed O
severe B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
and O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
dominant I-HPO_TERM
muscular I-HPO_TERM
weakness I-HPO_TERM
she O
could O
hold O
neither O
her O
head O
nor O
limbs O
up O
all O
deep B-HPO_TERM
tend I-HPO_TERM
##on I-HPO_TERM
re I-HPO_TERM
##ﬂ I-HPO_TERM
##ex I-HPO_TERM
##es I-HPO_TERM
were I-HPO_TERM
weak I-HPO_TERM

although O
complete O
blood O
count O
and O
ur O
##inal O
##ysis O
were O
un O
##rem O
##ark O
##able O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
dysfunction I-HPO_TERM
was O
obvious O
at O
the O
time O
of O
hospital O
##ization O
with O
the O
following O
laboratory O
test O
values O
as B-HPO_TERM
##par I-HPO_TERM
##tate I-HPO_TERM
amino I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
390 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
alan B-HPO_TERM
##ine I-HPO_TERM
amino I-HPO_TERM
##tra I-HPO_TERM
##ns I-HPO_TERM
##fera I-HPO_TERM
##se I-HPO_TERM
218 I-HPO_TERM
u I-HPO_TERM
l I-HPO_TERM
total O
bi O
##li O
##ru O
##bin O

1 O
6 O
mg O
dl O
total O
bile O
acids O
172 O
l O
##mo O
##l O
l O
c O
g O
##lu O
##tam O
##yl O
trans O
##pe O
##pt O
##ida O
##se O
179 O
i O
##u O
l O
le O
##uc O
##ine O
amino O
##pe O
##pt O
##ida O
##se O
268 O
i O
##u O
l O
and O
cho O
##lines O
##tera O
##se O
73 O
i O
##u O
l O
levels O
of O
serum O
cr O
##ea O
##tine O
kinase O
and O
blood O
glucose O
were O
normal O
ce B-HPO_TERM
##re I-HPO_TERM
##bro I-HPO_TERM
##sp I-HPO_TERM
##inal I-HPO_TERM
ﬂ I-HPO_TERM
##uid I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
examination I-HPO_TERM
showed I-HPO_TERM
elevated I-HPO_TERM
protein I-HPO_TERM
levels I-HPO_TERM
of O
304 O
mg O
dl O
and O
normal O
cell O
count O
and O
glucose O
levels O
lac B-HPO_TERM
##tic I-HPO_TERM
acid I-HPO_TERM
was I-HPO_TERM
elevated I-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
plasma I-HPO_TERM
and I-HPO_TERM
cs I-HPO_TERM
##f I-HPO_TERM
at O
15 O
9 O
mg O
dl O
and O
30 O
3 O
mg O
dl O
respectively O
p O
##yr O
##u O
##vic O
acid O
was O
normal O
in O
both O
plasma O
and O
cs O
##f O
metabolic O
screening O
tests O
including O
urine O
organic O
acids O
plasma O
and O
urine O
amino O
acids O
were O
un O
##rem O
##ark O
##able O
initial O
brain O
computed O
tom O
##ography O
ct O
and O
magnetic O
resonance O
imaging O
performed O
at O
6 O
months O
of O
age O
were O
un O
##rem O
##ark O
##able O
the O
electro B-HPO_TERM
##ence I-HPO_TERM
##pha I-HPO_TERM
##logram I-HPO_TERM
showed I-HPO_TERM
generalized I-HPO_TERM
slow I-HPO_TERM
wave I-HPO_TERM
activity I-HPO_TERM
only O
wave O
i O
was O
id O
##ent O
##i O
##ﬁ O
##able O
on O
auditory O
ev O
##oked O
potential O
##s O
motor B-HPO_TERM
nerve I-HPO_TERM
and I-HPO_TERM
sensory I-HPO_TERM
conduct I-HPO_TERM
##ion I-HPO_TERM
were I-HPO_TERM
mildly I-HPO_TERM
delayed I-HPO_TERM

muscle O
bio O
##psy O
ﬁ O
##nding O
##s O
at O
6 O
months O
of O
age O
showed O
a O
variation B-HPO_TERM
in I-HPO_TERM
ﬁ I-HPO_TERM
##ber I-HPO_TERM
type I-HPO_TERM
ragged O
red O
ﬁ O
##ber O
was O
not O
observed O
lip O
##id O
and O
g O
##ly O
##co O
##gen O
storage O
were O
not O
observed O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
stain O
##ing O
showed O
normal O
ﬁ O
##nding O
##s O
analysis O
of O
the O
rc O
##c O
enzyme O
activity O
revealed O
no O
abnormal O
##ity O
no O
mt O
##dna O
mutations O
were O
id O
##ent O
##i O
##ﬁ O
##ed O

soon O
after O
admission O
in I-HPO_TERM
feeding I-HPO_TERM
and O
vomiting B-HPO_TERM
aggravated O
and O
tube B-HPO_TERM
feeding I-HPO_TERM
along O
with O
parent O
##eral O
nutrition O
was O
required O
she O
experienced O
bouts B-HPO_TERM
of I-HPO_TERM
dia I-HPO_TERM
##rr I-HPO_TERM
##hea I-HPO_TERM
consciousness B-HPO_TERM
level I-HPO_TERM
decreased I-HPO_TERM
progressively I-HPO_TERM
and O
my B-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##ic I-HPO_TERM
jerk I-HPO_TERM
##s I-HPO_TERM
of O
the O
right O
and O
left O
arms O
were O
in O
##fr O
##e O
##quent O
##ly O
observed O
follow O
up O
ct O
revealed O
mild B-HPO_TERM
cerebral I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
at O
7 O
months O
of O
age O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cellular I-HPO_TERM
dysfunction I-HPO_TERM
ex O
##ace O
##rba O
##ted O
progressively O
and O
she O
died B-HPO_TERM
of I-HPO_TERM
multiple I-HPO_TERM
organ I-HPO_TERM
failure I-HPO_TERM
caused O
by O
he B-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
failure I-HPO_TERM
at O
8 B-AGE_DEATH
months I-AGE_DEATH
of O
age O
despite O
supplement O
##ation O
of O
multiple O
vitamin O
##s O
and O
coe O
##nz O
##yme O
q O
10 O
and O
was O
auto O
##ps O
##ied O
two O
years O
later O
another O
girl O
was O
born O
to O
the O
parents O
she O
had O
the O
same O
clinical O
course O
and O
laboratory O
ﬁ O
##nding O
##s O
observed O
in O
the O
present O
patient O
and O
died O
at O
7 O
months O
of O
age O
val O
##pro O
##ic O
acid O
was O
not O
used O
in O
either O
patient O

post O
##mo O
##rte O
##m O
examinations O
body O
weight O
was O
6 O
0 O
kg O
mean O
sd O
8 O
0 O
0 O
88 O
kg O
the O
weight O
of O
the O
at B-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
liver I-HPO_TERM
was O
200 O
g O
and O
the O
surface O
was O
yellowish O
irregular O
and O
hard O
the O
lungs B-HPO_TERM
were I-HPO_TERM
cong I-HPO_TERM
##ested I-HPO_TERM
and O
ad B-HPO_TERM
##ren I-HPO_TERM
##al I-HPO_TERM
glands I-HPO_TERM
were I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hic I-HPO_TERM
the O
other O
vis O
##cera O
##l O
organs O
were O
un O
##rem O
##ark O
##able O
on O
macro O
##scopic O

examination O
the O
brain O
weighed O
760 O
g O
and O
showed O
massive O
ed O
##ema O
and O
ca B-HPO_TERM
##uda I-HPO_TERM
##l I-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
microscopic O
##ally O
he O
##pa O
##to O
##cytes O
and O
ad O
##ren O
##al O
co O
##rti O
##cal O
cells O
were O
swollen O
and O
renal O
tubular O
cells O
contained O
ph O
##os O
##ph O
##oli O
##pid O
##s O
and O
foam I-HPO_TERM
cells I-HPO_TERM
similar O
foam O
cells O
were O
also O
seen O
in O
the O
lungs O
and O
cardiac O
muscle O
ﬁ O
##bers O
in O
the O
liver O
he B-HPO_TERM
##pati I-HPO_TERM
##c I-HPO_TERM
ﬁ I-HPO_TERM
##bro I-HPO_TERM
##sis I-HPO_TERM
micro B-HPO_TERM
##ves I-HPO_TERM
##icular I-HPO_TERM
ste I-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
and O
fatty B-HPO_TERM
de I-HPO_TERM
##gen I-HPO_TERM
##eration I-HPO_TERM
were O
observed O
fig O
1 O
in O
the O
central O
nervous O
system O
a O
sp B-HPO_TERM
##ong I-HPO_TERM
##y I-HPO_TERM
change I-HPO_TERM
was I-HPO_TERM
noted I-HPO_TERM
predominantly I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
cerebral I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
and O
ne B-HPO_TERM
##uron I-HPO_TERM
##al I-HPO_TERM
loss I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
cerebral I-HPO_TERM
and I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bella I-HPO_TERM
##r I-HPO_TERM
cortex I-HPO_TERM
was O
mild O
alzheimer B-HPO_TERM
type I-HPO_TERM
ii I-HPO_TERM
g I-HPO_TERM
##lia I-HPO_TERM
was O
observed O
in O
massive O
numbers O
in O
the O
cerebral O
and O
ce O
##re O
##bella O
##r O
white O
matter O
with O
a O
smaller O
amount O
in O
the O
cerebral O
cortex O
and O
deep O
gray O
matter O
ne O
##uron O
##al O
loss O
cap O
##illa O
##ry O
proliferation O
and O
sp B-HPO_TERM
##ong I-HPO_TERM
##iness I-HPO_TERM
were I-HPO_TERM
prominent I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
sub I-HPO_TERM
##stan I-HPO_TERM
##tia I-HPO_TERM
ni I-HPO_TERM
##gra I-HPO_TERM
fig O
2 O
recent O
linear B-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
was I-HPO_TERM
present I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
bilateral I-HPO_TERM
ca I-HPO_TERM
##uda I-HPO_TERM
##te I-HPO_TERM
nucleus I-HPO_TERM

ass O
##ay O
of O
respiratory O
chain O
complex O
enzyme O
activity O
in O
the O
liver O
the O
liver O
samples O
were O
immediately O
frozen O
at O
autopsy O
and O
stored O
at O
70 O
activities O
of O
rc O
##c O
i O
ii O
iii O
and O
iv O
were O
ass O
##ay O
##ed O
as O
described O
previously O
6 O
7 O
the O
percentage O
##s O
of O
rc O
##c O
i O
ii O
iii O
and O
iv O
activities O
relative O
to O
that O
of O
ci O
##tra O
##te O
synth O
##ase O
cs O
as O
a O
mitochondrial O
enzyme O
marker O
were O
calculated O
relative B-HPO_TERM
enzyme I-HPO_TERM
activities I-HPO_TERM
of I-HPO_TERM
rc I-HPO_TERM
##c I-HPO_TERM
i I-HPO_TERM
iii I-HPO_TERM
and I-HPO_TERM
iv I-HPO_TERM
to I-HPO_TERM
cs I-HPO_TERM
in I-HPO_TERM
the I-HPO_TERM
liver I-HPO_TERM
were I-HPO_TERM
reduced I-HPO_TERM
to O
0 O
10 O
and O
14 O
of O
normal O
values O
respectively O
while O
that O
of O
rc O
##c O
ii O
was O
reduced O
to O
29 O

analysis O
of O
quantitative O
polymer O
##ase O
chain O
reaction O
of O
mt O
##dna O
and O
dna O
sequence O
of O
pol O
##g O
gene O

written O
informed O
consent O
was O
obtained O
from O
the O
patient O
s O
parents O
in O
order O
to O
perform O
gene O
analysis O
the O
quantitative O
estimation O
of O
mt O
##dna O
was O
performed O
by O
real O
time O
amp O
##li O
##ﬁ O
##cation O
of O
fragments O
of O
n O
##d O
##1 O
in O
the O
mt O
##dna O
genome O
as O
previously O
described O
7 O
8 O
to O
determine O
the O
overall O
abundance O
of O
mt O
##dna O
we O
compared O
the O
real O
time O
amp O
##li O
##ﬁ O
##cation O
of O
n O
##d O
##1 O
with O
a O
single O
copy O
nuclear O
reference O
gene O
ex O
##on O
24 O
of O
the O
cf O
##tr O
gene O
7 O
9 O
the O
ratio O
of O
n O
##d O
##1 O
to O
cf O
##tr O
in O
the O
liver O
was O
reduced O
to O
3 O
3 O
sd O
1 O
2 O
as O
compared O
to O
the O
control O

mutation O
analysis O
was O
performed O
on O
the O
gen O
##omic O
dna O
using O
prime O
##rs O
designed O
to O
amp O
##li O
##fy O
the O
coding O
ex O
##ons O
and O
the O
ex O
##on O
intro O
##n O
boundaries O
of O
pol B-GENE
##g I-GENE
nm O
00 O
##26 O
##9 O
##3 O
2 O
fragments O
were O
analyzed O
by O
direct O
sequencing O
using O
ab O
##i O
313 O
##0 O
##x O
##l O
applied O
bio O
##systems O
tokyo O
japan O
the O
genetic O
analysis O
revealed O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
pol B-GENE
##g I-GENE
c B-GENE_VARIANT
287 I-GENE_VARIANT
##0 I-GENE_VARIANT
##c I-GENE_VARIANT
t I-GENE_VARIANT
p B-GENE_VARIANT
a I-GENE_VARIANT
##9 I-GENE_VARIANT
##57 I-GENE_VARIANT
##v I-GENE_VARIANT
and O
c B-GENE_VARIANT
355 I-GENE_VARIANT
##4 I-GENE_VARIANT
##t I-GENE_VARIANT
c I-GENE_VARIANT
p B-GENE_VARIANT
i I-GENE_VARIANT
##11 I-GENE_VARIANT
##85 I-GENE_VARIANT
##t I-GENE_VARIANT
the O
two O
dna O
mutations O

fig O
1 O
path O
##ological O
ﬁ O
##nding O
##s O
of O
the O
post O
##mo O
##rte O
##m O
liver O
a O
c O
hem O
##ato O
##xy O
##lin O
e O
##osi O
##n O
stain O
##ing O
d O
mass O
##on O
tri O
##chrome O
stain O
##ing O
a O
moderate O
in O
##ﬂ O
##am O
##mat O
##ory O
cell O
in O
##ﬁ O
##lt O
##ration O
ins O
##et O
with O
destroyed O
limiting O
plates O
and O
a O
rather O
progressive O
ﬁ O
##bro O
##sis O
with O
br O
##id O
##ging O
formation O
in O
the O
portal O
tracts O
were O
observed O
original O
mag O
##ni O
##ﬁ O
##cation O
x O
##40 O
b O
swollen O
he B-HPO_TERM
##pa I-HPO_TERM
##to I-HPO_TERM
##cytes I-HPO_TERM
containing I-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
droplets I-HPO_TERM
of O
various O
sizes O
were O
found O
bile B-HPO_TERM
plug I-HPO_TERM
##s I-HPO_TERM
white O
arrows O
in O
b O
and O
c O
were O
noted O
in O
the O
cy O
##top O
##las O
##m O
of O
he O
##pa O
##to O
##cytes O
and O
dil O
##ated O
canal O
##ic O
##uli O
x O
##100 O
c O
swollen O
he O
##pa O
##to O
##cytes O
containing O
lip O
##id O
droplets O
of O
various O
sizes O
were O
found O
bile O
plug O
##s O
were O
noted O
in O
the O
cy O
##top O
##las O
##m O
of O
he O
##pa O
##to O
##cytes O
x O
##400 O
d O
a O
rather O
progressive O
ﬁ O
##bro O
##sis O
with O
br O
##id O
##ging O
formation O
arrows O
in O
the O
portal O
tracts O
was O
found O
x O
##40 O

fig O
2 O
path O
##ological O
ﬁ O
##nding O
##s O
of O
the O
post O
##mo O
##rte O
##m O
brain O
a O
c O
e O
and O
g O
hem O
##ato O
##xy O
##lin O
e O
##osi O
##n O
stain O
##ing O
b O
d O
and O
f O
im O
##mun O
##oh O
##isto O
##chemical O
stain O
##ing O
against O
g O
##lia O
##l O
ﬁ O
##bri O
##llary O
acidic O
protein O
original O
mag O
##ni O
##ﬁ O
##cation O
x O
##400 O
marked O
sp O
##ong O
##y O
changes O
a O
with O
alzheimer B-HPO_TERM
type I-HPO_TERM
ii I-HPO_TERM
astro I-HPO_TERM
##cy I-HPO_TERM
##tosis I-HPO_TERM
b O
was O
observed O
in O
the O
cerebral O
white O
matter O
and O
less O
prominently O
in O
the O
cerebral O
cortex O
c O
and O
d O
and O
st O
##ria O
##tum O
e O
and O
f O
ne O
##uron O
##al O
loss O
sp O
##ong O
##iness O
and O
cap O
##illa O
##ry O
proliferation O
which O
were O
reminiscent O
of O
the O
ﬁ O
##nding O
##s O
of O
leigh O
syndrome O
were O
noted O
in O
the O
sub O
##stan O
##tia O
ni O
##gra O
g O

were O
not O
registered O
in O
neither O
of O
the O
1000 O
genome O
##s O
project O
database O
http O
www O
1000 O
##gen O
##ome O
##s O
org O
es O
##p O
##65 O
##00 O
database O
http O
ev O
##s O
gs O
washington O
ed O
##u O
ev O
##s O
or O
h O
##g O
##vd O
http O
www O
genome O
med O
kyoto O
u O
ac O
jp O
s O
##np O
##db O
index O
html O
the O
amino O
acid O
sequences O
of O
these O
two O
sites O
p O
a O
##9 O
##57 O
##v O
and O
p O
i O
##11 O
##85 O
##t O
are O
well O
conserved O
across O
species O
suggesting O
their O
importance O
fig O
3 O
in O

si O
##lic O
##o O
analyses O
were O
performed O
using O
the O
prediction O
algorithms O
si O
##ft O
http O
si O
##ft O
jc O
##vi O
org O
and O
poly O
##ph O
##en O
##2 O
http O
genetics O
b O
##w O
##h O
harvard O
ed O
##u O
pp O
##h O
##2 O
these O
mutations O
are O
predicted O
to O
be O
del O
##eter O
##ious O
by O
si O
##ft O
0 O
and O
0 O
respectively O
and O
poly O
##ph O
##en O
##2 O
0 O
98 O
##5 O
and O
0 O
99 O
##1 O
respectively O
programs O
the O
results O
of O
mutation O
analysis O
have O
been O
reported O
previously O
patient O
6 O
in O
ref O
9 O
fig O
3 O
conservation O
analysis O
of O
mutation O
sites O
in O
pol O
##g O
the O
sites O
of O
compound O
het O
##ero O
##zy O
##go O
##us O
amino O
acid O
mutations O
p O
95 O
##7 O
##a O
and O
p O
118 O
##5 O
##i O
are O
well O
conserved O
across O
species O
discussion O

the O
het O
##ero O
compound O
mutations O
in O
pol O
##g O
were O
not O
found O
in O
either O
of O
the O
1000 O
genome O
##s O
project O
database O
es O
##p O
##65 O
##00 O
database O
nor O
h O
##g O
##vd O
suggesting O
that O
these O
are O
pathogen O
##ic O
mutations O
the O
amino O
acid O
sequences O
of O
these O
two O
sites O
p O
a O
##9 O
##57 O
##v O
and O
p O
i O
##11 O
##85 O
##t O
are O
well O
conserved O
across O
species O
including O
sac O
##cha O
##rom O
##yce O
##s O
ce O
##re O
##vis O
##iae O
indicating O
their O
importance O
fig O
3 O
in O
si O
##lic O
##o O
analyses O
also O
predicted O
that O
these O
two O
amino O
acid O
mutations O
are O
del O
##eter O
##ious O
furthermore O
a O
##9 O
##57 O
##v O
has O
been O
reported O
by O
tang O
et O
al O
10 O
they O
reported O
a O
##9 O
##57 O
##v O
all O
##ele O
was O
shared O
in O
three O
unrelated O
patients O
and O
concluded O
this O
mutation O
is O
pathogen O
##ic O
the O
pathogen O
##ic O
mutations O
in O
the O
ﬂ O
##an O
##king O
region O
of O
p O
118 O
##5 O
##i O
p O
118 O
##4 O
##d O
11 O
12 O
and O
p O
118 O
##6 O
##d O
13 O
have O
been O
reported O
suggesting O
this O
region O
is O
also O
important O
thus O
we O
conclude O
the O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
of O
this O
patient O
cause O
the O
disease O
al O
##pers O
syndrome O
is O
de O
##ﬁ O
##ned O
as O
the O
clinical O
triad O
of O
1 O
ref O
##rac O
##tory O
mixed O
type O
seizures O
that O
often O
include O
a O
focal O
component O
2 O
psycho O
##moto O
##r O
regression O
often O
triggered O
by O
inter O
##cu O
##rre O
##nt O
infection O
and O
3 O
he O
##pa O
##top O
##athy O
with O
or O
without O
acute O
liver O
failure O
there O
is O
an O
overlap O
between O
the O
ph O
##eno O
##type O
##s O
of O
mc O
##hs O
and O
al O
##pers O
syndrome O
however O
the O
former O
usually O
shows O
an O
earlier O
onset O
age O
and O
more O
rapid O
disease O
progression O
while O
the O
latter O
is O
characterized O
by O
intra O
##ctable O
ep O
##ile O
##psy O
using O
the O
my O
##o O
pre O
##ﬁ O
##x O
in O
mc O
##hs O
may O
be O
confusing O
since O
the O
path O
##ological O
ﬁ O
##nding O
##s O
of O
muscles O
in O
this O
disorder O
often O
shows O
no O
evidence O
of O
mitochondrial O
my O
##opa O
##thy O
instead O
the O
h O
##yp O
##oton O
##ia O
observed O
in O
the O
triad O
can O
be O
regarded O
as O
a O
sy O
##mpt O
##om O
of O
brain O
dysfunction O
thus O
the O
clinical O
features O
of O
the O

patient O
discussed O
here O
##in O
were O
typical O
of O
mc O
##hs O

although O
wong O
et O
al O
3 O
excluded O
classical O
al O
##pers O
he O
##pa O
##top O
##athy O
by O
liver O
bio O
##psy O
in O
m O
##hc O
##s O
exact O
path O
##ological O
ﬁ O
##nding O
##s O
were O
not O
provided O
by O
the O
authors O
in O
the O
he O
##pa O
##top O
##athy O
observed O
in O
these O
two O
ph O
##eno O
##type O
##s O
have O
not O
been O
established O
path O
##ological O
characteristics O
of O
the O
liver O
in O
al O
##pers O
syndrome O
include O
ﬁ O
##bro O
##sis O
reg O
##ener O
##ative O
nod O
##ules O
he O
##pa O
##to O
##cy O
##te O
drop O
##out O
bile O
duct O
proliferation O
fatty O
changes O
and O
bile O
st O
##asi O
##s O
14 O
the O
ﬁ O
##nding O
##s O
of O
the O
present O
patient O
were O
compatible O
with O
those O
of O
al O
##pers O
syndrome O
similar O
to O
the O
case O
of O
pol O
##g O
related O
md O
##ds O
previously O
observed O
15 O
as O
for O
the O
ne O
##uro O
##path O
##ological O
ﬁ O
##nding O
##s O
al O
##pers O
syndrome O
usually O
shows O
a O
prefer O
##ential O
involvement O
of O
gray O
matter O
characterized O
by O
g O
##lio O
##sis O
nerve O
cell O
loss O
sp O
##ong O
##y O
de O
##gen O
##eration O
and O
accumulation O
of O
neural O
lip O
##ids O
in O
the O
cerebral O
cortex O
16 O
alzheimer O
type O
ii O
g O
##lia O
representing O
he O
##pati O
##c O
en O
##ce O
##pha O
##lo O
##pathy O
was O
also O
distributed O
predominantly O
in O
the O
gray O
matter O
17 O

a O
patient O
exhibiting O
a O
clinical O
evolution O
from O
mc O
##hs O
to O
al O
##pers O
ph O
##eno O
##type O
showed O
gray O
matter O
involvement O
and O
microscopic O
ﬁ O
##nding O
##s O
similar O
to O
those O
in O
leigh O
syndrome O
5 O
and O
brain O
bio O
##psy O
in O
another O
al O
##pers O
patient O
with O
prominent O
white O
matter O
signal O
change O
revealed O
path O
##ological O
characteristics O
typical O
of O
al O
##pers O
disease O
with O
intra O
##ctable O
seizures O
18 O
on O
the O
other O
hand O
marked O
g O
##lio O
##sis O
and O
sp O
##ong O
##iness O
of O
the O
white O
matter O
without O
path O
##ological O
changes O
in O
the O
cerebral O
cortex O
was O
observed O
in O
a O
patient O
with O
probable O
mc O
##hs O
17 O
apart O
from O
these O
we O
could O
not O
ﬁ O
##nd O
any O
mc O
##hs O
cases O
with O
a O
ne O
##uro O
##path O
##ological O
description O
in O
the O
literature O
the O
white O
matter O
predominant O
sp O
##ong O
##y O
de O
##gen O
##eration O
with O
alzheimer O
type O
ii O
astro O
##cy O
##tosis O
in O
the O
present O
patient O
may O
therefore O
be O
characteristic O
of O
mc O
##hs O

pol O
##g O
disorders O
often O
show O
elevated O
levels O
of O
lac O
##tate O
both O
in O
the O
serum O
and O
cs O
##f O
as O
well O
as O
elevated O
levels O
of O
he O
##pati O
##c O
enzymes O
however O
these O
ﬁ O
##nding O
##s O
are O
not O
spec O
##i O
##ﬁ O
##c O
for O
pol O
##g O
disorders O
rather O
they O
are O
hallmark O
##s O
of O
mitochondrial O
disorders O
analysis O
of O
the O
rc O
##c O
enzyme O
activity O
is O
the O
most O
valuable O
test O
for O
diagnosis O
of O
md O
##ds O
however O
rc O
##c O
enzyme O
activity O
varies O
among O
muscle O
liver O
kidney O
and O
brain O
tissues O
in O
the O
same O
patient O
1 O
19 O
presumably O
due O
to O
the O
degree O
of O
dna O
de O
##ple O
##tion O
among O
individual O
organs O
the O
constituents O
of O
complex O
ii O
are O
coded O
by O
genes O
in O
the O
nuclear O
not O
mitochondrial O
dna O
in O
the O
present O
patient O
the O
decreased O
complex O
ii O
enzyme O
activity O
in O
the O
bio O
##ps O
##ied O
liver O
may O
either O
result O
from O
augmented O
activity O
of O
control O
cs O
enzyme O
due O
to O
an O
increase O
of O
mit O
##och O
##ond O
##ria O
in O
number O
or O
may O
be O
secondary O
to O
the O
damage O
of O
he O
##pa O
##to O
##cytes O
with O
nec O
##rot O
##ic O
and O
ﬁ O
##bro O
##tic O
changes O
19 O
it O
is O
very O
important O
to O
keep O
in O
mind O
that O
morphological O
ﬁ O
##nding O
##s O
and O
rc O
##c O
enzyme O
activities O
in O
the O
muscle O
are O
sometimes O
un O
##rem O
##ark O
##able O
in O
mc O
##hs O
patients O
even O
though O
they O
show O
h O
##yp O
##oton O
##ia O
or O
muscular O
weakness O
as O
in O
the O
present O
case O
5 O
15 O
20 O
therefore O
analysis O
of O
rc O
##c O
enzyme O
activities O
in O
the O
liver O
should O
be O
considered O
when O
al O
##pers O
syndrome O
or O
mc O
##hs O
disorders O
are O
suspected O
even O
when O
the O
morphological O
ﬁ O
##nding O
##s O
of O
muscle O
or O
enzyme O
ass O
##ay O
results O
are O
un O
##rem O
##ark O
##able O

acknowledge O
##ments O
this O
study O
was O
supported O
in O
part O
by O
a O
grant O
from O
the O
research O
program O
of O
innovative O
cell O
biology O
by O
innovative O
technology O
cell O
innovation O
a O
grant O
in O
aid O
for O
the O
development O
of O
new O
technology O
from O
the O
promotion O
and O
mutual O
aid O
corporation O
for O
private O
schools O
of O
japan O
from O
me O
##xt O
to O
y O
ok O
##az O
##aki O
grants O
in O
aid O
for O
the O
research O
on O
intra O
##ctable O
diseases O
mitochondrial O
disease O
from O
the O
ministry O
of O
health O
labour O
and O
welfare O
of O
japan O
to O
a O
oh O
##take O
dr O
mu O
##raya O
##ma O
was O
supported O
by O
the O
ka O
##wan O
##o O
mas O
##anor O
##i O
memorial O
public O
interest O
incorporated O
foundation O
for O
promotion O
of O
pediatric O
##s O
references O

mora O
##es O
c O
shan O
##ske O
s O
tri O
##ts O
##ch O
##ler O
h O
##j O
april O
##le O
jr O
andre O
##etta O
f O
bon O
##illa O
e O
et O
al O
mt O
##dna O
de O
##ple O
##tion O
with O
variable O
tissue O
expression O
a O
novel O
genetic O
abnormal O
##ity O
in O
mitochondrial O
diseases O
am O
j O
hum O
gene O
##t O
1991 O
48 O
49 O
##2 O
501 O
sar O
##zi O
e O
bo O
##ur O
##don O
a O
ch O
##re O
##´ O
##tie O
##n O
d O
za O
##rh O
##rate O
m O
co O
##rco O
##s O
j O
slam O
##a O
a O
et O
al O
mitochondrial O
dna O
de O
##ple O
##tion O
is O
a O
prevalent O
cause O
of O
multiple O
respiratory O
chain O
de O
##ﬁ O
##ciency O
in O
childhood O
j O
pe O
##dia O
##tr O
2007 O
150 O
53 O
##1 O
4 O
e O
##6 O

wong O
l O
j O
na O
##via O
##ux O
r O
##k O
br O
##une O
##tti O
pier O
##ri O
n O
zhang O
q O
sc O
##hmi O
##tt O
es O
tr O
##uo O
##ng O
c O
et O
al O
molecular O
and O
clinical O
genetics O
of O
mitochondrial O
diseases O
due O
to O
pol O
##g O
mutations O
hum O
mu O
##tat O
2008 O
29 O
150 O
72 O
cohen O
b O
##h O
na O
##via O
##ux O
r O
##k O
the O
clinical O
diagnosis O
of O
pol O
##g O
disease O
and O
other O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O
methods O
2010 O
51 O
36 O
##4 O
73 O

scala O
##is O
e O
francois O
b O
sc O
##hl O
##ess O
##er O
p O
stevens O
r O
nut O
##tin O
c O
martin O
jj O
et O
al O
polymer O
##ase O
gamma O
de O
##ﬁ O
##ciency O
pol O
##g O
clinical O
course O
in O
a O
child O
with O
a O
two O
stage O
evolution O
from O
infant O
##ile O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
to O
an O
al O
##pers O
syndrome O
and O
ne O
##uro O
##path O
##ological O
ﬁ O
##nding O
##s O
of O
leigh O
s O
en O
##ce O
##pha O
##lo O
##pathy O
eu O
##r O
j O
pa O
##ed O
##ia O
##tr O
ne O
##uro O
##l O
2012 O
16 O
54 O
##2 O
8 O
kirby O
d O
##m O
crawford O
m O
clear O
##y O
ma O
dahl O
h O
##h O
den O
##nett O
x O
tour O
##burn O
dr O
respiratory O
chain O
complex O
i O
de O
##ﬁ O
##ciency O
an O
under O
##dia O
##gno O
##sed O
energy O
generation O
disorder O
ne O
##uro O
##logy O
1999 O
52 O
125 O
##5 O
64 O

ka O
##ji O
s O
mu O
##raya O
##ma O
k O
naga O
##ta O
i O
naga O
##saka O
h O
tak O
##ayan O
##agi O
m O
oh O
##take O
a O
et O
al O
flu O
##ct O
##uating O
liver O
functions O
in O
siblings O
with O
mp O
##v O
##17 O
mutations O
and O
possible O
improvement O
associated O
with O
dietary O
and O
pharmaceutical O
treatments O
targeting O
respiratory O
chain O
complex O
ii O
mo O
##l O
gene O
##t O
meta O
##b O
2009 O
97 O
292 O
6 O
pa O
##gna O
##ment O
##a O
at O
ta O
##an O
##man O
j O
##w O
wilson O
c O
##j O
anderson O
ne O
mar O
##ott O
##a O
r O
duncan O
aj O
et O
al O
dominant O
inheritance O
of O
premature O
o O
##var O
##ian O
failure O
associated O
with O
mutant O
mitochondrial O
dna O
polymer O
##ase O
gamma O
hum O
rep O
##rod O
2006 O
21 O
246 O
##7 O
73 O

ya O
##ma O
##zaki O
t O
mu O
##raya O
##ma O
k O
compton O
ag O
su O
##gia O
##na O
c O
hara O
##shima O
h O
am O
##emi O
##ya O
s O
et O
al O
molecular O
diagnosis O
of O
mitochondrial O
respiratory O
chain O
disorders O
in O
japan O
focusing O
on O
mitochondrial O
dna O
de O
##ple O
##tion O
syndrome O
pe O
##dia O
##tr O
int O
2014 O
56 O
180 O
7 O
tang O
s O
wang O
j O
lee O
nc O
milo O
##ne O
m O
hal O
##berg O
mc O
sc O
##hmi O
##tt O
es O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
an O
ever O
expanding O
molecular O
and O
clinical O
spectrum O
j O
med O
gene O
##t O
2011 O
48 O
66 O
##9 O
81 O

mart O
##ika O
##inen O
m O
##h O
hint O
##tal O
##a O
r O
maj O
##ama O
##a O
k O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
adult O
onset O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
en O
##ce O
##pha O
##lo O
##pathy O
b O
##m O
##j O
case O
reports O
2010 O
doi O
10 O
133 O
##6 O
bc O
##r O
01 O
2010 O
260 O
##4 O
go O
##nza O
##´ O
##lez O
vi O
##o O
##que O
e O
b O
##la O
##´ O
##zquez O
a O
fern O
##a O
##´ O
##nde O
##z O
more O
##ira O
d O
born O
##stein O
b O
bautista O
j O
ar O
##pa O
j O
et O
al O
association O
of O
novel O
pol O
##g O
mutations O
and O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
with O
variable O
clinical O
ph O
##eno O
##type O
##s O
in O
a O
spanish O
population O
arch O
ne O
##uro O
##l O
2006 O
63 O
107 O
11 O

che O
##ld O
##i O
a O
ron O
##chi O
d O
bo O
##rdon O
##i O
a O
bo O
##rdo O
b O
lan O
##fra O
##nco O
##ni O
s O
bell O
##otti O
mg O
et O
al O
pol O
##g O
##1 O
mutations O
and O
stroke O
like O
episodes O
a O
distinct O
clinical O
entity O
rather O
than O
an O
at O
##yp O
##ical O
mel O
##as O
syndrome O
b O
##mc O
ne O
##uro O
##l O
2013 O
13 O
8 O
nguyen O
kv O
sha O
##rie O
##f O
f O
##s O
chan O
ss O
copeland O
wc O
na O
##via O
##ux O
r O
##k O
molecular O
diagnosis O
of O
al O
##pers O
syndrome O
j O
he O
##pa O
##to O
##l O
2006 O
45 O
108 O
16 O
kurt O
b O
jae O
##ken O
j O
van O
hove O
j O
la O
##ga O
##e O
l O
lo O
##¨ O
f O
##gren O
a O
ever O
##man O
db O
et O
al O
a O
novel O
pol O
##g O
gene O
mutation O
in O
4 O
children O
with O
al O
##pers O
like O
he O
##pa O
##to O
##cer O
##eb O
##ral O
syndrome O
##s O
arch O
ne O
##uro O
##l O
2010 O
67 O
239 O
44 O

bo O
##ust O
##any O
r O
zu O
##cker O
a O
de O
##gen O
##erative O
disease O
primarily O
gray O
matter O
in O
sw O
##ai O
##man O
k O
##f O
ash O
##wal O
s O
fe O
##rrier O
##o O
d O
editors O
pediatric O
ne O
##uro O
##logy O
principles O
practice O
philadelphia O
mo O
##sby O
2006 O
p O
132 O
##6 O
8 O
ko O
##ll O
##berg O
g O
mo O
##sle O
##mi O
ar O
dar O
##in O
n O
ne O
##nne O
##smo O
i O
b O
##jar O
##nad O
##otti O
##r O
i O
uv O
##eb O
##rant O
p O
et O
al O
pol O
##g O
##1 O
mutations O
associated O
with O
progressive O
en O
##ce O
##pha O
##lo O
##pathy O
in O
childhood O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2006 O
65 O
75 O
##8 O
68 O
bao O
x O
wu O
y O
wong O
l O
##j O
zhang O
y O
xi O
##ong O
h O
cho O
##u O
pc O
et O
al O
al O
##pers O
syndrome O
with O
prominent O
white O
matter O
changes O
brain O
dev O
2008 O
30 O
295 O
300 O

de O
vr O
##ies O
m O
rode O
##nburg O
r O
##j O
mora O
##va O
e O
van O
ka O
##au O
##wen O
e O
ter O
la O
##ak O
h O
mu O
##lla O
##art O
r O
et O
al O
multiple O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
de O
##ﬁ O
##cie O
##ncies O
in O
severe O
childhood O
multi O
system O
disorders O
due O
to O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
mutations O
eu O
##r O
j O
pe O
##dia O
##tr O
2007 O
166 O
229 O
34 O
ferrari O
g O
lama O
##nte O
##a O
e O
dona O
##ti O
a O
fi O
##los O
##to O
m O
br O
##ie O
##m O
e O
carr O
##ara O
f O
et O
al O
infant O
##ile O
he O
##pa O
##to O
##cer O
##eb O
##ral O
syndrome O
##s O
associated O
with O
mutations O
in O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
a O
brain O
2005 O
128 O
72 O
##3 O
31 O

journal O
of O
the O
neurological O
sciences O
350 O
2015 O
93 O
97 O
short O
communication O
parkinson O
##ism O
cognitive O
de O
##ﬁ O
##cit O
and O
behaviour O
##al O
disturbance O
caused O
by O
a O
novel O
mutation O
in O
the O
polymer O
##ase O
gamma O
gene O
manuel O
delgado O
al O
##vara O
##do O
a O
c O
patricia O
de O
la O
ri O
##va O
b O
hari O
##tz O
jimenez O
ur O
##bie O
##ta O
a O
bel O
##en O
gag O
##o O
a O
c O
ala O
##z O
##ne O
ga O
##bil O
##ond O
##o O
b O
bel O
##en O
born O
##stein O
d O
maria O
cruz O
rodriguez O
oro O
##z O
a O
b O
c O
e O
a O
neuroscience O
area O
bio O
##don O
##ost O
##ia O
research O
institute O
san O
sebastian O
spain O
b O
university O
hospital O
don O
##ost O
##ia O
san O
sebastian O
spain O
c O
centro O
de O
invest O
##iga O
##cion O
bio O
##med O
##ica O
en O
red O
de O
en O
##fer O
##med O
##ades O
ne O
##uro O
##de O
##gen O
##era O
##tiv O
##as O
ci O
##ber O
##ned O
madrid O
spain O

d O
ser O
##vic O
##io O
de O
bio O
##qui O
##mic O
##a O
hospital O
un O
##iver O
##sit O
##ario O
pu O
##ert O
##a O
de O
hi O
##er O
##ro O
and O
centro O
de O
invest O
##iga O
##cion O
bio O
##med O
##ica O
en O
red O
de O
en O
##fer O
##med O
##ades O
ra O
##ras O
ci O
##ber O
##er O
madrid O
spain O
e O
ike O
##rba O
##sque O
basque O
foundation O
for O
science O
bilbao O
spain O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
29 O
september O
2014 O
received O
in O
revised O
form O
17 O
january O
2015 O
accepted O
3 O
february O
2015 O
available O
online O
11 O
february O
2015 O
key O
##words O
pol O
##g O
parkinson O
##ism O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pt O
##osis O
cognitive O
impairment O
ob O
##ses O
##sive O
disorder O
a O
b O
s O
t O
r O
a O
c O
t O

polymer O
##ase O
γ O
pol O
##g O
is O
the O
enzyme O
responsible O
for O
the O
replication O
and O
maintenance O
of O
mitochondrial O
dna O
mt O
##dna O
mutations O
in O
the O
pol O
##g O
##1 O
gene O
can O
lead O
to O
mitochondrial O
dysfunction O
producing O
a O
wide O
range O
of O
neurological O
and O
non O
neurological O
ph O
##eno O
##type O
##s O
neurological O
manifestation O
##s O
include O
ata O
##xia O
muscular O
weakness O
ep O
##ile O
##psy O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
pt O
##osis O
ne O
##uro O
##pathy O
psychiatric O
disorders O
and O
more O
rarely O
parkinson O
##ism O
we O
present O
the O
case B-PATIENT
of O
an O
80 O
year O
old O
female O
patient O
with O
a O
history O
of O
pe B-HPO_TERM
##o I-HPO_TERM
pt B-HPO_TERM
##osis I-HPO_TERM
childish B-HPO_TERM
behaviour I-HPO_TERM
ob B-HPO_TERM
##ses I-HPO_TERM
##sive I-HPO_TERM
disorder I-HPO_TERM
cognitive B-HPO_TERM
decline I-HPO_TERM
and O
parkinson B-HPO_TERM
##ism I-HPO_TERM
a O
comprehensive O
study O
showed O
st B-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
do I-HPO_TERM
##pa I-HPO_TERM
##mine I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
on O
dat O
scan O
and O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
as O
evidenced O
by O
go O
##mori O
stain O
##ing O
in O
a O
bio O
##psy O
of O
the O
biceps O
bra O
##chi O
##i O
multiple B-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
of I-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
were O
detected O
and O
sequencing O
of O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
id O
##ent O
##i O
##ﬁ O
##ed O
a O
novel O
substitution O

283 O
##4 O
##ant O
in O
ex O
##on O
18 O
changing O
the O
p B-GENE_VARIANT
his I-GENE_VARIANT
##9 I-GENE_VARIANT
##45 I-GENE_VARIANT
##le I-GENE_VARIANT
##u I-GENE_VARIANT
amino O
acid O
in O
si O
##lic O
##o O
analysis O
using O
poly O
##ph O
##en O
2 O
http O
genetics O
b O
##w O
##h O
hard O
##vard O
ed O
##u O
pp O
##h O
##2 O
predicted O
that O
this O
change O
is O
probably O
damaging O
with O
a O
score O
of O
1 O
0 O
0 O
1 O
2015 O
else O
##vier O
b O
v O
all O
rights O
reserved O
introduction O

mitochondrial O
respiratory O
chain O
dysfunction O
can O
cause O
a O
variety O
of O
diseases O
known O
as O
mitochondrial O
disorders O
polymer O
##ase O
γ O
pol O
##g O
is O
the O
enzyme O
responsible O
for O
the O
replication O
and O
repair O
of O
mitochondrial O
dna O
mt O
##dna O
pol O
γ O
##a O
the O
catalytic O
core O
of O
the O
enzyme O
is O
encoded O
by O
the O
nuclear O
pol O
##g O
##1 O
gene O
mutations O
of O
this O
gene O
are O
associated O
with O
multiple O
del O
##eti O
##ons O
and O
or O
de O
##ple O
##tion O
of O
mt O
##dna O
which O
may O
lead O
to O
impaired O
energy O
production O
in O
the O
mit O
##och O
##ond O
##ria O
and O
the O
so O
called O
pol O
##g O
syndrome O
##s O
1 O
since O
the O
discovery O
of O
the O
gene O
in O
1996 O
more O
than O
100 O
pathogen O
##ic O
mutations O
have O
been O
linked O
to O
a O
wide O
range O
of O
non O
##ne O
##uro O
##logical O
and O
neurological O
disorders O
among O
the O
neurological O
manifestation O
##s O
there O
is O
an O
overlapping O
ph O
##eno O
##typic O
spectrum O
that O
may O
include O
my O
##opa O
##thy O
ne O
##uro O
##pathy O
pt O
##osis O
ep O
##ile O
##psy O
muscle O
pain O
ata O
##xia O
and O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
although O
rare O
cases O
of O
parkinson O
##ism O
have O
also O
been O
described O
in O
association O
with O
pol O
##g O
##1 O
mutations O
we O
report O
on O
a B-PATIENT
patient I-PATIENT
with O
parkinson B-HPO_TERM
##ism I-HPO_TERM
pe B-HPO_TERM
##o I-HPO_TERM
pt B-HPO_TERM
##osis I-HPO_TERM
and O

abbreviation O
##s O
pol O
##g O
polymer O
##ase O
γ O
mt O
##dna O
mitochondrial O
dna O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pd O
parkinson O
s O
disease O
corresponding O
author O
at O
neuroscience O
area O
bio O
##don O
##ost O
##ia O
research O
institute O
pas O
##eo O
dr O
beg O
##ui O
##rist O
##ain O
s O
n O
2000 O
##14 O
san O
sebastian O
tel O
34 O
94 O
##30 O
##0 O
##6 O
##25 O
##8 O
e O
mail O
address O
maria O
rodriguez O
##oro O
##z O
bio O
##don O
##ost O
##ia O
org O
m O
c O
rodriguez O
oro O
##z O
behaviour B-HPO_TERM
##al I-HPO_TERM
and O
cognitive B-HPO_TERM
abnormalities I-HPO_TERM
associated O
with O
a O
novel O
mutation O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
case O
report O

the O
patient B-PATIENT
is O
an O
80 B-AGE_FOLLOWUP
year O
old O
female O
and O
the O
third O
of O
ﬁ O
##ve O
siblings O
she O
was O
born O
at O
term O
after O
an O
uneven O
##tf O
##ul O
pregnancy O
and O
labour O
her O
family O
history O
was O
positive O
for O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
with O
bilateral O
pt O
##osis O
and O
behaviour O
##al O
disturbances O
in O
only O
one O
of O
her O
brothers O
her O
mother O
suffered O
repetitive O
abortion O
##s O
but O
other O
disorders O
were O
not O
known O
in O
either O
of O
her O
parents O
who O
were O
not O
con O
##san O
##gui O
##neo O
##us O
as O
reported O
by O
the O
patient O
she O
ﬁ O
##rst O
presented O
with O
progressive B-HPO_TERM
bilateral I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
in O
her O
fort B-AGE_ONSET
##ies I-AGE_ONSET
and O
received O
correct O
##ive O
left O
eye O
##lid O
surgery O
with O
sub O
##op O
##ti O
##mal O
outcome O
refusing O
further O
interventions O
she O
underwent O
bilateral B-HPO_TERM
cat I-HPO_TERM
##ara I-HPO_TERM
##ct I-HPO_TERM
extraction O
at O
the O
age O
of O
67 O
she O
demonstrated O
childish B-HPO_TERM
behaviour I-HPO_TERM
and O
learning B-HPO_TERM
di I-HPO_TERM
##f I-HPO_TERM
##ﬁ I-HPO_TERM
##cu I-HPO_TERM
##lt I-HPO_TERM
##ies I-HPO_TERM
throughout O
her O
adult O
life O
as O
well O
as O
com B-HPO_TERM
##pu I-HPO_TERM
##ls I-HPO_TERM
##ive I-HPO_TERM
habits I-HPO_TERM
such O
as O
gathering O
items O
over O
the O
last O
twenty O
years O
she O
also O
suffered O
progressive B-HPO_TERM
cognitive I-HPO_TERM
decline I-HPO_TERM
with O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
in O
performing O
her O
habit O
##ual O
tasks O
and O
a O
degree B-HPO_TERM
of I-HPO_TERM
social I-HPO_TERM
impairment I-HPO_TERM
lack O
of O
interaction O
indifference O
etc O
during O
the O
past O
three O
years O
in O
the O
last O
year O
right O
hand B-HPO_TERM
rest I-HPO_TERM
tremor I-HPO_TERM
and O
cl B-HPO_TERM
##ums I-HPO_TERM
##iness I-HPO_TERM
were O
observed O
in O
addition O
a O
loss B-HPO_TERM
of I-HPO_TERM
facial I-HPO_TERM
expression I-HPO_TERM
had O
become O
evident O
in O
the O
last O
few O
years O

physical O
examination O
showed O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
with O
right O
pre O
##dom O
##ina O
##nce O
pe B-HPO_TERM
##o I-HPO_TERM
d B-HPO_TERM
##ys I-HPO_TERM
##phon I-HPO_TERM
##ia I-HPO_TERM
right B-HPO_TERM
hand I-HPO_TERM
rest I-HPO_TERM
tremor I-HPO_TERM
bilateral B-HPO_TERM
mild I-HPO_TERM
rigid I-HPO_TERM
##ity I-HPO_TERM
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
j O
##ns O
2015 O
02 O
01 O
##1 O
00 O
##22 O
510 O
##x O
2015 O
else O
##vier O
b O
v O
all O
rights O
reserved O
94 O
m O
delgado O
al O
##vara O
##do O
et O
al O
journal O
of O
the O
neurological O
sciences O
350 O
2015 O
93 O
97 O

and O
brady B-HPO_TERM
##kin I-HPO_TERM
##es I-HPO_TERM
##ia I-HPO_TERM
in O
the O
upper O
ex O
##tre O
##mit O
##ies O
no O
ce O
##re O
##bella O
##r O
or O
pyramid O
##al O
signs O
were O
found O
the O
patient O
s O
mini O
mental O
state O
examination O
score O
was O
22 O
30 O
ne O
##uro O
##psy O
##cho O
##logical O
tests O
revealed O
cognitive B-HPO_TERM
impairment I-HPO_TERM
with O
executive B-HPO_TERM
dysfunction I-HPO_TERM
language B-HPO_TERM
domain I-HPO_TERM
impairment I-HPO_TERM
and O
mild B-HPO_TERM
apr I-HPO_TERM
##ax I-HPO_TERM
##ia I-HPO_TERM
serum O
analyses O
showed O
a O
total O
ck O
activity O
of O
92 O
u O
l O
normal O
169 O
other O
serum O
parameters O
including O
the O
levels O
of O
p O
##yr O
##u O
##vate O
copper O
ce O
##ru O
##lo O
##pl O
##as O
##min O
f O
##olic O
acid O
vitamin O
b1 O
##2 O
and O
thyroid O
hormones O
were O
normal O
a O
brain O
mri O
scan O
revealed O
moderate B-HPO_TERM
en I-HPO_TERM
##lar I-HPO_TERM
##gement I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
vent I-HPO_TERM
##ric I-HPO_TERM
##les I-HPO_TERM
and O
diffuse B-HPO_TERM
brain I-HPO_TERM
at I-HPO_TERM
##rop I-HPO_TERM
##hy I-HPO_TERM
bilateral B-HPO_TERM
st I-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
do I-HPO_TERM
##pa I-HPO_TERM
##mine I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##ciency I-HPO_TERM
which O
was O
most O
marked O
in O
the O
left O
put O
##amen O
was O
evidenced O
by O
n O
ﬂ O
##uo O
##rop O
##rop O
##yl O
2 O
##β O
car O
##bo O
##met O
##ho O
##xy O
3 O
##β O
4 O
123 O
##i O
io O
##do O
##ph O
##en O
##yl O
##tro O
##pan O
##e O
spec O
##t O
the O
patient O
was O
initiated O
on O
lev O
##od O
##opa O
car O
##bid O
##opa O
300 O
75 O
mg O
per O
day O
to O
which O
she O
exhibited O
a O
partial O
response O
mild O
reduction O
in O
brady O
##kin O
##es O
##ia O
and O
rigid O
##ity O
electro O
##my O
##ography O
and O
nerve O
conduct O
##ion O
studies O
showed O
no O
abnormalities O
and O
echo O
##card O
##iography O
revealed O
no O
sign O
##i O
##ﬁ O
##can O
##t O
disturbances O
a O
mitochondrial O
disorder O
was O
suspected O
and O
a O
muscle O
bio O
##psy O
of O
the O
biceps O
bra O
##chi O
##i O
demonstrated O
ragged B-HPO_TERM
red I-HPO_TERM
ﬁ I-HPO_TERM
##bre I-HPO_TERM
##s I-HPO_TERM
based O
on O
go O
##mori O
stain O
##ing O
fig O
1 O
southern O
b O
##lot O
hybrid O
##ization O
analysis O
id O
##ent O
##i O
##ﬁ O
##ed O
multiple B-HPO_TERM
mt I-HPO_TERM
##dna I-HPO_TERM
del I-HPO_TERM
##eti I-HPO_TERM
##ons I-HPO_TERM
that O
were O
con O
##ﬁ O
##rmed O
using O
the O
long O
pc O
##r O
technique O
given O
this O
ﬁ O
##nding O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
was O
sequence O
##d O
by O
the O
standard O
sang O
##er O
method O
total O
dna O
was O
extracted O
from O
blood O
following O
written O
informed O
consent O
and O
using O
standard O
methods O
direct O
sequencing O
of O
pc O
##r O
amp O
##lic O
##ons O
of O
coding O
ex O
##ons O
of O
pol O
##g O
##1 O
was O
performed O
as O
described O
previously O
2 O
a O
novel O
het O
##ero O
##zy O
##go O
##us O
nu O
##cle O
##ot O
##idi O
##c O
variant O
c B-GENE_VARIANT
283 I-GENE_VARIANT
##4 I-GENE_VARIANT
##an I-GENE_VARIANT
t I-GENE_VARIANT
was O
id O
##ent O
##i O
##ﬁ O
##ed O
in O
ex O
##on O
18 O
of O
the O
pol O
##g O
##1 O
gene O
producing O
the O
p B-GENE_VARIANT
his I-GENE_VARIANT
##9 I-GENE_VARIANT
##45 I-GENE_VARIANT
##le I-GENE_VARIANT
##u I-GENE_VARIANT
amino O
acid O
change O
in O
si O
##lic O
##o O
analysis O
using O
poly O
##ph O
##en O
2 O
http O
genetics O
b O
##w O
##h O
hard O
##vard O
ed O
##u O
pp O
##h O
##2 O
predicted O
that O
this O
change O
was O
probably O
damaging O
with O
a O
score O
of O
1 O
000 O
sensitivity O
0 O
00 O
spec O
##i O
##ﬁ O
##city O
1 O
000 O
in O
addition O
an O
analysis O
conducted O
in O
control O
subjects O
in O

cl O
##uded O
in O
the O
1000 O
genome O
##s O
free O
database O
using O
the O
tool O
variant O
effect O
predict O
##or O
http O
browser O
1000 O
##gen O
##ome O
##s O
org O
homo O
sap O
##iens O
user O
##da O
##ta O
up O
##load O
##var O
##iation O
##s O
determined O
that O
the O
nu O
##cle O
##otide O
variant O
we O
have O
found O
in O
this O
patient O
was O
not O
present O
in O
any O
subject O
a O
targeted O
mutation O
##al O
analysis O
for O
spec O
##i O
##ﬁ O
##c O
point O
mutations O
in O
mt O
##dna O
did O
not O
ﬁ O
##nd O
any O
of O
the O
following O
mutations O
m O
324 O
##3 O
##ang O
in O
gene O
mt O
##tl O
##1 O
m O
34 O
##60 O
##gna O
in O
gene O
mt O
##nd O
##1 O
m O
83 O
##44 O
##ang O
in O
gene O
mt O
##t O
##k O
m O
89 O
##9 O
##3 O
##t O
##ng O
m O
89 O
##9 O
##3 O
##t O
##nc O
m O
91 O
##7 O
##6 O
##t O
##nc O
and O
m O
91 O
##7 O
##6 O
##t O
##ng O
in O
gene O
mt O
##at O
##p O
##6 O
m O
101 O
##58 O
##t O
##nc O
and O
m O
101 O
##9 O
##1 O
##t O
##nc O
in O
gene O
mt O
##nd O
##3 O
m O
117 O
##7 O
##7 O
##c O
##na O

m O
117 O
##7 O
##8 O
##gna O
and O
m O
118 O
##32 O
##gna O
in O
gene O
mt O
##nd O
##4 O
m O
135 O
##13 O
##gna O
and O
m O
135 O
##14 O
##ang O
in O
gene O
mt O
##nd O
##5 O
and O
m O
144 O
##59 O
##gna O
m O
144 O
##8 O
##2 O
##c O
##na O
m O
144 O
##8 O
##2 O
##c O
##ng O
m O
144 O
##8 O
##4 O
##t O
##nc O
and O
m O
144 O
##8 O
##7 O
##t O
##nc O
in O
gene O
mt O
##nd O
##6 O
discussion O

we O
report O
on O
a O
case B-PATIENT
of O
parkinson B-HPO_TERM
##ism I-HPO_TERM
pe B-HPO_TERM
##o I-HPO_TERM
pt B-HPO_TERM
##osis I-HPO_TERM
and O
behaviour B-HPO_TERM
##al I-HPO_TERM
and I-HPO_TERM
cognitive I-HPO_TERM
abnormalities I-HPO_TERM
associated O
with O
a O
novel O
mutation O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
in O
contrast O
to O
other O
manifestation O
##s O
parkinson O
##ism O
is O
less O
frequently O
observed O
in O
mutations O
of O
this O
gene O
it O
was O
ﬁ O
##rst O
described O
in O
ﬁ O
##ve O
families O
with O
some O
members O
presenting O
lev O
##od O
##opa O
responsive O
parkinson O
##ism O
n O
15 O
cat O
##ara O
##cts O
ata O
##xia O
and O
h O
##yp O
##oa O
##cus O
##is O
in O
different O
combinations O
two O
previously O
known O
mutations O
in O
the O
pol O
##g O
##1 O
gene O
as O
well O
as O
one O
novel O
mutation O
were O
described O
in O
these O
patients O
two O
siblings O
with O
parkinson O
##ism O
underwent O
18 O
##f O
β O
cf O
##t O
pet O
that O
revealed O
reduced O
up O
##take O
in O
the O
put O
##amen O
and O
ca O
##uda O
##te O
in O
contrast O
to O
their O
healthy O
siblings O
who O
had O
normal O
up O
##take O
3 O
since O
this O
initial O
report O
19 O
more O

cases O
of O
parkinson O
##ism O
in O
pol O
##g O
##1 O
gene O
mutation O
carriers O
have O
been O
reported O
their O
main O
clinical O
features O
are O
summarized O
in O
table O
1 O
1 O
4 O
20 O
previous O
literature O
shows O
that O
all O
except O
seven O
cases O
presented O
with O
pe O
##o O
and O
or O
pt O
##osis O
signs O
that O
were O
also O
present O
in O
our O
patient O
muscle O
weakness O
ne O
##uro O
##pathy O
and O
ata O
##xia O
were O
also O
common O
features O
not O
present O
in O
the O
case O
we O
report O
similar O
to O
our O
patient O
the O
average O
age O
of O
onset O

of O
the O
neurological O
signs O
was O
between O
the O
3rd O
and O
4th O
decades O
and O
parkinson O
##ism O
usually O
appeared O
after O
several O
years O
tended O
to O
improve O
with O
do O
##pa O
##mine O
##rg O
##ic O
treatment O
and O
was O
associated O
with O
a O
st O
##ria O
##tal O
do O
##pa O
##mine O
##rg O
##ic O
de O
##ﬁ O
##cit O
as O
observed O
in O
dat O
scan O
studies O
in O
a O
few O
cases O
other O
features O
such O
as O
cognitive O
dysfunction O
or O
psychiatric O
symptoms O
including O
depression O
anxiety O
and O
ob O
##ses O
##sive O
disorders O
were O
much O
less O
prevalent O
in O
our O
patient O
behaviour O
##al O
childish O
performance O
and O
cognitive O
abnormalities O
learning O
di O
##f O
##ﬁ O
##cu O
##lt O
##ies O
were O
probably O
the O
initial O
manifestation O
##s O
of O
the O
disease O
emerging O
in O
early O
adulthood O
although O
these O
symptoms O
had O
not O
previously O
been O
investigated O
the O
clinical O
picture O
subsequently O
evolved O
with O
two O
well O
recognized O
phases O
an O
initial O
stage O
in O
which O
pe O
##o O

fig O
1 O
biceps O
bra O
##chi O
##i O
muscle O
bio O
##psy O
specimen O
showing O
ragged B-GENE
red I-GENE
ﬁ I-GENE
##bre I-GENE
go O
##mori O
tri O
##chrome O
stain O
original O
mag O
##ni O
##ﬁ O
##cation O
##200 O
a O
and O
muscle O
ﬁ O
##bre O
##s O
with O
a O
peripheral O
rim O
due O
to O
mitochondrial O
proliferation O
ha O
##ema O
##to O
##xy O
##lin O
and O
e O
##osi O
##n O
stain O
original O
mag O
##ni O
##ﬁ O
##cation O
##100 O
b O
arrows O
n O
ﬂ O
##uo O
##rop O
##rop O
##yl O
2 O
##β O
car O
##bo O
##met O
##ho O
##xy O
3 O
##β O
4 O
123 O
##i O
io O
##do O
##ph O
##en O
##yl O
tr O
##opa O
##ne O
spec O
##t O
showing O
reduced O
up O
##take O
in O
the O
left O
put O
##amen O
c O
electro O
##pher O
##og O
##ram O
of O
the O
reverse O
strand O
sequence O
of O
ex O
##on O
18 O
of O
the O
pol O
##g O
##1 O
gene O
demonstrating O
a O
c O
283 O
##4 O
##ant O
het O
##ero O
##zy O
##go O
##us O
substitution O
d O
table O
1 O

summary O
of O
reported O
cases O
of O
parkinson O
##ism O
due O
to O
mutations O
in O
the O
pol O
##g O
##1 O
gene O
abbreviation O
##s O
pe O
##o O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pt O
##o O
pt O
##osis O
nr O
##p O
ne O
##uro O
##pathy O
ep O
##i O
ep O
##ile O
##psy O
at O
##x O
ata O
##xia O
w O
##k O
##n O
weakness O
d O
##ys O
d O
##ys O
##pha O
##gia O
d O
##yt O
d O
##yst O
##onia O
cat O
cat O
##ara O
##cts O
and O
po O
##f O
premature O
o O
##var O
##ian O
failure O
author O
year O
gen O
##otype O
gender O
age O
parkinson O
##ism O
presenting O
signs O
neurological O
clinical O
manifestation O
##s O
da O
##er O
##gic O
dat O
96 O
m O
delgado O
al O
##vara O
##do O
et O
al O
journal O
of O
the O
neurological O
sciences O
350 O
2015 O
93 O
97 O

and O
pt O
##osis O
appeared O
in O
her O
3rd O
decade O
and O
a O
second O
one O
in O
which O
ob O
##ses O
##sive O
disorder O
developed O
some O
years O
later O
followed O
by O
cognitive O
decline O
and O
parkinson O
##ism O
in O
her O
6th O
decade O
it O
has O
to O
be O
admitted O
that O
although O
all O
these O
clinical O
manifestation O
##s O
can O
be O
explained O
by O
the O
genetic O
variant O
we O
report O
the O
lack O
of O
genetic O
study O
in O
the O
sibling O
with O
a O
similar O
clinical O
picture O
or O
in O
any O
other O
relative O
she O
only O
has O
a O
healthy O
sister O
who O
has O
declined O
to O
be O
studied O
imp O
##edes O
to O
assess O
the O
segregation O
of O
this O
clinical O
picture O
in O
addition O
parkinson O
##ism O
could O
be O
a O
coe O
##xi O
##sti O
##ng O
condition O
particularly O
if O
we O
consider O
the O
prevalence O
of O
this O
entity O
at O
the O
age O
of O
our O
patient O
be O
that O
as O
it O
may O
similarly O
to O
the O
patient O
we O
describe O
it O
has O
to O
be O
noticed O
that O
in O
contrast O
to O
typical O
pd O
parkinson O
##ism O
associated O
with O
pol O
##g O
##1 O
mutations O
has O
additional O
features O
accounting O
for O
a O
more O
complex O
clinical O
ph O
##eno O
##type O
and O
departing O
from O
a O
diagnosis O
of O
pd O
on O
this O
regard O
cognitive O
impairment O
is O
a O
particularly O
interesting O
feature O
as O
it O
is O
observed O
in O
other O
mitochondrial O
disorders O
21 O
22 O
suggesting O
that O
the O
complexity O
of O
its O
pathogen O
##esis O
extends O
beyond O
the O
do O
##pa O
##mine O
##rg O
##ic O
system O

although O
the O
exact O
mechanism O
by O
which O
mitochondrial O
dysfunction O
leads O
to O
parkinson O
##ism O
is O
not O
clearly O
understood O
acc O
##um O
##ulating O
evidence O
suggests O
that O
it O
plays O
a O
crucial O
role O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O
disease O
pd O
1 O
methyl O
4 O
ph O
##en O
##yl O
1 O
2 O
3 O
6 O
te O
##tra O
##hy O
##drop O
##yr O
##idi O
##ne O
and O
rot O
##eno O
##ne O
inhibitors O
of O
the O
mitochondrial O
respiratory O
chain O
complex O
i O
have O
been O
reported O
to O
cause O
parkinson O
##ism O
in O
humans O
and O
other O
primate O
##s O
23 O
furthermore O
several O
of O
the O
genes O
ca O
##usa O
##tive O
of O
fa O
##mi O
##lia O
##l O
forms O
of O
pd O
are O
involved O
in O
mitochondrial O
function O
including O
pink O
##1 O
park O
##in O
and O
dj O
1 O
23 O
in O
addition O
mt O
##dna O
del O
##eti O
##ons O
have O
been O
shown O
in O
sub O
##stan O
##tia O
ni O
##gra O
s O
##n O
neurons O
of O
pd O
patients O
suggesting O
that O
this O
may O
be O
a O
pre O
##dis O
##po O
##sing O
factor O
to O
the O
death O
of O
these O
do O
##pa O
##mine O
##rg O
##ic O
neurons O
which O
are O
believed O
to O
be O
more O
vulnerable O
to O
mitochondrial O
dysfunction O
than O
other O
types O
of O
neurons O
24 O
the O
extent O
to O
which O
pol O
##g O
##1 O
variants O
may O
play O
a O
role O
in O
the O
pathogen O
##esis O
of O
pd O
is O
not O
well O
established O
but O
it O
has O
been O
shown O
that O
among O
441 O
cases O
of O
early O
onset O
pd O
two O
cases O
carried O
compound O
het O
##ero O
##zy O
##go O
##us O
mutations O
and O
the O
frequency O
of O
affected O
siblings O
was O
higher O
in O
patients O
carrying O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
##1 O
mutations O
19 O
in O
addition O
rare O
variants O
of O
the O
pol O
##g O
##1 O
ca O
##g O
repeat O
non O
10 O
11 O
##q O
variants O
in O
the O
ex O
##on O
2 O
which O
en O
##codes O
a O
poly O
##gl O
##uta O
##mine O
tract O
are O
more O
frequent O
in O
pd O
patients O
than O
in O
controls O

25 O
29 O

human O
pol O
γ O
is O
a O
het O
##ero O
##tri O
##mer O
comprising O
a O
catalytic O
subunit O
pol O
γ O
##a O
and O
a O
dime O
##r O
of O
an O
accessory O
subunit O
pol O
γ O
##b O
pol O
γ O
##a O
is O
a O
140 O
k O
##da O
poly O
##pe O
##pt O
##ide O
which O
has O
three O
major O
domains O
a O
n O
terminal O
ex O
##o O
domain O
which O
contains O
the O
ex O
##o O
active O
site O
a O
c O
terminal O
pol O
domain O
which O
contains O
the O
pol O
active O
site O
and O
a O
space O
##r O
domain O
which O
separates O
the O
ex O
##o O
and O
pol O
domains O
in O
primary O
sequence O
the O
clinical O
ph O
##eno O
##type O
of O
pol O
##g O
##1 O
mutations O
depends O
on O
the O
severity O
of O
the O
resultant O
pol O
γ O
functional O
defect O
and O
the O
z O
##y O
##gos O
##ity O
of O
the O
nu O
##cle O
##otide O
variant O
a O
ﬁ O
##ve O
cluster O
model O
of O
pol O
γ O
based O
on O
functional O
aspects O
has O
recently O
been O
designed O
and O
is O
capable O
of O
predicting O
the O
pathogen O
##ic O
potential O
and O
bio O
##chemical O
defects O
of O
novel O
mutations O
30 O
according O
to O
this O
model O
the O
novel O
mutation O
reported O
here O
p O
his O
##9 O
##45 O
##le O
##u O
change O
is O
placed O
in O
sub O
##cl O
##ust O
##er O
1 O
##e O

residues O
91 O
##4 O
96 O
##6 O
which O
acts O
to O
bind O
the O
correct O
de O
##ox O
##yn O
##uc O
##le O
##otide O
tri O
phosphate O
substrate O
d O
##nt O
##p O
within O
this O
region O
there O
is O
a O
motif O
known O
as O
the O
pol O
b O
motif O
residues O
94 O
##3 O
95 O
##8 O
which O
establishes O
spec O
##i O
##ﬁ O
##c O
contacts O
with O
correctly O
base O
paired O
d O
##nt O
##p O
in O
the O
closed O
conform O
##ation O
mutations O
at O
this O
level O
disrupt O
the O
spec O
##i O
##ﬁ O
##c O
contacts O
with O
the O
incoming O
d O
##nt O
##p O
and O
reduce O
the O
ﬁ O
##del O
##ity O
without O
affecting O
dna O
binding O
af O
##ﬁ O
##nity O
accordingly O
mutations O
at O
this O
site O
are O
capable O
of O
competing O
for O
d O
##nt O
##p O
binding O
with O
wild O
type O
pol O
γ O
but O
are O
unable O
to O
polymer O
##ize O
nu O
##cle O
##otide O
##s O
effectively O
causing O
mt O
##dna O
damage O
30 O

conclusion O
we O
report O
on O
a O
novel O
mutation O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
which O
leads O
to O
an O
amino O
acid O
change O
p B-GENE_VARIANT
his I-GENE_VARIANT
##9 I-GENE_VARIANT
##45 I-GENE_VARIANT
##le I-GENE_VARIANT
##u I-GENE_VARIANT
associated O
with O
parkinson B-HPO_TERM
##ism I-HPO_TERM
accompanied O
by B-HPO_TERM
a I-HPO_TERM
ni I-HPO_TERM
##gr I-HPO_TERM
##o I-HPO_TERM
st I-HPO_TERM
##ria I-HPO_TERM
##tal I-HPO_TERM
do I-HPO_TERM
##pa I-HPO_TERM
##mine I-HPO_TERM
##rg I-HPO_TERM
##ic I-HPO_TERM
de I-HPO_TERM
##ﬁ I-HPO_TERM
##cit I-HPO_TERM
and O
response O
to O
lev O
##od O
##opa O
cognitive B-HPO_TERM
disturbances I-HPO_TERM
ob B-HPO_TERM
##ses I-HPO_TERM
##sive I-HPO_TERM
disorder I-HPO_TERM
pe B-HPO_TERM
##o I-HPO_TERM
and O
pt B-HPO_TERM
##osis I-HPO_TERM
pol O
##g O
##1 O
gene O
mutations O
should O
therefore O
be O
considered O
in O
cases O
of O
parkinson O
##ism O
that O
display O
these O
characteristics O
con O
##ﬂ O
##ic O
##t O
of O
interest O
the O
authors O
declare O
that O
they O
do O
not O
have O
any O
con O
##ﬂ O
##ic O
##t O
of O
interest O
funding O
this O
work O
received O
no O
spec O
##i O
##ﬁ O
##c O
funding O
references O

lax O
nz O
he O
##pp O
##le O
##w O
##hit O
##e O
pd O
reeve O
ak O
nes O
##bit O
##t O
v O
mc O
##far O
##land O
r O
jar O
##os O
e O
et O
al O
ce O
##re O
##bella O
##r O
ata O
##xia O
in O
patients O
with O
mitochondrial O
dna O
disease O
a O
molecular O
clinic O
##opa O
##th O
##ological O
study O
j O
ne O
##uro O
##path O
##ol O
ex O
##p O
ne O
##uro O
##l O
2012 O
71 O
2 O
148 O
61 O
http O
d O
##x O
doi O
org O
10 O
109 O
##7 O
ne O
##n O
0 O
##b O
##01 O
##3 O
##e O
##31 O
##8 O
##24 O
##44 O
##7 O
##7 O
##d O

po O
##sa O
##da O
i O
##j O
gall O
##ardo O
me O
dom O
##ing O
##uez O
c O
rivera O
h O
cab O
##ello O
a O
arenas O
j O
et O
al O
mitochondrial O
dna O
de O
##ple O
##tion O
and O
pol O
##g O
mutations O
in O
a O
patient O
with O
sensory O
ata O
##xia O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
med O
cl O
##in O
2010 O
135 O
10 O
45 O
##2 O
5 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
med O
##cl O
##i O
2010 O
03 O
03 O
##1 O
de O
##ple O
##cion O
del O
acid O
##o O
des O
##ox O
##ir O
##ri O
##bon O
##uc O
##lei O
##co O
mit O
##oco O
##nd O
##rial O
y O
mu O
##ta O
##cion O
##es O
de O
pol O
##g O
en O
un O
pac O
##iente O
con O
ne O
##uro O
##pati O
##a O
sensor O
##ial O
ata O
##xi O
##ca O
di O
##sar O
##tri O
##a O
y O
of O
##tal O
##mo O
##ple O
##jia O

lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
ka O
##uk O
##one O
##n O
ja O
nu O
##pp O
##one O
##n O
n O
##n O
chalmers O
rm O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
94 O
##37 O
875 O
82 O
http O
d O
##x O
doi O
org O
10 O
1016 O
s O
##01 O
##40 O
67 O
##36 O
04 O
169 O
##8 O
##3 O
3 O
man O
##cus O
##o O
m O
fi O
##los O
##to O
m O
oh O
s O
##j O
dim O
##aur O
##o O
s O
a O
novel O
polymer O
##ase O
gamma O
mutation O
in O
a O
family O
with O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##pathy O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O
2004 O
61 O
11 O
1777 O
9 O
http O
d O
##x O
doi O
org O
10 O
100 O
##1 O
arch O
##ne O
##ur O
61 O
11 O
1777 O

t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
aa O
##sl O
##y O
j O
zev O
##iani O
m O
winter O
##th O
##un O
s O
et O
al O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
2006 O
129 O
pt O
7 O
1685 O
92 O
http O
d O
##x O
doi O
org O
10 O
109 O
##3 O
brain O
aw O
##l O
##0 O
##9 O
##7 O
pa O
##gna O
##ment O
##a O
at O
ta O
##an O
##man O
j O
##w O
wilson O
c O
##j O
anderson O
ne O
mar O
##ott O
##a O
r O
duncan O
aj O
et O
al O
dominant O
inheritance O
of O
premature O
o O
##var O
##ian O
failure O
associated O
with O
mutant O
mitochondrial O
dna O
polymer O
##ase O
gamma O
hum O
rep O
##rod O
2006 O
21 O
10 O
246 O
##7 O
73 O
http O
d O
##x O
doi O
org O
10 O
109 O
##3 O
hum O
##re O
##p O
del O
##0 O
##7 O
##6 O

david O
##zon O
g O
greene O
p O
man O
##cus O
##o O
m O
k O
##los O
k O
##j O
ahl O
##sko O
##g O
je O
hi O
##rano O
m O
et O
al O
early O
onset O
fa O
##mi O
##lia O
##l O
parkinson O
##ism O
due O
to O
pol O
##g O
mutations O
ann O
ne O
##uro O
##l O
2006 O
59 O
5 O
85 O
##9 O
62 O
http O
d O
##x O
doi O
org O
10 O
100 O
##2 O
ana O
208 O
##31 O
hudson O
g O
sc O
##hae O
##fer O
am O
taylor O
r O
##w O
tian O
##gy O
##ou O
w O
gibson O
a O
ve O
##nable O
##s O
g O
et O
al O
mutation O
of O
the O
link O
##er O
region O
of O
the O
polymer O
##ase O
gamma O
1 O
pol O
##g O
##1 O
gene O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
##ism O
arch O
ne O
##uro O
##l O
2007 O
64 O
4 O
55 O
##3 O
7 O
http O
d O
##x O
doi O
org O
10 O
100 O
##1 O
arch O
##ne O
##ur O
64 O
4 O
55 O
##3 O

in O
##vern O
##iz O
##zi O
f O
var O
##ane O
##se O
s O
thomas O
a O
carr O
##ara O
f O
ono O
##fr O
##j O
m O
zev O
##iani O
m O
two O
novel O
pol O
##g O
##1 O
mutations O
in O
a O
patient O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
lev O
##od O
##opa O
##res O
##pon O
##sive O
pseudo O
or O
##th O
##osta O
##tic O
tremor O
and O
parkinson O
##ism O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
6 O
460 O
4 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
nm O
##d O
2008 O
04 O
00 O
##5 O
re O
##mes O
am O
hint O
##tal O
##a O
r O
ka O
##rp O
##pa O
m O
so O
##ini O
h O
tak O
##alo O
r O
u O
##us O
##ima O
##a O
j O
et O
al O
parkinson O
##ism O
associated O
with O
the O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutation O
in O
the O
pol O
##g O
##1 O
gene O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2008 O
14 O
8 O
65 O
##2 O
4 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
park O
##rel O
##dis O
2008 O
01 O
00 O
##9 O

bet O
##ts O
henderson O
j O
jar O
##os O
e O
krishna O
##n O
k O
##j O
perry O
r O
##h O
reeve O
ak O
sc O
##hae O
##fer O
am O
et O
al O
alpha O
syn O
##uc O
##lein O
pathology O
and O
parkinson O
##ism O
associated O
with O
pol O
##g O
##1 O
mutations O
and O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
ne O
##uro O
##path O
##ol O
app O
##l O
ne O
##uro O
##bio O
##l O
2009 O
35 O
1 O
120 O
4 O
http O
d O
##x O
doi O
org O
10 O
111 O
##1 O
j O
136 O
##5 O
299 O
##0 O
2008 O
00 O
##9 O
##8 O
##1 O
x O
syn O
##of O
##zi O
##k O
m O
as O
##mus O
f O
rei O
##mo O
##ld O
m O
sc O
##hol O
##s O
l O
berg O
d O
sustained O
do O
##pa O
##mine O
##rg O
##ic O
response O
of O
parkinson O
##ism O
and O
depression O
in O
pol O
##g O
associated O
parkinson O
##ism O
mo O
##v O
di O
##sor O
##d O
2010 O
25 O
2 O
243 O
5 O
http O
d O
##x O
doi O
org O
10 O
100 O
##2 O
md O
##s O
228 O
##65 O

sato O
k O
ya O
##be O
i O
ya O
##guchi O
h O
nak O
##ano O
f O
kun O
##ied O
##a O
y O
sai O
##to O
##h O
s O
et O
al O
genetic O
analysis O
of O
two O
japanese O
families O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
##ism O
j O
ne O
##uro O
##l O
2011 O
258 O
7 O
132 O
##7 O
32 O
http O
d O
##x O
doi O
org O
10 O
100 O
##7 O
s O
##00 O
##41 O
##5 O
01 O
##1 O
59 O
##36 O
x O
gu O
##rge O
##l O
gia O
##nne O
##tti O
j O
cam O
##ar O
##gos O
st O
card O
##oso O
f O
hi O
##rano O
m O
dim O
##aur O
##o O
s O
pol O
##g O
##1 O
ar O
##g O
##9 O
##53 O
##cy O
##s O
mutation O
expanded O
ph O
##eno O
##type O
and O
recess O
##ive O
inheritance O
in O
a O
brazilian O
family O
muscle O
nerve O
2012 O
45 O
3 O
45 O
##3 O
4 O
http O
d O
##x O
doi O
org O
10 O
100 O
##2 O
mu O
##s O
223 O
##30 O

brandon O
br O
died O
##eric O
##h O
nj O
son O
##i O
m O
wit O
##te O
k O
wei O
##nh O
##old O
m O
k O
##raus O
##e O
m O
et O
al O
auto O
##som O
##al O
dominant O
mutations O
in O
pol O
##g O
and O
c1 O
##0 O
##orf O
##2 O
association O
with O
late O
onset O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
parkinson O
##ism O
in O
two O
patients O
j O
ne O
##uro O
##l O
2013 O
260 O
7 O
1931 O
3 O
http O
d O
##x O
doi O
org O
10 O
100 O
##7 O
s O
##00 O
##41 O
##5 O
01 O
##3 O
69 O
##75 O
2 O
do O
##l O
##hun O
r O
pre O
##sant O
em O
he O
##der O
##a O
p O
novel O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
gene O
mutation O
in O
the O
link O
##er O
domain O
associated O
with O
parkinson O
##ism O
b O
##mc O
ne O
##uro O
##l O
2013 O
13 O
92 O
http O
d O
##x O
doi O
org O
10 O
118 O
##6 O
147 O
##1 O
237 O
##7 O
13 O
92 O

band O
##etti O
##ni O
di O
po O
##ggio O
m O
nest O
##i O
c O
bruno O
c O
me O
##sch O
##ini O
mc O
sc O
##hen O
##one O
a O
santo O
##relli O
fm O
do O
##pa O
##mine O
ago O
##nist O
responsive O
parkinson O
##ism O
in O
a O
patient O
with O
the O
sand O
##o O
syndrome O
caused O
by O
pol O
##g O
mutation O
b O
##mc O
med O
gene O
##t O
2013 O
14 O
105 O
http O
d O
##x O
doi O
org O
10 O
118 O
##6 O
147 O
##1 O
235 O
##0 O
14 O
105 O
mu O
##kai O
m O
su O
##ga O
##ya O
k O
ya O
##be O
i O
got O
##o O
y O
yoko O
##chi O
f O
mi O
##yam O
##oto O
k O
et O
al O
ne O
##uro O
##mel O
##ani O
##n O
mri O
in O
a O
family O
with O
mitochondrial O
parkinson O
##ism O
harbor O
##ing O
a O
y O
##9 O
##55 O
##c O
mutation O
in O
pol O
##g O
##1 O
parkinson O
##ism O
re O
##lat O
di O
##sor O
##d O
2013 O
19 O
9 O
82 O
##1 O
4 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
park O
##rel O
##dis O
2013 O
04 O
01 O
##1 O

y O
##lone O
##n O
s O
y O
##lik O
##ot O
##ila O
p O
si O
##ito O
##nen O
a O
finn O
##ila O
s O
au O
##ter O
##e O
j O
maj O
##ama O
##a O
k O
variations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
in O
patients O
with O
parkinson O
s O
disease O
j O
ne O
##uro O
##l O
2013 O
260 O
12 O
314 O
##4 O
9 O
http O
d O
##x O
doi O
org O
10 O
100 O
##7 O
s O
##00 O
##41 O
##5 O
01 O
##3 O
71 O
##32 O
7 O
m O
delgado O
al O
##vara O
##do O
et O
al O
journal O
of O
the O
neurological O
sciences O
350 O
2015 O
93 O
97 O
97 O
milo O
##ne O
m O
wang O
j O
lie O
##wl O
##uck O
t O
chen O
lc O
lea O
##vitt O
ja O
wong O
l O
##j O
novel O
pol O
##g O
sp O
##lice O
site O
mutation O
and O
optic O
at O
##rop O
##hy O
arch O
ne O
##uro O
##l O
2011 O
68 O
6 O
80 O
##6 O
11 O
http O
d O
##x O
doi O
org O
10 O
100 O
##1 O
arch O
##ne O
##uro O
##l O
2011 O
124 O

inc O
##zed O
##y O
far O
##kas O
g O
tram O
##pus O
##h O
j O
##w O
per O
##cz O
##el O
for O
##int O
##os O
d O
beech O
d O
andre O
##jk O
##ovic O
##s O
m O
var O
##ga O
z O
et O
al O
mitochondrial O
dna O
mutations O
and O
cognition O
a O
case O
series O
report O
arch O
cl O
##in O
ne O
##uro O
##psy O
##cho O
##l O
2014 O
29 O
4 O
315 O
21 O
http O
d O
##x O
doi O
org O
10 O
109 O
##3 O
arc O
##lin O
ac O
##u O
##01 O
##6 O
fins O
##ter O
##er O
j O
cognitive O
decline O
as O
a O
manifestation O
of O
mitochondrial O
disorders O
mitochondrial O
dementia O
j O
ne O
##uro O
##l O
sci O
2008 O
272 O
1 O
2 O
20 O
33 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
j O
##ns O
2008 O
05 O
01 O
##1 O

reeve O
a O
me O
##agh O
##er O
m O
lax O
n O
sim O
##co O
##x O
e O
he O
##pp O
##le O
##w O
##hit O
##e O
p O
jar O
##os O
e O
et O
al O
the O
impact O
of O
pathogen O
##ic O
mitochondrial O
dna O
mutations O
on O
sub O
##stan O
##tia O
ni O
##gra O
neurons O
j O
ne O
##uro O
##sc O
##i O
2013 O
33 O
26 O
107 O
##90 O
80 O
##1 O
http O
d O
##x O
doi O
org O
10 O
152 O
##3 O
j O
##ne O
##uro O
##sc O
##i O
352 O
##5 O
12 O
2013 O
bu O
##ele O
##r O
h O
impaired O
mitochondrial O
dynamics O
and O
function O
in O
the O
pathogen O
##esis O
of O
parkinson O
s O
disease O
ex O
##p O
ne O
##uro O
##l O
2009 O
218 O
2 O
235 O
46 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
ex O
##p O
##ne O
##uro O
##l O
2009 O
03 O
00 O
##6 O

lu O
##oma O
pt O
ee O
##rol O
##a O
j O
ah O
##ola O
s O
ha O
##kon O
##en O
ah O
hell O
##strom O
o O
ki O
##vis O
##to O
k O
##t O
et O
al O
mitochondrial O
dna O
polymer O
##ase O
gamma O
variants O
in O
id O
##io O
##pathic O
sporadic O
parkinson O
disease O
ne O
##uro O
##logy O
2007 O
69 O
11 O
115 O
##2 O
9 O
http O
d O
##x O
doi O
org O
10 O
121 O
##2 O
01 O
w O
##nl O
000 O
##0 O
##27 O
##6 O
##9 O
##55 O
237 O
##35 O
e O
##b O
an O
##vre O
##t O
a O
west O
##er O
##lund O
m O
sy O
##do O
##w O
o O
willow O
##s O
t O
lin O
##d O
c O
gal O
##ter O
d O
et O
al O
variations O
of O
the O
ca O
##g O
tri O
##nu O
##cle O
##otide O
repeat O
in O
dna O
polymer O
##ase O
gamma O
pol O
##g O
##1 O
is O
associated O
with O
parkinson O
s O
disease O
in O
sweden O
ne O
##uro O
##sc O
##i O
let O
##t O
2010 O
48 O
##5 O
2 O
117 O
20 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
ne O
##ule O
##t O
2010 O
08 O
08 O
##2 O

ee O
##rol O
##a O
j O
lu O
##oma O
pt O
pe O
##ural O
##inn O
##a O
t O
sc O
##holz O
s O
pa O
##isan O
ruiz O
c O
su O
##oma O
##lain O
##en O
a O
et O
al O
pol O
##g O
##1 O
poly O
##gl O
##uta O
##mine O
tract O
variants O
associated O
with O
parkinson O
s O
disease O
ne O
##uro O
##sc O
##i O
let O
##t O
2010 O
47 O
##7 O
1 O
1 O
5 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
ne O
##ule O
##t O
2010 O
04 O
02 O
##1 O
bala O
##fk O
##an O
n O
t O
##zo O
##uli O
##s O
c O
muller O
b O
ha O
##uga O
##r O
##vo O
##ll O
k O
ty O
##s O
##nes O
ob O
larsen O
jp O
et O
al O
number O
of O
ca O
##g O
repeats O
in O
pol O
##g O
##1 O
and O
its O
association O
with O
parkinson O
disease O
in O
the O
norwegian O
population O
mit O
##och O
##ond O
##rion O
2012 O
12 O
6 O
640 O
3 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
mit O
##o O
2012 O
08 O
00 O
##4 O

gui O
y O
##x O
xu O
z O
##p O
l O
##v O
w O
liu O
hm O
zhao O
jj O
hu O
x O
##y O
association O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
gene O
pol O
##g O
##1 O
poly O
##morphism O
##s O
with O
parkinson O
##ism O
in O
chinese O
populations O
pl O
##os O
one O
2012 O
7 O
12 O
e O
##500 O
##86 O
http O
d O
##x O
doi O
org O
10 O
137 O
##1 O
journal O
po O
##ne O
00 O
##500 O
##86 O
far O
##num O
ga O
nur O
##mine O
##n O
a O
ka O
##gun O
##i O
l O
##s O
mapping O
136 O
pathogen O
##ic O
mutations O
into O
functional O
modules O
in O
human O
dna O
polymer O
##ase O
gamma O
establishes O
predict O
##ive O
gen O
##otype O
ph O
##eno O
##type O
correlation O
##s O
for O
the O
complete O
spectrum O
of O
pol O
##g O
syndrome O
##s O
bio O
##chi O
##m O
bio O
##phy O
##s O
act O
##a O
2014 O
1837 O
7 O
111 O
##3 O
21 O
http O
d O
##x O
doi O
org O
10 O
1016 O
j O
bb O
##abi O
##o O
2014 O
01 O
02 O
##1 O

act O
##a O
ne O
##uro O
##l O
bel O
##g O
2017 O
117 O
39 O
##9 O
401 O
doi O
10 O
100 O
##7 O
s O
##13 O
##7 O
##60 O
01 O
##6 O
06 O
##7 O
##2 O
8 O
late O
onset O
of O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
an O
unusual O
cause O
of O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
and O
liver O
failure O
fr O
##e O
##´ O
##de O
##´ O
##ric O
london O
##1 O
na O
##wal O
had O
##ho O
##um O
##1 O
olivier O
out O
##tery O
##ck O
##1 O
2 O
patrick O
ve O
##rm O
##ers O
##ch O
##1 O
3 O
he O
##´ O
##le O
ne O
ze O
##´ O
##phi O
##r O
##1 O
4 O
received O
3 O
june O
2016 O
accepted O
8 O
july O
2016 O
published O
online O
15 O
july O
2016 O
belgian O
neurological O
society O
2016 O
key O
##words O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
liver O
failure O
val O
##pro O
##ic O
acid O
pol O
##g O
mutation O
introduction O

al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
ah O
##s O
is O
an O
uncommon O
inherited O
mitochondrial O
disease O
characterized O
by O
a O
clinical O
triad O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
he O
##pa O
##top O
##athy O
and O
progressive O
psycho O
##moto O
##r O
regression O
1 O
it O
usually O
occurs O
in O
infancy O
or O
early O
childhood O
while O
juvenile O
onset O
is O
rare O
we O
present O
a O
16 O
years O
old O
girl O
with O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
in O
whom O
the O
diagnosis O
was O
suspected O
because O
of O
acute O
liver O
dysfunction O
fr O
##e O
##´ O
##de O
##´ O
##ric O
london O
london O
##fr O
##ede O
##ric O
gma O
##il O
com O
na O
##wal O
had O
##ho O
##um O
na O
##wal O
had O
##ho O
##um O
ch O
##ru O
lille O
fr O
olivier O
out O
##tery O
##ck O
olivier O
out O
##tery O
##ck O
ch O
##ru O
lille O
fr O
patrick O
ve O
##rm O
##ers O
##ch O
patrick O
ve O
##rm O
##ers O
##ch O
un O
##iv O
lille O
##2 O
fr O

he O
##´ O
##le O
ne O
ze O
##´ O
##phi O
##r O
helene O
ze O
##phi O
##r O
ch O
##ru O
lille O
fr O
1 O
de O
##´ O
##par O
##tem O
##ent O
de O
ne O
##uro O
##logie O
des O
neuroscience O
##s O
et O
de O
l O
app O
##are O
##il O
loco O
##mot O
##eur O
roger O
sale O
##ng O
##ro O
universite O
##´ O
de O
lille O
1 O
rue O
emile O
lai O
##ne O
590 O
##37 O
lille O
ce O
##de O
##x O
france O
2 O
un O
##iv O
lille O
ins O
##er O
##m O
u O
##11 O
##7 O
##1 O
chu O
lille O
590 O
##45 O
lille O
france O
3 O
un O
##iv O
lille O
chu O
lille O
li O
##ric O
ins O
##er O
##m O
u O
##9 O
##9 O
##5 O
f O
##hu O
imminent O
590 O
##00 O
lille O
france O
4 O
un O
##iv O
lille O
li O
##ric O
um O
##r O
99 O
##5 O
chu O
lille O
590 O
##45 O
lille O
france O
case O
report O

this O
previously O
healthy O
16 B-AGE_ONSET
year O
old O
female O
patient B-PATIENT
with O
normal O
psycho O
##moto O
##r O
development O
was O
admitted O
in O
december O
2014 O
because O
of O
a O
de O
novo O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
she O
had O
influenza B-HPO_TERM
like I-HPO_TERM
symptoms I-HPO_TERM
3 O
weeks O
ago O
and O
reported O
a O
1 O
week O
history O
of O
unusual O
headache B-HPO_TERM
##s I-HPO_TERM
with I-HPO_TERM
visual I-HPO_TERM
disturbances I-HPO_TERM
flashing O
lights O
electro B-HPO_TERM
##ence I-HPO_TERM
##pha I-HPO_TERM
##logram I-HPO_TERM
ee I-HPO_TERM
##g I-HPO_TERM
demonstrated I-HPO_TERM
continuous I-HPO_TERM
rhythmic I-HPO_TERM
1 I-HPO_TERM
1 I-HPO_TERM
5 I-HPO_TERM
hz I-HPO_TERM
high I-HPO_TERM
amplitude I-HPO_TERM
delta I-HPO_TERM
with I-HPO_TERM
super I-HPO_TERM
##im I-HPO_TERM
##posed I-HPO_TERM
spikes I-HPO_TERM
which O
over O
the O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
regions O
brain B-HPO_TERM
mri I-HPO_TERM
showed I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in O
t O
##2 O
weighted O
and O
diffusion O
weighted O
sequences O
in O
the O
right O
tha O
##lam O
##us O
right O
o O
##cci O
##pit O
##al O
cortex O
and O
left O
ce O
##re O
##bell O
##um O
without O
ga O
##do O
##lini O
##umen O
##han O
##ce O
##ment O
comprehensive O
work O
##up O
including O
extensive O
auto O
##im O
##mun O
##e O
laboratory O
tests O
was O
normal O
as O
well O
as O
the O
tests O
for O
hiv O
sy O
##phi O
##lis O
e O
##b O
##v O
cm O
##v O
hs O
##v O
hz O
##v O
and O
bo O
##rre O
##lia O
bu O
##rg O
##dorf O
##eri O
lu B-HPO_TERM
##mba I-HPO_TERM
##r I-HPO_TERM
pun I-HPO_TERM
##cture I-HPO_TERM
revealed I-HPO_TERM
a I-HPO_TERM
l I-HPO_TERM
##ym I-HPO_TERM
##ph I-HPO_TERM
##oc I-HPO_TERM
##ytic I-HPO_TERM
pl I-HPO_TERM
##eo I-HPO_TERM
##cy I-HPO_TERM
##tosis I-HPO_TERM
16 O
cells O
ll O
without O
ol O
##igo O
##cl O
##onal O
bands O
ce O
##re O
##bro O
##sp O
##inal O
fluid O
culture O
was O
sterile O
whole O
body O
computed O
tom O
##ography O
was O
normal O
due O
to O
a O
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
val O
##pro O
##ic O
acid O
vp O
##a O
was O
ad O
##mini O
##stra O
##ted O
improving O
ee O
##g O
and O
clinical O
status O

in O
april O
2015 O
while O
she O
remains O
free O
of O
seizures O
systematic O
blood O
tests O
revealed O
progressive B-HPO_TERM
liver I-HPO_TERM
failure I-HPO_TERM
with O
repeated B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##og I-HPO_TERM
##ly I-HPO_TERM
##ca I-HPO_TERM
##emia I-HPO_TERM
##s I-HPO_TERM
leading O
to O
urgent O
liver B-HPO_TERM
transplant I-HPO_TERM
##ation I-HPO_TERM
despite O
vp O
##a O
disco O
##nti O
##nu O
##ation O
serum O
markers O
of O
auto O
##im O
##mun O
##e O
and O
viral O
hepatitis O
were O
negative O
wilson O
disease O
was O
considered O
because O
of O
a O
low B-HPO_TERM
ce I-HPO_TERM
##ru I-HPO_TERM
##lo I-HPO_TERM
##pl I-HPO_TERM
##as I-HPO_TERM
##min I-HPO_TERM
and I-HPO_TERM
copper I-HPO_TERM
levels O
but O
was O
finally O
ruled O
out O
his O
##top O
##ath O
##ological O
study O
of O
liver B-HPO_TERM
showed I-HPO_TERM
a I-HPO_TERM
marked I-HPO_TERM
nec I-HPO_TERM
##rosis I-HPO_TERM
with O
diffuse O
fi O
##bro O
##sis O
around O
central O
veins O
and O
focal O
accumulation O
of O
poly O
##mo O
##rp O
##hon O
##uc O
##lea O
##r O
le O
##uk O
##ocytes O
micro B-HPO_TERM
##ves I-HPO_TERM
##icular I-HPO_TERM
ste I-HPO_TERM
##ato I-HPO_TERM
##sis I-HPO_TERM
was O
also O
observed O
but O
there O
was O
no O
iron O
over O
##load O

1 O
3 O
400 O
act O
##a O
ne O
##uro O
##l O
bel O
##g O
2017 O
117 O
39 O
##9 O
401 O

a O
few O
days O
later O
she O
developed O
neurological B-HPO_TERM
deterioration I-HPO_TERM
with O
te B-HPO_TERM
##tra I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
h B-HPO_TERM
##yp I-HPO_TERM
##oton I-HPO_TERM
##ia I-HPO_TERM
cognitive B-HPO_TERM
impairment I-HPO_TERM
and O
multi B-HPO_TERM
##fo I-HPO_TERM
##cal I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
ref B-HPO_TERM
##rac I-HPO_TERM
##tory I-HPO_TERM
partial I-HPO_TERM
seizures I-HPO_TERM
required O
lev O
##eti O
##race O
##tam O
cl O
##ona O
##ze O
##pa O
##m O
and O
top O
##ira O
##mate O
to O
obtain O
seizure O
control O
brain O
mri O
follow O
up O
demonstrated O
new O
t B-HPO_TERM
##2 I-HPO_TERM
flair I-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
arguing O
for O
metabolic O
lesions O
bilateral B-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
right B-HPO_TERM
frontal I-HPO_TERM
cortex I-HPO_TERM
and O
bilateral B-HPO_TERM
par I-HPO_TERM
##ie I-HPO_TERM
##tal I-HPO_TERM
cortex I-HPO_TERM
associated O
with O
post O
seizure O
hyper O
##si O
##gna O
##ls O
in O
tha O
##lam O
##i O
fig O
1a O
d O
proton O
magnetic O
resonance O
spec O
##tro O
##scopic O
imaging O
showed O
a O
lac B-HPO_TERM
##tate I-HPO_TERM
double I-HPO_TERM
##t I-HPO_TERM
peak I-HPO_TERM
mit O
##och O
##ond O
##rio O
##pathy O
was O
considered O
laboratory O
findings O
showed O
elevated B-HPO_TERM
lac I-HPO_TERM
##tate I-HPO_TERM
concentration I-HPO_TERM
8 O
mm O
##ol O
l O
but O
analysis O
of O
respiratory O
chain O
complexes O
in O
muscle O
bio O
##psy O
was O
negative O
ah O
##s O
was O
suspected O
and O
mutation O
analysis O
of O
the O
polymer O
##ase O
gamma O
gene O
pol B-GENE
##g I-GENE
revealed O
compound O
het O
##ero O
##zy O
##go O
##tes O
mutations O
a B-GENE_VARIANT
##46 I-GENE_VARIANT
##7 I-GENE_VARIANT
##t I-GENE_VARIANT
w B-GENE_VARIANT
##7 I-GENE_VARIANT
##48 I-GENE_VARIANT
##s I-GENE_VARIANT
family O
history O
did O
not O
provide O
any O
evidence O
of O
mitochondrial O
dysfunction O
especially O
in O
her O
two O
old O
brothers O
at O
1 B-AGE_FOLLOWUP
year I-AGE_FOLLOWUP
of I-AGE_FOLLOWUP
follow I-AGE_FOLLOWUP
up I-AGE_FOLLOWUP
she O
has O
severe O
disability O
requiring O
constant O
nursing O
care O
and O
attention O
rec O
##ur O
##rence O
of O
simple O
partial B-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
required O
adding O
lac O
##osa O
##mide O
to O
achieve O
a O
seizure O
free O
status O

fig O
1 O
brain O
mri O
performed O
6 O
months O
after O
disease O
onset O
and O
8 O
days O
after O
rec O
##ur O
##rence O
of O
seizures O
axial O
flair O
image O
a O
and O
d O
##wi O
##weight O
##ed O
image O
b O
showing O
hyper B-HPO_TERM
##int I-HPO_TERM
##ens I-HPO_TERM
##ities I-HPO_TERM
in I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
c O
axial O
flair O
image O
showing O
hyper B-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
les I-HPO_TERM
##ion I-HPO_TERM
in I-HPO_TERM
right I-HPO_TERM
o I-HPO_TERM
##cci I-HPO_TERM
##pit I-HPO_TERM
##al I-HPO_TERM
lobe I-HPO_TERM
d O
corona O
##l O
flair O
image O
demonstrating O
bilateral O
and O
symmetrical B-HPO_TERM
hyper I-HPO_TERM
##int I-HPO_TERM
##ense I-HPO_TERM
lesions I-HPO_TERM
in I-HPO_TERM
ce I-HPO_TERM
##re I-HPO_TERM
##bell I-HPO_TERM
##um I-HPO_TERM
and O
par O
##ie O
##tal O
cortex O
discussion O

ah O
##s O
is O
caused O
by O
mutations O
in O
mitochondrial O
dna O
pol O
##g O
and O
is O
associated O
with O
high O
and O
early O
mortality O
since O
death O
usually O
occurs O
within O
4 O
years O
when O
revealed O
by O
seizures O
1 O
onset O
is O
far O
more O
common O
in O
infancy O
or O
early O
childhood O
range O
3 O
months O
to O
8 O
years O
whereas O
juvenile O
or O
young O
adult O
onset O
is O
rare O
as O
we O
found O
few O
reported O
cases O
with O
a O
range O
of O
10 O
27 O
years O
at O
clinical O
presentation O
1 O
2 O
all O
patients O
are O
healthy O
before O
they O
developed O
a O
rapid O
onset O
of O
intra O
##ctable O
ep O
##ile O
##psy O
usually O
associated O
with O
headache O
followed O
by O
liver O
failure O
and O
developmental O
regression O
clinical O
course O
is O
always O
fatal O
within O
years O
and O
sometimes O
rapidly O
fu O
##lm O
##ina O
##nt O
1 O
as O
ah O
##s O
is O
an O
auto O
##som O
##al O
recess O
##ive O
disorder O
the O
inheritance O
of O
two O
pathogen O
##ic O
all O
##eles O
mutations O
in O
trans O
of O
pol O
##g O
is O
required O
for O
disease O
expression O
1 O
3 O
although O
segregation O
of O
the O
two O
mutations O
in O
pol O
##g O
within O
the O
family O
of O
our O
patient O
was O
not O
done O
and O
we O
cannot O
thus O
valid O
##ate O
that O
the O
mutations O
found O
are O
in O
trans O
these O
mutations O
are O
most O
likely O
found O
in O
trans O
and O
therefore O
path O
##ological O
1 O
4 O

homo O
##zy O
##go O
##us O
mutations O
are O
associated O
with O
a O
later O
onset O
and O
less O
severe O
disease O
whereas O
patients O
with O
het O
##ero O
##zy O
##go O
##us O
mutations O
have O
an O
early O
onset O
a O
more O
severe O
disease O
including O
an O
increased O
incidence O
of O
liver O
failure O
1 O
5 O
the O
presence O
of O
het O
##ero O
##zy O
##go O
##us O
mutations O
in O
our O
patient O
who O
presents O
a O
severe O
disease O
with O
late O
onset O
demonstrates O
that O
gen O
##otype O
is O
not O
sufficient O
to O
explain O
the O
ph O
##eno O
##typic O
variability O
environmental O
factors O
are O
probably O
involved O
as O
viral O
illness O
can O
pre O
##ci O
##pit O
##ate O
onset O
of O
ah O
##s O
whereas O
exposure O
to O
vp O
##a O
can O
promote O
liver O
failure O
which O
is O
a O
typical O
feature O
of O
ah O
##s O
1 O
as O
liver O
dysfunction O
is O
one O
of O
the O
two O
leading O
causes O
of O
death O
in O
ah O
##s O
the O
other O
one O
is O
un O
##con O
##tro O
##lled O
seizures O
vp O
##a O
must O
be O
strongly O
contra O
##ind O
##icated O
in O
this O
disorder O
although O
the O
risk O
of O
vp O
##a O
induced O
toxicity O
is O
intrinsic O
##ally O
related O
to O
pol O
##g O
mutation O
the O
mechanisms O
leading O
to O
high O
risk O
of O
vp O
##a O
induced O
he O
##pa O
##to O
##to O
##xi O
##city O
are O
not O
fully O
understood O
6 O

the O
mri O
abnormalities O
observed O
in O
our O
patient O
are O
consistent O
with O
the O
predominant O
and O
progressive O
involvement O
of O
o O
##cci O
##pit O
##al O
regions O
and O
ce O
##re O
##bell O
##um O
previously O
described O
in O
ah O
##s O
7 O
in O
conclusion O
pol O
##g O
gene O
testing O
should O
be O
considered O
in O
teenagers O
young O
adults O
with O
sudden O
onset O
of O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
of O
unknown O
origin O
before O
institut O
##ing O
vp O
##a O
therapy O
especially O
when O
mri O
reveals O
brain O
changes O
in O
regions O
suggest O
##ive O
of O
a O
mit O
##och O
##ond O
##rio O
##pathy O
although O
there O
is O
currently O
no O
specific O
therapy O
for O
ah O
##s O
recognition O
of O
the O
diagnosis O
is O
also O
of O
importance O
for O
genetic O
counsel O
##ling O

compliance O
with O
ethical O
standards O
conflict O
of O
interest O
the O
authors O
declare O
no O
conflict O
of O
interest O
related O
to O
this O
publication O
1 O
3 O
act O
##a O
ne O
##uro O
##l O
bel O
##g O
2017 O
117 O
39 O
##9 O
401 O
401 O
financial O
support O
no O
financial O
support O
was O
received O
for O
this O
submission O
ethical O
standard O
this O
article O
does O
not O
contain O
any O
studies O
with O
human O
participants O
or O
animals O
performed O
by O
any O
of O
the O
authors O
informed O
consent O
for O
this O
type O
of O
study O
formal O
consent O
is O
not O
required O
references O
sane O
##to O
r O
##p O
cohen O
b O
##h O
copeland O
wc O
na O
##via O
##ux O
r O
##k O
2013 O
al O
##pers O
##hu O
##tten O
##lo O
##cher O
syndrome O
pe O
##dia O
##tr O
ne O
##uro O
##l O
48 O
167 O
178 O

u O
##us O
##ima O
##a O
j O
hint O
##tal O
##a O
r O
ran O
##tal O
##a O
h O
pa O
##¨ O
##iva O
##¨ O
##rin O
##ta O
m O
her O
##va O
r O
ro O
##¨ O
##yt O
##ta O
##¨ O
m O
so O
##ini O
h O
moi O
##lane O
##n O
j O
##s O
re O
##mes O
am O
has O
##sin O
##en O
ie O
maj O
##ama O
##a O
k O
2008 O
homo O
##zy O
##go O
##us O
w O
##7 O
##48 O
##s O
mutation O
in O
the O
pol O
##g O
##1 O
gene O
in O
patients O
with O
juvenile O
onset O
al O
##pers O
syndrome O
ep O
##ile O
##ps O
##ia O
49 O
103 O
##8 O
104 O
##5 O
nguyen O
kv O
ø O
##ster O
##gaard O
e O
ra O
##vn O
sh O
bal O
##sle O
##v O
t O
daniels O
##en O
er O
var O
##da O
##g O
a O
mc O
##kie O
##rna O
##n O
p O
##j O
gray O
g O
na O
##via O
##ux O
r O
##k O
2005 O
pol O
##g O
mutations O
in O
al O
##pers O
syndrome O
ne O
##uro O
##logy O
8 O
149 O
##3 O
149 O
##5 O

chan O
ss O
long O
##ley O
m O
##j O
copeland O
wc O
2005 O
the O
common O
146 O
##7 O
##t O
mutation O
in O
the O
human O
mitochondrial O
dna O
polymer O
##ase O
pol O
##g O
compromise O
##s O
catalytic O
efficiency O
and O
interaction O
with O
the O
accessory O
subunit O
j O
bio O
##l O
che O
##m O
280 O
313 O
##41 O
313 O
##46 O
t O
##zo O
##uli O
##s O
c O
eng O
##els O
##en O
ba O
tel O
##stad O
w O
aa O
##sl O
##y O
j O
zev O
##iani O
m O
win O
##ther O
##th O
##un O
s O
ferrari O
g O
aa O
##rse O
##th O
j O
##h O
bind O
##off O
la O
2006 O
the O
spectrum O
of O
clinical O
disease O
caused O
by O
the O
a O
##46 O
##7 O
##t O
and O
w O
##7 O
##48 O
##s O
pol O
##g O
mutations O
a O
study O
of O
26 O
cases O
brain O
129 O
1685 O
1692 O

stewart O
jd O
ho O
##rva O
##th O
r O
bar O
##uf O
##fin O
##i O
e O
ferrer O
##o O
i O
bu O
##ls O
##t O
s O
watkins O
p O
##b O
fontana O
r O
##j O
day O
cp O
chin O
##nery O
p O
##f O
2010 O
polymer O
##ase O
gamma O
gene O
pol O
##g O
determines O
the O
risk O
of O
sodium O
val O
##pro O
##ate O
induced O
liver O
toxicity O
he O
##pa O
##tology O
52 O
1791 O
1796 O
eng O
##els O
##en O
ba O
t O
##zo O
##uli O
##s O
c O
karl O
##sen O
b O
lille O
##b O
##ø O
a O
la O
##eg O
##re O
##id O
l O
##m O
aa O
##sl O
##y O
j O
zev O
##iani O
m O
bind O
##off O
la O
2008 O
pol O
##g O
##1 O
mutations O
cause O
a O
syn O
##dro O
##mic O
ep O
##ile O
##psy O
with O
o O
##cci O
##pit O
##al O
lobe O
pre O
##di O
##le O
##ction O
brain O
131 O
81 O
##8 O
82 O
##8 O
1 O
3 O

case O
report O
late O
onset O
presentation O
of O
pol B-GENE
##g I-GENE
##1 I-GENE
associated O
mitochondrial O
disease O
br O
##una O
mei O
##ra O
1 O
rafael O
ro O
##que O
2 O
miguel O
pinto O
1 O
andre O
ca O
##etano O
##1 O
1 O
##ne O
##uro O
##logy O
department O
centro O
hospital O
##ar O
de O
li O
##sb O
##oa O
o O
##cide O
##ntal O
ep O
##e O
li O
##sb O
##oa O
portugal O
2 O
##ne O
##uro O
##path O
##ology O
unit O
ne O
##uro O
##logy O
department O
centro O
hospital O
##ar O
li O
##sb O
##oa O
norte O
ep O
##e O
li O
##sb O
##oa O
portugal O
correspondence O
to O
dr O
br O
##una O
mei O
##ra O
b O
##mei O
##ra O
rm O
##m O
gma O
##il O
com O
accepted O
8 O
march O
2019 O
summary O
mutations O
in O
the O
nuclear O
pol O
##g O
##1 O
gene O
compromise O
the O
integrity O
of O
mitochondrial O
dna O
and O
show O
great O

all O
##eli O
##c O
and O
clinical O
het O
##ero O
##gen O
##eit O
##y O
among O
adult O
pol O
##g O
##1 O
##ass O
##oc O
##iated O
mitochondrial O
disease O
the O
main O
clinical O
feature O
is O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
other O
related O
clinical O
manifestation O
##s O
are O
sensory O
or O
ce O
##re O
##bella O
##r O
ata O
##xia O
peripheral O
ne O
##uro O
##pathy O
my O
##opa O
##thy O
or O
extra O
##py O
##ram O
##idal O
symptoms O
we O
report O
the O
case B-PATIENT
of O
a O
72 B-AGE_ONSET
year O
old O
man O
who O
presented O
with O
a O
late O
onset O
sensory B-HPO_TERM
ne I-HPO_TERM
##uron I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
chronic O
progressive O
external O

op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
ga B-HPO_TERM
##it I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
and O
parkinson B-HPO_TERM
##ism I-HPO_TERM
genetic O
studies O
showed O
a O
compound O
het O
##ero O
##zy O
##gos O
##ity O
of O
known O
pathogen O
##ic O
mutations O
in O
the O
pol B-GENE
##g I-GENE
##1 I-GENE
gene O
variant O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##2 I-GENE_VARIANT
##i I-GENE_VARIANT
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
l I-GENE_VARIANT
in O
cis O
configuration O
in O
all O
##ele O
1 O
and O
variant O
r B-GENE_VARIANT
##80 I-GENE_VARIANT
##7 I-GENE_VARIANT
##c I-GENE_VARIANT
in O
all O
##ele O
2 O
late O
life O
presentation O
highlights O
that O
mitochondrial O
disorders O
should O
be O
considered O
regardless O
of O
age O
of O
onset O
of O
symptoms O
background O

mutations O
in O
the O
nuclear O
gene O
encoding O
the O
catalytic O
subunit O
of O
mitochondrial O
dna O
polymer O
##ase O
1 O
pol O
##g O
##1 O
gene O
located O
on O
chromosome O
15 O
are O
associated O
to O
ph O
##eno O
##typical O
##ly O
het O
##ero O
##gen O
##eous O
mitochondrial O
diseases O
1 O
evidence O
shows O
that O
mutations O

on O
this O
gene O
cause O
an O
inability O
to O
replicate O
mitochondrial O
genome O
##s O
mt O
##dna O
and O
consequently O
an O
accumulation O
of O
multiple O
del O
##eti O
##ons O
of O
mitochondrial O
dna O
1 O
2 O
among O
adult O
pol O
##g O
##1 O
associated O
mitochondrial O
diseases O
the O
main O
clinical O
feature O
is O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
cp O
##eo O
1 O
2 O
frequently O
cp O
##eo O
is O
associated O
with O
a O
large O
spectrum O
of O
others O
manifestation O
##s O
cp O
##eo O
##pl O
##us O
disorders O
including O
the O
triad O
of O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
d O
##ys O
##pha O
##gia O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
syndrome O
3 O
4 O
only O
a O
few O
cases O
of O
sand O
##o O
associated O
to O
pol O
##g O
##1 O
mutations O
have O
been O
reported O
3 O
9 O
however O
the O
combination O
of O
cp O
##eo O
and O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
incomplete O
sand O
##o O
has O
been O
more O
often O
reported O
8 O
although O
pol O
##g O
##1 O
mutations O
are O
associated O
with O
a O
wide O
range O
of O
clinical O
manifestation O
##s O
and O
age O
of O
onset O
disease O
previously O
reported O
patients O
with O
cp O
##eo O
or O
sand O
##o O
presented O
generally O
before O
the O
fifth O
decade O
of O
life O
##1 O
4 O
7 O
8 O
and O
seldom O
after O
the O
sixth O
decade O
of O
life O
5 O
9 O
10 O
parkinson O
##ism O
is O
another O
clinical O
feature O
of O
patients O
with O
pol O
##g O
##1 O
mutations O
usually O
presenting O
as O
a O
rare O
and O
late O
onset O
com O
##plication O
of O
cp O
##eo O
or O
sand O
##o O
10 O
11 O
until O
this O
moment O
over O
200 O
mutations O
on O
pol O
##g O
gene O
were O
identified O
but O
there O
is O
still O
some O
uncertainty O
regarding O
the O
pathogen O
##ic O

b O
##m O
##j O
publishing O
group O
limited O
2019 O
no O
commercial O
re O
use O
see O
rights O
and O
permission O
##s O
published O
by O
b O
##m O
##j O
figure O
1 O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
and O
o O
##cular O
movements O
examination O
showing O
a O
severe B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
a O
dex O
##tro O
##version O
b O
lev O
##overs O
##ion O
c O
su O
##pr O
##aver O
##sion O
d O
in O
##fra O
##version O

figure O
2 O
muscle O
bio O
##psy O
findings O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
stain O
10 O
##× O
##10 O
bio O
##psy O
from O
the O
del O
##to O
##id O
muscle O
showing O
dark O
peripheral O
areas O
suggest O
##ive O
of O
clustered O
mit O
##och O
##ond O
##ria O
a O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
sd O
##h O
stain O
10 O
##× O
##10 O
showing O
several O
cox B-HPO_TERM
negative I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
b O
no O
ragged O
red O
fibre O
##s O
were O
seen O
in O
ha O
##ema O
##to O
##xy O
##lin O
e O
##osi O
##n O
or O
go O
##mori O
tri O
##chrome O
stains O
not O
shown O
contribution O
of O
each O
of O
these O
mutations O
to O
disease O
presentation O
as O
well O
as O
any O
obvious O
gen O
##otype O
ph O
##eno O
##type O
correlation O
1 O
2 O
4 O

we O
report O
the O
case B-PATIENT
of O
a O
72 B-AGE_ONSET
year O
old O
man O
who O
presented O
with O
a O
late O
onset O
mitochondrial O
disease O
whose O
genetic O
studies O
showed O
known O
pathogen O
##ic O
mutations O
in O
the O
pol O
##g O
##1 O
gene O
this O
case O
figure O
3 O
location O
of O
mutations O
in O
the O
pol B-GENE
##g I-GENE
gene O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
and B-GENE_VARIANT
p I-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
##l I-GENE_VARIANT
mutations O
in O
cis O
configuration O
were O
found O
in O
the O
ex O
##on O
##uc O
##lea O
##se O
motif O
and O
link O
##er O
regions O
respectively O
in O
all O
##ele O
1 O
r B-GENE_VARIANT
##80 I-GENE_VARIANT
##7 I-GENE_VARIANT
##c I-GENE_VARIANT
mutation O
was O
identified O
in O
the O
polymer O
##ase O
motif O
in O
all O
##ele O
2 O
highlights O
the O
importance O
of O
considering O
the O
diagnosis O
of O
a O
mitochondrial O
disorder O
regardless O
of O
age O
of O
onset O
of O
symptoms O
case O
presentation O

we O
present O
the O
case B-PATIENT
of O
a O
72 B-AGE_ONSET
year O
old O
man O
with O
type B-HPO_TERM
2 I-HPO_TERM
diabetes I-HPO_TERM
with O
good O
metabolic O
control O
and O
arterial B-HPO_TERM
hyper I-HPO_TERM
##tension I-HPO_TERM
who O
presented O
with O
a O
3 O
year O
history O
of O
progressive B-HPO_TERM
distal I-HPO_TERM
lower I-HPO_TERM
limb I-HPO_TERM
weakness I-HPO_TERM
and O
bilateral B-HPO_TERM
partial I-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
he O
also O
claimed O
driving O
had O
become O
progressively O
difficult O
due O
to O
a O
limitation B-HPO_TERM
in I-HPO_TERM
lateral I-HPO_TERM
eye I-HPO_TERM
version I-HPO_TERM
as O
well O
as O
due O
to O
a O
decreased B-HPO_TERM
sensation I-HPO_TERM
on I-HPO_TERM
the I-HPO_TERM
plant I-HPO_TERM
##ar I-HPO_TERM
surface I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
feet I-HPO_TERM
additionally O
he O
had O
slight O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
family O
history O
was O
un O
##rem O
##ark O
##able O
born O
of O
non O
con O
##san O
##gui O
##neo O
##us O
parents O
four O
healthy O
siblings O
observation O
in O
the O
ne O
##uro O
##logy O
clinic O
disclosed O
slight O
ga B-HPO_TERM
##it I-HPO_TERM
ata I-HPO_TERM
##xia I-HPO_TERM
with O
inability B-HPO_TERM
to I-HPO_TERM
walk I-HPO_TERM
in I-HPO_TERM
tandem I-HPO_TERM
minor O
pro B-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
para I-HPO_TERM
##par I-HPO_TERM
##esis I-HPO_TERM
general B-HPO_TERM
##ised I-HPO_TERM
are I-HPO_TERM
##fle I-HPO_TERM
##xia I-HPO_TERM
distal B-HPO_TERM
h I-HPO_TERM
##yp I-HPO_TERM
##oes I-HPO_TERM
##thes I-HPO_TERM
##ia I-HPO_TERM
and O
h B-HPO_TERM
##yp I-HPO_TERM
##opa I-HPO_TERM
##lles I-HPO_TERM
##thes I-HPO_TERM
##ia I-HPO_TERM
of I-HPO_TERM
upper I-HPO_TERM
and I-HPO_TERM
lower I-HPO_TERM
limbs I-HPO_TERM
severe B-HPO_TERM
external I-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
and O
bilateral B-HPO_TERM
pt I-HPO_TERM
##osis I-HPO_TERM
figure O
1 O
vertical B-HPO_TERM
dip I-HPO_TERM
##lo I-HPO_TERM
##pia I-HPO_TERM
in I-HPO_TERM
up I-HPO_TERM
##ga I-HPO_TERM
##ze I-HPO_TERM
mild O
d B-HPO_TERM
##ys I-HPO_TERM
##arth I-HPO_TERM
##ria I-HPO_TERM
and O
a B-HPO_TERM
pill I-HPO_TERM
rolling I-HPO_TERM
tremor I-HPO_TERM
of O
the O
upper O
right O
limb O
there O
was O
no O
path O
##ological O
muscle O
fat O
##iga O
##bility O

investigations O

laboratory O
results O
revealed O
a O
normal O
complete O
blood O
count O
and O
comprehensive O
metabolic O
panel O
with O
normal O
ck O
my O
##og O
##lo O
##bin O
and O
serum O
ace O
levels O
brain O
mri O
showed O
mild O
scattered O
per B-HPO_TERM
##ive I-HPO_TERM
##nt I-HPO_TERM
##ric I-HPO_TERM
##ular I-HPO_TERM
white I-HPO_TERM
matter I-HPO_TERM
disease I-HPO_TERM
ne O
##uro O
##phy O
##sio O
##logy O
evaluation O
showed O
a O
general O
##ised O
absence B-HPO_TERM
of I-HPO_TERM
sensory I-HPO_TERM
nerve I-HPO_TERM
action I-HPO_TERM
potential I-HPO_TERM
##s I-HPO_TERM
both O
upper O
and O
lower O
limbs O
without O
changes O
in O
motor O
conduct O
##ion O
studies O
suggest O
##ive O
of O
a O
sensory B-HPO_TERM
ne I-HPO_TERM
##uron I-HPO_TERM
##opa I-HPO_TERM
##thy I-HPO_TERM
needle O
electro O
##my O
##ography O
study O
of O
the O
frontal O
##is O
muscles O
demonstrated O
my B-HPO_TERM
##opa I-HPO_TERM
##thic I-HPO_TERM
potential I-HPO_TERM
##s I-HPO_TERM
there O
was O
no O
path O
##ological O
dec O
##rem O
##ental O
response O
with O
low O
frequency O
3 O
hz O
repetitive O
stimulation O
anti O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
mu O
##sk O
l O
##rp O
##4 O
and O
voltage O
gate O
##d O
calcium O
channel O
antibodies O
were O
negative O
thor O
##ac O
##ic O
ct O
showed O
no O
relevant O
changes O
namely O
no O
media O
##sti O
##nal O
l O
##ym O
##pha O
##den O
##opa O
##thi O
##es O
suggest O
##ive O
of O
sar O
##co O
##ido O
##sis O
negative O
anti O
gang O
##lio O
##side O
and O
anti O
ne O
##uron O
##al O
antibodies O
normal O
im O
##mun O
##olo O
##gic O
study O
and O
absence O
of O
toxic O
contact O
excluded O
other O
possible O
ae O
##ti O
##ologies O
of O
sensory O
ne O
##uron O
##opa O
##thy O

a O
del O
##to O
##id O
muscle O
bio O
##psy O
demonstrated O
signs O
of O
ox O
##ida O
##tive O
stress O
with O
multiple O
cy B-HPO_TERM
##to I-HPO_TERM
##chrome I-HPO_TERM
c I-HPO_TERM
ox I-HPO_TERM
##ida I-HPO_TERM
##se I-HPO_TERM
cox I-HPO_TERM
negative I-HPO_TERM
muscle I-HPO_TERM
fibre I-HPO_TERM
##s I-HPO_TERM
in O
a O
percentage O
higher O
to O
that O
expected O
for O
the O
patient O
age O
but O
no O
ragged O
red O
fibre O
##s O
figure O
2 O
analysis O
of O
mitochondrial O
respiratory O
chain O
complex O
activity O
by O
spec O
##tro O
##ph O
##oto O
##metry O
was O
otherwise O
normal O
the O
patient O
underwent O
genetic O
testing O
specific O
gene O
study O
by O
direct O
sequencing O
and O
bid O
##ire O
##ction O
##al O
all O
##ele O
specific O
pc O
##r O
that O
confirmed O
the O
presence O
of O
pathogen O
##ic O
mutations O
on O
pol B-GENE
##g I-GENE
gene O
variant O
t B-GENE_VARIANT
##25 I-GENE_VARIANT
##1 I-GENE_VARIANT
##i I-GENE_VARIANT
p B-GENE_VARIANT
##58 I-GENE_VARIANT
##7 I-GENE_VARIANT
l I-GENE_VARIANT
in O
cis O
configuration O
in O
all O
##ele O
1 O
and O
variant O
r B-GENE_VARIANT
##80 I-GENE_VARIANT
##7 I-GENE_VARIANT
##c I-GENE_VARIANT
in O
all O
##ele O
2 O
compound O
het O
##ero O
##zy O
##gos O
##ity O
of O
three O
known O
pathogen O
##ic O
mutations O
figure O
3 O

differential O
diagnosis O

our O
patient O
was O
initially O
considered O
to O
have O
possible O
o O
##cular O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
as O
well O
as O
a O
con O
##com O
##itan O
##t O
severe O
sensory O
dia O
##bet O
##ic O
poly O
##ne O
##uro O
##pathy O
despite O
not O
having O
a O
clear O
clinical O
fat O
##iga O
##bility O
given O
the O
age O
of O
our O
patient O
and O
his O
o O
##cular O
findings O
a O
diagnosis O
of O
o O
##cular O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
was O
our O
first O
diagnostic O
hypothesis O
the O
peripheral O
ne O
##uro O
##pathy O
is O
a O
well O
known O
com O
##plication O
of O
diabetes O
and O
therefore O
it O
was O
not O
unreasonable O
to O
think O
about O
this O
initial O
diagnosis O
since O
the O
patient O
had O
suffered O
from O
diabetes O
for O
several O
years O
however O
his O
ne O
##uro O
##phy O
##sio O
##logy O
evaluation O
was O
not O
in O
favour O
of O
a O
post O
syn O
##ap O
##tic O
ne O
##uro O
##mus O
##cular O
junction O
disorder O
the O
auto O
##ant O
##ib O
##odies O
for O
auto O
##im O
##mun O
##e O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O

were O
negative O
and O
treatment O
with O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
was O
ineffective O
prompting O
us O
to O
consider O
other O
diagnosis O
we O
considered O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
as O
a O
possible O
diagnosis O
given O
the O
slight O
d O
##ys O
##pha O
##gia O
eye O
##lid O
pt O
##osis O
and O
pro O
##xi O
##mal O
limb O
weakness O
as O
well O
as O
late O
life O
presentation O
however O
the O
prominence O
of O
sensory O
ata O
##xia O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
tremor O
found O
in O
our O
patient O
as O
well O
as O
absent O
family O
history O
did O
not O
support O
this O
diagnosis O
12 O

based O
on O
the O
patient O
s O
presentation O
and O
given O
the O
multiple O
neurological O
systems O
involved O
namely O
sensory O
nerves O
muscle O
fibre O
##s O
parkinson B-HPO_TERM
##ism I-HPO_TERM
and O
external B-HPO_TERM
op I-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
we O
considered O
the O
possibility O
of O
a O
mitochondrial O
disease O
the O
mitochondrial O
disorders O
are O
an O
inherited O
group O
of O
diseases O
maternal O
##ly O
transmitted O
or O
auto O
##som O
##al O
recess O
##ive O
or O
due O
to O
sporadic O
mutations O
compatible O
with O
the O
lack O
of O
family O
history O
in O
our O
patient O
treatment O

under O
the O
clinical O
suspicion O
of O
o O
##cular O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
the O
patient O
started O
treatment O
with O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
without O
any O
relevant O
response O
more O
recently O
after O
the O
diagnosis O
of O
mitochondrial O
disease O
our O
patient O
was O
treated O
with O
coe O
##nz O
##yme O
q O
##10 O
but O
he O
did O
not O
tolerate O
this O
drug O
due O
to O
side O
effects O
considering O
the O
worsened O
parkinson O
##ism O
the O
patient O
was O
started O
on O
lev O
##od O
##opa O
although O
with O
little O
clinical O
response O
the O
patient O
and O
his O
primary O
care O
physician O
were O
informed O
about O
the O
risk O
of O
taking O
val O
##pro O
##ic O
acid O
since O
it O
may O
pre O
##ci O
##pit O
##ate O
fu O
##lm O
##ina O
##nt O
liver O
disease O
2 O
outcome O
and O
follow O
up O

although O
there O
is O
no O
specific O
treatment O
for O
mitochondrial O
disease O
our O
patient O
has O
a O
moderate O
but O
stable O
disability O
after O
2 O
years O
of O
follow O
up O
parkinson O
##ism O
associated O
with O
mitochondrial O
disease O
usually O
does O
not O
have O
a O
good O
response O
to O
treatment O
with O
l O
do O
##pa O
and O
progressive O
worse O
##ning O
can O
lead O
to O
a O
marked O
disability O
he O
maintains O
regular O
follow O
up O
in O
our O
out O
##patient O
clinic O
for O
continued O
clinical O
monitoring O
and O
supportive O
care O
discussion O

the O
wide O
ph O
##eno O
##typical O
variation O
among O
patients O
with O
mitochondrial O
disorders O
makes O
the O
diagnosis O
difficult O
patients O
can O
present O
with O
sensory O
or O
ce O
##re O
##bella O
##r O
ata O
##xia O
op O
##ht O
##hal O
##mo O
##par O
##esis O
pt O
##osis O
peripheral O
ne O
##uro O
##pathy O
cognitive O
impairment O
my O
##opa O
##thy O
seizures O
en O
##ce O
##pha O
##lo O
##pathy O
he O
##pa O
##top O
##athy O
psychiatric O
disorders O
pyramid O
##al O
or O
extra O
pyramid O
##al O
symptoms O
and O
headache O
##s O
either O
isolated O
or O
combined O
1 O
2 O
pol O
##g O
mutations O
are O
a O
major O
cause O
of O
mitochondrial O
diseases O
accounting O
for O
up O
to O
25 O
of O
them O
13 O
interesting O
##ly O
despite O
the O
large O
number O
of O
pathogen O
##ic O
mutations O
reported O
in O
pol O
##g O
##1 O
associated O
mitochondrial O
disease O
the O
common O
final O
pathway O
seems O
to O
be O
an O
accumulation O
of O
errors O
on O
mt O
##dna O
with O
a O
subsequent O
abnormal O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
leading O
to O
clinical O
symptoms O
1 O
pol O
##g O
##1 O
related O
disorders O
are O
grouped O
within O
five O
major O
ph O
##eno O
##type O
##s O
al O
##pers O
hut O
##ten O
##lo O
##cher O
syndrome O
childhood O
my O
##oc O
##ere O
##bro O
##he O
##pa O
##top O
##athy O
spectrum O
disorders O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
my O
##opa O
##thy O
sensory O
ata O
##xia O
ata O
##xia O
ne O
##uro O
##pathy O
spectrum O
auto O
##som O
##al O
dominant O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
with O
or O
without O
sand O
##o O
2 O
ir O
##res O
##pe O
##ctive O
of O
the O
ph O
##eno O
##type O
lev O
##od O
##opa O
responsive O
parkinson O
##ism O
has O
been O
described O
as O
a O
rare O
and O
late O
onset O
com O
##plication O
of O
pol O
##g O
mutations O
preceded O
several O
years O
by O
the O
onset O
of O
cp O
##eo O
or O
sand O
##o O
manifestation O
##s O
10 O
11 O
in O
fact O
mitochondrial O
dysfunction O
leading O
to O
reduced O
atp O
production O
or O
ox O
##ida O
##tive O
stress O
has O
emerged O
as O
one O
of O
the O
ne O
##uro O
##de O
##gen O
##erative O
pathogen O
##ic O
mechanism O
associated O
with O
parkinson O
disease O
10 O
and O
according O
to O
lu O
##oma O
et O
al O
11 O

parkinson O
##ism O
seems O
to O
significantly O
co O
##se O
##gg O
##re O
##gate O
with O
pol O
##g O
mutations O
p O
0 O
000 O
##1 O
muscle O
fibre O
##s O
of O
patients O
with O
cp O
##eo O
due O
to O
pol O
##g O
##1 O
mutations O
seem O
to O
have O
more O
cox O
negative O
fibre O
##s O
than O
rr O
##f O
which O
could O
contribute O
to O
mis O
##dia O
##gno O
##sis O
especially O
in O
older O
patients O
considering O
that O
age O
related O
changes O
in O
human O
skeletal O
muscle O
mit O
##och O
##ond O
##ria O
result O
in O
an O
accumulation O
of O
del O
##eti O
##ons O
of O
mt O
##dna O
and O
in O
the O
natural O
appearance O
of O
ragged O
red O
fibre O
##s O
rr O
##f O
and O
cox O
negative O
fibre O
##s O
still O
despite O
the O
natural O
age O
##ing O
alterations O
that O
pre O
##va O
##il O
after O
40 O
50 O
years O
old O
the O
overall O
percentage O
of O
rr O
##f O
and O
cox O
negative O
fibre O
##s O
should O
remain O
at O
around O
1 O
in O
individuals O
without O
mitochondrial O
disorders O
14 O

in O
the O
specific O
case O
of O
sand O
##o O
fa O
##dic O
et O
al O
in O
1997 O
6 O
with O
the O
description O
of O
four O
patients O
hypothesis O
##ed O
for O
the O
first O
time O
that O
sand O
##o O
could O
represent O
a O
novel O
mitochondrial O
disease O
associated O
with O
multiple O
mitochondrial O
dna O
del O
##eti O
##ons O
since O
then O
a O
small O
number O
of O
cases O
has O
been O
reported O
and O
as O
such O
the O
real O
prevalence O
of O
this O
syndrome O
is O
unknown O
but O
it O
is O
believed O
as O
quite O
rare O
more O
recently O
han O
##isch O
et O
al O
##8 O
reported O
nine O
patients O
and O
two O
additional O
family O
members O
fulfilling O
the O
clinical O
criteria O
for O
sand O
##o O
within O
this O
group O
six O
of O
the O
11 O
patients O
had O
pol O
##g O
mutations O
the O
average O
age O
of O
onset O
in O
this O
group O
was O
38 O
3 O
years O
23 O
59 O
years O
old O
although O
among O
patients O
with O
pol O
##g O
mutations O
detected O
the O
oldest O
patient O
was O
49 O
years O
old O
the O
majority O
of O
the O
patients O
sought O
medical O
advice O
because O
of O
ga O
##it O
ata O
##xia O
and O
all O
patients O
with O
sand O
##o O
had O
mild O
d O
##ys O
##arth O
##ria O
none O
of O
the O
11 O
patients O
had O
parkinson O
##ism O
the O
most O
frequent O
mutation O
on O
their O
co O
##hort O
was O
the O
a O
##46 O
##7 O
##t O
mutation O
followed O
by O
the O
w O
##7 O
##48 O
##s O
mutation O
according O
to O
the O
same O
paper O
these O
results O
were O
consistent O
with O
previous O
studies O
on O
sand O
##o O
syndrome O
number O
of O
patients O
29 O
concerning O
age O
of O
onset O
symptoms O
and O
detected O
pol O
##g O
mutations O
8 O
other O
previous O
reported O
pol O
##g O
##1 O
mutations O
linked O
with O
the O
sand O
##o O
ph O
##eno O
##type O
include O
p O
##58 O
##7 O
##l O
t O
##25 O
##7 O
##i O
r O
##80 O
##7 O
##c O
our O
patient O
carries O
these O
three O
mutations O
l O
##30 O
##4 O
##r O
r O
##6 O
##27 O
##w O
r O
##3 O
##p O
r O
##11 O
##38 O
##c O
e O
##11 O
##43 O
##g O
g O
##7 O
##37 O
##r O
g O
##8 O
##48 O
##s O
p O
##64 O
##8 O
##r O
and O

a O
##6 O
##27 O
##q O
3 O
9 O
most O
mutations O
are O
found O
in O
compound O
het O
##ero O
##zy O
##go O
##tes O
containing O
multiple O
mutations O
in O
cis O
and O
in O
trans O
or O
in O
homo O
##zy O
##gos O
##ity O
1 O
2 O

in O
our O
particular O
case O
there O
was O
already O
a O
high O
clinical O
suspicion O
for O
mitochondrial O
disease O
before O
muscle O
bio O
##psy O
was O
performed O
milo O
##ne O
et O
al O
##4 O
reported O
five O
cases O
of O
adult O
onset O
auto O
##som O
##al O
recess O
##ive O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
op O
##ht O
##hal O
##mo O
##par O
##esis O
and O
concluded O
that O
given O
the O
inc O
##ons O
##iste O
##ncy O
of O
muscle O
findings O
the O
molecular O
analysis O
of O
pol O
##g O
gene O
remains O
the O
most O
inform O
##ative O
and O
definitive O
diagnostic O
test O
they O
suggest O
that O
genetic O
testing O
for O
pol O
##g O
mutations O
should O
be O
included O
among O
first O
line O
tests O
in O
patients O
with O
high O
suspicion O
for O
mitochondrial O
disorders O
in O
line O
with O
that O
according O
to O
tc O
##hi O
##k O
##vil O
##ad O
##ze O
et O
al O
15 O
the O
presence O
of O
more O
than O
three O
different O
clinical O
signs O
ne O
##uro O
##pathy O
pt O
##osis O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
axial O
limb O
muscle O
weakness O
ce O
##re O
##bella O
##r O
syndrome O
movement O
disorder O
psychiatric O
symptoms O
h O
##yp O
##oa O
##cous O
##ia O
cognitive O
defect O
and O
the O
absence O
of O
pyramid O
##al O
involvement O
is O
sufficient O
to O
directly O
perform O
pol O
##g O
sequencing O

mutations O
found O
in O
our O
patient O
were O
considered O
auto O
##som O
##al O
recess O
##ive O
in O
inheritance O
or O
sporadic O
since O
neither O
his O
parents O
nor O
siblings O
had O
symptoms O
all O
mutations O
were O
reported O
before O
in O
other O
cases O
involving O
either O
sand O
##o O
syndrome O
or O
parkinson O
##ism O
5 O
7 O
10 O
to O
our O
knowledge O
our O
patient O
is O
a O
compound O
het O
##ero O
##zy O
##go O
##te O
with O
a O
combination O
of O
mutations O
not O
previously O
described O
the O
age O
of O
disease O
onset O
in O
our O
patient O
is O
highly O
unusual O
making O
this O
case O
a O
unique O
presentation O
a O
combination O
of O
genetic O
ep O
##igen O
##etic O
and O
environmental O
factors O
may O
explain O
the O
delayed O
onset O
1 O

there O
is O
no O
specific O
treatment O
for O
mitochondrial O
diseases O
related O
to O
pol O
##g O
##1 O
mutations O
they O
tend O
to O
be O
progressive O
and O
can O
lead O
to O
marked O
disability O
in O
some O
patients O
neurological O
symptoms O
may O
worse O
##n O
during O
infections O
or O
other O
ph O
##ys O
##iol O
##og O
##ic O
stress O
##ors O
1 O
contributors O
all O
authors O
have O
contributed O
to O
the O
manuscript O
b O
##m O
planning O
drafting O
and O
rev O
##ising O
of O
the O
manuscript O
and O
image O
edition O
rr O
interpretation O
and O
reporting O
muscle O
bio O
##psy O
rev O
##ising O
of O
the O
manuscript O
mp O
and O
ac O
rev O
##ising O
of O
the O
manuscript O
for O
intellectual O
content O

funding O
the O
authors O
have O
not O
declared O
a O
specific O
grant O
for O
this O
research O
from O
any O
funding O
agency O
in O
the O
public O
commercial O
or O
not O
for O
profit O
sectors O
competing O
interests O
none O
declared O
patient O
consent O
for O
publication O
obtained O
proven O
##ance O
and O
peer O
review O
not O
commissioned O
externally O
peer O
reviewed O
references O
cohen O
b O
##h O
na O
##via O
##ux O
r O
##k O
the O
clinical O
diagnosis O
of O
pol O
##g O
disease O
and O
other O
mitochondrial O
dna O
de O
##ple O
##tion O
disorders O
methods O
2010 O
51 O
36 O
##4 O
73 O
stump O
##f O
jd O
sane O
##to O
r O
##p O
copeland O
wc O
clinical O
and O
molecular O
features O
of O
pol O
##g O
related O
mitochondrial O
disease O
cold O
spring O
ha O
##rb O
per O
##sp O
##ect O
bio O
##l O
2013 O
5 O
a O
##01 O
##13 O
##9 O
##5 O

van O
goethe O
##m O
g O
martin O
jj O
der O
##ma O
##ut O
b O
et O
al O
recess O
##ive O
pol O
##g O
mutations O
presenting O
with O
sensory O
and O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
in O
compound O
het O
##ero O
##zy O
##go O
##te O
patients O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2003 O
13 O
133 O
42 O
milo O
##ne O
m O
br O
##une O
##tti O
pier O
##ri O
n O
tang O
l O
##y O
et O
al O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
op O
##ht O
##hal O
##mo O
##par O
##esis O
caused O
by O
pol O
##g O
mutations O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2008 O
18 O
62 O
##6 O
32 O
weiss O
md O
sane O
##to O
r O
##p O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
with O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
in O
late O
life O
due O
to O
compound O
het O
##ero O
##zy O
##go O
##us O
pol O
##g O
mutations O
muscle O
nerve O
2010 O
41 O
88 O
##2 O
5 O

fa O
##dic O
r O
russell O
ja O
ve O
##dana O
##raya O
##nan O
v O
##v O
et O
al O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
as O
the O
presenting O
feature O
of O
a O
novel O
mitochondrial O
disease O
ne O
##uro O
##logy O
1997 O
49 O
239 O
45 O
gag O
##o O
m O
##f O
rosa O
##s O
m O
##j O
gui O
##mara O
##es O
j O
et O
al O
sand O
##o O
two O
novel O
mutations O
in O
pol O
##g O
##1 O
gene O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2006 O
16 O
50 O
##7 O
9 O
han O
##isch O
f O
ko O
##rn O
##hu O
##ber O
m O
als O
##ton O
cl O
et O
al O
sand O
##o O
syndrome O
in O
a O
co O
##hort O
of O
107 O
patients O
with O
cp O
##eo O
and O
mitochondrial O
dna O
del O
##eti O
##ons O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2015 O
86 O
630 O
4 O

lo O
##van O
a O
i O
##ht O
##sham O
ul O
ha O
##q O
bala O
##krishna O
##n O
n O
diagnostic O
challenges O
in O
movement O
disorders O
sensory O
ata O
##xia O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
sand O
##o O
syndrome O
b O
##m O
##j O
case O
rep O
2013 O
2013 O
bc O
##r O
##20 O
##13 O
##01 O
##0 O
##34 O
##3 O
miguel O
r O
gag O
##o O
m O
##f O
martins O
j O
et O
al O
pol O
##g O
##1 O
related O
lev O
##od O
##opa O
responsive O
parkinson O
##ism O
cl O
##in O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
2014 O
126 O
47 O
54 O
lu O
##oma O
p O
mel O
##berg O
a O
ri O
##nne O
jo O
et O
al O
parkinson O
##ism O
premature O
men O
##opa O
##use O
and O
mitochondrial O
dna O
polymer O
##ase O
gamma O
mutations O
clinical O
and O
molecular O
genetic O
study O
lance O
##t O
2004 O
36 O
##4 O
875 O
82 O
bra O
##is O
b O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
hand O
##b O
cl O
##in O
ne O
##uro O
##l O
2011 O
101 O
181 O
92 O

sc O
##uder O
##i O
c O
borg O
##ion O
##e O
e O
caste O
##llo O
f O
et O
al O
the O
in O
cis O
t O
##25 O
##1 O
##i O
and O
p O
##58 O
##7 O
##l O
pol O
##g O
##1 O
base O
changes O
description O
of O
a O
new O
family O
and O
literature O
review O
ne O
##uro O
##mus O
##cu O
##l O
di O
##sor O
##d O
2015 O
25 O
333 O
9 O
pe O
##sc O
##e O
v O
co O
##rmi O
##o O
a O
fra O
##cas O
##so O
f O
et O
al O
age O
related O
mitochondrial O
gen O
##ot O
##yp O
##ic O
and O
ph O
##eno O
##typic O
alterations O
in O
human O
skeletal O
muscle O
free O
ra O
##dic O
bio O
##l O
med O
2001 O
30 O
122 O
##3 O
33 O
tc O
##hi O
##k O
##vil O
##ad O
##ze O
m O
gill O
##eron O
m O
maison O
##obe O
t O
et O
al O
a O
diagnostic O
flow O
chart O
for O
pol O
##gre O
##lated O
diseases O
based O
on O
signs O
sensitivity O
and O
specific O
##ity O
j O
ne O
##uro O
##l O
ne O
##uro O
##sur O
##g O
psychiatry O
2015 O
86 O
64 O
##6 O
54 O

ep O
##ile O
##psy O
behavior O
reports O
12 O
2019 O
100 O
##33 O
##9 O
case O
report O
no O
effect O
of O
electrical O
trans O
##cr O
##anial O
direct O
current O
stimulation O
adjunct O
treatment O
for O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
in O
pol O
##g O
disease O
lynn O
mar O
##qua O
##rd O
##t O
a O
tom O
e O
##iche O
##le O
b O
laurence O
a O
bind O
##off O
b O
c O
hen O
##ning O
kris O
##tian O
ol O
##berg O
b O
g O
##yr O
##i O
ve O
##ib O
##y O
b O
he O
##ike O
e O
##iche O
##le O
a O
d O
isabella O
ku O
##sz O
##tri O
##ts O
a O
marco O
hi O
##rn O
##stein O
a O
a O
department O
of O
biological O
and O
medical O
psychology O
university O
of O
bergen O
jonas O
lies O
ve O
##i O
21 O
500 O
##9 O
bergen O
norway O
b O
department O
of O
ne O
##uro O
##logy O
ha O
##uke O
##land O
university O
hospital O
bergen O
jonas O
lies O
ve O
##i O
71 O
505 O
##3 O
bergen O
norway O

c O
department O
of O
ne O
##uro O
##logy O
section O
for O
clinical O
ne O
##uro O
##phy O
##sio O
##logy O
ha O
##uke O
##land O
d O
regional O
resource O
center O
for O
autism O
ad O
##hd O
tour O
##ette O
syndrome O
and O
na O
##rco O
##le O
##psy O
western O
norway O
ha O
##uke O
##land O
university O
hospital O
f O
##j O
##ø O
##san O
##ger O
##ve O
##ien O
36 O
505 O
##4 O
bergen O
norway O
a O
r O
t O
i O
c O
l O
e O
i O
n O
f O
o O
article O
history O
received O
12 O
july O
2019 O
received O
in O
revised O
form O
30 O
september O
2019 O
accepted O
4 O
october O
2019 O
available O
online O
25 O
october O
2019 O
key O
##words O
mitochondrial O
disease O
pol O
##g O
ne O
##uro O
##sti O
##mu O
##lation O
td O
##cs O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
a O
b O
s O
t O
r O
a O
c O
t O

we O
report O
a O
15 O
year O
old O
female O
with O
pol O
##g O
related O
mitochondrial O
disease O
who O
developed O
severe O
multi O
##fo O
##cal O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
un O
##res O
##pon O
##sive O
to O
standard O
anti O
seizure O
drug O
treatment O
and O
general O
an O
##esthesia O
based O
on O
an O
earlier O
case O
report O
we O
treated O
her O
focal O
seizures O
that O
affected O
her O
right O
upper O
limb O
with O
20 O
min O
sessions O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
td O
##cs O
at O
an O
intensity O
of O
2 O
ma O
on O
each O
of O
ﬁ O
##ve O
consecutive O
days O
the O
cat O
##ho O
##de O
was O
placed O
over O
the O
left O
primary O
motor O
cortex O
the O
an O
##ode O
over O
the O
contra O
##lateral O
orbit O
##of O
##ron O
##tal O
cortex O
surface O
electro O
##my O
##ography O
em O
##g O
were O
recorded O
20 O
min O
before O
20 O
min O
during O
and O
20 O
min O
after O
four O
of O
ﬁ O
##ve O
td O
##cs O
sessions O
to O
measure O
its O
effect O
on O
the O
muscle O
jerk O
##s O
the O
electro O
##ence O
##pha O
##log O
##raphy O
ee O
##g O
was O
recorded O
before O
and O
after O
td O
##cs O
to O
measure O
the O
frequency O
of O
spikes O
our O
results O
showed O
no O
statistical O
##ly O
or O
clinical O
##ly O
sign O
##i O
##ﬁ O
##can O
##t O
reduction O
of O
seizures O
or O
ep O
##ile O
##pt O
##iform O
activity O
using O
ee O
##g O
and O
em O
##g O
with O
this O
treatment O
protocol O
to O
our O
knowledge O
this O
is O
only O
the O
second O
time O
that O
adjunct O
td O
##cs O
treatment O
of O
ep O
##ile O
##ptic O
seizures O
has O
been O
tried O
in O
pol O
##g O
related O
mitochondrial O
disease O
taken O
together O
with O
the O
positive O
ﬁ O
##nding O
##s O
from O
the O
earlier O
case O
report O
the O
present O
study O
highlights O
that O
more O
data O
are O
needed O
to O
determine O
if O
and O
under O
which O
parameters O
the O
treatment O
is O
effective O

2019 O
the O
authors O
published O
by O
else O
##vier O
inc O
this O
is O
an O
open O
access O
article O
under O
the O
cc O
by O
nc O
n O
##d O
license O
http O
creative O
##com O
##mons O
org O
licenses O
by O
nc O
n O
##d O
4 O
0 O
introduction O

mitochondrial O
diseases O
are O
a O
group O
of O
genetic O
disorders O
affecting O
about O
one O
in O
5000 O
people O
1 O
the O
symptoms O
are O
diverse O
but O
since O
mit O
##och O
##ond O
##ria O
produce O
energy O
for O
body O
tissues O
through O
production O
of O
aden O
##osi O
##ne O
trip O
##hos O
##phate O
atp O
organs O
with O
high O
energy O
consumption O
such O
as O
the O
brain O
are O
often O
affected O
for O
example O
as O
many O
as O
35 O
to O
60 O
of O
people O
with O
mitochondrial O
disease O
develop O
seizures O
1 O
in O
pol O
##g O
related O
mitochondrial O
disease O
a O
genetic O
mutation O
interfere O
##s O
with O
a O
catalytic O
subunit O
of O
the O
mitochondrial O
dna O
polymer O
##ase O
gamma O
which O
replicate O
##s O
mitochondrial O
dna O
2 O
leading O
to O
depleted O
mitochondrial O
dna O
3 O
once O
the O
resulting O
ne O
##uron O
##al O
energy O
failure O
reaches O
a O
critical O
point O
ne O
##uron O
##al O
death O
en O
##su O
##es O
causes O
at O
##rop O
##hy O
and O
potentially O

corresponding O
author O
at O
department O
of O
biological O
and O
medical O
psychology O
university O
of O
bergen O
jonas O
lies O
ve O
##i O
91 O
500 O
##9 O
bergen O
norway O
e O
mail O
addresses O
lynn O
mar O
##qua O
##rd O
##t O
ui O
##b O
no O
l O
mar O
##qua O
##rd O
##t O
tom O
e O
##iche O
##le O
he O
##ls O
##e O
bergen O
no O
t O
e O
##iche O
##le O
laurence O
albert O
bind O
##off O
he O
##ls O
##e O
bergen O
no O
l O
a O
bind O
##off O
hen O
##ning O
kris O
##tian O
ol O
##berg O
he O
##ls O
##e O
bergen O
no O
h O
k O
ol O
##berg O
g O
##yr O
##i O
ve O
##ib O
##y O
he O
##ls O
##e O
bergen O
no O
g O
ve O
##ib O
##y O
he O
##ike O
e O
##iche O
##le O
ui O
##b O
no O
h O
e O
##iche O
##le O
isabella O
ku O
##sz O
##tri O
##ts O
ui O
##b O
no O
i O
ku O
##sz O
##tri O
##ts O
marco O
hi O
##rn O
##stein O
ui O
##b O
no O
m O
hi O
##rn O
##stein O

acts O
as O
the O
trigger O
for O
ep O
##ile O
##psy O
that O
in O
turn O
increases O
ne O
##uron O
##al O
loss O
4 O
a O
study O
found O
mitochondrial O
dysfunction O
in O
one O
third O
of O
patients O
with O
ep O
##ile O
##psy O
that O
underwent O
metabolic O
testing O
5 O
emphasizing O
that O
drug O
##res O
##istan O
##t O
seizures O
are O
a O
frequent O
problem O
in O
mitochondrial O
disease O
and O
that O
new O
treatments O
need O
to O
be O
developed O
in O
a O
previous O
case O
report O
focal O
seizures O
in O
a O
patient O
with O
pol O
##g O
related O
mitochondrial O
disease O
ceased O
after O
two O
weeks O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
td O
##cs O
6 O
since O
these O
seizures O
are O
often O
ref O
##rac O
##tory O
to O
medical O
treatment O
and O
the O
technique O
is O
non O
invasive O
we O
tested O
td O
##cs O
using O
similar O
parameters O
as O
in O
ng O
et O
al O
6 O
in O
a O
patient O
with O
pol O
##g O
related O
mitochondrial O
disease O
and O
drug O
resistant O
multi O
##fo O
##cal O
ep O
##ile O
##psy O

case B-PATIENT
report O
this O
15 B-AGE_ONSET
year O
old O
female O
was O
apparently O
healthy O
until O
the O
ﬁ O
##rst O
admission O
followed O
two O
consecutive O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
prior O
to O
the O
seizures O
she O
had O
experienced O
nausea B-HPO_TERM
headache B-HPO_TERM
reduced B-HPO_TERM
vision I-HPO_TERM
and O
para B-HPO_TERM
##esthesia I-HPO_TERM
in I-HPO_TERM
both I-HPO_TERM
upper I-HPO_TERM
limbs I-HPO_TERM
she O
was O
int O
##uba O
##ted O
during O
helicopter O
transfer O
to O
hospital O
due O
to O
reduced O
consciousness O
following O
admission O
she O
regained O
consciousness O
but O
developed O
continuous O
jerking O
of O
her O
right O
arm O
ee O
##g O
showed O
ongoing O
ep O
##ile O
##pt O
##iform O
discharge O
##s O
over O
the O
right O
o O
##cci O
##pit O
##al O
region O
fig O
1a O
that O
later O
involved O
most O
of O
the O

https O
doi O
org O
10 O
1016 O
j O
e O
##br O
2019 O
100 O
##33 O
##9 O
258 O
##9 O
98 O
##64 O
2019 O
the O
authors O
published O
by O
else O
##vier O
inc O
this O
is O
an O
open O
access O
article O
under O
the O
cc O
by O
nc O
n O
##d O
license O
http O
creative O
##com O
##mons O
org O
licenses O
by O
nc O
n O
##d O
4 O
0 O

fig O
1 O
pol O
##g O
disease O
visual O
##ized O
through O
ee O
##g O
examples O
panel O
a O
ee O
##g O
sample O
from O
the O
patient O
from O
an O
early O
clinical O
recording O
showing O
almost O
continuous B-HPO_TERM
2 I-HPO_TERM
hz I-HPO_TERM
poly I-HPO_TERM
##sp I-HPO_TERM
##ike I-HPO_TERM
and I-HPO_TERM
slow I-HPO_TERM
waves I-HPO_TERM
mainly O
over O
the O
right O
par O
##ie O
##to O
o O
##cci O
##pit O
##al O
region O
panel O
b O
continuous O
ee O
##g O
recording O
from O
the O
td O
##cs O
experiment O
showing O
channels O
from O
top O
to O
bottom O
c O
##4 O
c O
##3 O
p O
##3 O
o O
##1 O
and O
em O
##g O
##1 O
and O
em O
##g O
##2 O
being O
the O
right O
hand O
and O
left O
trap O
##ez O
##ius O
respectively O

right O
cerebral O
hemisphere O
and O
because O
of O
persist O
##ing O
un O
##con O
##tro O
##lled O
ep O
##ile O
##ptic O
activity O
she O
was O
loaded O
with O
ph O
##os O
##ph O
##en O
##yt O
##oin O
before O
using O
an O
##esthesia O
with O
prop O
##of O
##ol O
and O
ke O
##tam O
##ine O
at O
relevant O
clinical O
dos O
##ages O
to O
provide O
effective O
serum O
levels O
as O
well O
as O
lowering O
her O
core O
body O
temperature O
to O
33 O
in O
accordance O
with O
the O
norwegian O
treatment O
guidelines O
7 O
the O
clinical O
presentation O
with O
status B-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
involving O
an O
o O
##cci O
##pit O
##al O
lobe O
focus O
prompted O
investigation O
for O
pol B-GENE
##g I-GENE
mutation O
which O
was O
subsequently O
con O
##ﬁ O
##rmed O
through O
dna O
sequencing O
analysis O
showing O
a O
homo O
##zy O
##go O
##us O
gen O
##otype O
c B-GENE_VARIANT
224 I-GENE_VARIANT
##3 I-GENE_VARIANT
##gn I-GENE_VARIANT
##c I-GENE_VARIANT

following O
two O
episodes O
of O
prop O
##of O
##ol O
an O
##esthesia O
and O
achieving O
burst O
suppression O
she O
regained O
consciousness O
and O
her O
ep O
##ile O
##psy O
was O
then O
treated O
with O
ph O
##eno O
##bar O
##bit O
##al O
and O
ox O
##car O
##ba O
##ze O
##pine O
while O
withdrawing O
ph O
##en O
##yt O
##oin O
after O
stabilization O
the O
patient O
was O
discharged O
with O
ongoing O
medication O
treatment O
she O
was O
read O
##mit O
##ted O
a O
second O
and O
third O
time O

with O
headache B-HPO_TERM
and O
visual B-HPO_TERM
disturbances I-HPO_TERM
that O
quickly O
mor O
##ph O
##ed O
into O
generalized B-HPO_TERM
tonic I-HPO_TERM
cl I-HPO_TERM
##onic I-HPO_TERM
seizures I-HPO_TERM
followed O
by O
focal B-HPO_TERM
motor I-HPO_TERM
status I-HPO_TERM
ep I-HPO_TERM
##ile I-HPO_TERM
##ptic I-HPO_TERM
##us I-HPO_TERM
both O
episodes O
treated O
with O
an O
##esthesia O
and O
h O
##yp O
##oth O
##er O
##mia O
on O
the O
third O
occasion O
her O
mri O
showed O
new O
changes O
in O
both O
o O
##cci O
##pit O
##al O
regions O
during O
the O
second O
prolonged O
admission O
she O
still O
had O
jerking O
of O
her O
right O
arm O
despite O
maintaining O
ph O
##en O
##yt O
##oin O
lev O
##eti O
##race O
##tam O
ox O
##car O
##ba O
##ze O
##pine O

top O
##ira O
##mate O
and O
cl O
##ob O
##az O
##am O
at O
therapeutic O
doses O
at O
the O
point O
where O
td O
##cs O
treatment O
was O
instituted O
the O
patient O
had O
a O
multi B-HPO_TERM
##fo I-HPO_TERM
##cal I-HPO_TERM
seizures I-HPO_TERM
with O
multiple O
semi O
##ologies O
fig O
1a O
and O
b O
including O
a O
multi B-HPO_TERM
##fo I-HPO_TERM
##cal I-HPO_TERM
as I-HPO_TERM
##yn I-HPO_TERM
##ch I-HPO_TERM
##ron I-HPO_TERM
##ous I-HPO_TERM
my I-HPO_TERM
##oc I-HPO_TERM
##lon I-HPO_TERM
##us I-HPO_TERM
that O
was O
dominant O
and O
most O
de O
##bil O
##itating O
in O
the O
right O
hand O
we O
thus O
targeted O
the O
left O
primary O
motor O
cortex O
with O
td O
##cs O
as O
the O
my O
##oc O
##lon O
##us O
activity O
most O
likely O
arose O
from O
that O
area O
with O
the O
goal O
to O
relieve O
pain O
and O
disability O
methods O
of O
td O
##cs O
and O
ee O
##g O

the O
use O
of O
td O
##cs O
was O
discussed O
with O
the O
local O
ethical O
committee O
who O
considered O
it O
a O
form O
of O
supplementary O
experimental O
treatment O
whose O
purpose O
was O
to O
provide O
care O
for O
an O
individual O
and O
for O
which O
the O
caring O
physician O
could O
take O
responsibility O
without O
obtaining O
the O
committees O
approval O
verbal O
consent O
was O
obtained O
from O
the O
parents O
and O
treatment O
was O
reported O
in O
the O
patient O
s O
medical O
journal O
td O
##cs O
was O
applied O
for O
20 O
min O
at O
2 O
ma O
on O
each O
of O
ﬁ O
##ve O
consecutive O
days O
with O
a O
dc O
st O
##im O
##ulator O
plus O
ne O
##uro O
##con O
##n O
il O
##men O
##au O
germany O
through O
5 O
7 O
cm O
rubber O
electrode O
##s O
with O
saline O
soaked O
sponge O
##s O
giving O
a O
current O
density O
of O

0 O
05 O
##7 O
ma O
cm O
##2 O
the O
patient O
displayed O
continuous O
jerking O
in O
the O
right O
hand O
muscles O
and O
left O
shoulder O
muscles O
to O
reduce O
the O
jerking O
of O
the O
fig O
2 O
td O
##cs O
mont O
##age O
and O
results O
panel O
a O
placement O
of O
an O
##ode O
at O
f O
##p O
##2 O
red O
and O
cat O
##ho O
##de O
at O
c O
##3 O
blue O
within O
the O
international O
10 O
20 O
system O
panel O
b O
means O
of O
spikes O
jerk O
##s O
per O
second O
across O
all O
four O
days O
time O
in O
minutes O
panel O
c O
spikes O
jerk O
##s O
per O
second O
and O
95 O
con O
##ﬁ O
##den O
##ce O
intervals O
before O
during O
and O
after O
treatment O

right O
hand O
the O
cat O
##ho O
##de O
was O
placed O
over O
the O
contra O
##lateral O
left O
primary O
motor O
cortex O
at O
approximately O
c O
##3 O
of O
the O
10 O
20 O
ee O
##g O
system O
see O
fig O
2a O
the O
rational O
##e O
was O
that O
cat O
##ho O
##dal O
stimulation O
has O
been O
shown O
to O
reduce O
co O
##rti O
##cal O
ex O
##cit O
##ability O
in O
the O
brain O
area O
underneath O
the O
electrode O
and O
hence O
might O
reduce O
ep O
##ile O
##ptic O
activity O
causing O
the O
my O
##oc O
##lon O
##us O
8 O
the O
an O
##ode O
was O
placed O
on O
the O
right O
orbit O
##of O
##ron O
##tal O
cortex O
approximately O
f O
##p O
##2 O

by O
placing O
the O
electrode O
on O
the O
contra O
##lateral O
side O
the O
electric O
ﬁ O
##eld O
between O
an O
##ode O
and O
cat O
##ho O
##de O
crosses O
the O
mid O
##line O
and O
was O
hoped O
to O
affect O
the O
motor O
cortex O
most O
effectively O
since O
the O
an O
##ode O
is O
active O
and O
expected O
to O
increase O
co O
##rti O
##cal O
ex O
##cit O
##ability O
a O
better O
setup O
would O
have O
included O
an O
extra O
large O
an O
##ode O
that O
would O
effectively O
reduce O
the O
current O
strength O
however O
as O
the O
td O
##cs O
treatment O
was O
issued O
at O
short O
notice O
we O
did O
not O
have O
large O
electrode O
##s O
available O
at O
the O
time O
we O
chose O
the O
orbit O
##of O
##ron O
##tal O
region O
because O
it O
is O
often O
used O
as O
a O
control O
site O
in O
td O
##cs O
experiments O
9 O
and O
because O
it O
was O
not O
particularly O
affected O
by O
ep O
##ile O
##psy O
indeed O
we O
did O
not O
observe O
a O
worse O
##ning O
in O
the O
ee O
##g O
in O
this O
region O
after O
the O
treatment O
the O
td O
##cs O
setup O
was O
used O
in O
accordance O
with O
safety O
guidelines O
10 O
11 O

initial O
ee O
##g O
recordings O
and O
seizure O
monitoring O
during O
status O
ep O
##ile O
##ptic O
##us O
were O
done O
with O
continuous O
25 O
channel O
clinical O
ee O
##g O
and O
scored O
visually O
by O
experienced O
ne O
##uro O
##phy O
##sio O
##logists O
with O
the O
cat O
##ho O
##de O
placed O
over O
the O
left O
primary O
motor O
cortex O
we O
looked O
for O
improvement O
particularly O
in O
the O
right O
hand O
continuous O
ee O
##g O
was O
measured O
from O
c O
##3 O
and O
c O
##4 O
right O
motor O
cortex O
as O
control O
for O
20 O
min O
before O
and O
20 O
min O
after O
td O
##cs O
from O
a O
clinical O
ee O
##g O
setup O
following O
the O
10 O
20 O
system O
with O
6 O
2 O
f O
##3 O
f O
##4 O
p O
##3 O
p O
##4 O
o O
##1 O
o O
##2 O
electrode O
##s O
and O
video O
monitoring O
of O
the O
patient O
em O
##g O
data O
from O
the O
right O
hand O
and O
left O
trap O
##ez O
##ius O
was O
acquired O
continuously O
for O
20 O
min O
before O
td O
##cs O
during O
20 O
min O
td O
##cs O
and O
20 O
min O
after O
td O
##cs O
ee O
##g O
data O
was O
not O
interpret O
##able O
during O
td O
##cs O
due O
to O
amp O
##li O
##ﬁ O
##er O
blocking O
em O
##g O
and O
ee O
##g O
data O
were O
recorded O
on O
four O
out O
of O
ﬁ O
##ve O
days O

three O
separate O
rate O
##rs O
two O
ne O
##uro O
##phy O
##sio O
##logists O
te O
hk O
##o O
and O
the O
td O
##cs O
clinic O
##ian O
l O
##m O
counted O
the O
frequency O
of O
spikes O
ee O
##g O
and O
muscle O
jerk O
##s O
em O
##g O
drawn O
from O
multiple O
random O
samples O
spec O
##i O
##ﬁ O
##cal O
##ly O
the O
data O
were O
bin O
##ned O
into O
12 O
ﬁ O
##ve O
minute O
segments O
then O
each O
rate O
##r O
picked O
randomly O
ten O
artifact O
free O
one O
second O
periods O
from O
each O
ﬁ O
##ve O
minute O
segment O
on O
all O
four O
days O
and O
determined O
the O
mean O
number O
of O
ee O
##g O
spikes O
and O
em O
##g O
jerk O
##s O
per O
second O
hz O
for O
all O
four O
measurements O
c O
##3 O
c O
##4 O
right O
hand O
left O
trap O
##ez O
##ius O
subsequently O
means O
were O
calculated O
across O
rate O
##rs O
see O
fig O
2 O
##b O
and O
ee O
##g O
data O
was O
subjected O
to O
paired O
sample O
t O
tests O
and O
non O
para O
##metric O
wilcox O
##on O
tests O
comparing O
spikes O
before O
and O
after O
td O
##cs O
the O
means O
for O
em O
##g O
data O
were O
subjected O
to O
an O
an O
##ova O
with O
the O
repeated O
measures O
variable O
time O
before O
during O
after O
td O
##cs O
and O
a O
non O
para O
##metric O
friedman O
test O
non O
para O
##metric O
friedman O
and O
wilcox O
##on O
tests O
were O
included O
because O
not O
all O
variables O
met O
the O
normal O
di O
##st O
##ri O
##bu O

ti O
##on O
criterion O
necessary O
for O
t O
tests O
and O
an O
##ova O
##s O
due O
to O
the O
limited O
range O
of O
values O
for O
spikes O
jerk O
##s O
per O
second O
at O
the O
same O
time O
non O
##para O
##metric O
tests O
are O
sometimes O
not O
sensitive O
enough O
to O
pick O
up O
small O
effects O
in O
the O
interest O
of O
comprehensive O
##ness O
we O
thus O
decided O
to O
report O
ﬁ O
##nding O
##s O
from O
both O
an O
##ova O
friedman O
and O
paired O
sample O
t O
tests O
wilcox O
##on O
tests O
we O
also O
compared O
the O
pre O
td O
##cs O
data O
on O
day O
one O
baseline O
to O
the O
post O
td O
##cs O
data O
on O
day O
ﬁ O
##ve O
using O
tan O
##d O
wilcox O
##on O
tests O
assuming O
that O
the O
treatment O
effect O
should O
be O
strongest O
between O
these O
measurement O
points O
results O

fig O
2 O
##c O
shows O
the O
average O
frequency O
of O
ep O
##ile O
##ptic O
spikes O
and O
jerk O
##s O
in O
the O
right O
hand O
and O
left O
shoulder O
during O
treatment O
according O
to O
tt O
##est O
##s O
wilcox O
##on O
tests O
for O
ee O
##g O
data O
and O
the O
an O
##ova O
##s O
friedman O
tests O
for O
em O
##g O
data O
there O
were O
no O
sign O
##i O
##ﬁ O
##can O
##t O
differences O
in O
the O
means O
across O
all O
rate O
##rs O
in O
c O
##3 O
or O
c O
##4 O
spikes O
all O
ts O
15 O
0 O
61 O
##3 O
all O
ps O
0 O
54 O
##9 O
all O
χ O
##2 O
##s O
1 O
0 O
09 O
##1 O
all O
ps O
0 O
76 O
##3 O
as O
well O
as O
jerk O
##s O
in O
the O
right O
hand O
and O
left O
shoulder O
all O
f O
##s O
2 O
30 O
1 O
74 O
all O
ps O
0 O
192 O
all O
z O
##s O
0 O
64 O
##2 O
all O
ps O
0 O
521 O
the O
mean O
spikes O
and O
jerk O
##s O
across O
all O
rate O
##rs O
for O
pre O
td O
##cs O
on O
day O
one O
baseline O
versus O
post O
td O
##cs O
on O
day O
ﬁ O
##ve O
were O
for O
the O
right O
hand O
4 O
58 O
0 O
32 O
and O
4 O
42 O

0 O
57 O
left O
trap O
##ez O
##ius O
4 O
58 O
0 O
32 O
and O
4 O
08 O
0 O
42 O
jerk O
##s O
s O
c O
##3 O
4 O
50 O
0 O
43 O
and O
4 O
25 O
0 O
32 O
and O
c O
##4 O
4 O
25 O
0 O
32 O
and O
4 O
13 O
0 O
17 O
spikes O
s O
respectively O
none O
of O
these O
changes O
were O
sign O
##i O
##ﬁ O
##can O
##t O
all O
ts O
1 O
57 O
all O
ps O
0 O
215 O
all O
z O
##s O
1 O
34 O
all O
ps O
0 O
180 O

td O
##cs O
treatment O
was O
given O
in O
march O
2018 O
the O
stimulation O
itself O
was O
well O
tolerated O
the O
patient O
only O
reported O
short O
term O
skin O
irritation O
from O
the O
net O
holding O
the O
electrode O
##s O
in O
place O
four O
months O
after O
receiving O
td O
##cs O
the O
patient O
was O
discharged O
from O
the O
hospital O
still O
with O
upper O
limb O
jerking O
but O
was O
read O
##mit O
##ted O
in O
december O
2018 O
and O
died O
due O
to O
a O
super O
ref O
##rac O
##tory O
status O
ep O
##ile O
##ptic O
##us O
discussion O

neither O
spike O
nor O
jerk O
frequency O
changed O
over O
the O
course O
of O
ﬁ O
##ve O
td O
##cs O
sessions O
between O
before O
during O
and O
after O
td O
##cs O
or O
when O
comparing O
baseline O
spike O
jerk O
rates O
from O
day O
one O
to O
after O
treatment O
on O
day O
ﬁ O
##ve O
we O
therefore O
conclude O
that O
in O
this O
case O
study O
td O
##cs O
did O
not O
have O
a O
ben O
##e O
##ﬁ O
##cial O
treatment O
effect O
on O
treatment O
resistant O
ref O
##rac O
##tory O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
in O
pol O
##g O
related O
mitochondrial O
disease O
hence O
our O
results O
are O
inconsistent O
with O
those O
of O
ng O
et O
al O
6 O
who O
found O
that O
seizures O
stopped O
completely O
in O
a O
similar O
case O
study O

there O
are O
several O
differences O
between O
the O
two O
case O
studies O
that O
could O
explain O
the O
different O
outcomes O
ng O
et O
al O
6 O
placed O
the O
cat O
##ho O
##de O
over O
the O
right O
tempo O
##ro O
par O
##ie O
##tal O
o O
##cci O
##pit O
##al O
junction O
p O
##4 O
t O
##6 O
while O
in O
our O
study O
it O
was O
over O
the O
left O
primary O
motor O
cortex O
ng O
et O
al O
provided O
td O
##cs O
treatment O
twice O
once O
for O
three O
days O
and O
once O
for O
14 O
days O
while O

we O
provided O
td O
##cs O
treatment O
once O
for O
ﬁ O
##ve O
days O
however O
the O
treatment O
in O
our O
case O
was O
stopped O
before O
the O
completion O
of O
14 O
days O
because O
there O
was O
no O
sign O
of O
improvement O
and O
due O
to O
technical O
reasons O
staff O
availability O
moreover O
while O
the O
patients O
appeared O
to O
have O
similar O
seizure O
frequency O
their O
gen O
##otype O
##s O
were O
different O
the O
patient O
reported O
by O
ng O
and O
colleagues O
was O
homo O
##zy O
##go O
##us O
for O
the O
c O
139 O
##9 O
##gna O
whereas O
our O
patient O
was O
homo O
##zy O
##go O
##us O
for O
the O
c O
224 O
##3 O
##gn O
##c O
gen O
##otype O
both O
patients O
were O
also O
on O
multiple O
but O
different O
anti O
##con O
##vu O
##ls O
##ant O
regime O
##ns O
raising O
the O
possibility O
that O
competing O
mechanisms O
mod O
##ulated O
response O
to O
td O
##cs O
lastly O
our O
case O
was O
severe O
so O
by O
the O
time O
we O
started O
the O
intervention O
the O
seizures O
may O
have O
become O
ref O
##rac O
##tory O
to O
both O
medication O
and O
td O
##cs O
treatment O
we O
cannot O
rule O
out O
that O
cat O
##ho O
##dal O
stimulation O
elsewhere O
e O
g O
over O
the O
right O
o O
##cci O
##pit O
##al O
region O
might O
have O
yielded O
a O
better O
treatment O
response O
perhaps O
at O
an O
earlier O
stage O
of O
the O
disease O
however O
while O
the O
patient O
had O
a O
multi O
##fo O
##cal O
ep O
##ile O
##psy O
with O
multiple O
semi O
##ologies O
we O
spec O
##i O
##ﬁ O
##cal O
##ly O
targeted O
the O
left O
motor O
cortex O
to O
reduce O
the O
my O
##oc O
##lon O
##ic O
jerking O
of O
the O
right O
hand O
that O
the O
patient O
found O
very O
de O
##bil O
##itating O
similarly O
we O
cannot O
rule O
out O
that O
stimulating O
for O
more O
than O
ﬁ O
##ve O
days O
would O
have O
worked O
better O

according O
to O
guidelines O
published O
by O
a O
european O
expert O
consortium O

in O
2017 O
and O
several O
reviews O
it O
is O
not O
yet O
possible O
to O
draw O
conclusions O
regarding O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
td O
##cs O
in O
any O
kind O
of O
ep O
##ile O
##psy O
even O
though O
there O
are O
some O
promising O
results O
12 O
15 O
similarly O
it O
remains O
unclear O
whether O
trans O
##cr O
##anial O
magnetic O
stimulation O
t O
##ms O
another O
type O
of O
non O
invasive O
brain O
stimulation O
is O
an O
effective O
treatment O
of O
ep O
##ile O
##psy O
16 O
18 O
although O
there O
are O
some O
positive O
ﬁ O
##nding O
##s O
for O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
19 O
even O
less O
is O
known O
about O
how O
these O
non O
invasive O
brain O
stimulation O
techniques O
will O
affect O
patients O
with O
mitochondrial O
diseases O
however O
given O
that O
ref O
##rac O
##tory O
ep O
##ile O
##psy O
appears O
to O
be O
common O
in O
these O
diseases O
5 O
ﬁ O
##nding O
novel O
treatments O
is O
highly O
relevant O
to O
our O
knowledge O
this O
is O
only O
the O
second O
documented O
attempt O
to O
use O
td O
##cs O
in O
mit O
##o O

cho O
##nd O
##rial O
disease O
with O
one O
positive O
and O
one O
negative O
result O
it O
is O
too O
early O
to O
say O
whether O
td O
##cs O
will O
ﬁ O
##nd O
a O
place O
in O
the O
treatment O
of O
mitochondrial O
ep O
##ile O
##psy O
but O
during O
the O
early O
stages O
of O
any O
new O
treatment O
all O
ﬁ O
##nding O
##s O
negative O
or O
positive O
need O
to O
be O
published O
to O
obtain O
a O
clearer O
overall O
picture O
this O
is O
particularly O
relevant O
in O
this O
case O
where O
almost O
nothing O
is O
known O
about O
the O
e O
##f O
##ﬁ O
##ca O
##cy O
of O
td O
##cs O
for O
ep O
##ile O
##psy O
in O
patients O
with O
mitochondrial O
diseases O
further O
because O
the O
condition O
is O
so O
rare O
it O
is O
di O
##f O
##ﬁ O
##cu O
##lt O
to O
realize O
random O
##ized O
controlled O
trials O
with O
decent O
sample O

sizes O
and O
that O
could O
control O
for O
potential O
place O
##bo O
effects O
a O
ﬁ O
##nal O
reason O
for O
why O
we O
dee O
##m O
it O
important O
to O
report O
this O
negative O
ﬁ O
##nding O
is O
despite O
its O
limited O
contribution O
to O
the O
literature O
that O
there O
is O
growing O
awareness O
of O
reporting O
bias O
and O
replication O
issues O
in O
the O
sci O
##ent O
##i O
##ﬁ O
##c O
community O
and O
with O
it O
a O
growing O
recognition O
of O
the O
relevance O
of O
negative O
ﬁ O
##nding O
##s O
we O
hope O
that O
our O
ﬁ O
##nding O
##s O
contribute O
to O
a O
growing O
body O
of O
literature O
and O
encourage O
other O
scientists O
to O
provide O
larger O
samples O
and O
proper O
clinical O
trials O
author O
contribution O

conception O
and O
design O
of O
the O
study O
lab O
g O
##v O
and O
m O
##h O
acquisition O
of O
data O
l O
##m O
ik O
te O
hk O
##o O
m O
##h O
and O
lab O
analysis O
and O
interpretation O
of O
data O
l O
##m O
ik O
te O
hk O
##o O
and O
m O
##h O
drafting O
the O
manuscript O
or O
ﬁ O
##gur O
##es O
all O
authors O
critical O
review O
and O
revision O
all O
authors O
ac O
##k O
##now O
##led O
##gm O
##ents O
we O
express O
our O
deepest O
gratitude O
to O
the O
patient O
and O
would O
like O
to O
give O
our O
heart O
##felt O
condo O
##lence O
##s O
to O
the O
be O
##rea O
##ved O
family O
the O
present O
research O
was O
funded O
by O
a O
grant O
from O
the O
bergen O
research O
foundation O
bf O
##s O
##20 O
##16 O
##rek O
##0 O
##3 O
to O
marco O
hi O
##rn O
##stein O
and O
the O
ha O
##uke O
##land O
university O
hospital O
ethical O
statement O

the O
work O
described O
has O
been O
carried O
out O
in O
accordance O
with O
the O
code O
of O
ethics O
of O
the O
world O
medical O
association O
declaration O
of O
helsinki O
we O
con O
##ﬁ O
##rm O
that O
we O
have O
read O
the O
journal O
s O
position O
on O
issues O
involved O
in O
ethical O
publication O
and O
af O
##ﬁ O
##rm O
that O
this O
report O
is O
consistent O
with O
those O
guidelines O
declaration O
of O
competing O
interest O
none O
references O
rahman O
s O
mitochondrial O
disease O
and O
ep O
##ile O
##psy O
dev O
med O
child O
ne O
##uro O
##l O
2012 O
54 O
39 O
##7 O
406 O
bind O
##off O
la O
eng O
##els O
##en O
ba O
mitochondrial O
diseases O
and O
ep O
##ile O
##psy O
ep O
##ile O
##ps O
##ia O
2012 O
53 O
92 O
7 O

t O
##zo O
##uli O
##s O
c O
tran O
gt O
cox O
##head O
j O
bert O
##els O
##en O
b O
lille O
##ng O
p O
##k O
bala O
##fk O
##an O
n O
et O
al O
molecular O
pathogen O
##esis O
of O
polymer O
##ase O
gamma O
related O
ne O
##uro O
##de O
##gen O
##eration O
ann O
ne O
##uro O
##l O
2014 O
76 O
66 O
81 O
hi O
##km O
##at O
o O
e O
##iche O
##le O
t O
t O
##zo O
##uli O
##s O
c O
bind O
##off O
la O
understanding O
the O
ep O
##ile O
##psy O
in O
pol O
##g O
related O
disease O
int O
j O
mo O
##l O
sci O
2017 O
18 O
1845 O
par O
##ikh O
s O
cohen O
b O
##h O
gupta O
a O
lac O
##hh O
##wani O
d O
##k O
w O
##yl O
##lie O
e O
kota O
##gal O
p O
metabolic O
testing O
in O
the O
pediatric O
ep O
##ile O
##psy O
unit O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2008 O
38 O
191 O
5 O

ng O
y O
##s O
van O
ru O
##ite O
##n O
h O
lai O
hm O
scott O
r O
ram O
##esh O
v O
ho O
##rri O
##dge O
k O
et O
al O
the O
adjunct O
##ive O
application O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
in O
the O
management O
of O
de O
novo O
ref O
##rac O
##tory O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
in O
adolescent O
onset O
pol O
##g O
related O
mitochondrial O
disease O
ep O
##ile O
##ps O
##ia O
open O
2018 O
3 O
103 O
8 O
tor O
##gr O
##im O
##sen O
e O
ste O
##ns O
##land O
b O
l O
##j O
##ø O
##stad O
u O
my O
##gl O
##and O
a O
ep O
##ile O
##ps O
##i O
an O
##falls O
##kla O
##ssi O
##ﬁ O
##ser O
##ing O
og O
ak O
##ut O
##t O
##be O
##hand O
##ling O
til O
pas O
##iente O
##r O
med O
ep O
##ile O
##pt O
##isk O
##e O
an O
##fall O
in O
22 O
09 O
2017 O
ed O
he O
##ls O
##eb O
##ib O
##lio O
##tek O
##et O
no O
folk O
##eh O
##els O
##ein O
##sti O
##tu O
##tte O
##t O
2017 O
p O
6 O

ni O
##ts O
##che O
ma O
paul O
##us O
w O
ex O
##cit O
##ability O
changes O
induced O
in O
the O
human O
motor O
cortex O
by O
weak O
trans O
##cr O
##anial O
direct O
current O
stimulation O
j O
ph O
##ys O
##iol O
2000 O
52 O
##7 O
63 O
##3 O
9 O
ho O
##rva O
##th O
jc O
forte O
jd O
carter O
o O
quantitative O
review O
ﬁ O
##nds O
no O
evidence O
of O
cognitive O
effects O
in O
healthy O
populations O
from O
single O
session O
trans O
##cr O
##anial O
direct O
current O
stimulation O
td O
##cs O
brain O
st O
##im O
##ul O
2015 O
8 O
53 O
##5 O
50 O
st O
##ag O
##g O
c O
##j O
ni O
##ts O
##che O
ma O
physiological O
basis O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
ne O
##uro O
##sc O
##ient O
##ist O
2011 O
17 O
37 O
53 O

bi O
##kson O
m O
gross O
##man O
p O
thomas O
c O
za O
##nn O
##ou O
al O
jiang O
j O
ad O
##nan O
t O
et O
al O
safety O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
evidence O
based O
update O
2016 O
brain O
st O
##im O
##ul O
2016 O
9 O
64 O
##1 O
61 O
san O
juan O
d O
morales O
que O
##za O
##da O
l O
ga O
##rd O
##uno O
aj O
##o O
alonso O
vane O
##gas O
m O
gonzalez O
aragon O
m O
##f O
lopez O
da O
##e O
et O
al O
trans O
##cr O
##anial O
direct O
current O
stimulation O
in O
ep O
##ile O
##psy O
brain O
st O
##im O
##ul O
2015 O
8 O
45 O
##5 O
64 O
lin O
y O
wang O
y O
ne O
##uro O
##sti O
##mu O
##lation O
as O
a O
promising O
ep O
##ile O
##psy O
therapy O
ep O
##ile O
##ps O
##ia O
open O
2017 O
2 O
37 O
##1 O
87 O

le O
##fa O
##uche O
##ur O
j O
p O
ant O
##al O
a O
a O
##ya O
##che O
ss O
ben O
##ning O
##er O
dh O
br O
##une O
##lin O
j O
co O
##gia O
##mania O
##n O
f O
et O
al O
evidence O
based O
guidelines O
on O
the O
therapeutic O
use O
of O
trans O
##cr O
##anial O
direct O
current O
stimulation O
td O
##cs O
cl O
##in O
ne O
##uro O
##phy O
##sio O
##l O
2017 O
128 O
56 O
92 O
san O
juan O
d O
sar O
##miento O
ci O
gonzalez O
km O
barr O
##az O
##a O
o O
manuel O
j O
successful O
treatment O
of O
a O
drug O
resistant O
ep O
##ile O
##psy O
by O
long O
term O
trans O
##cr O
##anial O
direct O
current O
stimulation O
a O
case O
report O
front O
ne O
##uro O
##l O
2018 O
9 O
65 O

chen O
r O
spencer O
dc O
weston O
j O
nolan O
s O
##j O
trans O
##cr O
##anial O
magnetic O
stimulation O
for O
the O
treatment O
of O
ep O
##ile O
##psy O
cochrane O
database O
sy O
##st O
rev O
2016 O
8 O
cd O
##01 O
##10 O
##25 O
https O
doi O
org O
10 O
100 O
##2 O
146 O
##51 O
##85 O
##8 O
cd O
##01 O
##10 O
##25 O
pub O
##2 O
le O
##fa O
##uche O
##ur O
j O
p O
andre O
ob O
##adia O
n O
ant O
##al O
a O
a O
##ya O
##che O
ss O
bae O
##ken O
c O
ben O
##ning O
##er O
dh O
et O
al O
evidence O
based O
guidelines O
on O
the O
therapeutic O
use O
of O
repetitive O
trans O
##cr O
##anial O
magnetic O
stimulation O
rt O
##ms O
cl O
##in O
ne O
##uro O
##phy O
##sio O
##l O
2014 O
125 O
215 O
##0 O
206 O

fisher O
r O
zhou O
j O
fog O
##arty O
a O
joshi O
a O
marker O
##t O
m O
de O
##uts O
##ch O
g O
##k O
et O
al O
repetitive O
trans O
##cr O
##anial O
magnetic O
stimulation O
directed O
to O
a O
seizure O
focus O
localized O
by O
high O
density O
ee O
##g O
a O
case O
report O
ep O
##ile O
##psy O
be O
##h O
case O
rep O
2018 O
10 O
47 O
53 O
rot O
##enberg O
a O
bae O
eh O
take O
##oka O
m O
tor O
##mos O
j O
##m O
sc O
##ha O
##cht O
##er O
sc O
pas O
##cu O
##al O
leone O
a O
repetitive O
trans O
##cr O
##anial O
magnetic O
stimulation O
in O
the O
treatment O
of O
ep O
##ile O
##ps O
##ia O
partial O
##is O
con O
##tin O
##ua O
ep O
##ile O
##psy O
be O
##ha O
##v O
2009 O
14 O
253 O
7 O

case O
report O
r O
j O
m O
e O
romanian O
journal O
of O
morphology O
embryo O
##logy O
http O
www O
r O
##jm O
##e O
ro O
a O
rare O
case O
of O
mit O
##och O
##ond O
##rio O
##pathy O
with O
auto O
##som O
##al O
dominant O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
diagnosed O
through O
skeletal O
muscle O
bio O
##psy O
alexandra O
eugen O
##ia O
bas O
##tian O
##1 O
g O
##he O
##org O
##hita O
jug O
##ule O
##te O
##2 O
emilia O
man O
##ole O
##3 O
lu O
##mini O
##ta O
alexandra O
op O
##ris O
##an O
##4 O
1 O
department O
of O
pathology O
faculty O
of O
dental O
medicine O
carol O
da O
##vil O
##a O
university O
of O
medicine O
and O
pharmacy O
bucharest O
romania O
department O
of O
pathology O
cole O
##nti O
##na O
clinical O
hospital O
bucharest O
romania O

2 O
department O
of O
infectious O
diseases O
carol O
da O
##vil O
##a O
university O
of O
medicine O
and O
pharmacy O
bucharest O
romania O
clinical O
section O
ix O
pediatric O
##s O
prof O
dr O
mate O
##i O
bal O
##s O
national O
institute O
for O
infectious O
diseases O
bucharest O
romania O
3 O
department O
of O
pathology O
cole O
##nti O
##na O
research O
center O
cole O
##nti O
##na O
clinical O
hospital O
bucharest O
romania O
department O
of O
molecular O
biology O
victor O
babe O
##s O
national O
institute O
for O
research O
and O
development O
in O
pathology O
and O
biomedical O
sciences O
bucharest O
romania O

4 O
department O
of O
ne O
##uro O
##logy O
cole O
##nti O
##na O
clinical O
hospital O
bucharest O
romania O
department O
of O
ne O
##uro O
##logy O
carol O
da O
##vil O
##a O
university O
of O
medicine O
and O
pharmacy O
bucharest O
romania O
abstract O

mit O
##och O
##ond O
##rio O
##path O
##ies O
are O
a O
het O
##ero O
##gen O
##eous O
group O
of O
genetic O
diseases O
of O
all O
ages O
with O
a O
very O
diverse O
clinical O
presentation O
related O
to O
genetic O
het O
##ero O
##pl O
##as O
##my O
the O
clinical O
symptoms O
display O
a O
large O
variability O
and O
generally O
the O
more O
severe O
ph O
##eno O
##type O
##s O
have O
an O
early O
onset O
even O
from O
the O
neon O
##atal O
period O
while O
mild O
##er O
ones O
are O
manifested O
later O
in O
the O
adulthood O
most O
publications O
have O
already O
demonstrated O
del O
##eti O
##ons O
or O
point O
mutations O
in O
mitochondrial O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##lei O
##c O
acid O
dna O
but O
in O
recent O
years O
the O
field O
of O
investigation O
has O
expanded O
to O
syndrome O
##s O
caused O
by O
mutations O
in O
the O
nuclear O
dna O
n O
##dna O
with O
a O
men O
##del O
##ian O
inheritance O
we O
present O
the O
case O
of O
a O
male O
patient O
with O
a O
mit O
##och O
##ond O
##rio O
##pathy O
with O
ph O
##eno O
##type O
of O
chronic O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
due O
to O
an O
auto O
##som O
##al O
dominant O
mutation O
in O
n O
##dna O
in O
the O
dna O
polymer O
##ase O
subunit O
gamma O
pol O
##g O
gene O
the O
pathogen O
##ic O
variant O
c O
286 O
##4 O
##a O
g O
p O
ty O
##r O
##9 O
##55 O
##cy O
##s O
morphological O
##ly O
investigated O
and O
diagnosed O
using O
a O
skeletal O
muscle O
bio O
##psy O
the O
aim O
of O
this O
presentation O
is O
to O
emphasize O
the O
diagnostic O
value O
of O
the O
muscle O
bio O
##psy O
both O
in O
cases O
of O
clinical O
suspicion O
and O
in O
more O
challenging O
cases O
of O
mitochondrial O
diseases O
with O
at O
##yp O
##ical O
or O
unusual O
features O
although O
genetic O
testing O
may O
be O
the O
initial O
test O
of O
choice O
in O
cases O
with O
suggest O
##ive O
clinical O
presentation O
muscle O
bio O
##psy O
is O
an O
alternative O
diagnostic O
aid O
with O
high O
value O
even O
in O
our O
molecular O
era O
we O
present O
path O
##ological O
and O
ultra O
##st O
##ru O
##ct O
##ural O
data O
to O
confirm O
the O
diagnosis O

key O
##words O
mit O
##och O
##ond O
##rio O
##pathy O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
nuclear O
dna O
mutation O
electron O
microscopy O
introduction O

mit O
##och O
##ond O
##rio O
##path O
##ies O
are O
a O
het O
##ero O
##gen O
##eous O
group O
of O
genetic O
diseases O
of O
children O
and O
adults O
with O
a O
very O
diverse O
clinical O
presentation O
involving O
a O
single O
organ O
or O
even O
more O
frequently O
multi O
##sy O
##ste O
##mic O
making O
the O
diagnostic O
work O
##up O
a O
real O
challenge O
their O
worldwide O
prevalence O
is O
estimated O
to O
range O
between O
1 O
5000 O
and O
1 O
850 O
##0 O
with O
many O
und O
##ia O
##gno O
##sed O
cases O
worldwide O
this O
group O
of O
diseases O
is O
the O
result O
of O
dysfunction O
##s O
of O
the O
mitochondrial O
respiratory O
chain O
1 O
the O
clinical O
symptoms O
have O
a O
large O
variability O
and O
generally O
the O
more O
severe O
ph O
##eno O
##type O
##s O
have O
an O
early O
onset O
even O
from O
the O
neon O
##atal O
period O
while O
mild O
##er O
ones O
manifest O
later O
in O
the O
adulthood O

the O
most O
important O
types O
of O
mit O
##och O
##ond O
##rio O
##path O
##ies O
are O
mitochondrial O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
lac O
##tic O
acid O
##osis O
and O
stroke O
like O
episodes O
mel O
##as O
leigh O
syndrome O
sub O
##ac O
##ute O
nec O
##rot O
##izing O
en O
##ce O
##pha O
##lom O
##ye O
##lo O
##pathy O
my O
##oc O
##lon O
##ic O
ep O
##ile O
##psy O
with O
ragged O
red O
fibers O
mer O
##rf O
auto O
##som O
##al O
dominant O
or O
auto O
##som O
##al O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ad O
ar O
pe O
##o O
al O
##pers O
disease O
ep O
##ile O
##psy O
with O
liver O
failure O
sensory O
ata O
##xi O
##c O
ne O
##uro O
##pathy O
d O
##ys O
##arth O
##ria O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
sand O
##o O
le O
##ber O
hereditary O
optic O
ne O
##uro O
##pathy O
l O
##hon O
ne O
##uro O
##pathy O
ata O
##xia O
and O
re O
##tin O
##itis O
pigment O
##osa O
na O
##rp O
and O
ke O
##arns O
say O
##re O
syndrome O
ks O
##s O

the O
mit O
##och O
##ond O
##rion O
is O
the O
location O
of O
energy O
production O
in O
the O
cell O
through O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
this O
process O
has O
dual O
genetic O
control O
as O
it O
is O
regulated O
by O
genes O
in O
both O
mitochondrial O
de O
##ox O
##yr O
##ib O
##on O
##uc O
##lei O
##c O
acid O
mt O
##dna O
and O
nuclear O
dna O
n O
##dna O
thus O
mitochondrial O
my O
##opa O
##thi O
##es O
are O
produced O
by O
mutations O
in O
the O
nuclear O
or O
mitochondrial O
genome O
mit O
##och O
##ond O
##ria O
are O
ubiquitous O
in O
all O
tissues O
except O
for O
red O
blood O
cells O
and O
this O
is O
the O
explanation O
why O
clinical O
features O
manifest O
typically O
in O
tissues O
with O
high O
energy O
requirements O
like O
brain O
skeletal O
muscles O
my O
##oca O
##rdi O
##um O
or O
end O
##oc O
##rine O
organs O
over O
1500 O
mitochondrial O
proteins O
and O
37 O
mitochondrial O
genes O
are O
currently O
known O

most O
publications O
have O
already O
demonstrated O
del O
##eti O
##ons O
or O
point O
mutations O
in O
mt O
##dna O
but O
in O
recent O
years O
the O
field O
of O
investigation O
has O
expanded O
to O
syndrome O
##s O
caused O
by O
mutations O
in O
the O
n O
##dna O
with O
a O
men O
##del O
##ian O
inheritance O
2 O
the O
first O
mutations O
in O
n O
##dna O
associated O
with O
secondary O
multiple O
del O
##eti O
##ons O
in O
mt O
##dna O
were O
described O
in O
1999 O
by O
ni O
##shin O
##o O
et O
al O
3 O
they O
caused O
an O
auto O
##som O
##al O
recess O
##ive O
disease O
mitochondrial O
ne O
##uro O
##gas O
##tro O
##int O
##estinal O
en O
##ce O
##pha O
##lom O
##yo O
##pathy O
mn O
##gie O
it O
was O
followed O
by O
the O
discovery O
of O
issn O
print O
122 O
##0 O
05 O
##22 O
issn O
online O
206 O
##6 O
82 O
##7 O
##9 O

other O
nuclear O
genes O
involved O
in O
mitochondrial O
pathology O
like O
pe O
##o O
with O
men O
##del O
##ian O
inheritance O
most O
n O
##dna O
mutations O
are O
auto O
##som O
##al O
recess O
##ive O
but O
there O
are O
also O
few O
auto O
##som O
##al O
dominant O
and O
two O
mutations O
are O
linked O
to O
chromosome O
x O
2 O

pe O
##o O
chronic O
pe O
##o O
cp O
##eo O
or O
auto O
##som O
##al O
dominant O
pe O
##o O
##1 O
ad O
##pe O
##o O
##1 O
mit O
##och O
##ond O
##rio O
##pathy O
is O
a O
mitochondrial O
disease O
with O
cp O
##eo O
caused O
by O
an O
auto O
##som O
##al O
dominant O
mutation O
in O
n O
##dna O
dna O
polymer O
##ase O
subunit O
gamma O
pol O
##g O
gene O
on O
chromosome O
15 O
##q O
##25 O
with O
a O
men O
##del O
##ian O
transmission O
this O
gene O
en O
##codes O
for O
the O
catalytic O
subunit O
of O
the O
mt O
##dna O
polymer O
##ase O
pol O
γ O
and O
the O
disorders O
produced O
by O
a O
mutation O
in O
pol O
##g O
gene O
may O
be O
inherited O
both O
in O
a O
recess O
##ive O
and O
a O
dominant O
way O
4 O
5 O
defects O
in O
pol O
γ O
lead O
to O
multiple O
mt O
##dna O
del O
##eti O
##ons O
less O
commonly O
similar O
mutations O
may O
cause O
mt O
##dna O
de O
##ple O
##tion O
6 O
the O
precise O
molecular O
mechanisms O
underlying O
such O
variability O
have O
not O
yet O
been O
dec O
##ip O
##hered O
7 O

pe O
##o O
is O
clinical O
##ly O
characterized O
by O
onset O
between O
18 O
and O
40 O
years O
old O
pt O
##osis O
and O
weakening O
of O
the O
external O
eye O
muscles O
b O
##le O
##pha O
##rop O
##tosis O
and O
op O
##ht O
##hal O
##mo O
##par O
##esis O
weakness O
and O
wasting O
of O
pro O
##xi O
##mal O
limb O
muscles O
and O
exercise O
into O
##ler O
##ance O
are O
also O
associated O
with O
pe O
##o O

we O
present O
a O
rare O
case O
of O
adult O
onset O
pe O
##o O
##1 O
due O
to O
an O
auto O
##som O
##al O
dominant O
mutation O
in O
n O
##dna O
encoding O
for O
pol O
##g O
on O
chromosome O
15 O
##q O
##25 O
with O
a O
definitive O
molecular O
genetic O
confirmation O
achieved O
after O
a O
his O
##top O
##ath O
##ological O
recognition O
of O
the O
mitochondrial O
abnormalities O
our O
case O
demonstrates O
that O
a O
muscle O
bio O
##psy O
with O
optimal O
processing O
of O
the O
tissue O
may O
be O
a O
key O
diagnostic O
tool O
that O
can O
establish O
a O
fast O
and O
accurate O
diagnosis O
and O
direct O
molecular O
genetic O
testing O
in O
these O
diseases O
with O
incredible O
ph O
##eno O
##typic O
and O
genetic O
diversity O
case O
presentation O

the O
patient B-PATIENT
is O
a O
49 O
year O
old O
man O
p O
##n O
from O
urban O
area O
with O
higher O
education O
and O
professional O
activity O
with O
un O
##rem O
##ark O
##able O
past O
medical O
history O
who O
presented O
three O
years O
ago O
to O
the O
hospital O
department O
of O
ne O
##uro O
##logy O
cole O
##nti O
##na O
clinical O
hospital O
bucharest O
romania O
medical O
record O
no O
104 O
##55 O
##3 O
2015 O
for O
a O
specialized O
medical O
consultation O
because O
of O
progressive B-HPO_TERM
bilateral I-HPO_TERM
eye I-HPO_TERM
weakness I-HPO_TERM
and O
fatigue B-HPO_TERM
with O
dr B-HPO_TERM
##ooped I-HPO_TERM
eyelids I-HPO_TERM
without O
di O
##urn O
##al O
variation O
of O
the O
symptoms O
and O
slight O
difficulty B-HPO_TERM
in I-HPO_TERM
swallowing I-HPO_TERM
figure O
1 O

figure O
1 O
op B-HPO_TERM
##ht I-HPO_TERM
##hal I-HPO_TERM
##mo I-HPO_TERM
##ple I-HPO_TERM
##gia I-HPO_TERM
of O
the O
patient B-PATIENT
in O
2014 O
progressive B-HPO_TERM
bilateral I-HPO_TERM
eye I-HPO_TERM
weakness I-HPO_TERM
and O
fatigue B-HPO_TERM
with O
dr B-HPO_TERM
##ooped I-HPO_TERM
eyelids I-HPO_TERM
his O
63 O
year O
old O
brother O
and O
88 O
year O
old O
mother O
have O
no O
similar O
problems O
his O
father O
died O
when O
the O
patient O
was O
a O
small O
child O
but O
did O
not O
show O
any O
sign O
of O
ne O
##uro O
##mus O
##cular O
disease O
throughout O
his O
life O
nobody O
else O
in O
the O
family O
ever O
experienced O
similar O
symptoms O
both O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
and O
d O
##ys O
##pha O
##gia O
have O
evolved O
over O
time O
figure O
2 O
thinking O
retrospective O
##ly O
and O
analyzing O
photographs O
from O
his O
personal O

archive O
the O
patient O
realized O
that O
the O
symptoms O
actually O
started O
many O
years O
in O
advance O
probably O
around O
the O
age O
of O
35 B-AGE_ONSET
but O
remained O
unnoticed O
the O
patient O
also O
had O
a O
mild O
and O
very O
slowly O
progressive B-HPO_TERM
pro I-HPO_TERM
##xi I-HPO_TERM
##mal I-HPO_TERM
limb I-HPO_TERM
weakness I-HPO_TERM
figure O
2 O
evolution O
of O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
over O
time O
years O
2005 O
a O
2007 O
b O
and O
2011 O
c O
the O
first O
clinical O
diagnosis O
suspected O
by O
the O
op O
##ht O
##hal O
##mo O
##logist O
and O
then O
ne O
##uro O
##logist O
was O
my O
##ast O
##hen O
##ia O
gr O
##avi O
##s O
but O
anti O
ace O
##ty O
##lch O
##olin O
##e O
receptor O
and O
anti O
muscles O
##pe O
##ci O
##fi O
##c O
kinase O
mu O
##sk O
receptor O
antibody O
levels O
were O
normal O

other O
investigations O
like O
computed O
tom O
##ography O
scan O
sp O
##iro O
##metry O
electro O
##my O
##ography O
and O
do O
##pp O
##ler O
ultrasound O
were O
also O
performed O
at O
that O
time O
without O
con O
##clusive O
results O
serum B-HPO_TERM
cr I-HPO_TERM
##ea I-HPO_TERM
##tine I-HPO_TERM
kinase I-HPO_TERM
level I-HPO_TERM
was I-HPO_TERM
mildly I-HPO_TERM
elevated I-HPO_TERM
after O
injection O
of O
p O
##yr O
##ido O
##sti O
##gm O
##ine O
me O
##sti O
##non O
the O
eye O
##lid O
lifting O
effect O
was O
insignificant O
however O
he O
received O
co O
##rti O
##cos O
##ter O
##oid O
treatment O
and O
neo O
##sti O
##gm O
##ine O
for O
nine O
months O
without O
any O
clinical O
improvement O
after O
disco O
##nti O
##nu O
##ing O
treatment O
for O
several O
days O
on O
his O
own O
initiative O
the O
patient O
did O
not O
experienced O
any O
worse O
##ning O
of O
the O
symptoms O
however O
he O
continued O
the O
prescribed O
treatment O
with O
neo O
##sti O
##gm O
##ine O
and O
intermittent O
co O
##rti O
##cot O
##her O
##ap O
##y O
persistence O
of O
symptoms O
urged O
him O
to O
continue O
the O
investigations O
another O
consultation O
at O
the O
department O
of O
ne O
##uro O
##logy O
university O
emergency O
hospital O
bucharest O
raised O
the O
clinical O
suspicion O
of O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
based O
on O
the O
association O
of O
pt B-HPO_TERM
##osis I-HPO_TERM
with O
d B-HPO_TERM
##ys I-HPO_TERM
##pha I-HPO_TERM
##gia I-HPO_TERM
and O
a O
muscular O
bio O
##psy O
was O
recommended O
to O
confirm O
the O
clinical O
diagnosis O
it O
is O
important O
to O
note O
that O
a O
possible O
diagnosis O
of O
mitochondrial O
disease O
was O
never O
clinical O
##ly O
suspected O
before O
performing O
the O
muscle O
bio O
##psy O

an O
open O
muscle O
bio O
##psy O
from O
the O
left O
del O
##to O
##id O
muscle O
under O
local O
an O
##esthesia O
using O
lid O
##oca O
##ine O
sub O
##cut O
##aneous O
injection O
was O
performed O
at O
cole O
##nti O
##na O
clinical O
hospital O
bucharest O
after O
informed O
consent O
of O
the O
patient O
for O
the O
procedure O
was O
obtained O
the O
muscle O
tissue O
processing O
being O
accomplished O
in O
the O
department O
of O
pathology O
of O
the O
same O
hospital O

a O
skeletal O
muscle O
tissue O
fragment O
was O
snap O
frozen O
in O
liquid O
nitrogen O
cooled O
iso O
##pen O
##tan O
##e O
following O
the O
orientation O
of O
the O
muscle O
trans O
##vers O
##al O
8 O
μ O
##m O
thickness O
cry O
##ose O
##ctions O
were O
obtained O
they O
were O
processed O
and O
stained O
for O
examination O
with O
his O
##tology O
and O
his O
##to O
##chemist O
##ry O
techniques O
hem O
##ato O
##xy O
##lin O
e O
##osi O
##n O
he O
van O
gi O
##eson O
modified O
go O
##mori O
tri O
##chrome O
gt O
sudan O
bb O
periodic O
acid O
sc O
##hiff O
pas O
and O
enzyme O
his O
##to O
##chemical O
preparation O
for O
reduced O
nico O
##tina O
##mide O
aden O
##ine O
din O
##uc O
##le O
##otide O
te O
##tra O
##zo O
##lium O
red O
##uc O
##tase O
nad O
##h O
tr O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
sd O
##h O
lac O
##tate O
de O
##hy O
##dro O
##genase O
ld O
##h O
aden O
##osi O
##ne O
trip O
##hos O
##pha O
##tase O
atp O
##ase O
at O
ph O
9 O
4 O
4 O
63 O
and O
4 O
35 O
after O
muscle O
sections O
examination O
in O
light O
microscopy O
a O
cy O
##to O
##chrome O
ox O
##ida O
##se O
iv O
investigation O
using O
the O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O
cox O
or O
complex O
iv O
reaction O
and O
a O
combined O
cox O
sd O
##h O
stain O
##ing O
were O
ordered O
due O
to O
the O
presence O
of O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
on O
gt O
and O
he O
stain O
##ings O

another O
small O
longitudinal O
of O
0 O
5 O
mm O
length O
fragment O
of O
muscle O
tissue O
was O
fixed O
in O
buffer O
##ed O
2 O
5 O
g O
##lu O
##tara O
##lde O
##hy O
##de O
embedded O
in O
ep O
##on O
81 O
##2 O
resin O
after O
os O
##mic O
##ation O
semi O
##thi O
##n O
and O
ultra O
##thi O
##n O
sections O
were O
obtained O
and O
contrasted O
with O
ur O
##any O
##l O
ace O
##tate O
and O
lead O
ci O
##tra O
##te O
for O
ultra O
##st O
##ru O
##ct O
##ural O
examination O

a O
separate O
piece O
of O
muscle O
tissue O
was O
formal O
##in O
fixed O
para O
##ffin O
embedded O
and O
the O
sections O
were O
stained O
with O
he O
on O
examination O
in O
light O
microscopy O
the O
st O
##riated O
muscle O
tissue O
fragment O
had O
a O
well O
preserved O
overall O
architecture O
but O
an O
obvious O
fiber O
size O
variation O
with O
scattered O
elongated O
isolated O
at O
##rop O
##hic O
fibers O
figure O
3 O
very O
rare O
more O
intensely O

colored O
fibers O
or O
fibers O
with O
a O
clear O
external O
rim O
were O
noticed O
on O
he O
stain O
##ing O
figure O
4 O
with O
a O
gran O
##ular O
aspect O
and O
a O
fine O
reddish O
border O
red O
rim O
and O
irregular O
sar O
##co O
##pl O
##as O
##m O
on O
gt O
stain O
##ing O
giving O
a O
ragged O
red O
appearance O
and O
with O
more O
intense O
reaction O
on O
ox O
##ida O
##tive O
enzyme O
stain O
##ings O
figure O
5 O
the O
ragged B-HPO_TERM
red I-HPO_TERM
fibers I-HPO_TERM
were O
hyper O
reactive O
and O
stained O
darkly O
with O
sd O
##h O
figure O
6 O
the O
most O
sensitive O
stain O
##ing O
for O
detecting O
mitochondrial O
proliferation O
appearing O
as O
ragged O
blue O
fibers O
these O
fibers O
were O
cox B-HPO_TERM
negative I-HPO_TERM
a O
dominance B-HPO_TERM
of I-HPO_TERM
type I-HPO_TERM
i I-HPO_TERM
muscle I-HPO_TERM
fibers I-HPO_TERM
and O
small O
clusters O
of O
type O
ii O
fibers O
had O
also O
been O
observed O
figure O
7 O
increased B-HPO_TERM
focal I-HPO_TERM
pun I-HPO_TERM
##cta I-HPO_TERM
##te I-HPO_TERM
lip I-HPO_TERM
##id I-HPO_TERM
inclusion I-HPO_TERM
##s I-HPO_TERM
within I-HPO_TERM
some I-HPO_TERM
of I-HPO_TERM
the I-HPO_TERM
my I-HPO_TERM
##of I-HPO_TERM
##ibe I-HPO_TERM
##rs I-HPO_TERM
were O
highlighted O
by O
sudan O
bb O
stain O
##ing O
figure O
8 O
and O
pas O
stain O
##ing O
was O
more O
prominent O
in O
several O
fibers O
figure O
9 O
the O
cox O
reaction O
showed O
obvious O
scattered O
negative O
muscle O
fibers O
lacking O
cox O
activity O
figure O
10 O
stain O
##ing O
blue O
with O
the O
combined O
cox O
sd O
##h O
stain O
##ing O
a O
clearly O
path O
##ological O
aspect O
as O
in O
normal O
bio O
##ps O
##ies O
all O
fibers O
have O
stain O
##ing O
for O
cox O
these O
findings O
were O
diagnostic O
of O
mitochondrial O
my O
##opa O
##thy O
and O
ultra O
##st O
##ru O
##ct O
##ural O
examination O
was O
further O
performed O
the O
clinical O
suspicion O
of O
o O
##cu O
##lo O
##pha O
##ryn O
##ge O
##al O
muscular O
d O
##yst O
##rop O
##hy O
based O
on O
the O
association O
of O
pt O
##osis O
with O
d O
##ys O
##pha O
##gia O
could O
be O
ruled O
out O
by O
the O
absence O
of O
rim O
##med O
cy O
##top O
##las O
##mic O
va O
##cu O
##oles O
or O
other O
morphological O
aspects O
described O
in O
this O
disease O
and O
identification O
of O
ragged O
red O
ragged O
blue O
fibers O
highly O
suggest O
##ive O
for O
a O
mitochondrial O
disease O
the O
remaining O
muscle O
tissue O
was O
stored O
at O
800 O
##c O
in O
a O
deep O
freeze O
##r O

figure O
3 O
muscle O
cry O
##ose O
##ctions O
well O
preserved O
architecture O
with O
fiber O
size O
variation O
isolated O
at O
##rop O
##hic O
fibers O
he O
stain O
##ing O
100 O
##× O
figure O
6 O
muscle O
cry O
##ose O
##ctions O
the O
ragged O
blue O
fibers O
hyper O
reactive O
for O
sd O
##h O
sd O
##h O
stain O
##ing O
100 O
##× O
sd O
##h O
su O
##cci O
##nate O
de O
##hy O
##dro O
##genase O
figure O
4 O
muscle O
cry O
##ose O
##ctions O
very O
rare O
more O
intensely O
colored O
fibers O
with O
a O
gran O
##ular O
aspect O
he O
stain O
##ing O
100 O
##× O
figure O
7 O
muscle O
cry O
##ose O
##ctions O
a O
dominance O
of O
type O
i O
muscle O
fibers O
stained O
light O
and O
small O
clusters O
of O
type O
ii O
fibers O
stained O
dark O
atp O
##ase O
stain O
##ing O
at O
ph O
9 O
4 O
40 O
##× O
atp O
##ase O
aden O
##osi O
##ne O
trip O
##hos O
##pha O
##tase O

figure O
5 O
muscle O
cry O
##ose O
##ctions O
some O
fibers O
with O
a O
gran O
##ular O
aspect O
and O
a O
fine O
reddish O
border O
on O
gt O
stain O
##ing O
giving O
a O
ragged O
red O
appearance O
100 O
##× O
figure O
8 O
muscle O
cry O
##ose O
##ctions O
increased O
focal O
pun O
##cta O
##te O
lip O
##id O
within O
my O
##of O
##ibe O
##rs O
highlighted O
by O
sudan O
bb O
sudan O
bb O
stain O
##ing O
100 O
##× O
figure O
9 O
muscle O
cry O
##ose O
##ctions O
some O
pas O
more O
prominent O
fibers O
pas O
stain O
##ing O
100 O
##× O
figure O
10 O
muscle O
cry O
##ose O
##ctions O
the O
cox O
reaction O
revealing O
several O
negative O
muscle O
fibers O
lacking O
cox O
activity O
as O
##ter O
##isk O
a O
40 O
##× O
b O
100 O
##× O
cox O
cy O
##to O
##chrome O
c O
ox O
##ida O
##se O

routine O
transmission O
electron O
microscopy O
te O
##m O
was O
performed O
on O
ultra O
##thi O
##n O
sections O
stained O
with O
ur O
##any O
##l O
ace O
##tate O
and O
lead O
ci O
##tra O
##te O
te O
##m O
examination O
showed O
an O
increase O
in O
the O
number O
and O
size O
of O
the O
mit O
##och O
##ond O
##ria O
with O
sub O
##sar O
##col O
##em O
##mal O
and O
per O
##in O
##uc O
##lea O
##r O
accumulation O
of O
abnormal O
mit O
##och O
##ond O
##ria O
figure O
11 O
some O
of O
them O
with O
abnormal O

con O
##centric O
cr O
##ista O
##e O
figure O
12 O
and O
some O
others O
with O
round O
electron O
dense O
bodies O
inside O
and O
circular O
cr O
##ista O
##e O
figure O
13 O
con O
##centric O
cr O
##ista O
##e O
or O
onion O
like O
mit O
##och O
##ond O
##ria O
observed O
in O
patient O
s O
muscle O
samples O
are O
named O
also O
tubular O
parallel O
cr O
##ista O
##e O
or O
con O
##centric O
lam O
##inated O
bodies O
figure O
11 O
electron O
microscopy O
sub B-HPO_TERM
##sar I-HPO_TERM
##col I-HPO_TERM
##em I-HPO_TERM
##mal I-HPO_TERM
accumulation I-HPO_TERM
of I-HPO_TERM
mit I-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
some O
mit B-HPO_TERM
##och I-HPO_TERM
##ond I-HPO_TERM
##ria I-HPO_TERM
with I-HPO_TERM
abnormal I-HPO_TERM
con I-HPO_TERM
##centric I-HPO_TERM
cr I-HPO_TERM
##ista I-HPO_TERM
##e I-HPO_TERM
650 O
##0 O
##× O
figure O
12 O
electron O
microscopy O
con O
##centric O
cr O
##ista O
##e O
or O
onion O
like O
mit O
##och O
##ond O
##ria O
20 O
000 O
##× O

figure O
13 O
electron O
microscopy O
some O
mit O
##och O
##ond O
##ria O
with O
round O
electron O
dense O
bodies O
inside O
and O
circular O
cr O
##ista O
##e O
11 O
500 O
##× O
receiving O
a O
path O
##ological O
diagnosis O
which O
refers O
to O
a O
genetic O
progressive O
disease O
the O
patient O
became O
very O
anxious O
and O
concerned O
about O
the O
risk O
that O
his O
single O
14 O
year O
old O
healthy O
son O
might O
eventually O
inherit O
the O
disease O
for O
genetic O
confirmation O
and O
counseling O
a O
dna O
sample O
extracted O
from O
the O
patient O
s O
blood O
was O
prepared O
for O
genetic O
analysis O
in O
may O
2016 O
and O
was O
sent O
to O
belgium O
at O
the O
center O
for O
medical O
genetics O
u O
##z O
br O
##uss O
##el O

the O
first O
genetic O
tests O
addressed O
to O
the O
mitochondrial O
genome O
and O
did O
not O
identify O
any O
abnormal O
##ity O

at O
this O
stage O
of O
the O
diagnostic O
approach O
the O
genetic O
testing O
has O
been O
extended O
in O
august O
2016 O
to O
n O
##dna O
analysis O
using O
the O
panel O
for O
mitochondrial O
diseases O
and O
identified O
a O
mutation O
in O
the O
pol B-GENE
##g I-GENE
gene O
the O
pathogen O
##ic O
variant O
c B-GENE_VARIANT
286 I-GENE_VARIANT
##4 I-GENE_VARIANT
##a I-GENE_VARIANT
g I-GENE_VARIANT
p B-GENE_VARIANT
ty I-GENE_VARIANT
##r I-GENE_VARIANT
##9 I-GENE_VARIANT
##55 I-GENE_VARIANT
##cy I-GENE_VARIANT
##s I-GENE_VARIANT
in O
january O
2017 O
sequencing O
analysis O
with O
massive O
parallel O
sequencing O
of O
the O
coding O
ex O
##ons O
and O
part O
of O
the O
flanking O
intro O
##ns O
of O
the O
genes O
included O
in O
mitochondrial O
disease O
gene O
panel O
target O
capture O
roche O
was O
performed O
this O
mutation O
has O
been O
associated O
in O
literature O
with O
dominant O
pe O
##o O
and O
pe O
##o O
with O
parkinson O
using O
genetic O
testing O
the O
clinical O
suspicion O
of O
a O
mitochondrial O
disease O
was O
confirmed O
with O
the O
identification O
of O
an O
auto O
##som O
##al O
dominant O
gene O
defect O
in O
pol O
##g O
all O
siblings O
and O
children O
of O
this O
patient O
have O
an O
estimated O
risk O
of O
50 O
to O
be O
affected O
genetic O
counseling O
of O
the O
patient O
is O
now O
essential O

our O
patient O
currently O
performs O
normal O
physical O
and O
professional O
activity O
while O
scheduling O
surgery O
to O
correct O
pt O
##osis O
and O
for O
the O
time O
being O
decided O
to O
post O
##pone O
his O
son O
s O
genetic O
testing O
studying O
the O
op O
##ht O
##hal O
##mo O
##logical O
literature O
the O
patient O
also O
designed O
and O
made O
himself O
special O
cr O
##ut O
##ches O
attached O
to O
his O
glasses O
to O
keep O
the O
eyelids O
elevated O
discussions O
clinical O
diagnosis O
of O
mitochondrial O
disorders O
is O
complicated O
by O
various O
ph O
##eno O
##type O
##s O
that O
lead O
to O
dysfunction O
##s O
of O
almost O
any O
organ O
8 O

pe O
##o O
is O
a O
common O
manifestation O
of O
a O
mitochondrial O
disease O
with O
onset O
in O
adulthood O
and O
is O
usually O
associated O
with O
either O
primary O
mt O
##dna O
mutations O
or O
secondary O
mt O
##dna O
defects O
caused O
by O
mutations O
in O
n O
##dna O
with O
effect O
in O
disrupt O
##ing O
mt O
##dna O
maintenance O
many O
patients O
do O
not O
have O
a O
genetic O
diagnosis O
but O
have O
multiple O
del O
##eti O
##ons O
of O
mt O
##dna O
in O
skeletal O
muscle O
extremely O
rare O
cases O
of O
pe O
##o O
without O
pt O
##osis O
or O
late O
onset O
eye O
##lid O
pt O
##osis O
in O
the O
disease O
course O
were O
also O
described O
both O
auto O
##som O
##al O
dominant O
and O
auto O
##som O
##al O
recess O
##ive O
inheritance O
can O
occur O
auto O
##som O
##al O
recess O
##ive O
inheritance O
is O
usually O
more O
severe O
9 O

the O
most O
common O
clinical O
features O
in O
pe O
##o O
##1 O
are O
weakness O
of O
the O
external O
eye O
muscles O
and O
exercise O

into O
##ler O
##ance O
with O
rare O
and O
variable O
additional O
symptoms O
including O
cat O
##ara O
##ct O
sensory O
ax O
##onal O
ne O
##uro O
##pathy O
ata O
##xia O
hearing O
loss O
depression O
h O
##yp O
##ogo O
##nad O
##ism O
and O
parkinson O
##ism O
fortunately O
none O
of O
these O
possible O
additional O
signs O
have O
been O
observed O
in O
our O
patient O
besides O
the O
eye O
symptoms O
our O
patient O
had O
progressive O
d O
##ys O
##pha O
##gia O
with O
a O
gradual O
degradation O
of O
swallowing O
it O
is O
important O
to O
take O
into O
account O
the O
presence O
of O
all O
gas O
##tro O
##int O
##estinal O
manifestation O
##s O
in O
mitochondrial O
diseases O
diagnosis O
e O
g O
the O
mo O
##tility O
disorders O
d O
##ys O
##pha O
##gia O
can O
be O
caused O
by O
either O
central O
nervous O
system O
cn O
##s O
involvement O
peripheral O
nerves O
or O
involvement O
of O
smooth O
muscle O
cells O
this O
phenomenon O
is O
common O
in O
mitochondrial O
disease O
10 O
one O
of O
the O
most O
important O
measures O
in O
treating O
d O
##ys O
##pha O
##gia O
in O
mitochondrial O
diseases O
is O
avoidance O
of O
toxic O
drugs O
for O
mit O
##och O
##ond O
##rion O
such O
as O
di O
##ch O
##lor O
##oa O
##ce O
##tate O
line O
##zo O
##lid O
ch O
##lor O
##amp O
##hen O
##ico O
##l O
amino O
##gly O
##cos O
##ides O
val O
##pro O
##ic O
acid O
car O
##ba O
##ma O
##ze O
##pine O
ph O
##eno O
##bar O
##bit O
##al O
stat O
##ins O
or O
nu O
##cle O
##osi O
##de O
reverse O
transcript O
##ase O
nr O
##t O
inhibitors O
aspects O
which O
are O
not O
well O
known O
or O
taken O
into O
account O
by O
many O
physicians O
11 O

a O
genetic O
diagnosis O
can O
lead O
to O
the O
avoidance O
of O
muscle O
bio O
##psy O
but O
many O
cases O
with O
or O
without O
a O
genetic O
diagnosis O
require O
a O
muscular O
bio O
##psy O
for O
confirmation O
especially O
the O
cases O
of O
unknown O
mutations O
skeletal O
muscle O
is O
considered O
to O
be O
the O
best O
tissue O
to O
confirm O
a O
mitochondrial O
my O
##opa O
##thy O
using O
his O
##to O
##chemical O
and O
bio O
##chemical O
tests O
that O
can O
be O
done O
on O
tissue O
cox O
complex O
iv O
activity O
and O
sd O
##h O
complex O
ii O
activity O
12 O
some O
authors O
demonstrated O
that O
different O
mitochondrial O
syndrome O
##s O
have O
contrasting O
his O
##to O
##chemical O
features O
with O
ragged O
red O
fibers O
and O
cox O
negative O
fibers O
being O
more O
prevalent O
in O
pe O
##o O
than O
in O
mer O
##rf O
syndrome O
or O
mel O
##as O
13 O
negative O
cox O
muscle O
fibers O
may O
suggest O
a O
mitochondrial O
genetic O
problem O
that O
requires O
further O
investigations O
of O
specific O
gene O
panels O
ex O
##oso O
##me O
sequencing O
or O
whole O
genome O
sequencing O
14 O

a O
main O
path O
##ological O
challenge O
is O
to O
perform O
the O
muscle O
bio O
##psy O
and O
process O
the O
tissue O
using O
standardized O
protocols O
to O
preserve O
not O
only O
morphology O
of O
mit O
##och O
##ond O
##ria O
but O
also O
the O
en O
##zy O
##matic O
activity O
and O
genetic O
content O
of O
the O
tissue O
to O
allow O
further O
specific O
investigations O
like O
mitochondrial O
respiratory O
chain O
studies O
essential O
in O
these O
diseases O
this O
requirement O
can O
be O
achieved O
only O
through O
a O
multi O
##dis O
##ci O
##plin O
##ary O
approach O
including O
surgeon O
clinic O
##ian O
and O
path O
##ologist O
actual O
protocols O
require O
a O
small O
fragment O
of O
fresh O
muscle O
collected O
in O
rib O
##on O
##uc O
##lea O
##se O
rna O
##se O
free O
tubes O
to O
be O
snap O
frozen O
in O
liquid O
nitrogen O
for O
biochemistry O
and O
genetic O
testing O
15 O

not O
only O
processing O
but O
also O
interpretation O
of O
morphological O
findings O
in O
mit O
##och O
##ond O
##rio O
##path O
##ies O
is O
difficult O
because O
the O
his O
##to O
##logical O
and O
his O
##to O
##chemical O
features O
are O
not O
entirely O
specific O
separating O
primary O
from O
secondary O
abnormalities O
of O
mit O
##och O
##ond O
##ria O
implies O
integration O
##s O
of O
the O
morphological O
findings O
in O
the O
clinical O
picture O
the O
ragged O
red O
fibers O
considered O
to O
be O
the O
morphological O
hallmark O
of O
mitochondrial O
my O
##opa O
##thy O
are O
characterized O
by O
sub O
##sar O
##col O
##em O
##mal O
and O
inter O
##my O
##of O
##ib O
##rill O
##ar O
accumulation O
##s O
of O
mit O
##och O
##ond O
##ria O
with O
replacement O
of O
some O
of O
the O
contract O
##ile O
elements O
however O
ragged O
red O
fibers O
are O
not O
path O
##og O
##no O
##mon O
##ic O
and O
can O
be O
identified O
on O
muscle O
bio O
##ps O
##ies O
with O
aging O
in O
hereditary O
non O
mitochondrial O
diseases O
in O
cases O
of O
toxic O
or O
inflammatory O
my O
##opa O
##thi O
##es O
especially O
inclusion O
body O
my O
##osi O
##tis O

or O
in O
z O
##ido O
##vu O
##dine O
associated O
my O
##opa O
##thy O
of O
human O
im O
##mun O
##ode O
##fi O
##ciency O
virus O
hiv O
infected O
patients O
16 O
in O
recent O
publications O
scattered O
ragged O
red O
fibers O
were O
also O
described O
in O
cases O
of O
my O
##of O
##ib O
##rill O
##ar O
my O
##opa O
##thi O
##es O
where O
their O
presence O
can O
be O
explained O
by O
the O
functional O
interactions O
of O
intermediate O
fi O
##lam O
##ents O
and O
mit O
##och O
##ond O
##ria O
in O
the O
complex O
muscle O
fiber O
architecture O
17 O

ragged O
red O
fibers O
are O
often O
but O
not O
always O
cox O
##ne O
##gative O
additionally O
ragged O
red O
fibers O
and O
cox O
##de O
##fi O
##cie O
##nt O
fibers O
are O
not O
identified O
in O
all O
cases O
of O
mitochondrial O
my O
##opa O
##thy O
and O
are O
more O
frequently O
associated O
with O
mutations O
in O
mt O
##dna O
rather O
than O
in O
the O
nuclear O
genes O
but O
in O
our O
case O
both O
key O
morphological O
features O
were O
present O
on O
the O
bio O
##psy O
in O
children O
cox O
def O
##icient O
fibers O
may O
be O
more O
numerous O
than O
the O
ragged O
red O
ones O
or O
may O
be O
the O
only O
abnormal O
##ity O
in O
the O
muscle O
bio O
##psy O
18 O
19 O
sometimes O
no O
morphological O
abnormal O
##ity O
is O
noticed O
on O
the O
muscle O
bio O
##psy O
but O
this O
cannot O
clearly O
rule O
out O
a O
clinical O
suspicion O
of O
mit O
##och O
##ond O
##rio O
##pathy O

in O
skeletal O
muscle O
it O
is O
important O
that O
there O
is O
a O
strong O
correlation O
between O
mitochondrial O
function O
and O
ultra O
##st O
##ru O
##cture O
20 O
22 O
an O
important O
number O
of O
enzymes O
involved O
in O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
and O
not O
only O
are O
found O
in O
mitochondrial O
cr O
##ista O
##e O
and O
any O
morphological O
abnormal O
##ity O
in O
this O
area O
leads O
to O
physiological O
disturbances O
and O
alteration O
of O
the O
signaling O
pathways O
in O
which O
these O
enzymes O
are O
involved O

a O
classic O
feature O
of O
mitochondrial O
my O
##opa O
##thy O
is O
the O
sub O
##sar O
##col O
##em O
##mal O
accumulation O
of O
abnormal O
mit O
##och O
##ond O
##ria O
demonstrated O
by O
electron O
microscopy O
images O
but O
also O
by O
optical O
microscopy O
on O
sd O
##h O
stain O
##ing O
as O
ragged O
blue O
fibers O
or O
modified O
gt O
stain O
##ing O
ragged O
red O
fibers O
electron O
microscopy O
is O
an O
essential O
confirmation O
of O
mit O
##och O
##ond O
##rio O
##pathy O
moreover O
it O
may O
add O
extra O
data O
in O
cases O
where O
his O
##tology O
and O
his O
##to O
##chemist O
##ry O
are O
not O
el O
##o O
##quent O
or O
not O
enough O
ragged O
red O
ragged O
blue O
fibers O
are O
found O
or O
there O
are O
no O
cox O
negative O
fibers O
in O
the O
bio O
##psy O
sample O

in O
mit O
##och O
##ond O
##ria O
with O
con O
##centric O
cr O
##ista O
##e O
the O
width O
of O
the O
intra O
##cr O
##ista O
##e O
space O
was O
reduced O
by O
about O
15 O
indicating O
a O
thick O
##ening O
of O
cr O
##ista O
##e O
membranes O
moreover O
the O
distance O
between O
two O
adjacent O
cr O
##ista O
##e O
is O
substantially O
reduced O
in O
this O
type O
of O
mit O
##och O
##ond O
##ria O
as O
vincent O
et O
al O
showed O
23 O
same O
path O
##ological O
electron O
dense O
bodies O
in O
mit O
##och O
##ond O
##ria O
encountered O
in O
our O
patient O
s O
bio O
##psy O
were O
also O
observed O
by O
su O
##oma O
##lain O
##en O
et O
al O
in O
extra O
##oc O
##ular O
muscle O
from O
a O
pe O
##o O
patient O
with O
mt O
##dna O
del O
##eti O
##ons O
and O
brain O
involvement O
24 O
the O
significance O
is O
yet O
unknown O

concerning O
the O
correlation O
of O
his O
##tology O
with O
genetic O
results O
there O
is O
no O
specific O
morphological O
abnormalities O
typical O
for O
a O
certain O
genetic O
mutation O
each O
cell O
contains O
many O
mit O
##och O
##ond O
##ria O
and O
each O
mit O
##och O
##ond O
##rion O
contains O
many O
genome O
##s O
there O
is O
a O
phenomenon O
of O
genetic O
het O
##ero O
##pl O
##as O
##mia O
where O
a O
proportion O
of O
genome O
##s O
contain O
the O
mutation O
and O
a O
proportion O
represents O
the O
wild O
type O

our O
case O
illustrates O
the O
complexity O
of O
positive O
and O
differential O
diagnosis O
in O
mit O
##och O
##ond O
##rio O
##path O
##ies O
presenting O
a O
mitochondrial O
disease O
caused O
by O
an O
auto O
##som O
##al O
dominant O
n O
##dna O
mutation O
on O
chromosome O
15 O
in O
15 O
##q O
##26 O
1 O
which O
causes O
mt O
##dna O
del O
##eti O
##ons O
25 O
this O
mutation O
is O
associated O
with O
pe O
##o O
added O
to O
pe O
##o O
our O
patient O
had O
also O
swallowing O
difficulties O
over O
1500 O
nuclear O
genetic O
lo O
##ci O
en O
##code O
for O

mitochondrial O
proteins O
which O
are O
not O
only O
involved O
in O
ox O
##ida O
##tive O
ph O
##os O
##ph O
##ory O
##lation O
but O
also O
in O
many O
other O
functions O
of O
mit O
##och O
##ond O
##ria O
and O
about O
15 O
of O
the O
mitochondrial O
pro O
##te O
##ome O
await O
##s O
identification O
26 O
pe O
##o O
caused O
by O
mutation O
in O
the O
pol O
##g O
gene O
is O
associated O
with O
more O
severe O
ph O
##eno O
##type O
##s O
than O
those O
forms O
caused O
by O
mutation O
in O
the O
aden O
##ine O
nu O
##cle O
##otide O
trans O
##lo O
##cat O
##or O
1 O
ant O
##1 O
gene O
pe O
##o O
with O
mt O
##dna O
del O
##eti O
##ons O
auto O
##som O
##al O
dominant O
2 O
pe O
##oa O
##2 O
or O
c1 O
##0 O
##orf O
##2 O
gene O
pe O
##oa O
##3 O
5 O
mutations O
in O
n O
##dna O
that O
affect O
mit O
##och O
##ond O
##ria O
are O
very O
diverse O
and O
even O
include O
mt O
##dna O
defects O
which O
are O
responsible O
for O
maintenance O
replication O
and O
translation O
n O
##dna O
mutations O
can O
lead O
to O
ap O
##op O
##tosis O
changes O
in O
mitochondrial O
metabolism O
or O
mitochondrial O
cha O
##per O
##ones O
damage O
1 O
pol O
##g O
gene O
sequencing O
in O
patients O
with O
mitochondrial O
disease O
with O
pe O
##o O
is O
helpful O
for O
a O
diagnosis O
confirmation O
most O
of O
that O
the O
carrier O
testing O
pre O
##nat O
##al O
diagnosis O
and O
pre O
sy O
##mpt O
##oma O
##tic O
testing O
of O
the O
siblings O
are O
needed O

conclusions O

a O
precise O
diagnosis O
in O
mitochondrial O
disorders O
has O
important O
clinical O
implications O
and O
helps O
in O
providing O
an O
adequate O
genetic O
counseling O
performing O
a O
muscle O
bio O
##psy O
must O
be O
considered O
in O
the O
diagnostic O
work O
##up O
in O
order O
to O
confirm O
a O
mit O
##och O
##ond O
##rio O
##pathy O
in O
strong O
correlation O
with O
clinical O
features O
and O
guide O
genetic O
testing O
for O
n O
##dna O
and O
mt O
##dna O
to O
identify O
where O
the O
primary O
mutation O
is O
located O
the O
identification O
of O
defects O
in O
mitochondrial O
or O
nuclear O
genome O
leads O
to O
the O
con O
##clusive O
diagnosis O
of O
mitochondrial O
my O
##opa O
##thy O
the O
main O
morphological O
features O
of O
mit O
##och O
##ond O
##rio O
##path O
##ies O
are O
the O
presence O
of O
ragged O
red O
ragged O
blue O
fibers O
and O
decreased O
cox O
activity O
electron O
microscopy O
can O
confirm O
the O
his O
##top O
##ath O
##ological O
findings O
by O
highlighting O
sub O
##sar O
##col O
##em O
##mal O
accumulation O
of O
abnormal O
##ly O
structured O
mit O
##och O
##ond O
##ria O
the O
utility O
of O
muscle O
bio O
##psy O
is O
obvious O
considering O
that O
genetic O
testing O
in O
mit O
##och O
##ond O
##rio O
##path O
##ies O
is O
complex O
and O
sometimes O
not O
easily O
available O
a O
real O
challenge O
of O
the O
current O
period O
is O
finding O
the O
##ra O
##pies O
that O
may O
slow O
the O
progression O
of O
these O
diseases O
while O
further O
studies O
are O
required O
in O
the O
next O
years O
for O
a O
better O
understanding O
of O
all O
the O
factors O
interacting O
in O
the O
cross O
##talk O
between O
the O
mitochondrial O
and O
the O
nuclear O
genome O
##s O
and O
their O
implications O
for O
the O
spectrum O
of O
human O
mitochondrial O
diseases O

conflict O
of O
interests O
the O
authors O
report O
no O
relationships O
that O
could O
be O
con O
##st O
##rued O
as O
a O
conflict O
of O
interests O
authors O
contribution O
alexandra O
eugen O
##ia O
bas O
##tian O
and O
g O
##he O
##org O
##hita O
jug O
##ule O
##te O
equally O
contributed O
to O
this O
work O
ac O
##k O
##now O
##led O
##gm O
##ents O
the O
authors O
want O
to O
thank O
the O
patient O
for O
providing O
the O
photos O
used O
in O
the O
text O
and O
for O
his O
agreement O
for O
publication O
references O
chin O
##nery O
p O
##f O
mitochondrial O
disorders O
overview O
june O
8 O
2000 O
updated O
august O
14 O
2014 O
in O
adam O
mp O
ar O
##ding O
##er O
h O
##h O
pa O
##gon O
ra O
wallace O
se O
eds O
gene O
##re O
##view O
##s O
##® O
internet O

university O
of O
washington O
seattle O
wa O
usa O
1993 O
2017 O
available O
from O
https O
www O
nc O
##bi O
nl O
##m O
ni O
##h O
gov O
books O
n O
##b O
##k O
##12 O
##24 O
angel O
##ini O
c O
bell O
##o O
l O
spin O
##az O
##zi O
m O
fe O
##rra O
##ti O
c O
mitochondrial O
disorders O
of O
nuclear O
genome O
act O
##a O
my O
##ol O
2009 O
28 O
1 O
16 O
23 O
ni O
##shin O
##o O
i O
spin O
##az O
##zo O
##la O
a O
hi O
##rano O
m O
thy O
##mi O
##dine O
ph O
##os O
##ph O
##ory O
##lase O
gene O
mutations O
in O
mn O
##gie O
a O
human O
mitochondrial O
disorder O
science O
1999 O
283 O
540 O
##2 O
68 O
##9 O
69 O
##2 O
van O
goethe O
##m O
g O
der O
##ma O
##ut O
b O
lo O
##f O
##gren O
a O
martin O
jj O
van O
bro O
##eck O
##ho O
##ven O
c O
mutation O
of O
pol O
##g O
is O
associated O
with O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
characterized O
by O
mt O
##dna O
del O
##eti O
##ons O
nat O
gene O
##t O
2001 O
28 O
3 O
211 O
212 O

lama O
##nte O
##a O
e O
ti O
##rant O
##i O
v O
bo O
##rdon O
##i O
a O
to O
##scan O
##o O
a O
bono O
f O
ser O
##vid O
##ei O
s O
papa O
##dim O
##it O
##rio O
##u O
a O
sp O
##el O
##bri O
##nk O
h O
si O
##lves O
##tri O
l O
casa O
##ri O
g O
com O
##i O
gp O
zev O
##iani O
m O
mutations O
of O
mitochondrial O
dna O
polymer O
##ase O
gamma O
##a O
are O
a O
frequent O
cause O
of O
auto O
##som O
##al O
dominant O
or O
recess O
##ive O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
ann O
ne O
##uro O
##l O
2002 O
52 O
2 O
211 O
219 O
de O
##bal O
##si O
k O
##l O
ho O
##ff O
ke O
copeland O
wc O
role O
of O
the O
mitochondrial O
dna O
replication O
machinery O
in O
mitochondrial O
dna O
mu O
##tage O
##nes O
##is O
aging O
and O
age O
related O
diseases O
age O
##ing O
res O
rev O
2017 O
33 O
89 O
104 O

ho O
##rva O
##th O
r O
hudson O
g O
ferrari O
g O
fu O
##tter O
##er O
n O
ah O
##ola O
s O
lama O
##nte O
##a O
e O
pro O
##kis O
##ch O
h O
loch O
##mu O
##ller O
h O
mc O
##far O
##land O
r O
ram O
##esh O
v O
k O
##lo O
##ps O
##tock O
t O
fr O
##eis O
##inger O
p O
sal O
##vi O
f O
may O
##r O
ja O
sant O
##er O
r O
te O
##sar O
##ova O
m O
ze O
##man O
j O
ud O
##d O
b O
taylor O
r O
##w O
turnbull O
d O
hanna O
m O
fia O
##lho O
d O
su O
##oma O
##lain O
##en O
a O
zev O
##iani O
m O
chin O
##nery O
p O
##f O
ph O
##eno O
##typic O
spectrum O
associated O
with O
mutations O
of O
the O
mitochondrial O
polymer O
##ase O
gamma O
gene O
brain O
2006 O
129 O
pt O
7 O
167 O
##4 O
168 O
##4 O
mc O
##far O
##land O
r O
taylor O
r O
##w O
turnbull O
d O
##m O
a O
neurological O
perspective O
on O
mitochondrial O
disease O
lance O
##t O
ne O
##uro O
##l O
2010 O
9 O
8 O
82 O
##9 O
840 O

somme O
##r O
##ville O
e O
##w O
chin O
##nery O
p O
##f O
gorman O
gs O
taylor O
r O
##w O
adult O
onset O
men O
##del O
##ian O
pe O
##o O
associated O
with O
mitochondrial O
disease O
j O
ne O
##uro O
##mus O
##cu O
##l O
di O
##s O
2014 O
1 O
2 O
119 O
133 O
dim O
##aur O
##o O
s O
hi O
##rano O
m O
mitochondrial O
dna O
del O
##eti O
##on O
syndrome O
##s O
in O
pa O
##gon O
ra O
adam O
mp O
bird O
td O
do O
##lan O
cr O
f O
##ong O
ct O
stephens O
k O
eds O
gene O
##re O
##view O
##s O
university O
of O
washington O
seattle O
wa O
usa O
1993 O
gonzalez O
mor O
##on O
d O
bu O
##eri O
j O
ka O
##uf O
##fm O
##an O
m O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
pe O
##o O
due O
to O
a O
mutation O
in O
the O
c1 O
##0 O
##orf O
##2 O
pe O
##o O
##1 O
gene O
mimic O
##king O
a O
my O
##ast O
##hen O
##ic O
crisis O
b O
##m O
##j O
case O
rep O
2013 O
2013 O
bc O
##r O
##20 O
##13 O
##01 O
##01 O
##8 O
##1 O

greaves O
lc O
reeve O
ak O
taylor O
r O
##w O
turnbull O
d O
##m O
mitochondrial O
dna O
and O
disease O
j O
path O
##ol O
2012 O
226 O
2 O
274 O
286 O
collins O
s O
byrne O
e O
den O
##nett O
x O
contrasting O
his O
##to O
##chemical O
features O
of O
various O
mitochondrial O
syndrome O
##s O
act O
##a O
ne O
##uro O
##l O
scan O
##d O
1995 O
91 O
4 O
287 O
293 O
gorman O
gs O
chin O
##nery O
p O
##f O
dim O
##aur O
##o O
s O
hi O
##rano O
m O
ko O
##ga O
y O
mc O
##far O
##land O
r O
su O
##oma O
##lain O
##en O
a O
thor O
##burn O
dr O
zev O
##iani O
m O
turnbull O
d O
##m O
mitochondrial O
diseases O
nat O
rev O
di O
##s O
prime O
##rs O
2016 O
2 O
160 O
##80 O
ph O
##ad O
##ke O
r O
my O
##opa O
##th O
##ology O
of O
adult O
and O
pa O
##ed O
##ia O
##tric O
mitochondrial O
diseases O
j O
cl O
##in O
med O
2017 O
6 O
7 O
64 O

dal O
##aka O
##s O
mc O
ill O
##a O
i O
pe O
##zes O
##h O
##k O
##pour O
g O
##h O
lau O
##kai O
##tis O
jp O
cohen O
b O
griffin O
j O
##l O
mitochondrial O
my O
##opa O
##thy O
caused O
by O
long O
term O
z O
##ido O
##vu O
##dine O
therapy O
n O
eng O
##l O
j O
med O
1990 O
322 O
16 O
109 O
##8 O
110 O
##5 O
jackson O
s O
sc O
##hae O
##fer O
j O
mein O
##hardt O
m O
reich O
##mann O
h O
mitochondrial O
abnormalities O
in O
the O
my O
##of O
##ib O
##rill O
##ar O
my O
##opa O
##thi O
##es O
eu O
##r O
j O
ne O
##uro O
##l O
2015 O
22 O
11 O
142 O
##9 O
143 O
##5 O
nas O
##ci O
##mento O
a O
or O
##te O
##z O
c O
jo O
##u O
c O
o O
call O
##aghan O
m O
ramos O
f O
garcia O
ca O
##zo O
##rl O
##a O
a O
ne O
##uro O
##mus O
##cular O
manifestation O
##s O
in O
mitochondrial O
diseases O
in O
children O
semi O
##n O
pe O
##dia O
##tr O
ne O
##uro O
##l O
2016 O
23 O
4 O
290 O
305 O

sl O
##ei O
##gh O
k O
ball O
s O
hilton O
da O
quan O
##ti O
##fication O
of O
changes O
in O
muscle O
from O
individuals O
with O
and O
without O
mitochondrial O
disease O
muscle O
nerve O
2011 O
43 O
6 O
79 O
##5 O
800 O
mann O
##ella O
ca O
the O
relevance O
of O
mitochondrial O
membrane O
topology O
to O
mitochondrial O
function O
bio O
##chi O
##m O
bio O
##phy O
##s O
act O
##a O
2006 O
1762 O
2 O
140 O
147 O
per O
##nas O
l O
sc O
##orra O
##no O
l O
mit O
##o O
mor O
##ph O
##osis O
mitochondrial O
fusion O
fission O
and O
cr O
##ista O
##e O
re O
##mo O
##del O
##ing O
as O
key O
media O
##tors O
of O
cellular O
function O
ann O
##u O
rev O
ph O
##ys O
##iol O
2016 O
78 O
505 O
53 O
##1 O

mann O
##ella O
ca O
led O
##ere O
##r O
w O
##j O
ja O
##fr O
##i O
ms O
the O
connection O
between O
inner O
membrane O
topology O
and O
mitochondrial O
function O
j O
mo O
##l O
cell O
card O
##iol O
2013 O
62 O
51 O
57 O
vincent O
ae O
ng O
y O
##s O
white O
k O
davey O
t O
mann O
##ella O
c O
fa O
##lk O
##ous O
g O
fee O
##ney O
c O
sc O
##hae O
##fer O
am O
mc O
##far O
##land O
r O
gorman O
gs O
taylor O
r O
##w O
turnbull O
d O
##m O
pic O
##ard O
m O
the O
spectrum O
of O
mitochondrial O
ultra O
##st O
##ru O
##ct O
##ural O
defects O
in O
mitochondrial O
my O
##opa O
##thy O
sci O
rep O
2016 O
6 O
306 O
##10 O
su O
##oma O
##lain O
##en O
a O
maj O
##ander O
a O
halt O
##ia O
m O
some O
##r O
h O
lo O
##nn O
##qvist O
j O
sa O
##von O
##ta O
##us O
ml O
pe O
##lton O
##en O
l O
multiple O
del O
##eti O
##ons O
of O
mitochondrial O
dna O
in O
several O
tissues O
of O
a O
patient O
with O
severe O
re O
##tar O
##ded O

depression O
and O
fa O
##mi O
##lia O
##l O
progressive O
external O
op O
##ht O
##hal O
##mo O
##ple O
##gia O
j O
cl O
##in O
invest O
1992 O
90 O
1 O
61 O
66 O
nm O
00 O
##26 O
##9 O
##3 O
2 O
pol O
##g O
c O
286 O
##4 O
##a O
g O
p O
ty O
##r O
##9 O
##55 O
##cy O
##s O
cl O
##in O
##var O
last O
updated O
march O
31 O
2019 O
https O
www O
nc O
##bi O
nl O
##m O
ni O
##h O
gov O
cl O
##in O
##var O
variation O
134 O
##9 O
##5 O
cal O
##vo O
se O
mo O
##oth O
##a O
v O
##k O
the O
mitochondrial O
pro O
##te O
##ome O
and O
human O
disease O
ann O
##u O
rev O
gen O
##omics O
hum O
gene O
##t O
2010 O
11 O
25 O
44 O
corresponding O
author O

emilia O
man O
##ole O
senior O
researcher O
phd O
department O
of O
pathology O
cole O
##nti O
##na O
clinical O
hospital O
19 O
21 O
stefan O
ce O
##l O
mare O
highway O
sector O
2 O
02 O
##01 O
##25 O
bucharest O
romania O
department O
of O
molecular O
biology O
victor O
babe O
##s O
national O
institute O
for O
research O
and O
development O
in O
pathology O
and O
biomedical O
sciences O
99 O
101 O
independent O
##ei O
avenue O
sector O
5 O
050 O
##0 O
##9 O
##6 O
bucharest O
romania O
phone O
402 O
##1 O
317 O
42 O
45 O
fa O
##x O
402 O
##1 O
316 O
55 O
12 O
e O
mail O
emilia O
man O
##ole O
yahoo O
com O
received O
march O
12 O
2018 O
accepted O
may O
10 O
2019 O
